PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LOVE, JD; MINTON, KW				LOVE, JD; MINTON, KW			ULTRAVIOLET-INDUCED DIMERIZATION OF NONADJACENT PYRIMIDINES IN POLY[D(A-T)]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-HELIX FORMATION; DNA-BINDING-PROTEIN; ESCHERICHIA-COLI; THERMODYNAMICS; PHOTOREACTIVITY; SPECIFICITY; MECHANISM; COMPLEXES; SEQUENCES; MN-2+	The DNA photoproduct responsible for the ultraviolet (UV) light-induced -1 frameshift mutation remains unknown. We recently identified a UV photoproduct consisting of a cyclobutane dimer occurring between non-adjacent thymine residues in the same strand, [GRAPHICS] and proposed that replication across this unrepaired photoproduct might result in a - 1 frameshift mutation since the intervening base is extrahelical. Until now this novel photoproduct has only been identified in single-stranded DNA polymers and does not occur in UV-irradiated double-stranded polymers due to conformational restraint. This observation suggested that this photoproduct could only occur in vivo in chromosomal sites that were single-stranded. In the current work the cis-syn dithymine cyclobutane dimer has been identified in the self-complementary polymer poly[d(A-T)] when UV irradiated in solution conditions (concentrated manganese chloride or 60% ethanol plus trace salts) wherein this polymer remains double-stranded but the double-helix is partially destabilized. Taken together, the current findings suggest that dipyrimidine photoproducts between non-adjacent residues on the same strand could occur in vivo in double-stranded, but partially destabilized, DNA.	UNIFORMED SERV UNIV HLTH SCI,FE HEBERT SCH MED,DEPT PATHOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA								ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; ALBERGO DD, 1981, BIOCHEMISTRY-US, V20, P1413, DOI 10.1021/bi00509a002; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; ARNOLD FH, 1987, BIOCHEMISTRY-US, V26, P4068, DOI 10.1021/bi00387a049; ATTRI AK, 1986, ANAL BIOCHEM, V159, P88, DOI 10.1016/0003-2697(86)90311-8; BENHUR E, 1968, BIOCHIM BIOPHYS ACTA, V166, P9, DOI 10.1016/0005-2787(68)90485-1; BOSE SN, 1984, NUCLEIC ACIDS RES, V12, P7903, DOI 10.1093/nar/12.20.7903; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN DM, 1985, BIOCHEMISTRY-US, V24, P1676, DOI 10.1021/bi00328a016; EICHHORN GL, 1968, J AM CHEM SOC, V90, P7323, DOI 10.1021/ja01028a024; GLASSMAN TA, 1971, BIOCHEMISTRY-US, V10, P843; GRANOT J, 1982, BIOPOLYMERS, V21, P873, DOI 10.1002/bip.360210502; GRAY DM, 1980, NUCLEIC ACIDS RES, V8, P3695, DOI 10.1093/nar/8.16.3695; HOSSZU JL, 1967, BIOCHEM BIOPH RES CO, V29, P327, DOI 10.1016/0006-291X(67)90457-3; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; Kornberg A., 1980, DNA REPLICATION; KRAWIEC S, 1990, MICROBIOL REV, V54, P502, DOI 10.1128/MMBR.54.4.502-539.1990; KUMAR S, 1987, PHOTOCHEM PHOTOBIOL, V45, P571, DOI 10.1111/j.1751-1097.1987.tb07382.x; KUNTZ GPP, 1972, BIOCHEMISTRY-US, V11, P538, DOI 10.1021/bi00754a009; LEE CH, 1981, P NATL ACAD SCI-BIOL, V78, P2838, DOI 10.1073/pnas.78.5.2838; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LOVE JD, 1986, J BIOL CHEM, V261, P51; LUCK G, 1972, EUR J BIOCHEM, V29, P523; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MOROWITZ HJ, 1950, SCIENCE, V111, P229; NGUYEN HT, 1989, J MOL BIOL, V210, P869, DOI 10.1016/0022-2836(89)90114-9; NGUYEN HT, 1988, J MOL BIOL, V200, P681, DOI 10.1016/0022-2836(88)90480-9; PATRICK MH, 1976, PHOTOCHEM PHOTOBIOL, V24, P507, DOI 10.1111/j.1751-1097.1976.tb06867.x; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; POHL FM, 1976, NATURE, V260, P365, DOI 10.1038/260365a0; SETLOW RB, 1964, BIOCHIM BIOPHYS ACTA, V91, P446, DOI 10.1016/0926-6550(64)90075-1; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; VANDESANDE JH, 1982, EMBO J, V1, P777, DOI 10.1002/j.1460-2075.1982.tb01247.x; VARGHESE AJ, 1967, SCIENCE, V156, P955, DOI 10.1126/science.156.3777.955; VORLICKOVA M, 1985, J BIOMOL STRUCT DYN, V3, P67, DOI 10.1080/07391102.1985.10508399; VORLICKOVA M, 1982, NUCLEIC ACIDS RES, V10, P6969, DOI 10.1093/nar/10.21.6969; WANG SY, 1967, BIOCHEM BIOPH RES CO, V29, P543, DOI 10.1016/0006-291X(67)90519-0; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	40	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24953	24959						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460000				2022-12-27	WOS:A1992KB60300010
J	ROITELMAN, J; SIMONI, RD				ROITELMAN, J; SIMONI, RD			DISTINCT STEROL AND NONSTEROL SIGNALS FOR THE REGULATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; LOW-DENSITY-LIPOPROTEIN; HAMSTER OVARY CELLS; RECEPTOR GENE-EXPRESSION; MEMBRANE-BOUND DOMAIN; ENDOPLASMIC-RETICULUM; PROTEIN-DEGRADATION; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; ENHANCED DEGRADATION	The in vivo turnover rate of the endoplasmic reticulum protein 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate (MVA) pathway, is accelerated when excess MVA or sterols are added to the growth medium of cells. As we have shown recently (Roitelman, J., Bar-Nun, S., Inoue, S., and Simoni, R. D. (1991) J. Biol. Chem. 266, 16085-16091), perturbation of cellular Ca2+ homeostasis abrogates the MVA-accelerated degradation of HMG-CoA reductase and HMGal. Here we show that, in contrast, the sterol-accelerated degradation of HMG-CoA reductase is unaffected by Ca2+ perturbation achieved either by Ca2+ ionophore or by inhibitors of the endoplasmic reticulum Ca2+-ATPase. The differential effects of Ca2+ perturbation can be attributed neither to global alteration in protein synthesis nor to inhibition of MVA conversion to sterols. Yet, such manipulations markedly reduce the incorporation of MVA into cellular macromolecules, including prenylated proteins. Furthermore, we directly demonstrate that MVA gives rise to at least two distinct signals, one that is essential to support the effect of sterols and another that operates independently of sterols. Our results indicate that the cellular signals operating in the MVA-accelerated turnover of HMG-CoA reductase are distinct from those involved in the sterol-regulated degradation. A working model for the degradation pathway is proposed.			ROITELMAN, J (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26502] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOCK LH, 1991, P NATL ACAD SCI USA, V88, P9041, DOI 10.1073/pnas.88.20.9041; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BRADFUTE DL, 1992, J BIOL CHEM, V267, P18308; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; CHANG TY, 1981, J BIOL CHEM, V256, P6174; CHEN HW, 1982, BIOCHIM BIOPHYS ACTA, V712, P484, DOI 10.1016/0005-2760(82)90275-2; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CROOK RB, 1978, BIOCHEM J, V176, P47, DOI 10.1042/bj1760047; CUTHBERT JA, 1990, J LIPID RES, V31, P2067; DESGRANGES C, 1991, BIOCHEM PHARMACOL, V41, P1045, DOI 10.1016/0006-2952(91)90213-O; FAUST J, 1987, J BIOL CHEM, V262, P1996; FREIKOPF A, 1976, BIOCHEM BIOPH RES CO, V72, P1195, DOI 10.1016/S0006-291X(76)80257-4; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAVEL CM, 1992, ARCH BIOCHEM BIOPHYS, V294, P639, DOI 10.1016/0003-9861(92)90736-G; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HIDAKA Y, 1991, J BIOL CHEM, V266, P13171; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; HORIE M, 1990, J BIOL CHEM, V265, P18075; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; JOLY A, 1991, J BIOL CHEM, V266, P13495; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KOJIMA I, 1990, G PROTEINS, P503; KULKA RG, 1989, RBC-CELL BIOL REV, V21, P321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LISCUM L, 1985, J BIOL CHEM, V260, P522; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MAZZONE T, 1989, J BIOL CHEM, V264, P15529; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PANINI SR, 1989, J BIOL CHEM, V264, P11044; PANINI SR, 1992, J BIOL CHEM, V267, P12647; PIANSMITH MCM, 1988, ENDOCRINOLOGY, V123, P1984, DOI 10.1210/endo-123-4-1984; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROTH M, 1991, P NATL ACAD SCI USA, V88, P1888, DOI 10.1073/pnas.88.5.1888; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TANAKA RD, 1986, J LIPID RES, V27, P261; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; WILKIN DJ, 1992, J BIOL CHEM, V267, P2831; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; ZAMMIT VA, 1991, BIOCHEM J, V279, P377, DOI 10.1042/bj2790377; ZAMMIT VA, 1990, BIOCHEM J, V269, P373, DOI 10.1042/bj2690373	67	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25264	25273						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460026				2022-12-27	WOS:A1992KB60300055
J	HERZBERG, O				HERZBERG, O			AN ATOMIC MODEL FOR PROTEIN-PROTEIN PHOSPHORYL GROUP TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTRANSFERASE SYSTEM; MACROMOLECULAR STRUCTURES; REFINEMENT; DYNAMICS; PROGRAM; ENZYME; DOMAIN	The high resolution crystal structures of two interacting proteins from the phosphoenolpyruvate:sugar phosphotransferase system, the histidine-containing phosphocarrier protein (HPr) and the IIA domain of glucose permease (IIA(Glc)) from Bacillus subtilis, provide the basis for modeling the transient binary complex formed during the phosphoryl group transfer. The complementarity of the interacting surfaces implies that no major conformational transition is required. The negatively charged phosphoryl group is buried in the interface, suggesting a key role for electrostatic interactions. It is proposed that the phosphoryl transfer is triggered by a switch between two salt bridges involving Arg-17 of the HPr. The first, prior to phosphoryl group transfer, is intramolecular, with the phosphorylated His-15. The second, during the transfer, is intermolecular, with 2 aspartate residues associated with the active site of IIA(Glc). Such alternating ion pairs may be mechanistically important in other protein-protein phosphotransfer reactions.			HERZBERG, O (corresponding author), UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,SHADY GROVE CAMPUS,ROCKVILLE,MD 20850, USA.			Herzberg, Osnat/0000-0003-2823-7627				BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; JANIN J, 1990, J BIOL CHEM, V265, P16027; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; SAIER MH, 1990, RES MICROBIOL, V141, P1033, DOI 10.1016/0923-2508(90)90077-4; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	22	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24819	24823						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447219				2022-12-27	WOS:A1992KA26300099
J	SHACHAR, I; AMITAY, R; RABINOVICH, E; HAIMOVICH, J; BARNUN, S				SHACHAR, I; AMITAY, R; RABINOVICH, E; HAIMOVICH, J; BARNUN, S			POLYMERIZATION OF SECRETORY IGM IN LYMPHOCYTES-B IS PREVENTED BY A PRIOR TARGETING TO A DEGRADATION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EXOCRINE PANCREATIC-CELLS; CULTURED RAT HEPATOCYTES; IMMUNOGLOBULIN-J-CHAIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; GOLGI-COMPLEX; BREFELDIN-A; BINDING-PROTEIN; LIGHT-CHAIN	B lymphocytes express on their surface a membrane form of IgM (mIgM), and synthesize but fail to secrete a secretory form of IgM (sIgM). Plasma cells shift to the exclusive synthesis and efficient secretion of sIgM. The sIgM in B cells differs from that in plasma cells in its pattern of assembly: in plasma cells, monomers of sIgM are assembled into polymers and only polymers are secreted; in B lymphocytes, monomeric sIgM is neither polymerized nor secreted and is degraded intracellularly. In this article we blocked the export of proteins from the endoplasmic reticulum at low temperatures or with energy poisons or brefeldin A, and localized the different assembly steps of mIgM and sIgM in the 38C B lymphocytes and of sIgM in the 38C-derived sIgM-secreting D2 hybridoma. In both cell lines, sIgM assembly into monomers was not affected, whereas polymerization of sIgM in D2 cells and monomer formation of mIgM in 38C cells were strongly inhibited. Moreover, probing with specific lectins revealed galactosylated monomers and polymers in D2 cells and galactosylated hemimer and monomers only of mIgM in 38C cells. In addition, when Golgi functions were hampered with Tris base, monomerization of mIgM and polymerization of sIgM were attenuated. These results indicate that polymerization of sIgM in D2 cells and monomerization of mIgM in 38C cells are post-endoplasmic reticulum events, occurring in or beyond the trans-Golgi galactosylation compartment. Since only polymers are secreted from D2 cells and only monomeric mIgM is displayed on the surface of 38C cells, partially assembled molecules may traverse the secretory pathway yet are restricted from the cell surface. Furthermore, monomeric sIgM in 38C cells is never galactosylated, thus it is degraded prior to the galactosylation compartment. We conclude that targeting of sIgM to degradation in 38C cells precedes its assembly site into polymers in D2 cells. This implies that degradation of sIgM does not result from the incompetence of 38C cells to polymerize. Rather, assembly of sIgM into polymers and their subsequent secretion are prevented in B lymphocytes by preceding targeting of monomeric sIgM to degradation.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine								ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMITAY R, 1991, J BIOL CHEM, V266, P12568; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERGMAN Y, 1978, EUR J IMMUNOL, V8, P876, DOI 10.1002/eji.1830081210; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRENCKLE R, 1980, ARCH BIOCHEM BIOPHYS, V201, P160, DOI 10.1016/0003-9861(80)90499-3; CALAME KL, 1985, ANNU REV IMMUNOL, V3, P159, DOI 10.1146/annurev.iy.03.040185.001111; CATTANEO A, 1987, EMBO J, V6, P2753, DOI 10.1002/j.1460-2075.1987.tb02569.x; DAHMS NM, 1986, J BIOL CHEM, V261, P3186; DAVIS AC, 1989, MOL IMMUNOL, V26, P147, DOI 10.1016/0161-5890(89)90096-5; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DULIS BH, 1983, J BIOL CHEM, V258, P2181; ESHHAR Z, 1979, J IMMUNOL, V122, P2430; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; ODA K, 1988, J BIOL CHEM, V263, P12576; ORCI L, 1991, CELL, V64, P1183; PARKHOUSE RM, 1971, BIOCHEM J, V123, P635, DOI 10.1042/bj1230635; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; REEKE GN, 1974, ANN NY ACAD SCI, V234, P369, DOI 10.1111/j.1749-6632.1974.tb53049.x; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHUY W, 1986, EMBO J, V5, P2831, DOI 10.1002/j.1460-2075.1986.tb04576.x; SIDMAN C, 1981, CELL, V23, P379, DOI 10.1016/0092-8674(81)90133-1; SITIA R, 1988, MOL IMMUNOL, V25, P189, DOI 10.1016/0161-5890(88)90067-3; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; TARTAKOFF A, 1979, J CELL BIOL, V83, P284, DOI 10.1083/jcb.83.2.284; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; YOST CS, 1983, CELL, V34, P759	49	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24241	24247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447174				2022-12-27	WOS:A1992KA26300018
J	MONNING, U; KONIG, G; BANATI, RB; MECHLER, H; CZECH, C; GEHRMANN, J; SCHREITERGASSER, U; MASTERS, CL; BEYREUTHER, K				MONNING, U; KONIG, G; BANATI, RB; MECHLER, H; CZECH, C; GEHRMANN, J; SCHREITERGASSER, U; MASTERS, CL; BEYREUTHER, K			ALZHEIMER BETA-A4-AMYLOID PROTEIN-PRECURSOR IN IMMUNOCOMPETENT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PROTEIN; NEXIN-II; NERVOUS-SYSTEM; SECRETED FORM; IMMUNE-SYSTEM; DISEASE; MACROPHAGES; ADHESION; EXPRESSION; MICROGLIA	The mechanism of proteolytic breakdown of the betaA4-amyloid protein precursor (APP) has attracted much attention because of its relevance for Alzheimer's disease. Apart from the pathological role of APP in the amyloidogenesis, many efforts have been made to identify the functional significance of this widely expressed protein in various biological processes. Employing biochemical techniques, we demonstrate that APP is involved in the initiation of the immune response. Upon stimulation, it is expressed by the major functional types of T-lymphocytes, i.e. CD4+ and CD8+ cells. As was demonstrated for the CD4+ lymphoid cell line H9, APP is predominantly secreted. The remaining COOH-terminal fragments generated upon secretion were highly unstable. Of the APP produced by immunocompetent cells, considerable amounts were shown to be leukocyte-derived APP (L-APP). In addition, we were able to identify the KPI-containing L-APP isoform, L-APP733, as the major expressed L-APP isoform in immunocompetent cells, including rat microglial cells and astrocytes. The L-APP expression pattern of these cells showed high similarity. These findings seem to be indicative of an important function of APP within the immune system. Therefore, APP may be involved in various immunopathogenic conditions of the periphery and in the central nervous system.	MAX PLANCK INST PSYCHIAT,DEPT NEUROMORPHOL,W-8033 MARTINSRIED,GERMANY; CTR MENTAL HLTH,W-6700 MANNHEIM,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Max Planck Society; University of Melbourne	MONNING, U (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL HEIDELBERG,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY.			Czech, Christian/0000-0001-7746-0134				BANATI RB, 1991, J NEUROSCI RES, V30, P593, DOI 10.1002/jnr.490300402; BANATI RB, 1991, NEUROPATH APPL NEURO, V17, P223, DOI 10.1111/j.1365-2990.1991.tb00718.x; BAUER J, 1991, FEBS LETT, V282, P335, DOI 10.1016/0014-5793(91)80508-Z; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BUDKA H, 1989, ACTA NEUROPATHOL, V77, P225, DOI 10.1007/BF00687573; BUSH AI, 1990, J BIOL CHEM, V265, P15977; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Frei K., 1989, NEUROIMMUNE NETWORKS, P127; GAUDERNACK G, 1986, J IMMUNOL METHODS, V90, P179, DOI 10.1016/0022-1759(86)90074-8; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; INNOCENTI GM, 1983, DEV BRAIN RES, V11, P39, DOI 10.1016/0165-3806(83)90200-6; KAMETANI F, 1990, J NEUROL SCI, V97, P43, DOI 10.1016/0022-510X(90)90097-7; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; KONIG G, 1992, J BIOL CHEM, V267, P10804; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Masters CL, 1991, BRAIN PATHOL, V1, P226, DOI 10.1111/j.1750-3639.1991.tb00665.x; MCGEER PL, 1991, CAN J NEUROL SCI, V18, P376, DOI 10.1017/S0317167100032479; MCGEER PL, 1988, ACTA NEUROPATHOL, V76, P550, DOI 10.1007/BF00689592; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PODLISNY MB, 1990, BIOCHEM BIOPH RES CO, V167, P1094, DOI 10.1016/0006-291X(90)90635-Z; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1989, NATURE, V341, P546; WECKERLE H, 1986, TRENDS NEUROSCI, V9, P271; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887	54	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23950	23956						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429732				2022-12-27	WOS:A1992JZ23900078
J	MICHAN, C; ZHOU, LM; GALLEGOS, MT; TIMMIS, KN; RAMOS, JL				MICHAN, C; ZHOU, LM; GALLEGOS, MT; TIMMIS, KN; RAMOS, JL			IDENTIFICATION OF CRITICAL AMINO-TERMINAL REGIONS OF XYLS - THE POSITIVE REGULATOR ENCODED BY THE TOL PLASMID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							META-CLEAVAGE OPERON; ESCHERICHIA-COLI; PSEUDOMONAS-PUTIDA; NUCLEOTIDE-SEQUENCE; CONSTITUTIVE EXPRESSION; PATHWAY OPERON; PROTEIN; GENE; PROMOTER; DNA	The XylS protein is the positive regulator of the promoter controlling the meta-cleavage pathway (Pm) for catabolism of certain alkylbenzoates on the TOL plasmid of Pseudomonas. Transcription from Pm is mediated by XylS either in the presence of benzoate effectors or through XylS hyperproduction. Two regions of the NH2 terminus of XylS (residues 37-45) had been predicted to be involved in effector control of XylS transcriptional activation. Different methods were used to induce mutations in this region, including genetic selections (where Pm controlled a tetracycline resistance gene), bisulfite mutagenesis at a unique restriction site, and extensive oligonucleotide mutagenesis at residues 41 and 45. The mutants fell into four classes based on their phenotypes with respect to effector-mediated activation of a Pm-lacZ fusion: (a) effector profiles similar to wild type, (b) no Pm stimulation with benzoates, (c) altered effector specificity, and (d) higher basal Pm activities, in some cases including changes in effector specificity. In some mutants, higher basal Pm activity was apparently due to mutations that increased XylS stability. Substitutions at Arg-41 resulted in all four mutant phenotypes, indicating that this is a critical residue in XylS for effector stimulation of transcription activity.	CSIC, ESTAC EXPTL ZAIDIN, DEPT BIOQUIM VEGETAL, APTO 419, E-18080 GRANADA, SPAIN; GESELL BIOTECHNOL FORSCH GMBH, NATL RES CTR BIOTECHNOL, DIV MICROBIOL, W-3300 BRAUNSCHWEIG, GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Gesellschaft fur Biotechnologische Forschung mbH			Michan, Carmen/H-6325-2015; Gallegos, María-Trinidad M.T./K-6501-2014	Michan, Carmen/0000-0003-2921-0987; Gallegos, María-Trinidad M.T./0000-0001-7633-8807; Ramos, Juan L./0000-0002-8731-7435				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; BRUNELLE A, 1989, J MOL BIOL, V209, P607, DOI 10.1016/0022-2836(89)90598-6; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FRANKLIN FCH, 1981, P NATL ACAD SCI-BIOL, V78, P7458, DOI 10.1073/pnas.78.12.7458; GARMENDIA C, 1990, GENE, V88, P73, DOI 10.1016/0378-1119(90)90061-U; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARAYAMA S, 1990, MOL GEN GENET, V221, P113, DOI 10.1007/BF00280375; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; INOUYE S, 1986, GENE, V44, P235; INOUYE S, 1984, GENE, V29, P323; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MERMOD N, 1987, MOL GEN GENET, V207, P349, DOI 10.1007/BF00331600; MERMOD N, 1984, EMBO J, V3, P2461, DOI 10.1002/j.1460-2075.1984.tb02156.x; Miller J.H., 1972, EXPT MOL GENETICS; PABO CO, 1984, ANNU REV BIOCHEM, V53, P291; RAMOS JL, 1986, P NATL ACAD SCI USA, V83, P8467, DOI 10.1073/pnas.83.22.8467; RAMOS JL, 1990, NUCLEIC ACIDS RES, V18, P2149, DOI 10.1093/nar/18.8.2149; RAMOSGONZALEZ MI, 1992, J BACTERIOL, V174, P2978; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTLE D, 1978, P NATL ACAD SCI USA, V75, P2170, DOI 10.1073/pnas.75.5.2170; SPOONER RA, 1987, J BACTERIOL, V169, P3581, DOI 10.1128/jb.169.8.3581-3586.1987; SPOONER RA, 1986, J GEN MICROBIOL, V132, P1347; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOBIN JF, 1987, J MOL BIOL, V196, P789, DOI 10.1016/0022-2836(87)90405-0; TOBIN JF, 1990, J MOL BIOL, V211, P75, DOI 10.1016/0022-2836(90)90012-B; WEBSTER C, 1989, GENE, V83, P207, DOI 10.1016/0378-1119(89)90106-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU LM, 1990, J BACTERIOL, V172, P3707, DOI 10.1128/jb.172.7.3707-3710.1990	32	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22897	22901						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429638				2022-12-27	WOS:A1992JY16300031
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .2. EVALUATION OF MODEL CONSISTENCY AND ROBUSTNESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL SYSTEMS-THEORY	When kinetic models of complex biochemical systems are reconstructed from knowledge of the component reactions that have been characterized in vitro, or when values must be assumed for some of the parameters, errors are invariably encountered, and, as a consequence, the resulting model is frequently internally inconsistent. The simplest and most basic manifestations of such logical inconsistency are the failure of the model to exhibit a steady state or to yield a steady state that is in agreement with the actual steady state of the integrated system, or to yield a steady state that is dynamically stable. Models that are consistent may nonetheless be lacking in robustness, which is manifested as a pathological sensitivity to small changes in the values of their parameters. In this paper, we examine the current model of the tricarboxylic acid cycle in Dictyostelium discoideum (see Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22912-22918) with regard to these basic indicators of model quality. This may be viewed as a preliminary analysis; the object is to determine whether or not the model is reasonable and worthy of a more refined analysis and, if not, to diagnose the areas in need of modification before further analysis is undertaken. The results demonstrate that the current model of the tricarboxylic acid cycle is self-consistent and possesses a steady state that is in agreement with experimental evidence. However, the results also suggest that this model is not very robust. The high sensitivities of parameters influencing pyruvate metabolism indicate that the experimental characterization of these reactions might be fruit-fully re-examined. These high sensitivities lead us to predict that this model of the tricarboxylic acid cycle should be accurate only over a very narrow range in variation of the independent variables. This is verified by the results presented in the following paper (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267,22926-22933).	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-30054] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bode H. W., 1945, NETWORK ANAL FEEDBAC; CRUZ JB, 1973, SYSTEM SENSITIVITY A; IRVINE DH, 1991, CANONICAL NONLINEAR, P90; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; KELLY PJ, 1979, BIOCHEM J, V184, P581, DOI 10.1042/bj1840581; OKAMOTO M, 1984, BIOCHEMISTRY-US, V23, P1701, DOI 10.1021/bi00303a019; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU M. A., 1972, CURR TOP CELL REGUL, V6, P63, DOI DOI 10.1016/B978-0-12-152806-5.50010-2; SAVAGEAU MA, 1985, BIOMED BIOCHIM ACTA, V44, P875; SAVAGEAU MA, 1989, J THEOR BIOL, V141, P93, DOI 10.1016/S0022-5193(89)80011-6; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P370, DOI 10.1016/S0022-5193(69)80027-5; SAVAGEAU MA, 1971, ARCH BIOCHEM BIOPHYS, V145, P612, DOI 10.1016/S0003-9861(71)80021-8; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22926; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SORRIBAS A, 1989, MATH BIOSCI, V94, P161, DOI 10.1016/0025-5564(89)90064-3; VOIT EO, 1990, USERS GUIDE ESSYNS; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101	18	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22919	22925						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429642				2022-12-27	WOS:A1992JY16300035
J	MOSS, ML; PALMER, RE; KUZMIC, P; DUNLAP, BE; HENZEL, W; KOFRON, JL; MELLON, WS; ROYER, CA; RICH, DH				MOSS, ML; PALMER, RE; KUZMIC, P; DUNLAP, BE; HENZEL, W; KOFRON, JL; MELLON, WS; ROYER, CA; RICH, DH			IDENTIFICATION OF ACTIN AND HSP-70 AS CYCLOSPORINE-A BINDING-PROTEINS BY PHOTOAFFINITY-LABELING AND FLUORESCENCE DISPLACEMENT ASSAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPHILIN; FK-506; CALCINEURIN; ACTIVATION; PROFILIN	A novel family of cyclosporin A (CsA) binding proteins was identified by using the biologically active, radioiodinated photoaffinity probe [D-Lys-N(epsilon)-(4-azido-3-[I-125]iodophenyl)propionyl)]8-CsA. In addition to cyclophilin, proteins with molecular masses of 43 kDa and approximately 50-55 kDa were labeled in Jurkat extracts and bovine calf thymus. Sequence analysis of the 43-kDa protein purified from calf thymus and subsequent Western analysis of CsA affinity-purified material from Jurkat extracts identified the 43-kDa component as actin. [D-Lys-N(epsilon)-(5-dimethylamino-1-naphthalenesulfonyl)]8-CsA, a fluorescent analogue of CsA, was prepared and used to measure the binding constants of cyclosporin derivatives to actin by means of a new fluorescence displacement assay. [D-Lys-N(epsilon)-(5-dimethylamino-1-naphthalenesulfonyl)]8-CsA and [N(delta)-t-butoxycarbonyl diaminobutyryl)]8-CsA bind to bovine actin at physiologically relevant concentrations, with dissociation constants of 60 +/- 33 and 570 +/- 380 nM, respectively. Because the ATPase fragment of heat shock cognate 70 (HSC 70) is structurally related to actin, the yeast homologue SSA1 was tested and found to be radiolabeled by the cyclosporin A photoaffinity reagent. The binding constant for [D-Lys-N(epsilon)-(5-dimethylamino-1-naphthalenesulfonyl)]8-CsA to SSA1 was determined and is 53 +/- 48 nM. These results indicate that actin and the 70-kDa heat shock protein family contain a structurally related domain for binding of cyclosporin A-related peptides.	UNIV WISCONSIN,SCH PHARM,425 N CHARTER ST,MADISON,WI 53706; UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Royer, Catherine A/E-5266-2016	Royer, Catherine A/0000-0002-2670-3391; Henzel, William/0000-0003-2940-3797; Kuzmic, Petr/0000-0001-5250-8381	NIAID NIH HHS [AI24650] Funding Source: Medline; NIAMS NIH HHS [AR32007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032007] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBI JD, 1990, J MED CHEM, V33, P999, DOI 10.1021/jm00165a018; BOREL JF, 1983, TRANSPL P, V15, P2219; BOREL JF, 1989, PHARMACOL REV, V41, P423; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; COLUCCI WJ, 1990, J ORG CHEM, V55, P2895, DOI 10.1021/jo00296a061; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FLANAGAN WM, 1991, NATURE, V352, P802; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HENZEL W, 1987, J CHROMATOGR, V404, P4152; HESS AD, 1983, TRANSPLANT P 17, V1, P1419; INGLESE J, 1989, J MED CHEM, V32, P937, DOI 10.1021/jm00125a002; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOCK M, 1992, J AM CHEM SOC, V114, P2676; KOFRON JL, 1992, J AM CHEM SOC, V114, P2670, DOI 10.1021/ja00033a047; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KUZMIC P, 1992, ANAL BIOCHEM, V205, P65, DOI 10.1016/0003-2697(92)90579-V; LAL AA, 1985, J BIOL CHEM, V260, P132; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWNDES J, 1988, ANAL BIOCHEM, V80, P2849; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; PALASZYNSKI EW, 1991, CLIN BIOCHEM, V24, P63, DOI 10.1016/0009-9120(91)90252-A; RICH DH, 1990, PEPTIDES CHEM STRUCT, P49; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUOHO AE, 1984, MEMBRANES DETERGENTS, P119; SCOLARI F, 1987, TRANSPLANT P, V19, P1745; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SUNDELL CL, 1991, SCIENCE, V253, P1181; TUNG R, 1989, UCLA S MOL CELL BIOL, V86, P321; YEM AW, 1992, J BIOL CHEM, V267, P2868	35	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22054	22059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429556				2022-12-27	WOS:A1992JW71900014
J	ROGEL, A; HANSKI, E				ROGEL, A; HANSKI, E			DISTINCT STEPS IN THE PENETRATION OF ADENYLATE-CYCLASE TOXIN OF BORDETELLA-PERTUSSIS INTO SHEEP ERYTHROCYTES - TRANSLOCATION OF THE TOXIN ACROSS THE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; CALMODULIN-BINDING; IDENTIFICATION; PROTEINS; CALCIUM; PURIFICATION; DOMAINS; HLYA; EXPRESSION; ACTIVATION	Adenylate cyclase (AC) toxin from Bordetella pertussis penetrates eukaryotic cells and upon activation by calmodulin generates unregulated levels of intracellular cAMP. The process of toxin penetration into sheep erythrocytes was resolved into three consecutive steps including insertion, translocation, and intracellular cleavage. Insertion of the toxin into the cell membrane occurred over a wide temperature range (4-36-degrees-C). In contrast, translocation of the toxin, i.e. transfer of the NH2-terminal catalytically active fragment across the membrane, occurred only above 20-degrees-C and was highly temperature-dependent. While a single exposure of the toxin to Ca2+ was sufficient for its insertion into the plasma membrane, toxin translocation required exogenous Ca2+ at mM concentrations. Translocation was not affected by pretreatment of cells with trypsin, N-ethylmaleimide, and sodium carbonate at alkaline PH. The NH2-terminal fragment of the toxin was cleaved in the cell releasing the 45-kDa active AC into the cytosol. The cleavage was blocked by treatment of cells with N-ethylmaleimide. It is hypothesized that the COOH-terminal portion of the toxin creates in the membrane a channel through which the NH2-terminal fragment is translocated.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CLIN MICROBIOL,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628				ALLEN DW, 1979, BIOCHIM BIOPHYS ACTA, V551, P1, DOI 10.1016/0005-2736(79)90348-1; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BISSON R, 1987, TRENDS BIOCHEM SCI, V12, P181, DOI 10.1016/0968-0004(87)90087-9; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; BROWNLIE RM, 1988, MICROB PATHOGENESIS, V4, P335, DOI 10.1016/0882-4010(88)90061-7; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; CONFER DL, 1984, ADV CYCLIC NUCL PROT, V17, P183; CROALL DE, 1986, BIOCHIM BIOPHYS ACTA, V882, P287, DOI 10.1016/0304-4165(86)90250-3; EHRMANN IE, 1991, FEBS LETT, V1, P79; FARFEL Z, 1987, BIOCHEM J, V243, P153, DOI 10.1042/bj2430153; FRIEDMAN E, 1987, BIOCHEM J, V243, P145, DOI 10.1042/bj2430145; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1983, CLIN RES, V31, pA365; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1990, DHHS901164 US PHS DE, P13; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; LADANT D, 1988, J BIOL CHEM, V263, P2612; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; LUDWIG A, 1991, MOL GEN GENET, V193, P312; MASURE HR, 1988, J BIOL CHEM, V263, P6933; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; ROGEL A, 1988, J BIOL CHEM, V263, P13310; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SHATTUCK RL, 1985, BIOCHEMISTRY-US, V2, P6356; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	43	103	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22599	22605						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429610				2022-12-27	WOS:A1992JW71900095
J	MARRERO, PF; POULTER, CD; EDWARDS, PA				MARRERO, PF; POULTER, CD; EDWARDS, PA			EFFECTS OF SITE-DIRECTED MUTAGENESIS OF THE HIGHLY CONSERVED ASPARTATE RESIDUES IN DOMAIN-II OF FARNESYL DIPHOSPHATE SYNTHASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; CAROTENOID BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ESCHERICHIA-COLI; GENE; PRENYLTRANSFERASE; IDENTIFICATION; PURIFICATION	Comparison of the farnesyl diphosphate (FPP) synthase amino acid sequences from four species with amino acid sequences from the related enzymes hexaprenyl diphosphate synthase and geranylgeranyl diphosphate synthase show the presence of two aspartate rich highly conserved domains. The aspartate motif ((I, L, or V)XDDXXD) of the second of those domains has homology with at least 9 prenyl transfer enzymes that utilize an allylic prenyl diphosphate as one substrate. In order to investigate the role of this second aspartate-rich domain in rat FPP synthase, we mutated the first or third aspartate to glutamate, expressed the wild-type and mutant enzymes in Escherichia coli, and purified them to apparent homogeneity using a single chromatographic step. Approximately 12 mg of homogeneous protein was isolated from 120 mg of crude bacterial extract. The kinetic parameters of the purified wild-type recombinant FPP synthase containing the DDYLD motif were as follows: V(max) = 0.84 mumol/min/mg; GPP K(m) = 1.0 muM; isopentenyl diphosphate (IPP) K(m) = 2.7 muM. Substitution of glutamate for the first aspartate (EDYLD) decreased the V(max) by over 90-fold. The K(m) for IPP increased, whereas the K(m) for GPP remained the same in this D243E mutant. Substitution of glutamate for the third aspartate (DDYLE) did not result in altered enzyme kinetics in the D247E mutant. These results suggest that the first aspartate in the second domain is involved in the catalysis by FPP synthase.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Utah System of Higher Education; University of Utah			Marrero, Pedro F/I-1919-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GM 21326] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1989, J BIOL CHEM, V264, P635; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; ASHBY MN, 1960, J BIOL CHEM, V1, P286; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; EBERHARDT NL, 1975, J BIOL CHEM, V250, P863; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN DS, 1960, J LIPID RES, V1, P286; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOVICS FM, 1981, BIOCHEMISTRY-US, V20, P1893, DOI 10.1021/bi00510a027; LASKOVICS FM, 1979, J BIOL CHEM, V254, P9458; Maniatis T., 1982, MOL CLONING; PIDZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P127; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; POULTER CD, 1990, BIOCH CELL WALLS MEM, P169; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; YEH LS, 1977, ARCH BIOCHEM BIOPHYS, V183, P718, DOI 10.1016/0003-9861(77)90405-2	33	128	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21873	21878						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400496				2022-12-27	WOS:A1992JV01100094
J	SUGAI, M; CHEN, CH; WU, HC				SUGAI, M; CHEN, CH; WU, HC			STAPHYLOCOCCAL ADP-RIBOSYLTRANSFERASE-SENSITIVE SMALL G-PROTEIN IS INVOLVED IN BREFELDIN-A ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; PERIPHERAL MEMBRANE-PROTEIN; RHO-GENE-PRODUCT; GOLGI-APPARATUS; INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; COATED VESICLES; BETA-COP; CELLS; PURIFICATION	An early event in the action of brefeldin A (BFA) is the dissociation of beta-coat protein (beta-COP) from the Golgi membrane. We have recently shown that staphylococcal ADP-ribosyltransferase (epidermal cell differentiation inhibitor (EDIN)), which specifically modifies a small G protein, rho, mimics the action of BFA and disassembles the Golgi apparatus in Vero cells (Sugai, M., Chen, C-h., and Wu, H. C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8903-8907). Three independent BFA-resistant cell lines (BER-40 from Vero cells, PtK1, and MDCK) showed cross-resistance to EDIN regarding the release of the beta-COP from the Golgi membrane by EDIN or BFA. BFA as well as EDIN induced disassembly of the actin microfilaments in Vero cells, and they both failed to induce the disassembly of actin microfilaments in BER-40, PtK1, and MDCK cells. BFA inhibited protein secretion in Vero cells but not in BFA-resistant cell lines, whereas EDIN did not inhibit protein secretion in either Vero or other cell lines. AlF4- inhibited the effect of EDIN as well as that of BFA on the distribution of the beta-COP. These results suggest that an EDIN-sensitive rho protein together with trimeric and other small G protein(s) is involved in the regulation of the assembly of coated vesicles and vesicular transport in the Golgi apparatus.			WU, HC (corresponding author), UNIFORMED SERV UNIV HLTH SCI, DEPT MICROBIOL, BETHESDA, MD 20814 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028810] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28810] Funding Source: Medline; PHS HHS [R07317] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN C, 1992, IN PRESS EXP CELL RE; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; YOSHIDA T, 1990, EXP CELL RES, V190, P11, DOI 10.1016/0014-4827(90)90137-Y	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21297	21299						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400440				2022-12-27	WOS:A1992JV01100007
J	HAUSER, F; HOFFMANN, W				HAUSER, F; HOFFMANN, W			P-DOMAINS AS SHUFFLED CYSTEINE-RICH MODULES IN INTEGUMENTARY MUCIN C.1 (FIM-C.1) FROM XENOPUS-LAEVIS - POLYDISPERSITY AND GENETIC-POLYMORPHISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC SPASMOLYTIC POLYPEPTIDE; CANCER CELL-LINE; MOLECULAR-CLONING; EPITHELIAL MUCIN; O-GLYCOSYLATION; PROTEIN; PS2; RAT; EXPRESSION; SEQUENCE	A new frog integumentary mucin (FIM-C.1) has been discovered by molecular cloning. This mucin contains at least six typical P-domains as cysteine-rich modules. Shuffled P-domains have previously been detected in FIM-A.1, and they also form the basis of various P-domain peptides, which presumably have growth-modulating activities. Furthermore, FIM-C.1 contains at least three threonine-rich clusters, which consist of semi-repetitive cassettes. Various polydisperse transcripts have been characterized. They originate from two genes only and differ by deletions/insertions that are congruent with the semi-repetitive cassettes. Thus, polydispersities are probably generated by alternative splicing. Southern analysis revealed genetic polymorphism between different individuals. Furthermore, a specific antiserum was generated against a synthetic peptide deduced from the COOH-terminal end of FIM-C.1 and used for Western analysis.	MAX PLANCK INST PSYCHIAT,NEUROCHEM ABT,W-8033 MARTINSRIED,GERMANY	Max Planck Society			Hauser, Frank/M-2952-2014; Hoffmann, Werner/AAY-9182-2020	Hauser, Frank/0000-0001-5563-2345; Hoffmann, Werner/0000-0003-0031-9540				ALLEN A, 1983, TRENDS BIOCHEM SCI, V8, P169, DOI 10.1016/0968-0004(83)90166-4; BADALAMENT RA, 1992, J UROLOGY, V147, P482, DOI 10.1016/S0022-5347(17)37284-1; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARR MD, 1992, BIOCHEMISTRY-US, V31, P1998, DOI 10.1021/bi00122a015; COLLAWN JF, 1989, CURRENT PROTOCOLS MO; DEKKER J, 1991, BIOCHEM J, V277, P423, DOI 10.1042/bj2770423; DEKKER J, 1990, J BIOL CHEM, V265, P18116; DEVRIES AL, 1983, ANNU REV PHYSIOL, V45, P245, DOI 10.1146/annurev.ph.45.030183.001333; DOOLITTLE RF, 1986, URFS ORFS PRIMER ANA, P85; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; GALLY JA, 1992, P NATL ACAD SCI USA, V89, P3276, DOI 10.1073/pnas.89.8.3276; GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1991, J BIOL CHEM, V266, P22733; HAUSER F, 1991, J BIOL CHEM, V266, P21306; HAUSER F, 1992, J BIOL CHEM, V267, P14451; HAUSER F, 1990, EXP CELL RES, V189, P157, DOI 10.1016/0014-4827(90)90230-8; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KONIGSTORFER A, 1989, J BIOL CHEM, V264, P13689; KOURILSKY P, 1986, TRENDS GENET, V2, P60, DOI 10.1016/0168-9525(86)90179-4; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Neutra M., 1987, PHYSL GASTROINTESTIN, P975; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; PROBST JC, 1992, J BIOL CHEM, V267, P6310; ROSE K, 1989, BIOCHIM BIOPHYS ACTA, V998, P297, DOI 10.1016/0167-4838(89)90288-4; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SLOMIANY A, 1991, ARCH BIOCHEM BIOPHYS, V286, P383, DOI 10.1016/0003-9861(91)90055-N; SLOMIANY A, 1992, INT J BIOCHEM, V24, P1003, DOI 10.1016/0020-711X(92)90111-D; SPICER AP, 1991, J BIOL CHEM, V266, P15009; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; TORIBARA NW, 1991, AM REV RESPIR DIS, V88, P1005; WYSOCKI LJ, 1989, ANNU REV BIOCHEM, V58, P509; XU GQ, 1992, J BIOL CHEM, V267, P5401	45	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24620	24624						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447205				2022-12-27	WOS:A1992KA26300071
J	LEE, FJS; MOSS, J; VAUGHAN, M				LEE, FJS; MOSS, J; VAUGHAN, M			HUMAN AND GIARDIA ADP-RIBOSYLATION FACTORS (ARFS) COMPLEMENT ARF FUNCTION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; CHOLERA-TOXIN; ADENYLATE-CYCLASE; GENE DISRUPTION; MESSENGER-RNA; YEAST; GTP; EXPRESSION; ACTIVATORS; SEQUENCES	ADP-ribosylation factors (ARFs) are approximately 20-kDa guanine nucleotide-binding proteins that stimulate the ADP-ribosyltransferase activity of cholera toxin in vitro. ARFs are highly conserved, ubiquitously expressed in eukaryotic cells and appear to be involved in vesicular protein transport. The two yeast ARFs are >60% identical to mammalian ARFs and are essential for cell viability (Stearns, T., Kahn, R. A., Botstein, D., and Hoyt, M. A. (1990) Mol. Cell. Biol. 10, 6690-6699). Although the two yeast ARF proteins are 96% identical in amino acid sequence, the yeast ARF1 gene is constitutively expressed, whereas the ARF2 gene is repressed by glucose. Human ARF5 and ARF6 and a Giardia ARF differ substantially in size and amino acid identity from other mammalian and eukaryotic ARFs but will, as befits their designation, activate cholera toxin. Expression of human ARF5, ARF6, or Giardia ARF cDNA rescued the lethal yeast ARF double mutant (arf1, arf2). Strains rescued by human ARF5, ARF6, or Giardia ARF grew much more slowly than wild-type yeast or strains rescued with yeast ARF1. We infer from the impaired growth of these rescued strains that the homologous ARFs may have specific targeting information that does not interact effectively or efficiently with the yeast protein membrane trafficking system.			LEE, FJS (corresponding author), NHLBI,CELLULAR METAB LAB,RM 5N-307,BLDG 10,BETHESDA,MD 20892, USA.			LEE, FANG-JEN/0000-0002-2167-2426				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P2602; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1992, BIOTECHNIQUES, V12, P677; LEE FJS, IN PRESS BIOTECHNIQU; Maniatis T., 1982, MOL CLONING; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; REINER DS, 1990, EUR J CELL BIOL, V53, P142; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1986, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRECO DA, 1990, CURRENT PROTOCOL MOL; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772	33	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24441	24445						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447192				2022-12-27	WOS:A1992KA26300048
J	LU, Y; FLAHERTY, C; HENDRICKSON, W				LU, Y; FLAHERTY, C; HENDRICKSON, W			ARAC PROTEIN CONTACTS ASYMMETRIC SITES IN THE ESCHERICHIA-COLI ARAFGH PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARABINOSE OPERON; REGULATORY GENE; DNA RECOGNITION; RNA-POLYMERASE; BINDING; MUTAGENESIS; REPRESSION; MUTATIONS; OPERATOR; COMPLEX	AraC protein regulates the transcription of arabinose transport and catabolic operons in Escherichia coli through interaction with specific DNA sequences in the promoter regions of the operons. The interaction of AraC protein with two binding sites in the araFGH promoter was determined and compared to previously studied AraC binding sites in the araBAD promoter. Methylation and ethylation interference assays show that AraC protein binds along one side of the DNA to four adjacent major groove regions at each of the araFG1 and araFG2 sites. Mutations within any of the four regions of araFG1 greatly reduce protein binding in vitro. The promoter function in vivo is also greatly reduced, indicating that all four regions of the binding site are required. The chemical interference and genetic data, combined with the consensus sequence for AraC protein binding to ara promoters, support a binding motif in which two directly repeated units each span two adjacent turns of the DNA helix. The function of the two AraC binding sites was also examined. The proximal araFG1 site is required for promoter activation, whereas the distal araFG2 site has only a slight effect on the promoter activity.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIGMS NIH HHS [GM35917] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035917] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLKER M, 1989, EMBO J, V8, P2403, DOI 10.1002/j.1460-2075.1989.tb08370.x; BROWN CE, 1972, J BACTERIOL, V111, P606, DOI 10.1128/JB.111.2.606-613.1972; BRUNELLE A, 1989, J MOL BIOL, V209, P607, DOI 10.1016/0022-2836(89)90598-6; CASADABAN MJ, 1976, J MOL BIOL, V104, P557, DOI 10.1016/0022-2836(76)90120-0; CLARK AF, 1981, J BACTERIOL, V147, P920, DOI 10.1128/JB.147.3.920-924.1981; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ENGLESBE.E, 1965, J BACTERIOL, V90, P946, DOI 10.1128/JB.90.4.946-957.1965; ENGLESBERG E, 1962, J BACTERIOL, V84, P137, DOI 10.1128/JB.84.1.137-146.1962; FORST SA, 1989, J BACTERIOL, V171, P2949, DOI 10.1128/jb.171.6.2949-2955.1989; FRANCKLYN CS, 1988, J BIOL CHEM, V263, P4400; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; GREENBLATT J, 1971, NATURE-NEW BIOL, V233, P166, DOI 10.1038/newbio233166a0; HAHN S, 1984, J MOL BIOL, V180, P61, DOI 10.1016/0022-2836(84)90430-3; HENDRICKSON W, 1983, NUCLEIC ACIDS RES, V11, P1873, DOI 10.1093/nar/11.6.1873; HENDRICKSON W, 1990, J MOL BIOL, V215, P497, DOI 10.1016/S0022-2836(05)80163-9; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HENDRICKSON W, 1984, J MOL BIOL, V174, P611; HIRSH J, 1973, J MOL BIOL, V80, P433, DOI 10.1016/0022-2836(73)90414-2; HIRSH J, 1977, CELL, V11, P545, DOI 10.1016/0092-8674(77)90072-1; HO YS, 1988, GENE DEV, V2, P184, DOI 10.1101/gad.2.2.184; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HUO L, 1988, P NATL ACAD SCI USA, V85, P5444, DOI 10.1073/pnas.85.15.5444; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOLODRUBETZ D, 1981, J MOL BIOL, V151, P215, DOI 10.1016/0022-2836(81)90512-X; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE DH, 1989, P NATL ACAD SCI USA, V86, P476, DOI 10.1073/pnas.86.2.476; LEE N, 1987, P NATL ACAD SCI USA, V84, P8814, DOI 10.1073/pnas.84.24.8814; LEE NL, 1981, P NATL ACAD SCI-BIOL, V78, P752, DOI 10.1073/pnas.78.2.752; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MAKINO K, 1986, J MOL BIOL, V190, P37, DOI 10.1016/0022-2836(86)90073-2; Maniatis T., 1982, MOL CLONING; MARTIN K, 1986, P NATL ACAD SCI USA, V83, P3654, DOI 10.1073/pnas.83.11.3654; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; MCKENNEY K, 1982, GENE AMPLIFICATION A, P383; MILLER VL, 1987, CELL, V48, P271, DOI 10.1016/0092-8674(87)90430-2; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; OGDEN S, 1980, P NATL ACAD SCI-BIOL, V77, P3346, DOI 10.1073/pnas.77.6.3346; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; RAIBAUD O, 1989, MOL MICROBIOL, V3, P455; SCHLEIF R, 1987, ESCHERICHIA COLI SAL, P1473; Schleif R. F., 1981, PRACTICAL METHODS MO; SHORTLE D, 1978, P NATL ACAD SCI USA, V75, P2170, DOI 10.1073/pnas.75.5.2170; STEFFEN D, 1977, MOL GEN GENET, V157, P333, DOI 10.1007/BF00268671; STONER CM, 1983, J MOL BIOL, V170, P1049, DOI 10.1016/S0022-2836(83)80205-8; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TOMIZAWA J, 1985, CELL, V40, P527, DOI 10.1016/0092-8674(85)90201-6; WILCOX G, 1974, J BIOL CHEM, V249, P2946; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0	50	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24848	24857						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447222				2022-12-27	WOS:A1992KA26300103
J	WANG, H; DECHANT, E; KAVANAUGH, M; NORTH, RA; KABAT, D				WANG, H; DECHANT, E; KAVANAUGH, M; NORTH, RA; KABAT, D			EFFECTS OF ECOTROPIC MURINE RETROVIRUSES ON THE DUAL-FUNCTION CELL-SURFACE RECEPTOR BASIC-AMINO-ACID TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED ANIMAL-CELLS; PLASMA-MEMBRANE; ENVELOPE GLYCOPROTEIN; LEUKEMIA VIRUSES; GENE; PROTEIN; INTERFERENCE; MUTANT	The widely expressed Na+-independent transporter for basic amino acids (system y+) is the cell surface receptor (ecoR) for ecotropic host-range mouse retro-viruses (murine leukemia viruses (MuLVs)), a class of retroviruses that naturally infects only mice or rats. Accordingly, expression of mouse ecoR cDNA in mink CCL64 fibroblasts yields cells (CEN cells) that have y+ transporter activity above the endogenous background and that bind and are infected by ecotropic MuLVs. The effect of ecotropic MuLV infection on expression of y+ transporter was analyzed in mouse and in mink CEN fibroblasts. Chronic infection with ecotropic MuLVs caused 50-70% loss (down-modulation) of mouse y+ transporter in plasma membranes, detected as a reduced V(max) for uptake and outflow of L-[H-3]-arginine with no effect on K(m) values. Down-modulation was specific for mouse y+ and did not affect other transporters or the endogenous mink y+, suggesting that it results from specific interaction between mouse y+ and the viral envelope glycoprotein gp70 in the infected cells. Because this partial loss of mouse y+ from cell surfaces is insufficient to explain the complete interference to superinfection that occurs in cells chronically infected with ecotropic MuLVs, alternative explanations for interference are proposed. In contrast to the y+ down-modulation caused by chronic infection, binding of extracellular envelope glycoprotein gp70 at 37-degrees-C resulted in noncompetitive inhibition of amino acid import by mouse y+ but had no effect on export through this same transporter or on any transporter properties of mink y+. The effects of gp70 on transport kinetics suggest that it slows the rate-limiting step of the amino acid import cycle, a conformational transition of the empty transporter in which the binding site moves from the inside back to the outside of the cell, and that gp70 has no effect on the rate-limiting step of the amino acid export cycle. Infected cells retain substantial y+ activity. Moreover, the virus binding site on ecoR is in a mobile region that changes conformation during the amino acid transport cycle.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Oregon Health & Science University	WANG, H (corresponding author), OREGON HLTH SCI UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022		NATIONAL CANCER INSTITUTE [R01CA025810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003160, R37DA003160] Funding Source: NIH RePORTER; NCI NIH HHS [CA25810] Funding Source: Medline; NIDA NIH HHS [DA03160] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BOUR S, 1991, J VIROL, V65, P6387, DOI 10.1128/JVI.65.12.6387-6396.1991; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CLOYD MW, 1980, J EXP MED, V151, P542, DOI 10.1084/jem.151.3.542; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; DELWART EL, 1989, J VIROL, V63, P273, DOI 10.1128/JVI.63.1.273-280.1989; DEVES R, 1992, J PHYSIOL-LONDON, V446, pP409; DIXON WJ, 1951, INTRO STATISTICAL AN, P105; EVANS LH, 1977, J VIROL, V24, P865, DOI 10.1128/JVI.24.3.865-874.1977; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; HANDELIN BL, 1985, VIROLOGY, V140, P183, DOI 10.1016/0042-6822(85)90458-1; KABAT D, 1989, VIROLOGY, V171, P64; KAWAMURA I, 1989, J VIROL, V63, P3748, DOI 10.1128/JVI.63.9.3748-3754.1989; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLASSE PJ, 1992, AIDS, V6, P325, DOI 10.1097/00002030-199203000-00011; KLEINERMAN ES, 1987, J IMMUNOL, V139, P2329; KOZAK SL, 1990, J VIROL, V64, P3500, DOI 10.1128/JVI.64.7.3500-3508.1990; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RUTA M, 1980, J VIROL, V35, P844, DOI 10.1128/JVI.35.3.844-853.1980; SAHA K, 1992, J VIROL, V66, P2639, DOI 10.1128/JVI.66.5.2639-2646.1992; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; Stein WD, 1986, TRANSPORT DIFFUSION, P231; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; SZUREK PF, 1988, J VIROL, V62, P357, DOI 10.1128/JVI.62.1.357-360.1988; TINOCO I, 1978, PHYSICAL CHEM PRINCI, P294; Vile R G, 1991, Nature, V352, P666, DOI 10.1038/352666a0; WANG H, 1991, J VIROL, V65, P6468, DOI 10.1128/JVI.65.12.6468-6477.1991; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEISS R, 1984, RNA TUMOR VIRUSES, P209; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992	35	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23617	23624						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429703				2022-12-27	WOS:A1992JZ23900032
J	SRINIVASAN, AN; NAGINENI, CN; BHAT, SP				SRINIVASAN, AN; NAGINENI, CN; BHAT, SP			ALPHA-A-CRYSTALLIN IS EXPRESSED IN NONOCULAR TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LENS CRYSTALLINS; B-CRYSTALLIN; GENE; RAT; PROTEINS; CHAIN; CELLS; DIFFERENTIATION; ASSIGNMENT; SEQUENCE	Alpha-crystallin, the predominant structural protein of the ocular lens, has been and alphaB-crystallin. Of these two, alphaB-crystallin has been previously shown to be an extralenticular protein while alphaA-crystallin has been considered to be a lens-specific polypeptide. Using an antiserum directed against an N-terminal peptide of alpha-crystallin, we have detected a 20-kDa protein in various rat tissues including the brain, liver, lung, spleen, skin, and small intestine and in a number of established epithelial and fibroblast cell lines. PCR analysis of poly(A)-enriched RNA and Southern blot analysis indicated the presence of alphaA-crystallin mRNA sequences in different non-lenticular tissues. Among the non-ocular tissues examined, spleen showed the highest levels of alphaA-crystallin protein and mRNA. The identity of alphaA-crystallin sequences in the spleen was established by cloning and sequencing a polymerase chain reaction-amplified region of alphaA-crystallin mRNA. Sequences derived from spleen and eye revealed almost 100% identity at the nucleotide level. Interestingly, alphaA-crystallin and alphaB-crystallin seem to exist in an inverse quantitative relationship in the spleen and the heart, the two non-ocular tissues where they show highest concentrations, respectively. The known conserved evolution of alphaA-crystallin and the definitive demonstration of the non-ocular expression of this polypeptide suggest important non-crystallin functions for this protein.	UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,100 STEIN PLAZA,RM B118,LOS ANGELES,CA 90024; NIMH,IMMUNOL LAB,BETHESDA,MD 20892	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								AARTS HJM, 1989, EUR J BIOCHEM, V183, P31, DOI 10.1111/j.1432-1033.1989.tb14892.x; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Bloemendal H., 1981, MOL CELLULAR BIOL EY; BRAKENHOFF RH, 1990, HUM GENET, V85, P237, DOI 10.1007/BF00193203; CHIESA R, 1989, EXP EYE RES, V46, P199; CLAYTON RM, 1986, CURR TOP DEV BIOL, P137; COHEN LH, 1978, EUR J BIOCHEM, V89, P259, DOI 10.1111/j.1432-1033.1978.tb20921.x; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DEJONG WW, 1986, J MOL EVOL, V24, P121, DOI 10.1007/BF02099960; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; DOOLITTLE RF, 1988, NATURE, V336, P18, DOI 10.1038/336018a0; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; HAWKINS JW, 1987, HUM GENET, V76, P375, DOI 10.1007/BF00272448; HENDRIKS W, 1987, P NATL ACAD SCI USA, V84, P5320, DOI 10.1073/pnas.84.15.5320; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JOWARSKI CJ, 1991, J MOL EVOL, V33, P495; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; LEWIS GP, 1988, EXP EYE RES, V47, P839, DOI 10.1016/0014-4835(88)90067-X; MATSUO I, 1991, DEVELOPMENT, V113, P539; MCFALLNGAI MJ, 1985, EXP EYE RES, V41, P745, DOI 10.1016/0014-4835(85)90183-6; MOORMANN RJM, 1981, NUCLEIC ACIDS RES, V9, P4813, DOI 10.1093/nar/9.19.4813; MOSCONA AA, 1985, P NATL ACAD SCI USA, V82, P5570, DOI 10.1073/pnas.82.16.5570; NAGINENI CN, 1992, EXP EYE RES, V54, P193, DOI 10.1016/S0014-4835(05)80208-8; NAGINENI CN, 1988, DEV BIOL, V130, P402, DOI 10.1016/0012-1606(88)90446-0; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; NGO JT, 1989, GENOMICS, V5, P665, DOI 10.1016/0888-7543(89)90106-7; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5939, DOI 10.1073/pnas.79.19.5939; OKADA TS, 1983, CELL DIFFER DEV, V13, P177, DOI 10.1016/0045-6039(83)90087-8; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESINGER MJ, 1986, J CELL BIOL, V103, P321, DOI 10.1083/jcb.103.2.321; SKOW LC, 1985, IMMUNOGENETICS, V22, P291, DOI 10.1007/BF00404489; SLINGSBY C, 1985, TRENDS BIOCHEM SCI, V10, P281, DOI 10.1016/0968-0004(85)90088-X; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; THOMSON JA, 1985, EXP EYE RES, V40, P393, DOI 10.1016/0014-4835(85)90152-6; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; VERMORKEN AJM, 1978, NATURE, V271, P779, DOI 10.1038/271779a0; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	48	242	245	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23337	23341						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429679				2022-12-27	WOS:A1992JY16300096
J	BEARD, CA; SABORIO, JL; TEWARI, D; KRIEGLSTEIN, KG; HENSCHEN, AH; MANNING, JE				BEARD, CA; SABORIO, JL; TEWARI, D; KRIEGLSTEIN, KG; HENSCHEN, AH; MANNING, JE			EVIDENCE FOR 2 DISTINCT MAJOR PROTEIN-COMPONENTS, PAR-1 AND PAR-2, IN THE PARAFLAGELLAR ROD OF TRYPANOSOMA-CRUZI - COMPLETE NUCLEOTIDE-SEQUENCE OF PAR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; GENES; BRUCEI; DNA; TRANSCRIPTION; DEHYDROGENASE; LEISHMANIA; DROSOPHILA; CALMODULIN	The previously identified major protein components of the paraflagellar rod in Trypanosoma cruzi, PAR 1 and PAR 2, were analyzed to determine if they are distinct proteins or different conformations of a single polypeptide as has been suggested for other trypanosomatids. Amino acid sequence analysis showed PAR 1 and PAR 2 to be two distinct polypeptides. Antibodies specific against either PAR 1 or PAR 2 were shown to each react with a distinct band in Western blots of paraflagellar isolates of T. cruzi and other trypanosomatids if rigorous protease inhibition was used. The PAR 2 message was isolated and characterized by Northern blot and nucleic acid sequence analysis. Preliminary analysis of the PAR 2 gene indicates that PAR 2 is a member of a multigene family with all members residing on a single chromosome.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIAID NIH HHS [AI 18873] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018873] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; BEARD CA, 1985, MOL BIOCHEM PARASIT, V16, P199, DOI 10.1016/0166-6851(85)90087-8; BEARD CA, 1988, MOL BIOCHEM PARASIT, V28, P227, DOI 10.1016/0166-6851(88)90007-2; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; BRUN R, 1979, ACTA TROP, V36, P289; CHUNG SH, 1990, NUCLEIC ACIDS RES, V18, P4561, DOI 10.1093/nar/18.15.4561; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; DESOUZA W, 1980, J PARASITOL, V66, P229, DOI 10.2307/3280809; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; ENGMAN DM, 1987, MOL BIOCHEM PARASIT, V22, P115, DOI 10.1016/0166-6851(87)90041-7; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FOUTS DL, 1981, NUCLEIC ACIDS RES, V9, P7053, DOI 10.1093/nar/9.24.7053; GALLO JM, 1985, EUR J CELL BIOL, V36, P163; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; HYAMS JS, 1982, J CELL SCI, V55, P199; ISMACH R, 1989, J PROTOZOOL, V36, P617, DOI 10.1111/j.1550-7408.1989.tb01105.x; KENDALL G, 1990, EMBO J, V9, P2751, DOI 10.1002/j.1460-2075.1990.tb07462.x; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAR DE, 1984, MOL BIOCHEM PARASIT, V11, P119, DOI 10.1016/0166-6851(84)90059-8; LOTTSPEICH F, 1985, HIGH PERFORMANCE LIQ, P139; MAINGON R, 1988, EUR J BIOCHEM, V171, P285, DOI 10.1111/j.1432-1033.1988.tb13788.x; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; NELSON DJ, 1979, J BIOL CHEM, V254, P3959; ROZEK CE, 1983, CELL, V32, P23, DOI 10.1016/0092-8674(83)90493-2; SABORIO JL, 1989, J BIOL CHEM, V264, P4071; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLAEPPI K, 1989, J CELL BIOL, V109, P1695, DOI 10.1083/jcb.109.4.1695; SWINDLE J, 1988, EMBO J, V7, P1121, DOI 10.1002/j.1460-2075.1988.tb02921.x; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; WONG S, 1989, MOL BIOCHEM PARASIT, V37, P147, DOI 10.1016/0166-6851(89)90111-4; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	35	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21656	21662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400477				2022-12-27	WOS:A1992JV01100063
J	ELHAG, GA; BOURQUE, DP				ELHAG, GA; BOURQUE, DP			NUCLEAR-ENCODED TOBACCO CHLOROPLAST RIBOSOMAL PROTEIN-L24 - PROTEIN IDENTIFICATION, SEQUENCE-ANALYSIS OF CDNAS ENCODING ITS CYTOPLASMIC PRECURSOR, AND MESSENGER-RNA AND GENOMIC DNA ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SPC-OPERON; SACCHAROMYCES-CEREVISIAE; POLYADENYLATION SIGNALS; STRUCTURAL-ANALYSIS; GENE ORGANIZATION; TRANSIT PEPTIDE; PLANT GENES; EXPRESSION	Using a Nicotiana tabacum leaf cDNA library in the expression vector lambdagt11, two cDNAs encoding the full-length precursor polypeptide (M(r) 20,696) of tobacco chloroplast ribosomal protein L24 were identified and sequenced. These cDNAs encode a mature protein of 146 amino acids (M(r) 16,418) with a transit peptide of 41 amino acids (M(r) 4,278). The mature tobacco L24 protein has 78, 65, 45, and 35% sequence identity with ribosomal proteins L24 of pea, spinach, Bacillus subtilis, and Escherichia coli, respectively. The transit peptide of tobacco L24 is 54 and 57% identical with that of L24 chloroplast ribosomal proteins of pea and spinach, respectively. An expressed beta-galactosidase: L24 fusion protein, bound to nitrocellulose filters, was used as affinity matrix to purify monospecific antibody to L24 protein. Using this monospecific antibody, protein L24 was identified among high performance liquid chromatography (HPLC)-purified tobacco chloroplast ribosome 50 S subunit proteins. The predicted amino terminus of the mature L24 protein was confirmed by partial sequencing of the HPLC-purified L24 protein. Northern blot analysis revealed a single mRNA band (0.85-0.90 kilobase) corresponding in size to full-length L24 cDNA. The presence of multiple genes for L24 is suggested by Southern blot hybridization and characterization of two cDNAs for L24 which only differ in their 3'-noncoding sequences.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV ARIZONA,DEPT CELLULAR & MOLEC BIOL,TUCSON,AZ 85721	University of Arizona; University of Arizona					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026937] Funding Source: NIH RePORTER; NCRR NIH HHS [507RR07002] Funding Source: Medline; NIGMS NIH HHS [GM26937] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; BARTSCH M, 1982, P NATL ACAD SCI-BIOL, V79, P6871, DOI 10.1073/pnas.79.22.6871; BEDBROOK J, 1981, PLANT MOL BIOL NEWSL, V2, P24; BISANZSEYER C, 1992, PLANT MOL BIOL, V18, P337, DOI 10.1007/BF00034960; BONHAMSMITH PC, 1990, CHROMOSOMES EUKARYOT, P179; Bourque D. P., 1982, METHODS CHLOROPLAST, P617; BOZZONI I, 1981, NUCLEIC ACIDS RES, V9, P1069, DOI 10.1093/nar/9.5.1069; BRANLANT C, 1973, FEBS LETT, V35, P265, DOI 10.1016/0014-5793(73)80301-1; BRANLANT C, 1977, EUR J BIOCHEM, V74, P155, DOI 10.1111/j.1432-1033.1977.tb11377.x; CAPEL MS, 1982, J BIOL CHEM, V257, P7746; CAROL P, 1991, GENE, V103, P139, DOI 10.1016/0378-1119(91)90266-E; CERRETTI DP, 1988, J MOL BIOL, V204, P309, DOI 10.1016/0022-2836(88)90578-5; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dabbs ER, 1986, STRUCTURE FUNCTION G, P733; DEAN C, 1986, NUCLEIC ACIDS RES, V14, P2229, DOI 10.1093/nar/14.5.2229; DEAN D, 1981, NATURE, V289, P89, DOI 10.1038/289089a0; DHAESE P, 1983, EMBO J, V2, P419, DOI 10.1002/j.1460-2075.1983.tb01439.x; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; ELHAG GA, 1992, NUCLEIC ACIDS RES, V20, P689, DOI 10.1093/nar/20.4.689; ELHAG GA, 1992, BIOCHEMISTRY-US, V131, P6856; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIED HM, 1981, J BIOL CHEM, V256, P176; GANTT JS, 1990, J BIOL CHEM, V265, P2763; GANTT JS, 1986, MOL GEN GENET, V202, P186, DOI 10.1007/BF00331635; GANTT JS, 1988, CURR GENET, V14, P519, DOI 10.1007/BF00521278; GANTT JS, 1991, EMBO J, V10, P3073, DOI 10.1002/j.1460-2075.1991.tb07859.x; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; GIESE K, 1991, FEBS LETT, V288, P72, DOI 10.1016/0014-5793(91)81005-S; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEIDECKER G, 1986, ANNU REV PLANT PHYS, V37, P439, DOI 10.1146/annurev.arplant.37.1.439; HENKIN TM, 1989, NUCLEIC ACIDS RES, V17, P7469, DOI 10.1093/nar/17.18.7469; HEWLETT NG, 1986, METHOD ENZYMOL, V118, P201; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; HUNT AG, 1987, PLANT MOL BIOL, V8, P23, DOI 10.1007/BF00016431; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KEMP DJ, 1981, P NATL ACAD SCI-BIOL, V78, P4520, DOI 10.1073/pnas.78.7.4520; KROL A, 1978, NUCLEIC ACIDS RES, V5, P4933, DOI 10.1093/nar/5.12.4933; LEE KY, 1988, EMBO J, V7, P1241, DOI 10.1002/j.1460-2075.1988.tb02937.x; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P5027, DOI 10.1093/nar/13.14.5027; MARTIN W, 1990, CURR GENET, V18, P553, DOI 10.1007/BF00327027; MATTHEAKIS LC, 1988, J BACTERIOL, V170, P4484, DOI 10.1128/jb.170.10.4484-4492.1988; MATTHEAKIS LC, 1989, P NATL ACAD SCI USA, V886, P448; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; MOUNT DW, 1986, NUCLEIC ACIDS RES, V14, P443, DOI 10.1093/nar/14.1.443; NIERHAUS KH, 1980, RIBOSOMES STRUCTURE, P267; NISHI K, 1987, J BACTERIOL, V169, P4854, DOI 10.1128/jb.169.10.4854-4856.1987; NISHI K, 1986, EMBO J, V5, P1373, DOI 10.1002/j.1460-2075.1986.tb04369.x; NOWOTNY V, 1982, P NATL ACAD SCI-BIOL, V79, P7238, DOI 10.1073/pnas.79.23.7238; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PHUA SH, 1989, J BIOL CHEM, V264, P1968; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHMIDT RJ, 1984, J CELL BIOL, V98, P2011, DOI 10.1083/jcb.98.6.2011; SCHMIDT RJ, 1983, J CELL BIOL, V96, P1451, DOI 10.1083/jcb.96.5.1451; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; Silhavy T. J., 1984, EXPT GENE FUSIONS; SLOOF P, 1978, NUCLEIC ACIDS RES, V5, P3503, DOI 10.1093/nar/5.10.3503; SMITH HH, 1979, USDA TECH B, V1586, P1; SMITH HH, 1975, HDB GENETICS, V2, P281; SMOOKER PM, 1990, J BIOL CHEM, V265, P16699; SMOOKER PM, 1991, BIOCHIMIE, V73, P845, DOI 10.1016/0300-9084(91)90064-8; STERN DB, 1991, PLANT CELL, V3, P285; TAKAIWA F, 1982, EUR J BIOCHEM, V124, P13, DOI 10.1111/j.1432-1033.1982.tb05901.x; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; THOMPSON MD, 1992, PLANT MOL BIOL, V18, P931, DOI 10.1007/BF00019207; TOHDOH N, 1982, GENE, V17, P213, DOI 10.1016/0378-1119(82)90074-9; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WITTMANNLIEBOLD B, 1979, FEBS LETT, V108, P75, DOI 10.1016/0014-5793(79)81182-5; YATES JL, 1980, P NATL ACAD SCI-BIOL, V77, P1837, DOI 10.1073/pnas.77.4.1837; YOKOI F, 1990, FEBS LETT, V276, P88, DOI 10.1016/0014-5793(90)80514-J; ZHOU DX, 1989, MOL GEN GENET, V219, P204, DOI 10.1007/BF00261178	81	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21705	21711						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400480				2022-12-27	WOS:A1992JV01100070
J	KAMBOURIS, NG; BURKE, DJ; CREUTZ, CE				KAMBOURIS, NG; BURKE, DJ; CREUTZ, CE			CLONING AND CHARACTERIZATION OF A CYSTEINE PROTEINASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLEOMYCIN HYDROLASE; CATHEPSIN-B; THIOL PROTEASE; GENE-PRODUCT; YEAST; SEQUENCE; AMINOPEPTIDASE; PURIFICATION; DIFFERENTIATION; INVOLVEMENT	We have isolated a gene from Saccharomyces cerevisiae that encodes a protein homologous to the mammalian cysteine proteinase bleomycin hydrolase. Sequence comparison between the yeast and rabbit proteins indicates an amino acid identity of 41.5% over 277 residues and a similarity of 78.3% when conservative substitutions are included. The apparent mass of the yeast protein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis is 47 kDa, although sequence analysis indicates two potential initiator methionines that suggest calculated masses of either 51 or 55 kDa. The protein is nonessential in yeast as haploid mutants disrupted at several positions along the open reading frame remain viable. Furthermore, these mutants do not exhibit any readily observable growth defects under varying conditions of temperature, nutrients, osmotic strength, or exogenous bleomycin. However, the purified protein does exhibit marked hydrolytic activity toward the substrate arginine 4-methyl-7-coumarylamide (K(m) = 12.8 muM, V(max) = 2.56 mumol mg-1 h-1), and yeast cells engineered to express this protein at higher levels maintain increased resistance to bleomycin compared to wild-type cells. Because this protein represents the first example of a cysteine proteinase identified in yeast, we have named it Ycp1 (yeast cysteine proteinase).	UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040334] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33151] Funding Source: Medline; NIGMS NIH HHS [R29GM-40334] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1982, BIOCHEM BIOPH RES CO, V109, P341, DOI 10.1016/0006-291X(82)91726-0; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BENNETT JM, 1979, ANN INTERN MED, V90, P945, DOI 10.7326/0003-4819-90-6-945; Broach J. R., 1983, EXPT MANIPULATION GE, P83; Brocklehurst K., 1987, HYDROLYTIC ENZYMES, P39; CIGAN AM, 1987, GENE, V59, P1; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; CREUTZ CE, 1991, YEAST, V7, P229, DOI 10.1002/yea.320070305; DAVIS TN, 1987, METHOD ENZYMOL, V139, P248; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; DOCHERTY K, 1982, P NATL ACAD SCI-BIOL, V79, P4613, DOI 10.1073/pnas.79.15.4613; DUNN AD, 1991, J BIOL CHEM, V266, P20198; FILDERMAN AE, 1988, BIOCHEM PHARMACOL, V37, P1111, DOI 10.1016/0006-2952(88)90518-7; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; HAYASHI R, 1975, J BIOCHEM-TOKYO, V77, P1313; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; HOLLAND JP, 1983, J BIOL CHEM, V258, P5291; HUSAIN SS, 1969, BIOCHEM J, V114, P279, DOI 10.1042/bj1140279; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KREIGER TJ, 1991, J BIOL CHEM, V266, P8376; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETSINGER RH, 1986, NATURE, V320, P573, DOI 10.1038/320573a0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LAZO JS, 1988, MALIGNANT CELL RESIS; LOH YP, 1982, P NATL ACAD SCI-BIOL, V79, P108, DOI 10.1073/pnas.79.1.108; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; MOEHLE CM, 1989, J CELL BIOL, V108, P309, DOI 10.1083/jcb.108.2.309; MOORE CW, 1980, J ANTIBIOT, V33, P1369, DOI 10.7164/antibiotics.33.1369; NISHIMURA C, 1989, BIOCHEM BIOPH RES CO, V163, P788, DOI 10.1016/0006-291X(89)92291-2; NISHIMURA C, 1987, BIOCHEMISTRY-US, V26, P1574, DOI 10.1021/bi00380a013; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBTI SM, 1989, BIOCHEM PHARMACOL, V38, P141, DOI 10.1016/0006-2952(89)90160-3; SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003; SEBTI SM, 1987, BIOCHEMISTRY-US, V26, P4213, DOI 10.1021/bi00388a006; SEBTI SM, 1988, PHARMACOL THERAPEUT, V38, P321, DOI 10.1016/0163-7258(88)90009-5; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SHERMAN F, 1987, METHODS YEAST GENETI; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WIEDERANDERS B, 1991, FEBS LETT, V286, P189, DOI 10.1016/0014-5793(91)80971-5; WILLIAMS S, 1986, BIOTECHNIQUES, V4, P139; WOLF DH, 1978, FEBS LETT, V91, P59, DOI 10.1016/0014-5793(78)80017-9; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	53	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21570	21576						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400467				2022-12-27	WOS:A1992JV01100049
J	LEE, MJ; SANDIG, M; WANG, E				LEE, MJ; SANDIG, M; WANG, E			STATIN, A PROTEIN SPECIFICALLY PRESENT IN NONPROLIFERATING CELLS, IS A PHOSPHOPROTEIN AND FORMS A COMPLEX WITH A 45-KILODALTON SERINE THREONINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; PROLIFERATION; MARKER; FIBROBLASTS; EXPRESSION	The protein statin is found in nuclei of nonproliferating cells. Here we report that statin is a phosphoprotein, phosphorylated at serine residues in cultured cells. During immunoprecipitation with anti-statin (S44) antibody, a 45-kDa protein co-precipitates with the 57-kDa statin. In vitro kinase assays demonstrate that the S44 immunoprecipitates can phosphorylate, besides statin, immunoglobulins, enolase, and casein, at either serine or serine/threonine residues. Kinase assays with immunoprecipitated proteins performed on casein- or enolase-impregnated gels show that these substrates are phosphorylated by the 45-kDa (p45) protein. When the S44 immunoprecipitates from human cultured fibroblasts with different in vitro life-spans were compared, the p45 kinase activity was present only in young nongrowing and senescent cells, but not in young growing ones. In other cell cultures, the kinase is detected only in protein complexes precipitated from quiescent 3T3 cells, but not from cycling 3T3 cells or from transformed human glioma (U251-4) cells. Cell fractionation studies, indicating that the phosphorylating activity of S44 immunoprecipitates correlates both qualitatively and quantitatively with the amount of statin present, provide strong evidence that in vivo statin is specifically associated with the p45 kinase. These results suggest that the nonproliferation-specific nature of statin is indeed related to the phosphorylated property of this protein and maybe contributed by the associated kinase.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,BLOOMFIELD CTR RES AGING,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,DEPT ANAT,MONTREAL H3T 1E2,QUEBEC,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University					NIA NIH HHS [R01AG 07444] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007444] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEEMON K, 1978, J VIROL, V28, P552; BISSONNETTE R, 1990, J CELL SCI, V95, P247; CHING G, 1990, J CELL BIOL, V110, P255, DOI 10.1083/jcb.110.2.255; COOPER JA, 1984, J BIOL CHEM, V259, P7835; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; OLASHAW NE, 1983, REV BIOL RES AGING, V1, P225; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; SCHIPPER HM, 1990, BRAIN RES, V528, P250, DOI 10.1016/0006-8993(90)91665-4; SESTER U, 1989, EXP CELL RES, V182, P550, DOI 10.1016/0014-4827(89)90258-9; SWIM HE, 1957, AM J HYG, V66, P235, DOI 10.1093/oxfordjournals.aje.a119897; WANG E, 1985, J CELL BIOL, V100, P1466, DOI 10.1083/jcb.100.5.1466; WANG E, 1986, EXP CELL RES, V167, P135, DOI 10.1016/0014-4827(86)90211-9; WANG E, 1985, J HISTOCHEM CYTOCHEM, V33, P587, DOI 10.1177/33.6.3889143; WANG E, 1985, J CELL BIOL, V100, P545, DOI 10.1083/jcb.100.2.545; YOUNG F, 1990, NATURE, V347, P494	18	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21773	21781						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400486				2022-12-27	WOS:A1992JV01100080
J	FUJIINAKATA, T; ISHIMI, Y; OKUDA, A; KIKUCHI, A				FUJIINAKATA, T; ISHIMI, Y; OKUDA, A; KIKUCHI, A			FUNCTIONAL-ANALYSIS OF NUCLEOSOME ASSEMBLY PROTEIN, NAP-1 - THE NEGATIVELY CHARGED COOH-TERMINAL REGION IS NOT NECESSARY FOR THE INTRINSIC ASSEMBLY ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED HISTONES; XENOPUS-LAEVIS OOCYTES; MAMMALIAN-CELLS; CHROMATIN; DNA; INVITRO; COMPLEXES; ACID; H-3; IDENTIFICATION	A nucleosome assembly protein (NAP-1) of Saccharomyces cerevisiae facilitates the association of histones with DNA to form nucleosomes in vitro at physiological ionic conditions. The cloned gene was expressed in Escherichia coli using a T7 expression system, and the protein (417 amino acid residues) was purified by Mono Q column chromatography. Various deletion fragments of NAP-1 protein were also produced, and their nucleosome assembly activity was examined by supercoiling assay. The internal fragment containing the residues 43-365 was necessary and sufficient for the activity, and a long stretch of negatively charged region near the carboxyl terminus was dispensable. This minimal size fragment could form the 12 S NAP-1-histone complex as the whole protein could, whereas deleted fragments on either side could bind with core histones only to form aggregates.	MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN									ANNUNZIATO AT, 1982, J BIOL CHEM, V257, P8507; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CREMISI C, 1980, BIOCHEM BIOPH RES CO, V92, P1117, DOI 10.1016/0006-291X(80)90402-7; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; FELSENFELD G, 1978, NATURE, V271, P115, DOI 10.1038/271115a0; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; ISHIMI Y, 1985, CELL STRUCT FUNCT, V10, P373, DOI 10.1247/csf.10.373; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P16; JACKSON V, 1981, CELL, V23, P121, DOI 10.1016/0092-8674(81)90277-4; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; NELSON T, 1981, BIOCHEMISTRY-US, V20, P2594, DOI 10.1021/bi00512a035; OTTER R, 1983, METHOD ENZYMOL, V100, P171; SENSHU T, 1978, J BIOCHEM-TOKYO, V84, P985, DOI 10.1093/oxfordjournals.jbchem.a132213; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	29	137	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20980	20986						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400414				2022-12-27	WOS:A1992JT97800074
J	GILON, P; HENQUIN, JC				GILON, P; HENQUIN, JC			INFLUENCE OF MEMBRANE-POTENTIAL CHANGES ON CYTOPLASMIC CA2+ CONCENTRATION IN AN ELECTRICALLY EXCITABLE CELL, THE INSULIN-SECRETING PANCREATIC B-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-INDUCED OSCILLATIONS; BETA-CELLS; CALCIUM OSCILLATIONS; PYRIDINE-NUCLEOTIDES; RB-86+ FLUXES; ION CHANNELS; ISLETS; CA-2+; FLUORESCENCE; TOLBUTAMIDE	Glucose stimulation of insulin release involves metabolism of the sugar and elevation of cytoplasmic calcium (Ca2+i) in pancreatic B-cells. We compared the dynamic changes of metabolism (fluorescence of endogenous reduced pyridine nucleotides, NAD(P)H), membrane potential (intracellular microelectrodes), and Ca2+i (fura-2 technique), in intact mouse islets. Glucose (15 mM) sequentially triggered an increase in NAD(P)H fluorescence, a depolarization with electrical activity, and a rise in Ca2+i. The change in NAD(P)H was monophasic and regular, whereas the changes in membrane potential and Ca2+i were multiphasic, with steady-state regular oscillations of similar average frequencies (about 2.2/min). Digital image analysis revealed that Ca2+i oscillations were synchronous in all regions of the islets. Omission of extracellular Ca2+ abolished the rise in Ca2+i but not the increase in NAD(P)H. Both electrical and Ca2+i oscillations disappeared in low external Ca2+ (1 mM), and became larger but slower in high Ca2+ (10 mM). Sustained depolarization (by tolbutamide, arginine, or high K+) and hyperpolarization (by diazoxide) of B-cells caused sustained increases and decreases of Ca2+i, respectively. In conclusion, the changes in membrane potential induced by various secretagogues trigger synchronous changes in Ca2+i in all B-cells of the islets. The oscillatory pattern of the electrical and Ca2+i responses induced by glucose is not accompanied by and thus probably not due to similar oscillations of metabolism.	CATHOLIC UNIV LOUVAIN, FAC MED,UNITE DIABETOL & NUTR,UCL 5474, AVE HIPPOCRATE 54, B-1200 BRUSSELS, BELGIUM; UNIV SAARLAND, INST PHYSIOL, W-6650 HOMBURG, GERMANY	Universite Catholique Louvain; Saarland University								AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; Atwater I, 1980, Horm Metab Res Suppl, VSuppl 10, P100; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; CURRY DL, 1968, ENDOCRINOLOGY, V83, P572, DOI 10.1210/endo-83-3-572; DEAN PM, 1968, NATURE, V219, P389, DOI 10.1038/219389a0; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V151, P1299, DOI 10.1016/S0006-291X(88)80503-5; GRAPENGIESSER E, 1990, MOL PHARMACOL, V37, P461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; GYLFE E, 1988, J BIOL CHEM, V263, P13750; HENQUIN JC, 1990, DIABETES, V39, P1457, DOI 10.2337/diabetes.39.11.1457; HENQUIN JC, 1978, ENDOCRINOLOGY, V102, P723, DOI 10.1210/endo-102-3-723; HENQUIN JC, 1982, BIOCHEM PHARMACOL, V31, P1407, DOI 10.1016/0006-2952(82)90036-3; HENQUIN JC, 1981, AM J PHYSIOL, V240, pE245, DOI 10.1152/ajpendo.1981.240.3.E245; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HIRIART M, 1991, ENDOCRINOLOGY, V128, P3193, DOI 10.1210/endo-128-6-3193; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MEISSNER HP, 1990, METHOD ENZYMOL, V192, P235; MEISSNER HP, 1976, J PHYSIOL-PARIS, V72, P757; PANTEN U, 1986, DIABETOLOGIA, V29, P648, DOI 10.1007/BF00869265; PANTEN U, 1973, DIABETOLOGIA, V9, P477, DOI 10.1007/BF00461692; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RIBALET B, 1980, AM J PHYSIOL, V239, pC124, DOI 10.1152/ajpcell.1980.239.3.C124; SALOMON D, 1986, EXP CELL RES, V162, P507, DOI 10.1016/0014-4827(86)90354-X; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SHERMAN A, 1988, BIOPHYS J, V54, P411, DOI 10.1016/S0006-3495(88)82975-8; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; SORIA B, 1991, DIABETES, V40, P1069, DOI 10.2337/diabetes.40.8.1069; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; WANG JL, 1990, BIOCHEM BIOPH RES CO, V166, P813, DOI 10.1016/0006-291X(90)90882-N; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; YADA T, 1992, CELL CALCIUM, V13, P69, DOI 10.1016/0143-4160(92)90031-M	39	243	245	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20713	20720						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400388				2022-12-27	WOS:A1992JT97800033
J	NIKAIDO, K; AMES, GF				NIKAIDO, K; AMES, GF			PURIFICATION AND CHARACTERIZATION OF THE PERIPLASMIC LYSINE-BINDING, ARGININE-BINDING, ORNITHINE-BINDING PROTEIN (LAO) FROM SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE TRANSPORT COMPONENT; AMINO-ACID TRANSPORT; PRELIMINARY-X-RAY; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; SYSTEMS; CRYSTALLIZATION; MODEL; HISJ	The lysine-, arginine-, ornithine-binding protein (LAO) from Salmonella typhimurium has been purified to homogeneity and characterized. The dissociation constants (K(D)) were determined by equilibrium dialysis assay to be 14, 15, and 29 nM for L-arginine, L-lysine, and L-ornithine respectively. L-Histidine was found to be a relatively good ligand (K(D), 500 nM). Methods have been developed for the separation of liganded from unliganded LAO, for the estimation of bound ligand, and for unliganding LAO. Liganded and unliganded LAO are shown to have distinct UV spectra. The UV spectrum also varies with the nature of the substrate. Inhibition studies with substrate analogs yielded information useful for understanding the nature of the ligand-binding pocket.			NIKAIDO, K (corresponding author), UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R37DK012121, R01DK043747] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43747, DK12121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1989, J BIOL CHEM, V264, P15739; AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; AMES GFL, 1972, J BIOL CHEM, V247, P4309; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; EASLEY CW, 1969, BIOCHIM BIOPHYS ACTA, V175, P211, DOI 10.1016/0005-2795(69)90161-5; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; KANG CH, 1989, J MOL BIOL, V207, P643, DOI 10.1016/0022-2836(89)90475-0; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KERPPOLA RE, 1990, THESIS U CALIFORNIA; KUSTU SG, 1979, J BACTERIOL, V138, P218, DOI 10.1128/JB.138.1.218-234.1979; KUSTU SG, 1973, J BACTERIOL, V116, P107, DOI 10.1128/JB.116.1.107-113.1973; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVER JE, 1972, J BIOL CHEM, V247, P4317; LEVER JE, 1972, ANAL BIOCHEM, V50, P73, DOI 10.1016/0003-2697(72)90487-3; MAO B, 1982, J BIOL CHEM, V257, P1131; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miller J. H, 1972, EXPT MOL GENETICS; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PETRONILLI V, 1991, BIOPHYS  J, V59, P322; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; QUAY S, 1974, J BIOL CHEM, V249, P7011; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; ROSEN BP, 1973, J BIOL CHEM, V248, P1211; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SHIFRIN S, 1966, J BIOL CHEM, V241, P3424; SLETZINGER M, 1968, J MED CHEM, V11, P261, DOI 10.1021/jm00308a015; TRAKHANOV SD, 1989, J MOL BIOL, V207, P847, DOI 10.1016/0022-2836(89)90253-2; ZUKIN RS, 1986, BIOPHYS J, V49, P1229, DOI 10.1016/S0006-3495(86)83752-3	37	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20706	20712						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400387				2022-12-27	WOS:A1992JT97800032
J	BARTLETT, JD; LUETHY, JD; CARLSON, SG; SOLLOTT, SJ; HOLBROOK, NJ				BARTLETT, JD; LUETHY, JD; CARLSON, SG; SOLLOTT, SJ; HOLBROOK, NJ			CALCIUM IONOPHORE-A23187 INDUCES EXPRESSION OF THE GROWTH ARREST AND DNA DAMAGE INDUCIBLE CCAAT ENHANCER-BINDING PROTEIN (C/EBP)-RELATED GENE, GADD153 - CA2+ INCREASES TRANSCRIPTIONAL ACTIVITY AND MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; KINASE-C; INTRACELLULAR CALCIUM; HYDROGEN-PEROXIDE; MAMMALIAN-CELLS; LIVER NUCLEI; HEAT-SHOCK; ACTIVATION; TOXICITY; INHIBITOR	gadd153 is a CCAAT/enhancer-binding protein (C/EBP)-related gene whose expression is induced in response to growth arrest and DNA damage. This investigation explored the possibility that Ca2+ might play a role in regulating expression of gadd153. We have demonstrated that treatment of HeLa cells with the calcium ionophores A23187 and ionomycin leads to the induction of gadd153 mRNA. The induction was rapid; increases in mRNA were detected by 90 min of treatment, and near maximum levels were achieved within 5-h exposure to A23187. Elevated mRNA levels resulted from both an increase in the rate of gadd153 transcription and an increase in the stability of the gadd153 mRNA. The response was not dependent on protein kinase C nor was it coupled to c-fos expression. Buffering intracellular and extracellular Ca2+ by combined treatment with BAPTA-AM (acetoxymethyl ester form of bis(aminophenoxy)ethane N,N'-tetraacetic acid) and EGTA prevented the induction of gadd153 mRNA by A23187. In addition, these treatments prevented the induction of gadd153 mRNA in response to the DNA damaging agent methyl methanesulfonate. We conclude that intracellular Ca2+ plays a role in regulating gadd153 expression. More specifically, Ca2+ likely plays a role in the induction of gadd153 mRNA following DNA damage.	NIA, MOLEC GENET LAB, BALTIMORE, MD 21224 USA; NIA, CARDIOVASC SCI LAB, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Bartlett, John/L-9832-2017	Bartlett, John/0000-0003-2052-6299				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERTRAND R, 1991, BIOCHEM PHARMACOL, V42, P77, DOI 10.1016/0006-2952(91)90683-V; BOOBIS AR, 1990, BIOCHEM PHARMACOL, V39, P1277, DOI 10.1016/0006-2952(90)90003-4; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; Campbell A.K, 1983, INTRACELLULAR CALCIU; CANTONI O, 1989, EUR J BIOCHEM, V182, P209, DOI 10.1111/j.1432-1033.1989.tb14819.x; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; DYPBUKT JM, 1990, FREE RADICAL RES COM, V8, P347, DOI 10.3109/10715769009053368; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JONES DP, 1989, J BIOL CHEM, V264, P6398; KAINA B, 1989, NATO ADV SCI I A-LIF, V182, P149; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MCMAHON G, 1984, P NATL ACAD SCI-BIOL, V81, P7461, DOI 10.1073/pnas.81.23.7461; MOORE JP, 1986, J BIOL CHEM, V261, P8158; MORGAN JI, 1988, CELL CALCIUM, V9, P303, DOI 10.1016/0143-4160(88)90011-5; MUEL AS, 1986, J CELL PHYSIOL, V127, P167, DOI 10.1002/jcp.1041270120; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; POLLA BS, 1988, J CELL BIOL, V107, P373, DOI 10.1083/jcb.107.1.373; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WEINSTEIN IB, 1991, ENVIRON HEALTH PERSP, V93, P175, DOI 10.2307/3431186	39	128	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20465	20470						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400365				2022-12-27	WOS:A1992JR85800111
J	TROELSEN, JT; OLSEN, J; NOREN, O; SJOSTROM, H				TROELSEN, JT; OLSEN, J; NOREN, O; SJOSTROM, H			A NOVEL INTESTINAL TRANSFACTOR (NF-LPH1) INTERACTS WITH THE LACTASE-PHLORHIZIN HYDROLASE PROMOTER AND CO-VARIES WITH THE ENZYMATIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-TYPE HYPOLACTASIA; MESSENGER-RNA; INTRACELLULAR-TRANSPORT; LACTOSE-INTOLERANCE; EPITHELIAL-CELLS; BIOSYNTHESIS; TRANSCRIPTION; PROTEINS; EXPRESSION; RAT	The promoter of the pig lactase-phlorizin hydrolase was cloned and showed to be functional in the human intestinal cell line Caco2. The proximal promoter was analyzed for binding of nuclear proteins from small intestine and liver. DNase I footprinting and electrophoretic mobility shift assays show, that an intestinal nuclear factor (NF-LPH1) binds to a sequence (-40 to -54) located close to the TATA-box. Enterocytes from newborn pigs with high lactase activity contain high amounts of NF-LPH1, whereas enterocytes from adult pigs with low lactase activity contain low amounts of NF-LPH1. The liver does not contain lactase activity, and NF-LPH1 is not present in liver nuclear extracts in detectable amounts. This indicates that NF-LPH1 is involved in the decline of lactase at weaning and may be of importance for the molecular explanation of hypolactasia in humans. It was demonstrated by transfection of two different promoter-reporter gene constructs into Caco2 cells, that there are additional cis-element(s) in the region -142 to approximately -980, which are important for the transcription of the lactase-phlorizin hydrolase gene.			TROELSEN, JT (corresponding author), UNIV COPENHAGEN,PANUM INST,DEPT BIOCHEM C,BLEGDAMSVEJ 3,DK-2200 COPENHAGEN,DENMARK.		Troelsen, Jesper Thorvald T/B-6264-2013	Troelsen, Jesper Thorvald T/0000-0002-4177-3267; Olsen, Jorgen/0000-0003-1974-6446				AURICCHIO S, 1963, LANCET, V2, P324; BOLL W, 1991, AM J HUM GENET, V48, P889; BULLER HA, 1987, J BIOL CHEM, V262, P17206; BULLER HA, 1990, J BIOL CHEM, V265, P6978; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DAHLQVIST A, 1963, GASTROENTEROLOGY, V45, P488, DOI 10.1016/S0016-5085(19)34844-9; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; ESCHER JC, 1992, J CLIN INVEST, V89, P480, DOI 10.1172/JCI115609; FREUND JN, 1989, FEBS LETT, V248, P39, DOI 10.1016/0014-5793(89)80427-2; FREUND JN, 1990, CELL MOL BIOL, V36, P729; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; LACEY S W, 1991, Gastroenterology, V100, pA223; LLOYD M, 1992, J CLIN INVEST, V89, P524, DOI 10.1172/JCI115616; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; OLSEN J, 1991, J BIOL CHEM, V266, P18089; PINTO M, 1983, BIOL CELL, V47, P323; POTTER J, 1985, BIOCH GENET, V23, P432; SAHI T, 1973, LANCET, V2, P823; Sambrook J, 1989, MOL CLONING LABORATO; SANGILD PT, 1991, 5TH P INT S DIG PHYS, P73; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; Semenza G, 1989, METABOLIC BASIS INHE, V6th, P2975; SKOVBJERG H, 1980, GUT, V21, P360, DOI 10.1136/gut.21.5.360; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WITTE J, 1990, J CLIN INVEST, V86, P1338, DOI 10.1172/JCI114843; 1991, LANCET, V338, P663	38	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20407	20411						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400359				2022-12-27	WOS:A1992JR85800102
J	BURKE, J; PETTITT, JM; SCHACHTER, H; SARKAR, M; GLEESON, PA				BURKE, J; PETTITT, JM; SCHACHTER, H; SARKAR, M; GLEESON, PA			THE TRANSMEMBRANE AND FLANKING SEQUENCES OF BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-I SPECIFY MEDIAL-GOLGI LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; BREFELDIN-A CAUSES; ENDOPLASMIC-RETICULUM; RETENTION SIGNAL; IMMUNOELECTRON MICROSCOPY; MONOCLONAL-ANTIBODIES; SECRETORY PROTEINS; ESCHERICHIA-COLI; COMPLEX; APPARATUS	UDP-GlcNAc:alpha3-D-mannoside beta1,2-N-acetylglucosaminyltransferase I (GnTI) is an N(in)/C(out) (type II) membrane protein, localized in the medial-Golgi, that initiates the conversion of high mannose N-glycans to complex N-glycans. Anti-rabbit GnTI antibodies were generated using a purified, enzymatically active, bacterial recombinant fusion protein as immunogen. Rabbit GnTI was effectively retained in the Golgi complex of transfected COS-1 cells and murine L cells, as assessed by indirect immunofluorescence using the species-specific anti-GnTI antibodies; no surface expression of rabbit GnTI could be detected in the transfected cells. Rabbit GnTI, stably expressed in murine L cells, was localized by immunoperoxidase electron microscopy to the medial-cisternae of the Golgi stack. The role of the transmembrane domain of GnTI in Golgi localization was examined by generation of a hybrid construct containing the amino-terminal 31 amino acids of GnTI, corresponding to the 25-residue transmembrane (signal/anchor) domain and flanking hydrophilic sequences, fused with ovalbumin; this ovalbumin/GnTI hybrid molecule was retained in the Golgi complex of transfected COS cells and stably transfected murine L cells. No surface expression of ovalbumin/GnTI was detected. In contrast, ovalbumin fused to the equivalent domains of the human transferrin receptor, a type II cell-surface protein, was efficiently expressed on the cell surface of transfected cells. The ovalbumin/GnTI hybrid molecules in the transfected L cells were N-glycosylated, indicating an N(in)/C(out) membrane orientation, and were localized by immunoperoxidase electron microscopy to one or two cisternae of the medial-Golgi (90% of stained Golgi profiles showed medial-cisternae staining). These results show that a signal contained within the transmembrane domain and flanking residues of GnTI specifies medial-Golgi localization.	MONASH UNIV,ALFRED HOSP,SCH MED,DEPT PATHOL & IMMUNOL,COMMERCIAL RD,MELBOURNE,VIC 3181,AUSTRALIA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	Florey Institute of Neuroscience & Mental Health; Monash University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Gleeson, Paul/0000-0002-5336-6503				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLABE CG, 1980, J BIOL CHEM, V255, P9236; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOOY J, 1991, IMMUNOLOGY, V72, P418; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MCCARTHY K, 1963, LANCET, V2, P593; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTH J, 1982, J CELL BIOL, V92, P223; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SARKAR M, 1990, GLYCOCONJUGATE J, V7, P380; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TANG BL, 1992, J BIOL CHEM, V267, P10122; TASSIN AM, 1985, J CELL BIOL, V101, P630, DOI 10.1083/jcb.101.2.630; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; ULRICH JT, 1986, J BIOL CHEM, V261, P7975; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WASSLER M, 1987, BIOCHEM J, V247, P407, DOI 10.1042/bj2470407; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; ZAMBONI L, 1967, J CELL BIOL, V35, P148	59	80	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24433	24440						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447191				2022-12-27	WOS:A1992KA26300047
J	KUROKI, R; NITTA, K; YUTANI, K				KUROKI, R; NITTA, K; YUTANI, K			THERMODYNAMIC CHANGES IN THE BINDING OF CA2+ TO A MUTANT HUMAN LYSOZYME (D86/92) - ENTHALPY-ENTROPY COMPENSATION OBSERVED UPON CA2+ BINDING TO PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ALPHA-LACTALBUMIN; CALCIUM-BINDING; HEAT-CAPACITY; CRYSTAL-STRUCTURES; EQUINE LYSOZYME; CALMODULIN; STABILITY; PROPERTY; CA-2+; SITE	The thermodynamic change in the binding of Ca2+ to a mutant human lysozyme having an engineered Ca2+ binding site (Kuroki, R., Taniyama, Y., Seko, C., Nakamura, H., Kikuchi, M., and Ikehara, M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6903-6907) was analyzed by calorimetry and interpreted in terms of structural information obtained from x-ray crystallography. It was found that the enthalpic contribution for the Ca2+ binding reaction was small, driven primarily by entropy release (10 kcal/mol). This release of entropy was also observed in some organic chelators. Moreover, through the information of the tertiary structures of the apo- and holomutant lysozyme, it was confirmed that the entropy release (10 kcal/mol) upon the binding of Ca2+ arises primarily from the release of bound water molecules hydrating the free Ca2+. Previous studies of Ca2+ binding to proteins have involved significant changes in protein conformation. They can now be reevaluated to determine the contribution of conformational changes to Ca2+ binding. After removing the thermodynamic contribution of Ca2+ binding itself, it is found that upon the binding of Ca2+ the enthalpy change is negative but is almost compensated by the negative entropy change. The negative change in both enthalpy and entropy is characteristic of values seen in the thermodynamic change upon the folding of proteins.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; HOKKAIDO UNIV,FAC SCI,DEPT POLYMER SCI,SAPPORO,HOKKAIDO 060,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Hokkaido University; Osaka University								ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; COX JA, 1990, J BIOL CHEM, V265, P6633; DESMET J, 1989, J INORG BIOCHEM, V37, P185, DOI 10.1016/0162-0134(89)80041-8; DESMET J, 1987, BIOCHIM BIOPHYS ACTA, V912, P211, DOI 10.1016/0167-4838(87)90091-4; ELWELL ML, 1977, BIOCHIM BIOPHYS ACTA, V494, P367, DOI 10.1016/0005-2795(77)90166-0; ENDERBY JE, 1981, SCI PROG, V67, P553; HIRAOKA Y, 1980, BIOCHEM BIOPH RES CO, V95, P1098, DOI 10.1016/0006-291X(80)91585-5; IKEDASAITO M, 1983, J MOL BIOL, V170, P1009, DOI 10.1016/S0022-2836(83)80200-9; IMAIZUMI M, 1987, EUR J BIOCHEM, V262, P7693; INAKA K, 1991, J BIOL CHEM, V266, P12599; INAKA K, 1991, J BIOL CHEM, V266, P20666; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; KUROKI R, 1992, P NATL ACAD SCI USA, V89, P6803, DOI 10.1073/pnas.89.15.6803; LEVINE M, 1982, CLIN PSYCHOL REV, V2, P1, DOI 10.1016/0272-7358(82)90002-2; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; LUMRY R, 1986, FLUCTUATING ENZYME, P1; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; NITTA K, 1988, BIOL CHEM H-S, V369, P671, DOI 10.1515/bchm3.1988.369.2.671; NITTA K, 1987, FEBS LETT, V223, P405, DOI 10.1016/0014-5793(87)80328-9; PFIEL W, 1976, BIOPHYS CHEM, V4, P23; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; REID RE, 1981, J BIOL CHEM, V256, P2742; SEGAWA T, 1983, J BIOCHEM-TOKYO, V93, P1321, DOI 10.1093/oxfordjournals.jbchem.a134266; SOPHIANOPOULOS AJ, 1964, J BIOL CHEM, V239, P2516; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANOKURA M, 1990, EUR J BIOCHEM, V188, P23, DOI 10.1111/j.1432-1033.1990.tb15366.x; TANOKURA M, 1987, BIOCHEMISTRY-US, V26, P7668, DOI 10.1021/bi00398a020; TANOKURA M, 1984, J BIOCHEM-TOKYO, V95, P643, DOI 10.1093/oxfordjournals.jbchem.a134653; VANCEUNEBROECK JC, 1985, J BIOL CHEM, V260, P944; WANG MYR, 1979, J AM CHEM SOC, V101, P7394, DOI 10.1021/ja00518a044; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	33	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24297	24301						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447179				2022-12-27	WOS:A1992KA26300026
J	KONDO, T; INUI, H; KONISHI, F; INAGAMI, T				KONDO, T; INUI, H; KONISHI, F; INAGAMI, T			PHOSPHOLIPASE-D MIMICS PLATELET-DERIVED GROWTH-FACTOR AS A COMPETENCE FACTOR IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHORBOL ESTERS STIMULATE; SIGNAL TRANSDUCTION; DNA-SYNTHESIS; 12-O-TETRADECANOYLPHORBOL 13-ACETATE; PHOSPHATIDYLCHOLINE HYDROLYSIS; DIACYLGLYCEROL FORMATION; ENDOTHELIAL-CELLS; RAT FIBROBLASTS; 2ND MESSENGER	Recent studies have suggested the importance of phosphatidylcholine (PC) metabolism in growth factor-stimulated cells. In these cells, PC is hydrolyzed not only by PC-specific phospholipase C but also by phospholipase D (PLD). In the present investigation, we show that the simple addition of PC-hydrolyzing PLD from Streptomyces chromofuscus to the culture medium of vascular smooth muscle cells elicits choline release into the medium accompanied by the formation of phosphatidic acid. In the presence of ethanol, this treatment elicits a formation of phosphatidylethanol (PEt) at the expense of phosphatidic acid. Furthermore, we show here that exogenous addition of S. chromofuscus PLD induces a marked DNA synthesis in quiescent vascular smooth muscle cells. This DNA synthesis induced by S. chromofuscus PLD is, like platelet-derived growth factor (PDGF)-elicited DNA synthesis, largely dependent on the presence of insulin. In addition, S. chromofuscus PLD-induced PEt formation and DNA synthesis were not affected by protein kinase C down-regulation, whereas PDGF-induced PEt formation and DNA synthesis were significantly inhibited. These observations strongly suggest that protein kinase-dependent activation of PLD is involved in mitogenic signal in PDGF-stimulated cells and that exogenously added PLD acts as a competence factor in the same way as PDGF.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA	Vanderbilt University			Inui, Hiroshi/C-7721-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035323, P50HL014192] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35323, HL-14192] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CABOT MC, 1988, BIOCHIM BIOPHYS ACTA, V959, P46, DOI 10.1016/0005-2760(88)90148-8; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; FISHER DB, 1968, P NATL ACAD SCI USA, V60, P1396, DOI 10.1073/pnas.60.4.1396; GROVE RI, 1982, BIOCHIM BIOPHYS ACTA, V711, P272, DOI 10.1016/0005-2760(82)90036-4; GUSTAVSSON L, 1990, J NEUROCHEM, V54, P737, DOI 10.1111/j.1471-4159.1990.tb02313.x; GUY GR, 1982, CANCER RES, V42, P1980; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HII CST, 1989, FEBS LETT, V257, P35, DOI 10.1016/0014-5793(89)81779-X; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUANG CL, 1991, J BIOL CHEM, V266, P4045; IMAGAWA W, 1989, P NATL ACAD SCI USA, V86, P4122, DOI 10.1073/pnas.86.11.4122; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KONISHI F, 1991, BIOCHEM BIOPH RES CO, V179, P1070, DOI 10.1016/0006-291X(91)91928-6; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LISCOVITCH M, 1987, BIOCHEM J, V241, P81, DOI 10.1042/bj2410081; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARTIN TW, 1990, BIOCHIM BIOPHYS ACTA, V1053, P162, DOI 10.1016/0167-4889(90)90009-3; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MUELLER GC, 1988, P NATL ACAD SCI USA, V85, P9778, DOI 10.1073/pnas.85.24.9778; MUFSON RA, 1981, CARCINOGENESIS, V2, P1095; NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OGAWARA H, 1986, J ANTIBIOT, V39, P606, DOI 10.7164/antibiotics.39.606; OHTSUKA T, 1990, J BIOL CHEM, V265, P15418; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUTHERFORD RB, 1976, J CELL BIOL, V69, P196, DOI 10.1083/jcb.69.1.196; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WARDEN CH, 1984, BIOCHIM BIOPHYS ACTA, V792, P270, DOI 10.1016/0005-2760(84)90194-2; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202; YANG SF, 1967, J BIOL CHEM, V242, P477; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	50	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23609	23616						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429702				2022-12-27	WOS:A1992JZ23900031
J	HOMMA, T; AKAI, Y; BURNS, KD; HARRIS, RC				HOMMA, T; AKAI, Y; BURNS, KD; HARRIS, RC			ACTIVATION OF S6 KINASE BY REPEATED CYCLES OF STRETCHING AND RELAXATION IN RAT GLOMERULAR MESANGIAL CELLS - EVIDENCE FOR INVOLVEMENT OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PHORBOL ESTER STIMULATION; REDUCED RENAL MASS; ANGIOTENSIN-II; GROWTH-FACTOR; VENTRICULAR HYPERTROPHY; COLLAGEN PRODUCTION; HYPERTENSIVE RAT; CARDIAC-MUSCLE; PHOSPHORYLATION	Quiescent rat glomerular mesangial cells were exposed to repeated cycles of stretching and relaxation, and the effects on the rate of collagen production, proliferation, and S6 kinase activity were investigated. Stretch/relaxation induced increases in production of both collagen and non-collagenous proteins. Proliferation of mesangial cells was stimulated by stretch/relaxation and epidermal growth factor, but not by angiotensin II; however, administration of angiotensin II augmented stretch/relaxation-induced cell proliferation. Cytosolic S6 kinase activity was stimulated by stretch/relaxation, angiotensin II, epidermal growth factor, or phorbol 12-myristate 13-acetate. The increased S6 kinase activity was detectable within 30 min after initiation of stretch/relaxation and was blocked by either inhibitors of protein kinase C or prior down-regulation of protein kinase C following prolonged incubation with phorbol 12-myristate 13-acetate. Both translocation of protein kinase C from the cytosolic to the membrane fraction and phosphorylation of an endogenous 80-kDa protein were observed within 5 min of initiation of stretch/relaxation. These results demonstrate that in mesangial cells, mechanical factors alone can induce increases in production of collagen and non-collagenous proteins and in cell proliferation. The observation that stretch/relaxation induced stimulation of S6 kinase activity through protein kinase C-dependent mechanisms suggests that activation of protein kinase C may be a key event in initiating adaptive responses of mesangial cells to increased workload.	VANDERBILT UNIV, MED CTR,SCH MED,DEPT MED,DIV NEPHROL, MED CTR N S 3223, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT PEDIAT, NASHVILLE, TN 37232 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226, P50DK039261] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38226, DK39261] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLO SN, 1991, J BIOL CHEM, V266, P22003; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BRATTSAND G, 1989, SCAND J IMMUNOL, V30, P233, DOI 10.1111/j.1365-3083.1989.tb01206.x; BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; COOPER G, 1985, J CLIN INVEST, V75, P1403, DOI 10.1172/JCI111842; DZAU VJ, 1987, AM J CARDIOL, V60, pI99; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1987, HYPERTENSION, V9, P181; HARALSON MA, 1987, LAB INVEST, V57, P513; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HARRIS RC, 1992, AM J PHYSIOL, V263, pF127, DOI 10.1152/ajprenal.1992.263.1.F127; HARRIS RC, 1992, LAB INVEST, V66, P548; HARRIS RC, 1988, J CLIN INVEST, V82, P1028, DOI 10.1172/JCI113659; HARRIS RC, 1990, J AM SOC NEPHROL, V1, P719; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOMMA T, 1990, J BIOL CHEM, V265, P17613; HOMMA T, 1990, AM J PHYSIOL, V258, pC862, DOI 10.1152/ajpcell.1990.258.5.C862; HOSGETTER TH, 1981, AM J PHYSIOL, V241, pF85; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; HOSTETTER TH, 1986, KIDNEY INT, V30, P509, DOI 10.1038/ki.1986.215; HOVAKHOFER I, 1985, J BIOL CHEM, V260, P10314; KIRA Y, 1984, AM J PHYSIOL, V246, pC247, DOI 10.1152/ajpcell.1984.246.3.C247; KOLLROS PR, 1987, LAB INVEST, V56, P410; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KORECKY B, 1978, AM J PHYSIOL, V234, pH123, DOI 10.1152/ajpheart.1978.234.2.H123; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MEIER KE, 1990, J BIOL CHEM, V265, P4635; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MINAFRA IP, 1986, J SUBMICR CYTOL PATH, V18, P795; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1983, CIRC RES, V53, P491, DOI 10.1161/01.RES.53.4.491; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; PENNINGTON SR, 1990, J BIOL CHEM, V265, P2456; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; SAKAI T, 1987, ANAT EMBRYOL, V176, P373; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SCHWARTZ SM, 1984, PROG CARDIOVASC DIS, V26, P355, DOI 10.1016/0033-0620(84)90010-0; SCOTTBURDEN T, 1988, BIOCHEM BIOPH RES CO, V151, P583, DOI 10.1016/0006-291X(88)90634-1; SETOYAMA C, 1986, BIOCHEM BIOPH RES CO, V136, P1042, DOI 10.1016/0006-291X(86)90438-9; SIMONSON MS, 1989, EXP CELL RES, V184, P484, DOI 10.1016/0014-4827(89)90346-7; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUGDEN PH, 1991, BIOCHEM J, V273, P21, DOI 10.1042/bj2730021; SUMPIO BE, 1988, ARCH SURG-CHICAGO, V123, P1233; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; WILSON CB, 1986, KIDNEY, V2, P800; WOLF G, 1992, AM J PATHOL, V140, P95; ZAK R, 1974, CIRC RES, V35, P17; ZASLOFF M, 1971, P NATL ACAD SCI USA, V68, P3059, DOI 10.1073/pnas.68.12.3059; ZIERHUT W, 1989, CIRC RES, V65, P1417, DOI 10.1161/01.RES.65.5.1417	63	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23129	23135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429660				2022-12-27	WOS:A1992JY16300066
J	AKIYAMA, Y; KAMITANI, S; KUSUKAWA, N; ITO, K				AKIYAMA, Y; KAMITANI, S; KUSUKAWA, N; ITO, K			INVITRO CATALYSIS OF OXIDATIVE FOLDING OF DISULFIDE-BONDED PROTEINS BY THE ESCHERICHIA-COLI DSBA (PPFA) GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; MOLECULAR CHAPERONES; CELL; MEMBRANE; TRANSLOCATION; THIOREDOXIN; BIOGENESIS; SYSTEMS; YEAST	It was shown previously that the Escherichia coli gene ppfA (dsbA) encodes a periplasmic protein, and its inactivation leads to a deficiency in disulfide bond formation of envelope proteins (Kamitani, S., Akiyama, Y., and Ito, K. (1992) EMBO J. 11, 57-62; Bardwell, J. C. A., McGovern, K., and Beckwith, J. (1991) Cell 67, 581-589). The DsbA/PpfA protein was overproduced, purified, and examined for its activities in vitro. Its abundance in a wild-type cell was estimated to be about 850 molecules which probably exist as homodimers as suggested by size exclusion chromatography. Purified DsbA markedly stimulated disulfide bond formation of E. coli alkaline phosphatase, either in vitro synthesized or purified and denatured, as well as of reduced bovine ribonuclease A. The DsbA-catalyzed rapid disulfide bond formation occurred after a lag period which appeared to be determined by the redox state of the reaction mixture and concentration of DsbA. Inclusion of higher concentrations of oxidized glutathione or DsbA shortened the lag period. We propose that DsbA, which proved to directly catalyze disulfide bond formation, may also have a role in maintaining the bacterial periplasm oxidative.	TAKARA SHUZO BIOTECHNOL RES LABS, OTSU, SHIGA 52021, JAPAN		AKIYAMA, Y (corresponding author), KYOTO UNIV, INST VIRUS RES, KYOTO 60601, JAPAN.			Kamitani, Shigeki/0000-0002-1268-4652				AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BLACKBURN P, 1979, J BIOL CHEM, V254, P2484; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; INOUYE H, 1977, J MOL BIOL, V110, P75, DOI 10.1016/S0022-2836(77)80099-5; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; NEU HC, 1965, J BIOL CHEM, V240, P3685; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; STOCK JB, 1977, J BIOL CHEM, V252, P7850; TACHIKAWA H, 1991, J BIOCHEM, V110, P306, DOI 10.1093/oxfordjournals.jbchem.a123576; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WIENHUES U, 1992, BIOESSAYS, V14, P17, DOI 10.1002/bies.950140105; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	33	116	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22440	22445						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429594				2022-12-27	WOS:A1992JW71900071
J	RUF, W; MILES, DJ; REHEMTULLA, A; EDGINGTON, TS				RUF, W; MILES, DJ; REHEMTULLA, A; EDGINGTON, TS			TISSUE FACTOR RESIDUES 157-167 ARE REQUIRED FOR EFFICIENT PROTEOLYTIC ACTIVATION OF FACTOR-X AND FACTOR-VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; BLOOD-COAGULATION; EXTRINSIC PATHWAY; FACTOR-IX; RECOGNITION; RECEPTOR; BINDING; SITES; SUPERFAMILY; INITIATION	The cell surface receptor tissue factor (TF) initiates coagulation by supporting the proteolytic activation of factors X and IX as well as VII to active serine proteases. Architectural similarity of TF to the cytokine receptor family suggests a strand-loop-strand structure for TF residues 151-174. Site-directed Ala exchanges in the predicted surface loop demonstrated that residues Tyr157, Lys159, Ser163, Gly164, Lys165, and Lys166 are important for function. Addition of side chain atoms at the Ser162 position decreased function, whereas the Ala exchange was tolerated. The dysfunctional mutants bound VII with high affinity and fully supported the catalysis of small peptidyl substrates by the mutant TF . VIIa complex. Lys159 --> Ala substitution was compatible with efficient activation of factor X, whereas the Tyr157 --> Ala exchange and mutations in the carboxyl aspect of the predicted loop resulted in diminished activation of factor X. The specific plasma procoagulant activity of all functionally deficient mutants increased 7- to 200-fold upon the supplementation of VIIa suggesting that TF residues 157-167 also provide important interactions that accelerate the activation of VII to VIIa. These data are consistent with assignment of the TF 157-167 region as contributing to protein substrate recognition and cleavage by the TF . VIIa complex.			RUF, W (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS BS, 1991, GENE, V98, P265, DOI 10.1016/0378-1119(91)90184-D; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; Creighton T. E., 1984, PROTEINS; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; JANIN J, 1990, J BIOL CHEM, V265, P16027; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; REHEMTULLA A, 1992, BIOCHEM J, V282, P737, DOI 10.1042/bj2820737; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	26	72	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22206	22210						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429572				2022-12-27	WOS:A1992JW71900035
J	HILL, JR; MORRIS, DR				HILL, JR; MORRIS, DR			CELL-SPECIFIC TRANSLATION OF S-ADENOSYLMETHIONINE DECARBOXYLASE MESSENGER-RNA - REGULATION BY THE 5' TRANSCRIPT LEADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED LYMPHOCYTES; ORNITHINE DECARBOXYLASE; EUKARYOTIC RIBOSOMES; ENZYMATIC AMPLIFICATION; INCREASED EFFICIENCY; PROTEIN-SYNTHESIS; RIBONUCLEIC-ACID; SARCOMA VIRUS; INITIATION; SEQUENCE	The mRNA encoding S-adenosylmethionine decarboxylase (AdoMetDC) has an unusual distribution in polysomes from cells of T lymphocyte origin. It associates predominantly with monosomes and small polysomes with none located in the preribosomal or ribonucleoprotein pool. In sharp contrast, it associates broadly with larger polysomes in several nonlymphoid cell lines, including fibroblasts and the adrenal carcinoma line, Y1. The AdoMetDC 5'-transcript leader (5'-TL) is highly conserved between human and bovine mRNAs. It has a length of about 330 nucleotides and contains a 21-nucleotide upstream open reading frame (uORF) approximately 14 nucleotides downstream of the cap site. The AdoMetDC 5'-TL, when used to replace the 5'-TL of the human growth hormone gene in a chimeric expression construct, causes a suppressed polysomal distribution of the chimeric mRNA identical to that of the endogenous AdoMetDC mRNA in the T cell line, Jurkat. In contrast, mRNA encoded by the same chimeric construct, when expressed in Y1 cells, mimics the broad polysomal distribution of the endogenous AdoMetDC mRNA. Mutations that remove the uORF, or prevent its initiation, abolish the translational suppression in T cells, establishing that the uORF is a negative element that modulates the cell-specific polysomal distribution of AdoMetDC mRNA.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Morris, David/G-4503-2011		NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266, P01GM042508] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NIGMS NIH HHS [GM42508, GM07266-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, NEW BIOL, V3, P511; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO MC, 1990, EUR J BIOCHEM, V187, P361, DOI 10.1111/j.1432-1033.1990.tb15313.x; Davis R H, 1988, Adv Exp Med Biol, V250, P627; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; FILLINGA.RH, 1973, BIOCHEMISTRY-US, V12, P4479, DOI 10.1021/bi00746a028; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; GODEFROYCOLBURN T, 1981, J BIOL CHEM, V256, P1762; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREENE JM, 1988, CURRENT PROTOCOLS; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LODISH HF, 1971, J BIOL CHEM, V246, P7131; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MACH M, 1986, J BIOL CHEM, V261, P1697; Maniatis T., 1982, MOL CLONING; Marton LJ, 1987, INHIB POLYAM METABOL, P79; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; MORRIS DR, 1981, MED BIOL, V59, P314; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PELLETIER J, 1969, NATURE, V244, P682; POSO H, 1982, BIOCHEMISTRY-US, V21, P3116, DOI 10.1021/bi00256a013; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEYFRIED CE, 1982, BIOCHIM BIOPHYS ACTA, V716, P169, DOI 10.1016/0304-4165(82)90265-3; SHIRAHATA A, 1986, J BIOL CHEM, V261, P3833; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STIMAC E, 1987, J CELL PHYSIOL, V133, P590, DOI 10.1002/jcp.1041330323; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TAHARA SM, 1991, J BIOL CHEM, V266, P3594; THEIL EC, 1990, J BIOL CHEM, V265, P4771; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x; WHITE MW, 1988, PHYSL POLYAMINES, P331; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176; YAMAMOTO T, 1980, CELL, V22, P787, DOI 10.1016/0092-8674(80)90555-3; [No title captured]	61	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21886	21893						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400498				2022-12-27	WOS:A1992JV01100096
J	MILSTONE, DS; SHAW, SK; PARKER, KL; SZYF, M; SEIDMAN, JG				MILSTONE, DS; SHAW, SK; PARKER, KL; SZYF, M; SEIDMAN, JG			AN ELEMENT REGULATING ADRENAL-SPECIFIC STEROID 21-HYDROXYLASE EXPRESSION IS LOCATED WITHIN THE SLP GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-LIMITED PROTEIN; BETA-GLOBIN GENE; TRANSGENIC MICE; COMPLEMENT COMPONENT; MURINE 21-HYDROXYLASE; SEQUENCE-ANALYSIS; 4TH COMPONENT; TUMOR-CELLS; HIGH-LEVEL; ENHANCER	In this report we demonstrate that a transcriptional regulatory element for one gene lies within a second, seemingly unrelated gene. Specifically, the 3' portion of the murine sex-limited protein (slp) gene, located within the class III region of the major histocompatibility complex, contains an element that regulates expression of the linked steroid 21-hydroxylase gene. A 4.2-kilobase (kb) major histocompatibility complex region, located between -2.2 and -6.4 kb upstream of 21OH-A, is required for expression of a chloramphenicol acetyltransferase reporter gene in transgenic mice. Two short regions of DNA, located between -5.3 and -6.0 kb, stimulate chloramphenicol acetyltransferase expression in Y1 adrenocortical tumor cells, and both of these active regions lie within the slp gene. A 21-base pair sequence, which is required for activity of the most 3' region, does not contain any of over 100 previously identified transcriptional regulatory elements. This juxtaposition of structural and regulatory elements of otherwise unrelated genes suggests a mechanism by which the evolutionarily conserved genetic linkage of 21OH-A and slp (or the homologous complement component C4) might provide a selective advantage. Analogous genetic arrangements may explain other examples of conserved linkage of disparate genes.	HARVARD UNIV,SCH MED,DEPT GENET,HOWARD HUGHES MED INST,BOSTON,MA 02115; DUKE UNIV,MED CTR,DEPT MED,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University	MILSTONE, DS (corresponding author), BRIGHAM & WOMENS HOSP,LONGWOOD MED RES CTR,DEPT PATHOL,DIV VASC RES,221 LONGWOOD AVE,BOSTON,MA 02115, USA.			Shaw, Sunil/0000-0001-9701-6065	NHLBI NIH HHS [R01-HL19874] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAPLIN DD, 1985, IMMUNOL REV, V87, P61, DOI 10.1111/j.1600-065X.1985.tb01145.x; CHAPLIN DD, 1983, P NATL ACAD SCI-BIOL, V80, P6947, DOI 10.1073/pnas.80.22.6947; CHAPLIN DD, 1986, P NATL ACAD SCI USA, V83, P9601, DOI 10.1073/pnas.83.24.9601; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENTON RG, 1988, SCIENCE, V241, P1089, DOI 10.1126/science.2970670; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HANDLER JD, 1989, ENDOCR RES, V15, P31, DOI 10.1080/07435808909039087; HANDLER JD, 1988, J BIOL CHEM, V263, P13068; HEMENWAY C, 1986, NUCLEIC ACIDS RES, V14, P2539, DOI 10.1093/nar/14.6.2539; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; KAWAGUCHI H, 1990, EUR J IMMUNOL, V20, P739, DOI 10.1002/eji.1830200405; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; OGATA RT, 1991, J IMMUNOL, V147, P2756; OGATA RT, 1989, J BIOL CHEM, V264, P16565; OGATA RT, 1985, J IMMUNOL, V135, P4239; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PARKER KL, 1986, J BIOL CHEM, V261, P5353; PARKER KL, 1985, P NATL ACAD SCI USA, V82, P7860, DOI 10.1073/pnas.82.23.7860; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RICE DA, 1990, J BIOL CHEM, V265, P8052; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SCHREFFLER DC, 1982, HISTOCOMPATIBILITY A, P110; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STAVENHAGEN JB, 1988, CELL, V55, P247, DOI 10.1016/0092-8674(88)90047-5; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WHITE PC, 1985, P NATL ACAD SCI USA, V82, P1089, DOI 10.1073/pnas.82.4.1089; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	39	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21924	21927						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400503				2022-12-27	WOS:A1992JV01100102
J	CHUNG, AB; STEPIEN, G; HARAGUCHI, Y; LI, K; WALLACE, DC				CHUNG, AB; STEPIEN, G; HARAGUCHI, Y; LI, K; WALLACE, DC			TRANSCRIPTIONAL CONTROL OF NUCLEAR GENES FOR THE MITOCHONDRIAL MUSCLE ADP/ATP TRANSLOCATOR AND THE ATP SYNTHASE BETA-SUBUNIT - MULTIPLE FACTORS INTERACT WITH THE OXBOX REBOX PROMOTER SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDASE; THYROID-HORMONE; DNA-BINDING; SKELETAL-MUSCLE; DIMERIZATION DOMAINS; CONTRACTILE ACTIVITY; REGULATORY PROTEINS; MOUSE MUSCLE; EXPRESSION; RECEPTOR	The OXBOX promoter regions of the genes for the muscle-specific adenine nucleotide translocator (ANT1) and the beta subunit of the ATPsynthase (ATPsynbeta) have been implicated in the increased transcription of these nuclear-encoded oxidative phosphorylation (OXPHOS) genes in heart and skeletal muscle. DNA binding, electrophoretic mobility shift (gel-shift) assays now reveal that the OXBOX region has two unique but overlapping elements, the 13-base pair (bp) OXBOX and an 8-bp REBOX. The OXBOX binding factors are found only in myogenic cell lines, whereas the REBOX factors are ubiquitous. Methylation interference experiments have defined the boundaries of the OXBOX and REBOX elements, confirmed that the OXBOX factors are muscle-specific, and shown that the OXBOX and REBOX factors do not bind concurrently. The binding of the REBOX factors was found to be sensitive to NADH and thyroxine, suggesting that it may modulate OXPHOS gene expression in response to environmental and hormonal changes. Hence, the OXBOX/REBOX complex provides one mechanism by which mammalian energy metabolism can be adapted to developmental and environmental demands.	EMORY UNIV,SCH MED,DEPT GENET & MOLEC MED,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL45572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBOC D, 1990, TRANSPLANTATION, V50, P751; DUBOC D, 1988, J APPL PHYSIOL, V64, P2692, DOI 10.1152/jappl.1988.64.6.2692; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; HOCHACHKA PW, 1991, P NATL ACAD SCI USA, V88, P5764, DOI 10.1073/pnas.88.13.5764; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JOSTE V, 1989, EUR J BIOCHEM, V184, P255, DOI 10.1111/j.1432-1033.1989.tb15015.x; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; KOUZARIDES T, 1991, ONCOGENE, V6, P195; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; LLOUBES R, 1988, J MOL BIOL, V204, P1049, DOI 10.1016/0022-2836(88)90062-9; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MOSKALUK CA, 1989, VIROLOGY, V169, P236, DOI 10.1016/0042-6822(89)90062-7; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; MUTVEI A, 1989, EUR J BIOCHEM, V180, P235, DOI 10.1111/j.1432-1033.1989.tb14638.x; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SCHROTH GP, 1991, NUCLEIC ACIDS RES, V19, P511, DOI 10.1093/nar/19.3.511; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SCHULTHEISS HP, 1984, EUR J BIOCHEM, V143, P599, DOI 10.1111/j.1432-1033.1984.tb08412.x; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TOVAR K, 1989, NUCLEIC ACIDS RES, V17, P6515, DOI 10.1093/nar/17.16.6515; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931; ZHANG XK, 1991, J BIOL CHEM, V266, P8248; ZHANG XK, 1991, NEW BIOL, V3, P169; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	57	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21154	21161						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400425				2022-12-27	WOS:A1992JT97800099
J	ZIERLER, M; CHRISTY, RJ; HUANG, RCC				ZIERLER, M; CHRISTY, RJ; HUANG, RCC			NUCLEAR-PROTEIN BINDING TO THE 5' ENHANCER REGION OF THE INTRACISTERNAL-A PARTICLE LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; BLOTTING PROCEDURE; GENE; DNA; PROMOTER; IDENTIFICATION; EXPRESSION; SEQUENCES	The interactions of nuclear proteins from embryonal carcinoma cells (PCC3) with the long terminal repeats (LTRs) of murine intracisternal A particle (IAP) genes were studied. Two protein-DNA complexes were detected between PCC3 nuclear extract and IAP LTRs in a gel mobility shift assay. An additional complex was observed when enriched fractions from a heparin-agarose column were used as the source of proteins. Two regions within the LTR of IAP 81 were identified as the sites of protein interaction by DNase I protection. One region encompasses 43 nucleotides within the U3 region at the 5' end of LTR 81. The other covers a 78 base pair region lying within 100 nucleotides upstream from the transcription initiation site. Studies using constructs containing intact or deleted versions of the LTR fused to the bacterial chloramphenicol acetyltransferase gene indicated that the absence of the 5' 47 base pairs reduced the level of chloramphenicol acetyltransferase transcription to 20% of that driven by the entire LTR. Southwestern analysis of PCC3 nuclear extracts and column fractions revealed that a 28,000- and a 46,000-dalton protein were the major species that interact with the 5' end of IAP LTR 81.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA048263] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA48263] Funding Source: Medline; NIGMS NIH HHS [5 T33 GM07231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPEL MC, 1978, DIABETOLOGIA, V15, P327, DOI 10.1007/BF02573827; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BENOIST C, 1980, NUCLEIC ACIDS RES, V8, P127, DOI 10.1093/nar/8.1.127; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURT DW, 1984, NUCLEIC ACIDS RES, V12, P8579, DOI 10.1093/nar/12.22.8579; CALARCO PG, 1969, J EXP ZOOL, V171, P253, DOI 10.1002/jez.1401710303; CANIVET M, 1980, EUR J CANCER, V16, P609, DOI 10.1016/0014-2964(80)90200-5; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; DEOCA FH, 1983, J VIROL, V46, P307, DOI 10.1128/JVI.46.1.307-310.1983; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; ENDERS AC, 1965, PREIMPLANTATION STAG, P29; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FALZON M, 1988, J VIROL, V62, P4070, DOI 10.1128/JVI.62.11.4070-4077.1988; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM DI, 1976, NEUROPATH APPL NEURO, V2, P451, DOI 10.1111/j.1365-2990.1976.tb00519.x; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HOWE CC, 1986, MOL CELL BIOL, V6, P150, DOI 10.1128/MCB.6.1.150; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITER EH, 1984, AM J PATHOL, V114, P46; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; Maxam A M, 1980, Methods Enzymol, V65, P499; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MORGAN RA, 1987, DEV GENET, V8, P125, DOI 10.1002/dvg.1020080302; MORGAN RA, 1988, DEVELOPMENT, V102, P23; MOSHIER JA, 1985, INTERRELATIONSHIP AG, P101; ONO M, 1980, CELL, V21, P465, DOI 10.1016/0092-8674(80)90483-3; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SHENONG GLC, 1982, J VIROL, V42, P411, DOI 10.1128/JVI.42.2.411-421.1982; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WIVEL NA, 1971, INT J CANCER, V7, P167, DOI 10.1002/ijc.2910070119; WUJCIK KM, 1984, J VIROL, V52, P29, DOI 10.1128/JVI.52.1.29-36.1984	45	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21200	21206						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400431				2022-12-27	WOS:A1992JT97800106
J	KOVELMAN, R; ROEDER, RG				KOVELMAN, R; ROEDER, RG			PURIFICATION AND CHARACTERIZATION OF 2 FORMS OF HUMAN TRANSCRIPTION FACTOR-IIIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; TATA-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; FACTOR-TAU; FUNCTIONAL COMPONENTS; U6 GENE; ADENOVIRUS; ACTIVATION; DNA	We showed previously that HeLa cell nuclear extracts contain two forms of transcription factor IIIC (TFIIIC) that formed chromatographically distinct TFIIIC-promoter complexes (Hoeffler, W. K., Kovelman, R., and Roeder, R. G. (1988) Cell 53, 907-920). One of these forms, the upper-band form, correlated with TFIIIC transcriptional activity, whereas the lower-band form bound to the VA1 promoter but supported little or no transcriptional activity. Using both transcription and DNA-binding assays, we have now purified both the upper-band form and the lower-band form of TFIIIC to near-homogeneity. The upper-band form is composed of five polypeptides with estimated sizes of 220, 110, 102, 90, and 63 kDa. The largest of these polypeptides can be cross-linked to the VA1 promoter. The lower-band form has a polypeptide structure similar to that of the upper-band form except for the absence or modification of the 110-kDa subunit. Direct assays show that the lower-band form is indeed transcriptionally inactive at all stages of purification, even when assayed with an unfractionated, heat-treated nuclear extract as a complementation system. This inactivity does not result from altered DNA-binding properties; instead, we suggest that the alteration of one of the subunits of TFIIIC renders it unable to interact productively with a downstream component of the transcription complex.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,1230 YORK AVE,BOX 268,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA042567, T32CA009673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007233] Funding Source: NIH RePORTER; NCI NIH HHS [9T32 CA09673, 5R35 CA42567] Funding Source: Medline; NIAID NIH HHS [AI07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BERGER SL, 1985, NUCLEIC ACIDS RES, V13, P1413, DOI 10.1093/nar/13.4.1413; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK ME, 1990, MOL CELL BIOL, V10, P5106, DOI 10.1128/MCB.10.10.5106; CROMLISHJA, 1989, J BIOL CHEM, V264, P18100; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FUHRMAN SA, 1984, J BIOL CHEM, V259, P1934; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GAYNOR RB, 1985, SCIENCE, V230, P447, DOI 10.1126/science.2996135; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KOVELMAN R, 1992, THESIS ROCKEFELLER U, V6; KOVELMAN R, 1989, UCLA U CALIF LOS ANG, V95, P151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MARTIN PL, 1985, THESIS WASHINGTON U; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PAVRIN JD, 1992, CELL, V68, P1135; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REYNOLDS WF, 1992, MOL CELL BIOL, V12, P946, DOI 10.1128/MCB.12.3.946; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUET A, 1984, EMBO J, V3, P343, DOI 10.1002/j.1460-2075.1984.tb01809.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHNEIDER HR, 1989, NUCLEIC ACIDS RES, V17, P5003, DOI 10.1093/nar/17.13.5003; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SETZER DR, 1985, J BIOL CHEM, V260, P2483; STILLMAN DJ, 1985, J MOL BIOL, V185, P451, DOI 10.1016/0022-2836(85)90417-6; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WOLFFE AP, 1988, EMBO J, V7, P1071, DOI 10.1002/j.1460-2075.1988.tb02915.x; WU C, 1988, GENETIC ENG, V10, P67; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726	59	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24446	24456						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447193				2022-12-27	WOS:A1992KA26300049
J	MAEMURA, K; FUKUDA, M				MAEMURA, K; FUKUDA, M			POLY-N-ACETYLLACTOSAMINYL O-GLYCANS ATTACHED TO LEUKOSIALIN - THE PRESENCE OF SIALYL LEX STRUCTURES IN O-GLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; HUMAN-GRANULOCYTES; CELL-ADHESION; BIOSYNTHESIS; GLYCOPROTEINS; CARBOHYDRATE; LACTOSAMINOGLYCAN; GLYCOSYLATION; PURIFICATION; GLYCOLIPIDS	Poly-N-acetyllactosamine extension has been found in O-glycans in addition to N-glycans and glycosphingolipids. Attempts were made in HL-60 and K562 cells to determine the amount of poly-N-acetyllactosaminyl O-glycans in the major sialoglycoprotein, leukosialin. Leukosialin was immunoprecipitated from [H-3]glucosamine-labeled HL-60 and K562 cells. Glycopeptides were prepared by Pronase digestion, and O-glycan-containing glycopeptides were isolated by affinity chromatography using Jacalin-agarose. The glycopeptides bound to Jacalin-agarose and those unbound were treated with alkaline borohydride, and the released O-glycans were fractionated by Bio-Gel P-4 filtration. Sequential glycosidase digestion of the O-glycans, with or without pretreatment by fucosidase or neuraminidase, revealed the following conclusions. 1) Leukosialin from HL-60 cells contains about 1-2 poly-N-acetyllactosaminyl O-glycan chains/molecule. 2) About 50% of these poly-N-acetyllactosaminyl O-glycans contain sialyl Le(x) termini, NeuNAcalpha2-->3Galbeta1-->4(Fucalpha1-->3)GlcNAcbeta1-->R. The amount of sialyl Le(x) structure in leukosialin is roughly equivalent to that on cell surfaces of HL-60 cells. 3) Leukosialin from K562 cells, on the other hand, contains no detectable amount of poly-N-acetyllactosaminyl O-glycans. 4) The presence of poly-N-acetyllactosamine in O-glycans is dependent on the core 2 beta1,6-N-acetylglucosaminyl transferase. 5) Jacalin-agarose binds to sialylated small oligosaccharides such as NeuNAcalpha2-->3Galbeta1-->3(NeuNAcalpha2-->6) GalNAc but not the hexasaccharide NeuNAcalpha2-->3Galbeta1-->3(NeuNAcalpha2-->3Galbeta1-->4GlcNAcbeta1-->6) GalNAc. These results indicate that the formation of polylactosaminyl O-glycans and sialyl Le(x) structure in O-glycans is dependent on the core 2 formation.			MAEMURA, K (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037, USA.				NATIONAL CANCER INSTITUTE [R01CA033895, R01CA048737] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA33895, CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEYER TA, 1979, J BIOL CHEM, V254, P2531; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HO MK, 1983, J BIOL CHEM, V258, P636; HORTIN GL, 1990, ANAL BIOCHEM, V191, P262, DOI 10.1016/0003-2697(90)90217-W; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE N, 1990, J BIOL CHEM, V265, P20476; LEE YC, 1972, J BIOL CHEM, V247, P5733; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MEINDL P, 1969, H-S Z PHYSIOL CHEM, V350, P1088, DOI 10.1515/bchm2.1969.350.2.1088; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1988, J BIOL CHEM, V263, P15146; SAITOH O, 1992, CANCER RES, V267, P5700; SANO M, 1992, J BIOL CHEM, V267, P1522; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	40	171	185	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24379	24386						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447188				2022-12-27	WOS:A1992KA26300039
J	TEMIZER, DH; YOSHIZUMI, M; PERRELLA, MA; SUSANNI, EE; QUERTERMOUS, T; LEE, ME				TEMIZER, DH; YOSHIZUMI, M; PERRELLA, MA; SUSANNI, EE; QUERTERMOUS, T; LEE, ME			INDUCTION OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR MESSENGER-RNA BY PHORBOL ESTER AND ANGIOTENSIN-II IN RAT AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VASCULAR INJURY; GENE-EXPRESSION; MYC-GENE; ATHEROSCLEROSIS; PROLIFERATION; ATHEROGENESIS; HETEROGENEITY; TRANSCRIPTION; PATHOGENESIS	To determine whether the gene encoding the recently identified heparin-binding epidermal growth factor-like growth factor (HB-EGF), a potent smooth muscle cell (SMC) mitogen of macrophage origin, is transcribed and regulated in vascular SMC, we isolated cDNA clones encoding rat HB-EGF from a macrophage library. Using the rat HB-EGF cDNA as a probe for RNA blot analysis, we detected low levels of HB-EGF mRNA in rat aortic SMC in culture. However, 20 nM 12-O-tetradecanoylphorbol-13-acetate (TPA) and 10(-6) M angiotensin II (AII) induced a marked increase in HB-EGF mRNA levels in rat aortic SMC (11- and 4.6-fold, respectively) that was both dose- and time-dependent. In response to TPA and AII, HB-EGF mRNA levels increased rapidly, peaked at 2 h, and returned to base line at 7 h. This effect of AII on HB-EGF induction was specific, as evidenced by the fact that it could be completely blocked by the AII antagonist saralasin. This is the first demonstration that HB-EGF is transcribed and regulated in SMC. The inducible transcription of this potent SMC mitogen gene in vascular SMC suggests that HB-EGF may have an important autocrine role in the proliferation of SMC in vascular diseases such as atherosclerosis and hypertension.	HARVARD UNIV, SCH PUBL HLTH,CARDIOVASC BIOL LABS,BLDG 2, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, CARDIAC UNIT, BOSTON, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Quertermous, Thomas/0000-0002-7645-9067				BARATH P, 1990, AM J PATHOL, V137, P503; BERK BC, 1987, J BIOL CHEM, V262, P5057; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LEE ME, 1991, J BIOL CHEM, V266, P16188; LIBBY P, 1991, LAB INVEST, V64, P5; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MOYER CF, 1991, AM J PATHOL, V138, P951; MUNRO JM, 1988, LAB INVEST, V58, P249; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OWENS GK, 1987, HYPERTENSION, V9, P178, DOI 10.1161/01.HYP.9.2.178; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; [No title captured]	36	110	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24892	24896						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447224				2022-12-27	WOS:A1992KA26300109
J	WARIISHI, H; VALLI, K; GOLD, MH				WARIISHI, H; VALLI, K; GOLD, MH			MANGANESE(II) OXIDATION BY MANGANESE PEROXIDASE FROM THE BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM - KINETIC MECHANISM AND ROLE OF CHELATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN-DEGRADING BASIDIOMYCETE; EXTRACELLULAR HEME ENZYME; SPECTRAL CHARACTERIZATION; HORSERADISH-PEROXIDASE; OXIDIZED STATES; MODEL COMPOUNDS; DEGRADATION; BIODEGRADATION; INVITRO	Manganese oxidation by manganese peroxidase (MnP) was investigated. Stoichiometric, kinetic, and Mn(II) binding studies demonstrated that MnP has a single manganese binding site near the heme, and two Mn(III) equivalents are formed at the expense of one H2O2 equivalent. Since each catalytic cycle step is irreversible, the data fit a peroxidase ping-pong mechanism rather than an ordered bi-bi ping-pong mechanism. Mn(III)-organic acid complexes oxidize terminal phenolic substrates in a second-order reaction. Mn(III)-lactate and -tartrate also react slowly with H2O2, with third-order kinetics. The latter slow reaction does not interfere with the rapid MnP oxidation of phenols. Oxalate and malonate are the only organic acid chelators secreted by the fungus in significant amounts. No relationship between stimulation of enzyme activity and chelator size was found, suggesting that the substrate is free Mn(II) rather than a Mn(II)-chelator complex. The enzyme competes with chelators for free Mn(II). Optimal chelators, such as malonate, facilitate Mn(III) dissociation from the enzyme, stabilize Mn(III) in aqueous solution, and have a relatively low Mn(II) binding constant.	OREGON GRAD INST SCI & TECHNOL,DEPT CHEM & BIOL SCI,19600 NW VON NEUMANN DR,BEAVERTON,OR 97006									AITKEN MD, 1990, ARCH BIOCHEM BIOPHYS, V276, P405, DOI 10.1016/0003-9861(90)90739-L; ALIC M, 1987, APPL ENVIRON MICROB, V53, P1464, DOI 10.1128/AEM.53.7.1464-1469.1987; ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452, DOI 10.1016/0003-9861(82)90049-2; BUSWELL JA, 1987, CRC CR REV BIOTECHN, V6, P1, DOI 10.3109/07388558709086984; CASELLA L, 1991, BIOCHEM J, V279, P245, DOI 10.1042/bj2790245; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; CUI F, 1990, HOLZFORSCHUNG, V44, P279, DOI 10.1515/hfsg.1990.44.4.279; Davies G, 1968, INORG CHEM, V7, P146, DOI 10.1021/ic50059a031; DEMMER H, 1980, COORDINATION COMPOUN, V56, P1; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; Eigen M., 1963, PURE APPL CHEM, V6, P97, DOI [10.1351/pac196306010097, DOI 10.1351/PAC196306010097]; EVANS WP, 1954, J CHEM SOC, P550, DOI 10.1039/jr9540000550; GIERER J, 1973, ACTA CHEM SCAND, V27, P2909, DOI 10.3891/acta.chem.scand.27-2909; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1989, ACS SYM SER, V389, P127; HAMMEL KE, 1991, ENZYME MICROB TECH, V13, P15, DOI 10.1016/0141-0229(91)90182-A; HARRIS RZ, 1991, J BIOL CHEM, V266, P8751; IRVING H, 1962, J CHEM SOC, P5222, DOI 10.1039/jr9620005222; JOLK V, 1964, J CHROMATOGR, V14, P71; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; LACKNER R, 1991, BIOCHEM BIOPH RES CO, V178, P1092, DOI 10.1016/0006-291X(91)91004-V; LEISOLA MSA, 1987, J BIOL CHEM, V262, P419; MCAULEY A, 1967, J CHEM SOC, P4458; MINO Y, 1988, J BIOL CHEM, V263, P7029; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; PEASE EA, 1989, J BIOL CHEM, V264, P13531; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SARKANEN KV, 1971, LIGNINS; TAKAO S, 1965, APPL MICROBIOL, V13, P732, DOI 10.1128/AEM.13.5.732-737.1965; THOMPSON DHP, 1987, J AM CHEM SOC, V109, P2003, DOI 10.1021/ja00241a017; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TRIPATHY KK, 1967, INDIAN J CHEM, V5, P511; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; VALLI K, 1992, APPL ENVIRON MICROB, V58, P221, DOI 10.1128/AEM.58.1.221-228.1992; VALLI K, 1991, J BACTERIOL, V173, P345, DOI 10.1128/jb.173.1.345-352.1991; VALLI K, 1992, J BACTERIOL, V174, P2131, DOI 10.1128/JB.174.7.2131-2137.1992; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1989, J BIOL CHEM, V264, P14185; WARIISHI H, 1989, BIOCHEMISTRY-US, V28, P6017, DOI 10.1021/bi00440a044; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X	46	876	907	8	117	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23688	23695						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429709				2022-12-27	WOS:A1992JZ23900042
J	CHIANNILKULCHAI, N; MOENNE, A; SENTENAC, A; MANN, C				CHIANNILKULCHAI, N; MOENNE, A; SENTENAC, A; MANN, C			BIOCHEMICAL AND GENETIC DISSECTION OF THE SACCHAROMYCES-CEREVISIAE RNA-POLYMERASE C53-SUBUNIT THROUGH THE ANALYSIS OF A MITOCHONDRIALLY MIS-SORTED MUTANT CONSTRUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE FUNCTION; 2ND-LARGEST SUBUNIT; SHUTTLE VECTORS; COMMON SUBUNITS; SRK1 GENE; YEAST; ENCODES; TRANSCRIPTION; SUPPRESSOR; IMPORT	RPC53 has previously been shown to encode an essential subunit required for tRNA gene transcription by RNA polymerase C in vivo (Mann, C., Micouin, J.Y., Chiannilkulchai, N., Treich, I., Buhler, J.-M., and Sentenac, A. (1992) Mol. Cell. Biol. 12, in press). In this paper, we have determined that an unusual rho+ lethality associated with the rpc53::HIS3-1 disruption mutation is due to the inadvertent formation of a Pet56-C53 fusion protein. This fusion protein is mis-sorted to mitochondria, thereby reducing the quantity of the C53 subunit available for RNA polymerase C assembly. We show that the carboxyl-terminal region of C53 contains the essential functional domain of the subunit and that a mutant RNA polymerase containing only this domain is thermolabile for its function in vivo and in vitro. The thermolability of the carboxyl-terminal C53 domain is suppressed by five different genes on multicopy plasmids, including RPC160, encoding the largest subunit of RNA polymerase C and SSD1/SRK1, which has been implicated in the activity of protein phosphatases.	CTR ETUD SACLAY,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE					Mann, Carl/0000-0001-7212-1512				ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; BELL GI, 1976, NATURE, V261, P429, DOI 10.1038/261429a0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BREWER BJ, 1980, P NATL ACAD SCI-BIOL, V77, P5380, DOI 10.1073/pnas.77.9.5380; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; BUHLER JM, 1980, J BIOL CHEM, V255, P9949; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHIANNILKULCHAI N, 1992, IN PRESS MOL CELL BI, V12; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; Dujon B., 1981, MOL BIOL YEAST SACCH; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FELDMAN O, 1981, NUCLEIC ACIDS RES, V9, P2949; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; Guthrie C, 1991, METHODS ENZYMOL, V194; HALDI M, 1989, J BIOL CHEM, V264, P17107; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HUET J, 1982, J BIOL CHEM, V257, P2613; HUET J, 1985, J BIOL CHEM, V260, P5304; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ITTMANN M, 1987, MOL CELL BIOL, V7, P3386, DOI 10.1128/MCB.7.10.3386; JAMES P, 1991, J BIOL CHEM, V266, P5616; KALINICH JF, 1989, J BIOL CHEM, V264, P17979; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; Maniatis T, 1989, DECONTAMINATION DILU; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MANN C, 1992, IN PRESS MOL CELL BI, V12; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; MECCECHINI ML, 1979, P NATL ACAD SCI USA, V76, P343; MEMET S, 1988, J BIOL CHEM, V263, P2830; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; ROISE D, 1988, J BIOL CHEM, V263, P4509; RUET A, 1984, EMBO J, V3, P343, DOI 10.1002/j.1460-2075.1984.tb01809.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STETTLER S, 1992, J BIOL CHEM, V267, P21390; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2; Treich Isabelle, 1992, Gene Expression, V2, P31; WERNER M, 1992, MOL CELL BIOL, V12, P1087, DOI 10.1128/MCB.12.3.1087; WILSON RB, 1991, MOL CELL BIOL, V11, P3369, DOI 10.1128/MCB.11.6.3369; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754	52	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23099	23107						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429657				2022-12-27	WOS:A1992JY16300062
J	MATHERLY, LH; ANGELES, SM; CZAJKOWSKI, CA				MATHERLY, LH; ANGELES, SM; CZAJKOWSKI, CA			CHARACTERIZATION OF TRANSPORT-MEDIATED METHOTREXATE RESISTANCE IN HUMAN TUMOR-CELLS WITH ANTIBODIES TO THE MEMBRANE CARRIER FOR METHOTREXATE AND TETRAHYDROFOLATE COFACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-HYDROXYSUCCINIMIDE ESTER; DIHYDROFOLATE-REDUCTASE; FOLATE TRANSPORT; LEUKEMIA-CELLS; L1210 CELLS; PROTEIN; BINDING; INVITRO; DEGLYCOSYLATION; IDENTIFICATION	An earlier report (Matherly, L. H., Czajkowski, C. A., and Angeles, S. M. (1991) Cancer Res. 51, 3420-3426) described a K562 human erythroleukemia line (K562.4CF), characterized by an elevated uptake capacity for methotrexate (MTX) and 5-formyltetrahydrofolate, and the identification of a highly glycosylated membrane transporter (GP-MTX) by radioaffinity labeling with N-hydroxysuccinimide [H-3] methotrexate. In the present study, radioaffinity-labeled GP-MTX from K562.4CF cells was isolated by Ricinus communis agglutinin I-agarose affinity chromatography, coupled with gel filtration and preparative electrophoresis. Antiserum to the purified, radiolabeled protein was raised in a rabbit and screened by immunoblot analysis of K562.4CF plasma membrane proteins or purified GP-MTX. The antiserum detected a broad GP-MTX band centered at 92 kDa on 7.5% gels. On 4-10% gels, the apparent molecular mass for GP-MTX shifted to 99 kDa. Antiserum specificity was established by quantitatively converting the immunoreactive glycoprotein in plasma membrane homogenates to its N- and O-deglycosylated forms with N- and O-glycanases, respectively. Whereas the methotrexate uptake capacity of K562.4CF cells was elevated 6.1-fold over parental cells, the GP-MTX content on immunoblots was increased approximately 3-fold. For two methotrexate-resistant K562 lines (33- and 70-fold), decreased drug uptake (28 and 18% of parental levels) closely correlated with their reduced GP-MTX contents. A GP-MTX isoform was also detected on immunoblots of membrane proteins from CCRF-CEM human lymphoblastic leukemia cells. With a transport-impaired CCRF-CEM line (13% of wild type uptake), an aberrant electrophoretic migration for GP-MTX was observed, establishing the presence of structural modifications in the transport protein. These structural differences were independent of carrier glycosylation since they were detected following the glycosidase treatments. These findings implicate important roles for distinct carrier-specific alterations in the expression of diminished drug transport in methotrexate-resistant human tumor cells.			MATHERLY, LH (corresponding author), MICHIGAN CANC FDN,DEV THERAPEUT PROGRAM,110 E WARREN AVE,DETROIT,MI 48201, USA.							AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FABRE I, 1984, CANCER RES, V44, P3190; FAN JG, 1991, J BIOL CHEM, V266, P14862; FAN JG, 1991, BIOCHEMISTRY-US, V30, P4573, DOI 10.1021/bi00232a030; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FRY DW, 1982, J BIOL CHEM, V257, P1890; GALIVAN J, 1979, CANCER RES, V39, P735; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GREEN DE, 1955, J BIOL CHEM, V217, P551; HANKS JH, 1949, P SOC EXP BIOL MED, V71, P196; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KESSEL D, 1965, SCIENCE, V150, P752, DOI 10.1126/science.150.3697.752; KESSEL D, 1968, CANCER RES, V28, P564; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHERLY LH, 1991, CANCER RES, V51, P3420; MATHERLY LH, 1984, CANCER RES, V44, P2325; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NEILANDS JB, 1955, METHOD ENZYMOL, V1, P449, DOI 10.1016/0076-6879(55)01074-4; NORRIS MD, 1991, CANCER, V68, P981, DOI 10.1002/1097-0142(19910901)68:5<981::AID-CNCR2820680512>3.0.CO;2-W; OHNUMA T, 1985, CANCER RES, V45, P1815; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; RODENHUIS S, 1986, CANCER RES, V46, P6513; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; ROSOWSKY A, 1985, CANCER RES, V45, P6205; ROSOWSKY A, 1985, J MED CHEM, V28, P660, DOI 10.1021/jm50001a021; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P3992; TAKASAKI S, 1976, J BIOL CHEM, V251, P3603; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WOODWARD HD, 1987, BIOCHEMISTRY-US, V26, P5315, DOI 10.1021/bi00391a015; YANG CH, 1992, J BIOL CHEM, V267, P6628; YANG CH, 1988, J BIOL CHEM, V263, P9703	40	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23253	23260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429671				2022-12-27	WOS:A1992JY16300084
J	TSIRKA, S; COFFINO, P				TSIRKA, S; COFFINO, P			DOMINANT NEGATIVE MUTANTS OF ORNITHINE DECARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFLUOROMETHYLORNITHINE; INHIBITION; TURNOVER; CLONING; ENZYME; ALPHA; SITES	Conserved lysines of mouse ornithine decarboxylase were individually mutated to arginines. The mutations at amino acid residues 69, 115, and 169 greatly reduced or abolished enzymatic activity. Lysine 69 is the site of Schiff base formation with the cofactor pyridoxal phosphate; the functional role of the other two lysines essential for activity is not known. Coexpression of wild type ornithine decarboxylase along with the lysine 115 to arginine mutant reduced the activity of the former without diminishing the amount of wild type protein. This form of negative complementation was seen when wild type and mutant protein were coexpressed either by in vitro translation or in bacteria. The data are consistent with the conclusion that a wild type and mutant subunit form a heterodimer that is enzymatically inactive.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,BOX 0414,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Tsirka, Stella/AAD-4018-2019		NCI NIH HHS [R01 CA29048] Funding Source: Medline; NIGMS NIH HHS [R01 GM45335] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bey P., 1987, INHIBITION POLYAMINE, P1; COFFINO P, 1989, ORNITHINE DECARBOXYL, P135; FOZARD JR, 1980, EUR J PHARMACOL, V65, P379, DOI 10.1016/0014-2999(80)90342-8; FOZARD JR, 1980, SCIENCE, V208, P505; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JACKSON FR, 1990, J MOL EVOL, V31, P325, DOI 10.1007/BF02101126; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURAMITSU S, 1987, BIOCHEM BIOPH RES CO, V146, P416, DOI 10.1016/0006-291X(87)90545-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MACRAE M, 1987, MOL CELL BIOL, V7, P564, DOI 10.1128/MCB.7.1.564; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; PILZ RB, 1990, J BIOL CHEM, V265, P8880; POULIN R, 1992, J BIOL CHEM, V267, P150; PRICHARD ML, 1981, BIOCHEM BIOPH RES CO, V100, P1597; Queen C, 1983, J Mol Appl Genet, V2, P1; ROBEY EA, 1985, P NATL ACAD SCI USA, V82, P361, DOI 10.1073/pnas.82.2.361; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x	25	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23057	23062						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429654				2022-12-27	WOS:A1992JY16300055
J	ULMASOV, T; GUILFOYLE, TJ				ULMASOV, T; GUILFOYLE, TJ			SEQUENCE OF THE 5TH LARGEST SUBUNIT OF RNA POLYMERASE-II FROM PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; DROSOPHILA; EXPRESSION; TEMPERATURE; PROMOTER; CLONING; ENZYMES; GROWTH; GENES	An affinity-purified antibody raised against the fifth largest subunit of cauliflower (Brassica oleracea) RNA polymerase II was used to screen an expression library and isolate an Arabidopsis thaliana cDNA clone. This cDNA clone was used to isolate a soybean (Glycine max) cDNA clone, and both clones were sequenced. The open reading frames contain 176 amino acids and predict polypeptides of 19.5 and 19.6 kDa for Arabidopsis and soybean, respectively. The amino acid sequences of the Arabidopsis and soybean polypeptides are 91.5% identical. The fifth largest subunit in plant RNA polymerase II is present at unit stoichiometry in purified enzyme and does not dissociate from the holoenzyme during nondenaturing polyacrylamide gel electrophoresis. The gene encoding the 19.5-kDa subunit has been isolated and sequenced from Arabidopsis. The gene is single copy and contains five introns. The size of the mRNA encoding this RNA polymerase II subunit in Arabidopsis and soybean is approximately 1 kilobase. None of the published yeast or animal RNA polymerase subunit sequences show similarity to the fifth largest subunit in plants.	UNIV MISSOURI,DEPT BIOCHEM,117 SCHWEITZER HALL,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia					NIGMS NIH HHS [GM37950] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; DEZELEE S, 1976, EUR J BIOCHEM, V65, P543, DOI 10.1111/j.1432-1033.1976.tb10372.x; DIETRICH MA, 1990, PLANT MOL BIOL, V15, P207, DOI 10.1007/BF00036908; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; GUILFOYLE TJ, 1978, BIOCHEMISTRY-US, V17, P1860, DOI 10.1021/bi00603a009; GUILFOYLE TJ, 1984, J BIOL CHEM, V259, P640; GUILFOYLE TJ, 1983, ENZYMES NUCLEIC ACID, V2, P1; HAGEN G, 1984, PLANTA, V162, P147, DOI 10.1007/BF00410211; HAGEN G, 1991, PLANT MOL BIOL, V17, P567, DOI 10.1007/BF00040658; HALROW E, 1988, ANTIBODIES LABORATOR, P310; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JENDRISAK J, 1978, BIOCHEMISTRY-US, V17, P1322, DOI 10.1021/bi00600a029; JENDRISAK J, 1983, PLANT PHYSIOL, V72, P1068, DOI 10.1104/pp.72.4.1068; JENDRISAK JJ, 1977, BIOCHEMISTRY-US, V16, P1959, DOI 10.1021/bi00628a032; JENDRISAK JJ, 1975, BIOCHEMISTRY-US, V14, P4639, DOI 10.1021/bi00692a012; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KLENK HP, 1992, P NATL ACAD SCI USA, V89, P407, DOI 10.1073/pnas.89.1.407; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SITZLER S, 1991, GENE, V100, P155, DOI 10.1016/0378-1119(91)90361-E; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	34	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23165	23169						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429663				2022-12-27	WOS:A1992JY16300071
J	BENAMIRA, M; SINGH, U; MARNETT, LJ				BENAMIRA, M; SINGH, U; MARNETT, LJ			SITE-SPECIFIC FRAMESHIFT MUTAGENESIS BY A PROPANODEOXYGUANOSINE ADDUCT POSITIONED IN THE (CPG)4 HOT-SPOT OF SALMONELLA-TYPHIMURIUM HISD3052 CARRIED ON AN M13 VECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMULTANEOUS PARTIAL INTERCALATION; SINGLE ACETYLAMINOFLUORENE ADDUCT; RESTRICTION ENDONUCLEASES HINDII; LOCATED OPPOSITE DEOXYADENOSINE; DNA-SEQUENCE ANALYSIS; ESCHERICHIA-COLI; NUCLEIC-ACID; CARCINOGEN N-ACETOXY-N-2-ACETYLAMINOFLUORENE; OXADIAZABICYCLONONENE RESIDUES; TRANSIENT MISALIGNMENT	Malondialdehyde induces frameshift mutations in Salmonella typhimurium strain hisD3052. The ability of propanodeoxyguanosine (PdG), a structural analog of the major malondialdehyde-deoxyguanosine adduct, to induce site-specific frameshift mutations was tested in the (CpG)4 hot-spot of hisD3052 carried on an M13 vector (M13MB102). PdG was introduced at position 6248 of duplex M13MB102 by ligation of the oligonucleotide 5'-CGC(PdG)CGGCATG-3' into a heteroduplex containing an 11-nucleotide gap in the (-)strand between the SphI and BssHII restriction sites and deoxyuridine in place of thymidine in the (+)strand. Ligation proceeded with 70% efficiency, and closed circular duplex DNA molecules were isolated in 40% yield. The adducted genome was sensitive to cleavage by SphI but resistant to cleavage by BssHII. Transformation of Escherichia coli strain JM105 with adducted M13MB102 led to 25% reduced survival relative to unadducted M13MB102 and produced frameshift mutations in 2.5% of the progeny phage. All of the mutations were deletions, and 70% occurred by deletion of CpG. Unadducted genomes exhibited a 40-fold lower mutation frequency, and all the mutations were single-base deletions at the sites of ligation of the 11-mer. These results illustrate that PdG, a structural analog of the major malondialdehyde-deoxyguanosine adduct, induces frameshift mutations in M13MB102 and that single-stranded nicks are efficient premutagenic lesions in this recombinant bacteriophage.	VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,DEPT BIOCHEM,AB HANCOCK JR MEM LAB CANC RES,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,DEPT CHEM,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47479] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BASU AK, 1988, CHEM RES TOXICOL, V1, P53, DOI 10.1021/tx00001a010; BASU AK, 1983, CARCINOGENESIS, V4, P331, DOI 10.1093/carcin/4.3.331; BASU AK, 1987, BIOCHEMISTRY-US, V26, P5626, DOI 10.1021/bi00392a007; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BASU AK, 1984, CANCER RES, V44, P2848; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BELGUISEVALLADIER P, 1991, BIOCHEMISTRY-US, V30, P10091, DOI 10.1021/bi00106a005; BELL DA, 1991, MUTAT RES, V252, P35, DOI 10.1016/0165-1161(91)90249-8; BENASUTTI M, 1988, CHEM RES TOXICOL, V1, P160, DOI 10.1021/tx00003a006; BERNHEIM F, 1948, J BIOL CHEM, V174, P257; BICHARA M, 1985, J MOL BIOL, V183, P341, DOI 10.1016/0022-2836(85)90005-1; BODNAR JW, 1983, J BIOL CHEM, V258, P5206; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CEBULA TA, 1990, PROG CLIN BIOL RES, V340, P367; CHENG KC, 1991, P NATL ACAD SCI USA, V88, P9974, DOI 10.1073/pnas.88.22.9974; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; CUPPLES CG, 1990, GENETICS, V125, P275; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; FOWLER KW, 1982, J AM CHEM SOC, V104, P1050, DOI 10.1021/ja00368a023; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; FUCHS RPP, 1984, J MOL BIOL, V177, P173, DOI 10.1016/0022-2836(84)90063-9; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; FUSCOE JC, 1988, MUTAT RES, V201, P241, DOI 10.1016/0027-5107(88)90131-5; George W. O., 1968, J CHEM SOC B, P132, DOI DOI 10.1039/J29680000132; GREEN CL, 1984, P NATL ACAD SCI-BIOL, V81, P13, DOI 10.1073/pnas.81.1.13; GROLLMAN A P, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P682; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; IDE H, 1991, J BIOL CHEM, V266, P1469; ISONO K, 1974, P NATL ACAD SCI USA, V71, P1612, DOI 10.1073/pnas.71.5.1612; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; JAWORSKI A, 1989, J MOL BIOL, V207, P513, DOI 10.1016/0022-2836(89)90461-0; JIRICNY J, 1986, NUCLEIC ACIDS RES, V14, P1943, DOI 10.1093/nar/14.5.1943; JIRICNY J, 1986, NUCLEIC ACIDS RES, V14, P6579, DOI 10.1093/nar/14.16.6579; JOHNSON DL, 1986, BIOCHEMISTRY-US, V25, P449, DOI 10.1021/bi00350a026; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KOEHL P, 1989, NUCLEIC ACIDS RES, V17, P9531, DOI 10.1093/nar/17.23.9531; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P3262, DOI 10.1021/bi00227a014; KOUCHAKDJIAN M, 1990, BIOCHEMISTRY-US, V29, P4456, DOI 10.1021/bi00470a028; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPCHELLA E, 1991, ENVIRON MOL MUTAGEN, V18, P224, DOI 10.1002/em.2850180404; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; LASKO DD, 1987, BIOCHEMISTRY-US, V26, P3072, DOI 10.1021/bi00385a019; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; Maniatis T, 1989, DECONTAMINATION DILU; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; MARNETT LJ, 1986, J AM CHEM SOC, V108, P1348, DOI 10.1021/ja00266a065; MARNETT LJ, 1985, MUTAT RES, V148, P25; MASUREKAR M, 1991, GENETICS, V127, P453; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Miller J. H., 1972, EXPT MOL GENETICS, P433; MUKAI FH, 1976, SCIENCE, V191, P868, DOI 10.1126/science.766187; NAIR V, 1984, J AM CHEM SOC, V106, P3370, DOI 10.1021/ja00323a061; NASER LJ, 1988, BIOCHEMISTRY-US, V27, P4357, DOI 10.1021/bi00412a024; OHARA SM, 1991, MUTAT RES, V247, P45, DOI 10.1016/0027-5107(91)90032-J; OSMAN MM, 1972, HELV CHIM ACTA, V55, P239, DOI 10.1002/hlca.19720550127; PALEJWALA VA, 1991, BIOCHEMISTRY-US, V30, P8736, DOI 10.1021/bi00100a004; REID TM, 1990, BIOCHEMISTRY-US, V29, P6153, DOI 10.1021/bi00478a007; RICHARDSON FC, 1991, MOL CARCINOGEN, V4, P162, DOI 10.1002/mc.2940040212; RIPLEY LS, 1986, P NATL ACAD SCI USA, V83, P6954, DOI 10.1073/pnas.83.18.6954; RIPLEY LS, 1988, J MOL BIOL, V200, P665, DOI 10.1016/0022-2836(88)90479-2; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SETO H, 1991, CHEM PHARM BULL, V39, P515; SETO H, 1983, B CHEM SOC JPN, V56, P1799, DOI 10.1246/bcsj.56.1799; SETO H, 1986, CHEM PHARM BULL, V34, P5079; Spalding J. W., 1988, NATL TOXICOL PROGRAM, V331, P5; STONE K, 1990, CHEM RES TOXICOL, V3, P467, DOI 10.1021/tx00017a013; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; USHAY HM, 1981, BIOCHEMISTRY-US, V20, P3744, DOI 10.1021/bi00516a012; VOIGT JM, 1990, BIOCHEMISTRY-US, V29, P1632, DOI 10.1021/bi00458a039; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAU TM, 1979, MECH AGEING DEV, V11, P137, DOI 10.1016/0047-6374(79)90031-9	82	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22392	22400						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429591				2022-12-27	WOS:A1992JW71900064
J	VOLONTE, C; GREENE, LA				VOLONTE, C; GREENE, LA			NERVE GROWTH FACTOR-ACTIVATED PROTEIN KINASE-N - CHARACTERIZATION AND RAPID NEAR HOMOGENEITY PURIFICATION BY NUCLEOTIDE AFFINITY-EXCHANGE CHROMATOGRAPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; PURINE ANALOGS; TYROSINE PHOSPHORYLATION; RIBOSOMAL PROTEIN-S6; CYCLIC AMP; MITOGEN; PC12-CELLS; EXPRESSION	Protein kinase N (PKN) is a protein kinase rapidly activated by nerve growth factor (NGF) and other agents in PC12 pheochromocytoma and additional cell types. PKN is selectively inhibited by purine analogs, and this property has served both as a diagnostic for PKN activity and to establish its apparent involvement in certain pathways of the NGF mechanism of action. The present work has focused on further characterization, identification, and purification of NGF-activated PKN. We show here that PKN can be substantially enriched by elution from ion exchange resins with ATP. We exploited this novel technique (nucleotide affinity exchange chromatography) to devise two alternative isolation schemes for PKN. One utilizes sequential chromatographic steps and provides a preparation that is apparently 60% homogeneous for PKN and represents a total enrichment of approximately 10,000-fold. The other is a single column procedure and includes prewashes with NAD. This method yields material that is about 5-10% homogeneous for PKN, requires about 1 h, and can be applied to multiple samples in parallel. The ATP elution technique furthermore distinguishes NGF-regulated from basal PKN activity and thereby suggests the presence of distinct PKN isoforms. The applications of sucrose gradient centrifugation, gel filtration chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)/silver staining, affinity labeling with 8-azido-ATP/SDS-PAGE, and autophosphorylation (after SDS-PAGE, blotting and renaturation) all indicate that PKN has an apparent molecular mass of 45-47 kDa and is mainly monomeric in solution. These and additional properties appear to distinguish PKN from many previously described protein kinases.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Columbia University			Volonté, Cinzia/N-6474-2013	Volonté, Cinzia/0000-0001-7362-8307	NINDS NIH HHS [NS-16036] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016036] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALETTA JM, 1988, J CELL BIOL, V106, P1573, DOI 10.1083/jcb.106.5.1573; BATISTATOU A, 1992, MOL BIOL CELL, V3, P363, DOI 10.1091/mbc.3.3.363; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1990, J NEUROSCI, V10, P1479; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HASHIMOTO S, 1990, J NEUROCHEM, V55, P970, DOI 10.1111/j.1471-4159.1990.tb04586.x; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVI A, 1988, MOL NEUROBIOL, V2, P201, DOI 10.1007/BF02935346; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MUTOH T, 1988, J BIOL CHEM, V263, P15853; PINES J, 1990, New Biologist, V2, P389; POTTER RL, 1982, METHOD ENZYMOL, V91, P613; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; ROMANO C, 1987, J NEUROSCI, V7, P1294; ROWLAND EA, 1987, J BIOL CHEM, V262, P7504; ROWLANDGAGNE E, 1990, J NEUROCHEM, V54, P424, DOI 10.1111/j.1471-4159.1990.tb01890.x; SANO M, 1990, J NEUROCHEM, V55, P427, DOI 10.1111/j.1471-4159.1990.tb04154.x; TSAO H, 1990, J BIOL CHEM, V265, P15471; VOLONTE C, 1992, BIOTECHNIQUES, V12, P854; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; VOLONTE C, 1992, J NEUROCHEM, V58, P700, DOI 10.1111/j.1471-4159.1992.tb09774.x; VOLONTE C, 1990, J BIOL CHEM, V265, P11050; Volonte C, 1990, GROWTH FACTORS, V2, P321; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	39	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21663	21670						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400478				2022-12-27	WOS:A1992JV01100064
J	BORDEN, LA; SMITH, KE; HARTIG, PR; BRANCHEK, TA; WEINSHANK, RL				BORDEN, LA; SMITH, KE; HARTIG, PR; BRANCHEK, TA; WEINSHANK, RL			MOLECULAR HETEROGENEITY OF THE GAMMA-AMINOBUTYRIC-ACID (GABA) TRANSPORT-SYSTEM - CLONING OF 2 NOVEL HIGH-AFFINITY GABA TRANSPORTERS FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; UPTAKE INHIBITORS; EXPRESSION; DNA; IDENTIFICATION; MECHANISM; KIDNEY; CHAIN	cDNA clones encoding two novel gamma-aminobutyric acid (GABA) transporters (designated GAT-2 and GAT-3) have been isolated from rat brain, and their functional properties have been examined in mammalian cells. The transporters display high affinity for GABA (K(m) almost-equal-to 10 muM) and exhibit pharmacological properties distinct from the previously cloned neuronal GABA transporter (GAT-1). Both transporters require sodium and chloride for transport activity. The nucleotide sequences of GAT-2 and GAT-3 predict proteins of 602 and 627 amino acids, respectively, which can be modeled with 12 transmembrane domains, similar to the topology proposed for other cloned neurotransmitter transporters. Localization studies indicate that both transporters are present in brain and retina, while GAT-2 is also present in peripheral tissues. The cloning of these transporter genes from rat brain reveals previously undescribed heterogeneity in GABA transporter.	SYNAPT PHARMACEUT CORP,15 COLL RD,PARAMUS,NJ 07652									AMENTA F, 1988, PHARMACOLOGY, V36, P390, DOI 10.1159/000138327; ANDRADE R, 1986, SCIENCE, V234, P1261, DOI 10.1126/science.2430334; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DICHTER MA, 1980, BRAIN RES, V190, P111, DOI 10.1016/0006-8993(80)91163-4; ERDO SL, 1990, J NEUROCHEM, V54, P363, DOI 10.1111/j.1471-4159.1990.tb01882.x; FALCH E, 1990, DRUG DEVELOP RES, V21, P169, DOI 10.1002/ddr.430210304; GOODYER PR, 1985, BIOCHIM BIOPHYS ACTA, V818, P45, DOI 10.1016/0005-2736(85)90136-1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IVERSEN LL, 1972, BRAIN RES, V41, P131, DOI 10.1016/0006-8993(72)90621-X; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KRNJEVIC K, 1991, GABA MECH EPILEPSY, P47; KROGSGAARDLARSEN P, 1987, EPILEPSY RES, V1, P77, DOI 10.1016/0920-1211(87)90012-X; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINUK GY, 1984, HEPATOLOGY, V4, P180, DOI 10.1002/hep.1840040203; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; ROGAWSKI MA, 1990, PHARMACOL REV, V42, P224; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schousboe A, 1991, GABA MECHANISMS EPIL, P165; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; TWYMAN RE, 1991, GABA MECHANISMS EPIL, P89; WILLIAMS M, 1990, PROG CLIN BIOL RES, V361, P131; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YUNGER LM, 1984, J PHARMACOL EXP THER, V228, P109	28	274	291	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21098	21104						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400419				2022-12-27	WOS:A1992JT97800091
J	SHIRABE, K; YUBISUI, T; BORGESE, N; TANG, CY; HULTQUIST, DE; TAKESHITA, M				SHIRABE, K; YUBISUI, T; BORGESE, N; TANG, CY; HULTQUIST, DE; TAKESHITA, M			ENZYMATIC INSTABILITY OF NADH-CYTOCHROME-B5 REDUCTASE AS A CAUSE OF HEREDITARY METHEMOGLOBINEMIA TYPE-I (RED-CELL TYPE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B5 REDUCTASE; AMINO-ACID SEQUENCE; ENCODING NITRATE REDUCTASE; SITE-DIRECTED MUTAGENESIS; RAT-LIVER MICROSOMES; NADH-BINDING SITE; NADPH-CYTOCHROME-P-450 REDUCTASE; CONGENITAL METHEMOGLOBINEMIA; HUMAN-ERYTHROCYTES; ESCHERICHIA-COLI	Nucleotide substitutions in the gene for NADH-cytochrome b5 reductase were identified in three independent probands of hereditary methemoglobinemia type I. Patients in Kagoshima and Okinawa in Japan were shown to possess the same base change, from guanine to adenine at codon 57, which results in amino acid substitution from Arg to Gln. This nucleotide change was the same as formerly found in a patient in Toyoake, Japan (Katsube, T., Sakamoto, N., Kobayashi, Y., Seki, R., Hirano, M., Tanishima, K., Tomoda, A., Takazakura, E., Yubisui, T., Takeshita, M., Sakaki, Y., and Fukumaki, Y. (1991) Am. J. Hum. Genet. 48, 799-808). A type I patient in Italy was shown to have a base change from guanine to adenine at codon 105 which causes substitution from Val to Met. To characterize the enzymes of type I patients, Arg-57 --> Gln and Val-105 --> Met mutant enzymes were overexpressed in Escherichia coli and purified to homogeneity. k(cat)/K(m) values (NADH) of these two enzymes were 25% in Arg-57 --> Gln and 14.5% in Val-105 --> Met compared with that of the wild type enzyme, while the value of type II (generalized, severe form of the disease) mutant enzyme was 3% of the normal value (Yubisui, T., Shirabe, K., Takeshita, M., Kobayashi, Y., Fukumaki, Y., Sakaki, Y., and Takano, T. (1991) J. Biol. Chem. 266, 66-70). The type I mutant enzymes were less heat-stable and more susceptible to proteinase treatment than the wild type. From these results we conclude that restriction of enzyme deficiency to red cells in hereditary methemoglobinemia type I may be generally derived from instability and increased proteolytic susceptibility of variant NADH-cytochrome b5 reductases due to a point mutation.	UNIV MILAN, CNR, CTR CYTOPHARMACOL, I-20129 MILAN, ITALY; UNIV MILAN, DIPARTIMENTO FARMACOL, I-20129 MILAN, ITALY; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48104 USA	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Milan; University of Michigan System; University of Michigan	SHIRABE, K (corresponding author), OITA MED UNIV, DEPT BIOCHEM, HASAMA, OITA 87955, JAPAN.		Borgese, Nica/GWZ-8895-2022	Borgese, Nica/0000-0002-7537-3974				BEUTLER E, 1968, BLOOD, V31, P131, DOI 10.1182/blood.V31.2.131.131; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BORGESE N, 1987, J CLIN INVEST, V80, P1296, DOI 10.1172/JCI113205; CHENG CL, 1988, EMBO J, V7, P3309, DOI 10.1002/j.1460-2075.1988.tb03201.x; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FRIEMANN A, 1991, MOL GEN GENET, V227, P97, DOI 10.1007/BF00260713; GRAY GR, 1973, LANCET, V2, P530; HARRIS H, 1980, PRINCIPLES HUMAN BIO; HOPKINSO.DA, 1970, ANN HUM GENET, V34, P1, DOI 10.1111/j.1469-1809.1970.tb00214.x; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; HYDE GE, 1991, J BIOL CHEM, V266, P23542; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; JAFFE ER, 1989, METABOLIC BASIS INHE, P2267; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KATSUBE T, 1991, AM J HUM GENET, V48, P799; KEYES SR, 1980, J BIOL CHEM, V255, P1357; KOBAYASHI Y, 1990, BLOOD, V75, P1408; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROUX A, 1975, NATURE, V258, P619, DOI 10.1038/258619a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURAKAMI H, 1986, DNA-J MOLEC CELL BIO, V5, P1, DOI 10.1089/dna.1986.5.1; MURAKAMI K, 1989, J BIOCHEM, V105, P312, DOI 10.1093/oxfordjournals.jbchem.a122659; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OZOLS J, 1985, J BIOL CHEM, V260, P1953; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; PRCHAL JT, 1990, AM J MED, V89, P516, DOI 10.1016/0002-9343(90)90384-P; PRINS HK, 1966, BLOOD-J HEMATOL, V27, P145, DOI 10.1182/blood.V27.2.145.145; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; RICE RH, 1971, J BIOL CHEM, V246, P831; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER DA, 1981, BIOCHEM BIOPH RES CO, V100, P1555, DOI 10.1016/0006-291X(81)90696-3; SCOTT EM, 1959, BIOCHIM BIOPHYS ACTA, V34, P584, DOI 10.1016/0006-3002(59)90324-5; SHIRABE K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P189, DOI 10.1016/0167-4781(80)90007-X; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; STRITTMATTER P, 1965, J BIOL CHEM, V240, P4481; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; TANAKA K, 1988, FEBS LETT, V236, P159, DOI 10.1016/0014-5793(88)80306-5; TANISHIMA K, 1985, BLOOD, V66, P1288; TISCHLER ME, 1977, FEBS LETT, V76, P99, DOI 10.1016/0014-5793(77)80129-4; TOMATSU S, 1989, GENE, V80, P353; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WILLIAMS GT, 1985, EXP CELL RES, V160, P419, DOI 10.1016/0014-4827(85)90189-2; YUBISUI T, 1980, J BIOL CHEM, V255, P2454; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCHEM-TOKYO, V99, P407, DOI 10.1093/oxfordjournals.jbchem.a135495; YUBISUI T, 1991, J BIOL CHEM, V266, P66	53	57	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20416	20421						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400360				2022-12-27	WOS:A1992JR85800104
J	YU, H; TOYOSHIMA, I; STEUER, ER; SHEETZ, MP				YU, H; TOYOSHIMA, I; STEUER, ER; SHEETZ, MP			KINESIN AND CYTOPLASMIC DYNEIN BINDING TO BRAIN MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULES; AXONAL-TRANSPORT; SOLUBLE FACTORS; MICROTUBULES; LOCALIZATION; MOTOR; IDENTIFICATION; ORGANELLES; MOVEMENT; MOTILITY	Movement of cellular organelles in a directional manner along polar microtubules is driven by the motor proteins, kinesin and cytoplasmic dynein. The binding of these proteins to a microsomal fraction from embryonic chicken brain is investigated here. Both motors exhibit saturation binding to the vesicles, and proteolysis of vesicle membrane proteins abolishes binding. The maximal binding for kinesin is 12 +/- 1.7 and 43 +/- 2 pmol per mg of vesicle protein with or without 1 mM ATP, respectively. The maximal binding for cytoplasmic dynein is 55 +/- 3.8 and 73 +/- 3.7 pmol per mg of vesicle protein with or without ATP, respectively. These values correspond to 1-6 sites per vesicle of 100-nm diameter. The nonhydrolyzable ATP analog, adenyl-5'-yl imidodiphosphate (AMP-PNP), inhibited kinesin binding to vesicles but increased kinesin binding to microtubules. An antibody to the kinesin light chain also inhibited vesicle binding to kinesin. In the absence but not presence of ATP, competition between the two motors for binding was observed. We suggest that there are two distinguishable binding sites for kinesin and cytoplasmic dynein on these organelles in the presence of ATP and a shared site in the absence of ATP.	DUKE UNIV,MED CTR,DEPT CELL BIOL,BOX 3709,DURHAM,NC 27710	Duke University			Yu, Hanry/L-6050-2019; Yu, Hanry/C-7375-2011; Yu, Hanry/C-1031-2013	Yu, Hanry/0000-0002-0339-3685; Yu, Hanry/0000-0002-0339-3685	NIGMS NIH HHS [GM36277] Funding Source: Medline; NINDS NIH HHS [NS23345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; Chambers J. M., 1983, GRAPHICAL METHODS DA, P94; COHN S, 1987, NATURE, V326, P16, DOI 10.1038/326016a0; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; GROLIG F, 1988, EUR J CELL BIOL, V47, P22; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Kelly RB, 1990, CURR OPIN CELL BIOL, V2, P105, DOI 10.1016/S0955-0674(05)80039-0; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MILLER RH, 1987, SCIENCE, V235, P220, DOI 10.1126/science.2432661; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; ROTHWELL SW, 1989, J CELL BIOL, V108, P2313, DOI 10.1083/jcb.108.6.2313; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SHEETZ MP, 1987, BIOESSAYS, V7, P165, DOI 10.1002/bies.950070406; SHEETZ MP, 1989, TRENDS NEUROSCI, V12, P474, DOI 10.1016/0166-2236(89)90099-4; SHERLINE P, 1977, J CELL BIOL, V72, P380, DOI 10.1083/jcb.72.2.380; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SUPRENANT KA, 1982, J CELL BIOL, V93, P164, DOI 10.1083/jcb.93.1.164; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vale RD, 1990, CURR OPIN CELL BIOL, V2, P15, DOI 10.1016/S0955-0674(05)80025-0; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	34	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20457	20464						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400364				2022-12-27	WOS:A1992JR85800110
J	CHAPMAN, ER; ESTEP, RP; STORM, DR				CHAPMAN, ER; ESTEP, RP; STORM, DR			PALMITYLATION OF NEUROMODULIN (GAP-43) IS NOT REQUIRED FOR PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING-PROTEIN; GROWTH-ASSOCIATED PROTEIN; AXONALLY TRANSPORTED PROTEINS; LONG-TERM POTENTIATION; ADULT-RAT BRAIN; NEURITE OUTGROWTH; PHORBOL ESTER; B-50 GAP-43; POLYPHOSPHOINOSITIDE METABOLISM; SUBCELLULAR FRACTION	Neuromodulin (also designated GAP-43, B-50, and F-1) is a prominent protein kinase C substrate attached to the membranes of neuronal growth cones during development and to presynaptic membranes in discrete subsets of adult synapses. In this study, we have examined the relationship between the attachment of neuromodulin to membranes and its phosphorylation by protein kinase C. To address this issue, we have compared wild-type and mutant neuromodulins expressed in cells that normally lack the protein. Wild-type neuromodulin expressed in Chinese hamster ovary cells was associated with membranes, incorporated [H-3]palmitic acid, and was phosphorylated in response to phorbol ester treatment. Substitution of serine 41, the in vitro protein kinase C site, abolished the phorbol ester response, indicating that serine 41 serves as the sole protein kinase C phosphorylation site in vivo. Substitution of the putative fatty acylation sites, cysteines 3 and 4, abolished membrane association as well as [H-3]palmitic acid labeling of neuromodulin. Fatty acylation therefore appears to serve as the mechanism for anchoring neuromodulin to membranes. Surprisingly, the soluble cysteine substitution mutant was phosphorylated by protein kinase C at a rate indistinguishable from that of the wild-type protein. Therefore, membrane association may not be required for the phosphorylation of neuromodulin by protein kinase C.			CHAPMAN, ER (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.			Chapman, Edwin/0000-0001-9787-8140	NHLBI NIH HHS [HL-23606] Funding Source: Medline; NIGMS NIH HHS [GM-07270, GM-33708] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270, R01GM033708] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERS R, 1987, J NEUROSCI, V7, P3977; AKERS RF, 1985, BRAIN RES, V334, P147, DOI 10.1016/0006-8993(85)90576-1; AKITA Y, 1990, J BIOL CHEM, V265, P354; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ALLSOPP TE, 1989, J NEUROSCI, V9, P13; APEL ED, 1991, J BIOL CHEM, V266, P10544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; AU DC, 1989, BIOCHEMISTRY-US, V28, P8142, DOI 10.1021/bi00446a027; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CHAKRAVARTHY BR, 1989, BIOCHEM BIOPH RES CO, V160, P340, DOI 10.1016/0006-291X(89)91661-6; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CIMLER BM, 1985, J BIOL CHEM, V260, P784; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; DEGRAAN PNE, 1988, NEUROSCI RES COMMUN, V3, P175; DEGRAAN PNE, 1989, J NEUROCHEM, V52, P17; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; GIRARD PR, 1990, J NEUROCHEM, V54, P300, DOI 10.1111/j.1471-4159.1990.tb13315.x; GISPEN WH, 1985, BRAIN RES, V328, P381, DOI 10.1016/0006-8993(85)91054-6; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HALL FL, 1988, J BIOL CHEM, V263, P4460; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; HSU L, 1984, CANCER RES, V44, P4607; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRIVEE DC, 1987, J NEUROCHEM, V49, P1747, DOI 10.1111/j.1471-4159.1987.tb02432.x; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; Maniatis T., 1982, MOL CLONING; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; MATTSON MP, 1988, J NEUROSCI RES, V21, P447, DOI 10.1002/jnr.490210236; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MEIRI KF, 1988, J NEUROSCI, V8, P2571; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; MEIRI KF, 1990, J NEUROSCI, V10, P256; MOSS DJ, 1990, J NEUROCHEM, V54, P729, DOI 10.1111/j.1471-4159.1990.tb02312.x; MURPHY K M M, 1983, Science (Washington D C), V222, P1036, DOI 10.1126/science.6316499; NELSON RB, 1989, J NEUROSCI, V9, P381; NIELANDER HB, 1990, J NEUROCHEM, V55, P1442, DOI 10.1111/j.1471-4159.1990.tb03159.x; PERRONEBIZZOZERO NI, 1989, J NEUROCHEM, V52, P1149, DOI 10.1111/j.1471-4159.1989.tb01860.x; PERSAUD SJ, 1989, FEBS LETT, V245, P80, DOI 10.1016/0014-5793(89)80196-6; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; PISANO MR, 1988, BIOCHEM BIOPH RES CO, V155, P1207, DOI 10.1016/S0006-291X(88)81268-3; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V43, P3, DOI 10.1016/S0163-1047(85)91426-8; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SKENE JHP, 1981, J CELL BIOL, V89, P86, DOI 10.1083/jcb.89.1.86; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; SPENCER SA, 1991, NEUR ABSTR, V17, P52515; SPINELLI W, 1982, CANCER RES, V42, P5067; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; VANDONGEN CJ, 1985, BIOCHEM BIOPH RES CO, V128, P1219, DOI 10.1016/0006-291X(85)91070-8; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0; ZWIERS H, 1985, J NEUROCHEM, V44, P1083, DOI 10.1111/j.1471-4159.1985.tb08728.x	70	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25233	25238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460023				2022-12-27	WOS:A1992KB60300050
J	LIU, W; HANSEN, JN				LIU, W; HANSEN, JN			ENHANCEMENT OF THE CHEMICAL AND ANTIMICROBIAL PROPERTIES OF SUBTILIN BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE ANTIBIOTIC NISIN; ARTIFICIAL MEMBRANES; PROTEIN; BACTERIAL; MODE; EXPRESSION; PRECURSOR; MECHANISM; LIPOSOMES	Subtilin and nisin are gene-encoded antibiotic peptides that are ribosomally synthesized by Bacillus subtilis and Lactococcus lactis, respectively. Gene-encoded antibiotics are unique in that their structures can be manipulated by mutagenesis of their structural genes. Although subtilin and nisin share considerable structural homology, subtilin has a greater tendency than nisin to undergo spontaneous inactivation. This inactivation is accompanied by chemical modification of the dehydroalanine at position 5 (DHA5) with a kinetic first-order t1/2 of 0.8 days. It was hypothesized that the R group carboxyl of Glu4 in subtilin participates in the chemical modification of the adjacent DHA5. Noting that nisin has Ile at position 4, site-directed mutagenesis was used to change Glu4 of subtilin to Ile, in order to eliminate this carboxyl-group participation. The DHA5 of this mutant subtilin (E4I-subtilin) underwent modification with a t1/2 of 48 days, which is 57-fold slower than natural subtilin, and the rate of loss of biological activity dropped by a like amount. These results suggest that an intact DHA5 is critical for subtilin activity against bacterial spore outgrowth. A double mutant of subtilin, in which the DHA5 residue of E4I-subtilin was mutated to Ala was devoid of detectable inhibition against spore outgrowth. The specific activity of E4I-subtilin was 3-4-fold higher than natural subtilin, suggesting that an increase in the hydrophobicity of the N-terminal end of the molecule enhances activity. These are the first mutants of subtilin that have been reported, and E4I-subtilin is the first example of any lantibiotic whose properties have been improved by mutagenesis. In order to carry out the mutagenesis, a host-vector pair was constructed that permits a deletion replacement in which the natural subtilin gene is replaced by the mutant gene at the normal location in the chromosome. This maintains normal gene dosage and regulatory responses, as well as eliminates ambiguities caused by expression of the normal and mutant genes in the same cell.	UNIV MARYLAND, DEPT CHEM & BIOCHEM, COLL PK, MD 20742 USA	University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI024454, R01AI024454] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24454] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BIERBAUM G, 1989, FEMS MICROBIOL LETT, V58, P223, DOI 10.1016/S0378-1097(97)00526-0; BOTT KF, 1967, J BACTERIOL, V94, P562, DOI 10.1128/JB.94.3.562-570.1967; BROADBENT JR, 1989, J DAIRY SCI, V72, P3342, DOI 10.3168/jds.S0022-0302(89)79496-0; BRON S, 1990, MOL BIOL METHODS BAC, P75; BRUICE TC, 1992, P NATL ACAD SCI USA, V89, P1700, DOI 10.1073/pnas.89.5.1700; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CHUNG YJ, 1992, J BACTERIOL, V174, P1417, DOI 10.1128/jb.174.4.1417-1422.1992; CHUNG YJ, 1992, J BACTERIOL, V174, P6699, DOI 10.1128/JB.174.20.6699-6702.1992; DEVOS WM, 1991, NISIN NOVEL LANTIBIO, P457; FEENEY RE, 1948, ARCH BIOCHEM, V17, P435; GAO FH, 1991, APPL ENVIRON MICROB, V57, P2164, DOI 10.1128/AEM.57.8.2164-2170.1991; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; GROSS E, 1973, H-S Z PHYSIOL CHEM, V354, P810; GROSS E, 1978, ANTIBIOTICS ISOLATIO, P415; Gross E, 1975, PEPTIDES CHEM STRUCT, P31; Hansen JN, 1991, NISIN NOVEL LANTIBIO, P287; HANSEN JN, 1989, J FOOD SAFETY, V10, P121; HAWKINS G, 1990, THESIS U MARYLAND CO; HEDGE PJ, 1985, NATURE, V318, P478, DOI 10.1038/318478a0; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; INGRAM L, 1970, BIOCHIM BIOPHYS ACTA, V224, P263, DOI 10.1016/0005-2787(70)90642-8; INGRAM LC, 1969, BIOCHIM BIOPHYS ACTA, V184, P216, DOI 10.1016/0304-4165(69)90121-4; Jansen E. F., 1944, ARCH BIOCHEM, V4, P297; JAY JM, 1983, FOOD MICROBIOL, V8, P117; KELLNER R, 1988, EUR J BIOCHEM, V177, P53, DOI 10.1111/j.1432-1033.1988.tb14344.x; KELLNER R, 1989, ANGEW CHEM INT EDIT, V28, P616, DOI 10.1002/anie.198906161; KORDEL M, 1988, J BACTERIOL, V170, P84, DOI 10.1128/jb.170.1.84-88.1988; KORDEL M, 1989, FEBS LETT, V244, P99, DOI 10.1016/0014-5793(89)81171-8; KUIPERS OP, 1991, NISIN NOVEL LANTIBIO, P250; LIU W, 1991, J BACTERIOL, V173, P7387, DOI 10.1128/jb.173.22.7387-7390.1991; LIU W, 1990, APPL ENVIRON MICROB, V56, P2551, DOI 10.1128/AEM.56.8.2551-2558.1990; Maniatis T., 1982, MOL CLONING; Mattick ATR, 1944, NATURE, V154, P551, DOI 10.1038/154551a0; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; Rogers LA, 1928, J BACTERIOL, V16, P321, DOI 10.1128/JB.16.5.321-325.1928; RUHR E, 1985, ANTIMICROB AGENTS CH, V27, P841, DOI 10.1128/AAC.27.5.841; SAHL HG, 1985, MICROBIOL SCI, V2, P212; SCHULLER F, 1989, EUR J BIOCHEM, V182, P181, DOI 10.1111/j.1432-1033.1989.tb14815.x; SEARS P M, 1991, Journal of Dairy Science, V74, P203; STEEN M, 1992, THESIS U MARYLAND CO; WILSON GA, 1968, J BACTERIOL, V95, P1439, DOI 10.1128/JB.95.4.1439-1449.1968; YOUNG FE, 1974, HDB GENETICS, V1, P69	44	93	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25078	25085						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460009				2022-12-27	WOS:A1992KB60300028
J	MUDERHWA, JM; BROCKMAN, HL				MUDERHWA, JM; BROCKMAN, HL			LATERAL LIPID DISTRIBUTION IS A MAJOR REGULATOR OF LIPASE ACTIVITY - IMPLICATIONS FOR LIPID-MEDIATED SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLESTEROL ESTERASE; PROTEIN-KINASE-C; CARBOXYLESTER LIPASE; FATTY-ACIDS; GEOTRICHUM-CANDIDUM; SURFACE PHASES; BILE-SALTS; STATE; PHOSPHOLIPASE-A2; DIACYLGLYCEROL	Pancreatic carboxylester lipase catalyzes the exchange of O-18 between water and 13,16-cis,cis-docosadienoic acid (DA) in monolayers at the argon-buffer interface (Muderhwa, J. M., Schmid, P. C., and Brockman, H. L. (1992) Biochemistry 31, 141). In mixed monolayers of O-18, O-18-DA and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), both the extent and mechanism of O-18 exchange show characteristics of a critical transition in the range of 0.5-0.6 mol fraction of DA (Muderhwa, J. M., and Brockman, H. L. (1992) Biochemistry 31, 149). To determine if the regulatory behavior exhibited on this type of surface is limited to members of the carboxylester lipase gene family (cholinesterases), comparable experiments were performed with a genetically and functionally unrelated lipase, pancreatic colipase-dependent lipase (PL). PL readily catalyzed the exchange of O-18 between water and the carboxyl group of DA with enzyme at either monolayer or catalytic levels in the fatty acid-buffer interface. The oxygen exchange reaction obeyed a random, sequential mechanism, indicating that the dissociation of the enzyme.DA complex is much faster than the rate-limiting step in the overall exchange process. Kinetic analysis of oxygen exchange in pure DA monolayers showed a first-order dependence on interfacial PL and DA concentrations from which k(cat)/K(m) values were calculated. The oxygen exchange reaction proceeded with a rate constant of 16 x 10(-2) cm2 pmol-1 s-1, a value comparable to that for hydrolysis of the ester substrate, 1,3-dioleoylglycerol. With a monolayer of PL adsorbed to the interfacial phase, k(cat)/K(m) for oxygen exchange was about 600-fold lower than the value obtained with catalytic levels of adsorbed enzyme, indicating a possible restriction of substrate diffusion in the protein-covered fatty acid monolayer. With constant bulk PL concentration and mixed lipid monolayers containing DA and the non-substrate lipid, POPC, the extent of oxygen exchange increased abruptly as the abundance of DA in the interface was increased from 0.5 to 0.6 mol fraction. Concomitant with this critical transition was a change in the apparent mechanism of oxygen exchange from coupled to random, sequential. For both the extent of oxygen exchange and its mechanism shift, the critical transition was independent of the lipid packing density, i.e. surface pressure, of the interface. These results show that PL responds similarly to carboxylester lipase with respect to changes in interfacial lipid mole fraction in DA-POPC surfaces. This strengthens the hypothesis that lateral lipid distribution in a phospholipid-substrate surface puts substantial constraints on lipase adsorption to the interface, the in-plane accessibility of substrate to adsorbed lipases, and, possibly, the "interfacial activation" of lipases. The apparent dominance of surface structure as a regulator of lipases suggests that the lateral distribution of fatty acids and diacylglycerols in cell membranes could play an important role in lipid-mediated signal transduction.	UNIV MINNESOTA,HORMEL INST,801 16TH AVE NE,AUSTIN,MN 55912	University of Minnesota System					NHLBI NIH HHS [HL49180] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHKONG QF, 1973, BIOCHEM J, V136, P147, DOI 10.1042/bj1360147; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; BERNBACK S, 1990, J CLIN INVEST, V85, P1221, DOI 10.1172/JCI114556; BHAT SG, 1982, BIOCHEMISTRY-US, V21, P1547, DOI 10.1021/bi00536a013; BHAT SG, 1981, J BIOL CHEM, V256, P3017; BITTMAN R, 1986, BIOCHIM BIOPHYS ACTA, V863, P115, DOI 10.1016/0005-2736(86)90393-7; BROCKMAN HL, 1991, GBF MONOGR SER, V16, P95; Brockman HL, 1984, LIPASES, P1; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURGER KNJ, 1991, BIOCHIM BIOPHYS ACTA, V1068, P249, DOI 10.1016/0005-2736(91)90216-U; Cullis P.R., 1985, PHOSPHOLIPIDS CELLUL, P1; CUNNINGHAM BA, 1989, BIOCHEMISTRY-US, V28, P32, DOI 10.1021/bi00427a006; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DAWSON RMC, 1984, BIOCHEM BIOPH RES CO, V125, P836, DOI 10.1016/0006-291X(84)90615-6; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; ESSAM JW, 1980, REP PROG PHYS, V43, P833, DOI 10.1088/0034-4885/43/7/001; GARNER CW, 1970, BIOCHEM BIOPH RES CO, V39, P672, DOI 10.1016/0006-291X(70)90258-5; GAWLINSKI ET, 1981, J PHYS A-MATH GEN, V14, pL291, DOI 10.1088/0305-4470/14/8/007; GOMEZFERNANDEZ JC, 1990, PROG CLIN BIOL RES, V343, P53; HIDE WA, 1992, J LIPID RES, V33, P167; HOSHEN J, 1976, PHYS REV B, V14, P3438, DOI 10.1103/PhysRevB.14.3438; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KOYNOVA RD, 1987, BIOCHIM BIOPHYS ACTA, V903, P186, DOI 10.1016/0005-2736(87)90168-4; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; KUWAE T, 1990, J BIOL CHEM, V265, P5002; LACHOWIEZ RM, 1988, FEBS LETT, V234, P195, DOI 10.1016/0014-5793(88)81332-2; LINDSTROM MB, 1988, BIOCHIM BIOPHYS ACTA, V959, P178, DOI 10.1016/0005-2760(88)90029-X; MOMSEN WE, 1978, J LIPID RES, V19, P1032; MUDERHWA JM, 1990, J BIOL CHEM, V265, P19644; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P149, DOI 10.1021/bi00116a022; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P141, DOI 10.1021/bi00116a021; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PEIRONI G, 1979, J BIOL CHEM, V254, P10090; PIERONI G, 1990, ADV COLLOID INTERFAC, V32, P341, DOI 10.1016/0001-8686(90)80023-S; Rudd E.A., 1984, P185; SCHMID PC, 1988, CHEM PHYS LIPIDS, V46, P165, DOI 10.1016/0009-3084(88)90018-7; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SEN A, 1991, BIOCHEMISTRY-US, V30, P4516, DOI 10.1021/bi00232a021; SHIMADA Y, 1990, J BIOCHEM-TOKYO, V107, P703, DOI 10.1093/oxfordjournals.jbchem.a123112; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SMABY JM, 1984, BIOCHEMISTRY-US, V23, P3312, DOI 10.1021/bi00309a030; SMABY JM, 1985, BIOPHYS J, V48, P701, DOI 10.1016/S0006-3495(85)83828-5; SMABY JM, 1992, LANGMUIR, V8, P563, DOI 10.1021/la00038a042; STAUFFER D, 1985, INTRO PERCOLATION TH, P15; Stauffer D., 1985, INTRO PERCOLATION TH, P1; THUREN T, 1988, FEBS LETT, V229, P95, DOI 10.1016/0014-5793(88)80805-6; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8430, DOI 10.1021/bi00399a060; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8423, DOI 10.1021/bi00399a059; TSUJITA T, 1989, J BIOL CHEM, V264, P8612; Verger R, 1980, Methods Enzymol, V64, P340; VERGER R, 1969, BIOCHIM BIOPHYS ACTA, V188, P272, DOI 10.1016/0005-2795(69)90075-0; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	55	92	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24184	24192						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447168				2022-12-27	WOS:A1992KA26300010
J	BLOMHOFF, HK; SMELAND, EB; ERIKSTEIN, B; RASMUSSEN, AM; SKREDE, B; SKJONSBERG, C; BLOMHOFF, R				BLOMHOFF, HK; SMELAND, EB; ERIKSTEIN, B; RASMUSSEN, AM; SKREDE, B; SKJONSBERG, C; BLOMHOFF, R			VITAMIN-A IS A KEY REGULATOR FOR CELL-GROWTH, CYTOKINE PRODUCTION, AND DIFFERENTIATION IN NORMAL B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN-RECEPTOR; RETINOIC ACID; LYMPHOCYTES-B; IMMUNE-RESPONSE; DEPLETED RATS; BETA-CAROTENE; CYCLIC-AMP; HUMANS; POLYSACCHARIDE; PROLIFERATION	In the present paper we demonstrate that retinol-retinol-binding protein and chylomicron remnant retinyl esters in concentrations normally found in human plasma inhibit growth of normal human B lymphocytes. Physiological concentrations of retinoic acid (about 30 nM) were less active than physiological concentrations of retinol (about 3 muM). Pharmacological concentrations of retinol and retinoic acid were more active than the concentrations normally found in plasma. Retinol (3 muM) inhibited anti-IgM-mediated DNA synthesis as measured by [H-3]thymidine uptake at 72 h by 78%. Furthermore, we found that the cells were blocked in the mid-G1 phase of the cell cycle. Thus, neither MYC up-regulation measured at 3 h nor the expression of the early activation antigen 4F2 was reduced by retinol, whereas the late activation markers transferrin receptor expression and actinomycin (D staining at 48 h of stimulation) were markedly inhibited. Retinol reduced the interleukin 6 production induced by anti-IgM and interleukin 4 after 48 h, whereas the induction of interleukin 6 and tumor necrosis factor by O-tetradecanoylphorbol-13-acetate and ionomycin was less affected. We also noted that the retinoids reduced the formation of plaque-forming cells (i.e. Ig synthesis). These data imply that vitamin A present in human plasma is a normal modulator of B cell function.	UNIV OSLO,INST NUTR RES,N-0316 OSLO,NORWAY	University of Oslo	BLOMHOFF, HK (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,DEPT PATHOL,IMMUNOL LAB,N-0310 OSLO,NORWAY.		Smeland, Erlend/AAO-3214-2020					BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1990, J INTERN MED, V228, P207, DOI 10.1111/j.1365-2796.1990.tb00219.x; BOHMER RM, 1981, CYTOMETRY, V2, P31, DOI 10.1002/cyto.990020107; BOSMA M, 1988, J CELL PHYSIOL, V135, P317, DOI 10.1002/jcp.1041350220; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; EGELAND T, 1988, SCAND J IMMUNOL, V27, P439, DOI 10.1111/j.1365-3083.1988.tb02369.x; FINDLEY HW, 1984, EXP HEMATOL, V12, P768; FRIEDMAN A, 1989, BRIT J NUTR, V62, P439, DOI 10.1079/BJN19890044; FRIEDMAN A, 1991, J NUTR, V121, P395, DOI 10.1093/jn/121.3.395; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GJOEN T, 1987, J BIOL CHEM, V262, P10926; GODAL T, 1983, CLIN EXP IMMUNOL, V54, P756; HOLTE H, 1988, EUR J IMMUNOL, V18, P1359, DOI 10.1002/eji.1830180909; ISRAEL H, 1991, CLIN IMMUNOL IMMUNOP, V59, P417, DOI 10.1016/0090-1229(91)90037-B; JETTEN AM, 1984, FED PROC, V43, P134; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LARGMAN C, 1989, BLOOD, V74, P99; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MARX JL, 1988, SCIENCE, V239, P975, DOI 10.1126/science.3422766; PASATIEMPO AMG, 1990, FASEB J, V4, P2518, DOI 10.1096/fasebj.4.8.2110538; PASATIEMPO AMG, 1991, J NUTR, V121, P556, DOI 10.1093/jn/121.4.556; PRABHALA RH, 1991, CANCER, V67, P1556, DOI 10.1002/1097-0142(19910315)67:6<1556::AID-CNCR2820670616>3.0.CO;2-O; Roberts A.B., 1984, RETINOIDS, V2, P210; SIDELL N, 1991, J IMMUNOL, V146, P3809; SIDELL N, 1984, CELL IMMUNOL, V88, P374, DOI 10.1016/0008-8749(84)90170-9; SKJONSBERG C, 1991, BLOOD, V77, P2445; SMELAND E, 1985, P NATL ACAD SCI USA, V82, P6255, DOI 10.1073/pnas.82.18.6255; SMELAND EB, 1989, J EXP MED, V170, P1463, DOI 10.1084/jem.170.4.1463; STOKKE T, 1988, CANCER RES, V48, P6708; WATHNE KO, 1989, BIOCHEM J, V257, P239, DOI 10.1042/bj2570239; WATSON RR, 1991, AM J CLIN NUTR, V53, P90, DOI 10.1093/ajcn/53.1.90; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5	34	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23988	23992						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429735				2022-12-27	WOS:A1992JZ23900083
J	KAMAGATA, Y; MATTEI, MG; NINOMIYA, Y				KAMAGATA, Y; MATTEI, MG; NINOMIYA, Y			ISOLATION AND SEQUENCING OF CDNAS AND GENOMIC DNAS ENCODING THE ALPHA-4 CHAIN OF BASEMENT-MEMBRANE COLLAGEN TYPE-IV AND ASSIGNMENT OF THE GENE TO THE DISTAL LONG ARM OF HUMAN CHROMOSOME-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOODPASTURE ANTIGEN; ALPORT SYNDROME; GLOBULAR DOMAIN; X-CHROMOSOME; IDENTIFICATION; LOCALIZATION; CLONING; EPITOPE; ALPHA-1-CHAIN; PROTEINS	We cloned three overlapping cDNAs covering 2,452 base pairs encoding a new basement membrane collagen chain, alpha4(IV), from rabbit corneal endothelial cell RNA. Nucleotide sequence analysis demonstrated that the clones encoded a triple-helical domain of 392 1/3 amino acid residues and a carboxyl non-triple-helical (NC1) domain of 231 residues. We also isolated a genomic DNA fragment for the human alpha4(IV) chain, which contained two exons encoding from the carboxyl end of the triple-helical domain to the amino end of the NC 1 domain. Identification of the clones was based on the amino acid sequence identity between the cDNA-deduced amino acid sequence and the reported amino acid sequence obtained from a fragment of the alpha4(IV) collagen polypeptide M28+ (Butkowski, R. J., Shen, G.-Q., Wieslander, J., Michael, A. F., and Fish, A. J. (1990) J. Lab. Clin. Med. 115, 365-373). When compared with four other type IV collagen chains, the NC1 domain contained 12 cysteinyl residues in positions identical to those of the residues in those chains. The domain demonstrated 61, 70, 55, and 60% amino acid similarity with human alpha1, human alpha2, bovine alpha3, and human alpha5 chains, respectively. The human genomic DNA fragment allowed us to map the alpha4(IV) gene (COL4A4) to the 2q35-2q37.1 region of the human genome.	OKAYAMA UNIV, SCH MED, DEPT MOLEC BIOL & BIOCHEM, 2-5-1 SHIKATA CHO, OKAYAMA 700, JAPAN; HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA; HOP ENFANTS, GRP HOSP TIMONE, INSERM, U242, F-13385 MARSEILLE, FRANCE	Okayama University; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille					NEI NIH HHS [EY07334] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007334] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1990, J LAB CLIN MED, V115, P365; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESJARDINS M, 1991, J CELL BIOL, V113, P689, DOI 10.1083/jcb.113.3.689; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; EMANUEL BS, 1985, P NATL ACAD SCI USA, V82, P3385, DOI 10.1073/pnas.82.10.3385; FEINGOLD J, 1985, KIDNEY INT, V27, P672, DOI 10.1038/ki.1985.63; GRANT WT, 1985, J BIOL CHEM, V260, P3798; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1987, FEBS LETT, V224, P297, DOI 10.1016/0014-5793(87)80473-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KASHTAN C, 1986, J CLIN INVEST, V78, P1035, DOI 10.1172/JCI112658; KINO J, 1991, AM J PATHOL, V138, P911; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; Maniatis T., 1982, MOL CLONING; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; MYERS JC, 1990, AM J HUM GENET, V46, P1024; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1989, J BIOL CHEM, V264, P6318; SAUS J, 1988, J BIOL CHEM, V263, P13374; SOININEN R, 1987, FEBS LETT, V225, P188; SOLOMON E, 1985, P NATL ACAD SCI USA, V82, P3330, DOI 10.1073/pnas.82.10.3330; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VASIOS G, 1987, STRUCTURE FUNCTION C, P283; WEIL D, 1988, AM J HUM GENET, V42, P435; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; YAMAGUCHI N, 1991, INVEST OPHTH VIS SCI, V32, P2924; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	43	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23753	23758						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429714				2022-12-27	WOS:A1992JZ23900051
J	RUDNICK, DA; JOHNSON, RL; GORDON, JI				RUDNICK, DA; JOHNSON, RL; GORDON, JI			STUDIES OF THE CATALYTIC ACTIVITIES AND SUBSTRATE SPECIFICITIES OF SACCHAROMYCES-CEREVISIAE MYRISTOYL-COENZYME-A - PROTEIN N-MYRISTOYLTRANSFERASE DELETION MUTANTS AND HUMAN YEAST NMT CHIMERAS IN ESCHERICHIA-COLI AND SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; ADP-RIBOSYLATION FACTOR; 2 GENES; COA; TRANSFERASE; TEMPERATURE; SEQUENCE; BINDING; OXYGEN; PURIFICATION	Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) is an essential, 455-residue, monomeric enzyme. Amino- and carboxyl-terminal deletion mutants of Nmt1p were genetically engineered to determine the minimal domain necessary to maintain catalytic activity. Enzyme activity was assessed by (i) sequentially inducing Nmt1p or its mutant derivatives and one of two eukaryotic substrates for the wild type enzyme (S. cerevisiae Gpa1p and rat G(oalpha) in Escherichia coli, a bacterium with no endogenous myristoyltransferase activity, and monitoring Nmt-dependent incorporation of exogenous [H-3]myristate into the G protein alpha subunits or (ii) an in vitro enzyme assay using lysates prepared from bacteria producing wild type or mutant Nmts. The data indicate that the minimal catalytic domain of Nmt1p is located between Ile59 --> Phe96 and Gly451 --> Leu455. Analyses of the ability of mutant nmtps to rescue the lethal phenotype of an nmt1 null allele in a haploid strain of yeast grown on rich media, with or without blockade of cellular fatty acid synthetase, suggest that the amino-terminal 59 residues of Nmt1p may play an important noncatalytic role, functioning as a targeting signal so this cytosolic enzyme can access cellular myristoyl-CoA pools generated from activation of exogenous C14:0 by acyl-CoA synthetase(s). Moreover, there appear to be differences in the location or accessibility of myristoyl-CoA pools derived from fatty acid synthetase and acyl-CoA synthetases. The E. coli co-expression system was used to map structural elements that determine differences in the peptide substrate specificities of Nmt1p and the orthologous human Nmt. Rat G(oalpha) is a substrate for both enzymes, whereas human G(zalpha) is a substrate only for human NMT. Studies of a series of chimeric enzymes composed of elements from the amino- or carboxyl-terminal portions of human and yeast Nmts indicate that (i) recognition/utilization of G(zalpha) involves elements distributed from the amino-terminal half through the region defined by Leu352 --> Lys410 of the 416 residue human enzyme and (ii) formation of a fully functional peptide binding site and a fully functional myristoyl-CoA binding site in either of these enzymes requires contributions from both their amino-terminal and carboxyl-terminal halves.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,600 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30188, AI27179] Funding Source: Medline; NIGMS NIH HHS [GM07200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARR SA, 1982, P NATL ACAD SCI USA, V79, P612; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FREIRE E, 1990, ANAL CHEM, V62, pA950, DOI 10.1021/ac00217a002; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; GOKEL GW, 1992, IN PRESS ISRAEL J CH, V33; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HORI T, 1987, J BIOCHEM-TOKYO, V101, P949, DOI 10.1093/oxfordjournals.jbchem.a121964; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; MEYER KH, 1974, J BACTERIOL, V117, P345, DOI 10.1128/JB.117.2.345-350.1974; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; OKUYAMA H, 1979, J BIOL CHEM, V254, P2281; PAIGE LA, 1989, J MED CHEM, V32, P1667; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SCHWEIZER E, 1970, P NATL ACAD SCI USA, V67, P660, DOI 10.1073/pnas.67.2.660; SHERMAN F, 1987, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591	58	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23852	23861						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429724				2022-12-27	WOS:A1992JZ23900064
J	DERKX, FHM; DEINUM, J; LIPOVSKI, M; VERHAAR, M; FISCHLI, W; SCHALEKAMP, MADH				DERKX, FHM; DEINUM, J; LIPOVSKI, M; VERHAAR, M; FISCHLI, W; SCHALEKAMP, MADH			NONPROTEOLYTIC ACTIVATION OF PRORENIN BY ACTIVE SITE-DIRECTED RENIN INHIBITORS AS DEMONSTRATED BY RENIN-SPECIFIC MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA INACTIVE RENIN; IDENTIFICATION; PREKALLIKREIN; CONVERSION; KALLIKREIN; SYSTEM; RATS	Incubation of human plasma prorenin (PR), the enzymatically inactive precursor of renin (EC 3.4.23.15), with a number of nonpeptide high-affinity active site-directed renin inhibitors induces a conformational change in PR, which was detected by a monoclonal antibody that reacts with active renin but not with native inactive PR. This conformational change also occurred when inactive PR was activated during exposure to low pH. Nonproteolytically acid-activated PR, and inhibitor-"activated" PR, as well as native PR, were retained on a blue Sepharose column, in contrast to proteolytically activated PR. Kinetic analysis of the activation of plasma prorenin by renin inhibitor (INH) indicated that native plasma contains an open intermediary form of prorenin, PR(oi), in which the active site is exposed and which is in rapid equilibrium with the inactive closed form, PR(c). PR(oi) reacts with inhibitor to form a reversible complex, PR(oi).INH, which undergoes a conformational change resulting in a tight complex of a modified open form of prorenin, PR(o), and the inhibitor, PR(oi).INH --> PR(o).INH. The PR(oi)-to-PR(o) conversion leads to the expression of an epitope on the renin part of the molecule that is recognized by a renin-specific monoclonal antibody. Presumably, PR(o) corresponds to the enzymatically active form of PR that is formed during exposure to low pH. Thus, it seems that the propeptide of PR interacts with the renin part of the molecule not only at or near the enzyme's active site but also at some distance from the active site. Interference with the first interaction by renin inhibitor leads to destabilization of the propeptide, by which the second interaction is disrupted and the enzyme assumes its active conformation. The results of this study may provide a model for substrate-mediated prorenin activation and increase the likelihood that enzymatically active prorenin is formed in vivo.	ERASMUS UNIV,UNIV HOSP DYKZIGT,DEPT INTERNAL MED 1,RM H 362,3015 GD ROTTERDAM,NETHERLANDS; F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND	Erasmus University Rotterdam; Roche Holding			Verhaar, Marianne/A-6577-2008	Verhaar, Marianne/0000-0002-3276-6428; Lipovsky, Myriam/0000-0002-5387-9288				CUMIN F, 1985, J BIOL CHEM, V290, P9154; DEGASPARO M, 1989, BRIT J CLIN PHARMACO, V27, P587; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; DERKX FHM, 1979, NATURE, V280, P315, DOI 10.1038/280315a0; DERKX FHM, 1986, J CLIN ENDOCR METAB, V63, P1008, DOI 10.1210/jcem-63-4-1008; DERKX FHM, 1983, HYPERTENSION, V5, P244, DOI 10.1161/01.HYP.5.2.244; DERKX FHM, 1991, AM J HYPERTENS, V4, P602, DOI 10.1093/ajh/4.7.602; FISCHLI W, 1991, HYPERTENSION, V18, P22, DOI 10.1161/01.HYP.18.1.22; GALEN FX, 1984, J CLIN INVEST, V74, P723, DOI 10.1172/JCI111488; Guesdon J L, 1981, Methods Enzymol, V73, P471; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; HEINRIKSON RL, 1990, HYPERTENSION PATHOPH, P1179; HIROSE S, 1985, J BIOL CHEM, V260, P6400; HSUEH WA, 1991, HYPERTENSION, V17, P469, DOI 10.1161/01.HYP.17.4.469; HSUEH WA, 1981, HYPERTENSION, V3, P22; INAGAMI T, 1982, J CLIN ENDOCR METAB, V55, P619, DOI 10.1210/jcem-55-4-619; KITZ R, 1962, J BIOL CHEM, V237, P3245; KLEINERT HD, 1988, HYPERTENSION, V11, P613, DOI 10.1161/01.HYP.11.6.613; LECKIE BJ, 1980, NATURE, V288, P702, DOI 10.1038/288702a0; MENARD J, 1985, J HYPERTENS, V3, pS275; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OSMOND DH, 1975, CAN J PHYSL PHARM, V51, P705; SEALEY JE, 1976, AM J MED, V61, P731, DOI 10.1016/0002-9343(76)90154-6; SEALEY JE, 1979, P NATL ACAD SCI USA, V76, P5914, DOI 10.1073/pnas.76.11.5914; SEALEY JE, 1989, AM J HYPERTENS, V2, P358, DOI 10.1093/ajh/2.5.358; SHINAGAWA T, 1990, P NATL ACAD SCI USA, V87, P1927, DOI 10.1073/pnas.87.5.1927; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SIMON D, 1987, CLIN EXP HYPERTENS A, V9, P133; YAMAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P27, DOI 10.1093/oxfordjournals.jbchem.a123005	29	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22837	22842						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429632				2022-12-27	WOS:A1992JY16300023
J	GUEST, PC; ARDEN, SD; BENNETT, DL; CLARK, A; RUTHERFORD, NG; HUTTON, JC				GUEST, PC; ARDEN, SD; BENNETT, DL; CLARK, A; RUTHERFORD, NG; HUTTON, JC			THE POSTTRANSLATIONAL PROCESSING AND INTRACELLULAR SORTING OF PC2 IN THE ISLETS OF LANGERHANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETORY-GRANULE; NEWLY SYNTHESIZED PROINSULIN; ISOLATED RAT ISLETS; CARBOXYPEPTIDASE-H; ENDOPLASMIC-RETICULUM; CELLS; IDENTIFICATION; BIOSYNTHESIS; PROTEINS; CONSTITUENTS	Proinsulin conversion in the insulin secretory granule is mediated by two sequence-specific endoproteases related to the Kex2 homologues, PC2 and PC3 (Bennett, D. L., Bailyes, E. M., Nielsen, E., Guest, P. C., Rutherford, N. G., Arden, S. D., and Hutton, J. C. (1992) J. Biol. Chem. 267, 15229-15236; Bailyes, E. M., Bennett, D. L., and Hutton, J. C. (1992) Enzyme, in press). Radiolabeling studies using isolated rat islets showed that PC2 was synthesized initially as a 76-kDa glycoprotein which was converted by limited proteolysis to the mature 64-66-kDa form. Conversion was initiated approximately 1 h after synthesis and proceeded via intermediates of 71, 68, and 66 kDa with a t1/2 of 140 min. Release of only the 66- and 64-66-kDa radiolabeled forms of PC2 was induced by glucose and then only at times more than 2 h following synthesis. Proinsulin conversion, by contrast, was more rapid (delay = 30 min, t1/2 = 60 min), and release commenced as soon as 1 h after synthesis with the secreted material being comprised of the precursor, intermediate, and mature forms of insulin. Ultrastructural analysis of islet beta cells showed that PC2 was concentrated in secretory granules. Subcellular fractionation combined with immunoblot analysis showed that insulinoma secretory granules contained only the mature 64-66-kDa form of PC2, whereas fractions enriched in Golgi and endoplasmic reticulum contained a mixture of the 76- and 66-kDa forms of the enzyme. These results indicate that post-translational proteolysis of PC2 is initiated before sorting into the regulated pathway of secretion and that the relative proportions of proinsulin and PC2 packaged into secretory granules will change with physiological conditions.	UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	GUEST, PC (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.			guest, paul/0000-0002-5030-7137	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARVAN P, 1991, J BIOL CHEM, V266, P14171; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BAILYES EM, 1992, IN PRESS ENZYME; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BARRETT AJ, 1977, LYSOZOMES LABORATORY, P9; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BOWERS GN, 1975, CLIN CHEM, V21, P1988; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREENAN SO, 1991, J BIOL CHEM, V266, P21504; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAVIDSON HW, 1982, ANN REV PHYSL, V44, P625; GOLD G, 1984, DIABETES, V33, P556, DOI 10.2337/diabetes.33.6.556; GRAY IP, 1987, DIABETES, V36, P684, DOI 10.2337/diabetes.36.6.684; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1989, BIOCHEM J, V264, P503, DOI 10.1042/bj2640503; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; HEATON DA, 1991, BRIT MED J, V129, P3053; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; HUTTON JC, 1987, BIOCHEM J, V244, P449, DOI 10.1042/bj2440449; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MOLLOY SS, 1992, IN PRESS P NATL ACAD; NAGAMATSU S, 1987, ENDOCRINOLOGY, V120, P1225, DOI 10.1210/endo-120-4-1225; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; SANDO H, 1972, J CLIN INVEST, V51, P1476, DOI 10.1172/JCI106944; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMITH LF, 1966, AM J MED, V40, P662, DOI 10.1016/0002-9343(66)90145-8; SOPWITH AM, 1981, DIABETOLOGIA, V21, P224; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; WARD WK, 1987, DIABETOLOGIA, V30, P698, DOI 10.1007/BF00296991	49	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22401	22406						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429592				2022-12-27	WOS:A1992JW71900065
J	LOKESHWAR, VB; BOURGUIGNON, LYW				LOKESHWAR, VB; BOURGUIGNON, LYW			THE LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN GP85 (CD44) IS A NOVEL GUANINE NUCLEOTIDE-BINDING PROTEIN WHICH REGULATES GP85 (CD44)-ANKYRIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; CELL-SURFACE GLYCOPROTEINS; GTP-BINDING; MONOCLONAL-ANTIBODIES; PERTUSSIS TOXIN; HOMING RECEPTOR; PLASMA-MEMBRANE; ALPHA-SUBUNITS; EXPRESSION; ANKYRIN	In this study, we have used photoaffinity labeling by [P-32]azido-GTP as well as [P-32]ADP-ribosylation by pertussis toxin (PT) and cholera toxin (CT) to identify GTP-binding proteins associated with mouse T-lymphoma plasma membranes. Our results indicate that GP85 (CD44) can be photoaffinity labeled by [P-32] azido-GTP and [P-32]ADP-ribosylated by both PT and CT. Using purified GP85 (CD44) obtained by Triton X-100 extraction, wheat germ agglutinin-Sepharose, and anti-GP85 (CD44) antibody affinity chromatographies, we have further characterized GP85 (CD44) as a GTP-binding protein. GP85 (CD44) is found to bind guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) in a time- and dose-dependent manner with a dissociation constant of 0.83 nM. Importantly, GP85 (CD44) appears to display a GTPase activity which hydrolyzes [gamma-P-32]GTP at a rate of 0.011 mol of P(i) released/mol of GP85 (CD44)/min. This GTPase activity can be readily inhibited by PT- or CT-mediated ribosylation of GP85 (CD44). Most interestingly, GTP binding significantly enhances the interaction of purified GP85 (CD44) with ankyrin, whereas ADP-ribosylation of GP85 (CD44) by PT or CT inhibits the GTP-induced increase in ankyrin binding to GP85 (CD44). In addition to GP85 (CD44) being the first reported transmembrane GTP-binding protein, these results suggest that GTP plays an important role in promoting the interaction between GP85 (CD44) and its underlying membrane cytoskeleton through ankyrin.	UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA	University of Miami					NIGMS NIH HHS [GM 36353] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BIRNBAUMER L, 1991, BIOL REPROD, V44, P207, DOI 10.1095/biolreprod44.2.207; BOURGUIGNON LYW, 1990, J IMMUNOL, V144, P2242; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD RC, 1987, J IMMUNOL, V138, P3120; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ERDOS JJ, 1981, ADV CYCL NUCL RES<D>, V14, P69; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARDEN TK, 1989, INOSITOL LIPIDS CELL, P113; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HUET S, 1989, J IMMUNOL, V143, P798; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LESLEY J, 1985, IMMUNOGENETICS, V22, P149, DOI 10.1007/BF00563512; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; LOWRY DR, 1989, NATURE, V341, P384; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; PANG IH, 1990, J BIOL CHEM, V265, P18707; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; RODBELL M, 1971, J BIOL CHEM, V246, P1877; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1989, J CELL BIOL, V109, P2677; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; STYRE L, 1986, REV CELL BIOL, V2, P391; SUNYER T, 1989, MOL ENDOCRINOL, V3, P1115, DOI 10.1210/mend-3-7-1115; TAYLOR CW, 1990, BIOCHEM J, V272, P1; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TROWBRIDGE IS, 1985, NATURE, V315, P666, DOI 10.1038/315666a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	61	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22073	22078						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429559				2022-12-27	WOS:A1992JW71900017
J	MORII, N; TERUUCHI, T; TOMINAGA, T; KUMAGAI, N; KOZAKI, S; USHIKUBI, F; NARUMIYA, S				MORII, N; TERUUCHI, T; TOMINAGA, T; KUMAGAI, N; KOZAKI, S; USHIKUBI, F; NARUMIYA, S			A RHO GENE-PRODUCT IN HUMAN BLOOD-PLATELETS .2. EFFECTS OF THE ADP-RIBOSYLATION BY BOTULINUM C3 ADP-RIBOSYLTRANSFERASE ON PLATELET-AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-BOTULINUM; GPIIB-IIIA; G-PROTEIN; IDENTIFICATION; CELLS; RAS; PURIFICATION; SUBSTRATE; BINDING; TOXIN	In the accompanying paper (Nemoto, Y., Namba, T., Teru-uchi, T., Ushikubi, F., Morii, N., and Narumiya, S. (1992) J. Biol. Chem. 267,20916-20920), we have identified rhoA protein as the sole substrate protein for botulinum C3 ADP-ribosyltransferase (C3 exoenzyme) in human blood platelets. Here we examined the role of rhoA protein in platelet functions. C3 exoenzyme added to washed platelets dose- and time-dependently ADP-ribosylated rhoA protein in situ in the cells. Concomitant with this modification, inhibition of thrombin-induced platelet aggregation was observed. This inhibition was not reversed by washing the treated platelets, but was not found when C3 exoenzyme was pretreated with mouse monoclonal anti-C3 exoenzyme antibody. C3 exoenzyme treatment did not affect thrombin-induced inositol 1,4,5-trisphosphate production. Secretion of preloaded [C-14]serotonin was delayed by the enzyme treatment, but the extent of the secretion was not influenced. In addition, the enzyme treatment did not change the expression of the glycoprotein IIb-IIIa complex on the platelet surface. The enzyme treatment also suppressed platelet aggregation induced by phorbol myristate acetate. These results suggest that rhoA protein plays a role mainly in the aggregation process downstream from receptor-phospholipase C coupling. This, together with the previous finding that rhoA protein modulates stress fiber formation in cultured fibroblasts (Paterson, H. F., Self, A. J., Garrett, M. D., Just, I., Aktories, K., and Hall, A. (1990) J. Cell Biol. 1111, 1001-1007), suggests that rhoA protein regulates the assembly of actin filaments and the avidity of the platelet integrin (glycoprotein IIb-IIIa) in the aggregation process.	UNIV OSAKA PREFECTURE, COLL AGR, DEPT VET SCI, SAKAI, OSAKA 591, JAPAN	Osaka Metropolitan University	MORII, N (corresponding author), KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN.							AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARROLL RC, 1982, CELL, V30, P385, DOI 10.1016/0092-8674(82)90236-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PACKHAM MA, 1984, THROMB HAEMOSTASIS, V51, P140; PAINTER RG, 1984, EXP CELL RES, V155, P198, DOI 10.1016/0014-4827(84)90781-X; PAINTER RG, 1985, J CELL BIOL, V100, P652, DOI 10.1083/jcb.100.2.652; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SEKINE A, 1989, J BIOL CHEM, V264, P8602; WEISS HJ, 1974, J CLIN INVEST, V54, P421, DOI 10.1172/JCI107778; WHITE JG, 1990, PLATELET 1990 PLATEL, P1	30	157	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20921	20926						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400407				2022-12-27	WOS:A1992JT97800065
J	MERTENS, G; CASSIMAN, JJ; VANDENBERGHE, H; VERMYLEN, J; DAVID, G				MERTENS, G; CASSIMAN, JJ; VANDENBERGHE, H; VERMYLEN, J; DAVID, G			CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS FROM HUMAN VASCULAR ENDOTHELIAL-CELLS - CORE PROTEIN CHARACTERIZATION AND ANTITHROMBIN-III BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG FIBROBLASTS; LIPOPROTEIN-LIPASE; GROWTH-FACTOR; BASEMENT-MEMBRANES; MOLECULAR-CLONING; DISTINCT MEMBRANE; HIGH-AFFINITY; MATRIX; CULTURES; FORMS	Human aortic endothelial cells (HAEC) and human umbilical vein endothelial cells (HUVEC) were labeled with (SO42-)-S-35 for 48 h. The membrane-associated proteoglycans were solubilized from these monolayers with detergent and purified by ion-exchange chromatography on Mono Q, incorporation in liposomes, and gel filtration. The liposome-intercalated proteoglycans were I-125-iodinated and treated with heparitinase before SDS-polyacrylamide gel electrophoresis. Radiolabeled proteins with apparent molecular masses of 130, 60, 46, 35, and 30 kDa (HAEC) and 180, 130, 62, 43, and 35 kDa (HUVEC) were detected by autoradiography. Further characterization by affinity chromatography on immobilized monoclonal antibodies and by Northern blot analysis provided evidence for the expression of syndecan, glypican, and fibroglycan in human endothelial cells. Most of the heparan sulfate which accumulated in the subendothelial matrix was implanted on a 400-kDa core protein. This protein was immunologically related to perlecan and bound to fibronectin. Binding studies on immobilized antithrombin III suggested that all membrane-associated heparan sulfate proteoglycan forms had the capacity to bind to antithrombin III but that high affinity binding was more typical for glypican. Most of the proteoglycans isolated from the extracellular matrix also bound only with low affinity to antithrombin III. These results imply that glypican may specifically contribute to the antithrombotic properties of the vascular wall.	CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,CAMPUS GASTHUISBERG,O&N6,HERESTR 49,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven								ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1014, P178, DOI 10.1016/0167-4889(89)90031-1; COLBURN P, 1982, BIOCHEM BIOPH RES CO, V104, P220, DOI 10.1016/0006-291X(82)91962-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; GRIESMACHER A, 1987, EUR J BIOCHEM, V168, P95, DOI 10.1111/j.1432-1033.1987.tb13392.x; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HEREMANS A, 1989, J CELL BIOL, V109, P3199, DOI 10.1083/jcb.109.6.3199; HOYER LW, 1973, J CLIN INVEST, V52, P2737, DOI 10.1172/JCI107469; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LINDBLOM A, 1989, BIOCHEM J, V261, P145, DOI 10.1042/bj2610145; LORIES V, 1992, J BIOL CHEM, V267, P1116; LORIES V, 1987, J BIOL CHEM, V262, P854; LORIES V, 1989, J BIOL CHEM, V264, P7009; LORIES V, 1986, EUR J BIOCHEM, V158, P351, DOI 10.1111/j.1432-1033.1986.tb09758.x; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MILLERANDERSSON M, 1974, THROMB RES, V5, P439, DOI 10.1016/0049-3848(74)90001-2; OOHIRA A, 1983, J BIOL CHEM, V258, P2014; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAKU T, 1989, J BIOL CHEM, V264, P3514; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	38	218	221	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20435	20443						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400362				2022-12-27	WOS:A1992JR85800107
J	SAMELSON, LE; KLAUSNER, RD				SAMELSON, LE; KLAUSNER, RD			TYROSINE KINASES AND TYROSINE-BASED ACTIVATION MOTIFS - CURRENT RESEARCH ON ACTIVATION VIA THE T-CELL ANTIGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							AMINO-TERMINAL DOMAIN; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ZETA-CHAIN; CYTOPLASMIC DOMAINS; CD4 RECEPTOR; P56LCK; PHOSPHORYLATION; ASSOCIATION; COMPLEXES				SAMELSON, LE (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.							ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, IN PRESS CELL; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; DIANZANI U, 1992, J IMMUNOL, V148, P678; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAUEN LKT, 1992, IN PRESS MOL CELL BI; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, IN PRESS INT IMMUNOL; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WASSMER P, 1985, J IMMUNOL, V135, P2237; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359	61	281	283	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24913	24916						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459994				2022-12-27	WOS:A1992KB60300001
J	WEBB, DC; ROSENBERG, H; COX, GB				WEBB, DC; ROSENBERG, H; COX, GB			MUTATIONAL ANALYSIS OF THE ESCHERICHIA-COLI PHOSPHATE-SPECIFIC TRANSPORT-SYSTEM, A MEMBER OF THE TRAFFIC ATPASE (OR ABC) FAMILY OF MEMBRANE TRANSPORTERS - A ROLE FOR PROLINE RESIDUES IN TRANSMEMBRANE HELICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PERIPLASMIC PERMEASES; BINDING PROTEIN; ADENOSINE-TRIPHOSPHATASE; PROTON TRANSLOCATION; NUCLEOTIDE-SEQUENCE; MUTANTS; HYPOTHESIS; REGULON	The Escherichia coli Pst system is a periplasmic phosphate permease. A mutational analysis of the requirement for function of specific charged residues or proline residues in the two hydrophobic subunits (PstC and PstA) has been carried out. No residues, among 19 charged residues altered, were found to be essential for phosphate uptake, although some alterations resulted in partial effects. Evidence was obtained that the 3 residues, R220 in the PstA protein and R237 and E241 in the PstC protein, previously shown to be required for phosphate transport (Cox, G. B., Webb, D., Godovac-Zimmermann, J., and Rosenberg, H. (1988) J. Bacteriol. 170, 2283-2286; Cox, G. B., Webb, D., and Rosenberg, H. (1989) J. Bacteriol. 171, 1531-1534), interact with each other. A feature of the proposed structures of the PstA and PstC proteins was 2 pairs of proline residues in putative transmembrane helices 3 and 4. While individual substitutions of these proline residues by leucine resulted in loss of phosphate transport activity substitution by alanine only had partial effects. However, if the proline to alanine changes were paired then, depending on the particular subunit, markedly different effects were obtained. The double mutation in the PstA protein resulted in a permanently "closed" system, whereas the double mutation in the PstC protein resulted in a permanently "open" transport system.			WEBB, DC (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,MEMBRANE BIOCHEM GRP,CANBERRA,ACT 2601,AUSTRALIA.		Webb, Andrew C/GOK-1601-2022					AMEMURA M, 1985, J MOL BIOL, V184, P241, DOI 10.1016/0022-2836(85)90377-8; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1988, J BIOENERG BIOMEMBR, V20, P1, DOI 10.1007/BF00762135; AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; BRACHA M, 1973, MOL GEN GENET, V122, P53, DOI 10.1007/BF00337973; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; COX GB, 1989, J BACTERIOL, V171, P1531, DOI 10.1128/jb.171.3.1531-1534.1989; COX GB, 1988, J BACTERIOL, V170, P2283, DOI 10.1128/jb.170.5.2283-2286.1988; COX GB, 1981, J BACTERIOL, V148, P1; DAMOGLOU AP, 1968, BIOCHEM J, V110, P775, DOI 10.1042/bj1100775; DOWNIE JA, 1980, J BACTERIOL, V143, P8, DOI 10.1128/JB.143.1.8-17.1980; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GAY NJ, 1984, J BACTERIOL, V158, P820, DOI 10.1128/JB.158.3.820-825.1984; GERDES RG, 1974, BIOCHIM BIOPHYS ACTA, V351, P77, DOI 10.1016/0005-2795(74)90066-X; GUTOWSKI SJ, 1976, BIOCHEM J, V160, P813, DOI 10.1042/bj1600813; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HOWITT SM, 1988, BIOCHIM BIOPHYS ACTA, V936, P74, DOI 10.1016/0005-2728(88)90253-8; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KUBENA BD, 1986, J BIOL CHEM, V261, P7995; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; PITTARD J, 1965, J BACTERIOL, V89, P680, DOI 10.1128/JB.89.3.680-686.1965; Rosenberg H, 1979, Methods Enzymol, V56, P388; ROSENBERG H, 1977, J BACTERIOL, V131, P505, DOI 10.1128/JB.131.2.505-511.1977; ROSENBERG H, 1975, BIOCHEM J, V146, P417, DOI 10.1042/bj1460417; Rosenberg H., 1987, ION TRANSPORT PROKAR, P205; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELKER E, 1977, J BACTERIOL, V124, P388; SURIN BP, 1985, J BACTERIOL, V161, P189, DOI 10.1128/JB.161.1.189-198.1985; SURIN BP, 1987, PHOSPHATE METABOLISM, P145; Torriani A., 1985, MOL BIOL BACTERIAL G, P224; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WANNER BL, 1980, GENETICS, V96, P353; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001	38	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24661	24668						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447208				2022-12-27	WOS:A1992KA26300077
J	WONG, CN; GRALLA, JD				WONG, CN; GRALLA, JD			A ROLE FOR THE ACIDIC TRIMER REPEAT REGION OF TRANSCRIPTION FACTOR SIGMA(54) IN SETTING THE RATE AND TEMPERATURE-DEPENDENCE OF PROMOTER MELTING INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; ACTIVATOR; MECHANISM; BINDING; INITIATION; PROTEINS; GENES; SEQUENCES; ENHANCERS	Sigma54 is an atypical sigma factor involved in enhancer-dependent transcription in Escherichia coli. In vivo assays were developed for following the kinetics and thermodynamics of sigma54-dependent melting of the glnAP2 promoter start site. These assays were applied to a series of three sigma54 polymerases containing zero, one, and two copies of the highly acidic trimer repeat region. The results showed that at least one copy of this acid region is required for a complete melting transition at physiological temperature, but is not required for a low temperature melting transition. The rate of melting the promoter in vivo increased with number of copies of this region. Taken together with other observations, the experiments point to a role for the acid region in triggering conformational changes that lead to specific promoter melting. The acid region is required for these changes to occur fully at physiological temperature and influences the rate at which they occur.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754, T32GM007185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754, GM07185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKMAN K, 1981, P NATL ACAD SCI USA, V78, P3743; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GRIMES E, 1991, NUCLEIC ACIDS RES, V19, P6113, DOI 10.1093/nar/19.22.6113; GROSS C, 1992, IN PRESS COLD SPRING; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MERRICK M, 1987, MOL GEN GENET, V210, P323, DOI 10.1007/BF00325701; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SIPPEL A, 1968, BIOCHIM BIOPHYS ACTA, V157, P218, DOI 10.1016/0005-2787(68)90286-4; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; Wehrli W, 1976, RNA POLYMERASE, P397; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	30	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24762	24768						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447214				2022-12-27	WOS:A1992KA26300091
J	MICHAELI, J; BUSQUETS, X; ORLOW, I; YOUNES, A; COLOMER, D; MARKS, PA; RIFKIND, RA; KOLESNICK, RN				MICHAELI, J; BUSQUETS, X; ORLOW, I; YOUNES, A; COLOMER, D; MARKS, PA; RIFKIND, RA; KOLESNICK, RN			A RISE AND FALL IN 1,2-DIACYLGLYCEROL CONTENT SIGNAL HEXAMETHYLENE BISACETAMIDE-INDUCED ERYTHROPOIESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN KINASE-C; MURINE ERYTHROLEUKEMIA-CELLS; INDUCED DIFFERENTIATION; ERYTHROID DIFFERENTIATION; PITUITARY-CELLS; PHORBOL ESTERS; EXPRESSION; PHOSPHATIDYLINOSITOL; TRANSLOCATION; SENSITIVITY	Previous studies have suggested a role for protein kinase C (PKC) during induction of murine erythroleukemia cell (MELC) differentiation by hexamethylene bisacetamide (HMBA) (Melloni, E., Pontremoli, S., Viotti, P. L., Patrone, M., Marks, P. A., and Rifkind, R. A. (1989) J. Biol. Chem. 264, 18414-18418). The present studies assess the effect of HMBA on the content of 1,2-diacylglycerol (DG), the physiologic activator of PKC, in MELC variants. Exposure of parental Sc9 cells to HMBA induced a rapid rise and fall in DG content. The DG level increased within seconds from 225 pmol.10(6) cells-1 to a maximum of 305 pmol-10(6) cells-1 at 5 min. Thereafter, DG content fell reaching control levels at 30 min and 46% of control at 4 h. Similar DG elevations were detected in HMBA-resistant, phorbol ester-resistant, and vincristine-resistant MELC lines. Early DG elevation was followed by the characteristic rapid fall in both the phorbol ester-resistant and vincristine-resistant lines, both of which differentiate rapidly in response to HMBA. In contrast, in an HMBA-resistant MELC the DG level failed to fall for at least 10 h. Selection of HMBA-resistant cells for vincristine resistance restores both HMBA sensitivity and the rapid fall in DG content. Addition of a synthetic DG, 1-oleyl-2-acetyl glycerol (OAG), along with HMBA and every 2 h for the next 48 h blocked differentiation, as measured by accumulation of benzidine-reactive cells or by the commitment assay in methyl-cellulose. However, if addition of OAG was delayed for just a few minutes, until endogenous DG levels began to fall, differentiation was no longer inhibited. Rapid elevation of DG content is the earliest reported event during HMBA action and a subsequent fall in the DG content appears to be a critical step in the process of commitment to terminal differentiation.	MEM SLOAN KETTERING CANC CTR,SIGNAL TRANSDUCT LAB,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEWITT WALLACE RES LAB,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University			Busquets, Xavier/M-5574-2018; COLOMER, DOLORS/ABG-6894-2020	Busquets, Xavier/0000-0003-1157-5590; COLOMER, DOLORS/0000-0001-7486-8484	NATIONAL CANCER INSTITUTE [P30CA008748, R01CA042385] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08748, CA-42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASS DA, 1987, J BIOL CHEM, V262, P6643; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GIROLDI L, 1986, CARCINOGENESIS, V7, P1183, DOI 10.1093/carcin/7.7.1183; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; KASZKIN M, 1991, CANCER RES, V51, P4328; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; MARKS PA, 1987, CANCER RES, V47, P659; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MELLONI E, 1988, P NATL ACAD SCI USA, V85, P3835, DOI 10.1073/pnas.85.11.3835; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MICHAELI J, 1990, MOL CELL BIOL, V10, P3535, DOI 10.1128/MCB.10.7.3535; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PINCUS SM, 1984, BIOCHEM BIOPH RES CO, V125, P491, DOI 10.1016/0006-291X(84)90567-9; POWELL T, 1992, P NATL ACAD SCI USA, V89, P147; PREISS J, 1986, J BIOL CHEM, V261, P8597; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; RIFKIND RA, 1990, MECHANISMS DIFFERENT, V2, P93; ROVERA G, 1977, P NATL ACAD SCI USA, V74, P2894, DOI 10.1073/pnas.74.7.2894; STALFORS P, 1988, NATURE, V335, P554; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; YOUNES A, 1992, J BIOL CHEM, V267, P842	28	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23463	23466						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429688				2022-12-27	WOS:A1992JZ23900008
J	NAKAMURA, M; TSUNODA, A; SAKOE, K; GU, J; NISHIKAWA, A; TANIGUCHI, N; SAITO, M				NAKAMURA, M; TSUNODA, A; SAKOE, K; GU, J; NISHIKAWA, A; TANIGUCHI, N; SAITO, M			TOTAL METABOLIC FLOW OF GLYCOSPHINGOLIPID BIOSYNTHESIS IS REGULATED BY UDP-GLCNAC - LACTOSYLCERAMIDE BETA-1-]3N-ACETYLGLUCOSAMINYLTRANSFERASE AND CMP-NEUAC LACTOSYLCERAMIDE ALPHA-2-]3 SIALYLTRANSFERASE IN HUMAN HEMATOPOIETIC-CELL LINE HL-60 DURING DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; NEOLACTO-SERIES GANGLIOSIDES; PROTEIN KINASE-C; MONOCYTIC DIFFERENTIATION; MONOCLONAL-ANTIBODY; GRANULOCYTIC DIFFERENTIATION; PHORBOL ESTERS; ANTIGENS; GM3; EXPRESSION	We have previously reported that ganglioside GM3 was remarkably increased during monoeytoid differentiation of human myelogenous leukemia cell line HL-60 cells and that neolacto series gangliosides (NeuAcn-Lc) were enriched during granulocytoid differentiation. In addition, HL-60 was differentiated into monocytic lineage by exogenous GM3 and into granulocytoid by NeuAc-nLc. In the present report, the enzymatic bases of glycosphingolipid biosynthesis in HL-60 during differentiation induced by 12-O-tetradecanoylphorbol-13-acetate and all-trans-retinoic acid were investigated. The following results were of particular interest. (i) Lactosylceramide alpha2-->3sialyltransferase (GM3 synthase) was remarkably up-regulated during monocyte differentiation, while the GM3 synthase level did not change in granulocytic differentiation. (ii) By contrast, lactosylceramide beta1-->3N-acetylglucosaminyltransferase (Lc3Cer synthase) was down-regulated during monocytic differentiation, while the activity of Lc3Cer synthase was found to increase in granulocytic differentiation. (iii) The activities of four downstream glycosyltransferases (for synthesis of NeuAc-nLc) were found to increase or to remain unchanged during monocytic and granulocytic differentiation. These results strongly suggested the following. The dramatic GM3 increase and the decrease of NeuAc-nLc during monocytic differentiation are the consequences of the up-regulation of GM3 synthase and the down-regulation of Lc3Cer synthase, although the downstream enzymes are ready to catalyze their enzyme reactions. The notable increase of NeuAc-nLc and the relative decrease of GM3 during granulocytic differentiation are the results of the unchanged level of GM3 synthase and the up-regulation of LC3Cer synthase together with the activation of the downstream glycosyltransferases. These results suggest that these two key upstream glycosyltransferases, GM3 synthase and Lc3Cer synthase, play critical roles in regulating the glycosphingolipid biosynthesis in HL-60 cells during differentiation. This switching mechanism of these two glycosyltransferases, together with our previous findings, might be one of the most important parts of the determining system of differentiation direction in human myeloid cells into monocytic or granulocytic lineages.	JICHI MED SCH,INST HEMATOL,DIV HEMOPOIESIS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; OSAKA UNIV,FAC MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	Jichi Medical University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Nishikawa, Atsushi/E-6766-2013; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Nishikawa, Atsushi/0000-0003-4325-1160; 				BASU M, 1984, J BIOL CHEM, V259, P2557; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BURCZAK JD, 1984, J LIPID RES, V25, P1541; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; FEIZI T, 1981, TRENDS BIOCHEM SCI, V6, P333, DOI 10.1016/0968-0004(81)90119-5; FUJIMOTO J, 1987, LAB INVEST, V57, P350; GAHMBERG CG, 1975, J BIOL CHEM, V250, P2438; GU J, 1992, J BIOL CHEM, V267, P2994; HAKOMORI S, 1983, J BIOL CHEM, V258, P1819; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASHIMOTO Y, 1984, J BIOCHEM-TOKYO, V95, P1543, DOI 10.1093/oxfordjournals.jbchem.a134766; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; ITO M, 1989, J BIOL CHEM, V264, P9510; IVATT RJ, 1981, P NATL ACAD SCI-BIOL, V78, P4021, DOI 10.1073/pnas.78.7.4021; KANNAGI R, 1983, P NATL ACAD SCI-BIOL, V80, P2844, DOI 10.1073/pnas.80.10.2844; KASAI N, 1984, J BIOCHEM-TOKYO, V96, P261, DOI 10.1093/oxfordjournals.jbchem.a134821; KITAGAWA S, 1989, J BIOL CHEM, V264, P16149; KOEFFLER HP, 1981, CANCER RES, V41, P919; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MOMOI T, 1986, J BIOL CHEM, V261, P6270; NAKAMURA M, 1989, BIOCHEM BIOPH RES CO, V161, P782, DOI 10.1016/0006-291X(89)92668-5; NAKAMURA M, 1991, CANCER RES, V51, P1940; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; NOJIRI H, 1984, BLOOD, V64, P534; NOZAWA S, 1989, CANCER RES, V49, P6401; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; SAITO M, 1985, BIOCHEM BIOPH RES CO, V132, P223, DOI 10.1016/0006-291X(85)91011-3; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHIGETA K, 1987, J BIOL CHEM, V262, P1358; STEVENS VL, 1989, CANCER RES, V49, P3229; SUZUKI Y, 1991, J BIOCHEM-TOKYO, V109, P354; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; 1977, LIPIDS, V12, P455	49	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23507	23514						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429695				2022-12-27	WOS:A1992JZ23900017
J	ROTH, RI; LEVIN, J				ROTH, RI; LEVIN, J			PURIFICATION OF LIMULUS-POLYPHEMUS PROCLOTTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYMPH COAGULATION SYSTEM; AMEBOCYTE LYSATE; CLOTTING ENZYME; HORSESHOE-CRAB; TACHYPLEUS-TRIDENTATUS; ENDOTOXIN; SENSITIVITY; HEMOCYTES; PROTEASES; GELS	Horseshoe crabs (Limulus polyphemus and Tachypleus tridentatus) possess a proteolytic blood coagulation system within their amebocytes that, after release and endotoxin activation, generates a polymerized insoluble coagulin clot. Clotting enzyme from horseshoe crab amebocyte lysate is the protease that activates the clottable protein (coagulogen) which then forms the coagulin clot. Comparison of the previously published descriptions of this enzyme has revealed significantly discordant biochemical characteristics. We purified a 60-kDa proclotting enzyme from L. polyphemus amebocyte lysate to a single band on polyacrylamide gel electrophoresis. After electrophoresis, evaluation of enzymatic activity of this protein within gels demonstrated that the band of purified protein corresponded to enzymatic activity, as detected by amidolytic activity for chromogenic substrates and by gelation of coagulogen applied to the gel. The enzymatic activity was inhibited by serine protease inhibitors. The purified proclotting enzyme had a molecular weight and amino acid composition different from the previously published characterizations of proclotting enzymes from both L. polyphemus and T. tridentatus.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT LAB MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	ROTH, RI (corresponding author), VET ADM MED CTR,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIDDK NIH HHS [DK 43102] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043102] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		IWANAGA S, 1986, J PROTEIN CHEM, V5, P255, DOI 10.1007/BF01025424; KELLEHER PJ, 1984, ANAL BIOCHEM, V136, P470, DOI 10.1016/0003-2697(84)90246-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA S, 1982, J BIOCHEM, V92, P781, DOI 10.1093/oxfordjournals.jbchem.a133990; NAKAMURA S, 1982, BIOCHEM BIOPH RES CO, V108, P1619, DOI 10.1016/S0006-291X(82)80094-6; NAKAMURA S, 1982, BIOCHIM BIOPHYS ACTA, V707, P217, DOI 10.1016/0167-4838(82)90354-5; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; OHKI M, 1980, FEBS LETT, V120, P217, DOI 10.1016/0014-5793(80)80301-2; ROSLANSKY PF, 1991, J CLIN MICROBIOL, V29, P2477, DOI 10.1128/JCM.29.11.2477-2483.1991; ROTH RI, 1989, J LAB CLIN MED, V114, P306; ROTH RI, 1989, J BIOCHEM BIOPH METH, V19, P129, DOI 10.1016/0165-022X(89)90021-3; SEID RC, 1980, FRONTIERS PROTEIN CH, V10, P481; SEKIGUCHI K, 1980, EVOLUTION, V34, P712, DOI 10.1111/j.1558-5646.1980.tb04010.x; SODERHALL K, 1985, BIOL BULL-US, V169, P661, DOI 10.2307/1541308; SOLUM NO, 1980, THROMB DIATH HAEMO, V23, P170; SULLIVAN JD, 1975, BIOCHEM BIOPH RES CO, V66, P848, DOI 10.1016/0006-291X(75)90587-2; TAI JY, 1977, J BIOL CHEM, V252, P2178; TAI JY, 1977, J BIOL CHEM, V252, P4773; TORANO AE, 1984, THROMB RES, V34, P407, DOI 10.1016/0049-3848(84)90245-7; YOUNG NS, 1972, J CLIN INVEST, V51, P1790, DOI 10.1172/JCI106980	23	9	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24097	24102						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429741				2022-12-27	WOS:A1992JZ23900100
J	DUBIEL, W; FERRELL, K; PRATT, G; RECHSTEINER, M				DUBIEL, W; FERRELL, K; PRATT, G; RECHSTEINER, M			SUBUNIT-4 OF THE 26-S PROTEASE IS A MEMBER OF A NOVEL EUKARYOTIC ATPASE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTICATALYTIC PROTEINASE COMPLEX; SUBSTRATE-SPECIFICITY; DEPENDENT PROTEASE; 26S COMPLEX; UBIQUITIN; YEAST; PEPTIDES; PATHWAY; KINASE; CELLS	Ubiquitinated proteins are degraded by a 26 S ATP-dependent protease. SDS-polyacrylamide gel electrophoresis analysis of the purified 26 S enzyme reveals more than 20 polypeptides ranging in apparent molecular masses from 20 to 110 kDa. Although many of the subunits smaller than 30 kDa are members of the multicatalytic protease family, the identity and function of the larger polypeptides have remained unknown. We report here the cDNA sequence for subunit 4, a 51-kDa chain of the 26 S protease. Subunit 4 belongs to a recently identified eukaryotic ATPase family, which includes proteins involved in peroxisome formation, secretion, and human immunodeficiency virus gene expression. Subunit 4 also shows weak similarity to ClpA, the ATP-binding subunit of the Escherichia coli protease, Clp.			DUBIEL, W (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132, USA.			Dubiel, Wolfgang/0000-0002-3393-0701	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMON T, 1990, J BIOL CHEM, V265, P20723; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KURTH J, 1990, BIOL CHEM H-S, V371, P675, DOI 10.1515/bchm3.1990.371.2.675; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TANAKA K, 1992, NEW BIOL, V4, P173; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	44	188	191	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22699	22702						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429620				2022-12-27	WOS:A1992JY16300002
J	HWANG, DS; KORNBERG, A				HWANG, DS; KORNBERG, A			OPPOSED ACTIONS OF REGULATORY PROTEINS, DNAA AND ICIA, IN OPENING THE REPLICATION ORIGIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ORIGIN; INITIATION; INVITRO; SEQUENCE; HYBRID; LAMBDA; BINDS	The opening of the three tandem 13-mers (iterons) in the replication origin (oriC) of Escherichia coli by DnaA protein, assisted by protein HU or IHF (Hwang, D. S., and Kornberg, A. (1992) J. Biol. Chem. 267, 23083-23086), represents an essential early stage in the initiation of chromosomal replication (Bramhill, D., and Kornberg, A. (1988) Cell 54, 915-918). We now show by mutational alterations of the 13-mer region that oriC function, both in vitro and in vivo, requires AT-richness in the left 13-mer and sequence specificity in the middle and right 13-mers. Interactions of DnaA protein with the middle and right 13-mers are crucial for the opening of the region. Binding of the protein to the top strand of the 13-mers appeared to maintain single-strandedness in the bottom strand. IciA protein, the inhibitor of initiation, binds the three 13-mers and blocks the opening of the region. The degrees of inhibition by IciA protein of 13-mer opening and of oriC plasmid replication observed with mutant forms of the 13-mers could be correlated with the binding affinity of IciA protein. Whereas the binding of IciA protein to the 13-mers did not affect the binding of DnaA protein to its four 9-mer boxes, interaction of DnaA protein with the 13-mers was blocked. The selective interactions of DnaA and IciA proteins with the 13-mer region appear to be components of the on/off switch that controls initiation of E. coli chromosomal replication.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; DODSON M, 1989, J BIOL CHEM, V264, P10719; Furth M., 1983, LAMBDA 2, P145; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kornberg A., 1992, DNA REPLICATION; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; POLACZEK P, 1990, New Biologist, V2, P265; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; THONY B, 1991, P NATL ACAD SCI USA, V88, P4066, DOI 10.1073/pnas.88.10.4066; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; ZYLICZ M, 1908, MOL GEN GENET, V196, P401; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	25	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23087	23091						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429656				2022-12-27	WOS:A1992JY16300060
J	JONES, DE; BEVINS, CL				JONES, DE; BEVINS, CL			PANETH CELLS OF THE HUMAN SMALL-INTESTINE EXPRESS AN ANTIMICROBIAL PEPTIDE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; INSITU HYBRIDIZATION; HUMAN-NEUTROPHILS; MICROSCOPIC OBSERVATIONS; ANTIBACTERIAL PEPTIDES; ANTIBIOTIC PROTEINS; CDNA CLONES; WISTAR RATS; DEFENSIN; DNA	Mucosal surfaces of several organ systems are important interfaces for host defense against microbes. Recent evidence suggests that antimicrobial peptides contribute to the defense of these surfaces. Defensins are one family of antimicrobial peptide, but their known distribution in humans has been limited to four members found in cells of myeloid origin. We sought to determine if the human defensin family was more complex. We found that the family of human defensins is diverse and is not restricted to expression in leukocytes. Southern blot and genomic clone analyses reveal that numerous defensin-related sequences are present in the human genome. A gene for a new human defensin family member was characterized. This gene, designated human defensin-5, is highly expressed in Paneth cells of the small intestine. This is the first example of an antimicrobial peptide gene expressed in an epithelial cell in humans. The data support the hypotheses that epithelial defensins equip the human small bowel with a previously unrecognized defensive capability which would augment other antimicrobial defenses.	CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania			Bevins, Charles L/P-4438-2015	Bevins, Charles L/0000-0003-2725-2622	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; BATEMAN A, 1991, J BIOL CHEM, V266, P7524; BEHNKE O, 1964, J CELL BIOL, V22, P633, DOI 10.1083/jcb.22.3.633; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; DECKX RJ, 1967, BIOCHIM BIOPHYS ACTA, V139, P204, DOI 10.1016/0005-2744(67)90136-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; EISENHAUER PB, 1989, INFECT IMMUN, V57, P2021, DOI 10.1128/IAI.57.7.2021-2027.1989; ERLANDSEN SL, 1974, J HISTOCHEM CYTOCHEM, V22, P401, DOI 10.1177/22.6.401; FIELDS PI, 1989, SCIENCE, V227, P1435; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GANZ T, 1989, J IMMUNOL, V143, P1358; GANZ T, 1990, EUR J HAEMATOL, V44, P1; GELLER SA, 1983, ARCH PATHOL LAB MED, V107, P476; GILMAN M, 1987, CURRENT PROTOCOLS MO; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hertzog AJ, 1937, AM J PATHOL, V13, P351; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KESHAV S, 1990, J EXP MED, V171, P327, DOI 10.1084/jem.171.1.327; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLOCKARS M, 1975, J HISTOCHEM CYTOCHEM, V23, P932, DOI 10.1177/23.12.1104708; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; LENDRUM AC, 1947, J PATHOL BACTERIOL, V59, P399, DOI 10.1002/path.1700590306; LICHTENSTEIN A, 1991, J CLIN INVEST, V88, P93, DOI 10.1172/JCI115310; MARS WM, 1988, BLOOD, V71, P1713; MCDERMID HE, 1989, GENOMICS, V5, P1, DOI 10.1016/0888-7543(89)90079-7; OUELLETTE AJ, 1988, GASTROENTEROLOGY, V94, P114, DOI 10.1016/0016-5085(88)90618-X; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; OUELLETTE AJ, 1990, J BIOL CHEM, V265, P9831; Paneth J., 1887, ARCH MIKROSK ANAT, V31, P113, DOI [10.1007/BF02955706, DOI 10.1007/BF02955706]; PARSOT C, 1991, P NATL ACAD SCI USA, V88, P1641, DOI 10.1073/pnas.88.5.1641; PATERSON JC, 1961, AM J PATHOL, V38, P243; PATTERSON S, 1989, J VIROL METHODS, V23, P105, DOI 10.1016/0166-0934(89)90124-9; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICE WG, 1987, BLOOD, V70, P757; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANDOW MJ, 1979, GUT, V20, P420, DOI 10.1136/gut.20.5.420; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH Y, 1989, ANAT REC, V225, P124, DOI 10.1002/ar.1092250207; SATOH Y, 1990, J ELECTRON MICR TECH, V16, P69, DOI 10.1002/jemt.1060160109; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1986, ANAT EMBRYOL, V173, P317, DOI 10.1007/BF00318915; SCHWALBE G, 1872, ARCH MIKROSK ANAT, V8, P92; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1987, INFECT IMMUN, V55, P2281, DOI 10.1128/IAI.55.9.2281-2286.1987; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; SINGH A, 1988, BIOCHEM BIOPH RES CO, V155, P524, DOI 10.1016/S0006-291X(88)81118-5; SPITZNAGEL JK, 1990, J CLIN INVEST, V86, P1381, DOI 10.1172/JCI114851; TRIER JS, 1963, J CELL BIOL, V18, P599, DOI 10.1083/jcb.18.3.599; WIEDEMANN LM, 1989, LEUKEMIA, V3, P227; WILDE CG, 1989, J BIOL CHEM, V264, P11200; YOUNG WS, 1986, NEUROSCI LETT, V70, P198; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	71	453	480	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23216	23225						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429669				2022-12-27	WOS:A1992JY16300079
J	LIAO, DQ; DENNIS, PP				LIAO, DQ; DENNIS, PP			THE ORGANIZATION AND EXPRESSION OF ESSENTIAL TRANSCRIPTION TRANSLATION COMPONENT GENES IN THE EXTREMELY THERMOPHILIC EUBACTERIUM THERMOTOGA-MARITIMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBOSOMAL-PROTEIN; NUCLEOTIDE-SEQUENCE; HALOBACTERIUM-CUTIRUBRUM; MESSENGER-RNA; LARGE SUBUNIT; TARGET SITE; CLUSTER; OPERON; L12	A 5789-nucleotide-long EcoRI fragment from the genome of Thermotoga maritima, identified by cross-hybridization to L11, L1, L10, and L12 ribosomal protein gene sequences from Escherichia coli, was cloned and sequenced. The fragment encodes five tRNAs (tRNA(met1), anticodon complementary to AUG; tRNA(met2), AUG; tRNA(thr), ACA; tRNA(tyr), UAC; tRNA(trP), UGG), the transcription termination-antitermination factor nusG, the four 50 S subunit ribosomal proteins L11, L1, L10, and L12, and the amino-terminal portion of the RNA polymerase beta subunit protein. The five tRNA genes, the nusG gene, and the L11, L1, L10, and L12 ribosomal protein genes form a complex transcription unit. Transcripts appear to be initiated from an upstream promoter, P1, located in front of the tRNA(met1) gene and from three internal promoters: P2 is located immediately in front of the tRNA(met2) gene; P(L10) is near the beginning of the L1-L10 intergenic space, and P(L12) is at the end of the L10 gene sequence. The tRNA sequences are excised from the leader regions of the P1- and P2-initiated transcripts. Three putative but potentially important regulatory sequences were identified within this operon: an L1 translational control site, a transcription attenuator, and a strong rho-independent terminator. The strong terminator located distal to the L12 gene overlaps a fifth promoter, P(beta), which is used to initiate transcripts of the downstream RNA polymerase beta subunit gene. The T. maritima NusG protein exhibits 43% amino acid sequence identity when aligned to the E. coli protein; the alignment is interrupted by a large 171-amino acid-long insertion into the T. maritima protein after codon 45.	UNIV BRITISH COLUMBIA,CANADIAN INST ADV RES,PROGRAM EVOLUT BIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA	Canadian Institute for Advanced Research (CIFAR); University of British Columbia; University of British Columbia			Liao, Daiqing/A-8941-2008					ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; AN G, 1980, GENE, V12, P33, DOI 10.1016/0378-1119(80)90013-X; ARRAIANO CM, 1988, J BACTERIOL, V170, P4625, DOI 10.1128/jb.170.10.4625-4633.1988; BACHLEITNER M, 1989, FEMS MICROBIOL LETT, V57, P115, DOI 10.1111/j.1574-6968.1989.tb03231.x; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BAUGHMAN G, 1983, CELL, V34, P979, DOI 10.1016/0092-8674(83)90555-X; CHRISTENSEN T, 1984, EMBO J, V3, P1609, DOI 10.1002/j.1460-2075.1984.tb02018.x; DENNIS PP, 1974, J MOL BIOL, V88, P25, DOI 10.1016/0022-2836(74)90293-9; DENNIS PP, 1985, J MOL BIOL, V186, P457, DOI 10.1016/0022-2836(85)90117-2; DOWNING W, 1991, J BIOL CHEM, V266, P1304; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; DOWNING WL, 1987, J MOL BIOL, V194, P609, DOI 10.1016/0022-2836(87)90238-5; DRAPER DE, 1990, RIBOSOME, P160; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIIL NP, 1980, CELL, V19, P837, DOI 10.1016/0092-8674(80)90074-4; GOLD L, 1987, ESCHERICHIA COLI SAL, P1302; HARDY SJS, 1975, MOL GEN GENET, V140, P253, DOI 10.1007/BF00334270; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOOPES BC, 1987, ESCHERICHIA COLI SAL, P1231; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; JOHNSEN M, 1982, EMBO J, V1, P999, DOI 10.1002/j.1460-2075.1982.tb01284.x; LAKE JA, 1981, J MOL BIOL, V153, P979, DOI 10.1016/0022-2836(81)90462-9; LINDAHL L, 1986, ANNU REV GENET, V20, P297; LINDAHL L, 1975, P NATL ACAD SCI USA, V72, P2743, DOI 10.1073/pnas.72.7.2743; LINN T, 1992, J BIOL CHEM, V267, P1449; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; PETERSEN C, 1990, J BACTERIOL, V172, P431, DOI 10.1128/JB.172.1.431-436.1990; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SHIMMIN LC, 1989, EMBO J, V8, P1225, DOI 10.1002/j.1460-2075.1989.tb03496.x; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; STRYCHARZ W, 1987, J MOL BIOL, V126, P123; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; THOMAS MS, 1987, NUCLEIC ACIDS RES, V15, P3085, DOI 10.1093/nar/15.7.3085; TIBONI O, 1991, J MOL EVOL, V33, P142, DOI 10.1007/BF02193628; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1986, SYST APPL MICROBIOL, V7, P161; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	48	51	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22787	22797						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429627				2022-12-27	WOS:A1992JY16300016
J	OLSON, MW; KAGUNI, LS				OLSON, MW; KAGUNI, LS			3'-]5' EXONUCLEASE IN DROSOPHILA MITOCHONDRIAL-DNA POLYMERASE - SUBSTRATE-SPECIFICITY AND FUNCTIONAL COORDINATION OF NUCLEOTIDE POLYMERIZATION AND MISPAIR HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE-INHIBITION; FIDELITY; MELANOGASTER; MECHANISM; GAMMA; SUBUNIT; EMBRYOS; ALPHA; MUTAGENESIS; PRIMASE	A mispair-specific 3'-->5' exonuclease copurifies quantitatively with the near-homogeneous Drosophila gamma polymerase (Kaguni, L. S., and Olson, M. W. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6469-6473). The exonuclease and polymerase exhibit similar reaction requirements and optima, suggesting functional coordination of their activities. Under nonpolymerization conditions, the 3'-->5' exonuclease hydrolyzes 3'-terminal mispairs approximately 15-fold more efficiently than 3'-terminal base pairs on primed single-stranded DNA substrates, whereas it does not discriminate between any of three specific mispairs (dAMP:dAMP; dGMP:dGMP; dGMP:dAMP). Under polymerization conditions, gamma polymerase does not extend a 3'-terminal mispair from the "stationary" state, even in the presence of a large excess of the next correct nucleotide. Instead, 3'-terminal mispairs are hydrolyzed quantitatively by the 3'-->5' exonuclease over the reaction time course. During DNA synthesis by gamma polymerase in the "polymerization" mode, limited misincorporation and subsequent mispair extension do occur. Here, it appears that mis-incorporation and not mispair extension is rate-limiting. Template-primer challenge experiments suggest that the mechanism of template-primer transfer from the 3'-->5' exonuclease active site to the DNA polymerase active site is intermolecular; transfer from the exonuclease to polymerase mode appears to require dissociation and reassociation of mitochondrial DNA polymerase.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; BYRNES JJ, 1977, BIOCHEMISTRY-US, V16, P3740, DOI 10.1021/bi00636a002; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DRAKE JW, 1969, NATURE, V221, P1132, DOI 10.1038/2211132a0; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Fansler B S, 1974, Methods Enzymol, V29, P53; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1987, P NATL ACAD SCI USA, V84, P4865, DOI 10.1073/pnas.84.14.4865; KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MIZRAHI V, 1986, P NATL ACAD SCI USA, V83, P5769, DOI 10.1073/pnas.83.16.5769; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P3085, DOI 10.1073/pnas.86.9.3085; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; QUE BG, 1978, BIOCHEMISTRY-US, V17, P1603, DOI 10.1021/bi00602a004; REEMS JA, 1991, J BIOL CHEM, V266, P4878; REYLAND ME, 1988, J BIOL CHEM, V263, P6518; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WEYMOUTH LA, 1978, P NATL ACAD SCI USA, V75, P1924, DOI 10.1073/pnas.75.4.1924	35	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23136	23142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429661				2022-12-27	WOS:A1992JY16300067
J	PAN, BS; POTTER, JD				PAN, BS; POTTER, JD			2 GENETICALLY EXPRESSED TROPONIN-T FRAGMENTS REPRESENTING ALPHA AND BETA ISOFORMS EXHIBIT FUNCTIONAL DIFFERENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE TROPONIN; PYRENE-LABELED TROPOMYOSIN; SINGLE GENE; THIN FILAMENT; RABBIT; BINDING; GENERATION; ACTIVATION	The carboxyl-terminal isoforms of troponin T (TnT), alpha and beta, differing in the sequence of a region near the COOH terminus, arise from alternative splicing of a primary transcript of the TnT gene and are expressed in a tissue-specific and developmentally regulated manner (Medford, R. M., Nguyen, H. T., Destree, A. T., Summers, E., and Nadal-Ginard, B. (1984) Cell 38, 409-421). To date, the beta isoform has not been studied directly at the protein level. To explore the potential functional differences between the alpha and beta sequences, we isolated two rabbit skeletal TnT cDNA clones: a full-length cDNA for a beta isoform and a partial-length cDNA for an alpha isoform. Two restriction fragments derived from the cDNA clones were used to direct overexpression, in Escherichia coli, of two TnT fragments, T2p-alpha and T2p-beta, each containing the last 108 amino acid residues of the alpha or beta isoform of TnT. Using purified T2p-alpha and T2p-beta along with fluorescent derivatives of troponin C (TnC) and alphaalpha-tropomyosin (Tm), we showed that T2p-alpha bound more strongly to TnC than did T2p-beta both in the presence and absence of Ca2+, and exhibited a higher affinity for Tm than did T2p-beta. More interestingly, the Ca2+ affinities of the Ca2+-specific regulatory sites of TnC in the T2p-alpha.TnC complex were found to be 3-fold higher than in T2p-beta.TnC complex. These results support the hypothesis that the sequence divergence between the alpha and beta isoforms of TnT may have functional significance in possibly contributing to the determination of the Ca2+ sensitivity of muscle fibers.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,POB 016189,MIAMI,FL 33101	University of Miami					NHLBI NIH HHS [HL42325] Funding Source: Medline; NIAMS NIH HHS [AR37701, AR40727] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042325, R37HL042325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037701, R01AR040727] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bagshaw C. R., 1987, SPECTROPHOTOMETRY SP, P91; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X; BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GRACEFFA P, 1980, J BIOL CHEM, V255, P1296; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; HASTINGS KEM, 1985, J BIOL CHEM, V260, P3699; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; ISHII Y, 1991, J BIOL CHEM, V266, P6894; KERRICK WGL, 1976, NATURE, V260, P440, DOI 10.1038/260440a0; MACLENNAN DH, 1985, NATURE, V316, P695; MEDFORD RM, 1984, CELL, V38, P409, DOI 10.1016/0092-8674(84)90496-3; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PEARLSTONE JR, 1981, FEBS LETT, V128, P119, DOI 10.1016/0014-5793(81)81095-2; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; PRENDERGAST FG, 1979, BIOPHYS J, V25, pA250; PUTNEY SD, 1983, NATURE, V302, P718, DOI 10.1038/302718a0; REISER P J, 1989, Biophysical Journal, V55, p592A; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILKINSON JM, 1984, EUR J BIOCHEM, V143, P47, DOI 10.1111/j.1432-1033.1984.tb08337.x	29	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23052	23056						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429653				2022-12-27	WOS:A1992JY16300054
J	VAZIRI, C; DOWNES, CP				VAZIRI, C; DOWNES, CP			ASSOCIATION OF A RECEPTOR AND G-PROTEIN-REGULATED PHOSPHOLIPASE-C WITH THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ERYTHROCYTE-MEMBRANES; SIGNAL TRANSDUCTION; TURKEY ERYTHROCYTES; PLASMA-MEMBRANES; STREPTOLYSIN-O; BOVINE BRAIN; PURIFICATION; KINASE; CELLS	Approximately 98% of turkey erythrocyte phospholipase C (PLC) is cytosolic and is released by hypotonic lysis of the cells and extensive washing of the resultant erythrocyte ghosts. Well washed turkey erythrocyte ghosts retain a fraction of tightly associated PLC, which is activated by the P2y-purinergic receptor and G-protein present in ghost membranes. The particulate PLC is sufficient to couple to all the available purinergic receptor-regulated G-protein. In contrast to ghosts, turkey erythrocyte plasma membrane preparations contain no detectable PLC. To investigate the subcellular location of the ghost-associated PLC, cytoskeletons were prepared by Triton X-100 extraction of turkey erythrocyte ghosts. The ghost-associated PLC was quantitatively recovered in cytoskeleton preparations. Cytoskeleton-associated PLC was solubilized by sodium cholate extraction, partially purified, and shown to reconstitute with PLC-free plasma membrane preparations in an agonist and guanine nucleotide-dependent fashion, indicating that the cytoskeleton-associated PLC is G-protein-regulated. Dissociation of erythrocyte ghost cytoskeletons with the actin-binding protein DNase 1 resulted in a dose-dependent inhibition of agonist and guanine nucleotide-stimulated PLC responses in ghosts and caused release of PLC from ghost or cytoskeleton preparations. These data demonstrate the specific association of a receptor and G-protein-regulated PLC with a component of the detergent-insoluble cytoskeleton and indicate that the integrity of the actin cytoskeleton is important for localization and effective coupling of PLC to the relevant G-protein.			VAZIRI, C (corresponding author), UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND.							BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P6010, DOI 10.1021/bi00440a043; BANNO Y, 1992, J BIOL CHEM, V267, P6488; BEAM KG, 1979, J CELL BIOL, V83, P1, DOI 10.1083/jcb.83.1.1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOYER JL, 1990, J BIOL CHEM, V265, P13515; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; COHEN WD, 1986, METHOD ENZYMOL, V134, P232; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; IRVINE RF, 1978, J NEUROCHEM, V31, P1427, DOI 10.1111/j.1471-4159.1978.tb06568.x; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1987, CELL, V51, P345, DOI 10.1016/0092-8674(87)90631-3; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MARTIN TFJ, 1989, J BIOL CHEM, V264, P20917; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MCPHEE F, 1991, BIOCHEM J, V275, P187, DOI 10.1042/bj2750187; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAYRASTRE B, 1991, BIOCHIM BIOPHYS ACTA, V1056, P19, DOI 10.1016/S0005-2728(05)80068-4; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROY G, 1991, J BIOL CHEM, V266, P11495; SHEETZ MP, 1979, J CELL BIOL, V81, P266, DOI 10.1083/jcb.81.1.266; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STUTCHFIELD J, 1991, EUR J BIOCHEM, V197, P119, DOI 10.1111/j.1432-1033.1991.tb15889.x; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WALLACE MA, 1985, J BIOL CHEM, V260, P9527	37	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22973	22981						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429646				2022-12-27	WOS:A1992JY16300043
J	BENNETT, SE; MOSBAUGH, DW				BENNETT, SE; MOSBAUGH, DW			CHARACTERIZATION OF THE ESCHERICHIA-COLI URACIL-DNA GLYCOSYLASE.INHIBITOR PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; BACILLUS-SUBTILIS; SACCHAROMYCES-CEREVISIAE; BACTERIOPHAGE PBS2; REPAIR ENZYME; N-GLYCOSIDASE; RAT-LIVER; PURIFICATION; NUCLEAR; INHIBITOR	The Bacillus subtilis bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) protein was characterized and shown to form a stable complex with Escherichia coli uracil-DNA glycosylase (Ung). As determined by mass spectrometry, the Ugi protein had a molecular weight of 9,474. We confirmed this value by sedimentation equilibrium centrifugation and determined that Ugi exists as a monomeric protein in solution. Amino acid analysis performed on both Ugi and Ung proteins was in excellent agreement with the amino acid composition predicted from the respective nucleotide sequence of each gene. The Ung.Ugi complex was resolved from its constitutive components by nondenaturing polyacrylamide gel electrophoresis and shown to possess a 1:1 stoichiometry. Analytical ultracentrifugation studies revealed that the Ung.Ugi complex had a molecular weight of 35,400, consistent with the complex containing one molecule each of Ung and Ugi. The acidic isoelectric points of the protein species were 6.6 (Ung) and 4.2 (Ugi), whereas the Ung.Ugi complex had an isoelectric point of 4.9. Dissociation of the Ung.Ugi complex by SDS-polyacrylamide gel electrophoresis revealed no apparent alteration in the molecular weight of either polypeptide subsequent to binding. Furthermore, when the Ung.Ugi complex was treated with urea and resolved by urea-polyacrylamide gel electrophoresis, both uracil-DNA glycosylase and inhibitor activities were recovered from the dissociated complex. Thus, the complex seems to be reversible. In addition, we demonstrated that the Ugi interaction with Ung prevents enzyme binding to DNA and dissociates uracil-DNA glycosylase from a preformed DNA complex.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,ENVIRONM HLTH SCI CTR,CORVALLIS,OR 97331	Oregon State University; Oregon State University; Oregon State University; Oregon State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1990, GENOMICS, V7, P139, DOI 10.1016/0888-7543(90)90532-Y; ANDERSON CTM, 1980, NUCLEIC ACIDS RES, V8, P875; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERS PMJ, 1986, J BACTERIOL, V166, P905, DOI 10.1128/jb.166.3.905-913.1986; CARADONNA SJ, 1980, J BIOL CHEM, V255, P2293; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; CONE R, 1980, J BIOL CHEM, V255, P354; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; GUPTA PK, 1981, CANCER RES, V41, P3133; HITZEMAN RA, 1978, J BIOL CHEM, V253, P8518; HOLLAND JP, 1979, J BIOL CHEM, V254, P9839; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; KULBE KD, 1975, BIOCHEM BIOPH RES CO, V67, P35, DOI 10.1016/0006-291X(75)90279-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL J, 1981, CHROMOSOME DAMAGE RE, P117; LEBLANC JP, 1982, J BIOL CHEM, V257, P3477; LEE TD, 1989, 37TH P AM SOC MASS S; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINN S, 1981, CHROMOSOME DAMAGE RE, P97; MARTY L, 1984, BIOCHEM BIOPH RES CO, V118, P767; MCKEEKIN TL, 1952, SCIENCE, V116, P142; MEJEAN V, 1991, NARES, V18, P6693; MEYER-SIEGLER K, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P4; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; MOSBAUGH DW, 1988, REV BIOCHEM TOXICOL, V9, P69; MULLER SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P197, DOI 10.1016/0167-4781(91)90055-Q; NOWAK K, 1981, FEBS LETT, V134, P143, DOI 10.1016/0014-5793(81)80587-X; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PRICE AR, 1972, J VIROL, V9, P602, DOI 10.1128/JVI.9.4.602-610.1972; PRICE AR, 1973, J BIOL CHEM, V248, P1372; REISNER AH, 1984, METHOD ENZYMOL, V104, P439; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEAL G, 1987, BIOCHIM BIOPHYS ACTA, V925, P226, DOI 10.1016/0304-4165(87)90113-9; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; VIAENE A, 1989, NUCLEIC ACIDS RES, V17, P1251, DOI 10.1093/nar/17.3.1251; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31; WILLIAMS MV, 1990, J BACTERIOL, V172, P2979, DOI 10.1128/jb.172.6.2979-2985.1990; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988	49	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22512	22521						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429601				2022-12-27	WOS:A1992JW71900082
J	DUBIEL, W; PRATT, G; FERRELL, K; RECHSTEINER, M				DUBIEL, W; PRATT, G; FERRELL, K; RECHSTEINER, M			PURIFICATION OF AN 11-S REGULATOR OF THE MULTICATALYTIC PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; MOLECULAR-WEIGHT PROTEINASE; RED-BLOOD-CELLS; MACROPAIN PROTEASOME; ENDOGENOUS INHIBITOR; CDNA CLONING; GENE FAMILY; 26S COMPLEX; RAT-LIVER; UBIQUITIN	We have identified and purified a protein complex from human red blood cells that activates the multicatalytic protease (MCP). The complex, which we call the regulator, sediments at 11 S and is composed of 30-kDa subunits. The regulator does not hydrolyze fluorogenic peptides, but when multicatalytic protease and regulator are combined, MCP cleaves succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin and Leu-Leu-Glu-p-nitroanilide as much as 60-fold faster. Hydrolysis of several other fluorogenic peptides is stimulated to a lesser extent, and activated MCP does not degrade ubiquitin-lysozyme conjugates, bovine serum albumin, or lysozyme. Latent and activated forms of MCP display similar sensitivity to protease inhibitors, suggesting that activation does not generate new kinds of catalytic sites. In addition, ATP suppresses peptide hydrolysis by activated and latent MCPs to the same extent. Activation involves binding of regulator to MCP, and activated MCP migrates slower on native acrylamide gels. Dissociation of the MCP regulator complex during prolonged sedimentation on glycerol gradients releases active regulator and MCP molecules capable of being reactivated. Moreover, two-dimensional electrophoresis does not reveal changes in MCP or regulator subunits following activation. Thus, activation appears to result from reversible association of regulator subunits with MCP.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah				Dubiel, Wolfgang/0000-0002-3393-0701	NIGMS NIH HHS [GM 39007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM039007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMON T, 1990, J BIOL CHEM, V265, P20723; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DEMARTINO GN, 1982, BIOCHEMISTRY-US, V21, P4297, DOI 10.1021/bi00261a019; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HAASS C, 1990, GENE, V90, P235, DOI 10.1016/0378-1119(90)90185-T; HAASS C, 1990, NUCLEIC ACIDS RES, V18, P4018, DOI 10.1093/nar/18.13.4018; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1986, J BIOL CHEM, V261, P2391; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LEE DH, 1992, BIOCHEM BIOPH RES CO, V182, P452, DOI 10.1016/0006-291X(92)91753-D; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LEE WJ, 1990, BIOCHEM INT, V22, P163; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; MASON RW, 1990, BIOCHEM J, V265, P479, DOI 10.1042/bj2650479; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P2279; MELLGREN RL, 1990, INTRACELLULAR CALCIU; MURACHI T, 1989, BIOCHEM INT, V18, P263; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PONTREMOLI S, 1988, P NATL ACAD SCI USA, V85, P1740, DOI 10.1073/pnas.85.6.1740; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SHIBA E, 1992, BIOCHEM BIOPH RES CO, V182, P461, DOI 10.1016/0006-291X(92)91754-E; SORIMACHI H, 1990, EUR J BIOCHEM, V193, P775, DOI 10.1111/j.1432-1033.1990.tb19399.x; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAKEYAMA Y, 1986, FEBS LETT, V194, P110, DOI 10.1016/0014-5793(86)80060-6; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1988, J BIOL CHEM, V263, P16209; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YU B, 1991, J BIOL CHEM, V266, P17396; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	52	337	345	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22369	22377						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429590				2022-12-27	WOS:A1992JW71900061
J	FOUCAUD, C; POOLMAN, B				FOUCAUD, C; POOLMAN, B			LACTOSE TRANSPORT-SYSTEM OF STREPTOCOCCUS-THERMOPHILUS - FUNCTIONAL RECONSTITUTION OF THE PROTEIN AND CHARACTERIZATION OF THE KINETIC MECHANISM OF TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE-VESICLES; MELIBIOSE CARRIER; SOLUTE TRANSPORT; TRANSLOCATION; PH; PHOSPHOLIPIDS; PERMEASE; BACTERIA; EFFLUX	The kinetic mechanism of the lactose transport system of Streptococcus thermophilus was studied in membrane vesicles fused with cytochrome c oxidase containing liposomes and in proteoliposomes in which cytochrome c oxidase was coreconstituted with the lactose transport protein. Selective manipulation of the components of the proton (and sodium) motive force indicated that both a membrane potential and a PH gradient could drive transport. The galactoside/proton stoichiometry was close to unity. Experiments which discriminate between the effects of internal pH and DELTApH as driving force on galactoside/proton symport showed that the carrier is highly activated at alkaline internal pH values, which biases the transport system kinetically toward the pH component of the proton motive force. Galactoside efflux increased with increasing pH with a pK(a) of about 8, whereas galactoside exchange (and counterflow) exhibited a pH optimum around 7 with pK(a) values of 6 and 8, respectively. Imposition of DELTApH (interior alkaline) retarded the rate of efflux at any pH value tested, whereas the rate of exchange was stimulated by an imposed DELTApH at pH 5.8, not affected at pH 7.0, and inhibited at pH 8.0 and 9.0. The results have been evaluated in terms of random and ordered association/dissociation of galactoside and proton on the inner surface of the membrane. Imposition of DELTAPSI (interior negative) decreased the rate of efflux but had no effect on the rate of exchange, indicating that the unloaded transport protein carries a net negative charge and that during exchange and counterflow the carrier recycles in the protonated form.	UNIV GRONINGEN,DEPT MICROBIOL,KERKLAAN 30,9751 NN HAREN,NETHERLANDS	University of Groningen			Poolman, Bert/D-1882-2012					BASSILANA M, 1987, J BIOL CHEM, V262, P16865; CITTI JE, 1965, J BACTERIOL, V89, P937, DOI 10.1128/JB.89.4.937-942.1965; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; DRIESSEN AJM, 1987, J BIOL CHEM, V262, P12438; DRIESSEN AJM, 1992, IN PRESS METHODS ENZ; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; ELLIKER PR, 1956, J DAIRY SCI, V39, P1611, DOI 10.3168/jds.S0022-0302(56)94896-2; GARCIA ML, 1983, BIOCHEMISTRY-US, V22, P2525; HUTKINS RW, 1991, APPL ENVIRON MICROB, V57, P941, DOI 10.1128/AEM.57.4.941-944.1991; KABACK HR, 1990, BACTERIA, V12, P151; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3691, DOI 10.1021/bi00584a009; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; KAGAWA Y, 1973, J BIOL CHEM, V248, P676; KONINGS WN, 1989, CRC CR REV MICROBIOL, V16, P419, DOI 10.3109/10408418909104474; LEBLANC G, 1990, ION COUPLED SUGAR TR; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALONEY PC, 1973, BIOCHIM BIOPHYS ACTA, V330, P196, DOI 10.1016/0005-2736(73)90225-3; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; OKO N, 1982, BIOCHIM BIOPHYS ACTA, V691, P332; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; PAGE MGP, 1987, BIOCHIM BIOPHYS ACTA, V897, P112, DOI 10.1016/0005-2736(87)90319-1; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1990, J BACTERIOL, V172, P4037, DOI 10.1128/jb.172.7.4037-4047.1990; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; POOLMAN B, 1987, MICROBIOL REV, V51, P498, DOI 10.1128/MMBR.51.4.498-508.1987; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; THOMAS TD, 1984, APPL ENVIRON MICROB, V48, P186, DOI 10.1128/AEM.48.1.186-191.1984; VELD GI, 1992, BIOCHIM BIOPHYS ACTA, V1104, P250; VIITANEN P, 1983, BIOCHEMISTRY-US, V22, P2531, DOI 10.1021/bi00279a034; WILSON DM, 1985, MEMBRANE BIOCHEM, V5, P269, DOI 10.3109/09687688509150282; WRIGHT JK, 1986, BIOCHIM BIOPHYS ACTA, V855, P391; YU CA, 1975, J BIOL CHEM, V250, P1383	34	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22087	22094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429561				2022-12-27	WOS:A1992JW71900019
J	OLDBERG, A; ANTONSSON, P; LINDBLOM, K; HEINEGARD, D				OLDBERG, A; ANTONSSON, P; LINDBLOM, K; HEINEGARD, D			COMP (CARTILAGE OLIGOMERIC MATRIX PROTEIN) IS STRUCTURALLY RELATED TO THE THROMBOSPONDINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESIVE GLYCOPROTEIN; ENDOTHELIAL-CELLS; GENE; ANGIOGENESIS; ATTACHMENT; PLATELETS; INHIBITOR; CALCIUM; MOUSE; 2ND	Cloning and sequence analysis of cartilage oligomeric matrix protein (COMP) cDNA, representing a cartilage pentameric protein, revealed a protein of 755 amino acid residues with a calculated molecular mass of 82,700 Da. Expression of the cDNA in COS cells showed that COMP is a homopolymer composed of five identical disulfide-linked subunits. COMP is homologous to the carboxyl-terminal half of thrombospondin, and the homologies include 89% and 54% of the residues in COMP and thrombospondin, respectively. The similarities are most pronounced in the carboxyl-terminal domains and in the calcium binding type 3 repeat domains in which about 60% of the amino acid residues are identical. In the type 2/epidermal growth factor repeat domains the two proteins contain 41 % identical residues. The sequence of the amino-terminal 84-amino acid residues is unique for COMP. Comparison of the amino acid sequences in the type 2 and type 3 repeat domains of COMP and the thrombospondins shows that COMP is the product of a unique gene and not the result of an alternatively spliced thrombospondin gene.			OLDBERG, A (corresponding author), UNIV LUND,DEPT MED & PHYSIOL CHEM,POB 94,S-22100 LUND,SWEDEN.							ALLEN G, 1981, LABORATORY TECHNIQUE, P35; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ASH AS, 1989, PROG HEMOSTASIS THRO, V9, P157; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER J, 1986, BLOOD, V67, P1197; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; VARANI J, 1988, J CLIN INVEST, V81, P1537, DOI 10.1172/JCI113486; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704	31	285	304	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22346	22350						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429587				2022-12-27	WOS:A1992JW71900057
J	SCHMUTZLER, C; DARMER, D; DIEKHOFF, D; GRIMMELIKHUIJZEN, CJP				SCHMUTZLER, C; DARMER, D; DIEKHOFF, D; GRIMMELIKHUIJZEN, CJP			IDENTIFICATION OF A NOVEL TYPE OF PROCESSING SITES IN THE PRECURSOR FOR THE SEA-ANEMONE NEUROPEPTIDE ANTHO-RFAMIDE (LESS-THAN-GLU-GLY-ARG-PHE-NH2) FROM ANTHOPLEURA-ELEGANTISSIMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LESS-THAN GLU-GLY-ARG-PHE-NH2; PEPTIDE AMIDATION; MOLECULAR-CLONING; DNA; ACID; SEQUENCES; MUSCLES; ENZYME	Neuropeptides are synthesized as large precursor proteins that undergo posttranslational cleavages and modifications to produce bioactive peptides. Here, we have cloned two closely related precursor proteins for the sea anemone neuropeptide Antho-RFamide (<Glu-Gly-Arg-Phe-NH2) from Anthopleura elegantissima. The first precursor (435 amino acids long) contains 13 copies of immature Antho-RFamide (Gln-Gly-Arg-Phe-Gly) and nine other, Antho-RFamide-related neuropeptide sequences that are in the C-terminal part of the protein. The second precursor (429 amino acid residues) harbors 14 copies of immature Antho-RFamide and eight other related peptide sequences. Each copy of Antho-RFamide or Antho-RFamide-related peptide is followed, at its C-terminal side, by a single Arg residue, which is an established signal for post-translational cleavage. At the N terminus of each Antho-RFamide sequence, however, basic residues are lacking, and instead one or more acidic residues occur. These acidic residues are the cleavage sites for a new type of processing enzyme occurring in neurons. This enzyme could either be an amino- or endopeptidase hydrolyzing at the C-terminal side of Asp or Glu residues. The N-terminal regions of the two precursor proteins harbor eight copies of the putative neuropeptide sequence Pro-Gln-Phe-Trp-Lys-Gly-Arg-Phe-Ser and three additional, closely related sequences. The total number of all established and putative neuropeptides that may be cleaved from the precursors is 33. Thus, the Antho-RFamide precursors belong to the most complex peptide precursor proteins known so far.			SCHMUTZLER, C (corresponding author), UNIV HAMBURG,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.			Grimmelikhuijzen, Cornelis Johannes Pieter/0000-0001-6486-2046				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARMER D, 1991, P NATL ACAD SCI USA, V88, P2555, DOI 10.1073/pnas.88.6.2555; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER WH, 1987, P NATL ACAD SCI USA, V84, P3628; GRAFF D, 1988, FEBS LETT, V239, P137, DOI 10.1016/0014-5793(88)80560-X; GRAFF D, 1988, BRAIN RES, V442, P354, DOI 10.1016/0006-8993(88)91525-9; GRIMMELIKHUIJZEN CJP, 1992, AM ZOOL, V32, P1; GRIMMELIKHUIJZEN CJP, 1986, P NATL ACAD SCI USA, V83, P9817, DOI 10.1073/pnas.83.24.9817; GRIMMELIKHUIJZEN CJP, 1990, P NATL ACAD SCI USA, V87, P5410, DOI 10.1073/pnas.87.14.5410; GRIMMELIKHUIJZEN CJP, 1989, ARCH HISTOL CYTOL, V52, P265, DOI 10.1679/aohc.52.Suppl_265; HUDSON P, 1981, NATURE, V291, P127, DOI 10.1038/291127a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KREIL G, 1990, TRENDS BIOCHEM SCI, V15, P23, DOI 10.1016/0968-0004(90)90126-V; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; MCFARLANE ID, 1991, J EXP BIOL, V155, P669; MCFARLANE ID, 1987, J EXP BIOL, V133, P157; MCFARLANE ID, 1991, J EXP BIOL, V156, P419; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; NEWCOMB RW, 1987, J NEUROCHEM, V49, P574, DOI 10.1111/j.1471-4159.1987.tb02902.x; POHL T, 1991, P NATL ACAD SCI USA, V88, P10059, DOI 10.1073/pnas.88.22.10059; RICHTER K, 1990, FEBS LETT, V262, P353, DOI 10.1016/0014-5793(90)80227-A; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; TAGER HS, 1973, J BIOL CHEM, V248, P3476; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	34	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22534	22541						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429603				2022-12-27	WOS:A1992JW71900085
J	KOBAYASHI, M; KOMEDA, H; YANAKA, N; NAGASAWA, T; YAMADA, H				KOBAYASHI, M; KOMEDA, H; YANAKA, N; NAGASAWA, T; YAMADA, H			NITRILASE FROM RHODOCOCCUS-RHODOCHROUS J1 - SEQUENCING AND OVEREXPRESSION OF THE GENE AND IDENTIFICATION OF AN ESSENTIAL CYSTEINE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-N CLEAVAGE; CATALYZED PRODUCTION; AROMATIC NITRILES; PURIFICATION; ENZYMOLOGY; FRAGMENTS; CLONING; VECTORS; CELLS	The amino acid sequences of the NH2 terminus and internal peptide fragments of a Rhodococcus rhodochrous J1 nitrilase were determined to prepare synthetic oligonucleotides as primers for the polymerase chain reaction. A 750-base DNA fragment thus amplified was used as the probe to clone a 5.4-kilobase PstI fragment coding for the whole nitrilase. The nitrilase gene modified in the sequence upstream from the presumed ATG start codon was expressed to approximately 50% of the total soluble protein in Escherichia coli. The predicted amino acid sequence of the nitrilase gene showed similarity to that of the bromoxynil nitrilase from Klebsiella ozaenae. The 5,5'-dithiobis(2-nitrobenzoic acid) modification of the nitrilase from R. rhodochrous J1 resulted in inactivation with the loss of one sulfhydryl group/enzyme subunit. Of 4 cysteine residues in the Rhodococcus nitrilase, only Cys-165 is conserved in the Klebsiella nitrilase. Mutant enzymes containing Ala or Ser instead of Cys-165 did not exhibit nitrilase activity. These findings suggest that Cys-165 plays an essential role in the function of the active site.	NAGOYA UNIV,FAC AGR,DEPT FOOD SCI & TECHNOL,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University	KOBAYASHI, M (corresponding author), KYOTO UNIV,FAC AGR,DEPT AGR CHEM,KITASHIRAKAWA OIWAKE CHO,SAKYO KU,KYOTO 606,JAPAN.		Yanaka, Noriyuki/P-9096-2016					BANDYOPADHYAY AK, 1986, APPL ENVIRON MICROB, V51, P302, DOI 10.1128/AEM.51.2.302-306.1986; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GETHING MJH, 1972, EUR J BIOCHEM, V30, P352; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HARPER DB, 1985, INT J BIOCHEM, V17, P677, DOI 10.1016/0020-711X(85)90364-7; HARPER DB, 1977, BIOCHEM J, V167, P685, DOI 10.1042/bj1670685; HARPER DB, 1977, BIOCHEM J, V165, P309, DOI 10.1042/bj1650309; HOOK RH, 1964, J BIOL CHEM, V239, P4263; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KOBAYASHI M, 1990, J ANTIBIOT, V43, P1316, DOI 10.7164/antibiotics.43.1316; KOBAYASHI M, 1989, EUR J BIOCHEM, V182, P349, DOI 10.1111/j.1432-1033.1989.tb14837.x; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1129, P23, DOI 10.1016/0167-4781(91)90208-4; KOBAYASHI M, 1988, APPL MICROBIOL BIOT, V29, P231; KOBAYASHI M, 1990, J BACTERIOL, V172, P4807, DOI 10.1128/jb.172.9.4807-4815.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NAGASAWA T, 1991, EUR J BIOCHEM, V196, P581, DOI 10.1111/j.1432-1033.1991.tb15853.x; NAGASAWA T, 1990, EUR J BIOCHEM, V194, P765, DOI 10.1111/j.1432-1033.1990.tb19467.x; NAGASAWA T, 1988, ARCH MICROBIOL, V150, P89, DOI 10.1007/BF00409723; NAGASAWA T, 1988, APPL ENVIRON MICROB, V54, P1766, DOI 10.1128/AEM.54.7.1766-1769.1988; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; ROBINSON WG, 1964, J BIOL CHEM, V239, P4257; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STALKER DM, 1988, J BIOL CHEM, V263, P6310; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	35	99	106	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20746	20751						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400390				2022-12-27	WOS:A1992JT97800038
J	MAYER, ML; CAPLIN, BE; MARSHALL, MS				MAYER, ML; CAPLIN, BE; MARSHALL, MS			CDC43 AND RAM2 ENCODE THE POLYPEPTIDE SUBUNITS OF A YEAST TYPE-I PROTEIN GERANYLGERANYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; GTP-BINDING; GENE; FARNESYLTRANSFERASE; CYSTEINE; IDENTIFICATION; CELLS	The question regarding the identity of the alpha and beta subunits of the yeast type I protein geranylgeranyl-transferase was explored using prokaryotic expression of candidate genes. The Saccharomyces cerevisiae CDC43 and RAM2 genes were expressed in Escherichia coli and cell extracts examined for the ability to transfer [H-3]geranylgeranyl diphosphate to an appropriate CaaX protein substrate. Individual expression of each gene yielded no activity; however, co-expression of the two genes resulted in high levels of [H-3] geranylgeranyl incorporation into the substrate protein Ras-Cys-Val-Val-Leu. The activity was partially purified yielding approximately 12,600 units/liter. The partially purified enzyme geranylgeranylated the Ras-Cys-Val-Val-Leu, Ras-Cys-Ala-Ile-Leu, Ras-Cys-Ile-Ile-Leu, and Ras-Cys-Thr-Ile-Leu substrates but not the Ras-Cys-Val-Leu-Ser or Ras-Ser-Val-Leu-Ser substrates. The protein geranylgeranyltransferase was highly specific for geranylgeranyl diphosphate and poorly transferred farnesyl. The recombinant enzyme was indistinguishable from the native type I geranylgeranyltransferase in yeast extracts. As has been reported for the protein farnesyltransferase, the yeast type I protein geranylgeranyltransferase is also a magnesium-requiring, zinc metalloenzyme. Interestingly, the recombinant enzyme functioned with calcium as the only divalent cation, although addition of zinc increased calcium-dependent activity 2-fold.	INDIANA UNIV,DEPT MED,DIV HEMATOL & ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute								BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HE B, 1991, P NATL ACAD SCI USA, V88, P4448; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KOHL NE, 1991, J BIOL CHEM, V266, P18884; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OHYA Y, 1984, MOL GEN GENET, V193, P389, DOI 10.1007/BF00382073; OHYA Y, 1991, J BIOL CHEM, V266, P12356; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	27	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20589	20593						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400380				2022-12-27	WOS:A1992JT97800016
J	SINDELAR, P; CHOJNACKI, T; VALTERSSON, C				SINDELAR, P; CHOJNACKI, T; VALTERSSON, C			PHOSPHATIDYLETHANOLAMINE DOLICHOL ACYLTRANSFERASE - CHARACTERIZATION AND PARTIAL-PURIFICATION OF A NOVEL RAT-LIVER ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TISSUES; RETINOL ESTERIFICATION; PLASMA-MEMBRANES; PHOSPHATE; LOCALIZATION; LIPOPROTEIN; MICROSOMES; ESTERS; POLYPRENOLS; HYDROLYSIS	Incubation of rat or human post-heparin plasma with [H-3]dolichol incorporated in liposomes consisting of dioleoyl phosphatidylcholine:dioleoyl phosphatidylethanolamine (3:1) resulted in the formation of radioactive dolichyl oleate. Non-heparinized plasma did not esterify dolichol, and, hence, the enzyme involved is probably associated with the cell surface and released into the blood by heparin. The major location of this activity was the liver, and, therefore, a partial purification of the enzyme from heparinized rat liver perfusates was performed using DEAE-Sephacel and heparin-Sepharose chromatography. The dolichol acyltransferase activity copurified with hepatic lipase activity in a lipid-protein complex of 350 kDa. Optimal acylation is achieved at pH 7.5 in the presence of 5% plasma and 20 mM Ca2+. Esterification can only be obtained when dolichol is present in a phospholipid bilayer, and the reaction is strongly stimulated by unsaturated phosphatidylethanolamine or phosphatidylserine. Radiolabeling experiments demonstrated that the primary acyl donor is phosphatidylethanolamine from which the fatty acid is transferred exclusively from position 1. Neither cholesterol nor retinol are esterified by the enzyme, and the reaction is not stimulated by acyl-CoA. Both the extracellular localization and the mechanism of transacylation clearly distinguish this new enzyme from the acyl-CoA:dolichol acyltransferase described earlier in microsomes.	KAROLINSKA INST,HUDDINGE HOSP,CTR CLIN RES,S-14186 HUDDINGE,SWEDEN; UNIV STOCKHOLM,INST BIOCHEM,S-10691 STOCKHOLM,SWEDEN; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; Stockholm University; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences								BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; Brown M S, 1979, Harvey Lect, V73, P163; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CHOJNACKI T, 1975, ANAL BIOCHEM, V69, P114, DOI 10.1016/0003-2697(75)90572-2; Dallner G, 1974, Methods Enzymol, V31, P191; DEROPP JS, 1985, J BIOL CHEM, V260, P5669; EGGENS I, 1983, BIOCHIM BIOPHYS ACTA, V751, P355, DOI 10.1016/0005-2760(83)90294-1; Ehnholm C, 1986, Methods Enzymol, V129, P716; ELMBERGER PG, 1987, EUR J BIOCHEM, V168, P1, DOI 10.1111/j.1432-1033.1987.tb13379.x; ELMBERGER PG, 1988, J LIPID RES, V29, P1651; Fiske CH, 1925, J BIOL CHEM, V66, P375; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; HEMMING FW, 1983, BIOSYNTHESIS ISOPREN, V2, P305; IBATA K, 1983, BIOCHEM J, V213, P305, DOI 10.1042/bj2130305; ISHINAGA M, 1990, AGR BIOL CHEM TOKYO, V54, P943, DOI 10.1080/00021369.1990.10870053; KALEN A, 1990, LIPIDS, V25, P93, DOI 10.1007/BF02562211; KEENAN RW, 1982, BIOCHIM BIOPHYS ACTA, V711, P490, DOI 10.1016/0005-2760(82)90063-7; KEENAN RW, 1976, BIOCHEMISTRY-US, V15, P1586, DOI 10.1021/bi00652a032; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CS, 1984, FEBS LETT, V169, P279, DOI 10.1016/0014-5793(84)80333-6; LANDS WEM, 1963, J BIOL CHEM, V238, P898; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALVAR TM, 1985, ARCH BIOCHEM BIOPHYS, V238, P401, DOI 10.1016/0003-9861(85)90180-8; MANKOWSKI T, 1976, BIOCHEMISTRY-US, V15, P2125, DOI 10.1021/bi00655a015; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ONG DE, 1988, J BIOL CHEM, V263, P5787; RAPPORT MM, 1957, J NEUROCHEM, V1, P303, DOI 10.1111/j.1471-4159.1957.tb12086.x; RIP JW, 1988, BIOCHIM BIOPHYS ACTA, V959, P58, DOI 10.1016/0005-2760(88)90149-X; RIP JW, 1981, J BIOL CHEM, V256, P1929; ROSS AC, 1982, J BIOL CHEM, V257, P2453; ROSS AC, 1982, J LIPID RES, V23, P133; RUPAR CA, 1982, J BIOL CHEM, V257, P3090; RUPAR CA, 1978, LIPIDS, V13, P291, DOI 10.1007/BF02533673; SCHER MG, 1981, BIOCHEM BIOPH RES CO, V99, P675, DOI 10.1016/0006-291X(81)91797-6; SIGGIA S, 1948, ANAL CHEM, V20, P762, DOI 10.1021/ac60020a026; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; TOLLBOM O, 1988, J BIOL CHEM, V263, P1347; TOLLBOM O, 1989, J BIOL CHEM, V264, P9836; TOLLBOM O, 1986, BRIT J EXP PATHOL, V67, P757; VALTERSSON C, 1985, J BIOL CHEM, V260, P2742; VANDUIJN G, 1986, BIOCHIM BIOPHYS ACTA, V861, P211; WAITE M, 1973, J BIOL CHEM, V248, P7985; WEINSTEIN JN, 1986, METHOD ENZYMOL, V128, P657; WONG TK, 1982, J BIOL CHEM, V257, P6619	45	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20594	20599						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400381				2022-12-27	WOS:A1992JT97800017
J	TERADA, N; OR, R; WEINBERG, K; DOMENICO, J; LUCAS, JJ; GELFAND, EW				TERADA, N; OR, R; WEINBERG, K; DOMENICO, J; LUCAS, JJ; GELFAND, EW			TRANSCRIPTION OF IL-2 AND IL-4 GENES IS NOT INHIBITED BY CYCLOSPORINE-A IN COMPETENT T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-2; CALCIUM IONOPHORES; PHORBOL ESTERS; LYMPHOCYTES-T; EXPRESSION; PROGRESSION; ACTIVATION; RECEPTOR; BINDING; SIGNALS	Cyclosporin A (CsA) inhibits T-cell proliferation primarily by blocking the transcription of several early activation genes, especially those of the important T-cell growth factors IL-2 and IL-4. This effect seems to be mediated through inhibition of the activity of the transcription factor NF-AT which is essential for IL-2 and probably for IL-4 gene transcription. However, once T cells are rendered "competent" to proliferate following a brief exposure to the phorbol ester, phorbol 12,13-dibutyrate (PDBu), and the calcium ionophore, ionomycin, CsA no longer inhibits cell cycle progression supported by the presence of PDBu alone. Here it is shown that transcription of the IL-2 and IL-4 genes occurs normally throughout this "progression" phase, even in the presence of CsA. However, further production of functional NF-AT, which began during the competence phase of the cell cycle, is inhibited. These data indicate that, although the primary initiation of transcription of IL2 and IL-4 mRNA during induction of competence may be NF-AT-dependent and CsA-sensitive, the augmentation in the progression phase is both NF-AT-independent and CsA-resistant.	CHILDRENS HOSP,DIV RES IMMUNOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles	TERADA, N (corresponding author), RAYMOND & BEVERLY SACKLER FDN,NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026490, R29AI025071, R01AI029704] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-29704, AI-25071, AI-26490] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI N, 1989, J IMMUNOL, V142, P274; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN M, 1988, J IMMUNOL, V131, P504; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FUJITA T, 1983, P NATL ACAD SCI-BIOL, V80, P7437, DOI 10.1073/pnas.80.24.7437; GELFAND EW, 1984, J CELL PHYSIOL, V121, P533, DOI 10.1002/jcp.1041210312; KUMAGAI N, 1988, J IMMUNOL, V141, P3747; KUMAGAI N, 1988, J CELL PHYSIOL, V137, P329, DOI 10.1002/jcp.1041370217; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OATES JA, 1989, NEW ENGL J MED, V321, P1725; OR R, 1992, CLIN IMMUNOL IMMUNOP, V64; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RENZ H, 1991, J IMMUNOL, V146, P3049; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TERADA N, 1990, BLOOD, V75, P453; TERADA N, 1991, J IMMUNOL, V147, P698; TORDAI A, 1992, BIOCHEM BIOPH RES CO, V185, P363, DOI 10.1016/S0006-291X(05)80994-5; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	20	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21207	21210						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400432				2022-12-27	WOS:A1992JT97800107
J	MAO, XH; GREEN, JM; SAFER, B; LINDSTEN, T; FREDERICKSON, RM; MIYAMOTO, S; SONENBERG, N; THOMPSON, CB				MAO, XH; GREEN, JM; SAFER, B; LINDSTEN, T; FREDERICKSON, RM; MIYAMOTO, S; SONENBERG, N; THOMPSON, CB			REGULATION OF TRANSLATION INITIATION-FACTOR GENE-EXPRESSION DURING HUMAN T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; CAP-BINDING-PROTEIN; MESSENGER-RNA; HELA-CELLS; STIMULATES PHOSPHORYLATION; FACTORS EIF-4F; LYMPHOCYTES-T; GROWTH-FACTOR; CLONING; INHIBITION	Activation of quiescent T cells leads to a dramatic increase in the rate of protein synthesis. It is believed that this pronounced increase of protein synthesis is regulated primarily at the level of translational initiation. Although considerable evidence demonstrates that translational initiation can be regulated at the post-translational level by the phosphorylation/dephosphorylation of translation initiation factors (eIFs) such as eIF-4E and eIF-2alpha, additional mechanisms of eIF gene expression may also play a role in the regulation of translation in quiescent cells and/or during their subsequent induction to enter the cell cycle. To address this issue, gene expression of eIF-2alpha, -4E, and -4A was studied in quiescent human peripheral blood T cells following stimulation through the T cell receptor-CD3 complex. Quiescent T cells expressed low levels of eIF-2alpha, -4E, and -4A mRNAs and proteins as compared to proliferating T cells. Activation of resting T cells resulted in a rapid increase (20-50-fold) in the levels of these three mRNAs. This increase did not require new protein synthesis. Furthermore, transcription rates of these three eIF genes showed only minor increase over the induction period as measured by nuclear run-on assays. Despite the rapid increase in initiation factor mRNA levels, increases in eIF protein levels lagged significantly behind. Western blot analysis also showed that the protein levels of the three eIFs were differentially increased. eIF-4A protein levels increased in proportion to the observed increase in cellular protein synthetic activity while the increases in eIF-4E and eIF-2alpha proteins were proportionately less. The low levels of eIF proteins in quiescent T cells appear to correlate with low protein synthesis rate in such cells. The induction of eIF proteins by post-transcriptional/translational mechanisms appears to contribute to the pronounced stimulation of protein synthesis that occurs during T cell activation.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; NHLBI, MOLEC HEMATOL LAB, PROT BIOSYNTH SECT, BETHESDA, MD 20892 USA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); McGill University	MAO, XH (corresponding author), UNIV MICHIGAN, MED CTR, DEPT MICROBIOL IMMUNOL, ANN ARBOR, MI 48109 USA.			Green, Jonathan/0000-0002-7449-4387	NATIONAL CANCER INSTITUTE [R29CA054521] Funding Source: NIH RePORTER; NCI NIH HHS [CA54521] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHERN T, 1973, BIOCHIM BIOPHYS ACTA, V331, P91, DOI 10.1016/0005-2787(73)90422-X; AHERN T, 1974, NATURE, V248, P519, DOI 10.1038/248519a0; ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; AMALDI F, 1989, TRENDS BIOCHEM SCI, V14, P175, DOI 10.1016/0968-0004(89)90269-7; ASHMAN RF, 1984, FUNDAMENTAL IMMUNOLO, P267; BRANDHORST BP, 1974, J MOL BIOL, V85, P451, DOI 10.1016/0022-2836(74)90444-6; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; COOPER HL, 1977, J CELL PHYSIOL, V93, P213, DOI 10.1002/jcp.1040930207; COOPER HL, 1969, J BIOL CHEM, V244, P5590; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; EDERY I, 1983, J BIOL CHEM, V258, P1398; ERICKSON JM, 1981, GENE, V16, P1, DOI 10.1016/0378-1119(81)90055-X; ERNST H, 1987, J BIOL CHEM, V262, P1206; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GREEN RC, 1977, EXP CELL RES, V110, P215, DOI 10.1016/0014-4827(77)90287-7; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HERMAN RC, 1977, BIOCHEMISTRY-US, V16, P3460, DOI 10.1021/bi00634a026; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAY JE, 1975, BIOCHIM BIOPHYS ACTA, V378, P241, DOI 10.1016/0005-2787(75)90112-4; KAY JE, 1966, BIOCHEM J, V100, P815, DOI 10.1042/bj1000815; KAY JE, 1971, BIOCHIM BIOPHYS ACTA, V247, P322, DOI 10.1016/0005-2787(71)90680-0; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; LENGYEL J, 1975, CELL, V5, P281, DOI 10.1016/0092-8674(75)90103-8; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; WELLINGTON C L, 1992, Current Biology, V2, P216, DOI 10.1016/0960-9822(92)90544-K; WETTENHALL REH, 1979, BIOCHIM BIOPHYS ACTA, V563, P400, DOI 10.1016/0005-2787(79)90059-5	56	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20444	20450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400363				2022-12-27	WOS:A1992JR85800108
J	WEST, M; MIKOVITS, J; PRINCLER, G; LIU, YL; RUSCETTI, FW; KUNG, HF; RAZIUDDIN				WEST, M; MIKOVITS, J; PRINCLER, G; LIU, YL; RUSCETTI, FW; KUNG, HF; RAZIUDDIN			CHARACTERIZATION AND PURIFICATION OF A NOVEL TRANSCRIPTIONAL REPRESSOR FROM HELA-CELL NUCLEAR EXTRACTS RECOGNIZING THE NEGATIVE REGULATORY ELEMENT REGION OF HUMAN IMMUNODEFICIENCY VIRUS-1 LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; RNA POLYMERASE-II; HTLV-III; GENE-EXPRESSION; TRANS-ACTIVATOR; PROMOTER-REGION; REPLICATION; SEQUENCES; ANTIGENS; COMPLEX	Cellular transcription factors play critical roles in regulating human immunodeficiency virus (HIV) gene transcription, although the precise mechanism(s) defining their roles are not well established. Primarily it has been suggested that sequence-specific interaction of trans-activating proteins with cis-acting DNA elements plays a crucial role in regulating the target genes. The negative regulatory element (NRE) of HIV-1 long terminal repeat (LTR) is one such defined region that has been reported to down-regulate LTR-directed HIV gene expression. Information regarding the role of this region in the regulation of HIV expression is lacking. Here we describe an attempt to further characterize the role of NRE cis-elements and define any sequence-specific interaction with cellular factors. Using gel mobility shift DNA-binding and Southwestern blot assays, we have mapped a distinct region of NRE (-290 to -260, a 30-base pair (bp) domain of NRE-A) sequences of HIV-1 LTR, which recognizes a specific DNA-binding protein from HeLa cell nuclear extracts. This factor is a 38-kDa polypeptide which can be affinity-purified to near homogeneity by this 30-bp specific oligonucleotide in affinity chromatography. The cellular factor from HeLa cell nuclear extract exhibits specific interaction only with the 30-bp NRE-A domain of HIV-1 LTR and acts as a strong transcriptional repressor/inhibitor molecule in the DNA-protein gel binding, as well as in in vitro transcriptional studies with the nuclear extracts from cells with productive HIV-1 infection. To our knowledge, this is the first report of a factor recognizing a distinct segment within NRE that has been shown to exert an inhibitory effect on transcriptionally active DNA-protein "pre-initiation" complex formation, suggesting a possible role in HIV-1 gene regulation.	NCI,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,BIOCHEM PHYSIOL LABS,FREDERICK,MD 21702; NCI,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LABS,FREDERICK,MD 21702; FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074102, N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALVERT I, 1991, GENE, V101, P171, DOI 10.1016/0378-1119(91)90408-4; CLOUSE KA, 1989, J IMMUNOL, V142, P431; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MIKOVITS JA, 1990, J EXP MED, V171, P1705, DOI 10.1084/jem.171.5.1705; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; RAZIUDDIN MJA, 1991, P NATL ACAD SCI USA, V88, P9426; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; VERMA R, 1992, J BIOL CHEM, V267, P1648; WEIL PA, 1979, CELL, V18, P469; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	30	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24948	24952						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459999				2022-12-27	WOS:A1992KB60300009
J	GODEAU, F; LUESCHER, IF; OJCIUS, DM; SAUCIER, C; MOTTEZ, E; CABANIE, L; KOURILSKY, P				GODEAU, F; LUESCHER, IF; OJCIUS, DM; SAUCIER, C; MOTTEZ, E; CABANIE, L; KOURILSKY, P			PURIFICATION AND LIGAND-BINDING OF A SOLUBLE CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE CONSISTING OF THE 1ST 3 DOMAINS OF H-2KD FUSED TO BETA-2-MICROGLOBULIN EXPRESSED IN THE BACULOVIRUS-INSECT CELL SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; HIGH-LEVEL EXPRESSION; B ANTIGENS INVIVO; IMMUNOGENIC PEPTIDES; RAPID TRANSFER; FOREIGN GENES; HEAVY-CHAINS; HLA-A; MHC; PROTEINS	A recombinant baculovirus encoding a single-chain murine major histocompatibility complex class I molecule in which the first three domains of H-2K(d) are fused to beta2-microglobulin (beta2-m) via a 15-amino acid linker has been isolated and used to infect lepidopteran cells. A soluble, 391-amino acid single-chain H-2K(d) (SC-K(d)) molecule of 48 kDa was synthesized and glycosylated in insect cells and could be purified in the absence of detergents by affinity chromatography using the anti-H-2K(d) monoclonal antibody SF1.1.1.1. We tested the ability of SC-K(d) to bind antigenic peptides using a direct binding assay based on photo-affinity labeling. The photoreactive derivative was prepared from the H-2K(d)-restricted Plasmodium berghei circumsporozoite protein (P.b. CS) peptide 253-260 (YIPSAEKI), a probe that we had previously shown to be unable to bind to the H-2K(d) heavy chain in infected cells in the absence of co-expressed beta2-microglobulin. SC-K(d) expressed in insect cells did not require additional mouse beta2-m to bind the photoprobe, indicating that the covalently attached beta2-m could substitute for the free molecule. Similarly, binding of the P.b. CS photoaffinity probe to the purified SC-K(d) molecule was unaffected by the addition of exogenous beta2-m. This is in contrast to H-2K(d)Q10, a soluble H-2K(d) molecule in which beta2-m is noncovalently bound to the soluble heavy chain, whose ability to bind the photoaffinity probe is greatly enhanced in the presence of an excess of exogenous beta2-m. The binding of the probe to SC-K(d) was allele-specific, since labeling was selectively inhibited only by antigenic peptides known to be presented by the H-2K(d) molecule.	INST PASTEUR,UNITE TECHNOL CELLULAIRE,F-75724 PARIS 15,FRANCE; LUDWIG INST CANC RES,CH-1066 EPALINGES,SWITZERLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ludwig Institute for Cancer Research	GODEAU, F (corresponding author), INSERM,U277,UNITE BIOL MOLEC GENE,28 RUE DU DOCTEUR ROUX,F-75005 PARIS,FRANCE.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DARGEMONT C, 1989, SCIENCE, V246, P803, DOI 10.1126/science.2683083; DEGRAFF BA, 1974, J AM CHEM SOC, V96, P7491, DOI 10.1021/ja00831a017; DOBBERSTEIN B, 1979, CELL, V17, P759, DOI 10.1016/0092-8674(79)90316-7; DOVER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GODEAU F, 1991, RES IMMUNOL, V142, P409, DOI 10.1016/0923-2494(91)90039-L; GODEAU JF, 1992, INT IMMUNOL, V4, P265; GODEAU JF, 1990, TRANSFERT EXPRESSION, P33; HARLOW E, 1988, ANTIBODIES LABORATOR; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUESCHER IF, 1987, ELECTROPHORESIS, V8, P508, DOI 10.1002/elps.1150081103; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; LUESCHER IF, 1992, J IMMUNOL, V148, P1003; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MAEDA S, 1989, ANNU REV ENTOMOL, V34, P351, DOI 10.1146/annurev.en.34.010189.002031; MARGULIES DH, 1986, P NATL ACAD SCI USA, V83, P5252, DOI 10.1073/pnas.83.14.5252; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOTTEZ E, 1991, EUR J IMMUNOL, V21, P467, DOI 10.1002/eji.1830210232; NATORI T, 1976, J IMMUNOGENET, V3, P123; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; NUTCHERN JG, 1989, NATURE, V339, P223; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; OZATO K, 1980, J IMMUNOL, V125, P2473; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; Sambrook J, 1989, MOL CLONING LABORATO; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	65	35	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24223	24229						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447172				2022-12-27	WOS:A1992KA26300015
J	STEINER, DF; SMEEKENS, SP; OHAGI, S; CHAN, SJ				STEINER, DF; SMEEKENS, SP; OHAGI, S; CHAN, SJ			THE NEW ENZYMOLOGY OF PRECURSOR PROCESSING ENDOPROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							YEAST SACCHAROMYCES-CEREVISIAE; PROSOMATOSTATIN-CONVERTING ENZYMES; MICROINJECTED XENOPUS OOCYTES; PROTEOLYTIC CLEAVAGE SITE; SUBTILISIN-LIKE PROTEASE; KEX2 PROTEASE; GENE-PRODUCT; FUNCTIONAL EXPRESSION; SECRETORY PATHWAY; MUTATIONAL ANALYSIS		UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MED,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago	STEINER, DF (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK013914, R37DK013914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13914, DK20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BARR PJ, 1991, CELL, V6, P1; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BIRCH NP, 1991, BIOCHEM BIOPH RES CO, V179, P1311, DOI 10.1016/0006-291X(91)91716-P; BIRCH NP, 1991, BIOCHEM BIOPH RES CO, V177, P920, DOI 10.1016/0006-291X(91)90626-I; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BOURBONNAIS Y, 1991, J BIOL CHEM, V266, P13203; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BRENNAN SO, 1990, J BIOL CHEM, V265, P21494; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; Eipper B A, 1980, Endocr Rev, V1, P1; Freinkel N., 1972, HDB PHYSL, V1, P175; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1990, MOL ENDOCRINOL, V4, P1572, DOI 10.1210/mend-4-10-1572; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KEMMLER W, 1973, J BIOL CHEM, V248, P4544; KEMMLER W, 1971, J BIOL CHEM, V246, P6786; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LERNER CG, 1990, J BIOL CHEM, V33, P20085; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MACKIN RB, 1990, METABOLISM, V39, P30, DOI 10.1016/0026-0495(90)90204-P; MACKIN RB, 1987, J BIOL CHEM, V262, P6453; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; ODA K, 1988, J BIOCHEM-TOKYO, V104, P159, DOI 10.1093/oxfordjournals.jbchem.a122432; OHAGI S, 1992, P NATL ACAD SCI USA, V89, P4977, DOI 10.1073/pnas.89.11.4977; PATERSON RG, 1989, J VIROL, V63, P1293, DOI 10.1128/JVI.63.3.1293-1301.1989; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PEACH RJ, 1989, BIOCHIM BIOPHYS ACTA, V990, P276, DOI 10.1016/S0304-4165(89)80045-5; PETERS K, 1991, WORM BREEDERS GAZETT, V11, P28; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; REHEMTULLA A, 1992, BLOOD, V79, P2349; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; ROBICHON A, 1991, ENDOCRINOLOGY, V128, P1974, DOI 10.1210/endo-128-4-1974; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; ROEBROEK AJM, 1991, FEBS LETT, V289, P133, DOI 10.1016/0014-5793(91)81052-A; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; Schwartz TW, 1990, MOL BIOL ISLETS LANG, P153; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, DNA CELL BIOL, V11, P283, DOI 10.1089/dna.1992.11.283; SEIDAH NG, 1991, GENOMICS, V11, P103, DOI 10.1016/0888-7543(91)90106-O; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SMEEKENS SP, 1992, PROG BRAIN RES, V92, P235, DOI 10.1016/S0079-6123(08)61179-6; SPAETE RR, 1990, J VIROL, V64, P2922, DOI 10.1128/JVI.64.6.2922-2931.1990; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; THOMAS G, 1986, SCIENCE, V232, P1641, DOI 10.1126/science.3754979; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1991, J BIOL CHEM, V266, P13607; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1066; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	101	592	607	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23435	23438						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429684				2022-12-27	WOS:A1992JZ23900001
J	TRIPATHI, RK; HEARING, VJ; URABE, K; AROCA, P; SPRITZ, RA				TRIPATHI, RK; HEARING, VJ; URABE, K; AROCA, P; SPRITZ, RA			MUTATIONAL MAPPING OF THE CATALYTIC ACTIVITIES OF HUMAN TYROSINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IA OCULOCUTANEOUS ALBINISM; SINGLE BASE INSERTION; MAMMALIAN TYROSINASE; GENE MUTATION; DNA; PIGMENTATION; MELANIN; MOUSE; BIOSYNTHESIS; PATIENT	Tyrosinase (EC 1.14.18.1) is a copper-containing metalloglycoprotein that catalyzes several steps in the melanin pigment biosynthetic pathway; the hydroxylation of tyrosine to L-3,4-dihydroxyphenylalanine (dopa) and the subsequent oxidation of dopa to dopaquinone. It has been proposed that tyrosinase is also able to oxidize 5,6-dihydroxyindole (DHI), a later product in the melanogenic pathway, to indole-5,6-quinone. Tyrosinase enzymatic activity is deficient in patients with classic type I oculocutaneous albinism (OCA), and more than 50 distinct mutations have now been identified in the tyrosinase genes of such patients. To determine the effects of the various tyrosinase gene mutations on the catalytic activities of the enzyme, we carried out site-directed mutagenesis of human tyrosinase cDNA, transiently expressed the mutant cDNAs in transfected HeLa cells, and assayed the resultant encoded proteins for tyrosine hydroxylase, dopa, and DHI oxidase activities, and resulting melanin production. The tyrosine hydroxylase activity of normal tyrosinase is thermostable, whereas its dopa oxidase and DHI oxidase activities are temperature-sensitive. Although all amino acid substitutions tested generally affected the dopa oxidase and DHI oxidase activities in parallel, several exerted distinctly different effects on the tyrosine hydroxylase activities. Together, these results confirm the DHI oxidase activity of mammalian tyrosinase and suggest that the dopa oxidase and DHI oxidase activities of tyrosinase share a common catalytic site, whereas the tyrosine hydroxylase catalytic site is at least partially distinct in the tyrosinase polypeptide.	UNIV WISCONSIN, DEPT MED GENET, GENET LAB 317, 445 HENRY MALL, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017	Aroca, Pilar/0000-0002-7557-6931	NIAMS NIH HHS [AR-39892] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENIGNI JD, 1965, J HETEROCYCLIC CHEM, V2, P387, DOI 10.1002/jhet.5570020413; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; BRAMHALL S, 1969, ANAL BIOCHEM, V31, P146, DOI 10.1016/0003-2697(69)90251-6; CHINTAMANENI CD, 1991, P NATL ACAD SCI USA, V88, P5272, DOI 10.1073/pnas.88.12.5272; DUCKWORTH HW, 1970, J BIOL CHEM, V245, P1613; GIEBEL LB, 1991, J CLIN INVEST, V87, P1119, DOI 10.1172/JCI115075; GIEBEL LB, 1991, AM J HUM GENET, V48, P1159; GIEBEL LB, 1991, GENOMICS, V9, P435, DOI 10.1016/0888-7543(91)90409-8; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GIEBEL LB, 1990, P NATL ACAD SCI USA, V87, P3255, DOI 10.1073/pnas.87.9.3255; GIEBEL LB, 1991, J MED GENET, V28, P464, DOI 10.1136/jmg.28.7.464; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HUSAIN I, 1982, J INVEST DERMATOL, V78, P243, DOI 10.1111/1523-1747.ep12506603; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KIKUCHI H, 1990, HUM GENET, V85, P123; KING RA, 1991, MOL BIOL MED, V8, P19; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; Lerch K, 1988, Prog Clin Biol Res, V256, P85; LERNER AB, 1949, J BIOL CHEM, V178, P185; LERNER AB, 1950, PHYSIOL REV, V30, P91, DOI 10.1152/physrev.1950.30.1.91; LERNER AB, 1951, J BIOL CHEM, V191, P799; MARTINEZ JH, 1985, BIOCHEM INT, V11, P729; OETTING WS, 1991, AM J HUM GENET, V49, P199; OETTING WS, 1991, J INVEST DERMATOL, V97, P15, DOI 10.1111/1523-1747.ep12477808; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POMERANT SH, 1967, J BIOL CHEM, V242, P5308; POMERANT.SH, 1966, J BIOL CHEM, V241, P161; SHIMAO K, 1962, BIOCHIM BIOPHYS ACTA, V62, P205; SPRITZ RA, 1991, AM J HUM GENET, V48, P318; SPRITZ RA, 1990, NEW ENGL J MED, V322, P1724, DOI 10.1056/NEJM199006143222407; TAKEDA A, 1990, J BIOL CHEM, V265, P17792; TOMITA Y, 1989, BIOCHEM BIOPH RES CO, V164, P990, DOI 10.1016/0006-291X(89)91767-1; TRIPATHI RK, 1991, GENE EXPRESSION, V1, P103; TRIPATHI RK, 1988, BIOCHEM J, V252, P481, DOI 10.1042/bj2520481; TRIPATHI RK, 1992, AM J MED GENET, V43, P865, DOI 10.1002/ajmg.1320430523; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; TSUKAMOTO K, 1992, BIOCHEM J, V286, P491, DOI 10.1042/bj2860491; WITKOP CJ, 1989, METABOLIC BASIS INHE; WITTBJER A, 1989, ACTA DERM-VENEREOL, V69, P125; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	46	127	130	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23707	23712						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429711				2022-12-27	WOS:A1992JZ23900044
J	BAZZI, MD; NELSESTUEN, GL				BAZZI, MD; NELSESTUEN, GL			AUTOPHOSPHORYLATION OF PROTEIN-KINASE-C MAY REQUIRE A HIGH-ORDER OF PROTEIN-PHOSPHOLIPID AGGREGATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; X-100 MIXED MICELLES; RAT-BRAIN; CELLULAR-REGULATION; ACTIVATION; PHOSPHATIDYLSERINE; SUBSTRATE; SPECIFICITY; CALCIUM; PHOSPHORYLATION	The activation of protein kinase C (PKC) usually displays cofactor requirements that include phosphatidylserine (PS), diacylglycerol, and calcium. A complicating factor is that good exogenous substrates of PKC are polycationic proteins or peptides that form aggregates with PS in the assay. This study examined the autophosphorylation of PKC using assays with phospholipid provided in the form of vesicles or phospholipid-Triton mixed micelles. The results showed a close correlation between PKC autophosphorylation and the formation of aggregated assay components. Aggregation occurred primarily by the action of Mg2+ on phospholipids and appeared to underlie a number of major features of PKC autophosphorylation. For example, autophosphorylation required higher concentrations of PS than phosphorylation of exogenous substrates. This appeared to be the result of the different PS requirements of aggregation by divalent metal ions and cationic substrates. An unanticipated result was that aggregation of mixed micelles showed specificity for PS, high cooperativity with respect to several agents, and a requirement for calcium. These parameters were remarkably similar to those describing PKC autophosphorylation. Several major implications are evident in this study. Since the autophosphorylation assay is not a well defined system of monodisperse materials, autophosphorylation of PKC may proceed by intra- or interpeptide mechanism. The uniform correlation between aggregation and production of PKC activity suggested that kinetic parameters may represent interactions of assay components other than the enzyme. Aggregation, which appeared necessary for in vitro activation of PKC, may represent the expression of important but undefined in vivo requirements for this enzyme's function.			BAZZI, MD (corresponding author), UNIV MINNESOTA, DEPT BIOCHEM, 1479 GORTNER AVE, ST PAUL, MN 55108 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P5002, DOI 10.1021/bi00390a018; BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOLEN EJ, 1992, BIOCHEMISTRY-US, V31, P5945, DOI 10.1021/bi00140a034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HUANG KP, 1986, J BIOL CHEM, V261, P2134; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE MH, 1992, BIOCHEMISTRY-US, V31, P5176, DOI 10.1021/bi00137a013; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MCLAUGHLIN S, 1981, J GEN PHYSIOL, V77, P445, DOI 10.1085/jgp.77.4.445; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NEWTON AC, 1990, BIOCHEMISTRY-US, V29, P6656, DOI 10.1021/bi00480a015; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOOIJ EHD, 1962, BIOCHIM BIOPHYS ACTA, V62, P608, DOI 10.1016/0006-3002(62)90254-8; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; SNOEK GT, 1988, BIOCHEM J, V255, P629; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; WALKER JM, 1988, J BIOL CHEM, V263, P4537	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22891	22896						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429637				2022-12-27	WOS:A1992JY16300030
J	NAKAMURA, Y; TAKEDA, M; AIMOTO, S; HOJO, H; TAKAO, T; SHIMONISHI, Y; HARIGUCHI, S; NISHIMURA, T				NAKAMURA, Y; TAKEDA, M; AIMOTO, S; HOJO, H; TAKAO, T; SHIMONISHI, Y; HARIGUCHI, S; NISHIMURA, T			ASSEMBLY REGULATORY DOMAIN OF GLIAL FIBRILLARY ACIDIC PROTEIN - A SINGLE PHOSPHORYLATION DIMINISHES ITS ASSEMBLY-ACCELERATING PROPERTY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT PROTEINS; BOMBARDMENT MASS-SPECTROMETRY; HELICAL HEAD DOMAIN; KINASE-C; HEADPIECE DOMAIN; NUCLEAR LAMINA; CNBR FRAGMENTS; INVITRO; DESMIN; VIMENTIN	Phosphorylation of glial fibrillary acidic protein (GFAP) induces disassembly of the filaments. An amino-terminal fragment of bovine GFAP (G-Hf) was produced by lysylendopeptidase digestion. G-Hf formed ribbon-like filaments in the presence of GFAP even in low ionic strength, whereas the fragment itself did not form any structures. Only one (PK3) of the five V8 protease fragments of G-Hf accelerated GFAP assembly to the same degree as G-Hf did, whereas the other fragments did not. When PK3 was cleaved into two fragments, it lost the assembly-accelerating property. The sequence of PK3 was determined as RRRVTSATRRSYVSSSE, which corresponded to residues 3-19 of porcine GFAP. It was concluded that PK3 contains a sequence indispensable for GFAP assembly and that neither PK1 (RRRVTS) nor PK2 (ATRRSYVSSSE) included all of the sequence. A single phosphorylation of PK3 by cyclic AMP-dependent protein kinase diminished its assembly-accelerating property. The phosphorylation site was determined as Ser-12 of porcine GFAP. It was shown that single phosphorylation of the amino-terminal head domain, which contains an indispensable sequence for GFAP assembly, might be sufficient for GFAP disassembly.	OSAKA UNIV,SCH MED,DEPT NEUROPSYCHIAT,1-1-50 FUKUSHIMA,FUKUSHIMA KU,OSAKA 553,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Hojo, Hironobu/ACL-6191-2022					ANDO S, 1990, PEPTIDE CHEM 1990, P199; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BALCAREK JM, 1985, NUCLEIC ACIDS RES, V13, P5527, DOI 10.1093/nar/13.15.5527; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; EVANS RM, 1988, FEBS LETT, V234, P73, DOI 10.1016/0014-5793(88)81306-1; EVANS RM, 1988, EUR J CELL BIOL, V46, P152; FENSELAU C, 1985, ANAL BIOCHEM, V150, P309, DOI 10.1016/0003-2697(85)90515-9; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GEISLER N, 1983, EMBO J, V2, P2059, DOI 10.1002/j.1460-2075.1983.tb01700.x; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HERRMANN H, 1989, DEVELOPMENT, V105, P299; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; HOLMES CFB, 1987, BIOCHIM BIOPHYS ACTA, V929, P208, DOI 10.1016/0167-4889(87)90178-9; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; IP W, 1990, CELL BIOL INT REP, V14, P1119, DOI 10.1016/0309-1651(90)90020-Y; KITAMURA S, 1989, J BIOL CHEM, V264, P5674; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER RK, 1991, J CELL BIOL, V113, P843, DOI 10.1083/jcb.113.4.843; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; NAKAMURA Y, 1991, GLIA, V4, P101, DOI 10.1002/glia.440040112; NAKAMURA Y, 1990, ABSTR SCI NEUR, V16, P51; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OTOVOS L, 1988, J PROTEIN CHEM, V7, P365; OTVOS L, 1990, J CHROMATOGR, V512, P265, DOI 10.1016/S0021-9673(01)89493-0; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; QUINLAN RA, 1989, J CELL SCI, V93, P71; RAATS JMH, 1990, J CELL BIOL, V111, P1971, DOI 10.1083/jcb.111.5.1971; REEVES SA, 1989, P NATL ACAD SCI USA, V86, P5178, DOI 10.1073/pnas.86.13.5178; RUEGER DC, 1979, J MOL BIOL, V135, P53, DOI 10.1016/0022-2836(79)90340-1; SAEED T, 1989, BIOCHEM BIOPH RES CO, V165, P1059, DOI 10.1016/0006-291X(89)92709-5; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; TAKAO T, 1991, RAPID COMMUN MASS SP, V5, P312, DOI 10.1002/rcm.1290050703; TAKAO T, 1987, J BIOL CHEM, V262, P3541; TANAKA J, 1989, NEUROCHEM INT, V15, P421, DOI 10.1016/0197-0186(89)90159-9; TRAUB P, 1983, J CELL SCI, V63, P43; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WIEGERS W, 1991, CELL BIOL INT REP, V15, P287, DOI 10.1016/0309-1651(91)90167-H; YANG ZW, 1988, BIOCHEMISTRY-US, V27, P7038, DOI 10.1021/bi00418a055; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x	46	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23269	23274						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429673				2022-12-27	WOS:A1992JY16300086
J	SHIBA, K; SCHIMMEL, P				SHIBA, K; SCHIMMEL, P			TRIPARTITE FUNCTIONAL ASSEMBLY OF A LARGE CLASS-I AMINOACYL TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEART CYTOCHROME-C; ESCHERICHIA-COLI; ISOLEUCYL-TRANSFER; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; BACILLUS-STEAROTHERMOPHILUS; STRUCTURAL RELATIONSHIPS; 3-DIMENSIONAL STRUCTURE; NEUROSPORA-CRASSA; ACID-SEQUENCE	A 939-amino acid monomeric class I tRNA synthetase has been split into three inactive peptides. The three peptides spontaneously assemble in vivo to reconstitute active protein. Active tripartite complexes were demonstrated in vitro. The tripartite assembly of this synthetase increases by several-fold the size of a polypeptide that has been demonstrated to be assembled from more than two constituent pieces. The results indicate that contemporary single-chain tRNA synthetases or other large proteins could in principle develop from intermediates composed of non-covalent assemblages of multiple peptides.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Shiba, Kiyotaka/I-9588-2014	Shiba, Kiyotaka/0000-0001-6459-0204	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVALOS J, 1991, FEBS LETT, V286, P176, DOI 10.1016/0014-5793(91)80968-9; BENAROUS R, 1988, GENETICS, V119, P805; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P2480, DOI 10.1021/bi00383a012; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOW CM, 1989, MOL CELL BIOL, V9, P4631, DOI 10.1128/MCB.9.11.4631; CORRADIN G, 1971, P NATL ACAD SCI USA, V68, P3036, DOI 10.1073/pnas.68.12.3036; CSANK C, 1992, J BIOL CHEM, V267, P4592; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DARDEL F, 1984, J BACTERIOL, V160, P1115, DOI 10.1128/JB.160.3.1115-1122.1984; ENGLISCH U, 1987, BIOL CHEM H-S, V368, P971, DOI 10.1515/bchm3.1987.368.2.971; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; GALAKATOS NG, 1987, BIOCHEMISTRY-US, V26, P8475, DOI 10.1021/bi00399a066; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P9081, DOI 10.1093/nar/15.21.9081; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P10199, DOI 10.1093/nar/15.24.10199; HECK JD, 1988, J BIOL CHEM, V263, P868; HOHMANN S, 1991, GENBAK RELEASE 710; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUTONDJI C, 1986, BIOCHIMIE, V68, P868; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; JENAL U, 1991, J BIOL CHEM, V266, P10570; JORDANA X, 1987, J BIOL CHEM, V262, P7189; JUILLERAT M, 1980, J BIOL CHEM, V255, P845; KATO I, 1969, J BIOL CHEM, V244, P1004; KUBELIK AR, 1991, GENBANK RELEASE 700; LI CH, 1976, P NATL ACAD SCI USA, V73, P1476, DOI 10.1073/pnas.73.5.1476; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; MARTINDALE DW, 1989, CURR GENET, V15, P99, DOI 10.1007/BF00435455; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MECHULAM Y, 1991, NUCLEIC ACIDS RES, V19, P3673, DOI 10.1093/nar/19.13.3673; Miller J.H., 1972, EXPT MOL GENETICS; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; NUREKI O, 1991, J BIOL CHEM, V266, P3268; RICHARDS FM, 1971, ENZYMES, V4, P647; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAINTGIRONS I, 1987, J BIOL CHEM, V262, P622; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; Schimmel P, 1991, CURR OPIN STRUC BIOL, V1, P811, DOI 10.1016/0959-440X(91)90183-T; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZAGOLOFF A, 1989, EUR J BIOCHEM, V179, P365, DOI 10.1111/j.1432-1033.1989.tb14562.x; TZAGOLOFF A, 1988, J BIOL CHEM, V263, P850; WALTER P, 1983, P NATL ACAD SCI-BIOL, V80, P2437, DOI 10.1073/pnas.80.9.2437; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679	49	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22703	22706						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429621				2022-12-27	WOS:A1992JY16300003
J	ZHANG, YH; CONWAY, C; ROSATO, M; SUH, Y; MANSON, MD				ZHANG, YH; CONWAY, C; ROSATO, M; SUH, Y; MANSON, MD			MALTOSE CHEMOTAXIS INVOLVES RESIDUES IN THE N-TERMINAL AND C-TERMINAL DOMAINS ON THE SAME FACE OF MALTOSE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED CROSS-LINKING; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; L-ARABINOSE; MEMBRANE-COMPONENTS; SIGNAL-TRANSDUCER; ACTIVE-TRANSPORT; CONFORMATIONAL CHANGE; BACTERIAL CHEMOTAXIS; CYTOPLASMIC MEMBRANE	The periplasmic maltose-binding protein (MBP) of Escherichia coli is the recognition component of the maltose chemoreceptor and of the active transport system for maltose. It interacts with the Tar chemotactic signal transducer and the integral cytoplasmic-membrane components (the MalF and MalG proteins) of the maltose transport system. Maltose binds in a cleft between the globular N-terminal and C-terminal domains of MBP, which are connected by a moveable hinge. The two domains undergo a large motion relative to one another as the protein moves from the open, unbound state to the closed, ligand-bound state. We generated, by doped-primer mutagenesis, amino acid substitutions that specifically disrupt the chemotactic function of MBP. These substitutions cluster in two well-defined regions that are nearly contiguous on the surface of MBP in its closed conformation. One region is in the N-terminal domain and one is in the C-terminal domain. The distance between the two regions is expected to change substantially as the protein goes from the open to the closed form. These results support a model in which ligand binding brings two recognition sites on MBP into the proper spatial relationship to interact with complementary sites on Tar. Mutations in MBP that appear to cause defects in interaction with MalF and MalG are distributed differently from mutations that primarily affect maltose taxis. We conclude that the regions of MBP that contact Tar and those that contact MalF and MalG are adjacent on the face of the protein opposite the hinge connecting the two domains and that those regions are largely, although perhaps not entirely, distinct.			ZHANG, YH (corresponding author), TEXAS A&M UNIV SYST,DEPT BIOL,COLLEGE STN,TX 77843, USA.				NIGMS NIH HHS [GM 39376] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUHAMAD WN, 1991, MOL MICROBIOL, V5, P1035, DOI 10.1111/j.1365-2958.1991.tb01876.x; ADLER J, 1973, J BACTERIOL, V115, P824, DOI 10.1128/JB.115.3.824-847.1973; ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; AKSAMIT RR, 1974, BIOCHEMISTRY-US, V13, P4473, DOI 10.1021/bi00719a001; ARDITTI R, 1973, J BACTERIOL, V114, P652, DOI 10.1128/JB.114.2.652-655.1973; BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BOOS W, 1972, J BIOL CHEM, V247, P917; BRASS JM, 1984, J BACTERIOL, V157, P881, DOI 10.1128/JB.157.3.881-890.1984; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CLARKE S, 1979, J BIOL CHEM, V254, P9695; DAHL MK, 1989, MOL GEN GENET, V218, P199, DOI 10.1007/BF00331269; DAHL MK, 1985, J BACTERIOL, V164, P1057, DOI 10.1128/JB.164.3.1057-1063.1985; DIETZEL I, 1978, ARCH MICROBIOL, V118, P207, DOI 10.1007/BF00415731; DUPLAY P, 1987, J MOL BIOL, V194, P675, DOI 10.1016/0022-2836(87)90244-0; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; HAZELBAUER GL, 1971, NATURE-NEW BIOL, V230, P101, DOI 10.1038/newbio230101a0; HAZELBAUER GL, 1981, J BACTERIOL, V145, P35, DOI 10.1128/JB.145.1.35-42.1981; HAZELBAUER GL, 1975, J BACTERIOL, V122, P206, DOI 10.1128/JB.122.1.206-214.1975; HENGGE R, 1983, BIOCHIM BIOPHYS ACTA, V737, P443, DOI 10.1016/0304-4157(83)90009-6; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; KOMAN A, 1979, J BACTERIOL, V138, P739, DOI 10.1128/JB.138.3.739-747.1979; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MANSON MD, 1986, J BACTERIOL, V165, P34, DOI 10.1128/jb.165.1.34-40.1986; MANSON MD, 1986, NATURE, V321, P253, DOI 10.1038/321253a0; MARTINEAU P, 1990, J MOL BIOL, V214, P337, DOI 10.1016/0022-2836(90)90165-I; MARTINEAU P, 1990, BIOCHIMIE, V72, P397, DOI 10.1016/0300-9084(90)90063-M; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miller J. H., 1972, EXPT MOL GENETICS, P433; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MIZUNO T, 1986, J BACTERIOL, V165, P890, DOI 10.1128/jb.165.3.890-895.1986; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; NAKAE T, 1980, J BACTERIOL, V142, P735, DOI 10.1128/JB.142.3.735-740.1980; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; OLSON ER, 1991, J BACTERIOL, V173, P234, DOI 10.1128/jb.173.1.234-244.1991; QUIOCHO FA, 1977, J BIOL CHEM, V252, P5142; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; RANDALL LL, 1978, P NATL ACAD SCI USA, V75, P1209, DOI 10.1073/pnas.75.3.1209; RASMUSSEN BA, 1985, J BACTERIOL, V161, P258, DOI 10.1128/JB.161.1.258-264.1985; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLLE A, 1987, MOL GEN GENET, V208, P247, DOI 10.1007/BF00330450; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SPRINGER MS, 1977, P NATL ACAD SCI USA, V74, P3312, DOI 10.1073/pnas.74.8.3312; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VYAS NK, 1991, J BIOL CHEM, V266, P5226; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; WANDERSMAN C, 1979, J BACTERIOL, V140, P1; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; ZUKIN RS, 1979, BIOCHEMISTRY-US, V18, P2139, DOI 10.1021/bi00578a001	69	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22813	22820						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429629				2022-12-27	WOS:A1992JY16300020
J	EMILIE, D; MAILLOT, MC; NICOLAS, JF; FIOR, R; GALANAUD, P				EMILIE, D; MAILLOT, MC; NICOLAS, JF; FIOR, R; GALANAUD, P			ANTAGONISTIC EFFECT OF INTERFERON-GAMMA ON TAT-INDUCED TRANSACTIVATION OF HIV LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR NECROSIS FACTOR; CD8+ T-CELLS; REPLICATION INVITRO; LYMPHOCYTE-T; FACTOR-ALPHA; IFN-GAMMA; HTLV-III; KAPPA-B; INFECTION	Interferon-gamma (IFN-gamma) has been shown to inhibit human immunodeficiency virus (HIV) replication in macrophages. However, the site of its effect on the HIV infectious cycle is unknown. We show here that IFN-gamma inhibits the transactivation of HIV long terminal repeat (LTR) during viral infection and that it antagonizes tat effect in HT4LacZ-1 cells. HT4LacZ-1 is an indicator CD4+ HeLa cell line for HIV infectivity, because it harbors a HIV LTR-LacZ gene susceptible to transactivation by tat. It was used in combination with a computer-assisted image analyzer to quantify: (i) the number of transactivated foci following HIV infection, (ii) their individual level of transactivation, and (iii) the fusion potency of infected cells. IFN-gamma induced a 75% decrease of the number of transactivated foci following infection of HT4LacZ-1 cells by HIV. The remaining 25% foci still susceptible to transactivation were transactivated at a lower level than in control cultures, and the fusion potency of infected cells was strongly decreased. IFN-gamma acted after HIV entry into the cell and independently of reverse transcription. IFN-gamma antagonized tat-induced LTR transactivation: it inhibited transactivation of HT4LacZ-1 cells when tat was provided either from a SV40-based expression vector of tat or by polyethylene glycol-induced cell fusion with HeLa-tat-III cells. These results suggest that IFN-gamma affects the expression or the activity of cellular factors interacting with tat and that the high level of IFN-gamma production associated with HIV infection plays a role in the establishment of HIV latency.	INST PASTEUR,CNRS,UA 1148,UNITE BIOL MOLEC DEV,F-75724 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	EMILIE, D (corresponding author), INSERM,U131,32 RUE CARNETS,F-92140 CLAMART,FRANCE.			NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X				BALTIMORE D, 1989, NEW ENGL J MED, V321, P1673, DOI 10.1056/NEJM198912143212409; BARRY PA, 1991, J VIROL, V65, P1392, DOI 10.1128/JVI.65.3.1392-1399.1991; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DEVERGNE O, 1991, AIDS, V5, P1071, DOI 10.1097/00002030-199109000-00002; DRYSDALE CM, 1991, J VIROL, V65, P3044, DOI 10.1128/JVI.65.6.3044-3051.1991; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; EMILIE D, 1990, AIDS, V4, P791, DOI 10.1097/00002030-199008000-00011; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; FUCHS D, 1989, J ACQ IMMUN DEF SYND, V2, P158; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585; HAMMER SM, 1986, P NATL ACAD SCI USA, V83, P8734, DOI 10.1073/pnas.83.22.8734; HARTSHORN KL, 1987, AIDS RES HUM RETROV, V3, P125, DOI 10.1089/aid.1987.3.125; HEAGY W, 1990, J ACQ IMMUN DEF SYND, V3, P584; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; ISRAEL N, 1989, J IMMUNOL, V143, P3956; KANNAGI M, 1990, J VIROL, V64, P3399, DOI 10.1128/JVI.64.7.3399-3406.1990; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KORNBLUTH RS, 1990, CLIN IMMUNOL IMMUNOP, V54, P200, DOI 10.1016/0090-1229(90)90082-2; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; LANE HC, 1989, J CLIN IMMUNOL, V9, P351, DOI 10.1007/BF00918667; MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O; MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595; NAKASHIMA H, 1986, INT J CANCER, V38, P433, DOI 10.1002/ijc.2910380320; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHARA CJ, 1989, PATHOLOGY PATHOPHYSI, P36; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; POPIK W, 1991, P NATL ACAD SCI USA, V88, P9573, DOI 10.1073/pnas.88.21.9573; RINALDO C, 1988, J IMMUNOL, V140, P3389; ROCANCOURT D, 1990, J VIROL, V64, P2660, DOI 10.1128/JVI.64.6.2660-2668.1990; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; SANCEAU J, 1987, P NATL ACAD SCI USA, V84, P2906, DOI 10.1073/pnas.84.9.2906; STAHMER I, 1991, EUR J IMMUNOL, V21, P1873, DOI 10.1002/eji.1830210814; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Wheelock E F, 1973, Adv Immunol, V16, P123, DOI 10.1016/S0065-2776(08)60297-7; WONG GHW, 1988, J IMMUNOL, V140, P120; YAMAMOTO JK, 1986, J INTERFERON RES, V6, P143, DOI 10.1089/jir.1986.6.143	48	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20565	20570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400376				2022-12-27	WOS:A1992JT97800012
J	KULMBURG, P; JUDEWICZ, N; MATHIEU, M; LENOUVEL, F; SEQUEVAL, D; FELENBOK, B				KULMBURG, P; JUDEWICZ, N; MATHIEU, M; LENOUVEL, F; SEQUEVAL, D; FELENBOK, B			SPECIFIC BINDING-SITES FOR THE ACTIVATOR PROTEIN, ALCR, IN THE ALCA PROMOTER OF THE ETHANOL REGULON OF ASPERGILLUS-NIDULANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; POSITIVE REGULATORY GENE; GLUCOCORTICOID RECEPTOR; DNA RECOGNITION; CREA GENE; DOMAIN; CLONING; EXPRESSION; COMPLEX; DIMER	ALCR is the specific activator of the Aspergillus nidulans ethanol-utilization pathway, mediating the induction of its own transcription and that of the structural genes alcA and aldA, encoding respectively, alcohol dehydrogenase I and aldehyde dehydrogenase. ALCR is a DNA binding protein in which 6 cysteines are coordinated in a zinc binuclear cluster. This domain was fused to glutathione-S-transferase (GST) and isolated as a GST-ALCR(7-58*) fusion protein from Escherichia coli. Mobility shift assays showed that the ALCR fusion protein binds at sites upstream of the alcA promoter. DNaseI protection footprinting experiments revealed three specific binding sites, two that are direct repeats and one that is an inverted repeat with the same half-site 5'-CCGCA-3'. The half-sites are separated by a variable number of nucleotides in both types of target. The interaction of the ALCR fusion protein with direct and inverted repeats were examined by using interference and protection footprinting assays. In both binding sites, modification of the guanines in the half-sites interfered with the formation of the DNA complex, but the adjacent ones did not. Our results suggest that the ALCR protein makes contact in the major groove of the DNA helix of the half-sites. The functionality of two out of three binding sites of the GST-ALCR protein was demonstrated after their deletion. Therefore, the region encompassing these binding sites is a cis-acting element involved in the full induction of the alcA gene.	UNIV PARIS 11,CTR ORSAY,INST GENET & MICROBIOL,BATIMENT 409,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay								BAILEY C, 1975, EUR J BIOCHEM, V51, P573, DOI 10.1111/j.1432-1033.1975.tb03958.x; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; DALE RMK, 1985, PLASMID, V13, P141; DOWZER CEA, 1989, CURR GENET, V15, P457, DOI 10.1007/BF00376804; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FELENBOK B, 1991, J BIOTECHNOL, V17, P11, DOI 10.1016/0168-1656(91)90023-O; FREEMONT PS, 1991, BIOCHEM J, V278, P1; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HALVORSEN YDC, 1990, J BIOL CHEM, V265, P13283; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1771; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KULMBURG P, 1991, FEBS LETT, V280, P11, DOI 10.1016/0014-5793(91)80193-7; KULMBURG P, 1992, MOL CELL BIOL, V12, P1932, DOI 10.1128/MCB.12.5.1932; LOCKINGTON R, 1987, MOL MICROBIOL, V1, P275, DOI 10.1111/j.1365-2958.1987.tb01933.x; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Maxam A M, 1980, Methods Enzymol, V65, P499; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; PATEMAN JA, 1983, PROC R SOC SER B-BIO, V217, P243, DOI 10.1098/rspb.1983.0009; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RAIBAUD O, 1989, MOL MICROBIOL, V3, P455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; UPSHALL A, 1986, MOL GEN GENET, V204, P349, DOI 10.1007/BF00425521; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679	39	51	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21146	21153						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400424				2022-12-27	WOS:A1992JT97800098
J	WEN, DX; LIVINGSTON, BD; MEDZIHRADSZKY, KF; KELM, S; BURLINGAME, AL; PAULSON, JC				WEN, DX; LIVINGSTON, BD; MEDZIHRADSZKY, KF; KELM, S; BURLINGAME, AL; PAULSON, JC			PRIMARY STRUCTURE OF GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE DETERMINED BY MASS-SPECTROMETRY SEQUENCE-ANALYSIS AND MOLECULAR-CLONING - EVIDENCE FOR A PROTEIN MOTIF IN THE SIALYLTRANSFERASE GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; CELL-ADHESION MOLECULES; RAT-LIVER; ENZYMATIC CHARACTERIZATION; LEWIS-X; CDNA; EXPRESSION; PURIFICATION; PEPTIDES	The Galbeta1,39(4)GlcNAc alpha2,3-sialyltransferase forms the NeuAcalpha2,3Galbeta1,3(4)GlcNAc sequences found in terminal carbohydrate groups of glycoproteins and glycolipids. High energy collision-induced dissociation analysis of tryptic peptides from only 300 pmol of the purified Galbeta1,3(4)GlcNAc alpha2,3-sialyltransferase provided 25% of the total amino acid sequence and led to the successful cloning of this enzyme. The peptide sequence information was used to design short degenerate primers for use in the polymerase chain reaction. A long specific cDNA fragment was amplified which was used to isolate a clone from a rat liver cDNA library. The cloned cDNA encodes a 374-amino acid protein containing an amino-terminal signal-anchor sequence characteristic of all cloned glycosyltransferases and produced sialyltransferase activity when transiently expressed in COS-1 cells. When compared with two other cloned sialyltransferases, the primary structure of Galbeta1,3(4)GlcNAc alpha2,3-sialyltransferase revealed a homologous region in all three enzymes consisting of a stretch of 55 amino acids located in their catalytic domains. This feature together with lack of homology in the remaining 85% of the sequence of the three sialyltransferases defines a pattern of sequence homology not found in cloned cDNAs of other glycosyltransferase families.	Scripps Res Inst, DEPT CHEM, SAN DIEGO, CA 92121 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, SAN DIEGO, CA 92121 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco	WEN, DX (corresponding author), CYTEL CORP, SAN DIEGO, CA 92121 USA.		Paulson, James/AAG-3565-2019; Kelm, Soerge/C-5403-2013	Kelm, Soerge/0000-0001-5277-9421	NCRR NIH HHS [P41RR01614] Funding Source: Medline; NIGMS NIH HHS [GM27904] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027904] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BAIROCH A, 1990, RPOSITE DICT PROTEIN; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BROUDE NE, 1989, FEBS LETT, V257, P1, DOI 10.1016/0014-5793(89)81773-9; BUECHTER DD, 1992, J BIOL CHEM, V267, P2173; BURLINGAME AL, 1990, BIOL MASS SPECTROM, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P136; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DEVER TE, 1989, J BIOL CHEM, V264, P20518; DEWOLF WE, 1988, BIOCHEMISTRY-US, V27, P9093, DOI 10.1021/bi00426a005; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FALICK AM, 1989, ANAL BIOCHEM, V182, P165, DOI 10.1016/0003-2697(89)90736-7; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; FALICK AM, 1990, RAPID COMMUN MASS SP, V4, P318, DOI 10.1002/rcm.1290040905; FUNAKOSHI I, 1982, J BIOL CHEM, V257, P3782; GARCIAFERNANDEZ J, 1991, P NATL ACAD SCI USA, V88, P7338, DOI 10.1073/pnas.88.16.7338; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; GU TJ, 1990, FEBS LETT, V275, P83, DOI 10.1016/0014-5793(90)81444-S; GU XB, 1990, BIOCHEM BIOPH RES CO, V166, P387, DOI 10.1016/0006-291X(90)91957-T; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALL SC, 1991, 39TH P ASMS C MASS S, P473; HASCALL VC, 1981, BIOL CARBOHYDRATES, V1, P13; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HODGMAN TC, 1989, COMPUT APPL BIOSCI, V5, P1; HUSEH EC, 1986, J BIOL CHEM, V261, P4940; JOHNSON RS, 1989, BIOMED ENVIRON MASS, V18, P945, DOI 10.1002/bms.1200181102; JOHNSON RS, 1987, ANAL CHEM, V59, P2621, DOI 10.1021/ac00148a019; JOHNSON RS, 1988, INT J MASS SPECTROM, V86, P137, DOI 10.1016/0168-1176(88)80060-0; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KAUR S, 1990, BIOLOGICAL MASS SPECTROMETRY /, P285; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LANCE P, 1989, BIOCHEM BIOPH RES CO, V164, P225, DOI 10.1016/0006-291X(89)91706-3; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MATHEWS WR, 1987, J BIOL CHEM, V262, P7537; MCCLOSKEY JA, 1991, METHOD ENZYMOL, V193, P1; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; MEDZIHRADSZKY KF, 1992, EUR J BIOCHEM, V203, P327, DOI 10.1111/j.1432-1033.1992.tb16553.x; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; Paulson J, 1985, THE RECEPTORS, V2, P131; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1984, EUR J BIOCHEM, V140, P523, DOI 10.1111/j.1432-1033.1984.tb08133.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; REARICK JI, 1979, J BIOL CHEM, V254, P4444; Rutishauser U, 1990, Adv Exp Med Biol, V265, P179; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADLER JE, 1979, J BIOL CHEM, V254, P5934; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHAUER R, 1982, SIALIC ACIDS CHEM ME, P5; SETTINERI CA, 1990, BIOMED ENVIRON MASS, V19, P665, DOI 10.1002/bms.1200191106; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; STERNBERG MJE, 1991, NATURE, V349, P111, DOI 10.1038/349111a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; VANDENEIJNDEN DH, 1981, J BIOL CHEM, V256, P3159; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146	81	203	207	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21011	21019						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400416				2022-12-27	WOS:A1992JT97800079
J	DEVARAJAN, P; JOHNSTON, JJ; GINSBERG, SS; VANWART, HE; BERLINER, N				DEVARAJAN, P; JOHNSTON, JJ; GINSBERG, SS; VANWART, HE; BERLINER, N			STRUCTURE AND EXPRESSION OF NEUTROPHIL GELATINASE CDNA - IDENTITY WITH TYPE-IV COLLAGENASE FROM HT1080 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; STROMELYSIN; METALLOPROTEINASES; BIOSYNTHESIS; FIBROBLASTS; MACROPHAGES; METASTASIS; HOMOLOGY; SECRETE; PROTEIN	Neutrophils synthesize and store intracellularly a 92-kDa type IV collagenase (gelatinase), the primary structure of which is unknown. We designed a primer based on the highly conserved cysteine-switch region of metalloproteinases and employed the polymerase chain reaction to generate a probe of the human neutrophil gelatinase (HNG) gene. This probe was used to clone the cDNA encoding HNG by screening a chronic granulocytic leukemia cDNA library. In vitro translation of the cDNA-derived HNG mRNA yielded a major product of 78 kDa and smaller autolytically activated or degraded products, all of which were recognized by anti-HNG antibody. The HNG cDNA sequence is nearly identical to that encoding a 92-kDa gelatinase secreted by HT1080 cells. In addition, primer extension and S1 analysis reveal that the above two gelatinase transcripts have similar initiation sites. The HNG cDNA hybridized to a 2.8-kilobase mRNA from chronic granulocytic leukemia cells. HNG mRNA expression was absent from uninduced HL60 cells and from HL60 cells induced to granulocytic maturation with Me2SO. However, unlike other neutrophil secondary granule genes, HNG mRNA was detected in HL60 cells induced to monocytic maturation with 12-O-tetradecanoylphorbol 13-acetate. This suggests that the HNG gene may be subject to differential control pathways in two related but distinct hematopoietic lineages.	YALE UNIV,HEMATOL SECT,WWW 423,333 CEDAR ST,NEW HAVEN,CT 06510; SYNTEX RES,INST CANC & DEV BIOL,PALO ALTO,CA 94303	Yale University; Syntex Corporation					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027939] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-22297] Funding Source: Medline; NIDDK NIH HHS [DK-42347] Funding Source: Medline; NIGMS NIH HHS [GM-27939] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DEVARAJAN P, 1991, BLOOD, V77, P2731; FIBACH E, 1982, LEUKEMIA RES, V6, P781, DOI 10.1016/0145-2126(82)90060-1; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JOHNSTON J, 1992, GENOMICS, V12, P459, DOI 10.1016/0888-7543(92)90435-U; JOHNSTON J, 1989, J BIOL CHEM, V264, P15754; JOHNSTON J, 1992, IN PRESS BLOOD; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, J CELL SCI, V92, P487; RADO TA, 1987, BLOOD, V70, P989; RADO TA, 1984, BLOOD, V64, P1103; SAUS J, 1988, J BIOL CHEM, V263, P6742; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VANWART HE, 1990, BIOL RESPONSE MODIFI, P23; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1983, J BIOL CHEM, V258, P4162; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; [No title captured]	31	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25228	25232						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460022				2022-12-27	WOS:A1992KB60300049
J	OGATA, M; FRYLING, CM; PASTAN, I; FITZGERALD, DJ				OGATA, M; FRYLING, CM; PASTAN, I; FITZGERALD, DJ			CELL-MEDIATED CLEAVAGE OF PSEUDOMONAS EXOTOXIN BETWEEN ARG(279) AND GLY(280) GENERATES THE ENZYMATICALLY ACTIVE FRAGMENT WHICH TRANSLOCATES TO THE CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; CHIMERIC TOXINS; AERUGINOSA; SEQUENCE; EXPRESSION; DELETION; GENE; SITE	Pseudomonas exotoxin (PE) is a three-domain toxin which is cleaved by a cellular protease within cells and then reduced to generate two prominent fragments (Ogata, M., Chaudhary, V. K., Pastan, I., and Fitz-Gerald, D. J. (1990) J. Biol. Chem. 265, 20678-20685). The N-terminal fragment is 28 kDa in size and contains the binding domain. The 37-kDa C-terminal fragment, which translocates to the cytosol, contains the translocation domain and the ADP-ribosylation domain. Cleavage followed by reduction is essential for toxicity since mutant forms of the toxin that cannot be cleaved by cells are nontoxic. Previous results with these mutants suggested that cleavage occurred in an arginine-rich (arginine residues are at positions 274, 276, and 279) disulfide loop near the beginning of the translocation domain, but the exact site of cleavage was not determined. Since very few molecules of the 37-kDa fragment are generated within cells it was not possible to determine the site of cleavage by performing a conventional N-terminal sequence analysis of the 37-kDa fragment. Two experimental approaches were used to overcome this limitation. First, existing amino acids near the cleavage sites were replaced with methionine residues; this was followed by the addition of [S-35]methionine-labeled versions of these toxins to cells. The pattern of radioactive toxin fragments recovered from the cells indicated that the toxin was cleaved either just before or just after Arg279. Second, [H-3]leucine-labeled toxin was produced and added to the cells. Sequential Edman degradations were performed on the small amount of radioactive 37-kDa fragment that could be recovered from toxin-treated cells. A peak of radioactivity in the fifth fraction indicated that leucine was the 5th amino acid on the C-terminal side of the cleavage site. This result confirmed that cleavage was between Arg279 and Gly280.	NCI,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270	NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004869] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NCRR NIH HHS [RR-04869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DELANGE RJ, 1976, P NATL ACAD SCI USA, V73, P69, DOI 10.1073/pnas.73.1.69; FITZGERALD D, 1980, CELL, V21, P867, DOI 10.1016/0092-8674(80)90450-X; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JINNO Y, 1989, J BIOL CHEM, V264, P15953; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LUKAC M, 1988, INFECT IMMUN, V56, P3095, DOI 10.1128/IAI.56.12.3095-3098.1988; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MORRIS RE, 1985, SURV SYN PATHOL RES, V4, P34; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; NEVILLE DM, 1986, ANNU REV BIOCHEM, V55, P195, DOI 10.1146/annurev.biochem.55.1.195; OGATA M, 1990, J BIOL CHEM, V265, P20678; Olsnes S, 1991, Semin Cell Biol, V2, P7; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PASTAN I, 1989, J BIOL CHEM, V264, P15157; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEUER CP, 1992, J BIOL CHEM, V267, P16872; THOMPSON MR, 1991, J BIOL CHEM, V266, P2390; WICK MJ, 1990, ANNU REV MICROBIOL, V44, P335, DOI 10.1146/annurev.mi.44.100190.002003; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673	26	152	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25396	25401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460035				2022-12-27	WOS:A1992KB60300074
J	PRONGAY, AJ; WILLIAMS, CH				PRONGAY, AJ; WILLIAMS, CH			OXIDATION-REDUCTION PROPERTIES OF ESCHERICHIA-COLI THIOREDOXIN REDUCTASE ALTERED AT EACH ACTIVE-SITE CYSTEINE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISMS; SULFUR; FLAVIN	Thioredoxin is a small oxidation-reduction (redox) mediator protein. Its reduction by NADPH is catalyzed by the flavoenzyme thioredoxin reductase. Site-directed mutagenesis has provided forms of the reductase in which Cys135 and Cys138 have each been changed to a serine residue (Prongay, A. J., Engelke, D. R., and Williams, C. H., Jr. (1989) J. Biol. Chem. 264, 2656-2664). Cys135 and Cys138 form the redox-active disulfide in the oxidized enzyme. The redox properties of the two altered forms of Escherichia coli thioredoxin reductase have been determined from pH 6.0 to 9.0. Photoreduction of TRR(Ser135,Cys138) produces the blue, neutral semiquinone species, which disproportionates (K(f) = 0.73) to an apparent maximum of 29% of the total enzyme as the semiquinone. In contrast, the semiquinone formed on TRR(Cys135,Ser138) during a photoreductive titration does not disproportionate and 70% of the enzyme is stabilized as the semiquinione. Reductive titrations have demonstrated that 1 mol of sodium dithionite (2 electrons)/mol of FAD is required to fully reduce TRR(Ser135,Cys138) whereas 2 mol of dithionite/mol of FAD are required to fully reduce TRR(Cys135,Ser138). The oxidation-reduction midpoint potentials for the 1-electron and 2-electron reductions of TRR(Ser135,Cys138) have been determined by NADH/NAD+ titrations in the presence of a mediator, benzyl viologen. The midpoint potential for the 2-electron reduction of TRR(Ser135,Cys138) is -280 mV, at pH 7.0 and 20-degrees-C. Thus, the redox potential is similar to that of the FAD/FADH2 couple in the dithiol form of wild type enzyme, -270 mV (corrected to 20-degrees-C) (O'Donnell, M. E., and Williams, C. H., Jr. (1983) J. Biol. Chem. 258,13795-13805). The DELTAE(m)/DELTApH is -57.1 mV, which corresponds to a proton stoichiometry of 2 H+/2 e-. A maximum of 19% of the enzyme forms a stable semiquinone species during the titration, and the potentials for the oxidized enzyme/semiquinone couple, E2, and the semiquinone/reduced enzyme couple, E1, are -306 and -256 mV, respectively, at pH 7.0 and 20-degrees-C. These studies provide evidence that the residue at position 138 exerts a greater effect on the FAD than does the residue at position 135.	VET AFFAIRS MED CTR, MED RES SERV 151, 2215 FULLER RD, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan					NIGMS NIH HHS [GM21444] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Capozzi G., 1974, CHEM THIOL GROUP 2; CLARK WM, 1960, OXIDATION REDUCTION, P186; Crampton MR., 1974, CHEM THIOL GROUP, P379; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1977, J BIOL CHEM, V252, P5612; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P1, DOI 10.1021/bi00594a001; MOORE EC, 1964, J BIOL CHEM, V239, P3453; ODONNELL ME, 1983, J BIOL CHEM, V258, P3795; POOLE LB, 1989, J BIOL CHEM, V264, P12330; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; PRONGAY AJ, 1990, J BIOL CHEM, V265, P18968; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; SMITH WW, 1977, J MOL BIOL, V117, P195, DOI 10.1016/0022-2836(77)90031-6; SNYDER JP, 1977, J AM CHEM SOC, V99, P2931, DOI 10.1021/ja00451a014; THELANDER L, 1968, EUR J BIOCHEM, V4, P407, DOI 10.1111/j.1432-1033.1968.tb00227.x; WILLIAMS CH, 1979, METHOD ENZYMOL, V62, P183; ZANETTI G, 1968, J BIOL CHEM, V243, P4013; ZANETTI G, 1967, J BIOL CHEM, V242, P5232	22	20	20	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25181	25188						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460018				2022-12-27	WOS:A1992KB60300042
J	BORHANI, DW; HARTER, TM; PETRASH, JM				BORHANI, DW; HARTER, TM; PETRASH, JM			THE CRYSTAL-STRUCTURE OF THE ALDOSE REDUCTASE.NADPH BINARY COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRELIMINARY CRYSTALLOGRAPHIC ANALYSIS; PARA-HYDROXYBENZOATE HYDROXYLASE; DIABETIC COMPLICATIONS; DIHYDROFOLATE-REDUCTASE; GLUTATHIONE-REDUCTASE; DINUCLEOTIDE BINDING; ESCHERICHIA-COLI; HUMAN-TISSUES; CRYSTALLIZATION; ALDEHYDE	Aldose reductase is an NADPH-dependent oxidoreductase that catalyzes the reduction of a broad range of aldehydes, including glucose. Since aldose reductase has been strongly implicated in the development of the chronic complications of diabetes mellitus, much effort has been devoted to understanding the structure and mechanism of this enzyme, and many aldose reductase inhibitors have been developed as potential drugs for the treatment of these complications. We describe here the 2.75 angstrom crystal structure of recombinant human aldose reductase (Cys-298 to Ser mutant) complexed with NADPH. This mutant displays unusual kinetic behavior characterized by high K(m)/high V(max) substrate kinetics and reduced sensitivity to certain aldose reductase inhibitors. The crystal structure revealed that the enzyme is a beta/alpha-barrel with the coenzyme-binding domain located at the carboxyl-terminal end of the parallel strands of the barrel. The enzyme undergoes a large conformational change upon binding NADPH which involves the reorientation of loop 7 to a position which appears to lock the coenzyme into place. NADPH is bound to aldose reductase in an unusual manner, more similar to FAD- rather than NAD(P)-dependent oxidoreductases. No disulfide bridges were observed in the crystal structure.	WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,660 S EUCLID AVE,CAMPUS BOX 8096,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; BIOCRYST PHARMACEUT INC,BIRMINGHAM,AL 35244	Washington University (WUSTL); Washington University (WUSTL)				Borhani, David/0000-0002-8486-8792; Harter, Theresa/0000-0002-7039-2236	NATIONAL EYE INSTITUTE [R23EY005856, R01EY005856, R55EY005856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER; NEI NIH HHS [EY05856] Funding Source: Medline; NIDDK NIH HHS [P60 DK20579] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JA, 1991, BIOCHEMISTRY-US, V30, P11046, DOI 10.1021/bi00110a006; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; BOULTON AJM, 1990, DIABETOLOGIA, V33, P431, DOI 10.1007/BF00404095; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DAS B, 1985, DIABETES, V34, P1145, DOI 10.2337/diabetes.34.11.1145; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; ELKABBANI O, 1991, J MOL BIOL, V218, P695, DOI 10.1016/0022-2836(91)90257-7; FELDMAN HB, 1977, BIOCHIM BIOPHYS ACTA, V480, P14, DOI 10.1016/0005-2744(77)90316-3; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; FLYNN TG, 1982, BIOCHEM PHARMACOL, V31, P2705, DOI 10.1016/0006-2952(82)90123-X; FLYNN TG, 1975, J BIOL CHEM, V250, P2933; GONZALEZ AM, 1986, DIABETES, V35, P1200, DOI 10.2337/diabetes.35.11.1200; GREENE D, 1988, METABOLISM, V37, P25, DOI 10.1016/0026-0495(88)90184-9; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; HAYMAN S, 1965, J BIOL CHEM, V240, P877; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1985, P NATL ACAD SCI USA, V82, P6855, DOI 10.1073/pnas.82.20.6855; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RONDEAU JM, 1987, J MOL BIOL, V195, P945, DOI 10.1016/0022-2836(87)90498-0; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; RONDEAU JM, 1992, J MOL BIOL, V355, P469; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SPIELBERG SP, 1991, ANN INTERN MED, V114, P720, DOI 10.7326/0003-4819-114-9-720; SRIVASTAVA SK, 1982, CURR EYE RES, V2, P407, DOI 10.3109/02713688209000786; STURA EA, 1983, J MOL BIOL, V170, P529, DOI 10.1016/S0022-2836(83)80160-0; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TILTON RG, 1992, KIDNEY INT, V41, P778, DOI 10.1038/ki.1992.121; TILTON RG, 1989, DIABETES, V38, P1258, DOI 10.2337/diabetes.38.10.1258; TUCKLE IJ, 1985, MOL REPLACEMENT, P22; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; WEBB LE, 1973, BIOCHEMISTRY-US, V12, P5101, DOI 10.1021/bi00749a013; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; ZENON GJ, 1990, CLIN PHARMACY, V9, P446; 1979, CCP4 DAR LAB SERC UK; 1990, ARCH OPHTHALMOL-CHIC, V108, P1234	56	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24841	24847						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447221				2022-12-27	WOS:A1992KA26300102
J	GAIDO, KW; MANESS, SC; LEONARD, LS; GREENLEE, WF				GAIDO, KW; MANESS, SC; LEONARD, LS; GREENLEE, WF			2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN-DEPENDENT REGULATION OF TRANSFORMING GROWTH FACTORS-ALPHA AND FACTOR-BETA(2) EXPRESSION IN A HUMAN KERATINOCYTE CELL-LINE INVOLVES BOTH TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; FACTOR-BETA; EPITHELIAL-CELLS; TERMINAL DIFFERENTIATION; TGF-BETA; DIOXIN; CLONING; RNA; INDUCTION; TCDD	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a potent modulator of epithelial cell growth and differentiation, has been shown to induce transforming growth factor (TGF)-alpha in cultures of human keratinocytes and in the human keratinocyte cell line, SCC-12F. In this report, we investigated the mechanisms by which TCDD alters TGF-alpha expression. In addition, we studied the actions of TCDD on TGF-beta1 and TGF-beta2 expression. Treatment of SCC-12F cells with TCDD resulted in an increase in TGF-alpha and a reduction in TGF-beta2 mRNA levels while mRNA levels for TGF-beta1 were unchanged. Changes in TGF-alpha and TGF-beta2 expression were maximal by 24 h. No change in the rate of transcription of TGF-alpha was detected following treatment with TCDD as determined by nuclear run-off analysis. TCDD treatment resulted in a stabilization of TGF-alpha mRNA as judged by an approximately 2-fold higher level of TGF-alpha mRNA in treated versus control cells in the presence of actinomycin D. In contrast to TGF-alpha, the rate of transcription of TGF-beta2 was significantly reduced following TCDD treatment. These findings demonstrate that the induction of TGF-alpha expression in SCC-12F cells by TCDD occurs post-transcriptionally, primarily by mRNA stabilization, while TGF-beta2 expression is reduced due to a decrease in the rate of TGF-beta2 gene transcription.			GAIDO, KW (corresponding author), CHEM IND INST TOXICOL, POB 12137, RES TRIANGLE PK, NC 27709 USA.							BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; CHOI EJ, 1991, J BIOL CHEM, V266, P9591; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DERYNCK R, 1990, MOL REPROD DEV, V27, P3, DOI 10.1002/mrd.1080270104; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GLICK AB, 1990, MOL ENDOCRINOL, V4, P46, DOI 10.1210/mend-4-1-46; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GREENLEE WF, 1990, PROG CLIN BIOL RES, V331, P177; GREENLEE WF, 1987, REV BIOCHEM TOXICOL, V8, P1; HEBERT CD, 1990, CARCINOGENESIS, V11, P1335, DOI 10.1093/carcin/11.8.1335; HUDSON LG, 1983, BIOCHEM BIOPH RES CO, V115, P611, DOI 10.1016/S0006-291X(83)80188-0; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P747, DOI 10.1210/mend-2-8-747; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KNUTSON JC, 1982, CELL, V30, P225, DOI 10.1016/0092-8674(82)90028-9; MADISEN L, 1988, DNA-J MOLEC CELL BIO, V7, P1, DOI 10.1089/dna.1988.7.1; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILSTONE LM, 1984, J INVEST DERMATOL, V82, P532, DOI 10.1111/1523-1747.ep12261149; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OSBORNE R, 1985, TOXICOL APPL PHARM, V77, P434, DOI 10.1016/0041-008X(85)90183-8; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PARTRIDGE M, 1989, BRIT J CANCER, V60, P542, DOI 10.1038/bjc.1989.310; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; QUATTROCHI LC, 1985, DNA-J MOLEC CELL BIO, V4, P395, DOI 10.1089/dna.1985.4.395; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; RICE RH, 1984, CARCINOGENESIS, V5, P367, DOI 10.1093/carcin/5.3.367; RICE RH, 1989, ENVIRON HEALTH PERSP, V80, P239, DOI 10.2307/3430749; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSA F, 1992, J BIOL CHEM, V267, P8050; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; STAIANOCOICO L, 1990, EXP CELL RES, V191, P286, DOI 10.1016/0014-4827(90)90016-4; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WHITLOCK JP, 1988, GENE SIGNAL TRANSDUC, P207; WILLEY JC, 1984, CARCINOGENESIS, V5, P209, DOI 10.1093/carcin/5.2.209	46	136	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24591	24595						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447203				2022-12-27	WOS:A1992KA26300067
J	NAZIMIEC, M; GROSSMAN, L; TANG, MS				NAZIMIEC, M; GROSSMAN, L; TANG, MS			A COMPARISON OF THE RATES OF REACTION AND FUNCTION OF UVRB IN UVRABC-MEDIATED AND UVRAB-MEDIATED ANTHRAMYCIN-N2-GUANINE-DNA REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; ESCHERICHIA-COLI UVRB; DNA-POLYMERASE-I; ANTITUMOR ANTIBIOTICS; HELICASE-II; NUCLEASE; ANTHRAMYCIN; COMPLEX; BINDING; ADDUCTS	The repair of anthramycin-DNA adducts by the UVR proteins in Escherichia coli follows two pathways: the adducts may be incised by the combined actions of UVRA, UVRB, and UVRC, or alternatively, the anthramycin may be removed by UVRA and UVRB in the absence of UVRC and with no DNA strand incision. To assess the competition between these two competing pathways, the rate of UVRABC-mediated excision repair of anthramycin-N2-guanine DNA adducts and the rate of UVRAB-mediated removal of the adduct were measured with single end-labeled DNAs under identical reaction conditions. UVR protein concentrations of 15 nM UVRA, 100 nM UVRB, and 10 nM UVRC protein were chosen to mimic in vivo concentrations. With these UVR protein concentrations and anthramycin-DNA concentrations of 1-2 nM the incision reaction and the release reactions are described by first-order kinetics. The rate of the UVRABC reaction, measured as the increase in incised fragments, was six to seven times faster than the rate of the UVRAB reaction, measured as the decrease in incised fragments. The UVRABC incision rate on anthramycin-modified linear DNA was four to five times the incision rate measured on the same DNA irradiated with ultraviolet light. We also investigated the role of the ATPase function of UVRB in UVRAB-mediated anthramycin removal. We found that a UVRB analogue with alanine at arginine 51, which retains near wild type ATPase activity, supported removal of anthramycin in the presence of UVRA, whereas a UVRB analogue with alanine at lysine 45, which abolishes the ATPase activity, did not. UVRB*, a specific proteolytic cleavage product of UVRB which retains the ATPase activity, did support removal of anthramycin in the presence of UVRA.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV RES,SCI PK,SMITHVILLE,TX 78957; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University					NIEHS NIH HHS [ES 03124] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003124] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; Friedberg E C, 1980, Methods Enzymol, V65, P191; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HERTZBERG RP, 1986, BIOCHEMISTRY-US, V25, P1249, DOI 10.1021/bi00354a009; HURLEY LH, 1986, ACCOUNTS CHEM RES, V19, P230, DOI 10.1021/ar00128a001; HURLEY LH, 1977, BIOCHIM BIOPHYS ACTA, V475, P521, DOI 10.1016/0005-2787(77)90067-3; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; MAXAM AM, 1980, METHOD ENZYMOL, V28, P779; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PIERCE JR, 1989, BIOCHEMISTRY-US, V28, P5821, DOI 10.1021/bi00440a018; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; TANG MS, 1991, J MOL BIOL, V220, P855, DOI 10.1016/0022-2836(91)90358-D; URLEY LH, 1984, PHARMACEUT RES, V1, P53; VANHOUTEN B, 1988, J BIOL CHEM, V263, P16553; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALTER RB, 1988, J MOL BIOL, V203, P939, DOI 10.1016/0022-2836(88)90119-2	25	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24716	24724						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447212				2022-12-27	WOS:A1992KA26300085
J	RETZINGER, GS; CHANDLER, LJ; COOK, BC				RETZINGER, GS; CHANDLER, LJ; COOK, BC			COMPLEXATION WITH HEPARIN PREVENTS ADHESION BETWEEN FIBRIN-COATED SURFACES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX; HUMAN-PLASMA; THROMBIN; PROTEINS; BINDING; GLYCOSAMINOGLYCANS; ANTITHROMBIN; INTERFACE; POLYMER; MONOMER	Heparin, in Langmuirian fashion, binds stoichiometrically with high affinity, K(d) is similar to 100 nM, to both fibrinogen and fibrin adsorbed as monomolecular films to lecithin-coated, microscopic, polystyrene-divinylbenzene beads. Complex formation inhibits aggregation of fibrin-coated beads, and it also results in dissociation of preformed aggregates of fibrin-coated beads. These phenomena are not caused by desorption of fibrin(ogen), indirect inhibition of thrombin activity, or mere electrostatic repulsion of charged particles. Instead, these data are consistent with the proposal that the complexed heparin interferes directly with dimer formation between fibrin molecules adsorbed to colliding beads. We describe these phenomena and their application to the development of sensitive analytical methods for quantitating heparin. Based on these observations, we also propose a role for endogenous heparin in the physiologic regulation of fibrin-mediated adhesion of surfaces.			RETZINGER, GS (corresponding author), MED COLL WISCONSIN, DEPT PATHOL, MILWAUKEE, WI 53226 USA.							AZAROVA LA, 1991, GEMATOL TRANSFUZIOL, V36, P23; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BAGNALL RD, 1978, J BIOMED MATER RES, V12, P203, DOI 10.1002/jbm.820120206; Baier R E, 1969, J Biomed Mater Res, V3, P191, DOI 10.1002/jbm.820030115; Barrowcliffe T. W., 1989, HEPARIN CHEM BIOL PR, P393; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; BLOMBACK B, 1966, BIOCHIM BIOPHYS ACTA, V115, P371, DOI 10.1016/0304-4165(66)90437-5; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; CHANDY T, 1985, J COLLOID INTERF SCI, V108, P104, DOI 10.1016/0021-9797(85)90240-1; COLVIN RB, 1975, J EXP MED, V142, P1377, DOI 10.1084/jem.142.6.1377; COOK BC, 1992, J COLLOID INTERF SCI, V153, P1, DOI 10.1016/0021-9797(92)90292-T; COPLEY AL, 1983, ANN NY ACAD SCI, V416, P377, DOI 10.1111/j.1749-6632.1983.tb35200.x; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; EDELMAN ER, 1990, P NATL ACAD SCI USA, V87, P3773, DOI 10.1073/pnas.87.10.3773; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HEMKER HC, 1989, ANN NY ACAD SCI, V556, P146; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HORNE MK, 1988, BLOOD, V71, P273; JACOBSSON K-G, 1979, Thrombosis and Haemostasis, V42, P84; KEFALIDES NA, 1987, HEMOSTASIS THROMBOSI, P798; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindahl, 1989, HEPARIN CHEM BIOL PR, P51; LINDON JN, 1986, BLOOD, V68, P355; MAAT B, 1981, J CANCER RES CLIN, V101, P275, DOI 10.1007/BF00410113; MATTOCK P, 1971, NATURE-NEW BIOL, V233, P277, DOI 10.1038/newbio233277a0; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; RETZINGER GS, 1991, ANAL BIOCHEM, V195, P18, DOI 10.1016/0003-2697(91)90288-5; RETZINGER GS, 1990, ANAL BIOCHEM, V186, P169, DOI 10.1016/0003-2697(90)90592-W; RETZINGER GS, 1985, ANAL BIOCHEM, V150, P131, DOI 10.1016/0003-2697(85)90451-8; RETZINGER GS, 1981, J BIOL CHEM, V256, P8208; ROSENBERG RD, 1987, HEMOSTASIS THROMBOSI, P1373; SEAMAN GVH, 1986, AM CLIN PROD REV, V5, P25; SNOW AD, 1987, BIOMED BIOCHIM ACTA, V46, P537; STAPRANS I, 1985, J CLIN INVEST, V76, P1984, DOI 10.1172/JCI112198; THUNBERG L, 1980, THROMB HAEMOSTASIS, V44, P125; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIANTAPHYLLOPO.DC, 1964, NATURE, V204, P1096, DOI 10.1038/2041096b0; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; ZUCKER MB, 1977, FED PROC, V36, P47	44	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24356	24362						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447186				2022-12-27	WOS:A1992KA26300035
J	LAU, KS; HERRING, WJ; CHUANG, JL; MCKEAN, M; DANNER, DJ; COX, RP; CHUANG, DT				LAU, KS; HERRING, WJ; CHUANG, JL; MCKEAN, M; DANNER, DJ; COX, RP; CHUANG, DT			STRUCTURE OF THE GENE ENCODING DIHYDROLIPOYL TRANSACYLASE-(E2) COMPONENT OF HUMAN BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX AND CHARACTERIZATION OF AN E2 PSEUDOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP-URINE-DISEASE; BOVINE LIVER; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SUBUNIT STRUCTURE; LIPOYL-BEARING; MESSENGER-RNA; FAR-UPSTREAM; 3T3-L1 CELLS; CORE DOMAIN	We have determined the structural organization of the dihydrolipoyl transacylase (E2) gene of the human branched chain alpha-keto acid dehydrogenase complex. The single copy E2 gene spans approximately 68 kilobases of genomic DNA. The complete coding region consisting of the 5'- and 3'-untranslated regions, the mitochondrial targeting sequence (61 amino acids), and the mature E2 sequence (421 amino acids) are encoded by 11 exons ranging from 62 to 2239 base pairs. All the donor and acceptor splice sites conform to the gt-ag rule. Sequence analysis of the promoter-regulatory region showed the presence of a "CAAT box"-like sequence 537 bases upstream of the transcription initiation site. The "TATA box"-like sequence is absent. Also located in this region are sequences resembling glucocorticoid-responsive and cAMP-responsive elements, fat-specific elements, and Sp1- and AP-2-binding sites. Several sets of direct and inverted repeats are also present. Promoter assays using human hepatoma cells (Hep-G2) and Swiss mouse preadipocytes (3T3-L1) showed that a 4.1-kilobase PstI fragment upstream of the transcription start site confers high expression of the luciferase reporter gene. Moreover, an intronless E2 pseudogene was isolated. It corresponds to the complete mitochondrial presequence and the lipoyl-bearing domain that are encoded by exons I through IV of the functional E2 gene. However, the E2 pseudogene contains multiple base changes, deletions, and insertions, and is flanked by short direct repeats. The data indicate that the E2 pseudogene is a retroposon.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; EMORY UNIV,SCH MED,DEPT PEDIAT,DIV MED GENET,ATLANTA,GA 30322	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University					NIDDK NIH HHS [DK-26758, DK-37373] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037373, R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATES DL, 1977, NATURE, V268, P313, DOI 10.1038/268313a0; BROWN RM, 1990, SOMAT CELL MOLEC GEN, V16, P487, DOI 10.1007/BF01233198; CATE RL, 1980, J BIOL CHEM, V255, P7556; CHUANG DT, 1983, BIOCHEM J, V214, P177, DOI 10.1042/bj2140177; CHUANG DT, 1984, J BIOL CHEM, V259, P9277; CHUANG DT, 1985, J BIOL CHEM, V260, P3779; COLLINS JH, 1977, P NATL ACAD SCI USA, V74, P4223, DOI 10.1073/pnas.74.10.4223; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DANNER DJ, 1989, J BIOL CHEM, V264, P7742; Danner DJ, 1989, METABOLIC BASIS INHE, P671; DAVIS LG, 1986, BASIC METHODS MOL BI, P185; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FATANIA HR, 1983, FEBS LETT, V158, P234, DOI 10.1016/0014-5793(83)80585-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER CW, 1991, BIOCHEM BIOPH RES CO, V174, P804, DOI 10.1016/0006-291X(91)91489-Y; FRERMAN FE, 1983, J BIOL CHEM, V258, P7087; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8993; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; HEFFELFINGER SC, 1983, BIOCHEMISTRY-US, V22, P5519, DOI 10.1021/bi00293a011; HERRING WJ, 1991, AM J HUM GENET, V48, P342; HERRING WJ, 1992, BIOCHIM BIOPHYS ACTA, V1138, P236, DOI 10.1016/0925-4439(92)90043-M; HU CWC, 1986, J BIOL CHEM, V261, P343; HU CWC, 1988, J BIOL CHEM, V263, P9007; HUMMEL KB, 1988, J BIOL CHEM, V263, P6165; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIMURA M, 1983, EVOLUTION GENES PROT, P797; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAU KS, 1991, FEBS LETT, V279, P229, DOI 10.1016/0014-5793(91)80155-V; LAU KS, 1988, BIOCHEMISTRY-US, V27, P1972, DOI 10.1021/bi00406a025; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITSUBUCHI H, 1991, J BIOL CHEM, V266, P14686; MITSUBUCHI H, 1991, J CLIN INVEST, V87, P1207, DOI 10.1172/JCI115120; NOBUKUNI Y, 1989, BIOCHEM BIOPH RES CO, V161, P1035, DOI 10.1016/0006-291X(89)91347-8; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PETIT FH, 1978, P NATL ACAD SCI USA, V75, P4881; REED LJ, 1980, ENZYME REGULATION ME, P47; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; WYMAN AR, 1985, P NATL ACAD SCI USA, V82, P2880, DOI 10.1073/pnas.82.9.2880; ZNEIMER SM, 1991, GENOMICS, V10, P740, DOI 10.1016/0888-7543(91)90458-Q	48	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24090	24096						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429740				2022-12-27	WOS:A1992JZ23900099
J	HARADA, N; YANG, G; MIYAJIMA, A; HOWARD, M				HARADA, N; YANG, G; MIYAJIMA, A; HOWARD, M			IDENTIFICATION OF AN ESSENTIAL REGION FOR GROWTH SIGNAL TRANSDUCTION IN THE CYTOPLASMIC DOMAIN OF THE HUMAN INTERLEUKIN-4 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; HUMAN LYMPHOCYTES-B; HIGH-AFFINITY; EXPRESSION CLONING; MOLECULAR-CLONING; LIGAND-BINDING; CELL-LINES; BETA-CHAIN; CDNA CLONE; INTERNALIZATION	Interleukin-4 (IL-4) is a pleiotropic lymphokine which plays an important role in the immune system by regulating proliferation and differentiation of a wide variety of lymphoid and myeloid cells. These biological effects are manifested via binding of IL-4 to specific membrane-associated high affinity receptors. While the IL-4 receptor (IL-4R) cDNA expresses high affinity binding sites when transfected in COS7 cells, its intracellular domain lacks consensus motifs for known signal transducing molecules such as a tyrosine kinase. In this study, we use a DNA deletion approach to explore the mechanism of signal transduction utilized by the human IL-4R cDNA expressed in a murine pro-B cell line, Ba/F3 cells. Using this system, we have identified the critical region of the cytoplasmic domain of human IL-4R for human IL-4-induced transduction of a growth signal in these cells. Our data indicate that the critical region for signal transduction is located between amino acid residues 433-473 numbering from the carboxyl terminus. This region is highly conserved between mouse and human IL-4R but lacks homology with other cytokine receptors. Our studies additionally demonstrate that the cytoplasmic domain is not essential for forming high affinity IL-4-binding sites nor for ligand internalization.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	HARADA, N (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.							BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; CHAIKIN E, 1990, J BIOL CHEM, V265, P22109; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; FINNEY M, 1990, EUR J IMMUNOL, V20, P151, DOI 10.1002/eji.1830200122; FOXWELL BMJ, 1989, EUR J IMMUNOL, V19, P1637, DOI 10.1002/eji.1830190918; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GALIZZI JP, 1989, J BIOL CHEM, V264, P6984; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HUDAK SA, 1987, P NATL ACAD SCI USA, V84, P4606, DOI 10.1073/pnas.84.13.4606; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2215; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAJIMA K, 1987, J IMMUNOL, V139, P774; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PARK LS, 1988, J CELL BIOCH SA, V12, P111; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070; ZLOTNIK A, 1987, P NATL ACAD SCI USA, V84, P3856, DOI 10.1073/pnas.84.11.3856	36	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22752	22758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429625				2022-12-27	WOS:A1992JY16300012
J	KAHLE, P; BURTON, LE; SCHMELZER, CH; HERTEL, C				KAHLE, P; BURTON, LE; SCHMELZER, CH; HERTEL, C			THE AMINO TERMINUS OF NERVE GROWTH-FACTOR IS INVOLVED IN THE INTERACTION WITH THE RECEPTOR TYROSINE KINASE P140TRKA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRK PROTOONCOGENE; NGF RECEPTOR; CELLS; BINDING; LINE	The amino terminus of nerve growth factor (NGF) is susceptible to proteolytic cleavage. A comparison of the bioactivity of highly purified full-length recombinant human (1-118)rhNGF and NH2-terminal truncated (10-118)rhNGF revealed lower potency of (10-118)rhNGF with regard to early NGF responses in neuron-like PC12 cells. Approximately 50 times higher concentrations of (10-118)rhNGF than (1-118)rhNGF were required to elicit the same extent of tyrosine phosphorylation of key enzymes in different second messenger pathways, i.e. the NGF receptor tyrosine kinase p140trkA, phospholipase C(gamma-1), and the extracellular signal-regulated kinase ERK1. A similar reduced potency for induction of the transcription factor c-Fos was observed with (10-118)rhNGF compared to (1-118)rhNGF. The lower potency of (10-118)rhNGF in triggering early responses correlated with its 40-fold lower affinity for PC12 cells. Whereas (10-118)rhNGF had a more than 300-fold lower affinity for the high affinity receptor p140trkA than (1-118)rhNGF, amino-terminal truncation of NGF changed its affinity for the low affinity receptor p75NGFR only slightly (5-10-fold). These observations suggest that amino acids 1-9 of NGF are important for binding to the signal transducing receptor p140trkA. Proteolytic cleavage of the NGF amino terminus, therefore, reduces its potency in starting several second messenger pathways leading to neuronal differentiation of PC12 cells.	F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES 70334,CH-4002 BASEL,SWITZERLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Roche Holding; Genentech								BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BURTON LE, 1992, IN PRESS J NEUROCHEM; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FIELDS KL, 1975, P NATL ACAD SCI USA, V72, P1296, DOI 10.1073/pnas.72.4.1296; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1990, EXP NEUROL, V110, P274, DOI 10.1016/0014-4886(90)90039-U; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; OEMAR BS, 1991, J BIOL CHEM, V266, P24241; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; Rodbard D, 1975, Methods Enzymol, V37, P3; SCHMELZER CH, 1992, IN PRESS J NEUROCHEM; TAYLOR R A V, 1991, Society for Neuroscience Abstracts, V17, P712; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VALE RD, 1985, METHOD ENZYMOL, V109, P21; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650	30	62	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22707	22710						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429622				2022-12-27	WOS:A1992JY16300004
J	GATI, WP; PATERSON, ARP; TYRRELL, DLJ; CASS, CE; MORAVEK, J; ROBINS, MJ				GATI, WP; PATERSON, ARP; TYRRELL, DLJ; CASS, CE; MORAVEK, J; ROBINS, MJ			NUCLEOBASE TRANSPORTER-MEDIATED PERMEATION OF 2',3'-DIDEOXYGUANOSINE IN HUMAN ERYTHROCYTES AND HUMAN T-LYMPHOBLASTOID CCRF-CEM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONFACILITATED DIFFUSION; NUCLEOSIDE TRANSPORT; LEUKEMIA-CELLS; MAMMALIAN-CELLS; CULTURED-CELLS; PURINE; 2',3'-DIDEOXYNUCLEOSIDES; MEMBRANE; INHIBITION; ADENOSINE	Several 2',3'-dideoxynucleosides (ddNs), agents that inhibit the replication of human immunodeficiency virus and hepatitis B virus, enter mammalian cells by simple diffusion. In this report, we show that the membrane permeation of 2',3'-dideoxyguanosine (ddG) in human erythrocytes and CCRF-CEM cells, in contrast with that of other ddNs, is transporter-mediated. Inward fluxes of ddG in both cell types were inhibited by adenine, hypoxanthine, and acyclovir, but not by inhibitors of nucleoside transport (nitrobenzylthioinosine, dipyridamole, dilazep). Fluxes of ddG in human erythrocytes were attributable to a single, rate-saturable process (K(m), 380 +/- 90 muM and V(max), 7.9 +/- 0.8 pmol/s/mul cell water) that was competitively inhibited by adenine (K(i), 16 muM). These results showed that ddG entered human erythrocytes and CCRF-CEM cells by a transporter-mediated process that was also the basis for entry of purine nucleobases. In contrast, inward fluxes of 2,6-diaminopurine-2',3'-dideoxyriboside (ddDAPR), a prodrug of ddG, were not affected by purine nucleobases or nucleoside transport inhibitors in either cell type. Thus, the permeation properties of ddDAPR resembled those of 2',3'-dideoxyadenosine, a diffusional permeant (cell uptake is transporter-independent), and contrasted with those of ddG, the deamination product of ddDAPR. This study demonstrated that the nucleobase moiety of ddNs is an important determinant of membrane permeation.	UNIV ALBERTA,DEPT MED MICROBIOL & INFECT DIS,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; MORAVEK BIOCHEM INC,BREA,CA 92621; BRIGHAM YOUNG UNIV,DEPT CHEM,PROVO,UT 84602	University of Alberta; University of Alberta; Brigham Young University	GATI, WP (corresponding author), UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,ALBERTA,CANADA.							AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; ARONOW B, 1986, J BIOL CHEM, V261, P2014; ARONOW B, 1986, MOL CELL BIOL, V6, P2957, DOI 10.1128/MCB.6.8.2957; AUGUST EM, 1991, MOL PHARMACOL, V39, P246; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; CRAWFORD CR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P289, DOI 10.1016/0005-2736(90)90357-T; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DOMIN BA, 1988, BIOCHEM BIOPH RES CO, V154, P825, DOI 10.1016/0006-291X(88)90214-8; DOMIN BA, 1988, J BIOL CHEM, V263, P9276; DOMIN BA, 1991, BIOCHEM PHARMACOL, V42, P147, DOI 10.1016/0006-2952(91)90693-Y; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GATI WP, 1984, BIOCHEM PHARMACOL, V33, P3325, DOI 10.1016/0006-2952(84)90101-1; GATI WP, 1989, BIOCHEM J, V263, P957, DOI 10.1042/bj2630957; GATI WP, 1989, RED BLOOD CELL MEMBR, P635; HAO Z, 1988, MOL PHARMACOL, V34, P431; HARLEY ER, 1982, CANCER RES, V42, P1289; LEE B, 1989, ANTIMICROB AGENTS CH, V33, P336, DOI 10.1128/AAC.33.3.336; MAHONY WB, 1988, J BIOL CHEM, V263, P9285; MAHONY WB, 1991, BIOCHEM PHARMACOL, V41, P263, DOI 10.1016/0006-2952(91)90485-N; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; OLIVER JM, 1971, CAN J BIOCHEM CELL B, V49, P262, DOI 10.1139/o71-038; PATERSON ARP, 1984, BIOCHEM J, V224, P1001, DOI 10.1042/bj2241001; PATERSONARP, 1991, ROLE ADENOSINE ADENI, P133; PAUL B, 1975, J MED CHEM, V18, P968, DOI 10.1021/jm00244a003; PLAGEMANN PGW, 1987, BIOCHIM BIOPHYS ACTA, V905, P17, DOI 10.1016/0005-2736(87)90004-6; PLAGEMANN PGW, 1984, J MEMBRANE BIOL, V81, P255, DOI 10.1007/BF01868718; PLAGEMANN PGW, 1989, BIOCHEM PHARMACOL, V38, P3469, DOI 10.1016/0006-2952(89)90116-0; PLAGEMANN PGW, 1989, MOL PHARMACOL, V36, P185; PRUS KL, 1990, CANCER RES, V50, P1817; STEIN WD, 1986, TRANSPORT DIFFUSION, P72; SUZUKI S, 1988, BIOCHEM BIOPH RES CO, V156, P1144, DOI 10.1016/S0006-291X(88)80752-6; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	33	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22272	22276						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429579				2022-12-27	WOS:A1992JW71900045
J	KAVANAUGH, MP; ARRIZA, JL; NORTH, RA; AMARA, SG				KAVANAUGH, MP; ARRIZA, JL; NORTH, RA; AMARA, SG			ELECTROGENIC UPTAKE OF GAMMA-AMINOBUTYRIC-ACID BY A CLONED TRANSPORTER EXPRESSED IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BRAIN GABA TRANSPORTER; RAT-BRAIN; GLIAL-CELLS; MEMBRANE; CLONING; NEUROTRANSMITTERS; SYNAPTOSOMES; MECHANISM; SODIUM	GAT-1, a gamma-aminobutyric acid (GABA) transporter cloned from rat brain, was expressed in Xenopus oocytes. Voltage-clamp measurements showed concentration-dependent, inward currents in response to GABA (K0.5 4.7 muM). The transport current required extracellular sodium and chloride ions; the Hill coefficient for chloride was 0.7, and that for sodium was 1.7. Correlation of current and [H-3]GABA uptake measurements indicate that flux of one positive charge occurs per molecule of GABA transported. Membrane hyperpolarization from -40 to -100 mV increased the transport current approximately 3-fold. The results indicate that the transport of one molecule of GABA involves the co-transport of two sodium ions and one chloride ion.			KAVANAUGH, MP (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022	Amara, Susan/0000-0001-8914-1106	NATIONAL INSTITUTE ON DRUG ABUSE [R37DA003160, R01DA003160, R37DA007595, R01DA007595] Funding Source: NIH RePORTER; NIDA NIH HHS [DA03160, DA07595] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAUSTEIN MP, 1976, J MEMBRANE BIOL, V30, P153, DOI 10.1007/BF01869665; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAYCOCK JW, 1978, J NEUROCHEM, V30, P1113, DOI 10.1111/j.1471-4159.1978.tb12406.x; IVERSEN LL, 1975, BIOCHEM PHARMACOL, V24, P933, DOI 10.1016/0006-2952(75)90422-0; IVERSEN LL, 1968, J NEUROCHEM, V15, P1141, DOI 10.1111/j.1471-4159.1968.tb06831.x; KAILA K, 1992, J PHYSIOL-LONDON, V453, P627, DOI 10.1113/jphysiol.1992.sp019248; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KROGSGAARDLARSEN P, 1975, J NEUROCHEM, V25, P797, DOI 10.1111/j.1471-4159.1975.tb04410.x; LAEUGER P, 1991, ELECTROGENIC ION PUM, P61; MALCHOW RP, 1990, P NATL ACAD SCI USA, V87, P8945, DOI 10.1073/pnas.87.22.8945; MARTIN DL, 1972, J NEUROCHEM, V19, P841, DOI 10.1111/j.1471-4159.1972.tb01398.x; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P142; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0	22	124	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22007	22009						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429551				2022-12-27	WOS:A1992JW71900006
J	BOUABOULA, M; LEGOUX, P; PESSEGUE, B; DELPECH, B; DUMONT, X; PIECHACZYK, M; CASELLAS, P; SHIRE, D				BOUABOULA, M; LEGOUX, P; PESSEGUE, B; DELPECH, B; DUMONT, X; PIECHACZYK, M; CASELLAS, P; SHIRE, D			STANDARDIZATION OF MESSENGER-RNA TITRATION USING A POLYMERASE CHAIN-REACTION METHOD INVOLVING COAMPLIFICATION WITH A MULTISPECIFIC INTERNAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE GENE-EXPRESSION; REACTION ASSAY; QUANTITATION; CELLS; TRANSCRIPTION; INTERLEUKIN-2; RECEPTOR; TISSUES; INVIVO; PCR	We describe a simplified and reliable polymerase chain reaction-based method for assaying RNAs of low abundancy. The technique involves the co-amplification of cellular RNA-derived cDNA with a multispecific cDNA of synthetic origin added as an internal standard, using primer pairs common to both templates. We show that the co-amplified templates accumulate in a parallel manner throughout both the exponential and nonexponential phases of amplification, even when the starting amounts of the templates differ by up to 2 orders of magnitude. This finding means that preliminary experiments designed to determine either the late exponential region or the amplification efficiency for each pair of primers are unnecessary. This has enabled us to develop a greatly simplified quantitation protocol. We illustrate our approach by quantifying the effect of the immunosuppressor cyclosporin A on the accumulation of interleukin-4, interferon-gamma, and interleukin-2 receptor mRNAs in phytohemagglutinin-stimulated human peripheral blood mononuclear cells.	SANOFI RECH,DEPT IMMUNOPHARMACOL,371 RUE PROFESSEUR J BLAYAC,F-34184 MONTPELLIER,FRANCE; SANOFI ELF BIO RECH,LABEGE,FRANCE; UNIV MONTPELLIER 2,BIOL MOLEC LAB,CNRS,UNITE RECH GENET MOLEC 1191,F-34060 MONTPELLIER,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597				BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHIRMULE N, 1991, J IMMUNOL METHODS, V137, P141, DOI 10.1016/0022-1759(91)90403-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELIDOW BC, 1989, GENE ANAL TECH, V6, P120, DOI 10.1016/0735-0651(89)90002-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRYE RA, 1989, ONCOGENE, V4, P1153; FUNK CD, 1991, J BIOL CHEM, V266, P12508; GAUCHAT JF, 1989, EUR J IMMUNOL, V19, P1079, DOI 10.1002/eji.1830190618; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GRABSTEIN K, 1986, J IMMUNOL, V136, P4503; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; HEMAR A, 1990, EUR J IMMUNOL, V20, P2629, DOI 10.1002/eji.1830201216; HOOF T, 1991, ANAL BIOCHEM, V196, P161, DOI 10.1016/0003-2697(91)90133-E; KAASHOEK JGJ, 1991, LYMPHOKINE CYTOK RES, V10, P231; LEVENSON C, 1990, PCR PROTOCOLS GUIDE, P99; MOHLER KM, 1991, MOL IMMUNOL, V28, P437, DOI 10.1016/0161-5890(91)90157-F; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; MURRAY LJ, 1990, EUR J IMMUNOL, V20, P163, DOI 10.1002/eji.1830200124; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P71; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SHIRE D, 1990, GENE, V93, P183, DOI 10.1016/0378-1119(90)90223-E; STIEGER M, 1991, J VIROL METHODS, V34, P149, DOI 10.1016/0166-0934(91)90095-H; URDEA MS, 1988, NUCLEIC ACIDS RES, V16, P4937, DOI 10.1093/nar/16.11.4937; WACHTER L, 1986, NUCLEIC ACIDS RES, V14, P7985, DOI 10.1093/nar/14.20.7985; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	29	370	371	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21830	21838						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400493				2022-12-27	WOS:A1992JV01100088
J	ZHANG, JZ; REDMAN, CM				ZHANG, JZ; REDMAN, CM			IDENTIFICATION OF B-BETA CHAIN DOMAINS INVOLVED IN HUMAN FIBRINOGEN ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; RECOMBINANT HUMAN FIBRINOGEN; HEP G2 CELLS; DNA; BIOSYNTHESIS; MUTAGENESIS; SEQUENCES; SECRETION; EFFICIENT; MODEL	Fibrinogen chains are assembled in a stepwise manner in the rough endoplasmic reticulum prior to secretion of the final six-chain dimeric molecule. Previous studies indicated that the synthesis of Bbeta may be a rate-limiting factor in the assembly of human fibrinogen. To determine the domains of Bbeta which interact with the other two component chains of fibrinogen, deletion mutants of Bbeta were transiently co-expressed, together with Aalpha and gamma chains, in COS cells, and fibrinogen assembly and secretion were measured. Deletion of the COOH-terminal half of the Bbeta chain (amino acids 208-461) did not affect assembly and secretion. Assembly of Aalpha, gamma, and Bbeta also occurred when the first NH2-terminal 72 amino acids of Bbeta were deleted, but not when 93 amino acids were deleted. This indicates that the Bbeta domain between amino acids 73 and 93 is necessary for the assembly of the three fibrinogen chains. This domain marks the start of the alpha-helical "coiled-coil" region of fibrinogen.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	New York Blood Center					NHLBI NIH HHS [HL37457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMONDHIRY HAB, 1975, BLOOD, V45, P607; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; Crabtree G. R., 1987, MOL BASIS BLOOD DISE, P631; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; KANT JA, 1983, P NATL ACAD SCI-BIOL, V80, P3953, DOI 10.1073/pnas.80.13.3953; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU CY, 1985, J BIOL CHEM, V260, P4390; RAO SPS, 1991, J MOL BIOL, V222, P6578; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; YU S, 1980, BIOCHEM BIOPH RES CO, V96, P1032, DOI 10.1016/0006-291X(80)90056-X; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1987, THROMB RES, V46, P281, DOI 10.1016/0049-3848(87)90290-8; YU S, 1983, J BIOL CHEM, V258, P3407; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	28	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21727	21732						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400483				2022-12-27	WOS:A1992JV01100073
J	FILHOL, O; BAUDIER, J; DELPHIN, C; LOUEMACKENBACH, P; CHAMBAZ, EM; COCHET, C				FILHOL, O; BAUDIER, J; DELPHIN, C; LOUEMACKENBACH, P; CHAMBAZ, EM; COCHET, C			CASEIN KINASE-II AND THE TUMOR SUPPRESSOR PROTEIN P53 ASSOCIATE IN A MOLECULAR-COMPLEX THAT IS NEGATIVELY REGULATED UPON P53 PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; EPIDERMAL GROWTH-FACTOR; SV40-TRANSFORMED CELLS; CATALYTIC SUBUNIT; CARCINOMA-CELLS; BETA-SUBUNIT; CALF THYMUS; WILD-TYPE; ONCOGENE; TRANSFORMATION	Selective immunoisolation of P53 from Sf9 cells co-expressing wild-type P53 and casein kinase II yielded a preparation containing casein kinase II, thus suggesting that the two proteins may associate in a molecular complex in the intact cell. Such a complex could indeed be demonstrated in vitro between purified recombinant P53 and oligomeric casein kinase II and was shown to dissociate when P53 became phosphorylated by the kinase. This suggested that the P53 C-terminal domain, which contains the casein kinase II phosphorylation site was involved in the protein-protein interaction; this was confirmed by the fact that an anti-P53 monoclonal antibody directed to that domain inhibited the P53-casein kinase II association. Studies with isolated recombinant casein kinase II subunits disclosed that although the alpha (catalytic) subunit could phosphorylate P53, the formation of a stable P53-casein kinase II association required the presence of the beta subunit of the kinase. This was confirmed by immunoisolation of a P53-beta subunit complex from cells expressing both polypeptides. Although the biological significance of a reversible P53-casein kinase II molecular complex in the control of cell proliferation processes remains to be defined, these observations suggest the possibility of a novel mechanism regulating P53 and casein kinase II activities in the intact cell.	CEN,INSERM,U244,F-38041 GRENOBLE,FRANCE; CEN,DEPT BIOL MOLEC & STRUCT,INSERM,U309,85X,F-38041 GRENOBLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Filhol-Cochet, Odile/I-3962-2016; Baudier, Jacques/O-2183-2016	Cochet, Claude/0000-0002-1772-4270; jacques, baudier/0000-0001-8427-4444; Filhol, Odile/0000-0003-1964-7958				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEIGE JJ, 1983, BIOCHEMISTRY-US, V22, P1452, DOI 10.1021/bi00275a020; FEIGE JJ, 1980, FEBS LETT, V121, P139, DOI 10.1016/0014-5793(80)81283-X; FEIGE JJ, 1985, RECENT PROGR POLYAMI, V13, P181; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FIRZLAFF J M, 1989, New Biologist, V1, P44; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LANE DP, 1987, ONCOGENE, V1, P241; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P124; VANROY F, 1984, MOL CELL BIOL, V4, P232, DOI 10.1128/MCB.4.2.232	47	120	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20577	20583						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400378				2022-12-27	WOS:A1992JT97800014
J	LEE, JI; HWANG, PP; HANSEN, C; WILSON, TH				LEE, JI; HWANG, PP; HANSEN, C; WILSON, TH			POSSIBLE SALT BRIDGES BETWEEN TRANSMEMBRANE ALPHA-HELICES OF THE LACTOSE CARRIER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC PERMEASE; MEMBRANE-PROTEINS; PROTON TRANSLOCATION; DIRECTED MUTAGENESIS; MELIBIOSE CARRIER; CYTOPLASMIC SIDE; GENETIC-ANALYSIS; COOH TERMINUS; TRANSPORT; TOPOLOGY	Although it is energetically extremely unfavorable to have charged amino acid residues of a polypeptide in the hydrophobic environment of the membrane phospholipid bilayer, a few such charged residues are found in membrane-spanning regions of membrane proteins. Ion pairs (salt bridges) would be much more stable in low dielectric media than single ionized residues. This paper provides indirect evidence for a salt bridge between Asp-240 and Lys-319 in the lactose carrier of Escherichia coli. When Asp-240 was changed to alanine by site-directed mutagenesis, there was a loss of the ability to accumulate methyl-beta-D-thiogalactopyranoside (TMG), melibiose, or lactose. Fast-growing revertants were isolated on melibiose minimal agar plates. Two second-site revertants were isolated: Asp-240 --> Ala plus Gly-268 --> Val and Asp-240 --> Ala plus Lys-319 --> Gln. These revertants showed extremely poor accumulation of TMG, melibiose, and lactose, but showed significant "downhill" lactose entry into beta-galactosidase-containing cells with sugar concentrations of 2 and 5 mM. It is concluded that there is some important interaction between Asp-240 and Lys-319, possibly a salt bridge.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Hwang, Pung-Pung/AAH-1538-2022; Hwang, Pung-Pung/AEQ-4633-2022		NIDDK NIH HHS [DK05736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005736, R01DK005736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CARRASCO N, 1985, ANN NY ACAD SCI, V456, P305, DOI 10.1111/j.1749-6632.1985.tb14880.x; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FOSTER DL, 1983, J BIOL CHEM, V258, P31; GARTY H, 1988, J BIOL CHEM, V263, P5550; HELLER KB, 1979, J BACTERIOL, V140, P395, DOI 10.1128/JB.140.2.395-399.1979; HOBSON AC, 1977, J BACTERIOL, V131, P830, DOI 10.1128/JB.131.3.830-838.1977; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; KABACK HR, 1988, ANNU REV PHYSIOL, V50, P243; KABACK HR, 1988, PHIL T R SOC LOND B, V326, P425; KARLISH SJD, 1985, SODIUM PUMP, P487; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MACARA IG, 1981, BIOCHEMISTRY-US, V20, P5695, DOI 10.1021/bi00523a009; MANOIL C, 1988, TRENDS GENET, V4, P223, DOI 10.1016/0168-9525(88)90154-0; MCCARTHY MP, 1992, STRUCTURE BIOL MEMBR, P395; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MITCHELL P, 1976, BIOCHEM SOC T, V4, P399, DOI 10.1042/bst0040399; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; REITHMEIER RAF, 1992, STRUCTURE BIOL MEMBR, P337; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; SECKLER R, 1983, J BIOL CHEM, V258, P817; SENIOR AE, 1983, BIOCHIM BIOPHYS ACTA, V726, P81, DOI 10.1016/0304-4173(83)90001-0; STERN LJ, 1989, J BIOL CHEM, V264, P14202; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON DM, 1981, BIOCHIM BIOPHYS ACTA, V649, P377, DOI 10.1016/0005-2736(81)90427-2; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WILSON DM, 1986, METHOD ENZYMOL, V125, P377; WILSON TH, 1990, BIOCHIM BIOPHYS ACTA, V1029, P113, DOI 10.1016/0005-2736(90)90443-R	43	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20758	20764						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400392				2022-12-27	WOS:A1992JT97800040
J	NISHITANI, K; TOMINAGA, R				NISHITANI, K; TOMINAGA, R			ENDOXYLOGLUCAN TRANSFERASE, A NOVEL CLASS OF GLYCOSYLTRANSFERASE THAT CATALYZES TRANSFER OF A SEGMENT OF XYLOGLUCAN MOLECULE TO ANOTHER XYLOGLUCAN MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED SYCAMORE CELLS; VIGNA-ANGULARIS; WEIGHT DISTRIBUTIONS; WALLS; AUXIN; OLIGOSACCHARIDES; POLYSACCHARIDES; PURIFICATION; HYPOCOTYLS; PH	Xyloglucans are the major component of plant cell walls and bind tightly to the surface of individual cellulose microfibrils, thereby cross-linking them into a complex polysaccharide network of the cell wall. The cleavage and reconnection of xyloglucan cross-links are considered to play the leading role during chemical processes essential for wall expansion and, therefore, cell growth and differentiation. Although it is hypothesized that some transglycosylation is involved in these chemical processes, the enzyme responsible for the reaction was not identified. We have now purified a novel class of endo-type glycosyltransferase to apparent homogeneity from the extracellular space or the cell wall of the epicotyls of Vigna angularis, a bean plant. The enzyme is a glycoprotein with a molecular mass of about 33 kDa. The enzyme catalyzes both 1) endo-type splitting of a xyloglucan molecule and 2) linking of a newly generated reducing end of the xyloglucan to the nonreducing end of another xyloglucan molecule, thereby mediating the transfer of a large segment of the xyloglucan to another xyloglucan molecule. The transferase exhibits no glycosidase or glycanase activity. Substrate specificity of the enzyme was investigated using several polysaccharides with different glycosidic linkages as donor substrates and pyridylamino oligosaccharides as acceptor substrates, in which the reducing end of the carbohydrate was tagged with a fluorescent group. The enzyme required a basic xyloglucan structure, i.e. a beta-(1-->4)-glucosyl backbone with xylosyl side chains, for both acceptor and donor activity. Galactosyl or fucosyl side chains on the main chain were not required for the acceptor activity. The enzyme exhibited higher reaction rates when xyloglucans with higher M(r) were used as donor substrates. Xyloglucans smaller than 10 kDa were no longer the donor substrate. On the other hand, pyridylamino heptasaccharide acted as a good acceptor as did xyloglucan polymers. Based on these results we propose to designate this novel enzyme a xyloglucan: xyloglucano-transferase, to be abbreviated endo-xyloglucan transferase (EXT) or xyloglucan recombinase. This enzyme is the first enzyme identified that mediates the transfer of a high M(r) segment between polysaccharide molecules to generate chimeric polymers. We conclude that endo-xyloglucan transferase functions as a reconnecting enzyme for xyloglucans and is involved in the interweaving or reconstruction of cell wall matrix, which is responsible for chemical creepage that leads to morphological changes in the cell wall.			NISHITANI, K (corresponding author), KAGOSHIMA UNIV, COLL LIBERAL ARTS, DEPT BIOL, KAGOSHIMA 890, JAPAN.			Nishitani, Kazuhiko/0000-0002-0073-9564				Albersheim P, 1976, PLANT BIOCH, P225; BAUER WD, 1973, PLANT PHYSIOL, V51, P174, DOI 10.1104/pp.51.1.174; BAYDOUN EAH, 1989, J PLANT PHYSIOL, V134, P453, DOI 10.1016/S0176-1617(89)80009-4; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLELAND RE, 1987, PHYSL CELL EXPANSION, P18; COSGROVE D J, 1989, Planta (Heidelberg), V177, P121, DOI 10.1007/BF00392162; FANUTTI C, 1991, PLANTA, V184, P137, DOI 10.1007/BF00208247; FRY SC, 1992, BIOCHEM J, V282, P821, DOI 10.1042/bj2820821; FRY SC, 1986, ANNU REV PLANT PHYS, V37, P165, DOI 10.1146/annurev.arplant.37.1.165; FRY SC, 1988, GROWING PLANT CELL W, P238; HASE S, 1979, J BIOCHEM-TOKYO, V85, P217, DOI 10.1093/oxfordjournals.jbchem.a132314; JACOBS M, 1976, PLANT PHYSIOL, V58, P203, DOI 10.1104/pp.58.2.203; KEEGSTRA K, 1973, PLANT PHYSIOL, V51, P188, DOI 10.1104/pp.51.1.188; KOIZUMI K, 1989, J CHROMATOGR, V464, P365; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUDA Y, 1978, BOT MAG TOKYO, P103; MCDOUGALL GJ, 1989, PLANT PHYSIOL, V89, P883, DOI 10.1104/pp.89.3.883; MCNEIL M, 1984, ANNU REV BIOCHEM, V53, P625, DOI 10.1146/annurev.bi.53.070184.003205; MORROW DL, 1986, PHYSIOL PLANTARUM, V67, P397, DOI 10.1111/j.1399-3054.1986.tb05754.x; NISHITANI K, 1983, PLANT CELL PHYSIOL, V24, P345; NISHITANI K, 1981, PHYSIOL PLANTARUM, V52, P482, DOI 10.1111/j.1399-3054.1981.tb02720.x; NISHITANI K, 1982, PLANT SCI LETT, V28, P87, DOI 10.1016/S0304-4211(82)80010-2; NISHITANI K, 1991, PHYSIOL PLANTARUM, V82, P490, DOI 10.1111/j.1399-3054.1991.tb02937.x; NISHITANI K, 1988, PLANT PHYSIOL, V87, P883, DOI 10.1104/pp.87.4.883; NISHITANI K, 1991, J BIOL CHEM, V266, P6539; NISHITANI K, 1992, IN PRESS PLANT CELL; TAIZ L, 1984, ANNU REV PLANT PHYS, V35, P585, DOI 10.1146/annurev.pp.35.060184.003101; TALBOTT LD, 1992, PLANT PHYSIOL, V98, P357, DOI 10.1104/pp.98.1.357; TALBOTT LD, 1992, PLANT PHYSIOL, V98, P369, DOI 10.1104/pp.98.1.369; TOYAMA N, 1964, J FERMENT TECHNOL, V42, P199; WAKABAYASHI K, 1991, PLANT PHYSIOL, V95, P1070, DOI 10.1104/pp.95.4.1070	32	439	471	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21058	21064						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400418				2022-12-27	WOS:A1992JT97800086
J	PAL, PK; MA, ZP; COLEMAN, PS				PAL, PK; MA, ZP; COLEMAN, PS			THE AMP-BINDING DOMAIN ON ADENYLATE KINASE - EVIDENCE FOR A CONFORMATIONAL CHANGE DURING BINARY-TO-TERNARY COMPLEX-FORMATION VIA PHOTOAFFINITY-LABELING ANALYSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE TRANSPHOSPHORYLASES; AMINO-ACID-SEQUENCE; ATP-BINDING; ESCHERICHIA-COLI; BETA-SUBUNIT; X-RAY; SITE; F1-ATPASE; PROTEINS; MUSCLE	The topological location of the nucleotide substrate binding environments on adenylate kinase has been explored with the fluorescent molecule [4-benzoyl]benzoyl-1-amidofluorescein (BzAF) and the nucleotide analog 3'-O-[4-benzoyl]benzoyl-ATP (BzATP), which are site-directed photoaffinity probes that bind covalently at the individual nucleotide sites. The MgBzATP substituted for MgATP as a substrate for this enzyme, whereas BzAF, which is neither a substrate nor a nucleotide, behaved as a competitive inhibitor for each nucleotide site independently. BzAF could be directed specifically to either of the nucleotide sites by near saturation of the second site with its natural nucleotide substrate. Using this second site blocking approach, each nucleotide site, in turn, could be protected competitively from BzAF-induced photoinhibition by the presence of its natural substrate. This strategy showed that under photolysis, the K(d(BzAF)) of 0.1 mM (for the MgATP site) and 0.2 mM (for the AMP site) were nearly identical with the K(m(app)) values determined for MgATP and AMP, respectively. Pseudo first-order photolysis kinetics with [H-3]BzAF revealed covalent binding stoichiometries for full inhibition of 1 mol of probe/mol of enzyme at either site. Thus, we prepared the binary complex {[H-3]BzAF-enzyme} by photo-labeling the MgATP site-blocked enzyme with [H-3]BzAF to 1:1 molar stoichiometry. Tryptic digestion followed by partial sequencing of the [H-3]BzAF-labeled enzyme disclosed that BzAF was bound specifically within the peptide span Gly64 --> Arg77. This amino acid domain therefore probably constitutes the neighborhood identifiable with AMP binding. Furthermore, we also achieved double photocovalent labeling of adenylate kinase with both photoprobes, by first cross-linking with approximately 1 mol of MgBzATP, followed by approximately 0.9 mol of [H-3]BzAF, thus generating a ternary covalent complex. Comparison of the fluorescence of the binary species and the ternary {BzATP-enzyme-[H-3]BzAF} complex revealed altered fluorescence emission profiles, which could indicate that a conformational change occurs during formation of the ternary (or transition state) complex.	BOSTON BIOMED RES INST, DEPT METAB REGULAT, 20 STANIFORD ST, BOSTON, MA 02114 USA	Boston Biomedical Research Institute					NIGMS NIH HHS [GM-36619] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036619] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALOISE P, 1991, J BIOL CHEM, V266, P10368; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUAN H, 1989, J BIOL CHEM, V264, P7981; COLE DG, 1990, J BIOL CHEM, V265, P22537; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P20; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FRY DC, 1987, BIOCHEMISTRY-US, V26, P1645, DOI 10.1021/bi00380a024; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; HAMADA M, 1978, ARCH BIOCHEM BIOPHYS, V190, P772, DOI 10.1016/0003-9861(78)90338-7; HAMADA M, 1991, STUDY ENZYMES, V2, P403; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KUBY SA, 1978, ARCH BIOCHEM BIOPHYS, V187, P34, DOI 10.1016/0003-9861(78)90004-8; KUBY SA, 1984, BIOCHEMISTRY-US, V23, P2393, DOI 10.1021/bi00306a012; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; MARTIN MM, 1975, J LUMIN, V10, P381, DOI 10.1016/0022-2313(75)90003-4; MILDVAN AS, 1987, ADV ENZYMOL RAMB, V59, P241; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NODA L, 1975, EUR J BIOCHEM, V51, P229, DOI 10.1111/j.1432-1033.1975.tb03923.x; NODA L, 1957, J BIOL CHEM, V226, P541; OKAJIMA T, 1991, J BIOL CHEM, V266, P11442; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PAL PK, 1990, J BIOL CHEM, V265, P14996; PENEFSKY H, 1991, ADV ENZYMOL REL AREA, V64, P173; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO BDN, 1978, J BIOL CHEM, V253, P1149; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RHOADS DG, 1968, J BIOL CHEM, V243, P3963; ROHATGI KK, 1972, J INDIAN CHEM SOC, V49, P1311; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P23, DOI 10.1016/0022-2836(77)90280-7; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHIRMER I, 1970, FEBS LETT, V10, P333, DOI 10.1016/0014-5793(70)80466-5; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; THUMA E, 1972, BIOCHIM BIOPHYS ACTA, V268, P81, DOI 10.1016/0005-2744(72)90200-8; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VETTER IR, 1991, BIOCHEMISTRY-US, V30, P4137, DOI 10.1021/bi00231a005; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; VONZABERN I, 1976, EUR J BIOCHEM, V68, P281; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YAGAMI T, 1988, FEBS LETT, V229, P261, DOI 10.1016/0014-5793(88)81137-2; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007	46	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25003	25009						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460003				2022-12-27	WOS:A1992KB60300017
J	SUN, S; CHASTEEN, ND				SUN, S; CHASTEEN, ND			FERROXIDASE KINETICS OF HORSE SPLEEN APOFERRITIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY ABSORPTION; IRON DEPOSITION; FERRITIN; MECHANISM; COMPLEX; BINDING; OXIDATION; SPECTROSCOPY; SUPEROXIDE; PROTEIN	Protein ferroxidase site(s), which catalyze the reaction between ferrous ion and dioxygen, have long been thought to play a role in core formation in ferritin; however, the mechanism of the reaction has never been studied in detail. In the present work, the enzymatic activity of ferritin was examined using oximetry, the net Fe2+ oxidation reaction being as follows. Fe2+ + 1/2O2 + 2H2O --> FeOOH(core) + 1/2H2O2 + 2H+ (Reaction 1S) The reaction exhibits saturation kinetics with respect to both Fe2+ and O2 (apparent Michaelis constants: K(m,Fe) = 0.35 +/- 0.01 mM and K(m,O2) = 0.14 +/- 0.03 mM). The enzyme has a turnover number k(cat) = 80 +/- 3 min-1 at 20-degrees-C with maximal activity at pH 7. The kinetics are discussed in terms of two mechanisms, one involving monomeric and the other dimeric iron protein complexes. In both instances Fe(II) oxidation occurs in 1-electron steps. Zinc(II) is a competitive inhibitor of iron(II) oxidation at Zn2+/apoprotein ratios greater-than-or-equal-to 6 (inhibitor constant K(I,Zn) = 0.067 +/- 0.011 mM) but appears to be a noncompetitive inhibitor at lower ratios (less-than-or-equal-to 2), indicating the presence of more than one type of zinc binding site on the protein. At increments of 50 Fe2+/protein or less, all of the iron is oxidized via the protein ferroxidase site(s), independent of the amount of core already present. However, when larger increments are employed, some iron oxidation appears to occur on the surface of the mineral core. The results of these studies emphasize the role of the protein shell in all phases of core growth and confirm the presence of a functionally important catalytic site in ferritin in addition to other binding sites on the protein for iron.	UNIV NEW HAMPSHIRE, DEPT CHEM, PARSONS HALL, DURHAM, NH 03824 USA	University System Of New Hampshire; University of New Hampshire					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020194, R37GM020194] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20194] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN TG, 1975, BIOCHEM BIOPH RES CO, V63, P1056, DOI 10.1016/0006-291X(75)90676-2; AROSIO P, 1978, J BIOL CHEM, V253, P4451; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BAUMINGER ER, 1989, BIOCHEMISTRY-US, V28, P5486, DOI 10.1021/bi00439a025; BI X, 1991, J BIOL CHEM, V266, P19965; BORGGAARD OK, 1972, ACTA CHEM SCAND, V26, P393, DOI 10.3891/acta.chem.scand.26-0393; CHASTEEN ND, 1985, J BIOL CHEM, V260, P2926; CHASTEEN ND, 1982, J BIOL CHEM, V257, P7672; CHENG YG, 1991, BIOCHEMISTRY-US, V30, P2947, DOI 10.1021/bi00225a031; CRICHTON RR, 1978, J MOL CATAL, V4, P75; DESILVA D, 1992, ARCH BIOCHEM BIOPHYS, V293, P409, DOI 10.1016/0003-9861(92)90413-Q; Eigen M., 1965, MECH INORGANIC REACT, P55, DOI [10.1021/ba-1965-0049.ch003, DOI 10.1021/BA-1965-0049.CH003]; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GRADY JK, 1989, J BIOL CHEM, V264, P20224; GRADY JK, 1991, IRON BIOMINERALS, P315; HANNA PM, 1991, J BIOL CHEM, V266, P886; HARRIS DC, 1973, BIOCHIM BIOPHYS ACTA, V329, P156, DOI 10.1016/0304-4165(73)90019-6; HARRISON PM, 1991, ADV INORG CHEM, V36, P449, DOI 10.1016/S0898-8838(08)60046-X; HARRISON PM, 1986, J INORG BIOCHEM, V27, P287, DOI 10.1016/0162-0134(86)80068-X; HARRISON PM, 1986, FRONTIERS BIOINORGAN, P268; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; HEWKIN DJ, 1970, COORDIN CHEM REV, V5, P45, DOI 10.1016/S0010-8545(00)80074-0; JACOBS D, 1989, BIOCHEMISTRY-US, V28, P9216, DOI 10.1021/bi00449a038; KURIMURA Y, 1969, B CHEM SOC JPN, V42, P2238, DOI 10.1246/bcsj.42.2238; KURIMURA Y, 1968, B CHEM SOC JPN, V41, P2234, DOI 10.1246/bcsj.41.2234; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; MACARA IG, 1973, BIOCHEM J, V135, P343, DOI 10.1042/bj1350343; MCCLUNE GJ, 1977, J AM CHEM SOC, V99, P5220, DOI 10.1021/ja00457a074; MERRITT MV, 1977, J AM CHEM SOC, V99, P3713, DOI 10.1021/ja00453a033; NG FTT, 1980, CAN J CHEM, V58, P1773, DOI 10.1139/v80-280; ROBERTS DV, 1977, ENZYME KINETICS, P83; ROHRER JS, 1987, J BIOL CHEM, V262, P13385; SADA E, 1987, IND ENG CHEM RES, V26, P1468, DOI 10.1021/ie00067a033; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SEGEL IH, 1975, KINETICS MECHANISMS, P884; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; TREFFRY A, 1984, J INORG BIOCHEM, V21, P9, DOI 10.1016/0162-0134(84)85035-7; TREFFRY A, 1992, FEBS LETT, V302, P108, DOI 10.1016/0014-5793(92)80417-F; Treffry A., 1977, PROTEINS IRON METABO, P3; Walsh C., 1979, ENZYMATIC REACTION M, P33; WARDESKA JG, 1986, J BIOL CHEM, V261, P6677; WILKINS RG, 1991, KINETICS MECH REACTI, P202; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016; [No title captured]	49	97	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25160	25166						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460015				2022-12-27	WOS:A1992KB60300039
J	DELLIS, S; SCHATZ, T; RUTLIN, K; INMAN, RB; FILUTOWICZ, M				DELLIS, S; SCHATZ, T; RUTLIN, K; INMAN, RB; FILUTOWICZ, M			2 ALTERNATIVE STRUCTURES CAN BE FORMED BY IHF PROTEIN-BINDING TO THE PLASMID-R6K GAMMA-ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI BINDS; DNA-REPLICATION; TRANSCRIPTIONAL ACTIVATION; BACTERIOPHAGE-LAMBDA; CHROMOSOMAL ORIGIN; INITIATOR PROTEIN; SITES; R6K; TELESTABILITY	Escherichia coli integration host factor (IHF) contributes to the regulation of R6K plasmid copy number by counteracting the inhibitory activity of the plasmid-encoded replication protein pi. Two IHF-binding sites (ihf1 and ihf2) flank seven iterons in the origin which bind pi protein. As previously shown by electron microscopy, IHF can compact a large segment of the R6K gamma origin DNA, encompassing site ihf1, an AT-rich domain containing ihf1, and some of the seven iterons located downstream of ihf1. We termed this phenomenon IHF-mediated DNA folding. This folding requires a high IHF concentration, and the region of the origin (replication enhancer) located to the left of the AT-rich domain. However, site ihf2 is not necessary in forming the folded structure. As reported here, IHF binding to ihf2 can be detected in gel mobility shift assays only if the leftmost enhancer region is absent. Sites ihf1 and ihf2 each contain two consensus IHF sequences. Site-directed mutagenesis was performed to determine which sequences are recognized by IHF protein and which sites are involved in forming the various gamma origin-IHF complexes. Finally, we define the boundaries of protection from DNaseI digestion when IHF is bound to ihf2. We propose a model in which IHF protein bound to ihf1, in the absence of the enhancer region, facilitates IHF binding to ihf2.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; UNIV WISCONSIN,INST MOLEC VIROL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM 40314, GM 14711] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040314, R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1990, J BIOL CHEM, V265, P10797; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BIEK DP, 1989, J BACTERIOL, V171, P2056, DOI 10.1128/jb.171.4.2056-2065.1989; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BURD JF, 1975, J BIOL CHEM, V250, P6002; BURD JF, 1975, J BIOL CHEM, V250, P5109; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DELLIS S, 1991, J BACTERIOL, V173, P1279, DOI 10.1128/jb.173.3.1279-1286.1991; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FILUTOWICZ M, 1991, J BIOL CHEM, V266, P24077; FILUTOWICZ M, 1988, NUCLEIC ACIDS RES, V16, P3829, DOI 10.1093/nar/16.9.3829; FILUTOWICZ M, 1990, New Biologist, V2, P818; FILUTOWICZ M, 1985, J MOL BIOL, V187, P225; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GAMAS P, 1986, MOL GEN GENET, V204, P85, DOI 10.1007/BF00330192; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GREENSTEIN D, 1988, P NATL ACAD SCI USA, V85, P6262, DOI 10.1073/pnas.85.17.6262; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; KOLTER R, 1979, THESIS U CALIFORNIA; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUR J, 1989, GENE, V81, P1, DOI 10.1016/0378-1119(89)90331-4; LEONG JM, 1985, J BIOL CHEM, V260, P4468; LILLEY DMJ, 1988, TRENDS GENET, V4, P111, DOI 10.1016/0168-9525(88)90099-6; Maniatis T., 1982, MOL CLONING; MENSAWILMOT K, 1989, EMBO J, V8, P2393, DOI 10.1002/j.1460-2075.1989.tb08369.x; MUKERJI P, 1992, J BACTERIOL, V74, P4777; ROUVIEREYANIV J, 1975, P NATL ACAD SCI USA, V72, P3428, DOI 10.1073/pnas.72.9.3428; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; SULLIVAN KM, 1988, NUCLEIC ACIDS RES, V16, P1079, DOI 10.1093/nar/16.3.1079; SULLIVAN KM, 1986, CELL, V47, P817, DOI 10.1016/0092-8674(86)90524-6; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	46	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24426	24432						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447190				2022-12-27	WOS:A1992KA26300046
J	JUVONEN, M; PIHLAJANIEMI, T				JUVONEN, M; PIHLAJANIEMI, T			CHARACTERIZATION OF THE SPECTRUM OF ALTERNATIVE SPLICING OF ALPHA-1(XIII) COLLAGEN TRANSCRIPTS IN HT-1080 CELLS AND CALVARIAL TISSUE RESULTED IN IDENTIFICATION OF 2 PREVIOUSLY UNIDENTIFIED ALTERNATIVELY SPLICED SEQUENCES, ONE PREVIOUSLY UNIDENTIFIED EXON, AND 9 NEW MESSENGER-RNA VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE FORMS; XIII COLLAGEN; 5' END; GENE; CHAIN; ISOFORMS; DOMAINS; PROCOLLAGEN; EXPRESSION; INHIBITORS	Amplification of a COL1-encoding region of alpha1(XIII) collagen transcripts of HT-1080 cell RNA suggested that exon 3 of the alpha1(XIII) collagen gene, which was previously deduced to be of 35 base pairs (bp) may consist of a constitutive 8-bp exon and an alternatively spliced 27-bp exon, termed here exons 3A and 3B, respectively. Furthermore, a previously unidentified alternatively spliced Gly-Xaa-Yaa-encoding exon designated as 4B was found between the sequences encoded by exons 4, redesignated here as 4A and 5. Six of the 16 potential combinations of the four consecutive alternatively spliced exons 3B, 4A, 4B, and 5 were found to exist in mRNAs, and as a result, the length of the COL1 domain may vary between 57 and 104 amino acid residues. Most of the NC2 domain is encoded by the alternatively spliced exons 12 and 13. Where previous analysis of cDNAs indicated that mRNA variants exist that contain either exon 12 or 13 sequences, amplification studies indicated here that there are also variants that lack both exons 12 and 13 but none that contain both exons simultaneously. Thus, the predicted length of this domain is either 12, 31, or 34 residues. Analyses covering both the COL1 and NC2 domains demonstrate that at least 12 mRNA species exist through the alternations of exons 3B-5, 12, and 13.	UNIV OULU, DEPT MED BIOCHEM, KAJAANINTIE 52A, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; COOPER TA, 1985, J BIOL CHEM, V260, P1140; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REYES AA, 1991, MOL CELL BIOL, V11, P1654, DOI 10.1128/MCB.11.3.1654; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SANDBERG M, 1989, J CELL BIOL, V109, P1371, DOI 10.1083/jcb.109.3.1371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; TIKKA L, 1991, J BIOL CHEM, V266, P17713; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	32	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24693	24699						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447209				2022-12-27	WOS:A1992KA26300082
J	KAUPPINEN, S				KAUPPINEN, S			STRUCTURE AND EXPRESSION OF THE KAS12 GENE ENCODING A BETA-KETOACYL-ACYL CARRIER PROTEIN SYNTHASE-I ISOZYME FROM BARLEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; HOUSEKEEPING GENE; SEQUENCE-ANALYSIS; MESSENGER-RNAS; PLANT GENES; CDNA CLONE; START SITE; DNA; IDENTIFICATION; CERULENIN	The beta-ketoacyl-acyl carrier protein (ACP) synthase I in the plant fatty acid synthetase catalyzes the condensations of acetate units to a growing acyl-ACP leading to the synthesis of palmitoyl-ACP. Barley chloroplasts contain three cerulenin sensitive beta-ketoacyl-ACP synthase I isoforms, alpha2, alphabeta, and beta2. The Kas12 gene encoding the beta2 isozyme has been isolated and sequenced. The gene spans 3.8 kilobases and contains seven exons separated by six intervening sequences varying from 75 to 1008 base pairs in length. The mosaic gene structure is different compared with that of the beta-ketoacyl synthase in the multifunctional rat and goose fatty acid synthetases. Southern blot analyses of genomic DNA from barley, wheat, and the barley-wheat chromosome addition lines indicate that Kas12 is a single copy gene located on chromosome 2. Primer extension analyses identified four transcription start sites located 168-171 nucleotides upstream from the translation initiation codon. The Kas12 promoter lacks an appropriately positioned TATA box and contains a GC-rich region including two GC elements similar to the Sp1 transcription factor-binding site. In this regard Kas12 closely resembles a set of ubiquitously expressed eucaryotic genes. In accord with this deduction, polymerase chain reaction analysis showed that the Kas12 transcript is present in barley roots, germinating embryos, developing kernels, and leaves.			KAUPPINEN, S (corresponding author), CARLSBERG LAB,DEPT PHYSIOL,GAMLE CARLSBERG VEJ 10,DK-2500 COPENHAGEN,DENMARK.							AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BROCK K, 1976, CARLSBERG RES COMMUN, V41, P121, DOI 10.1007/BF02906537; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOJECKI J, 1986, CARLSBERG RES COMMUN, V51, P203, DOI 10.1007/BF02907324; CHOJECKI J, 1986, CARLSBERG RES COMMUN, V51, P211, DOI 10.1007/BF02907325; DESILVA J, 1990, PLANT MOL BIOL, V14, P537, DOI 10.1007/BF00027499; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; GERLACH WL, 1979, NUCLEIC ACIDS RES, V7, P1869, DOI 10.1093/nar/7.7.1869; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; HANLEY BA, 1988, NUCLEIC ACIDS RES, V16, P7159, DOI 10.1093/nar/16.14.7159; HANSEN L, 1991, MOL GEN GENET, V229, P467, DOI 10.1007/BF00267471; HLOUSEKRADOJCIC A, 1992, PLANT PHYSIOL, V98, P206, DOI 10.1104/pp.98.1.206; HOJ PB, 1982, CARLSBERG RES COMMUN, V47, P119, DOI 10.1007/BF02914031; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISLAM AKMR, 1981, HEREDITY, V46, P161, DOI 10.1038/hdy.1981.24; JAWORSKI JG, 1989, PLANT PHYSIOL, V90, P41, DOI 10.1104/pp.90.1.41; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; MATSUOKA M, 1988, J BIOL CHEM, V263, P11080; METZLER MC, 1989, PLANT MOL BIOL, V12, P713, DOI 10.1007/BF00044162; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRAY EE, 1989, NUCLEIC ACIDS RES, V17, P477, DOI 10.1093/nar/17.2.477; PELEMAN J, 1989, PLANT CELL, V1, P81, DOI 10.1105/tpc.1.1.81; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROTHERMEL BA, 1989, J BIOL CHEM, V264, P19587; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID KM, 1990, PLANT MOL BIOL, V15, P765, DOI 10.1007/BF00016126; SHIMAKATA T, 1982, P NATL ACAD SCI-BIOL, V79, P5808, DOI 10.1073/pnas.79.19.5808; SIGGAARDANDERSEN M, 1991, P NATL ACAD SCI USA, V88, P4114, DOI 10.1073/pnas.88.10.4114; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; von Wettstein-Knowles P., 1992, BARLEY GENETICS 6, V2, P753; ZOT AS, 1990, J BIOL CHEM, V265, P20988	46	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23999	24006						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429736				2022-12-27	WOS:A1992JZ23900085
J	LIN, LL; LIN, AY; DEWITT, DL				LIN, LL; LIN, AY; DEWITT, DL			INTERLEUKIN-1-ALPHA INDUCES THE ACCUMULATION OF CYTOSOLIC PHOSPHOLIPASE-A(2) AND THE RELEASE OF PROSTAGLANDIN-E(2) IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; GROUP-II PHOSPHOLIPASE-A2; EXPRESSION; PROTEIN; PURIFICATION; CELLS	Treatment of the human lung fibroblast cell line, WI-38, with interleukin-1alpha (IL-1alpha) results in a large increase in the production of cytosolic phosholipase A2 (cPLA2) and prostaglandin E2 (PGE2). The IL-1-induced accumulation of cPLA2 is closely correlated with increased PGE2 release. In contrast to cPLA2, the level of cyclooxygenase remains unchanged following IL-1alpha treatment. The glucocorticoid, dexamethasone, blocks the IL-1alpha-mediated increases in both cPLA2 and PGE2 without affecting the cyclooxygenase level. Taken together, these data suggest that in these cells, the regulation of prostaglandin production by IL-1 and glucocorticoid can be attributed to the level of cPLA2. These results provide a new mechanism for the effect of IL-1 and glucocorticoids on eicosanoid synthesis and provide additional support for an important role of cPLA2 in the inflammatory response.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University	LIN, LL (corresponding author), GENET INST, 87 CAMBRIDGE PK DR, CAMBRIDGE, MA 02140 USA.							BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; ELIAS JA, 1987, J IMMUNOL, V138, P3812; FU JY, 1990, J BIOL CHEM, V265, P16737; GILMAN SC, 1988, ARTHRITIS RHEUM, V31, P127, DOI 10.1002/art.1780310118; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; IKEDA U, 1990, ATHEROSCLEROSIS, V84, P183, DOI 10.1016/0021-9150(90)90089-2; KERR JS, 1989, BIOCHEM BIOPH RES CO, V165, P1079, DOI 10.1016/0006-291X(89)92712-5; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NAKANO T, 1990, J BIOL CHEM, V265, P12745; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OKA S, 1991, J BIOL CHEM, V266, P9956; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PFEILSCHIFTER J, 1991, BIOCHEM J, V273, P199, DOI 10.1042/bj2730199; PFEILSCHIFTER J, 1989, EUR J BIOCHEM, V181, P237, DOI 10.1111/j.1432-1033.1989.tb14717.x; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X	31	254	257	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23451	23454						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429687				2022-12-27	WOS:A1992JZ23900005
J	VOLLAND, C; GARNIER, C; HAGUENAUERTSAPIS, R				VOLLAND, C; GARNIER, C; HAGUENAUERTSAPIS, R			INVIVO PHOSPHORYLATION OF THE YEAST URACIL PERMEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMINO-ACID PERMEASES; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; SECRETORY PATHWAY; GENE; GLUCOSE; TRANSPORT; SEQUENCE; INACTIVATION	The uptake of uracil by the yeast Saccharomyces cerevisiae is mediated by a specific permease encoded by the FUR4 gene. This uracil permease is a multispanning membrane protein that follows the secretory pathway to the plasma membrane. We have used in vivo pulse labeling and immunoprecipitation to show that the uracil permease is phosphorylated. Phosphoamino acid analysis indicates that the phosphorylation occurs on seryl residues. Experiments with temperature sensitive secretory mutants, blocked at successive steps of the secretory pathway, have established that the phosphorylation of the permease takes place at the plasma membrane. Under steady state conditions, Western immunoblotting showed multiple phosphorylated permease species. Their relative abundance appeared susceptible to metabolic conditions. This study is, therefore, a first step toward identifying a molecular mechanism involved in the post-translational control of a yeast transporter.	UNIV PARIS 07, INST J MONOD, TOUR 43, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	UDICE-French Research Universities; Universite Paris Cite			Haguenauer-Tsapis, Rosine/C-5446-2012					BEGGS JD, 1981, GENETIC ENG, V2, P175; BEHRENS MM, 1988, BIOCHEM BIOPH RES CO, V151, P561, DOI 10.1016/0006-291X(88)90631-6; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CHEVALLIER MR, 1982, MOL CELL BIOL, V2, P977, DOI 10.1128/MCB.2.8.977; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EMR SD, 1984, MOL CELL BIOL, V4, P2347, DOI 10.1128/MCB.4.11.2347; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KOLAROV J, 1988, J BIOL CHEM, V263, P10613; KRUCKEBERG AL, 1990, MOL CELL BIOL, V10, P5903, DOI 10.1128/MCB.10.11.5903; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAMOS J, 1989, J BACTERIOL, V171, P3545, DOI 10.1128/jb.171.6.3545-3548.1989; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SILVE S, 1987, MOL CELL BIOL, V7, P3306, DOI 10.1128/MCB.7.9.3306; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; THEVELEIN JM, 1987, J GEN MICROBIOL, V133, P2197; TSCHOPP JF, 1986, J BACTERIOL, V166, P313, DOI 10.1128/jb.166.1.313-318.1986; VANDENBOL M, 1990, MOL GEN GENET, V222, P393, DOI 10.1007/BF00633845; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	29	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23767	23771						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429716				2022-12-27	WOS:A1992JZ23900053
J	CHAVEZ, RA; MALOOF, J; BEESON, D; NEWSOMDAVIS, J; HALL, ZW				CHAVEZ, RA; MALOOF, J; BEESON, D; NEWSOMDAVIS, J; HALL, ZW			SUBUNIT FOLDING AND ALPHA-DELTA HETERODIMER FORMATION IN THE ASSEMBLY OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR - COMPARISON OF THE MOUSE AND HUMAN ALPHA SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COS CELLS; RESIDUES 173-204; EPSILON SUBUNIT; XENOPUS OOCYTES; GAMMA-SUBUNIT; CDNA SEQUENCE; MUSCLE; TORPEDO; BINDING; SITE	We have used the mouse alpha (alpha(M)) and human alpha (alpha(H)) subunits to investigate the molecular mechanisms of assembly of the mammalian acetylcholine receptor (AChR) transiently expressed in COS cells. COS cells expressing hybrid receptors incorporating alpha(H) along with other mouse subunits exhibited a 2-fold higher level of surface alpha-bungarotoxin (BuTx) binding than cells expressing the wild-type mouse AChR. When expressed either alone or with the delta subunit in COS cells, alpha(H) acquired the BuTx binding conformation (alpha(Tx)) more efficiently than did alpha(M). By oligonucleotide-directed mutagenesis we showed that 2 residues in the amino-terminal domain were responsible for the differences between alpha(M) and alpha(H). Alpha(M)ST, the modified mouse alpha subunit, both folded more efficiently to form alpha(Tx). and was more effective in forming a stable alphadelta heterodimer than was alpha(M). The kinetics of alpha(Tx) and alphadelta heterodimer formation revealed that the delta subunit increased the conversion of immature forms of the alpha subunit into the BuTx binding form and therefore provides evidence for interaction between the delta subunit and the immature form of the alpha subunit. These results provide evidence of the importance of the amino-terminal domains of the AChR subunits in the assembly process.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, 513 PARNASSUS AVE, BOX 0444, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; JOHN RADCLIFFE HOSP, INST MOLEC MED, NEUROSCI GRP, OXFORD OX3 9DU, ENGLAND	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Oxford				Maloof, Julin/0000-0002-9623-2599				ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; BEESON D, 1990, EMBO J, V9, P2101, DOI 10.1002/j.1460-2075.1990.tb07378.x; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; CONROY WG, 1990, J BIOL CHEM, V265, P21642; DEVILLERSTHIERY A, 1983, P NATL ACAD SCI-BIOL, V80, P2067, DOI 10.1073/pnas.80.7.2067; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KARLIN A, 1991, HARVEY LECT, V85, P71; KARLIN A, 1969, J GEN PHYSIOL, V54, pS245; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MAYNE KM, 1987, MOL BRAIN RES, V2, P191, DOI 10.1016/0169-328X(87)90026-X; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9250, DOI 10.1073/pnas.83.23.9250; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2633, DOI 10.1021/bi00357a052; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SAKMANN B, 1985, NATURE, V318, P538, DOI 10.1038/318538a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SMITH MM, 1987, J BIOL CHEM, V262, P4367; TAKAI T, 1985, NATURE, V315, P761, DOI 10.1038/315761a0; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WHITE MM, 1985, P NATL ACAD SCI USA, V82, P4852, DOI 10.1073/pnas.82.14.4852; WILSON PT, 1988, BIOCHEMISTRY-US, V27, P6667, DOI 10.1021/bi00418a004; WILSON PT, 1988, MOL PHARMACOL, V34, P643; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	44	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23028	23034						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429651				2022-12-27	WOS:A1992JY16300051
J	RIBBA, AS; VOORBERG, J; MEYER, D; PANNEKOEK, H; PIETU, G				RIBBA, AS; VOORBERG, J; MEYER, D; PANNEKOEK, H; PIETU, G			CHARACTERIZATION OF RECOMBINANT VONWILLEBRAND-FACTOR CORRESPONDING TO MUTATIONS IN TYPE-IIA AND TYPE-IIB VONWILLEBRAND DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IB; VON WILLEBRAND FACTOR; MURINE MONOCLONAL-ANTIBODY; RISTOCETIN-INDUCED BINDING; FACTOR-VIII; FACTOR VWF; ARTERY SUBENDOTHELIUM; MULTIMERIC STRUCTURE; PLATELET-ADHESION; IIB/IIIA COMPLEX	Type IIA and IIB von Willebrand disease (vWD) result from defects in von Willebrand factor (vWF). Although both type IIA and IIB vWD are characterized by the absence of high molecular weight multimers in plasma, vWF from patients with type IIA vWD demonstrates a decreased affinity for the platelet receptor glycoprotein Ib (GPIb), whereas vWF from patients with type IIB vWD show an increased affinity for GPIb. To investigate how structural alterations in vWF affect its interaction with GPIb, we reproduced the reported potential mutations in type IIA and IIB vWD in vWF cDNA and expressed the recombinant proteins in COS-1 cells. The type IIA vWF potential mutation was represented by a G --> A transversion which results in the substitution of Lys for Glu at position 875 in the mature vWF subunit (rvWFLyS875). The type IIB vWF mutation corresponds to a duplicated ATG codon, resulting in three contiguous methionines starting at position 540-541 in the normal vWF sequence (rvWFduplMet540-541). The subunit composition and multimeric structure of both mutant proteins were similar to the wild-type rvWF. The rvWFLys875 bound to fixed platelets in the presence of ristocetin similar to wild-type rvWF. The rvWFduplMet540-541 bound to fixed platelets in the absence of agonist. The rvWFLys875 appears to interact normally with GPIb, and the decreased affinity for the platelet receptor observed in plasma is probably a consequence of prior reduction in multimeric size resulting from the defect. In contrast, the duplication of Met540-541 increases the reactivity of vWF for its platelet receptor.	HOP BICETRE, INSERM, U143, PARIS, FRANCE; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, DEPT MOLEC BIOL, CENT LAB, AMSTERDAM, NETHERLANDS	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay			ribba, anne-sophie/N-3109-2013	Ribba, Anne-Sophie/0000-0001-5342-8455; Voorberg, Jan/0000-0003-4585-2621				ARDAILLOU N, 1978, THROMB RES, V12, P817, DOI 10.1016/0049-3848(78)90276-1; BAHNAK BR, 1992, BIOCHEM BIOPH RES CO, V182, P561, DOI 10.1016/0006-291X(92)91769-M; BARUCH D, 1989, PLATELET DISORDERS; BERKOWITZ SD, 1987, J CLIN INVEST, V79, P524, DOI 10.1172/JCI112843; BERNDT MC, 1991, THROMB HAEMOSTASIS, V65, P748; CHANG HY, 1989, BLOOD S, V74, pA131; CHRISTOPHE O, 1991, BLOOD, V78, P2310; COLLER BS, 1983, BLOOD, V61, P99; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; COONEY KA, 1992, P NATL ACAD SCI USA, V89, P2869, DOI 10.1073/pnas.89.7.2869; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; DONNER M, 1991, EUR J HAEMATOL, V47, P342; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GINSBURG D, 1989, P NATL ACAD SCI USA, V86, P3723, DOI 10.1073/pnas.86.10.3723; GIRMA JP, 1986, BLOOD, V67, P1356; GRALNICK HR, 1985, P NATL ACAD SCI USA, V82, P5968, DOI 10.1073/pnas.82.17.5968; HOLMBERG L, 1991, BLOOD S, V78, pA150; IANNUZZI MC, 1991, AM J HUM GENET, V48, P757; KAO KJ, 1979, J CLIN INVEST, V63, P656, DOI 10.1172/JCI109348; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRONER PA, 1991, J BIOL CHEM, V266, P19146; KRONER PA, 1992, BLOOD, V79, P2048; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERGNE JM, 1992, IN PRESS BR J HAEMAT; LILLICRAP D, 1991, BRIT J HAEMATOL, V79, P612, DOI 10.1111/j.1365-2141.1991.tb08089.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOPEZFERNANDEZ MF, 1987, VOX SANG, V52, P15, DOI 10.1111/j.1423-0410.1987.tb02981.x; LYNCH DC, 1985, CELL, V41, P49, DOI 10.1016/0092-8674(85)90060-1; LYONS SE, 1992, J BIOL CHEM, V267, P4424; MANCUSO DJ, 1991, BIOCHEMISTRY-US, V30, P253, DOI 10.1021/bi00215a036; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MANCUSO DJ, 1991, BLOOD S, V78, pA67; MEULIEN P, 1992, THROMB HAEMOSTASIS, V67, P154; MEYER D, 1987, ANN NY ACAD SCI, V509, P118, DOI 10.1111/j.1749-6632.1987.tb30989.x; MEYER D, 1984, BRIT J HAEMATOL, V57, P609, DOI 10.1111/j.1365-2141.1984.tb08550.x; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NISHINO M, 1989, BLOOD, V74, P1591; PIETU G, 1992, BIOCHEM J, V284, P711, DOI 10.1042/bj2840711; RABINOWITZ I, 1991, BLOOD S, V78, pA179; RANDI AM, 1991, J CLIN INVEST, V87, P1220, DOI 10.1172/JCI115122; RANDI AM, 1991, BLOOD, V78, pA179; READ MS, 1978, P NATL ACAD SCI USA, V75, P4514, DOI 10.1073/pnas.75.9.4514; RIBBA AS, 1991, BLOOD, V78, P1738; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; RUGGERI ZM, 1980, NEW ENGL J MED, V302, P1047, DOI 10.1056/NEJM198005083021902; RUGGERI ZM, 1982, BLOOD, V60, P1453; RUGGERI ZM, 1987, BLOOD, V70, P895; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLEK J, 1984, J CLIN INVEST, V73, P421, DOI 10.1172/JCI111228; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VERWEIJ CL, 1985, NUCLEIC ACIDS RES, V13, P4699, DOI 10.1093/nar/13.13.4699; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946	64	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23209	23215						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429668				2022-12-27	WOS:A1992JY16300078
J	WADA, A; WATERMAN, MR				WADA, A; WATERMAN, MR			IDENTIFICATION BY SITE-DIRECTED MUTAGENESIS OF 2 LYSINE RESIDUES IN CHOLESTEROL SIDE-CHAIN CLEAVAGE CYTOCHROME-P450 THAT ARE ESSENTIAL FOR ADRENODOXIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-CORTEX; MESSENGER-RNA; MOLECULAR-CLONING; ESCHERICHIA-COLI; EXPRESSION; SEQUENCE; P-450SCC; CDNA; INHIBITORS; REDUCTASE	Utilizing site-directed mutagenesis and an Escherichia coli expression system for bovine cholesterol side chain cleavage cytochrome P450, lysine residues at 377 and 381 are found to play crucial roles in binding bovine adrenodoxin, required for transfer of electrons to mitochondrial P450s. These lysine residues are conserved among mitochondrial P450s and have been implicated previously by chemical modification studies as being important for adrenodoxin binding. In the present study, site-directed mutagenesis producing either neutral or positive amino acids at 377 or 381 has no effect on the structure of side chain cleavage cytochrome P450 as determined spectrally or on the enzymatic conversion of cholesterol to pregnenolone. However, the estimated K(S) of adrenodoxin binding is increased approximately 150-600-fold depending on the particular mutation. Therefore these conserved positively charged residues in mitochondrial P450s are the key sites for adrenodoxin binding which is electrostatic in nature.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037942, R01GM037942] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37942] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BLONDEL A, 1991, NUCLEIC ACIDS RES, V19, P181, DOI 10.1093/nar/19.1.181; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4321, DOI 10.1016/S0021-9258(19)69436-6; HEYL BL, 1986, J BIOL CHEM, V261, P2743; JEFCOATE CR, 1982, J BIOL CHEM, V257, P4731; KIDO T, 1979, J BIOL CHEM, V254, P1806; KIRITA S, 1988, J BIOCHEM-TOKYO, V104, P683, DOI 10.1093/oxfordjournals.jbchem.a122533; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1982, J BIOL CHEM, V257, P1876; LAMBETH JD, 1980, J BIOL CHEM, V255, P138; LI YC, 1990, J BIOL CHEM, V265, P12012; MATSUKAWA N, 1990, BIOCHEM BIOPH RES CO, V169, P245, DOI 10.1016/0006-291X(90)91460-A; MOROHASHI K, 1984, P NATL ACAD SCI-BIOL, V81, P4647, DOI 10.1073/pnas.81.15.4647; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NONAKA Y, 1985, J BIOCH, V98, P259; OMURA T, 1964, J BIOL CHEM, V239, P2370; OONK RB, 1989, J BIOL CHEM, V264, P21934; ORMEJOHNSON NR, 1979, J BIOL CHEM, V254, P2103; PETERSON JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P654, DOI 10.1016/0003-9861(92)90738-I; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; POULOS TL, 1985, J BIOL CHEM, V260, P16222; SAGARA Y, 1992, FEBS LETT, V300, P208, DOI 10.1016/0014-5793(92)80847-A; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUHARA K, 1972, BIOCHIM BIOPHYS ACTA, V263, P272, DOI 10.1016/0005-2795(72)90079-7; TAKIKAWA O, 1978, ARCH BIOCHEM BIOPHYS, V190, P300, DOI 10.1016/0003-9861(78)90279-5; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4535, DOI 10.1021/bi00388a055; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P6899, DOI 10.1021/bi00443a019; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; TULS J, 1989, J BIOL CHEM, V264, P16421; WADA A, 1991, ARCH BIOCHEM BIOPHYS, V290, P376, DOI 10.1016/0003-9861(91)90554-V; WATERMAN MR, 1985, MOL CELL ENDOCRINOL, V39, P81, DOI 10.1016/0303-7207(85)90123-6; WHITE PC, 1984, P NATL ACAD SCI-BIOL, V81, P1986, DOI 10.1073/pnas.81.7.1986; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	39	137	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22877	22882						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429635				2022-12-27	WOS:A1992JY16300028
J	OVERMEYER, JH; MALTESE, WA				OVERMEYER, JH; MALTESE, WA			ISOPRENOID REQUIREMENT FOR INTRACELLULAR-TRANSPORT AND PROCESSING OF MURINE LEUKEMIA-VIRUS ENVELOPE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NEURO-BLASTOMA CELLS; C-TERMINAL REGION; VESICULAR TRANSPORT; MEVALONATE SYNTHESIS; MOLECULAR-BIOLOGY; YPT1 PROTEIN; MEMBRANE; GLYCOPROTEINS; ERYTHROLEUKEMIA	Lovastatin blocks the biosynthesis of the isoprenoid precursor, mevalonate. When Friend murine erythroleukemia (MEL) cells are cultured in medium containing lovastatin, the precursor of murine leukemia virus envelope glycoprotein (gPr90env) fails to undergo proteolytic processing, which normally occurs in the Golgi complex. Consequently, newly synthesized envelope proteins are not incorporated into viral particles that are shed into the culture medium. gPr90env appears to be localized in a pre-Golgi membrane compartment, based on its enrichment in subcellular fractions containing NADPH-cytochrome c reductase activity and the sensitivity of its carbohydrate chains to digestion with endoglycosidase H. Arrest of gPr90env processing occurs at concentrations of lovastatin that are not cytostatic, and the effect of the inhibitor is prevented by addition of mevalonate to the medium. The low molecular mass GTP-binding proteins, rab1p and rab6p, which are believed to function in early steps of the exocytic pathway, are normally modified posttranslationally by geranylgeranyl isoprenoids. However, in MEL cells treated with 1 muM lovastatin, nonisoprenylated forms of these proteins accumulate in the cytosol prior to arrest of gPr90env processing. These observations suggest that lovastatin may prevent viral envelope precursors from reaching the Golgi compartment by blocking the isoprenylation of rab proteins required for ER to Golgi transport.	GEISINGER MED CLIN, WEIS CTR RES, 100 N ACAD AVE, DANVILLE, PA 17822 USA	Geisinger Medical Center					NCI NIH HHS [CA34569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BEDGOOD RM, 1992, J BIOL CHEM, V267, P7060; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DUNCAN HM, 1966, J BIOL CHEM, V241, P1694; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FITTING T, 1982, J BIOL CHEM, V257, P4011; FREED EO, 1987, J VIROL, V61, P2852, DOI 10.1128/JVI.61.9.2852-2856.1987; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; GLINIAK BC, 1991, J BIOL CHEM, V266, P22991; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1979, J BIOL CHEM, V254, P5403; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYLES DS, 1981, J VIROL, V39, P263, DOI 10.1128/JVI.39.1.263-272.1981; MALTESE WA, 1979, J CELL PHYSIOL, V101, P459, DOI 10.1002/jcp.1041010312; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MALTESE WA, 1985, J CELL PHYSIOL, V125, P540, DOI 10.1002/jcp.1041250326; MALTESE WA, 1985, J BIOL CHEM, V260, P1524; MALTESE WA, 1992, ACS SYM SER, V10, P48; MURRAY MJ, 1979, J BIOL CHEM, V254, P1340; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; PIQUE C, 1992, J VIROL, V66, P906, DOI 10.1128/JVI.66.2.906-913.1992; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; POLONOFF E, 1982, J BIOL CHEM, V257, P4023; REPKO EM, 1989, J BIOL CHEM, V264, P9945; ROSNER MR, 1980, P NATL ACAD SCI-BIOL, V77, P6420, DOI 10.1073/pnas.77.11.6420; RUTA M, 1982, J BIOL CHEM, V257, P126; SCHIMMEL SD, 1973, P NATL ACAD SCI USA, V70, P3195, DOI 10.1073/pnas.70.11.3195; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; ULMER JB, 1991, J BIOL CHEM, V266, P9173; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	50	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22686	22692						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429616				2022-12-27	WOS:A1992JW71900106
J	VANSCHRAVENDIJK, CFH; KIEKENS, R; PIPELEERS, DG				VANSCHRAVENDIJK, CFH; KIEKENS, R; PIPELEERS, DG			PANCREATIC BETA-CELL HETEROGENEITY IN GLUCOSE-INDUCED INSULIN-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED PROINSULIN; B-CELLS; PITUITARY-CELLS; STORED INSULIN; RELEASE; RAT; ISLETS; GROWTH	Rat pancreatic beta cells differ in their individual sensitivity to glucose-inducible metabolic changes. The present study examines whether beta cells with a higher metabolic threshold require higher glucose levels for stimulation of their secretory activity. Purified beta cells were distributed according to their metabolic redox state at 7.5 mM glucose; the metabolically responsive (high responsive) and unresponsive (low responsive) subpopulations of comparable size and viability were reaggregated in the presence of [H-3]tyrosine and then perfused at 2.8 mM glucose with 10-min pulses of increasing glucose concentration. Glucose elicited first-phase insulin release in both high and low responsive subpopulations from, respectively, 4.2 and 8.3 mM on. The amplitude of both secretory responses increased dose dependently, the rates in the high responsive sub-population being 2-fold higher than in the low responsive one. At all stimulating glucose levels, fractional release of H-3-labeled insulin was 3- to 4-fold higher than that of immunoreactive insulin. Preferential release of newly formed insulin was already maximally stimulated at 4.2 mM glucose in the high responsive subpopulation, whereas it increased dose-dependently in the low responsive one. These results indicate the existence of intercellular differences in the secretory activity of glucose-exposed beta cells, both in terms of glucose sensitivity and of amplitude. This heterogeneity in beta cell secretory responsiveness parallels that which has been previously described for the cellular metabolic and biosynthetic functions. It is concluded that glucose dose-dependently recruits beta cells into both biosynthetic and secretory activities. Co-existence of inactive and activated cells can explain preferential release of newly synthesized over preformed hormone during glucose stimulation.			VANSCHRAVENDIJK, CFH (corresponding author), VRIJE UNIV BRUSSELS,DEPT METAB & ENDOCRINOL,LAARBEEKLAAN 103,B-1090 BRUSSELS,BELGIUM.			Pipeleers, Daniel/0000-0002-6440-2485				ARVAN P, 1991, J BIOL CHEM, V266, P14171; BOSCO D, 1991, ENDOCRINOLOGY, V129, P3157, DOI 10.1210/endo-129-6-3157; ELLERKMANN E, 1991, ENDOCRINOLOGY, V129, P838, DOI 10.1210/endo-129-2-838; GOLD G, 1982, SCIENCE, V218, P56, DOI 10.1126/science.6181562; GRILL V, 1979, J CLIN INVEST, V64, P700, DOI 10.1172/JCI109512; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; HIRIART M, 1991, ENDOCRINOLOGY, V128, P3193, DOI 10.1210/endo-128-6-3193; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; KINEMAN RD, 1990, ENDOCRINOLOGY, V127, P2229, DOI 10.1210/endo-127-5-2229; MATCHINSKY FM, 1990, DIABETES, V39, P647; MILLER JA, 1990, PROG ENERG COMBUST, V16, P347, DOI 10.1016/0360-1285(90)90043-3; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; REAVEN EP, 1979, J CLIN INVEST, V64, P591, DOI 10.1172/JCI109498; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; SALOMON D, 1986, EXP CELL RES, V162, P507, DOI 10.1016/0014-4827(86)90354-X; SANDO H, 1973, DIABETES, V22, P354, DOI 10.2337/diab.22.5.354; SANDO H, 1972, J CLIN INVEST, V51, P1476, DOI 10.1172/JCI106944; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SMITH PF, 1984, ENDOCRINOLOGY, V115, P2484, DOI 10.1210/endo-115-6-2484; STUDER H, 1989, ENDOCR REV, V10, P125, DOI 10.1210/edrv-10-2-125; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; VANSCHRAVENDIJK CFH, 1990, DIABETOLOGIA, V33, P649, DOI 10.1007/BF00400565	27	134	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21344	21348						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400446				2022-12-27	WOS:A1992JV01100016
J	GANGULY, C; BAINES, IC; KORN, ED; SELLERS, J				GANGULY, C; BAINES, IC; KORN, ED; SELLERS, J			REGULATION OF THE ACTIN-ACTIVATED ATPASE AND INVITRO MOTILITY ACTIVITIES OF MONOMERIC AND FILAMENTOUS ACANTHAMOEBA MYOSIN-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; 3 PHOSPHORYLATION SITES; AMINO-ACID-SEQUENCE; HEAVY-CHAIN; CYTOPLASMIC MYOSINS; LIGHT CHAIN; PURIFICATION; TAIL; QUANTITATION; CASTELLANII	The actin-activated Mg2+-ATPase activity of filamentous Acanthamoeba myosin II is inhibited by phosphorylation of 3 serine residues at the tip of the tail of each heavy chain. From previous studies, it had been concluded that the activity of each molecule in the filament was regulated by the global state of phosphorylation of the filament and was independent of its own phosphorylation state. The actin-activated Mg2+-ATPase activity of monomeric phosphorylated myosin II was not known because it polymerizes under the ionic conditions necessary for the expression of this activity. We have now found conditions to maintain myosin II monomeric and active during the enzyme assay. The actin-activated Mg2+-ATPase activities of monomeric dephosphorylated and phosphorylated myosin II were found to be the same as the activity of filamentous dephosphorylated myosin II. These results support the conclusion that phosphorylation regulates filamentous myosin II by affecting filament conformation. Consistent with their equivalent enzymatic activities, monomeric and filamentous dephosphorylated myosin II were equally active in an in vitro motility assay in which myosin adsorbed to a surface drives the movement of F-actin. In contrast to their very different enzymatic activities, however, filamentous and monomeric phosphorylated myosin II had similar activities in the in vitro motility assay; both were much less active than monomeric and filamentous dephosphorylated myosin II. One interpretation of these results is that the rate-limiting steps in the two assays are different and that, while the rate-limiting step for actin-activated Mg2+-ATPase activity is regulated only at the level of the filament, the rate-limiting step for motility can also be regulated at the level of the monomer.	NHLBI,CELL BIOL LAB,BLDG 3,RM B122,BETHESDA,MD 20892; NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ATKINSON MAL, 1989, J BIOL CHEM, V264, P4127; ATKINSON MAL, 1986, J BIOL CHEM, V261, P1844; ATKINSON MAL, 1986, J BIOL CHEM, V261, P3382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIESIOLKA T, 1988, ANAL BIOCHEM, V168, P280, DOI 10.1016/0003-2697(88)90319-3; COLLINS JH, 1982, J BIOL CHEM, V257, P4529; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COLLINS JH, 1981, J BIOL CHEM, V256, P2586; COTE GP, 1984, J BIOL CHEM, V259, P2781; COTE GP, 1981, J BIOL CHEM, V256, P2811; GANGULY C, 1992, J BIOL CHEM, V267, P20905; GANGULY C, 1990, J BIOL CHEM, V265, P9993; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HAYASHI H, 1989, J BIOCHEM-TOKYO, V105, P875, DOI 10.1093/oxfordjournals.jbchem.a122771; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; IKEBE M, 1985, J BIOL CHEM, V260, P27; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KUZNICKI J, 1985, J BIOL CHEM, V260, P1967; KUZNICKI J, 1983, J BIOL CHEM, V259, P6011; MARUTA H, 1977, J BIOL CHEM, V252, P6501; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1978, J BIOL CHEM, V253, P4798; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SINARD JH, 1989, J CELL BIOL, V109, P1537, DOI 10.1083/jcb.109.4.1537; SINARD JH, 1989, J CELL BIOL, V109, P1529, DOI 10.1083/jcb.109.4.1529; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WIJMENGA SS, 1987, J BIOL CHEM, V262, P15803	33	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20900	20904						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400404				2022-12-27	WOS:A1992JT97800061
J	LEVINGER, L; VASISHT, V; GREENE, V; ARJUN, I				LEVINGER, L; VASISHT, V; GREENE, V; ARJUN, I			THE EFFECTS OF STEM-I AND LOOP-A ON THE PROCESSING OF 5-S RIBOSOMAL-RNA FROM DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RIBOSOMAL-RNA; BINDING-SITE; TRANSCRIPTION; GENE; PRECURSOR; SEQUENCES; NUCLEASE; REQUIRES; COMPLEX; COMMON	The 135-nucleotide Drosophila melanogaster 5 S RNA precursor is processed by removal of 15 nucleotides from its 3' end before incorporation into the large ribosomal subunit. Mature 5 S RNA consists of five helical stem-loops; stem IV and part of V are dispensible, whereas stem III and the 1/118 G-C base pair closest to the processing site at nucleotide 120 are required for processing (Preiser, P., and Levinger, L. (1991) J. Biol. Chem. 266, 7509-7516; Preiser, P., and Levinger, L. (1991) J. Biol. Chem. 266, 23602-23605). We have investigated the effects of stem I and loop A transversions, transitions, selected additions and deletions on 5 S RNA processing. Stem I single substitutions generally prevent processing, whereas compensatory double substitutions restore a range of processing rates. Proximal to the processing site, stem I double substitutions inhibit processing. In the distal portion of stem I and loop A, the processing effect of paired sequence changes varies widely in an irregular pattern. The 7/112 GU pair and nucleotide 13A least tolerate sequence changes; several mutations clustered close to the stem I-loop A boundary stimulate processing. We interpret these results in terms of the RNA helix path and possible RNA-protein contacts.			LEVINGER, L (corresponding author), CUNY YORK COLL,DEPT NAT SCI,BIOL DISCIPLINE,JAMAICA,NY 11451, USA.				NIGMS NIH HHS [GM4603, GM08153] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABOCK MG, 1992, IN PRESS COMPUTATION; BROW DA, 1987, J BIOL CHEM, V262, P13959; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3908; ESCHALIER G, 1970, IN VITRO, V6, P162; GARRETT RA, 1981, TRENDS BIOCHEM SCI, V6, P137, DOI 10.1016/0968-0004(81)90051-7; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; HUBER PW, 1986, J BIOL CHEM, V261, P3002; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; IMBODEN MA, 1992, J BIOL CHEM, V267, P24601; IYER RK, 1988, GENE ANAL TECH, V5, P125, DOI 10.1016/0735-0651(88)90012-X; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; PACE B, 1984, J BIOL CHEM, V259, P1454; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREISER P, 1990, THESIS U DELAWARE NE; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PREISER PR, 1991, J BIOL CHEM, V266, P23602; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; ROMANIUK PJ, 1988, NUCLEIC ACIDS RES, V16, P2295, DOI 10.1093/nar/16.5.2295; ROMANIUK PJ, 1989, MOL BIOL RNA P UCLA, P123; RUBIN GM, 1975, CELL, V6, P207, DOI 10.1016/0092-8674(75)90011-2; RYNER L, 1988, MOL CELL BIOL, V7, P495; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN LH, 1988, SCIENCE, V240, P1591, DOI 10.1126/science.2454505; SHARP S, 1984, NUCLEIC ACIDS RES, V12, P7617, DOI 10.1093/nar/12.20.7617; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; STAHL DA, 1984, J BIOL CHEM, V259, P1448; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TEKAMP PA, 1980, J BIOL CHEM, V255, P9501; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451; VANKNIPPENBERG PH, 1990, BIOCHIM BIOPHYS ACTA, V1051, P14; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; ZHANG P, 1989, NUCLEIC ACIDS RES, V17, P7295, DOI 10.1093/nar/17.18.7295	34	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23683	23687						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429708				2022-12-27	WOS:A1992JZ23900041
J	ZHANG, ZY; CLEMENS, JC; SCHUBERT, HL; STUCKEY, JA; FISCHER, MWF; HUME, DM; SAPER, MA; DIXON, JE				ZHANG, ZY; CLEMENS, JC; SCHUBERT, HL; STUCKEY, JA; FISCHER, MWF; HUME, DM; SAPER, MA; DIXON, JE			EXPRESSION, PURIFICATION, AND PHYSICOCHEMICAL CHARACTERIZATION OF A RECOMBINANT YERSINIA PROTEIN TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; VIRULENCE DETERMINANT; HYDROLYSIS; GENES; CATALYSIS; ENZYMES; CLONING; SYSTEM; AXONS	The Yersinia protein tyrosine phosphatase (PTPase) Yop51, a C235R point mutation (Yop51*), and a protein lacking the first 162 amino acids at the NH2 terminus (Yop51*DELTA162) have been overexpressed in Escherichia coli and purified to homogeneity through the use of CM Sephadex C25 cation exchange chromatography followed by Sephadex G-100 gel filtration. Greater than 50 mg of homogeneous Yop51* and Yop51*DELTA162 can be obtained from a single liter of bacterial culture, whereas the same procedure yields only 5 mg of pure Yop51. Large, diffraction-quality crystals have been obtained for Yop51*DELTA162. Size exclusion chromatography, sedimentation equilibrium, and enzyme concentration dependence experiments have established that the Yersinia PTPases exist and function as monomers in solution. Yop51 and Yop51* display identical UV, CD, and fluorescence spectra and have identical kinetic and structural stability properties. These full-length Yersinia PTPases have 31% alpha-helix, an emission maximum of 342 nm, a turn-over number of 1200 s-1 at pH 5.0, 30-degrees-C, and an unfolding DELTAG value of 6 kcal/mol at 25-degrees-C. Yop51*DELTA162 has very similar kinetic and fluorescence characteristics to the full-length molecules, whereas its CD and UV spectra show noticeable differences due to the elimination of 162 NH2-terminal residues. The Yersinia PTPases are by far the most active PTPases known, and their kinetic parameters are extremely sensitive to the ionic strength of reaction medium.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					PHS HHS [18849] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; CHERVENKA CH, 1973, MANUAL METHODS ANAL, P55; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DUMPHY WG, 1991, CELL, V67, P189; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GOLDSTEIN L, 1972, BIOCHEMISTRY-US, V11, P4072, DOI 10.1021/bi00772a009; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HARTLEY RW, 1968, BIOCHEMISTRY-US, V7, P2401, DOI 10.1021/bi00846a050; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1986, ENZYMES, V17, P191; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KESVATERA T, 1990, BIOORG CHEM, V18, P13, DOI 10.1016/0045-2068(90)90011-S; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEW JB, 1982, BIOCHEMISTRY-US, V21, P4989, DOI 10.1021/bi00263a024; MATTHEWS B, 1968, J MOL BIOL, V33, P5036; Pace C N, 1986, Methods Enzymol, V131, P266; POT DA, 1991, J BIOL CHEM, V266, P19688; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516	38	185	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23759	23766						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429715				2022-12-27	WOS:A1992JZ23900052
J	ZHOU, DX; LI, YF; ROCIPON, M; MACHE, R				ZHOU, DX; LI, YF; ROCIPON, M; MACHE, R			SEQUENCE-SPECIFIC INTERACTION BETWEEN S1F, A SPINACH NUCLEAR FACTOR, AND A NEGATIVE CIS-ELEMENT CONSERVED IN PLASTID-RELATED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; DNA-BINDING PROTEINS; RBCS-3A GENE; NICOTIANA-PLUMBAGINIFOLIA; REGULATORY ELEMENTS; CAB GENE; PROMOTER; UPSTREAM; GT-1	The nuclear gene rps1 coding for the spinach plastid ribosomal protein CS1 exhibits both a constitutive and leaf-specific expression pattern. In contrast to other chloroplast-related genes like rbcS and cab, the leaf induction of rps1 expression is light-independent. These unique features of rps1 expression provide good models to study the mechanisms regulating plastid development and differentiation in higher plants. We report on the identification of a spinach leaf nuclear factor, designated S1F, interacting with the rps1 promoter. The S1F binding site is conserved in the promoter region of many plastid-related genes, including rbcS, cab, and rpl21. A binding activity similar to S1F was detected in nuclear extract from dark-grown dedifferentiated soybean suspension cells. Through site-specific mutagenesis and transient expression in soybean cell protoplasts, we show that the S1F binding site is a negative element down-regulating the promoter activity of rps1. A ligated tetramer of S1F site was able to repress activity of the cauliflower mosaic virus 35 S promoter extending the negative function of the S1F binding site on promoter activity.			ZHOU, DX (corresponding author), UNIV J FOURIER,CNRS,URA 1178,BIOL MOLEC VEGETALE LAB,BP 53X,F-38041 GRENOBLE,FRANCE.			Zhou, Dao-Xiu/0000-0002-1540-0598				BENFEY PN, 1990, EMBO J, V9, P1677, DOI 10.1002/j.1460-2075.1990.tb08291.x; CASTRESANA C, 1988, EMBO J, V7, P1929, DOI 10.1002/j.1460-2075.1988.tb03030.x; CASTRESANA C, 1987, PLANT MOL BIOL, V10, P117, DOI 10.1007/BF00016149; Dixon R. A., 1985, PLANT CELL CULTURE P, P1; DONALD RGK, 1990, EMBO J, V9, P1717, DOI 10.1002/j.1460-2075.1990.tb08295.x; FRANZETTI B, 1992, NUCLEIC ACIDS RES, V16, P4153; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIDONI D, 1989, MOL GEN GENET, V215, P337, DOI 10.1007/BF00339739; GILMARTIN PM, 1990, PLANT CELL, V2, P396; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREEN PJ, 1988, EMBO J, V7, P4035, DOI 10.1002/j.1460-2075.1988.tb03297.x; GREEN PJ, 1987, EMBO J, V6, P2543, DOI 10.1002/j.1460-2075.1987.tb02542.x; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KUHLEMEIER C, 1987, GENE DEV, V1, P247, DOI 10.1101/gad.1.3.247; KUHLEMEIER C, 1987, ANNU REV PLANT PHYS, V38, P221; KUHLEMEIER C, 1989, PLANT CELL, V1, P471, DOI 10.1105/tpc.1.4.471; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAM E, 1990, SCIENCE, V248, P471, DOI 10.1126/science.2330508; LAWTON MA, 1991, PLANT MOL BIOL, V16, P235, DOI 10.1007/BF00020555; LEGUAY JJ, 1987, DEV GENET, V8, P351, DOI 10.1002/dvg.1020080506; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEGRUTIU I, 1987, PLANT MOL BIOL, V8, P363, DOI 10.1007/BF00015814; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEPF E, 1980, CHLOROPLASTS RESULTS, V10, P1; SIMPSON J, 1986, NATURE, V323, P551, DOI 10.1038/323551a0; SIMPSON J, 1985, EMBO J, V4, P2723, DOI 10.1002/j.1460-2075.1985.tb03995.x; SO JS, 1991, PLANT MOL BIOL, V17, P309, DOI 10.1007/BF00040627; SORGER PK, 1990, PROTEIN FUNCTION PRA, P199; SUGITA M, 1987, P NATL ACAD SCI USA, V84, P7104, DOI 10.1073/pnas.84.20.7104; UEDA T, 1989, PLANT CELL, V1, P217, DOI 10.1105/tpc.1.2.217; WANNER LA, 1991, PLANT CELL, V3, P1289, DOI 10.1105/tpc.3.12.1289	34	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23515	23519						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429696				2022-12-27	WOS:A1992JZ23900018
J	AVICHEZER, D; KATCOFF, DJ; GARBER, NC; GILBOAGARBER, N				AVICHEZER, D; KATCOFF, DJ; GARBER, NC; GILBOAGARBER, N			ANALYSIS OF THE AMINO-ACID-SEQUENCE OF THE PSEUDOMONAS-AERUGINOSA GALACTOPHILIC PA-I LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-SPECIFIC LECTIN; NUCLEOTIDE-SEQUENCE; SEED LECTIN; KLEBSIELLA-PNEUMONIAE; BINDING PROTEIN; ANIMAL LECTINS; CONCANAVALIN-A; CDNA CLONING; GENE; IDENTIFICATION	Based on the NH2-terminal 30-amino acid sequence of Pseudomonas aeruginosa galactophilic PA-I lectin, two degenerate primer oligonucleotides were synthesized and used in polymerase chain reaction with the bacterial chromosomal DNA as a template. A predominant DNA fragment of the appropriate size was radiolabeled and used as a probe for screening a P. aeruginosa genomic lambdagt11 library. One positive clone carrying an insert of about 630 base pairs encompassing the entire PA-I lectin gene was isolated and found to contain a 369-base pair open reading frame between an initiation codon (19 base pairs downstream from the insertion site, subsequent to a Shine-Dalgarno sequence) and two consecutive stop codons, followed by an oligo (seven) A sequence, in a partial dyad symmetry. The deduced amino acid sequence shows excellent agreement with the quantitative amino acid analysis and a perfect match with the NH2-terminal amino acid sequence of the purified lectin. It reveals that the PA-I lectin subunit contains 121 amino acids (M(r) 12,754; pI 4.94) with a predominant central hydrophilic core between two hydrophobic domains. Secondary structure algorithms predict that it is rich in beta sheets and contains several highly antigenic epitopes, but no signal peptide. In the carboxyl region a potential glycosylation site (Asn-Asn-Ser) was identified. Comparative analyses of this lectin sequence with those of lectins from other sources, reported in the protein and gene data banks, did not reveal any extensive homology.	BAR ILAN UNIV,DEPT LIFE SCI,IL-52900 RAMAT GAN,ISRAEL	Bar Ilan University								ABRAHAM SN, 1987, J BACTERIOL, V169, P5530, DOI 10.1128/jb.169.12.5530-5536.1987; ADAR R, 1989, FEBS LETT, V257, P81, DOI 10.1016/0014-5793(89)81791-0; ANTHONY JL, 1991, PLANT PHYSIOL, V97, P839, DOI 10.1104/pp.97.2.839; AVICHEZER D, 1991, TOXICON, V29, P1305, DOI 10.1016/0041-0101(91)90117-A; AVICHEZER D, 1989, INFECTION, V17, P407, DOI 10.1007/BF01645561; AVICHEZER D, 1992, ISRAEL J MED SCI, V28, P74; BAKER N, 1990, INFECT IMMUN, V58, P2361, DOI 10.1128/IAI.58.7.2361-2366.1990; BANAS JA, 1990, INFECT IMMUN, V58, P667, DOI 10.1128/IAI.58.3.667-673.1990; BARONDES SH, 1988, BIOCHIMIE, V70, P1627, DOI 10.1016/0300-9084(88)90298-2; BECKER JW, 1975, J BIOL CHEM, V250, P1513; BLADIER D, 1991, NEUROCHEM INT, V18, P275, DOI 10.1016/0197-0186(91)90195-J; BUIKEMA WJ, 1987, J BACTERIOL, V169, P1120, DOI 10.1128/jb.169.3.1120-1126.1987; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cryz S., 1984, BACTERIAL VACCINES, P317; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOIG P, 1989, CAN J MICROBIOL, V35, P1141, DOI 10.1139/m89-189; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FUKUMORI F, 1989, FEBS LETT, V250, P153, DOI 10.1016/0014-5793(89)80709-4; GARBER N, 1992, BIOCHIM BIOPHYS ACTA, V1116, P331, DOI 10.1016/0304-4165(92)90048-Y; GARBER N, 1985, INFECT IMMUN, V50, P336, DOI 10.1128/IAI.50.1.336-337.1985; GERLACH GF, 1989, J BACTERIOL, V171, P1262, DOI 10.1128/jb.171.3.1262-1270.1989; Gilboa-Garber N, 1986, MICROBIAL LECTINS AG, P255; GILBOAGARBER N, 1977, CAN J BIOCHEM CELL B, V55, P975, DOI 10.1139/o77-145; GILBOAGARBER N, 1988, ZBL BAKT-INT J MED M, V270, P3; GILBOAGARBER N, 1982, METHOD ENZYMOL, V83, P378; GILBOAGARBER N, 1992, GLYCOCONJUGATES COMP, P541; GILBOAGARBER N, 1982, ADV PATHOLOGY, V1, P31; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GLICK J, 1983, J GEN MICROBIOL, V129, P3085; HASE CC, 1991, J BACTERIOL, V173, P3311; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KAMEYAMA T, 1982, AGR BIOL CHEM TOKYO, V46, P523, DOI 10.1080/00021369.1982.10865091; KAMIYA Y, 1990, J BIOCHEM-TOKYO, V108, P139, DOI 10.1093/oxfordjournals.jbchem.a123153; KIDA H, 1987, VIROLOGY, V159, P109, DOI 10.1016/0042-6822(87)90353-9; KO HL, 1987, INFECTION, V15, P237, DOI 10.1007/BF01644121; KONAMI Y, 1991, J BIOCHEM-TOKYO, V109, P650, DOI 10.1093/oxfordjournals.jbchem.a123435; KONAMI Y, 1990, FEBS LETT, V268, P281, DOI 10.1016/0014-5793(90)81028-M; KRIVAN HC, 1988, ARCH BIOCHEM BIOPHYS, V260, P493, DOI 10.1016/0003-9861(88)90473-0; KUSUI K, 1991, J BIOCHEM, V109, P899, DOI 10.1093/oxfordjournals.jbchem.a123477; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; MARCUS H, 1989, INFECT IMMUN, V57, P1050, DOI 10.1128/IAI.57.4.1050-1053.1989; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MESSNER P, 1991, Glycobiology, V1, P545, DOI 10.1093/glycob/1.6.545; MURAMOTO K, 1990, BIOCHIM BIOPHYS ACTA, V1039, P42, DOI 10.1016/0167-4838(90)90224-4; OSTROFF RM, 1990, J BACTERIOL, V172, P5915, DOI 10.1128/jb.172.10.5915-5923.1990; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; RAMPHAL R, 1983, INFECT IMMUN, V41, P339, DOI 10.1128/IAI.41.1.339-344.1983; RELMAN DA, 1989, P NATL ACAD SCI USA, V86, P2637, DOI 10.1073/pnas.86.8.2637; ROMEO JM, 1986, P NATL ACAD SCI USA, V83, P6332, DOI 10.1073/pnas.83.17.6332; Sabath L.D., 1980, PSEUDOMONAS AERUGINO; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNELL DJ, 1988, J BIOL CHEM, V263, P14648; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; STROSBERG AD, 1986, LECTINS PROPERTIES F, P249; TAKAHASHI H, 1985, J BIOL CHEM, V260, P2228; VANDRIESSCHE E, 1988, ADV LECTIN RES, V1, P73; VODKIN LO, 1983, CELL, V34, P1023, DOI 10.1016/0092-8674(83)90560-3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; YAMAUCHI D, 1990, FEBS LETT, V260, P127, DOI 10.1016/0014-5793(90)80083-U; YOUNG NM, 1991, EUR J BIOCHEM, V196, P631, DOI 10.1111/j.1432-1033.1991.tb15859.x	72	38	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23023	23027						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429650				2022-12-27	WOS:A1992JY16300050
J	BAKER, RT; TOBIAS, JW; VARSHAVSKY, A				BAKER, RT; TOBIAS, JW; VARSHAVSKY, A			UBIQUITIN-SPECIFIC PROTEASES OF SACCHAROMYCES-CEREVISIAE - CLONING OF UBP2 AND UBP3, AND FUNCTIONAL-ANALYSIS OF THE UBP GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; ESCHERICHIA-COLI; THIOL PROTEASES; REGION UPSTREAM; HOST STRAINS; YEAST; EXPRESSION; DNA; TRANSFORMATION; PROTEIN	In eukaryotes, both natural and engineered ubiquitin (Ub) fusions to itself or other proteins are cleaved by processing proteases after the last (Gly76) residue of ubiquitin. YUH1 and UBP1, the genes for two ubiquitin-specific proteases of the yeast Saccharomyces cerevisiae, have been cloned previously and shown to encode nonhomologous proteins. Using an Escherichia coli-based genetic screen, we have isolated two other yeast genes for ubiquitin-specific proteases, named UBP2 and UBP3. Ubp2 (1,264 residues), Ubp3 (912 residues), and the previously cloned Ubp1 (809 residues) are largely dissimilar except for two short regions containing Cys and His which encompass their putative active sites. Neither of these proteases has sequence similarities to Yuh1. Both Ubp2 and the previously identified Ubp1 cleave in vitro at the C terminus of the ubiquitin moiety in natural and engineered fusions irrespective of their size, poly-Ub being the exception. However, both Ubp1 and Ubp2 are also capable of cleaving poly-Ub when coexpressed with it in E. coli, suggesting that such cleavage is largely cotranslational. Although inactive in E. coli extracts, Ubp3 was active with all of the tested ubiquitin fusions except poly-Ub when coexpressed with them in E. coli. Null yuh1 ubp1 ubp2 ubp3 quadruple mutants are viable and retain the ability to deubiquitinate ubiquitin fusions, indicating the presence of at least one more ubiquitin-specific processing protease in S. cerevisiae.	CALTECH, DIV BIOL, 147-75, PASADENA, CA 91125 USA	California Institute of Technology					NIA NIH HHS [AG08991] Funding Source: Medline; NIGMS NIH HHS [GM31530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008991] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel FM, 1988, MOL REPROD DEV; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER R, 1991, NUCLEIC ACIDS RES, V19, P1945, DOI 10.1093/nar/19.8.1945; BAKER RE, 1982, EMBO J, V1, P291, DOI 10.1002/j.1460-2075.1982.tb01162.x; BAKER RT, 1987, NUCLEIC ACIDS RES, V15, P443, DOI 10.1093/nar/15.2.443; BAMEZAI S, 1990, BIOCHEMISTRY-US, V29, P5389, DOI 10.1021/bi00474a026; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BROSIUS J, 1987, METHOD ENZYMOL, V153, P54; BUTT TR, 1989, P NATL ACAD SCI USA, V86, P2540, DOI 10.1073/pnas.86.8.2540; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GUTHRIE C, 1991, IN PRESS METHODS ENZ, V194; HADARI T, 1992, J BIOL CHEM, V267, P719; HAUBER J, 1988, NUCLEIC ACIDS RES, V16, P10623, DOI 10.1093/nar/16.22.10623; HEGEMANN JH, 1986, MOL GEN GENET, V205, P305, DOI 10.1007/BF00430443; HEMPEL J, 1991, PROTEINS, V11, P176, DOI 10.1002/prot.340110303; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JONNALAGADDA S, 1989, J BIOL CHEM, V264, P10637; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LOHE AR, 1987, J MOL BIOL, V194, P171, DOI 10.1016/0022-2836(87)90366-4; LU C, 1990, BIOCHEM BIOPH RES CO, V171, P138, DOI 10.1016/0006-291X(90)91367-2; MAK P, 1989, J BIOL CHEM, V264, P21613; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; OHMEN JD, 1990, MOL CELL BIOL, V10, P3027, DOI 10.1128/MCB.10.6.3027; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PICKART CM, 1988, UBIQUITIN, P77; Rose I. A., 1988, UBIQUITIN, P135; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; Sambrook J, 1989, MOL CLONING LABORATO; Schlesinger M J, 1987, Oxf Surv Eukaryot Genes, V4, P77; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRADLING AC, 1987, EMBO J, V6, P1045, DOI 10.1002/j.1460-2075.1987.tb04857.x; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; SYLVESTER JE, 1989, GENE, V84, P193, DOI 10.1016/0378-1119(89)90155-8; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WARMINGTON JR, 1986, NUCLEIC ACIDS RES, V14, P3475, DOI 10.1093/nar/14.8.3475; WICKNER RB, 1988, P NATL ACAD SCI USA, V85, P6007, DOI 10.1073/pnas.85.16.6007; WILDEMAN AG, 1986, J BIOL CHEM, V261, P3401; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WILKINSON KD, 1988, UBIQUITIN, P5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOO Y, 1989, J BIOL CHEM, V264, P17078	62	196	206	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23364	23375						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429680				2022-12-27	WOS:A1992JY16300100
J	INIGUEZLLUHI, JA; SIMON, MI; ROBISHAW, JD; GILMAN, AG				INIGUEZLLUHI, JA; SIMON, MI; ROBISHAW, JD; GILMAN, AG			G-PROTEIN BETA-GAMMA SUBUNITS SYNTHESIZED IN SF9 CELLS - FUNCTIONAL-CHARACTERIZATION AND THE SIGNIFICANCE OF PRENYLATION OF GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; GTP-BINDING; CATALYTIC SUPPORT; ADENYLATE-CYCLASE; ADP-RIBOSYLATION; BOVINE BRAIN; K+-CHANNEL; TRANSDUCIN; RECEPTOR; ALPHA	Heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) consist of a nucleotide-binding alpha subunit and a high-affinity complex of beta and gamma subunits. There is molecular heterogeneity of beta and gamma, but the significance of this diversity is poorly understood. Different G protein beta and gamma subunits have been expressed both singly and in combinations in Sf9 cells. Although expression of individual subunits is achieved in all cases, betagamma subunit activity (support of pertussis toxin-catalyzed ADP-ribosylation of rG(ialpha1)) is detected only when beta and gamma are expressed concurrently. Of the six combinations of betagamma tested (beta1 or beta2 with gamma1, gamma2, or gamma3), only one, beta2gamma1, failed to generate a functional complex. Each of the other five complexes has been purified by subunit exchange chromatography using G(oalpha)-agarose as the chromatographic matrix. We have detected differences in the abilities of the purified proteins to support ADP-ribosylation of G(ialpha1); these differences are attributable to the gamma component of the complex. When assayed for their ability to inhibit calmodulin-stimulated type-I adenylylcyclase activity or to potentiate G(salpha)-stimulated type-II adenylylcyclase, recombinant beta1gamma1 and transducin betagamma are approximately 10 and 20 times less potent, respectively, than the other complexes examined. Prenylation and/or further carboxyl-terminal processing of gamma are not required for assembly of the betagamma subunit complex but are indispensable for high affinity interactions of betagamma with either G protein alpha subunits or adenylylcyclases.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; GEISINGER MED CLIN, WEIS CTR RES, DANVILLE, PA 17822 USA; CALTECH, DEPT BIOL, PASADENA, CA 91125 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Geisinger Medical Center; California Institute of Technology				Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NIGMS NIH HHS [GM34236, GM34497, GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R01GM034497, R37GM034497, R29GM039867, R37GM034236, R01GM039867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYER JL, 1989, J BIOL CHEM, V264, P13917; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAO B, 1987, J BIOL CHEM, V262, P17254; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HAGA K, 1992, J BIOL CHEM, V267, P2222; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; OKABE K, 1990, J BIOL CHEM, V265, P12854; PAGE M J, 1990, Methods (Orlando), V1, P221, DOI 10.1016/S1046-2023(05)80321-4; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	50	282	283	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23409	23417						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429682				2022-12-27	WOS:A1992JY16300106
J	OSTANIN, K; HARMS, EH; STEVIS, PE; KUCIEL, R; ZHOU, MM; VANETTEN, RL				OSTANIN, K; HARMS, EH; STEVIS, PE; KUCIEL, R; ZHOU, MM; VANETTEN, RL			OVEREXPRESSION, SITE-DIRECTED MUTAGENESIS, AND MECHANISM OF ESCHERICHIA-COLI ACID-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION; CLONING; PH; MICROCOMPUTER; RESIDUE; OPTIMUM	Site-directed mutagenesis was used to examine the catalytic importance of 2 histidine and 4 arginine residues in Escherichia coli periplasmic acid phosphatase (EcAP). The residues that were selected as targets for mutagenesis were those that were also conserved in a number of high molecular weight acid phosphatases from eukaryotic organisms, including human prostatic and lysosomal acid phosphatases. Both wild type EcAP and mutant proteins were overproduced in E. coli using an expression system based on the T7 RNA polymerase promoter, and the proteins were purified to homogeneity. Examination of the purified mutant proteins by circular dichroism and proton NMR spectroscopy revealed no significant conformational changes. The replacement of Arg16 and His17 residues that were localized in a conserved N-terminal RHGXRXP motif resulted in the complete elimination of EcAP enzymatic activity. Critical roles for Arg20, Arg92, and His303 were also established because the corresponding mutant proteins exhibited residual activities that were not higher than 0.4% of that of wild type enzyme. In contrast, the replacement of Arg63 did not cause a significant alteration of the kinetic parameters. The results are in agreement with a previously postulated distant relationship between acid phosphatases, phosphoglycerate mutases, and fructose-2,6-bisphosphatase. These and earlier results are also consistent with the conclusion that 2 histidine residues participate in the catalytic mechanism of acid phosphatases, with His17 playing the role of a nucleophilic acceptor of the phospho group, whereas His303 may act as a proton donor to the alcohol or phenol.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27713] Funding Source: Medline; NIGMS NIH HHS [GM 27003] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIMA K, 1983, NUCLEIC ACIDS RES, V11, P1657, DOI 10.1093/nar/11.6.1657; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; CHERNOFF J, 1990, P NATL ACAD SCI USA, V86, P9642; DASSA E, 1981, FEBS LETT, V135, P148, DOI 10.1016/0014-5793(81)80964-7; DASSA E, 1982, J BIOL CHEM, V257, P6669; DASSA J, 1990, J BACTERIOL, V172, P5497, DOI 10.1128/jb.172.9.5497-5500.1990; DAVIDSON RE, 1990, THESIS PURDUE U W LA; ELLIOTT S, 1986, J BIOL CHEM, V261, P2936; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; GEIER C, 1991, BIOL CHEM H-S, V372, P301, DOI 10.1515/bchm3.1991.372.1.301; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HAN CH, 1979, J BIOL CHEM, V254, P8836; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARMS E, 1988, J BACTERIOL, V170, P4798, DOI 10.1128/jb.170.10.4798-4807.1988; HICKEY ME, 1972, ARCH BIOCHEM BIOPHYS, V152, P423, DOI 10.1016/0003-9861(72)90232-9; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KLEPPE K, 1971, J MOL BIOL, V56, P341, DOI 10.1016/0022-2836(71)90469-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P422, DOI 10.1016/0005-2744(78)90044-X; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P407, DOI 10.1016/0005-2744(78)90043-8; MEIERING EM, 1991, BIOCHEMISTRY-US, V30, P11348, DOI 10.1021/bi00111a022; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; Rose Z B, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P211; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1990, CURRENT PROTOCOL S11, V2; TAULER A, 1990, J BIOL CHEM, V265, P15617; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; YANNOUKAKOS D, 1991, BLOOD, V78, P1117	37	119	136	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22830	22836						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429631				2022-12-27	WOS:A1992JY16300022
J	WILLIAMS, BA; CHERVENAK, MC; TOONE, EJ				WILLIAMS, BA; CHERVENAK, MC; TOONE, EJ			ENERGETICS OF LECTIN-CARBOHYDRATE BINDING - A MICROCALORIMETRIC INVESTIGATION OF CONCANAVALIN A-OLIGOMANNOSIDE COMPLEXATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDES; PROTEIN; RECOGNITION; SPECIFICITY; MODEL; THERMODYNAMICS; GLYCOPEPTIDES; ATTACHMENT; SALMONELLA; AGGLUTININ	Despite years of study, a comprehensive picture of the binding of the lectin from Canavalia ensiformis, concanavalin A, to carbohydrates remains elusive. We report here studies on the interaction of concanavalin A with methyl 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside, the minimum carbohydrate epitope that completely fills the oligosaccharide binding site, and the two conceptual disaccharide "halves" of the trisaccharide, methyl 3-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside and methyl 6-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside, using titration microcalorimetry. In all cases the interaction of protein and carbohydrate is enthalpically driven, with an unfavorable entropic contribution. The choice of concentration scales has an important impact on both the magnitude and, in some cases, the sign of the entropic component of the free energy of binding. The thermodynamic data suggest binding of the two disaccharides may take place in distinct sites, as opposed to binding in a single high affinity site. In contrast to carbohydrate-antibody binding, DELTAC(p) values were small and negative, pointing to possible differences in the motifs used by the two groups of proteins to bind carbohydrates. The thermodynamic data are interpreted in terms of solvent reorganization. Cooperativity during lectin-carbohydrate binding was also investigated. Significant cooperativity was observed only for binding of the trisaccharide, and gave a Hill plot coefficient of 1.3 for dimeric protein.	DUKE UNIV, DEPT CHEM, DURHAM, NC 27706 USA	Duke University								AGRAWAL BBL, 1967, BIOCHIM BIOPHYS ACTA, V147, P262, DOI 10.1016/0005-2795(67)90404-7; AMBROSINO R, 1987, BIOCHEMISTRY-US, V26, P3971, DOI 10.1021/bi00387a034; BARTLES JR, 1980, J BIOL CHEM, V255, P30; BECVAR J, 1982, J BIOL CHEM, V257, P5607; BEIERBECK H, 1990, CAN J CHEM, V68, P820, DOI 10.1139/v90-130; BERTRAND GL, 1989, J PHYS CHEM-US, V93, P6863, DOI 10.1021/j100355a057; BISWAS M, 1987, CARBOHYD RES, V160, P151, DOI 10.1016/0008-6215(87)80309-9; Bittiger H, 1976, CONCANAVALIN A TOOL; BOCK G, 1989, CIBA F S, V145; BRESLAUER KJ, 1987, P NATL ACAD SCI USA, V84, P8922, DOI 10.1073/pnas.84.24.8922; BREWER F, 1985, BIOCHEM BIOPH RES CO, V127, P1066, DOI 10.1016/S0006-291X(85)80053-X; Bubois M., 1956, ANAL CHEM, V28, P350; CARVER JP, 1985, BIOPOLYMERS, V24, P49, DOI 10.1002/bip.360240106; CARVER JP, 1989, CIBA F SYMP, V145, P6; CHICKEN CA, 1985, BIOCHIM BIOPHYS ACTA, V814, P125, DOI 10.1016/0005-2736(85)90427-4; CHICKEN CA, 1984, BIOCHIM BIOPHYS ACTA, V774, P110, DOI 10.1016/0005-2736(84)90281-5; CUATRECA.P, 1973, BIOCHEMISTRY-US, V12, P1312, DOI 10.1021/bi00731a011; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; EINSTARH HN, 1991, T AM CRYSTALLOGR ASS, V25; FEIZI T, 1987, BIOCHEM J, V245, P1; GORDON JA, 1979, J BIOL CHEM, V254, P1932; GRANT CWM, 1984, BIOCHIM BIOPHYS ACTA, V779, P403, DOI 10.1016/0304-4157(84)90018-2; GURNEY RW, 1956, IONIC PROCESSES SOLU, pCH5; HINZ HJ, 1983, ANNU REV BIOPHYS BIO, V12, P285, DOI 10.1146/annurev.bb.12.060183.001441; KAKU H, 1991, CARBOHYD RES, V213, P109, DOI 10.1016/S0008-6215(00)90602-5; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KETIS NV, 1982, BIOCHIM BIOPHYS ACTA, V689, P194, DOI 10.1016/0005-2736(82)90251-6; LEINER IE, 1986, LECTINS PROPERTIES F; LEMIEUX RU, 1991, CIBA F SYMP, V158, P231; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; MANOCHA MS, 1990, CAN J MICROBIOL, V36, P69, DOI 10.1139/m90-014; MARKY LA, 1987, P NATL ACAD SCI USA, V84, P4359, DOI 10.1073/pnas.84.13.4359; MUNSKE GR, 1978, BIOCHEM BIOPH RES CO, V84, P684, DOI 10.1016/0006-291X(78)90759-3; Paulson J, 1985, THE RECEPTORS, V2, P131; PRUJANSKY A, 1978, BIOCHIM BIOPHYS ACTA, V508, P137, DOI 10.1016/0005-2736(78)90195-5; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHARON N, 1989, LECTINS; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; SMITHRUD DB, 1991, J AM CHEM SOC, V113, P5420, DOI 10.1021/ja00014a038; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPOHR U, 1992, CAN J CHEM, V70, P254, DOI 10.1139/v92-036; STANLEY P, 1977, P NATL ACAD SCI USA, V74, P5056, DOI 10.1073/pnas.74.11.5056; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TYSON BC, 1961, ANAL CHEM, V33, P1640, DOI 10.1021/ac60180a009; WINNIK FM, 1982, CARBOHYD RES, V103, P15, DOI 10.1016/S0008-6215(82)80004-9; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YARIV J, 1968, BIOCHIM BIOPHYS ACTA, V165, P303, DOI 10.1016/0304-4165(68)90063-9; ZIDOVETZKI R, 1988, MOL IMMUNOL, V25, P379, DOI 10.1016/0161-5890(88)90032-6	54	95	96	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22907	22911						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429640				2022-12-27	WOS:A1992JY16300033
J	WOEHLKE, G; LAUSSERMAIR, E; SCHWARZ, E; OESTERHELT, D; REINKE, H; BEYREUTHER, K; DIMROTH, P				WOEHLKE, G; LAUSSERMAIR, E; SCHWARZ, E; OESTERHELT, D; REINKE, H; BEYREUTHER, K; DIMROTH, P			SEQUENCE OF THE BETA-SUBUNIT OF OXALOACETATE DECARBOXYLASE FROM KLEBSIELLA-PNEUMONIAE - A CORRECTION OF THE C-TERMINAL PART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg	WOEHLKE, G (corresponding author), SWISS FED INST TECHNOL,INST MIKROBIOL,CH-8092 ZURICH,SWITZERLAND.			Woehlke, Gunther/0000-0001-8462-9962				DIMROTH P, 1986, METHOD ENZYMOL, V125, P530; LAUSSERMAIR E, 1989, J BIOL CHEM, V264, P14710; Mamur J, 1961, J MOL BIOL, V3, P208; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SCHWARZ E, 1985, EMBO J, V4, P1599, DOI 10.1002/j.1460-2075.1985.tb03823.x; Simmons JS, 1926, J INFECT DIS, V39, P209, DOI 10.1093/infdis/39.3.209; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971	9	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22804	22805						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429628				2022-12-27	WOS:A1992JY16300018
J	BOGAERT, R; TILLER, GE; WEIS, MA; GRUBER, HE; RIMOIN, DL; COHN, DH; EYRE, DR				BOGAERT, R; TILLER, GE; WEIS, MA; GRUBER, HE; RIMOIN, DL; COHN, DH; EYRE, DR			AN AMINO-ACID SUBSTITUTION (GLY853 -] GLU) IN THE COLLAGEN ALPHA-1(II) CHAIN PRODUCES HYPOCHONDROGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II ACHONDROGENESIS-HYPOCHONDROGENESIS; TRIPLE HELICAL DOMAIN; SPONDYLOEPIPHYSEAL DYSPLASIA; OSTEOGENESIS IMPERFECTA; CARTILAGE; GLYCINE; IDENTIFICATION; MUTATIONS; CYSTEINE; CLEAVAGE	The spondyloepiphyseal dysplasia subclassification of bone dysplasias includes achondrogenesis, hypochondrogenesis, and spondyloepiphyseal dysplasia congenita. The phenotypic expression of these disorders ranges from mild to perinatal lethal forms. We report the detection and partial characterization of a defect in type II collagen in a perinatal lethal form of hypochondrogenesis. Electrophoresis in sodium dodecyl sulfate-polyacrylamide of CB peptides (where CB represents cyanogen bromide) from type II collagen of the diseased cartilage showed a doublet band for peptide alpha1(II)CB10 and evidence for post-translational overmodification of the major peptides (CB8, CB10, and CB11) seen as a retarded electrophoretic mobility. Peptide CB10 was digested by endoproteinase Asp-N; and on reverse-phase high pressure liquid chromatography, fragments of abnormal mobility were noted. Sequence analysis of a unique peptide D12 revealed a single amino acid substitution (Gly --> Glu) at position 853 of the triple helical domain. This was confirmed by sequence analysis of amplified COL2A1 cDNA, which revealed a single nucleotide substitution (GGA --> GAA) in 5 of 10 clones. Electron micrographs of the diseased cartilage showed a sparse extracellular matrix and chondrocytes containing dilated rough endoplasmic reticulum, which suggested impaired assembly and secretion of the mutant protein. This case further documents the molecular basis of the spondyloepiphyseal dysplasia spectrum of chondrodysplasias as mutations in COL2A1.	UNIV WASHINGTON,DEPT ORTHOPAED,RK-10,SEATTLE,WA 98195; CEDARS SINAI MED CTR,STEVEN SPIELBERG PEDIAT RES CTR,AHMANSON DEPT PEDIAT,LOS ANGELES,CA 90048; UNIV WASHINGTON,DEPT ORAL BIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	University of Washington; University of Washington Seattle; Cedars Sinai Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036794, R37AR037318, R01AR037318] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37318, R01 AR036794, R37 AR037318] Funding Source: Medline; NICHD NIH HHS [P01 HD22657] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BATEMAN JF, 1986, ANAL BIOCHEM, V154, P338, DOI 10.1016/0003-2697(86)90534-8; BENSON S A, 1984, Biotechniques, V2, P66; BYERS PH, 1988, AM J HUM GENET, V42, P237; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN DH, 1988, J BIOL CHEM, V263, P14605; EYRE D, 1987, METHOD ENZYMOL, V144, P115; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; EYRE DR, 1986, AM J HUM GENET, V39, P52; EYRE DR, 1975, BIOCHEM J, V151, P595, DOI 10.1042/bj1510595; EYRE DR, 1988, PATHOL IMMUNOPATH R, V7, P90, DOI 10.1159/000157101; GODFREY M, 1988, AM J HUM GENET, V43, P894; GODFREY M, 1988, AM J HUM GENET, V43, P904; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; Lachman R S, 1975, Birth Defects Orig Artic Ser, V11, P231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; MURRAY LW, 1988, PATHOL IMMUNOPATH R, V7, P99, DOI 10.1159/000157111; MURRAY LW, 1989, AM J HUM GENET, V45, P5; RIMOIN DL, 1990, PRINCIPLES PRACTICE, P895; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; Spranger J, 1975, Birth Defects Orig Artic Ser, V11, P177; SPRANGER JW, 1970, RADIOLOGY, V94, P313, DOI 10.1148/94.2.313; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; STEGEMANN H, 1958, H-S Z PHYSIOL CHEM, V311, P41, DOI 10.1515/bchm2.1958.311.1.41; TAYBI H, 1990, RADIOLOGY SYNDROMES, P733; TILLER GE, 1990, P NATL ACAD SCI USA, V87, P3889, DOI 10.1073/pnas.87.10.3889; VISSING H, 1989, J BIOL CHEM, V264, P18265	32	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22522	22526						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429602				2022-12-27	WOS:A1992JW71900083
J	EKSTROM, RC; CARNEY, EM; LAMM, MLG; HUNZICKERDUNN, M				EKSTROM, RC; CARNEY, EM; LAMM, MLG; HUNZICKERDUNN, M			REVERSAL OF THE DESENSITIZED STATE OF PIG OVARIAN FOLLICULAR HUMAN CHORIOGONADOTROPIN-SENSITIVE ADENYLYLCYCLASE BY GUANOSINE 5'-O-(2-THIODIPHOSPHATE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; GTP-BINDING PROTEINS; HORMONE LH RECEPTORS; ADENYLATE-CYCLASE; LUTEINIZING-HORMONE; GRANULOSA-CELLS; REGULATORY SITE; LIGAND-BINDING; BOVINE BRAIN	We investigated the stability of the desensitized state of the human choriogonadotropin (hCG)-sensitive adenylylcyclase of the pig ovarian follicle. A 20,000 x g membrane preparation of pig follicular membranes was incubated under conditions which resulted in the hormone-induced desensitization of the hCG-responsive adenylylcyclase. The desensitized state was maintained upon subsequent incubation of the membranes with GTP, GDP, GMP, ATP, ADP, AMP, CTP, UTP, adenyl-5'-yl imidodiphosphate (AMP-P(NH)P), and adenyl (beta,gamma-methylene)-diphosphonate (AMP-P(CH2)P); however, the desensitized state was reverted to a fully active state upon incubation with guanosine 5'-O-(2-thiodiphosphate) (GDPbetaS) and guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). The reversal effect of GDPbetaS on hCG-responsive adenylylcyclase activity was time- and temperature-dependent, and showed a selectivity for GDPbetaS over adenosine 5'-O-(2-thiodiphosphate) (ADPbetaS) (half-maximal effective dose of 12 muM versus 260 muM, respectively). GDPbetaS had no effect on the binding affinity or apparent number of luteinizing hormone (LH)/CG receptors or on the dissociation rate of I-125-hCG from the receptor. GDPbetaS promoted an hCG- and time-dependent release of guanine nucleotides from the membranes. A model is proposed which accounts for the unique characteristics of LH/CG-sensitive adenylylcyclase desensitization and subsequent reactivation by GDPbetaS.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University								ABRAMOWITZ J, 1982, ENDOCRINOLOGY, V111, P970, DOI 10.1210/endo-111-3-970; AMIRZALTSMAN Y, 1980, ENDOCRINOLOGY, V106, P1166, DOI 10.1210/endo-106-4-1166; AMSTERDAM A, 1980, P NATL ACAD SCI-BIOL, V77, P3440, DOI 10.1073/pnas.77.6.3440; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BRANDT DR, 1985, J BIOL CHEM, V260, P266; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1990, ENDOCRINOLOGY, V127, P2578, DOI 10.1210/endo-127-5-2578; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; EZRA E, 1980, J BIOL CHEM, V255, P653; EZRA E, 1981, J BIOL CHEM, V256, P5377; GOSPODAROWICZ D, 1973, J BIOL CHEM, V248, P5042; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUHTANIEMI IT, 1981, ENDOCRINOLOGY, V108, P1931, DOI 10.1210/endo-108-5-1931; HUNZICKERDUNN M, 1981, BIOL REPROD, V24, P279, DOI 10.1095/biolreprod24.2.279; HUNZICKERDUNN M, 1981, ENDOCRINOLOGY, V109, P345, DOI 10.1210/endo-109-2-345; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P185, DOI 10.1210/endo-99-1-185; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P198, DOI 10.1210/endo-99-1-198; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LAMPRECHT SA, 1977, J CYCLIC NUCL PROT, V3, P69; LAMPRECHT SA, 1973, J ENDOCRINOL, V57, P217, DOI 10.1677/joe.0.0570217; LAPOLT PS, 1990, ENDOCRINOLOGY, V126, P3277, DOI 10.1210/endo-126-6-3277; LEE CY, 1973, BIOCHEMISTRY-US, V12, P4609, DOI 10.1021/bi00747a011; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MARSH JM, 1973, BIOCHIM BIOPHYS ACTA, V304, P197, DOI 10.1016/0304-4165(73)90128-1; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAMBI P, 1985, J BIOL CHEM, V260, P2165; NAMBI P, 1984, J BIOL CHEM, V259, P4629; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; RASENICK MM, 1989, BRAIN RES, V488, P105, DOI 10.1016/0006-8993(89)90698-7; Rodbell M, 1975, Adv Cyclic Nucleotide Res, V5, P3; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SCHWALL RH, 1984, ENDOCRINOLOGY, V114, P1114, DOI 10.1210/endo-114-4-1114; SEGALOFF DL, 1981, ENDOCRINOLOGY, V108, P632, DOI 10.1210/endo-108-2-632; SIBLEY DR, 1988, ENDOCR REV, V9, P38, DOI 10.1210/edrv-9-1-38; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZOR U, 1976, BIOCHIM BIOPHYS ACTA, V428, P761, DOI 10.1016/0304-4165(76)90206-3	53	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22183	22189						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429569				2022-12-27	WOS:A1992JW71900032
J	MUKAI, K; ITOH, S; MORIMOTO, H				MUKAI, K; ITOH, S; MORIMOTO, H			STOPPED-FLOW KINETIC-STUDY OF VITAMIN-E REGENERATION REACTION WITH BIOLOGICAL HYDROQUINONES (REDUCED FORMS OF UBIQUINONE, VITAMIN-K, AND TOCOPHEROLQUINONE) IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; LIPID-PEROXIDATION; ANTIOXIDANT ACTIVITY; ALPHA-TOCOPHEROL; MITOCHONDRIA; CHAIN; RESONANCE; RADICALS; HOMOLOGS; TISSUES	A kinetic study of the regeneration reaction of vitamin E (tocopherol) with eight biological hydroquinones (HQs) (ubiquinol-10 (Q10H-2 1); ubiquinol-0 (Q0H-2 2); vitamin K1 HQ (VK1H2 3); vitamin K3 HQ (VK3H2 4); alpha-, beta-, gamma-tocopherol-HQs (alpha-, beta-, and gamma-TQH-2 5-7); and 2,3,5-trimethyl-1,4-HQ (TMQH-2 8)) in solution was performed. The second-order rate constants (k4) for the reaction of HQs 1-8 with alpha-tocopheroxyl and 5,7-diisopropyltocopheroxyl radicals in ethanol, benzene, and isopropyl alcohol/water (5:1, v/v) solutions were measured with a stopped-flow spectrophotometer. The order of magnitude of k4 values obtained for HQs is VK1H2 > VK3H2 > alpha-TQH-2 > beta-TQH-2 is similar to gamma-TQH-2 is similar to TMQH-2 > Q10H-2 > Q0H-2, being independent of the kinds of tocopheroxyl radicals and the polarity of the solvents. The log of the k4 values obtained for HQs was found to correlate with their peak oxidation potentials. Comparing the k2 value (2.68 x 10(6) m-1 s-1 obtained for the reaction of alpha-tocopheroxyl with vitamin C (sodium ascorbate) with those (k4 = 2.54 x 10(5) and 8.15 x 10(5) m-1 s-1) obtained for the reaction of alpha-tocopheroxyl with Q10H-2 and alpha-TQH-2 in isopropyl alcohol/water mixtures, the former is approximately 11 and 3 times as reactive as the latter, respectively. On the other hand, the k2 value obtained for sodium ascorbate is smaller than the k4 values obtained for VK1H2 and VK3H2. These results suggest that mixtures of vitamin E and these HQs (as well as those of vitamins E and C) may function synergistically as antioxidants in various tissues and mitochondria.			MUKAI, K (corresponding author), EHIME UNIV, FAC SCI, DEPT CHEM, BUNKYO CHO 2-5, MATSUYAMA, EHIME 790, JAPAN.							BEYER RE, 1986, BIOMEDICAL CLIN ASPE, V5, P17; BOOTH RFG, 1982, BIOCHEM INT, V5, P151; BURLAKOVA YB, 1979, BIOPHYSICS-USSR, V24, P989; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; IKENOYA S, 1981, CHEM PHARM BULL, V29, P158; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; KAGAN VE, 1990, FREE RADICAL BIO MED, V9, P117, DOI 10.1016/0891-5849(90)90114-X; KATAYAMA K, 1980, BIOCHEM BIOPH RES CO, V95, P971, DOI 10.1016/0006-291X(80)91568-5; MARUBAYASHI S, 1984, BIOCHIM BIOPHYS ACTA, V797, P1; MELLORS A, 1966, J BIOL CHEM, V241, P4353; MUKAI K, 1990, BIOCHIM BIOPHYS ACTA, V1035, P77, DOI 10.1016/0304-4165(90)90176-W; MUKAI K, 1989, J ORG CHEM, V54, P552, DOI 10.1021/jo00264a010; MUKAI K, 1982, CHEM PHYS LIPIDS, V30, P337, DOI 10.1016/0009-3084(82)90027-5; MUKAI K, 1986, B CHEM SOC JPN, V59, P3113, DOI 10.1246/bcsj.59.3113; MUKAI K, 1991, J BIOL CHEM, V266, P274; NAUMOV VV, 1983, BIOFIZIKA+, V28, P730; NIKI E, 1984, J BIOL CHEM, V259, P4177; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; OKAMOTO T, 1988, J CHROMATOGR-BIOMED, V430, P11, DOI 10.1016/S0378-4347(00)83129-1; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; RIEKER A, 1965, LIEBIGS ANN CHEM, V689, P78; ROBESON CD, 1962, J AM CHEM SOC, V84, P3196, DOI 10.1021/ja00875a040; SCARPA M, 1984, BIOCHIM BIOPHYS ACTA, V801, P215, DOI 10.1016/0304-4165(84)90070-9; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; SUGINO K, 1987, SURGERY, V101, P746; SUGINO K, 1989, SURGERY, V105, P200; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; TAKESHIGE K, 1980, BIOMEDICAL CLIN ASPE, V2, P15; YAMADA I, 1990, SOIL SCI PLANT NUTR, V36, P505, DOI 10.1080/00380768.1990.10416920	31	111	119	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22277	22281						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429580				2022-12-27	WOS:A1992JW71900046
J	YAMAGUCHI, M; MICHISHITA, M; HIRAYOSHI, K; YASUKAWA, K; OKUMA, M; NAGATA, K				YAMAGUCHI, M; MICHISHITA, M; HIRAYOSHI, K; YASUKAWA, K; OKUMA, M; NAGATA, K			DOWN-REGULATION OF INTERLEUKIN-6 RECEPTORS OF MOUSE MYELOMONOCYTIC LEUKEMIC-CELLS BY LEUKEMIA INHIBITORY FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NECROSIS-FACTOR RECEPTORS; GROWTH-FACTOR RECEPTORS; IL-6 SIGNAL TRANSDUCER; HIGH-AFFINITY; T-CELLS; GM-CSF; NEURONAL DIFFERENTIATION; MOLECULAR-CLONING; MURINE IL-6	We examined the effect of leukemia inhibitory factor (LIF) on the expression of interleukin 6 receptors (IL-6R) on mouse myelomonocytic leukemic M1 cells. Binding studies using I-125-labeled human and murine IL-6 revealed that LIF caused a decrease in IL-6 binding to M1 cells. The decrease became evident within 1 h, and the maximum decrease was observed at 3-6 h. Scatchard plot analysis revealed that M1 cells had a single class of high affinity receptors for IL-6 and that LIF-induced decrease in IL-6 binding was due to a decrease in the number of IL-6R on the cell surface and not to changes in their affinity. The affinity of IL-6R on M1 cells to human IL-6 (K(d) = 2.25 nM) was about 10-fold lower than that to murine IL-6 (K(d) = 200 pM). The amount of IL-6 secreted into culture media by M1 cells that were treated with LIF for up to 12 h was not enough to cause receptor down-regulation. Northern blot analysis demonstrated that IL-6R mRNA was down-regulated by LIF treatment, and similar regulation was also observed when the cells were treated with IL-6. The time course of the IL-6R mRNA level was similar to that of IL-6R expression on the cell surface, suggesting that the main mechanism responsible for the loss of high affinity IL-6R was the regulation of IL-6R mRNA. Although the half-life of IL-6R on the cell surface was about 30 min, the addition of LIF reduced it to 16 min, suggesting the existence of an additional mechanism responsible for the loss of high affinity IL-6R on the cell surface.	KYOTO UNIV,DEPT CELL BIOL,CHEST DIS RES INST,KYOTO 606,JAPAN; KYOTO UNIV,DIV INTERNAL MED 1,KYOTO 606,JAPAN; TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA 252,JAPAN	Kyoto University; Kyoto University; Tosoh Corporation								ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537; BAUMANN H, 1989, J BIOL CHEM, V264, P8046; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CARMICHAEL J, 1987, CANCER RES, V47, P936; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; DANLEY DE, 1991, FEBS LETT, V283, P135, DOI 10.1016/0014-5793(91)80571-J; FERNANDEZBOTRAN R, 1989, J EXP MED, V169, P379, DOI 10.1084/jem.169.2.379; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; HENSCHLER R, 1991, FEBS LETT, V283, P47, DOI 10.1016/0014-5793(91)80550-M; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HIRAYOSHI K, 1991, FEBS LETT, V282, P401, DOI 10.1016/0014-5793(91)80523-6; HORII Y, 1988, J IMMUNOL, V141, P1529; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LEARY AG, 1990, BLOOD, V75, P1960; LOTEM J, 1988, BLOOD, V72, P1595; LOTEM J, 1989, LEUKEMIA, V3, P804; LOTEM J, 1975, INT J CANCER, V15, P731, DOI 10.1002/ijc.2910150504; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1985, LEUKEMIA RES, V9, P35, DOI 10.1016/0145-2126(85)90020-7; METCALF D, 1989, LEUKEMIA, V3, P349; MICHISHITA M, 1990, J BIOL CHEM, V265, P8751; MIYAURA C, 1989, BIOCHEM BIOPH RES CO, V158, P660, DOI 10.1016/0006-291X(89)92772-1; NABHOLZ M, 1987, EUR J IMMUNOL, V17, P783, DOI 10.1002/eji.1830170608; NAGATA K, 1979, J CELL PHYSIOL, V98, P167, DOI 10.1002/jcp.1040980118; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; PARK LS, 1989, J BIOL CHEM, V264, P5420; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; ROBB RJ, 1987, J IMMUNOL, V139, P855; SAITO T, 1991, J IMMUNOL, V147, P168; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SHABO Y, 1988, BLOOD, V72, P2070; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMIDA M, 1986, FEBS LETT, V207, P271, DOI 10.1016/0014-5793(86)81503-4; TOMIDA M, 1984, J BIOL CHEM, V259, P978; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VINK A, 1988, EUR J IMMUNOL, V18, P607, DOI 10.1002/eji.1830180418; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WATANABE N, 1988, J BIOL CHEM, V263, P10262; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	60	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22035	22042						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429553				2022-12-27	WOS:A1992JW71900011
J	COLL, RJ; MURPHY, AJ				COLL, RJ; MURPHY, AJ			FLUORIDE-INHIBITED CALCIUM ATPASE OF SARCOPLASMIC-RETICULUM - MAGNESIUM AND FLUORIDE STOICHIOMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; REACTION-MECHANISM; FLUORESCENCE MEASUREMENTS; BINDING-SITES; CAATPASE; CA-2+-ATPASE; AFFINITY; PHOSPHORYLATION; PUMP	The sarcoplasmic reticulum (SR) CaATPase is inactivated by fluoride in the presence of magnesium (Murphy, A. J., and Coll, R. J. (1992) J. Biol. Chem. 267, 5229-5235). The inactive complex is very stable and can be isolated free of other components by 48 h of dialysis at 4-degrees-C (Murphy, A. J., and Coll, R. J. (1992) J. Biol. Chem. 267, 16990-16994). In this study, we used a fluoride-specific electrode to determine that the amount of tightly bound fluoride in the complex was 9.4 +/- 2 nmol mg-1 SR protein. The rate constant of inactivation was very similar to the rate constant of fluoride incorporation and varied directly as the square of the fluoride concentration. Luminal Ca2+ accelerated reactivation of the inhibited enzyme, and the rate constants of activity regain and fluoride release were very similar. Although required for inhibition, added magnesium did not accelerate reactivation. Analysis for magnesium using antipyrylazo III of the inhibited enzyme showed 4.1 +/- 0.4 nmol mg-1 SR protein. As there is much evidence in the literature supportive of an estimate of calcium pumps equal to approximately 4-5 nmol mg-1 SR protein, our results indicate that each inhibited enzyme contains two tightly bound fluorides and one tightly bound magnesium.			COLL, RJ (corresponding author), UNIV PACIFIC, SCH DENT, DEPT BIOCHEM, SAN FRANCISCO, CA 94115 USA.				NIGMS NIH HHS [GM31083] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031083] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; ANDERSON KW, 1983, J BIOL CHEM, V258, P4276; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; COLL RJ, 1984, J BIOL CHEM, V259, P4249; COLL RJ, 1986, BIOCHEM BIOPH RES CO, V138, P652, DOI 10.1016/S0006-291X(86)80546-0; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; GARRAHAN PJ, 1976, BIOCHIM BIOPHYS ACTA, V448, P121, DOI 10.1016/0005-2736(76)90081-X; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; HIGHSMITH S, 1984, BIOCHEM BIOPH RES CO, V124, P183, DOI 10.1016/0006-291X(84)90934-3; HIGHSMITH S, 1984, J BIOL CHEM, V259, P4651; INESI G, 1984, J BIOL CHEM, V259, P996; INESI G, 1992, ADV ENZYMOL RELAT AR, V65, P185; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY AJ, 1992, J BIOL CHEM, V267, P16995; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MURPHY AJ, 1990, BIOCHEMISTRY-US, V29, P11236, DOI 10.1021/bi00503a012; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; MYUNG J, 1991, FEBS LETT, V278, P35, DOI 10.1016/0014-5793(91)80077-G; PANG DC, 1977, J BIOL CHEM, V252, P3262; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; TAKAKUWA Y, 1982, J BIOL CHEM, V257, P426; TAKISAWA H, 1978, J BIOCHEM-TOKYO, V83, P1275, DOI 10.1093/oxfordjournals.jbchem.a132034; YAMADA S, 1980, J BIOL CHEM, V255, P3108	35	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21584	21587						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400469				2022-12-27	WOS:A1992JV01100051
J	SCHULTZ, JR; GONG, EL; MCCALL, MR; NICHOLS, AV; CLIFT, SM; RUBIN, EM				SCHULTZ, JR; GONG, EL; MCCALL, MR; NICHOLS, AV; CLIFT, SM; RUBIN, EM			EXPRESSION OF HUMAN APOLIPOPROTEIN-A-II AND ITS EFFECT ON HIGH-DENSITY-LIPOPROTEINS IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; HEPATIC TRIGLYCERIDE LIPASE; PARTICLE-SIZE DISTRIBUTION; ISCHEMIC HEART-DISEASE; CHOLESTEROL-ACYLTRANSFERASE; STRUCTURAL ORGANIZATION; NUCLEOTIDE-SEQUENCE; GEL-ELECTROPHORESIS; ACID SEQUENCE; MESSENGER-RNA	Apolipoproteins A-I and A-II comprise approximately 70 and 20%, respectively, of the total protein content of HDL. Evidence suggests that apoA-I plays a central role in determining the structure and plasma concentration of HDL, while the role of apoA-II is uncertain. To help define the function of apoA-II and determine what effect increasing its plasma concentration has on HDL, transgenic mice expressing human apoA-II and both human apoA-I and human apoA-II were produced. Human apoA-II mRNA is expressed exclusively in the livers of transgenic animals, and the protein exists as a dimer as it does in humans. High level expression of human apoA-II did not increase HDL concentrations or decrease plasma concentrations of murine apoA-I and apoA-II in contrast to what was observed in mice overexpressing human apoA-I. The primary effect of overexpressing human apoA-II was the appearance of small HDL particles composed exclusively of human apoA-II. HDL from mice transgenic for both human apoA-I and human apoA-II displayed a unique size distribution when compared with either apoA-I or apoA-II transgenic mice and contain particles with both these human apolipoproteins. These results in mice, indicating that human apoA-II participates in determining HDL size, parallel results from human studies.	LAWRENCE BERKELEY LAB, DIV LIFE SCI, 1 CYCLOTRON RD, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574, R01HL046281] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL46281, HL18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], CURR OPIN LIPIDOL; ASSMANN G, 1977, J CLIN INVEST, V60, P242, DOI 10.1172/JCI108761; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1991, J LIPID RES, V32, P383; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEEB SS, 1991, J BIOL CHEM, V266, P13654; DEEB SS, 1990, AM J HUM GENET, V46, P822; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; EDELSTEIN C, 1976, BIOCHEMISTRY-US, V15, P1262, DOI 10.1021/bi00651a014; EGGERMAN TL, 1991, J LIPID RES, V32, P821; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FIELDING CJ, 1982, MED CLIN N AM, V66, P363, DOI 10.1016/S0025-7125(16)31425-0; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HOGAN B, 1986, MANIPULATING MOUSE E; HWANG JL, 1985, J BIOL CHEM, V260, P5660; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KNOTT TJ, 1985, NUCLEIC ACIDS RES, V13, P6387, DOI 10.1093/nar/13.17.6387; KUBO M, 1982, J BIOCHEM, V92, P865, DOI 10.1093/oxfordjournals.jbchem.a134000; LACKNER KJ, 1984, BIOCHEM BIOPH RES CO, V122, P877, DOI 10.1016/0006-291X(84)91172-0; LACKNER KJ, 1985, NUCLEIC ACIDS RES, V13, P4597, DOI 10.1093/nar/13.12.4597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSIS AJ, 1983, J BIOL CHEM, V258, P5071; Maniatis T., 1982, MOL CLONING; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MOORE MN, 1984, BIOCHEM BIOPH RES CO, V123, P1, DOI 10.1016/0006-291X(84)90371-1; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NICHOLS AV, 1987, J LIPID RES, V28, P719; NICOLOSI RJ, 1984, J LIPID RES, V25, P879; NOMA A, 1983, ATHEROSCLEROSIS, V37, P157; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCANU AM, 1982, CRC CR REV BIOCH MOL, V13, P109, DOI 10.3109/10409238209108711; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAELS B, 1990, ENDOCRINOLOGY, V127, P1144, DOI 10.1210/endo-127-3-1144; STAELS B, 1989, J LIPID RES, V30, P1137; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STOFFEL W, 1983, H-S Z PHYSIOL CHEM, V364, P227, DOI 10.1515/bchm2.1983.364.1.227; TSAO YK, 1985, J BIOL CHEM, V260, P5222; WALSH A, 1989, J BIOL CHEM, V264, P6488	55	98	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21630	21636						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400473				2022-12-27	WOS:A1992JV01100059
J	KAZANIETZ, MG; KRAUSZ, KW; BLUMBERG, PM				KAZANIETZ, MG; KRAUSZ, KW; BLUMBERG, PM			DIFFERENTIAL IRREVERSIBLE INSERTION OF PROTEIN-KINASE-C INTO PHOSPHOLIPID-VESICLES BY PHORBOL ESTERS AND RELATED ACTIVATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE-BRAIN CYTOSOL; TUMOR-PROMOTING ACTIVITIES; 6TH RHOADS MEMORIAL; 12,13-DIBUTYRATE BINDING; 12-MYRISTATE 13-ACETATE; CELLULAR-REGULATION; SYNTHETIC ANALOGS; RAT-BRAIN; MEMBRANE; RECEPTOR	Incubation of protein kinase C (PKC) alpha with phorbol 12,13-dibutyrate and phospholipid vesicles promoted a time-dependent irreversible insertion of the enzyme into the vesicles and the generation of a calcium-independent kinase activity. Calcium neither caused insertion nor influenced the insertion induced by the phorbol ester. The effect was strongly dependent on the phosphatidylserine concentration in the vesicle and could also be supported by other anionic phospholipids. An analysis of the structure-activity relations of PKC activators for the calcium-independent kinase activity revealed marked relative differences in potencies for binding and for insertion. Compounds such as phorbol 13-myristate 12-acetate and mezerein were very efficient at inducing insertion. In contrast, 12-deoxyphorbol esters and diacylglycerol were relatively inefficient at inducing insertion, requiring higher concentrations than expected from their binding affinities. The insertion of PKC alpha depended substantially on the length of the aliphatic esters in the 12- and 13-positions of the phorbol derivatives, and once again, potencies for insertion and binding were not directly proportional. Our findings suggest two different sites for ligand interaction on the molecule of PKC alpha with different structure-activity requirements. We speculate that the differential ability of compounds to promote insertion could contribute to the documented marked differences in the biological behavior of PKC activators.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1988, BIOCHEM BIOPH RES CO, V152, P336, DOI 10.1016/S0006-291X(88)80719-8; BAZZI MD, 1987, BIOCHEM BIOPH RES CO, V146, P203, DOI 10.1016/0006-291X(87)90711-X; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOREK C, 1991, P NATL ACAD SCI USA, V88, P1953, DOI 10.1073/pnas.88.5.1953; BUDAY L, 1990, FEBS LETT, V276, P223, DOI 10.1016/0014-5793(90)80547-V; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DEVRIES DJ, 1988, BIOCHEM PHARMACOL, V37, P4069, DOI 10.1016/0006-2952(88)90097-4; DRUST DS, 1985, BIOCHEM BIOPH RES CO, V128, P531, DOI 10.1016/0006-291X(85)90079-8; FUJIKI H, 1985, P JPN ACAD B-PHYS, V61, P45, DOI 10.2183/pjab.61.45; FUJIKI H, 1984, GANN, V75, P866; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HERGENHAHN M, 1982, J CANCER RES CLIN, V104, P31, DOI 10.1007/BF00402051; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; Irie K., 1988, MEM COLL AGR KYOTO U, V132, P1; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KONIG B, 1985, J CELL BIOCHEM, V27, P255, DOI 10.1002/jcb.240270307; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEACH KL, 1985, CANCER RES, V45, P1958; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MORIN MJ, 1987, J BIOL CHEM, V262, P11758; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1989, ANNU REV BIOCHEM, V58, P31; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; SHARKEY NA, 1989, CARCINOGENESIS, V10, P1937; SHARKEY NA, 1985, CANCER RES, V45, P19; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SZALLASI Z, 1991, CANCER RES, V51, P5355; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; Yeh E, 1987, PHYTOTHER RES, V1, P135	44	94	95	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20878	20886						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400402				2022-12-27	WOS:A1992JT97800058
J	LIUKKONEN, J; HAATAJA, S; TIKKANEN, K; KELM, S; FINNE, J				LIUKKONEN, J; HAATAJA, S; TIKKANEN, K; KELM, S; FINNE, J			IDENTIFICATION OF N-ACETYLNEURAMINYL ALPHA-2-]3 POLY-N-ACETYLLACTOSAMINE GLYCANS AS THE RECEPTORS OF SIALIC ACID-BINDING STREPTOCOCCUS-SUIS STRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; BLOOD-GROUP ACTIVITIES; ESCHERICHIA-COLI; MYCOPLASMA-PNEUMONIAE; POLYACRYLAMIDE GELS; ADHESION RECEPTORS; SUGAR CHAINS; OLIGOSACCHARIDES; GLYCOSPHINGOLIPIDS; GLYCOPROTEINS	Streptococcus suis is a common cause of sepsis, meningitis, and other serious infections in young piglets and also causes meningitis in humans. The cell-binding specificity of sialic acid-recognizing strains of Streptococcus suis was investigated. Treatment of human erythrocytes with sialidase or mild periodate abolished hemagglutination. Hemagglutination inhibition experiments with sialyl oligosaccharides indicated that the adhesin preferred the sequence NeuN Acalpha2-3Galbeta1-4Glc(NAc). Resialylation of desialylated erythrocytes with Galbeta1-3(4)GlcNAc alpha2-3-sialyltransferase induced a strong hemagglutination, whereas no or only weak hemagglutination was obtained with cells resialylated with two other sialyltransferases. Binding of radiolabeled bacteria to blots of erythrocyte membrane proteins revealed binding to the poly-N-acetyllactosamine-containing components Band 3, Band 4.5, and polyglycosyl ceramides and to glycophorin A. The involvement of glycophorin A as a major ligand was excluded by the strong hemagglutination of trypsin-treated erythrocytes and En(a-) erythrocytes defective in glycophorin A. Sensitivity of the hemagglutination toward endo-beta-galactosidase treatment of erythrocytes and inhibition by purified poly-N-acetyllactosaminyl glycopeptides indicated that the adhesin bound to glycans containing the following structure: NeuNAcalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-	UNIV TURKU, DEPT MED BIOCHEM, KIINAMYLLNKATU 10, SF-20520 TURKU 52, FINLAND; UNIV KUOPIO, DEPT BIOCHEM & BIOTECHNOL, SF-70211 KUOPIO, FINLAND; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV KIEL, INST BIOCHEM, W-2300 KIEL 1, GERMANY	University of Turku; University of Eastern Finland; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Kiel			Haataja, Sauli/AAR-5103-2020; Kelm, Soerge/C-5403-2013; Finne, Jukka/B-6881-2008	Kelm, Soerge/0000-0001-5277-9421; Finne, Jukka/0000-0002-8076-3344				BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BRENNAN MJ, 1991, J BIOL CHEM, V266, P18827; DEAL CD, 1990, J BIOL CHEM, V265, P12774; DZANDU JK, 1985, BIOCHEM BIOPH RES CO, V126, P50, DOI 10.1016/0006-291X(85)90569-8; EVANS DG, 1988, INFECT IMMUN, V56, P2896, DOI 10.1128/IAI.56.11.2896-2906.1988; FINNE J, 1980, REV FR TRANSFUS IMMU, V23, P545, DOI 10.1016/S0338-4535(80)80158-9; FINNE J, 1980, EUR J BIOCHEM, V104, P181, DOI 10.1111/j.1432-1033.1980.tb04414.x; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FIRON N, 1982, BIOCHEM BIOPH RES CO, V105, P1426, DOI 10.1016/0006-291X(82)90947-0; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GAHMBERG CG, 1976, J BIOL CHEM, V251, P6108; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; ISHIKAWA H, 1987, INFECT IMMUN, V55, P1607, DOI 10.1128/IAI.55.7.1607-1609.1987; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KORHONEN TK, 1985, ENTEROBACTERIAL SURF, P301; Koscielak J, 1978, Methods Enzymol, V50, P211; KOSCIELAK J, 1976, EUR J BIOCHEM, V71, P9, DOI 10.1111/j.1432-1033.1976.tb11083.x; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KRUSIUS T, 1978, EUR J BIOCHEM, V92, P289, DOI 10.1111/j.1432-1033.1978.tb12747.x; KURL DN, 1989, INFECT IMMUN, V57, P384, DOI 10.1128/IAI.57.2.384-389.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE N, 1990, J BIOL CHEM, V265, P20476; LINDSTEDT R, 1991, INFECT IMMUN, V59, P1086, DOI 10.1128/IAI.59.3.1086-1092.1991; LOOMES LM, 1984, NATURE, V307, P560, DOI 10.1038/307560a0; MORELL AG, 1972, METHODS ENZYMOLOGY B, V28, P205; MOTOYOSHI F, 1990, CLIN IMMUNOL IMMUNOP, V54, P495, DOI 10.1016/0090-1229(90)90061-T; MOURICOUT M, 1990, INFECT IMMUN, V58, P98, DOI 10.1128/IAI.58.1.98-106.1990; MURAMATSU T, 1988, BIOCHIMIE, V70, P1587, DOI 10.1016/0300-9084(88)90294-5; MURRAY PA, 1982, BIOCHEM BIOPH RES CO, V106, P390, DOI 10.1016/0006-291X(82)91122-6; NIKKILA EA, 1960, SCAND J CLIN LAB INV, V12, P209, DOI 10.3109/00365516009062424; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; PARKKINEN J, 1991, THROMB HAEMOSTASIS, V65, P483; PARKKINEN J, 1988, J CLIN INVEST, V81, P860, DOI 10.1172/JCI113395; PARKKINEN J, 1987, METHOD ENZYMOL, V138, P289, DOI 10.1016/0076-6879(87)38024-3; PAULSON JC, 1987, METHOD ENZYMOL, V138, P162; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; SMIT H, 1984, INFECT IMMUN, V46, P578, DOI 10.1128/IAI.46.2.578-584.1984; STROMBERG N, 1990, J BIOL CHEM, V265, P11251; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAISANENRHEN V, 1983, FEBS LETT, V159, P233, DOI 10.1016/0014-5793(83)80453-0; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WINDSOR RS, 1977, VET REC, V101, P378, DOI 10.1136/vr.101.19.378; YAMASHITA Y, 1989, MOL IMMUNOL, V26, P905; ZANEN HC, 1979, PATHOGENIC STREPTOCO, P232; ZHU BCR, 1985, J BIOL CHEM, V260, P4041	50	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21105	21111						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400420				2022-12-27	WOS:A1992JT97800092
J	NUGENT, MA; EDELMAN, ER				NUGENT, MA; EDELMAN, ER			TRANSFORMING GROWTH-FACTOR BETA-1 STIMULATES THE PRODUCTION OF BASIC FIBROBLAST GROWTH-FACTOR BINDING PROTEOGLYCANS IN BALB/C3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR PRODUCTION; HEPARAN-SULFATE PROTEOGLYCAN; CAPILLARY ENDOTHELIAL-CELLS; HIGH-AFFINITY RECEPTORS; SMOOTH-MUSCLE CELLS; TGF-BETA; PROTEOLYTIC DEGRADATION; SURFACE PROTEOGLYCAN; ANGIOGENIC PROTEIN	Basic fibroblast growth factor (bFGF) binds to cell surface receptors and to heparan sulfate proteoglycans. Heparan sulfate binding may limit bFGF degradation and be an obligatory step for bFGF cell interaction. Transforming growth factor-beta1 (TGF-beta1) is a potent regulator of proteoglycan production and composition. The possibility that TGF-beta1 synergistically regulates bFGF activity by altering bFGF-proteoglycan interactions was investigated. TGF-beta1 increased I-125-bFGF binding to the extracellular matrix (ECM) of Balb/c3T3 cells 2-4-fold by increasing the number of bFGF binding sites. Increased bFGF binding correlated with a 2-5-fold increase in the production of sulfated proteoglycans, including heparan sulfate proteoglycans. TGF-beta1 selectively stimulated production of high molecular mass proteoglycans (190-300 kDa) in conditioned medium and stimulated all proteoglycans in ECM. I-125-bFGF bound to TGF-beta1 induced proteoglycans immobilized onto cationic nylon filters. Furthermore, ECM isolated from TGF-beta1-treated cells incorporated more mitogenically active bFGF than native ECM. The mitogenic potential of the ECM was significantly reduced by treatment with heparinase. These results suggest that the ability of TGF-beta1 to stimulate binding of bFGF to ECM, increase ECM heparan sulfate proteoglycan, and potentiate the mitogenic activity of bFGF are linked. Thus one aspect of TGF-beta1/bFGF synergy may involve modulation of the ECM.	HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Nugent, Matthew/0000-0002-8630-4712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER; NIA NIH HHS [K12 AG00294] Funding Source: Medline; NIGMS NIH HHS [F32 GM14003] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; ASSOIAN RK, 1985, J BIOL CHEM, V260, P9613; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BIKFALVI A, 1989, EXP CELL RES, V181, P75, DOI 10.1016/0014-4827(89)90183-3; BRADSHAW RA, 1990, PEPTIDE GROWTH FACTO, V1, P17; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DODGE GR, 1990, J BIOL CHEM, V265, P18023; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; FENG P, 1986, J BIOL CHEM, V261, P14167; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1439; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HIRAKI Y, 1988, BIOCHIM BIOPHYS ACTA, V969, P91, DOI 10.1016/0167-4889(88)90092-4; HORTON WE, 1989, J CELL PHYSIOL, V141, P8, DOI 10.1002/jcp.1041410103; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INOUE H, 1989, J CELL PHYSIOL, V138, P329, DOI 10.1002/jcp.1041380216; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Linker A., 1972, METHODS ENZYMOL, P902; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MASSAGUE J, 1985, J CELL BIOL, V100, P1508, DOI 10.1083/jcb.100.5.1508; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOENNER M, 1986, P NATL ACAD SCI USA, V83, P5024, DOI 10.1073/pnas.83.14.5024; MORALES TI, 1988, J BIOL CHEM, V263, P12828; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NUGENT MA, 1989, CANCER RES, V49, P3884; NUGENT MA, 1989, J BIOL CHEM, V264, P18060; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PLOUET J, 1989, J CELL PHYSIOL, V141, P392, DOI 10.1002/jcp.1041410221; RAPRAEGER A, 1989, ANAL BIOCHEM, V179, P361, DOI 10.1016/0003-2697(89)90145-0; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RASMUSSEN S, 1988, J CELL BIOL, V107, P1959, DOI 10.1083/jcb.107.5.1959; REDINI F, 1988, FEBS LETT, V234, P172, DOI 10.1016/0014-5793(88)81327-9; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V1, P3; TAKAHARA K, 1987, CELL, V49, P415; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANG VC, 1985, J BIOL CHEM, V260, P1849; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; [No title captured]	68	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21256	21264						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400436				2022-12-27	WOS:A1992JT97800115
J	GARRETT, KP; SERIZAWA, H; HANLEY, JP; BRADSHER, JN; TSUBOI, A; ARAI, N; YOKOTA, T; ARAI, K; CONAWAY, RC; CONAWAY, JW				GARRETT, KP; SERIZAWA, H; HANLEY, JP; BRADSHER, JN; TSUBOI, A; ARAI, N; YOKOTA, T; ARAI, K; CONAWAY, RC; CONAWAY, JW			THE CARBOXYL TERMINUS OF RAP30 IS SIMILAR IN SEQUENCE TO REGION-4 OF BACTERIAL SIGMA FACTORS AND IS REQUIRED FOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; ESCHERICHIA-COLI SIGMA-70; TRANSCRIPTION FACTOR-IIF; PREINITIATION COMPLEX; FACTOR-EPSILON; FACTOR-TAU; INITIATION; PROTEINS; SUBUNIT; DNA	Transcription factor betagamma(RAP30/74) from rat liver was previously shown in biochemical studies to control the binding of RNA polymerase II to promoters by a mechanism analogous to that utilized by bacterial sigma factors, by decreasing the affinity of polymerase for nonpromoter sites on DNA and by increasing the affinity of the enzyme for the preinitiation complex (Conaway, R. C., Garrett, K. P., Hanley, J. P., and Conaway, J. W. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6205-6209). By constructing and analyzing mutants of betagamma, we have identified a novel functional domain located in the carboxyl terminus of the gamma(RAP30) subunit. This domain shares sequence similarity with region 4 of bacterial sigma factors; in particular, it exhibits striking similarity to the carboxyl-terminal regions 4.1 and 4.2 of SpoIIIC (Bacillus subtilis sigma(k)). Evidence from biochemical studies argues that a mutant gamma(RAP30), lacking amino acid sequences similar to sigma homology region 4.2, is able to assemble with the beta(RAP74) subunit to form a mutant betagamma(RAP30/74) with impaired ability to interact with RNA polymerase II.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; DNAX RES INST MOLEC & CELLULAR BIOL INC,MOLEC & CELLULAR BIOL RES INST,DEPT MOLEC BIOL,PALO ALTO,CA 94304; UNIV TOKYO,INST MED SCI,DEPT MOLEC BIOL,MINATO KU,TOKYO 108,JAPAN	Oklahoma Medical Research Foundation; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Tokyo			Yokota, Takashi/J-8483-2015; Tsuboi, Akio/R-6793-2019	Tsuboi, Akio/0000-0002-4790-4512; Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERRINGTON J, 1987, FEBS LETT, V224, P257, DOI 10.1016/0014-5793(87)80465-9; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GREENBLATT J, 1991, TRENDS BIOCHEM SCI, V16, P408, DOI 10.1016/0968-0004(91)90165-R; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HORIKOSHI M, 1991, NUCLEIC ACIDS RES, V19, P5436, DOI 10.1093/nar/19.19.5436; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN KH, 1991, BIOTECHNIQUES, V11, P748; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRAGIER P, 1989, SCIENCE, V243, P507, DOI 10.1126/science.2536191; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	39	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23942	23949						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429731				2022-12-27	WOS:A1992JZ23900077
J	HANADA, K; NISHIJIMA, M; KISO, M; HASEGAWA, A; FUJITA, S; OGAWA, T; AKAMATSU, Y				HANADA, K; NISHIJIMA, M; KISO, M; HASEGAWA, A; FUJITA, S; OGAWA, T; AKAMATSU, Y			SPHINGOLIPIDS ARE ESSENTIAL FOR THE GROWTH OF CHINESE-HAMSTER OVARY CELLS - RESTORATION OF THE GROWTH OF A MUTANT DEFECTIVE IN SPHINGOID BASE BIOSYNTHESIS BY EXOGENOUS SPHINGOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN SYNTHASE; SIALIC-ACID; MODULATION; INHIBITION; GLYCOSPHINGOLIPIDS; GLUCOSYLCERAMIDE; DERIVATIVES; INVOLVEMENT	We previously isolated a temperature-sensitive Chinese hamster ovary cell mutant (strain SPB-1) with thermolabile serine palmitoyltransferase, which is involved in the first step of sphingolipid synthesis (Hanada, K., Nishijima, M., and Akamatsu, Y. (1990) J. Biol. Chem. 265, 22137-22142). In this study, sphingolipid-deficient culture medium was used to examine the effect of exogenous sphingolipids on the cell growth of SPB-1. When cultivated in the sphingolipid-deficient medium, SPB-1 cells ceased growing at non-permissive temperatures. Under these conditions, de novo sphingolipid synthesis ceased in the SPB-1 cells, resulting in a decrease in levels of sphingomyelin and ganglioside sialyl lactosylceramide (G(M3)), whereas the parental CHO-K1 cells grew logarithmically with normal sphingolipid synthesis. Exogenous sphingosine restored the contents of both sphingomyelin and G(M3) in the SPB-1 cells near to the parental levels through metabolic utilization and allowed the mutant cells to grow even at the non-permissive temperature. Similarly, exogenous sphingomyelin restored the sphingomyelin levels and only partly the G(M3) levels and also suppressed the temperature-sensitivity of the SPB-1 cell growth. In contrast, exogenous glucosylceramide, which restored the G(M3) levels but not the sphingomyelin levels, failed to suppress the temperature sensitivity of the SPB-1 cell growth. Combination of exogenous sphingomyelin with ceramide, glucosylceramide, G(M3), or sphingoid bases did not show any synergistic or additive effect on the SPB-1 cell growth enhancement, compared with sphingomyelin alone. The results indicated that the temperature sensitivity of the SPB-1 cell growth was due to the lack of cellular sphingolipids, possibly that of sphingomyelin.	NATL INST HLTH,DEPT CHEM,SHINAGAWA KU,TOKYO 141,JAPAN; GIFU UNIV,DEPT APPL BIOORGAN CHEM,GIFU 50111,JAPAN; MECT CO LTD,SAITAMA 359,JAPAN; UNIV TOKYO,DEPT CELLULAR BIOCHEM,TOKYO 113,JAPAN; RIKEN,WAKO,SAITAMA 35101,JAPAN	Gifu University; University of Tokyo; RIKEN			Ogawa, Tomoya/C-3655-2009	Hanada, Kentaro/0000-0003-1383-2781				BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; DAWSON G, 1976, J LIPID RES, V17, P125; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; GERLACH E, 1963, BIOCHEM Z, V337, P477; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; HANADA K, 1990, J BIOL CHEM, V265, P22137; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; KANFER JN, 1983, HDB LIPID RES, V3, P167; KARLSSON KA, 1970, LIPIDS, V5, P878, DOI 10.1007/BF02531119; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; KISHIMOTO Y, 1983, ENZYMES, V16, P357; KISO M, 1986, CARBOHYD RES, V158, P101, DOI 10.1016/0008-6215(86)84009-5; KOIKE K, 1986, CARBOHYD RES, V158, P113, DOI 10.1016/0008-6215(86)84010-1; KUGE O, 1986, J BIOL CHEM, V261, P5790; Kundu S K, 1981, Methods Enzymol, V72, P185, DOI 10.1016/S0076-6879(81)72012-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MORRISON WR, 1969, BIOCHIM BIOPHYS ACTA, V176, P537, DOI 10.1016/0005-2760(69)90220-3; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PANINI SR, 1990, J BIOL CHEM, V265, P14118; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STANLEY P, 1980, J CELL BIOL, V85, P60, DOI 10.1083/jcb.85.1.60; STEIN Y, 1991, BIOCHIM BIOPHYS ACTA, V1084, P87, DOI 10.1016/0005-2760(91)90059-Q; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; SUZUKI K, 1965, J NEUROCHEM, V12, P629, DOI 10.1111/j.1471-4159.1965.tb04256.x; TAKEDA A, 1990, SCIENCE, V250, P676, DOI 10.1126/science.2146743; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; WELLS GB, 1983, J BIOL CHEM, V258, P200; White D.A., 1973, FORM FUNCTION PHOSPH; WILSON E, 1988, J BIOL CHEM, V263, P9304; YOGEESWARAN G, 1974, BIOCHEM BIOPH RES CO, V56, P1010, DOI 10.1016/S0006-291X(74)80289-5; YU RK, 1972, J LIPID RES, V13, P680; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	48	139	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23527	23533						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429697				2022-12-27	WOS:A1992JZ23900020
J	HUGHES, MJ; JIRICNY, J				HUGHES, MJ; JIRICNY, J			THE PURIFICATION OF A HUMAN MISMATCH-BINDING PROTEIN AND IDENTIFICATION OF ITS ASSOCIATED ATPASE AND HELICASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIR MISMATCHES; ESCHERICHIA-COLI; HUMAN-CELLS; NUCLEAR EXTRACTS; GENE-PRODUCT; STREPTOCOCCUS-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; EXCISION REPAIR; DNA HELICASE; G.T MISPAIRS	A mismatch-binding protein has been purified an estimated 4500-fold from HeLa nuclear extracts using four different chromatographic steps. Two polypeptides of apparent molecular weight of 160,000 and 100,000 were present in the final affinity-purified fraction as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Partial proteolytic clipping of the protein-DNA complexes visualized after UV treatment indicated that the 100-kDa polypeptide is most likely a degradation product of the 160-kDa polypeptide. UV cross-linking experiments have shown that both these polypeptides bind specifically to oligonucleotide duplexes containing G/T mismatches. Direct DNA binding studies and band-shift competition assays showed that although the mismatch-binding protein binds with highest affinity to oligonucleotides containing G/T mismatches, it is also capable of binding to oligonucleotides containing other mispairs. The purified protein has an associated Mg2+-dependent ATPase activity, which is markedly enhanced in the presence of single-stranded DNA. A helicase capable of unwinding a 34-mer oligonucleotide, annealed to a complementary sequence in single-stranded M13, also copurified with the mismatch-binding protein. This reaction occurs in an ATP- and magnesium-dependent manner.	IST RIC BIOL MOLEC, VIA PONTINA KM 30600, I-00040 POMEZIA, ITALY									AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; BURK RR, 1983, METHOD ENZYMOL, V91, P246; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; FUJII H, 1989, J BIOL CHEM, V264, P10057; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1991, BIOMETHODS, V5, P221; HUGHES MJ, 1990, NUCLEIC ACIDS RES, V17, P8511; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JIRICNY J, 1986, NUCLEIC ACIDS RES, V14, P6579, DOI 10.1093/nar/14.16.6579; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LACKS SA, 1982, CELL, V31, P327, DOI 10.1016/0092-8674(82)90126-X; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1985, MOL GEN GENET, V199, P465; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1989, J BIOL CHEM, V264, P6597; PRIEBE SD, 1988, J BACTERIOL, V170, P190, DOI 10.1128/jb.170.1.190-196.1988; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SMITH ML, 1990, MOL CELL BIOL, V10, P6003, DOI 10.1128/MCB.10.11.6003; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; WELSH KM, 1987, J BIOL CHEM, V262, P15624; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; WOOD RD, 1991, BIOESSAYS, V13, P447, DOI 10.1002/bies.950130904; WOOD SG, 1986, NUCLEIC ACIDS RES, V14, P6591, DOI 10.1093/nar/14.16.6591; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	43	77	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23876	23882						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429725				2022-12-27	WOS:A1992JZ23900067
J	PERIDES, G; RAHEMTULLA, F; LANE, WS; ASHER, RA; BIGNAMI, A				PERIDES, G; RAHEMTULLA, F; LANE, WS; ASHER, RA; BIGNAMI, A			ISOLATION OF A LARGE AGGREGATING PROTEOGLYCAN FROM HUMAN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONIC-ACID; POLYACRYLAMIDE GELS; BINDING-PROTEIN; CARTILAGE PROTEOGLYCANS; EXTRACELLULAR-MATRIX; CHROMATOGRAPHY; SEQUENCE; COMPLEX	A large proteoglycan (365 kDa), identified with monoclonal antibodies raised against chondroitin sulfate, was isolated from human brain. The isolation required anion-exchange chromatography followed by gel filtration through a Sephacryl S-500 column. The proteoglycan bound specifically to [H-3]hyaluronate (HA). The binding was not reduced by high salt concentrations (up to 4 M) and was inhibited at low pH (<4.0). The binding was inhibited by the octamer and decamer (but not the hexamer) oligosaccharides of HA. Limited proteolysis of the proteoglycan gave rise to a relatively stable polypeptide (80 kDa). The amino-terminal sequence of the 80-kDa polypeptide was identical to the cDNA-derived amino-terminal sequence of versican, a large human fibroblast proteoglycan. A monoclonal antibody raised against bovine proteoglycans and recognizing the versican core protein reacted by immunoblotting with the proteoglycan isolated from human brain. The antibody was used to localize the proteoglycan in acetone-fixed cryostat sections of bovine spinal cord. The localization of the proteoglycan in the central nervous system was identical to that previously reported for glial hyaluronate-binding protein (GHAP), a 60-kDa glycoprotein of the brain extracellular matrix (ECM). However, a major difference was observed with respect to the sensitivity of the two antigens to hyaluronidase. As previously reported, GHAP was released from the tissue by hyaluronidase digestion, whereas the proteoglycan persisted under these conditions. We conclude that the protein-hyaluronate aggregates in brain ECM contain both GHAP and versican, that GHAP is only retained in the ECM by its interaction with hyaluronate, and that the proteoglycan is anchored in some other manner and probably connects cell surfaces with the ECM since it was not released by hyaluronidase digestion.	DEPT VET AFFAIRS MED CTR, SPINAL CORD INJURY RES LAB, BOSTON, MA 02132 USA; UNIV ALABAMA, SCH MED, DEPT ORAL BIOL, BIRMINGHAM, AL 35294 USA; HARVARD UNIV, BIOL LABS, MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	University of Alabama System; University of Alabama Birmingham; Harvard University	PERIDES, G (corresponding author), HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA.				NIDCR NIH HHS [DE 08466] Funding Source: Medline; NINDS NIH HHS [NS 13034] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013034] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; BIGNAMI A, 1989, BRAIN RES BULL, V22, P67, DOI 10.1016/0361-9230(89)90129-9; BIGNAMI A, 1992, ADV STRUCTURAL BIOL, V1, P1; BRATT P, 1992, IN PRESS INT J BIOCH; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; EBERT RF, 1986, ANAL BIOCHEM, V154, P431, DOI 10.1016/0003-2697(86)90010-2; FALTZ LL, 1979, J BIOL CHEM, V254, P1381; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HASCALL VC, 1974, J BIOL CHEM, V249, P4232; KNUDSEN PJ, 1980, J CHROMATOGR, V187, P373, DOI 10.1016/S0021-9673(00)80469-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARJAVA H, 1992, BIOCHEM J, V284, P267, DOI 10.1042/bj2840267; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NICHOLSON C, 1986, ANN NY ACAD SCI, V481, P55, DOI 10.1111/j.1749-6632.1986.tb27139.x; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERIDES G, 1991, BIOCHIM BIOPHYS ACTA, V1075, P248, DOI 10.1016/0304-4165(91)90273-J; RAHEMTULLA F, 1988, J DENT RES, V67, pA373; ROUGHLEY PJ, 1985, BIOCHEM J, V231, P129, DOI 10.1042/bj2310129; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNDERHILL CB, 1987, CONNECT TISSUE RES, V16, P225, DOI 10.3109/03008208709006978; WALL RS, 1988, ANAL BIOCHEM, V175, P298, DOI 10.1016/0003-2697(88)90392-2; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	26	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23883	23887						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429726				2022-12-27	WOS:A1992JZ23900068
J	TSUJITA, T; OKUDA, H				TSUJITA, T; OKUDA, H			FATTY-ACID ETHYL-ESTER SYNTHASE IN RAT ADIPOSE-TISSUE AND ITS RELATIONSHIP TO CARBOXYLESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONOXIDATIVE ETHANOL-METABOLISM; PURIFICATION; LIVER; HYDROLASE; LIPASE; LOCALIZATION; ENZYME	Fatty acid ethyl ester (FAEE) synthase was obtained from rat adipose tissue in an electrophoretically homogeneous form. The enzyme associated with carboxylesterase activity was purified by acetone precipitation followed by successive chromatographies on DEAE-cellulose, phenyl-Sepharose, and Sephadex G-100 gel. The two activities in rat adipose tissue were associated as judged by their co-elution profiles, co-purifications at different steps, co-precipitations by antibody raised against purified FAEE synthase, and identical profiles of inhibition by diisopropyl fluorophosphate. The enzyme catalyzed the hydrolyses of both tri- and monoacylglycerols, and the susceptibilities of substrates increase with decreasing acyl chain length of the fatty acid moiety. Ethyl oleate-hydrolyzing activity was about one-eighth of the synthesizing activity. The N-terminal amino acid sequence of the first 27 residues of the purified enzyme was identical to that of the carboxylesterase from rat liver. With a polyclonal rabbit antibody against the rat adipose tissue FAEE synthase, the enzyme was demonstrated in the liver, lung, and testis, but not in the kidney. The antibody removed the FAEE-synthesizing activities in adipose tissue (86%), liver (23%), lung (62%), and testis (82%). These results suggest that carboxylesterase contributes to the nonoxidative ethanol metabolism (FAEE synthesis) in various organs.			TSUJITA, T (corresponding author), EHIME UNIV,SCH MED,DEPT MED BIOCHEM,SHIGENOBU,EHIME 79102,JAPAN.							BJORNTORP P, 1990, J INTERN MED, V228, P557; CHEN RF, 1967, J BIOL CHEM, V242, P173; GAUSTAD R, 1991, BIOCHEM J, V274, P693, DOI 10.1042/bj2740693; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; JAMES LK, 1966, ADV ENZYMOL RAMB, V28, P1; Krisch K., 1971, ENZYMES            A, V5, P43; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; LANGE LG, 1982, P NATL ACAD SCI-BIOL, V79, P3954, DOI 10.1073/pnas.79.13.3954; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; LAPOSATA EA, 1990, J BIOL CHEM, V265, P9688; LAPOSATA EA, 1989, ARCH PATHOL LAB MED, V113, P762; MCLAREN DA, 1970, ADV ENZYMOL REL S BI, V33, P245; MENTLEIN R, 1984, BIOCHEM PHARMACOL, V33, P1243, DOI 10.1016/0006-2952(84)90176-X; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MENTLEIN R, 1986, J BIOL CHEM, V261, P7816; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; MOGELSON S, 1984, BIOCHEMISTRY-US, V23, P4075, DOI 10.1021/bi00313a010; OAKESHOTT JG, 1987, P NATL ACAD SCI USA, V84, P3359, DOI 10.1073/pnas.84.10.3359; RILEY DJS, 1990, BIOCHEMISTRY-US, V29, P3848, DOI 10.1021/bi00468a007; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; TORNQVIST H, 1976, J BIOL CHEM, V251, P813; TSUJITA T, 1982, BIOCHIM BIOPHYS ACTA, V715, P181, DOI 10.1016/0304-4165(82)90357-9; TSUJITA T, 1990, J LIPID RES, V31, P831; TSUJITA T, 1988, J BIOCHEM, V103, P327, DOI 10.1093/oxfordjournals.jbchem.a122269; TSUJITA T, 1970, NATURE, V227, P680	27	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23489	23494						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429692				2022-12-27	WOS:A1992JZ23900014
J	GRASSL, SM				GRASSL, SM			HUMAN PLACENTAL BRUSH-BORDER MEMBRANE NA+-PANTOTHENATE COTRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLES; TRANSPORT	Membrane transport pathways for transplacental transfer of the water-soluble vitamin pantothenate were investigated by assessing the possible presence of a Na+-pantothenate cotransport mechanism in the maternal facing membrane of human placental epithelial cells. The presence of Na+-pantothenate cotransport was determined from radiolabeled tracer flux measurements of pantothenate uptake using preparations of purified brush-border membrane vesicles. Compared with other cations the imposition of an inward Na+ gradient stimulated vesicle uptake of pantothenate to levels approximately 40-fold greater than those observed at equilibrium. The observed stimulation of pantothenate uptake was not the result of indirect electrostatic coupling to an inside positive Na+ diffusion potential. In the absence of Na+ and pantothenate concentration gradients an inside negative voltage difference induced a Na+-dependent net influx of pantothenate, suggesting the presence of an electrogenic Na+-pantothenate cotransport mechanism. The effect of biotin on the kinetics of Na+-dependent pantothenate uptake and the effect of pantothenate on the kinetics of Na+-dependent biotin uptake suggested that placental absorption of biotin and pantothenate from the maternal circulation occurs by a common Na+ cotransport mechanism in apical brush-border membrane.			GRASSL, SM (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,766 IRVING AVE,SYRACUSE,NY 13210, USA.				NIDDK NIH HHS [DK37907] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK037907] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER H, 1975, AM J CLIN NUTR, V28, P56, DOI 10.1093/ajcn/28.1.59; BARBARAT B, 1986, J BIOL CHEM, V261, P4455; BARBARAT B, 1991, J PHYSIOL-LONDON, V443, P79, DOI 10.1113/jphysiol.1991.sp018823; BOWERS GN, 1966, CLIN CHEM, V12, P70; EARL DCN, 1965, BIOCHEM J, V94, P721, DOI 10.1042/bj0940721; GRASSL SM, 1989, J BIOL CHEM, V264, P11103; GRASSL SM, 1992, J BIOL CHEM, V267, P17760; GRASSL SM, 1987, J BIOL CHEM, V262, P2682; ILLSLEY NP, 1990, BIOCHIM BIOPHYS ACTA, V1029, P218, DOI 10.1016/0005-2736(90)90157-J; JORGENSEN PL, 1968, BIOCHIM BIOPHYS ACTA, V151, P212, DOI 10.1016/0005-2744(68)90176-9; KELLY LK, 1987, AM J PHYSIOL, V252, pC38; Machlin, 1991, HDB VITAMINS; MOISEENOK A G, 1988, Fiziologicheskii Zhurnal SSSR Imeni I M Sechenova, V74, P113; NEAME KD, 1972, ELEMENTARY KINETICS, P56; NELSON MM, 1957, J NUTR, V62, P395; OGIN C, 1989, BIOCHIM BIOPHYS ACTA, V980, P248, DOI 10.1016/0005-2736(89)90406-9; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; TRUMAN P, 1984, BIOCHIM BIOPHYS ACTA, V779, P129; WALLACH DFH, 1966, METHOD ENZYMOL, V8, P165	19	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22902	22906						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429639				2022-12-27	WOS:A1992JY16300032
J	KLUMP, H; DIRUGGIERO, J; KESSEL, M; PARK, JB; ADAMS, MWW; ROBB, FT				KLUMP, H; DIRUGGIERO, J; KESSEL, M; PARK, JB; ADAMS, MWW; ROBB, FT			GLUTAMATE-DEHYDROGENASE FROM THE HYPERTHERMOPHILE PYROCOCCUS-FURIOSUS - THERMAL-DENATURATION AND ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEBACTERIUM SULFOLOBUS-SOLFATARICUS; IRON-SULFUR PROTEIN; PURIFICATION; FERREDOXIN; DOMAINS	Pyrococcus furiosus is a marine hyperthermophile that grows optimally at 100-degrees-C. Glutamate dehydrogenase (GDH) from P. furiosus is a hexamer of identical subunits and has an M(r) = 270,000 +/- 5500 at 25-degrees-C. Electron micrographs showed that the subunit arrangement is similar to that of GDH from bovine liver (i.e. 3/2 symmetry in the form of a triangular antiprism). However, GDH from P.furiosus is inactive at temperatures below 40-degrees-C and undergoes heat activation above 40-degrees-C. Both NAD+ and NADP+ are utilized as cofactors. Apparently the inactive enzyme also binds cofactors, since the enzyme maintains the ability to bind to an affinity column (Cibacron blue F3GA) and is specifically eluted with NADP+. Conformational changes that accompany activation and thermal denaturation were detected by precision differential scanning microcalorimetry. Thermal denaturation starts at 110-degrees-C and is completed at 118-degrees-C. DELTA(cal) = 414 Kcal [mol GDH]-1. T(m) = 113-degrees-C. This increase in heat capacity indicates an extensive irreversible unfolding of the secondary structure as evidenced also by a sharp increase in absorbance at 280 nm and inactivation of the enzyme. The process of heat activation of GDH from 40 to 80-degrees-C is accompanied by a much smaller increase in absorbance at 280 nm and a reversible increase in heat capacity with DELTA(cal) = 187 Kcal [mol GDH]-1 and T(m) = 57-degrees-C. This absorbance change as well as the moderate increase in heat capacity suggest that thermal activation leads to some exposure of hydrophobic groups to solvent water as the GDH structure is opened slightly. The increase in absorbance at 280 nm during activation is only 12% of that for denaturation. Overall, GDH appears to be well adapted to correspond with the growth response of P. furiosus to temperature.	UNIV CAPE TOWN,DEPT BIOCHEM,RONDEBOSCH 7700,SOUTH AFRICA; UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University of Cape Town; University System of Maryland; University of Maryland College Park; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	KLUMP, H (corresponding author), UNIV MARYLAND,CTR MARINE BIOTECHNOL,600 E LOMBARD ST,BALTIMORE,MD 21202, USA.			Robb, Frank/0000-0001-5833-6496; Adams, Michael/0000-0002-9796-5014				ADAMS MWW, 1990, FEMS MICROBIOL REV, V75, P125; AONO S, 1989, J BACTERIOL, V171, P3433, DOI 10.1128/jb.171.6.3433-3439.1989; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; CONSALVI V, 1991, EUR J BIOCHEM, V196, P459, DOI 10.1111/j.1432-1033.1991.tb15837.x; COSTANTINO HR, 1990, J BACTERIOL, V172, P3654, DOI 10.1128/jb.172.7.3654-3660.1990; EGGEN R, 1990, FEMS MICROBIOL LETT, V71, P17; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; JOSEPHS R, 1971, J MOL BIOL, V55, P147, DOI 10.1016/0022-2836(71)90188-4; McCord Adams Marilyn, 1991, PROTOCOLS ARCHAEBACT, P1; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1192, P267; SCHINKINGER MF, 1991, BIOCHIM BIOPHYS ACTA, V1073, P142, DOI 10.1016/0304-4165(91)90194-L; SHRAKE A, 1989, BIOCHEMISTRY-US, V28, P6281, DOI 10.1021/bi00441a021; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; 1990, BIORAD TECHNICAL B B, V1107	19	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22681	22685						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429615				2022-12-27	WOS:A1992JW71900105
J	ADACHI, Y; COPELAND, TD; TAKAHASHI, C; NOSAKA, T; AHMED, A; OROSZLAN, S; HATANAKA, M				ADACHI, Y; COPELAND, TD; TAKAHASHI, C; NOSAKA, T; AHMED, A; OROSZLAN, S; HATANAKA, M			PHOSPHORYLATION OF THE REX PROTEIN OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; HTLV-I; MESSENGER-RNA; STRUCTURAL PROTEINS; ACTIVATOR PROTEIN; GENE-PRODUCT; EXPRESSION; SEQUENCE; P40X; DNA	Rex protein, the posttranscriptional regulator of human T-cell leukemia virus type I (HTLV-I), is required for the control of viral structural protein expression and virus replication. Rex is a phosphoprotein found predominantly in the cell nucleolus, whose function is thought to be regulated by its nucleolar localization and phosphorylation. Therefore, we investigated the in vivo phosphorylation of Rex protein in more detail. Phosphorylation of Rex occurred in all HTLV-I-infected cell lines examined in vivo, primarily at serine residues and to a very small extent at threonine residues. Treatment of cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) led to significant but transient enhancement of the incorporation of [P-32]orthophosphate into Rex protein. N-terminal truncation of Rex protein abolished TPA-dependent phosphorylation. Chymotryptic digestion of phosphorylated Rex yielded two phosphopeptides. In vivo phosphorylation sites were identified as serine residues 70 and 177 and threonine residue 174. Serine 70 was a TPA-dependent phosphorylation site within a regulatory domain. We have already shown that the protein kinase C inhibitor H-7 (1-(5-isoquinolinylsulfonyl)-2-methylpiperazine specifically blocked accumulation of viral unspliced gag-pol mRNA. Therefore, the phosphorylation at serine 70 may be involved in the regulation of Rex function in response to extracellular stimuli.	KYOTO UNIV, INST VIRUS RES, KYOTO 606, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, BASIC RES PROGRAM, MOLEC VIROL & CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1988, BIOL CHEM H-S, V369, P223; ADACHI Y, 1990, ADV SEC MESS PHOSPH, V24, P478; ADACHI Y, 1990, BIOCHEM BIOPH RES CO, V169, P469, DOI 10.1016/0006-291X(90)90355-Q; ADACHI Y, 1991, J BIOL CHEM, V266, P3968; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHIDA K, 1986, J BIOL CHEM, V261, P3013; COCHRANE A, 1989, VIROLOGY, V171, P264, DOI 10.1016/0042-6822(89)90535-7; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; CURRAN T, 1984, CELL, V36, P259; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOFER L, 1991, J VIROL, V65, P3379, DOI 10.1128/JVI.65.6.3379-3383.1991; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; NAGASHIMA K, 1986, J VIROL, V60, P394, DOI 10.1128/JVI.60.2.394-399.1986; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; PASTI G, 1986, NATURE, V324, P375, DOI 10.1038/324375a0; PATSKAN GJ, 1985, J BIOL CHEM, V260, P2899; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126/science.6089351; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TATENO M, 1984, J EXP MED, V159, P1105, DOI 10.1084/jem.159.4.1105; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	45	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21977	21981						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400509				2022-12-27	WOS:A1992JV01100110
J	CAPDEVILA, JH; WEI, S; YAN, J; KARARA, A; JACOBSON, HR; FALCK, JR; GUENGERICH, FP; DUBOIS, RN				CAPDEVILA, JH; WEI, S; YAN, J; KARARA, A; JACOBSON, HR; FALCK, JR; GUENGERICH, FP; DUBOIS, RN			CYTOCHROME-P-450 ARACHIDONIC-ACID EPOXYGENASE - REGULATORY CONTROL OF THE RENAL EPOXYGENASE BY DIETARY SALT LOADING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS EPOXYEICOSATRIENOIC ACIDS; MICROSOMAL CYTOCHROME-P-450; OMEGA-HYDROXYLASE; MEPHENYTOIN 4-HYDROXYLASE; MESSENGER-RNA; CDNA CLONING; 2 FORMS; METABOLISM; EXPRESSION; SEQUENCE	The rat kidney microsomal epoxygenase catalyzed the asymmetric epoxidation of arachidonic acid to generate as major products: 8(R),9(S)-, 11 (R), 12(S)- and 14(S),15(R)-epoxyeicosatrienoic acids with optical purities of 97, 88, and 70%, respectively. Inhibition studies utilizing a panel of polyclonal antibodies to several rat liver cytochrome P-450 isoforms, indicated that the renal epoxygenase(s) belongs to the cytochrome P-450 2C gene family. Dietary salt, administered either as a 2-2.5% (w/v) solution in the drinking water or as a modified solid diet containing 8% NaCl (w/w), resulted in marked and selective increases in the renal microsomal epoxygenase activity (416 and 260% of controls, for the liquid and solid forms of NaCl, respectively) with no significant changes in the microsomal omega/omega-1 oxygenase or in the hepatic arachidonic acid monooxygenase reaction. Immunoblotting studies demonstrated that dietary salt induced marked increases in the concentration of a cytochrome P-450 isoform(s) recognized by polyclonal antibodies raised against human liver cytochrome P-450 2C10 or rat liver cytochrome P-450 2C11. Comparisons of the stereochemical selectivity of the induced and non-induced microsomal epoxygenase(s) with that of purified rat liver cytochrome P-450 2C11 suggest that the salt-induced protein(s) is catalytically and structurally different from liver cytochrome P-450 2C11. The in vivo significance of dietary salt in regulating the activities of the kidney endogenous arachidonic acid epoxygenase was established by the demonstration of a salt-induced 10-20-fold increase in the urinary output of epoxygenase metabolites. These results, in conjunction with published evidence demonstrating the potent biological activities of its metabolites, suggest a role for the epoxygenase in the renal response to dietary salt.	VANDERBILT UNIV, MED CTR, SCH MED, DIV NEPHROL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DIV GASTROENTEROL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Southwestern Medical Center Dallas			DuBois, Raymond N./AAX-8869-2020	Falck, John/0000-0002-9219-7845	NCI NIH HHS [CA44353] Funding Source: Medline; NICHD NIH HHS [NIHDK 38226] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CARROLL MA, 1990, AM J PHYSIOL, V258, pF1084; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; COREY EJ, 1980, J AM CHEM SOC, V102, P1433, DOI 10.1021/ja00524a043; FALCK JR, 1982, TETRAHEDRON LETT, V23, P1755, DOI 10.1016/S0040-4039(00)86732-5; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; IWAI N, 1991, HYPERTENSION, V17, P161, DOI 10.1161/01.HYP.17.2.161; JACOBSON HR, 1984, PROSTAGLANDINS MEMBR; JOHNSON EF, 1992, FASEB J, V6, P700, DOI 10.1096/fasebj.6.2.1537459; JOHNSON EF, 1990, BIOCHEMISTRY-US, V29, P873, DOI 10.1021/bi00456a004; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KARARA A, 1991, J BIOL CHEM, V266, P7561; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P503, DOI 10.1089/dna.1.1989.8.503; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; LAPUERTA L, 1988, AM J MED SCI, V295, P275, DOI 10.1097/00000441-198804000-00010; MALEE MP, 1991, P NATL ACAD SCI USA, V88, P4731, DOI 10.1073/pnas.88.11.4731; MATSUBARA S, 1987, J BIOL CHEM, V262, P13366; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; MULLER J, 1991, ENDOCR RES, V17, P165; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; PORTER TD, 1991, J BIOL CHEM, V266, P13469; ROMERO MF, 1991, ADV PROSTAG THROMB L, V21, P205; Sambrook J, 1989, MOL CLONING LABORATO; SHIBATA H, 1991, ENDOCRINOLOGY, V128, P2534, DOI 10.1210/endo-128-5-2534; SHIMADA T, 1986, J BIOL CHEM, V261, P909; TREMBLAY A, 1991, J BIOL CHEM, V266, P2245; UMBENHAUER DR, 1987, BIOCHEMISTRY-US, V26, P1094, DOI 10.1021/bi00378a016; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; YOKOTANI N, 1989, J BIOL CHEM, V264, P21665	44	152	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21720	21726						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400482				2022-12-27	WOS:A1992JV01100072
J	HOSHINO, T; KOSETERAI, K; SATO, K				HOSHINO, T; KOSETERAI, K; SATO, K			SOLUBILIZATION AND RECONSTITUTION OF THE PSEUDOMONAS-AERUGINOSA HIGH-AFFINITY BRANCHED-CHAIN AMINO-ACID-TRANSPORT SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN; BRA GENES; PAO; CLONING; PURIFICATION; PERMEASE; CARRIER	The high affinity branched-chain amino acid transport system (LIV-I) in Pseudomonas aeruginosa is composed of five components: BraC, a periplasmic binding protein for branched-chain amino acids; BraD and BraE, integral membrane proteins; BraF and BraG, putative nucleotide-binding proteins. By using a T7 RNA polymerase/promoter system we overproduced the BraD, BraE, BraF, and BraG proteins in Escherichia coli. The proteins were found to form a complex in the E. coli membrane and solubilized from the membrane with octyl glucoside. The LIV-I transport system was reconstituted into proteoliposomes from solubilized proteins by a detergent dilution procedure. In this reconstituted system, leucine transport was completely dependent on the presence of all five Bra components and on ATP loaded internally to the proteoliposomes. Alanine and threonine in addition to branched-chain amino acids were transported by the proteoliposomes, reflecting the substrate specificity of the BraC protein. GTP replaced ATP well as an energy source, and CTP and UTP also replaced ATP partially. Consumption of loaded ATP and concomitant production of orthophosphate were observed only when BraC and leucine, a substrate for LIV-I, were added together to the proteoliposomes, indicating that the LIV-I transport system has an ATPase activity coupled to translocation of branched-chain amino acids across the membrane.			HOSHINO, T (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							AMANUMA H, 1974, J BIOCHEM, V76, P1165, DOI 10.1093/oxfordjournals.jbchem.a130669; AMANUMA H, 1976, J BIOCHEM, V79, P1167, DOI 10.1093/oxfordjournals.jbchem.a131172; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERGER EA, 1974, J BIOL CHEM, V249, P7747; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOOS W, 1983, BIOCHIM BIOPHYS ACTA, V737, P443; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; GERLACH E, 1963, BIOCHEM Z, V337, P477; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HOSHINO T, 1989, J BACTERIOL, V171, P6300, DOI 10.1128/jb.171.11.6300-6306.1989; HOSHINO T, 1979, J BACTERIOL, V139, P705, DOI 10.1128/JB.139.3.705-712.1979; HOSHINO T, 1990, J BACTERIOL, V172, P5531, DOI 10.1128/jb.172.10.5531-5539.1990; HOSHINO T, 1980, J BACTERIOL, V141, P1055, DOI 10.1128/JB.141.3.1055-1063.1980; HOSHINO T, 1990, J BACTERIOL, V172, P5540, DOI 10.1128/jb.172.10.5540-5543.1990; HOSHINO T, 1991, J BACTERIOL, V173, P1855, DOI 10.1128/jb.173.6.1855-1861.1991; HOSHINO T, 1990, MOL GEN GENET, V220, P461, DOI 10.1007/BF00391754; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLATE CA, 1979, J BACTERIOL, V137, P221, DOI 10.1128/JB.137.1.221-225.1979; RICHARME G, 1992, BIOCHIM BIOPHYS ACTA, V1104, P201, DOI 10.1016/0005-2736(92)90151-B; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMATO Y, 1980, J BACTERIOL, V144, P36; [No title captured]	32	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21313	21318						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400443				2022-12-27	WOS:A1992JV01100011
J	LIMON, I; COUPRY, I; LANIER, SM; PARINI, A				LIMON, I; COUPRY, I; LANIER, SM; PARINI, A			PURIFICATION AND CHARACTERIZATION OF MITOCHONDRIAL IMIDAZOLINE-GUANIDINIUM RECEPTIVE SITE FROM RABBIT KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL PROXIMAL TUBULE; BINDING-SITES; H-3 IDAZOXAN; OUTER-MEMBRANE; PROTEINS; CELLS; LIVER; RESOLUTION; DRUGS	The imidazoline-guanidinium receptive site (IGRS) is a membrane-bound protein that may mediate some of the pharmacological effects of imidazoline and guanidinium compounds. The structure and functionality of this protein are unknown but, in addition to its location at the plasma membrane, it is found in high density in the outer membrane of mitochondria (Tesson, F., Prip-Buus, C., Lemoine, A., Pegorier, J.-P., and Parini, A. (1991) J. Biol. Chem. 266, 155-160). Using a two-step procedure, we report the purification of mitochondrial IGRS from rabbit kidney to the apparent homogeneity. After solubilization of mitochondrial membranes with digitonin, an apparently homogeneous IGRS preparation was obtained by two sequential purification steps, chromatofocusing and hydroxylapatite-agarose chromatography. One- and two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the purified preparation after silver staining or radioiodination indicated that IGRS binding subunit was purified at the apparent homogeneity since a single band (M(r) approximately 60,000) was observed. IGRS behaves as an acidic protein (pI 5.5) whose binding activity is regulated by H+ concentration near a physiological pH of 7.4. The ability to achieve rapid purification of IGRS should facilitate efforts to define molecular properties and functionality of this protein.	MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29208	Medical University of South Carolina	LIMON, I (corresponding author), FAC MED NECKER ENFANTS MALAD,CNRS,URA 1482,F-75015 PARIS,FRANCE.		Limon, Isabelle/AAJ-6169-2020; COUPRY, Isabelle/L-4900-2014; Limon, Isabelle/P-2750-2017	Limon, Isabelle/0000-0002-8773-6971; Limon, Isabelle/0000-0002-8773-6971; Parini, Angelo/0000-0002-9848-8838; Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTKIEWICZMICHALUK L, 1988, MOL PHARMACOL, V34, P272; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIDET M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P173, DOI 10.1016/0005-2736(90)90221-9; BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232; BROWN CM, 1990, BRIT J PHARMACOL, V99, P803, DOI 10.1111/j.1476-5381.1990.tb13010.x; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293; GASNIER F, 1987, BIOCHIM BIOPHYS ACTA, V925, P297, DOI 10.1016/0304-4165(87)90195-4; GORBUNOFF MJ, 1984, ANAL BIOCHEM, V136, P425, DOI 10.1016/0003-2697(84)90239-2; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; LACHAUDPETTITI V, 1991, EUR J PHARM-MOLEC PH, V206, P23, DOI 10.1016/0922-4106(91)90142-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGIN D, 1990, MOL PHARMACOL, V37, P876; LANGIN D, 1989, EUR J PHARMACOL, V159, P199, DOI 10.1016/0014-2999(89)90707-3; MICHEL MC, 1989, MOL PHARMACOL, V35, P324; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARINI A, 1989, J BIOL CHEM, V264, P11874; PAVLICA RJ, 1990, BIOCHIM BIOPHYS ACTA, V1022, P115, DOI 10.1016/0005-2736(90)90407-F; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TESSON F, 1991, J BIOL CHEM, V266, P155; WIKBERG JES, 1990, J NEUROCHEM, V55, P192, DOI 10.1111/j.1471-4159.1990.tb08838.x; ZONNENSCHEIN R, 1990, EUR J PHARMACOL, V190, P203, DOI 10.1016/0014-2999(90)94127-J	24	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21645	21649						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400475				2022-12-27	WOS:A1992JV01100061
J	RAPAPORT, D; FUCHS, O; NUDEL, U; YAFFE, D				RAPAPORT, D; FUCHS, O; NUDEL, U; YAFFE, D			EXPRESSION OF THE DUCHENNE MUSCULAR-DYSTROPHY GENE-PRODUCTS IN EMBRYONIC STEM-CELLS AND THEIR DIFFERENTIATED DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SKELETAL-MUSCLE; BRAIN; MEMBRANE; RNA; ISOFORMS; TERMINUS; PROMOTER; LINE	Three protein products of the Duchenne muscular dystrophy (DMD) gene were identified so far. These include the two very similar muscle and brain type dystrophins, which are encoded by 14-kilobase (kb) mRNAs, and Dp71, which is much smaller. Dp71 is encoded by a 6.5-kb mRNA, which is transcribed from approximately 6% of the giant dystrophin gene. The present investigation shows that Dp71 is the first product of the DMD gene detectable during development. It is already expressed in the pluripotent embryonic stem cells. The two 14-kb mRNAs encoding the dystrophins are detectable only after differentiation of specialized cell types. The possible implication of these findings with regard to the ontogenetic activation and the evolution of the DMD gene are discussed.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAR S, 1990, BIOCHEM J, V272, P557, DOI 10.1042/bj2720557; BARNEA E, 1990, NEURON, V5, P881, DOI 10.1016/0896-6273(90)90348-J; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; DENDUNNEN JT, 1992, NEUROMUSCULAR DISORD, V1, P327; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; EVANS MJ, 1983, CANCER SURV, V2, P185; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HELLIWELL TR, 1992, AM J HUM GENET, V50, P508; HOFFMAN EP, 1991, ANN NEUROL, V30, P605, DOI 10.1002/ana.410300414; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; Makover A, 1991, Neuromuscul Disord, V1, P39, DOI 10.1016/0960-8966(91)90041-P; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; NUDEL U, 1992, NEUROMUSCULAR DEV DI, P341; RAPAPORT D, 1992, DIFFERENTIATION, V49, P187, DOI 10.1111/j.1432-0436.1992.tb00666.x; RECAN D, 1992, J CLIN INVEST, V89, P712, DOI 10.1172/JCI115640; SHINAR D, 1989, DIFFERENTIATION, V41, P116, DOI 10.1111/j.1432-0436.1989.tb00739.x; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WILLIAMS DA, 1990, J PHYSIOL-LONDON, V428, P243, DOI 10.1113/jphysiol.1990.sp018210; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	30	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21289	21292						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400438				2022-12-27	WOS:A1992JV01100005
J	YOSHIMOTO, T; ARAKAWA, T; HADA, T; YAMAMOTO, S; TAKAHASHI, E				YOSHIMOTO, T; ARAKAWA, T; HADA, T; YAMAMOTO, S; TAKAHASHI, E			STRUCTURE AND CHROMOSOMAL LOCALIZATION OF HUMAN ARACHIDONATE 12-LIPOXYGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC 15-LIPOXYGENASE; INSITU HYBRIDIZATION; PORCINE LEUKOCYTES; MOLECULAR-CLONING; COMPLETE SEQUENCE; MESSENGER-RNA; EXPRESSION; PROMOTER; CDNA; LIPOXYGENASES	Arachidonate 12-lipoxygenase introduces a molecular oxygen into the C-12 position of arachidonic acid to produce 12(S)-hydroperoxy-5,8,10,14-eicosatetraenoic acid. With the aid of cDNA probes for the enzyme, we isolated overlapping lambda clones encompassing the human 12-lipoxygenase gene and flanking regions from a human genomic library. The gene consists of 14 exons with 13 introns and spans approximately 15 kilobases of DNA. All the exon-intron junctions conform to the GT/AG rule. Neither a typical TATA box nor a CAAT box was found in approximately 1-kb sequence of 5'-upstream region of the translation initiation site. However, this region contains several regulatory elements including four GC boxes, two CACCC boxes, three AP-2 binding sequences, and a glucocorticoid-responsive element. The major transcription initiation site was determined by primer-extension analysis as an adenosine residue at 306 bases upstream from the translation initiation codon. The chromosomal localization of the human 12-lipoxygenase gene was examined by fluorescence in situ hybridization, and the gene was assigned to the sub-band p13.1 of chromosome 17.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,KURAMOTO CHO,TOKUSHIMA 770,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 260,JAPAN	Tokushima University; National Institutes for Quantum Science & Technology								ARAKAWA T, 1992, J BIOL CHEM, V267, P12188; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HADA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P89, DOI 10.1016/0005-2760(91)90128-5; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NICOLETTA DM, 1992, AM J PHYSIOL, V262, pL198; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINJO F, 1986, J BIOL CHEM, V261, P3377; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; UEDA N, 1990, J BIOL CHEM, V265, P2311; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P638; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L	29	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24805	24809						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447217				2022-12-27	WOS:A1992KA26300097
J	WILLADSEN, KA; BUTTERS, CA; HILL, LE; TOBACMAN, LS				WILLADSEN, KA; BUTTERS, CA; HILL, LE; TOBACMAN, LS			EFFECTS OF THE AMINO-TERMINAL REGIONS OF TROPOMYOSIN AND TROPONIN-T ON THIN FILAMENT ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ALPHA-TROPOMYOSIN; RABBIT SKELETAL-MUSCLE; COOPERATIVE EQUILIBRIUM BINDING; MYOSIN SUBFRAGMENT-1; LABELED TROPOMYOSIN; ACTIN; COMPLEX; FLUORESCENCE; FRAGMENTS; MODEL	Bacterially expressed a-tropomyosin lacks the amino-terminal acetylation present in muscle tropomyosin and binds poorly to actin (Hitchcock-DeGregori, S. E., and Heald, R. W. (1987) J. Biol. Chem. 262, 9730-9735). Using a linear lattice model, we determined the affinity (K(o)) of unacetylated tropomyosin or troponin-unacetylated tropomyosin for an isolated site on the actin filament and the fold increase in affinity (y) when binding is to an adjacent site. The absence of tropomyosin acetylation decreased K(o) 2 orders of magnitude in the absence of troponin. Tropomyosin acetylation also enhanced troponin-tropomyosin binding to actin, not by increasing cooperativity (y), but rather by increasing K(o). These results suggest that the amino-terminal region of tropomyosin is a crucial actin binding site. Troponin promoted unacetylated tropomyosin binding to actin, increasing K(o) more than 1,000-fold. Troponin70-259, which lacks the troponin T peptide (1-69) spanning the overlap between adjacent tropomyosins, behaved similarly to intact troponin. Cooperative interactions between adjacent troponin-tropomyosin complexes remained strong despite the use of a non-polymerizable tropomyosin and a troponin unable to bridge neighboring tropomyosins physically. The K(o) for troponin70-259-unacetylated tropomyosin was 500-fold greater than for troponin159-259-unacetylated tropomyosin, indicating that troponin T residues 70-158 are critical for anchoring troponin-tropomyosin to F-actin. The mechanism of cooperative thin filament assembly is discussed.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa; University of Iowa					NHLBI NIH HHS [HL38834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038834, R29HL038834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; CHO YJ, 1990, J BIOL CHEM, V265, P538; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HELFMAN DM, 1984, J BIOL CHEM, V259, P4136; HILL LE, 1992, J BIOL CHEM, V267, P16106; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HILL TL, 1983, P NATL ACAD SCI-BIOL, V80, P60, DOI 10.1073/pnas.80.1.60; HILL TL, 1985, COOPERATIVITY THEORY, P344; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; MAK AS, 1980, J BIOL CHEM, V255, P3647; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; OHTSUKI I, 1974, J BIOCHEM-TOKYO, V75, P753, DOI 10.1093/oxfordjournals.jbchem.a130448; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; ZASEDATELEV A S, 1971, Molekulyarnaya Biologiya (Moscow), V5, P245	32	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23746	23752						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429713				2022-12-27	WOS:A1992JZ23900050
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .3. ANALYSIS OF STEADY-STATE AND DYNAMIC BEHAVIOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL SYSTEMS-THEORY	The examination of model robustness in the previous paper (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22919-22925 led to the suggestion that the current model for the tricarboxylic acid cycle in Dictyostelium discoideum is ill-determined with respect to one or more of the features reflecting pyruvate metabolism. This conclusion is further supported here by results of steady state and dynamic analyses. The tricarboxylic acid cycle, according to the current model, is poised on a knife's edge with its behavior rigidly determined; any alteration of the system's components leads to nonviable behavior, as exemplified by explosive accumulation of pyruvate and loss of steady state in response to a minute change in the level of malate dehydrogenase. With the additional results in this paper, we are able to refine the diagnosis of the problem and suggest three different areas of the current model that might profitably be re-examined by experiment. These include the kinetics of the reactions at the malate branch point, the turnover times for the alanine, glutamate, and aspartate pools in vivo, and the dynamic mass balances for the cofactor NAD. We also suggest a minimal modification in the current model that could alleviate or circumvent some of these problems.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM-30054] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBE KR, 1992, J BIOL CHEM, V267, P3106; Bode H. W., 1945, NETWORK ANAL FEEDBAC; Chua L.O., 1969, INTRO NONLINEAR NETW; CORNISHBOWDEN A, 1989, J THEOR BIOL, V136, P365, DOI 10.1016/S0022-5193(89)80154-7; IRVINE DH, 1990, SIAM J NUMER ANAL, V27, P704, DOI 10.1137/0727042; KACSER H, 1981, GENETICS, V97, P639; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU MA, 1992, J THEOR BIOL, V154, P131, DOI 10.1016/S0022-5193(05)80194-8; SAVAGEAU MA, 1989, J THEOR BIOL, V141, P93, DOI 10.1016/S0022-5193(89)80011-6; SAVAGEAU MA, 1971, ARCH BIOCHEM BIOPHYS, V145, P612, DOI 10.1016/S0003-9861(71)80021-8; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22919; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SORRIBAS A, 1989, MATH BIOSCI, V94, P161, DOI 10.1016/0025-5564(89)90064-3; VANVALKENBURG ME, 1958, NETWORK ANAL; Voit E., 1991, CANONICAL NONLINEAR; VOIT EO, 1990, USERS GUIDE ESSYNS	19	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22926	22933						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429643				2022-12-27	WOS:A1992JY16300036
J	MOORE, WR; SCHATZMAN, GL				MOORE, WR; SCHATZMAN, GL			PURIFICATION OF 2,3-OXIDOSQUALENE CYCLASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LANOSTEROL; CYCLIZATION; MOLECULES; PROTEIN	A rapid and simple purification of milligram amounts of 2,3-oxidosqualene cyclase, an integral membrane enzyme that catalyzes the cyclization of squalene epoxide to lanosterol, is reported. Several nonionic detergents (Triton X-100, Tween 80, Emulphogene, and lauryl maltoside) were evaluated for solubilization of oxidosqualene cyclase from rat liver microsomes. At a detergent concentration of 5 mg/ml, lauryl maltoside was approximately 10 times more effective than Emulphogene in the solubilization of oxidosqualene cyclase; Triton X-100 and Tween 80 were less effective than Emulphogene as judged by the relative specific activities of the solubilized enzyme. Treatment of microsomes with lauryl maltoside resulted in a selective solubilization of the cyclase with concomitant activation of the enzyme. The solubilized enzyme was purified to homogeneity by fast protein liquid chromatography. The purified enzyme consists of a single subunit that has an apparent molecular weight of 65,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The enzyme obeys saturation kinetics and the apparent K(m) of (2,3)-oxidosqualene is 15 muM; the apparent k(cat)/k(m) is 200 M-1.min-1. An improved assay of the enzyme that utilizes high performance liquid chromatography methods is also described.			MOORE, WR (corresponding author), MARION MERRELL DOW RES INST,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.							BARTON DHR, 1975, J CHEM SOC PERK T 1, P1134, DOI 10.1039/p19750001134; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTEL L, 1986, LIPIDS, V21, P31, DOI 10.1007/BF02534300; CHENG TY, 1979, J BIOL CHEM, V254, P11258; COREY EJ, 1967, J AM CHEM SOC, V89, P2797, DOI 10.1021/ja00987a089; COREY EJ, 1991, J AM CHEM SOC, V113, P4025, DOI 10.1021/ja00010a073; CORNFORT.JW, 1968, ANGEW CHEM INT EDIT, V7, P903, DOI 10.1002/anie.196809031; CORNFORT.JW, 1965, J AM CHEM SOC, V87, P3224, DOI 10.1021/ja01092a038; DEAN P D G, 1971, Steroidologia, V2, P143; DEAN PDG, 1967, J BIOL CHEM, V242, P3014; DEWAR MJS, 1984, J AM CHEM SOC, V106, P1744, DOI 10.1021/ja00318a033; DURIATTI A, 1988, BIOCHEM BIOPH RES CO, V151, P1378, DOI 10.1016/S0006-291X(88)80515-1; DURIATTI A, 1985, BIOCHEM PHARMACOL, V34, P2765, DOI 10.1016/0006-2952(85)90578-7; DURRIATI A, 1985, BIOCHEM PHARMACOL, V34, P2765; JAYME M, 1970, J AM CHEM SOC, V92, P2059, DOI 10.1021/ja00710a044; JOLIDON S, 1990, BIOCHEM SOC T, V18, P47, DOI 10.1042/bst0180047; KUSANO M, 1991, CHEM PHARM BULL, V39, P239; MAUDGAL RK, 1958, J AM CHEM SOC, V80, P2589, DOI 10.1021/ja01543a063; NADEAU RG, 1969, METHOD ENZYMOL, V15, P346; Neugebauer J.M., 1988, GUIDE PROPERTIES USE; RAHIER A, 1981, LIPIDS, V21, P52; REES HH, 1968, BIOCHEM J, V107, P417, DOI 10.1042/bj1070417; SAAT YA, 1976, J BIOL CHEM, V251, P5155; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; VANTAMELEN EE, 1982, J AM CHEM SOC, V104, P6480, DOI 10.1021/ja00387a070; VANTAMELEN EE, 1975, ACCOUNTS CHEM RES, V8, P152, DOI 10.1021/ar50089a002; YAMAMOTO S, 1969, P NATL ACAD SCI USA, V63, P110, DOI 10.1073/pnas.63.1.110	27	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22003	22006						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429550				2022-12-27	WOS:A1992JW71900005
J	AKAZAWA, C; SASAI, Y; NAKANISHI, S; KAGEYAMA, R				AKAZAWA, C; SASAI, Y; NAKANISHI, S; KAGEYAMA, R			MOLECULAR CHARACTERIZATION OF A RAT NEGATIVE REGULATOR WITH A BASIC HELIX-LOOP-HELIX STRUCTURE PREDOMINANTLY EXPRESSED IN THE DEVELOPING NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; DROSOPHILA-MELANOGASTER; AUTORADIOGRAPHIC ANALYSIS; CELL-DIFFERENTIATION; TRANSGENE EXPRESSION; GENE-COMPLEX; MOUSE RETINA; N-MYC; PROTEIN; SEQUENCE	We report here the cDNA cloning and characterization of a rat basic helix-loop-helix (HLH) factor, designated HES-5. This factor has a distant sequence homology to Drosophila hairy and Enhancer-of-split proteins, both of which are required for normal neurogenesis. DNase I footprinting analyses show that HES-5 binds to the sequence CACNAG (called N box), a recognition sequence of Enhancer-of-split proteins. Although HES-5 does not bind to the sequence CANNTG (called E box) recognized by other HLH factors, it attenuates the binding of E47, an HLH activator, to E box by forming a hetero-oligomer. In cotransfection analyses using NIH 3T3 cells, HES-5 significantly represses transcription originating from the promoter containing the N box sequences. Furthermore, HES-5 also partially inhibits the E47-induced expression from the promoter containing E boxes. Northern blot, RNase protection, and in situ hybridization analyses demonstrate that the HES-5 mRNA is specifically expressed in the nervous system. Prominent expression is observed in the ventricular zones of the embryonal brain vesicles and the outer nuclear layer of the neural retina. These results suggest that the negative regulator HES-5 may play an important role in neural development.			AKAZAWA, C (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN.							BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLANKS JC, 1977, J COMP NEUROL, V174, P317, DOI 10.1002/cne.901740208; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FUJITA S, 1963, J COMP NEUROL, V120, P37, DOI 10.1002/cne.901200104; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; Gilbert SF, 1991, DEV BIOL; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; OBERDICK J, 1988, NEURON, V1, P367, DOI 10.1016/0896-6273(88)90186-9; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; TSUCHIDA K, 1990, EUR J BIOCHEM, V193, P751, DOI 10.1111/j.1432-1033.1990.tb19396.x; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	35	276	286	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21879	21885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400497				2022-12-27	WOS:A1992JV01100095
J	CHO, WL; RAIKHEL, AS				CHO, WL; RAIKHEL, AS			CLONING OF CDNA FOR MOSQUITO LYSOSOMAL ASPARTIC PROTEASE - SEQUENCE-ANALYSIS OF AN INSECT LYSOSOMAL-ENZYME SIMILAR TO CATHEPSIN-D AND CATHEPSIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITELLOGENIN MESSENGER-RNA; MYELIN BASIC-PROTEIN; FAT-BODY; TRANSLATIONAL REGULATION; MOLECULAR-CLONING; DEGRADATION; PRECURSOR; GLUCOCORTICOIDS; IDENTIFICATION; PEPSINOGEN	A cDNA coding for the lysosomal aspartic protease from the mosquito (mLAP) was cloned and sequenced. The mLAP cDNA is 1420 base pairs long with an open reading frame of 387 amino acids. The deduced amino acid sequence contains a signal pre-propeptide sequence of 18 amino acids followed by 369 amino acids with a 35-amino acid putative pro-enzyme domain in the NH2-terminal. The amino acid sequence of mLAP is 92 and 81% similar to human cathepsin D and cathepsin E, respectively. Typical cleavage sites for cathepsin D processing into light and heavy chains are lacking in mLAP. A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D. The mLAP sequence shares putative phosphorylation determinants, which in cathepsins D are linked to the formation of mannose 6-phosphate. In the mosquito fat body, lysosomal enzymes specifically degrade organelles involved in the biosynthesis and secretion of vitellogenin. The mLAP mRNA accumulates to its highest level 24 h after initiation of vitellogenin synthesis and 12 h before the peak of mLAP protein accumulation and its enzymatic activity. Translational regulation of mLAP mRNA may occur. The 5'-untranslated region of mLAP mRNA is similar to elements conferring negative translational control by steroids.	MICHIGAN STATE UNIV, PROGRAM GENET, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT ENTOMOL, E LANSING, MI 48824 USA	Michigan State University; Michigan State University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716, R01AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24716] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; ATHAUDA SBP, 1990, BIOCHEM BIOPH RES CO, V168, P878, DOI 10.1016/0006-291X(90)92403-M; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; AZUMA T, 1989, J BIOL CHEM, V264, P16748; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERNIER L, 1987, J NEUROSCI, V7, P2703; BOSE SG, 1988, BIOCHEM BIOPH RES CO, V155, P436, DOI 10.1016/S0006-291X(88)81105-7; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; Cardelli J.A., 1988, P363; CHO WL, 1991, INSECT BIOCHEM, V21, P165, DOI 10.1016/0020-1790(91)90047-I; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; Dean R.L., 1985, P155; FAUST PL, 1989, J BIOL CHEM, V264, P479; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; GLAUMANN H, 1981, INT REV CYTOL, V73, P149, DOI 10.1016/S0074-7696(08)61288-7; GORDON DA, 1988, J BIOL CHEM, V263, P2625; GRUSBY MJ, 1990, NUCLEIC ACIDS RES, V18, P4008, DOI 10.1093/nar/18.13.4008; Hagedorn H.H., 1989, P279; Hagedorn H.H., 1985, P205; HARRIS TJR, 1982, NUCLEIC ACIDS RES, V10, P2177, DOI 10.1093/nar/10.7.2177; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; HORIUCHI H, 1988, J BACTERIOL, V170, P272, DOI 10.1128/jb.170.1.272-278.1988; ICHIMARU E, 1990, J BIOCHEM-TOKYO, V108, P1009, DOI 10.1093/oxfordjournals.jbchem.a123299; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; Kunkel J.G., 1985, P83; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEA ARDEN O., 1964, J MED ENTOMOL, V1, P40, DOI 10.1093/jmedent/1.1.40; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Locke M., 1980, P227; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; NAGAO E, 1987, INSECT BIOCHEM, V17, P531, DOI 10.1016/0020-1790(87)90051-5; NEWMAN S, 1987, P NATL ACAD SCI USA, V84, P886, DOI 10.1073/pnas.84.3.886; NIELSEN DA, 1990, MOL CELL BIOL, V10, P371, DOI 10.1128/MCB.10.1.371; NORDIN JH, 1984, COMP BIOCHEM PHYS B, V79, P379, DOI 10.1016/0305-0491(84)90392-4; ORCI L, 1984, J CELL BIOL, V98, P222, DOI 10.1083/jcb.98.1.222; OSIR EO, 1986, INSECT BIOCHEM, V16, P471, DOI 10.1016/0020-1790(86)90023-5; RACIOPPI JV, 1986, INSECT BIOCHEM, V16, P255, DOI 10.1016/0020-1790(86)90104-6; Raikhel A.S., 1992, Advances in Disease Vector Research, V9, P1; RAIKHEL AS, 1986, J INSECT PHYSIOL, V32, P879, DOI 10.1016/0022-1910(86)90103-4; RAIKHEL AS, 1986, TISSUE CELL, V18, P125, DOI 10.1016/0040-8166(86)90012-1; RAIKHEL AS, 1986, J INSECT PHYSIOL, V32, P597, DOI 10.1016/0022-1910(86)90088-0; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; RUNEBERGROOS P, 1991, EUR J BIOCHEM, V202, P1021, DOI 10.1111/j.1432-1033.1991.tb16465.x; SAMBROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEWALE JG, 1984, P NATL ACAD SCI-BIOL, V81, P3703, DOI 10.1073/pnas.81.12.3703; SMITH RE, 1966, J CELL BIOL, V31, P319, DOI 10.1083/jcb.31.2.319; SOGAWA K, 1983, J BIOL CHEM, V258, P5306; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; UENO E, 1989, J BIOCHEM-TOKYO, V105, P878, DOI 10.1093/oxfordjournals.jbchem.a122772; VERDI JM, 1989, J NEUROCHEM, V52, P321, DOI 10.1111/j.1471-4159.1989.tb10935.x; VERDI JM, 1990, J BIOL CHEM, V265, P20314; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wyatt G.R., 1980, P201; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	60	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21823	21829						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400492				2022-12-27	WOS:A1992JV01100087
J	LEACH, KL; RUFF, VA; JARPE, MB; ADAMS, LD; FABBRO, D; RABEN, DM				LEACH, KL; RUFF, VA; JARPE, MB; ADAMS, LD; FABBRO, D; RABEN, DM			ALPHA-THROMBIN STIMULATES NUCLEAR DIGLYCERIDE LEVELS AND DIFFERENTIAL NUCLEAR-LOCALIZATION OF PROTEIN-KINASE-C ISOZYMES IN IIC9-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLCHOLINE BREAKDOWN; SIGNAL TRANSDUCTION; CULTURED FIBROBLASTS; MITOGENIC RESPONSE; LIVER NUCLEI; RAT-BRAIN; CELLS; PHOSPHORYLATION; HEPATOCYTES	The mechanism by which an agonist, binding to a cell surface receptor, exerts an effect on events in the nucleus is not known. We have previously shown (Leach, K. L., Ruff, V. A., Wright, T. M., Pessin, M. S., and Raben, D. M. (1991) J. Biol. Chem. 266, 3215-3221) that alpha-thrombin treatment of IIC9 cells results in increased levels of cellular 1,2-diacylglycerol (DAG) and activation of protein kinase C (PKC). Here, we have examined whether changes in nuclear PKC and nuclear DAG also are induced following alpha-thrombin treatment. IIC9 cells were treated with 500 ng/ml alpha-thrombin, and nuclei were then isolated. Western blot analysis using isozyme-specific antibodies demonstrated the presence of PKC alpha, but not PKC epsilon or zeta in the nuclei of cells treated with either phorbol 12-myristate 13-acetate or alpha-thrombin. The increase in nuclear PKC alpha levels was accompanied by a 10-fold increase in nuclear PKC specific activity and stimulated phosphorylation of at least six nuclear proteins. The rise in nuclear PKC levels occurred rapidly and reached a maximum at 30-60 s, which was followed by a decline back to the control level over the next 15 min. In addition, alpha-thrombin treatment resulted in an immediate rise in DAG mass levels in the nuclear fractions. Kinetic analysis indicated that a maximum increase in DAG levels occurred 2.5-5 min after the addition of alpha-thrombin and remained elevated for at least 30 min. In cells labeled with [H-3]myristic acid, alpha-thrombin treatment induced an increase in radiolabeled nuclear diglycerides, suggesting that the stimulated nuclear DAGs are derived, at least in part, from phosphatidylcholine. Our results suggest that increases in both nuclear DAG levels and PKC activity following alpha-thrombin treatment may play a role in mediating thrombin-induced nuclear responses such as changes in gene expression and cellular proliferation.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; UPJOHN CO,DEPT BIOCHEM,KALAMAZOO,MI 49001; CIBA GEIGY AG,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Johns Hopkins University; Pfizer; Novartis	LEACH, KL (corresponding author), UPJOHN CO,DEPT CELL BIOL,7239-267-3,KALAMAZOO,MI 49001, USA.							ADAMS LD, 1987, CURRENT PROTOCOLS MO; AMES BN, 1960, J BIOL CHEM, V235, P769; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER AP, 1986, J BIOL CHEM, V261, P9421; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; HAGIWARA M, 1990, BIOCHEM BIOPH RES CO, V168, P161, DOI 10.1016/0006-291X(90)91688-O; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; HUANG KP, 1988, J BIOL CHEM, V263, P14839; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JOHNSON HM, 1985, J IMMUNOL, V134, P967; KARIN M, 1991, HORMONAL CONTROL REG, P235; KILEY SC, 1991, J BIOL CHEM, V266, P23761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEACH KL, 1989, J CELL BIOL, V109, P605; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; MACFARLANE DE, 1986, J BIOL CHEM, V261, P6947; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MESSING RO, 1991, J BIOL CHEM, V266, P23428; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROSCOFF PM, 1988, CELL, V54, P73; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SAMUELS DS, 1989, FEBS LETT, V259, P57, DOI 10.1016/0014-5793(89)81493-0; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; THOMAS TP, 1988, CANCER RES, V48, P1910; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	51	117	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21816	21822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400491				2022-12-27	WOS:A1992JV01100086
J	LOKESHWAR, VB; BOURGUIGNON, LYW				LOKESHWAR, VB; BOURGUIGNON, LYW			TYROSINE PHOSPHATASE-ACTIVITY OF LYMPHOMA CD45 (GP180) IS REGULATED BY A DIRECT INTERACTION WITH THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE-C; F-ACTIN-BINDING; HUMAN-PLACENTA; T-CELLS; SIGNAL TRANSDUCTION; T200 GLYCOPROTEIN; MESSENGER-RNA; LY-5 ISOFORMS	GP180 is one of the major transmembrane glycoproteins in mouse T-lymphoma cells. This molecule is an isoform of CD45 and is known to contain an intrinsic protein tyrosine phosphatase (PTPase) activity. Using several complementary biochemical techniques, we have found that fodrin (a spectrin-like protein) is preferentially co-isolated with CD45 (GP180), suggesting that a complex between CD45 (GP180) and the cytoskeleton exists in mouse T-lymphoma cells. Furthermore, we have determined that this CD45 (GP180)-fodrin complex is dissociated by high salt treatment. Using in vitro binding assays, we have shown that CD45 (GP180) binds directly and specifically to fodrin (K(d) almost-equal-to 1.1 nM) or spectrin (K(d) almost-equal-to 3.2 nM) in a saturable manner. Additional analyses indicate that a 48-kDa phosphopeptide of CD45 (GP180) contains the fodrin/spectrin-binding domain. Most importantly, the direct binding of fodrin/spectrin to CD45 (GP180) is found to significantly stimulate the PTPase activity of CD45. Enzyme kinetic analysis indicates that fodrin and spectrin increase the V(max) of CD45 (GP180)-mediated dephosphorylation by 7.5 and 3.2-fold, respectively, without significantly changing the K(m) value. These results strongly suggest that the cytoskeletal proteins, fodrin and spectrin, play an important role in the regulation of the CD45 (GP180) PTPase activity during lymphocyte activation.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA06057] Funding Source: Medline; NIGMS NIH HHS [GM 36353] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; BENNETT V, 1983, METHOD ENZYMOL, V96, P314; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; BOURGUIGNON LYW, 1984, ENERGETICS SECRETION, V1, P83; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLENNEY JR, 1982, J BIOL CHEM, V257, P9781; GLENNEY JR, 1982, CELL, V28, P843, DOI 10.1016/0092-8674(82)90063-0; GLENNEY JR, 1982, P NATL ACAD SCI-BIOL, V79, P4002, DOI 10.1073/pnas.79.13.4002; HALL LR, 1988, J IMMUNOL, V141, P2781; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MINAMI Y, 1991, J BIOL CHEM, V266, P9222; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PIKE LJ, 1984, J BIOL CHEM, V259, P9913; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAGA Y, 1990, IMMUNOGENETICS, V31, P296, DOI 10.1007/BF02115003; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SHACKELFORD DA, 1986, J BIOL CHEM, V261, P8334; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; SUCHARD SJ, 1987, BIOCHIM BIOPHYS ACTA, V896, P35, DOI 10.1016/0005-2736(87)90353-1; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; THOMAS ML, 1987, CELL, V41, P8393; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	46	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21551	21557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400466				2022-12-27	WOS:A1992JV01100046
J	LOW, BC; ROSS, IK; GRIGOR, MR				LOW, BC; ROSS, IK; GRIGOR, MR			ANGIOTENSIN-II STIMULATES GLUCOSE-TRANSPORT ACTIVITY IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SPONTANEOUSLY HYPERTENSIVE RATS; NECROSIS-FACTOR-ALPHA; EARLY GENE-EXPRESSION; FACTOR-A-CHAIN; MESSENGER-RNA; 3T3-L1 PREADIPOCYTES; PHORBOL ESTER; PROTEIN; SERUM	The glucose transport system in cultured rat vascular smooth muscle cells has been examined by measuring the uptake of 2-deoxyglucose. Angiotensin II (Ang II) stimulated 2-deoxyglucose uptake in cells made quiescent by removing serum from the culture medium in a dose- and time-dependent manner that was shown to be receptor-mediated. Epidermal growth factor (EGF), fetal calf serum, thrombin, and arginine vasopressin also stimulated glucose transport. Cycloheximide did not affect the immediate-early (30 min) activation by either Ang II or EGF, but abolished any further increase. This suggested that, whereas the initial activation of glucose transport was independent of protein synthesis, the sustained increase required the synthesis of new glucose transporters. This was supported by 4-fold and 2-fold accumulations of GLUT-1 mRNA 4 h after exposure to Ang II and EGF, respectively. The induction of GLUT-1 mRNA was preceded by rapid and transient expression of c-fos and c-jun protoonco-genes. In nuclear run-on assays, nuclei from Ang II-treated cells showed increased synthesis of GLUT-1 mRNA at 30 min and 1 h after hormone treatment. In contrast, in cells exposed to actinomycin D, pretreatment with Ang II had no effect on the turnover rates of GLUT-1 mRNA. These results are consistent with Ang II acting to stimulate the rate of transcription of the GLUT-1 gene leading to increased production of GLUT-1 protein and glucose transport.	UNIV OTAGO,DEPT BIOCHEM,POB 56,DUNEDIN 9001,NEW ZEALAND	University of Otago			Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X				BERK BC, 1987, J BIOL CHEM, V262, P5065; BERK BC, 1985, J CLIN INVEST, V75, P1083, DOI 10.1172/JCI111772; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; GIBBONS GH, 1990, CLIN RES, V38, P287; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HADRAVA V, 1989, HYPERTENSION, V13, P589, DOI 10.1161/01.HYP.13.6.589; HARRIS EL, 1990, BIOCHEM BIOPH RES CO, V170, P1249, DOI 10.1016/0006-291X(90)90528-U; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; ITOH H, 1991, BIOCHEM BIOPH RES CO, V176, P1601, DOI 10.1016/0006-291X(91)90471-I; JONES TLZ, 1989, J BIOL CHEM, V264, P7874; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; NABIKA T, 1985, J BIOL CHEM, V260, P4661; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; PEKALA P, 1990, J BIOL CHEM, V265, P18051; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; Sambrook J, 1989, MOL CLONING LABORATO; SCHELLING P, 1979, J CELL PHYSIOL, V98, P503, DOI 10.1002/jcp.1040980309; SCHELLING P, 1991, J HYPERTENS, V9, P3; SCOTTBURDEN T, 1988, BIOCHEM BIOPH RES CO, V151, P583, DOI 10.1016/0006-291X(88)90634-1; SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKEUCHI K, 1990, BIOCHEM BIOPH RES CO, V172, P1189, DOI 10.1016/0006-291X(90)91574-C; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513; ZAR JH, 1974, MULTIPLE COMP BIOSTA, P151	42	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20740	20745						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400389				2022-12-27	WOS:A1992JT97800037
J	OMOTE, H; MAEDA, M; FUTAI, M				OMOTE, H; MAEDA, M; FUTAI, M			EFFECTS OF MUTATIONS OF CONSERVED LYS-155 AND THR-156 RESIDUES IN THE PHOSPHATE-BINDING GLYCINE-RICH SEQUENCE OF THE F1-ATPASE-BETA SUBUNIT OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTON-ATPASE; HEART MITOCHONDRIAL ATPASE; SITE-DIRECTED MUTAGENESIS; ONCOGENE PRODUCT P21; BETA-SUBUNIT; H+-ATPASE; NUCLEOTIDE-BINDING; ALPHA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; TRANSLOCATING ATPASE	BetaLys-155 in the glycine-rich sequence of the beta subunit of Escherichia coli F1-ATPase has been shown to be near the gamma-phosphate moiety of ATP by affinity labeling (Ida, K., Noumi, T., Maeda, M., Fukui, T., and Futai, M. (1991) J. Biol. Chem. 266, 5424-5429). For examination of the roles of betaLys- 155 and betaThr-156, mutants (betaLys-155 --> Ala, Ser, or Thr; betaThr-156 --> Ala, Cys, Asp, or Ser; betaLys-155/betaThr-156 --> betaThr-155/betaLys-156; and betaThr-156/betaVal-157 --> betaAla-156/betaThr-157) were constructed, and their properties were studied extensively. The betaSer-156 mutant was active in ATP synthesis and had approximately 1.5-fold higher membrane ATPase activity than the wild type. Other mutants were defective in ATP synthesis, had <0.1% of the membrane ATPase activity of the wild type, and showed no ATP-dependent formation of an electrochemical proton gradient. The mutants had essentially the same amounts of F1 in their membranes as the wild type. Purified mutant enzymes (betaAla-155, betaSer-155, betaAla-156, and betaCys-156) showed low rates of multisite (<0.02% of the wild type) and unisite (<1.5% of the wild type) catalyses. The k1 values of the mutant enzymes for unisite catalysis were lower than that of the wild type: not detectable with the betaAla-156 and betaCys-156 enzymes and 10(2)-fold lower with the betaAla-155 and betaSer-155 enzymes. The betaThr-156 --> Ala or Cys enzyme showed an altered response to Mg2+, suggesting that betaThr-156 may be closely related to Mg2+ binding. These results suggest that betaLys-155 and betaThr-156 are essential for catalysis and are possibly located in the catalytic site, although betaThr-156 could be replaced by a serine residue.			OMOTE, H (corresponding author), OSAKA UNIV,INST SCI & IND RES,DEPT ORGAN CHEM & BIOCHEM,IBARAKI,OSAKA 567,JAPAN.		OMOTE, Hiroshi/B-1635-2011					CROSS RL, 1982, J BIOL CHEM, V257, P2101; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HANADA H, 1989, FEBS LETT, V257, P465, DOI 10.1016/0014-5793(89)81597-2; HIRANO M, 1984, BIOCHEMISTRY-US, V23, P1652, DOI 10.1021/bi00303a011; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; IDA K, 1991, J BIOL CHEM, V266, P5424; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; NOUMI T, 1984, J BIOL CHEM, V259, P76; NOUMI T, 1986, J BIOL CHEM, V261, P9196; OHMI N, 1988, J BIOL CHEM, V263, P14261; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WISE JG, 1981, J BIOL CHEM, V256, P383; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5	38	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20571	20576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400377				2022-12-27	WOS:A1992JT97800013
J	SASAKI, J; SHICHIDA, Y; LANYI, JK; MAEDA, A				SASAKI, J; SHICHIDA, Y; LANYI, JK; MAEDA, A			PROTEIN-CHANGES ASSOCIATED WITH REPROTONATION OF THE SCHIFF-BASE IN THE PHOTOCYCLE OF ASP(96)-]ASN BACTERIORHODOPSIN - THE M(N) INTERMEDIATE WITH UNPROTONATED SCHIFF-BASE BUT N-LIKE PROTEIN-STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRIVEN PROTON PUMP; HALOBACTERIUM-HALOBIUM; ASPARTIC ACID-96; PURPLE MEMBRANE; DEPROTONATION; MECHANISM; SPECTROSCOPY; ASPARTATE-96; TRANSITION; SPECTRA	The difference Fourier transform infrared spectrum for the N intermediate in the photoreaction of the light-adapted form of bacteriorhodopsin can be recorded at pH 10 at 274 K (Pfefferle, J.-M., Maeda, A., Sasaki, J., and Yoshizawa, T. (1991) Biochemistry 30, 6548-6556). Under these conditions, Asp96-->Asn bacteriorhodopsin gives a photoproduct which shows changes in protein structure similar to those observed in N of wild-type bacteriorhodopsin. However, decreased intensity of the chromophore bands and the single absorbance maximum at about 400 nm indicate that the Schiff base is unprotonated, as in the M intermediate. This photoproduct was named M(N). At pH 7, where the supply of proton is not as restricted as at pH 10, Asp96-->Asn bacteriorhodopsin yields N with a protonated Schiff base. The Asn96 residue, which cannot deprotonate as Asp96 in wild-type bacteriorhodopsin, is perturbed upon formation of both M(N) at pH 10 and N at pH 7. We suggest that the reprotonation of the Schiff base is preceded by a large change in the protein structure including perturbation of the residue at position 96.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	Kyoto University; University of California System; University of California Irvine			Lanyi, Janos/C-3808-2011					BOUSCHE O, 1991, J BIOL CHEM, V266, P11063; BRAIMAN MS, 1987, P NATL ACAD SCI USA, V84, P5221, DOI 10.1073/pnas.84.15.5221; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; CAO Y, 1991, BIOCHEMISTRY-US, V30, P10972, DOI 10.1021/bi00109a023; DOLLINGER G, 1986, METHOD ENZYMOL, V127, P649; ENGELHARD M, 1985, BIOCHEM, V24, P100; FAHMY K, 1989, J MOL STRUCT, V214, P257, DOI 10.1016/0022-2860(89)80017-1; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; HEBERLE J, 1990, FEBS LETT, V277, P277, DOI 10.1016/0014-5793(90)80864-F; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; Lehninger A.L., 1970, BIOCH MOL BASIS CELL; LIN GC, 1991, BIOPHYS J, V60, P172, DOI 10.1016/S0006-3495(91)82040-9; LIU SY, 1990, BIOPHYS J, V57, P943, DOI 10.1016/S0006-3495(90)82614-X; MAEDA A, 1992, BIOCHEMISTRY-US, V31, P4684, DOI 10.1021/bi00134a022; MAEDA A, 1992, BIOCHEMISTRY-US, V31, P462, DOI 10.1021/bi00117a023; MAEDA A, 1991, PHOTOCHEM PHOTOBIOL, V53, P911; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MILLER A, 1990, BIOCHIM BIOPHYS ACTA, V1020, P57, DOI 10.1016/0005-2728(90)90093-J; NEEDLEMAN R, 1991, J BIOL CHEM, V266, P11478; NI B, 1990, GENE, V90, P169, DOI 10.1016/0378-1119(90)90456-2; Oesterhelt D, 1974, Methods Enzymol, V31, P667; ORMOS P, 1991, P NATL ACAD SCI USA, V88, P473, DOI 10.1073/pnas.88.2.473; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; PFEFFERLE JM, 1991, BIOCHEMISTRY-US, V30, P6548, DOI 10.1021/bi00240a027; SCHULTEN K, 1978, NATURE, V272, P85, DOI 10.1038/272085a0; TITTOR J, 1989, EMBO J, V8, P3477, DOI 10.1002/j.1460-2075.1989.tb08512.x; VARO G, 1990, BIOCHEMISTRY-US, V29, P6858, DOI 10.1021/bi00481a015; VARO G, 1991, BIOCHEMISTRY-US, V30, P5016, DOI 10.1021/bi00234a025; VARO G, 1991, BIOCHEMISTRY-US, V30, P5008, DOI 10.1021/bi00234a024	32	110	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20782	20786						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400394				2022-12-27	WOS:A1992JT97800043
J	SWARTZ, DR; MOSS, RL				SWARTZ, DR; MOSS, RL			INFLUENCE OF A STRONG-BINDING MYOSIN ANALOG ON CALCIUM-SENSITIVE MECHANICAL-PROPERTIES OF SKINNED SKELETAL-MUSCLE FIBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PSOAS FIBERS; ACTOMYOSIN ATPASE ACTIVITY; X-RAY-DIFFRACTION; TROPONIN-TROPOMYOSIN; THIN-FILAMENT; CA-2+ SENSITIVITY; ADENOSINE-TRIPHOSPHATASE; LABELED TROPOMYOSIN; FORCE GENERATION; REGULATORY SITES	The ability of strong-binding myosin heads to activate the thin filament was investigated by incubating skinned single muscle fibers with N-ethylmaleimide-(NEM) modified myosin subfragment-1 (S1). Isometric force was influenced in a complex manner: during maximal calcium activation, NEM-S1 inhibited force with half-maximal inhibition at 20 muM while at submaximal calcium, NEM-S1 potentiated force with greatest effect at 6 muM. When fibers were treated with NEM-SI (4-8 muM), the tension-pCa (-log [Ca2+]) relationship became less steep (i.e. the Hill coefficient decreased from 5.4 to 3.0 upon treatment with NEM-S1), but the midpoint was unchanged. These results support the idea that strong binding of intrinsic heads contributes to the cooperativity observed in Ca2+ activation of force. The NEM-S1-induced increase in force at low Ca2+ was associated with an acceleration of a kinetic transition, and this transition was activated to near maximum while force was not. The rate of force redevelopment following restretch (k(tr)) at submaximal calcium was increased by NEM-S1 in a concentration-dependent manner, yielding a maximum rate at low [Ca2+] which was similar to that observed during full activation. The effects of NEM-S1 on force and k(tr) indicate that strong-binding myosin cross-bridges are involved in activation of the thin filament.			SWARTZ, DR (corresponding author), UNIV WISCONSIN, DEPT PHYSIOL, MADISON, WI 53706 USA.				NCRR NIH HHS [RR 00570] Funding Source: Medline; NHLBI NIH HHS [HL25861, HL08400-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000570] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008400, R01HL025861] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRABAREK Z, 1983, J BIOL CHEM, V258, P14098; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BRANDT PW, 1990, J MOL BIOL, V212, P473, DOI 10.1016/0022-2836(90)90326-H; BRANDT PW, 1982, J GEN PHYSIOL, V79, P997, DOI 10.1085/jgp.79.6.997; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BRENNER B, 1988, Pfluegers Archiv European Journal of Physiology, V412, pR79; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; BRENNER B, 1986, P NATL ACAD SCI USA, V83, P3542, DOI 10.1073/pnas.83.10.3542; BRENNER B, 1986, BIOPHYS J, V50, P1101, DOI 10.1016/S0006-3495(86)83554-8; BRENNER B, 1986, BIOPHYS J, V50, P685, DOI 10.1016/S0006-3495(86)83509-3; BRENNER B, 1990, MOL MECHANISMS MUSCU; BURTON K, 1989, J PHYSIOL-LONDON, V418, pP66; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHALOVICH JM, 1986, J BIOL CHEM, V261, P5088; CHALOVICH JM, 1981, J BIOL CHEM, V256, P575; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; EDMAN KAP, 1980, ACTA PHYSIOL SCAND, V109, P15, DOI 10.1111/j.1748-1716.1980.tb06559.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARROW AJ, 1988, J MUSCLE RES CELL M, V9, P261, DOI 10.1007/BF01773896; GILLIS JM, 1975, J MOL BIOL, V99, P445, DOI 10.1016/S0022-2836(75)80137-9; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1986, J BIOL CHEM, V282, P1279; GREENE LE, 1980, P NATL ACAD SCI USA, V77, P2626; GUTH K, 1987, J BIOL CHEM, V262, P13627; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HILL TL, 1983, BIOPHYS J, V44, P383, DOI 10.1016/S0006-3495(83)84312-4; HOAR PE, 1987, PFLUG ARCH EUR J PHY, V410, P30, DOI 10.1007/BF00581892; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; LU Z, 1991, Biophysical Journal, V59, p417A; LU Z, 1992, BIOPHYS J, V61, P294; MEEUSEN RL, 1979, J CELL BIOL, V82, P57, DOI 10.1083/jcb.82.1.57; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MOSS RL, 1979, J PHYSIOL-LONDON, V292, P177, DOI 10.1113/jphysiol.1979.sp012845; MOSS RL, 1983, BIOPHYS J, V43, P115, DOI 10.1016/S0006-3495(83)84329-X; MOSS RL, 1986, J PHYSIOL-LONDON, V377, P487, DOI 10.1113/jphysiol.1986.sp016199; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PATE E, 1989, J MUSCLE RES CELL M, V10, P181, DOI 10.1007/BF01739809; PEMRICK S, 1976, BIOCHEMISTRY-US, V15, P5193, DOI 10.1021/bi00668a038; REISLER E, 1974, BIOCHEMISTRY-US, V13, P2014, DOI 10.1021/bi00707a003; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SEKINE T, 1964, BIOCHIM BIOPHYS ACTA, V81, P336, DOI 10.1016/0926-6569(64)90049-5; Squire J, 1981, STRUCTURAL BASIS MUS; SWARTZ DR, 1991, J CELL BIOL, V59, pA587; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WALKER JW, 1990, BIOPHYS J, V57, pA538; WALKER JW, 1992, J BIOL CHEM, V267, P2459; WALKER JW, 1991, BIOPHYS J, V59, P418; WALSH TP, 1984, J MOL BIOL, V182, P265; WATERSON JG, 1975, EUR J BIOCHEM, V56, P79; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; WELLS JA, 1980, BIOCHEMISTRY-US, V19, P1711, DOI 10.1021/bi00549a030; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; ZOT AS, 1989, BIOCHEMISTRY-US, V28, P6751, DOI 10.1021/bi00442a031; [No title captured]	71	148	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20497	20506						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400367				2022-12-27	WOS:A1992JR85800116
J	HOROWITZ, PM; BUTLER, M; MCCLURE, GD				HOROWITZ, PM; BUTLER, M; MCCLURE, GD			REDUCING SUGARS CAN INDUCE THE OXIDATIVE INACTIVATION OF RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; AUTOXIDATIVE GLYCOSYLATION; GLUCOSE AUTOXIDATION; DENATURED RHODANESE; PROTEIN; MECHANISM; FORMS	The enzyme rhodanese (thiosulfate sulfurtransferase, EC 2.8.1.1) is inactivated on incubation with reducing sugars such as glucose, mannose, or fructose, but is stable with non-reducing sugars or related polyhydroxy compounds. The enzyme is inactivated with (ES) or without (E) the transferable sulfur atom, although E is considerably more sensitive, and inactivation is accentuated by cyanide. Inactivation of E is accompanied by increased proteolytic susceptibility, a decreased sulfhydryl titer, a red-shift and quenching of the protein fluorescence, and the appearance of hydrophobic surfaces. Superoxide dismutase and/or catalase protect rhodanese. Inactive enzyme can be partially reactivated during assay and almost completely reactivated by incubation with thiosulfate, lauryl maltoside, and 2-mercaptoethanol. These results are similar to those observed when rhodanese is inactivated by hydrogen peroxide. These observations, as well as the cyanide-dependent, oxidative inactivation by phenylglyoxal, are explained by invoking the formation of reactive oxygen species such as superoxide or hydrogen peroxide from autooxidation of alpha-hydroxy carbonyl compounds, which can be facilitated by cyanide.			HOROWITZ, PM (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, BIOCHIM BIOPHYS ACTA, V956, P30, DOI 10.1016/0167-4838(88)90294-4; ARAKAWA T, 1982, BIOCHEMISTRY-US, V21, P6536, DOI 10.1021/bi00268a033; CANNELLA C, 1986, BIOCHEMISTRY-US, V25, P7319, DOI 10.1021/bi00371a012; CANNELLA C, 1983, FEBS LETT, V162, P180, DOI 10.1016/0014-5793(83)81074-6; CERAMI A, 1986, TRENDS BIOCHEM SCI, V11, P311, DOI 10.1016/0968-0004(86)90281-1; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; HAYWARD LD, 1977, CARBOHYD RES, V53, P13; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HOROWITZ PM, 1989, J BIOL CHEM, V264, P331; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; Maizel JV, 1971, METHOD VIROL, V5, P179; MASHINO T, 1987, ARCH BIOCHEM BIOPHYS, V252, P163, DOI 10.1016/0003-9861(87)90020-8; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NANDI D, 1990, 10TH MIDW ENZ CHEM C; OGATA K, 1989, J BIOL CHEM, V264, P2718; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1986, J BIOL CHEM, V261, P5615; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; WANG SF, 1968, J BIOL CHEM, V243, P5465; WENG L, 1978, J BIOL CHEM, V253, P8109; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243	28	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23596	23600						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429701				2022-12-27	WOS:A1992JZ23900029
J	KRISHNASWAMY, S				KRISHNASWAMY, S			THE INTERACTION OF HUMAN FACTOR-VIIA WITH TISSUE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-X; EXTRINSIC PATHWAY; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; COFACTOR FUNCTION; ENZYME COMPLEXES; CELL-LINE; ACTIVATION; BINDING; EXPRESSION	The interaction of factor VIIa with tissue factor (TF) results in an increase in the catalytic efficiency for the hydrolysis of several synthetic peptidyl p-nitroanilide substrates by factor VIIa. The binding of human recombinant factor VIIa to recombinant human TF incorporated into vesicles containing phosphatidylcholine (TF/PC) or phosphatidylcholine/phosphatidylserine (TF/PCPS) was studied using the increased rate of H-D-phenylalanyl L-pipecoyl L-arginine p-nitroanilide (S2238) hydrolysis as a signal for the interaction. The saturable dependence of rate on increasing concentrations of factor VIIa or TF/PCPS yielded no obvious evidence for cooperativity and could be analyzed according to the interaction of factor VIIa with independent noninteracting sites (K(d) = 259 +/- 60 pM, n = 1.05 +/- 0.12 mol of factor VIIa/mol of TF at saturation). Identical titration curves and equilibrium parameters were derived from titrations using TF/PC or TF in the absence of phospholipids, indicating that possible protein-membrane interactions do not further stabilize the extrinsic Xase complex. The dissociation constant for the interaction of factor VIIa with TF/PCPS inferred from measurements of factor X activation (K(d) = 197 +/- 38 pM) was comparable with the values obtained from measurements of S2238 hydrolysis. In contrast to the membrane-independent nature of the enzyme-cofactor interaction, the rate of factor X activation was reduced by approximately 50-fold when the enzyme complex was assembled using solution-phase TF. Collectively, the results indicate that the membrane dependence of extrinsic Xase function primarily results from an influence of the membrane surface on factor X utilization.			KRISHNASWAMY, S (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,ATLANTA,GA 30322, USA.				NHLBI NIH HHS [HL-38337, HL-47465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R29HL038337] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Berman M., 1978, SAAM MANUAL; Berman M, 1983, CONSAM USERS GUIDE; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; Cleland W W, 1979, Methods Enzymol, V63, P103; CRAMER BJW, 1988, BIOCHEM J, V239, P757; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; DRAKE TA, 1989, AM J PATHOL, V134, P1087; ESMON NL, 1982, J BIOL CHEM, V257, P859; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FORMAN SD, 1986, P NATL ACAD SCI USA, V83, P4675, DOI 10.1073/pnas.83.13.4675; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GUHA A, 1986, P NATL ACAD SCI USA, V83, P299, DOI 10.1073/pnas.83.2.299; Hem ker HC, 1983, HDB SYNTHETIC SUBSTR; KRISHNASWAMY S, 1992, FASEB J, V6, pA328; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LAWSON JH, 1992, IN PRESS METHODS ENZ; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1982, PROG HEMOST THROMB, V6, P237; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; ZUR M, 1978, J BIOL CHEM, V253, P2203; ZUR M, 1980, J BIOL CHEM, V255, P5703	48	91	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23696	23706						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429710				2022-12-27	WOS:A1992JZ23900043
J	KIM, CM; GOLDSTEIN, JL; BROWN, MS				KIM, CM; GOLDSTEIN, JL; BROWN, MS			CDNA CLONING OF MEV, A MUTANT PROTEIN THAT FACILITATES CELLULAR UPTAKE OF MEVALONATE, AND IDENTIFICATION OF THE POINT MUTATION RESPONSIBLE FOR ITS GAIN OF FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; HUMAN-FIBROBLASTS; RAT-LIVER; EXPRESSION; ACID; MECHANISM; SEQUENCE; INHIBITION; REDUCTASE	We report the expression cloning of pMev, a cDNA that facilitates cellular uptake of mevalonate. pMev was isolated from the met-18b-2 clone of Chinese hamster ovary (CHO) cells, which were selected for growth in low concentrations of mevalonate when synthesis is blocked by compactin (Faust, J. R., and Krieger, M. (1987) J. Biol. Chem. 262,1996-2004). pMev encodes a 494-residue protein, Mev, that is predicted to have 12 membrane-spanning regions, consistent with a membrane transporter. Surprisingly, levels of Mev mRNA and protein are similar in CHO and met-18b-2 cells. The Mev gene differs from the wild-type gene by a single base change that substitutes a cysteine for phenylalanine in the 10th membrane-spanning region. met-18b-2 cells are heterozygous for this dominant gain-of-function mutation. Transfection of a cDNA encoding pMev, but not the wild-type cDNA, elicited a marked increase in [H-3]mevalonate uptake and incorporation into cellular lipids in stably and transiently transfected cells. The availability of pMev will facilitate studies of [H-3]mevalonate incorporation into trace products, including p21ras and other prenylated proteins.			KIM, CM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 07062, GM 08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEISIEGEL U, 1981, J BIOL CHEM, V256, P4071; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVINE SE, 1992, P NATL ACAD SCI USA, V889, P4564; FAUST J, 1987, J BIOL CHEM, V262, P1996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLSTROM KH, 1973, J CLIN INVEST, V52, P1303, DOI 10.1172/JCI107301; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAVE JF, 1985, BIOCHEM J, V227, P247, DOI 10.1042/bj2270247; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PARKER TS, 1984, J CLIN INVEST, V74, P795, DOI 10.1172/JCI111495; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SNYDER SH, 1991, NATURE, V354, P187, DOI 10.1038/354187a0; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; van der Eb A J, 1980, Methods Enzymol, V65, P826; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	41	116	122	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23113	23121						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429658				2022-12-27	WOS:A1992JY16300064
J	AGELLON, LB; ZHANG, PQ; JIANG, XC; MENDELSOHN, L; TALL, AR				AGELLON, LB; ZHANG, PQ; JIANG, XC; MENDELSOHN, L; TALL, AR			THE CCAAT ENHANCER-BINDING PROTEIN TRANSACTIVATES THE HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; HIGH-DENSITY LIPOPROTEINS; HEPATOMA-CELLS; LIVER; C/EBP; EXPRESSION; ALBUMIN; INVITRO; FAMILY; DNA	The plasma cholesteryl ester transfer protein (CETP), primarily synthesized in the liver of several species, is expressed at very low levels in a number of transformed human liver cell lines. The human CETP gene promotor contains a sequence that closely resembles the binding site for the transcription factor CCAAT/enhancer-binding protein (C/EBP). This site is capable of binding C/EBP, as shown by electrophoretic mobility shift and DNase I footprint analyses. Transient expression of the bacterial chloramphenicol acetyltransferase gene under the control of the human CETP gene promotor gave low activities in the human hepatoma cell line, HepG2. However, in the presence of C/EBP, CAT activity was markedly elevated indicating that CETP gene promoter activity was enhanced. In primary cultures of isolated hepatocytes, CETP mRNA was lost rapidly and in parallel with the C/EBP mRNA. C/EBP may play an important role in the proper maintenance of CETP gene promoter activity, and its low levels in proliferating or cultured cells may account for the low level of the CETP gene expression in immortalized human liver cell lines or cultured hepatocytes.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032	Columbia University	AGELLON, LB (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,INST HUMAN NUTR,NEW YORK,NY 10032, USA.		Tall, Alan/AAT-8528-2021		NHLBI NIH HHS [HL21006, HL43165] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL043165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO Z, 1991, GENE DEV, V5, P1530; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; FAUST RA, 1987, ARTERIOSCLEROSIS, V7, P267, DOI 10.1161/01.ATV.7.3.267; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDRIKS HFJ, 1990, METHOD ENZYMOL, V190, P49; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JIANG XC, 1992, IN PRESS J CLIN INVE; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; PAPE ME, 1991, J BIOL CHEM, V266, P12829; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; RO HS, 1991, MOL CELL BIOL, V11, P2303, DOI 10.1128/MCB.11.4.2303; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; STEWART MJ, 1991, J BIOL CHEM, V266, P11594; STEWART MJ, 1990, MOL CELL BIOL, V10, P5007, DOI 10.1128/MCB.10.9.5007; SWENSON TL, 1987, J BIOL CHEM, V262, P16271; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764	34	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22336	22339						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429586				2022-12-27	WOS:A1992JW71900055
J	BRIGLE, KE; WESTIN, EH; HOUGHTON, MT; GOLDMAN, ID				BRIGLE, KE; WESTIN, EH; HOUGHTON, MT; GOLDMAN, ID			INSERTION OF AN INTRACISTERNAL-A PARTICLE WITHIN THE 5'-REGULATORY REGION OF A GENE ENCODING FOLATE-BINDING PROTEIN IN L1210 LEUKEMIA-CELLS IN RESPONSE TO LOW FOLATE SELECTION - ASSOCIATION WITH INCREASED PROTEIN EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT; INTEGRATION SITES; MURINE L1210; DNA; ACTIVATION; ACID; SEQUENCE; ONCOGENE; PROMOTER; GROWTH	We have previously described a subline of L1210 murine leukemia cells (LL1) selected in a low level of 5-formyltetrahydrofolate which overexpresses a membrane-bound folate-binding protein (FBP1) and exhibits a rearrangement at the locus encoding this protein. Genomic clones containing the entire FBP1-encoding DNA from both L1210 and LL1 were isolated and characterized. Sequence analysis indicates that, with exception of the 5'-region, the FBP1-encoding locus in both cell lines is identical. The rearrangement in LL1 results from the insertion of an intracisternal A particle (IAP) in the head-to-head (antisense) orientation 72 base pairs (bp) upstream of the FBP1 ATG start codon. The IAP likely provides an alternative promoter for FBP1 expression which may produce a novel transcript with enhanced stability. Presence of the IAP appears to inactivate or relocate normal cis-acting regulatory sequences as expression of the FBP1 transcript in LL1 is not regulated by the folate status of the cell.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,BOX 230,MCV STN,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NCI NIH HHS [CA-09340, CA-39807] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOTA S, 1987, GENE, V56, P1, DOI 10.1016/0378-1119(87)90153-3; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BUTTERWORTH CE, 1992, JAMA-J AM MED ASSOC, V267, P528, DOI 10.1001/jama.267.4.528; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; CONEY LR, 1991, CANCER RES, V51, P6125; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKSON C, 1990, J VIROL, V64, P784, DOI 10.1128/JVI.64.2.784-793.1990; ELWOOD PC, 1989, J BIOL CHEM, V264, P5806; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1990, BIOCHEM PHARMACOL, V39, P2019, DOI 10.1016/0006-2952(90)90624-T; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; JANSEN G, 1990, CANCER RES, V50, P7544; JANSEN G, 1991, CANCER CHEMOTH PHARM, V28, P115, DOI 10.1007/BF00689699; JANSEN G, 1989, CANCER RES, V49, P2455; Kamen B A, 1980, Methods Enzymol, V66, P678, DOI 10.1016/0076-6879(80)66527-6; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MILLER PN, 1989, TERATOLOGY, V39, P375, DOI 10.1002/tera.1420390409; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1987, BIOCHIM BIOPHYS ACTA, V925, P36, DOI 10.1016/0304-4165(87)90145-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; TARUSCIO D, 1991, CHROMOSOMA, V101, P141, DOI 10.1007/BF00355364; WESTERHOF GR, 1991, CANCER RES, V51, P5507; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	36	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22351	22355						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429588				2022-12-27	WOS:A1992JW71900058
J	CHEN, S; ZHOU, DJ				CHEN, S; ZHOU, DJ			FUNCTIONAL DOMAINS OF AROMATASE CYTOCHROME-P450 INFERRED FROM COMPARATIVE ANALYSES OF AMINO-ACID-SEQUENCES AND SUBSTANTIATED BY SITE-DIRECTED MUTAGENESIS EXPERIMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING HUMAN AROMATASE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; MEMBRANE TOPOLOGY; EXPRESSION; CDNA; P-450; GENE; ESTROGEN; BREAST	Several functional domains, especially the active site regions, in aromatase cytochrome P450 were inferred by alignment of amino acid sequences of the enzyme from five species, human, rat, mouse, chicken, and trout, and that of Pseudomonas putida cytochrome P450cam, whose x-ray structure has been determined (Poulos, T. L., Finzel, B. C., and Howard, A. J. (1987) J. Mol. Biol. 195, 687-700). The predicted functions of these domains have been evaluated by site-directed mutagenesis. Eighteen mutants, including seven new mutants, have been generated in this laboratory. The seven newly prepared mutants are Q123E, Q123H, T310S, T310C, R365K, R365A, and NDELTA20 (a mutant without the first 20 amino acids). The preparation and characterization of these new mutants are described. The structural model described in this paper should be very useful for future structure-function studies of aromatase by site-directed mutagenesis.			CHEN, S (corresponding author), CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010, USA.				NCI NIH HHS [CA 44735, CA 33572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA044735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; BROWN CA, 1989, J BIOL CHEM, V264, P4442; CHEN SU, 1988, DNA-J MOLEC CELL BIO, V7, P27, DOI 10.1089/dna.1988.7.27; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GOTOH O, 1992, J BIOL CHEM, V267, P83; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GRANAMLORENCE S, 1991, J BIOL CHEM, V266, P11939; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARADA N, 1988, BIOCHEM BIOPH RES CO, V156, P725, DOI 10.1016/S0006-291X(88)80903-3; HICKEY GJ, 1990, MOL ENDOCRINOL, V4, P3, DOI 10.1210/mend-4-1-3; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KADOHAMA M, 1992, IN PRESS J STEROID B; KALB VF, 1988, P NATL ACAD SCI USA, V85, P7221, DOI 10.1073/pnas.85.19.7221; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; KILLINGER D W, 1987, Steroids, V50, P523, DOI 10.1016/0039-128X(87)90036-5; KITAMURA M, 1991, MOL ENDOCRINOL, V5, P1373, DOI 10.1210/mend-5-10-1373; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACLUSKY N J, 1987, Steroids, V50, P459, DOI 10.1016/0039-128X(87)90032-8; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; PICADOLEONARD J, 1988, MOL ENDOCRINOL, V2, P1145, DOI 10.1210/mend-2-11-1145; POMPON D, 1989, MOL ENDOCRINOL, V3, P1477, DOI 10.1210/mend-3-9-1477; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; REED MJ, 1989, INT J CANCER, V44, P233, DOI 10.1002/ijc.2910440208; SHIMADA H, 1990, 27 YAM C INT S OXYG, P107; SILVA MC, 1989, CANCER RES, V49, P2588; TANAKA M, 1992, J MOL ENDOCRINOL, V8, P53, DOI 10.1677/jme.0.0080053; TERASHIMA M, 1991, ARCH BIOCHEM BIOPHYS, V285, P231, DOI 10.1016/0003-9861(91)90354-L; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TODA K, 1989, FEBS LETT, V247, P371, DOI 10.1016/0014-5793(89)81373-0; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; ZHOU D, 1990, CANCER RES, V50, P6949; ZHOU D, 1992, J BIOL CHEM, V267, P762; ZHOU DJ, 1991, P NATL ACAD SCI USA, V88, P410, DOI 10.1073/pnas.88.2.410	42	82	90	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22587	22594						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429608				2022-12-27	WOS:A1992JW71900093
J	EISENSTEIN, E; HAN, MS; WOO, TS; RITCHEY, JM; GIBBONS, I; YANG, YR; SCHACHMAN, HK				EISENSTEIN, E; HAN, MS; WOO, TS; RITCHEY, JM; GIBBONS, I; YANG, YR; SCHACHMAN, HK			NEGATIVE COMPLEMENTATION IN ASPARTATE-TRANSCARBAMYLASE - ANALYSIS OF HYBRID ENZYME MOLECULES CONTAINING DIFFERENT ARRANGEMENTS OF POLYPEPTIDE-CHAINS FROM WILD-TYPE AND INACTIVE MUTANT CATALYTIC SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISUBSTRATE ANALOG N-(PHOSPHONACETYL)-L-ASPARTATE; CONCERTED ALLOSTERIC TRANSITION; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; INTERCHAIN INTERACTIONS; SULFHYDRYL-GROUPS; ACTIVE-SITES; CARBAMOYLTRANSFERASE; BINDING; MODEL	A comprehensive set of hybrid molecules of aspartate transcarbamylase (ATCase) from Escherichia coli has been constructed of wild-type and mutationally altered catalytic chains. The mutant enzymes that were virtually devoid of activity contained a replacement of Gly-128 in the catalytic polypeptide chains by either Asp or Arg. The kinetic properties of these hybrid enzyme-like molecules were analyzed to evaluate the basis for the unusual quaternary constraint demonstrated by an intersubunit hybrid containing one wild-type catalytic subunit, one inactive mutant subunit (containing the Gly to Asp replacement), and three wild-type regulatory subunits. A similar intersubunit hybrid was constructed from the wild-type catalytic subunit and the mutant in which Gly-128 was replaced by Arg, and it too demonstrated a pronounced decrease in activity relative to that expected for a hybrid containing three active sites. Moreover, neither of these hybrid holoenzymes exhibited the cooperativity with respect to aspartate that is characteristic of wild-type ATCase. In contrast, hybrid holoenzymes containing at least one wild-type chain in each catalytic subunit showed cooperativity. Also, hybrid enzymes containing different arrangements of five, four, three, or two wild-type catalytic chains with an appropriate complement of mutant chains had specific activities proportional to the number of wild-type chains in the holoenzymes. Exceptions were observed only in hybrids in which one of the two subunits in the holoenzyme was composed completely of mutant catalytic chains. For these hybrids the negative complementation was manifested as a much lower enzyme activity than expected from the number of wild-type chains in the enzyme and the loss of cooperativity. Thus, the activity and allosteric properties of these hybrids is dependent on the arrangement of catalytic chains in the holoenzyme, in contrast to results obtained for hybrids containing native and chemically modified catalytic chains. Intrasubunit hybrid catalytic trimers containing one or two wild-type chains exhibited one-third and two-thirds the activity of the intact wild-type catalytic subunit, respectively, indicating the dominant negative effect that was seen in intersubunit hybrid holoenzymes is absent within trimers.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 WENDELL M STANLEY HALL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,VIRUS LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIGMS NIH HHS [GM 12159, GM 11067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM012159, R01GM012159, F32GM011067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEWELL NM, 1989, ANNU REV BIOPHYS BIO, V18, P71, DOI 10.1146/annurev.bb.18.060189.000443; BECKWITH JR, 1962, J MOL BIOL, V5, P618, DOI 10.1016/S0022-2836(62)80090-4; BETHELL MR, 1968, P NATL ACAD SCI USA, V60, P1442, DOI 10.1073/pnas.60.4.1442; BLACKBURN MN, 1977, BIOCHEMISTRY-US, V16, P5084, DOI 10.1021/bi00642a022; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; COLLINS KD, 1969, J BIOL CHEM, V244, P1869; DAVIES GE, 1970, J BIOL CHEM, V245, P1175; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; EISENSTEIN E, 1989, P NATL ACAD SCI USA, V86, P3094, DOI 10.1073/pnas.86.9.3094; EISENSTEIN E, 1989, PROTEIN FUNCTION PRA, P135; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1962, J BIOL CHEM, V237, P891; GIBBONS I, 1974, P NATL ACAD SCI USA, V71, P4452, DOI 10.1073/pnas.71.11.4452; GIBBONS I, 1975, P NATL ACAD SCI USA, V72, P4298, DOI 10.1073/pnas.72.11.4298; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P1324, DOI 10.1021/bi00651a024; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P52, DOI 10.1021/bi00646a009; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JUSTESEN J, 1975, J BACTERIOL, V123, P851, DOI 10.1128/JB.123.3.851-854.1975; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1984, P NATL ACAD SCI-BIOL, V81, P4037, DOI 10.1073/pnas.81.13.4037; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KRAUSE KL, 1985, P NATL ACAD SCI USA, V82, P1643, DOI 10.1073/pnas.82.6.1643; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWELL JO, 1989, J BIOL CHEM, V264, P2476; PETERSON CB, 1991, P NATL ACAD SCI USA, V88, P458, DOI 10.1073/pnas.88.2.458; ROBEY EA, 1986, P NATL ACAD SCI USA, V83, P5934, DOI 10.1073/pnas.83.16.5934; ROBEY EA, 1985, P NATL ACAD SCI USA, V82, P361, DOI 10.1073/pnas.82.2.361; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; SUBRAMANI S, 1981, J BIOL CHEM, V256, P1255; SUBRAMANI S, 1982, J BIOL CHEM, V257, P2219; SUBRAMANI S, 1980, J BIOL CHEM, V255, P8136; SYVANEN JM, 1973, J MOL BIOL, V76, P363, DOI 10.1016/0022-2836(73)90510-X; WALL KA, 1979, J BIOL CHEM, V254, P1910; WALLKA, 1979, J BIOL CHEM, V254, P11917; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; Yang Y R, 1978, Methods Enzymol, V51, P35; YANG YR, 1987, ANAL BIOCHEM, V163, P188, DOI 10.1016/0003-2697(87)90111-4; YANG YR, 1988, ENZYME DYNAMICS REGU, P394; YOUNG TS, 1985, THESIS DUKE U	44	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22148	22155						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429567				2022-12-27	WOS:A1992JW71900027
J	FERRANTI, P; MALORNI, A; MARINO, G; PUCCI, P; GOODWIN, GH; MANFIOLETTI, G; GIANCOTTI, V				FERRANTI, P; MALORNI, A; MARINO, G; PUCCI, P; GOODWIN, GH; MANFIOLETTI, G; GIANCOTTI, V			MASS-SPECTROMETRIC ANALYSIS OF THE HMGY PROTEIN FROM LEWIS LUNG-CARCINOMA - IDENTIFICATION OF PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEINS; AMINO-ACID SEQUENCES; NUCLEAR PROTEINS; CDC2 KINASE; HISTONE H-1; CELLS; DNA; BINDING; FRACTIONATION; CASEIN	The primary structure of the Lewis lung carcinoma protein HMGY belonging to the nuclear group of proteins HMGI (high mobility group I) was determined using electrospray and fast atom bombardment mass spectrometry. It was demonstrated that the sequence of the tumor protein corresponds to the amino acid sequence derived from the cDNA from cultured cells and that the N-terminal serine residue is N-acetylated. Moreover, the two high performance liquid chromatography-purified forms Y1 and Y2 of the protein HMGY were shown to differ at the level of serine phosphorylation, since they contain three phosphate and two phosphate groups, respectively, in the C-terminal region. No other modification was detected in the remaining part of the molecule.	UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC,VIA A VALERIO 38,I-34127 TRIESTE,ITALY; CTR INGN GENET,NAPLES,ITALY; INST CANC RES,CHESTER BEATTY RES INST,SUTTON SM2 5PX,SURREY,ENGLAND; CNR,SERV SPETTROMETRIA MASSA,I-80131 NAPLES,ITALY	University of Trieste; University of London; Institute of Cancer Research - UK; Consiglio Nazionale delle Ricerche (CNR)			Ferranti, Pasquale/ABF-8111-2021	FERRANTI, Pasquale/0000-0002-6250-6512; PUCCI, Pietro/0000-0002-5885-1495; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601				ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; FASHENA JS, 1992, MOL CELL BIOL, V12, P894; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GOODWIN GH, 1985, EUR J BIOCHEM, V149, P47, DOI 10.1111/j.1432-1033.1985.tb08891.x; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LUND T, 1987, BIOCHEM BIOPH RES CO, V146, P725, DOI 10.1016/0006-291X(87)90589-4; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; LUND T, 1983, FEBS LETT, V152, P163, DOI 10.1016/0014-5793(83)80370-6; LUND T, 1985, FEBS LETT, V180, P163; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; MORRIS HR, 1983, BIOCHEM BIOPH RES CO, V117, P299, DOI 10.1016/0006-291X(83)91575-9; NAYLOR S, 1986, J AM CHEM SOC, V108, P6359, DOI 10.1021/ja00280a037; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OHE Y, 1986, J BIOCHEM-TOKYO, V100, P359, DOI 10.1093/oxfordjournals.jbchem.a121722; OHE Y, 1989, J BIOCHEM-TOKYO, V106, P844, DOI 10.1093/oxfordjournals.jbchem.a122941; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; PALVIMO J, 1986, BIOCHEM BIOPH RES CO, V134, P617, DOI 10.1016/S0006-291X(86)80464-8; PETRILLI P, 1986, BIOCHEM BIOPH RES CO, V140, P28, DOI 10.1016/0006-291X(86)91053-3; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUCCI P, 1992, BIOL MASS SPECTROM, V21, P22, DOI 10.1002/bms.1200210106; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; REEVES R, 1990, J BIOL CHEM, V265, P8753; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; VANFLETEREN JR, 1988, BIOCHEM J, V255, P647; VONHOLT C, 1979, FEBS LETT, V100, P201, DOI 10.1016/0014-5793(79)80337-3	35	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22486	22489						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429598				2022-12-27	WOS:A1992JW71900078
J	SUGITA, M; FUJII, H; INAGAKI, F; SUZUKI, M; HAYATA, C; HORI, T				SUGITA, M; FUJII, H; INAGAKI, F; SUZUKI, M; HAYATA, C; HORI, T			POLAR GLYCOSPHINGOLIPIDS IN ANNELIDA - A NOVEL SERIES OF GLYCOSPHINGOLIPIDS CONTAINING CHOLINE PHOSPHATE FROM THE EARTHWORM, PHERETIMA-HILGENDORFI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-BOTTLE FLY; FRESH-WATER BIVALVE; LUCILIA-CAESAR; HYRIOPSIS-SCHLEGELII; SUGAR SEQUENCES; LARVAE; SPERMATOZOA	A novel series of glycosphingolipids containing choline phosphate has been demonstrated in whole tissues of the earthworm, Pheretima hilgendorfi. The thin layer chromatographic pattern of the total polar glycolipids revealed the presence of more than three components with positive reactions toward orcinol-sulfuric acid (sugar), molybdate (phosphate), and Dragendorff's (choline) spray reagents. Two of these polar glycolipids (PGL1 and PGL2) were purified by the use of successive column chromatography on QAE-Sephadex A-25 and silicic acid (Iatrobeads) and detected during elution by the presence of galactose-bound choline phosphate. The structural elucidation of the oligosaccharide moieties was performed by compositional sugar analysis, hydrogen fluoride degradation, proton magnetic resonance spectroscopy, fast atom bombardment mass spectrometry, and methylation analysis. Thus, the structures of PGL1 and PGL2 were deduced to be as follows: cholinephosphoryl --> 6Galbeta1-1Cer and cholinephosphoryl-->6Galbeta1-6Galbeta1-1Cer. Although the oligosaccharide structures of both PGL1 and PGL2 have previously been found in other organisms, the presence of a choline phosphate group as an oligosaccharide substituent is the first finding in nature. The main molecular species of the ceramide moieties were composed of beheninyl- and lignocerinyloctadecasphingenines and their nonadecasphingenine homologues.	TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; SHIGA JR COLL CULTURAL STUDIES,YOKAICHI,SHIGA 527,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	SUGITA, M (corresponding author), SHIGA UNIV,FAC LIBERAL ARTS & EDUC,DEPT CHEM,OTSU,SHIGA 520,JAPAN.							BJORNDAL H, 1970, ANGEW CHEM, V82, P643; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; HORI T, 1977, J BIOCHEM-TOKYO, V81, P107, DOI 10.1093/oxfordjournals.jbchem.a131424; HORI T, 1977, J BIOCHEM-TOKYO, V82, P1281, DOI 10.1093/oxfordjournals.jbchem.a131815; HORI T, 1983, J BIOL CHEM, V258, P2239; HORI T, 1981, J BIOL CHEM, V256, P979; ITONORI S, 1991, BIOCHIM BIOPHYS ACTA, V1081, P321, DOI 10.1016/0005-2760(91)90289-T; ITONORI S, 1991, J BIOCHEM-TOKYO, V110, P479, DOI 10.1093/oxfordjournals.jbchem.a123607; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; OKAMURA N, 1985, P NATL ACAD SCI USA, V82, P6779, DOI 10.1073/pnas.82.20.6779; ROE JH, 1955, J BIOL CHEM, V212, P335; SUGITA M, 1989, J BIOL CHEM, V264, P15028; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P327, DOI 10.1093/oxfordjournals.jbchem.a133938; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P881, DOI 10.1093/oxfordjournals.jbchem.a134002; SUGITA M, 1981, J BIOCHEM-TOKYO, V90, P1529, DOI 10.1093/oxfordjournals.jbchem.a133620; SUGITA M, 1990, J BIOCHEM-TOKYO, V107, P899, DOI 10.1093/oxfordjournals.jbchem.a123145; SUGITA M, 1992, YUKAGAKU, V41, P568	19	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22595	22598						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429609				2022-12-27	WOS:A1992JW71900094
J	AFFORD, SC; PONGRACZ, J; STOCKLEY, RA; CROCKER, J; BURNETT, D				AFFORD, SC; PONGRACZ, J; STOCKLEY, RA; CROCKER, J; BURNETT, D			THE INDUCTION BY HUMAN INTERLEUKIN-6 OF APOPTOSIS IN THE PROMONOCYTIC CELL-LINE U937 AND HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; GROWTH-FACTOR; PROTEIN-SYNTHESIS; T-CELLS; DEATH; RNA; DIFFERENTIATION; BETA	Apoptosis of neutrophils at sites of inflammation in vivo is thought to lead to their recognition and safe elimination by macrophages. Little is known, however, about the regulation of apoptosis in myeloid cells. We report here that the human promonocytic leukemic cell line, U937, and mature human neutrophils can be induced to become apoptotic when cultured with interleukin-6. Apoptosis of U937 cells, assessed morphologically and by the presence of DNA fragmentation, was increased significantly in a dose-dependent fashion by concentrations of 0.5-100 ng/ml interleukin-6. Apoptosis of U937 cells was evident after 48 h of incubation with 20 ng/ml interleukin-6, and the effect was eliminated by adsorption of interleukin-6 with a specific monoclonal antibody. Apoptosis was not evident in the presence of the differentiating agent phorbol 12-myristate 13 acetate; the induction of apoptosis in U937 cells was not therefore a consequence of differentiation. Apoptosis of mature neutrophils was enhanced after 24 h in culture with interleukin-6. Interleukin-6 might be an important factor in the normal resolution of inflammation through the induction of apoptosis of neutrophils.	GEN HOSP,LUNG IMMUNOBIOCHEM RES LAB,CLIN TEACHING BLOCK,STEELHOUSE LANE,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,DEPT HISTOPATHOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			Pongracz, Judit E/N-7927-2018; Pongracz, Judit E/J-7517-2019	Pongracz, Judit E/0000-0002-0278-5556; Pongracz, Judit E/0000-0002-0278-5556	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; CASTELL JV, 1990, HEPATOLOGY, V12, P1179, DOI 10.1002/hep.1840120517; CHEN L, 1988, FEBS LETT, V239, P299, DOI 10.1016/0014-5793(88)80939-6; CONTENT J, 1982, P NATL ACAD SCI-BIOL, V79, P2768, DOI 10.1073/pnas.79.9.2768; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; JEPSEN LV, 1982, SCAND J CLIN LAB INV, V42, P235; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SEHGAL PB, 1980, NATURE, V288, P95, DOI 10.1038/288095a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WHYTE M K B, 1992, American Review of Respiratory Disease, V145, pA278; WHYTE M K B, 1991, American Review of Respiratory Disease, V143, pA331; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	127	128	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21612	21616						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400472				2022-12-27	WOS:A1992JV01100056
J	DAVIS, RC; WONG, H; NIKAZY, J; WANG, K; HAN, Q; SCHOTZ, MC				DAVIS, RC; WONG, H; NIKAZY, J; WANG, K; HAN, Q; SCHOTZ, MC			CHIMERAS OF HEPATIC LIPASE AND LIPOPROTEIN-LIPASE - DOMAIN LOCALIZATION OF ENZYME-SPECIFIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC LIPASE; N-LINKED GLYCOSYLATION; MESSENGER-RNA LEVELS; TRIGLYCERIDE LIPASE; GENE FAMILY; MOLECULAR-CLONING; CDNA SEQUENCE; TRIAD FORMS; GUINEA-PIG; EXPRESSION	Chimeric molecules between human lipoprotein lipase (LPL) and rat hepatic lipase (HL) were used to identify structural elements responsible for functional differences. Based on the close sequence homology with pancreatic lipase, both LPL and HL are believed to have a two-domain structure composed of an amino-terminal (NH2-terminal) domain containing the catalytic Ser-His-Asp triad and a smaller carboxyl-terminal (COOH-terminal) domain. Experiments with chimeric lipases containing the HL NH2-terminal domain and the LPL COOH-terminal domain (HL/LPL) or the reverse chimera (LPL/HL) showed that the NH2-terminal domain is responsible for the catalytic efficiency (V(max)/K(m)) of these enzymes. Furthermore, it was demonstrated that the stimulation of LPL activity by apolipoprotein C-II and the inhibition of activity by 1 M NaCl originate in structural features within the NH2-terminal domain. HL and LPL bind to vascular endothelium, presumably by interaction with cell surface heparan sulfate proteoglycans. However, the two enzymes differ significantly in their heparin affinity. Experiments with the chimeric lipases indicated that heparin binding avidity was primarily associated with the COOH-terminal domain. Specifically, both HL and the LPL/HL chimera were eluted from immobilized heparin by 0.75 M NaCl, whereas 1.1 M NaCl was required to elute LPL and the HL/LPL chimera. Finally, HL is more active than LPL in the hydrolysis of phospholipid substrates. However, the ratio of phospholipase to neutral lipase activity in both chimeric lipases was enhanced by the presence of the heterologous COOH-terminal domain, demonstrating that this domain strongly influences substrate specificity. The NH2-terminal domain thus controls the kinetic parameters of these lipases, whereas the COOH-terminal domain modulates substrate specificity and heparin binding.	UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	DAVIS, RC (corresponding author), VET ADM WADSWORTH MED CTR, DEPT LIPID RES, LOS ANGELES, CA 90073 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMEIS D, 1990, J BIOL CHEM, V265, P6552; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; Borgstrom B., 1984, P151; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAILLAN C, 1992, BIOCHEM BIOPH RES CO, V184, P206, DOI 10.1016/0006-291X(92)91179-T; CHANG SF, 1991, FEBS LETT, V289, P69, DOI 10.1016/0014-5793(91)80910-U; CHENG CF, 1985, J BIOL CHEM, V260, P720; COOPER DA, 1989, BIOCHIM BIOPHYS ACTA, V1008, P92, DOI 10.1016/0167-4781(89)90174-7; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; EMI M, 1990, J BIOL CHEM, V265, P5910; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HEERY DM, 1990, TRENDS GENET, V6, P173; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; LOWE ME, 1989, J BIOL CHEM, V264, P20042; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OKA K, 1989, ANN NY ACAD SCI, V556, P173; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; ROJAS C, 1991, EUR J BIOCHEM, V197, P315, DOI 10.1111/j.1432-1033.1991.tb15913.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; STAHNKE G, 1991, J LIPID RES, V32, P477; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; TWU JS, 1984, BIOCHIM BIOPHYS ACTA, V792, P330, DOI 10.1016/0005-2760(84)90201-7; Verger R., 1984, P83; WARREN RJ, 1991, J LIPID RES, V32, P1333; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	52	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21499	21504						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400461				2022-12-27	WOS:A1992JV01100038
J	HOLMBERG, L; MELANDER, Y; NYGARD, O				HOLMBERG, L; MELANDER, Y; NYGARD, O			RIBOSOME-BOUND EUKARYOTIC ELONGATION FACTOR-II PROTECTS 5-S RIBOSOMAL-RNA FROM MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; ESCHERICHIA-COLI; FACTOR-II; CROSS-LINKING; BIOLOGICAL PROPERTIES; 70S RIBOSOMES; BINDING SITE; TRANSFER-RNA; FACTOR EF-2; 23S RNA	The interaction between eukaryotic elongation factor eEF-2 and reconstituted 80 S ribosomes was investigated by analyzing the accessibility of 5 S ribosomal RNA for chemical and enzymatic modification. Ribosomes reconstituted from derived subunits were modified, and the positions of the modified sites were identified by primer extension using a 5 S rRNA-specific probe. All reactive sites were located between nucleotides 38 and 99, and most of them were found in putative single-stranded regions of the 5 S rRNA. Conversion of the ribosomes to the post-translocation type of particles by treatment with the translational inhibitor ricin resulted in the exposure of 3 additional bases for chemical modification, suggesting that the 5 S rRNA was more exposed in this type of ribosome. After binding of eEF-2 in complex with the non-hydrolyzable GTP analogue guanosine 5'-(beta, gamma-methylene)-triphosphate, most of the exposed bases in the 5 S rRNA were protected against both chemical and enzymatic modification.	UNIV STOCKHOLM, ARRHENIUS LAB, DEPT ZOOL CELL BIOL, S-10691 STOCKHOLM, SWEDEN	Stockholm University								BRAWERMAN G, 1972, BIOCHEMISTRY-US, V11, P637, DOI 10.1021/bi00754a027; BRUNEL C, 1991, J MOL BIOL, V221, P293; BURMA DP, 1984, BIOCHEM BIOPH RES CO, V124, P970, DOI 10.1016/0006-291X(84)91053-2; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ENDO Y, 1991, J MOL BIOL, V221, P193, DOI 10.1016/0022-2836(91)90814-M; FARBER NM, 1981, J MOL BIOL, V146, P241, DOI 10.1016/0022-2836(81)90434-4; GRUMMT F, 1974, EUR J BIOCHEM, V43, P343, DOI 10.1111/j.1432-1033.1974.tb03418.x; HAPKE B, 1976, J MOL BIOL, V105, P97, DOI 10.1016/0022-2836(76)90196-0; HERR W, 1979, J MOL BIOL, V130, P421, DOI 10.1016/0022-2836(79)90432-7; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NILSSON L, 1984, BIOCHIM BIOPHYS ACTA, V782, P49, DOI 10.1016/0167-4781(84)90105-2; NILSSON L, 1986, EUR J BIOCHEM, V161, P111, DOI 10.1111/j.1432-1033.1986.tb10130.x; NYGARD O, 1987, BIOCHIM BIOPHYS ACTA, V908, P46, DOI 10.1016/0167-4781(87)90020-0; NYGARD O, 1987, BIOCHIM BIOPHYS ACTA, V910, P245; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; NYGARD O, 1989, EUR J BIOCHEM, V179, P603, DOI 10.1111/j.1432-1033.1989.tb14589.x; NYGARD O, 1990, J BIOL CHEM, V265, P6030; NYGARD O, 1982, EMBO J, V1, P357, DOI 10.1002/j.1460-2075.1982.tb01174.x; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; OVCHINNIKOV LP, 1978, FEBS LETT, V88, P21, DOI 10.1016/0014-5793(78)80598-5; PALEOLOGUE A, 1986, FEBS LETT, V208, P373, DOI 10.1016/0014-5793(86)81052-3; Sambrook J, 1989, MOL CLONING LABORATO; SARGE KD, 1991, BIOCHIM BIOPHYS ACTA, V1088, P57, DOI 10.1016/0167-4781(91)90153-D; SILBERKLANG M, 1983, NUCLEIC ACIDS RES, V11, P605, DOI 10.1093/nar/11.3.605; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SPIRIN AS, 1969, COLD SPRING HARB SYM, V34, P197, DOI 10.1101/SQB.1969.034.01.026; TAKAHASHI Y, 1985, EUR J BIOCHEM, V152, P279, DOI 10.1111/j.1432-1033.1985.tb09195.x; TERAO K, 1975, BIOCHIM BIOPHYS ACTA, V402, P230, DOI 10.1016/0005-2787(75)90042-8; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; VANDIGGELEN OP, 1973, EUR J BIOCHEM, V39, P511; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WOOL IG, 1984, TRENDS BIOCHEM SCI, V9, P14, DOI 10.1016/0968-0004(84)90040-9	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21906	21910						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400500				2022-12-27	WOS:A1992JV01100099
J	KAWAI, T; NISHIKIMI, M; OZAWA, T; YAGI, K				KAWAI, T; NISHIKIMI, M; OZAWA, T; YAGI, K			A MISSENSE MUTATION OF L-GULONO-GAMMA-LACTONE OXIDASE CAUSES THE INABILITY OF SCURVY-PRONE OSTEOGENIC DISORDER RATS TO SYNTHESIZE L-ASCORBIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; MESSENGER-RNAS; GENE; LIVER; PROTEINS; ENZYME	The osteogenic disorder Shionogi (ODS) rat is a mutant Wistar rat that is subject to scurvy, because it lackS L-gulono-gamma-lactone oxidase, a key enzyme in L-ascorbic acid biosynthesis. Sequencing of polymerase chain reaction-amplified cDNAs for mutant and normal rat L-gulono-gamma-lactone oxidases demonstrated that the mutant cDNA has a single base mutation from G to A at nucleotide 182, which mutation alters the 61st amino acid residue from Cys to Tyr. To test the effect of this mutation on the expression of L-gulono-gamma-lactone oxidase, we inserted a region of the cDNAs coding for normal and mutant L-gulono-gamma-lactone oxidases into an expression vector, pSVL, and transfected COS-1 cells with such vectors. The result indicated that the defined amino acid substitution does decrease both the amount of immunologically detectable protein and the level of enzyme activity to about one-tenth of their normal values, while it does not affect the amount of the mRNA produced in the transfected cells. This situation is similar to our previous observation that L-gulono-gamma-lactone oxidase is expressed in the liver of the ODS rat at a very low level irrespective of the presence of a normal amount of L-gulono-gamma-lactone oxidase-specific mRNA of a normal size (Nishikimi, M., Koshizaka, T., Kondo, K., and Yagi, K. (1989) Experientia (Basel) 45, 126-129). Thus it became clear that the Cys --> Tyr substitution is responsible for the L-gulono-gamma-lactone oxidase deficiency in the ODS rat.	INST APPL BIOCHEM,YAGI MEM PK,MITAKE,GIFU 50501,JAPAN; NAGOYA UNIV,FAC MED,DEPT BIOL CHEM,NAGOYA,AICHI 466,JAPAN	Nagoya University								BURNS JJ, 1976, METABOLIC PATHWAYS, V1, P394; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KITO M, 1991, BIOCHEM INT, V24, P131; KOSHIZAKA T, 1989, J CLIN BIOCHEM NUTR, V7, P185; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835; Markwell M A, 1981, Methods Enzymol, V72, P296; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MIZUSHIMA Y, 1984, EXPERIENTIA, V40, P359, DOI 10.1007/BF01952551; NISHIKIMI M, 1989, EXPERIENTIA, V45, P126, DOI 10.1007/BF01954844; NISHIKIMI M, 1988, BIOCHEM INT, V16, P615; NISHIKIMI M, 1976, ARCH BIOCHEM BIOPHYS, V175, P427, DOI 10.1016/0003-9861(76)90530-0; NISHIKIMI M, 1992, J BIOL CHEM, V267, P21967; NISHIKIMI M, 1989, BIOCHEM BIOPH RES CO, V159, P19, DOI 10.1016/0006-291X(89)92398-X; NISHIKIMI M, 1988, ARCH BIOCHEM BIOPHYS, V267, P842, DOI 10.1016/0003-9861(88)90093-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	23	62	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21973	21976						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400508				2022-12-27	WOS:A1992JV01100109
J	NISHIKIMI, M; KAWAI, T; YAGI, K				NISHIKIMI, M; KAWAI, T; YAGI, K			GUINEA-PIGS POSSESS A HIGHLY MUTATED GENE FOR L-GULONO-GAMMA-LACTONE OXIDASE, THE KEY ENZYME FOR L-ASCORBIC-ACID BIOSYNTHESIS MISSING IN THIS SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL CONTROL; MESSENGER-RNAS; SEQUENCE; SUBSTITUTIONS; ELEMENTS; SIGNALS; REGIONS; RAT	Guinea pigs cannot synthesize L-ascorbic acid because of their deficiency in L-gulono-gamma-lactone oxidase, a key enzyme for the biosynthesis of this vitamin in higher animals. In this study we isolated the L-gulono-gamma-lactone oxidase gene of the rat and the homologue of this gene of the guinea pig by screening rat and guinea pig genomic DNA libraries in lambda phage vectors, respectively, using a rat L-gulono-gamma-lactone oxidase cDNA as a probe. Sequencing analysis showed that the amino acid sequence of the rat enzyme is encoded by 12 exons and that all the intron/exon boundaries follow the GT/AG rule. On the other hand, regions corresponding to exons I and V were not identified in the guinea pig L-gulono-gamma-lactone oxidase gene homologue. Other defects found in this gene homologue are a deletion of the nucleotide sequence corresponding to a 3' 84-base pair part of rat exon VI, a 2-base pair deletion in the remaining exon VI-related region, and nonconformance to the GT/AG rule at one of the putative intron/exon boundaries. Furthermore, a large number of mutations were found in the amino acid-coding regions of the guinea pig sequence; more than half of them lead to nonconservative amino acid changes, and there are three stop codons as well. Thus it is clear that the guinea pig homologue of the L-gulono-gamma-lactone oxidase gene exists as a pseudogene that randomly accumulated a large number of mutations without functional constraint since the gene ceased to be active during evolution. On the basis of the neutral theory of evolution, the date of the loss of L-gulono-gamma-lactone oxidase in the ancestors of the guinea pig was roughly calculated to be less than 20 million years ago.			NISHIKIMI, M (corresponding author), INST APPL BIOCHEM, YAGI MEM PK, GIFU 50501, JAPAN.							BENOIST C, 1980, NUCLEIC ACIDS RES, V8, P127, DOI 10.1093/nar/8.1.127; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURNS JJ, 1957, NATURE, V180, P552, DOI 10.1038/180553a0; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYASHIDA H, 1983, P NATL ACAD SCI-BIOL, V80, P2671, DOI 10.1073/pnas.80.9.2671; HENDRIKS W, 1987, P NATL ACAD SCI USA, V84, P5320, DOI 10.1073/pnas.84.15.5320; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JUKES T H, 1969, P21; Kimura M., 1983, NEUTRAL THEORY MOL E; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MIYATA T, 1980, J MOL EVOL, V16, P23, DOI 10.1007/BF01732067; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEI M, 1986, MOL BIOL EVOL, V3, P418; NISHIKIMI M, 1976, P NATL ACAD SCI USA, V73, P2066, DOI 10.1073/pnas.73.6.2066; NISHIKIMI M, 1988, ARCH BIOCHEM BIOPHYS, V267, P842, DOI 10.1016/0003-9861(88)90093-8; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SWIMMER C, 1985, NUCLEIC ACIDS RES, V13, P8053, DOI 10.1093/nar/13.22.8053	26	116	122	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21967	21972						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400507				2022-12-27	WOS:A1992JV01100108
J	OKADA, Y; GONOJI, Y; NAKA, K; TOMITA, K; NAKANISHI, I; IWATA, K; YAMASHITA, K; HAYAKAWA, T				OKADA, Y; GONOJI, Y; NAKA, K; TOMITA, K; NAKANISHI, I; IWATA, K; YAMASHITA, K; HAYAKAWA, T			MATRIX METALLOPROTEINASE-9 (92-KDA GELATINASE TYPE-IV COLLAGENASE) FROM HT-1080 HUMAN FIBROSARCOMA CELLS - PURIFICATION AND ACTIVATION OF THE PRECURSOR AND ENZYMATIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; HUMAN 72-KDA PROGELATINASE; TISSUE INHIBITOR; BASEMENT-MEMBRANE; TUMOR INVASION; CARCINOMA; STROMELYSIN; MECHANISMS; PROCOLLAGENASE; AUTOACTIVATION	Matrix metalloproteinase 9 (MMP-9) has been purified as an inactive zymogen of M(r) 92,000 (proMMP-9) from the culture medium of HT 1080 human fibrosarcoma cells. The NH2-terminal sequence of proMMP-9 is Ala-Pro-Arg-Gln-Arg-Gln-Ser-Thr-Leu-Val-Leu-Phe-Pro, which is identical to that of the 92-kDa type IV collagenase/gelatinase. The zymogen can be activated by 4-aminophenylmercuric acetate, yielding an intermediate form of M(r) 83,000 and an active species of M(r) 67,000, the second of which has a new NH2 terminus of Met-Arg-Thr-Pro-Arg-(Cys)-Gly-Val-Pro-Asp-Leu-Gly-Arg-Phe-Gln-Thr-Phe-Glu. Immunoblot analyses demonstrate that this activation process is achieved by sequential processing of both NH2- and COOH-terminal peptides. TIMP-1 complexed with proMMP-9 inhibits the conversion of the intermediate form to the active species of M(r) 67,000. The proenzyme is fully activated by cathepsin G, trypsin, alpha-chymotrypsin, and MMP-3 (stromelysin 1) but not by plasmin, leukocyte elastase, plasma kallikrein, thrombin, or MMP-1 (tissue collagenase). During the activation by MMP-3, proMMP-9 is converted to an active species of M(r) 64,000 that lacks both NH2- and COOH-terminal peptides. In addition, HOCl partially activates the zymogen by reacting with an intermediate species of M(r) 83,000. The enzyme degrades type I gelatin rapidly and also cleaves native collagens including alpha2 chain of type I collagen, collagen types III, IV, and V at undenaturing temperatures. These results indicate that MMP-9 has different activation mechanisms and substrate specificity from those of MMP-2 (72-kDa gelatinase/type IV collagenase).	KANAZAWA UNIV, SCH MED, DEPT ORTHOPED SURG, KANAZAWA, ISHIKAWA 920, JAPAN; FUJI CHEM IND CO LTD, TAKAOKA 933, JAPAN; AICHI GAKUIN UNIV, SCH DENT, DEPT BIOCHEM, NAGOYA 464, JAPAN	Kanazawa University; Aichi Gakuin University	OKADA, Y (corresponding author), KANAZAWA UNIV, SCH MED, DEPT PATHOL, 13-1 TAKARA MACHI, KANAZAWA, ISHIKAWA 920, JAPAN.		Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755				BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BERNHARD EJ, 1990, CANCER RES, V50, P3872; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DAVIS GE, 1990, CANCER RES, V50, P1113; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KODAMA S, 1990, J IMMUNOL METHODS, V127, P103, DOI 10.1016/0022-1759(90)90345-V; KODAMA S, 1987, COLLAGEN REL RES, V7, P341; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LYONS JG, 1991, BIOCHEMISTRY-US, V30, P1449, DOI 10.1021/bi00220a001; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MINAMOTO T, 1988, HUM PATHOL, V19, P815, DOI 10.1016/S0046-8177(88)80265-X; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MOLL UM, 1990, CANCER RES, V50, P6162; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; Nagase H, 1992, Matrix Suppl, V1, P421; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OKADA Y, 1989, FEBS LETT, V244, P473, DOI 10.1016/0014-5793(89)80586-1; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; REICH R, 1988, CANCER RES, V48, P3307; Ruoslahti E, 1978, Ann N Y Acad Sci, V312, P178, DOI 10.1111/j.1749-6632.1978.tb16802.x; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAH SV, 1987, J CLIN INVEST, V79, P25, DOI 10.1172/JCI112790; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STRICKLIN GP, 1992, MATRIX METALLOPROTEI, P325; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMAGATA S, 1988, BIOCHEM BIOPH RES CO, V151, P158, DOI 10.1016/0006-291X(88)90573-6; YAMAGATA S, 1989, BIOCHEM BIOPH RES CO, V158, P228, DOI 10.1016/S0006-291X(89)80202-5; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040	54	501	512	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21712	21719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400481				2022-12-27	WOS:A1992JV01100071
J	CYR, DM; LU, XY; DOUGLAS, MG				CYR, DM; LU, XY; DOUGLAS, MG			REGULATION OF HSP70 FUNCTION BY A EUKARYOTIC DNAJ HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; STRESS PROTEINS; BINDING; YEAST; NUCLEOTIDES; TRANSLOCATION	We report that a purified cytoplasmic Hsp70 homolog from saccharomyces cerevisiae, HSp70SSA1, exhibits a weak ATPase activity, which is stimulated by a purified eukaryotic dnaJp homolog (YDJ1p). Stable complex formation between Hsp70SSA1 and the permanently unfolded protein carboxymethylated alpha-lactalbumin (CMLA) was assayed by native gel electrophoresis. The affinity of Hsp70SSA1 for CMLA appeared to be regulated by YDJ1p. Significant reduction in both CMLA-Hsp70SSA1 Complex formation and the release of CMLA pre-bound to Hsp70SSA1 was observed only in the presence of both YDJ1p and ATP. Thus, Hsp70SSA1 and YDJ1p interact functionally in the execution of Hsp70SSA1 chaperone activities in the eukaryotic cell.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36537] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANG D, 1991, J BIOL CHEM, V266, P24233; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P327; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P29; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CYR DM, 1991, J BIOL CHEM, V266, P21700; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GAO BC, 1991, J BIOL CHEM, V266, P19565; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P1912; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIEBEREK K, 1991, J BIOL CHEM, V266, P14491; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SHOLOMAI J, 1980, J BIOL CHEM, V255, P6789; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0	28	236	240	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20927	20931						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400408				2022-12-27	WOS:A1992JT97800066
J	DELAIRE, M; LABIA, R; SAMAMA, JP; MASSON, JM				DELAIRE, M; LABIA, R; SAMAMA, JP; MASSON, JM			SITE-DIRECTED MUTAGENESIS AT THE ACTIVE-SITE OF ESCHERICHIA-COLI TEM-1 BETA-LACTAMASE - SUICIDE INHIBITOR-RESISTANT MUTANTS REVEAL THE ROLE OF ARGININE-244 AND METHIONINE-69 IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-ALBUS-G; BACILLUS-LICHENIFORMIS 749/C; PENICILLANIC ACID SULFONE; CLAVULANIC ACID; CRYSTAL-STRUCTURE; INACTIVATION; RESOLUTION; MECHANISM; SUBSTRATE; ENZYMES	Arginine 244 is a highly conserved residue in Class A beta-lactamases, while methionine 69 is not. Informational suppression experiments show that replacement of M69 by a leucine, or that of R244 by most other amino acids lead to clavulanic acid-resistant phenotypes. The arginyl 244 side chain is tightly held in a network of interactions within the active site. Its replacement by a glutamine or a threonine perturbs the enzyme kinetics but to a smaller extent than would have been predicted if it were directly involved in substrate binding. Clavulanic acid and sulbactam still interact specifically with the mutant enzymes but are much less efficiently metabolized. Substitutions at position 244 also unveil interactions between the C6 substituent of substrates and the Asn132/Glu104 region of the active site. Methionine 69 is located in a region of strong structural constraints and presents an unusual conformation. Molecular dynamics simulation showed that its replacement by a leucine does not release the strain in this area and induces only minor structural changes. Accordingly, the kinetic behavior of the mutant is only marginally perturbed, except for suicide inhibitors. Both clavulanic acid and sulbactam are well degraded by the mutant enzyme, while irreversible inactivation is dramatically decreased. The contribution of both residues to catalysis is discussed in the light of the kinetic and structural data.	CNRS,INST NATL SCI APPLIQUEES,205 ROUTE NARBONNE,F-31077 TOULOUSE,FRANCE; CNRS,DEPT BIOL STRUCT & INGN PROT,PHARMACOL & TOXICOL FONDAMENTALES LAB,F-31077 TOULOUSE,FRANCE; MUSEUM NATL HIST NAT,CNRS,URA 401,F-75231 PARIS 05,FRANCE; CNRS,INST BIOL MOLEC & CELLULAIRE,CRISTALLOG BIOL LAB,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BELAAOUAJ A, 1991, 31ST INT C ANT AG CH, P256; BLANCHINROLAND S, 1989, PROTEIN ENG, V2, P473, DOI 10.1093/protein/2.6.473; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DG, 1981, BIOCHEMISTRY-US, V20, P3680, DOI 10.1021/bi00516a003; BRENNER DG, 1984, BIOCHEMISTRY-US, V23, P5833, DOI 10.1021/bi00319a024; CARTWRIGHT SJ, 1983, MED RES REV, V3, P341, DOI 10.1002/med.2610030402; CHARNAS RL, 1981, BIOCHEMISTRY-US, V20, P3214, DOI 10.1021/bi00514a035; CHARNAS RL, 1978, BIOCHEMISTRY-US, V17, P2185, DOI 10.1021/bi00604a025; COLLATZ E, 1990, MOL MICROBIOL, V4, P1615, DOI 10.1111/j.1365-2958.1990.tb00537.x; DELAIRE M, 1991, PROTEIN ENG, V4, P805, DOI 10.1093/protein/4.7.805; DIDEBERG O, 1987, BIOCHEM J, V245, P911, DOI 10.1042/bj2450911; FISHER J, 1978, BIOCHEMISTRY-US, V17, P2180, DOI 10.1021/bi00604a024; FRERE JM, 1982, BIOCHEM J, V207, P429, DOI 10.1042/bj2070429; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; JACOBDUBUISSON F, 1991, PROTEIN ENG, V4, P811, DOI 10.1093/protein/4.7.811; JELSCH C, 1992, FEBS LETT, V299, P135, DOI 10.1016/0014-5793(92)80232-6; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KNOWLES JR, 1985, ACCOUNTS CHEM RES, V18, P97, DOI 10.1021/ar00112a001; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; LABIA R, 1973, FEBS LETT, V33, P42, DOI 10.1016/0014-5793(73)80154-1; LABIA R, 1979, ANN INST PASTEUR MIC, VB130, P295; LAMOTTEBRASSEUR J, 1991, BIOCHEM J, V279, P213, DOI 10.1042/bj2790213; LENFANT F, 1991, J BIOL CHEM, V266, P17187; LENFANT F, 1990, BIOCHIMIE, V72, P495, DOI 10.1016/0300-9084(90)90073-P; MANAVATHU EK, 1991, 31ST INT C ANT AG CH, P101; Maniatis T., 1982, MOL CLONING; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764	34	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20600	20606						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400382				2022-12-27	WOS:A1992JT97800018
J	DELL, KR; WILLIAMS, LT				DELL, KR; WILLIAMS, LT			A NOVEL FORM OF FIBROBLAST GROWTH-FACTOR RECEPTOR-2 - ALTERNATIVE SPLICING OF THE 3RD IMMUNOGLOBULIN-LIKE DOMAIN CONFERS LIGAND-BINDING SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EXPRESSION; FAMILY; MEMBER; GENE; IDENTIFICATION; PURIFICATION; MESODERM; CLONING; DIFFERENTIATION	The fibroblast growth factor receptor 2 (FGFR2) gene is expressed as alternatively spliced mRNAs that encode bacterially expressed kinase, the keratinocyte growth factor receptor, or K-sam. We have now isolated a novel FGFR2 cDNA that is identical with the previously cloned human bacterially expressed kinase, except in the third immunoglobulin-like domain. The ligand binding properties of FGFR2 were studied by expressing the protein in rat L6 muscle myoblasts. Unlike human bacterially expressed kinase which binds acidic and basic FGF with similar affinities, FGFR2 bound acidic FGF with approximately 1000-fold higher affinity than basic FGF. These results indicate that alternative splicing of the FGFR2 gene in the region encoding the carboxyl-terminal half of the third immunoglobulin domain determines the ligand specificity of this group of receptors.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIVI A, 1991, ONCOGENE, V6, P1089; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1988, ONCOGENE, V3, P9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	31	97	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21225	21229						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400433				2022-12-27	WOS:A1992JT97800110
J	GABRIEL, DA; MUGA, K; BOOTHROYD, EM				GABRIEL, DA; MUGA, K; BOOTHROYD, EM			THE EFFECT OF FIBRIN STRUCTURE ON FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; POLYACRYLAMIDE GELS; POLYMERIZATION; PLATELET	Fibrin structure contributes to the regulation of the fibrinolytic rate. As the fibrin fiber size is decreased, the fibrinolytic rate also decreases. Fibrin structure was altered by either changing the ratio of thrombin to fibrinogen, i.e. altering the assembly rate or by adding a fibrin assembly inhibitor, iopamidol. Changes in the fibrinolytic rate were followed by measuring the time dependence of the decrease in the fiber mass/length ratio during fibrinolysis. A measure of the overall fibrinolytic rate was determined from the decrease in the mass/length ratio versus time. An 8-fold reduction in the fibrinolytic rate was seen on decreasing the mass/length ratio from 2.7 x 10(12) daltons/cm to 0.5 x 10(12) daltons/cm. It is shown that thin fibrin fibers have a decreased rate of conversion of plasminogen to plasmin by tissue plasminogen activator and that thin fibrin fibers are lysed more slowly than thick fibrin fibers.			GABRIEL, DA (corresponding author), UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,DEPT MED,DIV HEMATOL,CB 7035,CHAPEL HILL,NC 27599, USA.							ALLEN RA, 1981, THROMB HAEMOSTASIS, V45, P43; BALE MD, 1986, J BIOL CHEM, V261, P862; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; CARR ME, 1980, MACROMOLECULES, V13, P1473, DOI 10.1021/ma60078a022; CARR ME, 1989, BIOCHEMISTRY-US, V28, P1384, DOI 10.1021/bi00429a066; CARR ME, 1987, THROMB RES, V45, P539, DOI 10.1016/0049-3848(87)90316-1; CARR ME, 1980, J LAB CLIN MED, V96, P985; CARRELL N, 1983, BLOOD, V62, P439; CHIBBER BAK, 1990, INT J PEPT PROT RES, V35, P73; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; GABRIEL DA, 1983, J LAB CLIN MED, V101, P545; GABRIEL DA, 1991, CIRC RES, V68, P881, DOI 10.1161/01.RES.68.3.881; GABRIEL DA, 1991, THROMB HAEMOSTASIS, V65, pA737; GALANAKIS DK, 1987, BIOCHEMISTRY-US, V26, P2389, DOI 10.1021/bi00382a046; GIBBS SJ, 1991, MACROMOLECULES, V24, P6110, DOI 10.1021/ma00023a010; HOLVOET P, 1985, J BIOL CHEM, V260, P2106; JANMEY PA, 1985, BIOCHIM BIOPHYS ACTA, V841, P151, DOI 10.1016/0304-4165(85)90016-9; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V755, P531, DOI 10.1016/0304-4165(83)90261-1; PARK IH, 1990, MACROMOLECULES, V23, P1548, DOI 10.1021/ma00207a052; PING JB, 1991, THROMB HAEMOSTASIS, V65, pA735; RAKOCZI I, 1978, BIOCHIM BIOPHYS ACTA, V540, P295, DOI 10.1016/0304-4165(78)90142-3; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SHEN LL, 1977, J BIOL CHEM, V252, P6184; SHEN LL, 1975, THROMB RES, V6, P255, DOI 10.1016/0049-3848(75)90073-0; SOTTRUPJENSEN L, 1978, ATLAS PROTEIN SEQ S3, V5, P73; STEWART UA, 1985, BIOPOLYMERS, V27, P173; VOSKUILEN M, 1987, J BIOL CHEM, V262, P5944; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WALLEN P, 1977, THROMBOSIS UROKINASE, V9, P91; YONEKAWA O, 1992, BIOCHEM J, V283, P187, DOI 10.1042/bj2830187	31	235	247	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24259	24263						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447176				2022-12-27	WOS:A1992KA26300021
J	MAKRIDES, SC; SCESNEY, SM; FORD, PJ; EVANS, KS; CARSON, GR; MARSH, HC				MAKRIDES, SC; SCESNEY, SM; FORD, PJ; EVANS, KS; CARSON, GR; MARSH, HC			CELL-SURFACE EXPRESSION OF THE C3B/C4B RECEPTOR (CR-1) PROTECTS CHINESE-HAMSTER OVARY CELLS FROM LYSIS BY HUMAN-COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; C5 CONVERTASE; C3B RECEPTOR; C3B-BINDING SITE; CR-1; BINDING; TYPE-1; MEMBRANE; PATHWAY; C4B	The C3b/C4b receptor, also known as complement receptor type 1 (CR1, CD35), is a single chain glycoprotein consisting of 30 repeating homologous protein domains known as short consensus repeats (SCR) followed by transmembrane and cytoplasmic domains. A series of recombinant proteins derived from CRI has been prepared and assessed for the capacity to inhibit complement lysis of the host Chinese hamster ovary (CHO) cells. The full-length recombinant CR1 inhibited human complement-mediated CHO cell lysis, and the efficiency of inhibition was directly proportional to the number of receptors/cell. The SCR 15-18 of CR1, but not SCR 15-16, inhibited complement lysis of the host CHO cell, bound monomeric C3b (K(d,app) = 6.5 x 10(-7) M), and dimeric C3b (K(d) = 1.8 x 10(-8) M), and served as a cofactor in the proteolysis of C3b by factor I, confirming and extending the observations of Fearon and colleagues (Kalli, K. R., Hsu, P., Bartow, T. J., Ahearn, J. M., Matsumoto, A. K., Klickstein, L. B., and Fearon, D. T. (1991) J. Exp. Med. 174, 1451-1460). The SCR 1-4 of CR1, but not SCR 1-2, also inhibited complement lysis of the host CHO cell, indicating that more than two SCR are necessary and that four SCR are sufficient for optimal C4b binding to CR1. Thus, the structural requirements for C4b binding are analogous to those for C3b binding, namely, four SCR of CR1 form the binding sites for each of these proteins. CR1 has long been recognized to regulate extrinsic complement activation, that is, to bind to and promote the degradation of fluid phase C3b and of C3b attached to immune complex. These results demonstrate that CR1 is also an intrinsic regulator of complement activation in that, under appropriate conditions, CRI inhibits complement-mediated lysis of the cell on which it is expressed.	T CELL SCI INC,38 SIDNEY ST,CAMBRIDGE,MA 02139					Marsh, Henry/0000-0001-5637-6013				ARNAOUT MA, 1981, J IMMUNOL, V127, P1348; ARNAOUT MA, 1983, IMMUNOLOGY, V48, P229; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016; BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109; CARSON GR, 1991, J BIOL CHEM, V266, P7883; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FEARON DT, 1979, P NATL ACAD SCI USA, V76, P5867, DOI 10.1073/pnas.76.11.5867; FEARON DT, 1983, J IMMUNOL, V130, P370; GIGLI I, 1981, FED PROC, V40, P1172; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HAMMER CH, 1988, COMPLEMENT SYSTEM, P17; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; IIDA K, 1981, J EXP MED, V153, P1138, DOI 10.1084/jem.153.5.1138; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KLICKSTEIN LB, 1987, J EXP MED, V165, P1095, DOI 10.1084/jem.165.4.1095; KOZONO H, 1990, J BIOL CHEM, V265, P14444; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; MARDINEY MR, 1968, AM J PATHOL, V53, P253; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1982, J EXP MED, V156, P1739, DOI 10.1084/jem.156.6.1739; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MEDVED LV, 1989, BIOCHEMISTRY-US, V28, P5408, DOI 10.1021/bi00439a014; Morrison D A, 1979, Methods Enzymol, V68, P326; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; PRUITT SK, 1991, J SURG RES, V50, P350, DOI 10.1016/0022-4804(91)90202-W; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TACK BF, 1981, METHOD ENZYMOL, V80, P64; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4512; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WALSH LA, 1991, EUR J IMMUNOL, V21, P847, DOI 10.1002/eji.1830210349; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WONG WW, 1991, J IMMUNOL, V146, P656; WONG WW, 1985, J IMMUNOL METHODS, V82, P303, DOI 10.1016/0022-1759(85)90362-X; YEH CG, 1991, J IMMUNOL, V146, P250; ZHAO J, 1991, J BIOL CHEM, V266, P13418	47	52	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24754	24761						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447213				2022-12-27	WOS:A1992KA26300090
J	SCHNITZER, JE; SUNG, A; HORVAT, R; BRAVO, J				SCHNITZER, JE; SUNG, A; HORVAT, R; BRAVO, J			PREFERENTIAL INTERACTION OF ALBUMIN-BINDING PROTEINS, GP30 AND GP18, WITH CONFORMATIONALLY MODIFIED ALBUMINS - PRESENCE IN MANY CELLS AND TISSUES WITH A POSSIBLE ROLE IN CATABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIUM; SERUM-ALBUMIN; CAPILLARY ENDOTHELIUM; SCAVENGER RECEPTOR; BONE-MARROW; RAT; TRANSCYTOSIS; SURFACE; PERMEABILITY; ENDOCYTOSIS	Albumin binding to the endothelial surface apparently initiates its transcytosis via plasmalemmal vesicles and also increases capillary permselectivity. Several albumin-binding proteins, which we call gp60, gp30, and gp18, have been identified; however, their functional relationship to each other is unclear. In this study, we show that gp30 and gp18 are both variably expressed by cultured rat fibroblasts, smooth muscle cells, and endothelial cells and are present in all tissues examined (heart, lung, skeletal muscle, diaphragm, duodenum, kidney, fat, brain, adrenal, pancreas, and liver). The binding of albumin-gold complexes (A-Au) to gp30 and gp18 was compared with that of native and modified albumins. Monomeric native bovine serum albumin (BSA) interacted much less avidly than A-Au and BSA that was chemically modified by formaldehyde (Fm-BSA) or maleic anhydride (Mal-BSA). Mal-BSA and A-Au have similar affinity constants for gp30 and gp18 (K(D) approximately 3-7 mug/ml (50-100 nM)), which is 1000-fold greater than BSA. These interactions were Ca2+-independent but sensitive to pH (<6.0) and high salt concentrations (greater-than-or-equal-to 1.0 M). Comparative biochemical characterization provided evidence of conformational changes for Mal-BSA, Fm-BSA, and A-Au. Anti-native BSA serum recognizes BSA much more avidly than modified BSA. Mal-BSA, Fm-BSA, and A-Au are much more sensitive to trypsin digestion than BSA. Cellular processing was also examined. A-Au and Mal-BSA bound at the endothelial cell surface were degraded, whereas BSA was not. Our results indicate that: (i) gp30 and gp18, unlike gp60, are expressed in all tissues tested regardless of the type of endothelia lining the microvasculature and the local mechanism of transendothelial albumin transport; (ii) BSA conformationally modified by either surface adsorption or chemical means not only interacts more avidly with gp30 and gp18 than native albumin but also is preferentially degraded by the cells; (iii) A-Au and native albumin are not equivalent probes for detecting albumin interaction sites; and (iv) gp30 and gp18 exhibit binding behavior resembling scavenger receptors. The possible roles of gp30 and gp18 in albumin binding, transcytosis, endocytosis, and even protein catabolism are discussed.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,INST BIOMED ENGN,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	SCHNITZER, JE (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		Bravo, Jose/F-8861-2015	Bravo, Jose/0000-0001-5752-2406	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade J.D., 1985, SURFACE CHEM PHYS, V1; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P1; BRAVO J, 1992, FASEB J, V6, pA1322; BUMBASIREVIC V, 1990, J SUBMICR CYTOL PATH, V22, P135; BUTLER PJG, 1969, BIOCHEM J, V112, P679, DOI 10.1042/bj1120679; CURRY FE, 1987, J PHYSIOL-LONDON, V387, P69, DOI 10.1113/jphysiol.1987.sp016563; CURRY FRE, 1985, FED PROC, V44, P2610; DEBRUYN PPH, 1985, CELL TISSUE RES, V240, P1; GALIS Z, 1988, EUR J CELL BIOL, V47, P358; GAMBLE J, 1983, J PHYSIOL-LONDON, V339, P505, DOI 10.1113/jphysiol.1983.sp014730; GEOFFROY JS, 1984, J ULTRA MOL STRUCT R, V89, P223, DOI 10.1016/S0022-5320(84)80039-8; GHINEA N, 1989, J BIOL CHEM, V264, P4755; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HORIUCHI S, 1985, J BIOL CHEM, V260, P475; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; HUXLEY VH, 1985, AM J PHYSIOL, V248, pH264, DOI 10.1152/ajpheart.1985.248.2.H264; LEVICK JR, 1973, Q J EXP PHYSIOL CMS, V58, P87, DOI 10.1113/expphysiol.1973.sp002194; MANN GE, 1981, J PHYSIOL-LONDON, V319, P311, DOI 10.1113/jphysiol.1981.sp013910; MANS GE, 1971, CHEM MODIFICATION PR, P125; MICHEL CC, 1980, J PHYSIOL-LONDON, V309, P341, DOI 10.1113/jphysiol.1980.sp013512; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; PARDRIDGE WM, 1985, AM J PHYSIOL, V249, pE264, DOI 10.1152/ajpendo.1985.249.3.E264; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; REED RG, 1989, J BIOL CHEM, V264, P9867; SCHNEEBERGER EE, 1984, AM J PHYSIOL, V247, pH206, DOI 10.1152/ajpheart.1984.247.2.H206; SCHNEEBERGER EE, 1990, AM J PHYSIOL, V258, pL89, DOI 10.1152/ajplung.1990.258.2.L89; SCHNITZER JE, 1990, EUR J CELL BIOL, V52, P241; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHNITZER JE, 1990, P NATL ACAD SCI USA, V87, P6843, DOI 10.1073/pnas.87.17.6843; SCHNITZER JE, 1988, AM J PHYSIOL, V254, pH425, DOI 10.1152/ajpheart.1988.254.3.H425; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; SCHNITZER JE, 1991, FASEB J, V5, pA529; SIFLINGERBIRNBOIM A, 1991, J CELL PHYSIOL, V149, P575, DOI 10.1002/jcp.1041490329; SIMIONESCU M, 1988, J SUBMICR CYTOL PATH, V20, P243; SIMIONESCU M, 1984, HDB PHYSL, P41; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; Taylor AE, 1984, HDB PHYSL 2, V4, P467; VILLASCHI S, 1986, MICROVASC RES, V32, P190, DOI 10.1016/0026-2862(86)90053-1; Waldmann T. A., 1977, ALBUMIN STRUCTURE FU, P255; YEDGAR S, 1983, AM J PHYSIOL, V244, pE101, DOI 10.1152/ajpendo.1983.244.1.E101; YOKOTA S, 1983, BIOMED RES-TOKYO, V4, P577, DOI 10.2220/biomedres.4.577	45	130	131	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24544	24553						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447200				2022-12-27	WOS:A1992KA26300061
J	TANG, CK; CHIN, J; HARFORD, JB; KLAUSNER, RD; ROUAULT, TA				TANG, CK; CHIN, J; HARFORD, JB; KLAUSNER, RD; ROUAULT, TA			IRON REGULATES THE ACTIVITY OF THE IRON-RESPONSIVE ELEMENT BINDING-PROTEIN WITHOUT CHANGING ITS RATE OF SYNTHESIS OR DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; AFFINITY PURIFICATION; UNTRANSLATED REGION; IRE-BP; ACONITASE; TRANSLATION; EXPRESSION; REPRESSOR; MECHANISM; SEQUENCE	The iron-responsive element binding protein (IRE-BP) interacts with specific sequence/structure motifs (iron-responsive elements) within the mRNAs encoding ferritin and the transferrin receptor and thereby post-transcriptionally regulates the expression of these two proteins involved in cellular iron homeostasis. The activity of the IRE-BP is itself regulated by iron such that when cells are treated with an iron source, the RNA binding activity is decreased. The expression of recombinant human IRE-BP in murine cells has been examined as have the expressions of the endogenous IRE-BP of both human and rabbit cells. In all cases, iron down-modulated the RNA binding activity of the IRE-BP, but in no instance was this decrease in activity accompanied by a decrease in the level of the protein as judged by quantitative Western blots. Moreover, the rate of synthesis of the IRE-BP and its rate of degradation have been found to be unaltered by iron manipulation of cells in culture. Consistent with IRE-BP regulation occurring post-translationally, the iron regulation of its activity was found to be unaffected by cycloheximide. These data are discussed in terms of a model of IRE-BP regulation involving the modification of the protein's iron-sulfur center.			TANG, CK (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P146, DOI 10.1016/0167-4781(90)90156-V; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SHOWS TB, 1977, CYTOGENET CELL GENET, V19, P26, DOI 10.1159/000130791; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005	29	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24466	24470						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447194				2022-12-27	WOS:A1992KA26300051
J	KATO, Y; UCHIDA, K; KAWAKISHI, S				KATO, Y; UCHIDA, K; KAWAKISHI, S			OXIDATIVE FRAGMENTATION OF COLLAGEN AND PROLYL PEPTIDE BY CU(II)/H2O2 - CONVERSION OF PROLINE RESIDUE TO 2-PYRROLIDONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; PROTEINS; DEGRADATION; MECHANISM; CLEAVAGE; TRYPTOPHAN; RADIOLYSIS; RADICALS; ION	Oxidative degradation of collagen and the model peptides by Cu(II)/H2O2 has been studied. The depolymerization of collagen was predominantly observed by use of gel filtration chromatography. Polyproline was used as a model for collagen, and the oxidative modification was examined by amino acid analysis. Glutamic acid and gamma-aminobutyric acid were identified in the hydrolysates of oxidized polyproline. The formation of glutamic acid was reduced by treatment with NaBH4. The model peptide, (Pro-Pro-Gly)10, was also degraded by Cu(II)/H2O2, and a new N-terminal glycine was generated in proportion to the reaction time. Hydroxyl radical scavengers show only partial inhibition of the degradation of (Pro-Pro-Gly)10. In order to estimate the fragmentation mechanism, we used N-tert-butoxycarbonyl (Boc)-L-prolylglycine as a model for collagen and (Pro-Pro-Gly)10. The degradation products were isolated and characterized. Then N-tert-Boc-2-pyrrolidone, which provides gamma-aminobutyric acid by acid hydrolysis, was identified. The formation of a 2-pyrrolidone compound from oxidized BOC-L-prolylglycine is direct evidence for the scission of the peptide bond. The time-dependent formation of N-tert-Boc-2-pyrrolidone and liberation of glycine from N-tert-Boc-L-prolylglycine exposed to Cu(II)/H2O2 was observed. These results suggest that the cleavage of the peptide bond (Pro-Gly) was caused by oxidation of the proline residue, which led to the formation of the 2-pyrrolidone compound. We confirmed that proline oxidation leads to the fragmentation of proteins, accompanied by the formation of a 2-pyrrolidone structure.	NAGOYA UNIV,DEPT FOOD SCI & TECHNOL,CHEM PLANT PROD LAB,FURO CHO,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University			Kato, Yoji/W-4779-2019	Kato, Yoji/0000-0002-8295-7337; Uchida, Koji/0000-0003-3894-5299				AMICI A, 1989, J BIOL CHEM, V264, P3341; BATEMAN RC, 1985, J BIOL CHEM, V260, P9088; BOWES JH, 1962, RADIAT RES, V16, P211, DOI 10.2307/3571153; COOPER B, 1985, BIOCHEM J, V228, P615, DOI 10.1042/bj2280615; CREMO CR, 1992, BIOCHEMISTRY-US, V31, P491, DOI 10.1021/bi00117a027; CURRAN SF, 1984, FEBS LETT, V176, P155, DOI 10.1016/0014-5793(84)80931-X; FONG LG, 1987, J LIPID RES, V28, P1466; GREHN L, 1986, ACTA CHEM SCAND B, V40, P745, DOI 10.3891/acta.chem.scand.40b-0745; HUNT JV, 1988, BIOCHEM J, V250, P87, DOI 10.1042/bj2500087; KANO Y, 1987, J BIOCHEM-TOKYO, V102, P839, DOI 10.1093/oxfordjournals.jbchem.a122123; KATO Y, 1992, J AGR FOOD CHEM, V40, P9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARX G, 1985, BIOCHEM J, V236, P397; MONBOISSE JC, 1983, BIOCHEM PHARMACOL, V32, P53, DOI 10.1016/0006-2952(83)90651-2; MONBOISSE JC, 1988, BIOCHIM BIOPHYS ACTA, V965, P29, DOI 10.1016/0304-4165(88)90147-X; NAGASAWA T, 1973, B CHEM SOC JPN, V46, P1269, DOI 10.1246/bcsj.46.1269; POSTON JM, 1987, FASEB J, V46, P1979; SCHUESSLER H, 1984, INT J RADIAT BIOL, V45, P267, DOI 10.1080/09553008414550381; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; TAPUHI Y, 1981, ANAL BIOCHEM, V115, P123, DOI 10.1016/0003-2697(81)90534-0; UCHIDA K, 1990, BIOCHEM BIOPH RES CO, V169, P265, DOI 10.1016/0006-291X(90)91463-3; UCHIDA K, 1992, J AGR FOOD CHEM, V40, P9, DOI 10.1021/jf00013a002; UCHIDA K, 1989, AGR BIOL CHEM TOKYO, V53, P3285, DOI 10.1080/00021369.1989.10869852; UCHIDA K, 1988, AGR BIOL CHEM TOKYO, V52, P1529; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399	26	75	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23646	23651						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429705				2022-12-27	WOS:A1992JZ23900036
J	SHIAH, HS; CHEN, TY; CHANG, CM; CHOW, JT; KUNG, HJ; HWANG, JL				SHIAH, HS; CHEN, TY; CHANG, CM; CHOW, JT; KUNG, HJ; HWANG, JL			PSEUDOMONAS EXOTOXIN A-EPIDERMAL GROWTH-FACTOR (EGF) MUTANT CHIMERIC PROTEIN AS AN INDICATOR FOR IDENTIFYING AMINO-ACID-RESIDUES IMPORTANT IN EGF-RECEPTOR INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR-MAGNETIC-RESONANCE; BACTERIAL TOXINS; ESCHERICHIA-COLI; H-1-NMR; CELLS; IDENTIFICATION; EXPRESSION; RESISTANCE; CLONING	Epidermal growth factor (EGF) was fused to the carboxyl end of a modified pseudomonas exotoxin A that has its toxin binding domain deleted. This chimeric toxin designated as PE(DELTAIa)-EGF kills A431 cells through the EGF receptor-mediated pathway. In this study, we used a random mutagenesis approach to make point mutations on EGF, followed by replacing the wild type EGF in PE(DELTAIa)-EGF with these EGF mutants. We have constructed 14 different PE(DELTAIa)-EGF(mutants), and examined their EGF receptor binding activity as well as their cytotoxicity to A431 cells. Our results showed that individual mutations of Val19 to Glu and Val34 to Asp in the EGF domain of PE(DELTAIa)-EGF(mutants) resulted in an increase in the binding affinity to EGF receptor and cytotoxicity to A431 cells. On the other hand, individual mutations of His16 to Asp and Gly18 to Ala in the EGF domain of PE(DELTAIa)-EGF(mutants) lead to a decrease in the binding affinity to EGF receptor and cytotoxicity to A431 cells. In addition, mutations of any of the cysteine residues of EGF in PE(DELTAIa)-EGF(mutants) resulted in the loss of their binding activity to EGF receptor and a corresponding loss of their cytotoxicity. This study indicates that the cytotoxicity of PE(DELTAIa)-EGF(mutant) to EGF receptor-bearing cells may be used as an indicator to screen mutations of EGF important in EGF-receptor interactions.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA	Academia Sinica - Taiwan; Case Western Reserve University			Kung, Hsing-Jien/C-7651-2013; Shiah, Her-Shyong/E-3668-2010					BUCKLEY A, 1985, P NATL ACAD SCI USA, V82, P7340, DOI 10.1073/pnas.82.21.7340; BURGESS AW, 1988, BIOCHEMISTRY-US, V27, P4977, DOI 10.1021/bi00414a005; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CARVER JA, 1986, FEBS LETT, V205, P77, DOI 10.1016/0014-5793(86)80869-9; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; CHOW JT, 1989, J BIOL CHEM, V264, P18818; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P90; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DUDGEON TJ, 1990, FEBS LETT, V261, P392, DOI 10.1016/0014-5793(90)80600-N; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; ENGLER DA, 1988, J BIOL CHEM, V263, P12384; FITZGERALD DJP, 1988, P NATL ACAD SCI USA, V83, P6627; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HEPPEL LA, 1971, STRUCTURE FUNCTION B, P223; HOLLENBERG MD, 1973, P NATL ACAD SCI USA, V70, P2964, DOI 10.1073/pnas.70.10.2964; HOMMEL U, 1991, BIOCHEMISTRY-US, V30, P8891, DOI 10.1021/bi00100a024; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU PV, 1966, J INFECT DIS, V116, P481, DOI 10.1093/infdis/116.4.481; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; LYALL RM, 1987, CANCER RES, V47, P2961; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; MOY FJ, 1989, P NATL ACAD SCI USA, V86, P9836, DOI 10.1073/pnas.86.24.9836; PASTAN IH, 1981, SCIENCE, V214, P504, DOI 10.1126/science.6170111; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIEGALL CB, 1990, MOL CELL BIOL, V10, P2443, DOI 10.1128/MCB.10.6.2443; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; XU Y, 1986, P NATL ACAD SCI USA, V81, P7308	45	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24034	24040						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429738				2022-12-27	WOS:A1992JZ23900090
J	FAGAN, JM; WAXMAN, L				FAGAN, JM; WAXMAN, L			THE ATP-INDEPENDENT PATHWAY IN RED-BLOOD-CELLS THAT DEGRADES OXIDANT-DAMAGED HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEOLYTIC SYSTEM; HUMAN-ERYTHROCYTES; OXYGEN RADICALS; MAMMALIAN-CELLS; CYSTEINE PROTEINASES; RAT-LIVER; DEGRADATION; PURIFICATION; INHIBITORS; PROTEASE	Studies were carried out to characterize further the cytoplasmic ATP- and ubiquitin-independent proteolytic system in red blood cells that degrades hemoglobin damaged by exposure to oxidants (Fagan, J. M., Waxman, L., and Goldberg, A. L. (1986) J. Biol. Chem. 261, 5705-5713). Several proteases were ruled out as having a major role in the degradation of oxidant-treated hemoglobin (Ox-Hb). Acid hydrolases are not active in this process since the degradation of Ox-Hb has a pH optimum between 6 and 8. The calpains are also not involved since inhibitors of cysteine proteases (leupeptin and trans-epoxysuccinyl-L-leucylamido-(3-methyl)butane) did not diminish the increased proteolysis in intact erythrocytes treated with oxidants or in lysates to which Ox-Hb was added. The degradation of Ox-Hb was unaffected by inhibitors of serine and aspartic proteases. Removal of the high M(r) multicatalytic proteinase by immunoprecipitation also did not significantly affect the degradation of Ox-Hb in erythrocyte lysates. The degradation of Ox-Hb was sensitive to metal chelators and sulfhydryl-modifying reagents but not to specific inhibitors of known metalloproteases. Insulin, which is rapidly degraded in lysates, completely blocked the degradation of Ox-Hb. Insulin- and Ox-Hb-hydrolyzing activity was also inhibited following immunoprecipitation of the 100-kDa metalloinsulinase. The metalloinsulinase, which is inhibited by sulfhydryl-modifying reagents and which requires divalent metals, may therefore participate in the degradation of hemoglobin damaged by oxidants in erythrocytes.			FAGAN, JM (corresponding author), RUTGERS STATE UNIV,DEPT ANIM SCI,POB 231,NEW BRUNSWICK,NJ 08903, USA.							BALOW RM, 1986, J BIOL CHEM, V261, P2409; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Beutler E, 1983, METABOLIC BASIS INHE, P1629; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DEFLORA A, 1985, BLOOD, V66, P294; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FAGAN JM, 1985, 13TH P INT C BIOCH, P96; GAETANI GF, 1979, BRIT J HAEMATOL, V43, P39, DOI 10.1111/j.1365-2141.1979.tb03717.x; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; GARCIA JV, 1987, J CELL BIOL, V100, P449; GOLDBERG AL, 1982, SCIENCE, V215, P1107, DOI 10.1126/science.7038874; GORDON PB, 1989, PROTEOLYTIC ENZYMES, P201; GREENLEE WJ, 1984, BIOCHEM BIOPH RES CO, V122, P791, DOI 10.1016/S0006-291X(84)80103-5; HASHIDA S, 1980, J BIOCHEM-TOKYO, V88, P1805, DOI 10.1093/oxfordjournals.jbchem.a133155; JOCHEN A, 1987, BIOCHEM BIOPH RES CO, V142, P205, DOI 10.1016/0006-291X(87)90472-4; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KIRSCHNER RJ, 1982, FED PROC, V41, P865; KIRSCHNER RJ, 1981, METHOD ENZYMOL, V80, P702; KOMINAMI E, 1987, BIOCHEM BIOPH RES CO, V144, P749, DOI 10.1016/S0006-291X(87)80028-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1979, AM J PHYSIOL, V237, pE35, DOI 10.1152/ajpendo.1979.237.1.E35; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MELLONI E, 1982, ARCH BIOCHEM BIOPHYS, V216, P495, DOI 10.1016/0003-9861(82)90238-7; MOMAND J, 1987, BIOCHEMISTRY-US, V26, P7798, DOI 10.1021/bi00398a040; MORELLI A, 1987, BLOOD, V69, P1753; MORIHARA K, 1974, ADV ENZYMOL RAMB, V41, P179; MUMFORD RA, 1982, BIOCHEM BIOPH RES CO, V109, P1303, DOI 10.1016/0006-291X(82)91919-2; MURACHI T, 1981, ADV ENZYME REGUL, V19, P407; NISHINO N, 1979, BIOCHEMISTRY-US, V18, P4340, DOI 10.1021/bi00587a012; NISHINO N, 1980, J BIOL CHEM, V255, P3482; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; POWERS JC, 1986, PROTEINASE INHIBITOR, P237; RASNICK D, 1978, BIOCHEMISTRY-US, V17, P4363, DOI 10.1021/bi00614a002; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; SACCHETTA P, 1990, BIOCHIM BIOPHYS ACTA, V1037, P337, DOI 10.1016/0167-4838(90)90035-E; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; TACK BF, 1980, J BIOL CHEM, V255, P8842; TANAKA K, 1986, J BIOL CHEM, V261, P5197; Umezawa H, 1976, Methods Enzymol, V45, P678; UMEZAWA H, 1977, PROTEINASES MAMMALIA, P637; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WAXMAN L, 1985, J BIOL CHEM, V260, P1994; WILLIAMSON DH, 1974, METHOD ENZYMAT AN, P1679; YAMAMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V790, P208, DOI 10.1016/0167-4838(84)90024-4; YAMAMOTO K, 1987, BIOCHEM BIOPH RES CO, V148, P267, DOI 10.1016/0006-291X(87)91105-3; YOSHIMOTO T, 1979, BIOCHIM BIOPHYS ACTA, V569, P184, DOI 10.1016/0005-2744(79)90053-6	56	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23015	23022						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429649				2022-12-27	WOS:A1992JY16300049
J	HOLLAND, MR; VENABLE, ME; WHATLEY, RE; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM				HOLLAND, MR; VENABLE, ME; WHATLEY, RE; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM			ACTIVATION OF THE ACETYL-COENZYME A-LYSOPLATELET-ACTIVATING FACTOR ACETYLTRANSFERASE REGULATES PLATELET-ACTIVATING-FACTOR SYNTHESIS IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LYSO-PAF-ACETYLTRANSFERASE; RAT SPLENIC MICROSOMES; COA ACETYLTRANSFERASE; HUMAN-NEUTROPHILS; 1-ALKYL-2-LYSO-SN-GLYCERO-3-PHOSPHOCHOLINE-ACETYL-COA ACETYLTRANSFERASE; INDEPENDENT TRANSACYLASE; SPLEEN MICROSOMES; ARACHIDONIC-ACID; MODULATION	Platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF) is a phospholipid with many physiological actions. It is synthesized by endothelial cells and a variety of others in response to stimulation with receptor-mediated agonists. In endothelial cells it remains associated with the surface of the cell and serves as a signal for adhesive interactions with leukocytes. Thus, its synthesis must be precisely regulated. In previous work we have shown that PAF synthesis is regulated at the initiating step, a phospholipase A2. Here we demonstrate that the subsequent step of PAF synthesis, the acetyl-CoA:lyso-PAF acetyltransferase, is rapidly activated when cells are exposed to thrombin or other agonists. We found that the activity increased from basal values (5 nmol/mg/min) to approximately 3-fold higher within 1 min following the addition of agonists. The enzyme activity returned to basal levels within 10 min. The pattern of activation and inactivation suggested covalent modification of the enzyme. This was supported in experiments in which we showed that homogenates had stable enhanced activity and that there was no evidence for an activator or inhibitor. Pretreatment of the cells with vanadate, an inhibitor of protein phosphatases, markedly prolonged the activation state. In subsequent studies we pretreated intact cells with vanadate to block inactivation of the enzyme and then measured the accumulation of PAF in response to thrombin. We found that it was markedly augmented and prolonged. From this we conclude that the synthesis of PAF in intact cells is regulated by the activity of the acetyltransferase. We characterized requirements for activation of acetyltransferase and found that it was not dependent on the influx of intracellular calcium but that calcium entry did influence the length of time for which the enzyme was activated. The acetyltransferase in endothelial cells was shown to be a specific enzyme that did not catalyze the transfer of long chain acyl groups from acyl-CoA to lysophospholipids and demonstrated modest specificity for the acceptor lysophospholipids. These results suggest that activation of the acetyltransferase is a crucial determinant of the amount of PAF synthesized in activated endothelial cells.	UNIV UTAH,NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INST,BLDG 500,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT INTERNAL MED,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; VET ADM MED CTR,SALT LAKE CITY,UT 84148	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Holland, Matthew/0000-0001-6595-0240	NHLBI NIH HHS [HL 43689, HL 07576, HL 34127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007576, R01HL034127, R29HL043689] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERT DH, 1984, BIOCHIM BIOPHYS ACTA, V796, P92, DOI 10.1016/0005-2760(84)90242-X; ALONSO F, 1982, J BIOL CHEM, V257, P3376; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUMENTHAL DK, 1988, BIOCHEM BIOPH RES CO, V156, P860, DOI 10.1016/S0006-291X(88)80923-9; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; CLUZEL M, 1989, J IMMUNOL, V143, P3659; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; FENNELL DF, 1991, ARTERIOSCLER THROMB, V11, P97, DOI 10.1161/01.ATV.11.1.97; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P511, DOI 10.1016/0167-4889(85)90218-6; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P516, DOI 10.1016/0167-4889(85)90219-8; GOMEZCAMBRONERO J, 1987, BIOCHEM J, V246, P893; HERRICKDAVIS K, 1991, J BIOL CHEM, V266, P18620; HOLLAND MR, 1991, TRENDS CARDIOVAS MED, V1, P117, DOI 10.1016/1050-1738(91)90005-Y; JOLY F, 1990, BIOCHEM J, V271, P501, DOI 10.1042/bj2710501; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LEE TC, 1985, J BIOL CHEM, V260, P952; LEE TC, 1986, J BIOL CHEM, V261, P5373; LENIHAN DJ, 1984, BIOCHEM BIOPH RES CO, V120, P834, DOI 10.1016/S0006-291X(84)80182-5; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MUELLER HW, 1984, J LIPID RES, V25, P383; MUELLER HW, 1991, BIOCHEM BIOPH RES CO, V176, P1557, DOI 10.1016/0006-291X(91)90465-J; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; NIES AS, 1991, J PHARMACOL EXP THER, V259, P590; NIETO ML, 1988, J BIOL CHEM, V263, P4607; NIETO ML, 1991, J BIOL CHEM, V266, P18699; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REINHOLD SL, 1989, J BIOL CHEM, V264, P21652; RUDEL LL, 1973, J LIPID RES, V14, P64; SEARGEANT LE, 1979, BIOCHEM J, V181, P247, DOI 10.1042/bj1810247; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; SWENDSEN CL, 1983, BIOCHEM BIOPH RES CO, V113, P72, DOI 10.1016/0006-291X(83)90433-3; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WHATLEY RE, 1988, ARTERIOSCLEROSIS, V8, P321, DOI 10.1161/01.ATV.8.3.321; WHATLEY RE, 1990, J BIOL CHEM, V265, P15550; WYKLE RL, 1980, J BIOL CHEM, V255, P256; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	44	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22883	22890						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429636				2022-12-27	WOS:A1992JY16300029
J	MURTHY, KHM; WINBORNE, EL; MINNICH, MD; CULP, JS; DEBOUCK, C				MURTHY, KHM; WINBORNE, EL; MINNICH, MD; CULP, JS; DEBOUCK, C			THE CRYSTAL-STRUCTURES AT 2.2-ANGSTROM RESOLUTION OF HYDROXYETHYLENE-BASED INHIBITORS BOUND TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE SHOW THAT THE INHIBITORS ARE PRESENT IN 2 DISTINCT ORIENTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC HIV-1 PROTEASE; X-RAY-DIFFRACTION; RETROVIRAL PROTEASES; ESCHERICHIA-COLI; COMPLEX; REFINEMENT; PRECURSOR; MODEL	As part of a structure-based drug design program directed against enzyme targets in the human immunodeficiency virus (HIV), we have determined the three-dimensional structures of the HIV type 1 protease complexed with two hydroxyethylene-based inhibitors. The inhibitors (SKF 107457 and SKF 108738) are hexapeptide substrate analogues with the scissile bond being replaced by a hydroxyethylene isostere. The structures were determined using x-ray diffraction data to 2.2 angstrom measured at the Cornell High Energy Synchrotron Source on hexagonal crystals of each of the complexes. The structures have been extensively refined using a reciprocal space least-squares method to conventional crystallographic R factors of 0.186 and 0.159, respectively. The protein structure differs from that in the unliganded state of the enzyme and is most similar to that of the structure of the other reported (Jaskolski, M., Tomasselli, A. G., Sawyer, T. K., Staples, D. G., Heinrikson, R. L., Schneider, J., Kent, S. B. H., and Wlodawer, A. (1990) Biochemistry 29, 5889-5907) hydroxyethylene-based inhibitor complex. Unlike in that structure, however, the inhibitors are observed, in the present crystal structures, in two equally abundant orientations that are a consequence of the homodimeric nature of the enzyme coupled with the asymmetric structures of the inhibitors. Although the differences between the two inhibitors used in the present study are confined to the P1' site, the van der Waals interactions made by the inhibitor atoms with the amino acid residues in the protein differ throughout the structures of the inhibitors.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MACRO MOLEC SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								CHENERA B, 1991, BIOORG MED CHEM LETT, V1, P219, DOI 10.1016/S0960-894X(00)80256-5; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DREYER GB, 1992, IN PRESS BIOCHEMISTR; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GERMAIN G, 1970, ACTA CRYSTALL B-STRU, VB 26, P274, DOI 10.1107/S056774087000225X; GRANT SK, 1991, BIOCHEMISTRY-US, V30, P8424, DOI 10.1021/bi00098a021; HARRISON SC, 1985, METHOD ENZYMOL, V114, P211; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HENDRICKSON WA, 1979, ACTA CRYSTALLOGR A, V35, P158, DOI 10.1107/S0567739479000279; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; MATHEWS BW, 1968, J MOL BIOL, V33, P491; McPherson A, 1982, PREPARATION ANAL PRO; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; MIYAHARA J, 1986, NUCL INSTRUM METH A, V246, P572, DOI 10.1016/0168-9002(86)90156-7; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; SALI A, 1989, EMBO J, V8, P2179, DOI 10.1002/j.1460-2075.1989.tb08340.x; SHANNON GW, 1991, GEOGRAPHY AIDS ORIGI, P71; SMITH JL, 1988, ACTA CRYSTALLOGR A, V44, P357, DOI 10.1107/S0108767388000303; STEIGEMANN W, 1985, PROTEIN USERS GUIDE; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0; WHITING BR, 1988, NUCL INSTRUM METH A, V266, P628, DOI 10.1016/0168-9002(88)90456-1; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; 1990, SIEMENS ANAL INSTRUM; 1989, SIEMENS ANAL INSTRUM; 1991, CHESS FACILITY DESCR	38	50	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22770	22778						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429626				2022-12-27	WOS:A1992JY16300014
J	TROULLIER, A; GIRARDET, JL; DUPONT, Y				TROULLIER, A; GIRARDET, JL; DUPONT, Y			FLUOROALUMINATE COMPLEXES ARE BIFUNCTIONAL ANALOGS OF PHOSPHATE IN SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-PHOSPHATE; BINDING-SITE; CALCIUM-PUMP; INORGANIC-PHOSPHATE; FLUORIDE COMPLEXES; STRUCTURAL ANALOGS; CATALYTIC SITE; F-ACTIN; ATPASE; MECHANISM	The mechanism of inhibition of the sarcoplamc reticulum (SR) Ca2+-ATPase by the fluoroaluminate complexes was investigated. First, AlF4- was shown to bind to the Ca2+-free conformation of the enzyme by a slow quasi-irreversible process. The rate constants of the reaction are k+ = 16 x 10(3) M-1 s-1 and k- < 1.5 10(-3) s-1. We directly measured a stoichiometry of about 4.8 nmol of AlF4- bound/mg of protein. Mg2+ was a necessary cofactor for the reaction with a dissociation constant of 3 mm. It was demonstrated (Dupont, Y., and Pougeois, R. (1983) FEBS Lett. 156, 93-98) that phosphorylation by P(i) induced a dehydration of the catalytic site. The same process has been shown here to occur upon AlF4- binding either by the use of Me2SO or by demonstration of an increase of bound 2',3'-O-(2,4,6-trinitrocyclohexadienyldene)adenosine triphosphate fluorescence. Phosphorylation by P(i) is inhibited by the binding of AlF4-. Second, a fluoroaluminate complex, presumably AlF4-, was also shown to bind to the Ca2+-bound conformation of the Ca2+-ATPase in the presence of ADP and stabilize a E1.Ca2.ADP.AlF(x) complex. The dissociation constant of the nucleotidic site for ADP was shifted to the micromolar range. The Ca2+ ions bound on the external high affinity sites became occluded upon binding of (ADP + AlF(x)). We propose that AlF4- mimics P(i) binding to the Ca2+-free conformation of the ATPase and stabilizes an intermediate similar to the acyl-phosphate derivative; it also acts as an analogue of the gamma-phosphate of ATP and stabilizes an E1.[Ca2].ADP-AlF4 complex where the Ca2+ ions are occluded.			TROULLIER, A (corresponding author), CEN, DEPT BIOL MOLEC & STRUCT, BIOPHYS MOLEC & CELLULAIRE LAB, CNRS, F-38041 GRENOBLE, FRANCE.							ANTONNY B, 1992, J BIOL CHEM, V267, P6710; ANTONNY B, 1990, FEBS LETT, V268, P277, DOI 10.1016/0014-5793(90)81027-L; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; DUPONT Y, 1988, METHOD ENZYMOL, V157, P206; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; HASSELBACH W, 1972, FEBS LETT, V20, P311, DOI 10.1016/0014-5793(72)80094-2; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1988, METHOD ENZYMOL, V157, P154; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Martell A.E., 1989, CRITICAL STABILITY C; MARTIN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1194; MISSIAEN L, 1988, BIOCHEM J, V253, P827, DOI 10.1042/bj2530827; MISSIAEN L, 1989, BIOCHEM J, V261, P655, DOI 10.1042/bj2610655; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; ROBINSON JD, 1986, J BIOENERG BIOMEMBR, V18, P521, DOI 10.1007/BF00743148; ROSSET R, 1985, J CHIM PHYS PCB, V82, P647, DOI 10.1051/jcp/1985820647; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; THORLEYL.DA, 1973, EUR J BIOCHEM, V40, P403, DOI 10.1111/j.1432-1033.1973.tb03209.x; VILSEN B, 1992, J BIOL CHEM, V267, P3539; 1982, IUPAC CHEM DATA 21	40	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22821	22829						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429630				2022-12-27	WOS:A1992JY16300021
J	YANG, ZH; WENSEL, TG				YANG, ZH; WENSEL, TG			N-MYRISTOYLATION OF THE ROD OUTER SEGMENT-G PROTEIN, TRANSDUCIN, IN CULTURED RETINAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; NH2-TERMINAL BLOCKING GROUP; MEMBRANE ASSOCIATION; ALPHA-SUBUNITS; GAMMA-SUBUNIT; GTP-BINDING; BETA-GAMMA; BOVINE; IDENTIFICATION; TRANSFORMATION	Bovine retinas incubated with [H-3]myristic acid incorporated detectable radiolabel into only a few proteins. The most heavily labeled was the alpha subunit of the rod outer segment G protein transducin (G(talpha)). The radiolabeled protein was specifically eluted from illuminated membranes in the presence of GTP, displaying the unique solubility properties of G(talpha). It comigrated with G(talpha) in electrophoresis and chromatography and was immunoprecipitated by G(talpha)-specific antibodies. The radiolabel was confirmed by hydrolysis, chemical derivatization, and chromatography to be amide-linked myristic acid. The solubility of the myristoylated G(talpha) indicates that myristoylation is not sufficient to cause tight membrane association of this normally membrane-bound subunit. Incorporation of [H-3]myristate was blocked by the protein synthesis inhibitor cycloheximide, suggesting that that fatty acid group is introduced during or soon after translation in the rod inner segment.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; Ames A 3rd, 1980, Neurochem Int, V1C, P393, DOI 10.1016/0197-0186(80)90075-3; ANANT JS, 1992, J BIOL CHEM, V267, P687; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CODINA J, 1991, J RECEPTOR RES, V11, P589; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DIZHOOR AM, 1992, INVEST OPHTH VIS SCI, V33, P1006; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HARLOW E, 1988, ANTIBODIES LABORATOR; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LIPKIN VM, 1987, RETINAL PROTEINS, P39; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEUBERT TA, 1992, INVEST OPHTH VIS SCI, V33, P872; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; QIN N, 1992, J BIOL CHEM, V267, P8458; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; WENSEL T G, 1992, Biophysical Journal, V61, pA98; WENSEL TG, 1988, ENZYME DYNAMICS REGU, P102; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23197	23201						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429667				2022-12-27	WOS:A1992JY16300076
J	BOLES, JO; TOLLESON, WH; SCHMIDT, JC; DUNLAP, RB; ODOM, JD				BOLES, JO; TOLLESON, WH; SCHMIDT, JC; DUNLAP, RB; ODOM, JD			SELENOMETHIONYL DIHYDROFOLATE-REDUCTASE FROM ESCHERICHIA-COLI - COMPARATIVE BIOCHEMISTRY AND SE-77 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIWAVELENGTH ANOMALOUS DIFFRACTION; CRYSTAL-STRUCTURES; ALPHA-CHYMOTRYPSIN; PURIFICATION; BINDING; ENZYME; PROTEINS; COMPLEX; LIVER; METHOTREXATE	The biosynthetic replacement of Met residues by selenomethionine (SeMet) facilitates the determination of three-dimensional structure by multiwavelength anomalous diffraction (Yang, W., Hendrickson, W. A., Crouch, R. J., and Satow, Y. (1990) Science 249, 1398-1405). In an effort to examine any biochemical effects due to the replacement of Met residues by SeMet, we chose to compare the kinetic and binding properties of selenomethionyl dihydrofolate reductase with those of the wt enzyme. There are 5 Met residues in Escherichia coli dihydrofolate reductase with 2 located in the Met-20 loop, which is a sequence of residues forming a lid over the active site. Utilizing plasmid pWT8, which affords 10-15% soluble protein as E. coli dihydrofolate reductase, we readily isolated both the. SeMet and wt enzymes from E.coli DL41 utilizing a novel purification protocol. Both enzymes exhibited essentially the same kinetic and binding properties, including specific activities (45 mumol/min/mg), K(m) (7,8-dihydrofolate = 0.39 muM; NADPH = 2.0 muM), k(cat) (13.5/s), and 1:1 noncovalent inhibitory binding ratios with methotrexate. The inhibitory effects of divalent and monovalent cations on activity were also assessed, with the SeMet-containing enzyme exhibiting a uniformly greater sensitivity than the wt enzyme. We conclude that the biochemical properties of dihydrofolate reductase are virtually unperturbed by SeMet inclusion. Analysis of SeMet dihydrofolate reductase by Se-77 nuclear magnetic resonance spectroscopy revealed five distinct resonances, thus indicating the potential value of this technique in employing selenium as a nonperturbing NMR probe of protein structure and function.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,DEPT PEDIAT,CHILDRENS CANC RES LAB,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia			Tolleson, William/T-9345-2019	Tolleson, William/0000-0002-7682-3113	NATIONAL CANCER INSTITUTE [R01CA015645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042907] Funding Source: NIH RePORTER; NCI NIH HHS [CA 15645] Funding Source: Medline; NCRR NIH HHS [1-510-RR0245-1] Funding Source: Medline; NIGMS NIH HHS [GM 42907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACCANARI DP, 1981, J BIOL CHEM, V256, P1738; BOLES JO, 1991, BIOCHEMISTRY-US, V30, P11073, DOI 10.1021/bi00110a009; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DUNLAP RB, 1988, PHOSPHORUS SULFUR, V38, P217, DOI 10.1080/03086648808079718; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ERICKSON JS, 1973, BIOCHEMISTRY-US, V12, P372, DOI 10.1021/bi00727a002; FARNUM MF, 1991, BIOCHEMISTRY-US, V30, P11567, DOI 10.1021/bi00113a012; FUTTERMAN S, 1957, J BIOL CHEM, V228, P1031; GETTINS P, 1991, J BIOL CHEM, V266, P3422; GETTINS P, 1991, J BIOL CHEM, V266, P4804; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P41; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HOUSE KL, 1992, IN PRESS J AM CHEM S; HUENNEKENS FM, 1970, CHEM BIOL PTERIDINES, P329; JARABAK J, 1971, ARCH BIOCHEM BIOPHYS, V142, P417, DOI 10.1016/0003-9861(71)90505-4; KAMEN BA, 1976, ANAL BIOCHEM, V70, P54, DOI 10.1016/S0003-2697(76)80047-4; LUTHRA NP, 1981, ANAL BIOCHEM, V117, P94, DOI 10.1016/0003-2697(81)90697-7; LUTHRA NP, 1983, J MAGN RESON, V52, P318, DOI 10.1016/0022-2364(83)90203-2; LUTHRA NP, 1982, J BIOL CHEM, V257, P1142; MANIATIS T, 1982, MOL CLONING LABORATO, P75; MATTHEWS DA, 1977, SCIENCE, V197, P452, DOI 10.1126/science.17920; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MCCULLOUGH JL, 1971, BIOCHEM PHARMACOL, V20, P561, DOI 10.1016/0006-2952(71)90143-2; MULLEN GP, 1986, BIOCHEMISTRY-US, V25, P5625, DOI 10.1021/bi00367a042; MULLEN GP, 1985, J AM CHEM SOC, V107, P7187, DOI 10.1021/ja00310a078; NIXON PF, 1968, J BIOL CHEM, V243, P4722; ODOM JD, 1979, J AM CHEM SOC, V101, P5815, DOI 10.1021/ja00513a058; POE M, 1972, BIOCHEMISTRY-US, V11, P1023, DOI 10.1021/bi00756a012; ROWE PB, 1973, J BIOL CHEM, V248, P984; SHEPHERD L, 1969, CAN J BIOCHEM CELL B, V47, P877, DOI 10.1139/o69-137; STONE SR, 1982, BIOCHEMISTRY-US, V21, P3757, DOI 10.1021/bi00259a006; WILLIAMS MN, 1977, J BIOL CHEM, V252, P6871; WILLIAMS TJ, 1977, ARCH BIOCHEM BIOPHYS, V181, P569, DOI 10.1016/0003-9861(77)90263-6; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	39	34	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22217	22223						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429574				2022-12-27	WOS:A1992JW71900037
J	KADOWAKI, M; POSO, AR; MORTIMORE, GE				KADOWAKI, M; POSO, AR; MORTIMORE, GE			PARALLEL CONTROL OF HEPATIC PROTEOLYSIS BY PHENYLALANINE AND PHENYLPYRUVATE THROUGH INDEPENDENT INHIBITORY SITES AT THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; PERFUSED-RAT-LIVER; PROTEIN-DEGRADATION; SKELETAL-MUSCLE; PRIMARY CULTURE; TRANSFER-RNA; HEPATOCYTES; LEUCINE; DEPRIVATION; ALANINE	Intracellular protein degradation in the rat hepatocyte is regulated by 7 amino acids of which Leu, Gln, and Tyr play major roles. Although Phe is known to inhibit proteolysis as effectively as Tyr at high concentrations, it has not been regarded as an active regulator because of its rapid hydroxylation to Tyr. We now show that proteolytic responses to Phe during liver perfusion differ strikingly from effects of the multiphasic regulators Leu, Gln, and Tyr in eliciting mirror image responses at half-normal and normal plasma concentrations. Since response curves to phenylpyruvate and Phe were identical, we considered the possibility that phenylpyruvate mediated its anomalous inhibition intracellularly. However, when phenylpyruvate was produced from phenyllactate intracellularly at a rate providing the same rate of transamination (and intracellular concentration) as that derived from the uptake of phenylpyruvate, no response was obtained. Hence, the effect of phenylpyruvate was not initiated within the cell but more likely from the plasma membrane. Comparable evidence for Phe is less direct. Recent findings indicate that recognition sites for Leu and Gln are located at the plasma membrane. Since Phe augments the concerted inhibition by Leu and Gln at 4-fold normal levels, Phe is probably recognized in close proximity to them. However, the failure of phenylpyruvate to substitute for Phe in this interaction suggests that proteolytic inhibition by phenylpyruvate and Phe is mediated through similar, although independent, plasma membrane sites.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIDDK NIH HHS [DK 21624] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021624] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; CARR FPA, 1981, BIOCHEM J, V198, P655, DOI 10.1042/bj1980655; HUTSON SM, 1978, J BIOL CHEM, V253, P8126; KADOWSKI M, 1908, INTRACELLULAR PROTEO, P488; KHAIRALLAH EA, 1976, J BIOL CHEM, V251, P1375; KILBERG MS, 1983, J BIOL CHEM, V258, P1524; KLEINHANS B, 1985, FED PROC, V44, P1091; LIVESEY G, 1985, J CHROMATOGR, V337, P98, DOI 10.1016/0378-4347(85)80012-8; MIOTTO G, 1989, BIOCHEM BIOPH RES CO, V158, P797, DOI 10.1016/0006-291X(89)92792-7; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; MITCH WE, 1984, BIOCHEM J, V222, P579, DOI 10.1042/bj2220579; MORI K, 1976, TETRAHEDRON, V32, P1101, DOI 10.1016/0040-4020(76)85032-6; MORTIMORE GE, 1988, J BIOL CHEM, V263, P19545; MORTIMORE GE, 1991, J BIOL CHEM, V266, P1021; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; NALECZ KA, 1984, BIOCHIM BIOPHYS ACTA, V805, P1; POSO AR, 1984, P NATL ACAD SCI-BIOL, V81, P4270, DOI 10.1073/pnas.81.14.4270; POSO AR, 1982, J BIOL CHEM, V257, P2114; RABKIN R, 1991, J LAB CLIN MED, V117, P505; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; TAPUHI Y, 1981, ANAL BIOCHEM, V115, P123, DOI 10.1016/0003-2697(81)90534-0; TISCHLER ME, 1982, J BIOL CHEM, V257, P1613; VENERANDO R, 1991, FASEB J, V5, pA1178; WANG SR, 1985, IN VITRO CELL DEV B, V21, P526; WEBER WW, 1966, J BIOL CHEM, V241, P1345	29	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22060	22065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429557				2022-12-27	WOS:A1992JW71900015
J	MASQUILIER, D; SASSONECORSI, P				MASQUILIER, D; SASSONECORSI, P			TRANSCRIPTIONAL CROSS-TALK - NUCLEAR FACTORS CREM AND CREB BIND TO AP-1 SITES AND INHIBIT ACTIVATION BY JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAYS; CYCLIC-AMP; LEUCINE ZIPPER; ADENYLATE-CYCLASE; FOS GENE; POSITIVE REGULATION; ENHANCER ELEMENTS; 2ND MESSENGERS; V-JUN	The proteins Fos and Jun dimerize to constitute the transcription factor AP-1 which is known to respond to treatment with phorbol esters. AP-1 binds to 12-O-tetradecanoylphorbol-13-acetate-responsive elements (TREs) palindromic sequences. cAMP-responsive elements (CREs) are very similar to TREs and CRE-binding proteins are similar in structure to Fos and Jun. Thus, the two main signal transduction pathways have closely related nuclear effectors which could possibly overlap and/or cross-talk. The gene CRE modulator (CREM) encodes both antagonists and an activator of the cAMP transcriptional response by alternative splicing. In this report we show that CREM antagonists are able to block the transcriptional activation elicited by c-Jun. The mechanism by which this repression is obtained does not require heterodimerization between CREM and the Fos and/or Jun proteins. In contrast, we show that both CREM and CRE-binding proteins (CREB) are able to bind TREs and therefore compete with c-Jun for this site. Removal of the phosphorylation domain in CREM does not affect the down-regulatory function. We also show that c-Fos does not affect the inhibitory function of CREM on c-Jun and that the transcriptional activation elicited by the other members of the jun family (JunB, JunD, and v-Jun) is also down-regulated by CREM.	FAC MED STRASBOURG, CNRS,GENET MOLEC EUCARYOTES LABS,INST CHIM BIOL, INSERM,U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BELL JD, 1985, J BIOL CHEM, V260, P2625; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRELLI E, 1992, IN PRESS CRIT REV ON; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1992, IN PRESS ONCOGENE; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELI E, 1988, FEBS LETT, V231, P407, DOI 10.1016/0014-5793(88)80860-3; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; Kessler S W, 1981, Methods Enzymol, V73, P442; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELLSTROM B, 1991, ONCOGENE, V6, P1959; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1991, ONCOGENE, V6, P223; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	73	198	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22460	22466						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429597				2022-12-27	WOS:A1992JW71900074
J	SRIVASTAVA, G; KAUR, KJ; HINDSGAUL, O; PALCIC, MM				SRIVASTAVA, G; KAUR, KJ; HINDSGAUL, O; PALCIC, MM			ENZYMATIC TRANSFER OF A PREASSEMBLED TRISACCHARIDE ANTIGEN TO CELL-SURFACES USING A FUCOSYL-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCOSYL-TRANSFERASE; SIALIC ACIDS; LEWIS-A; RECOGNITION; DETERMINANT; OLIGOSACCHARIDES; BINDING; ELAM-1; FETUIN; LEX	The Lewis alpha(1-->3/4)-fucosyltransferase (Le-FucT) is known to fucosylate both Type I (betaGal(1-->3)betaGlcNAc) and Type II (betaGal(1-->4)betaGlcNAc) sequences even when these are sialylated at OH-3 or fucosylated at OH-2 of the terminal Gal residues. These acceptor sequences are ubiquitous on mammalian cell-surface glycoproteins and glycolipids. The Le-FucT enzyme is therefore a potential candidate as a universal reagent for the modification of cell surfaces. We have found that a readily accessible, partially purified Le-FucT from human milk, which normally uses GDP-fucose (a 6-deoxy sugar) as the donor for the transfer of a single fucose residue, will also transfer a fucose residue substituted on C-6 by a very large sterically demanding structure, in this instance, a synthetic blood group antigen. As a demonstration of the ability of the Le-FucT to modify glycoconjugates in a mild and specific manner, we chemically synthesized the complex sugar-nucleotide alphaGal(1-->3)[alphaFuc(1-->2)]-betaGal-O-(CH2)8COHN(6)-beta-L-fucose-GDP (13) which is a GDP-fucose analog where the human blood group B trisaccharide antigen is covalently linked to C-6 of fucose through an amino group. It is shown that, in enzyme-linked immunosorbent assays, the Le-FucT uses both immobilized betaGal(1-->3)betaGlcNAc-bovine serum albumin conjugates and fetuin as acceptor substrates and renders them blood group B-active as detected by a monoclonal anti-B blood-grouping antibody. The fucose residue to which the B-trisaccharide is linked therefore becomes covalently attached to the acceptor oligosaccharide chains of those glycoproteins. Incubation of type "O" erythrocytes with the Le-FucT and complex donor 13 results in the covalent transfer of alphaGal(1-->3)[alphaFuc(1-->2)]betaGal-O-(CH2)8COHN(6)-beta-L-Fuc to cell-surface acceptors since the cells become phenotypically "B" and are agglutinated by the same antibody. It is proposed that the Le-FucT represents a powerful new tool with the ability to label animal cell surfaces with preassembled oligosaccharide and possibly also other complex recognition markers.	UNIV ALBERTA, DEPT CHEM, EDMONTON T6G 2G2, ALBERTA, CANADA	University of Alberta			Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583				BENDIAK B, 1989, BIOCHEMISTRY-US, V28, P6491, DOI 10.1021/bi00441a050; BERGH MLE, 1988, BANBURY REPORT, V29, P59; BEYER TA, 1981, ADV ENZYMOL, V52, P24; Brandley B K, 1991, Semin Cell Biol, V2, P281; Dennis JW, 1992, CELL SURFACE CARBOHY, P161; GAHMBERG CG, 1988, ANAL BIOCHEM, V170, P520, DOI 10.1016/0003-2697(88)90667-7; GOKHALE UB, 1990, CAN J CHEM, V68, P1063, DOI 10.1139/v90-165; GROSS HJ, 1987, EUR J BIOCHEM, V168, P595, DOI 10.1111/j.1432-1033.1987.tb13458.x; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; KELM S, 1986, CARBOHYD RES, V149, P59, DOI 10.1016/S0008-6215(00)90369-0; KESHVARA LM, 1992, GLYCOCONJUGATE J, V9, P16, DOI 10.1007/BF00731173; KLUKOWSKA JF, 1990, GENE DEV, V4, P11288; KOBATA A, 1988, BIOCHIMIE, V70, P1575, DOI 10.1016/0300-9084(88)90293-3; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; LEMIEUX RU, 1985, CAN J CHEM, V63, P2664, DOI 10.1139/v85-442; MONTREUIL J, 1982, COMPR BIOCHEM, V19B, P1; PALCIC MM, 1990, CARBOHYD RES, V196, P133, DOI 10.1016/0008-6215(90)84112-8; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PINTO BM, 1983, CARBOHYD RES, V124, P313, DOI 10.1016/0008-6215(83)88466-3; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; VARKI A, 1991, TRENDS GLYCOSCI GLYC, V3, P122; WALSH WL, 1972, TRANSFUSION, V12, P352; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275	27	59	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22356	22361						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429589				2022-12-27	WOS:A1992JW71900059
J	VULLIET, R; HALLORAN, SM; BRAUN, RK; SMITH, AJ; LEE, G				VULLIET, R; HALLORAN, SM; BRAUN, RK; SMITH, AJ; LEE, G			PROLINE-DIRECTED PHOSPHORYLATION OF HUMAN TAU-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; CENTRAL NERVOUS-SYSTEM; ALZHEIMER-DISEASE; ABNORMAL PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; KINASE; IDENTIFICATION; BINDING; BRAIN	The primary sequence of the microtubule-associated protein tau contains multiple repeats of the sequence -X-Ser/Thr-Pro-X-, the consensus sequence for the proline-directed protein kinase (p34cdc2/p58cyclin A). When phosphorylated by proline-directed protein kinase in vitro, tau was found to incorporate up to 4.4 mol of phosphate/mol of protein. Isoelectric focusing of the tryptic phosphopeptides demonstrated the presence of five distinct peptides with pl values of approximately 6.9, 6.5, 5.6-5.9, 4.7, and 3.6. Mapping of the tryptic phosphopeptides by high performance liquid chromatography techniques demonstrated three distinct peaks. Data from gas phase sequencing, amino acid analysis, and phosphoamino acid analysis suggest that proline-directed protein kinase phosphorylates tau at four sites. Each site demonstrates the presence of a proline residue on the carboxyl-terminal side of the phosphorylated residue. Two phosphorylation sites are located adjacent to the three-repeat microtubule-binding domain that has been found to be required for the in vivo co-localization of tau protein to microtubules. Two other putative phosphorylation sites are located within the identified epitope of the monoclonal antibody Tau-1. Phosphorylation of these sites altered the immunoreactivity of tau to Tau-1 antibody. Since the neuronal microtubule-associated protein tau is multiply phosphorylated in Alzheimer's disease, and Tau-1 immunoreactivity is similarly reduced in neurofibrillary tangles and enhanced after dephosphorylation, phosphorylation at one or more of these sites may correlate with abnormally phosphorylated sites in tau protein in Alzheimer's disease.	SCHWEIZER INST ALLERGIE & ASTHMA FORSCH, CH-7270 DAVOS, SWITZERLAND; STANFORD UNIV, BECKMAN CTR, STANFORD, CA 94305 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, CTR NEUROL DIS, BOSTON, MA 02115 USA	Stanford University; Harvard University; Brigham & Women's Hospital	VULLIET, R (corresponding author), UNIV CALIF DAVIS, SCH VET MED, DEPT VET PHARMACOL & TOXICOL, DAVIS, CA 95616 USA.		Lee, Gloria/F-5965-2011	Lee, Gloria/0000-0002-8633-1534; Braun, Rudolf/0000-0002-1778-9613	NIGMS NIH HHS [GM39300] Funding Source: Medline; NINDS NIH HHS [1RO1-NS28765-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028765] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZAWA H, 1990, J BIOL CHEM, V265, P13849; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BENOREPARSONS M, 1989, ARCH BIOCHEM BIOPHYS, V272, P274, DOI 10.1016/0003-9861(89)90220-8; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRION JP, 1988, NEUROSCIENCE, V25, P139, DOI 10.1016/0306-4522(88)90013-9; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHAPIN SJ, 1991, J CELL SCI, V98, P27; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; Hall F L, 1990, Proc West Pharmacol Soc, V33, P213; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HALLORAN SM, 1992, FASEB J, V6, pA1558; HARLOW E, 1988, ANTIBODIES LAB MANUA, P486; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYES TE, 1991, NEW BIOL, V3, P259; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Kosik KS, 1990, CURR OPIN CELL BIOL, V2, P101, DOI 10.1016/S0955-0674(05)80038-9; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MEININGER V, 1989, INT REV CYTOL, V114, P21; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PAPASOZOMENOS SC, 1991, P NATL ACAD SCI USA, V88, P4543, DOI 10.1073/pnas.88.10.4543; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	53	180	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22570	22574						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429606				2022-12-27	WOS:A1992JW71900090
J	GETTINS, P; CHOAY, J; CREWS, BC; ZETTLMEISSL, G				GETTINS, P; CHOAY, J; CREWS, BC; ZETTLMEISSL, G			ROLE OF TRYPTOPHAN-49 IN THE HEPARIN-COFACTOR ACTIVITY OF HUMAN ANTITHROMBIN-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-THROMBIN-III; HIGH-AFFINITY HEPARIN; H-1-NMR SPECTROSCOPY; ESCHERICHIA-COLI; DERMATAN SULFATE; BINDING-SITE; FACTOR-XA; PROTEINS; SEQUENCE; RESIDUES	To probe the functional role of tryptophan 49 in human antithrombin III, a mutant antithrombin, W49K, has been expressed in baby hamster kidney cells. The mutation reduces the affinity for heparin pentasaccharide by 1.8 kcal mol-1 but does not alter the heparin enhancement of the rate of factor X(a) inhibition. H-1 NMR spectra of W49K antithrombin show that the structure of the protein and the mode of heparin binding appear to be unaltered by the mutation, although tryptophan 49 is perturbed by heparin binding. F-19 NMR spectra of 6-fluorotryptophan-substituted antithrombin show that tryptophan 49 is in a solvent-exposed environment. The heparin-induced fluorescence enhancement of W49K antithrombin is significantly different from that of wild-type antithrombin. Pentasaccharide induces only a 24% enhancement of antithrombin fluorescence, while high affinity heparin induces an enhancement of 40%. The results indicate that tryptophan 49 is probably a heparin contact residue but can be mutated without altering the remaining heparin-antithrombin interactions or the heparin-induced conformational change and resultant activation toward Factor X(a). Hydrophobic as well as charge interactions are thus probably involved in the specificity of the antithrombin-heparin pentasaccharide interaction. The lower fluorescence enhancements suggest that the heparin-induced 40% fluorescence enhancement used as the hallmark of activating heparin species is not the best indicator of the structural change in antithrombin that results in enhancement of the rate of proteinase inhibition.	VANDERBILT UNIV, MED CTR, SCH MED, CTR MOLEC TOXICOL, NASHVILLE, TN 37232 USA; BEHRINGWERKE AG, RES LABS, W-3550 MARBURG, GERMANY; SANOFI RECH, CTR CHOAY, F-94256 GENTILLY, FRANCE	Vanderbilt University; Sanofi-Aventis; Sanofi France	GETTINS, P (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.				NCRR NIH HHS [S10 RR05805] Funding Source: Medline; NHLBI NIH HHS [HL32595] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; BJORK L, 1992, IN PRESS BIOCH J; BLACKBURN MN, 1984, J BIOL CHEM, V259, P939; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHANDRA T, 1983, P NATL ACAD SCI-BIOL, V80, P1845, DOI 10.1073/pnas.80.7.1845; Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; EINARSSON R, 1977, BIOCHIM BIOPHYS ACTA, V490, P104, DOI 10.1016/0005-2795(77)90110-6; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P4403, DOI 10.1021/bi00388a032; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUDZIAK RM, 1982, CELL, V31, P137, DOI 10.1016/0092-8674(82)90413-5; JORDAN R, 1979, J BIOL CHEM, V254, P2902; KALK A, 1976, J MAGN RESON, V24, P343, DOI 10.1016/0022-2364(76)90115-3; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCHANTIN GF, 1973, J BIOL CHEM, V248, P5956; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LOBERMANN H, 1984, J MOL BIOL, P731; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OWEN MC, 1987, BLOOD, V69, P1275; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; Petersen TE, 1979, PHYSL INHIBITORS BLO, P43; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; SHAH N, 1990, THROMB RES, V57, P343, DOI 10.1016/0049-3848(90)90250-G; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; SIXL F, 1990, BIOCHEM J, V266, P545, DOI 10.1042/bj2660545; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SYKES BD, 1974, P NATL ACAD SCI USA, V71, P469, DOI 10.1073/pnas.71.2.469; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; Zettlmeissl G, 1988, Behring Inst Mitt, P26; ZETTLMEISSL G, 1990, Patent No. 384122	51	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21946	21953						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400504				2022-12-27	WOS:A1992JV01100105
J	OHMICHI, M; DECKER, SJ; SALTIEL, AR				OHMICHI, M; DECKER, SJ; SALTIEL, AR			NERVE GROWTH-FACTOR STIMULATES THE TYROSINE PHOSPHORYLATION OF A 38-KDA PROTEIN THAT SPECIFICALLY ASSOCIATES WITH THE SRC HOMOLOGY DOMAIN OF PHOSPHOLIPASE-C-GAMMA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; PC12 PHEOCHROMOCYTOMA CELLS; COOH-TERMINAL TRUNCATION; HUMAN INSULIN-RECEPTOR; KINASE-ACTIVITY; RAT PHEOCHROMOCYTOMA; SIGNAL TRANSDUCTION; PHORBOL ESTERS; PC-12 CELLS; C-GAMMA	The cellular actions of nerve growth factor (NGF) involve changes in protein phosphorylation, initiated by the binding and subsequent activation of its tyrosine kinase receptor, the trk protooncogene (pp140c-trk). Upon exposure to NGF, a 38-kDa tyrosine-phosphorylated protein (pp38) is identified in both PC-12 pheochromocytoma cells and NIH3T3 cells transfected with the full-length human pp140c-trk cDNA (3T3-c-trk) that is specifically coimmunoprecipitated with pp140c-trk or phosphatidylinositol-phospholipase C (PLC)-gamma1. In both PC-12 and 3T3-c-trk cells, NGF rapidly stimulates the association of pp140c-trk and pp38 with a fusion protein containing the src homology (SH) domains of PLCgamma1. This phosphorylation and subsequent association are specific for NGF, since epidermal growth factor, platelet-derived growth factor, and insulin do not stimulate the tyrosine phosphorylation of these proteins or their association with the PLCgamma1 SH domains, although the receptors for these growth factors do undergo tyrosine phosphorylation and association with the PLC-gamma1 fusion protein under these conditions. Furthermore, the NGF-dependent pp38-SH binding is specific for the SH2 domains of PLC-gamma1, since the phosphoprotein does not bind to fusion proteins containing SH domains of ras GTPase-activating protein or the p85 subunit of phosphatidylinositol 3 kinase. Both amino- and carboxyl-terminal SH2 domains of PLC-gamma1 are necessary for the association of pp38 with PLC-gamma1, although each SH2 domain is sufficient for the association of pp140c-trk with PLC-gamma1. In both PC-12 and 3T3-c-trk cells, the phosphorylation and association of pp38 with PLCgamma1 is rapid, occurring maximally at 1 min and declining thereafter. Moreover, this effect of NGF is dose-dependent over a physiological concentration of the growth factor. The specificity and rapidity of pp38 phosphorylation and its association with PLC-gamma1 suggest that it may be an important component in signal transduction for NGF.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA37754] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033804, R23DK033804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALETTA TM, 1988, J CELL BIOL, V105, P1573; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HU P, 1992, IN PRESS MOL CELL BI; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P2832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRETH G, 1980, NATURE, V283, P202, DOI 10.1038/283202a0; LANDRETH GE, 1985, J CELL BIOL, V100, P677, DOI 10.1083/jcb.100.3.677; LEE KY, 1985, CELL, V57, P1101; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS B, 1990, EMBO J, V9, P4357; MATHUDA Y, 1987, J BIOL CHEM, V262, P2832; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MEISENHELDER J, 1989, CELL, V57, P1108; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAKANISHI N, 1985, J BIOL CHEM, V260, P7791; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OHMICHI M, 1992, IN PRESS NEURON; RAWLAND EA, 1987, J BIOL CHEM, V262, P7504; SALTIEL AR, 1991, MOL CELL ENDOCRINOL, V81, pC197, DOI 10.1016/0303-7207(91)90198-2; SUN XJ, 1988, SCIENCE, V242, P1697; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; ZHU G, IN PRESS P NATL ACAD	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21601	21606						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400471				2022-12-27	WOS:A1992JV01100054
J	OREAR, JJ				OREAR, JJ			A NOVEL LAMININ-B1 CHAIN VARIANT IN AVIAN EYE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BASEMENT-MEMBRANE; DROSOPHILA LAMININ; MULTIDOMAIN PROTEIN; A-CHAIN; SEQUENCE; REVEALS; DOMAINS; MOUSE; HOMOLOGY; B2-CHAIN	Two distinct recombinant cDNA clones having homology to mouse laminin B1 have been isolated from an adult chicken eye library by cross-species nucleic acid hybridization. DNA sequence analysis identified one cDNA as the chicken homologue of the prototypic EHS laminin B1 chain. The second recombinant cDNA encodes a portion of a laminin B1-like protein, which is neither the chicken homologue of laminin B1 nor s-laminin, and thus represents a new laminin B1 variant.			OREAR, JJ (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854, USA.							BRUBACHER D, 1991, EXP CELL RES, V197, P290, DOI 10.1016/0014-4827(91)90435-W; CHI HC, 1988, NUCLEIC ACIDS RES, V16, P7205, DOI 10.1093/nar/16.14.7205; CHI HC, 1989, J BIOL CHEM, V264, P1543; DURKIN ME, 1988, BIOCHEMISTRY-US, V27, P5198, DOI 10.1021/bi00414a038; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10452; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SCHITTNY JC, 1988, J CELL BIOL, V107, P1599, DOI 10.1083/jcb.107.4.1599; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	23	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20555	20557						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400373				2022-12-27	WOS:A1992JT97800009
J	RANDI, AM; JORIEUX, S; TULEY, EA; MAZURIER, C; SADLER, JE				RANDI, AM; JORIEUX, S; TULEY, EA; MAZURIER, C; SADLER, JE			RECOMBINANT VONWILLEBRAND-FACTOR ARG578-]GLN - A TYPE-IIB VONWILLEBRAND DISEASE MUTATION AFFECTS BINDING TO GLYCOPROTEIN-IB BUT NOT TO COLLAGEN OR HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; PLATELET MEMBRANE; HEMOPHILIA-A; BOTROCETIN; DOMAIN; COMPLEX; IDENTIFICATION; RISTOCETIN; SITES; IX	von Willebrand factor (vWF) is a multimeric plasma glycoprotein that mediates platelet adhesion to the subendothelium via binding to platelet glycoprotein Ib (GPIb) and to components of the vessel wall. Recently, missense mutations that cause type IIB von Willebrand disease (vWD) were described, clustered within a disulfide loop in the A1 domain of vWF that has binding sites for GPIb, collagen, and heparin. In type IIB vWD, plasma vWF exhibits increased affinity for platelet GPIb, but decreased binding to collagen and heparin. The effect was studied of a type IIB vWD mutation, Arg578 --> Gln, on the interaction of vWF with GPIb, collagen, and heparin. Recombinant wild type rvWF and mutant rvWF(R578Q) were expressed in COS-7 cells. Ristocetin-induced binding of rvWF(R578Q) to GPIb was markedly increased compared with rvWF, confirming that the Arg578 --> Gln mutation causes the characteristic gain-of-function abnormality of type IIB vWD; botrocetin-induced binding was only slightly increased. Binding to collagen type III and heparin-agarose was compared for rvWF(R578Q) and plasma vWF from patients with four different type IIB mutations: Arg543 --> Trp, Arg545 --> Cys, Val553 --> Met, Arg578 --> Gln. For all of the plasma samples, binding to collagen and to heparin was reduced compared with normal plasma. In contrast, binding of rvWF(R578Q) to collagen and heparin was normal compared with wild type rvWF. Therefore, the Arg578 --> Gln mutation increases the affinity of vWF for GPIb but does not directly impair vWF interaction with collagen or heparin. Arg578 may therefore be necessary to prevent normal vWF from interacting with GPIb. In type IIB vWD, the defective binding of plasma vWF to collagen and heparin may be secondary to post-synthetic modifications that occur in vivo, such as the loss of high molecular weight vWF multimers.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,HOWARD HUGHES MED INST,660 S EUCLID,BOX 8022,ST LOUIS,MO 63110; CTR REG TRANSFUS SANGUINE,RECH HEMOSTASE LAB,LILLE,FRANCE; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT MED & BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HLBI 07088, HLBI 14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIHARA M, 1988, THROMB HAEMOSTASIS, V59, P485; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; BRINKHOUS KM, 1980, BLOOD, V55, P517; BROWN JE, 1986, THROMB RES, V43, P303, DOI 10.1016/0049-3848(86)90150-7; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; COONEY KA, 1992, P NATL ACAD SCI USA, V89, P2869, DOI 10.1073/pnas.89.7.2869; DEGROOT PG, 1989, P NATL ACAD SCI USA, V86, P3793; DEGROOT PG, 1987, SEMIN THROMB HEMOST, V13, P416, DOI 10.1055/s-2007-1003518; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; DEROMEUF C, 1991, THROMB HAEMOSTASIS, V65, pA970; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; GILCHRIST M, 1990, THROMB RES, V57, P659, DOI 10.1016/0049-3848(90)90084-P; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOWARD MA, 1984, BRIT J HAEMATOL, V57, P25, DOI 10.1111/j.1365-2141.1984.tb02862.x; KRONER PA, 1992, BLOOD, V79, P2048; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAZURIER C, 1990, BRIT J HAEMATOL, V76, P372, DOI 10.1111/j.1365-2141.1990.tb06371.x; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NISHIKUBO T, 1991, THROMB HAEMOSTASIS, V65, P1128; NISHIO K, 1990, AM J HEMATOL, V33, P261, DOI 10.1002/ajh.2830330409; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; RANDI AM, 1991, J CLIN INVEST, V87, P1220, DOI 10.1172/JCI115122; RANDI AM, 1991, THROMB HAEMOSTASIS, V65, pA764; RIBBA AS, 1991, BLOOD, V78, P1738; RUGGERI ZM, 1980, NEW ENGL J MED, V302, P1047, DOI 10.1056/NEJM198005083021902; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1453; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SOUTAR AK, 1990, PROTEIN FUNCTION, P69; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946	36	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21187	21192						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400429				2022-12-27	WOS:A1992JT97800104
J	ARMSTRONG, C; SCHUBERT, J; UEDA, E; KNEZ, JJ; GELPERIN, D; HIROSE, S; SILBER, R; HOLLAN, S; SCHMIDT, RE; MEDOF, ME				ARMSTRONG, C; SCHUBERT, J; UEDA, E; KNEZ, JJ; GELPERIN, D; HIROSE, S; SILBER, R; HOLLAN, S; SCHMIDT, RE; MEDOF, ME			AFFECTED PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA LYMPHOCYTES-T HARBOR A COMMON DEFECT IN ASSEMBLY OF N-ACETYL-D-GLUCOSAMINE INOSITOL PHOSPHOLIPID CORRESPONDING TO THAT IN CLASS-A THY-1- MURINE LYMPHOMA MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; VARIANT SURFACE GLYCOPROTEIN; BIOSYNTHESIS; ANCHOR; IDENTIFICATION; RETINOBLASTOMA; EXPRESSION; ORIGIN; CELLS; GENE	Deficient expression of glycoinositol phospholipid (GPI) anchored proteins in affected paroxysmal nocturnal hemoglobinuria (PNH) cells has been traced to a defect in GPI anchor assembly. In a previous study (Schubert, J., Schmidt, R. E., and Medof, M. E. (1993) J. Biol. Chem., in press) we characterized the biosynthesis of putative Man-containing GPI anchor precursors in normal peripheral blood lymphocytes and investigated assembly of these intracellular GPI intermediates in CD48- affected and CD48+ unaffected T and natural killer cell lines of PNH patients. We found that affected T cells from five patients exhibited a uniform defect in which dolichol-phosphoryl-Man was synthesized but no GPI mannolipids were expressed. In this study, membranes of patients' affected T cells were labeled with UDP-[H-3]GlcNAc to evaluate earlier steps in GPI synthesis, and intact cells were fused to Thy-1- murine lymphoma mutants harboring different defects in early GPI assembly to test for the presence of corresponding or complementary lesions. In all cases, affected cell membranes failed to assemble GlcNAc-inositol phospholipid, the initial precursor of GPI anchor structures, and the intact cells failed to complement class A mutants while complementing other classes. Affected polymorphonuclear leukocytes from three additional patients of different origin were then labeled with [H-3]Man and the labeling patterns found to correspond to those obtained with the T lymphocytes. Taken together the data indicate that the genetic lesion in PNH cells resides in a DNA element which: 1) encodes a product required for the synthesis of GIcNAc-inositol phospholipid, 2) corresponds to that altered in class A Thy-1- murine lymphoma mutants, and 3) is commonly affected in different patients.	CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106; MED HSCH HANNOVER,IMMUNOL & TRANSFUSMED ABT,W-3000 HANNOVER 61,GERMANY; FUKUOKA UNIV,SCH MED,FUKUOKA 81401,JAPAN; NYU,MED CTR,NEW YORK,NY 10003; NATL INST HAEMATOL & BLOOD TRANSFUS,H-1113 BUDAPEST,HUNGARY	Case Western Reserve University; Hannover Medical School; Fukuoka University; New York University					NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAROTHERS DJ, 1990, J CLIN INVEST, V85, P47, DOI 10.1172/JCI114432; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HIROSE S, 1991, FASEB J, V5, P2459; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; MAHONEY JF, 1992, BLOOD, V79, P1400; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; SCHUBERT J, 1992, IN PRESS J BIOL CHEM; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; YOMTOVIAN R, 1993, IN PRESS TRANSFUSION	24	105	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25347	25351						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460030				2022-12-27	WOS:A1992KB60300066
J	LUND, E; BREUER, O; BJORKHEM, I				LUND, E; BREUER, O; BJORKHEM, I			EVIDENCE THAT 24-HYDROXYLATION AND 27-HYDROXYLATION ARE NOT INVOLVED IN THE CHOLESTEROL-INDUCED DOWN-REGULATION OF HYDROXYMETHYLGLUTARYL-COA REDUCTASE IN MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; RAT-LIVER; EXPRESSION; ENZYME; SERUM; ACID; 26-HYDROXYCHOLESTEROL; 7-ALPHA-HYDROXYLASE; 26-HYDROXYLATION; CLONING	Several authors have suggested that 27-hydroxycholesterol may be an important physiological regulator of cholesterol homeostasis. In the present study we investigated the possibility that 24- or 27-hydroxylation of cholesterol is of importance for the down-regulation of hydroxymethylglutaryl (HMG)-CoA reductase in mouse liver induced by dietary cholesterol. Using an accurate method based on isotope dilution-mass spectrometry with deuterated internal standards, we were able to detect significant levels of both 24- and 27-hydroxycholesterol in liver homogenates from normal mice. Feeding cholesterol, 2% for 4 days, increased the levels by 80 and 30%, respectively. No significant hepatic levels of 25-hydroxycholesterol could be demonstrated in untreated mice, and the level of this steroid in cholesterol-treated mice was just above the detection limit. Mouse liver mitochondria were able to catalyze 24- as well as 27-hydroxylation, but not 25-hydroxylation of cholesterol. There was no such conversion in liver microsomes. When using 24-H-2(2)- or 23,23,24,24,25-H-2(5)-labeled cholesterol as substrate a kinetic isotope effect of about 4.5 was observed for the mitochondrial 24-hydroxylation. When using 26,26,26,27,27,27-H-2(6)-labeled cholesterol as substrate a kinetic isotope effect of about 2.5 was observed for the 27-hydroxylation. Use of those deuterium-labeled cholesterol species thus allowed a specific suppression of the rate of 24- and 27-hydroxylation. Feeding mice with 0.05% unlabeled pure cholesterol in the diet for 24 h inhibited the hepatic HMG-CoA reductase activity by about 50%. The same degree of suppression was obtained after feeding with 23,23,24,24,25-H-2(5)- and 26,26,26,27,27,27-H-2(6)-labeled cholesterol. Were mitochondrial 24- and 27-hydroxylation of importance, one would expect reduced suppression of HMG-CoA reductase when feeding deuterated cholesterol, due to the isotope effects. As this was not the case, it is concluded that neither 24-hydroxylation nor 27-hydroxylation are critical for the cholesterol-induced down-regulation of HMG-CoA reductase in mouse liver.	KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet				Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGELIN B, 1984, J LIPID RES, V25, P1159; BIEMANN K, 1986, MASS SPECTROMETRY AN; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1988, J LIPID RES, V29, P136; BJORKHEM I, 1977, PHARMACOL THER PT A, V1, P327, DOI 10.1016/0362-5478(77)90021-3; BJORKHEM I, 1978, J BIOL CHEM, V253, P842; BJORKHEM I, 1974, CLIN CHIM ACTA, V54, P185, DOI 10.1016/0009-8981(74)90236-8; BJORKHEM I, 1974, J BIOL CHEM, V249, P2528; BREUER O, 1990, STEROIDS, V55, P185, DOI 10.1016/0039-128X(90)90109-O; BUCHER NLR, 1959, J BIOL CHEM, V234, P262; COREY EJ, 1972, J AM CHEM SOC, V94, P6190, DOI 10.1021/ja00772a043; DAHLBACK H, 1989, LIVER MITOCHONDRIAL; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; GUPTA A, 1986, J BIOL CHEM, V261, P8348; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; KALUZNY MA, 1985, J LIPID RES, V26, P135; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; LUND E, 1992, J BIOL CHEM, V267, P12462; MAKITA A, 1973, ANAL BIOCHEM, V5, P523; Melander L.C.S., 1960, ISOTOPE EFFECTS REAC; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; OFTEBRO H, 1980, J CLIN INVEST, V65, P1418, DOI 10.1172/JCI109806; REIHNER E, 1989, GASTROENTEROLOGY, V97, P1498, DOI 10.1016/0016-5085(89)90395-8; RENNERT H, 1990, ENDOCRINOLOGY, V127, P738, DOI 10.1210/endo-127-2-738; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; TANABE M, 1969, LIFE SCI PT 1 PHYSI, V8, P1123, DOI 10.1016/0024-3205(69)90166-0; TAYLOR FR, 1985, CHEM PHYS LIPIDS, V38, P187, DOI 10.1016/0009-3084(85)90066-0	32	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25092	25097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460011				2022-12-27	WOS:A1992KB60300030
J	DORN, GW; BECKER, MW; DAVIS, MG				DORN, GW; BECKER, MW; DAVIS, MG			DISSOCIATION OF THE CONTRACTILE AND HYPERTROPHIC EFFECTS OF VASOCONSTRICTOR PROSTANOIDS IN VASCULAR SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOXANE-A2/PROSTAGLANDIN-H2 RECEPTOR AGONIST; CELL-PROLIFERATION; ANGIOTENSIN-II; THROMBOXANE-A2 RECEPTORS; BINDING-SITE; LIGHT CHAIN; RAT AORTA; MYOSIN; PHOSPHORYLATION; HYPERPLASIA	To more clearly define the physiologic roles of thromboxane (TX)A2 and primary prostaglandins (PG) in vascular tissue we examined vascular contractility, cell signaling, and growth responses. The growth-promoting effects of (15S)-hydroxy-11alpha,9alpha-(epoxymethano)prosta-5Z,13E-dienoic acid (U46619; TXA2 agonist), PGF2alpha, and PGE2 Consisted of protein synthesis and proto-oncogene expression, but not DNA synthesis or cell proliferation. U46619 contracted rat aortas and increased cultured rat aortic vascular smooth muscle cell intracellular free calcium concentration [Ca2+]i, [H-3]inositol monophosphate (IP) accumulation, myosin light chain phosphorylation, and protein synthesis ([H-3]leucine incorporation) with EC50 values ranging from 10 to 50 nM. Each of these responses was inhibitable with the TXA2 receptor antagonist [1S] 1alpha,2beta(5Z),3beta,4alpha-7-(3-{2-[(phenylamino)carbonyl]hydrazino} methyl)-7-oxabicyclo[2.2.1]hept-2-yl-5-heptenoic acid (SQ29548). In contrast, PGF2alpha increased [Ca2+]i, [H-3]IP, and protein synthesis with EC50 values of 30-230 nM but contracted rat aortas with an EC50. of 4800 nM. PGE2 increased [Ca2+]i, [H-3]IP accumulation, protein synthesis, and contracted rat aortas with EC50 values of 2.5-3.5 muM. TXA2 receptor blockade prevented PGF2alpha- and PGE2-induced aortic contraction and cell myosin light chain phosphorylation, but not cell signaling or protein synthesis. Binding studies to vascular smooth muscle TXA2 receptors using 1S-[1alpha,2beta(5Z),3alpha(1E,3S),4alpha]-7-{3-[3-hydroxy-4-(p-[I-125] iodophenoxy)-1-butenyl]7-oxabicyclo[2.2.1]hept-2-yl}-5-heptenoic acid ([I-125]BOP) showed U46619, SQ29548, PGF2alpha, and PGE2 competition for TXA2 receptor binding at concentrations similar to their EC50 values for aortic contraction, while binding competition with [H-3]PGF2alpha and [H-3]PGE2 demonstrated the specificity of [I-125]BOP and SQ29548 for TXA2 receptors. The results suggest that 1) PGF2alpha- and E2-stimulated vessel contraction is due to cross-agonism at vascular TXA2 receptors; 2) PGF2alpha stimulates TXA2 receptor-independent vascular smooth muscle protein synthesis at nanomolar concentrations, consistent with an interaction at its primary receptor; and 3) TXA2 is a potent stimulus for vascular smooth muscle contraction and protein synthesis. We suggest that the main physiologic effect of PGF2alpha may be as a stimulus for vascular smooth muscle cell hypertrophy, not as a contractile agonist.	UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati	DORN, GW (corresponding author), UNIV CINCINNATI,COLL MED,DEPT MED CARDIOL,CINCINNATI,OH 45267, USA.			Becker, Michael/0000-0001-9890-8815				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; BERK BC, 1990, J BIOL CHEM, V265, P19632; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOBIK A, 1990, AM J PHYSIOL, V258, pC408, DOI 10.1152/ajpcell.1990.258.3.C408; BUNDY G L, 1975, Tetrahedron Letters, V24, P1957; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P379, DOI 10.1083/jcb.89.2.379; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORN GW, 1987, CIRC RES, V60, P952, DOI 10.1161/01.RES.60.6.952; DORN GW, 1991, AM J PHYSIOL, V261, pR145, DOI 10.1152/ajpregu.1991.261.1.R145; DORN GW, 1989, J CLIN INVEST, V84, P1883, DOI 10.1172/JCI114375; DORN GW, 1992, AM J PHYSIOL, V262, pC927, DOI 10.1152/ajpcell.1992.262.4.C927; DZAU VJ, 1991, HYPERTENSION, V18, P100, DOI 10.1161/01.HYP.18.4_Suppl.II100; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FRIEDMAN RJ, 1977, J CLIN INVEST, V60, P1191, DOI 10.1172/JCI108872; FUKUO K, 1986, BIOCHEM BIOPH RES CO, V136, P247, DOI 10.1016/0006-291X(86)90901-0; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANASAKI K, 1989, BIOCHIM BIOPHYS ACTA, V1013, P28, DOI 10.1016/0167-4889(89)90123-7; HANASAKI K, 1990, J BIOL CHEM, V265, P4871; HANASAKI K, 1990, BIOCHEM PHARMACOL, V40, P2535, DOI 10.1016/0006-2952(90)90096-4; HANASAKI K, 1988, BIOCHEM BIOPH RES CO, V150, P1170, DOI 10.1016/0006-291X(88)90752-8; HAWORTH SG, 1983, BRIT HEART J, V49, P517; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HORI M, 1992, J PHARMACOL EXP THER, V261, P506; IKEBE M, 1987, J BIOL CHEM, V262, P9569; JOHNSON DE, 1990, J AM COLL CARDIOL, V15, P419, DOI 10.1016/S0735-1097(10)80071-3; JOHNSON DE, 1991, J AM COLL CARDIOL, V17, P449, DOI 10.1016/S0735-1097(10)80114-7; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KENNEDY I, 1982, PROSTAGLANDINS, V24, P667, DOI 10.1016/0090-6980(82)90036-3; LESLIE JB, 1985, J NEUROSURG, V63, P659, DOI 10.3171/jns.1985.63.5.0659; MAIS DE, 1985, J PHARMACOL EXP THER, V233, P418; MORINELLI TA, 1989, J PHARMACOL EXP THER, V251, P557; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKAJIMA M, 1990, EUR J PHARMACOL, V191, P359; NAKAKI T, 1990, MOL PHARMACOL, V37, P30; OGLETREE ML, 1985, J PHARMACOL EXP THER, V234, P435; OWENS GK, 1987, VASCULAR SMOOTH MUSC, V1, P57; OZAKI H, 1990, JPN J PHARMACOL, V52, P509, DOI 10.1254/jjp.52.509; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; REVTYAK GE, 1987, THROMB RES, V48, P671, DOI 10.1016/0049-3848(87)90433-6; SINZINGER H, 1987, PROSTAGLANDINS, V33, P915, DOI 10.1016/0090-6980(87)90118-3; SMITH DL, 1984, PROSTA LEUKOTR MED, V16, P1, DOI 10.1016/0262-1746(84)90080-5; TAYLOR DA, 1989, J BIOL CHEM, V264, P6207; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WENDLING WW, 1991, STROKE, V22, P66, DOI 10.1161/01.STR.22.1.66; WILLERSON JT, 1991, P NATL ACAD SCI USA, V88, P10624, DOI 10.1073/pnas.88.23.10624	46	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24897	24905						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447225				2022-12-27	WOS:A1992KA26300110
J	HILBUSH, BS; LEVINE, JM				HILBUSH, BS; LEVINE, JM			MODULATION OF A CA2+ SIGNALING PATHWAY BY G(M1) GANGLIOSIDE IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE-HYDROXYLASE; GM1 GANGLIOSIDE; PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; NEURITE OUTGROWTH; NEURONAL DIFFERENTIATION; NEUROTRANSMITTER RELEASE; MEDIATED MODULATION; CYTOSOLIC CALCIUM	The effects of exogenous G(M1) ganglioside on depolarization and ligand-induced Ca2+ signaling were investigated in PC12 cells. Cellular responses to K+ depolarization and bradykinin application in control and G(M1)-treated cells were examined with respect to: 1) changes in the intracellular Ca2+ concentration ([Ca2+]i) measured using fura-2 fluorescence in single cells, and 2) changes in Ca2+-dependent protein kinase activity as assayed by two-dimensional phosphopeptide analysis of the site-specific phosphorylation of tyrosine hydroxylase. Pretreatment of cells with G(M1) (10 or 100 muM) enhanced K+ depolarization-stimulated increases in [Ca2+]i and in (PO4)-P-32 incorporation into tyrosine hydroxylase phosphopeptide T2, a Ca2+/calmodulin-dependent protein kinase II substrate. In contrast, G(M1) treatment had no effect on the transient increases in [Ca2+]i evoked by bradykinin or on bradykinin-induced increases in the site-specific phosphorylation of tyrosine hydroxylase. The depolarization-induced and G(M1)-enhanced increases in [Ca2+]i and T2 phosphorylation were prevented by removal of external Ca2+ or pretreatment with 1 muM nitrendipine, suggesting that these increases result from Ca2+ entry through dihydropyridine-sensitive Ca2+ Channels. The ability of exogenous gangliosides to potentiate increases in [Ca2+]i may underlie their diverse neuritogenic and neurotrophic actions in the nervous system.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								APPELL KC, 1989, BIOCHEM J, V263, P11, DOI 10.1042/bj2630011; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BUSH AB, 1991, J NEUROCHEM, V57, P562, DOI 10.1111/j.1471-4159.1991.tb03787.x; CAHILL AL, 1989, NEUROSCIENCE, V30, P811, DOI 10.1016/0306-4522(89)90172-3; CALLIES R, 1977, EUR J BIOCHEM, V80, P425, DOI 10.1111/j.1432-1033.1977.tb11897.x; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CHAN KFJ, 1987, J BIOL CHEM, V262, P5248; CIMINO M, 1987, ACTA PHYSIOL SCAND, V130, P317, DOI 10.1111/j.1748-1716.1987.tb08143.x; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; FERRARI G, 1983, DEV BRAIN RES, V8, P215, DOI 10.1016/0165-3806(83)90006-8; GOLDENRING JR, 1985, J NEUROCHEM, V44, P1229, DOI 10.1111/j.1471-4159.1985.tb08748.x; GORIO A, 1980, BRAIN RES, V197, P236, DOI 10.1016/0006-8993(80)90451-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASHIMOTO S, 1986, J NEUROCHEM, V46, P1599, DOI 10.1111/j.1471-4159.1986.tb01782.x; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HEIDELBERGER R, 1991, P NATL ACAD SCI USA, V88, P7135, DOI 10.1073/pnas.88.16.7135; HILBUSH BS, 1991, P NATL ACAD SCI USA, V88, P5616, DOI 10.1073/pnas.88.13.5616; HILLE B, 1975, PHILOS T R SOC B, V270, P301, DOI 10.1098/rstb.1975.0011; HILLE B, 1984, IONIC CHANNELS EXCIT, P316; KATER SB, 1991, J NEUROSCI, V11, P891; KATOHSEMBA R, 1984, J NEUROSCI RES, V12, P299, DOI 10.1002/jnr.490120217; KIM JYH, 1986, J NEUROSCI RES, V15, P159, DOI 10.1002/jnr.490150205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; LEON A, 1984, J NEUROSCI RES, V12, P277, DOI 10.1002/jnr.490120215; LEVINE JM, 1984, J NEUROSCI, V4, P820; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MCDANIEL RV, 1984, BIOCHEMISTRY-US, V23, P4618, DOI 10.1021/bi00315a016; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MCTIGUE M, 1985, J BIOL CHEM, V260, P9047; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; ODERFELDNOWAK B, 1984, J NEUROSCI RES, V12, P409, DOI 10.1002/jnr.490120225; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; SKAPER SD, 1985, DEV BRAIN RES, V23, P19, DOI 10.1016/0165-3806(85)90003-3; SPOERRI PE, 1990, DEV BRAIN RES, V56, P177, DOI 10.1016/0165-3806(90)90080-I; STALLCUP WB, 1979, J PHYSIOL-LONDON, V286, P525, DOI 10.1113/jphysiol.1979.sp012635; SUZUKI K, 1965, J NEUROCHEM, V17, P209; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TOLL L, 1982, J BIOL CHEM, V257, P13189; WILLINGER M, 1980, DEV BIOL, V74, P101, DOI 10.1016/0012-1606(80)90055-X; WU GS, 1990, J NEUROCHEM, V55, P484, DOI 10.1111/j.1471-4159.1990.tb04161.x	50	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24789	24795						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447216				2022-12-27	WOS:A1992KA26300095
J	KNAPP, A; DEGENHARDT, T; DODT, J				KNAPP, A; DEGENHARDT, T; DODT, J			HIRUDISINS - HIRUDIN-DERIVED THROMBIN INHIBITORS WITH DISINTEGRIN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; IIB-IIIA COMPLEX; PLATELET-AGGREGATION; ALPHA-THROMBIN; SECONDARY STRUCTURE; RECOMBINANT HIRUDIN; IONIC INTERACTIONS; GPIIB-IIIA; BINDING; ECHISTATIN	Recombinant hirudin variants have been designed which inhibit alpha-thrombin by the hirudin mechanism and which in addition exhibit disintegrin activity. These proteins, called "hirudisins," have been engineered by replacing the Ser-Asp-Gly-Glu sequence at the tip of hirudin's finger-like structure (residues 32-35) by Arg-Gly-Asp-Ser (RGDS) to yield hirudisin and Lys-Gly-Asp-Ser (KGDS) to obtain hirudisin-1. Comparison of thrombin inhibition activities showed that hirudisin is 2-fold more potent (K(i) = 160 +/- 70 fM) than hirudisin-1 (K(i) = 370 +/- 44 fM) and recombinant (r)-hirudin (K(i) = 270 +/- 50 fM). Alpha-thrombin-stimulated platelet aggregation was effectively inhibited by r-hirudin, hirudisin, and hirudisin-1 with IC50 of 5.7 to 6.8 nM. Unlike r-hirudin, hirudisin inhibits ADP-induced platelet aggregation (IC50 = 65 muM) 3- to 5-fold stronger than the linear GRGDS- and RGDS-peptide. Direct interaction of hirudisin with purified glycoprotein IIb-IIIa demonstrated that antiplatelet aggregation activity is due to the integrin-directed RGD motif. Disintegrin activity of hirudisin relative to that of reduced and carboxymethylated hirudisin suggests that the conformational strain favors binding to integrins. On the basis of these results, hirudisins appear to be interesting molecules for the design of potential antithrombotic agents with antithrombin as well as antiplatelet aggregation activities.	TH DARMSTADT,INST BIOCHEM,PETERSENSTR 22,W-6100 DARMSTADT,GERMANY	Technical University of Darmstadt								ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; BAGDY O, 1976, METHOD ENZYMOL, V45, P669; BETZ A, 1991, BIOCHEM J, V275, P801, DOI 10.1042/bj2750801; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CALVETE JJ, 1991, BIOCHEMISTRY-US, V30, P5225, DOI 10.1021/bi00235a016; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHURCH FC, 1991, J BIOL CHEM, V266, P11975; COOKE RM, 1991, EUR J BIOCHEM, V202, P323, DOI 10.1111/j.1432-1033.1991.tb16379.x; DALVIT C, 1991, EUR J BIOCHEM, V202, P315, DOI 10.1111/j.1432-1033.1991.tb16378.x; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DODT J, 1986, BIOL CHEM H-S, V367, P803, DOI 10.1515/bchm3.1986.367.2.803; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; DODT J, 1986, FEBS LETT, V202, P373, DOI 10.1016/0014-5793(86)80721-9; DODT J, 1990, J BIOL CHEM, V265, P713; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; GARSKY VM, 1989, P NATL ACAD SCI USA, V86, P4022, DOI 10.1073/pnas.86.11.4022; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HARVEY RP, 1986, P NATL ACAD SCI USA, V83, P1084, DOI 10.1073/pnas.83.4.1084; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZAR JB, 1991, J BIOL CHEM, V266, P685; LEATHERBARROW RG, 1990, GRAFIT VERSION 2 0; LIU LW, 1991, J BIOL CHEM, V266, P16977; Mann K G, 1976, Methods Enzymol, V45, P123; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARKWARDT F, 1989, SEMIN THROMB HEMOST, V15, P269, DOI 10.1055/s-2007-1002719; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MUSIAL J, 1990, CIRCULATION, V82, P261, DOI 10.1161/01.CIR.82.1.261; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NI F, 1990, BIOCHEMISTRY-US, V29, P4479, DOI 10.1021/bi00470a030; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1988, BLOOD, V71, P831; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUDEK V, 1991, EUR J BIOCHEM, V202, P329, DOI 10.1111/j.1432-1033.1991.tb16380.x; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCHMITZ T, 1991, EUR J BIOCHEM, V195, P251, DOI 10.1111/j.1432-1033.1991.tb15701.x; STONE SR, 1989, BIOCHEMISTRY-US, V28, P6857, DOI 10.1021/bi00443a012; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Tripier D, 1988, Folia Haematol Int Mag Klin Morphol Blutforsch, V115, P30; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALLACE A, 1989, BIOCHEMISTRY-US, V28, P10079, DOI 10.1021/bi00452a030; Williams J W, 1979, Methods Enzymol, V63, P437	56	40	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24230	24234						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447173				2022-12-27	WOS:A1992KA26300016
J	FITZSIMONS, DP; HERRING, BP; STULL, JT; GALLAGHER, PJ				FITZSIMONS, DP; HERRING, BP; STULL, JT; GALLAGHER, PJ			IDENTIFICATION OF BASIC RESIDUES INVOLVED IN ACTIVATION AND CALMODULIN BINDING OF RABBIT SMOOTH-MUSCLE MYOSIN LIGHT CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; PHOSPHORYLATION; DOMAIN; SITE; AUTOINHIBITION; CALCINEURIN; LOCATION; SEQUENCE	It is postulated that basic residues in the regulatory region of myosin light chain kinase are important for conferring autoinhibition by binding to the catalytic core. To investigate this proposal, 10 basic amino acids within the regulatory region of rabbit smooth muscle myosin light chain kinase (Lys961-Lys979) were replaced either singularly or in combination with acidic or nonpolar residues by site-directed mutagenesis. All active mutant kinases were dependent on Ca2+/calmodulin for catalytic activity. None of the mutants was active in the absence of Ca2+/calmodulin, suggesting that the autoinhibitory region has not been defined completely. Charge reversal mutants at Arg974, Arg975, and Lys976 resulted in loss of high affinity binding of calmodulin and increased the concentration of calmodulin required for half-maximal activation (K(CaM)). The charge reversal mutant at Lys979 also increased K(CaM) but to a lesser extent. Charge reversal mutants at Lys965 and Arg967 resulted in an inactive myosin light chain kinase that could not be proteolytically activated. When these residues were mutated to Ala, the expressed kinase was dependent upon Ca2+/calmodulin for activity and exhibited a decrease in K(CaM). Charge reversal mutants in Lys961 and Lys962 also had decreased K(CaM) values. These basic residues amino-terminal of the calmodulin binding domain may play an important role in the activation of the kinase.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL026043, R01 HL026043-20, R37 HL026043, HL26043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; FOSTER C, 1986, ARCH BIOCHEM BIOPHYS, V251, P616, DOI 10.1016/0003-9861(86)90371-1; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; IKEBE M, 1989, J BIOL CHEM, V264, P6967; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; Kamm K E, 1987, Prog Clin Biol Res, V245, P183; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MILLER JR, 1983, MOL PHARMACOL, V24, P235; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; POTTER JD, 1975, J BIOL CHEM, V250, P4628; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STULL JT, 1990, PROG CLIN BIOL RES, V327, P107; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1984, ADV ENZYME REGUL, V23, P123, DOI 10.1016/0065-2571(85)90043-3; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488	38	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23903	23909						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429728				2022-12-27	WOS:A1992JZ23900071
J	LEE, ST; LEE, S; PETERS, DP; HOFFMAN, GG; STACEY, A; GREENSPAN, DS				LEE, ST; LEE, S; PETERS, DP; HOFFMAN, GG; STACEY, A; GREENSPAN, DS			DELETION OF THE PRO-ALPHA-1(I) N-PROPEPTIDE AFFECTS SECRETION OF TYPE-I COLLAGEN IN CHINESE-HAMSTER LUNG-CELLS BUT NOT IN MOV-13 MOUSE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; ENDOPLASMIC-RETICULUM; HELICAL STRUCTURE; BINDING-PROTEIN; PROCOLLAGEN; TENDON; CHAINS; GENE; FIBROBLASTS; CLEAVAGE	We have introduced two mutations into a full-length human pro-alpha1(I) cDNA that delete 114 amino acids or the entire 139 amino acids of the N-propeptide domain. Wild-type and mutated versions of the cDNA were introduced into cultured Chinese hamster lung (CHL) cells, which do not produce endogenous type I collagen, and into Mov-13 mouse cells, which produce endogenous pro-alpha2(I) chains but not pro-alpha1(I) chains. As judged by resistance to proteases, neither mutation impaired intracellular triple helical assembly of human alpha1(I) homotrimers in CHL cells, or of chimeric type I collagen comprised of human alpha1(I) and mouse alpha2(I) chains in Mov-13 cells. Thus, the N-propeptide is not necessary for intracellular assembly of the main helical collagen domain of type I collagen. In CHL cells the rate of secretion of the mutant homotrimers was greatly reduced as compared to wild type homotrimers, and by immunofluorescence and immunoelectron microscopy, the mutant chains were shown to be accumulated in large vesicular expansions of the rough endoplasmic reticulum. When such cells were retransfected with cDNA encoding wild-type human alpha2(I) chains, mutant alpha1(I) chains were not rescued and heterotrimers containing the mutant chains were also retained in the intracellular vesicles. By contrast, deletion of the N-propeptide did not affect secretion of heterotrimers containing mutant chains from Mov- 13 cells. Thus, an intact N-propeptide appears necessary for efficient secretion of type I collagen from some but not all cell types.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706; UNIV WISCONSIN,PROGRAM CELL & MOLEC BIOL,MADISON,WI 53706; MIT,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02139	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Massachusetts Institute of Technology (MIT); Whitehead Institute			Lee, Seungbok/AAS-1529-2021	Lee, Seungbok/0000-0002-6620-6269; Greenspan, Daniel/0000-0001-8096-7446; Lee, Seung-Taek/0000-0001-7300-9784	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATEMAN JF, 1987, BIOCHEM J, V245, P677, DOI 10.1042/bj2450677; BELLAMY G, 1971, P NATL ACAD SCI USA, V68, P1138, DOI 10.1073/pnas.68.6.1138; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; DEAK SB, 1985, COLLAGEN REL RES, V5, P305; DEHM P, 1972, BIOCHIM BIOPHYS ACTA, V264, P375, DOI 10.1016/0304-4165(72)90302-9; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; DEWET W, 1987, J BIOL CHEM, V262, P16032; FESSLER LI, 1981, J BIOL CHEM, V256, P9646; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG BD, 1985, COLLAGEN REL RES, V5, P393; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENSPAN DS, 1985, MOL CELL BIOL, V5, P1894, DOI 10.1128/MCB.5.8.1894; GREENSPAN DS, 1989, J BIOL CHEM, V264, P20683; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; HARALSON MA, 1984, ARCH BIOCHEM BIOPHYS, V229, P509, DOI 10.1016/0003-9861(84)90182-6; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; LEE ST, 1990, J BIOL CHEM, V265, P21992; LEE ST, 1988, J BIOL CHEM, V263, P13414; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; PAGLIA L, 1979, BIOCHEMISTRY-US, V18, P5030, DOI 10.1021/bi00589a034; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROSENBLO.J, 1973, ARCH BIOCHEM BIOPHYS, V158, P478, DOI 10.1016/0003-9861(73)90539-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHNIEKE A, 1987, P NATL ACAD SCI USA, V84, P764, DOI 10.1073/pnas.84.3.764; STACEY A, 1987, J VIROL, V61, P2549, DOI 10.1128/JVI.61.8.2549-2554.1987; TIMPL R, 1981, CLIN ORTHOP RELAT R, V158, P224; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; UITTO J, 1974, BIOCHEM BIOPH RES CO, V60, P414, DOI 10.1016/0006-291X(74)90220-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590; WU CH, 1986, J BIOL CHEM, V261, P482; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	41	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24126	24133						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429742				2022-12-27	WOS:A1992JZ23900104
J	MOONEY, RA; FREUND, GG; WAY, BA; BORDWELL, KL				MOONEY, RA; FREUND, GG; WAY, BA; BORDWELL, KL			EXPRESSION OF A TRANSMEMBRANE PHOSPHOTYROSINE PHOSPHATASE INHIBITS CELLULAR-RESPONSE TO PLATELET-DERIVED GROWTH-FACTOR AND INSULIN-LIKE GROWTH FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; T-CELLS; RECEPTOR; CD45; FAMILY; ACTIVATION; ASSOCIATION; CLONING	Tyrosine phosphorylation is a mechanism of signal transduction shared by many growth factor receptors and oncogene products. Phosphotyrosine phosphatases (PTPases) potentially modulate or counter-regulate these signaling pathways. To test this hypothesis, the transmembrane PTPase CD45 (leukocyte common antigen) was expressed in the murine cell line C127. Hormone-dependent autophosphorylation of the platelet-derived growth factor (PDGF) and insulin-like growth factor-1 (IGF-1) receptors was markedly reduced in cells expressing the transmembrane PTPase. Tyrosine phosphorylation of other PDGF-dependent phosphoproteins (160, 140, and 55 kDa) and IGF-1-dependent phosphoproteins (145 kDa) was similarly decreased. Interestingly, the pattern of growth factor-independent tyrosine phosphorylations was comparable in cells expressing the PTPase and control cells. This suggests a selectivity or accessibility of the PTPase limited to a subset of cellular phosphotyrosyl proteins. The maximum mitogenic response to PDGF and IGF-1 in cells expressing the PTPase was decreased by 67 and 71%, respectively. These results demonstrate that a transmembrane PTPase can both affect the tyrosine phosphorylation state of growth factor receptors and modulate proximal and distal cellular responses to the growth factors.			MOONEY, RA (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT PATHOL & LAB MED,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038138] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; MEISENHELDER J, 1989, CELL, V57, P1008; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; MOONEY RA, 1992, J BIOL CHEM, V267, P14054; OMARY MB, 1980, J EXP MED, V152, P842, DOI 10.1084/jem.152.4.842; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; STREULI M, 1988, J IMMUNOL, V141, P3910; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401	29	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23443	23446						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429686				2022-12-27	WOS:A1992JZ23900003
J	SILBERSTEIN, S; KELLEHER, DJ; GILMORE, R				SILBERSTEIN, S; KELLEHER, DJ; GILMORE, R			THE 48-KDA SUBUNIT OF THE MAMMALIAN OLIGOSACCHARYLTRANSFERASE COMPLEX IS HOMOLOGOUS TO THE ESSENTIAL YEAST PROTEIN WBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SIGNAL-RECOGNITION PARTICLE; SEQUENCE CLEAVAGE SITES; MICROSOMAL-MEMBRANES; RIBOSOME-BINDING; RIBOPHORINS-I; MESSENGER-RNA; TRANSLOCATION; POLYPEPTIDES; TRANSLATION	Oligosaccharyltransferase has been purified from canine microsomal membranes as a protein complex with three nonidentical subunits of 66, 63/64, and 48 kDa. The 66- and 63/64-kDa subunits were found to be identical to ribophorins I and II, respectively. The ribophorins are integral membrane glycoproteins that were previously shown to be localized exclusively to the rough endoplasmic reticulum. The 48-kDa subunit (OST48) of the oligosaccharyltransferase complex is not a glycoprotein and is not recognized by antibodies to either ribophorin. Here, we describe the characterization of a cDNA clone that encodes OST48. Like ribophorins I and II, OST48 was found to be an integral membrane protein, with the majority of the polypeptide located within the lumen of the endoplasmic reticulum. OST48 does not show significant amino acid sequence homology to either ribophorin I or II. A 45-kDa integral membrane protein, designated WBP1, from the yeast Saccharomyces cerevisiae was found to be 25% identical in sequence to OST48. Recently, WBP1 was shown to be essential for in vivo and in vitro expression of oligosaccharyltransferase activity in yeast. We conclude that OST48 and WBP1 are homologous gene products.			SILBERSTEIN, S (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1991, METHOD CELL BIOL, V34, P23; GLABE CG, 1980, J BIOL CHEM, V255, P9236; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HERZ J, 1990, FEBS LETT, V276, P103, DOI 10.1016/0014-5793(90)80518-N; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MARCANTONIO EE, 1982, EUR J BIOCHEM, V124, P217, DOI 10.1111/j.1432-1033.1982.tb05928.x; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; PIROZZI G, 1991, BIOCHEM BIOPH RES CO, V176, P1482, DOI 10.1016/0006-291X(91)90454-F; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335	38	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23658	23663						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429707				2022-12-27	WOS:A1992JZ23900038
J	DUELAND, S; TRAWICK, JD; NENSETER, MS; MACPHEE, AA; DAVIS, RA				DUELAND, S; TRAWICK, JD; NENSETER, MS; MACPHEE, AA; DAVIS, RA			EXPRESSION OF 7-ALPHA-HYDROXYLASE IN NONHEPATIC CELLS RESULTS IN LIVER PHENOTYPIC RESISTANCE OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR TO CHOLESTEROL REPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN HEPATOCYTES; RAT HEPATOCYTES; ACID; REDUCTASE; GENE; 25-HYDROXYCHOLESTEROL; SECRETION; HAMSTER; PATHWAY; ENZYME	The goal of this study was to understand why the expression of low density lipoprotein (LDL) receptors by the liver is poorly down-regulated by cholesterol. We examined the hypothesis that 7alpha-hydroxylase may indirectly induce the expression of the LDL receptor by metabolizing, i.e. inactivating oxysterol repressors. Non-hepatic Chinese hamster ovary cells, transfected with a plasmid encoding 7alpha-hydroxylase, expressed both the mRNA and functional activity of this liver-specific enzyme. In the presence of 5% serum, expression of the LDL receptor by transfected cells was >20 times that of non-transfected cells despite a 50% increased content of cholesterol ester. Both cell types displayed an almost complete repression of the LDL receptor by the oxysterol 25-hydroxycholesterol, suggesting that transcriptional control of the LDL receptor gene remained intact in the transfected cells. However, only cells expressing 7alpha-hydroxylase showed a derepression of the LDL receptor with time. This transient sensitivity to 25-hydroxycholesterol repression was attributed to a 3-fold greater rate of metabolism of [H-3]25-hydroxycholesterol. The paradoxical induction of LDL receptor mRNA in transfected cells having greater amounts of cholesterol esters suggests that 7alpha-hydroxylase may preferentially use oxysterols rather than cholesterol as substrates. The combined data are consistent with the proposal that 7alpha-hydroxylase indirectly induces the LDL receptor gene by metabolizing (inactivating) oxysterol repressors. Liver-specific expression of 7alpha-hydroxylase can account for the relative resistance of hepatic LDL receptors to down-regulation.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; UNIV COLORADO,SCH MED,ATHEROSCLEROSIS RES CTR,DENVER,CO 80262	California State University System; San Diego State University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL30560] Funding Source: Medline; NIDDK NIH HHS [DK34914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELSON M, 1992, J BIOL CHEM, V267, P1701; AYAKI Y, 1989, J BIOL CHEM, V264, P3818; BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANG TY, 1981, J BIOL CHEM, V256, P6174; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RA, 1983, J BIOL CHEM, V258, P3661; EDGE SB, 1986, J BIOL CHEM, V261, P3800; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARDERSPENGEL K, 1982, P NATL ACAD SCI-BIOL, V79, P6355, DOI 10.1073/pnas.79.20.6355; HAVEKES LM, 1986, HEPATOLOGY, V6, P1356, DOI 10.1002/hep.1840060623; HUI DY, 1981, J BIOL CHEM, V256, P5646; HYLEMON PB, 1989, ANAL BIOCHEM, V182, P212, DOI 10.1016/0003-2697(89)90581-2; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MYANT NB, 1977, J LIPID RES, V18, P135; PANGBURN SH, 1981, J BIOL CHEM, V256, P3340; SCHNITZERPOLOKOFF R, 1982, J BIOL CHEM, V257, P472; SIPERSTEIN MD, 1952, P SOC EXP BIOL MED, V81, P720, DOI 10.3181/00379727-81-19999; SLATER HR, 1980, J BIOL CHEM, V255, P19219; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SPADY DK, 1986, J CLIN INVEST, V77, P1474, DOI 10.1172/JCI112460; SUDHOF TC, 1987, CELL, V262, P10773; SWELL L, 1981, BIOCHIM BIOPHYS ACTA, V663, P163, DOI 10.1016/0005-2760(81)90202-2; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; TAYLOR FR, 1985, METHOD ENZYMOL, V110, P9; WU GY, 1984, HEPATOLOGY, V4, P1190, DOI 10.1002/hep.1840040615	30	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22695	22698						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429619				2022-12-27	WOS:A1992JY16300001
J	BRAUN, BR; KASSAVETIS, GA; GEIDUSCHEK, EP				BRAUN, BR; KASSAVETIS, GA; GEIDUSCHEK, EP			BENDING OF THE SACCHAROMYCES-CEREVISIAE 5S RIBOSOMAL-RNA GENE IN TRANSCRIPTION FACTOR COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; RNA POLYMERASE-III; SITE-SPECIFIC RECOMBINATION; PROMOTER ELEMENTS; SEQUENCE ELEMENTS; ESCHERICHIA-COLI; DNA INTERACTIONS; RIBOSOMAL-RNA; PROTEIN; BINDING	Bending of the yeast 5S rRNA gene by its transcription factors (TF) IIIA, IIIC, and IIIB has been investigated by two electrophoretic methods that exploit the anomalous mobility of bent DNA in tight gel networks. A minor bend is induced by TFIIIA, and a very strong bend, centered at its upstream DNA-binding site, is induced by TFIIIB. Despite binding to different DNA sequences on the 5S rRNA gene and the previously analyzed tRNA(Glu) gene, TFIIIB generates nearly identical bends in each site. Fully assembled transcription factor complexes bend the 5S rRNA gene in the same net direction as does TFIIIB alone.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BRAUN BR, 1993, IN PRESS J MOL BIOL; BRAUN BR, 1992, THESIS U CALIFORNIA; CHALLICE JM, 1989, J BIOL CHEM, V264, P20060; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; EVANS CF, 1991, BIOCHEM BIOPH RES CO, V176, P826, DOI 10.1016/S0006-291X(05)80260-8; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, IN PRESS TRANSCRIPTI; GOTTESFELD JM, 1987, NATURE, V329, P460, DOI 10.1038/329460a0; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KELLER HJ, 1990, MOL CELL BIOL, V10, P5166, DOI 10.1128/MCB.10.10.5166; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; REYNOLDS WF, 1988, MOL CELL BIOL, V8, P5056, DOI 10.1128/MCB.8.11.5056; SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHROTH GP, 1991, NUCLEIC ACIDS RES, V19, P511, DOI 10.1093/nar/19.3.511; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; SHI YG, 1991, J BIOL CHEM, V266, P8015; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; TAYLOR MJ, 1985, J BIOL CHEM, V260, P4531; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; ULANOVSKY L, 1990, NATURE, V343, P190, DOI 10.1038/343190a0; VIDALINGIGLIARDI D, 1991, P NATL ACAD SCI USA, V88, P229, DOI 10.1073/pnas.88.1.229; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106; ZWIEB C, 1990, NUCLEIC ACIDS RES, V18, P583, DOI 10.1093/nar/18.3.583	50	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22562	22569						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429605				2022-12-27	WOS:A1992JW71900089
J	MIOTTO, G; VENERANDO, R; KHURANA, KK; SILIPRANDI, N; MORTIMORE, GE				MIOTTO, G; VENERANDO, R; KHURANA, KK; SILIPRANDI, N; MORTIMORE, GE			CONTROL OF HEPATIC PROTEOLYSIS BY LEUCINE AND ISOVALERYL-L-CARNITINE THROUGH A COMMON LOCUS - EVIDENCE FOR A POSSIBLE MECHANISM OF RECOGNITION AT THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; ISOLATED RAT HEPATOCYTES; PROTEIN-DEGRADATION; COLLOIDAL SILICA; LIVER LYSOSOMES; DEPRIVATION; ALANINE; MODULATION	Deprivation-induced proteolysis in the perfused rat liver is controlled through the multiphasic action of 7 regulatory amino acids of which L-leucine plays the dominant role. Recently, isovaleryl-L-carnitine (IVC) was shown to mimic the leucine's effects, suggesting that the two molecules share structural features that are recognized at a common site(s). In this study we find that each evokes identical responses consisting of inhibitory effects at 0.08 and 0.8 mM, separated by a sharp zonal loss of inhibition at 0.15 mM. As monitored by density shifts of beta-hexosaminidase in colloidal silica gradients, macroautophagy is suppressed by both. Responses to Leu and IVC at 0.08 and 0.15 mM are stereospecific and require a reactive group at the alpha-carbon (or equivalent) and a high degree of branched chain specificity. In addition, 0.5 mM Ala coregulates with IVC and Leu by decreasing the zonal loss at 0.15 mM. The fact that the multiphasic responses can be duplicated with equimolar mixtures of Leu + IVC indicates that both react at the same site(s). IVC is readily taken up by a saturable process, but owing to its rapid hydrolysis in the cell, the ratio of internal to external IVC remains low over a 4-fold concentration range. These findings, together with a kinetic analysis of concerted responses to regulatory amino acids, suggest that the recognition sites are at a position in the cell, possibly at the plasma membrane, to react reversibly with plasma amino acids.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Miotto, Giovanni/S-1903-2016	Miotto, Giovanni/0000-0002-4278-4873	NIDDK NIH HHS [DK 21624] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021624] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHMER T, 1968, BIOCHIM BIOPHYS ACTA, V152, P559, DOI 10.1016/0005-2760(68)90096-9; CARO LHP, 1989, EUR J BIOCHEM, V181, P717, DOI 10.1111/j.1432-1033.1989.tb14782.x; CRABB DW, 1978, J BIOL CHEM, V253, P1481; GRINDE B, 1981, BIOCHIM BIOPHYS ACTA, V676, P43, DOI 10.1016/0304-4165(81)90007-6; HIRSIMAKI P, 1983, PATHOBIOLOGY CELL ME, P201; HOKLAND BM, 1988, BIOCHIM BIOPHYS ACTA, V961, P324; LEVERVE XM, 1987, FEBS LETT, V219, P455, DOI 10.1016/0014-5793(87)80271-5; MIOTTO G, 1989, BIOCHEM BIOPH RES CO, V158, P797, DOI 10.1016/0006-291X(89)92792-7; MIOTTO G, 1990, FASEB Journal, V4, pA848; MORTIMORE GE, 1988, J BIOL CHEM, V263, P19545; MORTIMORE GE, 1991, J BIOL CHEM, V266, P1021; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; PATEL TB, 1981, J BIOL CHEM, V256, P9009; POSO AR, 1984, P NATL ACAD SCI-BIOL, V81, P4270, DOI 10.1073/pnas.81.14.4270; POSO AR, 1982, J BIOL CHEM, V257, P2114; SEGLEN PO, 1980, BIOCHIM BIOPHYS ACTA, V630, P103, DOI 10.1016/0304-4165(80)90141-5; SEGLEN PO, 1987, LYSOSOMES THEIR ROLE, P371; SURMACZ CA, 1983, AM J PHYSIOL, V245, pC52, DOI 10.1152/ajpcell.1983.245.1.C52; SURMACZ CA, 1983, AM J PHYSIOL, V245, pC61, DOI 10.1152/ajpcell.1983.245.1.C61; SURMACZ CA, 1987, BIOCHEM J, V242, P453, DOI 10.1042/bj2420453; TAM JP, 1989, METHOD ENZYMOL, V168, P7; WARD WF, 1978, J BIOL CHEM, V253, P3581; WERT JJ, 1992, BIOCHEM BIOPH RES CO, V186, P1327, DOI 10.1016/S0006-291X(05)81551-7	25	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22066	22072						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429558				2022-12-27	WOS:A1992JW71900016
J	GORR, SU; HAMILTON, JW; COHN, DV				GORR, SU; HAMILTON, JW; COHN, DV			REGULATED, BUT NOT CONSTITUTIVE, SECRETORY PROTEINS BIND PORCINE CHYMOTRYPSINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; PITUITARY-TUMOR CELLS; TRANS-GOLGI NETWORK; CHROMOGRANIN-A; POLYACRYLAMIDE GELS; ANTERIOR-PITUITARY; SECRETOGRANIN-I; GRANULES; CALCIUM; PATHWAYS	Endocrine and exocrine cells exhibit both a constitutive and a regulated secretory pathway. In the latter pathway, secretory proteins are stored at a high concentration in secretory granules and are released by exocytosis in response to appropriate external stimuli. Sorting between the two secretory pathways is believed to take place in the trans-Golgi tubular network. To account for experimental data, it has been proposed that sorting receptors exist which bind a variety of regulated secretory proteins, including foreign secretory proteins introduced into the cells by transfection. In support of the sorting receptor hypothesis Chung et al. (Chung, K.-N., Walter, P., Aponte, G. W., and Moore, H.-P. H. (1989) Science 243, 192-197) isolated a group of 25-kDa canine pancreatic "hormone-binding proteins" that bound regulated but not constitutive secretory proteins. To determine if similar proteins are present in other species and tissues, we have screened porcine pancreas, parathyroid, adrenal medulla, and pituitary glands. A 31-kDa protein, similar to that identified by Chung et al. (1989), which binds to regulated but not to constitutive secretory proteins was identified in porcine pancreas. This protein was not detected in the parathyroid, adrenal medulla, or pituitary glands, however, which argues against it serving as a general sorting receptor. NH2-terminal sequencing, immunoreactivity, and proteolytic activity data indicate that the porcine 31-kDa protein is similar if not identical to porcine chymotrypsinogen A or B.	UNIV LOUISVILLE,SCH DENT,DEPT BIOL & BIOPHYS SCI,CALCIUM REGULATING HORMONES LAB,LOUISVILLE,KY 40292; DEPT VET AFFAIRS MED CTR,CALCIUM ENDOCRINOL LAB,KANSAS CITY,MO 64128; UNIV KANSAS,MED CTR,SCH MED,DEPT BIOCHEM,KANSAS CITY,KS 66103	University of Louisville; University of Kansas; University of Kansas Medical Center	GORR, SU (corresponding author), UNIV LOUISVILLE,SCH DENT,ENDOCRINE CELL BIOL LAB,LOUISVILLE,KY 40292, USA.				NIDDK NIH HHS [DK38296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; BURGESS TL, 1984, J CELL BIOL, V99, P2223, DOI 10.1083/jcb.99.6.2223; CHARLES M, 1967, BIOCHIM BIOPHYS ACTA, V140, P395, DOI 10.1016/0005-2795(67)90514-4; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COHN DV, 1991, EXTRA INTRACELLULAR, P83; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1988, BONE MINER, V4, P17; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GORR SU, 1990, J BIOL CHEM, V265, P3012; GORR SU, 1987, CALCIUM REGULATION B, V9, P49; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HELLERMAN JG, 1984, P NATL ACAD SCI-BIOL, V81, P5340, DOI 10.1073/pnas.81.17.5340; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1989, SECRETION ITS CONTRO, P190; NEURATH H, 1961, CIBA F S EXOCRINE PA, P67; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PEANASKY RJ, 1969, BIOCHIM BIOPHYS ACTA, V181, P82, DOI 10.1016/0005-2795(69)90229-3; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; RAVAZZOLA M, 1976, ENDOCRINOLOGY, V98, P950, DOI 10.1210/endo-98-4-950; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; REGGIO H, 1978, J CELL BIOL, V78, P951, DOI 10.1083/jcb.78.3.951; ROBICHON A, 1991, ENDOCRINOLOGY, V128, P1974, DOI 10.1210/endo-128-4-1974; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; SCHWEITZER ES, 1990, J CELL SCI, V96, P375; SEIDAH NG, 1983, FEBS LETT, V159, P68, DOI 10.1016/0014-5793(83)80418-9; SHIELDS PP, 1990, J BIOL CHEM, V265, P10905; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WALTER P, 1983, METHOD ENZYMOL, V96, P84	43	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21595	21600						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400470				2022-12-27	WOS:A1992JV01100053
J	BLOCHBERGER, TC; CORNUET, PK; HASSELL, JR				BLOCHBERGER, TC; CORNUET, PK; HASSELL, JR			ISOLATION AND PARTIAL CHARACTERIZATION OF LUMICAN AND DECORIN FROM ADULT CHICKEN CORNEAS - A KERATAN SULFATE-CONTAINING ISOFORM OF DECORIN IS DEVELOPMENTALLY REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; CARTILAGE PROTEOGLYCAN; LINKAGE-REGION; RICH PROTEOGLYCANS; EMBRYONIC CHICKEN; COLLAGEN FIBRILS; MONKEY CORNEA; STROMA; OLIGOSACCHARIDES; TRANSPARENCY	The proteoglycans extracted from adult chicken were initially purified by DEAE-chromatography. Digestion of these proteoglycans with chondroitinase ABC generated a single 40-kDa core protein while digestion with keratanase generated a single 52-kDa core protein. Digestion with both enzymes combined, however, increased the amount of 40-kDa core protein produced. This suggested that the 40-kDa core protein exists with chondroitin/dermatan sulfate (C/DS) side chains alone and with both C/DS and keratan sulfate (KS) side chains. The proteoglycan fraction was initially digested with chondroitinase ABC, and the M(r) = 40,000 core protein derived from proteoglycans containing C/DS side chains alone was isolated. Amino-terminal sequencing showed it to be the chick cognate of decorin. The remaining proteoglycans were then digested with keratanase, and both the 40-kDa core protein and the 52-kDa core proteins derived from KS-containing proteoglycans were purified. The M(r) = 40,000 core protein derived from proteoglycans containing both C/DS and KS side chains had the same amino-terminal sequence as decorin and cross-reacted with antibodies to decorin. Sequence from the 52-kDa core protein derived from KS-containing proteoglycans showed it to be lumican. The results of this study suggest that adult chick corneas contain two isoforms of decorin: one containing C/DS side chains and the other, a hybrid, containing both C/DS and KS side chains. Embryonic corneas did not contain the hybrid isoform of decorin. These results suggest that different post-translational modifications occur to the decorin gene product during corneal development and maturation.	UNIV PITTSBURGH, SCH MED, DEPT OPHTHALMOL, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BLOCHBERGER, TC (corresponding author), EYE & EAR INST PITTSBURGH, PITTSBURGH, PA 15213 USA.				NATIONAL EYE INSTITUTE [R01EY008104, P30EY008098] Funding Source: NIH RePORTER; NEI NIH HHS [5 R01 EY08104, 5 P30 EY08098] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; AXELSSON I, 1980, EXP EYE RES, V31, P57, DOI 10.1016/0014-4835(80)90090-1; AXELSSON I, 1975, BIOCHEM J, V145, P491, DOI 10.1042/bj1450491; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BETTELHEIM FA, 1975, BIOCHIM BIOPHYS ACTA, V381, P203, DOI 10.1016/0304-4165(75)90202-0; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CONRAD GW, 1982, J BIOL CHEM, V257, P464; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GREGORY JD, 1982, J BIOL CHEM, V257, P6965; HASSELL JR, 1979, J BIOL CHEM, V254, P2346; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E D, 1969, Monogr Dev Biol, V1, P1; JOST CJ, 1991, J BIOL CHEM, V266, P13336; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; Maurice DM, 1984, EYE B, V1, P1; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; MIDURA RJ, 1989, J BIOL CHEM, V264, P1414; NAKAZAWA K, 1983, ARCH BIOCHEM BIOPHYS, V222, P105, DOI 10.1016/0003-9861(83)90507-6; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NAKAZAWA K, 1983, J BIOL CHEM, V258, P6051; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RADA JA, 1991, INVEST OPHTH VIS SCI, V32, P1010; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; SCOTT JE, 1988, BIOCHEM J, V253, P607, DOI 10.1042/bj2530607; SCOTT JE, 1991, BIOCHEM SOC T, V19, P877, DOI 10.1042/bst0190877; STEIN T, 1982, H-S Z PHYSIOL CHEM, V363, P825, DOI 10.1515/bchm2.1982.363.2.825; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207	35	67	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20613	20619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400383				2022-12-27	WOS:A1992JT97800020
J	NG, K; YE, RQ; WU, XC; WONG, SL				NG, K; YE, RQ; WU, XC; WONG, SL			SORBITOL DEHYDROGENASE FROM BACILLUS-SUBTILIS - PURIFICATION, CHARACTERIZATION, AND GENE CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; L-THREONINE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; ESCHERICHIA-COLI; ZINC ENVIRONMENT; ENZYME; RESOLUTION; QUANTITIES; EXPRESSION	Cloning of the sorbitol dehydrogenase gene (gutB) from Bacillus subtilis offers an excellent system for studying zinc binding, substrate specificity, and catalytic mechanism of this enzyme through protein engineering. As a first step to clone gutB, B. subtilis sorbitol dehydrogenase has been purified to homogeneity and characterized. It is a tetrameric enzyme with a molecular mass of 38 kDa for each subunit. Atomic absorption analysis shows the presence of 1 mol of zinc atom/subunit. Substrate specificity and stereospecificity of the enzyme toward C-2 and C-4 of hexitols were established. Sequence of the first 31 amino acids was determined, and a set of oligonucleotide probes was designed for gene cloning. A positive clone carrying a 5-kilobase pair HindIII insert was isolated and sequenced. Sequence alignment indicated that the deduced amino acid sequence of B. subtilis sorbitol dehydrogenase shows 36% identity in sequence with the liver sorbitol dehydrogenase from sheep, rat, and human. In reference to the sequence of alcohol dehydrogenase, two potential zinc binding sites were identified. Sequence information related to the structure-function relationships of the enzyme is discussed.	UNIV CALGARY,DEPT BIOL SCI,DIV BIOCHEM,2500 UNIV DR NW,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary				Ng, Kenneth K.S./0000-0001-7280-8445				AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; ARONSON BD, 1989, J BIOL CHEM, V264, P5226; BORRAS T, 1989, BIOCHEMISTRY-US, V28, P3133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALUMEAU H, 1978, J BACTERIOL, V134, P921; Dupont D. R., 1989, TECHNIQUES PROTEIN C, P284; EKLUND H, 1985, BIOCHEMISTRY-US, V24, P8005, DOI 10.1021/bi00348a025; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EPPERLY BR, 1991, J BIOL CHEM, V266, P6086; FEITERS MC, 1989, BIOCHEMISTRY-US, V28, P7257, DOI 10.1021/bi00444a017; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HALLING SM, 1977, BIOCHEMISTRY-US, V16, P2880, DOI 10.1021/bi00632a012; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; HORWITZ SB, 1964, J BIOL CHEM, V239, P830; JEFFERY J, 1988, ADV ENZYMOL RAMB, V61, P47; JEFFERY J, 1984, EUR J BIOCHEM, V140, P7, DOI 10.1111/j.1432-1033.1984.tb08059.x; JORNVALL H, 1984, EUR J BIOCHEM, V140, P17, DOI 10.1111/j.1432-1033.1984.tb08061.x; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; JORNVALL H, 1970, EUR J BIOCHEM, V16, P25, DOI 10.1111/j.1432-1033.1970.tb01049.x; KARLSSON C, 1989, EUR J BIOCHEM, V186, P543, DOI 10.1111/j.1432-1033.1989.tb15240.x; KARLSSON C, 1991, EUR J BIOCHEM, V198, P761, DOI 10.1111/j.1432-1033.1991.tb16077.x; KAWAMURA F, 1984, J BACTERIOL, V160, P442, DOI 10.1128/JB.160.1.442-444.1984; MARET W, 1988, BIOCHEMISTRY-US, V27, P1622, DOI 10.1021/bi00405a035; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P3408, DOI 10.1073/pnas.78.6.3408; TRAN L, 1991, J BACTERIOL, V173, P6364, DOI 10.1128/jb.173.20.6364-6372.1991; WONG SL, 1988, J GEN MICROBIOL, V134, P3269; WU XC, 1990, J BIOL CHEM, V265, P6845	29	54	59	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24989	24994						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460002				2022-12-27	WOS:A1992KB60300015
J	HOPKIN, KA; PAPAZIAN, MA; STEINMAN, HM				HOPKIN, KA; PAPAZIAN, MA; STEINMAN, HM			FUNCTIONAL DIFFERENCES BETWEEN MANGANESE AND IRON SUPEROXIDE DISMUTASES IN ESCHERICHIA-COLI K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS RESPONSES; SALMONELLA-TYPHIMURIUM; GENE; OXYGEN; PARAQUAT; BIOSYNTHESIS; SENSITIVITY; DEHYDRATASE; EXPRESSION; SEQUENCE	Superoxide dismutases are enzymes that defend against oxidative stress through decomposition of superoxide radical. Escherichia coli contains two highly homologous superoxide dismutases, one containing manganese (MnSOD) and the other iron (FeSOD). Although E. coli Mn and FeSOD catalyze the dismutation of superoxide with comparable rate constants, it is not known if they are physiologically equivalent in their protection of cellular targets from oxyradical damage. To address this issue, isogenic strains of E. coli containing either Mn or FeSOD encoded on a plasmid and under the control of tac promoter were constructed. SOD specific activity in the Mn and FeSOD strains could be controlled by the concentration of isopropyl beta-thiogalactoside in the medium. The tolerance of these strains to oxidative stress was compared at equal Mn and FeSOD specific activities. Our results indicate that E. coli Mn and FeSOD are not functionally equivalent. The MnSOD is more effective than FeSOD in preventing damage to DNA, while the FeSOD appears to be more effective in protecting a cytoplasmic superoxide-sensitive enzyme. These data are the first demonstration that Mn and FeSOD are adapted to different antioxidant roles in E. coli.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, 1300 MORRIS PK AVE, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40468, 2T32 GM07128] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; Beckwith J.R., 1987, ESCHERICHIA COLI SAL, V2, P1444; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FEE JA, 1991, MOL MICROBIOL, V5, P2599, DOI 10.1111/j.1365-2958.1991.tb01968.x; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GARDNER PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P106, DOI 10.1016/0003-9861(91)90270-S; GRALLA EB, 1992, IN PRESS ADV GENET; GRAY B, 1992, BIOCHEM J, V281, P795, DOI 10.1042/bj2810795; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HASSAN HM, 1977, J BACTERIOL, V129, P1574, DOI 10.1128/JB.129.3.1574-1583.1977; HASSAN HM, 1989, ADV GENET, V26, P65; HASSAN HM, 1984, METHOD ENZYMOL, V105, P523; KAO SM, 1985, J BIOL CHEM, V260, P478; KUO CF, 1987, J BIOL CHEM, V262, P4724; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; Miller J. H., 1972, EXPT MOL GENETICS, P431; MINAKAMI H, 1990, FASEB J, V4, P3239, DOI 10.1096/fasebj.4.14.2172063; MOODY CS, 1982, P NATL ACAD SCI-BIOL, V79, P2855, DOI 10.1073/pnas.79.9.2855; Olive C, 1975, Methods Enzymol, V41, P196; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P57; Omar B A, 1992, Adv Pharmacol, V23, P109, DOI 10.1016/S1054-3589(08)60964-3; PROHASKA JR, 1983, J NUTR, V113, P2048, DOI 10.1093/jn/113.10.2048; RUSSELL CB, 1989, J BACTERIOL, V171, P3609, DOI 10.1128/jb.171.7.3609-3618.1989; SAKAMOTO H, 1984, J BACTERIOL, V159, P418, DOI 10.1128/JB.159.1.418-420.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P217; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STALLINGS WC, 1991, FREE RADICAL RES COM, V12-3, P259, DOI 10.3109/10715769109145794; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; STEINMAN HM, 1992, MOL GEN GENET, V232, P427, DOI 10.1007/BF00266247; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; STEINMAN HM, 1985, J BACTERIOL, V162, P1255, DOI 10.1128/JB.162.3.1255-1260.1985; TAKEDA Y, 1986, NUCLEIC ACIDS RES, V14, P4577, DOI 10.1093/nar/14.11.4577; TOUATI D, 1988, FREE RADICAL BIO MED, V5, P393, DOI 10.1016/0891-5849(88)90113-X; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; TOUATI D, 1990, METHOD ENZYMOL, V186, P646	48	77	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24253	24258						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447175				2022-12-27	WOS:A1992KA26300020
J	SU, X; FRAENKEL, PG; BOGORAD, L				SU, X; FRAENKEL, PG; BOGORAD, L			EXCITATION-ENERGY TRANSFER FROM PHYCOCYANIN TO CHLOROPHYLL IN AN APCA-DEFECTIVE MUTANT OF SYNECHOCYSTIS SP PCC-6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIAL PHYCOBILISOMES; CHROMATIC ADAPTATION; ANABAENA-VARIABILIS; PHOTOSYSTEM-II; PCC 6803; PHYCOBILIPROTEINS; POLYPEPTIDE; PROTEIN; GENES	A greenish mutant of the normally blue-green cyanobacterium Synechocystis sp. PCC 6803, designated UV6p, has been isolated and characterized. UV6p possesses functional photosystems I and II (PSI and PSII) but lacks normal light harvesting phycobilisomes because allophycocyanin is absent and core-specific linker proteins are almost entirely absent. The mutation responsible for the UV6p phenotype has been identified; it is a base substitution which results in the creation of a termination codon within the coding region of the apcA gene. Phycocyanin (PC) and phycobilisome rod linker proteins are present in UV6p and, despite the absence of core components, at least 35% of the PC is associated with rod linker proteins. At 77 K, light absorbed by PC of UV6p elicits PSI fluorescence comparable to that of wild type cells but produces greatly diminished PSII fluorescence. The results indicate that the assembly of rods is independent of cores and that light energy absorbed by rods can be transferred principally and directly to PSI. This energy transfer pathway, which may also be present in wild type, may have a regulatory role in maintaining the balance of input of excitation energy into PSI versus PSII during photosynthesis.	HARVARD UNIV,BIOL LABS,16 DIVIN AVE,CAMBRIDGE,MA 02138	Harvard University								ANDERSON LK, 1984, ARCH MICROBIOL, V138, P237, DOI 10.1007/BF00402128; ANDERSON LK, 1990, J BACTERIOL, V172, P1289, DOI 10.1128/jb.172.3.1289-1296.1990; Barr R, 1971, METHOD ENZYMOL, V23, P372; BENNETT A, 1973, J CELL BIOL, V58, P419, DOI 10.1083/jcb.58.2.419; BIGGINS J, 1989, PHOTOSYNTH RES, V20, P1, DOI 10.1007/BF00028620; Bryant D.A., 1991, PHOTOSYNTHETIC APPAR, P257, DOI [10.1016/B978-0-12-715010-9.50014-1, DOI 10.1016/B978-0-12-715010-9.50014-1]; Bryant D.A., 1988, LIGHT ENERGY TRANSDU, P62; BRYANT DA, 1979, ARCH MICROBIOL, V123, P113, DOI 10.1007/BF00446810; CARILLO N, 1982, PLANT PHYSIOL, V69, P210; CECCARELLI EA, 1985, FEBS LETT, V190, P165, DOI 10.1016/0014-5793(85)80450-6; DELORIMIER R, 1990, BIOCHIM BIOPHYS ACTA, V1019, P29, DOI 10.1016/0005-2728(90)90121-J; DZELZKALNS VA, 1986, J BACTERIOL, V165, P964, DOI 10.1128/jb.165.3.964-971.1986; DZELZKALNS VA, 1989, PLANT PHYSIOL, V90, P617, DOI 10.1104/pp.90.2.617; DZELZKALNS VA, 1988, EMBO J, V7, P333, DOI 10.1002/j.1460-2075.1988.tb02817.x; ELMORJANI K, 1986, ARCH MICROBIOL, V146, P186, DOI 10.1007/BF00402349; Glazer A.N., 1987, CYANOBACTERIA, P69; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GRAY BH, 1975, PHOTOCHEM PHOTOBIOL, V21, P121, DOI 10.1111/j.1751-1097.1975.tb06638.x; HOUMARD J, 1988, J BACTERIOL, V170, P5512, DOI 10.1128/jb.170.12.5512-5521.1988; HOUNARD J, 1986, MOL GEN GENET, V205, P404; KRAMER HJM, 1985, PHYSIOL VEG, V23, P535; KREY A, 1966, BIOCHIM BIOPHYS ACTA, V120, P1, DOI 10.1016/0926-6585(66)90271-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MAXSON P, 1989, BIOCHIM BIOPHYS ACTA, V977, P40, DOI 10.1016/S0005-2728(89)80007-6; MIMURO M, 1989, BIOCHIM BIOPHYS ACTA, V973, P153, DOI 10.1016/S0005-2728(89)80416-5; MULLINEAUX CW, 1990, BIOCHIM BIOPHYS ACTA, V1015, P231, DOI 10.1016/0005-2728(90)90025-Y; PETERSON RB, 1981, BIOCHIM BIOPHYS ACTA, V634, P237, DOI 10.1016/0005-2728(81)90142-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUCHTER WM, 1992, BIOCHEMISTRY-US, V31, P3092, DOI 10.1021/bi00127a009; SU X, 1991, J BIOL CHEM, V266, P23698; TYAGI VVS, 1981, PLANT PHYSIOL, V68, P1479, DOI 10.1104/pp.68.6.1479; VALLEJOS RH, 1984, J BIOL CHEM, V259, P8048; Yamanaka G., 1983, PHOTOSYNTHETIC PROKA, P69; ZILINSKAS BA, 1978, PHOTOCHEM PHOTOBIOL, V27, P587, DOI 10.1111/j.1751-1097.1978.tb07650.x; ZILINSKAS BA, 1986, PHOTOSYNTH RES, V10, P7, DOI 10.1007/BF00024183	36	55	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22944	22950						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429645				2022-12-27	WOS:A1992JY16300038
J	HIGUTI, T; YOSHIHARA, Y; KUROIWA, K; KAWAMURA, Y; TODA, H; SAKIYAMA, F				HIGUTI, T; YOSHIHARA, Y; KUROIWA, K; KAWAMURA, Y; TODA, H; SAKIYAMA, F			A SIMPLE, RAPID METHOD FOR PURIFICATION OF EPSILON-SUBUNIT, COUPLING FACTOR-6, SUBUNIT-D, AND SUBUNIT-E FROM RAT-LIVER H+-ATP SYNTHASE AND DETERMINATION OF THE COMPLETE AMINO-ACID-SEQUENCE OF EPSILON-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; MECHANISM	The rat liver mitochondrial epsilon-subunit, coupling factor 6, subunit d, and subunit e of H+-ATP synthase, which are all extra subunits with no counterparts in Escherichia coli, were purified by reverse-phase high performance liquid chromatography. The complete amino acid sequence of the rat epsilon-subunit was determined by automated Edman degradation of the whole protein and derived peptides. The protein contains 50 amino acids and has a molecular mass of 5635 kDa. It is a basic hydrophilic protein with an isoelectric point of 10.5. The sequence of the rat epsilon-subunit is highly homologous with that of the epsilon-subunit of bovine heart and slightly similar to those of the epsilon-subunit of the yeast and sweet potato mitochondria. However, it has no homology with any subunit of bacterial or chloroplast H+-ATP synthase.	OSAKA UNIV,INST PROT RES,DIV PROT CHEM,SUITA,OSAKA 565,JAPAN	Osaka University	HIGUTI, T (corresponding author), UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN.							AMZEL LM, 1983, ANNU REV BIOCHEM, V52, P801, DOI 10.1146/annurev.bi.52.070183.004101; ARSELIN G, 1991, J BIOL CHEM, V266, P723; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; FILLINGAME RH, 1981, CURR TOP BIOENERG, V11, P35; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HIGUTI T, 1990, BIOCHEM BIOPH RES CO, V171, P1079, DOI 10.1016/0006-291X(90)90794-N; KAGAWA Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P45, DOI 10.1016/0304-4173(78)90008-3; KIMURA T, 1989, J BIOL CHEM, V264, P3183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOTOJIMA K, 1992, BIOCHEM BIOPH RES CO, V182, P1130, DOI 10.1016/0006-291X(92)91849-L; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; VINAS O, 1990, BIOCHEM J, V265, P321, DOI 10.1042/bj2650321; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YOSHIHARA Y, 1991, BIOCHEMISTRY-US, V30, P6854, DOI 10.1021/bi00242a008	18	12	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22658	22661						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429613				2022-12-27	WOS:A1992JW71900102
J	LEDU, MH; MARCHOT, P; BOUGIS, PE; FONTECILLACAMPS, JC				LEDU, MH; MARCHOT, P; BOUGIS, PE; FONTECILLACAMPS, JC			1.9-ANGSTROM RESOLUTION STRUCTURE OF FASCICULIN-1, AN ANTIACETYLCHOLINESTERASE TOXIN FROM GREEN MAMBA SNAKE-VENOM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDROASPIS-ANGUSTICEPS VENOM; NAJA-MOSSAMBICA-MOSSAMBICA; REFINED CRYSTAL-STRUCTURE; AMINO-ACID-SEQUENCE; X-RAY ANALYSIS; SECONDARY STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; AQUEOUS-SOLUTION; ERABUTOXIN-B; PROTEIN	The crystal structure of fasciculin 1, a potent acetylcholinesterase inhibitor from green mamba snake venom, has been solved by the multiple isomorphous replacement method complemented with anomalous scattering and subsequently refined at 1.9-angstrom resolution. The overall structure of fasciculin is similar to those of the short alpha-neurotoxins and cardiotoxins, with a dense core rich in disulfide bridges and three long loops disposed as the central fingers of a hand. A comparison of these three prototypic toxin types shows that fasciculin 1 has structural features that are intermediate between those of the other two molecules. Its core region, which can be defined as a continuous stretch of conserved residues, is very similar to that of erabutoxin b, whereas the orientation of its long loops resembles that of cardiotoxin V4II. This result introduces a new element in the study of phylogenetic relationships of snake toxins and suggests that, after divergency from an ancestral gene, convergent evolution may have played an important factor in the evolution of these proteins. In fasciculin 1, several arginine and lysine residues are well ordered and relatively exposed to the solvent medium and may play a role in the binding to the peripheral site of acetylcholinesterases.	CEN, DSV, DEPT INGN & ETUD PROT, CRISTALLOG & CRISTALLOGENESE PROT LAB, F-38041 GRENOBLE, FRANCE; UNIV AIX MARSEILLE 2, FAC MED,BIOCHIM LAB,CNRS,UNITE RECH ASSOCIEE 1455, F-13326 MARSEILLE 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite			BOUGIS, Pierre E/I-2111-2013; MARCHOT, Pascale/AAC-4752-2022	MARCHOT, Pascale/0000-0003-0630-0541				BETZEL C, 1991, J BIOL CHEM, V266, P21530; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P337; BOUGIS P, 1981, BIOCHEMISTRY-US, V20, P4915, DOI 10.1021/bi00520a017; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; Cervenansky C., 1991, P303; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; DODSON EJ, 1976, CRYSTALLOGRAPHIC COM, P259; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Ducancel F., 1991, P385; Dufton M.J., 1991, P259; DUFTON MJ, 1983, CRC CR REV BIOCH MOL, V14, P113, DOI 10.3109/10409238309102792; DUFTON MJ, 1989, TRENDS PHARMACOL SCI, V10, P258, DOI 10.1016/0165-6147(89)90019-9; DUFTON MJ, 1984, J MOL EVOL, V20, P128, DOI 10.1007/BF02257373; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; ENDO T, 1991, SNAKE TOXINS, P1165; FONTECILLACAMPS JC, 1989, J MOL EVOL, V29, P63, DOI 10.1007/BF02106182; HARVEY AL, 1984, J TOXICOL-TOXIN REV, V3, P91, DOI 10.3109/15569548409097923; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; IVANOV CP, 1979, TOXICON, V17, P205, DOI 10.1016/0041-0101(79)90210-1; JOHNSON MS, 1990, METHOD ENZYMOL, V183, P670; JOUBERT FJ, 1978, S AFR J CHEM, V31, P107; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; LABHARDT AM, 1988, EUR J BIOCHEM, V177, P295, DOI 10.1111/j.1432-1033.1988.tb14376.x; LAPLANTE SR, 1990, INT J PEPT PROT RES, V36, P227; LEDU MH, 1989, J BIOL CHEM, V264, P21401; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1976, P NATL ACAD SCI USA, V73, P2991, DOI 10.1073/pnas.73.9.2991; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MACHIN PA, 1984, DARESBURY LAB NEWS, V13, P17; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MENEZ A, 1990, BIOCHIMIE, V72, P575, DOI 10.1016/0300-9084(90)90121-V; MENEZ A, 1992, ADV DRUG DISCOVERY; MENEZ R, 1990, J MOL BIOL, V216, P233, DOI 10.1016/S0022-2836(05)80313-4; OSWALD RE, 1991, BIOCHEMISTRY-US, V30, P4901, DOI 10.1021/bi00234a010; RAMACHANDRAN GN, 1976, J MOL BIOL, V107, P85, DOI 10.1016/S0022-2836(76)80019-8; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; REES B, 1987, P NATL ACAD SCI USA, V84, P3132, DOI 10.1073/pnas.84.10.3132; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODRIGUEZITHURRALDE D, 1983, NEUROCHEM INT, V5, P267, DOI 10.1016/0197-0186(83)90028-1; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SANKAR P, 1989, TOXICON, V27, P832; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P74; SMITH JL, 1988, ACTA CRYSTALLOGR A, V44, P357, DOI 10.1107/S0108767388000303; STEINMETZ WE, 1988, EUR J BIOCHEM, V172, P101, DOI 10.1111/j.1432-1033.1988.tb13861.x; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; STRYDOM DJ, 1977, EUR J BIOCHEM, V76, P99, DOI 10.1111/j.1432-1033.1977.tb11574.x; STRYDOM DJ, 1979, HDB EXPT PHARM, V52, P159; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TSERNOGLOU D, 1976, FEBS LETT, V68, P1, DOI 10.1016/0014-5793(76)80390-0; VILJOEN CC, 1973, J BIOL CHEM, V248, P4915; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P398, DOI 10.1073/pnas.72.1.398; YU C, 1990, EUR J BIOCHEM, V193, P789, DOI 10.1111/j.1432-1033.1990.tb19401.x	57	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22122	22130						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429564				2022-12-27	WOS:A1992JW71900024
J	WOLF, WA; KUHN, DM				WOLF, WA; KUHN, DM			ROLE OF ESSENTIAL SULFHYDRYL-GROUPS IN DRUG-INTERACTIONS AT THE NEURONAL 5-HT TRANSPORTER - DIFFERENCES BETWEEN AMPHETAMINES AND 5-HT UPTAKE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HYDROXYTRYPTAMINE TRANSPORTER; CORTICAL MEMBRANES; ESCHERICHIA-COLI; BINDING; MECHANISM; SEROTONIN; PROTEIN	The sulfhydryl-selective alkylating agent, N-ethylmaleimide (NEM), has been used as a tool to discern whether different binding domains exist on the neuronal serotonin (5-HT) transporter for 5-HT and 5-HT uptake inhibitors (Reith, M. E. A., Allen, D. L., Sershen, H., and Lajtha, A. (1984) J. Neurochem. 43, 249-255; Graham, D., Esnaud, H., Habert, E., and Langer, S. Z. (1989) Biochem. Pharmacol. 38, 3819-3826). However, relatively high concentrations of NEM and long incubation times have been required for inactivation of the transporter-binding site which raises the possibility that NEM is reacting with other nucleophilic groups (Smyth, D. G., Blumenfeld, O. O., and Konigsberg, W. (1964) Biochem. J. 91, 589-595). In the present work, the reactivity and essential nature of sulfhydryl groups associated with substrate/inhibitor binding to the neuronal 5-HT transporter was assessed. [H-3]Paroxetine, a potent and selective 5-HT uptake inhibitor, was used to label the 5-HT transporter. The effects of a relatively wide range of sulfhydryl reagents on [H-3]paroxetine binding in digitonin-solubilized preparations of rat brain neuronal membranes and the relative abilities of different classes of drugs to protect against NEM-induced inactivation of [H-3]paroxetine binding were studied. It was observed that digitonin-solubilized preparations were more sensitive than membrane preparations to the inactivating effects of NEM. The pK(a) of the reactive group was estimated to be 6.17, in the range expected for a reactive sulfhydryl. Sulfhydryls essential to ligand binding reacted preferentially with hydrophobic compounds (p-hydroxymercuribenzoate = dithiobisnitrobenzoate > methyl methanethiosulfonate > N-phenylmaleimide > N-ethylmaleimide) and were unreactive toward hydrophilic reagents such as iodoacetate and iodoacetamide. 5-HT, 5-HT uptake inhibitors and cocaine protected the digitonin-solubilized transporter from NEM-induced inactivation while the amphetamine-related releasing agents p-chloroamphetamine and fenfluramine were ineffective. The observation that the binding of some, but not all, ligands requires reduced sulfhydryl groups, suggests that differential mechanisms and/or different binding domains do exist for agents which interact at the neuronal 5-HT trans porter.	WAYNE STATE UNIV, SCH MED, DEPT PSYCHIAT, CELLULAR & CLIN NEUROBIOL PROGRAM, DETROIT, MI 48201 USA	Wayne State University	WOLF, WA (corresponding author), LAFAYETTE CLIN, 951 E LAFAYETTE, DETROIT, MI 48207 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007172] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 07172] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DAVENPORT JW, 1988, J BIOL CHEM, V263, P16007; FOMENKO AM, 1990, EUR J PHARM-MOLEC PH, V189, P175, DOI 10.1016/0922-4106(90)90021-O; FULLER RW, 1980, NEUROCHEM RES, V5, P241, DOI 10.1007/BF00964612; FULLER RW, 1990, ANN N Y ACAD SCI, V600, P68; GRAHAM D, 1989, BIOCHEM PHARMACOL, V38, P3819, DOI 10.1016/0006-2952(89)90591-1; GUIDOTTI G, 1964, J BIOL CHEM, V239, P1474; HABERT E, 1986, EUR J PHARMACOL, V122, P197, DOI 10.1016/0014-2999(86)90103-2; HABERT E, 1985, EUR J PHARMACOL, V118, P107, DOI 10.1016/0014-2999(85)90668-5; HOLLAWAY MR, 1964, BIOCHIM BIOPHYS ACTA, V92, P111, DOI 10.1016/0926-6569(64)90275-5; LEMBERGER L, 1985, CLIN NEUROPHARMACOL, V8, P299, DOI 10.1097/00002826-198512000-00001; LINDLEY H, 1960, BIOCHEM J, V74, P577, DOI 10.1042/bj0740577; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; REITH MEA, 1984, J NEUROCHEM, V43, P249, DOI 10.1111/j.1471-4159.1984.tb06703.x; Riordan J.F., 1967, METHOD ENZYMOL, V11, P541; ROBILLARD GT, 1981, BIOCHEMISTRY-US, V20, P5025, DOI 10.1021/bi00520a032; ROBILLARD GT, 1982, EUR J BIOCHEM, V127, P597; ROBILLARD GT, 1987, FEBS LETT, V224, P391, DOI 10.1016/0014-5793(87)80490-8; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589	23	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20820	20825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400397				2022-12-27	WOS:A1992JT97800049
J	GULATI, J; BABU, A; SU, H				GULATI, J; BABU, A; SU, H			FUNCTIONAL DELINEATION OF THE CA2+-DEFICIENT EF-HAND IN CARDIAC-MUSCLE, WITH GENETICALLY ENGINEERED CARDIAC-SKELETAL CHIMERIC TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID SEQUENCE; CONTRACTION; CALMODULIN; SUBSTITUTION; ACTIVATION; DEPENDENCE; RESOLUTION; PROTEINS; BINDING	Cardiac and fast skeletal isoforms of TnC each comprise four putative EF-hand (helix-loop-helix) motifs as potential Ca2+-binding sites (sites 1-4), except that site 1 in cardiac TnC is deficient in Ca2+ coordination. In skeletal TnC, the N-terminal sites 1 and 2 are both essential for the trigger mechanism of the contraction switch. However, the mechanism in cardiac muscle is unsettled; it is obscure whether the cardiac site 1 is functionally inert due to calcium deficiency and consequently site 2 is the lone trigger site, or whether sites 1 and 2 perform interactively despite the impairment. These possibilities were addressed by mutagenizing site 1 in skeletal TnC to mimic the cardiac response. In one mutant (STnC-1), two selected Ca2+-ligands were abolished. In another (C1/S chimera), 41 N-terminal residues from cardiac TnC were spliced to STnC. The Ca2+-binding capacities as well as skinned fiber responses were measured. The STnC-1 derivative failed to switch on contraction. In contrast, the chimeric construct expressed close to full contractile potential in myocardium (74 +/- 3% P0; P0 = maximal tension) and also the manifest cardiac phenotype. By devising supplemental chimeric constructs, cardiac-type N-terminal overhang together with cardiac-type EF-hand for site 1 both were found essential for the phenotype. We conclude that cardiac TnC site 1 is actively engaged in the trigger mechanism and in fact dominates the phenotype despite the inability to chelate Ca2+. The N-terminal overhang also participates in this mechanism, which is a novel finding. The conclusion that a non-chelating site functions interactively with a proximal site in cardiac TnC may have wider significance, inasmuch as similar pairings of disparate EF-hands are of common occurrence.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOPHYS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	GULATI, J (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED & PHYSIOL,DIV CARDIOL,MOLEC PHYSIOL LAB,BRONX,NY 10461, USA.			Akella, Aravind/0000-0002-3396-7598	NHLBI NIH HHS [HL37412] Funding Source: Medline; NIAMS NIH HHS [AR33736] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033736] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMPHLETT GW, 1976, FEBS LETT, V72, P193; BABU A, 1989, J PHYSIOL-LONDON, V417, pP58; BABU A, 1988, J BIOL CHEM, V263, P15485; BABU A, 1988, SCIENCE, V240, P74, DOI 10.1126/science.3353709; BABU A, 1989, FEBS LETT, V251, P177, DOI 10.1016/0014-5793(89)81450-4; BABU A, 1987, J BIOL CHEM, V262, P5815; BABU A, 1992, J BIOL CHEM, V267, P15469; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GERDAY C, 1988, CALCIUM CALCIUM BIND, P23; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GULATI J, 1989, FEBS LETT, V248, P5, DOI 10.1016/0014-5793(89)80420-X; GULATI J, 1988, FEBS LETT, V236, P441, DOI 10.1016/0014-5793(88)80073-5; GULATI J, 1991, J PHYSIOL-LONDON, V441, P305, DOI 10.1113/jphysiol.1991.sp018753; GULATI J, 1992, MECHANISMS MYOFILAME; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KOBAYASHI T, 1989, J BIOCHEM-TOKYO, V105, P823, DOI 10.1093/oxfordjournals.jbchem.a122752; KRETSINGER RH, 1992, CELL CALCIUM, V13, P363, DOI 10.1016/0143-4160(92)90050-3; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; MOSS RL, 1986, J BIOL CHEM, V261, P6096; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; XU GQ, 1988, J BIOL CHEM, V263, P13962	29	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25073	25077						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460008				2022-12-27	WOS:A1992KB60300027
J	OLIVER, KG; BULLER, RML; HUGHES, PJ; PUTNEY, JW; PALUMBO, GJ				OLIVER, KG; BULLER, RML; HUGHES, PJ; PUTNEY, JW; PALUMBO, GJ			INHIBITION OF AGONIST-INDUCED ACTIVATION OF PHOSPHOLIPASE-C FOLLOWING POXVIRUS INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIN-BINDING PROTEIN; RAT PAROTID-GLAND; VACCINIA VIRUS; REGULATORY PROTEIN; INOSITOL 1,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE METABOLISM; PANCREATOMA CELLS; FACTOR RECEPTOR; HYDROLYSIS	Recent studies indicate that viruses may influence polyphosphoinositide levels. This study has examined the effects of vaccinia virus infection on phospholipase C activity. Infection of BS-C-1 cells, an African Green Monkey kidney cell line, or A431 cells, a human carcinoma cell line, with vaccinia virus inhibits receptor-mediated phospholipase C activation. As a consequence, agonist-mediated Ca2+ mobilization in BS-C-1 cells also was inhibited by vaccinia virus infection. Alleviation of the inhibition of phospholipase C activation was observed in vaccinia virus-infected cells treated with cycloheximide without influencing uninfected cells. Treatment of infected cells with alpha-amanitin, an inhibitor of host mRNA synthesis but not virus mRNA synthesis, failed to alleviate the inhibition of phospholipase C activation. Together these results suggest that a virus-encoded gene product mediates the inhibition of phospholipase C activation without the need of a virus-induced host factor. Analysis of the processes involved in the formation of inositol (1,4,5)-trisphosphate and mobilization of intracellular Ca2+ indicate that the vaccinia virus gene product exerts its inhibitory effects at the level of phospholipase C activity. This may occur by either directly reducing the amount of phospholipase C, reducing the specific activity of phospholipase C, or by inhibiting the association of phospholipase C with its substrate, phosphatidylinositol 4,5-bisphosphate.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	OLIVER, KG (corresponding author), NIEHS,NATL TOXICOL PROGRAM,CELLULAR & MOLEC PHARMACOL,CALCIUM REGULAT SECT,MAIL DROP 7-10,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; ALBRECHT T, 1990, INTERVIROLOGY, V31, P68, DOI 10.1159/000150140; BECKER Y, 1964, P NATL ACAD SCI USA, V54, P577; BENTON HP, 1989, BIOCHEM J, V258, P861, DOI 10.1042/bj2580861; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BLASCO R, 1991, J VIROL, V65, P4598, DOI 10.1128/JVI.65.9.4598-4608.1991; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1988, J VIROL, V62, P866, DOI 10.1128/JVI.62.3.866-874.1988; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DOWNES CP, 1983, BIOCHEM J, V216, P633, DOI 10.1042/bj2160633; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; Downie AW, 1939, J PATHOL BACTERIOL, V48, P361, DOI 10.1002/path.1700480212; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GUINEA R, 1989, J BIOL CHEM, V264, P21923; HANAFUSA T, 1960, BIKEN J, V3, P313; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; HRUBY DE, 1979, P NATL ACAD SCI USA, V76, P1887, DOI 10.1073/pnas.76.4.1887; HUGHES AR, 1991, MOL PHARMACOL, V40, P254; JUNGWIRT.C, 1968, J VIROL, V2, P401, DOI 10.1128/JVI.2.5.401-408.1968; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING CS, 1986, MOL CELL BIOL, V6, P332, DOI 10.1128/MCB.6.1.332; KIT S, 1962, VIROLOGY, V18, P274, DOI 10.1016/0042-6822(62)90014-4; LIANG M, 1991, J BIOL CHEM, V266, P13342; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSS B, 1968, J VIROL, V2, P1028, DOI 10.1128/JVI.2.10.1028-1037.1968; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; POGGIOLI J, 1983, MOL PHARMACOL, V23, P71; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REISNER AH, 1985, NATURE, V313, P801, DOI 10.1038/313801a0; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Schacht J, 1981, Methods Enzymol, V72, P626; SHEARS SB, 1987, BIOCHEM J, V242, P393, DOI 10.1042/bj2420393; SHEARS SB, 1991, PHARMACOL THERAPEUT, V49, P79, DOI 10.1016/0163-7258(91)90023-F; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; TAYLOR CW, 1986, BIOCHEM BIOPH RES CO, V136, P362, DOI 10.1016/0006-291X(86)90919-8; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS KL, 1989, NEUROPEPTIDES, V13, P191, DOI 10.1016/0143-4179(89)90091-7; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; VALYINAGY T, 1988, ARCH VIROL, V101, P199, DOI 10.1007/BF01311001; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327	53	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25098	25103						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460012				2022-12-27	WOS:A1992KB60300031
J	IWASAKI, M; SEKO, A; KITAJIMA, K; INOUE, Y; INOUE, S				IWASAKI, M; SEKO, A; KITAJIMA, K; INOUE, Y; INOUE, S			FISH EGG GLYCOPHOSPHOPROTEINS HAVE SPECIES-SPECIFIC N-LINKED GLYCAN UNITS PREVIOUSLY FOUND IN A STORAGE POOL OF FREE GLYCAN CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EMBRYO; UNFERTILIZED EGGS; ORYZIAS-LATIPES; YOLK PROTEINS; FREE SIALOOLIGOSACCHARIDES; HIGH-RESOLUTION; XENOPUS-LAEVIS; MEDAKA FISH; GLYCOPROTEINS; OLIGOSACCHARIDES	Recent findings (Ishii, K., Iwasaki, M., Inoue, S., Kenny, P. T. M., Komura, H., and Inoue, Y. (1989) J. Biol. Chem. 264, 1623-1630; Inoue, S., Iwasaki, M., Ishii, K., Kitajima, K., and Inoue, Y. (1989) J. Biol. Chem. 264, 18520-18526) of a relatively large quantity of complex-type free sialo-oligosaccharides in the unfertilized eggs of freshwater fish, Plecoglossus altivelis and Tribolodon hakonensis, prompted us to search for their progenitor glycoproteins. First we demonstrated a third occurrence of free sialoglycans in the unfertilized eggs of Medaka fish (Oryzias latipes). Next, in all three species studied, a uniformly high level of glycophosphoproteins (GPP) was identified and found to possess N-linked glycan units. The carbohydrate structures of the GPP were determined to be identical with those of the free glycans isolated from the unfertilized eggs of the respective fish species. Thus, the most likely candidate for the progenitor of free sialoglycans appeared to be the oocyte GPPs. This implies that the liberation of the free glycans by a putative peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase may represent a necessary biochemical event during vitellogenesis or oogenesis. The present results may provide insight into a new concept of a "protein N-glycosylation/de-N-glycosylation system" recently proposed by us (Seko, A., Kitajima, K., Inoue, Y., and Inoue, S.(1991) J. Biol. Chem. 266, 22110-22114).	SHOWA UNIV,SCH PHARMACEUT SCI,HATANODAI 1,TOKYO 142,JAPAN; UNIV TOKYO,FAC SCI,TOKYO 113,JAPAN	Showa University; University of Tokyo								CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEHN PF, 1973, J CELL BIOL, V58, P721, DOI 10.1083/jcb.58.3.721; DEVLAMING VL, 1980, COMP BIOCHEM PHYS B, V67, P613; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FUKUDA M, 1976, J BIOCHEM, V80, P1223, DOI 10.1093/oxfordjournals.jbchem.a131393; GOTTLIEB TA, 1982, J BIOL CHEM, V257, P95; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P305, DOI 10.1111/j.1432-1033.1982.tb05881.x; INOUE S, 1989, J BIOL CHEM, V264, P18520; INOUE S, 1990, TRENDS GLYCOSCI GLYC, V2, P225; ISHII K, 1989, J BIOL CHEM, V264, P1623; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; Iwasaki M., 1985, GLYCOCONJUGATE J, V2, P209, DOI [10.1007/BF01049269, DOI 10.1007/BF01049269]; KARI BE, 1985, DEV BIOL, V108, P18, DOI 10.1016/0012-1606(85)90004-1; KITAJIMA K, 1989, DEV BIOL, V132, P544, DOI 10.1016/0012-1606(89)90249-2; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; SCOTT LB, 1990, DEV BIOL, V137, P368, DOI 10.1016/0012-1606(90)90261-G; SEKO A, 1991, BIOCHEM BIOPH RES CO, V180, P1165, DOI 10.1016/S0006-291X(05)81318-X; SEKO A, 1989, J BIOL CHEM, V264, P15922; SEKO A, 1991, J BIOL CHEM, V266, P22110; SHAINKIN R, 1971, J BIOL CHEM, V246, P2278; SHAINKIN R, 1971, ARCH BIOCHEM BIOPHYS, V145, P693, DOI 10.1016/S0003-9861(71)80030-9; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAZAWA I, 1988, COMP BIOCHEM PHYS B, V89, P475, DOI 10.1016/0305-0491(88)90162-9; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WALLACE RA, 1985, J BIOL CHEM, V260, P1268; WIERUSZESKI JM, 1987, J BIOL CHEM, V262, P6650; WILEY HS, 1981, J BIOL CHEM, V256, P8626; YAMASHITA O, 1988, DEV GROWTH DIFFER, V30, P337	31	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24287	24296						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447178				2022-12-27	WOS:A1992KA26300025
J	MCGEE, MP; LI, LC; XIONG, H				MCGEE, MP; LI, LC; XIONG, H			DIFFUSION CONTROL IN BLOOD-COAGULATION - ACTIVATION OF FACTOR-X BY FACTOR-IXA FACTOR-VIIIA ASSEMBLED ON HUMAN MONOCYTE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHROMBINASE COMPLEX; FACTOR-VA; HUMAN LEUKOCYTES; PROTEIN; ASSOCIATION; KINETICS; BINDING; ENZYMES; PHOSPHOLIPIDS; PHAGOCYTOSIS	This study examines mechanisms that regulate the activation of blood coagulation proteases on intact cell membranes. The activation of factor X by factors IXa and VIIIa assembled on viable monocytes is presented as a biologically relevant model for membrane-dependent proteolysis of coagulation zymogens. The hypothesis that this reaction is limited by diffusion was tested by comparing predicted with observed concentration dependence, temperature dependence, and effective rate coefficient. Rates of factor X catalysis were measured using a chromogenic substrate specific for the product, factor Xa. The value of K(R) and of K1/2, i.e. concentrations giving half-maximal rates in reciprocal functional titrations with substrate and enzyme, respectively, were directly correlated with the concentration of the titrated component. Arrhenius plots constructed over temperatures encompassing 10-35-degrees-C were biphasic with downward concavity. Apparent activation energies were 6.01 +/- 0.93 and 35.84 +/- 8.9 kcal/mol for the interval above and below the inflection point, respectively. The effective rate coefficient calculated from apparent kinetic parameters was 3.58 +/- 0.1 x 10(12) M-1 s-1. This rate is similar to the maximal rate of collision between factor X molecules and the monocyte, i.e. 2.9 x 10(12) M-1 s-1 estimated from the steady-state von Smoluchowski equation for uniformly reacting spherical particles. The observed agreement between predicted and experimental results indicates that under biologically relevant conditions, the rate of factor X activation by the intrinsic protease is controlled by diffusion of factor X toward the catalytic site.			MCGEE, MP (corresponding author), BOWMAN GRAY SCH MED,DEPT MED,RHEUMATOL SECT,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042812] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42812] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1987, BIOCHEMISTRY-US, V26, P7994, DOI 10.1021/bi00398a067; AHMAD SS, 1989, J BIOL CHEM, V264, P20012; BARTON PG, 1969, BIOCHIM BIOPHYS ACTA, V187, P319, DOI 10.1016/0005-2760(69)90005-8; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; CALEF F, 1983, ANNU REV PHYS CHEM, V34, P126; Chandrasekhar S, 1943, REV MOD PHYS, V15, P0001, DOI 10.1103/RevModPhys.15.1; COHN ZA, 1982, CIBA F SYMP, V92, P15; DAEMEN FJM, 1965, THROMB DIATH HAEMOST, V13, P194; DELISI C, 1981, P NATL ACAD SCI-BIOL, V78, P5569, DOI 10.1073/pnas.78.9.5569; DOUGLAS KT, 1984, CHEM ENZYME ACTION, P114; Einstein A, 1926, INVESTIGATIONS THEOR, DOI DOI 10.2307/2298685; FELDERHOF BU, 1976, J CHEM PHYS, V64, P4551, DOI 10.1063/1.432087; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; GLASSTONE S, 1963, ELEMENTS PHYSICAL CH; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P446, DOI 10.1021/bi00376a016; JAHNIG F, 1982, BIOCHIM BIOPHYS ACTA, V690, P310, DOI 10.1016/0005-2736(82)90337-6; JORGENSEN PL, 1982, ANN NY ACAD SCI, V402, P2207; Laidler K J, 1980, Methods Enzymol, V64, P227; LEE AG, 1988, LIPID DOMAINS RELATI, P135; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; MAHONEY EM, 1977, P NATL ACAD SCI USA, V74, P4895, DOI 10.1073/pnas.74.11.4895; MANN KG, 1990, BLOOD, V76, P1; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MAYER LD, 1983, BIOCHIM BIOPHYS ACTA, V734, P48, DOI 10.1016/0005-2736(83)90073-1; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MCGEE MP, 1992, J EXP MED, V176, P27, DOI 10.1084/jem.176.1.27; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NEMERSON Y, 1988, BLOOD, V71, P1; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NOYES RM, 1961, PROG REACT KINET MEC, V1, P129; OFLAHERTY JT, 1978, AM J PATHOL, V90, P537; PISZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P27; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; ROSING J, 1985, BLOOD, V65, P319; SCHURR JM, 1970, BIOPHYS J, V10, P717, DOI 10.1016/S0006-3495(70)86331-7; SEGEL IH, 1975, ENZYME KINETICS, P72; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; Shinitzky M, 1979, Int Rev Cytol, V60, P121, DOI 10.1016/S0074-7696(08)61261-9; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SHOUP D, 1982, BIOPHYS J, V40, P33, DOI 10.1016/S0006-3495(82)84455-X; SMITH RL, 1973, J BIOL CHEM, V248, P2418; STOSSEL TP, 1974, NEW ENGL J MED, V290, P774, DOI 10.1056/NEJM197404042901405; SUNDARAM PV, 1970, CAN J CHEMISTRY, V48, P1498, DOI 10.1139/v70-245; SWEET WD, 1986, BIOCHEM J, V239, P301, DOI 10.1042/bj2390301; SWEET WD, 1988, LIPID DOMAINS RELATI, P17; THOMAS D, 1972, BIOCHIMIE, V54, P229, DOI 10.1016/S0300-9084(72)80108-1; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TREVAN MD, 1980, IMMOBILIZED ENZYMES, P37; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALLWORK SC, 1960, PHYSICAL CHEM, P145; WIEGEL FW, 1983, PHYS REP, V95, P289; ZIMMERMAN TS, 1988, SEMIN HEMATOL, V25, P25; ZWANZIG R, 1990, P NATL ACAD SCI USA, V87, P5856, DOI 10.1073/pnas.87.15.5856	61	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24333	24339						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447184				2022-12-27	WOS:A1992KA26300032
J	DELAFAILLE, MAC; WIRTH, DF				DELAFAILLE, MAC; WIRTH, DF			CREATION OF NULL/+ MUTANTS OF THE ALPHA-TUBULIN GENE IN LEISHMANIA-ENRIETTII BY GENE-CLUSTER DELETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEOMYCIN PHOSPHOTRANSFERASE GENE; BETA-TUBULIN; TRYPANOSOMA-BRUCEI; MESSENGER-RNAS; SACCHAROMYCES-CEREVISIAE; PARASITIC PROTOZOAN; AUTOREGULATED INSTABILITY; SCHIZOSACCHAROMYCES-POMBE; PELLICULAR MICROTUBULES; EXPRESSION	Tubulins are abundant structural proteins in the Leishmania parasite, and tubulin genes are examples of highly expressed genes, which are present in multiple copies arranged in tandem repeats. Functional analysis of such multicopy genes using genetic manipulation has not yet been possible. Here we describe a method for creating deletions of alpha-tubulin gene clusters by targeted gene replacement and report the isolation of null/+ mutants deleted for either of the two allelic tubulin clusters. We also report null/null mutants in which both clusters have been deleted from their chromosomal loci and in which alpha-tubulin genes are present as episomal elements. Characterization of tubulin mRNA expression in these mutants indicated a post-transcriptional up-regulation of alpha-tubulin mRNA stability in null/+ mutants which contained only one-third the normal number of alpha-tubulin genes. A parallel increase in beta-tubulin mRNA levels indicated coordinate regulation of tubulin mRNA in Leishmania.	HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021365] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1986, MOL CELL BIOL, V6, P2168, DOI 10.1128/MCB.6.6.2168; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ANDERSON WA, 1965, J PROTOZOOL, V12, P483, DOI 10.1111/j.1550-7408.1965.tb03247.x; ANGELOPOULOS E, 1970, J PROTOZOOL, V17, P39, DOI 10.1111/j.1550-7408.1970.tb05157.x; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENZEEV A, 1979, CELL, V17, P319, DOI 10.1016/0092-8674(79)90157-0; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CAIRNS BR, 1989, P NATL ACAD SCI USA, V86, P7682, DOI 10.1073/pnas.86.20.7682; CARON JM, 1985, NATURE, V317, P648, DOI 10.1038/317648a0; CHANG KP, 1985, LEISHMANIASIS, V1, P1; CLEVELAND DW, 1983, J CELL BIOL, V97, P919, DOI 10.1083/jcb.97.3.919; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COMEAU AM, 1986, MOL BIOCHEM PARASIT, V21, P161, DOI 10.1016/0166-6851(86)90019-8; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; EIDS JE, 1991, GENE DEV, V5, P2024; EIDS JE, 1991, P NATL ACAD SCI USA, V88, P2118; FONG D, 1981, P NATL ACAD SCI-BIOL, V78, P7624, DOI 10.1073/pnas.78.12.7624; GARDENER PJ, 1974, ANN TROP MED PARASIT, V68, P167, DOI 10.1080/00034983.1974.11686935; GARVEY EP, 1986, SCIENCE, V233, P535, DOI 10.1126/science.3726545; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; HUANG PL, 1984, MOL CELL BIOL, V4, P1372, DOI 10.1128/MCB.4.7.1372; LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LANDFEAR SM, 1986, MOL BIOCHEM PARASIT, V21, P235, DOI 10.1016/0166-6851(86)90129-5; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LENAR DF, 1981, MOL BIOCHEM PARASIT, V3, P377; LEON W, 1978, NUCLEIC ACIDS RES, V5, P491, DOI 10.1093/nar/5.2.491; MACRAE TH, 1989, BIOCHEM CELL BIOL, V67, P770, DOI 10.1139/o89-116; MESSIER PE, 1971, J PROTOZOOL, V18, P223, DOI 10.1111/j.1550-7408.1971.tb03312.x; MEYER H, 1976, J PROTOZOOL, V23, P385, DOI 10.1111/j.1550-7408.1976.tb03792.x; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PITTENGER MF, 1985, J CELL BIOL, V101, P1941, DOI 10.1083/jcb.101.5.1941; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3722, DOI 10.1128/MCB.6.11.3722; SEEBECK T, 1983, P NATL ACAD SCI-BIOL, V80, P4634, DOI 10.1073/pnas.80.15.4634; SISODIA S S, 1990, New Biologist, V2, P66; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TOBIN JF, 1992, J BIOL CHEM, V267, P4752; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; VICKERMAN K, 1970, J CELL SCI, V6, P365; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	53	36	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23839	23846						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429722				2022-12-27	WOS:A1992JZ23900062
J	AHMED, SA; MILES, EW				AHMED, SA; MILES, EW			EVIDENCE FOR 2 CONFORMERS OF THE BETA-SUBUNIT OF TRYPTOPHAN SYNTHASE IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE O-SULFATE; ESCHERICHIA-COLI; PYRIDOXAL 5'-PHOSPHATE; SALMONELLA-TYPHIMURIUM; MONOCLONAL-ANTIBODIES; B-PROTEIN; SYNTHETASE; INACTIVATION; MECHANISM; BINDING	To explain our finding that the dimeric beta subunit of tryptophan synthase is only 50% inactivated by beta-chloro-L-alanine (Ahmed, S. A., Ruvinov, S. B., Kayastha, A. M., and Miles, E. W. (1991) J. Biol. Chem. 266, 21548-21557), we have extended our investigation using spectroscopic, steady-state kinetic, and electrophoretic methods. The spectroscopic properties of the half-active beta2 dimer and the reactivation after alkali treatment show that the inactivation proceeds by an "enamine" mechanism. Although the fully active beta2 dimer associates with the tryptophan synthase alpha subunit to form alpha2beta2 complex, the inactive beta subunits in the half-active enzyme associate weakly or not at all with the alpha subunit. Our results provide evidence for two conformers of the beta subunit in solution: one is rapidly inactivated by beta-chloro-L-alanine and the other is not inactivated. Thermal inactivation studies and non-denaturing polyacrylamide gel electrophoresis of the half-active enzyme show that the beta2 dimer exists in both homologous and heterologous combinations of these two forms. After removal of the reaction products and unreacted beta-chloro-L-alanine from the half-active beta2 dimer by gel filtration, further incubation with beta-chloro-L-alanine results in the loss of 50% of the remaining activity. This result suggests that the subunits undergo rearrangement via an intermediate monomer form to regenerate the two conformers of the active beta subunit. This mechanism of rearrangement is supported by our finding that the extent of inactivation increases at lower concentrations of the beta2 dimer.			AHMED, SA (corresponding author), NIDDKD, BIOCHEM PHARMACOL LAB, BLDG 8, RM 2A-05, BETHESDA, MD 20892 USA.							ADACHI O, 1974, J BIOL CHEM, V249, P5430; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P4233, DOI 10.1021/bi00363a010; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; AHMED SA, 1991, J BIOL CHEM, V266, P21548; Arnone A, 1985, TRANSAMINASES, P138; BALK H, 1981, EUR J BIOCHEM, V121, P105, DOI 10.1111/j.1432-1033.1981.tb06437.x; BARTHOLMES P, 1976, BIOCHEMISTRY-US, V15, P4712, DOI 10.1021/bi00666a027; CHAFFOTTE AF, 1987, J MOL BIOL, V197, P131, DOI 10.1016/0022-2836(87)90615-2; CHAFFOTTE AF, 1984, EUR J BIOCHEM, V139, P47, DOI 10.1111/j.1432-1033.1984.tb07974.x; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; FLURI R, 1971, J BIOL CHEM, V246, P6620; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HATHAWAY GM, 1970, BIOCHEMISTRY-US, V9, P1801, DOI 10.1021/bi00810a020; HATHAWAY GM, 1969, BIOCHEMISTRY-US, V8, P989, DOI 10.1021/bi00831a032; HEILMANN HD, 1981, HOPPESEYLERS Z PHYSL, V342, P1567; HENIS YI, 1989, ALLOSTERIC ENZYMES, P153; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JAGER J, 1991, INT UNION B, V199, P117; JANSONIUS JN, 1985, TRANSAMINASES, P110; JOHNSON R. J., 1970, Methods in Enzymology, V18A, P433, DOI 10.1016/0076-6879(71)18345-0; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUMAGAI H, 1971, BIOCHEM BIOPH RES CO, V44, P1271, DOI 10.1016/S0006-291X(71)80223-1; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LEVITZKI A, 1974, J MOL BIOL, V90, P451, DOI 10.1016/0022-2836(74)90227-7; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1975, BIOCHEM BIOPH RES CO, V64, P248, DOI 10.1016/0006-291X(75)90245-4; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1970, J BIOL CHEM, V245, P6016; MILES EW, 1977, J BIOL CHEM, V252, P6594; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; SEIFERT T, 1985, BIOCHEMISTRY-US, V24, P339, DOI 10.1021/bi00323a016; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; TANIZAWA K, 1983, BIOCHEMISTRY-US, V22, P3594, DOI 10.1021/bi00284a009; THORNBERRY NA, 1991, J BIOL CHEM, V266, P21657; TSCHOPP J, 1980, BIOCHEMISTRY-US, V19, P4521, DOI 10.1021/bi00560a021; UENO H, 1982, BIOCHEMISTRY-US, V21, P4387, DOI 10.1021/bi00261a030; WADA H, 1962, J BIOL CHEM, V237, P127; WILSON DA, 1965, J BIOL CHEM, V240, P4801; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]; ZETINA CR, 1980, J BIOL CHEM, V255, P4381	49	4	4	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23309	23317						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429678				2022-12-27	WOS:A1992JY16300092
J	LEONARD, D; HART, MJ; PLATKO, JV; EVA, A; HENZEL, W; EVANS, T; CERIONE, RA				LEONARD, D; HART, MJ; PLATKO, JV; EVA, A; HENZEL, W; EVANS, T; CERIONE, RA			THE IDENTIFICATION AND CHARACTERIZATION OF A GDP-DISSOCIATION INHIBITOR (GDI) FOR THE CDC42HS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; BOVINE BRAIN CYTOSOL; SACCHAROMYCES-CEREVISIAE GENE; GUANINE-NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN; REGULATORY PROTEIN; MOLECULAR-CLONING; PLASMA-MEMBRANES; CELL POLARITY; RAS GTPASE	The ras-related protein, CDC42Hs, is a 22-kDa GTP-binding protein which is the human homolog of a Saccharomyces cerevisiae yeast-cell-division cycle protein. In attempting to isolate and biochemically characterize mammalian proteins capable of regulating various activities of CDC42Hs, we have identified an activity in bovine brain cytosol which effectively inhibits the dissociation of [H-3]GDP from the platelet- or the Spodoptera frugiperda-expressed CDC42Hs protein. The purification of this activity was achieved by a series of steps which included ammonium sulfate fractionation, DEAE-Sephacel, Mono-Q, and Mono-S chromatographies. The purified CDC42Hs regulatory protein has an apparent molecular weight of 28,000, and cyanogen bromide-generated peptide sequences of this protein were identical to sequences from the carboxyl-terminal portion of rho-GDP-dissociation inhibitor (rho-GDI) (Fukumoto, Y., Kaibuchi, K., Hori, Y., Fujioka, H., Araki, S., Ueda, T., Kikuchi, A., and Takai, Y. (1990) Oncogene 5, 1321-1328). In addition, an Escherichia coli-expressed, glutathione S-transferase-rho-GDI fusion protein fully substitutes for the GDI which we have purified from bovine brain in its ability to inhibit GDP dissociation from CDC42Hs. These findings suggest either that a common regulatory protein (GDI) is capable of inhibiting GDP dissociation from the rho and CDC42Hs proteins or that these two GTP-binding proteins interact with GDI proteins of very similar structure. The purified brain GDI protein shows little ability to inhibit GDP dissociation from the E. coli-expressed CDC42Hs and is capable of only a very weak inhibition of the dissociation of [S-35]guanosine 5'-3-0-(thio)triphosphate (GTPgammaS) from the Spodoptera frugiperda-expressed CDC42. However, brain GDI very effectively inhibits the ability of the human dbl oncogene product to catalyze GDP dissociation from CDC42Hs. In addition to influencing guanine nucleotide association with CDC42Hs, the purified brain GDI protein also appears to catalyze the dissociation of CDC42Hs from the plasma membranes of human placenta and human epidermoid carcinoma (A431) cells. This effect by the GDI protein is observed whether the membrane-associated CDC42Hs is preincubated with GDP, GTPgammaS, or no guanine nucleotides, and occurs over a similar concentration range as that necessary for the inhibition of the intrinsic GDP dissociation.	GENENTECH INC,DEPT CELL BIOL & PROT CHEM,S SAN FRANCISCO,CA 94080; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Roche Holding; Genentech; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University	LEONARD, D (corresponding author), CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,SCHURMAN HALL,ITHACA,NY 14853, USA.		Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; Henzel, William/0000-0003-2940-3797; Hart, Matthew/0000-0002-2683-480X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVANS T, 1986, J BIOL CHEM, V261, P7052; Evans T, 1991, CURR OPIN CELL BIOL, V3, P185, DOI 10.1016/0955-0674(91)90137-N; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GRAZIANI G, ONCOGENE, V7, P229; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HART MJ, 1990, J BIOL CHEM, V265, P5990; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1991, J BIOL CHEM, V266, P7646; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; UEDA T, 1990, J BIOL CHEM, V265, P9373; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	46	158	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22860	22868						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429634				2022-12-27	WOS:A1992JY16300026
J	MARTINPARRAS, L; HERNANDEZ, P; MARTINEZROBLES, ML; SCHVARTZMAN, JB				MARTINPARRAS, L; HERNANDEZ, P; MARTINEZROBLES, ML; SCHVARTZMAN, JB			INITIATION OF DNA-REPLICATION IN COLE1 PLASMIDS CONTAINING MULTIPLE POTENTIAL ORIGINS OF REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS TYPE-1 DNA; GEL-ELECTROPHORESIS; BACTERIAL PLASMIDS; YEAST CHROMOSOMES; RIBOSOMAL DNA; RNA-I; INVIVO; AMPLIFICATION; CEREVISIAE; DROSOPHILA	We have investigated the frequency of replication origin usage in bacterial plasmids containing more than one potential origin. Escherichia coli recA- cells were selectively transformed with pBR322 monomers, dimers, or trimers. Plasmid DNA was isolated and digested with a restriction enzyme that cut the monomer only once, and the replicative intermediates (RIs) were analyzed by neutral/neutral two-dimensional agarose gel electrophoresis. Evidence for initiation outside the linearized plasmid was found only for oligomers. Moreover, in dimers, the intensity of the signal indicative for external initiation was equivalent to that reflecting internal initiation, whereas it was approximately twice as strong in trimers. To determine whether initiation could occur simultaneously at two origins in a single plasmid, we studied the replication of a neodimer in which both units could be unambiguously distinguished. The results showed that although both origins were equally competent to initiate replication, only one was active per plasmid. These observations strongly suggest that in ColE1 plasmids, replication initiates at a single site even when there are several identical potential origins per plasmid. In addition to the conventional two-dimensional gel patterns, novel specific patterns were observed with intensities that varied from one DNA sample to another. These unique patterns were the result of breakage of the RIs at a replication fork. This type of breakage changes both the mass and shape of RIs. When the entire population of RIs is affected, a new population of molecules is formed that may generate a novel pattern in two-dimensional gels.	CSIC,CTR INVEST BIOL,VELAZQUEZ 144,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Schvartzman, Jorge B/J-9171-2014	Pablo, Hernandez/0000-0002-8113-1277				BAKER TA, 1991, NATURE, V353, P794, DOI 10.1038/353794a0; BELL L, 1983, ANAL BIOCHEM, V130, P527, DOI 10.1016/0003-2697(83)90628-0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BREWER BJ, 1988, CANCER CELL, V6, P229; BRUAND C, 1991, EMBO J, V10, P2171, DOI 10.1002/j.1460-2075.1991.tb07752.x; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; CROSA JH, 1975, MOL GEN GENET, V140, P39, DOI 10.1007/BF00268987; CROSA JH, 1980, J BIOL CHEM, V255, P1075; CROSA JH, 1976, NATURE, V261, P516, DOI 10.1038/261516a0; DAHR V, 1991, MOL CELL BIOL, V11, P6268; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; Hamlin JL, 1991, CURR OPIN CELL BIOL, V3, P414, DOI 10.1016/0955-0674(91)90068-A; HECK MMS, 1990, J CELL BIOL, V110, P903, DOI 10.1083/jcb.110.4.903; HERNANDEZ P, 1988, PLANT MOL BIOL, V10, P413, DOI 10.1007/BF00014947; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Kornberg A., 1992, DNA REPLICATION; KRYSAN PJ, 1991, MOL CELL BIOL, V11, P1464, DOI 10.1128/MCB.11.3.1464; LACATENA RM, 1981, NATURE, V294, P623, DOI 10.1038/294623a0; LEWIN B, 1990, GENES, V4, P857; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MASAI H, 1990, J BIOL CHEM, V265, P15124; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; NAWOTKA KA, 1988, MOL CELL BIOL, V8, P1408, DOI 10.1128/MCB.8.4.1408; NORDSTROM K, 1984, PLASMID, V12, P71, DOI 10.1016/0147-619X(84)90054-4; Pritchard R. H., 1978, DNA SYNTHESIS PRESEN, P1; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; SCOTT JR, 1984, MICROBIOL REV, V48, P1; SKRYABIN KG, 1984, NUCLEIC ACIDS RES, V12, P2955, DOI 10.1093/nar/12.6.2955; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; SUMMERS DK, 1984, CELL, V36, P1097, DOI 10.1016/0092-8674(84)90060-6; TIMMIS K, 1974, P NATL ACAD SCI USA, V71, P4556, DOI 10.1073/pnas.71.11.4556; TIMMIS K, 1976, NATURE, V261, P512, DOI 10.1038/261512a0; TOMIZAWA J, 1981, P NATL ACAD SCI USA, V48, P6096; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WALDECK W, 1984, EMBO J, V3, P2173, DOI 10.1002/j.1460-2075.1984.tb02109.x; WALMSLEY RM, 1984, MOL GEN GENET, V195, P260, DOI 10.1007/BF00332757; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WOOD DC, 1984, J BIOL CHEM, V259, P1184; YEE TW, 1990, P NATL ACAD SCI USA, V87, P1278, DOI 10.1073/pnas.87.4.1278	51	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22496	22505						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429600				2022-12-27	WOS:A1992JW71900080
J	HUTH, JR; MOUNTJOY, K; PERINI, F; BEDOWS, E; RUDDON, RW				HUTH, JR; MOUNTJOY, K; PERINI, F; BEDOWS, E; RUDDON, RW			DOMAIN-DEPENDENT PROTEIN FOLDING IS INDICATED BY THE INTRACELLULAR KINETICS OF DISULFIDE BOND FORMATION OF HUMAN CHORIONIC GONADOTROPIN-BETA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOCARCINOMA CELLS; RIBONUCLEASE-A; FORM; INTERMEDIATE; SECRETION; NMR; LYSOZYME; PATHWAY; BINDING; REGION	We have measured the intracellular rates of formation of the six disulfide bonds in the human chorionic gonadotropin beta subunit (hCG-beta) to determine whether the folding pathway of this molecule can be described by a simple sequential model. If such a model is correct, the formation of disulfide bonds, which is indicative of tertiary structural changes during protein folding, should occur in a discrete order. The individual rates of disulfide bridging were determined by identifying the extent of disulfide bond formation in hCG-beta intermediates purified from choriocarcinoma cells that had been metabolically labeled for 40 or 120 s and chased for 0 to 25 min. The results of these kinetic studies describe a folding pathway in which the disulfide bonds between cysteines 34-88, 38-57, 9-90 and 23-72 stabilize, in a discrete order, the putative domain(s) involving amino acids 1-90 of hCG-beta. However, the S-S bonds 93-100 and 26-110 begin to form before the complete formation of the disulfide bonds that stabilize the amino acid 1-90 domain(s), and continue to form after complete formation of these disulfide bonds, suggesting that hCG-beta does not fold by a simple sequential pathway. The order of completion of each of the six disulfide bonds of hCG-beta is: 34-88 (t1/2 = 1-2 min), 38-57 (t1/2 = 2-3 min), 9-90 and 23-72, 93-100, and 26-110. Moreover, 60-100% of each of the six disulfide bonds form posttranslationally, and nonnative disulfide bonds do not form in detectable amounts during intracellular folding of hCG-beta.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,600 S 42ND ST,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER; NCI NIH HHS [CA32949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CHEN F, 1991, J BIOL CHEM, V266, P6904; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; FLANAGAN JM, 1992, P NATL ACAD SCI USA, V89, P748, DOI 10.1073/pnas.89.2.748; GLINIAK BC, 1991, J BIOL CHEM, V266, P22991; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P2629, DOI 10.1073/pnas.89.7.2629; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; HEROLD M, 1991, BIOCHEMISTRY-US, V30, P3612, DOI 10.1021/bi00229a004; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1992, IN PRESS MOL ENDOCRI; LESK AM, 1981, P NATL ACAD SCI-BIOL, V78, P4304, DOI 10.1073/pnas.78.7.4304; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; MISE T, 1981, J BIOL CHEM, V256, P6587; PETERS BP, 1984, J BIOL CHEM, V259, P5123; POLLAK S, 1990, ENDOCRINOLOGY, V126, P199, DOI 10.1210/endo-126-1-199; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; RUDDON RW, 1979, P NATL ACAD SCI USA, V76, P5143, DOI 10.1073/pnas.76.10.5143; RUDDON RW, 1989, ENDOCRINOLOGY, V124, P862, DOI 10.1210/endo-124-2-862; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUDDON RW, 1981, J BIOL CHEM, V256, P1389; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SPACKMAN DH, 1960, J BIOL CHEM, V235, P648; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	34	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21396	21403						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400452				2022-12-27	WOS:A1992JV01100024
J	ISSAKIDIS, E; MIGINIACMASLOW, M; DECOTTIGNIES, P; JACQUOT, JP; CRETIN, C; GADAL, P				ISSAKIDIS, E; MIGINIACMASLOW, M; DECOTTIGNIES, P; JACQUOT, JP; CRETIN, C; GADAL, P			SITE-DIRECTED MUTAGENESIS REVEALS THE INVOLVEMENT OF AN ADDITIONAL THIOREDOXIN-DEPENDENT REGULATORY SITE IN THE ACTIVATION OF RECOMBINANT SORGHUM LEAF NADP-MALATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME REGULATION; ZEA-MAYS; REDUCTIVE ACTIVATION; PHENOTYPIC SELECTION; KINETIC-PROPERTIES; LIGHT-ACTIVATION; ACTIVE DITHIOL; FERREDOXIN; CHLOROPLASTS; LEAVES	The chloroplastic enzyme NADP-malate dehydrogenase is activated by a reversible thiol/disulfide interchange with reduced thioredoxin. Its target disulfide bridge is considered to be located at the amino terminus. To further substantiate the regulatory role of this disulfide, site-directed mutagenesis has been used to replace each or both of the amino-terminal cysteines of the sorghum leaf NADP-malate dehydrogenase, expressed in Escherichia coli, by serines. A truncation mutant lacking the amino terminus has also been produced. Surprisingly, the mutant proteins still required activation by reduced thioredoxin. However, their activation was almost instantaneous, whereas the native enzyme reached full activity after a 10-20 min preincubation. The s1/2 for reduced thioredoxin was decreased 2-fold in the mutants, but their K(m) values for NADPH and oxaloacetate did not change significantly. The inhibition of activation by NADP and inhibition of activity by thiol-derivatizing agents were also retained. These results are interpreted as an indication that two thioredoxin-dependent reduction steps are involved in NADP-dependent malate dehydrogenase light activation, hence that two disulfides per monomer participate in the process. The overall activation rate would depend on a conformational change following the reduction of the amino-terminal disulfide bridge. The amino terminus also plays a role in the dimerization of the protein.	UNIV PARIS 11, PHYSIOL VEGETALE MOLEC LAB,CNRS, UNITE RECH ASSOCIEE 1128,BT 430, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Jacquot, Jean-Pierre/A-1571-2012	Jacquot, Jean-Pierre/0000-0003-4975-8587; Issakidis-Bourguet, Emmanuelle/0000-0002-6144-4364				ABERG A, 1989, J BIOL CHEM, V264, P12249; ASHTON AR, 1983, ARCH BIOCHEM BIOPHYS, V227, P406, DOI 10.1016/0003-9861(83)90470-8; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DECOTTIGNIES P, 1990, CURRENT RES PHOTOSYN, V4, P247; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V252, P426, DOI 10.1016/0003-9861(87)90049-X; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V256, P372, DOI 10.1016/0003-9861(87)90458-9; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FERTE N, 1986, EUR J BIOCHEM, V154, P587, DOI 10.1111/j.1432-1033.1986.tb09439.x; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HATCH MD, 1970, ANN REV PLANT PHYSIO, V21, P141, DOI 10.1146/annurev.pp.21.060170.001041; HATCH MD, 1969, BIOCHEM BIOPH RES CO, V34, P589, DOI 10.1016/0006-291X(69)90778-5; JACQUOT JP, 1984, PHYSIOL VEG, V22, P487; JACQUOT JP, 1991, EUR J BIOCHEM, V199, P47, DOI 10.1111/j.1432-1033.1991.tb16090.x; JACQUOT JP, 1984, ARCH BIOCHEM BIOPHYS, V228, P170, DOI 10.1016/0003-9861(84)90058-4; JENKINS CLD, 1986, PLANT SCI, V45, P1, DOI 10.1016/0168-9452(86)90064-6; KAGAWA T, 1977, ARCH BIOCHEM BIOPHYS, V184, P290, DOI 10.1016/0003-9861(77)90353-8; KAGAWA T, 1988, ARCH BIOCHEM BIOPHYS, V260, P674, DOI 10.1016/0003-9861(88)90497-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMARECHAL P, 1989, J CHROMATOGR, V477, P305, DOI 10.1016/S0021-9673(01)89639-4; MAYHEW SG, 1971, ANAL BIOCHEM, V42, P191, DOI 10.1016/0003-2697(71)90025-X; METZLER MC, 1989, PLANT MOL BIOL, V12, P713, DOI 10.1007/BF00044162; MIGINIACMASLOW M, 1990, BIOCHIM BIOPHYS ACTA, V1017, P273, DOI 10.1016/0005-2728(90)90193-8; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; PERROTRECHENMANN C, 1983, PLANT SCI LETT, V30, P219, DOI 10.1016/0304-4211(83)90221-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIBE R, 1983, PLANTA, V157, P548, DOI 10.1007/BF00396887; SCHEIBE R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P1, DOI 10.1016/0167-4838(91)90212-I; SCHEIBE R, 1984, BIOCHIM BIOPHYS ACTA, V788, P241, DOI 10.1016/0167-4838(84)90267-X; SCHURMANN P, 1979, BIOCHIM BIOPHYS ACTA, V569, P309, DOI 10.1016/0005-2744(79)90067-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; WOLOSIUK RA, 1977, FEBS LETT, V81, P253, DOI 10.1016/0014-5793(77)80529-2	42	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21577	21583						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400468				2022-12-27	WOS:A1992JV01100050
J	MURAKAMIMUROFUSHI, K; SHIODA, M; KAJI, K; YOSHIDA, S; MUROFUSHI, H				MURAKAMIMUROFUSHI, K; SHIODA, M; KAJI, K; YOSHIDA, S; MUROFUSHI, H			INHIBITION OF EUKARYOTIC DNA POLYMERASE-ALPHA WITH A NOVEL LYSOPHOSPHATIDIC ACID (PHYLPA) ISOLATED FROM MYXOAMOEBAE OF PHYSARUM-POLYCEPHALUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CULTURED MESANGIAL CELLS; FACTOR MESSENGER-RNAS; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-C; STIMULATION; METABOLISM; RECEPTOR; COMPLEX; INFLUX	A specific inhibitor of DNA polymerase a was isolated from the lipid fraction prepared from myxoamoebae of a true slime mold, Physarum polycephalum. The purified substance was subjected to structural studies by fast atom bombardment mass spectroscopy, infrared spectroscopy, and two-dimensional nuclear magnetic resonance spectroscopy. The structure of this substance was thereby suggested to be a novel lysophosphatidic acid (LPA) composed of cyclic phosphate and cyclopropane-containing hexadecanoic acid. Then we named this substance PHYLPA (Physarum LPA). PHYLPA inhibited more than 80% of the affinity-purified calf thymus DNA polymerase alpha activity at a concentration of 10 mug/ml (approximately 20 muM). Inhibition was observed for DNA polymerase alpha but not for DNA polymerase beta or gamma from various eukaryotic species, nor did it inhibit DNA polymerase I from E. coli. From kinetic analyses, the inhibition was considered to be caused by the interaction of PHYLPA with the template DNA.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT PHYSIOL CHEM & NUTR,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,ITABASHI KU,TOKYO 173,JAPAN; NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,SYOWA KU,NAGOYA,AICHI 466,JAPAN	University of Tokyo; University of Tokyo; Nagoya University	MURAKAMIMUROFUSHI, K (corresponding author), OCHANOMIZU UNIV,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 112,JAPAN.							AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; ALTIN JG, 1987, BIOCHEM J, V247, P613, DOI 10.1042/bj2470613; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; CERNY RL, 1986, ORG MASS SPECTROM, V21, P655, DOI 10.1002/oms.1210211009; COCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890; DITTMER JC, 1964, J LIPID RES, V5, P126; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; Fansler B S, 1974, Methods Enzymol, V29, P53; HAJRA AK, 1986, ENZYMES LIPID METABO, V2, P199; HOKIN MR, 1953, J BIOL CHEM, V203, P967; KENNEDY EUGENE P., 1962, HARVEY LECTURES, V57, P143; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; MAY WS, 1986, P NATL ACAD SCI USA, V83, P1281, DOI 10.1073/pnas.83.5.1281; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MURAKAMIMUROFUSHI K, 1984, CELL STRUCT FUNCT, V9, P311, DOI 10.1247/csf.9.311; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHSAKO S, 1981, J BIOL CHEM, V256, P945; OTONAESS AB, 1976, BIOCHIM BIOPHYS ACTA, V454, P193; PHILIPSON KD, 1984, J BIOL CHEM, V259, P16; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SCHIEBEL W, 1980, FEBS LETT, V121, P81, DOI 10.1016/0014-5793(80)81271-3; SHIODA M, 1987, BIOCHEM BIOPH RES CO, V146, P61, DOI 10.1016/0006-291X(87)90690-5; SHIODA M, 1991, BIOCHEMISTRY-US, V30, P11403, DOI 10.1021/bi00112a006; SHIODA M, 1982, P NATL ACAD SCI-BIOL, V79, P7209, DOI 10.1073/pnas.79.23.7209; SIEGMANN DW, 1987, BIOCHEM BIOPH RES CO, V145, P228, DOI 10.1016/0006-291X(87)91310-6; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TANAKA M, 1987, CANCER RES, V47, P5971; TANIGUCHI M, 1984, CELL STRUCT FUNCT, V3, P181; TYSON CA, 1976, J BIOL CHEM, V251, P1326; UMEKAWA H, 1988, J BIOCHEM-TOKYO, V104, P333, DOI 10.1093/oxfordjournals.jbchem.a122469; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YOSHIDA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P61, DOI 10.1016/0167-4781(89)90130-9; YOSHIDA S, 1979, J BIOCHEM-TOKYO, V85, P1387, DOI 10.1093/oxfordjournals.jbchem.a132465; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	40	83	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21512	21517						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400463				2022-12-27	WOS:A1992JV01100040
J	STETTLER, S; MARIOTTE, S; RIVA, M; SENTENAC, A; THURIAUX, P				STETTLER, S; MARIOTTE, S; RIVA, M; SENTENAC, A; THURIAUX, P			AN ESSENTIAL AND SPECIFIC SUBUNIT OF RNA POLYMERASE-III-(C) IS ENCODED BY GENE RPC34 IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON SUBUNITS; GROWTH-RATE; YEAST; TRANSCRIPTION; MUTANTS; MUTAGENESIS; PROTEIN; FAMILY; DNA; SELECTION	The RPC34 gene of Saccharomyces cerevisiae was cloned by immunological screening, using antibodies raised against the C34 polypeptide of the RNA polymerase III (C). This single copy gene was located near the centromere of chromosome XIV. It included a coding sequence of 317 amino acids that strictly matched two internal oligopeptides of C34. This polypeptide is a specific component of RNA polymerase III, with no significant homology to any other RNA polymerase subunit known so far. It is an essential subunit, since inactivation by deletion or nonsense mutations led to a recessive lethal phenotype. Moreover, a partially blocked mutant, rpc34-F297, had a reduced tRNA synthesis in vivo but no detectable effect on 5 S RNA synthesis. The latter phenotype was observed for all conditionally defective RNA polymerase III mutants isolated so far.	CTR ETUD SACLAY, CEA,DEPT BIOL CELLULAIRE & MOLEC, SERV BIOCHIM & GENET MOLEC,BAT 142, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; DALESSIO JM, 1979, J BIOL CHEM, V254, P1282; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GUDENUS R, 1988, GENETICS, V119, P517; HOTTINGER H, 1982, MOL GEN GENET, V188, P219, DOI 10.1007/BF00332678; HUET J, 1985, J BIOL CHEM, V260, P5304; HUISMAN O, 1987, GENETICS, V116, P191; JAEHNING JA, 1977, J BIOL CHEM, V252, P8762; JAMES P, 1991, J BIOL CHEM, V266, P5616; JONES EW, 1977, GENETICS, V85, P23; KLAPHOLZ S, 1982, GENETICS, V100, P387; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LILJELUND P, 1992, IN PRESS P NATL ACAD; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; MCGOLDRICK EM, 1989, J GEN MICROBIOL, V135, P2407; MORTIMER RK, 1991, METHOD ENZYMOL, V194, P827; MORTIN MA, 1982, DEV BIOL, V103, P343; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; NEIGEBORN L, 1990, NUCLEIC ACIDS RES, V18, P4179, DOI 10.1093/nar/18.14.4179; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIVA M, 1986, P NATL ACAD SCI USA, V83, P1554, DOI 10.1073/pnas.83.6.1554; RIVA M, 1982, J BIOL CHEM, V257, P4570; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUET A, 1980, J BIOL CHEM, V255, P6450; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SENTENAC A, 1992, IN PRESS TRANSCRIPTI; SHERMAN F, 1991, METHOD ENZYMOL, V194, P1; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; Treich Isabelle, 1992, Gene Expression, V2, P31; VALENZUELA P, 1976, BIOCHEM BIOPH RES CO, V71, P1319, DOI 10.1016/0006-291X(76)90799-3; WALDRON C, 1975, J BACTERIOL, V122, P855, DOI 10.1128/JB.122.3.855-865.1975; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	52	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21390	21395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400451				2022-12-27	WOS:A1992JV01100023
J	GRISSMER, S; GHANSHANI, S; DETHLEFS, B; MCPHERSON, JD; WASMUTH, JJ; GUTMAN, GA; CAHALAN, MD; CHANDY, KG				GRISSMER, S; GHANSHANI, S; DETHLEFS, B; MCPHERSON, JD; WASMUTH, JJ; GUTMAN, GA; CAHALAN, MD; CHANDY, KG			THE SHAW-RELATED POTASSIUM CHANNEL GENE, KV3.1, ON HUMAN CHROMOSOME-11, ENCODES THE TYPE-L K+ CHANNEL IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LYMPHOCYTES-T; FUNCTIONAL EXPRESSION; RAT-BRAIN; MOLECULAR-CLONING; MEMBRANE-PROTEIN; DNA; CDNA; INACTIVATION; FRAGMENTS; DIVERSITY	T lymphocytes exhibit three distinct types of voltage-gated K+channels, n, n', and l, that are distributed in the T cell lineage according to subset, as well as the cells' activation and developmental status. Type l K+ channels are found sparingly in cytotoxic T cells from normal mice and abundantly in a specific T cell subset (CD4- CD8- Thy1+) from mice with autoimmune disease. Here, we show that the mouse Kv3.1 gene, when expressed in Xenopus oocytes, encodes a channel with properties remarkably similar to those of the l-type channel. Kv3.1 transcripts were found in T cells isolated from the lymph nodes of MRL-lpr mice with systemic lupus erythematosus and in a human lymphoma cell line that also expresses the l channel phenotype. By these criteria, we conclude that Kv3.1 encodes the voltage-gated type l K+ channel in lymphocytes. The Kv3.1 gene maps to human chromosome 11; the related Kv1.1 and Kv3.2 genes are localized on human chromosome 12, while the IsK gene maps to human chromosome 21.	UNIV CALIF IRVINE, SCH MED, DEPT PHYSIOL & BIOPHYS, RM C154, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT MICROBIOL & MOLEC GENET, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine			McPherson, John D/D-2633-2017	McPherson, John D/0000-0001-8049-9347	NIGMS NIH HHS [GM41514] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline; PHS HHS [24783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R37NS014609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTALI B, 1992, J BIOL CHEM, V267, P8650; Cahalan M D, 1987, Adv Exp Med Biol, V213, P85; CAHALAN MD, 1991, CURR TOP MEMBR, V39, P357; CAHALAN MD, 1985, J PHYSIOL-LONDON, V358, P197, DOI 10.1113/jphysiol.1985.sp015548; CAI YC, 1992, DNA CELL BIOL, V11, P163, DOI 10.1089/dna.1992.11.163; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHANDY KG, 1990, EUR J IMMUNOL, V20, P747; CHANDY KG, 1986, SCIENCE, V233, P1197, DOI 10.1126/science.2426784; CIRULLO RE, 1983, SOMAT CELL GENET, V9, P215, DOI 10.1007/BF01543178; CURRAN ME, 1992, GENOMICS, V12, P729, DOI 10.1016/0888-7543(92)90302-9; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1985, J NEUROIMMUNOL, V10, P71, DOI 10.1016/0165-5728(85)90035-9; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P379, DOI 10.1085/jgp.89.3.379; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GHANSHANI S, 1992, GENOMICS, V12, P190, DOI 10.1016/0888-7543(92)90365-Y; GRISSMER S, 1989, BIOPHYS J, V55, P203, DOI 10.1016/S0006-3495(89)82793-6; GRISSMER S, 1990, J IMMUNOL, V145, P2105; GRISSMER S, 1988, J IMMUNOL, V141, P1137; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LEWIS RS, 1988, SCIENCE, V239, P771, DOI 10.1126/science.2448877; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; OVERHAUSER J, 1987, NUCLEIC ACIDS RES, V15, P4617, DOI 10.1093/nar/15.11.4617; RUDY B, 1991, J NEUROSCI RES, V29, P401, DOI 10.1002/jnr.490290316; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SHAPIRO MS, 1988, BIOPHYS J, V53, pA550; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	46	79	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20971	20979						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400413				2022-12-27	WOS:A1992JT97800073
J	KANG, S; WELLS, RD				KANG, S; WELLS, RD			CENTRAL NON-PUR.PYR SEQUENCES IN OLIGO(DG.DC) TRACTS AND METAL-IONS INFLUENCE THE FORMATION OF INTRAMOLECULAR DNA TRIPLEX ISOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; HANDED Z-DNA; H-DNA; PLASMIDS; CELLS; CONFORMATIONS; REPLICATION; SPECIFICITY; POLYPURINE; ADOPT	The effect of the central non-Pur.Pyr sequences in oligo(dG.dC) inserts on determining the type of intramolecular DNA triplex isomers formed in negatively supercoiled plasmids was investigated. Different triplex types (H-r3, H-r5, and H-y3), revealed by a combination of chemical probing and Maxam-Gilbert sequencing reactions, were adopted by the oligo(dG.dC) tracts depending on the length and composition of the central non-Pur.Pyr sequences (0, 3, or 5 base pairs) and the kind of metal ions. The H-r3 triplex conformer, one isomer of a Pur.Pur.Pyr structure, was formed in the (C)20 and (C)10GCG(C)10 inserts in plasmids in the presence of certain metal ions. Interestingly, H-r5, the other isomer of the Pur.Pur.Pyr triplex which had not been detected previously, was formed in a (C)9GAATT(C)9 insert in the presence of either Mg2+ or Ca2+. Alternatively, H-y3, one isomer of a Pyr.Pur.Pyr triplex, was formed in the (C)9GAATT(C)9 insert in the absence of metal ions. Thus, central non-Pur.Pyr sequences and metal ions play a role as determinants of the types of intramolecular triplexes formed; they also reduce the requirement of longer Pur.Pyr repeat sequences to form intramolecular triplexes. Furthermore, the effects of MgCl2 concentration and pH on the formation of triplex isomers were examined. The Pur.Pur.Pyr conformations (H-r3 and H-r5) may be the favored conformations in the cellular milieu, since they are stable at physiological pH and metal ion concentration.	TEXAS A&M UNIV SYST,TEXAS MED CTR,INST BIOSCI & TECHNOL,COLL STN,TX 77843	Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [GM30822] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BRINTON BT, 1991, J BIOL CHEM, V266, P5153; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; GLOVER JNM, 1990, BIOCHEMISTRY-US, V29, P11110, DOI 10.1021/bi00502a014; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KANG S, 1992, J BIOL CHEM, V267, P19435; KANG S, 1992, J BIOL CHEM, V267, P1259; KARLOVSKY P, 1990, FEBS LETT, V274, P39, DOI 10.1016/0014-5793(90)81324-H; KLEIN RD, 1982, J BIOL CHEM, V257, P2954; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; KOHWI Y, 1991, NUCLEIC ACIDS RES, V19, P4267; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCLEAN MJ, 1987, NUCLEIC ACIDS RES, V15, P6917, DOI 10.1093/nar/15.17.6917; MCLEAN MJ, 1986, P NATL ACAD SCI USA, V83, P5884, DOI 10.1073/pnas.83.16.5884; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PANYUTIN IG, 1992, J BIOL CHEM, V267, P5495; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; USDIN K, 1989, J BIOL CHEM, V264, P15681; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20887	20891						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400403				2022-12-27	WOS:A1992JT97800059
J	COLLINS, RN; WARREN, G				COLLINS, RN; WARREN, G			SPHINGOLIPID TRANSPORT IN MITOTIC HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRING PYRIDINE-NUCLEOTIDE; VESICULAR STOMATITIS-VIRUS; SYNTHESIZED G-PROTEIN; GOLGI-APPARATUS; BREFELDIN-A; RAT-LIVER; GANGLIOSIDE BIOSYNTHESIS; MEIOTIC MATURATION; CERAMIDE SYNTHESIS; SURFACE FUNCTIONS	Mitotic and interphase HeLa cells were labeled with [H-3]serine. Ceramide and its derivatives, lactosylceramide and sphingomyelin, were biosynthetically labeled under both conditions. Only in the absence of nocodazole, as the cells entered telophase, was an additional glycosphingolipid synthesized which was identified as G(A2) (GalNAc(beta1,4)Gal(beta1,4)Glc(beta1,1)Cer). Ceramide, the basic sphingolipid precursor, is synthesized in the endoplasmic reticulum, whereas its immediate derivatives are synthesized in early Golgi compartments. Transport of newly synthesized proteins from the endoplasmic reticulum to the Golgi is inhibited in mitotic cells while ceramide acquires early Golgi modifications under the same conditions, suggesting that ceramide can be delivered to the Golgi by a different route. Since G(A2) is synthesized in late Golgi, its absence in mitotic cells strongly argues for an in vivo inhibition of intra-Golgi transport, an observation with important implications for the mechanism of Golgi division.			COLLINS, RN (corresponding author), IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ANSELL GB, 1982, NEW COMPREHENSIVE BI, V4, P1; BASU M, 1987, METHOD ENZYMOL, V138, P575; BERLIN RD, 1980, J CELL BIOL, V85, P660, DOI 10.1083/jcb.85.3.660; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CLARK RW, 1986, J CELL BIOL, V103, pA305; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; FAWCETT DW, 1965, J HISTOCHEM CYTOCHEM, V13, P75, DOI 10.1177/13.2.75; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; FOLCH J, 1957, J BIOL CHEM, V226, P497; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GRAY GM, 1967, BIOCHIM BIOPHYS ACTA, V144, P511, DOI 10.1016/0005-2760(67)90039-2; HESKETH TR, 1984, J CELL BIOL, V98, P2250, DOI 10.1083/jcb.98.6.2250; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KEENAN TW, 1974, J BIOL CHEM, V249, P310; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KREINER T, 1990, CELL REGUL, V1, P415, DOI 10.1091/mbc.1.5.415; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEAF DS, 1990, DEV BIOL, V141, P1, DOI 10.1016/0012-1606(90)90097-3; LI SC, 1970, J BIOL CHEM, V245, P5153; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PINES J, 1990, New Biologist, V2, P389; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; PYPAERT M, 1987, EUR J CELL BIOL, V45, P23; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; SAGER PR, 1984, CELL, V39, P275, DOI 10.1016/0092-8674(84)90005-9; SAITO M, 1984, BIOCHEMISTRY-US, V23, P1043, DOI 10.1021/bi00301a001; SCHACHTER H, 1980, BIOCH GLYCOPROTEINS, P85; SINGH I, 1980, ARCH BIOCHEM BIOPHYS, V202, P93, DOI 10.1016/0003-9861(80)90409-9; SRIBNEY M, 1966, BIOCHIM BIOPHYS ACTA, V125, P542, DOI 10.1016/0005-2760(66)90042-7; STANLEY P, 1980, ACS SYM SER, V128, P213; STEIN J, 1982, TECH LIPID MEMBR BIO, V404, P1; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1983, J CELL BIOL, V97, P1623, DOI 10.1083/jcb.97.5.1623; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YUSUF HKM, 1983, P NATL ACAD SCI-BIOL, V80, P7075, DOI 10.1073/pnas.80.23.7075; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	59	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24906	24911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447226				2022-12-27	WOS:A1992KA26300111
J	STEFFAN, JS; MCALISTERHENN, L				STEFFAN, JS; MCALISTERHENN, L			ISOLATION AND CHARACTERIZATION OF THE YEAST GENE ENCODING THE MDH3 ISOZYME OF MALATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-POLYACRYLAMIDE GELS; SODIUM DODECYL-SULFATE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ISOCITRATE DEHYDROGENASE; CITRATE SYNTHASE; DISRUPTION; PROTEINS; PEROXISOMES; CLONING	The MDH3 isozyme of Saccharomyces cerevisiae was purified from a haploid strain containing disruptions in genomic loci encoding the mitochondrial MDH1 and nonmitochondrial MDH2 isozymes. Partial amino acid sequence analysis of the purified enzyme was conducted and used to plan polymerase chain reaction techniques to clone the MDH3 gene. The isolated gene was found to encode a 343-residue polypeptide with a molecular weight of 37,200. The deduced amino acid sequence was closely related to those of MDH1 (50% residue identity) and of MDH2 (43% residue identity). The MDH3 sequence was found to contain a carboxyl-terminal SKL tripeptide, characteristic of many peroxisomal enzymes, and immunochemical analysis was used to confirm organellar localization of the MDH3 isozyme. Levels of MDH3 were determined to be elevated in cells grown with acetate as a carbon source, and under these conditions, MDH3 contributed approximately 10% of the total cellular malate dehydrogenase activity. Disruption of the chromosomal MDH3 locus produced a reduction in cellular growth rates on acetate, consistent with the presumed function of this isozyme in the glyoxylate pathway of yeast. Combined disruption of MDH1, MDH2, and MDH3 loci in a haploid strain resulted in the absence of detectable cellular malate dehydrogenase activity.	UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIGMS NIH HHS [GM-33218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATZPODIEN W, 1968, EUR J BIOCHEM, V7, P58, DOI 10.1111/j.1432-1033.1968.tb19573.x; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAUM G, 1982, J BIOL CHEM, V257, P3028; DICKMAN ER, 1976, THESIS YESHIVA U NEW; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GERGEN JP, 1979, NUCLEIC ACIDS RES, V7, P2115, DOI 10.1093/nar/7.8.2115; GIETL C, 1987, ISOZYMES-CURR T BIOL, V16, P175; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HAGELE E, 1978, EUR J BIOCHEM, V83, P67, DOI 10.1111/j.1432-1033.1978.tb12069.x; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOH T, 1987, J BIOL CHEM, V262, P15127; JOH T, 1987, BIOCHEMISTRY-US, V26, P2515, DOI 10.1021/bi00383a017; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KISPAL G, 1991, ARCH BIOCHEM BIOPHYS, V286, P132, DOI 10.1016/0003-9861(91)90018-E; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Maniatis T., 1982, MOL CLONING; Margulis L, 1970, ORIGIN EUKARYOTIC CE; MCALISTER L, 1982, J BIOL CHEM, V257, P7181; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MCALISTERHENN L, 1987, NUCLEIC ACIDS RES, V15, P4993, DOI 10.1093/nar/15.12.4993; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; MINARD KI, 1992, J BIOL CHEM, V267, P17458; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; NISHIYAMA M, 1986, J BIOL CHEM, V261, P14178; RODERICK SL, 1986, J BIOL CHEM, V261, P9461; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH K, 1986, BIOCHIM BIOPHYS ACTA, V884, P109, DOI 10.1016/0304-4165(86)90233-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEFFAN JS, 1991, ARCH BIOCHEM BIOPHYS, V287, P276, DOI 10.1016/0003-9861(91)90479-3; THOMPSON LM, 1988, BIOCHEMISTRY-US, V27, P8393, DOI 10.1021/bi00422a015; WANG Y, 1988, BIOTECHNIQUES, V6, P843; WATERHAM HR, 1992, J BACTERIOL, V174, P4057, DOI 10.1128/jb.174.12.4057-4063.1992	48	86	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24708	24715						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447211				2022-12-27	WOS:A1992KA26300084
J	YU, L; WEI, YY; USUI, S; YU, CA				YU, L; WEI, YY; USUI, S; YU, CA			CYTOCHROME-B(560) (QPS1) OF MITOCHONDRIAL SUCCINATE-UBIQUINONE REDUCTASE - IMMUNOCHEMISTRY, CLONING, AND NUCLEOTIDE SEQUENCING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; OXIDOREDUCTASE COMPLEX-II; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; C-REDUCTASE; DEHYDROGENATING SYSTEM; BEEF-HEART; MEMBRANE; RECONSTITUTION; FLAVOPROTEIN	Mitochondrial succinate-ubiquinone reductase is composed of two parts, a water-soluble succinate dehydrogenase and a two-polypeptide membrane-anchoring protein fraction (QPs). The larger polypeptide of QPs is believed to be associated with cytochrome b560 (QPs1). The structure of QPs1 was studied by immunochemistry and molecular cloning and sequencing. Antibodies against QPs1 were raised in rabbits, purified, and characterized by enzyme-linked immunosorbent assay and Western blotting. The purified antibodies inhibited 75% of the reconstitutive activity of QPs and reacted with both submitochondrial particles (SMP) and mitoplasts. The binding of these antibodies to SMP was greatly increased when succinate dehydrogenase was removed from SMP by alkaline treatment, indicating that QPs1 is a transmembranous protein and that some of its specific epitopes are covered by succinate dehydrogenase. Anti-QPs1 antibodies were used to screen one cDNA clone encoding QPs1 from a bovine heart cDNA lambdagt11 expression library. The cDNA insert is 946 base pairs with an open reading frame of 396 base pairs that encodes for 132 amino acid residues. The molecular weight of QPs1, calculated from the deduced amino acid sequence, is 14,320. Although the apparent molecular weight of QPs1, estimated by high resolution SDS-polyacrylamide gel electrophoresis, is approximately 11,000, the existence of a presequence was ruled out by mass spectrometric analysis of protein fragments. QPs1 is a very hydrophobic protein. Three probable membrane-spanning segments were revealed by a hydropathy plot of the sequence. QPs1 has a higher sequence similarity to the sdhC peptide of Escherichia coli than to the sdhC peptide (cytochrome b558) of Bacillus subtilis. Like the bacterial proteins, QPs1 has 2 conserved histidines at positions 34 and 90. The conserved nature and similar location of these 2 histidines, on the matrix-side surface of the membrane, suggest that they are involved in heme ligation of cytochrome b560.			YU, L (corresponding author), OKLAHOMA STATE UNIV, DEPT BIOCHEM, STILLWATER, OK 74078 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00317] Funding Source: Medline; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1980, J BIOL CHEM, V255, P2761; ACKRELL BAC, 1977, J BIOL CHEM, V252, P6963; BAGINSKY ML, 1969, J BIOL CHEM, V244, P5313; BARR PJ, 1986, BIOTECHNIQUES, V4, P428; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P436, DOI 10.1002/rcm.1290031208; BIRCHMACHIN MA, 1992, J BIOL CHEM, V267, P11553; CAMMACK R, 1986, IRON SULFUR PROTEIN, P40; CAPALDI RA, 1977, BIOCHEMISTRY-US, V16, P5707, DOI 10.1021/bi00645a009; COLE ST, 1982, EUR J BIOCHEM, V122, P479; DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; DAVIS KA, 1971, BIOCHEMISTRY-US, V10, P2509; FRIDEN H, 1990, MOL MICROBIOL, V4, P1045, DOI 10.1111/j.1365-2958.1990.tb00677.x; GIRDLESTONE J, 1981, BIOCHEMISTRY-US, V20, P152, DOI 10.1021/bi00504a025; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HARMON HJ, 1982, J BIOENERG BIOMEMBR, V14, P377, DOI 10.1007/BF00743065; HARMON HJ, 1976, BIOCHIM BIOPHYS ACTA, V440, P45, DOI 10.1016/0005-2728(76)90112-2; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HEDERSTEDT L, 1980, J BACTERIOL, V144, P941, DOI 10.1128/JB.144.3.941-951.1980; HEDERSTEDT L, 1992, IN PRESS MOL MECHANI; JENNER ER, 1973, Patent No. 3737516; JUHASZ P, 1992, 12TH P AM PEPT S, P558; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KEILIN D, 1958, NATURE, V181, P1520, DOI 10.1038/1811520a0; King T.E., 1967, METHOD ENZYMOL, V10, P322, DOI DOI 10.1016/0076-6879(67)10061-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERLI A, 1979, BIOCHEMISTRY-US, V18, P1393, DOI 10.1021/bi00575a001; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PAUDEL HK, 1991, BIOCHIM BIOPHYS ACTA, V1056, P159, DOI 10.1016/S0005-2728(05)80282-8; PHILLIPS MK, 1987, J BACTERIOL, V169, P864, DOI 10.1128/jb.169.2.864-873.1987; SALACH J, 1972, EUR J BIOCHEM, V26, P267, DOI 10.1111/j.1432-1033.1972.tb01765.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; STANWORTH DR, 1978, HDB EXPT IMMUNOLOGY, V1; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; TANIUCHI S, 1978, J BIOCHEM-TOKYO, V84, P907, DOI 10.1093/oxfordjournals.jbchem.a132203; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUSHURASHVILI PR, 1985, BIOCHIM BIOPHYS ACTA, V809, P145, DOI 10.1016/0005-2728(85)90057-X; USUI S, 1990, BIOCHEMISTRY-US, V29, P4618, DOI 10.1021/bi00471a017; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; VINOGRADOV AD, 1980, BIOCHIM BIOPHYS ACTA, V592, P13, DOI 10.1016/0005-2728(80)90110-3; Voller A., 1980, MANUAL CLIN IMMUNOLO, P359; WEBER K, 1969, J BIOL CHEM, V244, P4406; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; XU JX, 1987, BIOCHEMISTRY-US, V26, P7674, DOI 10.1021/bi00398a021; XU Y, 1987, BIOCHEM BIOPH RES CO, V144, P315, DOI 10.1016/S0006-291X(87)80512-0; YAO Y, 1986, IRON SULFUR PROTEIN, P240; YU CA, 1982, J BIOL CHEM, V257, P6127; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1980, BIOCHIM BIOPHYS ACTA, V593, P24, DOI 10.1016/0005-2728(80)90005-5; ZIEGLER DM, 1962, ARCH BIOCHEM BIOPHYS, V97, P41, DOI 10.1016/0003-9861(62)90042-5	59	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24508	24515						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447196				2022-12-27	WOS:A1992KA26300056
J	SCHIAVO, G; ROSSETTO, O; SANTUCCI, A; DASGUPTA, BR; MONTECUCCO, C				SCHIAVO, G; ROSSETTO, O; SANTUCCI, A; DASGUPTA, BR; MONTECUCCO, C			BOTULINUM NEUROTOXINS ARE ZINC PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; TETANUS TOXIN; NUCLEOTIDE-SEQUENCE; NEUROTRANSMITTER RELEASE; 3-DIMENSIONAL STRUCTURE; DIPHTHERIA-TOXIN; LIGHT-CHAINS; PURIFICATION; THERMOLYSIN; HEAVY	The available amino acid sequences of 150-kDa botulinum and tetanus neurotoxins show the presence of a closely homologous segment in the middle of the light chain (NH2-terminal 50 kDa), which is the intracellularly active portion of the toxin. This segment contains the zinc binding motif of metalloendopeptidases, HEXXH. Atomic adsorption analysis of botulinum neurotoxins (serotypes A, B, and E) made on the basis of this observation demonstrated the presence of one zinc atom/molecule of 150-kDa neurotoxin. Conditions were found for the removal of the zinc ion with chelating agents and for the restoration of the normal metal content. The conserved segment, which includes the zinc binding motif, was synthesized and shown to bind [Zn-65]2+. Chemical modification experiments indicated that two histidines and no cysteines are involved in Zn2+ coordination in agreement with a probable catalytic role for the zinc ion. The present findings suggest the possibility that botulinum neurotoxins are zine proteases.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,I-35121 PADUA,ITALY; UNIV SIENA,DIPARTIMENTO BIOL MOLEC,I-53100 SIENA,ITALY; UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706	University of Padua; University of Siena; University of Wisconsin System; University of Wisconsin Madison	SCHIAVO, G (corresponding author), UNIV PADUA,CNR,CTR BIOMEMBRANE,VIA TRIESTE 75,I-35121 PADUA,ITALY.		rossetto, ornella/AAC-3866-2022; Santucci, Annalisa/K-1932-2018	rossetto, ornella/0000-0002-6113-3857; Santucci, Annalisa/0000-0001-6976-9086; Schiavo, Giampietro/0000-0002-4319-8745	NINDS NIH HHS [NS17742] Funding Source: Medline; Telethon [170] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017742] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALOUF JE, 1991, SOURCEBOOK BACTERIAL; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BOROFF DA, 1966, J BACTERIOL, V92, P1580, DOI 10.1128/JB.92.5.1580-1581.1966; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; DASGUPTA BR, 1983, TOXICON, V21, P535, DOI 10.1016/0041-0101(83)90131-9; DASGUPTA BR, 1984, TOXICON, V22, P312, DOI 10.1016/0041-0101(84)90033-3; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; DasGupta BR, 1989, BOTULINUM NEUROTOXIN, P53; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HAUSER D, 1990, NUCLEIC ACIDS RES, V18, P4924, DOI 10.1093/nar/18.16.4924; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Miles E W, 1977, Methods Enzymol, V47, P431; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; PAPINI E, 1989, J BIOL CHEM, V264, P12385; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; POULAIN B, 1991, J BIOL CHEM, V266, P9580; POULAIN B, 1990, J PHYSIOL-PARIS, V84, P247; POULAIN B, 1988, P NATL ACAD SCI USA, V85, P4090, DOI 10.1073/pnas.85.11.4090; POULET S, 1992, BIOCHEM BIOPH RES CO, V183, P107, DOI 10.1016/0006-291X(92)91615-W; RAPPUOLI R, 1983, J CHROMATOGR, V268, P543, DOI 10.1016/S0021-9673(01)95457-3; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; THAYER MM, 1991, J BIOL CHEM, V266, P2864; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; WOODY MA, 1989, TOXICON, V27, P1143, DOI 10.1016/0041-0101(89)90008-1; [No title captured]	37	225	241	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23479	23483						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429690				2022-12-27	WOS:A1992JZ23900012
J	SINGH, K; MUKHERJEE, AB; DEVOUGE, MW; MUKHERJEE, BB				SINGH, K; MUKHERJEE, AB; DEVOUGE, MW; MUKHERJEE, BB			DIFFERENTIAL PROCESSING OF OSTEOPONTIN TRANSCRIPTS IN RAT KIDNEY-DERIVED AND OSTEOBLAST-DERIVED CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED PHOSPHOPROTEIN-I; TRANSFORMED MAMMALIAN-CELLS; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS; GROWTH-FACTORS; MESSENGER-RNA; BONE; EXPRESSION; PROTEINS; 2AR	Using immunoprecipitation and tryptic peptide microsequencing we confirmed the identity of normal rat kidney (NRK) cell-secreted 69-kDa major phosphoprotein as osteopontin (OP). We then immunoselected a 1.4-kilobase pair (kb) OP cDNA from a lambdagt11 library prepared from Kirsten sarcoma virus-transformed NRK (KNRK) cellular mRNA, using rabbit anti-69-kDa OP serum. Sequence analysis of this cDNA revealed the presence of a 52-nucleotide-long insert in the 5'-noncoding region, which was absent in OP cDNA cloned from the cDNA library of ROS 17/2.8 rat osteosarcoma cells. The insert sequence is flanked by putative intron splice junctions and is located 15-nucleotide upstream of the translational initiation site. An insert-specific 30-mer oligonucleotide probe hybridized to a single 1.5-kb RNA species from both NRK and KNRK cells, but not from ROS 17/2.8 cells. However, Southern analysis showed the presence of this insert sequence in the genomic DNA of both NRK and ROS 17/2.8 cells. Furthermore, PCR amplification of the insert-containing region using genomic DNAs from both NRK and ROS 17/2.8 cells gave products of identical size and sequence. Since OP is a single copy gene, these data provide strong evidence for differential cell type-specific processing of OP transcripts. In addition, we demonstrate that, in contrast to most transformed cells, levels of OP expression are significantly reduced in KNRK cells as compared to NRK cells.	MCGILL UNIV,CTR HUMAN GENET,MONTREAL H3A 1B1,QUEBEC,CANADA; NICHHD,HUMAN GENET BRANCH,DEV GENET SECT,BETHESDA,MD 20892	McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	SINGH, K (corresponding author), MCGILL UNIV,DEPT BIOL,1205 DR PENFIELD AVE,MONTREAL H3A 1B1,QUEBEC,CANADA.							ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLIN N, 1989, MOL CLONING LABORATO, P916; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CARIG AM, 1991, GENE AMST, V100, P163; CHACKALAPARAMPIL I, 1985, J VIROL, V53, P841, DOI 10.1128/JVI.53.3.841-850.1985; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEVOUGE MW, 1992, ONCOGENE, V7, P109; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERDURE GR, 1987, FEBS LETT, V222, P261, DOI 10.1016/0014-5793(87)80382-4; MULLER S, 1986, MOL IMMUNOL, V23, P593, DOI 10.1016/0161-5890(86)90095-7; NAGATA T, 1989, BIOCHEM BIOPH RES CO, V165, P234, DOI 10.1016/0006-291X(89)91059-0; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; SENGER DR, 1980, NATURE, V286, P619, DOI 10.1038/286619a0; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SINGH K, 1990, J BIOL CHEM, V265, P18696	34	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23847	23851						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429723				2022-12-27	WOS:A1992JZ23900063
J	HAILSTONES, D; BARTON, P; CHANTHOMAS, P; SASSE, S; SUTHERLAND, C; HARDEMAN, E; GUNNING, P				HAILSTONES, D; BARTON, P; CHANTHOMAS, P; SASSE, S; SUTHERLAND, C; HARDEMAN, E; GUNNING, P			DIFFERENTIAL REGULATION OF THE ATRIAL ISOFORMS OF THE MYOSIN LIGHT-CHAINS DURING STRIATED-MUSCLE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; GENE-EXPRESSION; MESSENGER-RNA; CDNA CLONES; FIBERS; ADULT; MYOGENESIS; KINETICS; SEQUENCE; VELOCITY	We have isolated a cDNA that encodes the human regulatory myosin light chain isoform predominant in adult atrial muscle. The cDNA contains an open reading frame of 175 amino acids and encodes a hydrophilic protein of a largely helical structure with two potential phosphorylation sites. The protein is different from any other regulatory myosin light chain so far described and is the product of a previously uncharacterized single copy gene. An isoform-specific probe was used to analyze the expression of this isoform in adult muscle and in cardiac and skeletal muscle development in vivo and in vitro. Parallel analysis of the corresponding human alkali myosin light chain (predominant in adult atrium) showed that both isoforms are expressed in early heart development, in both atrium and ventricle. Although the atrial alkali light chain is expressed throughout embryonic striated muscle development, the regulatory myosin light chain was not detected in skeletal myogenesis in vivo or in vitro. Thus the atrial isoforms are not universally or exclusively "paired' and can be independently regulated. We propose that the manner in which these particular isoforms fulfill the functional requirements of the muscle at different developmental times may have direct impact on their regulation.	CHILDRENS MED RES INST,CELL BIOL UNIT,LOCKED BAG 23,WENTWORTHVILLE,NSW 2145,AUSTRALIA; NATL HEART & LUNG INST,LONDON SW3 6LY,ENGLAND; CHILDRENS MED RES INST,MUSCLE DEV UNIT,WENTWORTHVILLE,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia; Imperial College London; Children's Medical Research Institute - Australia			Hailstones, Deborah/M-3243-2018; Sutherland, Colin/AAN-3939-2020; Gunning, Peter W/E-9058-2010; Hardeman, Edna C/F-8872-2012	Hailstones, Deborah/0000-0003-3042-5168; Sutherland, Colin/0000-0003-1592-6407; Barton, Paul/0000-0002-1165-7767; Gunning, Peter/0000-0003-0833-3128; Hardeman, Edna/0000-0003-1649-7712				ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BARTON PJR, 1988, J BIOL CHEM, V263, P12669; BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BARTON PJR, 1991, INT J CARDIOL, V30, P116, DOI 10.1016/0167-5273(91)90133-A; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; GRANT JW, 1990, J CELL BIOL, V111, P1127, DOI 10.1083/jcb.111.3.1127; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; HAILSTONES DL, 1990, MOL CELL BIOL, V10, P1095, DOI 10.1128/MCB.10.3.1095; HOFFMANN U, 1987, BASIC RES CARDIOL, V82, P348, DOI 10.1007/BF01907022; HOFMANN PA, 1990, J GEN PHYSIOL, V95, P477, DOI 10.1085/jgp.95.3.477; KUMAR CC, 1989, BIOCHEMISTRY-US, V28, P4027, DOI 10.1021/bi00435a059; KURABAYASHI M, 1988, J BIOL CHEM, V263, P13930; LENZ S, 1989, J BIOL CHEM, V264, P9009; LIBERA LD, 1989, NUCLEIC ACIDS RES, V17, P2360, DOI 10.1093/NAR/17.6.2360; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; MALHOTRA A, 1979, BIOCHEMISTRY-US, V18, P461, DOI 10.1021/bi00570a013; Maniatis T, 1989, DECONTAMINATION DILU; MORANO I, 1988, CIRC RES, V62, P632, DOI 10.1161/01.RES.62.3.632; MORANO I, 1989, BASIC RES CARDIOL, V84, P298, DOI 10.1007/BF01907977; MOSS RL, 1982, J BIOL CHEM, V257, P8588; NUDEL U, 1984, NUCLEIC ACIDS RES, V12, P7175, DOI 10.1093/nar/12.18.7175; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PRICE KM, 1980, BIOCHEM J, V191, P571, DOI 10.1042/bj1910571; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSOON D, 1988, DEVELOPMENT, V104, P603; SEIDEL U, 1987, NUCLEIC ACIDS RES, V15, P4989, DOI 10.1093/nar/15.12.4989; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	35	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23295	23300						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429676				2022-12-27	WOS:A1992JY16300090
J	FUJII, N; MINETTI, CASA; NAKHASI, HL; CHEN, SW; BARBEHENN, E; NUNES, PH; NGUYEN, NY				FUJII, N; MINETTI, CASA; NAKHASI, HL; CHEN, SW; BARBEHENN, E; NUNES, PH; NGUYEN, NY			ISOLATION, CDNA CLONING, AND CHARACTERIZATION OF AN 18-KDA HEMAGGLUTININ AND AMEBOCYTE AGGREGATION FACTOR FROM LIMULUS-POLYPHEMUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; AMINO-ACID-SEQUENCE; HORSESHOE-CRAB; INHIBITORY ACTIVITY; COMPLEMENT-SYSTEM; BINDING PROTEIN; PURIFICATION; PEPTIDE; CONSUMPTION; SIMILARITY	An 18-kDa hemagglutinin which possesses the property of inducing both aggregation of amebocytes and agglutination of erythrocytes has been isolated from Limulus polyphemus amebocytes and purified by ion exchange chromatography. This nonglycosylated, single chain polypeptide with an M(r) of 18,506 and isoelectric point of 8.3 is stored exclusively in the large secretory granules of amebocytes. Based on the partial N-terminal amino acid sequence of 63 residues, DNA probes have been synthesized for screening a pBR322 cDNA library constructed from Limulus amebocytes. The cDNA coding for this protein reveals the presence of a 19-residue signal peptide preceding the 153-residue open reading frame. Northern blot analysis indicates the presence of a single mRNA species. The primary structure derived from the corresponding cDNA sequence reveals an internal homology consisting of two consensus sequences, Val-Asn-Asp/Ser-Trp-Asp and Glu-Asp-Arg-Arg-Trp. The formation of 5 disulfide bonds between 10 half-cysteines divides the molecule into three looped domains each containing the Glu-Asp-Arg-Arg-Trp repeating unit. One of the novel features of this protein is that it shares 37% identity with a 22-kDa mammalian extracellular matrix protein isolated from fetal bovine skin (Neame, P. J., Choi, H. U., and Rosenberg, L. C. (1989) J. Biol. Chem. 264, 5474-5479). The two proteins exhibit a similar pattern of looped domains, each domain containing a homologous consensus sequence (i.e. Glu-Asp-Arg-Arg-Trp). The overall structure of both proteins seems to be highly related, with the exception of an N-terminal tyrosine-rich region present only in the mammalian extracellular matrix protein. The functional properties of the two proteins are similar in that the Limulus 18-kDa protein agglutinates horse erythrocytes and aggregates Limulus amebocytes, and the mammalian 22-kDa protein is an effective adhesion promoter for dermal fibroblasts. On the basis of these unique properties, the newly characterized hemagglutinin has been termed Limulus 18K agglutination-aggregation factor (18K-LAF).	US FDA, DIV CYTOKINE BIOL,CYTOKINE RES LAB,BLDG 29A, RM 2A-09, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)			Minetti, Conceicao/B-5077-2009; Minetti, Conceicao/AGD-6419-2022; Nunes, Paulo H. M./I-5768-2013	Minetti, Conceicao/0000-0002-9682-2898; Minetti, Conceicao/0000-0002-9682-2898; Nunes, Paulo H. M./0000-0001-9507-9337				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1985, BIOCHIM BIOPHYS ACTA, V827, P453, DOI 10.1016/0167-4838(85)90232-8; ARMSTRONG PB, 1980, J CELL SCI, V44, P243; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BISHAYEE S, 1980, BIOCHIM BIOPHYS ACTA, V623, P89, DOI 10.1016/0005-2795(80)90011-2; BLATTNER FR, 1977, SCIENCE, V196, P161, DOI 10.1126/science.847462; BROIDO MS, 1984, BIOCHEM BIOPH RES CO, V119, P663, DOI 10.1016/S0006-291X(84)80301-0; CARUTHERS MH, 1982, GENETIC ENG, V4, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEMEY J, 1981, CELL BIOL INT REP, V5, P889, DOI 10.1016/0309-1651(81)90204-6; DONOVAN MA, 1991, J BIOL CHEM, V266, P2121; EFSTRATIADIS A, 1976, CELL, V7, P279, DOI 10.1016/0092-8674(76)90027-1; FINSTAD CL, 1972, J IMMUNOL, V108, P1704; Fraenkel-Conrat H., 1967, METHOD ENZYMOL, V11, P151; GAL K, 1955, Acta Microbiol Acad Sci Hung, V3, P41; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; Goodman H M, 1979, Methods Enzymol, V68, P75; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOKAMA Y, 1962, J BACTERIOL, V83, P1017, DOI 10.1128/JB.83.5.1017-1024.1962; HUNKAPILLER MW, 1986, PROTEIN PEPTIDE SEQU; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVANDOWSKA K, 1991, J CELL SCI, V99, P657; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIU T, 1991, J BIOL CHEM, V266, P14813; Lofstrom G, 1944, BRIT J EXP PATHOL, V25, P21; MAXAM A, 1980, METHOD ENZYMOL, V68, P499; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MOVVA NR, 1980, J BIOL CHEM, V255, P27; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NEAME PJ, 1989, J BIOL CHEM, V264, P5474; NEWMAN GR, 1982, J MICROSC-OXFORD, V127, pRP5, DOI 10.1111/j.1365-2818.1982.tb00418.x; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; NOGUCHI H, 1903, ZENTRALBL BAKTERIO 1, V33, P352; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Pistole T.G., 1986, P331; RICKLES FR, 1979, BIOMEDICAL APPLICATI, P203; ROBEY FA, 1981, J BIOL CHEM, V256, P969; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEGEL J, 1974, J EXP MED, V140, P631, DOI 10.1084/jem.140.3.631; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SOTTRUPJENSEN L, 1990, COMP BIOCHEM PHYS B, V96, P621, DOI 10.1016/0305-0491(90)90066-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPACKMAN DH, 1963, FED PROC, V22, P244; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SRIMAL S, 1985, BIOCHEM J, V230, P321, DOI 10.1042/bj2300321; WANG CM, 1982, J BIOL CHEM, V257, P13610; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YEATON RW, 1981, DEV COMP IMMUNOL, V5, P391, DOI 10.1016/S0145-305X(81)80052-3	56	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22452	22459						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429596				2022-12-27	WOS:A1992JW71900073
J	FURUKAWA, S; SAKATA, N; GINSBERG, HN; DIXON, JL				FURUKAWA, S; SAKATA, N; GINSBERG, HN; DIXON, JL			STUDIES OF THE SITES OF INTRACELLULAR DEGRADATION OF APOLIPOPROTEIN-B IN HEP G2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CULTURED RAT HEPATOCYTES; BREFELDIN-A; ENDOPLASMIC-RETICULUM; COMBINED HYPERLIPIDEMIA; PROTEIN-DEGRADATION; GOLGI PROTEINS; OLEIC-ACID; APO-B; SECRETION	We previously reported that treatment of Hep G2 cells with oleate significantly increased apolipoprotein B (apoB) secretion by reducing early intracellular degradation of nascent apoB. In the current study, inhibitors of secretory protein transport (brefeldin A and monensin), cell fractionation studies, and protease protection assays were utilized to determine the location of apoB degradation and to better define the mechanism whereby oleate treatment reduces nascent apoB intracellular degradation. When cells were treated with brefeldin A, which blocks endoplasmic reticulum (ER) to Golgi protein transport, apoB degradation continued in control cells, suggesting that apoB is degraded in the ER. When oleate-treated cells were blocked with brefeldin A, oleate failed to protect apoB from intracellular degradation. The effects of brefeldin A were not due to effects on lipid synthesis as brefeldin A did not inhibit the synthesis of triglyceride, phospholipid, free cholesterol, or cholesteryl ester in control cells and did not prevent the increases in triglyceride (14-fold) and phospholipid (1.4-fold) synthesis seen in oleate-treated cells. Simultaneous treatment of cells with brefeldin A and nocodazole, which inhibits retrograde transport of proteins from Golgi to ER, added to the evidence for the ER as the site of apoB degradation. This conclusion received further support from experiments in which cells were treated with monensin, a Na+ ionophore which halts protein secretion at the level of the trans-Golgi network. Early degradation of nascent apoB (between 10 and 20 min of chase) was observed in monensin-treated cells, but then cellular apoB degradation ceased and apoB was stable during the remaining chase period. More apoB accumulated in the Golgi of cells that had been treated with oleate and monensin. These results suggest that ER degradation occurs in monensin-treated cells, but then stops as apoB is transferred to the Golgi. The results obtained in whole cells were confirmed in studies using isolated ER and Golgi, which indicated that ER contains a proteolytic activity which degrades apoB, in vitro, whereas Golgi does not. ApoB degradation in isolated ER was not reduced by pretreatment with oleate. Finally, protease protection assays carried out with isolated microsomes indicated that a majority of the apoB in both control or oleate-treated HepG2 cells was located on the cytosolic side of the membranes. Taken together, these results indicate that the rapid intracellular degradation of nascent apoB in HepG2 occurs in the ER, and suggest that the oleate treatment may prevent the interaction of an ER-associated protease with apoB during a vulnerable time period as the nascent protein associates with lipid and moves to the Golgi.			FURUKAWA, S (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Sakata, Nobuhiro/ACN-9770-2022		NHLBI NIH HHS [HL-36000, HL-47586, HL-21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047586, P50HL021006, R01HL036000, R01HL047586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAD Y, 1990, J LIPID RES, V31, P567; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNING A, 1992, J BIOL CHEM, V267, P5052; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GIBSON JC, 1983, J LIPID RES, V24, P886; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRINDE B, 1983, EXP CELL RES, V149, P27, DOI 10.1016/0014-4827(83)90377-4; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SATO R, 1990, J BIOL CHEM, V265, P11880; TABAS I, 1988, J BIOL CHEM, V263, P1266; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YU S, 1983, J BIOL CHEM, V258, P3407	38	130	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22630	22638						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429611				2022-12-27	WOS:A1992JW71900099
J	HILL, E; MACLOUF, J; MURPHY, RC; HENSON, PM				HILL, E; MACLOUF, J; MURPHY, RC; HENSON, PM			REVERSIBLE MEMBRANE ASSOCIATION OF NEUTROPHIL 5-LIPOXYGENASE IS ACCOMPANIED BY RETENTION OF ACTIVITY AND A CHANGE IN SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE 5-LIPOXYGENASE; LEUKOTRIENE SYNTHESIS INHIBITORS; PROTEIN; TRANSLOCATION; BIOSYNTHESIS; CELLS	Ionophore activation of the human polymorphonuclear neutrophil results in eicosanoid synthesis and the accumulation of inactive 5-lipoxygenase in a membrane compartment. We report here that inhibition of self-inactivation of 5-lipoxygenase in ionophore-treated neutrophils with the reversible inhibitor zileuton, results in the accumulation of active 5-lipoxygenase in the membrane fraction. In zileuton plus ionophore-treated cells, 77% of the specific activity of the cytosolic enzyme from resting cells was diverted to the membrane fraction compared to 22% of the activity translocated when ionophore alone was used to activate the neutrophils. Accumulation of active membrane-associated 5-lipoxygenase was inhibited and reversed by the 5-lipoxygenase translocation inhibitor MK-886. The membrane-associated 5-lipoxygenase was two times more efficient in the production of leukotriene A4 from arachidonate-derived 5-hydroperoxyeicosatetraenoic acid than the cytosolic enzyme. Unlike the cytosolic enzyme, membrane-associated 5-lipoxygenase could metabolize 12(S)- and 15(S)-hydroxyeicosatetraenoic acid to 5(S),12(S)- and 5(S),15(S)-dihydroxyeicosatetraenoic acid, respectively. The ability to metabolize hydroxy fatty acids was dependent upon 5-lipoxygenase-activating protein association, but was lost if 5-lipoxygenase was eluted from the membrane by MK-886. These studies reveal for the first time that significant quantities of active 5-lipoxygenase can be detected in the membrane fraction of activated neutrophils and show that membrane association can alter the substrate specificity of 5-lipoxygenase which is further evidence for the role of the membrane-associated enzyme in the synthesis of 5-lipoxygenase metabolites.	NATL JEWISH CTR IMMUNOL & RESP MED, 1400 JACKSON ST, DENVER, CO 80206 USA; HOP LARIBOISIERE, INSERM, U348, F-75475 PARIS 10, FRANCE	National Jewish Health; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORGEAT P, 1982, PROSTAGLANDINS, V23, P713, DOI 10.1016/S0090-6980(82)80009-9; BORGEAT P, 1982, LEUKOTRIENES OTHER L, P45; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; COFFEY M, 1992, J BIOL CHEM, V267, P570; DENIS D, 1991, J BIOL CHEM, V266, P5072; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; EVANS JF, 1991, MOL PHARMACOL, V40, P22; FITZPATRICK F, 1984, J BIOL CHEM, V259, P1403; FORDHUTCHINSON AW, 1989, LEUKOTRIENES LIPOXYG, P405; HASLETT C, 1985, AM J PATHOL, V119, P101; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; MACLOUF J, 1989, BLOOD, V74, P703; MANCINI JA, 1992, MOL PHARMACOL, V41, P267; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; REID GK, 1990, J BIOL CHEM, V265, P19818; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; ROUZER CA, 1988, J BIOL CHEM, V263, P10135; ROUZER CA, 1988, ANN NY ACAD SCI, V524, P1; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; UEDA N, 1986, J BIOL CHEM, V261, P7982; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018	23	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22048	22053						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429555				2022-12-27	WOS:A1992JW71900013
J	DURONIO, V; CLARKLEWIS, I; FEDERSPPIEL, B; WIELER, JS; SCHRADER, JW				DURONIO, V; CLARKLEWIS, I; FEDERSPPIEL, B; WIELER, JS; SCHRADER, JW			TYROSINE PHOSPHORYLATION OF RECEPTOR BETA SUBUNITS AND COMMON SUBSTRATES IN RESPONSE TO INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; GROWTH FACTOR-I; EXPRESSION CLONING; MOLECULAR-CLONING; INSULIN-RECEPTOR; GENE FAMILY; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION; ALPHA-CHAIN; PROTEIN	The receptors for interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) consist of two polypeptides each belonging to a new class of molecules referred to as the hemopoietin receptor family. When expressed alone, receptor polypeptides of this family often bind their respective factors with lower affinity than the receptors identified in whole cells. Despite the lack of structural evidence for any enzymatic activity of the receptor polypeptides, both IL-3 and GM-CSF stimulate tyrosine phosphorylation of multiple intracellular substrates. We investigated IL-3 and GM-CSF receptor structure and signaling in a myeloid cell line, FDC-P1, which is dependent on either IL-3 or GM-CSF for growth. Antiphosphotyrosine antibodies were used to immunoprecipitate tyrosine-phosphorylated proteins from P-32-labeled cells or to probe immunoblots. Both IL-3 and GM-CSF stimulated the phosphorylation of a similar pattern of polypeptides on tyrosine. One tyrosine phosphorylated polypeptide migrated with M(r) = 135,000 and increased to 150,000 over a period of 10 min following stimulation of cells with IL-3 or GM-CSF. The M(r) = 135,000-150,000 polypeptide phosphorylated in response to IL-3 was shown to be primarily the Aic-2A polypeptide, the low affinity IL-3 receptor. Phosphatase treatment showed that the dramatic IL-3-induced shift in apparent molecular weight from M(r) = 125,000 in unstimulated cells was entirely due to phosphorylation. The closely related receptor, Aic-2B, was also tyrosine phosphorylated in response to IL-3, although to a lesser extent than Aic-2A. Treatment with GM-CSF resulted in tyrosine phosphorylation of the Aic-2B polypeptide exclusively. It was intriguing that GM-CSF treatment did affect the mobility of the Aic-2A polypeptide on polyacrylamide gels. Together, these results suggest that the Aic-2A polypeptide is part of the IL-3 receptor complex, but not the GM-CSF receptor. In contrast, the Aic-2B polypeptide is a component of the GM-CSF receptor, but it can also be utilized in an IL-3 receptor.	UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of British Columbia	DURONIO, V (corresponding author), UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA.							BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEGUINOT F, 1988, BIOCHEMISTRY-US, V27, P3222, DOI 10.1021/bi00409a015; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CLARKLEWIS I, 1984, J BIOL CHEM, V259, P7488; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; CLARKLEWIS I, 1986, SCIENCE, V231, P134, DOI 10.1126/science.3079915; CLARKLEWIS I, 1990, PEPTIDES STRUCTURE B, P749; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DURONIO V, 1990, BIOCHEM J, V270, P27, DOI 10.1042/bj2700027; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; DURONIO V, 1992, EXP HEMATOL, V20, P505; DURONIO V, 1988, RECEPTOR BIOCH MET B, V12, P3; EVANS JPM, 1990, BLOOD, V75, P88; FARRAR W L, 1990, Cytokine, V2, P77, DOI 10.1016/1043-4666(90)90001-A; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PARK LS, 1989, J BIOL CHEM, V264, P5420; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SCHREURS J, 1991, INT IMMUNOL, V3, P1231, DOI 10.1093/intimm/3.12.1231; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELHAM MJ, 1992, IN PRESS J IMMUNOL; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; ZILTENER HJ, 1987, J IMMUNOL, V138, P1099	52	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21856	21863						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400495				2022-12-27	WOS:A1992JV01100092
J	KIKUCHI, K; BICHELL, DP; ROTWEIN, P				KIKUCHI, K; BICHELL, DP; ROTWEIN, P			CHROMATIN CHANGES ACCOMPANY THE DEVELOPMENTAL ACTIVATION OF INSULIN-LIKE GROWTH-FACTOR I GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACIDS; PLASMA SOMATOMEDIN-C; SERUM-ALBUMIN GENE; IGF-I; HYPOPHYSECTOMIZED RATS; DNA FRAGMENTS; TISSUE CONCENTRATIONS; HYPERSENSITIVE SITES; STIMULATES GROWTH; FACTOR (IGF)-I	Insulin-like growth factor I (IGF-I) is a potent regulator of postnatal growth in mammals, yet little is known about the developmental control of IGF-I synthesis. We have investigated the regulation of IGF-I expression in the rat in order to gain insight into the mechanisms of growth factor induction during early postnatal life. Steady-state levels of liver IGF-I mRNA increased by more than 15-fold during the period from fetal day 18 to postnatal day 7 and reached 50% of adult values by day 14. Transcription run-on experiments using isolated hepatic nuclei and direct analysis of nuclear RNA each demonstrated a comparable rise in nascent IGF-I mRNA over the same time period. Over 90% of transcripts were directed by promoter 1, the more 5' of the two IGF-I gene promoters. By contrast IGF-II gene transcription rates and mRNA levels fell during the first 3 weeks after birth, and albumin expression rose slightly. Analysis of chromatin structure around the IGF-I gene revealed 15 DNase I-hypersensitive sites in adult rat liver in the 120 kilobases (kb) comprising the 6 exon gene and its flanking regions (8 sites within 10 kb at the 5'-end including exons 1-3, 5 sites in the 50-kb third intron, and 2 sites in the 15-kb fifth intron). During development there was a progressive appearance of DNase I-hypersensitive sites that coincided with activation of IGF-I gene expression. One site that became fully hypersensitive by postnatal day 7 was mapped by in vivo DNAse I footprinting to the proximal 200 nucleotides of promoter 1. Since serum IGF-I values rose from 10 to 120 mug/liter during the initial postnatal week, these results indicate that transcriptional mechanisms are principally responsible for the stimulation of IGF-I synthesis that occurs shortly after birth. Because discrete changes in chromatin organization coincided with induction of IGF-I gene transcription, it is likely that a series of developmentally modulated transcription factors are involved the activation process.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	KIKUCHI, K (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110, USA.		Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817; Bichell, David/0000-0003-0227-1771	NATIONAL CANCER INSTITUTE [T32CA009621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037449, P60DK020579, P30DK020579] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09621] Funding Source: Medline; NIDDK NIH HHS [5-RO1-DK37449, DK20579] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO M, 1989, ENDOCRINOLOGY, V124, P2737, DOI 10.1210/endo-124-6-2737; ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend-5-11-1677; ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P6504, DOI 10.1073/pnas.83.17.6504; BROWN AL, 1986, J BIOL CHEM, V261, P3144; BUCCI C, 1989, NUCLEIC ACIDS RES, V17, P3596, DOI 10.1093/nar/17.9.3596; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUGHADAY WH, 1982, ENDOCRINOLOGY, V110, P575, DOI 10.1210/endo-110-2-575; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DONOVAN SM, 1991, ENDOCRINOLOGY, V129, P149, DOI 10.1210/endo-129-1-149; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EMLER CA, 1987, ENDOCRINOLOGY, V120, P832, DOI 10.1210/endo-120-2-832; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GRIFFEN SC, 1987, P NATL ACAD SCI USA, V84, P7300, DOI 10.1073/pnas.84.20.7300; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HOYT EC, 1988, MOL ENDOCRINOL, V2, P1077, DOI 10.1210/mend-2-11-1077; HYNES MA, 1987, MOL ENDOCRINOL, V1, P233, DOI 10.1210/mend-1-3-233; ISGAARD J, 1988, ENDOCRINOLOGY, V123, P2605, DOI 10.1210/endo-123-6-2605; JAGODZINSKI LL, 1981, P NATL ACAD SCI-BIOL, V78, P3521, DOI 10.1073/pnas.78.6.3521; Jost A, 1979, Contrib Gynecol Obstet, V5, P1; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; LUND PK, 1989, MOL ENDOCRINOL, V3, P2054, DOI 10.1210/mend-3-12-2054; MAES M, 1983, J ENDOCRINOL, V97, P243, DOI 10.1677/joe.0.0970243; MAES M, 1984, ENDOCRINOLOGY, V115, P786, DOI 10.1210/endo-115-2-786; MARZLUFF WF, 1984, TRANSCRIPTION TRANSL, P95; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P433, DOI 10.1210/endo-123-1-433; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SCHEIWILLER E, 1986, NATURE, V323, P169, DOI 10.1038/323169a0; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; SHIMATSU A, 1987, NUCLEIC ACIDS RES, V15, P7196, DOI 10.1093/nar/15.17.7196; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRAUS DS, 1990, MOL ENDOCRINOL, V4, P91, DOI 10.1210/mend-4-1-91; STRAUS DS, 1991, ENDOCRINOLOGY, V128, P518, DOI 10.1210/endo-128-1-518; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIONG TS, 1992, MOL CELL ENDOCRINOL, V83, P133, DOI 10.1016/0303-7207(92)90154-X; VANDEHAAR MJ, 1991, J ENDOCRINOL, V130, P305, DOI 10.1677/joe.0.1300305; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	55	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21505	21511						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400462				2022-12-27	WOS:A1992JV01100039
J	MCKENZIE, TL; JIANG, GJ; STRAUBHAAR, JR; CONRAD, DG; SHECHTER, I				MCKENZIE, TL; JIANG, GJ; STRAUBHAAR, JR; CONRAD, DG; SHECHTER, I			MOLECULAR-CLONING, EXPRESSION, AND CHARACTERIZATION OF THE CDNA FOR THE RAT HEPATIC SQUALENE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SECONDARY-STRUCTURE; PROTEINS; SYNTHETASE; SEQUENCE; ACID; SOLUBILIZATION; PURIFICATION; PYROPHOSPHATE; PRODUCTS	Amino acid sequence information was obtained for the NH2 terminus, and for endogenous peptides generated by trypsin digestion, of a purified, truncated form of rat hepatic squalene synthase (RSS, EC 2.5.1.21) (Shechter, I., Klinger, E., Rucker, M. L., Engstrom, R. G., Spirito, J. A., Islam, M. A., Boettcher, B. R., and Weinstein, D. B. (1992) J. Biol. Chem. 267, 8628-8635). Degenerate primers, based on the amino acid sequences, were synthesized and used for the amplification and sequencing of a 1708-base pair (bp) cDNA for RSS from the rat hepatoma cell line H35. An open reading frame of 1248 bp encoding 416 amino acids (M(r) = 48,103) was detected for RSS. We have constructed a pRSS1327 expression vector by molecular cloning of a 1327-bp cDNA, which includes sequences of the entire coding region for RSS, into pBluescript. Expression in Escherichia coli of a functional, full-length RSS was confirmed by immunoblot analysis and enzymatic activity. We present and evaluate a model for the secondary structure of RSS and its possible membrane orientation. The model predicts a 315-residue domain at the center of the protein that contains the catalytic site and is released in a soluble form by partial proteolysis. The 33-residue NH2-terminal and 98-residue COOH-terminal sections are not involved in catalysis. Sequence analysis of the catalytic domain of RSS indicate three regions with high homology to sequences in a number of functionally distinct proteins that utilize polyprenyl diphosphate substrates.	ELEANOR ROOSEVELT INST,1899 GAYLOR ST,DENVER,CO 80206									AGNEW WS, 1978, J BIOL CHEM, V253, P4574; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P975; ASHBY NM, 1992, J BIOL CHEM, V267, P4128; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAM BE, 1976, J LIPID RES, V17, P176; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANDLER B, 1991, ABSTR PAP AM CHEM S, V201, P1; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P363, DOI 10.1080/00021369.1979.10863433; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LISCUM L, 1985, J BIOL CHEM, V260, P522; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, P413; RAY J, 1987, NUCLEIC ACIDS RES, V15, P10587, DOI 10.1093/nar/15.24.10587; RILLING HC, 1969, J AM CHEM SOC, V19, P1041; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SHECHTER I, 1971, J BIOL CHEM, V246, P7690; SHECHTER I, 1992, J BIOL CHEM, V267, P8628	39	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21368	21374						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400448				2022-12-27	WOS:A1992JV01100020
J	KOUNNAS, MZ; ARGRAVES, WS; STRICKLAND, DK				KOUNNAS, MZ; ARGRAVES, WS; STRICKLAND, DK			THE 39-KDA RECEPTOR-ASSOCIATED PROTEIN INTERACTS WITH 2 MEMBERS OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR FAMILY, ALPHA-2-MACROGLOBULIN RECEPTOR AND GLYCOPROTEIN-330	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; LDL-RECEPTOR; HIGH-AFFINITY; BRUSH-BORDER; BINDING; IDENTIFICATION; LIGAND; GP330; PURIFICATION; ANTIBODY	The 39-kDa receptor-associated protein (RAP) binds to the alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2MR/LRP) and inhibits binding of ligands to this receptor. The in vivo function of RAP may be to regulate ligand binding and/or assist in the correct biosynthetic processing or trafficking of the alpha2MR/LRP. Here we show that RAP binds another putative receptor, the kidney glycoprotein 330 (gp330). Gp330 is a high molecular weight glycoprotein that is structurally similar to both the alpha2MR/LRP and low density lipoprotein receptor. The ability of RAP to bind to gp330 was demonstrated by ligand blotting and solid phase binding assays, which showed that RAP binds to gp330 with high affinity (K(d) = 8 nM). Exploiting the interaction of gp330 and RAP, we purified gp330 by affinity chromatography with a column of RAP coupled to Sepharose. Gp330 preparations obtained by this procedure were notably more homogeneous than those obtained by conventional methods. Immunocytochemical staining of human kidney sections localized RAP to the brush-border epithelium of proximal tubules. The fact that gp330 is also primarily expressed by proximal tubule epithelial cells strengthens the likelihood that the interaction between gp330 and RAP occurs in vivo. The functional significance of RAP binding to gp330 may be to antagonize ligand binding as has been demonstrated for the alpha2MR/LRP or to assist in the biosynthetic processing and/or trafficking of this receptor.	AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912, R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02113] Funding Source: Medline; NIGMS NIH HHS [GM42912, GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEORGE R, 1987, J BIOL CHEM, V262, P16838; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	27	192	201	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21162	21166						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400426				2022-12-27	WOS:A1992JT97800100
J	SCHRODER, G; SCHRODER, J				SCHRODER, G; SCHRODER, J			A SINGLE CHANGE OF HISTIDINE TO GLUTAMINE ALTERS THE SUBSTRATE PREFERENCE OF A STILBENE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLANT-SPECIFIC PATHWAYS; RESVERATROL SYNTHASE; CHALCONE SYNTHASES; GENES; MUTAGENESIS; EXPRESSION; VECTORS; ENZYMES; DNA	Stilbene and chalcone synthases are related polyketide synthases which use the same substrates but form different products. The environment of the condensing active site cysteine is highly conserved, except for the positions -2 and -3. All chalcone synthases contain Gln-Gln and prefer 4-coumaroyl-CoA as starter CoA ester, while the two known stilbene synthases contain Gln-His or His-Gln (preference phenylpropionyl-CoA and 4-coumaroyl-CoA, respectively). We investigated whether the presence and/or position of the histidine influences the substrate preference and the product specificity (stilbene or chalcone). The two amino acid motifs in the chalcone synthase from Pinus sylvestris (Gln-Gln) and in the stilbene synthases from P. sylvestris (Gln-His) and Arachis hypogaea (His-Gln) were changed by site-directed mutagenesis into all sequence combinations as found in the natural enzymes. Assays with the mutant proteins showed that the histidine does not determine the product specificity. With the chalcone and the stilbene synthase from P. sylvestris, any sequence deviation reduced the activity without marked effects on the substrate preference. The stilbene synthase from A. hypogaea was different. The change from His-Gln to Gln-His abolished enzyme activity almost completely with all three substrates. The change to Gln-Gln selectively reduced the activity with 4-coumaroyl-CoA, and the kinetic analysis indicated a slight increase in K(m) and a 3-fold reduction of V(max), when compared with the parent enzyme. This converted the enzyme from a resveratrol-forming into a dihydropinosylvin-forming stilbene synthase.	UNIV FREIBURG,INST BIOL 2,SCHANZLESTR 1,W-7800 FREIBURG,GERMANY	University of Freiburg								AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; FLIEGMANN J, 1992, PLANT MOL BIOL, V18, P489, DOI 10.1007/BF00040665; Gorham J., 1989, METHODS PLANT BIOCH, V1, P159; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANZ T, 1990, PLANTA, V181, P169, DOI 10.1007/BF02411534; LANZ T, 1991, J BIOL CHEM, V266, P9971; MELCHIOR F, 1991, ARCH BIOCHEM BIOPHYS, V288, P552, DOI 10.1016/0003-9861(91)90234-A; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; Sambrook J, 1989, MOL CLONING LABORATO; Sandermann H. Jr., 1989, Acid deposition: sources, effects and controls., P243; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; SCHRODER J, 1990, Z NATURFORSCH C, V45, P1; TERADA K, 1991, EUR J BIOCHEM, V202, P797, DOI 10.1111/j.1432-1033.1991.tb16435.x; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	15	28	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20558	20560						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400374				2022-12-27	WOS:A1992JT97800010
J	LESSL, M; BALZER, D; PANSEGRAU, W; LANKA, E				LESSL, M; BALZER, D; PANSEGRAU, W; LANKA, E			SEQUENCE SIMILARITIES BETWEEN THE RP4 TRA2 AND THE TI VIRB REGION STRONGLY SUPPORT THE CONJUGATION MODEL FOR T-DNA TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; F-SEX FACTOR; AGROBACTERIUM-TUMEFACIENS; ESCHERICHIA-COLI; PLASMID RP4; HOST-RANGE; MEMBRANE LOCALIZATION; REGULATORY SEQUENCES; PROTEIN COMPLEX; NICK REGIONS	Transfer genes of the IncP plasmid RP4 are grouped in two separate regions, designated Tra1 and Tra2. Tra2 gene products are proposed to be mainly responsible for the formation of mating pairs in conjugating cells. To provide information relevant to understanding the function of Tra2 gene products, the nucleotide sequence of the entire RP4 Tra2 region is presented here. Twelve open reading frames were identified in the Tra2 core region, being essential for intraspecific Escherichia coli matings. Predicted sizes of 11 of the 12 Tra2 polypeptides could be verified by expression in E. coli. Based on hydropathy plot analysis, most of the Tra2 open reading frames encode proteins that may interact with membranes. Interestingly, six of the predicted Tra2 gene products exhibited significant sequence similarities to gene products encoded by the VirB operon of the Agrobacterium Ti plasmid. VirB proteins are thought to function in the formation of a transmembrane structure that mediates the passage of T-DNA molecules from bacteria into plant cells. Because of this analogy and the hydropathy of Tra2 gene products, we assume that the DNA transfer machineries acting in bacterial conjugation and T-DNA transfer are structurally and functionally similar. Therefore, the data presented here, support the hypothesis that Ti vir and IncP tra genes evolved from a common ancestor. This suggestion is favored by previous findings of sequence similarities between the IncP and Ti DNA transfer system.	MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								ALDOORI Z, 1982, GENET RES, V39, P99, DOI 10.1017/S0016672300020772; BALZER D, 1992, NUCLEIC ACIDS RES, V20, P1851, DOI 10.1093/nar/20.8.1851; BARTH PT, 1978, J BACTERIOL, V133, P43, DOI 10.1128/JB.133.1.43-52.1978; BAUGHMAN G, 1984, P NATL ACAD SCI-BIOL, V81, P5389, DOI 10.1073/pnas.81.17.5389; BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURKARDT HJ, 1979, J GEN MICROBIOL, V114, P341, DOI 10.1099/00221287-114-2-341; CHRISTIE PJ, 1989, P NATL ACAD SCI USA, V86, P9677, DOI 10.1073/pnas.86.24.9677; DATTA N, 1972, J GEN MICROBIOL, V70, P453, DOI 10.1099/00221287-70-3-453; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURRENBERGER F, 1989, P NATL ACAD SCI USA, V86, P9154, DOI 10.1073/pnas.86.23.9154; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGSTROM P, 1987, J MOL BIOL, V197, P635, DOI 10.1016/0022-2836(87)90470-0; FONG ST, 1989, J GEN MICROBIOL, V135, P499; FRANKLIN FCH, 1989, PROMISCUOUS PLASMIDS, P247; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GRINTER NJ, 1981, PLASMID, V5, P267, DOI 10.1016/0147-619X(81)90004-4; GUINEY DG, 1989, PROMISCUOUS PLASMIDS, P27; HAAS D, 1989, PROMISCUOUS PLASMIDS, P185; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; HERRERAESTRELLA A, 1988, EMBO J, V7, P4055, DOI 10.1002/j.1460-2075.1988.tb03299.x; HOWARD EA, 1989, P NATL ACAD SCI USA, V86, P4017, DOI 10.1073/pnas.86.11.4017; JAGURABURDZY G, 1992, IN PRESS NUCLEIC ACI, V20; JALAJAKUMARI MB, 1989, GENE, V81, P195, DOI 10.1016/0378-1119(89)90179-0; JOVANOVIC OS, 1992, J BACTERIOL, V174, P4842, DOI 10.1128/JB.174.14.4842-4846.1992; KULDAU GA, 1990, MOL GEN GENET, V221, P256, DOI 10.1007/BF00261729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1983, PLASMID, V10, P303, DOI 10.1016/0147-619X(83)90047-1; LESSL M, 1991, MOL GEN GENET, V227, P120, DOI 10.1007/BF00260716; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; MANNING PA, 1979, BACTERIAL OUTER MEMB, P409; Miele L, 1991, DNA Seq, V2, P145, DOI 10.3109/10425179109039685; Miller J. H., 1972, EXPT MOL GENETICS, P431; MIRANDA A, 1992, J BACTERIOL, V174, P2288, DOI 10.1128/JB.174.7.2288-2297.1992; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MOTALLEBIVESHAREH M, 1992, MOL MICROBIOL, V6, P907, DOI 10.1111/j.1365-2958.1992.tb01541.x; OKAMOTO S, 1991, MOL GEN GENET, V228, P24, DOI 10.1007/BF00282443; OLSEN RH, 1973, J BACTERIOL, V113, P772, DOI 10.1128/JB.113.2.772-780.1973; PALOMBO EA, 1989, PLASMID, V22, P59, DOI 10.1016/0147-619X(89)90036-X; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; PERUMAL NB, 1984, J BIOL CHEM, V259, P5357; ROGOWSKY PM, 1990, PLASMID, V23, P85, DOI 10.1016/0147-619X(90)90028-B; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO T, 1990, P NATL ACAD SCI USA, V87, P142, DOI 10.1073/pnas.87.1.142; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SHIRASU K, 1990, MOL MICROBIOL, V4, P1153, DOI 10.1111/j.1365-2958.1990.tb00690.x; SIMON R, 1989, PROMISCUOUS PLASMIDS, P207; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; SMITH CA, 1984, NUCLEIC ACIDS RES, V12, P3619, DOI 10.1093/nar/12.8.3619; SMITH CA, 1989, PROMISCUOUS PLASMIDS, P57; STACHEL SE, 1986, CELL, V47, P155, DOI 10.1016/0092-8674(86)90437-X; STRACK B, 1992, J BIOL CHEM, V267, P13062; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1987, J BIOL CHEM, V262, P16212; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; THOMPSON DV, 1988, NUCLEIC ACIDS RES, V16, P4621, DOI 10.1093/nar/16.10.4621; VOGEL AM, 1992, J BACTERIOL, V174, P303, DOI 10.1128/jb.174.1.303-308.1992; VOGLER AP, 1991, J BACTERIOL, V173, P3564, DOI 10.1128/jb.173.11.3564-3572.1991; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD ER, 1988, SCIENCE, V242, P927, DOI 10.1126/science.242.4880.927; WARD JE, 1988, J BIOL CHEM, V263, P5804; WARD JE, 1990, J BACTERIOL, V172, P5200, DOI 10.1128/jb.172.9.5200-5210.1990; WARD JE, 1990, J BIOL CHEM, V265, P4768; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; WATERS VL, 1992, IN PRESS J BACTERIOL, V174; WATSON J, 1980, PLASMID, V4, P175, DOI 10.1016/0147-619X(80)90007-4; WILKINS B, 1992, IN PRESS BACTERIAL C; WILLETTS N, 1984, MICROBIOL REV, V48, P224; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG C, 1988, J BACTERIOL, V170, P3367, DOI 10.1128/jb.170.8.3367-3374.1988; YOUNG C, 1985, P NATL ACAD SCI USA, V82, P7374, DOI 10.1073/pnas.82.21.7374; YU F, 1986, J BIOL CHEM, V261, P2284; Ziegelin G, 1991, DNA Seq, V1, P303, DOI 10.3109/10425179109020786	83	137	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20471	20480						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400366				2022-12-27	WOS:A1992JR85800112
J	MARSH, ME; CHANG, DK; KING, GC				MARSH, ME; CHANG, DK; KING, GC			ISOLATION AND CHARACTERIZATION OF A NOVEL ACIDIC POLYSACCHARIDE CONTAINING TARTRATE AND GLYOXYLATE RESIDUES FROM THE MINERALIZED SCALES OF A UNICELLULAR COCCOLITHOPHORID ALGA PLEUROCHRYSIS-CARTERAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PHOSPHOPROTEIN PARTICLES; MULTIPLE QUANTUM NMR; HYMENOMONAS-CARTERAE; POLYACRYLAMIDE GELS; CALCIUM; PROTEINS; DENTIN; SPECTROSCOPY; SENSITIVITY; RECEPTOR	The characterization of mineral-associated polyanions from the unicellular alga Pleurochrysis carterae is described. This species is useful for the study of mineralization, because it produces calcified scales known as coccoliths in homogeneous cell culture. Three acidic polysaccharides (PS-1, PS-2, and PS-3) were extracted from the coccoliths with EDTA and were separated and purified by differential precipitation with magnesium ions and chromatography on DEAE-cellulose. PS-1 and PS-3 are predominantly polymers of galacturonic acid containing lesser amounts of other monosaccharides. PS-2 has an unusual structure. Chemical, enzymatic, and two-dimensional NMR analyses demonstrate that the repeating unit of PS-2 is [--> 4)D-glucuronate(beta 1 --> 2) meso-tartrate (3 --> 1) glyoxylate(1-]n. Thus PS-2 has a high density of negatively charged groups available for calcium ion binding, similar to the phosphoprotein polyanions of other species. Polysaccharides containing tartrate and/or glyoxylate have not been previously described; these residues may be introduced into PS-2 by a postpolymerization process involving oxidative cleavage of glucuronate or mannuronate residues.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,WM KECK CTR COMP BIOL,HOUSTON,TX 77251	Rice University	MARSH, ME (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST DENT SCI,POB 20068,HOUSTON,TX 77225, USA.		Chang, Ding-Kwo/E-7079-2015		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036239] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-05759] Funding Source: Medline; NIAMS NIH HHS [AR-36239] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEYGUNAWARDANA C, 1990, BIOCHEMISTRY-US, V29, P234, DOI 10.1021/bi00453a032; ABEYGUNAWARDANA C, 1991, BIOCHEMISTRY-US, V30, P6528, DOI 10.1021/bi00240a025; AONO R, 1990, BIOCHEM J, V270, P363, DOI 10.1042/bj2700363; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BARTNICKIGARCIA S, 1968, BIOCHIM BIOPHYS ACTA, V170, P54, DOI 10.1016/0304-4165(68)90160-8; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BERGMEYER HU, 1984, METHOD ENZYMAT AN, V6, P624; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BUTLER WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P178, DOI 10.1016/0003-9861(83)90021-8; BYRD RA, 1987, CARBOHYD RES, V166, P47, DOI 10.1016/0008-6215(87)80043-5; CASSELS FJ, 1990, J BIOL CHEM, V265, P14127; de Vrind-de Jong E. W., 1986, BIOMINERALIZATION LO, P205; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; GREEN MR, 1973, ANAL BIOCHEM, V56, P43, DOI 10.1016/0003-2697(73)90167-X; Guillard R.R.L., 1975, CULTURE MARINE INVER, P29, DOI [10.1007/978-1-4615-8714-9_3., 10.1007/978-1-4615-8714-9_3]; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SL, 1977, BIOCHEMISTRY-US, V16, P2971, DOI 10.1021/bi00632a026; LERNER L, 1987, CARBOHYD RES, V166, P35, DOI 10.1016/0008-6215(87)80042-3; Lyman J, 1940, J MAR RES, V3, P134; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARSH ME, 1984, BIOCHEMISTRY-US, V23, P1448, DOI 10.1021/bi00302a017; MARSH ME, 1986, J EXP ZOOL, V239, P207, DOI 10.1002/jez.1402390208; MARSH ME, 1983, J EXP ZOOL, V226, P193, DOI 10.1002/jez.1402260204; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P339, DOI 10.1021/bi00427a046; MENZIES IS, 1969, CHROMATOGR ELECTROPH, V1, P310; OUTKA DE, 1971, J PROTOZOOL, V18, P285, DOI 10.1111/j.1550-7408.1971.tb03319.x; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; STAFFORD HA, 1959, AM J BOT, V46, P347, DOI 10.2307/2439194; TAYLOR RL, 1972, BIOCHEMISTRY-US, V11, P1383, DOI 10.1021/bi00758a009; TSUCHIHASHI H, 1981, CARBOHYD RES, V98, P65, DOI 10.1016/S0008-6215(00)87142-6; VANDERWAL P, 1983, J ULTRA MOL STRUCT R, V85, P139, DOI 10.1016/S0022-5320(83)90103-X; VANDERWAL P, 1983, J ULTRASTRUCT RES, V35, P215; VANDERWAL P, 1983, ECOLOGICAL B, V35, P215; VAUGHN RH, 1946, J BACTERIOL, V52, P311, DOI 10.1128/JB.52.3.311-325.1946; WILLIAMS M, 1979, PHYTOCHEMISTRY, V18, P953, DOI 10.1016/S0031-9422(00)91456-0; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YASHPHE J, 1965, ANAL BIOCHEM, V13, P345, DOI 10.1016/0003-2697(65)90203-4; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	42	75	78	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20507	20512						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400368				2022-12-27	WOS:A1992JR85800117
J	DUGI, KA; DICHEK, HL; TALLEY, GD; BREWER, HB; SANTAMARINAFOJO, S				DUGI, KA; DICHEK, HL; TALLEY, GD; BREWER, HB; SANTAMARINAFOJO, S			HUMAN LIPOPROTEIN-LIPASE - THE LOOP COVERING THE CATALYTIC SITE IS ESSENTIAL FOR INTERACTION WITH LIPID SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC LIPASE; INTERFACIAL ACTIVATION; DENSITY LIPOPROTEINS; HYDROLYSIS; TRIBUTYRIN; SEQUENCE; PROTEINS; BINDING; ENZYME; HELIX	Lipoprotein lipase (LPL), a key enzyme which initiates the hydrolysis of triglycerides present in chylomicrons and very low density lipoproteins, consists of multiple functional domains which are necessary for normal activity. The catalytic domain of LPL mediates the esterase function of the enzyme but separate lipid binding sites have been proposed to be involved in the interaction of LPL with emulsified lipid substrates at the water-lipid interface. Like pancreatic lipase (PL), LPL contains a surface loop covering the catalytic pocket that may modulate access of the substrate to the active site of the enzyme. Secondary structural analysis of this loop reveals a helix-turn-helix motif with two short amphipathic helices that have hydrophobic moments of 0.64 and 0.68. In order to investigate the role of the loop in the initial interaction of LPL with its substrate, we utilized site-directed mutagenesis to generate eight constructs in which the amphipathic properties of the loop were altered and expressed them in human embryonal kidney-293 cells. Reducing the amphiphilicity without changing the predicted secondary structure of the loop abolished the ability of the lipase to hydrolyze emulsified, long chain fatty acid triglycerides (triolein) but not the water soluble substrate tributyrin. Replacing the loop of LPL with the loop of hepatic lipase, which differs in 15 of 22 amino acids but is also amphiphilic, led to the expression of an enzyme that retained both triolein and tributyrin hydrolyzing activity. Substitution of the LPL loop by a short four amino acid peptide, which may allow more direct access to the active site than the 22 amino acid loop, enhanced hydrolysis of short chain fatty acid triglycerides by more than 2-fold, while the ability to hydrolyze emulsified substrates was abolished. Thus, disruption of the amphipathic structure of the LPL loop selectively decreases the hydrolysis of emulsified lipid substrate without affecting the esterase or catalytic function of the enzyme. These studies establish that the loop with its two amphipathic helices is essential for hydrolysis of long chain fatty acid substrate by LPL providing new insight into the role of the LPL loop in lipid-substrate interactions. We propose that the interaction between the lipoprotein substrates and the amphipathic helices within this loop may in part determine lipase substrate specificity.	NHLBI,MOLEC DIS BRANCH,BLDG 10,RM 7N117,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BENGTSSON G, 1981, EUR J BIOCHEM, V113, P547, DOI 10.1111/j.1432-1033.1981.tb05097.x; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CHAIT A, 1982, J CLIN INVEST, V69, P490, DOI 10.1172/JCI110473; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4980, DOI 10.1021/bi00668a006; CHENG CF, 1981, J BIOL CHEM, V256, P2893; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DICHEK HL, 1992, CLIN RES, V40, pA312; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAVEL RJ, 1973, BIOCHEMISTRY-US, V12, P1828, DOI 10.1021/bi00733a026; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; HIDE WA, 1992, J LIPID RES, V33, P167; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOBAYASHI J, 1992, BIOCHEM BIOPH RES CO, V182, P70, DOI 10.1016/S0006-291X(05)80113-5; KOBAYASHI J, 1989, EUR J CLIN INVEST, V19, P424, DOI 10.1111/j.1365-2362.1989.tb00254.x; LAROSA JC, 1970, BIOCHEM BIOPH RES CO, V41, P57, DOI 10.1016/0006-291X(70)90468-7; MCLEAN LR, 1991, BIOCHEMISTRY-US, V30, P31, DOI 10.1021/bi00215a005; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; PERSSON B, 1991, FEBS LETT, V288, P33, DOI 10.1016/0014-5793(91)80997-H; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; RAPP D, 1978, EUR J BIOCHEM, V91, P379, DOI 10.1111/j.1432-1033.1978.tb12690.x; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SARDA L, 1958, BIOCHIM BIOPHYS ACTA, V30, P513, DOI 10.1016/0006-3002(58)90097-0; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; SHIRAI K, 1984, BIOCHIM BIOPHYS ACTA, V795, P9; VAZQUEZ SR, 1992, J BIOL CHEM, V267, P7406; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG H, 1991, P NATL ACAD SCI USA, V88, P1120; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	43	101	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25086	25091						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460010				2022-12-27	WOS:A1992KB60300029
J	OZKAYNAK, E; SCHNEGELSBERG, PNJ; JIN, DF; CLIFFORD, GM; WARREN, FD; DRIER, EA; OPPERMANN, H				OZKAYNAK, E; SCHNEGELSBERG, PNJ; JIN, DF; CLIFFORD, GM; WARREN, FD; DRIER, EA; OPPERMANN, H			OSTEOGENIC PROTEIN-2 - A NEW MEMBER OF THE TRANSFORMING GROWTH-FACTOR-BETA SUPERFAMILY EXPRESSED EARLY IN EMBRYOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULLERIAN INHIBITING SUBSTANCE; OVARIAN FOLLICULAR-FLUID; DECAPENTAPLEGIC GENE; DROSOPHILA-MELANOGASTER; BONE-FORMATION; FAMILY; IDENTIFICATION; MESODERM; BOVINE; OP-1	Osteogenic protein-2, OP-2, a new member of the transforming growth factor-beta (TGF-beta) superfamily, closely related to the osteogenic/bone morphogenetic proteins, was discovered in mouse embryo and human hippocampus cDNA libraries. The TGF-beta domain of OP-2 shows 74% identity to OP-1, 75% to Vgr-1, and 76% to BMP-5, hence OP-2 may also have bone inductive activity. The genomic locus of OP-2 has seven exons, like OP-1, and spans more than 27 kilobases (kb). In the C-terminal TGF-beta domain, OP-2 has a unique additional cysteine. Mouse embryos express relatively high levels of OP-2 mRNA at 8 days, two species of 3 and 5 kb. A careful study of mRNA expression of the osteogenic proteins in specific organs revealed discrete mRNA species for BMP-3, BMP-4, BMP-5, and BMP-6/Vgr-1 in lung or liver of young and adult mice. OP-1 is expressed in kidney; however, OP-2 and BMP-2 mRNAs were not detected in any organs studied, suggesting an early developmental role.			OZKAYNAK, E (corresponding author), CREAT BIOMOLECULES INC,35 SOUTH ST,HOPKINTON,MA 01748, USA.							AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK SD, 1991, J MINERAL RES S1, V6; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; HAMMONDS RG, 1991, MOL ENDOCRINOL, V5, P149, DOI 10.1210/mend-5-1-149; Huggins CB, 1931, ARCH SURG-CHICAGO, V22, P377, DOI 10.1001/archsurg.1931.01160030026002; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1987, BIOTECHNIQUES, V5, P770; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SAMPATH TK, 1981, P NATL ACAD SCI-BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEGAL D, 1985, GENETICS, V109, P119; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WAGNER P, 1990, FEBS LETT, V275, P1, DOI 10.1016/0014-5793(90)81425-N; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	38	273	288	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25220	25227						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460021				2022-12-27	WOS:A1992KB60300048
J	STADDON, JM; BOUZYK, MM; ROZENGURT, E				STADDON, JM; BOUZYK, MM; ROZENGURT, E			INTERCONVERSION OF GRP78/BIP - A NOVEL EVENT IN THE ACTION OF PASTEURELLA-MULTOCIDA TOXIN, BOMBESIN, AND PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SWISS 3T3 CELLS; GLUCOSE-REGULATED PROTEIN; CHAIN-BINDING-PROTEIN; ADP-RIBOSYLATION; ENDOPLASMIC-RETICULUM; POTENT MITOGEN; BIOCHEMICAL-CHARACTERIZATION; HAMSTER FIBROBLASTS; RESPONSIVE GENES	Incubation of Swiss 3T3 cells with [2-H-3]adenine,as in other cell types, reveals the ADP-ribosylation of GRP78 (the 78-kDa glucose-regulated protein, also known as BiP, the immunoglobulin heavy chain-binding protein), a resident endoplasmic reticulum Protein that assists in the processing of proteins destined for secretion or cell surface expression. Here we show that Pasteurella multocida toxin, a potent growth factor for cultured fibroblasts, decreased the ADP-ribosylation of GRP78/BiP to 16 +/- 6% of the control value (n = 23). The action of the toxin occurred after a lag period, was blocked by lysosomotrophic agents, and potentiated by increased incubation time (ED50 4 ng/ml and 1 ng/ml in 4 and 8 h, respectively), thus indicating that the toxin enters the cells to act. Bombesin and platelet-derived growth factor (PDGF) similarly decreased the ADP-ribosylation of GRP78/BiP (ED50 0.5 nM and 2.5 ng/ml, respectively) but acted more rapidly than the toxin. Signaling pathways activated by the toxin, bombesin, and PDGF had effects on the ADP-ribosylation of GRP78/BiP. Thus, activation of protein kinase C alone by phorbol 12,13-dibutyrate was partially effective, and down-regulation of protein kinase C attenuated but did not block the action of the toxin, bombesin, and PDGF. Agents that mobilize Ca2+ from the endoplasmic reticulum (A23187, ionomycin, and thapsigargin) caused a decrease in the ADP-ribosylation of GRP78/BiP that was similar in magnitude to that achieved by the toxin, bombesin, and PDGF, implicating a role for inositol 1,4,5-trisphosphate-mediated Ca2+ mobilization in the action of the mitogenic agents. The growth factor-induced decrease in the ADP-ribosylation of GRP78/BiP may represent its conversion from an inactive to an active state.	IMPERIAL CANC RES FUND, POB 123, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CHANTER N, 1986, J GEN MICROBIOL, V132, P1089; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1988, P NATL ACAD SCI USA, V85, P2250, DOI 10.1073/pnas.85.7.2250; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; LEDFORD BE, 1986, EUR J BIOCHEM, V161, P661, DOI 10.1111/j.1432-1033.1986.tb10491.x; LEE AS, 1984, J BIOL CHEM, V259, P4616; LENO GH, 1989, EUR J BIOCHEM, V186, P205, DOI 10.1111/j.1432-1033.1989.tb15196.x; LENO GH, 1990, FEBS LETT, V276, P29, DOI 10.1016/0014-5793(90)80499-9; LOPEZRIVAS A, 1984, AM J PHYSIOL, V247, pC156, DOI 10.1152/ajpcell.1984.247.3.C156; MACER DRJ, 1988, J CELL SCI, V91, P61; Mehmet H, 1990, GROWTH FACTORS, V3, P83, DOI 10.3109/08977199009108271; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, J CELL SCI, P43; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1991, CURR TOP MICROBIOL, V167, P31; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	60	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25239	25245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460024				2022-12-27	WOS:A1992KB60300051
J	UNNI, E; MEISTRICH, ML				UNNI, E; MEISTRICH, ML			PURIFICATION AND CHARACTERIZATION OF THE RAT SPERMATID BASIC NUCLEAR PROTEIN-TP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CHROMOSOMAL PROTEIN; TRANSITION PROTEIN-2; MAMMALIAN SPERMATIDS; MOUSE SPERMATIDS; TESTIS; SPERMATOGENESIS; CDNA; BOAR; BULL; TP2	Following elongation of spermatids in mammals, the histones are replaced by a set of basic nuclear transition proteins; in the rat there are four, named TP1-TP4. Of these, TP1 and TP2 are well characterized. Here we report the purification to homogeneity of TP4 from rat spermatids. It is a low molecular mass (about 13-20 kDa) basic protein with arginine and lysine constituting 24 mol % and histidine 2.2 mol %. Its 25 N-terminal amino acids were sequenced, and no sequence homologies with any known protein were found. Polyclonal antibodies raised against it in rabbit did not cross-react with other transition proteins, protamines, or histones. The presence of TP4 during sperm development was monitored by cell separation studies. No TP4 was detected in round spermatids, and along with TP1 and TP2, it is present in step 13-15 spermatids and its amount decreased in steps 16-19. Trace amounts of TP4 were also detected in epididymal sperm. A possible role for TP4 in spermatid and sperm chromatin structure is discussed.			UNNI, E (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL RADIOTHERAPY,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD-16843] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016843] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMA K, 1990, BIOCHIM BIOPHYS ACTA, V1041, P264, DOI 10.1016/0167-4838(90)90282-K; BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; Balhorn R., 1989, P366; BASKARAN R, 1990, J BIOL CHEM, V265, P21039; BASKARAN R, 1991, BIOCHEM BIOPH RES CO, V179, P1491, DOI 10.1016/0006-291X(91)91741-T; BUNICK D, 1990, EXP CELL RES, V188, P147, DOI 10.1016/0014-4827(90)90290-Q; COURTENS JL, 1981, J ULTRA MOL STRUCT R, V74, P327, DOI 10.1016/S0022-5320(81)80124-4; DUPRESSOIR T, 1985, EXP CELL RES, V161, P63, DOI 10.1016/0014-4827(85)90490-2; GRIMES SR, 1977, EXP CELL RES, V110, P31, DOI 10.1016/0014-4827(77)90266-X; GRIMES SR, 1986, COMP BIOCHEM PHYS B, V83, P495, DOI 10.1016/0305-0491(86)90285-3; Hecht N.B., 1989, P396; HECHT NB, 1990, J REPROD FERTIL, V88, P679, DOI 10.1530/jrf.0.0880679; Hecht NB, 1989, HISTONES OTHER BASIC, P347; HEIDARAN MA, 1988, J CELL BIOL, V106, P1427, DOI 10.1083/jcb.106.5.1427; HEIDARAN MA, 1987, J BIOL CHEM, V262, P13309; KISTLER WS, 1989, HISTONES OTHER BASIC, P331; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; KREMLING H, 1989, DIFFERENTIATION, V40, P184, DOI 10.1111/j.1432-0436.1989.tb00597.x; LANNEAU M, 1982, J REPROD FERTIL, V65, P163, DOI 10.1530/jrf.0.0650163; LOIR M, 1978, BIOCHEM BIOPH RES CO, V80, P975, DOI 10.1016/0006-291X(78)91341-4; LUERSSEN H, 1989, NUCLEIC ACIDS RES, V17, P3585, DOI 10.1093/nar/17.9.3585; MARUSHIGE K, 1971, J BIOL CHEM, V246, P5799; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; MAYER JF, 1981, BIOL REPROD, V25, P1041, DOI 10.1095/biolreprod25.5.1041; Meistrich M., 1989, HISTONES OTHER BASIC, P165; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MEISTRICH ML, 1980, FED PROC, V39, P1884; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; MEISTRICH ML, 1978, FED PROC, V37, P2522; MEISTRICH ML, 1981, BIOREGULATORS REPROD, P151; Platz R D, 1977, Methods Cell Biol, V16, P297; REINHART N, 1991, BIOL CHEM H-S, V372, P431, DOI 10.1515/bchm3.1991.372.1.431; RISLEY MS, 1990, CHROMOSOMES EUKARYOT, V2, P61; SEYEDIN SM, 1980, J BIOL CHEM, V255, P5949; SINGH J, 1987, INDIAN J BIOCHEM BIO, V24, P181; SINGH J, 1987, J BIOL CHEM, V262, P734; SINGH J, 1988, BIOCHEM INT, V17, P701; TROSTLEWEIGE PK, 1982, J BIOL CHEM, V257, P5560; WHITE FH, 1967, METHOD ENZYMOL, V11, P481	40	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25359	25363						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460032				2022-12-27	WOS:A1992KB60300068
J	JACQUET, E; VANONI, M; FERRARI, C; ALBERGHINA, L; MARTEGANI, E; PARMEGGIANI, A				JACQUET, E; VANONI, M; FERRARI, C; ALBERGHINA, L; MARTEGANI, E; PARMEGGIANI, A			A MOUSE CDC25-LIKE PRODUCT ENHANCES THE FORMATION OF THE ACTIVE GTP COMPLEX OF HUMAN RAS-P21 AND SACCHAROMYCES-CEREVISIAE RAS2 PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; ADENYLATE-CYCLASE PATHWAY; MOLECULAR-CLONING; GENE; GDP; P21RAS; SITE	GDP-dissociation stimulators (GDSs) are the key element for the regeneration of the active state of ras proteins, but despite intensive investigations, little is so far known about their functional and structural properties, particularly in mammals. A growing number of genes from various organisms have been postulated to encode GDSs on the basis of sequence similarity with the Saccharomyces cerevisiae CDC25 gene, whose product acts as a GDS of RAS proteins. However, except for CDC25 and the related SDC25 C-domain, no biochemical evidence of ras GDS activity for these CDC25-like proteins has yet been available. We show that the product of a recently isolated mouse CDC25-like gene (CDC25Mm) can strongly enhance (more than 1000 times) the GDP release from both human c-Ha-ras p21 and yeast RAS2 in vitro. As a consequence, the CDC25Mm induces a rapid formation of the biologically active Ras.GTP complex. This GDS is much more active on the GDP than on the GTP complex and has a narrow substrate specificity, since it was found to be inactive on several ras-like proteins. The mouse GDS can efficiently substitute for yeast CDC25 in an in vitro adenylylcyclase assay on RAS2 cdc25 yeast membranes. Our results show that a cloned GDP to GTP exchange factor of mammalian ras belongs to the novel family of CDC25-like proteins.	ECOLE POLYTECH,BIOCHIM,CNRS,STRUCT DIVERSE INTERVENT 61840,F-91128 PALAISEAU,FRANCE; UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,SEZ BIOCHIM COMPARATA,I-20133 MILAN,ITALY	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; University of Milan				JACQUET, Eric/0000-0001-6366-8436; Alberghina, Lilia/0000-0003-1694-931X; VANONI, MARCO ERCOLE/0000-0002-8690-2587; Martegani, Enzo/0000-0001-9196-4224				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CASPERSON GF, 1983, J BIOL CHEM, V258, P7911; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HUGHES DA, 1990, NATURE, V344, P357; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; MARTEGANI E, 1986, EMBO J, V5, P2363, DOI 10.1002/j.1460-2075.1986.tb04505.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	24	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24181	24183						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447167				2022-12-27	WOS:A1992KA26300009
J	WEST, AH; CLARK, DJ; MARTIN, J; NEUPERT, W; HARTL, FU; HORWICH, AL				WEST, AH; CLARK, DJ; MARTIN, J; NEUPERT, W; HARTL, FU; HORWICH, AL			2 RELATED GENES ENCODING EXTREMELY HYDROPHOBIC PROTEINS SUPPRESS A LETHAL MUTATION IN THE YEAST MITOCHONDRIAL PROCESSING ENHANCING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; SEQUENCE-ANALYSIS; SACCHAROMYCES-CEREVISIAE; MULTIGENE FAMILY; IMPORT; MEMBRANE; HSP60; INSERTION; PEPTIDASE; COMPLEX	The processing enhancing protein of mitochondria (PEP) is an essential component that has been shown to participate in proteolytic removal of NH2-terminal signal peptides from precursor proteins imported into the mitochondrial matrix. Using a yeast strain bearing a PEP mutation that renders it temperature-sensitive, an approach of genetic suppression was taken in order to identify additional components that could be involved with protein import: high copy plasmids comprising a yeast genomic library were tested for ability to suppress the 37-degrees-C growth defect. Two plasmids were isolated, pSMF1 and pSMF2, which suppressed the growth defect nearly as well as the cloned PEP gene itself. Sequence analysis of the rescuing genes predicted extremely hydrophobic proteins with sizes of 63 and 60 kDa, respectively. Remarkably, the predicted SMF1 and SMF2 products are 49% identical to each other overall. To test the requirement for SMF1 and SMF2, the chromosomal genes were disrupted. Individual disruption was without effect, but cells in which both genes were disrupted grew poorly. When mitochondria were prepared from the double disruption strain grown in a nonfermentable carbon source, they were morphologically normal but defective for translocation of radiolabeled precursor proteins. SMF1 protein was provisionally localized to the mitochondrial membranes using epitope tagging. We suggest that SMF1 and SMF2 are mitochondrial membrane proteins that influence PEP-dependent protein import, possibly at the step of protein translocation.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; SLOAN KETTERING MEM CANC CTR,CELLULAR BIOCHEM PROGRAM,NEW YORK,NY 10021; UNIV MUNICH,INST PHYSIOL CHEM,W-8000 MUNICH 2,GERMANY; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Memorial Sloan Kettering Cancer Center; University of Munich; Yale University			Hartl, F. Ulrich/Y-8206-2019					BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FREITAG H, 1982, EUR J BIOCHEM, V126, P197, DOI 10.1111/j.1432-1033.1982.tb06766.x; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P327, DOI 10.1093/nar/14.1.327; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; Maniatis T., 1982, MOL CLONING; Morelle G, 1989, FOCUS, V11, P7; MURAKAMI K, 1988, J BIOL CHEM, V263, P18437; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TOWBIN H, 1979, P NATL ACAD SCI USA, V84, P4767; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	40	69	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24625	24633						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447206				2022-12-27	WOS:A1992KA26300072
J	ZARDENETA, G; HOROWITZ, PM				ZARDENETA, G; HOROWITZ, PM			ANALYSIS OF THE PERTURBATION OF PHOSPHOLIPID MODEL MEMBRANES BY RHODANESE AND ITS PRESEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORTED MITOCHONDRIAL PROTEIN; GUANIDINIUM CHLORIDE; DENATURED RHODANESE; PRECURSOR PROTEIN; SIGNAL SEQUENCES; PRE-SEQUENCE; PEPTIDE; BINDING; HELIX; FORM	The ability of the cytoplasmically synthesized mitochondrial enzyme rhodanese and its putative import signal sequence to interact with model phospholipid membranes was characterized. Membrane perturbation assays were used to test a current hypothesis that the initial step in protein translocation may involve binding of signal sequences with membrane lipids. Here we show comparative studies on the effect of native and various forms of denatured rhodanese, as well as two peptides, rho(1-23) and rho(11-23), derived from its NH2-terminal sequence, on the perturbation of 6-carboxyfluorescein-containing large unilamellar vesicles composed of either cardiolipin, phosphatidylcholine, or phosphatidylserine. We monitored the degree of perturbation by measuring dye leakage and found differential perturbation by either peptide or protein. Unfolded rhodanese perturbed vesicles in the order phosphatidylserine > cardiolipin >> phosphatidylcholine. Denatured rhodanese was approximately 25 times more effective (on a molar basis) than rho(1-23) in the disruption of anionic liposomes. Rho(11-23) was unable to perturb liposomes. We found an inverse correlation between degree of activity of rhodanese folding intermediates and their ability to perturb liposomes. On urea denaturation, enzymatic activity was completely lost before membrane perturbation ability reached significant levels. Analysis of the peptides by circular dichroism showed that anionic liposomes can induce alpha-helical structure only in rho(1-23) and denatured rhodanese. Intrinsic peptide fluorescence studies showed that only rho(1-23) and denatured rhodanese partitioned into these model membranes. Results obtained here imply that peptides from naturally occurring alpha-helical structures may need adjacent motifs for helical structure induction in lipid environments, and the subsequent secondary structure may, in turn, promote partitioning of these segments into the lipid phase and ultimately lead to membrane perturbation.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DEKROON AIP, 1990, BIOCHEMISTRY-US, V29, P8229, DOI 10.1021/bi00488a006; DEKROON AIPM, 1989, BIOCHIM BIOPHYS ACTA, V981, P371, DOI 10.1016/0005-2736(89)90051-5; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HOROWITZ PM, 1986, J BIOL CHEM, V261, P13887; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; KURABAN GP, 1991, PROTEIN EXP PURIF, V2, P379; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LIN KC, 1982, NATURE, V296, P164, DOI 10.1038/296164a0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1123; TAMM LK, 1986, BIOCHEMISTRY-US, V25, P7470, DOI 10.1021/bi00371a032; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1987, J BIOL CHEM, V262, P4486; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; ZAMBRANO F, 1975, BIOCHIM BIOPHYS ACTA, V380, P357, DOI 10.1016/0005-2760(75)90104-6; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811	44	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24193	24198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447169				2022-12-27	WOS:A1992KA26300011
J	BLASQUEZ, VC; HALE, MA; TREVORROW, KW; GARRARD, WT				BLASQUEZ, VC; HALE, MA; TREVORROW, KW; GARRARD, WT			IMMUNOGLOBULIN-KAPPA GENE ENHANCERS SYNERGISTICALLY ACTIVATE GENE-EXPRESSION BUT INDEPENDENTLY DETERMINE CHROMATIN STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-TYPE SPECIFICITY; SEQUENCE ELEMENTS; HYPERSENSITIVE SITES; CONSERVED SEQUENCE; STABLE INTEGRATION; INTRONIC MAR; DNA-SEQUENCE; 5' ENDS; TRANSCRIPTION; BINDING	Previous studies have located transcriptional enhancer elements within both the intron and 3'-region of the mouse kappa immunoglobulin gene. Here we address the role of these two enhancers in specifying gene activity and specific chromatin structures. MOPC41 kappa gene constructs, either intact or containing deletions of one or both enhancers, were introduced into S194 mouse plasmacytoma cells for transient and stable expression studies. Transient expression assays revealed that the basal level expression exhibited by enhancerless constructs was activated 100-200-fold by the two enhancers together in a synergistic fashion. A similar trend was observed when both enhancers were present in stably integrated constructs, although the synergy was less pronounced. Analysis of DNase I hypersensitive sites in the chromatin revealed that stably integrated constructs established hypersensitive sites about the enhancer sequences. These sites demonstrated the same nuclease susceptibility as those associated with the endogenous gene(s), and their establishment was independent of the presence of the other enhancer. Thus, although both enhancers are required for maximal gene expression, the elements act independently in determining specific chromatin structures.	UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,NOTRE DAME,IN 46556	University of Notre Dame	GARRARD, WT (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM29935, GM22201, GM31689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029935, P01GM031689, R01GM022201] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; CHUNG SY, 1983, P NATL ACAD SCI-BIOL, V80, P2427, DOI 10.1073/pnas.80.9.2427; CURRIE RA, 1989, MOL CELL BIOL, V9, P4239, DOI 10.1128/MCB.9.10.4239; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FOSTER J, 1985, NATURE, V315, P423, DOI 10.1038/315423a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARSLOW TG, 1983, NUCLEIC ACIDS RES, V11, P4775, DOI 10.1093/nar/11.14.4775; PARSLOW TG, 1982, NATURE, V299, P449, DOI 10.1038/299449a0; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; REUDELHUBER TL, 1982, NUCLEIC ACIDS RES, V10, P1311, DOI 10.1093/nar/10.4.1311; SEIDMAN JG, 1978, NATURE, V276, P790, DOI 10.1038/276790a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; XU M, 1986, J BIOL CHEM, V261, P3838; XU M, 1989, J BIOL CHEM, V264, P21190; XU M, 1989, THESIS U TEXAS SW ME	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23888	23893						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429727				2022-12-27	WOS:A1992JZ23900069
J	ZHENG, RL; KEMP, RG				ZHENG, RL; KEMP, RG			THE MECHANISM OF ATP INHIBITION OF WILD-TYPE AND MUTANT PHOSPHOFRUCTO-1-KINASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; PHOSPHOFRUCTOKINASE; SITE; MUTAGENESIS; EXPRESSION; SUBSTRATE; BINDING; GENE	Escherichia coli 6-phosphofructo-1-kinase was inhibited by high concentrations of ATP at alkaline pH. The mechanism of the inhibition was studied with two mutants generated by site-directed mutagenesis; I126A, with a K(m) for fructose-6-P that was more than two orders of magnitude higher than that of wild type but with minimal changes in k(cat) and K(m) for ATP, and R72H, with little change in substrate half-saturation concentrations but with a k(cat) that was 300-fold lower that of wild type enzyme. ATP and fructose-6-P interacted in a mutually antagonistic manner; that is ATP decreased the apparent affinity for fructose-6-P and vice versa. The half-saturation concentrations for both substrates, most strikingly fructose-6-P, increased with increasing pH while the k(cat) increased. Studies with I126A suggested that ATP inhibition was not dependent on a dissociable group with a pK in the alkaline range and that the inhibition was not caused by abortive binding of substrate to the wrong substrate site. Inhibition was not the result of differential affinity of ATP for the R and T states of the enzyme. The low k(cat) mutant, R72H, did not display ATP inhibition. These data indicate that ATP inhibition results from substrate antagonism coupled with a steady state random mechanism wherein the high rate of catalysis does not permit equilibration of substrates.	UNIV HLTH SCI CHICAGO MED SCH,DEPT BIOL CHEM,3333 GREEN BAY RD,N CHICAGO,IL 60064	Chicago Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019912] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19912] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON DE, 1965, J BIOL CHEM, V240, P757; BANAS T, 1988, BIOCHIM BIOPHYS ACTA, V957, P178, DOI 10.1016/0167-4838(88)90270-1; BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BERGER SA, 1991, BIOCHEMISTRY-US, V30, P8477, DOI 10.1021/bi00098a027; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVILLEBONNE D, 1991, FEBS LETT, V290, P173, DOI 10.1016/0014-5793(91)81253-5; DEVILLEBONNE D, 1991, BIOCHEMISTRY-US, V30, P5750, DOI 10.1021/bi00237a017; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; HELLINGA HW, 1985, EUR J BIOCHEM, V149, P363, DOI 10.1111/j.1432-1033.1985.tb08934.x; JENSEN RA, 1970, J BIOL CHEM, V245, P2018; KEMP RG, 1967, BIOCHEMISTRY-US, V6, P423, DOI 10.1021/bi00854a009; KOTLARZ D, 1982, METHOD ENZYMOL, V90, P60; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADROR US, 1991, J BIOL CHEM, V266, P16550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; LEBRAS G, 1985, J BIOL CHEM, V260, P3450; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL IH, 1975, ENZYME KINETICS, P649; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; UHR ML, 1974, J BIOL CHEM, V249, P2920; WU LF, 1991, J BACTERIOL, V173, P3117, DOI 10.1128/JB.173.10.3117-3127.1991	26	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23640	23645						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429704				2022-12-27	WOS:A1992JZ23900035
J	PRADINESFIGUERES, A; RAETZ, CRH				PRADINESFIGUERES, A; RAETZ, CRH			PROCESSING AND SECRETION OF TUMOR-NECROSIS-FACTOR-ALPHA IN ENDOTOXIN-TREATED MONO MAC-6 CELLS ARE DEPENDENT ON PHORBOL-MYRISTATE ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; FACTOR GENE-EXPRESSION; MESSENGER-RNA; LIPID-A; MURINE MACROPHAGES; HUMAN-MONOCYTES; DOWN-REGULATION; FACTOR TNF; LIPOPOLYSACCHARIDE; CACHECTIN	Lipopolysaccharide (LPS, endotoxin) is a potent stimulator of tumor necrosis factor alpha (TNFalpha) synthesis and secretion in mouse macrophage tumor cells (Golenbock, D. T., Hampton, R. Y., Qureshi, N., Takayama, K., and Raetz, C. H. R. (1991) J. Biol. Chem. 266, 19490-19498). In contrast, addition of LPS (10 ng/ml) to human monomyelocytic (Mono Mac 6) cells induces very little production of TNFalpha, as judged by immunoassay of the growth medium. When 30 ng/ml 4-beta-phorbol-12-myristate 13-acetate (PMA) is added together with LPS, large amounts of TNFalpha are secreted. PMA alone is inactive. Maximal TNFalpha levels in the medium are achieved at 1 ng/ml of LPS. Protein kinase C inhibitors, such as H7 (1-(5-isoquinolinylsulfonyl)-2-methylpiperazine), staurosporine, and sphingosine, reduce TNFalpha secretion stimulated by PMA. The effect of PMA has been investigated at each stage of TNFalpha biogenesis. Treatment of Mono Mac 6 cells with LPS alone results in rapid, transient, and full expression of TNFalpha mRNA. Concomitant addition of PMA does not increase TNFalpha mRNA synthesis any further, but it prolongs the half-life of TNFalpha mRNA about 3-fold. However, mRNA stabilization does not account for the striking effect of PMA on TNFalpha secretion. Analysis of TNFalpha synthesis and secretion by immunoprecipitation indicates that LPS alone is fully effective in stimulating the formation of the intracellular 26-kDa TNFalpha precursor. LPS alone is not sufficient to allow processing of the precursor and secretion of mature 17-kDa TNFalpha. The rate of TNFalpha secretion observed immediately after the addition of PMA to LPS-pretreated cells is similar to the maximum rate from LPS/PMA-treated cells, but without the lag observed in cells after being exposed to LPS and PMA simultaneously. In summary, PMA is required for the completion of TNFalpha precursor processing and secretion in LPS-treated human Mono Mac 6 cells, whereas murine RAW cells are able to complete the terminal steps of TNFalpha processing in the absence of PMA.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,RAHWAY,NJ 07065	Merck & Company								ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; BEUSCHER HU, 1988, J BIOL CHEM, V263, P4023; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CHANTRY D, 1989, J IMMUNOL, V142, P4295; CHEN LL, 1987, NATURE, V328, P164, DOI 10.1038/328164a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DEGLIANTONI G, 1985, J EXP MED, V162, P1512, DOI 10.1084/jem.162.5.1512; DESCOTEAUX A, 1990, J IMMUNOL, V145, P846; ESPEVIK T, 1987, IMMUNOLOGY, V61, P443; FISHER H, 1990, J IMMUNOL, V144, P4663; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; GROVE DS, 1988, BIOCHEM BIOPH RES CO, V151, P94, DOI 10.1016/0006-291X(88)90563-3; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; INTRONA M, 1986, J IMMUNOL, V137, P2711; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; KOYABASHI Y, 1988, J IMMUNOL, V140, P2279; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LUETTIG B, 1989, J IMMUNOL, V143, P4034; MARTIN CA, 1990, CELL IMMUNOL, V128, P555, DOI 10.1016/0008-8749(90)90048-V; MOHRI M, 1990, J IMMUNOL, V144, P2678; MULLER R, 1986, FEBS LETT, V197, P99, DOI 10.1016/0014-5793(86)80306-4; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; ROSEN A, 1989, J BIOL CHEM, V264, P9118; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SCUDERI P, 1989, J IMMUNOL, V143, P4034; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SHIRAI T, 1985, NATURE, V313, P803, DOI 10.1038/313803a0; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; SUNG SSJ, 1991, J IMMUNOL, V147, P2047; TAKASUKA N, 1991, J IMMUNOL, V146, P3824; TAKAYAMA K, 1984, INFECT IMMUN, V45, P350, DOI 10.1128/IAI.45.2.350-355.1984; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TURNER M, 1987, EUR J IMMUNOL, V17, P1807, DOI 10.1002/eji.1830171220; WALTERS P, 1986, J CELL BIOL, V102, P1543; WIGHTMAN PD, 1984, J BIOL CHEM, V259, P48; WOLD F, 1986, TRENDS BIOCHEM SCI, V11, P58, DOI 10.1016/0968-0004(86)90254-9; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	52	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23261	23268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429672				2022-12-27	WOS:A1992JY16300085
J	MELNICK, J; AVIEL, S; ARGON, Y				MELNICK, J; AVIEL, S; ARGON, Y			THE ENDOPLASMIC-RETICULUM STRESS PROTEIN-GRP94, IN ADDITION TO BIP, ASSOCIATES WITH UNASSEMBLED IMMUNOGLOBULIN-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID SUBSTITUTION; LUMINAL ER PROTEINS; HEAVY-CHAIN; BINDING-PROTEIN; MONOCLONAL-ANTIBODIES; DISULFIDE-ISOMERASE; VARIABLE REGION; LIGHT-CHAINS; SECRETION; GLUCOSE	The molecular chaperone BiP/GRP78 associates with various polypeptides in the endoplasmic reticulum, including immunoglobulin chains. We now show, using chemical cross-linking, that another endoplasmic reticulum stress protein, GRP94, associates with newly synthesized immunoglobulin light and heavy chains. We demonstrate the presence of ternary complexes composed of immunoglobulin chains, BiP and GRP94. Because both BiP and GRP94 associate far less with fully assembled immunoglobulin than with unassembled subunits, our data suggest that GRP94, like BiP, functions as a molecular chaperone. The presence of both BiP and GRP94 in the same complex further suggests that the two stress proteins work in concert during the folding and assembly of immunoglobulins.	DUKE UNIV,MED CTR,DEPT IMMUNOL,POB 3010,DURHAM,NC 27710; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Duke University					NCI NIH HHS [CA-09058] Funding Source: Medline; NIAID NIH HHS [AI-30178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGON Y, 1984, J IMMUNOL, V133, P1627; ARGON Y, 1983, EUR J IMMUNOL, V13, P301, DOI 10.1002/eji.1830130406; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DUL JL, 1992, J IMMUNOL, V149, P1927; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOCH G, 1986, J CELL SCI, V86, P217; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LENNY N, 1991, J BIOL CHEM, V266, P20532; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; MAKI RG, 1990, P NATL ACAD SCI USA, V87, P5658, DOI 10.1073/pnas.87.15.5658; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MOSMANN TR, 1980, CELL, V20, P283, DOI 10.1016/0092-8674(80)90614-5; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WIEST DL, 1989, J CELL BIOL, V110, P1501; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7	38	222	232	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21303	21306						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400441				2022-12-27	WOS:A1992JV01100009
J	SENIOR, AE; ALSHAWI, MK				SENIOR, AE; ALSHAWI, MK			FURTHER EXAMINATION OF 17 MUTATIONS IN ESCHERICHIA-COLI F1-ATPASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL ATPASE; UNISITE CATALYTIC PATHWAY; SITE-DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; TRANSLOCATING ATPASE; ELEMENTARY STEPS; ALPHA-SUBUNITS; MUTANT STRAINS; RATE CONSTANTS; H+-ATPASE	Seventeen mutations in beta-subunit of Escherichia coli F1-ATPase which had previously been characterized in strain AN1272 (Mu-induced mutant) were expressed in strain JP17 (beta-subunit gene deletion). Six showed unchanged behavior, namely: C137Y; G142D; G146S; G207D; Y297F; and Y354F. Five failed to assemble F1F0 correctly, namely: G149I; G154I; G149I,G154I; G223D; and P403S,G415D. Six assembled F1F0 correctly, but with membrane ATPase lower than in AN1272, namely: K155Q; K155E; E181Q; E192Q; D242N; and D242V. AN1272 was shown to unexpectedly produce a small amount of wild-type beta-subunit; F1-ATPase activities reported previously in AN1272 were referable to hybrid enzymes containing both mutant and wild-type beta-subunits. Purified F1 was obtained from K155Q; K155E; E181Q; E192Q; and D242N mutants in JP17. V(max) ATPase values were lower, and unisite catalysis rate and equilibrium constants were perturbed to greater extent, than in AN1272. However, general patterns of perturbation revealed by difference energy diagrams were similar to those seen previously, and the new data correlated well in linear free energy relationships for reaction steps of unisite catalysis. Correlation between multisite and unisite ATPase activity was seen in the new enzymes. Overall, the data give strong support to previously proposed mechanisms of unisite catalysis, steady-state catalysis, and energy coupling in F1-ATPases (Al-Shawi, M. K., Parsonage, D. and Senior, A. E. (1990) J. Biol. Chem. 265, 4402-4410). The K155Q, K155E, D242N, and E181Q mutations caused 5000-fold, 4000-fold, 1800-fold, and 700-fold decrease, respectively, in V(max). ATPase, implying possibly direct roles for these residues in catalysis. Experiments with the D242N mutant suggested a role for residue betaD242 in catalytic site Mg2+ binding.			SENIOR, AE (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; FAYLE DRH, 1978, BIOCHEM J, V172, P523, DOI 10.1042/bj1720523; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; KIRONDE FAS, 1989, BIOCHEM J, V259, P421, DOI 10.1042/bj2590421; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NOUMI T, 1986, J BIOL CHEM, V261, P7070; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; PARSONAGE D, 1988, FEBS LETT, V232, P111, DOI 10.1016/0014-5793(88)80397-1; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PARSONAGE D, 1988, ARCH BIOCHEM BIOPHYS, V261, P222, DOI 10.1016/0003-9861(88)90121-X; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; PERLIN DS, 1985, BIOCHIM BIOPHYS ACTA, V807, P238, DOI 10.1016/0005-2728(85)90254-3; SATRE M, 1979, BIOCHEMISTRY-US, V18, P3134, DOI 10.1021/bi00581a034; SENIOR AE, 1983, BIOCHEM J, V210, P395, DOI 10.1042/bj2100395; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SKERRETT KJ, 1981, BIOCHIM BIOPHYS ACTA, V638, P120, DOI 10.1016/0005-2728(81)90194-8; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1992, J BIOL CHEM, V267, P1712; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5	36	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21471	21478						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400460				2022-12-27	WOS:A1992JV01100034
J	SHIGEMATSU, Y; MIYATA, T; HIGASHI, S; MIKI, T; SADLER, JE; IWANAGA, S				SHIGEMATSU, Y; MIYATA, T; HIGASHI, S; MIKI, T; SADLER, JE; IWANAGA, S			EXPRESSION OF HUMAN SOLUBLE TISSUE FACTOR IN YEAST AND ENZYMATIC-PROPERTIES OF ITS COMPLEX WITH FACTOR-VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDNA; GENE; PROTEIN; PURIFICATION; COAGULATION; RECEPTOR; BINDING; INITIATION; SEQUENCE	The extracellular domain of human tissue factor (TF, amino acids 1-217) was expressed in Saccharomyces cerevisiae, using the inducible yeast acid phosphatase promoter and the yeast invertase signal sequence to direct its secretion into the culture broth. Two active soluble forms sTFalpha (high molecular weight form) and sTFbeta (low molecular weight form) were purified, the yield being approximately 10 and 1 mg/liter of culture supernatant, respectively. sTFalpha had an apparent molecular mass of 150 kDa on SDS-polyacrylamide gel electrophoresis and contained more than 200 residues of mannose/mol of protein. sTFbeta had an apparent molecular mass of 37 kDa and contained 22 residues of mannose/mol of protein. N-Glycosidase F treatments of both rTFs reduced the apparent molecular mass to 35 kDa. The amino-terminal sequences and amino acid compositions of sTFalpha and sTFbeta were consistent with those deduced from the cDNA sequence, thereby indicating that the difference in molecular mass is caused by heterogeneity of oligosaccharide structures. Of these recombinant TFs, sTFbeta enhanced factor VIIa-amidolytic activity 40-fold toward the chromogenic substrate and 147-fold toward the fluorogenic substrate, affecting mainly the k(cat) value. The enhancement was comparable with that of TF purified from human placenta. The TF-mediated enhancement of factor VIIa-amidolytic activity was inhibited by heparin-activated antithrombin III, forming a high molecular weight complex. As treatment of sTFbeta with denaturants such as guanidine hydrochloride or urea led to a biphasic loss of the activity, the extracellular domain of TF probably consists of two discrete domains. This expression system provides a significant amount of the extracellular domain of TF so that studies of interactions with factor VII are feasible.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,FAC PHARMACEUT SCI,FUKUOKA 812,JAPAN; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	Kyushu University; Kyushu University; Kyushu University; Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI 14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS BS, 1991, GENE, V98, P265, DOI 10.1016/0378-1119(91)90184-D; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOSTIAN KA, 1980, P NATL ACAD SCI-BIOL, V77, P4504, DOI 10.1073/pnas.77.8.4504; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; BROZE GJ, 1985, J BIOL CHEM, V260, P917; COLBURN JC, 1987, METHOD ENZYMOL, V139, P188; DMOCHOWSKA A, 1987, CELL, V50, P573, DOI 10.1016/0092-8674(87)90030-4; FISHER KL, 1987, THROMB RES, V48, P89, DOI 10.1016/0049-3848(87)90349-5; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYANOHARA A, 1983, P NATL ACAD SCI-BIOL, V80, P1, DOI 10.1073/pnas.80.1.1; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NEMERSON Y, 1988, BLOOD, V71, P1; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PAWASHE A, 1991, THROMB HAEMOSTASIS, V66, P315; PENKE B, 1974, ANAL BIOCHEM, V60, P45, DOI 10.1016/0003-2697(74)90129-8; RANGANATHAN G, 1991, J BIOL CHEM, V266, P496; REHEMTULLA A, 1991, THROMB HAEMOSTASIS, V65, P521; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; Sambrook J, 1989, MOL CLONING LABORATO; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; TAKAYENOKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1145, DOI 10.1016/0006-291X(91)92058-R; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; VANDAMMIERAS MCE, 1983, HDB SYNTHETIC SUBSTR; YAMAMOTO A, 1989, J BIOCHEM-TOKYO, V106, P552, DOI 10.1093/oxfordjournals.jbchem.a122892	36	58	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21329	21337						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400445				2022-12-27	WOS:A1992JV01100014
J	WALKER, B; KRISHNASASTRY, M; ZORN, L; BAYLEY, H				WALKER, B; KRISHNASASTRY, M; ZORN, L; BAYLEY, H			ASSEMBLY OF THE OLIGOMERIC MEMBRANE PORE FORMED BY STAPHYLOCOCCAL ALPHA-HEMOLYSIN EXAMINED BY TRUNCATION MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN; AUREUS; MECHANISM; PROTEINS; CHANNEL; BINDING; SUBUNIT; DOMAIN; DAMAGE	The alpha-hemolysin (alphaHL) from Staphylococcus aureus causes the lysis of susceptible cells such as rabbit erythrocytes (rRBCs). Lysis is associated with the formation of a hexameric pore in the plasma membrane. Here we show that truncation mutants of alphaHL missing 2 to 22 N-terminal amino acids form oligomers on the surfaces of rRBCs but fail to lyse the cells. By contrast, mutants missing 3 or 5 amino acids at the C terminus are very inefficient at oligomerization but do lyse rRBCs, albeit extremely slowly. The C-terminal truncation mutants, retarded as monomers on the cell surface, undergo a conformational change in which the protease-sensitive loop located near the midpoint of the polypeptide chain becomes occluded. Judged by this criterion, polypeptides truncated at the N terminus, frozen as nonlytic oligomers, are in a similar conformation. A second proteolytic site near the N terminus of the polypeptide becomes inaccessible in the lytic pore formed by the wild-type polypeptide, supporting the idea that a second conformational change occurs upon pore formation. These findings suggest a pathway for assembly of the lytic pore in which alphaHL first binds to target cells as a monomer, which is converted to a nonlytic oligomeric intermediate before formation of the pore. In keeping with this model, an N-terminal truncation mutant blocks the slow lysis induced by a C-terminal truncation mutant, presumably by diverting the weakly lytic subunits into inactive oligomers.	UNIV MASSACHUSETTS,MED CTR,GRAD SCH BIOMED SCI,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester	WALKER, B (corresponding author), WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545, USA.			Bayley, Hagan/0000-0003-2499-6116				ARBUTHNOTT JP, 1967, J BACTERIOL, V94, P1170, DOI 10.1128/JB.94.4.1170-1177.1967; BHAKDI S, 1983, TRENDS BIOCHEM SCI, V8, P134, DOI 10.1016/0968-0004(83)90237-2; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BLOMQVIST L, 1988, MICROB PATHOGENESIS, V4, P223, DOI 10.1016/0882-4010(88)90072-1; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCNIVEN AC, 1972, J MED MICROBIOL, V5, P113, DOI 10.1099/00222615-5-1-113; OLOFSSON A, 1990, J MOL BIOL, V214, P299, DOI 10.1016/0022-2836(90)90162-F; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9496; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TOBKES N, 1986, THESIS COLUMBIA U NE; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VERALL S, 1992, CELL, V68, P23; WALKER B, 1992, J BIOL CHEM, V267, P10902	32	157	166	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21782	21786						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400487				2022-12-27	WOS:A1992JV01100081
J	GILCHRIST, JSC; WANG, KKW; KATZ, S; BELCASTRO, AN				GILCHRIST, JSC; WANG, KKW; KATZ, S; BELCASTRO, AN			CALCIUM-ACTIVATED NEUTRAL PROTEASE EFFECTS UPON SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM PROTEIN-STRUCTURE AND CALCIUM RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED CA-2+ RELEASE; RYANODINE RECEPTOR; TERMINAL CISTERNAE; INHIBITOR CALPASTATIN; ENDOGENOUS INHIBITOR; CHANNEL; MEMBRANE; VESICLES; CALPAIN; CALMODULIN	In this study, the effects of Ca2+-activated neutral protease (CANP) upon skeletal muscle heavy sarcoplasmic reticulum (HSR) structure and function were investigated. CANP was immunolocalized to the 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid detergent-insoluble fraction of purified HSR membranes. Ca2+ activation of the endogenous membrane-bound CANP produced a characteristic partial fragmentation of the HSR 565-kDa Ca2+ release channel. Similarly, the major substrate for both micromolar and millimolar Ca2+-sensitive isoforms of exogenous CANP was the Ca2+ release channel with proteolysis of a 88-kDa HSR protein also observed. Ca2+ release channel proteolysis was initiated at a single cleavage site with coincidental production of 410- and 150-kDa peptide fragments. Appearance of 160- and 137-kDa limiting peptides accompanied secondary proteolysis of the primary 410- and 150-kDa fragments, respectively. Despite extensive proteolysis of the Ca2+ release channel, CANP did not dramatically alter the Ca2+ handling and ryanodine binding properties of HSR membranes. The association of CANP with isolated HSR membranes suggests that, in vivo, this protease may modify an additional property of the Ca2+ release channel. This may be related to the CANP-susceptible structural association of the Ca2+ release channel with dihydropyridine receptors at T-tubule/sarcoplasmic reticulum junctions.	UNIV BRITISH COLUMBIA,FAC GRAD STUDIES,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,FAC EDUC,DIV KINESIOL,VANCOUVER V6T 1Z1,BC,CANADA; PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48105	University of British Columbia; University of British Columbia; University of British Columbia; Pfizer				Wang, Kevin/0000-0002-9343-6473				BELLES B, 1988, PFLUG ARCH EUR J PHY, V412, P554, DOI 10.1007/BF00582548; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; CADWELL JJS, 1982, J CELL BIOL, V93, P543, DOI 10.1083/jcb.93.3.543; CASWELL AH, 1989, J BIOENERG BIOMEMBR, V21, P149, DOI 10.1007/BF00812067; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GILCHRIST JSC, 1990, BIOCHEM BIOPH RES CO, V168, P364, DOI 10.1016/0006-291X(90)91717-7; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; GILCHRIST JSC, 1990, P INT S CA2 PLUS BIN; GILCHRIST JSC, 1989, 1ST P EUR S CA2 PLUS; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P13936; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; KIM KC, 1990, J MEMBRANE BIOL, V113, P221, DOI 10.1007/BF01870074; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAI FA, 1989, J BIOL CHEM, V264, P16676; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKS AR, 1990, BIOPHYS J, V57, pA176; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MELLGREN RL, 1987, BIOCHEM BIOPH RES CO, V142, P1025, DOI 10.1016/0006-291X(87)91517-8; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MORII H, 1985, J BIOL CHEM, V260, P1536; MURACHI T, 1989, BIOCHEM INT, V18, P263; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; REEDY MK, 1975, J BIOL CHEM, V250, P4278; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUEST L, 1985, CAN J CHEM, V63, P2840, DOI 10.1139/v85-474; SEILER S, 1984, J BIOL CHEM, V259, P8550; SHOSHANBARMATZ V, 1988, J BIOL CHEM, V263, P16772; SHOSHANBARMATZ V, 1987, J BIOL CHEM, V262, P11559; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMM JL, 1988, J BIOL CHEM, V263, P17443; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; ZAIDI SIM, 1989, J MEMBRANE BIOL, V110, P209, DOI 10.1007/BF01869151; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	48	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20857	20865						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400400				2022-12-27	WOS:A1992JT97800056
J	KULL, FC; LEBAN, JJ; LANDAVAZO, A; STEWART, KD; STOCKSTILL, B; MCDERMED, JD				KULL, FC; LEBAN, JJ; LANDAVAZO, A; STEWART, KD; STOCKSTILL, B; MCDERMED, JD			CONVEYANCE OF PARTIAL AGONISM ANTAGONISM TO BOMBESIN GASTRIN-RELEASING PEPTIDE ANALOGS ON SWISS 3T3 CELLS BY A CARBOXYL-TERMINAL LEUCINE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ANTAGONISTS; LUNG-CANCER; ANTIMITOTIC ACTIVITY; PANCREATIC ACINAR; CROSS-LINKING; POTENT; STIMULATION; CARCINOMA; GROWTH; SOMATOSTATIN	Gastrin-releasing peptide (GRP) is a neuroendocrine hormone that may be involved in the pathophysiology of small cell lung carcinoma. We describe carboxyl-terminal peptide analogues of GRP and bombesin, a 14-residue amphibian homologue, that were modeled after the antagonist [Leu13-psi(CH2NH)-Leu14]bombesin and retained the psi bond. Three novel peptides contained a Leu insertion amino to the psi bond, i.e. ...Leu13Leu14psiX (residues numbered after bombesin) where X = LeuNH2 or norleucine-NH2). The Leu-insertion analogues behaved as pure partial agonists/antagonists when examined for the ability to stimulate [H-3]thymidine incorporation into quiescent Swiss 3T3 cells (agonist activity) and to diminish the agonist response of GRP (antagonist activity). A time course of [H-3]thymidine incorporation into quiescent cells indicated maximal incorporation at 20-h post-peptide addition for bombesin and GRP and a Leu-insertion peptide, but the extent of the incorporation for the Leu-insertion peptide was half that of GRP and bombesin. The agonist dose responses of the Leu-insertion peptides (EC50 values of 1-10 nM) paralleled GRP and bombesin, but the maximal response of the Leu-insertion peptides, even at concentrations as high as 10(-4) M, was half the maximal value of GRP or bombesin. High concentrations of the Leu-insertion peptides antagonized 10 nM GRP (a concentration that produced a near-maximal GRP response) yielding a response that was half the maximal value of GRP and equivalent to the maximal response of the Leu-insertion peptides alone. Analogues of the form ... Leu13psiX behaved as complete antagonists. The K(D) values of the Leu-insertion peptides for competitive binding versus I-125-GRP (2-50 nM) were as potent as parent...Leu14 agonists. Stability studies indicated that peptide potencies for both agonist and antagonist activities diminished upon peptide incubation in medium or on cells. The results suggested that, for the Leu-insertion peptides, degradation into distinct products with different activities was not responsible for their partial agonist/antagonist behavior. Computer-generated molecular modeling studies indicated that the novel structures could adopt energy minimized conformations for either an agonist or an antagonist as proposed earlier (Coy, D. H., Heinz-Erian, P., Jiang, N.-Y., Sasaki, Y., Taylor, J., Moreau, J.-P., Wolfrey, W. T., Gardner, J. D., and Jensen, R. T. (1988) J. Biol. Chem. 263, 5056-5060).	WELLCOME RES LABS,DEPT CHEM,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	KULL, FC (corresponding author), WELLCOME RES LABS,DIV CELL BIOL,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.			Stewart, Kent/0000-0001-6417-6927				BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; CARNEY DN, 1987, CANCER RES, V47, P821; COY DH, 1988, J BIOL CHEM, V263, P5056; COY DH, 1989, J BIOL CHEM, V264, P14691; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; HEIMBROOK DC, 1989, J BIOL CHEM, V264, P11258; HEIMBROOK DC, 1988, SYNTHETIC PEPTIDES A, P295; JENSEN RT, 1991, TRENDS PHARMACOL SCI, V12, P13, DOI 10.1016/0165-6147(91)90483-9; JENSEN RT, 1978, P NATL ACAD SCI USA, V75, P6139, DOI 10.1073/pnas.75.12.6139; KRIS RM, 1987, J BIOL CHEM, V262, P11215; LEBACQVERHEYDEN AM, 1990, PEPTIDE GROWTH FACTO, V2, P71; MAHMOUD S, 1991, CANCER RES, V51, P1798; MARUNO K, 1989, CANCER RES, V49, P629; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAEED ZA, 1989, PEPTIDES, V10, P597, DOI 10.1016/0196-9781(89)90149-6; SASAKI Y, 1987, J MED CHEM, V30, P1162, DOI 10.1021/jm00390a008; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; TACHE Y, 1987, ANN NY ACAD SCI, V547, P1; WANG LH, 1990, BIOCHEMISTRY-US, V29, P616, DOI 10.1021/bi00455a004; WANG LH, 1990, J BIOL CHEM, V265, P15695; WOOD SM, 1981, J CLIN ENDOCR METAB, V53, P1310, DOI 10.1210/jcem-53-6-1310; YAMAGUCHI K, 1983, CANCER RES, V43, P3932; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616	31	18	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21132	21138						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400423				2022-12-27	WOS:A1992JT97800096
J	HAMILTON, DS; CREIGHTON, DJ				HAMILTON, DS; CREIGHTON, DJ			INHIBITION OF GLYOXALASE I BY THE ENEDIOL MIMIC S-(N-HYDROXY-N-METHYLCARBAMOYL)GLUTATHIONE - THE POSSIBLE BASIS OF A TUMOR-SELECTIVE ANTICANCER STRATEGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRIOSEPHOSPHATE ISOMERASE; GLUTATHIONE DERIVATIVES; PATHWAY; PROBE	In principle, competitive inhibitors of glyoxalase I that also serve as substrates for the thioester hydrolase glyoxalase II might function as tumor-selective anti-cancer agents, given the role of these enzymes in removing cytotoxic methylglyoxal from cells and the observation that glyoxalase II activity is abnormally low in some types of cancer cells. In support of the feasibility of this anticancer strategy, an inhibitor of this type has been synthesized by a thioester-interchange reaction between glutathione and N-hydroxy-N-methylcarbamate 4-chlorophenyl ester to give S-(N-hydroxy-N-methylcarbamoyl) glutathione (1). This compound was designed to be a tight-binding inhibitor of glyoxalase I, on the basis of its stereoelectronic similarity to the enediol(ate) intermediate that forms along the reaction pathway of this enzyme. Indeed, 1 is a competitive inhibitor of yeast glyoxalase I, with an inhibition constant (K(i) = 68 muM) that is approximately 30-fold lower than that reported for S-D-lactoylglutathione and approximately 7-fold lower than the K(m) for glutathione-methylglyoxal thiohemiacetal. In addition, 1 is a substrate for bovine liver glyoxalase II, with a K(m) (0.48 mm) approximately equal to that of the normal substrate S-D-lactoylglutathione and a k(cat) approximately 2 x 10(-5)-fold that of the normal substrate. Membrane transport studies show that 1 can be delivered into human erythrocytes (used here as a model cell) either by direct diffusion of 1 across the cell membrane or by more rapid diffusion of the glycylethyl ester of 1 across the cell membrane, followed by the catalyzed hydrolysis of the ester to give 1.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,CHEM DYNAM LAB,CATONSVILLE,MD 21228									ALTIMARI A, 1986, BIOCHIM BIOPHYS ACTA, V870, P160, DOI 10.1016/0167-4838(86)90020-8; ALTIMARI A, 1986, BIOCHIM BIOPHYS ACTA, V870, P219, DOI 10.1016/0167-4838(86)90225-6; ANDERSON ME, 1989, ANAL BIOCHEM, V183, P16, DOI 10.1016/0003-2697(89)90164-4; ANDERSON ME, 1985, ARCH BIOCHEM BIOPHYS, V239, P538, DOI 10.1016/0003-9861(85)90723-4; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; CREIGHTON DJ, 1988, BIOCHEMISTRY-US, V27, P7376, DOI 10.1021/bi00419a031; CREIGHTON DJ, 1988, MOL STRUCTURE ENERGE, V9, P353; GROBNER P, 1974, EUR J MED CHEM, V9, P341; HAMILTON DS, 1992, BIOCHIM BIOPHYS ACTA, V1159, P203, DOI 10.1016/0167-4838(92)90026-A; JERZYKOWSKI T, 1978, INT J BIOCHEM, V9, P853, DOI 10.1016/0020-711X(78)90036-8; JERZYKOWSKI T, 1975, EXPERIENTIA, V31, P32, DOI 10.1007/BF01924663; KELLUM MW, 1978, ANAL BIOCHEM, V85, P586, DOI 10.1016/0003-2697(78)90258-0; MURPHY CM, 1991, 39TH P ASMS C MASS S, P1681; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; Rabenstein D.L., 1989, COENZYMES COFACTORS, V3, P67; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; VINCE R, 1969, BIOCHEM BIOPH RES CO, V35, P593, DOI 10.1016/0006-291X(69)90445-8; VINCE R, 1971, J MED CHEM, V14, P35, DOI 10.1021/jm00283a009; WOLFENDEN R, 1972, ACCOUNTS CHEM RES, V5, P10, DOI 10.1021/ar50049a002	21	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24933	24936						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459997				2022-12-27	WOS:A1992KB60300006
J	ROTHMAN, BS; DEKRUYFF, S; TALEBIAN, M; MENON, JG; SQUIRE, CR; YEH, CH; LEE, TD				ROTHMAN, BS; DEKRUYFF, S; TALEBIAN, M; MENON, JG; SQUIRE, CR; YEH, CH; LEE, TD			APLYSIA PEPTIDE NEUROTRANSMITTERS BETA-BAG CELL PEPTIDE, PHE-MET-ARG-PHE-AMIDE, AND SMALL CARDIOEXCITATORY PEPTIDE-B ARE RAPIDLY DEGRADED BY A LEUCINE AMINOPEPTIDASE-LIKE ACTIVITY IN HEMOLYMPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOCYTOLOGICAL LOCALIZATION; CARDIOACTIVE PEPTIDE; SINGLE GENE; NEUROPEPTIDES; NEURONS; INHIBITOR; FMRFAMIDE; SCPA; CALIFORNICA; SYSTEM	We have been investigating the role of proteolytic enzymes in the inactivation of peptide neurotransmitters in the marine snail Aplysia. Previous studies (Squire, C. R., Talebian, M., Menon, J. G., Dekruyff, S. D., Lee, T. D., Shively, J. E., and Rothman, B. S. (1991) J. Biol. Chem. 266, 22355-22363) showed that neuroactive fragments of the neurotransmitter alpha-bag cell peptide (alpha-BCP) were rapidly degraded (t1/2 = 0.5-2.7 min) in plasma, hemolymph that had been cleared by centrifugation. Degradation was caused by one or more enzymes resembling mammalian leucine aminopeptidase (LAP, EC 3.4.11.1). In this report we show that three other Aplysia peptide neurotransmitters, beta-BCP(1-5) (Arg-Leu-Arg-Phe-His), FMRFa (Phe-Met-Arg-Phe-amide), and SCP(B)(1-9) (Met-Asn-Tyr-Leu-Ala-Phe-Pro-Arg-Met-amide) are rapidly degraded (t1/2 = 0.3-2.4 min) in plasma by apparently the same LAP-like enzyme(s). Our findings strongly suggest that the LAP-like enzyme(s), by means of its broad substrate specificity and access to the extracellular spaces of the nervous system in vivo, plays a significant role in the inactivation of many Aplysia peptide neurotransmitters, and they raise the possibility that proteolytic enzymes in the extracellular fluid contribute significantly to the inactivation of peptide neurotransmitters in other animal species.	CITY HOPE NATL MED CTR, BECKMAN RES INT, DUARTE, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	ROTHMAN, BS (corresponding author), SAN FRANCISCO STATE UNIV, DEPT BIOL, SAN FRANCISCO, CA 94132 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024046, K04NS001177] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33155] Funding Source: Medline; NINDS NIH HHS [NS-01177, NS-24046] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOYAGI T, 1978, J ANTIBIOT, V31, P636, DOI 10.7164/antibiotics.31.636; BROWN R O, 1984, Society for Neuroscience Abstracts, V10, P691; BROWN RO, 1989, J NEUROSCI, V9, P1443; COGGESHALL RE, 1967, J NEUROPHYSIOL, V30, P1263, DOI 10.1152/jn.1967.30.6.1263; ELLIS S, 1964, BIOCHEM BIOPH RES CO, V16, P502; GREENBERG MJ, 1983, FED PROC, V42, P82; LLOYD PE, 1985, J NEUROSCI, V5, P1851; LLOYD PE, 1987, J NEUROSCI, V7, P1123; LLOYD PE, 1988, J NEUROPHYSIOL, V59, P1613, DOI 10.1152/jn.1988.59.5.1613; LLOYD PE, 1985, J COMP PHYSIOL A, V156, P659, DOI 10.1007/BF00619115; MAHON AC, 1985, P NATL ACAD SCI USA, V82, P3925, DOI 10.1073/pnas.82.11.3925; MCDONALD JK, 1986, MAMMALIAN PROTEASES, V2; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; NEWCOMB R, 1988, J BIOL CHEM, V263, P12514; NEWCOMB R, 1987, J NEUROSCI, V7, P854; OWENS DF, 1992, J NEUROBIOL, V23, P656, DOI 10.1002/neu.480230605; PHARES G A, 1989, Society for Neuroscience Abstracts, V15, P665; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; REED W, 1988, J COMP NEUROL, V272, P358, DOI 10.1002/cne.902720306; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROTHMAN B S, 1987, Society for Neuroscience Abstracts, V13, P39; ROTHMAN BS, 1983, P NATL ACAD SCI-BIOL, V80, P5753, DOI 10.1073/pnas.80.18.5753; ROTHMAN BS, 1985, GENE EXPRESSION BRAI, P235; ROTHMAN BS, 1992, T AM SOC NEUROCHEM, V23, P231; SCHAEFER M, 1985, CELL, V41, P457, DOI 10.1016/S0092-8674(85)80019-2; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SQUIRE CR, 1991, J BIOL CHEM, V266, P22355; SQUIRE CR, 1990, THESIS SAN FRANCISCO; TERENIUS L, 1988, INT REV NEUROBIOL, V30, P101; UMEZAWA H, 1983, J ANTIBIOT, V36, P1572, DOI 10.7164/antibiotics.36.1572; UMEZAWA H, 1985, J ANTIBIOT, V38, P1629, DOI 10.7164/antibiotics.38.1629; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; UMEZAWA H, 1983, PROTEINASE INHIBITOR, P3	35	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25135	25140						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460014				2022-12-27	WOS:A1992KB60300036
J	CHEN, Q; YU, K; STEVENS, JL				CHEN, Q; YU, K; STEVENS, JL			REGULATION OF THE CELLULAR STRESS RESPONSE BY REACTIVE ELECTROPHILES - THE ROLE OF COVALENT BINDING AND CELLULAR THIOLS IN TRANSCRIPTIONAL ACTIVATION OF THE 70-KILODALTON HEAT-SHOCK PROTEIN GENE BY NEPHROTOXIC CYSTEINE CONJUGATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; BETA-LYASE; OXIDATIVE STRESS; ADDUCT FORMATION; LLC-PK1 CELLS; INVITRO; HSP70; METABOLISM; TOXICITY; CALCIUM	The cytotoxicity of nephrotoxic cysteine conjugates (NCC) in the renal epithelial cell line, LLC-PK1, is due to the covalent binding of a reactive electrophilic metabolite produced from NCC metabolism by cysteine conjugate beta-lyase. Covalent binding of NCC-derived reactive metabolites leads to a cascade of events including depletion of cellular non-protein sulfhydryls, increased cytosolic free calcium, and lipid peroxidation, which is ultimately responsible for cell death. We have used this model to investigate the signalling mechanism(s) through which reactive electrophiles increase synthesis of the 70-kD heat shock protein (HSP70). NCC treatment resulted in increased HSP70 synthesis as well as time- and dose-dependent increases in hsp70 mRNA in LLC-PK1 cells. The induction of hsp70 mRNA was blocked by actinomycin D, and nuclear run-on experiments showed that the hsp70 gene was transcriptionally activated. Inhibition of protein synthesis did not block the increase in hsp70 mRNA or transcriptional activation of the hsp70 gene suggesting that induction occurs due to activation of existing transcription factors. Inhibiting the covalent binding with a beta-lyase inhibitor, aminooxyacetic acid, blocked the increase in hsp70 mRNA. Agents which do not alter binding but do prevent toxicity by blocking the rise in cytosolic free calcium and lipid peroxidation were not effective inhibitors of hsp70 mRNA accumulation. However, the thiol reducing agent, dithiothreitol, inhibited induction of hsp70 mRNA by NCC. The data suggest that covalent binding and alterations in cellular non-protein thiols serve as signals for activation of pre-existing transcription factors which increase hsp70 gene expression. It is proposed that reactive electrophiles may have a primary effect on protein conformation resulting in activation of the hsp70 gene.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946						NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925] Funding Source: NIH RePORTER; NCI NIH HHS [CA37589] Funding Source: Medline; NIDDK NIH HHS [DK38925] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANG D, 1991, J BIOL CHEM, V266, P24233; ANSUBEL FM, 1991, CURRENT PROTOCOLS MO; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; ELLIS JR, 1991, ANNU REV BIOCHEM, V60, P321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HARRISON GS, 1987, SOMAT CELL MOLEC GEN, V13, P119, DOI 10.1007/BF01534692; HAYDEN P, 1987, METHOD ENZYMOL, V143, P228; HAYDEN PJ, 1992, CHEM RES TOXICOL, V5, P231, DOI 10.1021/tx00026a013; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, J BIOL CHEM, V266, P18415; HAYDEN PJ, 1991, BIOCHEMISTRY-US, V30, P5935, DOI 10.1021/bi00238a018; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HUNT CR, 1985, P NATL ACAD SCI USA, V78, P3775; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; LARSON JS, 1988, NATURE, V336, P184, DOI 10.1038/336184a0; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Lever JE., 1985, TISSUE CULTURE EPITH, P3; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lis J.T., 1990, STRESS PROTEINS BIOL, P411; MORIMOTO R I, 1990, P1; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; SAMBROOK J, 1987, MOL CLONING LABORATO; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHAEFFER VH, 1987, MOL PHARMACOL, V31, P506; SHRECK R, 1991, EMBO J, V10, P2247; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEVENS J, 1986, J BIOL CHEM, V261, P3325; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; VAMVAKAS S, 1990, MOL PHARMACOL, V38, P455; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1990, STRESS PROTEINS BIOL, P429; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; Yost HJ, 1990, STRESS PROTEINS BIOL, P379; YU K, 1991, TOXICOLOGIST, V11, P250; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124	64	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24322	24327						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447182				2022-12-27	WOS:A1992KA26300030
J	COOK, JC; CHOCK, PB				COOK, JC; CHOCK, PB			ISOFORMS OF MAMMALIAN UBIQUITIN-ACTIVATING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE Y-CHROMOSOME; L-CELL DEFECT; ELECTROPHORETIC TRANSFER; DEPENDENT PROTEOLYSIS; GEL-ELECTROPHORESIS; POLYACRYLAMIDE GELS; CONJUGATING ENZYME; MOLECULAR-CLONING; DNA-REPLICATION; GENE	Ubiquitin-activating enzyme,"E1," is the first enzyme in the pathway leading to formation of ubiquitin-protein conjugates and represents a potential target for regulation in the metabolic control of the conjugation reaction. Antiserum raised against human E1 recognizes two immunoreactive proteins in extracts from several human cell lines and animal tissues. We have characterized these two immunoreactive proteins in HeLa cells and present evidence that they are isoforms of E1. We have designated these isoforms as "E1(110 kDa)" and "E1(117 kDa)" to reflect their apparent molecular masses determined from SDS-polyacrylamide gel electrophoresis. These two immunoreactive proteins are immunologically similar, have nearly identical peptide maps, and comigrate with enzymatic activity characteristic of E1 in native polyacrylamide gel electrophoretic separations. Pulse-labeling experiments reveal that both isoforms are long-lived in vivo with degradation rates which are inconsistent with a proenzyme/enzyme model. Furthermore, their rates of degradation, which vary depending on the cell line studied, are kinetically distinguishable in contact-inhibited human lung fibroblasts. This work represents the first demonstration of E1 isoforms in a non-plant species and carries important implications for studies of the regulatory mechanisms controlling ubiquitin conjugation.	NHLBI,BIOCHEM LAB,METAB REGULAT,BLDG 3,RM 202,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BOND U, 1985, MOL CELL BIOL, V5, P949, DOI 10.1128/MCB.5.5.949; BOND U, 1986, MOL CELL BIOL, V6, P4602, DOI 10.1128/MCB.6.12.4602; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P93, DOI 10.1007/BF01534674; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOYER A, 1980, J BIOL CHEM, V255, P7525; COOK J, 1988, Biofactors, V1, P133; COOK JC, 1991, P NATL ACAD SCI USA, V88, P11388, DOI 10.1073/pnas.88.24.11388; COOK JC, 1991, BIOCHEM BIOPH RES CO, V174, P564, DOI 10.1016/0006-291X(91)91454-K; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HARLOW E, 1988, ANTIBODIES LABORATOR; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Hurn B A, 1980, Methods Enzymol, V70, P104; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KUDO M, 1991, EXP CELL RES, V192, P110, DOI 10.1016/0014-4827(91)90164-P; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; RECHLIN M, 1980, METHOD ENZYMOL, V70, P159; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROSE IA, 1987, P NATL ACAD SCI USA, V84, P1477, DOI 10.1073/pnas.84.6.1477; SALINOVICH O, 1986, ANAL BIOCHEM, V156, P341, DOI 10.1016/0003-2697(86)90263-0; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; TAKAHASHI E, 1992, CYTOGENET CELL GENET, V59, P268, DOI 10.1159/000133266; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU RS, 1981, J BIOL CHEM, V256, P5916; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZACKSENHAUS E, 1990, CYTOGENET CELL GENET, V53, P20, DOI 10.1159/000132887; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x; ZOLA H, 1987, MONOCLONAL ANTIBODIE, P166	53	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24315	24321						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447181				2022-12-27	WOS:A1992KA26300029
J	LEE, RH; LIEBERMAN, BS; YAMANE, HK; BOK, D; FUNG, BKK				LEE, RH; LIEBERMAN, BS; YAMANE, HK; BOK, D; FUNG, BKK			A 3RD FORM OF THE G-PROTEIN BETA-SUBUNIT .1. IMMUNOCHEMICAL IDENTIFICATION AND LOCALIZATION TO CONE PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ROD OUTER SEGMENTS; HUMAN PLACENTAL MEMBRANES; AMINO-ACID SEQUENCE; GAMMA-SUBUNITS; RETINAL ROD; CYCLIC-GMP; ADENYLATE-CYCLASE; MOLECULAR-CLONING; ALPHA-SUBUNIT	Vertebrate retinal cones play a major role in both photopic vision and color perception. Although the molecular mechanism of visual excitation in the cone is not as well understood as in the rod, it is generally thought to involve a cone-specific G protein (cone transducin) that couples the cone visual pigment to a cGMP phosphodiesterase. Like all other G proteins, cone transducin is most likely a heterotrimer consisting of Galpha, Gbeta, and Ggamma subunits. A Galpha subunit of cone transducin has been localized to the outer segment of bovine cones, but its associated Gbeta and Ggamma subunits are unknown. To identify the Gbeta subunit involved in the phototransduction process of cones, we have developed a panel of antipeptide antisera against the most diverse region of the amino acid sequences encoded by Gbeta1, Gbeta2, and Gbeta3 cDNAs and used them to determine the distribution of the Gbeta isoforms in different retinal preparations. We found that the Gbeta3 subunit is present in bovine retinal transducin and phosducin-Tbetagamma complex preparations which were previously thought to contain only Gbeta1. Analysis of its subcellular distribution indicated that Gbeta3 is predominantly cytoplasmic. Immunocytochemical staining of bovine retinal sections with the anti-Gbeta3 antiserum further revealed a specific localization of Gbeta3 in cones but not in rods. In contrast, anti-Gbeta1 antiserum stained only the rods. These results suggest that Gbeta3 is the Gbeta subunit of cone transducin and confirms the proposition that rods and cones utilize distinct signaling proteins for phototransduction.	UNIV CALIF LOS ANGELES, SCH MED, JULES STEIN EYE INST, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LEE, RH (corresponding author), VET ADM MED CTR, MOLEC NEUROBIOL LAB 151B9, SEPULVEDA, CA 91343 USA.				NEI NIH HHS [EY05895, EY00395, EY 00444] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000444, R37EY000444, R01EY005895] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; ATTWELL D, 1985, NATURE, V317, P14, DOI 10.1038/317014a0; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CERIONE RA, 1986, J BIOL CHEM, V261, P9514; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; EVANS T, 1986, J BIOL CHEM, V261, P7052; EVANS T, 1987, J BIOL CHEM, V262, P176; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2126; FUNG BKK, 1992, J BIOL CHEM, V267, P24782; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1986, PROG RETIN RES, V6, P151; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HO Y-K, 1990, Investigative Ophthalmology and Visual Science, V31, P215; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATADA T, 1984, J BIOL CHEM, V259, P3586; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, EXP EYE RES, V44, P115, DOI 10.1016/S0014-4835(87)80030-1; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OVCHINNIKOV YA, 1985, FEBS LETT, V179, P107, DOI 10.1016/0014-5793(85)80201-5; PUGH EN, 1986, VISION RES, V26, P1613, DOI 10.1016/0042-6989(86)90051-9; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weizsacker E. V., 1992, BIOCHEM BIOPH RES CO, V183, P350; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WOOLKALIS MJ, 1987, MOL PHARMACOL, V32, P1; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936; YAU KW, 1992, INVEST OPHTH VIS SCI, V33, P1004	55	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24776	24781						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447215				2022-12-27	WOS:A1992KA26300093
J	SCHLENSTEDT, G; GUDMUNDSSON, GH; BOMAN, HG; ZIMMERMANN, R				SCHLENSTEDT, G; GUDMUNDSSON, GH; BOMAN, HG; ZIMMERMANN, R			STRUCTURAL REQUIREMENTS FOR TRANSPORT OF PREPROCECROPINA AND RELATED PRESECRETORY PROTEINS INTO MAMMALIAN MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; M13 PROCOAT PROTEIN; HONEYBEE PREPROMELITTIN; NASCENT PREPROLACTIN; SECRETORY PROTEIN; DOCKING PROTEIN; ENERGY-REQUIREMENTS; EUKARYOTIC CELLS; PRECURSOR FORMS	The presecretory protein preprocecropinA (which comprises 64 amino acid residues) as well as a synthetic hybrid between preprocecropinA and dihydrofolate reductase (which comprises 252 amino acid residues) are processed by and transported into mammalian microsomes. Transport of both precursor proteins can take place cotranslationally, i.e. with the aid of ribosome and signal recognition particle, or posttranslationally, i.e. independently of these ribonucleoparticles (RNPs). We investigated the role of the precursor structure with respect to competence for RNP-independent transport by constructing deletion mutants and hybrid proteins. The results demonstrate that the signal peptide is essential for RNP-independent transport. Furthermore, the signal peptide is sufficient for translocation of preprocecropinA derivatives up to 85 amino acid residues in size. However, the conformation of the precursor protein is decisive in the case of larger hybrid proteins.	UNIV GOTTINGEN, BIOCHEM ABT 2, ZENTRUM BIOCHEM, W-3400 GOTTINGEN, GERMANY; UNIV STOCKHOLM, DEPT MICROBIOL, S-10691 STOCKHOLM, SWEDEN	University of Gottingen; Stockholm University			Gudmundsson, Gudmundur H/K-9178-2015	Gudmundsson, Gudmundur H/0000-0001-5793-0565				AINGER KJ, 1986, EMBO J, V5, P951, DOI 10.1002/j.1460-2075.1986.tb04308.x; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1989, J BIOL CHEM, V264, P5852; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; FRITZ HJ, 1988, NUCLEIC ACIDS RES, V16, P6987, DOI 10.1093/nar/16.14.6987; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LIDHOLM DA, 1987, FEBS LETT, V226, P8, DOI 10.1016/0014-5793(87)80540-9; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; Maniatis T., 1982, MOL CLONING; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MULLER G, 1987, EMBO J, V6, P2099, DOI 10.1002/j.1460-2075.1987.tb02476.x; MULLER G, 1988, EMBO J, V7, P639, DOI 10.1002/j.1460-2075.1988.tb02858.x; OKUN MM, 1992, J BIOL CHEM, V267, P11476; OKUN MM, 1990, J BIOL CHEM, V265, P7478; PARHAM P, 1991, NATURE, V351, P271, DOI 10.1038/351271a0; PARHAM P, 1992, NATURE, V357, P193, DOI 10.1038/357193a0; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; SCHLENSTEDT G, 1988, EMBO J, V7, P639; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WIECH H, 1987, EMBO J, V6, P1011, DOI 10.1002/j.1460-2075.1987.tb04853.x; WIECH H, 1991, FEBS LETT, V285, P182, DOI 10.1016/0014-5793(91)80800-I; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; ZIMMERMANN R, 1990, J BIOENERG BIOMEMBR, V22, P711; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x; ZIMMERMANN R, 1986, TRENDS BIOCHEM SCI, V11, P512, DOI 10.1016/0968-0004(86)90085-X; ZIMMERMANN R, 1990, BIOCHIMIE, V72, P95, DOI 10.1016/0300-9084(90)90134-3; ZIMMERMANN R, 1986, J BIOL CHEM, V261, P2889	53	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24328	24332						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447183				2022-12-27	WOS:A1992KA26300031
J	CHEN, D; MAGNUSON, V; HILL, S; ARNAUD, C; STEFFENSEN, B; KLEBE, RJ				CHEN, D; MAGNUSON, V; HILL, S; ARNAUD, C; STEFFENSEN, B; KLEBE, RJ			REGULATION OF INTEGRIN GENE-EXPRESSION BY SUBSTRATE ADHERENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; ALKALINE-PHOSPHATASE ACTIVITY; LIVER TRANSCRIPTION FACTORS; GROWTH FACTOR-BETA; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; DIFFERENTIATED PHENOTYPE; MONOCLONAL-ANTIBODIES; ADHESION RECEPTORS; RESPIRATORY BURST	Under substrate adherent conditions, integrin gene expression can be regulated by transforming growth factor-beta, interleukin-1beta, and prostaglandins. This report demonstrates a new mechanism that can differentially control the expression of several integrins. When MG-63 osteosarcoma cells are maintained in suspension, up-regulation of several integrin alpha-subunits takes place. Within as little as 4 h, the mRNA levels for both the alpha2- and alpha4-subunits are increased 4- and 6-fold, respectively. It was found that mRNA levels for the alpha2-, alpha4-, and alpha(v)-subunits were markedly increased in several differentiated cell lines under non-adherent conditions; however, cells that did not express a given integrin under substrate adherent conditions also did not express this integrin when maintained in suspension. The alpha5-subunit did not up-regulate during suspension growth. By immunocytochemistry, changes in integrin mRNA levels were confirmed at the protein level. Both cytochalasin B and a phorbol ester were found to induce the expression of the alpha2-subunit, but not the alpha4- and alpha5-subunits, in a dose-dependent fashion. Many investigators have documented changes in gene expression that result from changes in "cell shape." These phenomena may result from up-regulation of integrin gene expression induced by the lack of substrate adherence.			CHEN, D (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284, USA.				NIDCR NIH HHS [DE08144] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008144] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AULTHOUSE AL, 1989, IN VITRO CELL DEV B, V25, P659; BATES GP, 1987, IN VITRO CELL DEV B, V23, P374; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BISSELL MJ, 1989, ENVIRON HEALTH PERSP, V80, P61, DOI 10.2307/3430732; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BRADLEY WEC, 1982, SOMAT CELL GENET, V8, P207, DOI 10.1007/BF01538678; BRONNERFRASER M, 1986, DEV BIOL, V117, P528, DOI 10.1016/0012-1606(86)90320-9; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; CHEN LH, 1987, J BIOL CHEM, V262, P17247; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DEDHAR S, 1989, EXP CELL RES, V183, P207, DOI 10.1016/0014-4827(89)90430-8; DEDHAR S, 1989, CONNECT TISSUE RES, V20, P49, DOI 10.3109/03008208909023874; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUBOIS WT, 1991, J PERIODONTOL, V62, P190, DOI 10.1902/jop.1991.62.3.190; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; GETZENBERG RH, 1990, ENDOCR REV, V11, P399, DOI 10.1210/edrv-11-3-399; GLOWACKI J, 1983, P SOC EXP BIOL MED, V172, P93; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LUIKART SD, 1983, P NATL ACAD SCI-BIOL, V80, P3738, DOI 10.1073/pnas.80.12.3738; McDonald JA, 1989, CURR OPIN CELL BIOL, V1, P995, DOI 10.1016/0955-0674(89)90071-9; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILAM SB, 1991, J CELL PHYSIOL, V149, P173, DOI 10.1002/jcp.1041490202; MILAM SB, 1991, J ORAL MAXIL SURG, V49, P381, DOI 10.1016/0278-2391(91)90376-W; MILAM SB, 1991, CRIT REV ORAL BIOL M, V2, P451, DOI 10.1177/10454411910020040201; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1989, BLOOD, V73, P301; OPAS M, 1989, DEV BIOL, V131, P281, DOI 10.1016/S0012-1606(89)80001-6; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Reid LM, 1990, CURR OPIN CELL BIOL, V2, P121, DOI 10.1016/S0955-0674(05)80042-0; RICHARDSON RL, 1988, CELL TISSUE RES, V251, P123, DOI 10.1007/BF00215456; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SOLURSH M, 1991, J CELL BIOCHEM, V45, P258, DOI 10.1002/jcb.240450306; STEFFENSEN B, 1992, BIOCHIM BIOPHYS ACTA, V1137, P95, DOI 10.1016/0167-4889(92)90105-K; STEFFENSEN B, 1992, J PERIODONTOL, V63, P584, DOI 10.1902/jop.1992.63.7.584; STICKEL SK, 1988, J CELL BIOL, V107, P1231, DOI 10.1083/jcb.107.3.1231; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WERB Z, 1990, CELL DIFFER DEV, V32, P299, DOI 10.1016/0922-3371(90)90043-V; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMADA A, 1991, J IMMUNOL, V146, P53	52	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23502	23506						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429694				2022-12-27	WOS:A1992JZ23900016
J	TING, AT; SCHOON, RA; ABRAHAM, RT; LEIBSON, PJ				TING, AT; SCHOON, RA; ABRAHAM, RT; LEIBSON, PJ			INTERACTION BETWEEN PROTEIN KINASE-C-DEPENDENT AND G-PROTEIN-DEPENDENT PATHWAYS IN THE REGULATION OF NATURAL-KILLER-CELL GRANULE EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-T ACTIVATION; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; PHOSPHOLIPASE-C; CYTO-TOXICITY; SECRETION; CYTOTOXICITY; GENERATION; MECHANISMS	The binding of natural killer (NK) cells to either susceptible tumor cells or antibody-coated targets results in rapid activation of phospholipase C (PLC) in NK cells. PLC activation generates inositol-1,4,5-trisphosphate and sn-1,2-diacylglycerol as second messengers, which, in turn, increase intracellular free calcium concentrations ([Ca2+]i) and protein kinase C (PKC) activity, respectively. These proximal signals initiate a cascade of as yet undefined biochemical events, leading eventually to the exocytosis of preformed cytotoxic granules. To investigate the signal transduction pathways involved in granule exocytosis, we utilized streptolysin-O-permeabilized human NK cells as our experimental model. Our initial studies indicated that the separate activation of either PKC (using the phorbol ester, PMA) or G protein-dependent pathways (using guanosine-5'-O-(3-thiotriphosphate) (GTPgammaS)) stimulated granule exocytosis in a time-, concentration-, and Ca2+-dependent manner. PMA-stimulated exocytosis was inhibited by staurosporine or a PKC pseudosubstrate antagonist peptide, but was not affected by GDP. In contrast, GTPgammaS-stimulated exocytosis was effectively inhibited by GDP, but not by staurosporine or the PKC pseudosubstrate antagonist. These observations suggest that NK cell exocytosis can be stimulated by at least two separate pathways; one involving PKC and the other involving a G protein. However, co-stimulation with PMA and GTPgammaS synergistically enhanced exocytosis, suggesting that even though the two exocytotic pathways were biochemically distinct, cross-talk between the two pathways may potently influence the exocytotic process. These results define a regulatory role for PKC- and G protein-dependent pathways during granule exocytosis from NK cells.	MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic					NCI NIH HHS [CA47752] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047752] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ATKINSON EA, 1990, J LEUKOCYTE BIOL, V47, P39, DOI 10.1002/jlb.47.1.39; AUGUSTINE JA, 1991, J IMMUNOL, V146, P2889; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRAHMI Z, 1992, NK CELL MEDIATED CYT, P117; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; BURKHARDT JK, 1989, P NATL ACAD SCI USA, V86, P7128, DOI 10.1073/pnas.86.18.7128; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERGUSON WS, 1988, J EXP MED, V167, P528, DOI 10.1084/jem.167.2.528; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDFARB RH, 1986, HUM PATHOL, V17, P138, DOI 10.1016/S0046-8177(86)80286-6; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRAVES SS, 1986, J IMMUNOL, V137, P1977; HENKART P, 1988, PROG ALLERGY, V40, P82; HOLMSEN H, 1989, METHOD ENZYMOL, V169, P336; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KOREN HS, 1987, IMMUNOL TODAY, V8, P69, DOI 10.1016/0167-5699(87)90844-9; LARUSSO NF, 1979, J CLIN INVEST, V64, P948, DOI 10.1172/JCI109561; LEIBSON PJ, 1990, J IMMUNOL, V145, P1498; LEIBSON PJ, 1992, NK CELL MEDIATED CYT, P129; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; OWENS JR, 1985, J BIOL CHEM, V260, P5946; PAYA CV, 1990, J IMMUNOL, V144, P4370; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; SCHREZENMEIER H, 1988, J IMMUNOL, V141, P3785; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SITKOVSKY MV, 1988, IMMUNOL REV, V103, P127, DOI 10.1111/j.1600-065X.1988.tb00754.x; TAKAYAMA H, 1987, J IMMUNOL METHODS, V104, P183, DOI 10.1016/0022-1759(87)90502-3; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TING AT, 1991, J IMMUNOL, V147, P3122; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; WINDEBANK KP, 1988, J IMMUNOL, V141, P3951; YOUNG JDE, 1986, J CELL BIOCHEM, V32, P151, DOI 10.1002/jcb.240320207; ZANOVELLO P, 1989, J EXP MED, V170, P665, DOI 10.1084/jem.170.3.665	40	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23957	23962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429733				2022-12-27	WOS:A1992JZ23900079
J	KROLL, SD; CHEN, JH; DEVIVO, M; CARTY, DJ; BUKU, A; PREMONT, RT; IYENGAR, R				KROLL, SD; CHEN, JH; DEVIVO, M; CARTY, DJ; BUKU, A; PREMONT, RT; IYENGAR, R			THE Q205LG0-ALPHA-SUBUNIT EXPRESSED IN NIH-3T3-CELLS INDUCES TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; PERTUSSIS TOXIN; BINDING PROTEIN; GO-PROTEIN; CELLS; IDENTIFICATION; ONCOGENE; RECEPTOR; DIFFERENTIATION; MUTATIONS	The growth functions of the heterotrimeric G protein G(o) was studied by expression in heterologous systems. The alpha-subunit of G(o) was mutated to convert Gln-205 to Leu (Q205L). Mutation of this conserved glutamine residue in G protein alpha-subunits is thought to persistently activate G proteins by inhibiting their GTPase activity. The wild type and mutant G(o)-alpha subunits were expressed in NIH-3T3 fibroblasts. These cells do not contain any measurable amounts of G(o)-alpha mRNA or protein. Transfection of wild type or Q205LG(o)-alpha subunit cDNA under the control of a dexamethasone-inducible promoter results in dexamethasone-dependent transcription of the mRNA and expression of the protein. The Q205LG(o)-alpha, but not wild type G(o)-alpha, stimulates mitogenesis in NIH-3T3 fibroblasts without significantly stimulating phospholipase C activity. Continuous expression of mutant G(o)-alpha induces focus formation, whereas transfections with vector alone or vector containing the native G(o)-alpha cDNA were without significant transforming effect in NIH-3T3 cells. Q205L G(o)-alpha did not induce focus formation in RAT-1 fibroblasts. Q205LG(o)-alpha-transformed NIH-3T3 cells are capable of anchorage-independent growth, as assessed by colony formation in soft agar. Q205LG(o)-alpha transformed cells induced tumors when injected into Nu/Nu mice. These results indicate that mutant G(o)-alpha subunits whose GTPase activity is presumably inhibited can induce the neoplastic transformation of NIH-3T3 cells in a phospholipase C-independent manner.	CUNY MT SINAI SCH MED,DEPT PHARMACOL & PHYSIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOPHYS,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NCI NIH HHS [CA44998] Funding Source: Medline; NIDDK NIH HHS [DK38761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HOECK W, 1989, J BIOL CHEM, V264, P14396; IMAI A, 1987, METHOD ENZYMOL, V141, P100; IYENGAR R, 1987, J BIOL CHEM, V262, P9239; KROLL SD, 1991, P NATL ACAD SCI USA, V88, P5182, DOI 10.1073/pnas.88.12.5182; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MUMBY S, 1988, J BIOL CHEM, V263, P2020; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PADRELL E, 1991, J BIOL CHEM, V266, P9771; POUYSSEGUR J, 1990, G PROTEINS, P555; PREMONT RT, 1989, J BIOL CHEM, V264, P14960; ROSS EM, 1977, J BIOL CHEM, V252, P5761; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811	29	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23183	23188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429665				2022-12-27	WOS:A1992JY16300074
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .1. FORMULATION OF ALTERNATIVE KINETIC REPRESENTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL SYSTEMS-THEORY; DIFFERENTIAL-EQUATIONS; VARIANT THEORIES; COMPLEX-SYSTEMS; LAW; FORM	Enzyme systems within living cells have recently been shown to be highly ordered structures that violate classic assumptions of the Michaelis-Menten formalism, which originally was developed for the characterization of isolated reactions in vitro. This evidence suggests that a thorough examination of alternative kinetic formalisms for integrated biochemical systems is in order. The purpose of this series of papers is to assess the utility of an alternative power-law formalism by carrying out a detailed comparative analysis of a relatively large, representative system - the tricarboxylic acid cycle of Dictyostelium discoideum. This system was chosen because considerable experimental information already has been synthesized into a detailed kinetic model of the intact system. In this first paper, we set the stage for subsequent analysis within the framework of the power-law formalism: we review the underlying theory, emphasizing recent developments, formulate the model in terms that are convenient for the analysis to follow, and develop the system representation in both the Michaelis-Menten and power-law forms. In the second paper (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22919-22925), these alternative representations are shown to be internally consistent and locally equivalent. The third paper (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267,22926-22933) provides a complete analysis of the steady state behavior and also treats the dynamic behavior of the model.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM-30054] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENAVRAHAM D, 1990, J STAT PHYS, V60, P695, DOI 10.1007/BF01025990; Bode H. W., 1945, NETWORK ANAL FEEDBAC; Brody S, 1964, BIOENERGETICS GROWTH; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IRVINE DH, 1990, SIAM J NUMER ANAL, V27, P704, DOI 10.1137/0727042; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; KELLY PJ, 1979, BIOCHEM J, V184, P581, DOI 10.1042/bj1840581; KOPELMAN R, 1986, J STAT PHYS, V42, P185, DOI 10.1007/BF01010846; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MILLHAUSER GL, 1988, P NATL ACAD SCI USA, V85, P1503, DOI 10.1073/pnas.85.5.1503; Needham J, 1950, BIOCH MORPHOGENESIS; NEWHOUSE JS, 1986, J CHEM PHYS, V85, P6804, DOI 10.1063/1.451413; REISS MJ, 1950, ALLOMETRY GROWTH REP; Roels J.A., 1983, ENERGETICS KINETICS; Savageau M, 1976, BIOCH SYSTEMS ANAL S; Savageau M. A., 1992, FUNDAMENTALS MED CEL, V3A, P45; SAVAGEAU MA, 1991, NEW BIOL, V3, P190; SAVAGEAU MA, 1979, P NATL ACAD SCI USA, V76, P5413, DOI 10.1073/pnas.76.11.5413; SAVAGEAU MA, 1979, P NATL ACAD SCI USA, V76, P6023, DOI 10.1073/pnas.76.12.6023; SAVAGEAU MA, 1991, J THEOR BIOL, V151, P509, DOI 10.1016/S0022-5193(05)80367-4; SAVAGEAU MA, 1987, MATH BIOSCI, V87, P83, DOI 10.1016/0025-5564(87)90035-6; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P370, DOI 10.1016/S0022-5193(69)80027-5; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P365, DOI 10.1016/S0022-5193(69)80026-3; SAVAGEAU MA, 1971, ARCH BIOCHEM BIOPHYS, V145, P612, DOI 10.1016/S0003-9861(71)80021-8; SEGAL HL, 1959, ENZYMES, V1, P1; Segel I.H., 1975, ENZYME KINETICS; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22926; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22919; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SORRIBAS A, 1989, MATH BIOSCI, V94, P161, DOI 10.1016/0025-5564(89)90064-3; SORRIBAS A, 1989, MATH BIOSCI, V94, P195, DOI 10.1016/0025-5564(89)90065-5; Srere PA, 1989, STRUCTURAL ORG ASPEC; Voit E., 1991, CANONICAL NONLINEAR; VOIT EO, 1987, BIOCHEMISTRY-US, V26, P6869, DOI 10.1021/bi00395a042; Von Bertanlanffy L, 1960, FUNDAMENTAL ASPECTS, P137; WEBB JL, 1963, ENZYMES METABOL INH, V1, P29; WHITE GJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P285, DOI 10.1016/0006-3002(61)90441-3; WONG JTF, 1962, CAN J BIOCHEM PHYS, V40, P763; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101; WRIGHT BE, 1964, BIOCHEMISTRY PHYSIOL, V3, P341; [No title captured]	43	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22912	22918						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429641				2022-12-27	WOS:A1992JY16300034
J	HWANG, YW; CARTER, M; MILLER, DL				HWANG, YW; CARTER, M; MILLER, DL			THE IDENTIFICATION OF A DOMAIN IN ESCHERICHIA-COLI ELONGATION FACTOR-TU THAT INTERACTS WITH ELONGATION FACTOR-TS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING DOMAIN; H-RAS P21; EF-TU; TRIPHOSPHATE CONFORMATION; SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDES; FUNCTIONAL SITES; ONCOGENE PROTEIN; ALPHA-SUBUNIT; AMINO-ACIDS	A method has been developed to search for the elongation factor Tu (EF-Tu) domain(s) that interact with elongation factor Ts (EF-Ts). This method is based on the suppression of Escherichia coli EF-Tu-dominant negative mutation K136E, a mutation that exerts its effect by sequestering EF-Ts. We have identified nine single-amino acid- substituted suppression mutations in the region 146-199 of EF-Tu. These mutations are R154C, P168L, A174V, K176E, D181G, E190K, D196G, S197F, and I199V. All suppression mutations but one (R154C) significantly affect EF-Tu's ability to interact with EF-Ts under equilibrium conditions. Moreover, with the exception of mutation A174V, the GDP affinity of EF-Tu appears to be relatively unaffected by these mutations. These results suggest that the domain of residues 154 to 199 on EF-Tu is involved in interacting with EF-Ts. These suppression mutations are also capable of suppressing dominant negative mutants N135D and N135I to various degrees. This suggests that dominant negative mutants N135D and N135I are likely to have the same molecular basis as the K136E mutation. The method we have developed in this study is versatile and can be readily adapted to map other regions of EF-Tu. A model of EF-Ts-catalyzed guanine-nucleotide exchange is discussed.			HWANG, YW (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABILITIES, DEPT MOLEC BIOL, STATEN ISL, NY 10314 USA.				NCI NIH HHS [CA53782] Funding Source: Medline; NIGMS NIH HHS [GM30800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDE JE, 1988, FASEB J, V2, P2356, DOI 10.1096/fasebj.2.8.2452111; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CLARK BFC, 1990, BIOCHIM BIOPHYS ACTA, V1050, P203, DOI 10.1016/0167-4781(90)90167-Z; COOL RH, 1990, J BIOL CHEM, V265, P6744; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DIAZ JJ, 1991, BIOTECHNIQUES, V11, P204; ECCLESTON JF, 1984, J BIOL CHEM, V259, P2997; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUMUSEL F, 1990, BIOCHIM BIOPHYS ACTA, V1050, P215, DOI 10.1016/0167-4781(90)90169-3; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HWANG YW, 1989, NATO ADV SCI I A-LIF, V165, P77; HWANG YW, 1985, J BIOL CHEM, V260, P1498; HWANG YW, 1989, ARCH BIOCHEM BIOPHYS, V274, P394, DOI 10.1016/0003-9861(89)90452-9; HWANG YW, 1987, J BIOL CHEM, V262, P13081; HWANG YW, 1989, J BIOL CHEM, V264, P8304; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JAMESON DM, 1987, BIOCHEMISTRY-US, V26, P3894, DOI 10.1021/bi00387a023; JENSEN M, 1989, EUR J BIOCHEM, V182, P247, DOI 10.1111/j.1432-1033.1989.tb14824.x; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; JURNAK F, 1990, BIOCHIM BIOPHYS ACTA, V1050, P209, DOI 10.1016/0167-4781(90)90168-2; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; MILLER DL, 1977, FACTORS INVOLVED TRA; Miller J.H., 1972, EXPT MOL GENETICS; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; OGISO Y, 1990, CELL GROWTH DIFFER, V1, P217; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMEGGIANI A, 1987, P NATL ACAD SCI USA, V84, P3141, DOI 10.1073/pnas.84.10.3141; PARMEGGIANI A, 1985, ANNU REV MICROBIOL, V39, P357; PETER ME, 1990, NUCLEIC ACIDS RES, V18, P6889, DOI 10.1093/nar/18.23.6889; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; QUAN F, 1991, P NATL ACAD SCI USA, V88, P1898, DOI 10.1073/pnas.88.5.1898; ROMERO G, 1985, J BIOL CHEM, V260, P6167; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOOLLEY P, 1989, BIO-TECHNOL, V7, P913, DOI 10.1038/nbt0989-913	55	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22198	22205						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429571				2022-12-27	WOS:A1992JW71900034
J	NAH, HD; BAREMBAUM, M; UPHOLT, WB				NAH, HD; BAREMBAUM, M; UPHOLT, WB			THE CHICKEN ALPHA-1(XI) COLLAGEN GENE IS WIDELY EXPRESSED IN EMBRYONIC-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMB CARTILAGE DIFFERENTIATION; MESSENGER-RNA LEVELS; II COLLAGEN; XI COLLAGEN; TRANSIENT EXPRESSION; V COLLAGEN; IX; INTERFACES; CHAIN; IDENTIFICATION	Complementary DNA and genomic DNA clones corresponding to the chicken alpha1(XI) collagen gene were isolated and characterized. These recombinant DNA clones covered 2667 base pairs of the mRNA and encode 624 amino acids of the triple helical region plus the entire carboxyl-terminal propeptide. Northern blot analysis showed a major band of approximately 6.5 kilobases and a minor band of approximately 7.5 kilobases. A combination of Northern blot and in situ hybridization analyses showed that, in addition to its presence in cartilage, this mRNA also is present in a wide variety of chicken noncartilaginous embryonic tissues including brain, heart, skeletal muscle, calvaria, and skin, but was not detected in liver. Type II collagen mRNA has also been detected at low levels in these same tissues. Also, similar to the mRNA for the alpha1 chain for type II collagen, the alpha1(XI) collagen mRNA is detected in limb mesenchyme prior to condensation and differentiation of the core mesenchyme into cartilage.	UNIV CONNECTICUT,CTR HLTH,SCH DENT MED,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030	University of Connecticut					NICHD NIH HHS [HD22896] Funding Source: Medline; NIDCR NIH HHS [DE07131] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD022896, R01HD022896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007131] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERNARD M, 1988, J BIOL CHEM, V263, P17159; BROWN KE, 1991, J BIOL CHEM, V266, P23268; BURGESON RE, 1982, J BIOL CHEM, V257, P7852; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COELHO CND, 1991, MECH DEVELOP, V34, P143, DOI 10.1016/0925-4773(91)90051-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FITCH JM, 1989, DEVELOPMENT, V105, P85; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAREL R, 1992, J BIOL CHEM, V267, P10070; KIMURA T, 1988, BIOMED RES-TOKYO, V9, P319, DOI 10.2220/biomedres.9.319; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KOSHER RA, 1989, DEV BIOL, V131, P558, DOI 10.1016/S0012-1606(89)80026-0; KOSHER RA, 1986, J CELL BIOL, V102, P1151, DOI 10.1083/jcb.102.4.1151; KRAVIS D, 1985, DEV BIOL, V108, P164, DOI 10.1016/0012-1606(85)90018-1; KULYK WM, 1991, MATRIX, V11, P282, DOI 10.1016/S0934-8832(11)80236-2; LINSENMA.TF, 1973, DEV BIOL, V35, P232, DOI 10.1016/0012-1606(73)90020-1; MALLEINGERIN F, 1990, ROUX ARCH DEV BIOL, V198, P363, DOI 10.1007/BF00383774; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; NAH HD, 1991, J BIOL CHEM, V266, P23446; NAH HD, 1988, COLLAGEN REL RES, V8, P277; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; RAMIREZ F, 1965, ANN NY ACAD SCI, V460, P117; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SHEFFIELD VC, 1985, COLLAGEN REL RES, V5, P1; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; THOM JR, 1991, J BIOL CHEM, V266, P7262; THOROGOOD P, 1986, DEV BIOL, V116, P497, DOI 10.1016/0012-1606(86)90150-8; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WOOD A, 1991, DEVELOPMENT, V111, P955; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423	41	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22581	22586						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429607				2022-12-27	WOS:A1992JW71900092
J	PUOTI, A; CONZELMANN, A				PUOTI, A; CONZELMANN, A			STRUCTURAL CHARACTERIZATION OF FREE GLYCOLIPIDS WHICH ARE POTENTIAL PRECURSORS FOR GLYCOPHOSPHATIDYLINOSITOL ANCHORS IN MOUSE THYMOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; MUTANT LYMPHOMA-CELLS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; THY-1 GLYCOPROTEIN; PHOSPHOLIPASE-C	Biosynthesis of glycophosphatidylinositol-anchored membrane glycoproteins proceeds through the attachment of a preformed glycolipid onto a C-terminal amino acid rapidly after translation. Here we describe the structural analysis of two very polar glycolipids which can be observed after metabolic labeling of lymphoma cell lines S1A and EL-4 with either tritiated myo-inositol, mannose, or ethanolamine. These lipids are not made by mutant cells deficient in the biosynthesis of glycophosphatidylinositol anchors. The lipids were isolated, and their carbohydrate moiety was characterized using hydrofluoric acid dephosphorylation, nitrous acid deamination, acetolysis, exoglycosidase treatments, and combinations thereof to produce labeled fragments which could be analyzed by paper chromatography. Results are compatible with the structure (X-->)Manalpha1,2Manalpha1,6(Y-->)Manalpha-GlcN-acylinositol, X and Y being hydrofluoric acid-sensitive substituents (most likely phosphoethanolamine). The anchor oligosaccharide of the glycophosphatidylinositol protein anchors of S1A cells was isolated, similarly characterized, and found to contain the identical carbohydrate structure. Pulse-chase experiments indicate that the very polar glycolipids have half-lives which are much longer than the one of phosphatidylinositol. The results suggest that these very polar glycolipids represent supernumerary precursor glycolipids which did not get transferred onto proteins or represent processed forms of such precursors.	UNIV FRIBOURG,INST BIOCHIM,CH-1700 FRIBOURG,SWITZERLAND; UNIV LAUSANNE,INST BIOCHEM,CH-1000 LAUSANNE 17,SWITZERLAND	University of Fribourg; University of Lausanne			Puoti, Alessandro/E-5700-2012	Puoti, Alessandro/0000-0002-1396-7662				ALEMANY S, 1987, NATURE, V330, P77, DOI 10.1038/330077a0; BANGS JD, 1988, J BIOL CHEM, V263, P17697; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1990, J BIOL CHEM, V265, P611; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FATEMI SH, 1988, J BIOL CHEM, V263, P1288; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSSE WF, 1990, ANNU REV MED, V41, P431; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SUZUKI S, 1991, J BIOL CHEM, V266, P8115; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; TROWBRIDGE IS, 1978, CELL, V14, P21, DOI 10.1016/0092-8674(78)90297-0; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; VARKI A, 1983, J BIOL CHEM, V258, P2808; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	53	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22673	22680						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429614				2022-12-27	WOS:A1992JW71900104
J	AGGELER, R; CAPALDI, RA				AGGELER, R; CAPALDI, RA			CROSS-LINKING OF THE GAMMA-SUBUNIT OF THE ESCHERICHIA-COLI ATPASE (ECF(1)) VIA CYSTEINES INTRODUCED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING-SITES; COUPLING FACTOR-I; EPSILON-SUBUNIT; CATALYTIC SITE; H+-ATPASE; SYNTHASE; F1-ATPASE; CONFORMATION; AUROVERTIN	The gamma subunit of the Escherichia coli F1 ATPase (ECF1) has been altered by site-directed mutagenesis to create five different mutants, gamma-S8C, gamma-S81C, gamma-T106C, gamma-S179C, and gamma-V286C, respectively. ECF1 isolated from four of these mutants had ATPase activities similar to that of a wild-type isogenic strain used as a control, the exception was enzyme isolated from mutant gamma-S81C, which had an ATPase activity of around 70-80% of the wild type. ECF1 isolated from each of the various mutants was reacted with N-(4-(7-(diethylamino)-4-methylcoumarin-3-yl))maleimide (CM). The fluorescent reagent was incorporated into Cys residues placed at positions 8, 106, 179, and 286, but not at 81, indicating which of these Cys residues are on the surface of the gamma subunit in the enzyme complex. Modification of the Cys at position 106 with CM activated the enzyme, and modification of the Cys at position 8 inhibited ATPase activity a small amount; however, modification of Cys at 179 or 286 had no effect on enzyme activity. The four mutants with a reactive Cys were reacted with tetrafluorophenylazide maleimides (TFPAMs), novel photoactivatable cross-linkers. In the mutant gamma-S8C, cross-links were formed between the introduced Cys on the gamma subunit and sites on the beta subunit. This cross-linking between gamma and beta depended on nucleotide conditions under which the photolysis was carried out, with differently migrating cross-linked products being obtained in ATP + EDTA compared with ATP + Mg2+ or ATP + Mg2+ + P(i). Cross-linking between beta and gamma inhibited ATPase activity in proportion to the yield of cross-linked product. In the mutant gamma-V286C, cross-links were formed between the introduced Cys on gamma and the alpha subunit which were the same in all nucleotide conditions and which led to inhibition of ATPase activity.			AGGELER, R (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.				NHLBI NIH HHS [HL24536] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Battey, 1986, BASIC METHODS MOL BI; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GAVILANESRUIZ M, 1988, BIOCHEMISTRY-US, V27, P603, DOI 10.1021/bi00402a016; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; IDA K, 1991, J BIOL CHEM, V266, P5424; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KEANA JFW, 1990, J ORG CHEM, V55, P3640, DOI 10.1021/jo00298a048; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIGHTOWLERS R, 1987, THESIS AUSTR NATIONA; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Maniatis T., 1982, MOL CLONING; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1980, J BIOL CHEM, V255, P6670; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WISE JG, 1981, J BIOL CHEM, V256, P383	30	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21355	21359						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400447				2022-12-27	WOS:A1992JV01100018
J	COPELAND, WC; CHEN, MS; WANG, TSF				COPELAND, WC; CHEN, MS; WANG, TSF			HUMAN DNA POLYMERASE-ALPHA AND POLYMERASE-BETA ARE ABLE TO INCORPORATE ANTI-HIV DEOXYNUCLEOTIDES INTO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; BONE-MARROW-CELLS; AZIDOTHYMIDINE AZT; INSERTION FIDELITY; DOUBLE-BLIND; 3'-AZIDO-3'-DEOXYTHYMIDINE; THERAPY; 5'-TRIPHOSPHATE	Deoxynucleoside analogs, AZT and/or ddN, are the therapeutic agents currently utilized to inhibit the human immunodeficiency virus (HIV) reverse transcriptase. The effects of their anabolic products, AZT-triphosphate (AZT-TP) and ddCTP on human cellular DNA metabolic processes were studied using highly purified, structurally and enzymatically defined forms of the two major human host DNA polymerases, alpha and beta, and compared to those of the reverse transcriptase purified from HIV viron. Human DNA polymerase alpha during processive DNA synthesis is able to incorporate AZT-monophosphate (AZT-MP) but not ddCMP into DNA, causing chain termination. During its initial encounter with a primer terminus, polymerase alpha is able to incorporate both AZT-MP and ddCMP into DNA chains. Polymerase beta is able to incorporate AZT-MP and ddCMP into DNA, causing chain termination in both modes of DNA synthesis. Steady state kinetic analyses demonstrate that polymerase alpha inserts one AZT-MP molecule into DNA for every 2500 dTMP molecules incorporated. Polymerase beta incorporates ddCMP with efficiency nearly equal to that of dCMP. HIV reverse transcriptase prefers to incorporate AZT-MP and ddCMP rather than dTMP and dCMP, respectively. The findings described here raise the concern that the capability of the two major host DNA polymerases to incorporate AZT-MP or ddCMP into DNA might cause adverse side effects on human DNA metabolism and mutation in the genomes of patients under long term continuous treatment with AZT and ddC.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305; SYNTEX INC,INST BIOCHEM & CELL BIOL,PALO ALTO,CA 94304	Stanford University; Syntex Corporation			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028873] Funding Source: NIH RePORTER; NCI NIH HHS [CA14835] Funding Source: Medline; NIAID NIH HHS [AI28873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CHEN GY, 1986, J BIOL CHEM, V262, P2187; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COREY L, 1992, NEW ENGL J MED, V326, P484, DOI 10.1056/NEJM199202133260710; CRETTON EM, 1991, MOL PHARMACOL, V39, P258; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HUANG P, 1992, J BIOL CHEM, V267, P2817; HUANG P, 1990, J BIOL CHEM, V265, P11914; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUMAR A, 1990, J BIOL CHEM, V265, P2124; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; NICKEL W, 1992, J BIOL CHEM, V267, P848; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SOMMADOSSI JP, 1989, MOL PHARMACOL, V36, P9; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1984, J BIOL CHEM, V259, P1854; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; ZHU Z, 1991, MOL PHARMACOL, V40, P838	27	87	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21459	21464						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400458				2022-12-27	WOS:A1992JV01100032
J	PLISHKER, GA; CHEVALIER, D; SEINSOTH, L; MOORE, RB				PLISHKER, GA; CHEVALIER, D; SEINSOTH, L; MOORE, RB			CALCIUM-ACTIVATED POTASSIUM-TRANSPORT AND HIGH-MOLECULAR-WEIGHT FORMS OF CALPROMOTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED BLOOD-CELLS; VONWILLEBRAND-FACTOR; CYTOPLASMIC PROTEIN; K+ CHANNELS; MULTIMERIZATION; GHOSTS; EFFLUX; PH	Investigations of human red blood cells show that a cytoplasmic protein called calpromotin is involved in the regulation of calcium-activated potassium transport. Calpromotin associates with the membrane in the presence of calcium and undergoes a chemical transformation. High performance gel filtration and gel electrophoresis show that the cytoplasmic and membrane-bound calpromotin can exist in both low and high molecular weight forms. The biochemical properties of the high molecular weight membrane-bound calpromotin are not the same as the high molecular weight cytoplasmic calpromotin. The high molecular weight membrane forms of calpromotin are increased by leupeptin and diminished by iodoacetic acid. Therefore, the leupeptin enhancement and iodoacetic inhibition of calcium-activated potassium transport may involve the high molecular weight forms of membrane-bound calpromotin.	BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; UNIV SO ALABAMA,COMPREHENS SICKLE CELL CTR,MOBILE,AL 36617	Baylor College of Medicine; University of South Alabama								BENJAMIN AM, 1984, J CELL PHYSIOL, V121, P508, DOI 10.1002/jcp.1041210309; BLUM RM, 1971, J MEMBRANE BIOL, V6, P315, DOI 10.1007/BF02116577; FERREIRA HG, 1976, NATURE, V263, P336; GRYGORCZYK R, 1984, BIOPHYS J, V45, P693, DOI 10.1016/S0006-3495(84)84211-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEW VL, 1978, CURR TOP MEMBR TRANS, V10, P217; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MOORE RB, 1991, J BIOL CHEM, V266, P18964; PARKER JC, 1989, RED BLOOD CELL MEMBR, P507; PLISHKER GA, 1986, AM J PHYSIOL, V251, pC535, DOI 10.1152/ajpcell.1986.251.4.C535; PLISHKER GA, 1985, AM J PHYSIOL, V248, pC419, DOI 10.1152/ajpcell.1985.248.5.C419; SCHWARZ W, 1983, ANNU REV PHYSIOL, V45, P359, DOI 10.1146/annurev.ph.45.030183.002043; SIMONS TJB, 1976, J PHYSIOL-LONDON, V256, P227, DOI 10.1113/jphysiol.1976.sp011322; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320	15	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21839	21843						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400494				2022-12-27	WOS:A1992JV01100089
J	ROBINSON, PJ				ROBINSON, PJ			DIFFERENTIAL STIMULATION OF PROTEIN-KINASE-C ACTIVITY BY PHORBOL ESTER OR CALCIUM PHOSPHATIDYLSERINE INVITRO AND IN INTACT SYNAPTOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CORTICAL SYNAPTOSOMES; SUBSTRATE-SPECIFICITY; SIGNAL TRANSDUCTION; INDUCED MATURATION; DOWN-REGULATION; LEUKEMIA-CELLS; FATTY-ACIDS; PHOSPHORYLATION; ACTIVATION; BRAIN	Activation of protein kinase C (PKC) by phorbol 12-myristate 13-acetate (PMA) was compared with calcium/phosphatidylserine (Ca/PS). The substrate specificity of PKC was more limited with PS/PMA. Substrates could be divided into three overlapping groups according to their relative level of phosphorylation: C1, relatively preferred substrates with Ca/PS, included dephosphin, histone, and peptide GS1-10. C2, relatively preferred with PS/PMA, included myelin basic protein and MARCKS. C3, substrates independent of activators. PS/PMA altered the V(max) of PKC for substrate, and decreased the K(m) for Mg2+. Differential substrate phosphorylation by PS/PMA also occurred for PKC isozymes resolved by hydroxylapatite chromatography and was most dramatic for PKC-alpha, which could no longer phosphorylate histone or GS1-12. Differential activities of PKC were also observed in synaptosol and in intact synaptosomes where PMA stimulated phosphorylation of MARCKS, but not dephosphin. It was further shown that dephosphin was indeed a substrate of PKC in the intact synaptosomes by use of a repolarization-dependent dephosphin phosphorylation assay. The differential PKC activities could also be distinguished by inhibitors. H-7 was equipotent, palmitoylcarnitine did not inhibit in vitro C2 phosphorylation, but inhibited dephosphin in intact synaptosomes, and sphingosine did not inhibit Cl substrates and was without effect on dephosphin in intact synaptosomes. Therefore PS/PMA alters or limits the substrate specificity of PKC, leading to a differential substrate phosphorylation in vitro and in intact synaptosomes and differential inhibitor sensitivity. The pattern of protein phosphorylation observed after PKC activation in intact cells will therefore be dependent upon the activator.			ROBINSON, PJ (corresponding author), JOHN HUNTER HOSP,ENDOCRINE UNIT,LOCKED BAG 1,HUNTER REG MAIL CTR,SYDNEY 2310,AUSTRALIA.		Robinson, Phillip J/G-4008-2011	Robinson, Phillip J/0000-0002-7878-0313				AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; ARCOLEO JP, 1985, CARCINOGENESIS, V6, P213, DOI 10.1093/carcin/6.2.213; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUTURIER A, 1984, BIOCHEM BIOPH RES CO, V121, P448, DOI 10.1016/0006-291X(84)90203-1; DOERNER D, 1990, J NEUROSCI, V10, P1699; DUNKLEY PR, 1986, J NEUROCHEM, V46, P1692; DUNKLEY PR, 1986, PROG BRAIN RES, V69, P273; EBANKS R, 1989, BIOCHEM J, V258, P689, DOI 10.1042/bj2580689; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; EVANS FJ, 1991, BIOCHEM SOC T, V19, P397, DOI 10.1042/bst0190397; GROVE DS, 1988, BIOCHEM BIOPH RES CO, V151, P94, DOI 10.1016/0006-291X(88)90563-3; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANSSON A, 1987, ACTA CHEM SCAND B, V41, P174, DOI 10.3891/acta.chem.scand.41b-0174; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; HIDAKA H, 1987, TRENDS PHARMACOL SCI, V8, P162, DOI 10.1016/0165-6147(87)90155-6; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1989, FEBS LETT, V249, P243, DOI 10.1016/0014-5793(89)80632-5; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; ISSANDOU M, 1990, CANCER RES, V50, P5845; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KATOH N, 1981, P NATL ACAD SCI-BIOL, V78, P4813, DOI 10.1073/pnas.78.8.4813; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KISS Z, 1986, FEBS LETT, V198, P203, DOI 10.1016/0014-5793(86)80405-7; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; KUO JF, 1984, MOL CELL ENDOCRINOL, V35, P65, DOI 10.1016/0303-7207(84)90001-7; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LIU JP, 1992, IN PRESS MOL CELL EN; LOWE JHN, 1990, J BIOL CHEM, V265, P7188; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MORIN MJ, 1987, J BIOL CHEM, V262, P11758; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBRIAN CA, 1987, FEBS LETT, V214, P339, DOI 10.1016/0014-5793(87)80083-2; OBRIAN CA, 1987, BIOCHEM PHARMACOL, V36, P1231, DOI 10.1016/0006-2952(87)90075-X; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OISHI K, 1988, J BIOL CHEM, V263, P6865; OMRI B, 1987, EUR J BIOCHEM, V165, P83, DOI 10.1111/j.1432-1033.1987.tb11197.x; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; RAMSDELL JS, 1986, J BIOL CHEM, V261, P7073; ROBILLARD JE, 1988, SEMIN PERINATOL, V12, P143; Robinson P J, 1987, Adv Exp Med Biol, V221, P155; ROBINSON PJ, 1990, J PHARMACOL EXP THER, V255, P1392; ROBINSON PJ, 1984, J NEUROCHEM, V43, P659, DOI 10.1111/j.1471-4159.1984.tb12785.x; ROBINSON PJ, 1986, NEUROCHEM INT, V9, P455, DOI 10.1016/0197-0186(86)90088-4; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1986, NEUROSCI LETT, V68, P1, DOI 10.1016/0304-3940(86)90219-3; ROBINSON PJ, 1991, NEUROSCI RES COMMUN, V9, P167; ROBINSON PJ, 1992, IN PRESS BIOCH PHARM; ROBINSONPJ, 1992, MOL NEUROBIOL, V5, P87; RODNIGHT R, 1986, J PHYSIOLOGY PARIS, V81, P340; SAHAL D, 1987, ANAL BIOCHEM, V167, P23, DOI 10.1016/0003-2697(87)90129-1; SAKAI K, 1987, BIOCHEM INT, V14, P63; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHACHTELE C, 1988, BIOCHEM BIOPH RES CO, V151, P542, DOI 10.1016/0006-291X(88)90628-6; SEIFERT R, 1988, BIOCHEM BIOPH RES CO, V154, P20, DOI 10.1016/0006-291X(88)90643-2; SEIFERT R, 1988, BIOCHEM BIOPH RES CO, V152, P585, DOI 10.1016/S0006-291X(88)80078-0; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; VANDENBARK GR, 1984, J CLIN INVEST, V73, P448, DOI 10.1172/JCI111231; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WAYS DK, 1987, CANCER RES, V47, P3344; WITTERS LA, 1987, METHOD ENZYMOL, V141, P412; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YAMAMOTO S, 1985, J BIOL CHEM, V260, P4230	77	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21637	21644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400474				2022-12-27	WOS:A1992JV01100060
J	KOJIMA, K; OGAWA, HK; SENO, N; YAMAMOTO, K; IRIMURA, T; OSAWA, T; MATSUMOTO, I				KOJIMA, K; OGAWA, HK; SENO, N; YAMAMOTO, K; IRIMURA, T; OSAWA, T; MATSUMOTO, I			CARBOHYDRATE-BINDING PROTEINS IN BOVINE KIDNEY HAVE CONSENSUS AMINO-ACID-SEQUENCES OF ANNEXIN FAMILY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-C; GEL-ELECTROPHORESIS; GROWTH-FACTOR; LECTIN; PHOSPHORYLATION; IDENTIFICATION; MULTIPLE; RECEPTOR; ADHESION; RAT	Ca2+-dependent carbohydrate-binding proteins were purified from bovine kidney extracts. Upon SDS-polyacrylamide gel electrophoresis under nonreducing conditions, the purified fraction gave doublet protein bands corresponding to 33 kDa (p33) and 41 kDa (p41). Under reducing conditions, a single protein band (p33) was observed. p33 and p41 were submitted to proteolytic digestion with endoproteinase Lys-C, the peptides produced were separated by reversed-phase high performance liquid chromatography, and their amino acid sequences were determined by an automated gas-phase protein sequenator. Most of the resulting partial amino acid sequences of these proteins were strikingly homologous to annexin IV, an annexin family protein, i.e. Ca2+/phospholipid-binding proteins, especially in the consensus sequences. In the presence of Ca2+, both proteins bound to vesicles composed of phosphatidylserine and phosphatidylethanolamine, but not phosphatidylcholine. These results indicated that p33 and p41 are members of annexin family proteins.	OCHANOMIZU UNIV,FAC SCI,DEPT CHEM,2-1-1 OTSUKA,BUNKYO KU,TOKYO 112,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DIV CHEM TOXICOL & IMMUNOCHEM,BUNKYO KU,TOKYO 113,JAPAN	Ochanomizu University; University of Tokyo								ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARONDES SH, 1981, ANNU REV BIOCHEM, V50, P207, DOI 10.1146/annurev.bi.50.070181.001231; BLACKWELL GJ, 1982, BRIT J PHARMACOL, V76, P185, DOI 10.1111/j.1476-5381.1982.tb09205.x; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GRUNDMANN U, 1988, P NATL ACAD SCI USA, V85, P3708, DOI 10.1073/pnas.85.11.3708; HAMMAN HC, 1988, BIOCHEM BIOPH RES CO, V156, P660, DOI 10.1016/S0006-291X(88)80893-3; HUANG JM, 1990, ANAL BIOCHEM, V188, P114, DOI 10.1016/0003-2697(90)90537-J; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KOJIMA K, 1992, J CHROMATOGR, V597, P323, DOI 10.1016/0021-9673(92)80127-G; KONAMI Y, 1991, J BIOCHEM-TOKYO, V109, P650, DOI 10.1093/oxfordjournals.jbchem.a123435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; SOBEL M, 1992, J BIOL CHEM, V267, P8857; TAIT JF, 1987, J BIOL CHEM, V262, P1860; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G	25	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20536	20539						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400371				2022-12-27	WOS:A1992JT97800004
J	YAMASAKI, H; PRAGER, D; GEBREMEDHIN, S; MELMED, S				YAMASAKI, H; PRAGER, D; GEBREMEDHIN, S; MELMED, S			HUMAN INSULIN-LIKE GROWTH FACTOR-I RECEPTOR 950TYROSINE IS REQUIRED FOR SOMATOTROPH GROWTH-FACTOR SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED CELLS; TYROSINE PHOSPHORYLATION; PITUITARY-CELLS; SOMATOMEDIN-C; HORMONE GENE; RETROENDOCYTOSIS; DETERMINANTS; SPECIFICITY; ENDOCYTOSIS; EXPRESSION	Insulin-like growth factor I (IGF-I), a growth hormone (GH)-dependent growth factor exerts feedback regulation of GH by inhibiting GH gene expression. IGF-I inhibition of GH secretion is enhanced 3-5-fold in GC rat pituitary cells overexpressing the wild type 950Tyr human IGF-I receptor which autophosphorylates appropriately. To determine the critical amino acid sequence responsible for IGF-I signaling, insertion, deletion, and site-directed mutants were constructed to substitute for 950Tyr in exon 16 of the human IGF-I receptor beta-subunit transmembrane domain. All mutant transfectants bound IGF-I with a similar K(d) to untransfected cells but had markedly increased (7-34-fold) IGF-I-binding sites. GH responsiveness to IGF-I was tested in mutant transfectants. Overexpressed site-directed and insertion mutant IGF-I receptors exhibited a modest suppressive effect on GH in response to the IGF-I ligand, similar to that observed in untransfected cells. Deletion mutant (IG-FIR DELTA22) (amino acid 944-965) did not transduce the IGF-I signal to the GH gene. Site-directed and insertion mutants therefore did not enhance the IGF-I response of the endogenous rat receptor, unlike the 950Tyr wild type transfectants which enhanced the IGF-I signal. All mutant transfectants, except the deletion mutant, internalized radioactive ligand similarly to 950Tyr wild type transfectants. 950Tyr of the human IGF-I receptor is therefore required for IGF-I signal transduction in the pituitary somatotroph, but not for IGF-I-mediated internalization.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV ENDOCRINOL,B131,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002023, R01DK033802] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02023, DK 33802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE H, 1983, ENDOCRINOLOGY, V113, P1319, DOI 10.1210/endo-113-4-1319; BERELOWITZ M, 1981, SCIENCE, V212, P1279, DOI 10.1126/science.6262917; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHIN JE, 1991, J BIOL CHEM, V266, P15587; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; IZUMI T, 1987, J BIOL CHEM, V262, P1282; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P1228, DOI 10.1073/pnas.80.5.1228; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; LEVY JR, 1986, ENDOCRINOLOGY, V119, P572, DOI 10.1210/endo-119-2-572; MARSHALL S, 1985, J BIOL CHEM, V260, P3524; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; PRAGER D, 1988, J BIOL CHEM, V263, P16580; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THIES RS, 1990, J BIOL CHEM, V265, P10132; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YAMASAKI H, 1991, MOL ENDOCRINOL, V5, P890, DOI 10.1210/mend-5-7-890; YAMASAKI H, 1991, ENDOCRINOLOGY, V128, P857, DOI 10.1210/endo-128-2-857; YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832; YAMASHITA S, 1986, ENDOCRINOLOGY, V118, P176, DOI 10.1210/endo-118-1-176	27	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20953	20958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400411				2022-12-27	WOS:A1992JT97800070
J	LEAMON, CP; LOW, PS				LEAMON, CP; LOW, PS			CYTOTOXICITY OF MOMORDIN-FOLATE CONJUGATES IN CULTURED HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; RECEPTOR-MEDIATED ENDOCYTOSIS; THY 1.1 ANTIBODY; HUMAN KB-CELLS; BINDING-PROTEIN; DIPHTHERIA-TOXIN; MA104 CELLS; IMMUNOTOXINS; DELIVERY; INVITRO	We have shown previously that macromolecules can be nondestructively delivered into cultured cells via folate receptor-mediated endocytosis if the macromolecules are conjugated to folic acid prior to addition to receptor-bearing cells (Leamon, C.P., and Low, P. S. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 5572-5576). Although an intracellular destination of the folate-linked proteins could be easily documented, the spatial resolution of the earlier data was insufficient to evaluate whether any endocytosed material was delivered into the cytosol. To resolve this issue, a folate-toxin conjugate was constructed using the impermeable ribosome-inactivating protein, momordin. Diminution of [H-3]leucine incorporation into newly synthesized protein was then employed as a quantitative measure of the entry of the toxin into the cytosol. In studies with both HeLa and KB cells, cellular protein synthesis was found to be inhibited in a time- and concentration-dependent manner by the momordin-folate conjugate, but not by the underivatized toxin. IC50 values centered around 10(-9) M for the folate-linked samples. These observations provide direct evidence that folate conjugates not only reach the cytosol, but do so in a functionally active form.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				ANTONY AC, 1985, J BIOL CHEM, V260, P4911; BARBIERI L, 1980, BIOCHEM J, V186, P443, DOI 10.1042/bj1860443; BASU SK, 1990, BIOCHEM PHARMACOL, V40, P1941, DOI 10.1016/0006-2952(90)90222-7; BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P760; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HUCKETT B, 1990, BIOCHEM PHARMACOL, V40, P253, DOI 10.1016/0006-2952(90)90686-F; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; JANSEN G, 1989, CANCER RES, V49, P2455; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1989, LAB INVEST, V60, P737; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; MAGERSTADT M, 1991, ANTIBODY CONJUGATES; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; MISKIMINS WK, 1979, BIOCHEM BIOPH RES CO, V91, P143, DOI 10.1016/0006-291X(79)90595-3; OELTMANN TN, 1979, J BIOL CHEM, V254, P1028; OLSNES S, 1989, IMMUNOL TODAY, V10, P291; Olsnes S., 1982, PHARMACOL THERAPEUT, V15, P355; POZNANSKY MJ, 1989, FASEB J, V3, P152, DOI 10.1096/fasebj.3.2.2644147; RASO V, 1984, RECEPTOR MEDIATED TA, P73; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SAID HM, 1987, AM J PHYSIOL, V252, pG229, DOI 10.1152/ajpgi.1987.252.2.G229; Sambrook J, 1989, MOL CLONING LABORATO; SIEGALL CB, 1990, J BIOL CHEM, V265, P16318; SIMPSON DL, 1982, CELL, V29, P469, DOI 10.1016/0092-8674(82)90163-5; STIRPE F, 1988, NUCLEIC ACIDS RES, V16, P1349, DOI 10.1093/nar/16.4.1349; STIRPE F, 1986, FEBS LETT, V195, P1, DOI 10.1016/0014-5793(86)80118-1; STIRPE F, 1988, BRIT J CANCER, V58, P558, DOI 10.1038/bjc.1988.258; THORPE PE, 1985, J NATL CANCER I, V75, P151; THORPE PE, 1981, EUR J BIOCHEM, V116, P447, DOI 10.1111/j.1432-1033.1981.tb05356.x; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WU GY, 1987, J BIOL CHEM, V262, P4429	33	130	164	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24966	24971						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460001				2022-12-27	WOS:A1992KB60300012
J	OROURKE, KM; LAHERTY, CD; DIXIT, VM				OROURKE, KM; LAHERTY, CD; DIXIT, VM			THROMBOSPONDIN-1 AND THROMBOSPONDIN-2 ARE EXPRESSED AS BOTH HOMOTRIMERS AND HETEROTRIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE; CELLS	There exist two distinct thrombospondin molecules (designated TSP1 and TSP2) which are encoded by separate genes. TSP1 is a trimeric cell surface and extracellular matrix molecule. Sequence comparison reveals that the 2 cysteines involved in interchain disulfide linkage and trimer assembly in TSP1 are conserved in TSP2 (Laherty, C. D., O'Rourke, K., Wolf, F. W., Katz, R., Seldin, M. F., and Dixit, V. M. (1992) J. Biol. Chem. 267, 3274-3281). Swiss 3T3 fibroblasts express both TSP1 and TSP2, and, therefore, an important question is whether TSP in such cells is expressed as homotrimers or as heterotrimers. We find that Swiss 3T3 cells and epithelial cells transfected with TSP expression vectors express both homo- and heterotrimeric forms of TSP. In addition, homotrimeric TSP2 has a lower affinity for heparin than homotrimeric TSP1. Thus, the heparin affinity of TSP can be modulated by the expression of TSP as homo- or heterotrimers.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,BOX 0602,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA58182] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058182] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DIXIT VM, 1984, J BIOL CHEM, V259, P100; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; Marston F. A. O., 1987, DNA CLONING, P59; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1990, J CELL BIOL, V111, P2713, DOI 10.1083/jcb.111.6.2713; OSHEA KS, 1991, NEURON, V7, P1; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOLF FW, 1992, J BIOL CHEM, V267, P1317	17	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24921	24924						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459996				2022-12-27	WOS:A1992KB60300003
J	PEARSON, D; SASSE, J				PEARSON, D; SASSE, J			DIFFERENTIAL REGULATION OF BIGLYCAN AND DECORIN BY RETINOIC ACID IN BOVINE CHONDROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; GROWTH-FACTOR-BETA; MESSENGER-RNA; ARTICULAR-CARTILAGE; TRANSCRIPTIONAL REPRESSION; NEGATIVE REGULATION; KIDNEY-CELLS; CORE PROTEIN; MATRIX; GENE	The small, leucine-rich proteoglycans, decorin and biglycan, are prominent components of many extracellular matrices and are differentially regulated in various tissues. We have examined the effects of retinoic acid (RA) on the expression of biglycan and decorin at the protein and mRNA levels in cultured bovine articular chondrocytes. Biglycan protein expression is rapidly turned off after 1-2 days of treatment with RA. In contrast, decorin protein expression is increased 12-18-fold following 3 days of RA treatment. The level of biglycan mRNA was also rapidly reduced upon RA treatment, mirroring the protein expression. The reduction was apparent by 6 h, and, by 4 days, the levels were nearly undetectable. In contrast, decorin mRNA was induced upon treatment with RA. The increase in decorin message levels was first apparent by 24 h, reaching maximum by 2 days, and remained constant through 4 days. The repression of biglycan mRNA displayed equal sensitivity to RA concentrations from 10(-5) to 10(-9) M. Decorin mRNA was induced in a dose-dependent fashion by RA. Retinoic acid at a concentration of 10(-5) M, the highest dose examined, resulted in maximal induction of the message, and control levels were obtained with 10(-8) M. The protein synthesis inhibitor cycloheximide inhibited the induction of decorin mRNA, indicating that the induction by RA was a secondary event. In contrast, the repression of biglycan by RA was not significantly altered by cycloheximide, showing that the repression was a direct effect. Actinomycin D inhibited the induction of decorin mRNA, indicating that transcription was required for the induction. Nuclear run-on assays confirmed that RA was regulating biglycan mRNA expression at the transcription level. A 24-h RA treatment decreased the level of transcription of the biglycan gene 5-fold. In contrast, no increase in transcription from the decorin gene could be detected by nuclear run-on assays. Therefore, the elevation in decorin mRNA levels observed after RA treatment was the result of a post-transcriptional event, most likely the consequence of stabilization of the message. This study demonstrates that the genes for these two similar proteoglycans are under very different forms of regulation by RA in chondrocytes. The pattern of differential expression of biglycan and decorin could serve as an additional marker for indicating changes of the cartilage phenotype.	UNIV S FLORIDA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33620; SHRINERS HOSP CRIPPLED CHILDREN,TAMPA UNIT,TAMPA,FL 33612; UNIV S FLORIDA,INST BIOMOLEC SCI,TAMPA,FL 33620	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida								ANDRUS L, 1988, J BIOL CHEM, V263, P6183; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; CHEAH KSE, 1985, P NATL ACAD SCI USA, V82, P2555, DOI 10.1073/pnas.82.9.2555; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GIGUERE V, 1989, NATURE, V337, P566, DOI 10.1038/337566a0; HORTON WE, 1987, DEV BIOL, V123, P508, DOI 10.1016/0012-1606(87)90409-X; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; KOSHER RA, 1983, CARTILAGE, V1; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Maniatis T., 1982, MOL CLONING; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAMPAIO LD, 1988, BIOCHEM J, V254, P757; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9230; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; YAMADA Y, 1990, ANN NY ACAD SCI, V580, P81, DOI 10.1111/j.1749-6632.1990.tb17920.x; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	40	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25364	25370						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460033				2022-12-27	WOS:A1992KB60300069
J	TRUTER, S; DILIBERTO, M; INAGAKI, Y; RAMIREZ, F				TRUTER, S; DILIBERTO, M; INAGAKI, Y; RAMIREZ, F			IDENTIFICATION OF AN UPSTREAM REGULATORY REGION ESSENTIAL FOR CELL TYPE-SPECIFIC TRANSCRIPTION OF THE PRO-ALPHA-2(V) COLLAGEN GENE (COL5A2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; NUCLEAR FACTOR-I; SEQUENCE IDENTITY; MAMMALIAN-CELLS; V COLLAGEN; PROMOTER; ACTIVATION; EXPRESSION; PROCOLLAGEN; ELEMENT	The transcriptional features of the human alpha2(V) collagen gene (COL5A2) were examined by transfection experiments coupled to various DNA binding assays. This approach identified an upstream region essential for the cell type-specific expression of the COL5A2 promoter. Within this region are two nuclear factor-binding sites, FP-A and FP-B, responsible for the formation of distinct DNA-protein complexes. Mutations introduced across each of the two binding sites eliminated the formation of the cognate complex and decreased promoter activity by about 3-fold (FP-A) and 40-fold (FP-B) in transfection experiments. Competition experiments using recognition sequences for known transcription factors exhibiting some similarity to the FP-A- and FP-B-binding sites failed to inhibit COL5A2/protein interactions. Thus, COL5A2 expression appears to be under the positive control of a short regulatory sequence likely to harbor two novel nuclear factor-binding sites.			TRUTER, S (corresponding author), CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR038648, R01AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38648] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALITALO K, 1980, EUR J BIOCHEM, V109, P247, DOI 10.1111/j.1432-1033.1980.tb04790.x; ALITALO K, 1982, J BIOL CHEM, V257, P9016; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARSKY SH, 1982, AM J PATHOL, V108, P276; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DILIBERTO M, 1989, GENE DEV, V3, P973, DOI 10.1101/gad.3.7.973; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENSPAN DS, 1991, GENE EXPRESSION, V1, P29; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; INAGAKI Y, 1987, BIOCHEM BIOPH RES CO, V148, P869, DOI 10.1016/0006-291X(87)90956-9; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCULLAGH KA, 1975, NATURE, V258, P73, DOI 10.1038/258073a0; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MORRIS GF, 1986, P NATL ACAD SCI USA, V83, P3674, DOI 10.1073/pnas.83.11.3674; NARAYANAN AS, 1983, COLLAGEN REL RES, V3, P323; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAGE H, 1981, BIOCHEMISTRY-US, V20, P3778, DOI 10.1021/bi00516a017; Sambrook J, 1989, MOL CLONING LABORATO; TRUTER S, 1992, IN PRESS CONNECT TIS; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; VUORIO T, 1990, J BIOL CHEM, V265, P22480; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25389	25395						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460034				2022-12-27	WOS:A1992KB60300073
J	JOYCE, CM; SUN, XC; GRINDLEY, NDF				JOYCE, CM; SUN, XC; GRINDLEY, NDF			REACTIONS AT THE POLYMERASE ACTIVE-SITE THAT CONTRIBUTE TO THE FIDELITY OF ESCHERICHIA-COLI DNA-POLYMERASE-I (KLENOW FRAGMENT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIRS; CRYSTAL-STRUCTURE; REVERSE-TRANSCRIPTASE; B-DNA; HELIX; MISMATCHES; MECHANISM; EXTENSION; DYNAMICS; DUPLEXES	In order to study the structural principles governing DNA polymerase fidelity we have measured the rates of insertion of incorrect nucleotides and the rates of extension from the resulting mismatched base pairs, catalyzed by the Klenow fragment of DNA polymerase I. Using a combination of semi-quantitative and qualitative approaches, we have studied each of the 12 possible mismatches in a variety of sequence contexts. The results indicate that Klenow fragment discriminates between mismatches largely on the basis of the identity of the mismatch, with the surrounding sequence context playing a significant, but secondary, role. For purine-pyrimidine and pyrimidine-pyrimidine mispairs, the relative ease of mismatch synthesis and extension can be rationalized using a simple geometrical model, with the important criterion being the extent to which the mismatched base pair can conform to normal DNA geometry. Essentially similar conclusions have been reached in studies of other polymerases, suggesting that this aspect of mispair geometry is sensed and responded to in a similar way by all polymerases. Purine-purine mismatches form a less cohesive class, showing more variable behavior from mispair to mispair, and a greater apparent susceptibility to sequence context effects. Comparison of our data with studies of other polymerases also suggests that different polymerases respond to purine-purine mismatches in distinct and characteristic ways. An extensive analysis of each of the four purine-purine mispairs in approximately 100 different sequence contexts suggests that the reaction is influenced both by the local DNA structure and by the ability of the mismatched terminus to undergo slippage.			JOYCE, CM (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510, USA.				NIGMS NIH HHS [GM-28550] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; ARNOLD FH, 1987, BIOCHEMISTRY-US, V26, P4068, DOI 10.1021/bi00387a049; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BORDEN KLB, 1992, BIOCHEMISTRY-US, V31, P5411, DOI 10.1021/bi00138a024; BROWN T, 1985, NATURE, V315, P604, DOI 10.1038/315604a0; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN T, 1990, J MOL BIOL, V212, P437, DOI 10.1016/0022-2836(90)90320-L; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CHATTOPADHYAYA R, 1988, NATURE, V334, P175, DOI 10.1038/334175a0; CHUPRINA VP, 1983, NUCLEIC ACIDS RES, V11, P5205, DOI 10.1093/nar/11.15.5205; COGNET JAH, 1991, NUCLEIC ACIDS RES, V24, P6771; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FRANK R, 1979, NUCLEIC ACIDS RES, V6, P2069, DOI 10.1093/nar/6.6.2069; GAO XL, 1987, J BIOL CHEM, V262, P16973; HILLEBRAND GG, 1984, NUCLEIC ACIDS RES, V12, P3155, DOI 10.1093/nar/12.7.3155; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; JOYCE CM, 1988, DNA REPLICATION MUTA, P220; KAN LS, 1983, P NATL ACAD SCI-BIOL, V80, P4263, DOI 10.1073/pnas.80.14.4263; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LAI MD, 1988, BIOCHEMISTRY-US, V27, P1722, DOI 10.1021/bi00405a051; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ORNSTEIN RL, 1983, BIOPOLYMERS, V22, P1979, DOI 10.1002/bip.360220811; PATEL DJ, 1984, FED PROC, V43, P2663; PATEL DJ, 1982, BIOCHEMISTRY-US, V21, P437, DOI 10.1021/bi00532a003; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; POLTEV VI, 1987, J BIOMOL STRUCT DYN, V5, P307, DOI 10.1080/07391102.1987.10506396; POLTEV VI, 1978, J THEOR BIOL, V70, P69, DOI 10.1016/0022-5193(78)90303-X; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PRIVE GG, 1987, SCIENCE, V238, P498, DOI 10.1126/science.3310237; SHATZKYSCHWARTZ M, 1992, BIOCHEMISTRY-US, V31, P2339, DOI 10.1021/bi00123a019; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; WEBSTER GD, 1990, P NATL ACAD SCI USA, V87, P6693, DOI 10.1073/pnas.87.17.6693; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332	52	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24485	24500						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447195				2022-12-27	WOS:A1992KA26300054
J	KUIPERS, OP; ROLLEMA, HS; YAP, WMGJ; BOOT, HJ; SIEZEN, RJ; DEVOS, WM				KUIPERS, OP; ROLLEMA, HS; YAP, WMGJ; BOOT, HJ; SIEZEN, RJ; DEVOS, WM			ENGINEERING DEHYDRATED AMINO-ACID-RESIDUES IN THE ANTIMICROBIAL PEPTIDE NISIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC NISIN; GENE; CLONING; IDENTIFICATION; EXPRESSION; ASSIGNMENT; EPIDERMIN	The small antimicrobial peptide nisin, produced by Lactococcus lactis, contains the uncommon amino acid residues dehydroalanine and dehydrobutyrine and five thio ether bridges. Since these structures are post-translationally formed from Ser, Thr, and Cys residues, it is feasible to study their role in nisin function and biosynthesis by protein engineering. Here we report the development of an expression system for mutated nisin Z (nisZ) genes, using nisin A producing L. lactis as a host. Replacement by site-directed mutagenesis of the Ser-5 codon in nisZ by a Thr codon, led to a mutant with a dehydrobutyrine instead of a dehydroalanine residue at position 5, as shown by NMR. Its antimicrobial activity was 2-10-fold lower relative to wild-type nisin Z, depending on the indicator strain used. In another mutagenesis study a double mutation was introduced in the nisZ gene by replacing the codons for Met-17 and Gly-18 by codons for Gln and Thr, respectively, as in the third lanthionine ring of the related antimicrobial peptide subtilin from Bacillus subtilis. This resulted in the simultaneous production of two mutant species, one containing a Thr residue and the other containing a dehydrobutyrine residue at position 18, both having different bacteriocidal properties.			KUIPERS, OP (corresponding author), NETHERLANDS INST DAIRY RES, DEPT BIOPHYS CHEM, POB 20, 6710 BA EDE, NETHERLANDS.		Siezen, Roland J/P-5745-2015; Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735				ALLGAIER H, 1986, EUR J BIOCHEM, V160, P9, DOI 10.1111/j.1432-1033.1986.tb09933.x; BENZ R, 1991, NISIN NOVEL LANTIBIO, P359; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHAN WC, 1992, FEBS LETT, V300, P56, DOI 10.1016/0014-5793(92)80163-B; CHAN WC, 1989, FEBS LETT, V252, P29, DOI 10.1016/0014-5793(89)80884-1; CHAN WC, 1989, J CHEM SOC PERK T 1, P2359, DOI 10.1039/p19890002359; DELVESBROUGHTON J, 1990, FOOD TECHNOL-CHICAGO, V44, P100; DEVOS WM, 1987, FEMS MICROBIOL LETT, V46, P281, DOI 10.1111/j.1574-6968.1987.tb02466.x; DODD HM, 1990, J GEN MICROBIOL, V136, P555, DOI 10.1099/00221287-136-3-555; Fredenhagen A., 1991, NISIN NOVEL LANTIBIO, P131; GAO FH, 1991, APPL ENVIRON MICROB, V57, P2164, DOI 10.1128/AEM.57.8.2164-2170.1991; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; GROSS E, 1973, H-S Z PHYSIOL CHEM, V354, P799; GROSS E, 1976, PEPTIDES 1976, P183; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; Jung G, 1991, NISIN NOVEL LANTIBIO; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KUIPERS OP, 1991, NISIN NOVEL LANTIBIO, P250; LIAN LY, 1992, BIOCHEM J, V283, P413, DOI 10.1042/bj2830413; LIU W, 1990, APPL ENVIRON MICROB, V56, P2551, DOI 10.1128/AEM.56.8.2551-2558.1990; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; MULDERS JWM, 1991, EUR J BIOCHEM, V201, P581, DOI 10.1111/j.1432-1033.1991.tb16317.x; PIARD JC, 1992, APPL ENVIRON MICROB, V58, P279, DOI 10.1128/AEM.58.1.279-284.1992; RAUCH PJG, 1992, J BACTERIOL, V174, P1280, DOI 10.1128/jb.174.4.1280-1287.1992; Rollema H. S., 1991, NISIN NOVEL LANTIBIO, P123; Sahl H. G., 1991, NISIN NOVEL LANTIBIO, P347; SAHL HG, 1981, J GEN MICROBIOL, V127, P377; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SLIJPER M, 1989, FEBS LETT, V252, P22, DOI 10.1016/0014-5793(89)80883-X; VANDEVEN FJM, 1991, EUR J BIOCHEM, V202, P1181, DOI 10.1111/j.1432-1033.1991.tb16488.x; VANROOIJEN RJ, 1992, J BACTERIOL, V174, P2273, DOI 10.1128/JB.174.7.2273-2280.1992; WAKAMIYA T, 1985, TETRAHEDRON LETT, V26, P665, DOI 10.1016/S0040-4039(00)89174-1	36	164	170	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24340	24346						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447185				2022-12-27	WOS:A1992KA26300033
J	LESSER, DR; GRAJKOWSKI, A; KURPIEWSKI, MR; KOZIOLKIEWICZ, M; STEC, WJ; JENJACOBSON, L				LESSER, DR; GRAJKOWSKI, A; KURPIEWSKI, MR; KOZIOLKIEWICZ, M; STEC, WJ; JENJACOBSON, L			STEREOSELECTIVE INTERACTION WITH CHIRAL PHOSPHOROTHIOATES AT THE CENTRAL DNA KINK OF THE ECORI ENDONUCLEASE-GAATTC COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEREOCHEMICAL COURSE; NUCLEOSIDE PHOSPHOROTHIOATES; RECOGNITION SEQUENCE; REPRESSOR; OPERATOR; OLIGODEOXYRIBONUCLEOTIDES; RESOLUTION; CLEAVAGE; EQUILIBRIUM; INHIBITION	We have probed the contacts between EcoRI endonuclease and the central phosphate of its recognition site GAApTTC, using synthetic oligonucleotides containing single stereospecific R(p)- or S(p)-phosphorothioates (Ps). These substitutions produce subtle stereospecific effects on EcoRI endonuclease binding and cleavage. An S(p)-Ps substitution in one strand of the DNA duplex improves binding free energy by -1.5 kcal/mol, whereas the R(p)-Ps substitution has an unfavorable effect (+0.3 kcal/mol) on binding free energy. These effects derive principally from changes in the first order rate constants for dissociation of the enzyme-DNA complexes. The first order rate constants for strand scission are also affected, in that a strand containing S(p)-Ps substitution is cleaved 2 to 3 times more rapidly than a strand containing a normal prochiral phosphate, whereas a strand containing R(p)-Ps substitution is cleaved about 3 times slower than normal. As a result, single-strand substitutions produce pronounced asymmetry in the rates of cleavage of the two DNA strands, and this effect is exaggerated in an R(p),S(p)-heteroduplex. Ethylation-interference footprinting indicates that none of the Ps substitutions cause any major change in contacts between endonuclease and DNA phosphates. When an S(p)-Ps localizes P=O in the DNA major groove, a hydrogen-bonding interaction with the backbone amide-NH of Gly116 of the endonuclease is improved relative to that with a prochiral phosphate having intermediate P-O bond order and delocalized charge.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; POLISH ACAD SCI,CTR MOLEC & MACROMOLEC STUDIES,DEPT BIOORGAN CHEM,PL-90362 LODZ 40,POLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Polish Academy of Sciences; Centre of Molecular & Macromolecular Studies of the Polish Academy of Sciences			Grajkowski, Andrzej/AGZ-6815-2022; Koziolkiewicz, Maria/P-2983-2019	Koziolkiewicz, Maria/0000-0003-4628-4566	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029207, R01GM029207] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM029207, GM-29207] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BECKER MM, 1988, P NATL ACAD SCI USA, V85, P6247, DOI 10.1073/pnas.85.17.6247; BRYANT FR, 1979, BIOCHEMISTRY-US, V18, P2825, DOI 10.1021/bi00580a022; CONNOLLY BA, 1984, J BIOL CHEM, V259, P760; CONNOLLY BA, 1984, BIOCHEMISTRY-US, V23, P3443, DOI 10.1021/bi00310a010; CRUSE WBT, 1986, J BIOL CHEM, V260, P4501; ECKSTEIN F, 1989, TRENDS BIOCHEM SCI, V14, P97, DOI 10.1016/0968-0004(89)90130-8; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; GALLO KA, 1986, NUCLEIC ACIDS RES, V14, P7405, DOI 10.1093/nar/14.18.7405; JENJACOBSON L, 1983, J BIOL CHEM, V258, P4638; JENJACOBSON L, 1986, CELL, V45, P619, DOI 10.1016/0092-8674(86)90294-1; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; KOZIOLKIEWICZ M, 1989, NUCLEOS NUCLEOT, V8, P185, DOI 10.1080/07328318908054167; KOZIOLKIEWICZ M, 1986, CHEM SCRIPTA, V26, P251; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LESSER DR, 1988, THESIS U PITTSBURGH; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MILLIGAN JF, 1989, BIOCHEMISTRY-US, V28, P2849, DOI 10.1021/bi00433a016; OLSEN DB, 1990, J BIOL CHEM, V265, P14389; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SAYERS JR, 1989, NUCLEIC ACIDS RES, V17, P9495, DOI 10.1093/nar/17.22.9495; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEC WJ, 1988, REV HETEROATOM CHEM, P367; SUGGS JW, 1985, NUCLEIC ACIDS RES, V13, P5707, DOI 10.1093/nar/13.15.5707; TAYLOR R, 1984, ACCOUNTS CHEM RES, V17, P320, DOI 10.1021/ar00105a004	34	66	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24810	24818						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447218				2022-12-27	WOS:A1992KA26300098
J	GREEN, JDF; PERHAM, RN; ULLRICH, SJ; APPELLA, E				GREEN, JDF; PERHAM, RN; ULLRICH, SJ; APPELLA, E			CONFORMATIONAL STUDIES OF THE INTERDOMAIN LINKER PEPTIDES IN THE DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT OF THE PYRUVATE-DEHYDROGENASE MULTIENZYME COMPLEX OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN; PROTEIN; PROLINE; DOMAINS; SEGMENT; MOBILITY; RESIDUES; H-1-NMR; DESIGN; BONDS	Two peptides (PEP1, 26 residues, and PEP2, 22 residues) were synthesized with amino acid sequences identical to two of the long segments of polypeptide chain rich in alanine, proline, and charged amino acids that link the lipoyl domains together in the dihydrolipoyl acetyltransferase component of the pyruvate dehydrogenase multienzyme complex of Escherichia coli. The circular dichroism and 400-MHz H-1 NMR spectra of the peptides indicated that they lacked regular secondary structure. Even in the presence of 45% (v/v) hexafluoroisopropanol, they appeared to acquire a helical content of only 23-25%. However, C-13 NMR spectroscopy revealed that the Ala-Pro peptide bonds were all (>95%) in the trans configuration, compared with a value of 87% for the Ala-Pro bond in the model peptide AAPA, which is a recurrent sequence motif in PEP1 and PEP2. Likewise in peptides representing the N- and C-terminal halves of peptide PEP2, the Ala-Pro bonds were again all (>95%)-trans, suggesting that peptide length is the essential determinant of the cis:trans ratio. Antisera were raised against peptides PEP2 and PEP3, the latter representing a third interdomain segment of polypeptide chain (Radford, S. E., Laue, E. D., Perham, R. N., Martin, S. R., and Appella, E. (1989a) J. Biol. Chem. 264, 767-775). Despite extensive sequence similarity among peptides PEP1, PEP2, and PEP3, only limited immunological cross-reactivity was observed, which suggests that the antigenic epitope(s) in the peptides are different and distinct. It is likely that these peptides are representative of a class of inter-domain linkers or spacers found in a wide variety of proteins and endowed with varying degrees of flexibility and stiffness to match their particular biological purpose.	NCI, CELL BIOL LAB, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; UNIV CAMBRIDGE, CAMBRIDGE CTR MOLEC RECOGNIT, DEPT BIOCHEM, CAMBRIDGE CB2 1EW, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Cambridge								BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; CANTOR CR, 1989, BIOPHYSICAL CHEM T 2, P409; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DEBER CM, 1970, J AM CHEM SOC, V92, P6191, DOI 10.1021/ja00724a016; DESLAURIERS R, 1980, BIOL MAGN RESON, V2, P243; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; GRONENBORN AM, 1981, FEBS LETT, V215, P89; Jardetzky O., 1981, NMR MOL BIOL; JUY M, 1983, INT J PEPT PROT RES, V22, P437; MAIGRET B, 1970, J THEOR BIOL, V29, P275, DOI 10.1016/0022-5193(70)90022-6; MAYER R, 1983, FEBS LETT, V153, P339, DOI 10.1016/0014-5793(83)80638-3; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1989, ANN NY ACAD SCI, V573, P1, DOI 10.1111/j.1749-6632.1989.tb14983.x; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PERHAM RN, 1981, NATURE, V292, P474, DOI 10.1038/292474a0; RADFORD SE, 1989, J BIOL CHEM, V264, P767; RADFORD SE, 1989, FEBS LETT, V250, P336, DOI 10.1016/0014-5793(89)80750-1; RAMACHANDRAN GN, 1976, J MOL BIOL, V107, P85, DOI 10.1016/S0022-2836(76)80019-8; REED LJ, 1990, J BIOL CHEM, V265, P8971; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; TEXTER FL, 1988, BIOCHEMISTRY-US, V27, P289, DOI 10.1021/bi00401a044; ULLRICH SJ, 1986, MOL IMMUNOL, V23, P545, DOI 10.1016/0161-5890(86)90118-5; WAGENKNECHT T, 1990, J BIOL CHEM, V265, P22402	26	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23484	23488						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429691				2022-12-27	WOS:A1992JZ23900013
J	HEBERT, DN; CARRUTHERS, A				HEBERT, DN; CARRUTHERS, A			GLUCOSE TRANSPORTER OLIGOMERIC STRUCTURE DETERMINES TRANSPORTER FUNCTION - REVERSIBLE REDOX-DEPENDENT INTERCONVERSIONS OF TETRAMERIC AND DIMERIC GLUT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUGAR TRANSPORTER; CYTOCHALASIN-B BINDING; MONOSACCHARIDE TRANSPORTER; LIGAND-BINDING; KINETICS; CARRIER; PROTEIN; MEMBRANE; CELLS; SIZE	This study investigates the relationship between human erythrocyte glucose transport protein (GLUT1) oligomeric structure and glucose transporter function. Oligomeric structure was analyzed by hydrodynamic studies of cholate-solubilized GLUT1, by chemical cross-linking studies of membrane-resident GLUT1 and by using conformation-specific antibodies. Transporter function (substrate binding) was analyzed by equilibrium cytochalasin B and D-glucose binding measurements. Erythrocyte-resident glucose transporter is a GLUT1 homotetramer, binds 1 mol of cytochalasin B/2 mol of GLUT1, and presents at least two binding SiteS to D-glucose. Native structure and function appear to be stabilized by intramolecular disulfide bonds and are preserved during GLUT1 purification by the omission of reductant. Native structure is independent of in vitro and in vivo membrane GLUT1 density but is transformed to dimeric GLUT1 by alkaline reduction. Dimeric GLUT1 binds 1 mol of cytochalasin B/mol of GLUT1, presents a single population of binding sites to D-glucose, and is obtained upon GLUT1 purification in the presence of reductant. Native structure and function are restored by treatment of dimeric GLUT1 with glutathione-disulfide (K0.5, glutathione disulfide = 29 muM). We propose that native structure is established prior to transporter translocation to the plasma membrane and that intra-subunit disulfide bonds promote cooperative subunit interactions that stabilize transporter structure and function.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,373 PLANTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIDDK NIH HHS [DK 44888, DK 36081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036081, R01DK044888, R56DK036081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEMAN JR, 1989, BIOCHEMISTRY-US, V28, P8221, DOI 10.1021/bi00446a038; BAKER GF, 1973, J PHYSIOL-LONDON, V231, P143, DOI 10.1113/jphysiol.1973.sp010225; BALDWIN SA, 1982, BIOCHEMISTRY-US, V21, P3836, DOI 10.1021/bi00259a018; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; CAREY MC, 1970, AM J MED, V49, P590, DOI 10.1016/S0002-9343(70)80127-9; CARRUTHERS A, 1984, BIOCHEMISTRY-US, V23, P6901, DOI 10.1021/bi00321a096; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3898, DOI 10.1021/bi00230a014; CARRUTHERS A, 1989, BIOCHEMISTRY-US, V28, P8337, DOI 10.1021/bi00447a011; CARRUTHERS A, 1986, BIOCHEMISTRY-US, V25, P3592, DOI 10.1021/bi00360a018; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; CARRUTHERS A, 1988, ADV MEMBRANE FLUDITY, V2, P201; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CONNOLLY TJ, 1985, J BIOL CHEM, V260, P2617; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GORGA FR, 1982, BIOCHEMISTRY-US, V21, P1905, DOI 10.1021/bi00537a031; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HELGERSON AL, 1987, J BIOL CHEM, V262, P5464; JANIAK MJ, 1976, BIOCHEMISTRY-US, V15, P4575, DOI 10.1021/bi00666a005; JARVIS SM, 1986, BIOCHIM BIOPHYS ACTA, V855, P312, DOI 10.1016/0005-2736(86)90179-3; JUNG CY, 1980, J BIOL CHEM, V255, P361; KONDO T, 1987, P NATL ACAD SCI USA, V84, P7373, DOI 10.1073/pnas.84.21.7373; LOWE AG, 1986, BIOCHIM BIOPHYS ACTA, V857, P146, DOI 10.1016/0005-2736(86)90342-1; LUNDAHL P, 1991, BIOCHIM BIOPHYS ACTA, V26, P177; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAFTALIN RJ, 1977, MEMBRANE TRANSPORT R, P257; PESSINO A, 1991, J BIOL CHEM, V26, P20213; RAO US, 1990, J BIOL CHEM, V265, P7227; SOGIN DC, 1980, BIOCHEMISTRY-US, V19, P5417, DOI 10.1021/bi00564a041; STITT BL, 1988, J BIOL CHEM, V263, P11130; WHEELER TJ, 1981, J BIOL CHEM, V256, P8907; WIDDAS WF, 1952, J PHYSIOL-LONDON, V118, P23, DOI 10.1113/jphysiol.1952.sp004770; ZOCCOLI MA, 1978, J BIOL CHEM, V253, P6923	37	135	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23829	23838						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429721				2022-12-27	WOS:A1992JZ23900061
J	WASHKO, P; LEVINE, M				WASHKO, P; LEVINE, M			INHIBITION OF ASCORBIC-ACID TRANSPORT IN HUMAN NEUTROPHILS BY GLUCOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; FLUORIDE-MEDIATED ACTIVATION; DEHYDROASCORBATE TRANSPORT; ACCUMULATION; PLASMA	Because of the structural similarity between glucose and ascorbic acid, we investigated the effect of glucose on uptake and accumulation of ascorbic acid in isolated normal human neutrophils. Ascorbic acid accumulation was determined using high-performance liquid chromatography with coulometric electrochemical detection, in conjunction with liquid scintillation spectrometry. Ascorbic acid accumulation in neutrophils is mediated by a high and a low affinity transport activity. In neutrophils from different volunteers, glucose inhibited uptake and accumulation of ascorbic acid by both transport activities 3-9-fold. The mechanism of inhibition was different for each transport activity: inhibition of the high affinity transport activity was noncompetitive, while inhibition of the low affinity activity was competitive. Glucose-induced inhibition of both ascorbic acid transport activities occurred in neutrophils of all donors tested and was fully reversible. Although the mechanism of ascorbic acid accumulation appeared to be different than that for glucose transport, other monosaccharides and glucose transport inhibitors also inhibited ascorbic acid accumulation. These are the first data to suggest that ascorbic acid accumulation in neutrophils can be regulated by compounds of similar structure.	NIDDKD, CELL BIOL & GENET LAB, BLDG 8, RM 415, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERSON R, 1987, AM REV RESPIR DIS, V135, P1027; BASS DA, 1980, P NATL ACAD SCI-BIOL, V77, P5125, DOI 10.1073/pnas.77.9.5125; BATTAGLIA FC, 1960, BIOCHEM J, V75, P408, DOI 10.1042/bj0750408; BIGLEY R, 1983, DIABETES, V32, P545, DOI 10.2337/diabetes.32.6.545; Cooke JR, 1981, VITAMIN C, P167; Crandon JH, 1940, NEW ENGL J MED, V223, P353, DOI 10.1056/NEJM194009052231001; DECHATEL.LR, 1972, ANTIMICROB AGENTS CH, V1, P12, DOI 10.1128/AAC.1.1.12; DRATH DB, 1974, INFECT IMMUN, V10, P1077, DOI 10.1128/IAI.10.5.1077-1083.1974; EVANS RM, 1982, BRIT J NUTR, V47, P473, DOI 10.1079/BJN19820059; HARTFIELD PJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P176, DOI 10.1016/0167-4889(90)90239-A; JACOB RA, 1987, AM J CLIN NUTR, V46, P818, DOI 10.1093/ajcn/46.5.818; JACOB RA, 1992, J NUTR, V122, P1111, DOI 10.1093/jn/122.5.1111; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P438; KONO T, 1988, VITAM HORM, V44, P103; KUMAR M, 1969, J NUTR, V98, P41, DOI 10.1093/jn/98.1.41; LEFEVRE PG, 1951, J GEN PHYSIOL, V34, P515, DOI 10.1085/jgp.34.5.515; LITCHFIELD WJ, 1977, INFECT IMMUN, V16, P189, DOI 10.1128/IAI.16.1.189-197.1977; MANN GV, 1974, PERSPECT BIOL MED, V17, P210; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; MILLER TE, 1969, J BACTERIOL, V98, P949, DOI 10.1128/JB.98.3.949-955.1969; OKAMURA M, 1980, CLIN CHIM ACTA, V103, P259; OKUNO Y, 1986, FEBS LETT, V195, P303, DOI 10.1016/0014-5793(86)80182-X; RAMPAL AL, 1980, BIOCHEMISTRY-US, V19, P679, DOI 10.1021/bi00545a011; ROSS EM, 1990, PHARMACOL BASIS THER, P43; SATO P, 1978, VITAM HORM, V36, P33; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANKOVA L, 1975, INFECT IMMUN, V12, P252, DOI 10.1128/IAI.12.2.252-256.1975; STANKOVA L, 1984, METABOLISM, V33, P347, DOI 10.1016/0026-0495(84)90197-5; TOPER R, 1987, BIOCHIM BIOPHYS ACTA, V931, P262, DOI 10.1016/0167-4889(87)90215-1; UNGER R H, 1985, P1018; WASHKO P, 1990, FEBS LETT, V260, P101, DOI 10.1016/0014-5793(90)80077-V; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1	34	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23568	23574						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429700				2022-12-27	WOS:A1992JZ23900025
J	SEGAL, M; MARBACH, I; ENGELBERG, D; SIMCHEN, G; LEVITZKI, A				SEGAL, M; MARBACH, I; ENGELBERG, D; SIMCHEN, G; LEVITZKI, A			INTERACTION BETWEEN THE SACCHAROMYCES-CEREVISIAE CDC25 GENE-PRODUCT AND MAMMALIAN RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; GTPASE-ACTIVATING PROTEIN; TERMINAL DOMAIN; YEAST; CONSTRUCTION; DISRUPTION; EXCHANGE; MUTATION; IRA1; GAP	In order to characterize the interaction between the Saccharomyces cerevisiae Cdc25 protein and Harvey-ras (p21H-ras), we have constructed a yeast strain disrupted at the RAS1 and RAS2 loci, expressing both p21H-ras and the catalytic domain of the bovine GTPase activating protein (GAP) and containing the cdc25-2 mutation. Such a strain exhibits a temperature-sensitive phenotype. The shift to the nonpermissive temperature is accompanied by the loss of guanyl nucleotide-dependent activity of adenylylcyclase in vitro. The temperature-sensitive phenotype can be rescued by CDC25 itself, as well as by a plasmid containing a truncated SDC25 gene. In addition, wild type CDC25 significantly improves the guanyl nucleotide response observed in the background of the cdc25ts allele at the permissive temperature in a dosage-dependent manner and restores the guanyl nucleotide response at the restrictive temperature. Both CDC25 and a truncated SDC25 also restored p21H-ras-dependent guanyl nucleotide response in a strain isogenic to the one described above but containing a disrupted CDC25 locus instead of the temperature-sensitive allele. These results suggest that the S. cerevisiae Cdc25 protein interacts with p21H-ras expressed in yeast by promoting GDP-GTP exchange. It follows that the yeast system can be used for characterizing the interaction between guanyl nucleotide exchangers of Ras proteins and mammalian p21H-ras.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem				Segal, Marisa/0000-0003-1848-9388				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; CASPERSON GF, 1983, J BIOL CHEM, V258, P7911; CLARK SG, 1985, MOL CELL BIOL, V5, P2746, DOI 10.1128/MCB.5.10.2746; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; DANIEL J, 1986, CURR GENET, V10, P643, DOI 10.1007/BF00410911; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; ENGELBERG D, 1990, EMBO J, V9, P641, DOI 10.1002/j.1460-2075.1990.tb08156.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1986, LABORATORY COURSE MA; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8	30	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22747	22751						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429624				2022-12-27	WOS:A1992JY16300011
J	BAJT, ML; LOFTUS, JC; GAWAZ, MP; GINSBERG, MH				BAJT, ML; LOFTUS, JC; GAWAZ, MP; GINSBERG, MH			CHARACTERIZATION OF A GAIN OF FUNCTION MUTATION OF INTEGRIN-ALPHA-IIB-BETA-3 (PLATELET GLYCOPROTEIN-IIB-IIIA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-BETA-SUBUNIT; AMINO-ACID-SEQUENCE; GPIIB-IIIA; GAMMA-CHAIN; FIBRINOGEN RECEPTORS; MONOCLONAL-ANTIBODY; ADHESION RECEPTOR; RECOGNITION SITE; LIGAND-BINDING; CELLS	Integrin alpha(IIb)beta3 (platelet glycoprotein IIb-IIIa) is a prototype of integrins involved in cellular adhesive functions. As part of a structure-function analysis of this molecule, we constructed a mutant, designated alpha(IIb)beta3(beta1-2), by replacing 6 amino acids within a putative ligand binding domain of the beta3 subunit with sequences derived from beta1. The alteration did not affect the capacity of beta3(beta1-2) to combine with transfected alpha(IIb), nor did it cause it to combine with endogenous alpha5. Integrin alpha(IIb)beta3(beta1-2) was in a "resting" state on Chinese hamster ovary cells as judged by minimal binding of an activation-specific anti-alpha(IIb)beta3, PAC1. Nevertheless, cells expressing alpha(IIb)beta3(beta1-2) spontaneously bound fibrinogen with low affinity (K(a) = (4.85 +/- 0.84) x 10(6) M-1). Activation with an anti-beta3 antibody (monoclonal antibody 62) resulted in a 10-fold increase in fibrinogen binding affinity (K(a) = (4.55 +/- 0.77) x 10(7) M-1), which was 3-fold greater than fibrinogen binding to activated wild type alpha(IIb)beta3 (K(a) = (1.66 +/- 0.33) x 10(7) M-1, F = 7.46, p = 0.008). The mutant receptor also bound fibrinogen mimetic peptide ligands with enhanced affinity as measured by the conformation-specific antibody, anti-LIBS1. This indicates that the increased affinity for fibrinogen was caused by enhanced interaction of alpha(IIb)beta3(beta1-2) with known recognition sequences in fibrinogen. Thus, this gain of function mutant augments ligand binding function, supporting a role for this region of the beta subunit in ligand binding to integrins.			BAJT, ML (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042977, P01HL031950, R29HL042977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42977, HL31950] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRAVES WS, 1987, J CELL BIOL, V105, P1183; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; COLLER BS, 1980, BLOOD, V55, P169; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FROJMOVIC MM, 1991, BLOOD, V78, P369; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KUNDEL TA, 1985, P NATL ACAD SCI USA, V82, P488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORTENWALL P, 1990, J VASC SURG, V11, P403; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUPNICK MA, 1989, J VASC SURG, V9, P788, DOI 10.1067/mva.1989.vs0090788; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1986, BLOOD, V68, P1224; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; SUSUKI S, 1990, EMBO J, V9, P765; TAKADA Y, 1992, IN PRESS J CELL BIOL; TAUB R, 1989, J BIOL CHEM, V264, P259; WARLAW AJ, 1990, J EXP MED, V172, P335; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	56	43	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22211	22216						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429573				2022-12-27	WOS:A1992JW71900036
J	KATAGIRI, H; ASANO, T; ISHIHARA, H; TSUKUDA, K; LIN, JL; INUKAI, K; KIKUCHI, M; YAZAKI, Y; OKA, Y				KATAGIRI, H; ASANO, T; ISHIHARA, H; TSUKUDA, K; LIN, JL; INUKAI, K; KIKUCHI, M; YAZAKI, Y; OKA, Y			REPLACEMENT OF INTRACELLULAR C-TERMINAL DOMAIN OF GLUT1 GLUCOSE TRANSPORTER WITH THAT OF GLUT2 INCREASES V(MAX) AND K(M) OF TRANSPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSIVE TISSUES; MESSENGER-RNA; HUMAN-ERYTHROCYTE; CONFORMATIONAL CHANGE; GENE LOCALIZATION; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; SUGAR-TRANSPORT; CYTOCHALASIN-B; RAT-BRAIN	The intracellular C-terminal domain is diverse in size and amino acid sequence among facilitative glucose transporter isoforms. The characteristics of glucose transport are also divergent, and GLUT2 has far higher K(m) and V(max) values compared with GLUT1. To investigate the role of the intracellular C-terminal domain in glucose transport, we expressed in Chinese hamster ovary cells the mutated GLUT1 protein whose intracellular C-terminal domain was replaced with that of GLUT2 by means of engineering the chimeric cDNA. Cytochalasin B, for which GLUT2 protein has much lower affinity, bound to this chimeric protein in a fashion similar to GLUT1. In contrast, greater transport activity was observed in this chimeric glucose transporter compared with the wild-type GLUT1 at 10 mM 2-deoxy-D-glucose concentration. The kinetic studies on 2-deoxy-D-glucose uptake revealed a 3.8-fold increase in K(m) and a 4.3-fold increase in V(max) in this chimeric glucose transporter compared with the wild-type GLUT1. Thus, replacement of the intracellular C-terminal domain confers the GLUT2-like property on the glucose transporter. These results strongly suggest that the diversity of intracellular C-terminal domain contributes to the diversity of glucose transport characteristics among isoforms.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,SHINJUKU KU,TOKYO 160,JAPAN	University of Tokyo; Asahi Life Foundation								ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1989, J BIOL CHEM, V264, P3416; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P222; BALDWIN JM, 1980, BIOCHIM BIOPHYS ACTA, V599, P699, DOI 10.1016/0005-2736(80)90211-4; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CRAIK JD, 1979, BIOCHEM J, V182, P503, DOI 10.1042/bj1820503; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; ISHIHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P922, DOI 10.1016/S0006-291X(05)80274-8; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KRUPKA RM, 1971, BIOCHEMISTRY-US, V10, P1143, DOI 10.1021/bi00783a007; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, DIABETES, V39, P441, DOI 10.2337/diabetes.39.4.441; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7	36	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22550	22555						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429604				2022-12-27	WOS:A1992JW71900087
J	MAMER, OA; REIMER, MLJ				MAMER, OA; REIMER, MLJ			ON THE MECHANISMS OF THE FORMATION OF L-ALLOISOLEUCINE AND THE 2-HYDROXY-3-METHYLVALERIC ACID STEREOISOMERS FROM L-ISOLEUCINE IN MAPLE SYRUP URINE DISEASE PATIENTS AND IN NORMAL HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								2-Keto-3-methylvaleric acid (KMVA) has been found not to undergo spontaneous keto-enol tautomerization in neutral aqueous solution, alone or in the presence of large concentrations of pyridoxamine or pyridoxamine-5-phosphate. This finding denies the commonly held suppositions that 3R-KMVA is derived spontaneously from 3S-KMVA in vivo, and that L-alloisoleucine is the product of the reamination of this 3R-KMVA. Evidence presented here suggests that racemization of the 3-carbon of L-isoleucine occurs during transamination, that L-alloisoleucine is an inherently unavoidable by-product of L-isoleucine transamination (and vice versa), and that a KMVA enol is not obligate in this racemization. The four stereoisomers of 2-hydroxy-3-methylvaleric acid have been synthesized and the mass spectra of their trimethylsilyl derivatives recorded. An achiral methylsilicone column was used to separate the diastereomeric pairs and to determine their relative ratios in plasma and urine from normal controls and two maple syrup urine disease (MSUD) patients. The urinary ratio of the two diastereomers is different from that for plasma, both in normals and in MSUD patients. The plasma ratios may provide a rapid and simple measure of residual branched chain 2-keto acid dehydrogenase activity in MSUD patients.			MAMER, OA (corresponding author), MCGILL UNIV, MRC CANADA, BIOMED MASS SPECTROMETRY UNIT, MONTREAL H3A 1A3, QUEBEC, CANADA.							BABU UM, 1974, BIOCHEM BIOPH RES CO, V58, P460, DOI 10.1016/0006-291X(74)90387-8; COOPER AJL, 1976, J BIOL CHEM, V251, P1088; Danner DJ, 1989, METABOLIC BASIS INHE, P671; FUNK MA, 1987, J NUTR, V117, P1550, DOI 10.1093/jn/117.9.1550; HALPERN B, 1970, BIOCHEM MED METAB B, V4, P352, DOI 10.1016/0006-2944(70)90062-1; HOOD DW, 1950, J BIOL CHEM, V186, P195; JAKOBS C, 1977, J CHROMATOGR, V143, P31, DOI 10.1016/S0378-4347(00)81324-9; MAMER OA, 1986, BIOMED ENVIRON MASS, V13, P553, DOI 10.1002/bms.1200131007; MAMER OA, 1976, BIOCHEM J, V160, P417, DOI 10.1042/bj1600417a; MAMER OA, 1980, J CHROMATOGR, V182, P221, DOI 10.1016/S0378-4347(00)81626-6; MAMER OA, 1974, CLIN CHIM ACTA, V55, P199, DOI 10.1016/0009-8981(74)90295-2; MATTHEWS DE, 1980, PEDIATR RES, V14, P854, DOI 10.1203/00006450-198014070-00002; MEISTER A, 1955, ADV ENZYMOL REL S BI, V16, P185; MEISTER A, 1951, J BIOL CHEM, V190, P269; MEISTER A, 1951, J BIOL CHEM, V191, P211; REIMER MLJ, 1991, 39TH P ASMS C MASS S, P1027; SCHADEWALDT P, 1991, PEDIATR RES, V30, P430, DOI 10.1203/00006450-199111000-00007; SCHADEWALDT P, 1990, J INHERIT METAB DIS, V13, P137, DOI 10.1007/BF01799676; SNELL E E, 1962, Brookhaven Symp Biol, V15, P32; SNELL EE, 1959, J CELL COMPAR PHYSL, V54, P161, DOI 10.1002/jcp.1030540413; SNYDERMAN SE, 1964, PEDIATRICS, V34, P454; WEINBERG RB, 1977, BIOCHEM MED METAB B, V17, P164, DOI 10.1016/0006-2944(77)90020-5	22	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22141	22147						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429566				2022-12-27	WOS:A1992JW71900026
J	MANENTI, S; SOROKINE, O; VANDORSSELAER, A; TANIGUCHI, H				MANENTI, S; SOROKINE, O; VANDORSSELAER, A; TANIGUCHI, H			AFFINITY PURIFICATION AND CHARACTERIZATION OF MYRISTOYLATED ALANINE-RICH PROTEIN-KINASE-C SUBSTRATE (MARCKS) FROM BOVINE BRAIN - COMPARISON OF THE CYTOPLASMIC AND THE MEMBRANE-BOUND FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; CALMODULIN-BINDING-PROTEIN; MAJOR SPECIFIC SUBSTRATE; MOLECULAR-CLONING; BACTERIAL LIPOPOLYSACCHARIDE; 87-KDA PROTEIN; RAT-BRAIN; PHOSPHORYLATION; 80-KDA; EXPRESSION	A major in vivo substrate of Ca2+-phospholipid-dependent protein kinase (myristoylated alanine-rich C-kinase substrate (MARCKS)) has been-purified to apparent homogeneity from the particulate as well as from the cytoplasmic fractions of calf brain using a calmodulin affinity column. The two preparations were characterized and compared with various biochemical and biophysical techniques. Although they behave similarly in various chromatographic procedures during purification, their elution positions from the gel filtration column are markedly different. Stokes radii of 85 and 45 angstrom were measured for the cytoplasmic and membrane MARCKS, respectively. Once purified, however, they show a similar small Stokes radius (45 angstrom), suggesting the dissociation of a component or a drastic conformational change in the cytoplasmic preparation during purification. The electrospray mass spectroscopic analysis of the two preparations revealed the existence of at least three major subpopulations with molecular mass differences of 80 daltons, which suggests the presence of protein phosphorylated in different degrees. The cytoplasmic preparation contains more phosphorylated species compared with the membrane preparation, whereas the calculated molecular weight of each peak was indistinguishable between the two preparations. Correspondingly, when the two preparations were phosphorylated by purified protein kinase C in vitro, more phosphate groups were transferred to the membrane preparation (4 mol/mol) than to the cytoplasmic preparation (2.9 mol/mol). A significant difference was also observed in the inhibition of calmodulin of the phosphorylation reaction. On the other hand, the circular dichroism of the two preparations showed similar spectra rich in random coil with little contribution of alpha-helix (approximately 10%), suggesting that there is not a significant difference in the overall conformation. These results clearly established that the two preparations are the same protein coded by a single gene but they differ in their degree of phosphorylation, and that the difference observed in their Stokes radius is due to the presence of an unidentified factor that is removed from the cytoplasmic MARCKS during purification.	CNRS,URA 31,CHIM ORGAN SUBSTANCES NAT LAB,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	MANENTI, S (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; AMESS B, 1992, FEBS LETT, V297, P285; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; JAMES G, 1989, J BIOL CHEM, V264, P20928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MIZUTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P1395, DOI 10.1016/0006-291X(92)91888-W; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PATEL J, 1987, J BIOL CHEM, V262, P16686; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOKUMITSU H, 1989, BIOCHEM BIOPH RES CO, V163, P581, DOI 10.1016/0006-291X(89)92177-3; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V286, P94, DOI 10.1016/0003-9861(91)90012-8; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; ZHAO D, 1991, BIOCHEM J, V277, P445, DOI 10.1042/bj2770445	31	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22310	22315						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429582				2022-12-27	WOS:A1992JW71900051
J	STANTON, LW; WHITE, RT; BRYANT, CM; PROTTER, AA; ENDEMANN, G				STANTON, LW; WHITE, RT; BRYANT, CM; PROTTER, AA; ENDEMANN, G			A MACROPHAGE FC RECEPTOR FOR IGG IS ALSO A RECEPTOR FOR OXIDIZED LOW-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; HUMAN FIBROBLASTS; APOLIPOPROTEIN-B; DEGRADATION; RECOGNITION; OXIDATION; BINDING; DERIVATIZATION	The internalization of oxidized low density lipoprotein (OxLDL) by macrophages is hypothesized to contribute to foam cell formation and eventually to atherosclerotic lesion formation. OxLDL is a ligand for the acetylated low density lipoprotein (AcLDL) receptor, however, our data show that this receptor accounts for less than half of OxLDL uptake by mouse macrophages, suggesting additional receptors for OxLDL. We have developed a novel expression cloning strategy in order to isolate clones encoding OxLDL receptors. In addition to the AcLDL receptor, we isolated a molecular clone for a structurally unrelated receptor capable of mediating the high affinity uptake of OxLDL following transfection into cells. This receptor has been identified as the mouse FcgammaRII-B2, a member of a family of receptors known to mediate immune complex uptake through recognition of the Fc region of IgG. The uptake of OxLDL by cells transfected with the FcgammaRII-B2 clone is not blocked by AcLDL but is blocked by the anti-FcgammaRII monoclonal antibody, 2.4G2.	SCIOS INC,MT VIEW,CA 94043	Scios					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL047220] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 R43 HL47220-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FONG LG, 1987, J LIPID RES, V28, P1466; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFF HF, 1992, J BIOL CHEM, V267, P602; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; POGLITSCH CL, 1991, BIOCHEMISTRY-US, V30, P6662, DOI 10.1021/bi00241a005; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	34	187	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22446	22451						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429595				2022-12-27	WOS:A1992JW71900072
J	WANG, ZY; MADDEN, SL; DEUEL, TF; RAUSCHER, FJ				WANG, ZY; MADDEN, SL; DEUEL, TF; RAUSCHER, FJ			THE WILMS-TUMOR GENE-PRODUCT, WT1, REPRESSES TRANSCRIPTION OF THE PLATELET-DERIVED GROWTH-FACTOR A-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-GROWTH; EXPRESSION; DELETION	The Wilms' tumor locus on chromosome 11p13 contains a tumor suppressor gene, wt1, which encodes a DNA binding protein (WT1) with four zinc fingers and a glutamine-proline-rich N terminus and which functions as a repressor of transcription. The platelet-derived growth factor (PDGF) A-chain gene encodes a potent growth factor, which is expressed in high levels in a number of tumor cell lines. We initiated a search for WT1 target genes and now report that WT1 strikingly represses transcription of the PDGF A-chain gene in transient transfection assays and that the WT1 protein interacts directly with a highly G+C-rich region of the PDGF A-chain promoter in gel mobility shift assays. The results suggest that WT1 may function to repress expression of the PDGF A-chain gene and that loss of this or related repressor activities may contribute to the abnormal growth of Wilms' tumors.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	The Wistar Institute; Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA052009, P01CA047983] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10817, CA 47983, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; RAUSCHER FJ, 1990, SCIENCE, V250, P1257; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SPAETE RR, 1985, J VIROL, V56, P136; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WANG ZY, 1992, J BIOL CHEM, V267, P17022; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	20	222	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					21999	22002						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429549				2022-12-27	WOS:A1992JW71900004
J	ALAM, J; DEN, ZN				ALAM, J; DEN, ZN			DISTAL AP-1 BINDING-SITES MEDIATE BASAL LEVEL ENHANCEMENT AND TPA INDUCTION OF THE MOUSE HEME OXYGENASE-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHENOL-CHLOROFORM EXTRACTION; EMBRYONAL CARCINOMA-CELLS; SINGLE-STEP METHOD; MR 32,000 PROTEIN; BALB/C 3T3 CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSCRIPTIONAL ACTIVATION; ACCURATE TRANSCRIPTION; MAMMALIAN-CELLS	Basal expression of a chimeric gene (pMHO4CAT) consisting of approximately 7 kilobase pairs (kbp) of the 5'- flanking region of the mouse heme oxygenase-1 (HO-1) gene fused to the bacterial chloramphenicol acetyltransferase gene is 2- to 10-fold greater than that of an analogous construct containing only 1287 bp of the 5'-flanking region (pMHO1CAT) in transiently transfected cultured cells. The enhancer activity has been localized to a 268-base pair (bp) fragment positioned approximately 4 kilobase pairs upstream of the transcription initiation site. This fragment contains two high affinity protein binding sites, regions A and B, as determined by DNase I protection assays using nuclear protein extracts from rat C6 glioma cells. Both sites include core sequence elements, TGAGTCA (region A) and TGTGTCA (region B), that resemble the consensus binding site, TGA(G/C)TCA, of the Jun/Fos (AP-1) family of transcription factors. Purified, bacterially expressed AP-1 (c-Jun homodimer) specifically binds to both elements, exhibiting greater affinity for the region A motif. The expression of pMHO4CAT, but not of pMHO1CAT, is stimulated by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), and the 268-bp enhancer fragment confers TPA inducibility and c-Jun/c-Fos transactivation to the heterologous SV40 promoter. These functions are mediated by the AP-1 binding sites as multiple copies of the region A motif also confer TPA induction and c-Jun/c-Fos transactivation upon a heterologous promoter.			ALAM, J (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT MOLEC GENET,NEW ORLEANS,LA 70121, USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALAM J, 1989, J BIOL CHEM, V264, P6371; ALAM J, 1991, BIOTECHNIQUES, V10, P423; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APPLEGATE LA, 1991, CANCER RES, V51, P974; BAKKEN AF, 1972, J CLIN INVEST, V51, P530, DOI 10.1172/JCI106841; BISSELL DM, 1976, ARCH BIOCHEM BIOPHYS, V176, P91, DOI 10.1016/0003-9861(76)90144-2; BITAR M, 1984, DIABETES, V33, P37, DOI 10.2337/diabetes.33.1.37; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CANTONI L, 1991, BIOCHEM J, V279, P891, DOI 10.1042/bj2790891; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; GEMSA D, 1974, J CLIN INVEST, V53, P647, DOI 10.1172/JCI107599; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P45; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIWASA T, 1983, CANCER RES, V43, P5951; HIWASA T, 1982, P NATL ACAD SCI-BIOL, V79, P1800, DOI 10.1073/pnas.79.6.1800; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maxam A M, 1980, Methods Enzymol, V65, P499; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MITANI K, 1992, BLOOD, V79, P255; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDANA MK, 1980, J BIOL CHEM, V255, P1320; SARDANA MK, 1985, BIOCHEM PHARMACOL, V34, P2937, DOI 10.1016/0006-2952(85)90019-X; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169	58	167	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21894	21900						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400499				2022-12-27	WOS:A1992JV01100097
J	CONNER, GE				CONNER, GE			THE ROLE OF THE CATHEPSIN-D PROPEPTIDE IN SORTING TO THE LYSOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; PROCATHEPSIN-D; CARBOXYPEPTIDASE-Y; HEPG2 CELLS; ENZYME; EXPRESSION; YEAST; PROTEIN; BIOSYNTHESIS; SEQUENCES	The propeptides of lysosomal enzymes have been implicated in membrane association and mannose 6-phosphate-independent sorting to the lysosome (Rijnboutt, S., Aerts, H., Geuze, H. J., Tager, J. M., and Strous, G. J. (1991) J. Biol. Chem. 266, 4862-4868; McIntyre, G. F., and Erickson, A. H. (1991) J. Biol. Chem. 266, 15438-15445). In this report, the function of the propeptide of procathepsin D in sorting to the lysosome was directly assessed using a cathepsin D deletion mutant lacking the propeptide, and using a chimeric cDNA encoding the cathepsin D propeptide fused to the secretory protein alpha-lactalbumin. Proteins encoded by these cDNAs were expressed in mouse Ltk- cells and in human hepatoma Hep G2 cells, and then immunoprecipitated and analyzed by SDS-polyacrylamide gel electrophoresis. The deletion mutant was glycosylated but was rapidly degraded in a chloroquine-independent fashion and did not assume an active conformation. Thus the propeptide appeared to be necessary for correct folding. The chimeric protein was glycosylated and secreted. The coincidence of complex oligosaccharide modification and secretion of the chimeric protein suggested that it was slowly released from the endoplasmic reticulum and rapidly passed through the cell to the extracellular compartment. This was confirmed by immunofluorescent localization of the proteins. The data indicated that the propeptide appeared to be necessary for folding of cathepsin D but, unlike the yeast vacuolar propeptides, was not sufficient to direct a secretory protein to the lysosome in fibroblasts or in epithelial cells.			CONNER, GE (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101, USA.		Conner, Gregory/AAI-1285-2021	Conner, Gregory/0000-0003-2217-2252	NIGMS NIH HHS [GM35812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CONNER GE, 1990, DNA CELL BIOL, V9, P1, DOI 10.1089/dna.1990.9.1; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; DIMENT S, 1988, J BIOL CHEM, V263, P6901; ERICKSON AH, 1981, J BIOL CHEM, V256, P1224; FAUST PL, 1989, J BIOL CHEM, V264, P479; FISHER PA, 1982, J CELL BIOL, V92, P674, DOI 10.1083/jcb.92.3.674; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; HARRISON TM, 1989, PROTEINS, V5, P259, DOI 10.1002/prot.340050402; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HASILIK A, 1978, EUR J BIOCHEM, V91, P567, DOI 10.1111/j.1432-1033.1978.tb12710.x; HUANG JS, 1979, J BIOL CHEM, V254, P1405; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KNIGHT CG, 1976, BIOCHEM J, V155, P117, DOI 10.1042/bj1550117; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; ROACH A, 1984, GENE, V32, P389, DOI 10.1016/0378-1119(84)90014-3; ROTHMAN JH, 1989, J CELL BIOL, V109, P93, DOI 10.1083/jcb.109.1.93; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; WANG M, 1989, J BIOL CHEM, V264, P21116; WATERS M G, 1991, Current Opinion in Cell Biology, V3, P615, DOI 10.1016/0955-0674(91)90031-S; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	37	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21738	21745						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400484				2022-12-27	WOS:A1992JV01100075
J	DICKINSON, CJ; DAUGHERTY, D; GUO, YJ; HUGHES, P; YAMADA, T				DICKINSON, CJ; DAUGHERTY, D; GUO, YJ; HUGHES, P; YAMADA, T			MOLECULAR ANALYSIS OF DIBASIC ENDOPROTEOLYTIC CLEAVAGE SIGNALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CELL-LINES; EXPRESSION; CARBOXYPEPTIDASE; IDENTIFICATION; PROINSULIN; GASTRIN; DNA; PREPROGASTRIN; PURIFICATION	Biologically active peptide hormones are synthesized from larger precursor proteins by a variety of post-translational processing reactions. To characterize these processing reactions further we have expressed preprogastrin in two endocrine cell lines and examined the molecular determinants involved in endoproteolysis at dibasic cleavage sites. The Gly93-Arg94-Arg95 carboxyl-terminal processing site of progastrin must be processed sequentially by an endoprotease, a carboxypeptidase, and an amidating enzyme to produce bioactive gastrin. For these studies the dibasic Arg94-Arg95 residues that serve as signals for the initiation of this processing cascade were mutated to Lys94-Arg95, Arg94-Lys95, and Lys94-Lys95. In the GH3 cells the Lys94-Arg95 mutation slightly diminished synthesis of carboxyl-terminally amidated gastrin, whereas in the MTC 6-23 cells this mutation had no effect on amidated gastrin synthesis. In contrast, both Arg94-Lys95 and Lys94-Lys95 mutations resulted in significantly diminished production of amidated gastrin in both cell lines. A specific hierarchy of preferred cleavage signals at this progastrin processing site was demonstrated in both cell lines, indicating that cellular dibasic endoproteases have stringent substrate specificities. Progastrins with the Lys94-Arg95 mutation in GH3 cells also demonstrated diminished processing at the Lys74-Lys75 dibasic site, thus single amino acid changes at one processing site may alter cleavage at distant sites. These studies provide insight into the post-translational processing and biological activation of not only gastrin but other peptide hormones as well.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	DICKINSON, CJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT PEDIAT,PEDIAT GASTROENTEROL,C6105 MID,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001903, P30DK034933, R01DK034306] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-34306, K08-DK-01903, P30-DK-34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CALAM J, 1980, EUR J CLIN INVEST, V10, P241, DOI 10.1111/j.1365-2362.1980.tb00027.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAUGHERTY DF, 1991, AM J PHYSIOL, V260, pG783, DOI 10.1152/ajpgi.1991.260.5.G783; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; DICKERSON IM, 1990, ENDOCRINOLOGY, V127, P133, DOI 10.1210/endo-127-1-133; DICKINSON CJ, 1989, NEUROENDOCRINOLOGY G, P63; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOCKRAY GJ, 1975, GASTROENTEROLOGY, V68, P222; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRICKER LD, 1983, J BIOL CHEM, V258, P950; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILSTED L, 1986, ANAL BIOCHEM, V152, P119, DOI 10.1016/0003-2697(86)90129-6; INNIS MA, 1990, PCR PROTOCOLS; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARINO LR, 1991, J BIOL CHEM, V266, P6133; REHFELD JF, 1986, J BIOL CHEM, V261, P5841; REHFELD JF, 1981, REGUL PEPTIDES, V2, P333, DOI 10.1016/0167-0115(81)90037-9; ROSENQUIST GL, 1980, GASTROINTESTINAL HOR, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; SUGANO K, 1985, J BIOL CHEM, V260, P1724; TAKEUCHI T, 1991, J BIOL CHEM, V266, P17409; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; ZEYTINOGLU FN, 1980, ENDOCRINOLOGY, V107, P509, DOI 10.1210/endo-107-2-509	32	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21795	21801						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400488				2022-12-27	WOS:A1992JV01100083
J	LATHROP, BK; BILTONEN, RL				LATHROP, BK; BILTONEN, RL			CALCIUM AND MAGNESIUM DEPENDENCE OF PHOSPHOLIPASE-A2-CATALYZED HYDROLYSIS OF PHOSPHATIDYLCHOLINE SMALL UNILAMELLAR VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC PHOSPHOLIPASE-A2; AGKISTRODON-PISCIVORUS-PISCIVORUS; COBRA-VENOM PHOSPHOLIPASE-A2; TRANSITION-STATE ANALOG; CROTALUS-ADAMANTEUS; DIPALMITOYLPHOSPHATIDYLCHOLINE VESICLES; INTERFACIAL CATALYSIS; SUBSTRATE BINDING; CRYSTAL-STRUCTURE; ACTIVATION	The Ca2+ requirement for lipid hydrolysis catalyzed by phospholipase A2 from Agkistrodon piscivorus piscivorus (App-D49) and porcine pancreas has been examined using small, unilamellar vesicles of dipalmitoylphosphatidylcholine (DPPC SUV). Hydrolysis was affected by product inhibition even at early times, and the extent of this inhibition depended on the concentration of divalent cations. The Ca2+ requirement for half-maximal rates of hydrolysis reflected, in part, this non-catalytic role of divalent cations. The presence of 10 mM Mg2+, a cation which does not support catalysis, reduced the Ca2+ required for half-maximal rates of hydrolysis from millimolar concentrations to 40 muM for App-D49. Since the dissociation constant of the enzyme for Ca2+ in solution is 2 mM, these results indicate a change in the interaction of the enzyme with Ca2+ under catalytic conditions. The kinetic dissociation constant of Ca2+ for the pancreatic enzyme was 20 muM which is substantially lower than the dissociation constant in solution, 0.35 mM. The similarity of apparent kinetic dissociation constants for these enzymes suggests that structurally similar features determine the affinity for Ca2+ under catalytic conditions. Evidence is presented that the affinity of phospholipase A2 for Ca2+ changes subsequent to the initial interaction of the enzyme with the substrate interface. However, the apparent Michaelis constant, K(Mapp), for App-D49, 0.03-0.06 mM, is independent of [Ca2+] and is about the same as the equilibrium dissociation constant for DPPC SUV, 0.14 mM. We thus suggest that K(Mapp) is a steady-state constant.	UNIV VIRGINIA, HLTH SCI CTR, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037658] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37658] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL JD, 1992, J BIOL CHEM, V267, P11046; BELL JD, 1989, J BIOL CHEM, V264, P225; BELL JD, 1989, J BIOL CHEM, V264, P12194; BHAMIDIPATI SP, 1989, BIOCHEMISTRY-US, V28, P6667, DOI 10.1021/bi00442a020; DEHAAS GH, 1971, BIOCHIM BIOPHYS ACTA, V239, P252, DOI 10.1016/0005-2760(71)90171-8; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; DRAKENBERG T, 1984, BIOCHEMISTRY-US, V23, P2387, DOI 10.1021/bi00306a011; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDWIG GR, 1984, BIOPHYS CHEM, V19, P1, DOI 10.1016/0301-4622(84)85001-2; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; KRAUSE H, 1991, BIOCHEM BIOPH RES CO, V175, P532, DOI 10.1016/0006-291X(91)91597-6; KUPFERBERG JP, 1981, J BIOL CHEM, V256, P6274; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; PIETERSON WA, 1974, BIOCHEMISTRY-US, V13, P1439, DOI 10.1021/bi00704a019; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; ROBERTS MF, 1977, J BIOL CHEM, V252, P6011; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROMERO G, 1987, J BIOL CHEM, V262, P13476; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; SLOTBOOM AJ, 1978, BIOCHEMISTRY-US, V17, P4593, DOI 10.1021/bi00615a003; SUURKUUSK J, 1976, BIOCHEMISTRY-US, V15, P1393, DOI 10.1021/bi00652a007; TESHIMA K, 1989, J BIOCHEM, V106, P518, DOI 10.1093/oxfordjournals.jbchem.a122885; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VANDAMMIERAS MCE, 1975, BIOCHEMISTRY-US, V14, P5387, DOI 10.1021/bi00696a001; VANDENBERGH CJ, 1989, EUR J BIOCHEM, V182, P307; VERGER R, 1973, J BIOL CHEM, V248, P4023; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WELLS MA, 1972, BIOCHEMISTRY-US, V11, P1030, DOI 10.1021/bi00756a013; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; WONG M, 1982, BIOCHEMISTRY-US, V21, P4126, DOI 10.1021/bi00260a032	36	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21425	21431						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400456				2022-12-27	WOS:A1992JV01100028
J	RICHARDSON, DR; BAKER, E				RICHARDSON, DR; BAKER, E			INTERMEDIATE STEPS IN CELLULAR IRON UPTAKE FROM TRANSFERRIN - DETECTION OF A CYTOPLASMIC POOL OF IRON, FREE OF TRANSFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; RAT-LIVER; PLASMA-MEMBRANE; BOUND IRON; DIFERRIC TRANSFERRIN; ENDOTHELIAL-CELLS; ERYTHROID-CELLS; MELANOMA CELL; RELEASE; TRANSPORT	The uptake of transferrin-bound iron by receptor-mediated endocytosis has been the subject of extensive experimental investigation. However, the path followed by iron (Fe) after release from transferrin (Tf) remains obscure. Once Fe is released from Tf within the endosome, it must be transported across the endosomal membrane into the cell. The present investigation describes the presence of a cytoplasmic Tf-free Fe pool which is detectable only when cells are detached from their culture dishes at low temperature, after initial incorporation of diferric transferrin at 37-degrees-C. This cellular iron pool was greatly reduced if incubation temperatures were maintained at 37-degrees-C or if cells were treated with pronase. Human melanoma cells (SK-MEL-28) in culture were prelabeled by incubation with human I-125-Fe-59-transferrin for 2 h, washed, and reincubated at 4-degrees-C or 37-degrees-C in balanced salt solution in the presence or absence of pronase. The cells were then mechanically detached from the plates and separated into "internalized" and supernatant fractions by centrifugation. Approximately 90% of cellular Fe-59 and 20% of I-125-Tf remained internalized when this reincubation procedure was carried out in balanced salt solution at 37-degrees-C. However, at 4-degrees-C, cellular internalized iron was reduced to approximately 50% of the initial value. The release of this component of cellular Fe-59 (approximately 40% of total cell Fe-59) at 4-degrees-C was completely inhibited in the presence of pronase and other general proteinases at 4-degrees-C and at 37-degrees-C, without affecting internalized transferrin levels. Similar results were obtained in fibroblasts and hepatoma cells, indicating that this phenomenon is not unique to melanoma cells. The characterization of this Tf-free cellular Fe pool which is detectable at low temperature may yield valuable insights into the metabolic fate of iron following its transport across the membrane of the endocytotic vesicle.			RICHARDSON, DR (corresponding author), UNIV WESTERN AUSTRALIA, DEPT PHYSIOL, NEDLANDS, WA 6009, AUSTRALIA.			Richardson, Des/0000-0002-5506-3274; Richardson, Des/0000-0003-0960-6415				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; BAKER E, 1980, BRIT J HAEMATOL, V45, P607, DOI 10.1111/j.1365-2141.1980.tb07184.x; Baker E, 1988, Birth Defects Orig Artic Ser, V23, P89; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; CHAKRABORTY AK, 1992, FEBS LETT, V302, P126, DOI 10.1016/0014-5793(92)80421-C; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; FUCHS O, 1988, BIOCHIM BIOPHYS ACTA, V969, P158, DOI 10.1016/0167-4889(88)90071-7; HANKS JH, 1949, P SOC EXP BIOL MED, V71, P196; HEMMAPLARDH D, 1976, INT J APPL RADIAT IS, V27, P89, DOI 10.1016/0020-708X(76)90182-4; HOBBS AS, 1980, ANNU REV BIOPHYS BIO, V9, P259, DOI 10.1146/annurev.bb.09.060180.001355; HOLMES JM, 1989, AM J PHYSIOL, V256, pG1022, DOI 10.1152/ajpgi.1989.256.6.G1022; IACOPETTA BJ, 1983, J BIOL CHEM, V258, P9108; JACOBS A, 1977, BLOOD, V50, P433; KARIN M, 1981, J BIOL CHEM, V256, P3245; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; Kuhn L., 1990, IRON TRANSPORT STORA, P149; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCKINLEY DN, 1988, J CELL PHYSIOL, V136, P389, DOI 10.1002/jcp.1041360302; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MORGAN EH, 1988, ANN NY ACAD SCI, V526, P65, DOI 10.1111/j.1749-6632.1988.tb55493.x; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MUSGROVE E, 1984, J CELL PHYSIOL, V118, P6, DOI 10.1002/jcp.1041180103; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; PAGE M, 1986, AM J PHYSIOL, V246, pG26; PIPPARD MJ, 1982, BRIT J HAEMATOL, V52, P211, DOI 10.1111/j.1365-2141.1982.tb03883.x; RICHARDSON D, 1991, BIOCHIM BIOPHYS ACTA, V1093, P20, DOI 10.1016/0167-4889(91)90133-I; RICHARDSON D, 1992, J BIOL CHEM, V267, P13972; RICHARDSON DR, 1992, BIOCHIM BIOPHYS ACTA, V1103, P275, DOI 10.1016/0005-2736(92)90097-6; RICHARDSON DR, 1990, BIOCHIM BIOPHYS ACTA, V1053, P1, DOI 10.1016/0167-4889(90)90018-9; RICHARDSON DR, 1991, BIOCHIM BIOPHYS ACTA, V1091, P294, DOI 10.1016/0167-4889(91)90192-Z; RICHARDSON DR, 1990, THESIS U W AUSTR PER; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; SELIGMAN PA, 1986, AM J HUM GENET, V38, P540; SIPE DM, 1991, J BIOL CHEM, V266, P8002; STPIERRE TG, 1992, BIOCHIM BIOPHYS ACTA, V1135, P154; Stryer L, 1981, BIOCHEMISTRY; SUN IL, 1987, J BIOL CHEM, V262, P15915; THORSTENSEN K, 1990, BIOCHEM J, V271, P1; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; TRINDER D, 1986, HEPATOLOGY, V6, P852, DOI 10.1002/hep.1840060508; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; WRIGHT TL, 1988, J BIOL CHEM, V263, P1842; YOSHIDA M, 1977, P NATL ACAD SCI USA, V74, P936, DOI 10.1073/pnas.74.3.936; YOUNG SP, 1981, HEPATOLOGY, V1, P114, DOI 10.1002/hep.1840010205	53	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21384	21389						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400450				2022-12-27	WOS:A1992JV01100022
J	XIONG, WJ; ZSIGMOND, E; GOTTO, AM; RENEKER, LW; CHAN, L				XIONG, WJ; ZSIGMOND, E; GOTTO, AM; RENEKER, LW; CHAN, L			TRANSGENIC MICE EXPRESSING FULL-LENGTH HUMAN APOLIPOPROTEIN-B-100 - FULL-LENGTH HUMAN APOLIPOPROTEIN-B MESSENGER-RNA IS ESSENTIALLY NOT EDITED IN MOUSE INTESTINE OR LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; LOW-DENSITY LIPOPROTEIN; AMINO-ACID SEQUENCE; FAMILIAL HYPERCHOLESTEROLEMIA; COMBINED HYPERLIPIDEMIA; HEART-DISEASE; GENE; HYPERAPOBETALIPOPROTEINEMIA; PROTEIN; DOMAIN	Apolipoprotein (apo) B-100 mRNA is edited in the small intestine (in all mammals examined) and the liver (in mice and rats only) to produce apoB-48 mRNA. ApoB mRNA editing involves a C --> U conversion of the first base of the codon CAA for Gln-2153 in apoB-100, changing it to an in-frame stop codon (UAA). The edited mRNA encodes apoB-48, which is colinear with the N-terminal 48% of apoB-100. ApoB mRNA editing can be reproduced in vitro using cellular extracts from one species to edit synthetic apoB mRNA sequences from a different species. Editing of transcripts from transfected genes also appears not to be species-specific. We have produced transgenic mice that express full-length human apoB-100 mRNA at high levels in the liver and small intestine. Human apoB-100 (a 550-kDa protein) but not apoB-48 (a 260-kDa protein) is detected in total plasma (at approximately 22 mg/dl) and in very low density and low density lipoproteins. The endogenous mouse plasma apoB concentration is reduced by approximately 45% in the transgenic animals. Thus, the transgenic mice form an animal model for familial hyperapolipoprotein B, an inherited form of hyperlipidemia. To our surprise, we found that the full-length human apoB mRNA consists of >99% apoB-100 mRNA in both the liver and small intestine; <1% of edited (apoB-48) mRNA was detected. The proportions of endogenous mouse apoB-48 (edited) mRNA (60 and 90% in the liver and small intestine, respectively) were identical in transgenic mice and their nontransgenic littermates. Therefore, full-length human apoB mRNA is resistant to editing by the mouse editing enzyme in vivo; the unchanged proportion of endogenous mouse apoB-48 mRNA in the transgenic mice suggests that the human mRNA competes poorly with the mouse sequence for interacting with the editing enzyme. This observation has implications for the sequence specificity and mechanism of RNA editing. Furthermore, we should exercise caution in the interpretation of in vitro RNA-editing experiments.	BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine	XIONG, WJ (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA.				NHLBI NIH HHS [HL27341, HL45516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045516, P60HL027341, P50HL027341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CHAN L, 1992, IN PRESS BIOESSAYS; CHEN PF, 1988, EUR J BIOCHEM, V175, P111, DOI 10.1111/j.1432-1033.1988.tb14172.x; CHEN SH, 1986, J BIOL CHEM, V261, P2918; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HAZZARD WR, 1973, J CLIN INVEST, V52, P1569, DOI 10.1172/JCI107333; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KWITEROVICH PO, 1987, ARTERIOSCLEROSIS, V7, P211, DOI 10.1161/01.ATV.7.3.211; LAU PP, 1991, J BIOL CHEM, V266, P20550; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; SNIDERMAN AD, 1982, ANN INTERN MED, V97, P833, DOI 10.7326/0003-4819-97-6-833; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TENG BB, 1990, J BIOL CHEM, V265, P20616; WEI CF, 1985, J BIOL CHEM, V260, P5211; WU JH, 1990, J BIOL CHEM, V265, P12312; XIONG WJ, 1991, J BIOL CHEM, V266, P20893; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YAO ZM, 1992, J BIOL CHEM, V267, P1175	50	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21412	21420						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400454				2022-12-27	WOS:A1992JV01100026
J	CHEUNG, WF; HAMAGUCHI, N; SMITH, KJ; STAFFORD, DW				CHEUNG, WF; HAMAGUCHI, N; SMITH, KJ; STAFFORD, DW			THE BINDING OF HUMAN FACTOR-IX TO ENDOTHELIAL-CELLS IS MEDIATED BY RESIDUES 3-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-CARBOXYGLUTAMIC ACID; ATOM FORCE-FIELD; NUCLEIC-ACIDS; BOVINE PROTHROMBIN; FACTOR-X; PROTEINS; SIMULATIONS; ACTIVATION; INHIBITORS; SURFACE	We have used chimeras and point mutations of recombinant coagulation factor IX to examine factor IX's specific interaction with bovine endothelial cells. Previously (Toomey, J. R., Smith, K. J., Roberts, H. R., and Stafford, D. W. (1992) Biochemistry 31, 1806-1808), we restricted the region of factor IX responsible for binding to endothelial cells to its Gla domain. Molecular modeling of the Gla domain of factor IX using the coordinates of the Gla domain of bovine prothrombin-(1-145) (Soriano-Garcia, M., Padmanabhan, K., deVos, A. M., and Tulinsky, A. (1992) Biochemistry 31, 2554-2566) reveals two major surface determinants whose sequences differ among factors IX, X, and VII. A chimeric protein comprised of the Gla domain of factor VII with the remainder of the molecule of factor IX did not bind to the endothelial cell binding site. We changed residues 33, 34, 35, 39, and 40 to those of factor IX without restoring endothelial cell binding. Replacement of amino acid residues 3-10 with those of factor IX restored normal binding. With the knowledge that specific binding was localized to the first 11 amino acids, point mutations were made at residues predicted to be on the surface in this region of the factor IX molecule. Changing lysine 5 to alanine (K5A) or valine 10 to lysine (V10K) resulted in loss of binding with total retention of in vitro clotting activity. The lysine 5 to arginine (K5R) mutation also was fully active in vitro but displayed 3-fold tighter binding. In addition to defining the sequence of factor IX necessary for binding to endothelial cells, these results suggest that the binding site is not phospholipid but instead is specific, and in all likelihood, protein.	UNIV N CAROLINA,DEPT BIOL,442 WILSON HALL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNIV NEW MEXICO,SCH MED,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNITED BLOOD SERV,ALBUQUERQUE,NM 87131	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of New Mexico; University of New Mexico					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038973] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL38973-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAUNSTEIN KM, 1981, J CLIN INVEST, V68, P1420, DOI 10.1172/JCI110393; CHARIFSON PS, 1991, P NATL ACAD SCI USA, V88, P424, DOI 10.1073/pnas.88.2.424; CHEUNG WF, 1991, J BIOL CHEM, V266, P8797; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; HEIMARK RL, 1983, BIOCHEM BIOPH RES CO, V111, P723, DOI 10.1016/0006-291X(83)90365-0; JANIN J, 1990, J BIOL CHEM, V265, P16027; MAYNARD AT, 1988, INT J PEPT PROT RES, V31, P137; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RIMON S, 1987, J BIOL CHEM, V262, P6023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STERN DM, 1983, P NATL ACAD SCI-BIOL, V80, P4119, DOI 10.1073/pnas.80.13.4119; STERN DM, 1984, P NATL ACAD SCI-BIOL, V81, P913, DOI 10.1073/pnas.81.3.913; STERN DM, 1985, J BIOL CHEM, V260, P6717; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	20	71	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20529	20531						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400370				2022-12-27	WOS:A1992JT97800002
J	GAVINI, N; BURGESS, BK				GAVINI, N; BURGESS, BK			FEMO COFACTOR SYNTHESIS BY A NIFH MUTANT WITH ALTERED MGATP REACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII NITROGENASE; STRUCTURAL GENE-CLUSTER; CROSS-LINKING; PROTEIN; COMPONENTS; COMPLEX; BIOSYNTHESIS; PURIFICATION; SEQUENCES	We have characterized a Nif- mutant of Azotobacter vinelandii, designated UW91 (Shah, V. K., Davis, L. C., Gordon, J. K., Orme-Johnson, W. H., and Brill, W. J. (1973) Biochim. Biophys. Acta 292, 246-255). The specific Fe protein mutation giving rise to the Nif- phenotype was shown by DNA sequencing and site-directed mutagenesis to be the substitution of a conserved alanine at position 157 by a serine. The UW91 Fe protein was purified and shown to have a normal [4Fe-4S] cluster and normal MgATP binding activity. The substitution of alanine 157 by serine, however, prevents the MgATP-induced conformational change that occurs for the wild-type Fe protein, prevents MgATP hydrolysis, and prevents productive electron transfer to the MoFe protein. The UW91 Fe protein does bind to the MoFe protein to give a normal cross-linking pattern; however, it does not compete very successfully with wild-type Fe protein in an activity assay. The UW91 MoFe protein was also purified and characterized and shown to be indistinguishable from the wild-type protein. Thus, the substitution of Fe protein residue alanine 157 by serine does not change the Fe protein's ability to function in FeMo cofactor biosynthesis or insertion. This demonstrates that these events do not require the MgATP-induced conformational change, MgATP hydrolysis, or productive electron transfer to the MoFe protein.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NIGMS NIH HHS [GM43144] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRAAKSMA A, 1983, EUR J BIOCHEM, V121, P483; BRIGLE KE, 1985, GENE, V37, P37, DOI 10.1016/0378-1119(85)90255-0; BUI PT, 1968, P NATL ACAD SCI USA, V61, P1021, DOI 10.1073/pnas.61.3.1021; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; DILLELA AG, 1985, FOCUS, V7, P1; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; EMERICH DW, 1976, J BACTERIOL, V134, P936; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; FISKE CH, 1952, J BIOL CHEM, V66, P325; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HOOVER T R, 1988, Biofactors, V1, P199; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; LI JG, 1982, BIOCHEMISTRY-US, V21, P4393, DOI 10.1021/bi00261a031; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; LOWE DJ, 1980, RECENT ADV BIOL NITR, P34; Merrick M. J., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P293; MONOD J, 1951, BIOCHIM BIOPHYS ACTA, V7, P585, DOI 10.1016/0006-3002(51)90072-8; MORTENSON LE, 1976, 1ST P INT S NITR FIX, P117; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; Smith B. E., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P91; STEPHENS PJ, 1988, MOLYBDENUM ENZYMES, P117; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499; YANG SS, 1982, J BIOL CHEM, V257, P8042; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	84	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21179	21186						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400428				2022-12-27	WOS:A1992JT97800103
J	JOSHIBARVE, S; DEBENEDETTI, A; RHOADS, RE				JOSHIBARVE, S; DEBENEDETTI, A; RHOADS, RE			PREFERENTIAL TRANSLATION OF HEAT-SHOCK MESSENGER-RNAS IN HELA-CELLS DEFICIENT IN PROTEIN-SYNTHESIS INITIATION-FACTORS EIF-4E AND EIF-4-GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL INITIATION; FACTOR-III; BINDING; CAP; COMPLEX; INHIBITION; SEQUENCE; LEADER; VIRUS; INACTIVATION	Expression of antisense RNA against eukaryotic translation initiation factor 4E (eIF-4E) in HeLa cells causes a reduction in the levels of both eIF-4E and eIF-4gamma (p220) and a concomitant decrease in the rates of both cell growth and protein synthesis (De Benedetti, A., Joshi-Barve, S., Rinker-Schaffer, C., and Rhoads, R. E. (1991) Mol. Cell Biol. 11, 5435-5445). The synthesis of most proteins in the antisense RNA-expressing cells (AS cells) is decreased, but certain proteins continue to be synthesized. In the present study, we identified many of these as stress-inducible or heat shock proteins (HSPs). By mobilities on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and by reactivity with monoclonal antibodies generated against human HSPs, four of these were shown to be HSP 90, HSP 70, HSP 65, and HSP 27. The steady-state levels of HSP 90, 70, and 27 were elevated in relation to total protein in AS cells. Pulse labeling and immunoprecipitation indicated that HSP 90 and HSP 70 were synthesized more rapidly in AS cells than in control cells. The accelerated synthesis of HSPs in the AS cells was not due, however, to increased mRNA levels; the levels of HSP 90 and 70 mRNAs either remained the same or decreased after induction of antisense RNA expression. Actin mRNA, a typical cellular mRNA, was found on high polysomes in control cells but shifted to smaller polysomes in AS cells, as expected from the general decrease in translational initiation caused by eIF-4E and eIF-4gamma depletion. HSP 90 and 70 mRNAs showed the opposite behavior; they were associated with small polysomes in control cells but shifted to higher polysomes in AS cells. These results demonstrate that HSP mRNAs have little or no requirement in vivo for the cap-recognition machinery and suggest that these mRNAs may utilize an alternative, cap-independent mechanism of translational initiation.	UNIV KENTUCKY, DEPT BIOCHEM, LEXINGTON, KY 40536 USA	University of Kentucky				de benedetti, arrigo/0000-0002-4198-8647	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BIENZ M, 1984, P NATL ACAD SCI-BIOL, V81, P3138, DOI 10.1073/pnas.81.10.3138; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P5800; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1987, J BIOL CHEM, V262, P380; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HICKEY ED, 1982, BIOCHEMISTRY-US, V21, P1513, DOI 10.1021/bi00536a008; HULTMARK D, 1991, NATURE, V353, P14; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; KOCH F, 1985, MOL BIOL POLIOVIRUSE, P209; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LINDQUIST S, 1987, TRANSLATIONAL REGULA, P187; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; MORLEY SJ, 1990, BIOCHIMIE, V72, P259, DOI 10.1016/0300-9084(90)90081-Q; MUNOZ A, 1984, VIROLOGY, V137, P150, DOI 10.1016/0042-6822(84)90018-7; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; Sambrook J, 1989, MOL CLONING LABORATO; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007	36	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21038	21043						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400417				2022-12-27	WOS:A1992JT97800083
J	RAFNAR, T; GHOSH, B; METZLER, WJ; HUANG, SK; PERRY, MP; MUELLER, L; MARSH, DG				RAFNAR, T; GHOSH, B; METZLER, WJ; HUANG, SK; PERRY, MP; MUELLER, L; MARSH, DG			EXPRESSION AND ANALYSIS OF RECOMBINANT AMB-A-V AND AMB-T-V ALLERGENS - COMPARISON WITH NATIVE PROTEINS BY IMMUNOLOGICAL ASSAYS AND NMR-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT RAGWEED POLLEN; AMINO-ACID-SEQUENCE; DUST MITE ALLERGEN; HUMAN IMMUNE-RESPONSE; ESCHERICHIA-COLI; MAJOR ALLERGEN; GENETIC-MARKER; CELL RESPONSES; CDNA CLONING; P-II	The Amb V allergens are small, highly disulfide-bonded ragweed pollen allergens that serve as useful models for understanding the molecular basis of the human immune response. We have produced recombinant Amb a V and Amb t V (from short and giant ragweed pollens, respectively) in Escherichia coli and have compared their structural and functional characteristics to those of the native proteins. Recombinant Amb t V was indistinguishable from native Amb t V as determined by NMR spectroscopy and antibody-binding studies. Whereas inhibition analysis showed that recombinant Amb a V possessed only approximately 50% of the antibody-binding activity of native Amb a V, the two proteins were similarly effective in stimulating Amb a V-specific T-cells. Our results demonstrate that even highly homologous proteins exhibit different abilities to fold into their native three-dimensional conformations and establish the potential and limits of expressing the recombinant Amb V allergens intracellularly in E. coli.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,PRINCETON,NJ 08543	Bristol-Myers Squibb	RAFNAR, T (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD 21224, USA.		Huang, Shau-Ku/F-5509-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI019727, R01AI019727] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19727] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOND JF, 1991, J IMMUNOL, V146, P3380; CHOUDHURY AM, 1983, J PROTEIN CHEM, V2, P321, DOI 10.1007/BF01025597; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GHOSH B, 1991, GENE, V101, P231, DOI 10.1016/0378-1119(91)90416-9; GOODFRIEND L, 1985, MOL IMMUNOL, V22, P899, DOI 10.1016/0161-5890(85)90076-8; GREENE WK, 1991, J IMMUNOL, V147, P3768; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; HUANG SK, 1991, IMMUNOLOGY, V73, P363; LIN KH, 1991, BIOTECHNIQUES, V11, P748; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P5117, DOI 10.1021/bi00137a005; MOLE LE, 1975, BIOCHEMISTRY-US, V14, P1216, DOI 10.1021/bi00677a019; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROEBBER M, 1985, J IMMUNOL, V134, P3062; ROEBBER M, 1982, J IMMUNOL, V129, P120; ROGERS BL, 1991, J IMMUNOL, V147, P2547; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; SINGH MB, 1991, EMBO J, V88, P1384; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; WILKINSON DL, 1991, BIO-TECHNOL, V9, P443, DOI 10.1038/nbt0591-443; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	34	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21119	21123						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400422				2022-12-27	WOS:A1992JT97800094
J	SHIBATA, K; MURAOSA, Y; TOMITA, Y; TAGAMI, H; SHIBAHARA, S				SHIBATA, K; MURAOSA, Y; TOMITA, Y; TAGAMI, H; SHIBAHARA, S			IDENTIFICATION OF A CIS-ACTING ELEMENT THAT ENHANCES THE PIGMENT CELL-SPECIFIC EXPRESSION OF THE HUMAN TYROSINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE TYROSINASE; OCULOCUTANEOUS ALBINISM; MOLECULAR-BASIS; CDNA; TRANSCRIPTION; SUBSTITUTION; MELANOCYTES; MUTATION	To identify the cis-acting element that is responsible for the pigment cell-specific expression of the human tyrosinase gene, we analyzed the promoter activity of its 5'-flanking region by transient expression assays. The fusion genes were constructed by inserting the 5'-flanking region of the human tyrosinase gene upstream from the firefly luciferase gene and were introduced into human melanoma cells and HeLa cells. We thus found the element, located between 2.7 and 1.8 kilobase pairs upstream from the transcription initiation site, that enhances the transient expression of the luciferase reporter gene in melanoma cells, but not in HeLa cells, the tyrosinase gene expression of which is not detectable. Using the fusion genes containing putative enhancer elements under the control of the heterologous simian virus 40 promoter, we identified the pigment cell-specific enhancer of approximately 200 base pairs (bp) between -2.0 and -1.8 kilobase pairs and localized the core sequence to a 39-bp region. This 39-bp core element was then confirmed to direct the melanoma cell-specific expression of the reporter gene under the tyrosinase gene promoter. We thus propose that this core element is responsible for the pigment cell-specific expression of the human tyrosinase gene.	TOHOKU UNIV,SCH MED,DEPT APPL PHYSIOL & MOLEC BIOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT DERMATOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University			Shibahara, Shigeki/M-3644-2014					BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BRUGGEN J, 1981, CANCER IMMUNOL IMMUN, V10, P121; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KIKUCHI H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P283, DOI 10.1016/0167-4781(89)90115-2; KLUPPEL M, 1991, P NATL ACAD SCI USA, V88, P3777, DOI 10.1073/pnas.88.9.3777; LERNER AB, 1950, J BIOL CHEM, V187, P793; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1988, TOHOKU J EXP MED, V156, P403, DOI 10.1620/tjem.156.403; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SHIBATA K, 1992, BIOCHEM BIOPH RES CO, V184, P568, DOI 10.1016/0006-291X(92)90627-W; TAKEDA A, 1989, BIOCHEM BIOPH RES CO, V162, P984, DOI 10.1016/0006-291X(89)90770-5; TAKEDA A, 1990, J BIOL CHEM, V265, P17792; TANAKA S, 1990, DEVELOPMENT, V108, P223; TOMITA Y, 1989, BIOCHEM BIOPH RES CO, V164, P990, DOI 10.1016/0006-291X(89)91767-1; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121; [No title captured]	23	66	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20584	20588						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400379				2022-12-27	WOS:A1992JT97800015
J	YALOVSKY, S; NEEMAN, E; SCHUSTER, G; PAULSEN, H; HAREL, E; NECHUSHTAI, R				YALOVSKY, S; NEEMAN, E; SCHUSTER, G; PAULSEN, H; HAREL, E; NECHUSHTAI, R			ACCUMULATION OF A LIGHT-HARVESTING CHLOROPHYLL-A/B PROTEIN IN THE CHLOROPLAST GRANA-LAMELLAE - THE LATERAL MIGRATION OF THE MEMBRANE-PROTEIN PRECURSOR IS INDEPENDENT OF ITS PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-B-PROTEIN; BINDING-PROTEIN; TRANSIT PEPTIDE; BARLEY ETIOCHLOROPLASTS; THYLAKOID MEMBRANES; ESCHERICHIA-COLI; PHOTOSYSTEM-II; COMPLEX; IMPORT; INSERTION	The events that follow the import of pLHCPIIb, the apoprotein precursor of the major light-harvesting complex of photosystem II, were studied in intact pea chloroplasts. The distribution of the events of insertion into the membrane, and processing, to yield the mature form (LHCP) between stromal and granal lamellae regions of the thylakoids were followed. pLHCP was preferentially inserted into stromal lamellae (SL) from which it migrated to granal lamellae (GL). Migration occurred before or after processing, suggesting that migration and processing are independent of each other. When migration was slowed down, LHCP accumulated in SL. Prolonged inhibition of migration induced degradation of LHCP that had accumulated in SL, whereas inhibition of processing did not affect the migration of pLHCP into GL. A small difference in electrophoretic mobility was noted between LHCP in SL and in GL. The predominant mature form in SL migrated more slowly than LHCP from GL. When thylakoids were subjected to trypsin, all of the LHCP embedded in SL underwent cleavage, whereas up to 60% of the radioactive LHCP in GL was resistant to the enzyme. The possible implications of the differences in size and in the sensitivity to trypsin of LHCP are discussed.	HEBREW UNIV JERUSALEM,DEPT BOT,IL-91904 JERUSALEM,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC BIOL,IL-32000 HAIFA,ISRAEL; UNIV MUNICH,INST BOT,W-8000 MUNICH 2,GERMANY	Hebrew University of Jerusalem; Technion Israel Institute of Technology; University of Munich			Paulsen, Harald/D-3742-2011					ABAD MS, 1991, PLANT PHYSIOL, V96, P1220, DOI 10.1104/pp.96.4.1220; Andersson B, 1985, MOD METHOD PLANT, V1, P231; ARCHER EK, 1990, J BIOENERG BIOMEMBR, V22, P789; BENNETT J, 1983, BIOCHEM J, V212, P1; CHITNIS PR, 1988, PLANT MOL BIOL, V11, P95, DOI 10.1007/BF00015663; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CHITNIS PR, 1986, J CELL BIOL, V102, P982, DOI 10.1083/jcb.102.3.982; CHITNIS PR, 1988, PHOTOSYNTH RES, V16, P41, DOI 10.1007/BF00039485; CLARK SE, 1989, J BIOL CHEM, V264, P17544; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1986, J BIOL CHEM, V261, P4804; FULSOM DR, 1988, PLANT PHYSIOL, V86, P1120; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; KOHORN BD, 1990, J BIOL CHEM, V265, P2118; KOHORN BD, 1986, J CELL BIOL, V102, P972, DOI 10.1083/jcb.102.3.972; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LETO KJ, 1985, EMBO J, V4, P1645, DOI 10.1002/j.1460-2075.1985.tb03832.x; MACHOLD O, 1979, BIOCHIM BIOPHYS ACTA, V546, P472, DOI 10.1016/0005-2728(79)90082-3; MATOO AK, 1987, P NATL ACAD SCI USA, V84, P1497; MULLET JE, 1980, BIOCHIM BIOPHYS ACTA, V589, P100, DOI 10.1016/0005-2728(80)90135-8; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; RYRIE IJ, 1980, EUR J BIOCHEM, V107, P345; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT GW, 1981, J CELL BIOL, V91, P468, DOI 10.1083/jcb.91.2.468; SOMMER A, 1992, REGULATION CHLOROPLA, P143; STEINBACK KE, 1979, ARCH BIOCHEM BIOPHYS, V195, P546, DOI 10.1016/0003-9861(79)90381-3; THORNBER JP, 1986, ENCY PLANT PHYSL, V19, P98; VAINSTEIN A, 1989, PLANT PHYSIOL, V89, P602, DOI 10.1104/pp.89.2.602; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; YALOVSKY S, 1990, PLANT MOL BIOL, V14, P753, DOI 10.1007/BF00016508	32	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20689	20693						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400385				2022-12-27	WOS:A1992JT97800029
J	AGRAWAL, A; XU, YY; ANSARDI, D; MACON, KJ; VOLANAKIS, JE				AGRAWAL, A; XU, YY; ANSARDI, D; MACON, KJ; VOLANAKIS, JE			PROBING THE PHOSPHOCHOLINE-BINDING SITE OF HUMAN C-REACTIVE PROTEIN BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P-COMPONENT; COMPLEMENTARY-DNA; GENE-EXPRESSION; SYRIAN-HAMSTER; PHOSPHORYLCHOLINE; SEQUENCE; SPECIFICITY; POLYSACCHARIDE; LOCALIZATION; PURIFICATION	Human C-reactive protein (CRP) can activate the classical pathway of complement and function as an opsonin only when it is complexed to an appropriate ligand. Most known CRP ligands bind to the phosphocholine (PCh)-binding site of the protein. In the present study, we used oligonucleotide-directed site-specific mutagenesis to investigate structural determinants of the PCh-binding site of CRP. Eight mutant recombinant (r) CRP, Y40F; E42Q; Y40F, E42Q; K57Q; R58G; K57Q, R58G; W67K; and K57Q, R58G, W67K were constructed and expressed in COS cells. Wild-type and all mutant rCRP except for the W67K mutants bound to solid-phase PCh-substituted bovine serum albumin (PCh-BSA) with similar apparent avidities. However, W67K rCRP had decreased avidity for PCh-BSA and the triple mutant, K57Q, R58G, W67K, failed to bind PCh-BSA. Inhibition experiments using PCh and dAMP as inhibitors indicated that both Lys-57 and Arg-58 contribute to PCh binding. They also indicated that Trp-67 provides interactions with the choline group. The Y40F and E42Q mutants were found to have increased avidity for fibronectin compared to wild-type rCRP. We conclude that the residues Lys-57, Arg-58, and Trp-67 contribute to the structure of the PCh-binding site of human CRP. Residues Tyr-40 and Glu-42 do not appear to participate in the formation of the PCh-binding site of CRP, however, they may be located in the vicinity of the fibronectin-binding site of CRP.	UNIV ALABAMA,ANNA LOIS WATERS CHAIR MED RHEUMATOL,DEPT MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI15607] Funding Source: Medline; NIAMS NIH HHS [R01 AR068787] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON JK, 1978, FED PROC, V37, P1495; BARNUM S, 1982, ANN NY ACAD SCI, V389, P431, DOI 10.1111/j.1749-6632.1982.tb22158.x; DICAMELLI R, 1980, J IMMUNOL, V125, P1933; DOWTON SB, 1985, SCIENCE, V228, P1206, DOI 10.1126/science.2408337; DOWTON SB, 1990, BIOCHEM J, V270, P553, DOI 10.1042/bj2700553; DOWTON SB, 1991, BIOCHEMISTRY-US, V30, P9531, DOI 10.1021/bi00103a021; DUCLOS TW, 1988, J IMMUNOL, V141, P4266; DUCLOS TW, 1989, J IMMUNOL, V143, P2553; GIUSTI AM, 1987, P NATL ACAD SCI USA, V84, P2926, DOI 10.1073/pnas.84.9.2926; GOTSCHLICH EC, 1965, P NATL ACAD SCI USA, V54, P558, DOI 10.1073/pnas.54.2.558; HIGGINBOTHAM JD, 1970, P NATL ACAD SCI USA, V67, P138, DOI 10.1073/pnas.67.1.138; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KABAT EA, 1976, P NATL ACAD SCI USA, V73, P617, DOI 10.1073/pnas.73.2.617; KILPATRICK JM, 1982, MOL IMMUNOL, V19, P1159, DOI 10.1016/0161-5890(82)90326-1; KILPATRICK JM, 1991, IMMUNOL RES, V10, P43, DOI 10.1007/BF02918166; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LEI KJ, 1985, J BIOL CHEM, V260, P3377; LIU TY, 1963, J BIOL CHEM, V238, P1928; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; NISHIGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1366, DOI 10.1016/S0006-291X(88)81292-0; OHNISHI S, 1988, BIOCHEM BIOPH RES CO, V156, P814, DOI 10.1016/S0006-291X(88)80917-3; OLIVEIRA EB, 1980, J IMMUNOL, V124, P1396; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PADLAN EA, 1976, IMMUNOCHEMISTRY, V13, P945, DOI 10.1016/0019-2791(76)90239-1; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; ROBEY FA, 1983, J BIOL CHEM, V258, P3895; ROUX KH, 1983, J IMMUNOL, V131, P2411; SALONEN EM, 1984, J BIOL CHEM, V259, P1496; SIEGEL J, 1975, J EXP MED, V142, P709, DOI 10.1084/jem.142.3.709; SWANSON SJ, 1990, MOL IMMUNOL, V27, P679, DOI 10.1016/0161-5890(90)90011-N; SYIN C, 1986, J BIOL CHEM, V261, P5473; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; VOLANAKIS JE, 1978, J IMMUNOL METHODS, V23, P285, DOI 10.1016/0022-1759(78)90203-X; VOLANAKIS JE, 1979, NATURE, V281, P155, DOI 10.1038/281155a0; VOLANAKIS JE, 1989, DEFENSE MOL, P161; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOUNG NM, 1978, J IMMUNOL, V121, P1893; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	44	31	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25352	25358						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460031				2022-12-27	WOS:A1992KB60300067
J	BANECKI, B; ZYLICZ, M; BERTOLI, E; TANFANI, F				BANECKI, B; ZYLICZ, M; BERTOLI, E; TANFANI, F			STRUCTURAL AND FUNCTIONAL-RELATIONSHIPS IN DNAK AND DNAK756 HEAT-SHOCK PROTEINS FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; BACTERIOPHAGE-LAMBDA; NUCLEOPROTEIN STRUCTURES; CONFORMATIONAL-CHANGES; PLASMID REPLICATION; ATPASE ACTIVITY; INITIATION; GENE; GRPE; BINDING	The secondary structures of DnaK and the mutant DnaK756 heat-shock proteins from Escherichia coli have been investigated by Fourier transform infrared spectroscopy. The analysis of infrared data showed that DnaK and DnaK756 proteins have different secondary structures that are not affected by the presence of ATP or beta,gamma-methyleneadenosine 5'-triphosphate. The infrared data indicate also that the tertiary structures of DnaK and DnaK756 proteins are different and that DnaK protein undergoes conformational changes in its tertiary structure not only during binding of ATP but also during ATP hydrolysis. Using fluorescence spectroscopy of a single tryptophan located in the N-terminal domain of DnaK protein and fluorescence of 1,1'-bis(4-anilino)naphthalene-5,5'-disulfonic acid, which interacts with hydrophobic domains of DnaK protein, we were able to distinguish between two conformational states of DnaK protein. After binding of triphosphonucleotides, the C-terminal domain of DnaK protein changes in tertiary structure in such a way that fewer hydrophobic segments are exposed on the surface of the protein. After ATP hydrolysis, the number of hydrophobic segments on the surface of the protein is further reduced, and moreover the tertiary structure of the N-terminal domain of the protein changes. These data are discussed in terms of structural and functional relationships of both DnaK and DnaK756 proteins.	UNIV ANCONA,SCH MED,INST BIOCHEM,I-60100 ANCONA,ITALY; UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,PL-80822 GDANSK,POLAND	Marche Polytechnic University; Fahrenheit Universities; University of Gdansk			Tanfani, Fabio/F-1441-2010	Tanfani, Fabio/0000-0001-7685-4692				ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P1749, DOI 10.1073/pnas.87.5.1749; ANG D, 1991, J BIOL CHEM, V266, P24233; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BLUME A, 1988, BIOCHEMISTRY-US, V27, P8239, DOI 10.1021/bi00421a038; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; BYLER DM, 1989, P SOC PHOTO-OPT INS, V1145, P415; CALHOUN DB, 1983, BIOCHEMISTRY-US, V22, P1533, DOI 10.1021/bi00276a003; CASAL HL, 1988, BIOCHIM BIOPHYS ACTA, V957, P11, DOI 10.1016/0167-4838(88)90152-5; CHAPMAN D, 1989, BIOCHEM SOC T, V17, P951; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DODSON M, 1989, J BIOL CHEM, V264, P10719; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FINI C, 1992, BIOCHIM BIOPHYS ACTA, V1118, P187, DOI 10.1016/0167-4838(92)90149-8; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; Gross C. A., 1990, STRESS PROTEINS BIOL, P166; HARIS PI, 1989, BIOCHIM BIOPHYS ACTA, V995, P160, DOI 10.1016/0167-4838(89)90075-7; HARIS PI, 1986, BIOCHIM BIOPHYS ACTA, V874, P255, DOI 10.1016/0167-4838(86)90024-5; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JACKSON M, 1989, BIOCHIM BIOPHYS ACTA, V998, P75, DOI 10.1016/0167-4838(89)90121-0; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; LEE DC, 1987, BIOCHEMISTRY-US, V26, P5775, DOI 10.1021/bi00392a029; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; OSBORNE HB, 1982, METHOD ENZYMOL, V88, P676; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; UMEMURA J, 1980, BIOCHIM BIOPHYS ACTA, V602, P32, DOI 10.1016/0005-2736(80)90287-4; WADA M, 1982, JPN J GENET, V57, P407, DOI 10.1266/jjg.57.407; WADA M, 1986, J BACTERIOL, V168, P213, DOI 10.1128/jb.168.1.213-220.1986; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	54	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25051	25058						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460007				2022-12-27	WOS:A1992KB60300024
J	KAMITANI, T; MENON, AK; HALLAQ, Y; WARREN, CD; YEH, ETH				KAMITANI, T; MENON, AK; HALLAQ, Y; WARREN, CD; YEH, ETH			COMPLEXITY OF ETHANOLAMINE PHOSPHATE ADDITION IN THE BIOSYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; STRUCTURAL CHARACTERIZATION; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; THY-1 GLYCOPROTEIN	Biosynthetic intermediates for the mammalian glycosylphosphatidylinositol (GPI) anchor have been described. The earliest GPI anchor precursor is N-acetylglucosaminylphosphatidylinositol, which is deacetylated to give glucosaminylphosphatidylinositol. This is followed by fatty acylation of the inositol ring, sequential addition of mannose residues donated by dolichyl mannosyl phosphate, and finally addition of ethanolamine phosphate. Here, we show that the final steps of GPI anchor biosynthesis are more complex than we have previously reported. Six distinct GPI anchor precursors were found to contain at least 1 ethanolamine phosphate residue. The headgroups of these glycolipids were purified and analyzed by a combination of Bio-Gel P4 chromatography and high resolution thin-layer chromatography. The sizes of neutral glycans were determined following HF dephosphorylation. The position of the ethanolamine phosphate residue was inferred from results of alpha-mannosidase treatment. Finally, the number of negative charges on the headgroups were determined by Mono Q chromatography. Our results show that the addition of ethanolamine phosphate is controlled by at least two different genes. Thus, the class F mutant, though unable to add ethanolamine phosphate to the third mannose residue, does incorporate ethanolamine phosphate into the first and second mannose residues. Only the wild type cells are capable of incorporating ethanolamine phosphate into the third mannose residue. Furthermore, the GPI core contains up to 3 ethanolamine phosphate residues. These results should facilitate the elucidation of the biochemical defects in paroxysmal nocturnal hemoglobinuria.	ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114	Rockefeller University; Harvard University; Harvard Medical School; Massachusetts General Hospital			Kamitani, Tetsu/GSI-7613-2022	Menon, Anant Kumar/0000-0001-6924-2698; Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIAMS NIH HHS [AR-03564] Funding Source: Medline; NIDDK NIH HHS [DK-40930] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, J BIOL CHEM, V267, P18573; Defaye J., 1970, ADV CARBOHYD CHEM BI, V25, P181; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GUTHER MLS, 1992, J BIOL CHEM, V267, P6820; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16998; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P4982, DOI 10.1073/pnas.89.11.4982; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MAHONEY JF, 1992, BLOOD, V79, P1400; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSSE WF, 1990, ANNU REV MED, V41, P431; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; STAHL E, 1961, J CHROMATOGR, V5, P351, DOI 10.1016/S0021-9673(01)92868-7; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THOMAS LJ, 1992, J CLIN INVEST, V89, P1172, DOI 10.1172/JCI115700; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	40	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24611	24619						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447204				2022-12-27	WOS:A1992KA26300070
J	POGNONEC, P; KATO, H; ROEDER, RG				POGNONEC, P; KATO, H; ROEDER, RG			THE HELIX-LOOP-HELIX LEUCINE REPEAT TRANSCRIPTION FACTOR USF CAN BE FUNCTIONALLY REGULATED IN A REDOX-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION; BINDING-ACTIVITY; ACTIVATION; PROTEIN; PHOSPHORYLATION; INVITRO; HIV-1; FOS; JUN; DNA	We showed previously that the DNA-binding capacity of the helix-loop-helix/leucine repeat transcription factor USF43 is lowered dramatically under nonreducing conditions. This report defines the molecular basis of this effect by showing (i) that the only two USF43 cysteine residues, both present within the helix-loop-helix protein-protein interface domain, are required for this regulation, (ii) that the sulfhydryl groups of these cysteine residues are the actual targets of this regulation, (iii) that oxidation of these groups results in both intra- and intermolecular nonrandom covalent links, (iv) that this redox modulation of USF43 DNA-binding potential can translate in vitro into a specific modulation of its ability to activate transcription from a USF-responsive promoter. The implications of these modulations of USF43 function in response to redox changes are discussed with regard to the apparent paradox of USF strong activation potential and its ubiquitous distribution in all cell types tested.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; GUTZMANBARRON ES, 1951, ADV ENZYMOL, V11, P201; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	22	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24563	24567						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447201				2022-12-27	WOS:A1992KA26300063
J	MALHERBE, A; BLOCK, MA; JOYARD, J; DOUCE, R				MALHERBE, A; BLOCK, MA; JOYARD, J; DOUCE, R			FEEDBACK INHIBITION OF PHOSPHATIDATE PHOSPHATASE FROM SPINACH CHLOROPLAST ENVELOPE MEMBRANES BY DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE; SACCHAROMYCES-CEREVISIAE; INTACT CHLOROPLASTS; PLASTID ENVELOPE; SAFFLOWER SEEDS; LIPID-SYNTHESIS; OUTER-MEMBRANE; HIGHER-PLANTS; BIOSYNTHESIS; GALACTOSYLTRANSFERASE	Because the envelope phosphatidate phosphatase plays a pivotal role in chloroplast glycerolipid metabolism, we have analyzed whether diacylglycerol could be a regulatory factor of the enzyme. Using isolated envelope membranes in which the level of diacylglycerol was modified by thermolysin treatment of intact chloroplasts to destroy the galactolipid:galactolipid galactosyltransferase, we have demonstrated that phosphatidate phosphatase activity was reduced when the membrane was enriched in diacylglycerol. All 1,2-diacylglycerol molecular species assayed were demonstrated to inhibit the enzyme to about the same extent. Kinetic studies with envelope from thermolysin-treated chloroplasts were performed in the absence and presence of diacylglycerol, and diacylglycerol was shown to be a powerful competitive inhibitor of the reaction. Finally, using isolated intact spinach chloroplasts, we have demonstrated that in situ phosphatidate phosphatase activity can be modulated by the level of diacylglycerol present in the membrane. The relevance of phosphatidate phosphatase inhibition by diacylglycerol in the regulation of chloroplast glycerolipid biosynthesis is discussed.	UNIV JOSEPH FOURIER,F-38041 GRENOBLE,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	MALHERBE, A (corresponding author), CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,F-38041 GRENOBLE,FRANCE.							ALBAN C, 1989, BIOCHEM J, V259, P775, DOI 10.1042/bj2590775; ANDREWS J, 1985, PLANT PHYSIOL, V78, P459, DOI 10.1104/pp.78.3.459; [Anonymous], METHODS CHLOROPLAST; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARRON EJ, 1962, BIOCHIM BIOPHYS ACTA, V60, P329, DOI 10.1016/0006-3002(62)90408-0; Bell RM, 1983, ENZYMES, V16, P87; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLIGNY R, 1990, J BIOL CHEM, V265, P1319; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BLOCK MA, 1983, FEBS LETT, V169, P111; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; CARDE JP, 1982, BIOL CELL, V44, P315; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CLINE K, 1983, PLANT PHYSIOL, V71, P366, DOI 10.1104/pp.71.2.366; COLEMAN RA, 1983, ENZYMES, V16, P605; COVES J, 1988, P NATL ACAD SCI USA, V85, P4966, DOI 10.1073/pnas.85.14.4966; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Douce, 1987, BIOCH PLANTS, P215, DOI 10.1016/B978-0-12-675409-4.50015-0; DOUCE R, 1974, SCIENCE, V183, P852, DOI 10.1126/science.183.4127.852; DOUCE R, 1973, J BIOL CHEM, V248, P7215; Douce R., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P321; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; DOUCE R, 1990, METHODS PLANT BIOCH, V4, P71; ESKO JD, 1983, ENZYMES, V16, P207; FRENTZEN M, 1986, J PLANT PHYSIOL, V124, P193, DOI 10.1016/S0176-1617(86)80034-7; GARDINER SE, 1984, BIOCHEM J, V224, P637, DOI 10.1042/bj2240637; GARDINER SE, 1983, BIOCHEM J, V210, P949, DOI 10.1042/bj2100949; HAAS R, 1980, PLANTA, V148, P238, DOI 10.1007/BF00380033; HAJRA AK, 1974, LIPIDS, V9, P502, DOI 10.1007/BF02532495; Harwood J.L., 1984, LIPIDS PLANTS MICROB; HEEMSKERK JWM, 1988, PLANT PHYSIOL, V86, P971, DOI 10.1104/pp.86.3.971; Heinz E., 1977, Lipids and lipid polymers in higher plants., P102; HEINZ E, 1983, PLANT PHYSIOL, V72, P273, DOI 10.1104/pp.72.2.273; ICHIHARA K, 1984, ARCH BIOCHEM BIOPHYS, V232, P685, DOI 10.1016/0003-9861(84)90589-7; ICHIHARA K, 1991, PLANTA, V183, P353, DOI 10.1007/BF00197733; JOYARD J, 1991, EUR J BIOCHEM, V199, P489, DOI 10.1111/j.1432-1033.1991.tb16148.x; JOYARD J, 1977, BIOCHIM BIOPHYS ACTA, V486, P273, DOI 10.1016/0005-2760(77)90023-6; JOYARD J, 1986, BIOCHIM BIOPHYS ACTA, V879, P78, DOI 10.1016/0005-2760(86)90269-9; JOYARD J, 1979, FEBS LETT, V102, P147, DOI 10.1016/0014-5793(79)80947-3; JOYARD J, 1979, THESIS U GRENOBLE; KLEPPINGERSPARACE KF, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P77; KLEPPINGERSPARACE KF, 1985, ARCH BIOCHEM BIOPHYS, V240, P859, DOI 10.1016/0003-9861(85)90096-7; KOSMAC U, 1985, PLANT PHYSIOL, V79, P6466; LIN YP, 1989, J BIOL CHEM, V264, P8641; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARECHAL E, 1991, CR ACAD SCI III-VIE, V313, P521; MARTIN BA, 1984, LIPIDS, V19, P117, DOI 10.1007/BF02534501; MOLLER F, 1977, BIOCHIM BIOPHYS ACTA, V486, P359, DOI 10.1016/0005-2760(77)90032-7; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; MUDD JB, 1987, METHOD ENZYMOL, V148, P338; ROUGHAN PG, 1980, BIOCHEM J, V188, P17, DOI 10.1042/bj1880017; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; SAKAKI T, 1990, PLANT PHYSIOL, V94, P773, DOI 10.1104/pp.94.2.773; SEIFERT U, 1992, BOT ACTA, V105, P197, DOI 10.1111/j.1438-8677.1992.tb00287.x; Stymne S., 1987, Biochemistry of Plants, V9, P175; STYMNE S, 1983, BIOCHIM BIOPHYS ACTA, V752, P198, DOI 10.1016/0005-2760(83)90113-3; TEUCHER T, 1991, PLANTA, V184, P319, DOI 10.1007/BF00195332; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; WALSH JP, 1986, J BIOL CHEM, V261, P6239	60	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23546	23553						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429699				2022-12-27	WOS:A1992JZ23900022
J	WHITE, TC; HARRIS, GS; ORMEJOHNSON, WH				WHITE, TC; HARRIS, GS; ORMEJOHNSON, WH			ELECTROPHORETIC STUDIES ON THE ASSEMBLY OF THE NITROGENASE MOLYBDENUM-IRON PROTEIN FROM THE KLEBSIELLA-PNEUMONIAE NIFD AND NIFK GENE-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOFE PROTEIN; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; COMPLEMENTATION ANALYSIS; COFACTOR FEMOCO; FIXATION GENES; DEAE-CELLULOSE; CLUSTER; MUTANTS; PURIFICATION	The electrophoretic properties of the molybdenum-iron (MoFe) protein component of nitrogenase and an iron-molybdenum cofactor (FeMoco)-reactivatable apoMoFe protein from Klebsiella pneumoniae were examined under anaerobic ([O2] < 5 ppm), nondenaturing conditions. In wild type K. pneumoniae extracts, two immunoreactive species migrating more slowly than purified MoFe protein were detected using antiMoFe protein antibodies. The uppermost species co-migrates with the apoMoFe protein produced by a K. pneumoniae mutant unable to synthesize FeMoco (UN106) and by Escherichia coli harboring the plasmids pVL222+pVL15 (nifHDKTYUSWZM+A). In vitro FeMoco titration of the UN106 and pVL222+ pVL15 extracts increases the electrophoretic mobility of the apoMoFe protein to that of purified MoFe protein in a two-step process giving rise to a species of intermediate mobility between the apo- and holoMoFe proteins. Two-dimensional gel electrophoresis showed that a 20-kDa peptide is associated with the apoMoFe protein and with the intermediate species, but not with the holoMoFe protein. N-terminal sequencing identified this associated peptide as the nifY gene product, which we propose is acting as a temporary enforcer of the apoMoFe protein structure required for cofactor binding that is released upon FeMoco activation. This FeMoco-induced mobility shift was used to characterize the mutant apoMoFe proteins produced in E. coli as a result of deleting the various nitrogen fixation (nif) genes from the plasmid pVL222. E. coli extracts bearing plasmids deleted in nifH, nifS, nifTYUM, or nifWZM exhibit less than 10% of the apoMoFe protein activity of derepressed UN106 and contain an immunoreactive species whose electrophoretic mobility is increased upon addition of FeMoco from that of apoMoFe protein to that of holoMoFe protein in a single step. Anaerobic nondenaturing gel electrophoresis of Fe-55-labeled E. coli extracts followed by autoradiography showed that these inactive apoMoFe species do not contain iron, indicating that the P-clusters are absent. We therefore propose that NifH, S, U, W, Z, and M are all involved, to varying degrees, in P-cluster assembly. In addition, the presence of the P-clusters does appear to be necessary for the two-step FeMoco activation of the apoMoFe protein to occur.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM30943] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD W, 1988, J MOL BIOL, V203, P715, DOI 10.1016/0022-2836(88)90205-7; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRILL WJ, 1974, ANAL BIOCHEM, V60, P237, DOI 10.1016/0003-2697(74)90149-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DIXON R, 1977, MOL GEN GENET, V157, P189, DOI 10.1007/BF00267397; Eady R. R., 1980, Methods for evaluating biological nitrogen fixation., P213; Fazekas de St Groth S., 1963, BIOCHIM BIOPHYS ACTA, V71, P377; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; HARRIS GS, 1990, J BIOL CHEM, V265, P15909; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HAWKES TR, 1984, BIOCHEM J, V223, P783, DOI 10.1042/bj2230783; HOLLAND D, 1987, J BIOL CHEM, V262, P8814; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD KS, 1986, J BIOL CHEM, V261, P772; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1986, J BACTERIOL, V167, P480, DOI 10.1128/jb.167.2.480-486.1986; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKENNA CE, 1977, ANAL BIOCHEM, V82, P337; MCLEAN PA, 1987, J BIOL CHEM, V262, P12900; MCLEAN PA, 1989, BIOCHEMISTRY-US, V28, P9402, DOI 10.1021/bi00450a023; MEIRER W, 1963, HELV CHIM ACTA, V216, P1929; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; ORMEJOHNSON WH, 1980, CURRENT PERSPECTIVES, P79; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Puhler A., 1981, Bothe, H.; Trebst, A. : Biology of inorganic nitrogen and sulfur., P276; ROBERTS GP, 1978, J BACTERIOL, V136, P267, DOI 10.1128/JB.136.1.267-279.1978; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1978, BIOCHEM BIOPH RES CO, V81, P232, DOI 10.1016/0006-291X(78)91654-6; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; Smith B. E., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P91; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALMSLEY J, 1990, NITROGEN FIXATION AC, P599; WINK DA, 1989, BIOCHEMISTRY-US, V28, P9407, DOI 10.1021/bi00450a024	45	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24007	24016						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429737				2022-12-27	WOS:A1992JZ23900086
J	IKEDASAITO, M; HORI, H; ANDERSSON, LA; PRINCE, RC; PICKERING, IJ; GEORGE, GN; SANDERS, CR; LUTZ, RS; MCKELVEY, EJ; MATTERA, R				IKEDASAITO, M; HORI, H; ANDERSSON, LA; PRINCE, RC; PICKERING, IJ; GEORGE, GN; SANDERS, CR; LUTZ, RS; MCKELVEY, EJ; MATTERA, R			COORDINATION STRUCTURE OF THE FERRIC HEME IRON IN ENGINEERED DISTAL HISTIDINE MYOGLOBIN MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; MAGNETIC CIRCULAR-DICHROISM; SPERM WHALE MYOGLOBIN; LIGAND-BINDING; ESCHERICHIA-COLI; HORSERADISH-PEROXIDASE; APLYSIA MYOGLOBIN; CRYSTAL-STRUCTURE; ANIONIC LIGANDS; SPIN	Recombinant human myoglobin mutants with the distal His residue (E7, His64) replaced by Leu, Val, or Gln residues were prepared by site-directed mutagenesis and expression in Escherichia coli. Electronic and coordination structures of the ferric heme iron in the recombinant myoglobin proteins were examined by optical absorption, EPR, H-1 NMR, magnetic circular dichroism, and x-ray spectroscopy. Mutations, His --> Val and His --> Leu, remove the heme-bound water molecule resulting in a five-coordinate heme iron at neutral pH, while the heme-bound water molecule appears to be retained in the engineered myoglobin with His --> Gln substitution as in the wild-type protein. The distal Val and distal Leu ferric myoglobin mutants at neutral pH exhibited EPR spectra with g(perpendicular-to) values smaller than 6, which could be interpreted as an admixture of intermediate (S = 3/2) and high (S = 5/2) spin states. At alkaline pH, the distal Gln mutant is in the same so-called "hydroxy low spin' form as the wild-type protein, while the distal Leu and distal Val mutants are in high spin states. The ligand binding properties of these recombinant myoglobin proteins were studied by measurements of azide equilibrium and cyanide binding. The distal Leu and distal Val mutants exhibited diminished azide affinity and extremely slow cyanide binding, while the distal Gln mutant showed azide affinity and cyanide association rate constants similar to those of the wild-type protein.	OSAKA UNIV, FAC ENGN SCI, DEPT BIOPHYS ENGN, TOYONAKA, OSAKA 560, JAPAN; KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA; EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA	Osaka University; Kansas State University; Exxon Mobil Corporation	IKEDASAITO, M (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA.		Pickering, Ingrid J/A-4547-2013; Ikeda-Saito, Masao/A-5992-2008; George, Graham N/E-3290-2013; Ikeda-Saito, Masao/K-2703-2015	Pickering, Ingrid J/0000-0002-0936-2994; George, Graham/0000-0002-0420-7493	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039492, R01GM047485, R29GM047485, R01GM039359] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47485, GM39359, GM39492] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARENTS G, 1989, J MOL BIOL, V210, P149, DOI 10.1016/0022-2836(89)90297-0; BARTNICKI DE, 1983, J BIOL CHEM, V258, P1599; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BRACETE AM, 1991, BIOCHIM BIOPHYS ACTA, V1080, P264, DOI 10.1016/0167-4838(91)90012-O; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; DELEON JM, 1991, PHYS REV B, V44, P4146, DOI 10.1103/PhysRevB.44.4146; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; GEORGE GN, 1989, BIOCHEMISTRY-US, V28, P5075, DOI 10.1021/bi00438a026; GIACOMETTI GM, 1975, BIOCHEMISTRY-US, V14, P1584, DOI 10.1021/bi00679a006; GIACOMETTI GM, 1981, J MOL BIOL, V146, P363, DOI 10.1016/0022-2836(81)90393-4; HORI H, 1989, J BIOL CHEM, V264, P5715; HORI H, 1990, J BIOL CHEM, V265, P15028; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; Kotani M., 1968, ADV QUANTUM CHEM, V4, P227; KRISHNAMOORTHI R, 1984, J BIOL CHEM, V259, P265; LAMAR GN, 1990, J BIOL CHEM, V265, P16173; MALTEMPO MM, 1979, BIOCHEMISTRY-US, V18, P2935, DOI 10.1021/bi00581a003; MALTEMPO MM, 1974, J CHEM PHYS, V61, P2540, DOI 10.1063/1.1682376; MALTEMPO MM, 1974, BIOCHIM BIOPHYS ACTA, V342, P290, DOI 10.1016/0005-2795(74)90084-1; MINTOROVITCH J, 1988, BIOCHEMISTRY-US, V27, P8045, DOI 10.1021/bi00421a011; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NOZAWA T, 1976, BIOCHIM BIOPHYS ACTA, V427, P652, DOI 10.1016/0005-2795(76)90209-9; Palmer G., 1979, PORPHYRINS, P313; PEISACH J, 1971, J BIOL CHEM, V246, P3342; PEISACH J, 1984, J BIOL CHEM, V259, P2704; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; QUILLIN ML, 1992, BIOPHYS J, V61, pA446; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROTILLO G, 1971, BIOCHIM BIOPHYS ACTA, V236, P234, DOI 10.1016/0005-2795(71)90170-X; Sambrook J, 1989, MOL CLONING LABORATO; SEAMONDS B, 1972, BIOCHIM BIOPHYS ACTA, V263, P507, DOI 10.1016/0005-2795(72)90032-3; SHIRO Y, 1990, J AM CHEM SOC, V112, P2921, DOI 10.1021/ja00164a012; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P772, DOI 10.1021/bi00217a029; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; VICKERY L, 1976, J AM CHEM SOC, V98, P343, DOI 10.1021/ja00418a005; VUKPAVLOVIC S, 1977, BIOCHEM BIOPH RES CO, V79, P885, DOI 10.1016/0006-291X(77)91193-7; WILLIAMSSMITH DL, 1977, BIOCHEM J, V167, P593, DOI 10.1042/bj1670593; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518; YOSHIMURA T, 1984, ARCH BIOCHEM BIOPHYS, V230, P466, DOI 10.1016/0003-9861(84)90427-2	52	147	149	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22843	22852						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429633				2022-12-27	WOS:A1992JY16300024
J	WU, JJ; WOODS, PE; EYRE, DR				WU, JJ; WOODS, PE; EYRE, DR			IDENTIFICATION OF CROSS-LINKING SITES IN BOVINE CARTILAGE TYPE-IX COLLAGEN REVEALS AN ANTIPARALLEL TYPE-II-TYPE-IX MOLECULAR RELATIONSHIP AND TYPE-IX TO TYPE-IX BONDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE CHAIN(S); DISULFIDE-BONDED COLLAGEN; ARTICULAR-CARTILAGE; PROTEOGLYCAN; CDNA; POLYPEPTIDE; ANTIBODIES; SEQUENCE; CLEAVAGE; PROTEINS	Type IX collagen functions in covalent cross-linkage to type II collagen in cartilage (Eyre, D. R., Apone, S., Wu, J. J., Ericsson, L. H., and Walsh, K. A. (1987) FEBS Lett. 220, 337-341). To understand this molecular relationship better, an analysis of all cross-linking sites labeled by [H-3]borohydride was undertaken using the protein prepared from fetal bovine cartilage. Sequence analysis of tryptic peptides containing the H-3-labeled cross-links showed that each of the chains of type IX collagen, alpha1(IX), alpha2(IX), and alpha3(IX), contained a site of cross-linking at the amino terminus of the COL2 triple-helix to which the alpha1(II)N-telopeptide could bond. The alpha3(IX)COL2 domain alone also had an attachment site for the alpha1(II)C-telopeptide. The distance between the alpha1(II)N-telopeptide and alpha1(II)C-telopeptide interaction sites, 137 residues, is equal to the length of the hole zone (0.6D) in a type II collagen fibril. This implies an antiparallel type II to type IX cross-linking relationship. Peptide analysis also revealed an unknown amino acid sequence linked to the COL2 cross-linking domains in both the alpha1(IX) and alpha3(IX) chains. Using antibodies to this novel peptide, its origin in the collagen alpha3(IX)NC1 domain was established. In summary, the results confirm extensive covalent cross-linking between type IX and type II collagen molecules and reveal the existence of type IX-type IX bonding. These data provide a molecular basis for the proposed function of type IX collagen as a critical contributor to the mechanical stability and resistance to swelling of the collagen type II fibril frame-work of cartilage.			WU, JJ (corresponding author), UNIV WASHINGTON,DEPT ORTHOPAED,ORTHOPAED RES LABS,RK-10,SEATTLE,WA 98195, USA.				NIAMS NIH HHS [R01 AR036794, AR36794, R37 AR037318] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036794, R37AR037318, R01AR036794] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN G, 1981, LABORATORY TECHNIQUE, P30; AYAD S, 1991, BIOCHEM J, V278, P441, DOI 10.1042/bj2780441; AYAD S, 1982, FEBS LETT, V139, P300, DOI 10.1016/0014-5793(82)80875-2; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; EYRE D R, 1990, P188; EYRE DR, 1991, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049-0172(91)90035-X; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1987, J RHEUMATOL, V14, P25; EYRE DR, 1973, BIOCHEM J, V135, P393, DOI 10.1042/bj1350393; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; EYRE DR, 1990, METHODS CARTILAGE RE, P28; HAREL R, 1992, J BIOL CHEM, V267, P10070; Hodge A, 1963, ASPECTS PROTEIN STRU, P289; HUBER S, 1986, J BIOL CHEM, V261, P5965; HUBER S, 1988, J BIOL CHEM, V263, P752; IRWIN MH, 1986, J BIOL CHEM, V261, P6281; KIMURA T, 1989, EUR J BIOCHEM, V179, P71, DOI 10.1111/j.1432-1033.1989.tb14522.x; KONOMI H, 1986, J BIOL CHEM, V261, P6742; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MCDEVITT CA, 1976, J BONE JOINT SURG BR, V58, P94, DOI 10.1302/0301-620X.58B1.131804; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NINOMIYA Y, 1985, BIOCHEMISTRY-US, V24, P4223, DOI 10.1021/bi00336a061; NINOMIYA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3014, DOI 10.1073/pnas.81.10.3014; NORO A, 1983, J BIOL CHEM, V258, P9323; REESE CA, 1981, BIOCHEMISTRY-US, V20, P5443, DOI 10.1021/bi00522a014; SHIMOKOMAKI M, 1981, BIOSCIENCE REP, V1, P561, DOI 10.1007/BF01116305; SHIMOKOMAKI M, 1980, FEBS LETT, V121, P51, DOI 10.1016/0014-5793(80)81265-8; SHIMOKOMAKI M, 1990, ANN NY ACAD SCI, V580, P1, DOI 10.1111/j.1749-6632.1990.tb17912.x; STOCKWELL RA, 1983, J ANAT, V136, P425; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1985, J BIOL CHEM, V260, P220; VAUGHAN L, 1985, J BIOL CHEM, V260, P4758; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VONDERMARK K, 1982, EUR J BIOCHEM, V124, P57; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041; WU JJ, 1991, J BIOL CHEM, V266, P5625; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5	41	211	216	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23007	23014						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429648				2022-12-27	WOS:A1992JY16300048
J	DEKA, RK; KLEANTHOUS, C; COGGINS, JR				DEKA, RK; KLEANTHOUS, C; COGGINS, JR			IDENTIFICATION OF THE ESSENTIAL HISTIDINE RESIDUE AT THE ACTIVE-SITE OF ESCHERICHIA-COLI DEHYDROQUINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIKIMATE PATHWAY ENZYME; CHEMICAL MODIFICATION; 3-DEHYDROQUINASE	The shikimate pathway enzyme 3-dehydroquinase is very susceptible to inactivation by the group-specific reagent diethyl pyrocarbonate (DEP). Inactivation follows pseudo first-order kinetics and exhibits a second-order rate constant of 148.5 M-1 min-1. An equilibrium mixture of substrate and product substantially protects against inactivation by DEP, suggesting that residues within the active site are being modified. Complete inactivation of the enzyme correlates with the modification of 6 histidine residues/subunit as determined by difference spectroscopy at 240 nm. Enzymic activity can be restored by hydroxylamine treatment, which is also consistent with the modification occurring at histidine residues. Using the kinetic method of Tsou (Tsou, C.-L. (1962) Sci. Sin. 11, 1535-1558), it was shown that modification of a single histidine residue leads to inactivation. Ligand protection experiments also indicated that 1 histidine residue was protected from DEP modification. pH studies show that the pK(a) for this inactivation is 6.18, which is identical to the single pK(a) determined from the pH/log V(max) profile for the enzyme. A single active site peptide was identified by differential peptide mapping in the presence and absence of ligand. This peptide was found to comprise residues 141-158; of the 2 histidines in this peptide (His-143 and His-146), only one, His-143, is conserved among all type I dehydroquinases. We propose that His-143 is the active site histidine responsible for DEP-mediated inactivation of dehydroquinase and is a good candidate for the general base that has been postulated to participate in the mechanism of this enzyme.	UNIV GLASGOW, DEPT BIOCHEM, GLASGOW G12 8QQ, SCOTLAND; UNIV E ANGLIA, SCH BIOL SCI, MOLEC & MICROBIOL SECTOR, NORWICH NR4 7TJ, NORFOLK, ENGLAND	University of Glasgow; University of East Anglia								BADETDENISOT MA, 1992, ARCH BIOCHEM BIOPHYS, V292, P475, DOI 10.1016/0003-9861(92)90018-R; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BUTLER JR, 1974, J AM CHEM SOC, V96, P1617, DOI 10.1021/ja00812a069; CHAUDHURI S, 1991, BIOCHEM J, V275, P1; CHAUDHURI S, 1986, BIOCHEM J, V239, P699, DOI 10.1042/bj2390699; CHURCH FC, 1985, J BIOL CHEM, V260, P4936; COGGINS JR, 1989, SOC EXP BIOL SEM SER, V38, P97; DUNCAN K, 1986, BIOCHEM J, V238, P475, DOI 10.1042/bj2380475; GREWE R, 1968, BIOCH PREP, V12, P21; HANSON KR, 1963, P NATL ACAD SCI USA, V50, P981, DOI 10.1073/pnas.50.5.981; Haslam E., 1974, SHIKIMATE PATHWAY; HOLBROOK JJ, 1973, BIOCHEM J, V131, P729, DOI 10.1042/bj1310729; HORIIKE K, 1979, J THEOR BIOL, V79, P403, DOI 10.1016/0022-5193(79)90355-2; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10929; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10935; KLEANTHOUS C, 1992, BIOCHEM J, V282, P687, DOI 10.1042/bj2820687; KLEANTHOUS C, 1991, J BIOL CHEM, V266, P10893; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; Miles E W, 1977, Methods Enzymol, V47, P431; MITSUHASHI S, 1954, BIOCHIM BIOPHYS ACTA, V15, P54; OVADI J, 1967, Acta Biochimica et Biophysica Academiae Scientiarum Hungaricae, V2, P455; SERVOS S, 1991, J GEN MICROBIOL, V137, P147, DOI 10.1099/00221287-137-1-147; SHNEIER A, 1991, J AM CHEM SOC, V96, P175; TAKEUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1571, DOI 10.1093/oxfordjournals.jbchem.a135630; TSOU C, 1962, SCI SINICA, V11, P1535; VANGRYSPERRE W, 1989, BIOCHEM J, V263, P195, DOI 10.1042/bj2630195; WALSH CT, 1979, ENZYMATIC REACTION M; WEISS U, 1980, BIOSYNTHESIS AROMATI; WELLS MA, 1973, BIOCHEMISTRY-US, V12, P1086, DOI 10.1021/bi00730a011	29	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22237	22242						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429576				2022-12-27	WOS:A1992JW71900040
J	EICHHOLTZ, T; VOSSEBELD, P; VANOVERVELD, M; PLOEGH, H				EICHHOLTZ, T; VOSSEBELD, P; VANOVERVELD, M; PLOEGH, H			ACTIVATION OF PROTEIN-KINASE-C ACCELERATES INTERNALIZATION OF TRANSFERRIN RECEPTOR BUT NOT OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I, INDEPENDENT OF THEIR PHOSPHORYLATION STATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL-MYRISTATE ACETATE; CELL-SURFACE EXPRESSION; MHC CLASS-II; CYTOPLASMIC DOMAIN; STRUCTURAL FEATURES; T-CELLS; ENDOCYTOSIS; ANTIGENS; MOLECULES; HLA	Phosphorylation of membrane glycoproteins has often been invoked as a determinant of receptor internalization and receptor trafficking in a more general sense. Here we have studied the trafficking of major histocompatibility complex (MHC) Class I molecules and transferrin receptor (Tfr) related to their phosphorylation status in the human lymphoblastoid cell line JY. High resolution isoelectric focusing (IEF) allows the visualization of phosphorylated and non-phosphorylated protein species simultaneously, using protein backbone-labeling. Analysis on IEF was combined with a neuraminidase protection assay, in which sialic acid modification of the N-linked glycans present on Tfr and Class I molecules is used as a reporter group for cell surface expression. Phosphorylation of Class I heavy chains and Tfr was induced by exposure of cells to the phorbol ester tetradecanoyl phorbol acetate. We show that 1) phosphorylation of MHC Class I molecules is restricted to the cell surface fraction, 2) phosphorylation of MHC Class I molecules by protein kinase C (PKC) is not correlated with their internalization, as no internalization of Class I molecules, phosphorylated or non-phosphorylated, could be detected, 3) the initial rate, but not the final extent of the internalization of Tfr is affected by activation of PKC, and 4) phosphorylated Tfr behaves in a manner identical to nonphosphorylated Tfr in terms of internalization. The effect of activation of PKC on internalization of Tfr therefore most likely takes place at the level of the internalization machinery. Our data concerning the internalization of MHC Class I molecules contrast with earlier studies describing constitutive internalization in the B lymphoblastoid cell line A 46 and in HPB-ALL cells.	NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								ACRES RB, 1987, J IMMUNOL, V139, P2268; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BOYER C, 1989, J IMMUNOL, V143, P1905; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DASGUPTA JD, 1988, J IMMUNOL, V141, P2577; DAVIS JE, 1990, J IMMUNOL, V144, P990; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FALLON RJ, 1986, J BIOL CHEM, V261, P5081; FEUERSTEIN N, 1985, BIOCHEM BIOPH RES CO, V126, P206, DOI 10.1016/0006-291X(85)90592-3; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GUILD BC, 1984, J BIOL CHEM, V259, P9235; HOXIE JA, 1986, J IMMUNOL, V137, P1194; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LIPPE R, 1991, J EXP MED, V174, P1159, DOI 10.1084/jem.174.5.1159; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOUBE SR, 1983, BIOCHEM J, V210, P79, DOI 10.1042/bj2100079; MAY WS, 1984, P NATL ACAD SCI-BIOL, V81, P2016, DOI 10.1073/pnas.81.7.2016; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; MOLDERS HH, 1982, HUM IMMUNOL, V6, P111; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; PARHAM P, 1979, J IMMUNOL, V123, P342; PHILLIPS DR, 1970, BIOCHEM BIOPH RES CO, V40, P284, DOI 10.1016/0006-291X(70)91007-7; POBER JS, 1978, P NATL ACAD SCI USA, V75, P6002, DOI 10.1073/pnas.75.12.6002; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TSE DB, 1984, J EXP MED, V159, P193, DOI 10.1084/jem.159.1.193; VANDERIJN M, 1983, CYTOGENET CELL GENET, V36, P525, DOI 10.1159/000131967; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	44	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22490	22495						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429599				2022-12-27	WOS:A1992JW71900079
J	FEURLE, GE; HAMSCHER, G; KUSIEK, R; MEYER, HE; METZGER, JW				FEURLE, GE; HAMSCHER, G; KUSIEK, R; MEYER, HE; METZGER, JW			IDENTIFICATION OF XENIN, A XENOPSIN-RELATED PEPTIDE, IN THE HUMAN GASTRIC-MUCOSA AND ITS EFFECT ON EXOCRINE PANCREATIC-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT STOMACH; NEUROTENSIN; LOCALIZATION; INTESTINE; SEQUENCE; MAMMALS; CELLS	One of the peptides previously discovered in amphibians is the octapeptide xenopsin. As immunohistochemistry has also indicated the presence of xenopsin immunoreactivity in man, we extracted in the present investigation xenopsin-immunoreactive material from human gastric mucosa and purified it to homogeneity with several high performance liquid chromatography (HPLC) reverse phase and ion exchange chromatographic steps. The eluates were monitored with a radioimmunoassay for amphibian xenopsin. Determination of the amino acid sequence revealed a 25-amino acid peptide having 6 C-terminal amino acids in common with amphibian xenopsin. The sequence of this peptide, termed xenin 25, is M-L-T-K-F-E-T-K-S-A-R-V-K-G-L-S-F-H-P-K-R-P-W-I-L. The peptide was custom-synthesized. Mass spectrometry of the synthetic and the extracted peptide revealed identical molecular mass. Purification of 250 ml of human post-prandial plasma with Sep-Pak C18 cartridges, reverse phase HPLC, and ion exchange chromatography demonstrated circulating xenin immunoreactivity at a retention time identical to xenin 25. The amount of xenin immunoreactivity at the position of xenin 25 on C18-HPLC increased significantly after a meal. A radioimmunoassay utilizing antibodies to xenin 25 and a I-125-labeled analogue of xenin 25 was used to measure immunoreactive xenin in the plasma of 10 volunteers. There was a significant rise of xenin immunoreactivity in the plasma after a meal. Intravenous infusion of the synthetic peptide in dogs stimulated exocrine pancreatic secretion beginning at a dose of 4 pmol/kg/min. The maximal effect was seen with 64 pmol/kg/min. We have detected, therefore, a new peptide, xenin 25, in human gastric mucosa; we have provided evidence for the presence of this peptide in the human circulation, and have shown a rise of plasma xenin concentrations after a meal. This peptide stimulates exocrine pancreatic secretion. Its physiologic role deserves further investigation.	UNIV BONN,MED KLIN,W-5300 BONN,GERMANY; RUHR UNIV BOCHUM,INST PHYSIOL CHEM,W-4630 BOCHUM,GERMANY; UNIV TUBINGEN,INST ORGAN CHEM,W-7400 TUBINGEN 1,GERMANY	University of Bonn; Ruhr University Bochum; Eberhard Karls University of Tubingen	FEURLE, GE (corresponding author), STADTKRANKENHAUS NEUWIED,W-5450 NEUWIED,GERMANY.		Hamscher, Gerd/B-2100-2012					ARAKI K, 1975, CHEM PHARM BULL, V23, P3132; BACA I, 1982, DIGESTION, V23, P174, DOI 10.1159/000198725; BENARI G, 1969, ANN SURG, V170, P747, DOI 10.1097/00000658-196911000-00005; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CARRAWAY R, 1978, J BIOL CHEM, V253, P7996; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; CARRAWAY RE, 1985, J BIOL CHEM, V260, P921; CARRAWAY RE, 1990, PEPTIDES, V11, P747, DOI 10.1016/0196-9781(90)90190-G; CARRAWAY RE, 1990, REGUL PEPTIDES, V29, P229, DOI 10.1016/0167-0115(90)90085-B; CARRAWAY RE, 1988, REGUL PEPTIDES, V22, P303, DOI 10.1016/0167-0115(88)90107-3; FEURLE GE, 1985, J CLIN INVEST, V76, P156, DOI 10.1172/JCI111940; FEURLE GE, 1982, EXPERIENTIA, V38, P679, DOI 10.1007/BF01964091; HELMSTAEDTER V, 1977, HISTOCHEMISTRY, V53, P35, DOI 10.1007/BF00511208; MINAMINO N, 1984, BIOCHEM BIOPH RES CO, V122, P542, DOI 10.1016/S0006-291X(84)80067-4; RIX EW, 1986, HISTOCHEMISTRY, V85, P135, DOI 10.1007/BF00491760; WOOD FT, 1975, ANAL BIOCHEM, V69, P339, DOI 10.1016/0003-2697(75)90136-0	16	77	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22305	22309						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429581				2022-12-27	WOS:A1992JW71900050
J	MORIMOTO, RI; SARGE, KD; ABRAVAYA, K				MORIMOTO, RI; SARGE, KD; ABRAVAYA, K			TRANSCRIPTIONAL REGULATION OF HEAT-SHOCK GENES - A PARADIGM FOR INDUCIBLE GENOMIC RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN HSP70 PROMOTER; EMBRYONAL CARCINOMA-CELLS; ELEMENT-BINDING ACTIVITY; I-HYPERSENSITIVE SITES; MALE GERM LINE; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI	The heat shock response offers an ideal paradigm to understand how the cell recognizes and responds to acute and chronic exposures to environmental and physiological stress. Of the numerous inducible genomic responses, the heat shock response has contributed fascinating insights into the molecular and cellular mechanisms of adaptation, ranging from the regulation of heat shock gene expression to the function of stress proteins. The recent cloning of multiple heat shock transcription factor (HSF) genes in higher eukaryotes and studies on the biochemical and cellular properties of HSFs have revealed several novel features of the transcriptional response.			MORIMOTO, RI (corresponding author), NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,2153 SHERIDAN RD,EVANSTON,IL 60208, USA.				NIGMS NIH HHS [GM38109, GM47150] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047150, R37GM038109, R01GM038109] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ALLEN RL, 1988, MOL CELL BIOL, V8, P828, DOI 10.1128/MCB.8.2.828; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BANERJI SS, 1987, GENE DEV, V1, P946, DOI 10.1101/gad.1.9.946; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BARNIER JV, 1987, EXP CELL RES, V170, P186, DOI 10.1016/0014-4827(87)90128-5; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BENSAUDE O, 1983, NATURE, V305, P331, DOI 10.1038/305331a0; BENSAUDE O, 1983, EMBO J, V2, P173, DOI 10.1002/j.1460-2075.1983.tb01401.x; BOORSTEIN WR, 1990, MOL CELL BIOL, V10, P3262, DOI 10.1128/MCB.10.6.3262; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16991; BURCH JBE, 1984, NUCLEIC ACIDS RES, V12, P1117, DOI 10.1093/nar/12.2.1117; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COSTLOW N, 1984, MOL CELL BIOL, V4, P1853, DOI 10.1128/MCB.4.9.1853; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; CRAIG EA, 1990, STRESS PROTEINS BIOL, P279; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; FASHENA SJ, 1990, J IMMUNOL, V145, P177; FERRIS DK, 1988, P NATL ACAD SCI USA, V85, P3850, DOI 10.1073/pnas.85.11.3850; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDENBERG CJ, 1988, J BIOL CHEM, V263, P19734; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HIROMI Y, 1985, EMBO J, V4, P1681, DOI 10.1002/j.1460-2075.1985.tb03837.x; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KEENE MA, 1981, P NATL ACAD SCI-BIOL, V78, P143, DOI 10.1073/pnas.78.1.143; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KRAWCZYK Z, 1987, MOL BIOL REP, V12, P27, DOI 10.1007/BF00580647; KROES RA, 1991, P NATL ACAD SCI USA, V88, P4825, DOI 10.1073/pnas.88.11.4825; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; LUPTON SD, 1990, J IMMUNOL, V9, P3592; MEZGER V, 1989, MOL CELL BIOL, V9, P3888, DOI 10.1128/MCB.9.9.3888; MEZGER V, 1991, HEAT SHOCK DEV, P153; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORAN LA, 1982, CAN J BIOCHEM CELL B, V51, P488; MORANGE M, 1984, MOL CELL BIOL, V4, P730, DOI 10.1128/MCB.4.4.730; MORGAN WD, 1989, MOL CELL BIOL, V9, P4099, DOI 10.1128/MCB.9.9.4099; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; MORIMOTO R I, 1992, Current Opinion in Cell Biology, V4, P480, DOI 10.1016/0955-0674(92)90015-5; MORIMOTO RI, 1986, J BIOL CHEM, V261, P2692; MORIMOTO RI, 1990, STRESS PROTEINS BIOL, P323; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUES GI, 1986, J BIOL CHEM, V261, P874; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; NOVER L, 1990, HEAT SHOCK RESPONSE; OKAMOTO H, 1986, EMBO J, V5, P589, DOI 10.1002/j.1460-2075.1986.tb04251.x; Pardue M. L., 1989, UCLA S MOL CELL BIOL, V96; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PARKERTHORNBURG J, 1987, CELL, V51, P763, DOI 10.1016/0092-8674(87)90099-7; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PHILLIPS B, 1991, HEAT SHOCK DEV, P167; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; REBBE NF, 1989, J BIOL CHEM, V264, P15006; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHLESINGER M, 1990, STRESS PROTEINS INDU; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6910; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SIMCOX AA, 1985, MOL CELL BIOL, V5, P3397, DOI 10.1128/MCB.5.12.3397; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SOLOMON JM, 1991, NEW BIOL, V3, P1106; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P176, DOI 10.1128/MCB.10.1.176; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; TING LP, 1989, J BIOL CHEM, V264, P3404; VOELLMY R, 1985, P NATL ACAD SCI USA, V82, P4949, DOI 10.1073/pnas.82.15.4949; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; ZAKERI ZF, 1988, MOL CELL BIOL, V8, P2925, DOI 10.1128/MCB.8.7.2925; ZAKERI ZF, 1987, MOL CELL BIOL, V7, P1791, DOI 10.1128/MCB.7.5.1791; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	120	400	413	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					21987	21990						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429548				2022-12-27	WOS:A1992JW71900001
J	SCOTT, DL; ACHARI, A; VIDAL, JC; SIGLER, PB				SCOTT, DL; ACHARI, A; VIDAL, JC; SIGLER, PB			CRYSTALLOGRAPHIC AND BIOCHEMICAL-STUDIES OF THE (INACTIVE) LYS-49 PHOSPHOLIPASE-A(2) FROM THE VENOM OF AGKISTRIDON-PISCIVORUS PISCIVORUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PORCINE PANCREATIC PHOSPHOLIPASE-A2; TRIMERESURUS-FLAVOVIRIDIS VENOM; RAT PLATELET PHOSPHOLIPASE-A2; TRANSITION-STATE ANALOG; BASIC PROTEIN-II; CRYSTAL-STRUCTURE; LYSINE-49 PHOSPHOLIPASE-A2; CROTALUS-ATROX; SNAKE-VENOM	Chemical, genetic, and structural studies have defined a critical role for Asp-49 in the calcium-mediated activation of extracellular phospholipases A2 (PLA2). In 1984, a new class of PLA2 was isolated in which this invariant aspartate was replaced with a lysine (Maragnore, J. M., Merutka, G., Cho, W., Welches, W., Kezdy, F. J., and Heinrikson, R. L. (1984) J. Biol. Chem. 259, 13839-13843; Maragnore, J. M., and Heinrikson, R. L. (1986) J. Biol. Chem. 261, 4797-4804). The enzymatic activity of Lys-49 PLA2s has been questioned based on biochemical, mutational, and structural studies (van den Bergh, C. J., Slotboom, A.J., Verheij, H. M., and de Haas, G. H. (1988) Eur. J. Biochem. 176, 353-357). In this paper, we describe the structures of two crystal forms of the Lys-49 PLA2 isolated from the venom of Agkistridon piscivorus piscivorus. The refined models, along with complementary biochemical analysis, clarify the structural basis for the enzymatic inactivity of Lys-49 proteins.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520	Yale University; Howard Hughes Medical Institute; Yale University	SCOTT, DL (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637, USA.				NIGMS NIH HHS [GM22324] Funding Source: Medline; NINDS NIH HHS [NS 26857-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABITA JP, 1972, EUR J BIOCHEM, V30, P37, DOI 10.1111/j.1432-1033.1972.tb02069.x; ACHARI A, 1987, COLD SPRING HARB SYM, V52, P441, DOI 10.1101/SQB.1987.052.01.051; BLUHM MM, 1958, PROC R SOC LON SER-A, V246, P369, DOI 10.1098/rspa.1958.0145; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; CONDREA E, 1989, TOXICON, V27, P705, DOI 10.1016/0041-0101(89)90036-6; DEHAAS GH, 1971, BIOCHIM BIOPHYS ACTA, V239, P252, DOI 10.1016/0005-2760(71)90171-8; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P105; DELORI PJ, 1973, BIOCHIMIE, V55, P1031, DOI 10.1016/S0300-9084(73)80442-0; Dennis EA, 1983, ENZYMES, P307; DESNUELLE P, 1955, B STE CHIM BIOL, V37, P287; DHILLON DS, 1987, BIOCHEM PHARMACOL, V36, P1723, DOI 10.1016/0006-2952(87)90059-1; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; DIJKSTRA BW, 1982, ACTA CRYSTALLOGR B, V38, P793, DOI 10.1107/S0567740882004099; DUPUREUR CM, 1990, J AM CHEM SOC, V112, P7074, DOI 10.1021/ja00175a060; FAURE G, 1988, BIOCHEMISTRY-US, V27, P730, DOI 10.1021/bi00402a036; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FISCHER J, 1989, BIOCHEMISTRY-US, V28, P5939; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLEER EAM, 1981, EUR J BIOCHEM, V113, P283, DOI 10.1111/j.1432-1033.1981.tb05064.x; FOHLMAN J, 1977, FEBS LETT, V84, P367, DOI 10.1016/0014-5793(77)80726-6; FORST S, 1986, BIOCHEMISTRY-US, V25, P8381, DOI 10.1021/bi00374a008; FRANCIS B, 1991, ARCH BIOCHEM BIOPHYS, V284, P352, DOI 10.1016/0003-9861(91)90307-5; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V104, P767, DOI 10.1093/oxfordjournals.jbchem.a122547; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; HOWARD NL, 1975, TOXICON, V13, P21, DOI 10.1016/0041-0101(75)90154-3; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V905, P1, DOI 10.1016/0005-2736(87)90002-2; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRIZAJ I, 1989, BIOCHIM BIOPHYS ACTA, V999, P198, DOI 10.1016/0167-4838(89)90218-5; KUIPERS OP, 1990, PROTEIN ENG, V4, P199, DOI 10.1093/protein/4.2.199; LIND P, 1980, EUR J BIOCHEM, V111, P403, DOI 10.1111/j.1432-1033.1980.tb04954.x; LIND P, 1982, EUR J BIOCHEM, V128, P71; LIU SY, 1990, J BIOCHEM, V107, P400, DOI 10.1093/oxfordjournals.jbchem.a123057; LUDESCHER RD, 1988, BIOCHEMISTRY-US, V27, P6618, DOI 10.1021/bi00417a061; MAIN P, 1978, MULTAN 78 PROGRAM MA; MANCHEVA I, 1987, BIOL CHEM H-S, V368, P343, DOI 10.1515/bchm3.1987.368.1.343; MANCHEVA I, 1984, HOPPESEYLERS Z PHYSL, V365, P865; MARAGANORE JM, 1985, BIOCHEM BIOPH RES CO, V131, P129, DOI 10.1016/0006-291X(85)91780-2; MARAGANORE JM, 1986, J BIOL CHEM, V261, P4797; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; MINTON SA, 1986, TOXICON, V24, P71, DOI 10.1016/0041-0101(86)90167-4; MORENO E, 1988, TOXICON, V26, P363, DOI 10.1016/0041-0101(88)90004-9; Nieuwenhuizen W, 1974, Methods Enzymol, V32, P147; NISHIDA S, 1985, TOXICON, V23, P87, DOI 10.1016/0041-0101(85)90112-6; ONO T, 1988, J BIOL CHEM, V263, P5732; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PIETERSON WA, 1974, BIOCHEMISTRY-US, V13, P1455, DOI 10.1021/bi00704a021; PIETERSON WA, 1974, BIOCHEMISTRY-US, V13, P1439, DOI 10.1021/bi00704a019; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; RANDOLPH A, 1982, J BIOL CHEM, V257, P2155; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; RITONJA A, 1985, BIOCHIM BIOPHYS ACTA, V828, P306, DOI 10.1016/0167-4838(85)90312-7; RITONJA A, 1986, BIOL CHEM H-S, V367, P919, DOI 10.1515/bchm3.1986.367.2.919; ROSENBERG P, 1985, TOXICON, V23, P545; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SCOTT DL, 1986, J BIOL CHEM, V261, P2337; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Stryer L, 1981, BIOCHEMISTRY-US, P629; TAKASAKI C, 1988, BIOCHEM J, V253, P869, DOI 10.1042/bj2530869; TANAKA S, 1986, J BIOCHEM-TOKYO, V99, P281, DOI 10.1093/oxfordjournals.jbchem.a135471; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; TSAI IH, 1981, TOXICON, V19, P141; VANDEENEN LLM, 1963, BIOCHIM BIOPHYS ACTA, V70, P538; VANDENBERGH CJ, 1989, J CELL BIOCHEM, V39, P379, DOI 10.1002/jcb.240390404; VERGER R, 1982, BIOCHEMISTRY-US, V21, P6883, DOI 10.1021/bi00269a040; Waite M, 1987, HDB LIPID RES, V5, P155; WELLS MA, 1973, BIOCHEMISTRY-US, V12, P1080, DOI 10.1021/bi00730a010; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; YANG C C, 1984, Snake, V16, P90; YOSHIZUMI K, 1990, TOXICON, V28, P43, DOI 10.1016/0041-0101(90)90005-R; YUAN W, 1988, J AM CHEM SOC, V110, P2665, DOI 10.1021/ja00216a059; Zahler P, 1981, Methods Enzymol, V71 Pt C, P690; 1989, PROTEIN NUCLEIC ACID	79	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22645	22657						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429612				2022-12-27	WOS:A1992JW71900101
J	ISHIDA, H; NOSHIRO, M; OKUDA, K; COON, MJ				ISHIDA, H; NOSHIRO, M; OKUDA, K; COON, MJ			PURIFICATION AND CHARACTERIZATION OF 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE 12-ALPHA-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE; POLYACRYLAMIDE GELS; LIVER-MICROSOMES; BILE-ACIDS; CYTOCHROME-P-450; PROTEINS; CHROMATOGRAPHY	The isoform of cytochrome P450 that catalyzes the 12alpha-hydroxylation of 7alpha-hydroxy-4-cholesten-3-one, an intermediate in the conversion of cholesterol to cholic acid, was purified to homogeneity from rabbit liver microsomes. The extent of purification in the various steps was judged by an assay involving high performance liquid chromatography. The purified enzyme showed a single band on SDS-polyacrylamide gel electrophoresis (M(r) = 50,000). The NH2-terminal amino acid sequence is as follows: Val-Leu-Trp-Gly-Leu-Leu-Gly-Ala-Leu-Leu-Met-Val-Met-Val-Gly-, which is different from that of any other P450s so far reported. The specific content of the enzyme was 13.3 nmol of cytochrome P450/mg of protein. Upon reconstitution with NADPH-cytochrome P450 reduetase and cytochrome b5, the P450 enzyme showed a high activity of 12alpha-hydroxylation with a turnover number of 36.6 min-1 at 37-degrees-C. The omission of either cytochrome P450 or NADPH-cytochrome P450 reductase resulted in complete loss of activity, and the omission of cytochrome b5 resulted in 40% loss of activity. Antibodies prepared from mouse inhibited the 12alpha-hydroxylase activity of rabbit liver microsomes about 90% and that of the rat liver microsomes 50%. The enzyme activity was not inhibited by other antibodies raised against other forms of P450 that catalyze different monooxygenation reactions toward xenobiotics or endogenous substrates. Anti-cytochrome b5 antibody inhibited the activity 40%, suggesting the functional role of this protein, and anti-reductase inhibited the activity almost completely. The microsomal enzyme activity was markedly elevated by starvation or streptozotocin administration to the animals. However, an immunoblotting experiment showed no correlation between the enzyme activity and the amount of protein, suggesting that post-translational modification may occur.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	ISHIDA, H (corresponding author), HIROSHIMA UNIV,SCH DENT,DEPT BIOCHEM,KASUMI 1-2-3,MINAMI KU,HIROSHIMA 734,JAPAN.				NIDDK NIH HHS [DK 10339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK010339, R37DK010339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNHARDSSON C, 1973, BIOCHEM BIOPH RES CO, V54, P1030, DOI 10.1016/0006-291X(73)90797-3; BERSEUS O, 1965, J BIOL CHEM, V240, P2396; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; Coon M J, 1978, Methods Enzymol, V52, P109; EINARSSO.K, 1968, EUR J BIOCHEM, V5, P101, DOI 10.1111/j.1432-1033.1968.tb00342.x; HANSSON R, 1980, J BIOL CHEM, V255, P1643; Haslewood G. A. D, 1967, BILE SALTS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURAKAMI K, 1982, J BIOL CHEM, V257, P8030; MURAKAMI K, 1981, BIOCHEM BIOPH RES CO, V100, P91, DOI 10.1016/S0006-291X(81)80067-8; NERVI FO, 1978, BIOCHIM BIOPHYS ACTA, V529, P212, DOI 10.1016/0005-2760(78)90064-4; NOSHIRO M, 1978, J BIOCHEM, V83, P61, DOI 10.1093/oxfordjournals.jbchem.a131913; NOSHIRO M, 1985, STEROIDS, V45, P539, DOI 10.1016/0039-128X(85)90018-2; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OGISHIMA T, 1987, J BIOL CHEM, V262, P7646; OGURA Y, 1986, BIOL CHEM H-S, V367, P1095, DOI 10.1515/bchm3.1986.367.2.1095; OKUDA K, 1980, MICROSOMES DRUG OXID, V2, P745; OKUDA K, 1982, MICROSOMES DRUG OXID, P313; OMURA T, 1964, J BIOL CHEM, V239, P2370; POMPON D, 1984, J BIOL CHEM, V259, P5377; SHAW R, 1979, J BIOL CHEM, V254, P7177; SHIMASUE A, 1974, HIROSHIMA J MED SCI, V23, P265; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	26	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21319	21323						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400444				2022-12-27	WOS:A1992JV01100012
J	EIDE, D; DAVISKAPLAN, S; JORDAN, I; SIPE, D; KAPLAN, J				EIDE, D; DAVISKAPLAN, S; JORDAN, I; SIPE, D; KAPLAN, J			REGULATION OF IRON UPTAKE IN SACCHAROMYCES-CEREVISIAE - THE FERRIREDUCTASE AND FE(II) TRANSPORTER ARE REGULATED INDEPENDENTLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE; LIVER	Iron is required for the growth of Saccharomyces cerevisiae. High concentrations of iron, however, are toxic, forcing this yeast to tightly regulate its concentration of intracellular free iron. We demonstrate that S. cerevisiae accumulates iron through the combined action of a plasma membrane ferrireductase and an Fe(II) transporter. This transporter is highly selective for Fe(II). Several other transition metals did not inhibit iron uptake when these metals were present at a concentration 100-fold higher than the K(m) (0.15 muM) for iron transport. Pt(II) inhibited ferrireductase activity but not the ability of cells to transport iron that was chemically reduced to Fe(II). Incubation of cells in a synthetic iron-limited media resulted in the induction of both ferrireductase and Fe(II) transporter activities. In complex media, Fe(II) transport activity was regulated in response to media iron concentration, while the activity of the ferrireductase was not. When stationary phase cells were inoculated into fresh media, ferrireductase activity increased independent of the iron content of the media; in contrast, transporter activity varied inversely with iron levels. These results demonstrate that the ferrireductase and Fe(II) transporter are separately regulated and that iron accumulation may be limited by changes in either activity.	UNIV UTAH,COLL MED,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL 0636] Funding Source: Medline; NIDDK NIH HHS [DK 30534, DK 20630] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020630, R37DK030534, R01DK030534] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIENFAIT HF, 1985, J BIOENERG BIOMEMBR, V17, P73, DOI 10.1007/BF00744199; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; ECKER DJ, 1983, J BACTERIOL, V155, P616, DOI 10.1128/JB.155.2.616-622.1983; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; FUHRMANN GF, 1968, BIOCHIM BIOPHYS ACTA, V163, P325, DOI 10.1016/0005-2736(68)90117-X; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; LESUISSE E, 1991, BIOCHEM J, V280, P575; LIEB WR, 1982, RED CELL MEMBRANES M, P135; LIN CM, 1990, J BIOL CHEM, V265, P9194; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; Sherman F., 1986, METHODS YEAST GENETI; SUN IL, 1987, J BIOL CHEM, V262, P15915; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; Wigglesworth J. M., 1980, IRON BIOCH MED, VII, P29; Winkelmann G, 1987, IRON TRANSPORT MICRO; WRIGHT TL, 1986, J BIOL CHEM, V261, P909	23	164	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20774	20781						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400393				2022-12-27	WOS:A1992JT97800042
J	GANGULY, C; MARTIN, B; BUBB, M; KORN, ED				GANGULY, C; MARTIN, B; BUBB, M; KORN, ED			LIMITED PROTEOLYSIS REVEALS A STRUCTURAL DIFFERENCE IN THE GLOBULAR HEAD DOMAINS OF DEPHOSPHORYLATED AND PHOSPHORYLATED ACANTHAMOEBA MYOSIN-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; TAIL; CONFORMATION; CHAIN; CASTELLANII; MOLECULES; SEQUENCE; ACTIN	Phosphorylation at three sites at the tip of the tail of myosin II from Acanthamoeba castellanii inactivates the actin-activated Mg2+-ATPase activity of filamentous myosin and the in vitro motility activity of both monomeric and filamentous myosin. To seek a structural explanation for these effects, we examined the susceptibilities of dephosphorylated and phosphorylated myosins II to endoproteinases. Endoproteinase Arg-C cleaved myosin II preferentially at two sites in the globular head, Lys-621 and Arg-638, producing an NH2-terminal fragment of about 67,000 Da and a COOH-terminal fragment of about 112,000 Da. Dephosphorylated monomers and filaments were cleaved about 3 times more rapidly than their phosphorylated counterparts principally because of a much greater rate of cleavage at Arg-638; the ratio of cleavage at Arg-638:Lys-621 was about 3 for dephosphorylated myosins and about 0.5 for phosphorylated myosins. These data demonstrate that phosphorylation at the tip of the tail of Acanthamoeba myosin II causes a conformational change in the globular head that contains the catalytic sites; therefore, this conformational change may be related to the different catalytic and motile activities of the dephosphorylated and phosphorylated enzymes.	NHLBI,CELL BIOL LAB,BLDG 3,RM B1-22,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ATKINSON MAL, 1987, J BIOL CHEM, V262, P15809; COLLINS JH, 1982, J BIOL CHEM, V257, P4529; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; GANGULY C, 1992, J BIOL CHEM, V267, P20900; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; KUZNICKI J, 1984, J BIOL CHEM, V259, P9308; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; POLLARD TD, 1978, J BIOL CHEM, V253, P4798; RAU D, 1992, IN PRESS J CELL BIOL; REDOWICZ MJ, 1992, IN PRESS J CELL BIOL; RIMM DL, 1989, J CELL BIOL, V108, P1783, DOI 10.1083/jcb.108.5.1783; SATHYAMOORTHY V, 1990, BIOCHEMISTRY-US, V29, P3793, DOI 10.1021/bi00467a028; SINARD JH, 1989, J CELL BIOL, V109, P1537, DOI 10.1083/jcb.109.4.1537; TOYASHIMA YY, 1987, NATURE, V328, P536; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151	18	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20905	20908						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400405				2022-12-27	WOS:A1992JT97800062
J	MONTGOMERY, MK; MCFALLNGAI, MJ				MONTGOMERY, MK; MCFALLNGAI, MJ			THE MUSCLE-DERIVED LENS OF A SQUID BIOLUMINESCENT ORGAN IS BIOCHEMICALLY CONVERGENT WITH THE OCULAR LENS - EVIDENCE FOR RECRUITMENT OF ALDEHYDE DEHYDROGENASE AS A PREDOMINANT STRUCTURAL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTOPUS LENS; HUMAN-LIVER; CRYSTALLINS; BACTERIAL; CEPHALOPODA; ENZYMES; PIG	Many of the structural proteins of ocular lenses, commonly referred to as crystallins, are identical to specific enzymes or the result of a recent gene duplication (Piatigorsky, J., and Wistow, G. (1991) Science 252, 1078-1079). One such enzyme, aldehyde dehydrogenase (ALDH), has been recruited as a lens crystallin in certain mammals (Wistow, G., and Kim, H. (1991) J. Mol. Evol. 32, 262-269) and cephalopods (Tomarev, S., Zinovieva, R., and Piatigorsky, J. (1991) J. Biol. Chem. 266, 24226-24231). We report here that a transparent tissue, derived from muscle but functioning as a lens in the light-emitting organ of a squid, Euprymna scolopes, shows striking biochemical convergence with the epidermally derived ocular lenses of some mammals and cephalopods. In the light organ lens of E. scolopes, an ALDH-like protein is the predominant molecular component. The typical muscle-specific proteins are replaced as the dominant species by a protein composed of 54-kDa subunits. This protein, which we designate as L-crystallin, constitutes approximately 70% of the total soluble protein of the light organ lens. The amino acid sequences of three peptides of L-crystallin (approximately 9% of the total protein) showed 54.5% sequence identity with human cytosolic ALDH. Using polyclonal antiserum made against L-crystallin, we found that it is present in low abundance in other tissues of the squid, including muscle and the ocular lens. This polyclonal antiserum also cross-reacted with the ALDH-like crystallins found in the ocular lenses of certain mammals and cephalopods. L-Crystallin showed no ALDH activity, which is similar to several other enzyme/crystallins, including ALDH/eta-crystallin (Wistow, G., and Kim, H. (1991) J. Mol. Evol. 32, 262-269). The characteristics of this muscle-derived lens are evidence that a common biochemical basis underlies transparency and that certain proteins may possess properties that promote their selection as lens structural proteins.			MONTGOMERY, MK (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,UNIV PK,LOS ANGELES,CA 90089, USA.				ORS NIH HHS [1-SIORR05554-01] Funding Source: Medline	ORS NIH HHS		AMBROZIAK W, 1989, BIOCHEMISTRY-US, V28, P5367, DOI 10.1021/bi00439a008; ARNOLD JM, 1967, J ULTRA MOL STRUCT R, V17, P527, DOI 10.1016/S0022-5320(67)80139-4; Bloemendal H., 1981, MOL CELLULAR BIOL EY; CHIOU SH, 1988, FEBS LETT, V241, P261, DOI 10.1016/0014-5793(88)81073-1; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; DEITRICH RA, 1966, BIOCHEM PHARMACOL, V15, P1911; GREENFIELD NJ, 1977, BIOCHIM BIOPHYS ACTA, V483, P35, DOI 10.1016/0005-2744(77)90005-5; GUAN KL, 1988, ALCOHOL CLIN EXP RES, V12, P713, DOI 10.1111/j.1530-0277.1988.tb00270.x; HEMPEL J, 1984, EUR J BIOCHEM, V141, P21, DOI 10.1111/j.1432-1033.1984.tb08150.x; HERRING PJ, 1981, J MAR BIOL ASSOC UK, V61, P901, DOI 10.1017/S0025315400023043; HOLMES RS, 1989, COMP BIOCHEM PHYS B, V93, P271, DOI 10.1016/0305-0491(89)90081-3; JOHANSSON J, 1988, EUR J BIOCHEM, V172, P527, DOI 10.1111/j.1432-1033.1988.tb13920.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEICHT W, 1978, EUR J BIOCHEM, V83, P189, DOI 10.1111/j.1432-1033.1978.tb12083.x; McFall-Ngai M., 1991, Biochemistry and Molecular Biology of Fishes, V1, P77; MCFALLNGAI M, 1990, BIOL BULL, V179, P332, DOI 10.2307/1542325; MCFALLNGAI MJ, 1991, SCIENCE, V254, P1491, DOI 10.1126/science.1962208; PACKARD A, 1972, BIOL REV, V47, P241, DOI 10.1111/j.1469-185X.1972.tb00975.x; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; RAMSEY AJ, 1989, COMP BIOCHEM PHYS B, V93, P77, DOI 10.1016/0305-0491(89)90219-8; RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313, DOI 10.3109/10520296009114754; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; TOMAREV SI, 1991, J BIOL CHEM, V266, P24226; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINER H, 1979, BIOCH PHARMACOLOGY E, V1, P107; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749	28	49	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20999	21003						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400415				2022-12-27	WOS:A1992JT97800077
J	OGASAWARA, Y; KUROKI, Y; AKINO, T				OGASAWARA, Y; KUROKI, Y; AKINO, T			PULMONARY SURFACTANT PROTEIN-D SPECIFICALLY BINDS TO PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; A SP-A; II CELLS; LUNG; SECRETION; PURIFICATION; SEQUENCE; AFFINITY; LIPIDS; CP4	Alveolar type II cells produce and secrete a complex mixture of lipids and proteins called pulmonary surfactant of which phospholipids are the major components. Surfactant proteins (SP) A, B, and C interact with phospholipids and are believed to play important roles in alveolar spaces. However, whether surfactant protein D (SP-D) interacts with phospholipids is unknown. In the present study, we examined whether SP-D binds to phospholipids and investigated phospholipid specificities of SP-D binding and the structural requirements of phospholipids for that binding using I-125-SP-D as a probe. I-125-SP-D bound exclusively to phosphatidylinositol (PI) in various phospholipids or a fraction containing phospholipids extracted from surfactant, which were developed on thin layer chromatography. I-125-SP-D also bound to PI coated on microtiter wells in a manner dependent upon the SP-D concentration. Unlabeled SP-D competed well with I-125-SP-D for PI binding and the antibody against SP-D abolished I-125-SP-D binding to PI. PI liposome also attenuated I-125-SP-D binding to the solid phase PI. Ca2+ is absolutely required for the binding of SP-D to PI. SP-D failed to bind to lyso-PI, fatty acids derived from PI digested with phospholipase A2, or diacylglycerol obtained after phospholipase C treatment of PI. SP-D bound to neither phosphatidylinositol 4-monophosphate nor phosphatidylinositol 4,5-diphosphate. We conclude that SP-D specifically binds to PI. This is the first report that demonstrates that SP-D interacts with surfactant phospholipids.	SAPPORO MED COLL,DEPT BIOCHEM,SOUTH 1,WEST 17,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Sapporo Medical University								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; FAUVEL J, 1987, FEBS LETT, V221, P397, DOI 10.1016/0014-5793(87)80963-8; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1985, FEBS LETT, V192, P79, DOI 10.1016/0014-5793(85)80047-8; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; KATES M, 1972, TECHNIQUES LIPIDOLOG, P249; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KUROKI Y, 1991, BIOCHIM BIOPHYS ACTA, V1086, P185, DOI 10.1016/0005-2760(91)90006-4; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OGASAWARA Y, 1991, BIOCHIM BIOPHYS ACTA, V1083, P252, DOI 10.1016/0005-2760(91)90079-W; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; TSAO FHC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P29, DOI 10.1016/0005-2760(90)90200-H; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888	36	98	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21244	21249						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400434				2022-12-27	WOS:A1992JT97800113
J	BASSILANA, M; ARKOWITZ, RA; WICKNER, W				BASSILANA, M; ARKOWITZ, RA; WICKNER, W			THE ROLE OF THE MATURE DOMAIN OF PROOMPA IN THE TRANSLOCATION ATPASE REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; PRECURSOR PROTEINS; TRIGGER FACTOR; M13 PROCOAT; CYTOPLASMIC MEMBRANE; SIGNAL PEPTIDASE; LEADER PEPTIDASE; COAT PROTEIN	The export of proOmpA, the precursor of outer membrane protein A from Escherichia coli, requires preprotein translocase, which is comprised of SecA, SecY/E, and acidic phospholipids. Previous studies of proOmpA translocation intermediates (Schiebel, E., Driessen, A. J. M., Hartl, F.-U., and Wickner, W. (1991) Cell 64, 927-939) suggested that the "slippage" of the translocating polypeptide chain and the high level of ATP hydrolysis, characteristic of the "translocation ATPase," were part of a futile cycle. To examine the role of the mature domain of proOmpA in its translocation-dependent ATP hydrolysis, we used chemical cleavage to generate NH2-terminal fragments of this preprotein. Each fragment contained the 21-residue leader region and either 53 or 228 residues of the mature domain (preproteins P74 and P249, respectively). As observed with full-length proOmpA, the translocation of each fragment requires ATP and both the SecA and SecY/E domains of translocase and is stimulated by the transmembrane proton electrochemical gradient. The apparent maximal velocities of P74 and proOmpA translocation are similar. While the translocation of P74 and of proOmpA show the same apparent K(m) for ATP, far less ATP is hydrolyzed during the translocation of P74. Thus, the mature carboxyl-terminal domain of proOmpA has a major role in supporting the translocation ATPase.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; CEA, DEPT BIOL CELLULAIRE & MOLEC, LAB J MAETZ, F-06230 Villefranche Sur Mer, FRANCE	University of California System; University of California Los Angeles; CEA	BASSILANA, M (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.		Bassilana, Martine/AAS-5814-2021; arkowitz, robert/ABC-1860-2021	arkowitz, robert/0000-0002-5216-5013; Bassilana, Martine/0000-0001-9965-567X				BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; COLLIER DN, 1990, J BACTERIOL, V172, P6875, DOI 10.1128/jb.172.12.6875-6884.1990; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; FREUDL R, 1989, J MOL BIOL, V205, P771, DOI 10.1016/0022-2836(89)90321-5; GELLER BL, 1989, J BIOL CHEM, V264, P16465; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; KATO M, 1992, J BIOL CHEM, V267, P413; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; KUHN A, 1987, EMBO J, V6, P501, DOI 10.1002/j.1460-2075.1987.tb04781.x; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUPERSZTOCH YM, 1990, J BACTERIOL, V172, P2427, DOI 10.1128/jb.172.5.2427-2432.1990; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEE JI, 1992, J BIOL CHEM, V267, P938; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YAMANE K, 1988, J BIOL CHEM, V263, P5368; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	44	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25246	25250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460025				2022-12-27	WOS:A1992KB60300052
J	LI, XY; YODER, BL; BURGERS, PMJ				LI, XY; YODER, BL; BURGERS, PMJ			A SACCHAROMYCES-CEREVISIAE DNA HELICASE ASSOCIATED WITH REPLICATION FACTOR-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; UNWINDING ACTIVITY; POLYMERASE-DELTA; BINDING-PROTEIN; CALF THYMUS; HELA-CELLS; PURIFICATION; COMPLEX	A novel DNA helicase has been isolated from Saccharomyces cerevisiae. This DNA helicase co-purified with replication factor C (RF-C) during chromatography on S-Sepharose, DEAE-silica gel high performance liquid chromatography (HPLC), Affi-Gel Blue-agarose, heparin-agarose, single-stranded DNA-cellulose, fast protein liquid chromatography MonoS, and hydroxyapatite HPLC. Surprisingly, the helicase could be separated from RF-C by sedimentation on a glycerol gradient in the presence of 200 mM NaCl. The helicase is probably a homodimer of a 60-kDa polypeptide, which by UV cross-linking has been shown to bind ATP. It has a single-stranded DNA-dependent ATPase activity, with a K(m) for ATP of 60 muM. The DNA helicase activity depends on the hydrolysis of NTP (dNTP), with ATP and dATP the most efficient cofactors, followed by CTP and dCTP. The DNA helicase has a 5' to 3' directionality and is only marginally stimulated by coating the single-stranded DNA with the yeast single-stranded DNA-binding protein RF-A.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,660 S EUCLID,BOX 8231,ST LOUIS,MO 63110	Washington University (WUSTL)			Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1975, PROTEINS, V1, P2; BAUER GA, 1988, J BIOL CHEM, V263, P917; BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHA TA, 1989, J BIOL CHEM, V264, P12220; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DAILEY L, 1990, MOL CELL BIOL, V10, P6225, DOI 10.1128/MCB.10.12.6225; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAROSH I, 1989, J BIOL CHEM, V264, P20532; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KORNBERG A, 1991, DNA REPLICATION, P355; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1992, BIOCHEMISTRY-US, V31, P3507, DOI 10.1021/bi00128a027; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RUNYON GT, 1983, IN PRESS BIOCHEMISTR; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SEO YS, 1991, J BIOL CHEM, V266, P13161; SIEGAL S, 1992, J BIOL CHEM, V267, P13629; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; THOMMES P, 1990, J BIOL CHEM, V265, P14347; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YANAGISAWA J, 1992, J BIOL CHEM, V267, P3644; YODER BL, 1991, J BIOL CHEM, V266, P22689; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	42	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25321	25327						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460028				2022-12-27	WOS:A1992KB60300063
J	KUMAR, KA; MUNIYAPPA, K				KUMAR, KA; MUNIYAPPA, K			USE OF STRUCTURE-DIRECTED DNA LIGANDS TO PROBE THE BINDING OF RECA PROTEIN TO NARROW AND WIDE GROOVES OF DNA AND ON ITS ABILITY TO PROMOTE HOMOLOGOUS PAIRING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LINEAR DUPLEX DNA; CLOSED CIRCULAR DNA; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; NUCLEOPROTEIN FILAMENTS; NUCLEOSOME CORES; DOUBLE-HELIX; EXCHANGE; MECHANISM	We have used circular dichroism and structure-directed drugs to identify the role of structural features, wide and narrow grooves in particular, required for the cooperative polymerization, recognition of homologous sequences, and the formation of joint molecules promoted by recA protein. The path of cooperative polymerization of recA protein was deduced by its ability to cause quantitative displacement of distamycin from the narrow groove of duplex DNA. By contrast, methyl green bound to the wide groove was retained by the nucleoprotein filaments comprised of recA protein-DNA. Further, the mode of binding of these ligands and recA protein to DNA was confirmed by DNaseI digestion. More importantly, the formation of joint molecules was prevented by distamycin in the narrow groove while methyl green in the wide groove had no adverse effect. Intriguingly, distamycin interfered with the production of coaggregates between nucleoprotein filaments of recA protein-M13 ssDNA and naked linear M13 duplex DNA, but not with linear phiX174 duplex DNA. Thus, these data, in conjunction with molecular modeling, suggest that the narrow grooves of duplex DNA provide the fundamental framework required for the cooperative polymerization of recA protein and alignment of homologous sequences. These findings and their significance are discussed in relation to models of homologous pairing between two intertwined DNA molecules.	INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								AGGARWAL AK, 1988, SCIENCE, V242, P99; ARNOTT S, 1974, J MOL BIOL, V88, P523, DOI 10.1016/0022-2836(74)90499-9; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; COTTERILL SM, 1983, BIOCHEMISTRY-US, V22, P3525, DOI 10.1021/bi00283a034; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; DASGUPTA D, 1987, BIOCHEMISTRY-US, V26, P6381, DOI 10.1021/bi00394a011; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; DOMBROSKI DF, 1983, NUCLEIC ACIDS RES, V11, P7487, DOI 10.1093/nar/11.21.7487; DREW HR, 1982, P NATL ACAD SCI-BIOL, V79, P4040, DOI 10.1073/pnas.79.13.4040; FEUGHELMAN M, 1955, NATURE, V175, P834, DOI 10.1038/175834a0; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; GRIFFITH J, 1988, CRC CRIT REV BIOCH, V23, pS53; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HUANG Y, 1991, J BIOL CHEM, V266, P17424; JAIN SK, 1992, J BIOL CHEM, V267, P4215; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MCGAVIN S, 1977, HEREDITY, V39, P15, DOI 10.1038/hdy.1977.39; MENDOZA R, 1990, BIOCHEMISTRY-US, V29, P5035, DOI 10.1021/bi00473a006; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; MUNIYAPPA K, 1991, BIOCHIMIE, V73, P187, DOI 10.1016/0300-9084(91)90201-B; MUNIYAPPA K, 1991, NUCLEIC ACIDS RES, V73, P187; NORDEN B, 1977, CHEM PHYS LETT, V50, P508, DOI 10.1016/0009-2614(77)80379-5; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAMDAS J, 1989, J BIOL CHEM, V264, P17395; RAMDAS J, 1991, P NATL ACAD SCI USA, V88, P1344, DOI 10.1073/pnas.88.4.1344; RAO BJ, 1990, J MOL BIOL, V213, P789, DOI 10.1016/S0022-2836(05)80264-5; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; ROULD E, 1992, J MOL BIOL, V226, P127, DOI 10.1016/0022-2836(92)90129-8; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; SUCK D, 1988, NATURE, V332, P465; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; Vinter J G, 1987, J Comput Aided Mol Des, V1, P31, DOI 10.1007/BF01680556; WILKINS MHF, 1956, COLD SPRING HARB SYM, V21, P75, DOI 10.1101/SQB.1956.021.01.007; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; YONESAKI T, 1988, MOL GEN GENET, V213, P548, DOI 10.1007/BF00339630; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	59	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24824	24832						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447220				2022-12-27	WOS:A1992KA26300100
J	KAKUDO, S; KIKUCHI, N; KITADOKORO, K; FUJIWARA, T; NAKAMURA, E; OKAMOTO, H; SHIN, M; TAMAKI, M; TERAOKA, H; TSUZUKI, H; YOSHIDA, N				KAKUDO, S; KIKUCHI, N; KITADOKORO, K; FUJIWARA, T; NAKAMURA, E; OKAMOTO, H; SHIN, M; TAMAKI, M; TERAOKA, H; TSUZUKI, H; YOSHIDA, N			PURIFICATION, CHARACTERIZATION, CLONING, AND EXPRESSION OF A GLUTAMIC ACID-SPECIFIC PROTEASE FROM BACILLUS-LICHENIFORMIS ATCC-14580	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; STREPTOMYCES-GRISEUS; NUCLEOTIDE-SEQUENCES; SECONDARY-STRUCTURE; TRYPSIN-INHIBITOR; ESCHERICHIA-COLI; BOVINE TRYPSIN; BINDING-SITE; DNA; RESOLUTION	A glutamic acid-specific protease has been purified to homogeneity from Bacillus licheniformis ATCC 14580 utilizing Phe-LeU-D-Glu-OMe-Sepharose affinity chromatography and crystallized. The molecular weight of the protease was estimated to be approximately 25,000 by SDS-polyacrylamide gel electrophoresis. This protease, which we propose to call BLase (glutamic acid-specific protease from B. licheniformis ATCC 14580), was characterized enzymatically. Using human parathyroid hormone (13-34) and p-nitroanilides of peptidyl glutamic acid and aspartic acid, we found a marked difference between BLase and V8 protease, EC 3.4.21.9, although both proteases showed higher reactivity for glutamyl bonds than for aspartyl bonds. Diisopropyl fluorophosphate and benzyloxycarbonyl Leu-Glu chloromethyl ketone completely inhibited BLase, whereas EDTA reversibly inactivated the enzyme. The findings clearly indicate that BLase can be classified as a serine protease. To elucidate the complete primary structure and precursor of BLase, its gene was cloned from the genomic DNA of B. licheniformis ATCC 14580, and the nucleotide sequence was determined. Taking the amino-terminal amino acid sequence of the purified BLase into consideration, the clones encode a mature peptide of 222 amino acids, which follows a prepropeptide of 94 residues. The recombinant BLase was expressed in Bacillus subtilis and purified to homogeneity. Its key physical and chemical characteristics were the same as those of the wild-type enzyme. BLase was confirmed to be a protease specific for glutamic acid, and the primary structure deduced from the cDNA sequence was found to be identical with that of a glutamic acid-specific endopeptidase isolated from Alcalase(TM) (Svendsen, I., and Breddam, K. (1992) Eur. J. Biochem. 204, 165-171), being different from VS protease and the Glu-specific protease of Streptomyces griseus which consist of 268 and 188 amino acids, respectively.	SHIONOGI & CO LTD,SHIONOGI RES LAB,5-12-4 SAGISU,FUKUSHIMA KU,OSAKA 553,JAPAN	Shionogi & Company Limited				Kitadokoro, Kengo/0000-0001-5969-7939				BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720; GEHRIG LMB, 1985, J MOL BIOL, V185, P651, DOI 10.1016/0022-2836(85)90079-8; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; ISHIZAKI J, 1992, APPL MICROBIOL BIOT, V36, P483; KAKUDO S, 1992, IN PRESS APPL MICROB; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNICK M, 1987, GENE, V61, P103, DOI 10.1016/0378-1119(87)90369-6; Maniatis T., 1982, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; MORAN CP, 1981, CELL, V25, P783, DOI 10.1016/0092-8674(81)90186-0; MORIHARA K, 1968, ARCH BIOCHEM BIOPHYS, V126, P971, DOI 10.1016/0003-9861(68)90498-0; NARAHASHI Y, 1969, J BIOCHEM, V66, P743; NIIDOME T, 1990, J BIOCHEM-TOKYO, V108, P965, DOI 10.1093/oxfordjournals.jbchem.a123322; OHAMA T, 1989, J MOL EVOL, V29, P381, DOI 10.1007/BF02602908; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SEGAL DM, 1971, BIOCHEMISTRY-US, V10, P3728; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; SUEYOSHI T, 1985, J BIOCHEM-TOKYO, V97, P1811, DOI 10.1093/oxfordjournals.jbchem.a135241; SVENDSEN I, 1992, EUR J BIOCHEM, V204, P165, DOI 10.1111/j.1432-1033.1992.tb16619.x; SVENDSEN I, 1991, FEBS LETT, V292, P165, DOI 10.1016/0014-5793(91)80859-2; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; TERAOKA H, 1990, Patent No. 28811090; TERAOKA H, 1991, Patent No. 913097374; YOSHIDA N, 1988, J BIOCHEM, V104, P451, DOI 10.1093/oxfordjournals.jbchem.a122488; YOSHIDA N, 1971, FEBS LETT, V15, P129, DOI 10.1016/0014-5793(71)80039-X; YOSHIKAWA K, 1992, BIOCHIM BIOPHYS ACTA, V1121, P221, DOI 10.1016/0167-4838(92)90358-K	37	73	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23782	23788						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429718				2022-12-27	WOS:A1992JZ23900055
J	SACCHETTINI, JC; SCAPIN, G; GOPAUL, D; GORDON, JI				SACCHETTINI, JC; SCAPIN, G; GOPAUL, D; GORDON, JI			REFINEMENT OF THE STRUCTURE OF ESCHERICHIA-COLI-DERIVED RAT INTESTINAL FATTY-ACID BINDING-PROTEIN WITH BOUND OLEATE TO 1.75-ANGSTROM RESOLUTION - CORRELATION WITH THE STRUCTURES OF THE APOPROTEIN AND THE PROTEIN WITH BOUND PALMITATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HORMONE FUSION GENES; TRANSGENIC MICE; EXPRESSION; DIFFERENTIATION; PURIFICATION; EPITHELIUM; RETINOL; MODEL	The structure of rat intestinal fatty acid binding protein (1-FABP) with bound oleate (C18:1) has been refined with x-ray diffraction data to a resolution of 1.75 angstrom. The protein contains 10 anti-parallel, beta strands composed of 99 residues and 2 short helices of 14 residues. Oleate is located in the interior of the protein in a bent conformation with C1-C12 more ordered than C13-C18. Two of the eight ordered waters in I-FABP:oleate are part of a hydrogen bond network that includes the carboxylate of oleate, the guanidinium group of Arg106, the nitrogen of the indole group of Trp82 , and the side chain of Gln115. Most of the methylenes of bound oleate reside in a crevice formed by hydrophobic and aromatic side chains. Tyr70 and Tyr117 envelop the acyl chain from C3 to C8 forming contacts with both the convex and concave faces of its van der Waals surface. The hydroxyls of each phenolic side chain hydrogen bond to ordered water molecules. Two ordered waters make van der Waals contact with the concave face of the bound fatty acid. The omega-terminal methyl of oleate is oriented so that it points toward the center of the benzene of Phe55 allowing it to form van der Waals interactions with its component methylenes. Comparison of the structure of I-FABP:oleate with a recently refined 1.19-angstrom model of apoI-FABP and an earlier 2.0-angstrom model of I-FABP:palmitate revealed a remarkable degree of similarity in the positions of their main chain and side chain atoms and in the conformations of the bound oleate and palmitate. The principal differences were confined to a few discrete regions of the protein. The helical domain, the type I turn between beta strands C and D, and the ring of Phe55 together form a solvent-accessible portal to the interior of the protein. They are repositioned in I-FABP:oleate (and I-FABP:palmitate) so that the binding cavity is even more accessible to solvent and its volume is increased. The side chain of Phe55 which shows discrete disorder in the apoprotein functions as an omega-terminal "sensing device": moving progressively outward toward the surface as the chain length of the bound fatty acid increases by 2 methylenes. Tyr70 and Tyr117 which also show discrete disorder in the apoprotein structure due to rotation around their C(alpha)-C(beta) bonds, are stabilized in a single, well ordered position in the holoproteins. ApoI-FABP contains 24 waters, eight of which occupy positions virtually identical to those occupied by the eight internal waters of I-FABP oleate. The positions occupied by five of the 16 remaining waters in apoI-FABP correspond to those occupied by several methylenes of bound oleate. Together, these observations suggest that I-FABP may function as a molecular water pump, using (i) feeble forces (van der Waals contacts and hydrogen bonds) rather than prominent conformational adjustments to bind a fatty acid through interactions with ordered solvent and (ii) movement of ordered solvent to perhaps drive the binding mechanism.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	SACCHETTINI, JC (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461, USA.			GOPAUL, Deshmukh/0000-0003-1631-3303	NIDDK NIH HHS [DK30292] Funding Source: Medline; NIGMS NIH HHS [GM45859] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; CHENG L, 1991, J BIOL CHEM, V266, P24404; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1990, J BIOL CHEM, V265, P11549; LOCKE BC, 1992, IN PRESS BIOCHEMISTR; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MATARESE V, 1990, PROG LIPID RES, V28, P245; MILNERWHITE EJ, 1987, BIOCHIM BIOPHYS ACTA, V911, P261, DOI 10.1016/0167-4838(87)90017-3; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; NEMECZ G, 1991, J BIOL CHEM, V266, P17180; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; SALEMME FR, 1985, METHOD ENZYMOL, V114, P140; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SMITH JL, 1988, ACTA CRYSTALLOGR A, V44, P357, DOI 10.1107/S0108767388000303; STORCH J, 1989, J BIOL CHEM, V264, P8708; SUZUKI T, 1988, J HISTOCHEM CYTOCHEM, V36, P349, DOI 10.1177/36.4.3346538; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	41	99	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23534	23545						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429698				2022-12-27	WOS:A1992JZ23900021
J	TOESCU, EC; ONEILL, SC; PETERSEN, OH; EISNER, DA				TOESCU, EC; ONEILL, SC; PETERSEN, OH; EISNER, DA			CAFFEINE INHIBITS THE AGONIST-EVOKED CYTOSOLIC CA2+ SIGNAL IN MOUSE PANCREATIC ACINAR-CELLS BY BLOCKING INOSITOL TRISPHOSPHATE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; CARDIAC-CELLS; OSCILLATIONS; CHANNELS; ACTIVATION; 1,4,5-TRISPHOSPHATE; MOBILIZATION; FLUCTUATIONS; CONTRACTION	The inhibitory effects of caffeine on receptor-activated cytosolic Ca2+ signal generation in isolated mouse pancreatic acinar cells were investigated. Using the ability of caffeine to quench Indo-1 fluorescence we measured simultaneously the free intracellular Ca2+ concentration ([Ca2+]i) and the intracellular caffeine concentration ([caffeine]i). We also measured inositol 1,4,5-trisphosphate (InsP3) production with a radioreceptor assay. When caffeine was added to the extracellular solution during a sustained receptor-activated increase in [Ca2+]i, [caffeine]i rose to its steady level within a few seconds. This was accompanied by a decrease of [Ca2+]i, which started only after [caffeine]i had reached an apparent threshold concentration (about 2 mM in the case of 0.5 muM acetylcholine (ACh) stimulation). Above this [caffeine]i level there was a linear relationship between [caffeine]i and [Ca2+]i. Throughout the caffeine exposure [Ca2+]i remained at a steady low level. Following removal of caffeine from the bath, [caffeine]i decreased to zero within seconds. There was no significant increase in [Ca2+]i until [caffeine]i had been reduced to the threshold level (about 2 mM at 0.5 muM ACh). Caffeine inhibited Ca2+ signals evoked by ACh, cholecystokinin, and ATP and also inhibited signals generated in the absence of external Ca2+. Caffeine application had the same effect as removal of agonist allowing recovery from apparent desensitization. Caffeine inhibited the agonist-evoked production of InsP3 in a dose-dependent manner. Our results demonstrate the acute and reversible dose-dependent inhibition of agonist-evoked cytosolic Ca2+ signal generation due to rapid intracellular caffeine accumulation and washout. The inhibition can be explained by the reduction of agonist-evoked InsP3 production.	UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,POB 147,CROWN ST,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT VET PRECLIN SCI,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool			Petersen, Ole H/E-8708-2010; Eisner, David/A-6596-2008	Eisner, David/0000-0002-7002-3748; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1991, P ROY SOC B-BIOL SCI, V244, P57, DOI 10.1098/rspb.1991.0051; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FOSKETT JK, 1991, J BIOL CHEM, V266, P1435; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; ONEILL SC, 1990, J PHYSIOL-LONDON, V430, P519, DOI 10.1113/jphysiol.1990.sp018305; ONEILL SC, 1990, J PHYSIOL-LONDON, V425, P55, DOI 10.1113/jphysiol.1990.sp018092; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; OTUN H, 1991, EXP PHYSIOL, V76, P811, DOI 10.1113/expphysiol.1991.sp003547; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH2; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; SITSAPESAN R, 1990, J PHYSIOL-LONDON, V423, P425, DOI 10.1113/jphysiol.1990.sp018031; SMITH GL, 1988, J GEN PHYSIOL, V92, P351, DOI 10.1085/jgp.92.3.351; SUMIMOTO K, 1986, PFLUG ARCH EUR J PHY, V406, P173, DOI 10.1007/BF00586679; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; VALDEOLMILLOS M, 1989, PFLUG ARCH EUR J PHY, V413, P676, DOI 10.1007/BF00581820; WAKUI M, 1991, J MEMBRANE BIOL, V124, P179, DOI 10.1007/BF01870462; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7	31	128	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23467	23470						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429689				2022-12-27	WOS:A1992JZ23900009
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .4. RESOLUTION OF DISCREPANCIES BETWEEN ALTERNATIVE METHODS OF ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL SYSTEMS-THEORY; ENZYME-ENZYME INTERACTIONS; METABOLIC CONTROL-THEORY; VARIANT THEORIES; SUMMATION	Experimental studies of enzyme kinetics in vitro and metabolic fluxes in vivo have been used by Wright and her colleagues to develop a detailed kinetic model of the tricarboxylic acid cycle in Dictyostelium discoideum. This model has recently been been analyzed by two different methods (Albe, K. R., and Wright, B. E. (1992) J. Biol. Chem. 267, 3106-3114; Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22926-22933 in an effort to determine the response of individual fluxes and metabolite concentrations to changes in levels of the enzymes that constitute the system. Individual responses were found to differ significantly in magnitude as well as in sign. Perhaps the most glaring difference concerns the influence of the enzyme succinate dehydrogenase on the flux through the cycle; in one study, it has the maximum influence, whereas, in the other, it has absolutely no influence. In this paper, we provide a resolution of these discrepancies. We have reconstructed the methodology of Albe and Wright and have been able to reproduce their results in detail. We show that their methodology does not yield a valid steady state analysis, and, consequently, that the conclusions drawn from their analysis must be called into question. First, they concluded that their model is realistic and predictive. It is now clear that their model is ill-determined and has a steady state only for unrealistically narrow conditions. Second, they concluded that their analysis is valid for variations of less than 2% in the levels of the enzymes because they could satisfy summation relationships considered to be mathematically inevitable. It is now clear that these relationships are neither necessary nor sufficient for establishing the validity of an analysis or the appropriateness of a biochemical model. Third, they concluded on the basis of their empirical methodology that certain enzymes are most important in influencing flux through the cycle. It is now clear that these results are inaccurate because of deficiencies in their methodology. Finally, they concluded that steady state analyses cannot be carried out experimentally because of the small variations required in enzyme levels. It is now clear that the requirement for such small variations reflects the ill-determined character of the underlying model and is not a necessary property of the real system.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-30054] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBE KR, 1992, J BIOL CHEM, V267, P3106; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; CORNISHBOWDEN A, 1989, J THEOR BIOL, V136, P365, DOI 10.1016/S0022-5193(89)80154-7; GIERSCH C, 1988, EUR J BIOCHEM, V174, P509, DOI 10.1111/j.1432-1033.1988.tb14128.x; IRVINE DH, 1990, SIAM J NUMER ANAL, V27, P704, DOI 10.1137/0727042; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; PETTERSSON G, 1988, EUR J BIOCHEM, V175, P661, DOI 10.1111/j.1432-1033.1988.tb14242.x; SALTER M, 1986, BIOCHEM J, V234, P635, DOI 10.1042/bj2340635; SAURO HM, 1990, EUR J BIOCHEM, V187, P493, DOI 10.1111/j.1432-1033.1990.tb15330.x; Savageau M. A., 1992, FUNDAMENTALS MED CEL, V3A, P45; SAVAGEAU MA, 1987, MATH BIOSCI, V86, P147, DOI 10.1016/0025-5564(87)90008-3; SAVAGEAU MA, 1991, J THEOR BIOL, V151, P509, DOI 10.1016/S0022-5193(05)80367-4; SAVAGEAU MA, 1992, J THEOR BIOL, V154, P131, DOI 10.1016/S0022-5193(05)80194-8; SAVAGEAU MA, 1989, J THEOR BIOL, V141, P93, DOI 10.1016/S0022-5193(89)80011-6; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P365, DOI 10.1016/S0022-5193(69)80026-3; SAVAGEAU MA, 1971, ARCH BIOCHEM BIOPHYS, V145, P612, DOI 10.1016/S0003-9861(71)80021-8; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22926; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22919; SORRIBAS A, 1989, MATH BIOSCI, V94, P161, DOI 10.1016/0025-5564(89)90064-3; SORRIBAS A, 1989, MATH BIOSCI, V94, P195, DOI 10.1016/0025-5564(89)90065-5; Srere PA, 1989, STRUCTURAL ORG ASPEC; Vetterling W.T., 1988, NUMERICAL RECIPES C; VOIT EO, 1990, USERS GUIDE ESSYNS; WONG JTF, 1962, CAN J BIOCHEM PHYS, V40, P763; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101	27	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22934	22943						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429644				2022-12-27	WOS:A1992JY16300037
J	BREIMAN, A; FAWCETT, TW; GHIRARDI, ML; MATTOO, AK				BREIMAN, A; FAWCETT, TW; GHIRARDI, ML; MATTOO, AK			PLANT ORGANELLES CONTAIN DISTINCT PEPTIDYLPROLYL CIS, TRANS-ISOMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CIS-TRANS-ISOMERASE; CYTOSOLIC BINDING-PROTEIN; ESCHERICHIA-COLI; CYCLOSPORIN-A; CYCLOPHILIN; MEMBRANE; LIGANDS; LIVER	Peptidylprolyl cis,trans-isomerase (PPIase) activity was detected in the cytosol, mitochondria, and chloroplast of pea plants. Cyclosporin A inhibited the activity largely localized to the mitochondrial matrix while rapamycin inhibited the PPIase activity associated with the mitochondrial membranes. Differential inhibition hy the two immunosuppressive drugs, the specific binding of these drugs to different mitochondrial fractions, and the immunological detection of a putative 25-kDa rapamycin-binding protein (RBP) in mitochondrial extracts attests to the presence in plant mitochondria of both cyclophilin and RBP classes of PPIases. Cyclosporin A-sensitive PPIase detected in the chloroplast was mostly localized to the thylakoids, which is suggestive of its function in the folding of membranal proteins. PPIase associated with the chloroplast stroma and the thylakoids was not inhibited by rapamycin nor was any cross-reactive RBP detected in chloroplast extracts. These results demonstrate the presence of distinct classes of PPIases in the mitochondria and the chloroplasts of plants.	USDA ARS,BELTSVILLE AGR RES CTR,PSI,PLANT MOLEC BIOL LAB,BARC W,BLDG 006,RM 118,BELTSVILLE,MD 20705	United States Department of Agriculture (USDA)			Mattoo, Autar/G-9863-2011; Mattoo, Autar/U-9751-2019	Mattoo, Autar/0000-0001-9226-7164				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARTLETT SG, 1982, METHODS CHLOROPLAST, P985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMAN A, 1987, THEOR APPL GENET, V73, P563, DOI 10.1007/BF00289195; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALLAHAN FE, 1989, PLANT PHYSIOL, V91, P629, DOI 10.1104/pp.91.2.629; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, PLANT J, V1, P9, DOI 10.1111/j.1365-313X.1991.00009.x; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HACK E, 1991, PLANT PHYSIOL, V95, P561; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V342, P755; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; MARDER JB, 1986, METHOD ENZYMOL, V118, P384; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; WIERDERRECT G, 1992, BIOCHEM BIOPH RES CO, V185, P298	33	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21293	21296						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400439				2022-12-27	WOS:A1992JV01100006
J	GUM, JR; HICKS, JW; TORIBARA, NW; ROTHE, EM; LAGACE, RE; KIM, YS				GUM, JR; HICKS, JW; TORIBARA, NW; ROTHE, EM; LAGACE, RE; KIM, YS			THE HUMAN MUC2 INTESTINAL MUCIN HAS CYSTEINE-RICH SUBDOMAINS LOCATED BOTH UPSTREAM AND DOWNSTREAM OF ITS CENTRAL REPETITIVE REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDNA SEQUENCES; VONWILLEBRAND-FACTOR; GENE LOCUS; PROTEIN; GLYCOPROTEINS; DOMAINS; POLYMORPHISM; CONFORMATION; CONSERVATION	The human MUC2 mucin is a large secretory glycoconjugate that coats the epithelia of the intestines, airways, and other mucus membrane-containing organs. Previous work has shown that this mucin contains an extended tandem repeat-containing domain rich in Thr and Pro. In the present work we describe two additional regions of this mucin located both upstream and downstream of the tandem repeat array. The carboxyl-terminal domain contains 984 residues and can be divided into mucin-like (139 residues) and cysteine-rich (845 residues) subdomains. This latter subdomain exhibits varying degrees of sequence similarity to a wide range of mucins and mucin-like proteins including those isolated from rats, pigs, cows, and frogs. We also report here the sequence of 1270 residues lying immediately upstream of the tandem repeats. This region contains a repetitive, mucin-like subdomain and a second cysteine-rich stretch of more than 700 residues. Both cysteine-rich subdomains of this mucin have sequence similarity with von Willebrand factor, a serum protein that exists as a disulfide-linked polymer. This suggests that these cysteine-rich subdomains are important in the catenation of mucin monomers into oligomers, the structures that confer viscoelasticity upon mucus.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco	GUM, JR (corresponding author), DEPT VET AFFAIRS MED CTR, GASTROINTESTINAL RES LAB 151M2, SAN FRANCISCO, CA 94121 USA.							Allen A., 1981, PHYSL GASTROINTESTIN, P617; AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BYRD JC, 1988, CANCER RES, V48, P6678; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CONG NV, 1990, HUM GENET, V86, P167; DEKKER J, 1991, BIOCHEM J, V279, P251, DOI 10.1042/bj2790251; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FORSYTHE KH, 1989, TRANSPORT Q, V43, P259; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, P NATL ACAD SCI USA, V5, P11; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1991, J BIOL CHEM, V266, P22733; HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOYER LW, 1981, BLOOD, V58, P1; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MANTLE M, 1981, BIOCHEM J, V195, P277, DOI 10.1042/bj1950277; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROBERTON AM, 1989, BIOCHEM J, V261, P637, DOI 10.1042/bj2610637; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SHEEHAN JK, 1991, BIOCHEM J, V274, P293, DOI 10.1042/bj2740293; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; SIMPSON D, 1988, BIOCHEM BIOPH RES CO, V151, P487, DOI 10.1016/0006-291X(88)90619-5; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; THORNTON DJ, 1990, BIOCHEM J, V265, P179, DOI 10.1042/bj2650179; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401	46	250	256	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21375	21383						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400449				2022-12-27	WOS:A1992JV01100021
J	YE, SQ; OLSON, LM; REARDON, CA; GETZ, GS				YE, SQ; OLSON, LM; REARDON, CA; GETZ, GS			HUMAN PLASMA-LIPOPROTEINS REGULATE APOLIPOPROTEIN-E SECRETION FROM A POST-GOLGI COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; LOW-DENSITY LIPOPROTEINS; OVARIAN GRANULOSA-CELLS; BONE-MARROW; APO-E; BINDING; RAT; CHOLESTEROL; LIVER; METABOLISM	The molecular regulation of apolipoprotein E (apoE) synthesis and secretion is incompletely understood. In this study, we have examined the effect of human low density lipoprotein (LDL) on apoE mRNA and protein levels in HepG2 and other eukaryotic cells. Exposing HepG2 cells to LDL for times up to 4 h resulted in an increase in S-35-labeled apoE accumulation in the medium by 2.2-fold, relative to serum free controls (n = 10, p < 0.001), with no changes in apoE mRNA levels. Similar observations have been made in JeG-3 cells and Chinese hamster ovary cells stably transfected with human apoE cDNA constructs. These results indicate that the LDL effect operates at a post-transcriptional level. In pulse-chase experiments, the LDL effect on apoE accumulation in the media was observed when it was added only during the chase even in the presence of cycloheximide, indicating that LDL is functioning at a post-translational level. The use of brefeldin A (BFA), an agent that impedes protein transport from the endoplasmic reticulum to the Golgi apparatus, suggests that the LDL effect occurs in a post-Golgi compartment. The addition of protease inhibitors could not duplicate the effects of LDL on the apoE accumulation in the medium. ApoA-I accumulation in the medium of HepG2 cells, but not albumin, was also significantly increased by 1.9-fold (n = 5, p < 0.001).	UNIV CHICAGO,DEPT PATHOL,MC 3083,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago					NHLBI NIH HHS [HL 15062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DASHTI N, 1987, J LIPID RES, V28, P423; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DORY L, 1991, J LIPID RES, V32, P783; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; DRISCOLL DM, 1985, J BIOL CHEM, V260, P9031; ERIKSON SK, 1986, J LIPID RES, V27, P875; GETZ GS, 1988, ARCH PATHOL LAB MED, V112, P1048; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAIG WY, 1988, J BIOL CHEM, V263, P13880; HAY R, 1979, J LIPID RES, V20, P34; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HUI DY, 1981, J BIOL CHEM, V256, P5646; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; INOUE S, 1991, J BIOL CHEM, V266, P13311; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KUSHWAHA RS, 1991, J LIPID RES, V32, P1929; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MOKUNO H, 1990, GERONTOLOGY, V36, P42; NESS GC, 1991, J BIOL CHEM, V266, P14854; ORAM JF, 1980, J BIOL CHEM, V255, P475; ORCI L, 1991, CELL, V64, P1183; Sambrook J, 1989, MOL CLONING LABORATO; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHARKEY MF, 1990, J LIPID RES, V31, P2167; SHORE VG, 1973, BIOCHEMISTRY-US, V12, P502, DOI 10.1021/bi00727a022; TAM SP, 1986, SCIENCE, V234, P1234, DOI 10.1126/science.3022381; THUREN T, 1991, J BIOL CHEM, V266, P4853; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WU AL, 1979, J BIOL CHEM, V254, P7316; WYNE KL, 1989, J BIOL CHEM, V264, P16530; WYNE KL, 1989, J BIOL CHEM, V264, P981; YAMADA N, 1986, P NATL ACAD SCI USA, V83, P3479, DOI 10.1073/pnas.83.10.3479	46	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21961	21966						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400506				2022-12-27	WOS:A1992JV01100107
J	SARASWAT, LD; PASTRALANDIS, SC; LOWEY, S				SARASWAT, LD; PASTRALANDIS, SC; LOWEY, S			MAPPING SINGLE CYSTEINE MUTANTS OF LIGHT CHAIN-2 IN CHICKEN SKELETAL MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; MONOCLONAL-ANTIBODIES; MUSCLE-FIBERS; BINDING-SITES; SUBFRAGMENT-1; HEAD; ACANTHAMOEBA; ORIENTATION; CALMODULIN; POSITION	The NH2- and COOH-terminal regions of the regulatory light chain (LC2) have been mapped to the head/rod junction by immunoelectron microscopy, using monoclonal and anti-fluorescyl antibodies as probes. In order to map the entire length of the light chain, we have engineered and purified mutants that contain a single cysteine residue at positions 2, 73, 94, 126, or 155. The single cysteine residues were labeled with either 5-iodoacetamido fluorescein or N-ethylmaleimide-biotin. We observed that the reactivity of Cys126 is far greater than that of Cys155, confirming that cysteine 126 is the fast-reacting thiol in wild-type light chain. The labeled light chains were exchanged into myosin stripped of its native LC2 by immunoaffinity chromatography, and the reconstituted myosin was reacted with anti-fluorescein antibody or avidin prior to rotary shadowing for electron microscopy. The position of the antibody or avidin was found to be near the head/rod junction for all mutants. These mapping studies, together with our finding that cysteines widely separated in the primary sequence can form multiple disulfide bonds (Saraswat, L. D., and Lowey, S. (1991) J. Biol. Chem. 226, 19777-19785), support a model for LC2 as a flexible, globular molecule localized mainly in the vicinity of the head/rod junction of myosin.	WHEATON COLL,DEPT CHEM,NORTON,MA 02766		SARASWAT, LD (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254, USA.				NIAMS NIH HHS [R37AR17350] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXIS MN, 1978, BIOCHEMISTRY-US, V17, P2319, DOI 10.1021/bi00605a010; ARATA T, 1990, J MOL BIOL, V214, P471, DOI 10.1016/0022-2836(90)90194-Q; ATKINSON MAL, 1986, J BIOL CHEM, V261, P3382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANTLER PD, 1989, J MOL BIOL, V207, P631, DOI 10.1016/0022-2836(89)90472-5; HAMBLY B, 1991, BIOPHYS J, V59, P127, DOI 10.1016/S0006-3495(91)82205-6; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; MCNALLY EM, 1991, J CELL BIOL, V113, P585, DOI 10.1083/jcb.113.3.585; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MITCHELL EJ, 1986, EUR J BIOCHEM, V161, P25, DOI 10.1111/j.1432-1033.1986.tb10120.x; ONISHI H, 1992, BIOCHEMISTRY-US, V31, P1201, DOI 10.1021/bi00119a033; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RAYMENT I, 1984, P NATL ACAD SCI-BIOL, V81, P4378; RIMM DL, 1989, J CELL BIOL, V108, P1783, DOI 10.1083/jcb.108.5.1783; Sambrook J, 1989, MOL CLONING LABORATO; SARASWAT LD, 1991, J BIOL CHEM, V266, P19777; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOKUNAGA M, 1987, J MOL BIOL, V194, P245, DOI 10.1016/0022-2836(87)90372-X; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WINKELMANN DA, 1983, CELL, V34, P295, DOI 10.1016/0092-8674(83)90160-5; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2; YAMAMOTO K, 1980, J BIOCHEM, V87, P213, DOI 10.1093/oxfordjournals.jbchem.a132727; YAMAMOTO K, 1985, J MOL BIOL, V183, P287, DOI 10.1016/0022-2836(85)90222-0	26	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21112	21118						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400421				2022-12-27	WOS:A1992JT97800093
J	MATSUMOTO, K; TAJIMA, H; OKAZAKI, H; NAKAMURA, T				MATSUMOTO, K; TAJIMA, H; OKAZAKI, H; NAKAMURA, T			NEGATIVE REGULATION OF HEPATOCYTE GROWTH-FACTOR GENE-EXPRESSION IN HUMAN LUNG FIBROBLASTS AND LEUKEMIC-CELLS BY TRANSFORMING GROWTH FACTOR-BETA-1 AND GLUCOCORTICOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SCATTER FACTOR; FACTOR-BETA; EPITHELIAL-CELLS; RAT PLATELETS; MESSENGER-RNA; LIVER-REGENERATION; MOLECULAR-CLONING; HEPATOPOIETIN-A; DNA-SYNTHESIS; PURIFICATION	Hepatocyte growth factor (HGF), a mesenchymal-derived factor which regulates growth, motility, and morphogenesis of epithelial and endothelial cells, functions as a hepatotrophic and renotrophic factor for regeneration of the liver and kidney. We have now obtained evidence that transforming growth factor-beta1 (TGF-beta1) and glucocorticoids are negative regulators for HGF gene expression. When TGF-beta1 or dexamethasone was added to cultures of MRC-5 human embryonic lung fibroblasts and HL-60 human promyelocytic leukemic cells, the amount of HGF secreted into the culture medium was inhibited to 30-40% of that of control cultures by 10 ng/ml TGF-beta1 and to 40-50% by 10(-6) M dexamethasone. The inhibitory effect of TGF-beta1 and dexamethasone on HGF synthesis in MRC-5 cells was additive, thereby suggesting that TGF-beta1 and dexamethasone exert effects through distinct mechanisms. Hydrocortisone also inhibited HGF synthesis with the same potency as dexamethasone; however, testosterone, estriol, and beta-estradiol had no effect. The rate of HGF synthesis in MRC-5 cells, as measured by pulse labeling with [S-35]methionine and subsequent immunoprecipitation, was suppressed to 30-40% of the control with 10 ng/ml TGF-beta1, and to 30-45% by 10(-6) M dexamethasone. HGF mRNA levels in MRC-5 cells and HL-60 cells were dose-dependently suppressed by TGF-beta1 and dexamethasone; 10 ng/ml TGF-beta1 suppressed HGF mRNA levels to 32% and 35% of control culture, respectively, in MRC-5 cells and HL-60 cells, and 10(-6) M dexamethasone suppressed to 43% and 38%, respectively. Thus, TGF-beta1 and glucocorticoids seem to inhibit HGF synthesis by suppressing the expression of the HGF gene. We propose that a negative regulation of HGF gene expression by TGF-beta1 or glucocorticoids may be involved in physiological or pathological processes during tissue regeneration.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; PRESTO,RES DEV CORP JAPAN,CELL & INFORMAT GRP,KYOTO 600,JAPAN	Kyushu University; Japan Science & Technology Agency (JST)								ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BOTTARO DP, 1991, SCIENCE, V254, P1382; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CARR BI, 1986, CANCER RES, V46, P2330; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; ISHIKI Y, 1992, IN PRESS HEPATOLOGY; KAMALATI T, 1991, J CELL SCI, V101, P323; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1992, P NATL ACAD SCI USA, V89, P3800, DOI 10.1073/pnas.89.9.3800; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; MATSUMOTO K, 1992, IN PRESS BIOCH BIOPH; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCMAHON JB, 1986, CANCER RES, V46, P4665; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; NAGAIKE M, 1991, J BIOL CHEM, V266, P22781; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; OKADA F, 1989, J BIOCHEM-TOKYO, V106, P304, DOI 10.1093/oxfordjournals.jbchem.a122849; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; ZARNEGAR R, 1989, CANCER RES, V49, P3314	57	158	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24917	24920						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459995				2022-12-27	WOS:A1992KB60300002
J	OSTHEIMER, GJ; STARKEY, JR; LAMBERT, CG; HELGERSON, SL; DRATZ, EA				OSTHEIMER, GJ; STARKEY, JR; LAMBERT, CG; HELGERSON, SL; DRATZ, EA			NMR CONSTRAINED SOLUTION STRUCTURES FOR LAMININ PEPTIDE-11 - ANALOGS DEFINE STRUCTURAL REQUIREMENTS FOR INHIBITION OF TUMOR-CELL INVASION OF BASEMENT-MEMBRANE MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; HEPARIN-BINDING; WATER SOLUTION; ADHESION; SPECTROSCOPY; PENTAPEPTIDE; PROTEINS; FRAGMENTS; DOMAINS; CONFORMATIONS	Peptide 11, CDPGYIGSR-NH2, is a segment of laminin which blocks tumor cell invasion. A high affinity laminin receptor in tumor cells is thought to be blocked by the carboxyl-terminal YIGSR, and conformational energy calculations suggest that the glycine in YIGSR allows an important conformational bend. We replaced the YIGSR glycine residue in peptide 11 with either D-alanine or L-alanine to allow or disfavor the proposed glycine bend. We found the Gly7 --> D-Ala7 analog to be equal to peptide 11 in inhibiting tumor cell invasion of basement membrane matrix. The Gly7 --> L-Ala7 analog was much less capable of invasion inhibition. Two-dimensional H-1-H-1 NMR was used to study the solution conformations of the peptide 11 analogs. NOESY experiments revealed close NH-NH contacts in peptide 11 and the D-Ala7 analog, but not in the L-Ala7 analog. Molecular dynamics generated low energy structures with excellent NOE agreement for peptide 11 and its analogs. Both peptide 11 and the D-Ala7 analog, but not the less active L-Ala7 analog, were predicted to have similar bends around Gly7 or D-Ala7. These results suggest that a bend in the YIGSR region of peptide 11 may be important for the binding of laminin to its metastasis-associated receptor.	MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA; MONTANA STATE UNIV, DEPT MICROBIOL, BOZEMAN, MT 59717 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman			Lambert, Christophe/AAH-4448-2021	Lambert, Christophe/0000-0003-1994-2893	NEI NIH HHS [R01 EY06913] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006913] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BODENHAUSEN G, 1980, J MAGN RESON, V37, P93, DOI 10.1016/0022-2364(80)90096-7; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P149, DOI 10.1007/BF01025085; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; BURKE C, 1991, J BIOL CHEM, V266, P19407; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLEINMAN HK, 1985, J CELL BIOCHEM, V27, P317, DOI 10.1002/jcb.240270402; KRAMER RH, 1991, CANCER METAST REV, V10, P49, DOI 10.1007/BF00046843; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARION D, 1988, J MAGN RESON, V79, P352, DOI 10.1016/0022-2364(88)90230-2; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; MCKELVEY DR, 1991, J PROTEIN CHEM, V10, P265, DOI 10.1007/BF01025625; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; POSTE G, 1980, CANCER RES, V40, P1636; RAMOS DM, 1991, INVAS METAST, V11, P125; REED J, 1988, EUR J BIOCHEM, V178, P141, DOI 10.1111/j.1432-1033.1988.tb14439.x; REPESH LA, 1989, INVAS METAST, V9, P192; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; STARKEY JR, 1990, CANCER METAST REV, V9, P113, DOI 10.1007/BF00046338; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; WUTHRICK K, 1986, NMR PROTEINS NUCLEIC	35	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25120	25128						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460013				2022-12-27	WOS:A1992KB60300034
J	PRESLAND, RB; HAYDOCK, PV; FLECKMAN, P; NIRUNSUKSIRI, W; DALE, BA				PRESLAND, RB; HAYDOCK, PV; FLECKMAN, P; NIRUNSUKSIRI, W; DALE, BA			CHARACTERIZATION OF THE HUMAN EPIDERMAL PROFILAGGRIN GENE - GENOMIC ORGANIZATION AND IDENTIFICATION OF AN S-100-LIKE CALCIUM-BINDING DOMAIN AT THE AMINO TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT-ASSOCIATED PROTEIN; MOLECULAR-WEIGHT PRECURSOR; HISTIDINE-RICH PROTEIN; RETINOIC ACID; THYROID-HORMONE; KERATIN GENES; EUKARYOTIC RIBOSOMES; ICHTHYOSIS-VULGARIS; MAMMALIAN EPIDERMIS; NUCLEAR RECEPTORS	Filaggrin is an intermediate filament-associated protein which functions to aggregate keratin intermediate filaments in the stratum corneum of mammalian epidermis. It is synthesized as a large precursor protein, profilaggrin, that consists of multiple filaggrin units and is localized in keratohyalin granules. In this report, we describe the characterization of cosmid genomic clones containing the human profilaggrin gene coding for 11 complete filaggrin repeats of 324 amino acids each. At the amino- and carboxyl-terminal ends of human profilaggrin are leader and tail peptide sequences of 293 and 157 amino acids, respectively, which differ from filaggrin. The leader peptide is composed of two distinct domains: an 81-residue segment which shows significant homology to the S-100 family of EF hand-containing calcium-binding proteins, and a hydrophilic second domain of 212 residues. The gene is divided into three exons, with one intron (approximately 9.6 kilobase pairs) in the 5' noncoding region and a second one of 570 base pairs between the EF hands. The position of intron 2 is identical to that of other members of the S-100-like family. The presence of an S-100-like domain suggests that profilaggrin binds calcium and that the calcium binding domain is functionally significant in the formation of keratohyalin and/or the subsequent processing of profilaggrin to filaggrin, both of which may be calcium-dependent events.	UNIV WASHINGTON, DEPT PERIODONT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED DERMATOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	PRESLAND, RB (corresponding author), UNIV WASHINGTON, DEPT ORAL BIOL, EPITHELIAL BIOL LAB, SB-22, SEATTLE, WA 98195 USA.			Presland, Richard/0000-0003-1440-7402	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P01AM021557] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004660] Funding Source: NIH RePORTER; NCRR NIH HHS [S07-RR05346] Funding Source: Medline; NIADDK NIH HHS [P01 AM 21557] Funding Source: Medline; NIDCR NIH HHS [R37 DE 04660] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; Dale BA, 1990, CELLULAR MOL BIOL IN, P393; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELDER JT, 1990, J INVEST DERMATOL, V94, P19, DOI 10.1111/1523-1747.ep12873313; FIETZ MJ, 1990, J CELL BIOL, V110, P427, DOI 10.1083/jcb.110.2.427; FISHER C, 1987, J INVEST DERMATOL, V88, P661, DOI 10.1111/1523-1747.ep12470281; FLECKMAN P, 1987, J INVEST DERMATOL, V88, P640, DOI 10.1111/1523-1747.ep12470251; FLECKMAN P, 1985, J INVEST DERMATOL, V85, P507, DOI 10.1111/1523-1747.ep12277306; GAN SQ, 1991, BIOCHEMISTRY-US, V30, P5814; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HAUGENSCOFIELD J, 1988, J INVEST DERMATOL, V91, P553, DOI 10.1111/1523-1747.ep12476930; HAYDOCK PV, 1990, DNA CELL BIOL, V9, P251, DOI 10.1089/dna.1990.9.251; HAYDOCK PV, 1986, J BIOL CHEM, V261, P2520; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; JACKSON RJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P345, DOI 10.1016/0167-4781(91)90124-5; KIM HJ, 1987, J INVEST DERMATOL, V88, P624, DOI 10.1111/1523-1747.ep12470230; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LONSDALEECCLES JD, 1984, BIOCHEMISTRY-US, V23, P1239, DOI 10.1021/bi00301a034; LYNLEY AM, 1983, BIOCHIM BIOPHYS ACTA, V744, P28, DOI 10.1016/0167-4838(83)90336-9; MAMRACK MD, 1984, CANCER RES, V44, P2634; MANABE M, 1991, DIFFERENTIATION, V48, P43, DOI 10.1111/j.1432-0436.1991.tb00241.x; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Odland G.F., 1991, PHYSL BIOCH MOL BIOL, V1, P3; OGUIN MW, 1990, CELLULAR MOL BIOL IN, P301; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; RESING KA, 1985, BIOCHEMISTRY-US, V24, P4167, DOI 10.1021/bi00336a053; RESING KA, 1989, J BIOL CHEM, V264, P1837; RESING KA, 1987, PROCESSES CUTANEOUS, P165; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROGERS GE, 1991, ANN NY ACAD SCI, V642, P64; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCOTT IR, 1982, BIOCHIM BIOPHYS ACTA, V719, P110, DOI 10.1016/0304-4165(82)90314-2; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TOMIC M, 1990, CELL REGUL, V1, P965, DOI 10.1091/mbc.1.12.965; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VANELDIK LJ, 1982, INT REV CYTOL, V77, P1, DOI 10.1016/S0074-7696(08)62463-8; WILKINSON MM, 1988, J CELL SCI, V91, P221; WU CH, 1991, J BIOL CHEM, V266, P2983; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	72	140	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23772	23781						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429717				2022-12-27	WOS:A1992JZ23900054
J	BOGDAN, C; PAIK, J; VODOVOTZ, Y; NATHAN, C				BOGDAN, C; PAIK, J; VODOVOTZ, Y; NATHAN, C			CONTRASTING MECHANISMS FOR SUPPRESSION OF MACROPHAGE CYTOKINE RELEASE BY TRANSFORMING GROWTH-FACTOR-BETA AND INTERLEUKIN-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MURINE PERITONEAL-MACROPHAGES; EXPERIMENTAL CUTANEOUS LEISHMANIASIS; PHENOL CHLOROFORM EXTRACTION; TOXIC TRANSMEMBRANE PROTEIN; WEHI-164 SUBCLONE-13 ASSAY; FACTOR-ALPHA PRODUCTION; SENSITIVE CELL-LINE; SINGLE-STEP METHOD; HUMAN-MONOCYTES	Transforming growth factor (TGF)-beta and interleukin (IL)-10 inhibited lipopolysaccharide (LPS)-induced macrophage production of the inflammatory cytokines tumor necrosis factor-alpha (TNF), IL-1alpha, and IL-1beta by contrasting post-transcriptional mechanisms. TGF-beta acted slowly and late, as it required 12-16 h to exert a suppressive effect, and inhibited TNF production even when added 6 h after LPS. TGF-beta affected neither the level of TNF mRNA, the release of preformed TNF nor the degradation of TNF. Thus, TGF-beta appeared to inhibit translation of TNF mRNA. IL-10 not only suppressed TNF release to a 25-fold greater extent than TGF-beta, but also inhibited release of IL-1. In contrast to TGF-beta, IL-10 acted on an early step in cytokine production, its effect being maximal 3 h after addition of LPS. Unlike TGF-beta, IL-10 markedly suppressed TNF, IL-1alpha, and IL-1beta mRNA levels. However, this was accomplished without suppressing transcription of the corresponding genes. Moreover, cycloheximide antagonized the IL-10-dependent reduction in cytokine mRNA levels. Thus, IL-10 may induce a ribonuclease active on cytokine transcripts or may induce a protein that enhances the susceptibility of TNF, IL-1alpha, and IL-1beta mRNAs to ribonucleolytic action. We conclude that IL-10 and TGF-beta induce different phenotypes of macrophage deactivation, and deactivate macrophages by different mechanisms: IL-10 promotes degradation of cytokine mRNA, while TGF-beta primarily suppresses translation.			BOGDAN, C (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, BEATRICE & SAMUEL A SEAVER LAB, BOX 57, NEW YORK, NY 10021 USA.			Bogdan, Christian/0000-0002-2300-0631	NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHWICH PR, 1986, BIOCHEM BIOPH RES CO, V136, P94, DOI 10.1016/0006-291X(86)90881-8; BEUTLER B, 1988, BIOCHEM BIOPH RES CO, V152, P973, DOI 10.1016/S0006-291X(88)80379-6; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOGDAN C, 1991, MONONUCLEAR PHAGOCYT; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHANTRY D, 1989, J IMMUNOL, V142, P4295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; DING A, 1990, J IMMUNOL, V145, P940; ESKANDARI MK, 1990, IMMUNOL INVEST, V19, P69, DOI 10.3109/08820139009042026; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; FAST DJ, 1989, INFECT IMMUN, V57, P291, DOI 10.1128/IAI.57.1.291-294.1989; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRAY PW, 1986, J IMMUNOL, V137, P3644; GREENBERG ME, 1991, CURRENT PROTOCOLS IM, V1; HALL BF, 1991, IMMUNOPARASITOL TOD, pA22; HOFFMAN MK, 1986, LYMPHOKINE RES, V5, P255; HOPKINS SJ, 1989, J IMMUNOL METHODS, V120, P271, DOI 10.1016/0022-1759(89)90252-4; KILLION JJ, 1990, CURR OPIN IMMUNOL, V2, P693, DOI 10.1016/0952-7915(90)90032-C; KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008-8749(87)90326-1; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCartney-Francis N, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011007; MOSMANN TR, 1991, IMMUNOPARASITOL TOD, pA49; NATHAN CF, 1990, HDB EXPT PHARM, V95, P428; NELSON BJ, 1991, J IMMUNOL, V146, P1849; NELSON DS, 1981, AUST J EXP BIOL MED, V59, P229, DOI 10.1038/icb.1981.18; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OHMORI Y, 1990, J IMMUNOL, V145, P3333; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOMERS SD, 1986, J IMMUNOL, V136, P4199; SPRINGER T, 1991, CURRENT PROTOCOLS IM, V1; SRIMAL S, 1990, J EXP MED, V171, P1347, DOI 10.1084/jem.171.4.1347; STENGER S, 1991, EUR J IMMUNOL, V21, P1669, DOI 10.1002/eji.1830210713; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TREDE NS, 1991, J IMMUNOL, V146, P2310; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X	47	503	526	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23301	23308						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429677				2022-12-27	WOS:A1992JY16300091
J	DESAI, NN; ZHANG, H; OLIVERA, A; MATTIE, ME; SPIEGEL, S				DESAI, NN; ZHANG, H; OLIVERA, A; MATTIE, ME; SPIEGEL, S			SPHINGOSINE-1-PHOSPHATE, A METABOLITE OF SPHINGOSINE, INCREASES PHOSPHATIDIC-ACID LEVELS BY PHOSPHOLIPASE-D ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; LONG-CHAIN BASES; DIACYLGLYCEROL KINASE; SIGNAL TRANSDUCTION; CELLULAR PROLIFERATION; HUMAN-NEUTROPHILS; HUMAN-PLATELETS; HL-60 CELLS; 3T3 CELLS	Sphingosine and sphingosine-1-phosphate, metabolites of membrane sphingolipids, have recently been shown to stimulate release of calcium from internal sources and to increase proliferation of quiescent Swiss 3T3 fibroblasts (Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155-167). The present study demonstrates that mitogenic concentrations of sphingosine induce early increases in sphingosine-1-phosphate levels which precede the increase in the potent mitogen, phosphatidic acid. Sphingosine-1-phosphate itself induces a more rapid increase in phosphatidic acid, thus suggesting that it may mediate the effects of sphingosine on phosphatidic acid accumulation. The concentration dependence for the formation of phosphatidic acid induced by sphingosine-1-phosphate correlates with its effect on DNA synthesis. Similar to sphingosine, sphingosine-1-phosphate also stimulates the activity of phospholipase D, although a significant effect is observed at a much lower concentration. However, in contrast to previous reports with sphingosine, sphingosine-1-phosphate does not inhibit the phosphatidic acid phosphohydrolase activity in cell homogenates. Thus, in addition to its effect on mobilization of calcium, sphingosine-1-phosphate can increase the level of phosphatidic acid, most likely via activation of phospholipase D. We suggest that sphingosine-1-phosphate mediates the effect of sphingosine on phosphatidic acid accumulation in Swiss 3T3 fibroblasts and may regulate cellular proliferation by affecting multiple transmembrane signaling pathways.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,357 BASIC SCI BLDG,3900 RESERVOIR RD NW,WASHINGTON,DC 20007	Georgetown University					NIGMS NIH HHS [1RO1 GM43880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P777; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; EXTON JH, 1990, J BIOL CHEM, V265, P1; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P3138; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KISS Z, 1990, J BIOL CHEM, V265, P7345; KRISHNAMURTHI S, 1989, BIOCHIM BIOPHYS ACTA, V1010, P258, DOI 10.1016/0167-4889(89)90170-5; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MAHADEVAPPA VG, 1988, BIOCHEM BIOPH RES CO, V153, P1097, DOI 10.1016/S0006-291X(88)81341-X; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORRIS C, 1988, BIOCHEM BIOPH RES CO, V155, P561, DOI 10.1016/S0006-291X(88)80531-X; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NUNN DL, 1987, BIOCHEM J, V243, P809, DOI 10.1042/bj2430809; PAI JK, 1988, J BIOL CHEM, V263, P12472; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P635, DOI 10.1515/bchm2.1970.351.1.635; Sweely CC, 1985, BIOCH LIPIDS MEMBRAN, P361; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; WILSON E, 1988, J BIOL CHEM, V263, P9304; WILSON E, 1986, J BIOL CHEM, V261, P2616; WINICOV I, 1988, J BIOL CHEM, V263, P12179; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	50	162	165	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23122	23128						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429659				2022-12-27	WOS:A1992JY16300065
J	HWANG, DS; KORNBERG, A				HWANG, DS; KORNBERG, A			OPENING OF THE REPLICATION ORIGIN OF ESCHERICHIA-COLI BY DNAA PROTEIN WITH PROTEIN HU OR IHF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; HISTONE-LIKE PROTEINS; CHROMOSOMAL ORIGIN; ENZYMATIC REPLICATION; INITIATION PROTEIN; AUTO-REGULATION; BINDING; INVITRO; GENE; SITES	Opening of the three tandem repeats of a 13-mer in the replication origin (oriC) of Escherichia coli is a prime event in the replication in vitro of minichromosomes (Bramhill, D., and Kornberg, A. (1988) Cell 54, 915-918). DnaA, the initiator protein, requires protein HU or IHF, along with a millimolar level of ATP and negative superhelical density in the plasmid to open this region. The extent of opening, as judged by cleavage by a single-strand-specific endonuclease (i.e. Pl nuclease), correlated closely with replication of the oriC plasmid. In an initial complex, preceding opening of the 13-mers, the footprint of DnaA protein bound by ATP covered its four 9-mer recognition sequences. The footprint of the nucleotide-free form of the protein, by contrast, was more extensive and thus, less specific.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; GAMAS P, 1986, MOL GEN GENET, V204, P85, DOI 10.1007/BF00330192; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HANSEN FG, 1977, MOL GEN GENET, V155, P219, DOI 10.1007/BF00393163; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUISMAN O, 1989, J BACTERIOL, V171, P3704, DOI 10.1128/jb.171.7.3704-3712.1989; HWANG DS, 1992, J BIOL CHEM, V267, P23087; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWNAG DS, 1990, J BIOL CHEM, V265, P19244; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; Kornberg A., 1992, DNA REPLICATION; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; POLACZEK P, 1990, New Biologist, V2, P265; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHAMBROOK J, 1989, MOL CLONING LABORATO; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; THONY B, 1991, P NATL ACAD SCI USA, V88, P4066, DOI 10.1073/pnas.88.10.4066; VONMEYENBURG K, 1987, CELLULAR MOL BIOL, V2, P1555; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	46	220	221	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23083	23086						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429655				2022-12-27	WOS:A1992JY16300059
J	YAN, RQ; RYCHLIK, W; ETCHISON, D; RHOADS, RE				YAN, RQ; RYCHLIK, W; ETCHISON, D; RHOADS, RE			AMINO-ACID-SEQUENCE OF THE HUMAN PROTEIN-SYNTHESIS INITIATION FACTOR-EIF-4-GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA TRANSLATION; INFECTED HELA-CELLS; POLIOVIRUS RNA; FACTOR-III; SUBSTRATE-SPECIFICITY; 2A PROTEINASE; KINASE-C; COMPLEX; PHOSPHORYLATION	Eukaryotic protein synthesis initiation factor (eIF) 4gamma, also known as p220, is a component of the protein complex eIF-4, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome. Peptide sequence data from rabbit reticulocyte eIF-4gamma was used to synthesize oligonucleotide probes and polymerase chain reaction primers. These were used to screen lambda-cDNA libraries from rabbit and human brain, yielding a partial rabbit and a complete human cDNA sequence of 5.1 kilobases. Northern blot and primer extension analysis indicated that the cDNA sequence was complete. To confirm that the cDNA represented that of eIF-4gamma, three peptides were synthesized based on cDNA sequences and used to produce anti-peptide antibodies. The antibodies specifically recognized intact eIF-4gamma and its cleavage products following poliovirus infection. The eIF-4gamma mRNA contains AUG codons at nucleotides 6, 67, 90, 165, and 369, but only the last is followed by a long open reading frame. The eIF-4gamma polypeptide is 154 kDa (1396 amino acid residues) and contains sequence motifs of potential interest: a sequence (AGLGPR) that is similar to the substrate recognition sequence of protease 2A from rhinovirus serotype 14, five PEST regions with scores greater than 10, which are characteristic of rapidly degraded proteins, stretches of polyglutamic acid, and numerous potential phosphorylation sites.	UNIV KENTUCKY, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; UNIV KANSAS, MED CTR, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66160 USA	University of Kentucky; University of Kansas; University of Kansas Medical Center				Yan, Riqiang/0000-0001-7195-7617	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024356] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24356] Funding Source: Medline; NIGMS NIH HHS [GM20818] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN ML, 1992, J BIOL CHEM, V267, P23232; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BIENKOWSKASZEWCZYK K, 1988, J VIROL, V62, P3068, DOI 10.1128/JVI.62.8.3068-3072.1988; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; ETCHISON D, 1980, J VIROL, V107, P135; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GLASS DB, 1983, J BIOL CHEM, V258, P4797; GOLD L, 1984, P NATL ACAD SCI-BIOL, V81, P7061, DOI 10.1073/pnas.81.22.7061; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JOSHIBARVE S, 1992, IN PRESS J BIOL CHEM, V267; KAWASAKI E, 1990, PRC PROTOCOLS GUIDE, P119; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SONENBERG N, 1990, New Biologist, V2, P402; STANWAY G, 1984, NUCLEIC ACIDS RES, V12, P7859, DOI 10.1093/nar/12.20.7859; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; WEST RR, 1991, J BIOL CHEM, V266, P21886; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007	58	131	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23226	23231						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429670				2022-12-27	WOS:A1992JY16300080
J	BIRDSALL, DL; MCPHERSON, A				BIRDSALL, DL; MCPHERSON, A			CRYSTAL-STRUCTURE DISPOSITION OF THYMIDYLIC ACID TETRAMER IN COMPLEX WITH RIBONUCLEASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFRACTION DATA; ACTIVE-SITE; X-RAY; PANCREATIC RIBONUCLEASE; NEUTRON-DIFFRACTION; 2.8-A RESOLUTION; REFINEMENT; BINDING; MECHANISM; D(PA)4	The crystal structure of ribonuclease A with bound thymidylic acid tetramer is reported at 2.5-angstrom resolution. The diffusion of the tetramer into native orthorhombic crystals of the ribonuclease allows for the formation of a structurally stable complex where the single-stranded nucleic acid enters and leaves the enzyme's catalytic region in a persistent 5'-3' direction. The binding of the tetramer to the enzyme's surface is facilitated and mediated by electrostatic interactions between basic protein residues and nucleotide phosphates. Two pyrimidine nucleotides are bound to the enzyme's active site in a manner similar to that observed for other complexes between ribonuclease A and nucleic acid oligomers.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	BIRDSALL, DL (corresponding author), LAWRENCE LIVERMORE NATL LAB, DIV BIOMED SCI, LIVERMORE, CA 94550 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011235] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 F32 GM11235] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ANFINSEN CB, 1961, ENZYMES, V5; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BLACKBURN P, 1982, ENZYMES, V15; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BRAYER GD, 1982, J BIOL CHEM, V257, P3359; BROWN DM, 1955, NUCLEIC ACIDS, V1, P409; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CAMPBELL RL, 1987, BIOCHEMISTRY-US, V26, P8579, DOI 10.1021/bi00400a013; IWAHASHI K, 1981, J BIOCHEM-TOKYO, V90, P1685, DOI 10.1093/oxfordjournals.jbchem.a133644; JONES TA, 1982, COMPUTATIONAL CRYSTA, P307; KARPEL RL, 1981, BIOCHEM BIOPH RES CO, V100, P760, DOI 10.1016/S0006-291X(81)80240-9; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; MCPHERSON A, 1986, BIOPHYS J, V49, P209, DOI 10.1016/S0006-3495(86)83635-9; MCPHERSON A, 1986, J MOL BIOL, V189, P305, DOI 10.1016/0022-2836(86)90512-7; MCPHERSON A, 1982, PREPARATION ANAL PRO, P94; MITSUI Y, 1978, BIOCHIM BIOPHYS ACTA, V535, P299, DOI 10.1016/0005-2795(78)90096-X; MOEWS PC, 1976, J AM CHEM SOC, V98, P6628, DOI 10.1021/ja00437a035; NACHMAN J, 1990, BIOCHEMISTRY-US, V29, P928, DOI 10.1021/bi00456a012; PAVLOVSKY AG, 1978, FEBS LETT, V92, P258, DOI 10.1016/0014-5793(78)80766-2; PEARLMAN DA, 1990, J MOL BIOL, V211, P171, DOI 10.1016/0022-2836(90)90019-I; RICHARDS FM, 1973, ATLAS MOL STRUCTURES, V1; RICHARDS FM, 1971, ENZYMES, V4; SAENGER W, 1970, J MOL BIOL, V50, P153, DOI 10.1016/0022-2836(70)90112-9; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P69; SAWADA F, 1969, J BIOCHEM-TOKYO, V66, P415, DOI 10.1093/oxfordjournals.jbchem.a129162; SEKINE H, 1969, BIOCHIM BIOPHYS ACTA, V174, P202, DOI 10.1016/0005-2787(69)90243-3; SMYTH DG, 1963, J BIOL CHEM, V238, P227; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TENEYCK LF, 1976, ACTA CRYSTALLOGR A, V32, P349; USHER DA, 1972, P NATL ACAD SCI USA, V69, P115, DOI 10.1073/pnas.69.1.115; USHER DA, 1970, NATURE, V228, P663, DOI 10.1038/228663a0; WALZ FG, 1971, BIOCHEMISTRY-US, V10, P2156, DOI 10.1021/bi00787a031; WEBB LE, 1973, BIOCHEMISTRY-US, V12, P5101, DOI 10.1021/bi00749a013; WLODAWER A, 1983, BIOCHEMISTRY-US, V22, P2720, DOI 10.1021/bi00280a021; WLODAWER A, 1982, ACTA CRYSTALLOGR A, V38, P239, DOI 10.1107/S0567739482000527; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WLODAWER A, 1984, BIOL MACROMOL, P393; WLODAWER A, 1985, BIOL MACROMOL, V2, P395; WODAK SY, 1977, J MOL BIOL, V116, P855, DOI 10.1016/0022-2836(77)90275-3; WYCKOFF HW, 1970, J BIOL CHEM, V245, P305	45	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22230	22236						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429575				2022-12-27	WOS:A1992JW71900039
J	FIEDOR, L; ROSENBACHBELKIN, V; SCHERZ, A				FIEDOR, L; ROSENBACHBELKIN, V; SCHERZ, A			THE STEREOSPECIFIC INTERACTION BETWEEN CHLOROPHYLLS AND CHLOROPHYLLASE - POSSIBLE IMPLICATION FOR CHLOROPHYLL BIOSYNTHESIS AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOCHLOROPHYLL-A BIOSYNTHESIS; COLUMN CHROMATOGRAPHY; ORGANIC MEDIA; C-13 NMR; PHEOPHYTINS; EPIMER; LEAVES; INVIVO	Chlorophyllase-catalyzed hydrolysis and esterification of chlorophylls, bacteriochlorophylls, and their free acids, respectively, depend on the configuration around the C-13(2) atom of the corresponding substrate. The data suggest that the enzyme interacts preferentially with compounds having the isocyclic carbomethoxy and the C-17 propionic residues facing opposite sides of the porphyrin macrocycle. The relevance of this observation to chlorophyll biosynthesis and degradation in vivo is briefly discussed.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								Abraham R. J., 1991, CHLOROPHYLLS, P797; AKHTAR M, 1984, BIOCHEM J, V224, P187, DOI 10.1042/bj2240187; AMIRSHAPIRA D, 1987, P NATL ACAD SCI USA, V84, P1901, DOI 10.1073/pnas.84.7.1901; BENZ J, 1981, Z NATURFORSCH C, V36, P51; Brown SB., 1991, CHLOROPHYLLS, P465; CAMBOU B, 1984, J AM CHEM SOC, V106, P2687, DOI 10.1021/ja00321a033; EMERY VC, 1987, BIOCHEMISTRY-US, V26, P1200, DOI 10.1021/bi00378a031; HENDRY GAF, 1987, NEW PHYTOL, V107, P255, DOI 10.1111/j.1469-8137.1987.tb00181.x; HIYAMA T, 1987, FEBS LETT, V214, P97, DOI 10.1016/0014-5793(87)80020-0; Holden M, 1976, CHEM BIOCH PLANT PIG, P1; Hynninen P. H., 1991, CHEM CHLOROPHYLLS MO, P145; KOBAYASHI M, 1991, FEBS LETT, V284, P129, DOI 10.1016/0014-5793(91)80778-2; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1057, P89, DOI 10.1016/S0005-2728(05)80087-8; Liljenberg C., 1977, Lipids and lipid polymers in higher plants., P259; LOTJONEN S, 1983, ORG MAGN RESONANCE, V21, P757, DOI 10.1002/omr.1270211208; MCFEETERS RF, 1975, PLANT PHYSIOL, V55, P377, DOI 10.1104/pp.55.2.377; MCFEETERS RF, 1971, PLANT PHYSIOL, V47, P609, DOI 10.1104/pp.47.5.609; MICHALSKI TJ, 1988, J AM CHEM SOC, V110, P5888, DOI 10.1021/ja00225a047; OMATA T, 1983, PLANT CELL PHYSIOL, V24, P1093; PARIDA S, 1991, J AM CHEM SOC, V113, P2253, DOI 10.1021/ja00006a051; ROSENBACHBELKIN V, 1988, THESIS WEIZMANN I RE; RUDIGER W, 1989, NATURWISSENSCHAFTEN, V76, P453, DOI 10.1007/BF00366221; RUDIGER W, 1991, CHLOROPHYLLS, P451; RUDOI A B, 1982, Biokhimiya, V47, P733; SATO N, 1978, BIOCHIM BIOPHYS ACTA, V501, P103, DOI 10.1016/0005-2728(78)90099-3; SCHERZ A, 1984, BIOCHIM BIOPHYS ACTA, V766, P653, DOI 10.1016/0005-2728(84)90127-0; SCHOCH S, 1987, J PLANT PHYSL, V126, P283; Strain HH, 1942, J BIOL CHEM, V146, P275; THORNBER JP, 1987, PHYSIOL PLANTARUM, V71, P236, DOI 10.1111/j.1399-3054.1987.tb02874.x; WATANABE T, 1985, FEBS LETT, V191, P252, DOI 10.1016/0014-5793(85)80019-3; WATANABE T, 1985, BIOCHIM BIOPHYS ACTA, V807, P110, DOI 10.1016/0005-2728(85)90113-6; WATANABE T, 1984, ANAL CHEM, V56, P251, DOI 10.1021/ac00266a030; Willstatter R, 1911, LIEBIGS ANN CHEM, V380, P148	33	52	58	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22043	22047						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429554				2022-12-27	WOS:A1992JW71900012
J	FRUH, K; YANG, Y; ARNOLD, D; CHAMBERS, J; WU, L; WATERS, JB; SPIES, T; PETERSON, PA				FRUH, K; YANG, Y; ARNOLD, D; CHAMBERS, J; WU, L; WATERS, JB; SPIES, T; PETERSON, PA			ALTERNATIVE EXON USAGE AND PROCESSING OF THE MAJOR HISTOCOMPATIBILITY COMPLEX-ENCODED PROTEASOME SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II REGION; MULTICATALYTIC PROTEINASE COMPLEXES; RAT HEPATOMA-CELLS; HUMAN MHC; MOLECULAR-CLONING; ESCHERICHIA-COLI; CDNA CLONING; TRANSMEMBRANE PROTEINS; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR	The finding that two subunits of the proteasome, LMP2 and LMP7, are encoded in the major histocompatibility complex (MHC) has linked the proteasome which represents a major extralysosomal proteolytic system to the processing of intracellular antigens. Here we describe a second form of the human LMP7 cDNA, LMP7-E2, which has been identified during the characterization of novel genes in the MHC. The analysis of the genome organization of LMP7 revealed that LMP7-E1 and LMP7-E2 arise by alternative exon usage. Using specific antibodies against LMP2 and LMP7, we show that they are co-expressed with class I MHC molecules as well as a putative peptide transporter. The polypeptides encoded by LMP7 and LMP2 undergo proteolytic processing when incorporated into proteasomes, and the LMP7 precursor is derived mainly from LMP7-E2. Furthermore, our data suggest that LMP7 and LMP2 are mutually dependent for their incorporation into the proteasomal complex.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	FRUH, K (corresponding author), SCRIPPS RES INST, LA JOLLA, CA 92037 USA.			Frueh, Klaus/0000-0001-8014-3877				ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BLANCK G, 1988, J IMMUNOL, V141, P1734; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRENTZEL S, 1992, FEBS LETT, V302, P121, DOI 10.1016/0014-5793(92)80420-L; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KUMATORI A, 1990, FEBS LETT, V264, P279, DOI 10.1016/0014-5793(90)80267-M; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PARHAM P, 1992, NATURE, V357, P193, DOI 10.1038/357193a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Sambrook J, 1989, MOL CLONING LABORATO; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPIES T, 1989, P NATL ACAD SCI USA, V86, P8955, DOI 10.1073/pnas.86.22.8955; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWEENEY ST, 1989, BIOCHEM SOC T, V17, P1126, DOI 10.1042/bst0171126; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1990, BIOCHEMISTRY-US, V29, P3777, DOI 10.1021/bi00467a026; TOKUNAGA F, 1990, FEBS LETT, V263, P373, DOI 10.1016/0014-5793(90)81417-M; TOWSEND A, 1989, ANNU REV IMMUNOL, V7, P601; TROWSDALE J, 1991, IMMUNOL TODAY, V12, P443, DOI 10.1016/0167-5699(91)90017-N; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YANG Y, 1992, J BIOL CHEM, V267, P11669; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	55	118	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22131	22140						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429565				2022-12-27	WOS:A1992JW71900025
J	GIBSON, QH; REGAN, R; ELBER, R; OLSON, JS; CARVER, TE				GIBSON, QH; REGAN, R; ELBER, R; OLSON, JS; CARVER, TE			DISTAL POCKET RESIDUES AFFECT PICOSECOND LIGAND RECOMBINATION IN MYOGLOBIN - AN EXPERIMENTAL AND MOLECULAR-DYNAMICS STUDY OF POSITION 29 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; HEME-PROTEINS; GEMINATE RECOMBINATION; CARBON-MONOXIDE; HUMAN-HEMOGLOBIN; BINDING; SIMULATION; KINETICS; DISSOCIATION	Time courses for intramolecular NO and O2 recombination to native and three position 29 mutants of sperm whale myoglobins were measured after laser photolysis on picosecond and nanosecond time scales. The rates for the first phase of NO recombination were 1.8, 2.5, 29, and greater-than-or-equal-to 100 ns-1 for Ala29, Val29, Leu29(native), and Phe29 myoglobin, respectively, at room temperature. This order is not correlated with the overall association rate constants for NO binding which were all in the range 20-50 x 10(6) M-1 s-1 and is the opposite of that observed for the rate constants for the overall thermal dissociation of NO which were 5.0, 2.8, 0.98, and 0.21 x 10(-4) s-1 for Ala29, Val29, Leu29(native), and Phe29 myoglobin, respectively, at 20-degrees-C. This inverse correlation suggests that photo- and thermally dissociated ligand molecules experience similar kinetic and equilibrium barriers to rebinding. The larger side chains of Leu29 and Phe29 inhibit rapid movement of the ligand away from the iron atom facilitating geminate recombination. The smaller side chains of Val29 and Ala29 increase the space available to the ligand, decreasing the rate of geminate recombination and enhancing complete dissociation. Diffusion of NO in the distal pocket of myoglobin was simulated using a variant of the molecular dynamics program CHARMM that includes the locally enhanced sampling protocol (Elber, R., and Karplus, M. (1991) J. Am. Chem. Soc. 112, 9161-9175; Roitberg, A., and Elber, R. (1991) J. Chem. Phys. 95, 9277-9287) and the x-ray structures of Carver et al. (Carver, T. E., Brantley, R. E., Jr., Singleton, E. W., Arduini, R. M., Quillin, M. L., Phillips, G. N., Jr., and Olson, J. S. (1992) J. Biol. Chem. 267, 14443-14450). Both accelerated (5,000 K) and room temperature ligands were used, and comparisons were made between simulations with a complete hydration shell surrounding the protein and those with only eight water molecules near the distal histidine. Photodissociated ligands initially move away from the heme plane, past Leu29, and toward Leu32, Phe33, Ile107, and Ile111. These theoretical results confirm that a complete description of picosecond ligand recombination must include the dynamics of ligand movement in the distal portion of the heme pocket.	UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60680 USA; RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; RICE UNIV, WM KECK CTR COMPUTAT BIOL, HOUSTON, TX 77251 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rice University; Rice University	GIBSON, QH (corresponding author), CORNELL UNIV, DEPT BIOCHEM MOLEC & CELL BIOL, ITHACA, NY 14853 USA.			Olson, John/0000-0002-0760-5403	NIGMS NIH HHS [GM-41905, GM-35649, GM-14276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276, R01GM035649, R01GM041905] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI S, 1992, J BIOL CHEM, V267, P12614; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANSARI A, 1986, BIOCHEMISTRY-US, V25, P3139, DOI 10.1021/bi00359a011; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, PROTEINS, V4, P148, DOI 10.1002/prot.340040208; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CORNELIUS PA, 1981, P NATL ACAD SCI-BIOL, V78, P7526, DOI 10.1073/pnas.78.12.7526; CZERMINSKI R, 1991, PROTEINS, V10, P70, DOI 10.1002/prot.340100107; DUDDELL DA, 1980, PHOTOCHEM PHOTOBIOL, V31, P479, DOI 10.1111/j.1751-1097.1980.tb03732.x; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GREENE BI, 1978, P NATL ACAD SCI USA, V75, P5255, DOI 10.1073/pnas.75.11.5255; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1985, P NATL ACAD SCI USA, V82, P2034, DOI 10.1073/pnas.82.7.2034; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; MARDEN MC, 1986, BIOCHEMISTRY-US, V25, P2786, DOI 10.1021/bi00358a008; MATHEWS AJ, 1991, J BIOL CHEM, V266, P21631; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MOORE EG, 1976, J BIOL CHEM, V251, P2788; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; NOWAK W, 1991, J AM CHEM SOC, V113, P5627, DOI 10.1021/ja00015a016; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROITBERG A, 1991, J CHEM PHYS, V95, P9277, DOI 10.1063/1.461157; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SASSAROLI M, 1986, J BIOL CHEM, V261, P6292; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STRAJER V, 1991, BIOCHEMISTRY-US, V30, P4886; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; TILTON RF, 1986, J MOL BIOL, V192, P443, DOI 10.1016/0022-2836(86)90374-8; TILTON RF, 1988, J MOL BIOL, V199, P195, DOI 10.1016/0022-2836(88)90389-0	48	150	151	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22022	22034						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429552				2022-12-27	WOS:A1992JW71900010
J	MAENZ, DD; PATIENCE, JF				MAENZ, DD; PATIENCE, JF			L-THREONINE TRANSPORT IN PIG JEJUNAL BRUSH-BORDER MEMBRANE-VESICLES - FUNCTIONAL-CHARACTERIZATION OF THE UNIQUE SYSTEM-B IN THE INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; RAPID FILTRATION APPARATUS; CELL LINE; GLUCOSE COTRANSPORT; MOUSE BLASTOCYSTS; NA+; RABBIT; ASC; HEPATOCYTES	Uptake and inhibitory kinetics of [H-3]L-threonine were evaluated in preparations of pig jejunal brush border membrane vesicles. Uptake of [H-3]L-threonine under 0-trans, Na+ gradient, and 0-trans, Na+-free conditions was best described by high affinity transport (K(m) < 0.1 mM) plus a nonsaturable component. The maximal velocity of transport was 3-fold greater under Na+ gradient conditions. 100 mM concentrations of all of the dipolar amino acids and 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid caused complete inhibition of [H-3]L-threonine transport under Na+ gradient and Na+-free conditions. Imino acids, anionic amino acids, cationic amino acids, and methylamino-isobutyric acid caused significant partial inhibition of L-threonine uptake. Inhibitor concentration profiles for proline and lysine were consistent with low affinity competitive inhibition. The K(i) values of alanine and phenylalanine approximated 0.2 and 0.5 mM, respectively, under both Na+ gradient and Na+-free conditions. These data indicate that the transport system available for L-threonine in the intestinal brush border membrane (system B) is functionally distinct from other amino acid transport systems. Comparison of kinetics parameters in the presence and absence of a Na+ gradient suggests that both partially and fully loaded forms of the carrier can function to translocate substrate and that Na+ serves to accelerate L-threonine transport by a mechanism that does not involve enhanced substrate binding.			MAENZ, DD (corresponding author), UNIV SASKATCHEWAN,DEPT ANIM & POULTRY SCI,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA.		Patience, john F./A-2935-2009					BARS R, 1981, J BIOL CHEM, V256, P10259; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BERTELOOT A, 1991, J MEMBRANE BIOL, V122, P111, DOI 10.1007/BF01872635; BOERNER P, 1986, J BIOL CHEM, V261, P13957; CENTELLES JJ, 1991, BIOCHIM BIOPHYS ACTA, V1065, P239, DOI 10.1016/0005-2736(91)90236-2; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1510; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; KUHLMANN MK, 1991, J BIOL CHEM, V266, P15042; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; MAENZ DD, 1982, J MEMBRANE BIOL, V70, P125, DOI 10.1007/BF01870222; MAENZ DD, 1991, BIOCHIM BIOPHYS ACTA, V1069, P250, DOI 10.1016/0005-2736(91)90132-R; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; PARKINSO.DK, 1972, J CLIN INVEST, V51, P2292, DOI 10.1172/JCI107039; SAIER MH, 1988, J MEMBRANE BIOL, V104, P1, DOI 10.1007/BF01871898; SEMENZA G, 1984, BIOCHIM BIOPHYS ACTA, V779, P343, DOI 10.1016/0304-4157(84)90016-9; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1992, IN PRESS AM J PHYSL; STEVENS BR, IN PRESS MAMMALIAN A; VADGAMA JV, 1991, AM J PHYSIOL, V260, pC392, DOI 10.1152/ajpcell.1991.260.3.C392; VADGAMA JV, 1983, J BIOL CHEM, V258, P6422; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; VANWINKLE LJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P173, DOI 10.1016/0304-4157(88)90024-X; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118	29	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22079	22086						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429560				2022-12-27	WOS:A1992JW71900018
J	KAMATA, H; AKIYAMA, S; MOROSAWA, H; OHTA, T; HAMAMOTO, T; KAMBE, T; KAGAWA, Y; HIRATA, H				KAMATA, H; AKIYAMA, S; MOROSAWA, H; OHTA, T; HAMAMOTO, T; KAMBE, T; KAGAWA, Y; HIRATA, H			PRIMARY STRUCTURE OF THE ALANINE CARRIER PROTEIN OF THERMOPHILIC BACTERIUM-PS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; THERMUS-THERMOPHILUS; PROLINE CARRIER; SODIUM-ION; GENE; TRANSPORT; SUBUNIT; CHAIN; POLYPEPTIDE	Purified alanine carrier proteins were cleaved into peptides either chemically after solubilization in 1,1,1,3,3,3-hexafluoro-2-propanol or proteolytically with lysylendopeptidase. From the amino acid sequence analyses of these peptides, we synthesized a DNA probe and utilized it for successful cloning of a gene encoding the alanine carrier protein (acp gene). The 5'-flanking region was determined by an inverse polymerase chain reaction, and an open reading frame consisting of 1,335 nucleotides was found. The amino acid sequence deduced from the open reading frame consists of 445 amino acids, and all the partial amino acid sequences determined are included in the sequence. Although the calculated M(r) of 47,803 is significantly larger than the apparent M(r) of 42,500 as reported previously (Hirata, H., Kambe, T., and Kagawa, Y. (1984) J. Biol. Chem. 259, 10653-10656), an in vitro translation experiment revealed that the product of the acp gene migrates at a position coinciding with that of the purified alanine carrier. Hydropathy analysis suggests that the protein contains at least 8 hydrophobic segments presumably spanning membrane. A homology search on a database reveals relatively high scores of homology with either the Escherichia coli melibiose carrier or the human Na+/glucose symporter, particularly in the region from Leu246 to Glu286. Furthermore, the region also reveals low but significant similarities to other Na+-coupled symporters.	HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,HIMEJI,HYOGO 67812,JAPAN; JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV CHIBA,FAC HORT,DEPT AGR CHEM,CHIBA 271,JAPAN; UNIV TSUKUBA,SCH MED,DEPT MICROBIOL,TSUKUBA,IBARAKI 305,JAPAN; INST PHYS & CHEM RES,GLYCO MOLEC BIOL LAB,SAITAMA 35101,JAPAN	University of Hyogo; Jichi Medical University; Chiba University; University of Tsukuba; RIKEN			Kamata, Hideaki/N-3907-2017					DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; FOSTER DL, 1983, J BIOL CHEM, V258, P31; HASAN SM, 1977, BIOCHEM BIOPH RES CO, V78, P122, DOI 10.1016/0006-291X(77)91229-3; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HIRATA H, 1976, BIOCHEM BIOPH RES CO, V69, P665, DOI 10.1016/0006-291X(76)90927-X; HIRATA H, 1984, J BIOL CHEM, V259, P653; HIRATA H, 1986, METHOD ENZYMOL, V125, P485; HIRATA H, 1979, FUNCTION MOL ASPECTS, P505; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; KAGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P923, DOI 10.1093/oxfordjournals.jbchem.a121805; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MENICK DR, 1985, BIOCHEM BIOPH RES CO, V132, P860; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAGAHARI K, 1980, GENE, V10, P137; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; RIZZOLO LJ, 1976, BIOCHEMISTRY-US, V15, P3433, DOI 10.1021/bi00661a006; SAISHU T, 1986, BIOCHIM BIOPHYS ACTA, V867, P97, DOI 10.1016/0167-4781(86)90069-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONE N, 1988, J BIOCHEM-TOKYO, V103, P606, DOI 10.1093/oxfordjournals.jbchem.a122314; TSUCHIYA T, 1978, J MEMBRANE BIOL, V42, P45, DOI 10.1007/BF01870393; TSUCHIYA T, 1985, FEBS LETT, V168, P327; URATANI Y, 1989, J MEMBRANE BIOL, V107, P57, DOI 10.1007/BF01871083; YAMATO I, 1988, J BIOL CHEM, V263, P16055; YAZYU H, 1984, J BIOL CHEM, V259, P4320	27	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21650	21655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400476				2022-12-27	WOS:A1992JV01100062
J	LI, XJ; FORTE, M; NORTH, RA; ROSS, CA; SNYDER, SH				LI, XJ; FORTE, M; NORTH, RA; ROSS, CA; SNYDER, SH			CLONING AND EXPRESSION OF A RAT SOMATOSTATIN RECEPTOR ENRICHED IN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; CEREBRAL-CORTEX; SENILE DEMENTIA; BINDING-SITES; DISEASE; PEPTIDES; ANALOGS; NEURONS	The tetradecapeptide somatostatin (SRIF) is a hormone release-inhibiting substance that mediates diverse effects in brain and peripheral organs via specific receptors. A cDNA encoding a rat SRIF receptor was identified by use of degenerate oligonucleotide primers and polymerase chain reaction amplification of cDNA prepared from transcripts expressed in rat brain. The complete cDNA encodes a protein of 391 amino acids with seven potential transmembrane domains. Expression of the cDNA product in transfected COS-7 cell lines provides the same high affinity of binding to [I-125-Tyr11]SRIF-14 as that of rat cerebral cortex tissues. However, the binding of [I-125-Tyr11]SRIF-14 to cloned rat SRIF receptor is not displaced by MK678, a SRIF analog that partially displaces [I-125-Tyr11]SRIF-14 binding sites in membranes of rat cerebral cortex. Northern analysis and in situ hybridization indicate that mRNA (4.0 kilobases) for cloned rat SRIF receptor is preferentially expressed in rat brain regions such as cerebral cortex and hippocampus with no detectable expression in most peripheral organs. This pattern contrasts with the exclusive peripheral expression of a recently cloned human SRIF receptor. The cDNA probe of rat receptor detects mRNA from mouse brain but not from human cerebral cortex and cerebellum.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHARMACOL & MOLEC SCI,PORTLAND,OR 97201	Johns Hopkins University; Johns Hopkins University; Oregon Health & Science University; Oregon Health & Science University			North, Richard/GQA-6156-2022		NIDA NIH HHS [DA 00074, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AGUILERA G, 1981, NATURE, V292, P262, DOI 10.1038/292262a0; BEAL MF, 1985, SCIENCE, V229, P289, DOI 10.1126/science.2861661; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER PE, 1981, NEUROLOGY, V31, P64; DAVIES P, 1980, NATURE, V288, P279, DOI 10.1038/288279a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EPELBAUM J, 1982, J NEUROCHEM, V38, P1515, DOI 10.1111/j.1471-4159.1982.tb06627.x; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; GANZI, 1991, P NATL ACAD SCI USA, V88, P429; KEMP BE, 1990, TRENDS PHARMACOL SCI, V11, P492; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LI XJ, 1992, J BIOL CHEM, V267, P9; LI XJ, 1991, EMBO J, V10, P3221, DOI 10.1002/j.1460-2075.1991.tb04885.x; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; NEMEROFF C, 1984, SCIENCE, V221, P972; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; Pelletier G, 1986, Methods Enzymol, V124, P607; RAYNOR K, 1989, J PHARMACOL EXP THER, V251, P510; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REISINE T, 1991, METHODS NEUROSCI, V5, P215; REUBI JC, 1981, LIFE SCI, V28, P2191, DOI 10.1016/0024-3205(81)90628-7; REUBI JC, 1985, NEUROSCIENCE, V15, P1183, DOI 10.1016/0306-4522(85)90261-1; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSOR MN, 1980, NEUROSCI LETT, V20, P373, DOI 10.1016/0304-3940(80)90177-9; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRIKANT CB, 1981, P NATL ACAD SCI USA, V78, P3930; STRIKANT CB, 1981, NATURE, V294, P259; SURPRENANT A, 1990, J PHYSIOL-LONDON, V431, P585, DOI 10.1113/jphysiol.1990.sp018349; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TRAN VT, 1985, SCIENCE, V228, P492, DOI 10.1126/science.2858917; UHL GR, 1985, J COMP NEUROL, V240, P288, DOI 10.1002/cne.902400306; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	35	107	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21307	21312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400442				2022-12-27	WOS:A1992JV01100010
J	LOCKER, JK; ROSE, JK; HORZINEK, MC; ROTTIER, PJM				LOCKER, JK; ROSE, JK; HORZINEK, MC; ROTTIER, PJM			MEMBRANE ASSEMBLY OF THE TRIPLE-SPANNING CORONAVIRUS M-PROTEIN - INDIVIDUAL TRANSMEMBRANE DOMAINS SHOW PREFERRED ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; TRANS-GOLGI NETWORK; ONE SIGNAL SEQUENCE; SEMI-INTACT CELLS; E1 GLYCOPROTEIN; INTRACELLULAR-TRANSPORT; BREFELDIN-A; CHARGED RESIDUES; VACCINIA VIRUS	The M protein of mouse hepatitis virus strain A59 is a triple-spanning membrane protein which assembles with an uncleaved internal signal sequence, adopting an N(exo)C(cyt) orientation. To study the insertion mechanism of this protein, domains potentially involved in topogenesis were deleted and the effects analyzed in several ways. Mutant proteins were synthesized in a cell-free translation system in the presence of microsomal membranes, and their integration and topology were determined by alkaline extraction and by protease-protection experiments. By expression in COS-1 and Madin-Darby canine kidney-II cells, the topology of the mutant proteins was also analyzed in vivo. Glycosylation was used as a biochemical marker to assess the disposition of the NH2 terminus. An indirect immunofluorescence assay on semi-intact Madin-Darby canine kidney-II cells using domain-specific antibodies served to identify the cytoplasmically exposed domains. The results show that each membrane-spanning domain acts independently as an insertion and anchor signal and adopts an intrinsic preferred orientation in the lipid bilayer which corresponds to the disposition of the transmembrane domain in the wild-type assembled protein. These observations provide further insight into the mechanism of membrane integration of multispanning proteins. A model for the insertion of the coronavirus M protein is proposed.	UNIV UTRECHT,FAC VET,INST VIROL,DEPT INFECT DIS & IMMUNOL,YALELAAN 1,3584 CL UTRECHT,NETHERLANDS; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Utrecht University; Yale University; Yale University			Locker, Jacomine Krijnse/E-1009-2016; Locker, Jacomine Krijnse/AAX-1185-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024345, R01AI024345] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24345] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0; ARMSTRONG J, 1990, J CELL SCI, V95, P191; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FLEMING JO, 1989, VIROLOGY, V168, P162, DOI 10.1016/0042-6822(89)90415-7; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KAPKE PA, 1988, VIROLOGY, V165, P367, DOI 10.1016/0042-6822(88)90581-8; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAUDE H, 1987, J GEN VIROL, V68, P1687, DOI 10.1099/0022-1317-68-6-1687; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MAYER T, 1988, J BIOL CHEM, V263, P14956; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; RAPOPORT TA, 1986, CRC CR REV BIOCH MOL, V20, P73, DOI 10.3109/10409238609115901; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; ROTTIER P, 1985, J BIOL CHEM, V260, P4648; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987; ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981; ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990; VENNEMA H, 1991, VIROLOGY, V181, P327, DOI 10.1016/0042-6822(91)90499-2; VENNEMA H, 1992, J VIROL, V66, P4951, DOI 10.1128/JVI.66.8.4951-4956.1992; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; WILSON C, 1990, MOL CELL BIOL, V10, P449, DOI 10.1128/MCB.10.2.449; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	53	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21911	21918						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400501				2022-12-27	WOS:A1992JV01100100
J	MESHULAM, T; HERSCOVITZ, H; CASAVANT, D; BERNARDO, J; ROMAN, R; HAUGLAND, RP; STROHMEIER, GS; DIAMOND, RD; SIMONS, ER				MESHULAM, T; HERSCOVITZ, H; CASAVANT, D; BERNARDO, J; ROMAN, R; HAUGLAND, RP; STROHMEIER, GS; DIAMOND, RD; SIMONS, ER			FLOW CYTOMETRIC KINETIC MEASUREMENTS OF NEUTROPHIL PHOSPHOLIPASE-A ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; METHIONYL-LEUCYL-PHENYLALANINE; STIMULATED HUMAN-NEUTROPHILS; ARACHIDONIC-ACID METABOLISM; PLASMA-MEMBRANE VESICLES; SIGNAL TRANSDUCTION; CHEMOTACTIC PEPTIDE; DE-GRANULATION; RELEASE; PHE	The interrelationships between activation of phospholipases and neutrophil stimulus-induced Ca2+ responses remain unclear. We report here that immune complexes activate a phosphatidylcholine-specific phospholipase A in a neutrophil only after the cytoplasmic Ca2+ transient has been initiated in the same cell, while chemotactic peptide activation does not proceed via such a phospholipase A-mediated mechanism. Measurements of [Ca2+] changes and of phosphatidylcholine-specific phospholipase A activity were made by flow cytometry, using Indo-1 for Ca2+ indication, and a new fluorescent probe, bis-BODIPY(TM)-phosphatidylcholine, localized in the inner leaflet of the plasma membrane, to measure phospholipase A activation. Both 100 nM formyl-methionyl-leucyl-phenylalanine (with or without cytochalasin B) and 60 mug/ml insoluble immune complexes elicited cytoplasmic Ca2+ transients, but only insoluble immune complexes stimulated phospholipase A activation in a subpopulation of cells exhibiting an elevation of [Ca2+]in. Phospholipase A activation followed the Ca2+ transient, starting, in each cell, after [Ca2+]in had begun to decrease as Ca2+ redistributed in the activated cell. The products of this phospholipase activation were confirmed by thin layer chromatography. We conclude that neutrophils respond to immune complexes with an elevated cytoplasmic Ca2+-requiring phosphatidylcholine-specific phospholipase A activation and to chemotactic peptides by a different mechanism.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA; MOLEC PROBES INC, EUGENE, OR 97402 USA	Boston University				Herscovitz, Haya/0000-0001-8067-6091; Meshulam, Tova/0000-0002-7635-0328; Bernardo, John/0000-0002-3922-0559	NHLBI NIH HHS [HL07501, HL19177] Funding Source: Medline; NIADDK NIH HHS [AM31056] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM031056] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1987, TRENDS BIOCHEM SCI, V12, P241, DOI 10.1016/0968-0004(87)90118-6; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRUNKHORST BA, 1991, J BIOL CHEM, V266, P13035; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; DAVID EA, 1991, J CLIN INVEST, V88, P531; DELBUONO BJ, 1989, J CELL PHYSIOL, V141, P636, DOI 10.1002/jcp.1041410323; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DENNIS EA, 1987, DRUG DEVELOP RES, V10, P205, DOI 10.1002/ddr.430100404; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; GODFREY RW, 1987, J CELL BIOL, V104, P925, DOI 10.1083/jcb.104.4.925; HAINES KA, 1987, BIOCHEM J, V241, P55, DOI 10.1042/bj2410055; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; KAISER E, 1990, CLIN BIOCHEM, V23, P349, DOI 10.1016/0009-9120(90)90051-U; LAZZARI KG, 1990, J BIOL CHEM, V265, P10959; LAZZARI KG, 1986, J BIOL CHEM, V261, P9710; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; MATSUMOTO T, 1988, BIOCHEM J, V250, P343, DOI 10.1042/bj2500343; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OCHS DL, 1983, J BIOL CHEM, V258, P116; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PAGANO RE, 1981, J CELL BIOL, V91, P872, DOI 10.1083/jcb.91.3.872; PALMER RMJ, 1983, IMMUNOLOGY, V50, P65; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; REYNOLDS LJ, 1991, METHOD ENZYMOL, V197, P3; SCHONHORN J E, 1989, Journal of Cell Biology, V109, p211A; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WALKER BAM, 1991, J IMMUNOL, V146, P735; WYNKOOP EM, 1986, BIOCHEM J, V236, P829, DOI 10.1042/bj2360829	37	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21465	21470						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400459				2022-12-27	WOS:A1992JV01100033
J	SAXENA, SK; RYBAK, SM; DAVEY, RT; YOULE, RJ; ACKERMAN, EJ				SAXENA, SK; RYBAK, SM; DAVEY, RT; YOULE, RJ; ACKERMAN, EJ			ANGIOGENIN IS A CYTOTOXIC, TRANSFER RNA-SPECIFIC RIBONUCLEASE IN THE RNASE-A SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; AMINO-ACID SEQUENCE; FREE PROTEIN-SYNTHESIS; MAJOR BASIC-PROTEIN; XENOPUS OOCYTES; CATIONIC PROTEIN; RIBOSOMAL-RNA; ALPHA-SARCIN; TOXIN; INACTIVATION	Angiogenin is a 14.4-kDa human plasma protein with 65% homology to RNase A that retains the key active site residues and three of the four RNase A disulfide bonds. We demonstrate that recombinant angiogenin functions as a cytotoxic tRNA-specific RNase in cell-free lysates and when injected into Xenopus oocytes. Inhibition of protein synthesis by angiogenin correlates with degradation of endogenous oocyte tRNA. Exogenous, radiolabeled tRNA is also hydrolyzed by angiogenin, whereas oocyte rRNA and mRNA are not detectably degraded by angiogenin. Protein synthesis was restored to angiogenin-injected oocytes by injecting the RNase inhibitor RNasin(TM) plus total Xenopus or calf liver tRNAs, thereby demonstrating that the tRNA degradation induced by angiogenin was the sole cause of cytotoxicity. A similar tRNA-reversible inhibition of protein synthesis was seen in rabbit reticulocyte lysates. Angiogenin therefore appears to be a specific cellular tRNase, whereas five homologues in the RNase A superfamily lack angiogenin's specificity for tRNA. One of these homologues purified from human eosinophils, eosinophil-derived neurotoxin, nonspecifically degrades oocyte RNA similar to RNase A and is also cytotoxic at very low concentrations.	NIDDKD,GENET & BIOCHEM BRANCH,BLDG 10,RM 9D15,BETHESDA,MD 20892; NINDB,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Saxena, Shailendra K/ABK-6489-2022	Saxena, Shailendra K/0000-0003-2856-4185	PHS HHS [1-8325256] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKERMAN EJ, 1988, J BIOL CHEM, V263, P17076; ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BOND MD, 1989, BIOCHEMISTRY-US, V28, P6110, DOI 10.1021/bi00440a057; BOND MD, 1989, BIOCHEMISTRY-US, V28, P8262, DOI 10.1021/bi00446a044; DEUTSCHER MP, 1988, TRENDS BIOCHEM SCI, V13, P136, DOI 10.1016/0968-0004(88)90070-9; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; ENDO Y, 1983, J BIOL CHEM, V258, P2662; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Frankel A. E., 1988, IMMUNOTOXINS; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177, DOI DOI 10.1016/S0065-2776(08)60351-X; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HONJO T, 1968, J BIOL CHEM, V243, P3553; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LEE FS, 1989, BIOCHEM BIOPH RES CO, V161, P121, DOI 10.1016/0006-291X(89)91569-6; LUNDGREN JD, 1991, J ALLERGY CLIN IMMUN, V87, P689, DOI 10.1016/0091-6749(91)90390-A; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; RICHARDS FM, 1971, ENZYMES, V4, P647; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SAXENA SK, 1989, J BIOL CHEM, V264, P596; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1987, BIOCHEMISTRY-US, V26, P5141, DOI 10.1021/bi00390a037; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P8783, DOI 10.1073/pnas.84.24.8783; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SMYTH DG, 1963, J BIOL CHEM, V238, P227; STCLAIR DK, 1987, P NATL ACAD SCI USA, V84, P8330; STCLAIR DK, 1988, BIOCHEMISTRY-US, V27, P7263, DOI 10.1021/bi00419a013; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; VITETTA ES, 1990, J CLIN IMMUNOL, V10, pS15, DOI 10.1007/BF00918687; WEINER HL, 1987, SCIENCE, V237, P280, DOI 10.1126/science.2440105	38	135	144	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21982	21986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400510				2022-12-27	WOS:A1992JV01100111
J	XU, T; MURPHY, JR				XU, T; MURPHY, JR			BINDING OF THE METALLOREGULATORY PROTEIN DTXR TO THE DIPHTHERIA TOX OPERATOR REQUIRES A DIVALENT HEAVY-METAL ION AND PROTECTS THE PALINDROMIC SEQUENCE FROM DNASE-I DIGESTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-DIPHTHERIAE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; IRON; GENE; REPRESSOR; BETA; EXPRESSION; STRAINS	Transcription of the corynebacteriophage diphtheria tox operon has been shown to be regulated through a corynebacterial determined factor DtxR. The dtxR gene has been recently cloned and expressed in Escherichia coli, and shown to regulate the expression of beta-galactosidase expression from a diphtheria tox promoter/operator-lacZ transcriptional fusion. Tao et al. (Tao, X., Boyd, J., and Murphy, J. R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5897-5901) have recently shown by gel mobility shift assay that the binding of DtxR to the tox operator requires a divalent heavy metal ion, as well as the 27-base pair interrupted palindromic sequence. We now show the activation of DtxR in the presence of Co2+, Fe2+, or Mn2+ results in the protection of a 33- and 27-nucleotide region on the coding and non-coding strand from DNase I digestion, respectively. DtxR is also activated in the presence of Ni2+; however, this metalloregulatory factor is only weakly activated by Zn2+. The diphtheria tox regulatory region protected from DNase I digestion in the presence of activated DtxR encompasses the 27-base pair interrupted palindromic sequence.	UNIV HOSP BOSTON,DEPT MED,88 E NEWTON ST,BOSTON,MA 02118; UNIV HOSP BOSTON,EVANS DEPT CLIN RES,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021628] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21628] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BOYD J, 1990, P NATL ACAD SCI USA, V87, P5968, DOI 10.1073/pnas.87.15.5968; BOYD J, 1988, J BACTERIOL, V170, P5949, DOI 10.1128/jb.170.12.5949-5952.1988; BOYD JM, 1992, J BACTERIOL, V174, P1268, DOI 10.1128/jb.174.4.1268-1272.1992; BUCK GA, 1985, INFECT IMMUN, V49, P679, DOI 10.1128/IAI.49.3.679-684.1985; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; FOUREL G, 1989, INFECT IMMUN, V57, P3221, DOI 10.1128/IAI.57.10.3221-3225.1989; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; GROMAN N, 1979, J BACTERIOL, V135, P511; KACZOREK M, 1983, SCIENCE, V221, P855, DOI 10.1126/science.6348945; KANEI C, 1977, INFECT IMMUN, V18, P203, DOI 10.1128/IAI.18.1.203-209.1977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller J.H., 1972, EXPT MOL GENETICS; Mueller JH, 1941, J IMMUNOL, V40, P21; MURPHY JR, 1974, P NATL ACAD SCI USA, V71, P11, DOI 10.1073/pnas.71.1.11; MURPHY JR, 1976, J VIROL, V18, P235, DOI 10.1128/JVI.18.1.235-244.1976; MURPHY JR, 1979, MICROBIOLOGY 1979, P181; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SCHMITT MP, 1991, INFECT IMMUN, V59, P1899, DOI 10.1128/IAI.59.6.1899-1904.1991; SCHMITT MP, 1991, INFECT IMMUN, V59, P3903, DOI 10.1128/IAI.59.11.3903-3908.1991; TAO X, 1992, P NATL ACAD SCI USA, V89, P5897, DOI 10.1073/pnas.89.13.5897; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELKOS SL, 1981, J VIROL, V37, P936, DOI 10.1128/JVI.37.3.936-945.1981	24	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21761	21764						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400485				2022-12-27	WOS:A1992JV01100078
J	AMITAY, R; SHACHAR, I; RABINOVICH, E; HAIMOVICH, J; BARNUN, S				AMITAY, R; SHACHAR, I; RABINOVICH, E; HAIMOVICH, J; BARNUN, S			DEGRADATION OF SECRETORY IMMUNOGLOBULIN-M IN LYMPHOCYTES-B OCCURS IN A POSTENDOPLASMIC RETICULUM COMPARTMENT AND IS MEDIATED BY A CYSTEINE PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; PERIPHERAL MEMBRANE-PROTEIN; CULTURED RAT HEPATOCYTES; CLATHRIN-COATED VESICLES; PRE-GOLGI DEGRADATION; BREFELDIN-A ARRESTS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; RECYCLING PATHWAY	In 38C B lymphocytes, membrane IgM is expressed on the surface, whereas secretory IgM (sIgM) is rapidly degraded. Here, we localize this degradation and characterize the proteases involved in this process. Upon treatment with brefeldin A, degradation of sIgM in 38C cells was strongly inhibited, as was secretion from the sIgM-secreting D2 hybridoma. Moreover, the brefeldin A-induced Golgi resorption resulted in galactosylation of sIgM and partial resistance to endoglycosidase H. However, sIgM avoided degradation neither due to modified terminal glycosylation nor as a consequence of the brefeldin A-induced altered milieu of the endoplasmic reticulum. When these modifications were prevented by inhibiting retrograde transport with nocodazole or by abrogating terminal glycosylation with swainsonine, sIgM was still rescued from degradation. The unaffected breakdown in the presence of nocodazole also argued against recycling of sIgM to be degraded in the endoplasmic reticulum. Furthermore, upon removal of brefeldin A, degradation of galactosylated sIgM resumed in 38C cells, as did secretion from D2 cells. These results indicate that functional export of proteins from the endoplasmic reticulum is a prerequisite for sIgM degradation. Biochemical characterization of this novel postendoplasmic reticulum/pre-trans-Golgi proteolytic pathway included application of inhibitors to a broad spectrum of proteases. Among the compounds tested, only calpain inhibitor I exerted strong inhibition. The involvement of cysteine protease(s) in the degradation of sIgM was corroborated by the inhibitory effect of diamide. We conclude that B lymphocytes avoid secretion by active and selective targeting of sIgM to a developmentally regulated postendoplasmic reticulum degradation pathway in which degradation is mediated by a cysteine protease.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, SACKLER SCH MED, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, DEPT HUMAN MICROBIOL, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine								ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; AMITAY R, 1991, J BIOL CHEM, V266, P12568; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BRANDLI AW, 1991, BIOCHEM J, V276, P1; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; CURIEL DT, 1990, MOL CELL BIOL, V10, P47, DOI 10.1128/MCB.10.1.47; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DULIS BH, 1982, J BIOL CHEM, V257, P4369; ESSER V, 1988, J BIOL CHEM, V263, P13276; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUE S, 1991, J BIOL CHEM, V266, P13311; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LAU MMH, 1989, J BIOL CHEM, V264, P21376; LE A, 1990, J BIOL CHEM, V265, P14001; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1991, CELL, V64, P1183; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHACHAR I, 1992, IN PRESS J BIOL CHEM; SIDMAN C, 1981, CELL, V23, P379, DOI 10.1016/0092-8674(81)90133-1; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; ULMER JB, 1991, J BIOL CHEM, V266, P9173; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	71	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20694	20700						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400386				2022-12-27	WOS:A1992JT97800030
J	TONERWEBB, J; VANPATTEN, SM; WALSH, DA; TAYLOR, SS				TONERWEBB, J; VANPATTEN, SM; WALSH, DA; TAYLOR, SS			AUTOPHOSPHORYLATION OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; II REGULATORY SUBUNIT; AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE; PHOSPHORYLATION; BINDING; MECHANISM; INHIBITOR; HEART; 3',5'-MONOPHOSPHATE	The catalytic subunit of cAMP-dependent protein kinase contains two stable phosphorylation sites, Thr-197 and Ser-338 (Shoji, S., Titani, K., Demaille, J. G., and Fischer, E. H. (1979) J. Biol. Chem. 254, 6211-6214). Thr-197 is very resistant to dephosphorylation and thus cannot typically be autophosphorylated in vitro once the stable subunit is formed. Ser-338 is slowly dephosphorylated and can be rephosphorylated autocatalytically. In addition to these two stable phosphorylation sites, a new site of autophosphorylation, Ser-10, was identified. Phosphorylation at Ser-10 does not have a major effect on activity, and phosphates from Ser-10 or Ser-338 are not transferred to physiological substrates such as the type II regulatory subunit. Autophosphorylation at Ser-10 is associated with one of the two major isoelectric variants of the catalytic subunit. The form having the more acidic pI can be autophosphorylated at Ser-10 while the more basic form of the catalytic subunit cannot. Phosphorylation at Ser-10 does not account for the two isoenzyme forms. Since the reason for two isoelectric variants of the catalytic subunit is still unknown, it is not possible to provide a structural basis for the difference in accessibility of Ser-10 to phosphorylation. Either Ser-10 is not accessible in the more basic form of the catalytic subunit or some other type of post- or cotranslational modification causes Ser-10 to be a poor substrate. Whether the myristoyl group at the amino-terminal Gly is important for Ser-10 autophosphorylation remains to be established. The isoenzyme forms of the catalytic subunit do not correspond to the gene products coded for by the C(alpha) and C(beta) genes.	UNIV CALIF SAN DIEGO,DEPT CHEM 0654,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California San Diego; University of California System; University of California Davis					NIGMS NIH HHS [GM-19301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019301, R37GM019301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BUBIS J, 1985, BIOCHEMISTRY-US, V24, P2163, DOI 10.1021/bi00330a009; CARMICHAEL DF, 1982, J BIOL CHEM, V257, P440; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CERENKOV PA, 1934, DOKL AKAD NAUK SSSR, V2, P431; CHIU YS, 1978, J BIOL CHEM, V253, P7145; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DOOLITTLE LR, 1977, ANAL BIOCHEM, V78, P491, DOI 10.1016/0003-2697(77)90109-9; GEAHLEN RL, 1980, J BIOL CHEM, V255, P1164; GRANOT J, 1980, J BIOL CHEM, V255, P4569; HARTLEY BS, 1970, BIOCHEM J, V119, P805, DOI 10.1042/bj1190805f; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HO MF, 1988, J AM CHEM SOC, V110, P2680, DOI 10.1021/ja00216a068; HUANG LC, 1985, J CYCLIC NUCL PROT, V10, P485; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P486; KINZEL V, 1987, ARCH BIOCHEM BIOPHYS, V253, P341, DOI 10.1016/0003-9861(87)90187-1; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCHETKOV SN, 1977, EUR J BIOCHEM, V81, P111, DOI 10.1111/j.1432-1033.1977.tb11932.x; KOCHETKOV SN, 1976, FEBS LETT, V71, P212, DOI 10.1016/0014-5793(76)80934-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN LR, 1988, SCIENCE, V240, P68, DOI 10.1126/science.2832943; NELSON NC, 1981, J BIOL CHEM, V256, P3743; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; RANGELALDAO R, 1977, J BIOL CHEM, V252, P7140; RANGELALDAO R, 1976, J BIOL CHEM, V251, P7526; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; RUSSELL PJ, 1974, J BIOL CHEM, V249, P1874; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STEINBERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P910, DOI 10.1073/pnas.77.2.910; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TAYLOR SS, 1976, ANAL BIOCHEM, V76, P45, DOI 10.1016/0003-2697(76)90262-1; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; WRIGHT DE, 1981, P NATL ACAD SCI-BIOL, V78, P6048, DOI 10.1073/pnas.78.10.6048; ZICK SK, 1982, J BIOL CHEM, V257, P2287; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363; ZOLLER MJ, 1979, J BIOL CHEM, V254, P2408	46	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25174	25180						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460017				2022-12-27	WOS:A1992KB60300041
J	YAMASHITA, K; OHKURA, T; UMETSU, K; SUZUKI, T				YAMASHITA, K; OHKURA, T; UMETSU, K; SUZUKI, T			PURIFICATION AND CHARACTERIZATION OF A FUC-ALPHA-1-]2GAL-BETA-1-] AND GALNAC-BETA-1-]-SPECIFIC LECTIN IN ROOT TUBERS OF TRICHOSANTHES-JAPONICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE MOIETIES; COMBINING SITE; OLIGOSACCHARIDES; CHROMATOGRAPHY; GLYCOPROTEINS; GLYCOPEPTIDES; SPECIFICITY; CHAINS	A prominent lectin in the root tubers of Trichosanthes japonica was purified by affinity chromatography on a porcine stomach mucin-Sepharose column and termed TJA-II. The molecular mass of the native lectin was determined to be 64 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and TJA-II was separated into two different subunits of 33 and 29 kDa in the presence of 2-mercaptoethanol. The respective subunits contained mannose, N-acetylglucosamine, fucose, and xylose. It was determined by equilibrium dialysis to have two equal binding sites per molecule, the association constant toward tritium-labeled Fucalpha1-->2Galbeta1-->3GlcNAcbeta1-->3Galbeta1-->4Glc(OT) being K(alpha) = 3.05 x 10(5) M-1. The precise carbohydrate binding specificity of immobilized TJA-II was studied using various tritium-labeled oligosaccharides. A series of oligosaccharides possessing Fucalpha1-->2Galbeta1--> or GalNAcbeta1--> groups at their nonreducing terminals showed stronger binding ability than ones with Galbeta1-->GlcNAc (Glc) groups, indicating that TJA-II fundamentally recognizes a beta-galactosyl residue and the binding strength increases on substitution of the hydroxyl group at the C-2 position with a fucosyl or acetylamino group. This lectin column is useful for fractionating oligosaccharides or glycoproteins containing blood group type 1H, type 2H, and Sd antigenic determinants.	YAMAGATA UNIV, SCH MED, DEPT FORENS MED, YAMAGATA 99023, JAPAN	Yamagata University	YAMASHITA, K (corresponding author), SASAKI INST, DEPT BIOCHEM, KANDA SURUGADAI, CHIYODA KU, TOKYO 101, JAPAN.							BALDO BA, 1978, BIOCHEM J, V175, P467, DOI 10.1042/bj1750467; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6600, DOI 10.1021/bi00526a013; DATTA TK, 1981, BIOCHEM J, V197, P751, DOI 10.1042/bj1970751; HINDSGAUL O, 1982, CARBOHYD RES, V109, P109, DOI 10.1016/0008-6215(82)84034-2; HOREJSI V, 1980, BIOCHIM BIOPHYS ACTA, V623, P439, DOI 10.1016/0005-2795(80)90273-1; HOREJSI V, 1978, BIOCHIM BIOPHYS ACTA, V539, P287; KOBATA A, 1972, METHOD ENZYMOL, V28, P262; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHKURA T, 1985, BIOCHEMISTRY-US, V24, P503, DOI 10.1021/bi00323a038; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SMITH DF, 1989, METHOD ENZYMOL, V179, P30; TAKEUCHI M, 1987, J CHROMATOGR, V400, P207, DOI 10.1016/S0021-9673(01)81613-7; UMETSU K, 1979, TOHOKU J EXP MED, V129, P161, DOI 10.1620/tjem.129.161; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873; YAMASHITA K, 1979, J BIOL CHEM, V254, P4820; YAMASHITA K, 1981, J BIOL CHEM, V256, P4789; YAMASHITA K, 1974, ARCH BIOCHEM BIOPHYS, V161, P164, DOI 10.1016/0003-9861(74)90247-1; YAMASHITA K, 1976, NATURE, V262, P702, DOI 10.1038/262702a0; YAMASHITA K, 1988, J BIOL CHEM, V263, P17482; YAMASHITA K, 1977, J BIOL CHEM, V252, P5408; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	23	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25414	25422						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460036				2022-12-27	WOS:A1992KB60300077
J	ZILLIACUS, J; WRIGHT, APH; NORINDER, U; GUSTAFSSON, JA; CARLSTEDTDUKE, J				ZILLIACUS, J; WRIGHT, APH; NORINDER, U; GUSTAFSSON, JA; CARLSTEDTDUKE, J			DETERMINANTS FOR DNA-BINDING SITE RECOGNITION BY THE GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; HIGH-LEVEL EXPRESSION; GENE-EXPRESSION; PROTEIN INTERACTIONS; RESPONSIVE ELEMENT; ESTROGEN-RECEPTOR; AMINO-ACIDS; DOMAIN; TRANSACTIVATION; SUPERFAMILY	The glucocorticoid receptor binds with high specificity to glucocorticoid response elements, discriminating them from other closely related binding sites. Three amino acids in the recognition alpha-helix of the DNA-binding domain of the receptor are primarily responsible for this specific DNA binding activity. In this study we analyze in detail how these residues determine the specific DNA binding by studying a series of mutant glucocorticoid receptor DNA-binding domains containing all combinations of glucocorticoid and estrogen receptor-specific residues at these positions. Statistical analysis of the results enables us to create models describing the association between amino acids and base pairs. Several strategies appear to be used in accomplishing discrimination between the glucocorticoid and estrogen response elements. Single residues (i.e., Val-443 in the glucocorticoid receptor and Glu-439 in the estrogen receptor) appear to form both positive contacts with specific base pairs in the cognate binding site and negative contacts in the non-cognate site. In the glucocorticoid receptor Ser-440 is pleiotropically negative for all sites tested but the negative effect is stronger for the estrogen response element thus contributing to binding site discrimination. Furthermore, combinations of amino acids appear to act synergistically, most often causing a reduction in binding to non-cognate sites.	KARO BIO AB,S-14104 HUDDINGE,SWEDEN		ZILLIACUS, J (corresponding author), KAROLINSKA INST,CTR BIOTECHNOL,NOVUM,S-14157 HUDDINGE,SWEDEN.		Wright, Anthony PH/J-8187-2015	Norinder, Ulf/0000-0003-3107-331X				ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GREEN JBA, 1988, MOL GEN GENET, V215, P100, DOI 10.1007/BF00331310; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KUBINYI H, 1990, COMPREHENSIVE MED CH, V4, P589; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; NORINDER U, 1990, J COMPUT AID MOL DES, V4, P381, DOI 10.1007/BF00117403; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; REMEROWSKI ML, 1991, BIOCHEMISTRY-US, V30, P11620, DOI 10.1021/bi00114a003; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHERMAN F, 1986, LABORATORY COURSE MA; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Wold S., 1984, CHEMOMETRICS MATH ST, P17, DOI DOI 10.1007/978-94-017-1026-8_2; WOLD S, 1979, TECHNOMETRICS, V20, P379; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	39	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24941	24947						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459998				2022-12-27	WOS:A1992KB60300008
J	ZWEERINK, MM; EDISON, AM; WELLS, GB; PINTO, W; LESTER, RL				ZWEERINK, MM; EDISON, AM; WELLS, GB; PINTO, W; LESTER, RL			CHARACTERIZATION OF A NOVEL, POTENT, AND SPECIFIC INHIBITOR OF SERINE PALMITOYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITOL-CONTAINING SPHINGOLIPIDS; HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; BIOSYNTHESIS; INOSITOL; SPHINGOSINE; YEAST; PHOSPHATIDYLINOSITOL; CYCLOSERINE; ENZYMOLOGY	We have examined the mechanism of action of two natural products identified as broad spectrum antifungal agents (VanMiddlesworth, F., Dufresne, C., Wincott, F. E., Mosley, R. T., and Wilson, K. E. (1992) Tetrahedron Lett., in press; VanMiddlesworth, F., Giacobbe, R. A., Lopez, M. Garrity, G., Bland, J. A., Bartizal, K., Fromtling, R. A., Polishook, J., Zweerink, M. M., Edison, A. M., Rozdilsky, W., Wilson, K. E., and Monaghan, R. L. (1992) J. Antibiot. (Tokyo) 45, 861-867), designated sphingofungin B (2S-amino-3R,4R,5S,14-tetrahydroxyeicos-6-enoic acid) and sphingofungin C (2S-amino-5S-acetoxy-3R,4R,14-trihydroxyeicos-6-enoic acid), and find they are potent specific inhibitors of serine palmitoyltransferase, which catalyze the committed step of sphingolipid biosynthesis. We used Saccharomyces cerevisiae as a model to investigate the mechanism of the antifungal activity of these compounds. Macromolecular synthesis was not immediately affected by either sphingofungin B or C, synthesis continued for 60-90 min following the addition of drug to growing cultures. Significant loss of viability with sphingofungins required growing cultures and began only after several hours, with greater than 99.9% of drug-treated cells non-viable after 24 h. No lysis or other gross changes in cell morphology were observed in drug-treated cells. The structural similarity of sphingofungin B and C to sphingosine and phytosphingosine prompted us to investigate their effects on sphingolipid synthesis. Nanomolar levels of the drugs inhibited the incorporation of [H-3]inositol into sphingolipid before incorporation into the sphingolipid precursor, phosphatidylinositol was affected, suggesting specific inhibition of sphingolipid synthesis. This hypothesis was confirmed by experiments in which the growth inhibitory activity of both drugs was completely ablated by the addition of phytosphingosine, dihydrosphingosine, or ketodihydrosphingosine to the culture medium. Reversal of antifungal activity by ketodihydrosphingosine suggested that serine palmitoyltransferase could be the actual target of these compounds. Direct evidence for this hypothesis was the observation of inhibition of serine palmitoyltransferase activity in crude membrane preparations at nanomolar concentrations of each drug. The potent inhibition of serine palmitoyltransferase coupled with the apparent lack of effect of these compounds on other cellular functions suggests that sphingofungin B and C will prove to be important new tools for studying the role of sphingolipids in yeast and perhaps in other organisms.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT INFECT DIS RES,RAHWAY,NJ 07065; UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,LEXINGTON,KY 40536	Merck & Company; University of Kentucky					PHS HHS [A120600] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; BADET B, 1984, BIOCHEMISTRY-US, V23, P5188, DOI 10.1021/bi00317a016; BARR K, 1984, BIOCHEMISTRY-US, V23, P5581, DOI 10.1021/bi00318a031; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; HACKETT JA, 1977, FEBS LETT, V74, P259, DOI 10.1016/0014-5793(77)80859-4; HAKOMORI S, 1983, SPHINGOLIPID BIOCH; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANSON BA, 1980, J LIPID RES, V21, P309; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; KISHIMOTO Y, 1983, ENZYMES, P358; LESTER RL, 1992, IN PRESS ADV LIPID R; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1986, METHOD ENZYMOL, V122, P110; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1985, J LIPID RES, V26, P617; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; SMITH SW, 1974, J BIOL CHEM, V249, P3395; SNELL EE, 1970, CHEM PHYS LIPIDS, V5, P116, DOI 10.1016/0009-3084(70)90013-7; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; STOFFEL W, 1970, CHEM PHYS LIPIDS, V5, P139, DOI 10.1016/0009-3084(70)90014-9; SUNDARAM KS, 1984, ANTIMICROB AGENTS CH, V26, P211, DOI 10.1128/AAC.26.2.211; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; VANMIDDLESWORTH F, 1992, TETRAHEDRON LETT, V33, P297; VANMIDDLESWORTH F, 1992, J ANTIBIOT, V45, P861, DOI 10.7164/antibiotics.45.861; WALSH CT, 1984, ANNU REV BIOCHEM, V53, P493, DOI 10.1146/annurev.bi.53.070184.002425; WELLS GB, 1983, J BIOL CHEM, V258, P200; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9	33	128	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25032	25038						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460005				2022-12-27	WOS:A1992KB60300021
J	GARFINKEL, S; HAINES, DS; BROWN, S; WESSENDORF, J; GILLESPIE, DH; MACIAG, T				GARFINKEL, S; HAINES, DS; BROWN, S; WESSENDORF, J; GILLESPIE, DH; MACIAG, T			INTERLEUKIN-1-ALPHA MEDIATES AN ALTERNATIVE PATHWAY FOR THE ANTIPROLIFERATIVE ACTION OF POLY(I.C) ON HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; HUMAN-TUMOR CELLS; GROWTH-FACTOR; MESSENGER-RNA; SERIAL PROPAGATION; HUMAN INTERFERONS; VIRUS-INFECTION; IL-6 PRODUCTION; NECROSIS-FACTOR; EXPRESSION	The antiproliferative effect of double-stranded RNA (dsRNA) on human tumor and normal cells has been well established. However, the genes involved in the dsRNA-induced antiproliferative response and the molecular mechanisms by which this occurs remain less well defined. We have studied the ability of synthetic dsRNA, polyinosinic:polycytidylic acid (poly(I.C)) to modify human umbilical vein endothelial cell (HUVEC) growth and report that poly(I.C) induces a dose-dependent inhibition of HUVEC proliferation in vitro. In addition, the mRNA levels for the cytokines interleukin-1alpha (IL-1alpha) and interferon-beta1 are induced in poly(I.C)-treated cells. Moreover, the growth inhibitory effects of poly(I.C) are relieved when cells are grown in the presence of an IL-1alpha antisense oligonucleotide to the human IL-1alpha transcript. Thus, the effects of poly(I.C) appear to be mediated, in part, through the function of IL-1alpha, suggesting an alternative pathway for dsRNA-mediated inhibition of human endothelial cell growth.	AMER RED CROSS, HOLLAND LAB, DEPT MOLEC BIOL, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA; HAHNEMANN UNIV, DEPT NEOPLAST DIS, PHILADELPHIA, PA 19102 USA	American Red Cross; Drexel University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35627] Funding Source: Medline; NIA NIH HHS [AG07450] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; CHAPEKAR MS, 1988, MOL PHARMACOL, V34, P461; CONTENT J, 1985, EUR J BIOCHEM, V152, P253, DOI 10.1111/j.1432-1033.1985.tb09191.x; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; CURVEN KD, 1980, LAB INVEST, V42, P366; DICK RS, 1987, J NEURO-ONCOL, V5, P331, DOI 10.1007/BF00148390; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; EINHORN S, 1985, J CELL PHYSIOL, V122, P200, DOI 10.1002/jcp.1041220206; ELIAS JA, 1990, J IMMUNOL, V145, P161; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FRIEDMAN HM, 1981, J INFECT DIS, V143, P266, DOI 10.1093/infdis/143.2.266; FRIESEL R, 1987, J CELL BIOL, V104, P689, DOI 10.1083/jcb.104.3.689; GAY CG, 1990, J BIOL CHEM, V265, P3284; GHEZZI P, 1988, J IMMUNOL, V140, P4238; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; HUBBELL HR, 1991, P NATL ACAD SCI USA, V88, P906, DOI 10.1073/pnas.88.3.906; HUBBELL HR, 1986, INT J CANCER, V37, P359, DOI 10.1002/ijc.2910370306; HUBBELL HR, 1984, CANCER RES, V44, P3252; JAMESON P, 1982, TEX REP BIOL MED, V41, P135; JIRIK FR, 1989, J IMMUNOL, V142, P144; LIN SL, 1982, NATURE, V297, P417, DOI 10.1038/297417a0; MACGREGOR RR, 1980, J CLIN INVEST, V65, P1469, DOI 10.1172/JCI109811; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MINICK CR, 1979, AM J PATHOL, V96, P673; MONTESANO R, 1985, J CELL PHYSIOL, V122, P424, DOI 10.1002/jcp.1041220313; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; Sambrook J, 1989, MOL CLONING LABORATO; SIRONI M, 1989, J IMMUNOL, V142, P549; TANIGUCHI T, 1989, J INTERFERON RES, V9, P633, DOI 10.1089/jir.1989.9.633; TORRENCE PF, 1977, PHARMACOL THER PT A, V2, P1, DOI 10.1016/0362-5478(77)90009-2; VANDAMME J, 1985, NATURE, V314, P266, DOI 10.1038/314266a0; VANDAMME J, 1987, J IMMUNOL, V139, P1867; VILCEK J, 1987, J CELL PHYSIOL, V130, P37, DOI 10.1002/jcp.1041300107; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WILLIAMS BRG, 1980, TRENDS BIOCHEM SCI, V5, P138, DOI 10.1016/0968-0004(80)90057-2; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	43	34	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24375	24378						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447187				2022-12-27	WOS:A1992KA26300038
J	SMYTH, MJ; WILTROUT, T; TRAPANI, JA; OTTAWAY, KS; SOWDER, R; HENDERSON, LE; KAM, CM; POWERS, JC; YOUNG, HA; SAYERS, TJ				SMYTH, MJ; WILTROUT, T; TRAPANI, JA; OTTAWAY, KS; SOWDER, R; HENDERSON, LE; KAM, CM; POWERS, JC; YOUNG, HA; SAYERS, TJ			PURIFICATION AND CLONING OF A NOVEL SERINE PROTEASE, RNK-MET-1, FROM THE GRANULES OF A RAT NATURAL-KILLER-CELL LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTE-T; PORCINE PANCREATIC ELASTASE; CYTOLYTIC LYMPHOCYTES; CYTOPLASMIC GRANULES; SUBSTRATE-SPECIFICITY; DNA FRAGMENTATION; GENE-EXPRESSION; HUMAN-LEUKOCYTE; MEDIATED LYSIS; CYTO-TOXICITY	We have purified a 30-kDa serine protease (designated RNK-Met-1) from the granules of the rat large granular lymphocyte leukemia cell line (RNK-16) that hydrolytically cleaves model peptide substrates after methionine, leucine, and norleucine (Met-ase activity). Utilizing molecular sieve chromatography, heparin-agarose, chromatography, and reverse-phase high pressure liquid chromatography, RNK-Met-1 was purified to homogeneity and 25 NH2-terminal amino acids were sequenced. By using the polymerase chain reaction, oligonucleotide primers derived from amino acids at position 14-25 and from a downstream active site conserved in other serine protease genes were used to generate a 534-base pair cDNA clone encoding a novel serine protease from RNK-16 mRNA. This cDNA clone was used to isolate a full-length 867-base pair RNK-Met-1 cDNA from an RNK-16 lambda-gt11 library. The open reading frame predicts a mature protein of 238 amino acids with two potential sites for N-linked glycosylation. The cDNA also encodes a leader peptide of at least 20 amino acids. The characteristic lIe-lIe-Gly-Gly amino acids of the NH2 terminus and the His, Asp, and Ser residues that form the catalytic triad of serine proteases were both conserved. The amino acid sequence has less than 45% identity with any other member of the serine protease family, indicating that RNK-Met-I is distinct and may itself represent a new subfamily of serine proteases. Northern blot analysis of total cellular RNA detected a single 0.9-kilobase mRNA in the in vitro and in vivo variants of RNK-16 and in spleen-derived plastic-adherent rat lymphokine-activated killer cells. RNK-Met-1 mRNA was not detectable in freshly isolated rat splenocytes, thymocytes, brain, colon, and liver or activated nonadherent rat splenocytes and thymocytes. These data indicate that RNK-Met-1 is a serine protease with unique activity that is expressed in the granules of large granular lymphocytes.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, CLIN SERV PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, AIDS VACCINE DEV PROGRAM, FREDERICK, MD 21702 USA; GEORGIA INST TECHNOL, SCH CHEM & BIOCHEM, ATLANTA, GA 30332 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University System of Georgia; Georgia Institute of Technology	SMYTH, MJ (corresponding author), AUSTIN HOSP, AUSTIN RES INST, CELLULAR CYTOX LAB, HEIDELBERG, VIC 3084, AUSTRALIA.		Sayers, Thomas J/G-4859-2015; Smyth, Mark J/H-8709-2014; Young, Howard/A-6350-2008	Smyth, Mark J/0000-0001-7098-7240; Young, Howard/0000-0002-3118-5111; Trapani, Joseph/0000-0003-0983-1532	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029307] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102, CM42212] Funding Source: Medline; NHLBI NIH HHS [HL29307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKE G, 1989, IMMUNOL LETT, V20, P169, DOI 10.1016/0165-2478(89)90075-8; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CHANG TW, 1980, J IMMUNOL, V124, P1028; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; FRUTH U, 1987, EUR J IMMUNOL, V17, P1625, DOI 10.1002/eji.1830171116; GARCIASANZ JA, 1990, J IMMUNOL, V145, P3111; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARPER JW, 1984, BIOCHEMISTRY-US, V23, P2995, DOI 10.1021/bi00308a023; HENDERSON LE, 1984, J VIROL, V52, P492, DOI 10.1128/JVI.52.2.492-500.1984; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HENKART PA, 1987, J IMMUNOL, V139, P2398; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUDIG D, 1991, J IMMUNOL, V147, P1360; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; JIANG S, 1990, Protein Expression and Purification, V1, P77, DOI 10.1016/1046-5928(90)90049-5; JOAG S, 1989, J CELL BIOCHEM, V39, P239, DOI 10.1002/jcb.240390304; KAM CM, 1987, J BIOL CHEM, V262, P3444; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KWON BS, 1988, J EXP MED, V168, P1839, DOI 10.1084/jem.168.5.1839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LIU CC, 1987, CELL, V51, P393, DOI 10.1016/0092-8674(87)90635-0; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; MANYAK CL, 1989, J IMMUNOL, V142, P3707; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; MILLARD PJ, 1984, J IMMUNOL, V132, P3197; MUNGER WE, 1988, IMMUNOL REV, V103, P99, DOI 10.1111/j.1600-065X.1988.tb00752.x; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OJCIUS DM, 1991, P NATL ACAD SCI USA, V88, P4621, DOI 10.1073/pnas.88.11.4621; OSTERGAARD HL, 1989, J IMMUNOL, V143, P2120; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; POE M, 1991, J BIOL CHEM, V266, P98; REID KBM, 1986, NATURE, V322, P684, DOI 10.1038/322684a0; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS TJ, 1992, J IMMUNOL, V148, P292; SCHMID J, 1987, J IMMUNOL, V139, P250; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; SIMON MM, 1987, IMMUNOLOGY, V60, P219; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; VUJANOVIC NL, 1988, J EXP MED, V167, P15, DOI 10.1084/jem.167.1.15; WILDE CG, 1990, J BIOL CHEM, V265, P2038; YOUNG JD, 1986, CELL, V46, P641, DOI 10.1016/0092-8674(86)90336-3; YOUNG JDE, 1986, CELL, V47, P183, DOI 10.1016/0092-8674(86)90441-1; YOUNG JDE, 1989, PHYSIOL REV, V69, P250, DOI 10.1152/physrev.1989.69.1.250; ZUNINO SJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P331, DOI 10.1016/0304-4165(88)90095-5; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	65	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24418	24425						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447189				2022-12-27	WOS:A1992KA26300045
J	SOMMER, A; PRENNER, E; GORGES, R; STUTZ, H; GRILLHOFER, H; KOSTNER, GM; PALTAUF, F; HERMETTER, A				SOMMER, A; PRENNER, E; GORGES, R; STUTZ, H; GRILLHOFER, H; KOSTNER, GM; PALTAUF, F; HERMETTER, A			ORGANIZATION OF PHOSPHATIDYLCHOLINE AND SPHINGOMYELIN IN THE SURFACE MONOLAYER OF LOW-DENSITY-LIPOPROTEIN AND LIPOPROTEIN(A) AS DETERMINED BY TIME-RESOLVED FLUOROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE LIFETIME DISTRIBUTIONS; EGG-YOLK PHOSPHATIDYLCHOLINE; NUCLEAR-MAGNETIC-RESONANCE; HUMAN-SERUM LIPOPROTEINS; HUMAN-PLASMA; APOLIPOPROTEIN-B; CHOLESTERYL ESTERS; PHASE-SEPARATION; LIPID BILAYERS; DIPHENYLHEXATRIENE	Fluorescent analogs of phosphatidylcholine (PC) and sphingomyelin (SM) labeled with diphenylhexatrienylpropionic acid (DPH) were prepared and incorporated into the surface layer of human low density lipoprotein (LDL) and lipoprotein(a) (Lp(a)). Fluorescence anisotropy measurements of DPH-PC and DPH-SM in both lipoprotein classes were carried out at different temperatures ranging from 20 to 37-degrees-C. DPH-PC as well as DPH-SM were shown to reside in more rigid domains in Lp(a) than in LDL according to higher anisotropy values in Lp(a). In both LDL and Lp(a), DPH-PC experienced a more rigid environment than DPH-SM, suggesting different environments of PC and SM in the surface shell of the lipoproteins. Fluorescence lifetimes of the labeled lipoproteins were determined by phase and modulation fluorometry. We found bimodal Lorentzian distributions for the decay times of DPH-PC and DPH-SM in LDL and Lp(a). Lifetime distribution centers for labeled lipids were very similar except for DPH-PC in Lp(a) which was shifted to longer lifetimes, suggesting a less polar environment of PC in Lp(a) than in LDL. The distributional width of DPH-PC in Lp(a) was broader than in LDL. Accordingly, phosphatidylcholine must be localized in a more homogeneous environment in LDL as compared with Lp(a). On the other hand, no difference in distributional widths was observed for DPH-SM in both lipoproteins, showing that SM organization in Lp(a) is unaffected by apo(a). From the obtained fluorescence data we propose that apoproteins discriminate between the choline phospholipids and preferentially associate with phosphatidylcholine. This effect is enhanced in Lp(a) due to the presence of apolipoprotein(a).	GRAZ TECH UNIV,INST BIOCHEM & LEBENSMITTELCHEM,A-8010 GRAZ,AUSTRIA; GRAZ UNIV,INST MED BIOCHEM,A-8010 GRAZ,AUSTRIA	Graz University of Technology; University of Graz			Prenner, Elmar J/E-5549-2011					ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; ATKINSON D, 1977, P NATL ACAD SCI USA, V74, P1042, DOI 10.1073/pnas.74.3.1042; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BAUMSTARK MW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P48, DOI 10.1016/0167-4838(90)90100-T; BERLIN E, 1983, ATHEROSCLEROSIS, V48, P15, DOI 10.1016/0021-9150(83)90014-X; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; COHEN R, 1984, CHEM PHYS LIPIDS, V35, P371, DOI 10.1016/0009-3084(84)90079-3; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; DHAWAN S, 1983, BIOCHEMISTRY-US, V22, P3660, DOI 10.1021/bi00284a019; DOBRETSOV GE, 1982, BIOCHIM BIOPHYS ACTA, V710, P172, DOI 10.1016/0005-2760(82)90147-3; FENSKE DB, 1990, BIOCHEMISTRY-US, V29, P3973, DOI 10.1021/bi00468a026; FINER EG, 1975, BIOCHIM BIOPHYS ACTA, V380, P320, DOI 10.1016/0005-2760(75)90018-1; FIORINI RM, 1987, BIOCHEM BIOPH RES CO, V147, P460, DOI 10.1016/S0006-291X(87)80143-2; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; GRIES A, 1988, J LIPID RES, V29, P1; GRONBERG L, 1991, BIOCHEMISTRY-US, V30, P10746, DOI 10.1021/bi00108a020; HANDA T, 1992, BIOCHEMISTRY-US, V31, P1415, DOI 10.1021/bi00120a018; HERMETTER A, 1989, CHEM PHYS LIPIDS, V50, P57, DOI 10.1016/0009-3084(89)90026-1; HOERRMANN W, 1991, VASA-J VASCULAR DIS, V20, P319; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; JAMES DR, 1987, BIOCHEMISTRY-US, V26, P6272, DOI 10.1021/bi00393a047; JAMESON DM, 1983, NEW DIRECTIONS MOL L, P67; JONAS A, 1977, BIOCHIM BIOPHYS ACTA, V486, P10, DOI 10.1016/0005-2760(77)90065-0; KALB E, 1989, BIOPHYS J, V56, P1245, DOI 10.1016/S0006-3495(89)82771-7; KALLER H, 1961, BIOCHEM Z, V334, P451; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KARADI I, 1988, BIOCHIM BIOPHYS ACTA, V960, P91, DOI 10.1016/0005-2760(88)90013-6; KATES M, 1986, LAB TECHNIQUES BIOCH, V3, P186; KNIPPING G, 1986, BIOCHEMISTRY-US, V25, P5242, DOI 10.1021/bi00366a039; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; LAGGNER P, 1978, EUR J BIOCHEM, V84, P227, DOI 10.1111/j.1432-1033.1978.tb12160.x; LAGGNER P, 1981, J BIOL CHEM, V256, P1832; LAKOWICZ JR, 1981, J BIOCHEM BIOPH METH, V5, P131, DOI 10.1016/0165-022X(81)90012-9; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LENTZ BR, 1989, BIOPHYS J, V56, P723, DOI 10.1016/S0006-3495(89)82720-1; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LUNDKATZ S, 1990, J BIOL CHEM, V265, P12217; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2012, DOI 10.1021/bi00122a017; MOLOTKOVSKY JG, 1982, EUR J BIOCHEM, V122, P573; MULLER K, 1978, EUR J BIOCHEM, V82, P73, DOI 10.1111/j.1432-1033.1978.tb11998.x; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PARASASSI T, 1984, J BIOL CHEM, V259, P4011; PARASASSI T, 1991, BIOPHYS J, V59, P466, DOI 10.1016/S0006-3495(91)82240-8; PARENTE RA, 1986, BIOCHEMISTRY-US, V25, P1021, DOI 10.1021/bi00353a011; POWNALL HJ, 1980, ATHEROSCLEROSIS, V36, P299, DOI 10.1016/0021-9150(80)90211-7; SATTLER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P65, DOI 10.1016/0005-2760(91)90251-C; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, CURR OPIN LIPIDOL, V2, P253; SKLAR LA, 1980, BIOCHEMISTRY-US, V19, P1294, DOI 10.1021/bi00548a005; SKLAR LA, 1981, J BIOL CHEM, V256, P4286; SMUTZER G, 1988, BIOCHIM BIOPHYS ACTA, V958, P323, DOI 10.1016/0005-2760(88)90217-2; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; SOUTAR A, 1978, NATURE, V1, P11; SPENCER RD, 1969, ANN NY ACAD SCI, V158, P361, DOI 10.1111/j.1749-6632.1969.tb56231.x; STEYRER E, 1990, J LIPID RES, V31, P1247; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; TRELEAVEN WD, 1986, BIOCHIM BIOPHYS ACTA, V877, P198, DOI 10.1016/0005-2760(86)90135-9; VANCE JE, 1990, BIOCHIM BIOPHYS ACTA, V1045, P128, DOI 10.1016/0005-2760(90)90141-J; VAUHKONEN M, 1989, BIOCHIM BIOPHYS ACTA, V984, P81, DOI 10.1016/0005-2736(89)90345-3; WATT RM, 1981, BIOCHEMISTRY-US, V20, P3897, DOI 10.1021/bi00516a036; WILLIAMS BW, 1988, BIOCHEMISTRY-US, V27, P7994, DOI 10.1021/bi00421a004; WILLIAMS BW, 1990, BIOCHEMISTRY-US, V29, P3248, DOI 10.1021/bi00465a016; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YEAGLE PL, 1977, BIOCHEMISTRY-US, V16, P3487, DOI 10.1021/bi00634a031; YEAGLE PL, 1982, BIOCHEMISTRY-US, V21, P1249, DOI 10.1021/bi00535a022; ZAWADZKI Z, 1988, BIOCHEMISTRY-US, V27, P8474, DOI 10.1021/bi00422a027	79	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24217	24222						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447171				2022-12-27	WOS:A1992KA26300014
J	RICHIERI, GV; OGATA, RT; KLEINFELD, AM				RICHIERI, GV; OGATA, RT; KLEINFELD, AM			A FLUORESCENTLY LABELED INTESTINAL FATTY-ACID BINDING-PROTEIN - INTERACTIONS WITH FATTY-ACIDS AND ITS USE IN MONITORING FREE FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ARACHIDONIC-ACID; RAT; METABOLISM; RECEPTOR; CELLS; PURIFICATION; EXPRESSION; VESICLES	The fatty acid-binding protein from rat intestine (I-FABP) has been covalently modified with the fluorescent compound Acrylodan. Acrylodan was found to label Lys27, one of the few amino acid residues found by x-ray diffraction studies to change orientation upon fatty acid (FA) binding to I-FABP. Binding of FA to this Acrylodan-modified I-FABP (ADIFAB) induces a large shift in fluorescence emission wavelength from 432 to 505 nm. As a consequence, the ratio of emission intensities provides a direct measure of the concentration of FA bound to the protein. Binding of FA is well described by single site equilibrium for FA concentration below the critical micelle concentration. ADIFAB dissociation constants (K(d)) determined at 37-degrees-C and at concentrations below the critical micelle concentration for oleate, palmitate, linoleate, arachidonate, and linolenate were, respectively, 0.28, 0.33, 0.97, 1.6, and 2.5 muM. The variation of these K(d) values with FA molecular species is highly correlated with the solubility of the FA in water, suggesting that all these FA bind with a similar conformation in the I-FABP binding site. The ADIFAB response together with the measured equilibrium constants allows a direct determination of the concentration of long chain free fatty acid (FFA) in the concentration range, depending upon the FA molecular species, between 1 nM and >20 muM. As an example of its use as a probe to measure FFA levels, ADIFAB is used here to monitor the time course for FFA release from IgE receptor- and ionomycin-activated rat basophilic leukemia (RBL) cells.	MED BIOL INST,DIV MEMBRANE BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037						NIGMS NIH HHS [GM29831, GM44171] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029831, R01GM044171] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANEL A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P323, DOI 10.1016/0005-2760(90)90076-A; APGAR JR, 1990, J IMMUNOL, V145, P3814; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; CHINANDER LL, 1989, J BIOL CHEM, V264, P19564; CREWS FT, 1981, ARCH BIOCHEM BIOPHYS, V212, P561, DOI 10.1016/0003-9861(81)90399-4; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GOODMAN DS, 1958, J AM CHEM SOC, V80, P3887, DOI 10.1021/ja01548a023; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HWANG TC, 1990, P NATL ACAD SCI USA, V87, P5706, DOI 10.1073/pnas.87.15.5706; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; KLEINFELD AM, 1991, BIOPHYS J, V59, P637; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LIN PY, 1991, J IMMUNOL, V146, P1609; LOWE JB, 1987, J BIOL CHEM, V262, P5931; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; RICHIERI GV, 1990, J IMMUNOL, V145, P1074; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SEELIG J, 1971, EUR J BIOCHEM, V21, P17, DOI 10.1111/j.1432-1033.1971.tb01434.x; SIMPSON RB, 1974, J LIPID RES, V13, P415; SMALL DM, 1986, PHYSICAL CHEM LIPIDS; SPECTOR A A, 1978, P229; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; YAMAGUCHI T, 1986, BIOCHIM BIOPHYS ACTA, V861, P440, DOI 10.1016/0005-2736(86)90452-9	34	193	201	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23495	23501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429693				2022-12-27	WOS:A1992JZ23900015
J	KASTURI, S; KIHARA, A; FITZGERALD, D; PASTAN, I				KASTURI, S; KIHARA, A; FITZGERALD, D; PASTAN, I			ALANINE SCANNING MUTAGENESIS IDENTIFIES SURFACE AMINO-ACIDS ON DOMAIN-II OF PSEUDOMONAS EXOTOXIN REQUIRED FOR CYTOTOXICITY, PROPER FOLDING, AND SECRETION INTO PERIPLASM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TOXIN; AERUGINOSA; SITE; DELETION; TOXICITY; PROTEINS; BINDING	Pseudomonas exotoxin A (PE) is a single polypeptide chain that contains 613 amino acids and is arranged into three major structural domains. Domain la is responsible for cell recognition, domain II for translocation of PE across the membrane, and domain III for ADP-ribosylation of elongation factor 2. Recombinant PE can be produced in Escherichia coli and is efficiently secreted into the periplasm when an OmpA signal sequence is present. To investigate the role of the amino acids located on the surface of domain II in the action of the toxin against mammalian cells, we substituted alanine for each of the 27 surface amino acids present in domain II. Surprisingly, all 27 mutant proteins had some alteration in cytotoxicity when tested on human A431 or MCF7 cells or mouse L929 cells. Native PE has a compact structure and therefore is relatively protease resistant and very little ADP-ribosylation activity is detected in the absence of the denaturing agents like urea and dithiothreitol. Several of the mutations resulted in altered protease sensitivity of the toxin. Seven of the mutant molecules exhibited ADP-ribosylation activity without urea and dithiothreitol, indicating they are partially unfolded. Out of these seven mutants, six had increased cytotoxic activity on at least one of the target cell lines and the other retained its native cytotoxic potency.	NCI,DIV CANC BIOL DIAGN & CTR,MOLEC BIOL LAB,BLDG 37,RM 4E16,BETHESDA,MD 20891	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BUCHNER J, 1991, CURR OPIN BIOTECH, V2, P532, DOI 10.1016/0958-1669(91)90077-I; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JINNO Y, 1989, J BIOL CHEM, V264, P15953; JINNO Y, 1988, J BIOL CHEM, V263, P13203; JINNO Y, 1988, J BIOL CHEM, V263, P9470; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUKAC M, 1988, INFECT IMMUN, V56, P3095, DOI 10.1128/IAI.56.12.3095-3098.1988; OGATA M, 1990, J BIOL CHEM, V265, P20678; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2	20	19	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23427	23433						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429683				2022-12-27	WOS:A1992JY16300108
J	BREVIARIO, F; DANIELLO, EM; GOLAY, J; PERI, G; BOTTAZZI, B; BAIROCH, A; SACCONE, S; MARZELLA, R; PREDAZZI, V; ROCCHI, M; DELLAVALLE, G; DEJANA, E; MANTOVANI, A; INTRONA, M				BREVIARIO, F; DANIELLO, EM; GOLAY, J; PERI, G; BOTTAZZI, B; BAIROCH, A; SACCONE, S; MARZELLA, R; PREDAZZI, V; ROCCHI, M; DELLAVALLE, G; DEJANA, E; MANTOVANI, A; INTRONA, M			INTERLEUKIN-1-INDUCIBLE GENES IN ENDOTHELIAL-CELLS - CLONING OF A NEW GENE RELATED TO C-REACTIVE PROTEIN AND SERUM AMYLOID-P COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; DNA-SEQUENCE; COMPLEMENTARY-DNA; EXPRESSION; CYTOKINES; INDUCTION; ENCODES; SITES; TRANSCRIPTION; HYBRIDIZATION	Differential screening of a cDNA library constructed from human umbilical vein endothelial cells exposed for 1 h to interleukin-1beta (IL-1beta) has led to the identification of a novel gene (PTX3) related to pentaxins (C-reactive protein and serum amyloid P component in man), a subclass of acute phase proteins. Sequencing of the full-length cDNA clone and RNase mapping revealed that the PTX3 transcript is 1861 base pairs long and has a unique transcription start site. The predicted protein sequence of 381 amino acids is highly similar to pentaxins in its COOH-terminal half where it also contains a typical 8-amino acid "pentaxin signature" sequence. The NH2-terminal half of PTX3 shows no similarity to any known protein sequence and initiates with a putative signal peptide indicating that PTX3 is secreted. The genome of PTX3 is organized into three exons. Interestingly, the region of homology between PTX3 and pentaxins corresponds to the third PTX3 exon. The PTX3 gene has been localized on human chromosome 3 band q25 by Southern blots of somatic cell hybrids and by in situ hybridization. The PTX3 mRNA is induced in endothelial, hepatic, and fibroblastic cells by IL-1beta and tumor necrosis factor alpha but not by IL-6 and interferon-gamma. PTX3 may represent a novel marker of inflammatory reactions, particularly those involving the vessel wall.	MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY; CTR MED UNIV GENEVA,DEPT MED BIOCHEM,GENEVA,SWITZERLAND; UNIV PAVIA,DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAVERSO,I-27100 PAVIA,ITALY; IST GENET,I-70126 BARI,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Geneva; University of Pavia			Golay, Josee/AAA-4085-2022; Bairoch, Amos/X-7411-2019; Mantovani, Alberto/HCI-7449-2022; Introna, Martino/AAA-5823-2019; Saccone, Salvatore/H-1548-2012	Golay, Josee/0000-0002-7932-909X; Bairoch, Amos/0000-0003-2826-6444; Mantovani, Alberto/0000-0001-5578-236X; Introna, Martino/0000-0001-6216-0892; Saccone, Salvatore/0000-0001-7568-5823; Bottazzi, Barbara/0000-0002-1930-9257				Abernethy TJ, 1941, J EXP MED, V73, P173, DOI 10.1084/jem.73.2.173; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BERGER SL, 1987, METHOD ENZYMOL, V152, P324; Ciliberto G., 1989, ACUTE PHASE PROTEINS, P29, DOI [10.1007/978-1-4471-1739-1_3, DOI 10.1007/978-1-4471-1739-1_3]; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DEJANA E, 1987, BLOOD, V69, P695; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FUSCOE JC, 1983, MOL CELL BIOL, V3, P1086, DOI 10.1128/MCB.3.6.1086; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GOLAY J, 1991, BLOOD, V77, P149; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HLA T, 1990, J BIOL CHEM, V265, P9308; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUSHNER I, 1978, J EXP MED, V148, P466, DOI 10.1084/jem.148.2.466; KUSHNER I, 1989, ANN NY ACAD SCI, V557, P19; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEI KJ, 1985, J BIOL CHEM, V260, P3377; LI SP, 1990, J BIOL CHEM, V265, P4136; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3; MANTOVANI A, 1992, FASEB J, V6, P2597; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; MONTANARO V, 1991, AM J HUM GENET, V48, P183; MURPHY TM, 1991, J EXP MED, V173, P495, DOI 10.1084/jem.173.2.495; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OTTONE F, 1981, CYTOGENET CELL GENET; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; ROBINSON EA, 1989, P NATL ACAD SCI USA, V86, P1850, DOI 10.1073/pnas.86.6.1850; ROCCHI M, 1989, SOMAT CELL MOLEC GEN, V15, P185, DOI 10.1007/BF01535081; ROCCHI M, 1986, HUM GENET, V74, P30; ROSENSTRAUS M, 1975, P NATL ACAD SCI USA, V72, P493, DOI 10.1073/pnas.72.2.493; ROYLE NJ, 1987, SOMAT CELL MOLEC GEN, V13, P285, DOI 10.1007/BF01535211; Sambrook J, 1989, MOL CLONING LABORATO; STOEHR PJ, 1991, NUCLEIC ACIDS RES, V19, P2227, DOI 10.1093/nar/19.suppl.2227; STOEHR PJ, 1991, GENOME ANAL SEQUENCE, P177; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITEHEAD AS, 1983, SCIENCE, V221, P69, DOI 10.1126/science.6857266; WOLF FW, 1992, J BIOL CHEM, V267, P1317; WOO P, 1985, J BIOL CHEM, V260, P3384; YAP SH, 1991, BIOCHIM BIOPHYS ACTA, V1091, P405, DOI 10.1016/0167-4889(91)90207-E; ZAHEDI K, 1989, J IMMUNOL, V143, P2880	52	358	393	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22190	22197						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429570				2022-12-27	WOS:A1992JW71900033
J	DALLAIRE, L; BELIVEAU, R				DALLAIRE, L; BELIVEAU, R			PHOSPHATE-TRANSPORT BY CAPILLARIES OF THE BLOOD-BRAIN-BARRIER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; RAT-BRAIN; VESICLES; SODIUM; CELLS; MICROVESSELS; ACIDS	Capillaries were isolated from bovine brain cortex and used for phosphate transport studies. The influx of phosphate through capillary membranes was studied by incubation with [P-32i]phosphate followed by a rapid filtration technique. Phosphate uptake by brain capillaries was mediated by a saturable high-affinity system which is independent of the sodium concentration in the incubation medium. The apparent half-saturation constant (K(m)) and maximal influx (V(max)) were estimated to 160 muM and 0.37 nmol/mg protein/30 s. Transport was inhibited by the phosphate analogues arsenate and phosphonoformic acid with apparent inhibition constants of 5 and 11 mM, respectively. The metabolic inhibitors cyanide and ouabain had no effect on the transport activity. Competition experiments showed that phosphate uptake was inhibited up to 41% by various anions (pyruvate, acetate, citrate, glutamate, and sulfate). In addition, phosphate uptake was significantly decreased by two selective inhibitors of anionic exchangers, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid and 4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid. Chloride was not a substrate of the phosphate carrier as the replacement of external chloride, by nitrate, thiocyanate, or gluconate, did not increase phosphate transport. Aminohippuric acid and N'-methylnicotinamide, two specific substrates of anionic and cationic drug exchangers, did not compete with the phosphate carrier of cerebral capillaries. However, trans-stimulation with bicarbonate increased phosphate transport by 28%, and this stimulation was inhibited by 1 mM 4,4'-diisothiocyanostilbene-2, 2'-disulfonic acid, suggesting that the carrier of the cerebral capillaries could exchange phosphate with bicarbonate.	UNIV QUEBEC,MEMBRANOL GRP RECH & BIOTHERAPEUT MOLEC LAB,CP 8888,SUCC A,MONTREAL H3C 3P8,QUEBEC,CANADA	University of Quebec; University of Quebec Montreal								BELIVEAU R, 1990, BIOCHIM BIOPHYS ACTA, V1028, P110, DOI 10.1016/0005-2736(90)90146-F; BELIVEAU R, 1988, BIOCHEM J, V252, P801, DOI 10.1042/bj2520801; BELIVEAU R, 1987, M S-MED SCI, V3, P589, DOI 10.4267/10608/3611; BERNER W, 1976, BIOCHEM J, V160, P467, DOI 10.1042/bj1600467; BESSEGHIR K, 1987, RENAL PHYSIOL BIOCH, V10, P221; BETZ AL, 1983, J NEUROCHEM, V41, P1150, DOI 10.1111/j.1471-4159.1983.tb09065.x; BRADBURY MWB, 1984, FED PROC, V43, P186; BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0; BURCKHARDT G, 1989, KIDNEY INT, V36, P370, DOI 10.1038/ki.1989.205; CHEN ML, 1990, J CELL PHYSIOL, V143, P488, DOI 10.1002/jcp.1041430313; DALLAIRE L, 1991, BIOCHEM J, V276, P745, DOI 10.1042/bj2760745; Djuricic B M, 1978, Adv Neurol, V20, P197; DOUSA TP, 1982, MINER ELECTROL METAB, V7, P113; GANONG WF, 1989, REV MED PHYSL, P514; GOLDSTEIN GW, 1979, J PHYSIOL-LONDON, V286, P185, DOI 10.1113/jphysiol.1979.sp012613; HOFFMANN N, 1976, PFLUG ARCH EUR J PHY, V362, P147, DOI 10.1007/BF00583641; HUTCHISON HT, 1985, EXP NEUROL, V87, P260, DOI 10.1016/0014-4886(85)90216-X; KATZMAN R, 1981, BASIC NEUROCHEMISTRY, P497; MIYAMOTO Y, 1989, AM J PHYSIOL, V256, pF540, DOI 10.1152/ajprenal.1989.256.4.F540; OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502; OLDENDORF WH, 1973, AM J PHYSIOL, V224, P1450, DOI 10.1152/ajplegacy.1973.224.6.1450; OTT RJ, 1990, BIOCHEM PHARMACOL, V40, P659, DOI 10.1016/0006-2952(90)90572-3; PARDRIDGE WM, 1988, ANNU REV PHARMACOL, V28, P25; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; SMITH QR, 1984, J NEUROCHEM, V42, P754, DOI 10.1111/j.1471-4159.1984.tb02747.x; STEFFENS TG, 1989, AM J PHYSIOL, V256, pF596, DOI 10.1152/ajprenal.1989.256.4.F596; SZCZEPANSKAKONKEL M, 1986, J BIOL CHEM, V261, P6375; TAKUWA Y, 1985, BIOCHEM J, V230, P715, DOI 10.1042/bj2300715; WIETH JO, 1985, KIDNEY PHYSL PATHOPH, P49	29	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22323	22327						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429584				2022-12-27	WOS:A1992JW71900053
J	MCINTOSH, DB				MCINTOSH, DB			GLUTARALDEHYDE CROSS-LINKS LYS-492 AND ARG-678 AT THE ACTIVE-SITE OF SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; AMINO-ACID-SEQUENCE; PROTON-TRANSLOCATING ATPASE; CATION-TRANSPORTING ATPASES; NUCLEOTIDE-BINDING; ADENOSINE TRIPHOSPHOPYRIDOXAL; CA-2+-TRANSPORTING ATPASE; FUNCTIONAL CONSEQUENCES; ESCHERICHIA-COLI; CA-2+ PUMP	It has been shown previously that glutaraldehyde cross-links the Ca2+-ATPase of sarcoplasmic reticulum intramolecularly at the active site, involving residues participating in nucleotide binding and the conformational change that results in Ca2+ release to the vesicle lumen and formation of ADP-insensitive E2-P (Ross, D. C., Davidson, G. A., and McIntosh, D. B. (1991) J. Biol. Chem. 266, 4613-4621). This study shows that 10 nmol of [C-14]glutaraldehyde/mg of protein attached irreversibly to the ATPase under conditions optimal for formation of the intramolecular cross-link. Half of this amount (i.e. 1 mol/mol ATPase) was inhibited by nucleotide binding. Thermolysin digestion of derivatized vesicles released two nucleotide-sensitive C-14-labeled species, which were isolated and identified as FSRDR*S and FSRDR*S FA* FA*VEPS where the missing residues are Lys-492 and Arg-678. The majority of the C-14 label was released in the sixth cycle of both Edman degradations, confirming the cross-link position. Lys-492 and Arg-678 are evidently close together in the active site, but their distance apart in the linear sequence suggests that they may arise from separate domains, which together constitute an ATP binding cleft. Residues in both regions, and Lys-492 in particular (McIntosh, D. B., Woolley, D. G., and Berman, M. C. (1992) J. Biol. Chem. 267, 5301-5309), have been derivatized by nucleotide-based affinity probes. Mutations of both of these residues in some of the bacterial P-type ATPases suggest that they do not play an essential catalytic role, and the inability of the cross-linked ATPase to form E2-P and to release Ca2+ to the lumen is probably because an essential tertiary structural movement at the active site is blocked.			MCINTOSH, DB (corresponding author), UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,MRC,BIOMEMBRANE RES UNIT,CAPE TOWN 7925,SOUTH AFRICA.							ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; BARNA JJC, 1984, J LABELLED COMPD RAD, V21, P727, DOI 10.1002/jlcr.2580210806; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DAVIS CB, 1990, J BIOL CHEM, V265, P1300; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARDY PM, 1976, J CHEM SOC PERK T 1, P958, DOI 10.1039/p19760000958; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HINZ HR, 1990, J BIOL CHEM, V265, P10260; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KITAMOTO Y, 1980, J BIOCHEM-TOKYO, V87, P1519, DOI 10.1093/oxfordjournals.jbchem.a132893; KORN AH, 1972, J MOL BIOL, V65, P525, DOI 10.1016/0022-2836(72)90206-9; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAEDA K, 1971, J ANTIBIOT, V24, P402, DOI 10.7164/antibiotics.24.402; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MONSAN P, 1975, BIOCHIMIE, V57, P1281; MURPHY AJ, 1976, BIOCHEM BIOPH RES CO, V70, P1048, DOI 10.1016/0006-291X(76)91008-1; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; PETITHORY JR, 1990, BIOCHEMISTRY-US, V1018, P195; RICHARDS FM, 1968, J MOL BIOL, V37, P231, DOI 10.1016/0022-2836(68)90086-7; ROSS DC, 1987, J BIOL CHEM, V262, P12977; ROSS DC, 1991, J BIOL CHEM, V266, P4613; ROSS DC, 1987, J BIOL CHEM, V262, P2042; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; TAMARA S, 1989, J BIOL CHEM, V264, P8580; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TRAN CM, 1988, BIOPHYS J, V53, pA343; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILSEN B, 1991, J BIOL CHEM, V266, P16157; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976	41	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22328	22335						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429585				2022-12-27	WOS:A1992JW71900054
J	BOULAY, JL; PAUL, WE				BOULAY, JL; PAUL, WE			THE INTERLEUKIN-4-RELATED LYMPHOKINES AND THEIR BINDING TO HEMATOPOIETIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTORS; CYTOKINE GENE-CLUSTER; GM-CSF GENES; MOLECULAR-CLONING; BETA-CHAIN; ERYTHROPOIETIN RECEPTOR; 3-DIMENSIONAL STRUCTURE; EXPRESSION CLONING; SIGNAL TRANSDUCER				BOULAY, JL (corresponding author), NIAID,IMMUNOL LAB,BETHESDA,MD 20892, USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BOULAY JL, 1992, CURR OPIN IMMUNOL, V4, P294, DOI 10.1016/0952-7915(92)90079-T; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BURGESS AW, 1990, PEPTIDE GROWTH FACTO, P723; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DEUSTACHIO P, 1988, J IMMUNOL, V141, P3067; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; FERNANDEZBOTRAN R, 1991, J EXP MED, V174, P673, DOI 10.1084/jem.174.3.673; FROLOVA EI, 1991, P NATL ACAD SCI USA, V88, P4821, DOI 10.1073/pnas.88.11.4821; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ihle J. N., 1990, PEPTIDE GROWTH FACTO, P541; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEE JS, 1989, SOMAT CELL MOLEC GEN, V15, P143, DOI 10.1007/BF01535075; LEE JS, 1989, GENOMICS, V5, P359, DOI 10.1016/0888-7543(89)90070-0; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAKANISHI K, 1990, J IMMUNOL, V145, P1423; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PAUL WE, 1991, BLOOD, V77, P1859; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SWAIN SL, 1988, IMMUNOL REV, V102, P77, DOI 10.1111/j.1600-065X.1988.tb00742.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	58	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20525	20528						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400369				2022-12-27	WOS:A1992JT97800001
J	BRANDL, CJ; MARTENS, JA; LIAW, PCY; FURLANETTO, AM; WOBBE, CR				BRANDL, CJ; MARTENS, JA; LIAW, PCY; FURLANETTO, AM; WOBBE, CR			TATA-BINDING PROTEIN ACTIVATES TRANSCRIPTION WHEN UPSTREAM OF A GCN4-BINDING SITE IN A NOVEL YEAST PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; SATURATION MUTAGENESIS; MOLECULAR MECHANISMS; INITIATION SITE; TFIID COMPLEX; GENE PROMOTER; BOX FACTOR	In the gal-his3 hybrid promoter, his3-GG1, GCN4 stimulates transcription at the position normally occupied by a TATA element. This expression requires two elements within gal1-10 sequences, a REB1-binding site and a second element, Z, which resides 20 base pairs upstream of the GCN4-binding site. No obvious TATA element is present in this promoter. To characterize the function of Z, we replaced it with short random oligonucleotides and selected for expression in vivo. Fourteen elements were identified and classified into groups based upon sequence and phenotypic similarities. Group 1 elements contained functional TATA sequences that were essential for activity. TATA elements can thus function when positioned upstream of a GCN4-binding site. The Group 2 elements activated transcription poorly when used as conventional TATA elements; however, mutational analyses demonstrated that their activity required TATA-like sequences. These TATA-like sequences bound the yeast TATA-binding protein (TBP) poorly in vitro but function in vivo as TBP interaction sites based upon two criteria. First mutations that improved their TATA character correspondingly improved function and second their activity could be enhanced in the presence of an altered binding specificity mutant of TBP. Furthermore, the Group 2 elements enabled the identification of mutations outside of the TATA-like core that contribute to transcriptional activation without adversely affecting TBP binding. The finding that low affinity TBP-binding sites can be used at unconventional positions suggests that many "TATA-less' promoters contain a cryptic interaction site for TBP.	MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065	Merck & Company	BRANDL, CJ (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FINLEY RL, 1989, MOL CELL BIOL, V9, P4282, DOI 10.1128/MCB.9.10.4282; FINLEY RL, 1990, MOL CELL BIOL, V10, P5663, DOI 10.1128/MCB.10.11.5663; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GUARENTE L, 1988, CELL, V52, P303, DOI 10.1016/S0092-8674(88)80020-5; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOMA FL, 1988, GENE DEV, V2, P40, DOI 10.1101/gad.2.1.40; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MORROW BE, 1989, J BIOL CHEM, V264, P9061; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REACH M, 1991, EMBO J, V10, P3439, DOI 10.1002/j.1460-2075.1991.tb04908.x; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSENBERG AH, 1987, GENE AMST, V56, P126; SAFER B, 1991, J BIOL CHEM, V266, P10989; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STONE N, 1991, PHARM TECHNOL, V15, P36; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1982, NATURE, V300, P284, DOI 10.1038/300284a0; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TABOR S, 1990, CURRENT PROTOCOLS MO; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	81	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20943	20952						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400410				2022-12-27	WOS:A1992JT97800069
J	OBEID, LM; BLOBE, GC; KAROLAK, LA; HANNUN, YA				OBEID, LM; BLOBE, GC; KAROLAK, LA; HANNUN, YA			CLONING AND CHARACTERIZATION OF THE MAJOR PROMOTER OF THE HUMAN PROTEIN-KINASE-C BETA-GENE - REGULATION BY PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; HL-60 DIFFERENTIATION; CELLULAR-REGULATION; 5'-FLANKING REGION; MAMMALIAN-CELLS; EXPRESSION; FAMILY; BINDING; ISOZYMES; SEQUENCE	The expression of the beta isoenzyme for protein kinase C is regulated developmentally and in response to inducers of cell differentiation (such as phorbol esters and 1alpha,25-dihydroxyvitamin D3). The 5' segment of the gene for protein kinase C beta was cloned from a human leukocyte genomic library in EMBL3 bacteriophage. This segment of the gene (greater than 54 kilobases in length) encompassed the coding sequence for the amino-terminal regulatory domain of the enzyme, the 5'-untranslated region, and the 5'-flanking region. Initiation of transcription was identified by S1 nuclease analysis and confirmed by RNase protection analysis at 197 base pairs 5' of the initiator ATG. Sequence analysis of the 5'-flanking region revealed it to be extremely G+C-rich (>80%) with many features of a CpG island. Comparison of sequence with known cis-regulatory motifs disclosed a number of potential regulatory elements including an octamer binding motif at -76, Sp1-binding sites at -94 and -63, E boxes at -110, -26, and +18, an AP-1 site at -442, and an AP-2 site at -330. To demonstrate promoter activity, a 630-base pair fragment extending from -587 to +43 was subcloned in front of a promoterless luciferase gene. This fragment was able to drive the expression of luciferase in transient transfections of human hematopoietic cells. Deletion analysis demonstrated that a fragment -111 to +43 was necessary and sufficient for promoter activity; this fragment did not contain TATA or CAAT motifs. The promoter was stimulated 8-20-fold by phorbol esters accounting for the previously observed transcriptional activation of protein kinase C beta. This phorbol ester responsiveness was conferred by the basal promoter (-111 to +43) and was independent of the AP-1 site. These results define a novel mechanism of protein kinase C autoregulation at a transcriptional level.	DUKE UNIV,MED CTR,DEPT MED,DIV GERIATR,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University; Duke University			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; obeid, lina/0000-0002-0734-0847	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CHEN KH, 1990, J BIOL CHEM, V265, P19961; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEWIN B, 1990, GENES, V4; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MANIATIS T, 1982, MOL CLONING LABORATO, P320; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MCCACHREN SS, 1988, BIOCHEM BIOPH RES CO, V151, P574, DOI 10.1016/0006-291X(88)90633-X; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; Sambrook J, 1989, MOL CLONING LABORATO; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; WETSEL WC, 1992, J CELL BIOL, V117, P11; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	39	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20804	20810						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400396				2022-12-27	WOS:A1992JT97800047
J	WOO, KM; KIM, KI; GOLDBERG, AL; HA, DB; CHUNG, CH				WOO, KM; KIM, KI; GOLDBERG, AL; HA, DB; CHUNG, CH			THE HEAT-SHOCK PROTEIN CLPB IN ESCHERICHIA-COLI IS A PROTEIN-ACTIVATED ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE; ION GENE; REGULATORY SUBUNIT; LA; COMPONENT; SEQUENCE; BINDING; TI; HYDROLYSIS; EXPRESSION	The clpB gene in Escherichia coli encodes a heat-shock protein that is a close homolog of the clpA gene product. The latter is the ATPase subunit of the multimeric ATP-dependent protease Ti (Clp) in E. coli, which also contains the 21-kDa proteolytic subunit (ClpP). The clpB gene product has been purified to near homogeneity by DEAE-Sepharose and heparin-agarose column chromatographies. The purified ClpB consists of a major 93-kDa protein and a minor 79-kDa polypeptide as analyzed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. Upon gel filtration on a Superose-6 column, it behaves as a 350-kDa protein. Thus, ClpB appears to be a tetrameric complex of the 93-kDa subunit. The purified ClpB has ATPase activity which is stimulated 5-10-fold by casein. It is also activated by insulin, but not by other proteins, including globin and denatured bovine serum albumin. ClpB cleaves adenosine 5'-(alpha,beta-methylene)-triphosphate as rapidly as ATP, but not adenosine 5'-(beta,gamma-methylene)-triphosphate. GTP, CTP, and UTP are hydrolyzed 15-25% as well as ATP. ADP strongly inhibits ATP hydrolysis with a K(i) of 34 muM. ClpB has a K(m) for ATP of 1.1 mM, and casein increases its V(max) for ATP without affecting its K(m). A Mg2+ concentration of 3 mM is necessary for half-maximal ATP hydrolysis. Mn2+ supports ATPase activity as well as Mg2+, and Ca2+ has about 20% their activity. Anti-ClpB antiserum does not cross-react with ClpA nor does anti-ClpA antiserum react with ClpB. In addition, ClpB cannot replace ClpA in supporting the casein-degrading activity of ClpP. Thus, ClpB is distinct from ClpA in its structural and biochemical properties despite the similarities in their sequences.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SEOUL 151742,SOUTH KOREA; HARVARD UNIV,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,BOSTON,MA 02115	Seoul National University (SNU); Harvard University; Harvard Medical School			KIM, KEUN IL/D-2959-2011					Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKE MS, 1984, ANAL BIOCHEM, V136, P175; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FLYNN GC, 1989, SCIENCE, V248, P850; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENON AS, 1987, J BIOL CHEM, V262, P14921; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; PONTIS E, 1991, BIOCHEM BIOPH RES CO, V180, P1222, DOI 10.1016/S0006-291X(05)81326-9; SHEN WF, 1982, NUCLEIC ACIDS RES, V10, P3303, DOI 10.1093/nar/10.10.3303; SQUIRES CL, 1991, J BACTERIOL, V173, P4257; SWAMY KHS, 1983, ARCH BIOCHEM BIOPHYS, V224, P543, DOI 10.1016/0003-9861(83)90242-4; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WOO KM, 1989, J BIOL CHEM, V264, P2088	31	157	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20429	20434						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400361				2022-12-27	WOS:A1992JR85800106
J	KUWANO, Y; OLVERA, J; WOOL, IG				KUWANO, Y; OLVERA, J; WOOL, IG			THE PRIMARY STRUCTURE OF RAT RIBOSOMAL PROTEIN-S5 - A RIBOSOMAL-PROTEIN PRESENT IN THE RAT GENOME IN A SINGLE COPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENES; NUCLEOTIDE-SEQUENCE; CHLOROPLAST GENOME; EUKARYOTIC RIBOSOMES; ESCHERICHIA-COLI; ORGANIZATION; S7; S12; DNA; OPERON	The amino acid sequence of the rat 40 S ribosomal subunit protein S5 was deduced from the sequence of nucleotides in a recombinant cDNA and confirmed by the determination, directly from the protein, of 17 residues near the NH2 terminus. S5 has 204 amino acids; the molecular weight is 22,863. The protein designated S5a has the same amino acid sequence as S5 except that it lacks the NH2-terminal 5 residues. It is not known whether the conversion of a portion of S5 to S5a is physiological or fortuitous. The mRNA for S5 has about 820 nucleotides. Hybridization of the S5 cDNA to digests of nuclear DNA indicates that the rat genome has only a single copy of the gene; this is in distinction to the mouse and human genomes which have three to six copies of the S5 gene. Rat ribosomal protein S5 is related to the eubacteria, the archaebacteria, and the chloroplast family of S7 ribosomal proteins. There is a peptide of 16 residues at the carboxyl terminus of S5 that is highly conserved in 18 species spanning the three kingdoms and chloroplasts.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM-21769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUER J, 1991, SYST APPL MICROBIOL, V14, P14, DOI 10.1016/S0723-2020(11)80356-5; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHAN YL, 1987, J BIOL CHEM, V262, P12879; CHAN YL, 1990, ARCH BIOCHEM BIOPHYS, V283, P546, DOI 10.1016/0003-9861(90)90682-O; CHAN YL, 1988, J BIOL CHEM, V263, P2891; COLLATZ E, 1976, J BIOL CHEM, V251, P4666; COLLATZ E, 1977, J BIOL CHEM, V252, P9071; DAYHOFF MO, 1978, ATLAS PROTEIN SEQUEN, V5, P1; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GIESE K, 1987, J BIOL CHEM, V262, P15251; GLUCK A, 1989, EUR J BIOCHEM, V182, P105, DOI 10.1111/j.1432-1033.1989.tb14805.x; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; KIMURA M, 1991, AGR BIOL CHEM TOKYO, V55, P207; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUWANO Y, 1991, BIOCHEM BIOPH RES CO, V175, P551, DOI 10.1016/0006-291X(91)91600-H; LECHNER K, 1989, J MOL EVOL, V29, P20, DOI 10.1007/BF02106178; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; LEMISCHKA I, 1982, NATURE, V300, P330, DOI 10.1038/300330a0; LIMBACH KJ, 1985, NUCLEIC ACIDS RES, V13, P617, DOI 10.1093/nar/13.2.617; MADJAR JJ, 1980, MOL GEN GENET, V179, P89, DOI 10.1007/BF00268450; MADSEN HO, 1990, NUCLEIC ACIDS RES, V18, P1513, DOI 10.1093/nar/18.6.1513; MENG BY, 1989, MOL GEN GENET, V216, P25, DOI 10.1007/BF00332226; MONTANDON PE, 1984, NUCLEIC ACIDS RES, V12, P2851, DOI 10.1093/nar/12.6.2851; OHAMA T, 1987, J BACTERIOL, V169, P4770, DOI 10.1128/jb.169.10.4770-4777.1987; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PERRY RP, 1990, ENZYME, V44, P83, DOI 10.1159/000468749; PODKOWINSKI J, 1989, NUCLEIC ACIDS RES, V17, P8767, DOI 10.1093/nar/17.21.8767; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REINBOLT J, 1979, BIOCHIMIE, V61, P501, DOI 10.1016/S0300-9084(79)80207-2; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SIEMEISTER G, 1990, MOL GEN GENET, V220, P425, DOI 10.1007/BF00391749; VONALLMEN JM, 1987, NUCLEIC ACIDS RES, V15, P2387, DOI 10.1093/nar/15.5.2387; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WOOL IG, 1990, RIBOSOME, P203; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; YAKHNIN AV, 1990, NUCLEIC ACIDS RES, V18, P3659, DOI 10.1093/nar/18.12.3659; ZUERNER RL, 1990, J BACTERIOL, V172, P6165, DOI 10.1128/jb.172.10.6165-6168.1990	38	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25304	25308						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460027				2022-12-27	WOS:A1992KB60300060
J	SHERWOOD, AL; HOLMES, EH				SHERWOOD, AL; HOLMES, EH			BREFELDIN-A INDUCED-INHIBITION OF DENOVO GLOBO-SERIES AND NEOLACTO-SERIES GLYCOLIPID CORE CHAIN BIOSYNTHESIS IN HUMAN-CELLS - EVIDENCE FOR AN EFFECT ON BETA-1-]4GALACTOSYLTRANSFERASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLONIC ADENOCARCINOMA; TRANS-GOLGI CISTERNAE; ENDOPLASMIC-RETICULUM; GLYCOSYLTRANSFERASE ACTIVITIES; SUBCELLULAR ORGANIZATION; GANGLIOSIDE BIOSYNTHESIS; SECRETORY PROTEINS; HELA-CELLS; RAT-LIVER; 2 FORMS	De novo synthesis of neolacto-series glycolipids has been studied in human cell lines via metabolic labeling of ceramide with [H-3]serine. Intense labeling of ceramide mono- and dihexoside glycolipids occurred with labeling of progressively longer chain derivatives with increasing time. Most of the label was recovered in neutral glycolipids with about 5% of the total labeling in the ganglioside fraction. Experiments done using cell treatment with 2.5 mug/ml brefeldin A resulted in a stimulation in the total amount of labeling, accumulation of a neutral glycolipid identified as Lc3 due to inhibited transfer of the neolacto-series core chain terminal beta-Gal residue, and a corresponding inhibition of labeling of longer chain neutral glycolipids in all cell lines. Brefeldin A also blocked synthesis of the globo-series precursor, Gb3, longer chain sialylated structures such as IV3NeuAcnLc4, but not de novo G(M3) synthesis. Brefeldin A treatment had no effect on cellular beta1-->3N-acetylglucosaminyl-, beta1-->4galactosyl-, or alpha1-->3fucosyltransferase specific activities, nor was it inhibitory in beta1-->4galactosyltransferase assays in vitro. The results describe brefeldin A-induced blocks in globo- and neolacto-series glycolipid biosynthesis, consistent with differential localization of enzymes in intracellular membranes. In particular, the results suggest that the beta1-->4galactosyltransferase in these cells is either not redistributed by brefeldin A or is otherwise rendered nonfunctional.	PACIFIC NW RES FDN,720 BROADWAY,SEATTLE,WA 98122						NATIONAL CANCER INSTITUTE [K04CA001343, R01CA041521] Funding Source: NIH RePORTER; NCI NIH HHS [CA41521, K04 CA01343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHATTERJEE S, 1992, J BIOL CHEM, V267, P7148; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GINSBURG V, 1966, METHOD ENZYMOL, V8, P293; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HOLMES EH, 1990, J CELL BIOCHEM, V44, P93, DOI 10.1002/jcb.240440204; HOLMES EH, 1991, ARCH BIOCHEM BIOPHYS, V288, P87, DOI 10.1016/0003-9861(91)90168-I; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SAITO T, 1971, J LIPID RES, V12, P257; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SHAPER JH, 1988, BIOCHIMIE, V70, P1683, DOI 10.1016/0300-9084(88)90303-3; STROUS GJ, 1983, J CELL BIOL, V97, P723, DOI 10.1083/jcb.97.3.723; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; YAMATO K, 1982, J BIOCHEM-TOKYO, V92, P1123, DOI 10.1093/oxfordjournals.jbchem.a134028; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YU RK, 1972, J LIPID RES, V13, P680; 1977, LIPIDS, V12, P455	39	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25328	25336						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460029				2022-12-27	WOS:A1992KB60300064
J	CHEN, Y; BAL, BS; GORSKI, JP				CHEN, Y; BAL, BS; GORSKI, JP			CALCIUM AND COLLAGEN BINDING-PROPERTIES OF OSTEOPONTIN, BONE SIALOPROTEIN, AND BONE ACIDIC GLYCOPROTEIN-75 FROM BONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED GLYCOPROTEIN; DEVELOPMENTAL EXPRESSION; SPARC OSTEONECTIN; SKELETAL-MUSCLE; CHICKEN BONE; RAT BONE; PROTEIN; PHOSPHOPROTEIN; MATRIX; TISSUES	Calcium binding properties of bone acidic glycoprotein-75, osteopontin, and bone sialoprotein were determined in 10 mM imidazole buffer (pH 6.8), containing either 60 mM KCl or 150 mM NaCl. Proteins assayed were first bound to nitrocellulose to mimic substrate-bound forms in vivo; retention of phosphoproteins was determined through use of radioiodinated tracers. Binding studies were carried out both as a function of calcium concentration and the amount of phosphoprotein. In the presence of 60 mM KCl, bone acidic glycoprotein-75 exhibited the largest calcium binding capacity (139 atoms/molecule at saturation), with bone sialoprotein intermediary (83 atoms/molecule) and osteopontin lowest (50 atoms/molecule). Sites detected for each phosphoprotein exhibited overall binding constants in the 0.5-1.0 mM extracellular range. In 150 mM NaCl and 1-2 mM total calcium, phosphoproteins bound between 72 and 19 mol of calcium/mol with the same relative order. Binding was proportional to amount of phosphoprotein in either salt condition. The presence of 5 mM calcium had a different effect on concentration-dependent binding to type I collagen for each phosphoprotein. Bone acidic glycoprotein-75 alone was found to undergo an unusual calcium-enhanced polymerization reaction, confirmed by light scattering measurements, wherein collagen binding was greatest with polymeric forms. These findings demonstrate that acidic phosphoproteins from bone bind calcium atoms with a range of capacities. Calcium appears to induce conformational changes in bone acidic glycoprotein-75 which influences its self-association and binding to different substrata.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA; UNIV MISSOURI, SCH MED, DEPT ORTHOPED, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City				Bal, B. Sonny/0000-0002-9615-8632	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R15AR040923] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 40923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson HC, 1985, BONE MINERAL RES, V3, P109; AOKI T, 1987, BIOCHIM BIOPHYS ACTA, V911, P238, DOI 10.1016/0167-4838(87)90013-6; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BOYAN BD, 1989, CONNECT TISSUE RES, V22, P629, DOI 10.3109/03008208909114115; CHEN J, 1991, HISTOCHEM J, V23, P281, DOI 10.1007/BF01045047; CURLEYJOSEPH J, 1979, J DENT RES, V58, P1625, DOI 10.1177/00220345790580061201; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; FRANZEN A, 1985, CHEM BIOL MINERALIZE, P132; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FUJISAWA R, 1986, CALCIFIED TISSUE INT, V39, P248, DOI 10.1007/BF02555213; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; GORSKI JP, 1987, DEV DISEASES CARTILA, P377; GORSKI JP, 1992, CONNECT TISSUE RES, V27, P112; GOTOH Y, 1990, BIOCHEM BIOPH RES CO, V173, P471, DOI 10.1016/S0006-291X(05)81082-4; GRIZZUTI K, 1973, BIOCHEMISTRY-US, V12, P4399, DOI 10.1021/bi00746a016; HALE JE, 1987, J BIOL CHEM, V262, P1916; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; KELM RJ, 1991, J BIOL CHEM, V266, P9632; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS WJ, 1991, J STRUCT BIOL, V107, P116, DOI 10.1016/1047-8477(91)90015-O; LEVINE BA, 1983, BIOCHIM BIOPHYS ACTA, V726, P187, DOI 10.1016/0304-4173(83)90005-8; LOWNSTAM A, 1989, BIOMINERALISATION, P25; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARK MP, 1988, CELL TISSUE RES, V251, P23, DOI 10.1007/BF00215443; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAURER A, 1985, P NATL ACAD SCI USA, V82, P4036, DOI 10.1073/pnas.82.12.4036; MAYER U, 1991, EUR J BIOCHEM, V198, P141, DOI 10.1111/j.1432-1033.1991.tb15996.x; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PARALKAR VM, 1990, J BIOL CHEM, V265, P17281; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; Schmidt D. G., 1982, Developments in Dairy Chemistry, V1, P61; SOMERMAN MJ, 1988, CALCIFIED TISSUE INT, V43, P50, DOI 10.1007/BF02555169; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; ZANETTI M, 1981, EUR J BIOCHEM, V113, P541, DOI 10.1111/j.1432-1033.1981.tb05096.x; ZHANG R, 1990, J BIOL CHEM, V265, P15375	46	205	215	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24871	24878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447223				2022-12-27	WOS:A1992KA26300106
J	REISER, KM; AMIGABLE, MA; LAST, JA				REISER, KM; AMIGABLE, MA; LAST, JA			NONENZYMATIC GLYCATION OF TYPE-I COLLAGEN - THE EFFECTS OF AGING ON PREFERENTIAL GLYCATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ENZYMATIC GLYCOSYLATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; DIABETIC RATS; CROSS-LINKS; SKIN; DERIVATIZATION; COMPLICATIONS; PROTEIN	The present study was designed to investigate the effects of aging on preferential sites of glucose adduct formation on type I collagen chains. Two CNBr peptides, one from each type of chain in the type I tropocollagen molecule, were investigated in detail: alpha1(I)CB3 and alpha2CB3-5. Together these peptides comprise approximately 25% of the total tropocollagen molecule. The CNBr peptides were purified from rat tail tendon, obtained from animals aged 6, 18, and 36 months, by ion exchange chromatography, gel filtration, and high-performance liquid chromatography (HPLC). Sugar adducts were radiolabeled by reduction with (NaBH4)-H-3. Glycated tryptic peptides were prepared from tryptic digests of alpha2CB3-5 and alpha1(I)CB3 by boronate affinity chromatography and HPLC. Peptides were identified by sequencing and by compositional analysis. Preferential sites of glycation were observed in both CB3 and alpha2CB3-5. Of the 5 lysine residues in CB3, Lys-434 was the favored glycation site. Of the 18 lysine residues and 1 hydroxylysine residue in alpha2CB3-5, 3 residues (Lys-453, Lys-479, and Lys-924) contained more than 80% of the glucose adducts on the peptide. Preferential glycation sites were highly conserved with aging. In collagen that had been glycated in vitro, the relative distribution of glucose adducts in old animals differed from that of young animals. In vitro experiments suggest that primary structure is the major determinant of preferential glycation sites but that higher order structure may influence the relative distribution of glucose adducts among these preferred sites.	UNIV CALIF DAVIS,CALIF REG PRIMATE RES CTR,DAVIS,CA 95616	University of California System; University of California Davis	REISER, KM (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT INTERNAL MED,DAVIS,CA 95616, USA.				NCRR NIH HHS [RR00169] Funding Source: Medline; NIA NIH HHS [AGO5324, AGO7711] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005324, R01AG007711] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baynes J. W., 1989, MAILLARD REACTION AG, P43; Baynes JW, 1989, MAILLARD REACTION AG; BERNSTEIN RE, 1987, ADV CLIN CHEM, V26, P1, DOI 10.1016/S0065-2423(08)60321-2; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRENNAN M, 1989, J BIOL CHEM, V264, P20953; BROWNLEE M, 1983, DIABETES, V32, P680, DOI 10.2337/diabetes.32.7.680; BUCKINGHAM B, 1990, J CLIN INVEST, V86, P1046, DOI 10.1172/JCI114807; EINARSSON S, 1985, J CHROMATOGR, V348, P213, DOI 10.1016/S0021-9673(01)92455-0; FUJIMOTO D, 1988, CUTANEOUS AGING, P263; GALLOWAY D, 1982, COLLAGEN HLTH DISEAS, P528; GARLICK RL, 1983, J BIOL CHEM, V258, P6142; GERRIETS JE, 1989, FED PROC, V245, P1456; GLENNY RW, 1991, J APPL PHYSIOL, V70, P2351, DOI 10.1152/jappl.1991.70.6.2351; GONEN B, 1981, DIABETES, V30, P875, DOI 10.2337/diabetes.30.10.875; KOHN RR, 1989, AGING SKIN, P121; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAVKER RM, 1986, DERMATOL CLIN, V4, P379, DOI 10.1016/S0733-8635(18)30801-5; LEPAPE A, 1981, BIOCHEM BIOPH RES CO, V100, P1214, DOI 10.1016/0006-291X(81)91953-7; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; REISER IKM, 1991, FASEB J, V6, P2439; REISER KM, 1991, P SOC EXP BIOL MED, V196, P17; REISER KM, 1987, BIOCHIM BIOPHYS ACTA, V926, P339, DOI 10.1016/0304-4165(87)90220-0; REISER KM, 1980, ANAL BIOCHEM, V104, P87, DOI 10.1016/0003-2697(80)90280-8; REISER KM, 1983, CONNECT TISSUE RES, V12, P1, DOI 10.3109/03008208309005607; REISER KM, 1981, AM REV RESPIR DIS, V123, P58; REISER KM, 1983, LIQUID CHROMATOGR, V1, P498; REISER KM, 1990, DIABETES, V39, P28; Robins S.P., 1982, METHOD BIOCHEM ANAL, V28, P330; SHAKLAI N, 1984, J BIOL CHEM, V259, P3812; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SMITH L, 1989, CUTIS, V43, P414; TANAKA S, 1988, J MOL BIOL, V203, P495, DOI 10.1016/0022-2836(88)90015-0; TARSIO JF, 1988, DIABETES, V37, P532, DOI 10.2337/diabetes.37.5.532; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; VANDERREST M, 1982, EUR J BIOCHEM, V125, P491, DOI 10.1111/j.1432-1033.1982.tb06709.x; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; YAMAUCHI M, 1982, P NATL ACAD SCI-BIOL, V79, P7684, DOI 10.1073/pnas.79.24.7684; YUE DK, 1983, DIABETOLOGIA, V24, P282	39	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24207	24216						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447170				2022-12-27	WOS:A1992KA26300013
J	CHANDRASEKARAN, EV; JAIN, RK; MATTA, KL				CHANDRASEKARAN, EV; JAIN, RK; MATTA, KL			OVARIAN-CANCER ALPHA-1,3-L-FUCOSYL-TRANSFERASE - DIFFERENTIATION OF DISTINCT CATALYTIC SPECIES WITH THE UNIQUE SUBSTRATE, 3'-SULFO-N-ACETYLLACTOSAMINE IN CONJUNCTION WITH OTHER SYNTHETIC ACCEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE ANTIGENS; TYPE-2 CHAIN; LUNG-CANCER; GDP-FUCOSE; CELLS; EXPRESSION; BIOSYNTHESIS; PURIFICATION; GLYCOLIPIDS; SERUM	Several N-acetyllactosamine (LacNAc) derivatives were tested as acceptors for alpha1,3-L-fucosyltransferase present in human ovarian cancer sera and ovarian tumor. The enzyme of the soluble fraction of tumor was purified to apparent homogeneity by chromatography on bovine IgG glycopeptide-Sepharose followed by Sephacryl S-200 (M(r) < 67,000). As compared with 2'-methyl LacNAc, 3'-sulfo LacNAc was about 5-fold more sensitive in measuring alpha1,3-fucosyltransferase in sera (K(m), 3'-sulfo LacNAc, 0.12 mM; 2'-methyl LacNAc, 6.67 mM). When ovarian cancer serum was the enzyme source, either the sulfate group or a sialyl moiety at C-3' of LacNAc enhanced the acceptor ability (341 and 242%, respectively), whereas the sulfate group at C-2' or C-6' reduced the activity (22-36%); sulfate at C-6 or fucose at C-2' increased the activity (172 and 253%). The beta-benzylation of the reducing end, in general, increased the activity 2-3-fold. The enzyme of the soluble fraction of tumor exhibited more activity toward 3'-sulfo LacNAc (447%), 2'-fucosyl-LacNAc (436%), and 6-sulfo LacNAc (272%). Very low activity was observed with 3'-sialyl LacNAc (12.4%), 2'-sulfo LacNAc (33%), and 6'-sulfo LacNAc (5%); Fucalpha1,2Galbeta1,3GlcNAcbeta-O-p-nitrophenyl (166%), 2-methyl Galbeta1,3GlcNAcbeta-O-benzyl (204%), and 3-sulfo Galbeta1,3GlcNAc (415%) also acted as acceptors, indicating the coexistence of alpja1,3- and alpha1,4-fucosyltransferase. The tumor particulate enzyme behaved entirely different, exhibiting low activity with 3'-sulfo LacNAc (39%) and 2'-fucosyl-LacNAc (148%); 3'-sialyl, 6'-sulfo, 6-sulfo, or 2'-sulfo LacNAc were 3, 43, 53, and 10% active, respectively. Thus, the ovarian cancer serum al,3-fucosyltransferase acts equally well on H-type 2,3'-sialyl LacNAc and 3'-sulfo LacNAc, but not on H-type 1. The enzyme of soluble tumor fraction acts on H-type 2,3'-sulfo LacNAc as well as H-type 1 but poorly on 3'-sialyl LacNAc. The tumor particulate enzyme acts on H-type 2 but poorly on 3'-sulfo or 3'sialyl LacNAc and is inactive with H-type 1. When normal serum was examined with synthetic acceptors, >80% activity was found as alpha1,2-fucosyltransferase and the rest as alpha1,3-fucosyltransferase. A screening of 21 ovarian cancer and 3 normal sera (3'-sulfo LacNAc as acceptor) showed 17-572% increase (average increase, 188%) of alpha1,3-fucosyltransferase activity in cancer. A parallel testing of Triton X-100 extracts of normal ovarian tissue and ovarian tumor with synthetic acceptors revealed a high level of alpha1,3-fucosyltransferase in tumor (2.17-fold increase when assayed with 3'-sulfo LacNAc and 0.42-0.56-fold increase with other specific acceptors). An examination of four ovarian tumors along with one normal ovarian tissue indicated that three tumors had 0.37-2.36-fold increase of alpha1,3-fucosyltransferase activity, whereas all four tumors had 2.06-139.6-fold increase of alpha1,4-fucosyltransferase activity using 2-O-methyl Galbeta1 --> 3GlcNAcbeta1 --> O-benzyl as an acceptor.			CHANDRASEKARAN, EV (corresponding author), ROSWELL PK CANC INST, DEPT GYNECOL ONCOL, BUFFALO, NY 14263 USA.				NCI NIH HHS [CA 35329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAO T, 1989, CANCER, V64, P2541, DOI 10.1002/1097-0142(19891215)64:12<2541::AID-CNCR2820641222>3.0.CO;2-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATELANI G, 1988, CARBOHYD RES, V182, P297, DOI 10.1016/0008-6215(88)84011-4; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P633, DOI 10.1016/0003-9861(89)90479-7; HOLMES EH, 1985, J BIOL CHEM, V260, P7619; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; ITZKOWITZ SH, 1986, CANCER RES, V46, P2627; JOHNSON PH, 1985, BIOCHEM SOC T, V13, P1119, DOI 10.1042/bst0131119; KATO Y, 1989, J BIOL CHEM, V264, P3364; MADIYALAKAN R, 1986, CANCER LETT, V30, P201, DOI 10.1016/0304-3835(86)90089-3; MITSAKOS A, 1989, BIOL CHEM H-S, V370, P239, DOI 10.1515/bchm3.1989.370.1.239; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MURAMATSU H, 1986, EUR J BIOCHEM, V157, P71, DOI 10.1111/j.1432-1033.1986.tb09639.x; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; SEARS HF, 1982, J CLIN IMMUNOL, V2, P141, DOI 10.1007/BF00916898; TETTEROO PAT, 1987, J BIOL CHEM, V262, P15984; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WATKINS WM, 1988, BIOCHIMIE, V70, P1597, DOI 10.1016/0300-9084(88)90295-7; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YAZAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P563, DOI 10.1016/0006-291X(86)90477-8; YAZAWA S, 1989, Journal of Tumor Marker Oncology, V4, P355; YAZAWA S, 1989, J CANCER RES CLIN, V115, P451, DOI 10.1007/BF00393336; YAZAWA S, 1988, CANCER, V62, P516, DOI 10.1002/1097-0142(19880801)62:3<516::AID-CNCR2820620313>3.0.CO;2-4	30	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23806	23814						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429720				2022-12-27	WOS:A1992JZ23900058
J	LEE, RT; GABIUS, HJ; LEE, YC				LEE, RT; GABIUS, HJ; LEE, YC			LIGAND-BINDING CHARACTERISTICS OF THE MAJOR MISTLETOE LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISCUM-ALBUM L; GALACTOSIDE-SPECIFIC LECTIN; TOXIC LECTIN; PROTEINS; CELLS; ACETYLGALACTOSAMINE; 1-THIOGLYCOSIDES; GLYCOSIDES; EXTRACT; ABRIN	Carbohydrate binding specificity of the galactose-specific, major lectin of mistletoe extract (ML-1) was studied by an inhibition assay using monosaccharides, monosaccharide derivatives, disaccharides, and compounds containing multiple galactosyl terminals. The results indicate that 1) both alpha- and beta-galactosyl residues are recognized equally well; 2) each of the hydroxyl groups of galactose contributes to varying degrees to the binding process, the 4-OH being the most important and the 6-OH the least important hydroxyl group; 3) disaccharide sequences of Galbeta2Gal and Galbeta3Gal have much higher affinity than galactose, whereas affinity of all other Gal-disaccharides is only slightly better than galactose; 4) macromolecular ligands having 10 or more terminal galactosyl residues have 500-fold higher affinity than Gal; and 5) a group on ML-1 with pK(alpha) of 4.8 appears to be involved in the binding of ligand.	JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218; UNIV MARBURG,INST PHARMACEUT CHEM,DEPT GLYCOBIOCHEM & APPL TUMORLECTINOL,W-3550 MARBURG,GERMANY	Johns Hopkins University; Philipps University Marburg	LEE, RT (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.			Gabius, Hans-Joachim/0000-0003-3467-3900	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009970, R37DK009970] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-09970] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUTH J, 1992, CLIN INVESTIGATOR, V70, P658; BEUTH J, 1991, IN VIVO, V5, P19; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; FRANZ H, 1985, PHARMAZIE, V40, P97; GABIUS HJ, 1992, ANTICANCER RES, V12, P669; GABIUS HJ, 1990, ANAL BIOCHEM, V189, P91, DOI 10.1016/0003-2697(90)90050-J; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAJTO T, 1989, CANCER RES, V49, P4803; HAJTO T, 1990, CANCER RES, V50, P3322; HAUSER SP, 1992, IN PRESS THERAPIEWOC; JANSEN EF, 1946, J AM CHEM SOC, V68, P1475, DOI 10.1021/ja01212a025; JOHNSON G, 1975, CARBOHYD RES, V39, P271, DOI 10.1016/S0008-6215(00)86137-6; JOSHI SS, 1991, LECTINS CANC, P207; KAJIKAWA T, 1986, LIFE SCI, V39, P1177, DOI 10.1016/0024-3205(86)90349-8; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE RT, 1982, CARBOHYD RES, V101, P39, DOI 10.1016/S0008-6215(00)80793-4; LEE RT, 1979, CARBOHYD RES, V77, P270, DOI 10.1016/S0008-6215(00)83818-5; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEE RT, 1979, CARBOHYD RES, V77, P149, DOI 10.1016/S0008-6215(00)83801-X; LEE RT, 1974, CARBOHYD RES, V37, P193, DOI 10.1016/S0008-6215(00)87074-3; LEE RT, 1984, BIOCHEMISTRY-US, V23, P4255, DOI 10.1021/bi00313a037; LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; Lis H, 1986, LECTINS PROPERTIES F, P266; LONGCHAMBON F, 1981, ACTA CRYSTALLOGR B, V37, P601, DOI 10.1107/S0567740881003658; LUTHER P, 1980, INT J BIOCHEM, V11, P429, DOI 10.1016/0020-711X(80)90314-6; OFFNER H, 1990, J NEUROIMMUNOL, V28, P177, DOI 10.1016/0165-5728(90)90032-I; OLSNES S, 1982, J BIOL CHEM, V257, P13263; OLSNES S, 1982, MOL ACTIONS TOXINS V, P5; Porath J, 1976, Methods Enzymol, V44, P19; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RICE KG, 1990, ANAL BIOCHEM, V184, P249, DOI 10.1016/0003-2697(90)90676-Z; STIRPE F, 1982, J BIOL CHEM, V257, P13271; STULTS NL, 1983, ANAL BIOCHEM, V135, P392, DOI 10.1016/0003-2697(83)90701-7; VERNON J, 1980, CARBOHYD RES, V82, P59, DOI 10.1016/S0008-6215(00)85520-2; ZISKA P, 1981, EXPERIENTIA, V37, P219, DOI 10.1007/BF01991618	37	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23722	23727						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429712				2022-12-27	WOS:A1992JZ23900046
J	MAYTIN, EV				MAYTIN, EV			DIFFERENTIAL-EFFECTS OF HEAT-SHOCK AND UVB LIGHT UPON STRESS PROTEIN EXPRESSION IN EPIDERMAL-KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; DNA DAMAGE; ULTRAVIOLET-RADIATION; HUMAN-FIBROBLASTS; MESSENGER-RNA; RODENT CELLS; IRRADIATION; THERMOTOLERANCE; PURIFICATION; INDUCTION	Heat stress and ultraviolet light in the UVB range ("sunburn spectrum," 290-320 nm) were found to alter the synthesis of specific proteins in cultured keratinocytes derived from mouse skin. Using giant two-dimensional gels, approximately 2,000 cellular polypeptides labeled with [S-35]methionine at 4-5 h after exposure to heat or to UVB were analyzed. Cells conditioned at sublethal temperatures (42-degrees-C for 1 h, or 47-degrees-C for 15 min) developed thermotolerance, while cells conditioned with UVB did not develop thermotolerance. Under these heat or UVB conditions, 19 stress proteins were observed. Proteins fell into three classes based upon their inducibility by heat or UVB, dose-response, and induction mechanism (transcriptional versus post-transcriptional) as defined by metabolic blockade with cordycepin (3'-deoxyadenosine). Class 1 proteins were inducible only by heat shock. They included three major heat-shock proteins (hsp 72, hsp 78, hsp 90) and a 42.5-kDa, pI 5.43 protein, and all were induced at the transcriptional level. Class 2 proteins were inducible by heat and by UVB. These included hsp 110 and eight additional polypeptides. All but one were affected by heat at the post-transcriptional level and were induced by UVB at both low (20 mJ/cm2) and high (80 mJ/cm2) doses. Class 3 proteins were inducible only at high UVB doses (survival < 10%). Class 1 and Class 2 proteins could be functionally involved in thermotolerance, while Class 3 proteins are more likely related to damage or cell death.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	MAYTIN, EV (corresponding author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,DEPT DERMATOL,MGH E,BLDG 149,13TH ST,BOSTON,MA 02129, USA.				NIAMS NIH HHS [5T32AR07098-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON RL, 1988, INT J RADIAT BIOL, V54, P285, DOI 10.1080/09553008814551711; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; BEACH LR, 1978, J BIOL CHEM, V253, P2628; BREITKREUTZ D, 1984, DIFFERENTIATION, V26, P154, DOI 10.1111/j.1432-0436.1984.tb01389.x; BRUNET S, 1989, MUTAT RES, V219, P217, DOI 10.1016/0921-8734(89)90003-9; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; DIDOMENICO BJ, 1982, P NATL ACAD SCI-BIOL, V79, P6181, DOI 10.1073/pnas.79.20.6181; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; EPSTEIN JH, 1989, AGING SKIN, P307; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; GARMYN M, 1991, LAB INVEST, V65, P471; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HERRLICH P, 1986, ADV ENZYME REGUL, V25, P485, DOI 10.1016/0065-2571(86)90030-0; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; KARTASOVA T, 1988, EXP CELL RES, V174, P421, DOI 10.1016/0014-4827(88)90312-6; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; KLIGMAN LH, 1982, ARCH DERMATOL RES, V272, P229, DOI 10.1007/BF00509050; KOLLER LR, 1965, ULTRAVIOLET RAD, P105; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KUPPER TS, 1987, J CLIN INVEST, V80, P430, DOI 10.1172/JCI113090; LAMBERT ME, 1989, MOL CELL BIOL, V9, P847, DOI 10.1128/MCB.9.2.847; LANDRY J, 1982, CANCER RES, V42, P2457; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LEENDERS HJ, 1974, EXP CELL RES, V86, P25, DOI 10.1016/0014-4827(74)90642-9; LEVENSON RM, 1986, ANAL BIOCHEM, V158, P294, DOI 10.1016/0003-2697(86)90553-1; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MARCELO CL, 1978, J CELL BIOL, V79, P356, DOI 10.1083/jcb.79.2.356; MAYTIN EV, 1984, J BIOL CHEM, V259, P2135; MAYTIN EV, 1991, ANAL BIOCHEM, V194, P284, DOI 10.1016/0003-2697(91)90231-H; MAYTIN EV, 1990, J INVEST DERMATOL, V95, P635, DOI 10.1111/1523-1747.ep12514303; MAYTIN EV, 1985, J BIOL CHEM, V260, P2384; MCCORMICK W, 1969, J MOL BIOL, V39, P315, DOI 10.1016/0022-2836(69)90320-9; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORGAN RW, 1986, P NATL ACAD SCI USA, V83, P8059, DOI 10.1073/pnas.83.21.8059; PANNIERS R, 1984, EUR J BIOCHEM, V140, P209, DOI 10.1111/j.1432-1033.1984.tb08088.x; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; RONAI ZA, 1988, ONCOGENE, V2, P201; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SCOTT MP, 1981, P NATL ACAD SCI-BIOL, V78, P3353, DOI 10.1073/pnas.78.6.3353; SEKIGUCHI R, 1988, INT J RADIAT ONCOL, V14, P983, DOI 10.1016/0360-3016(88)90022-3; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STORTI RV, 1980, CELL, V22, P825, DOI 10.1016/0092-8674(80)90559-0; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAKASUGI M, 1971, TRANSPLANTATION, V12, P148, DOI 10.1097/00007890-197108000-00010; TANKE HJ, 1982, J IMMUNOL METHODS, V52, P91, DOI 10.1016/0022-1759(82)90353-2; VORIS BP, 1981, J BIOL CHEM, V256, P1319; WANG C, 1981, P NATL ACAD SCI-BIOL, V78, P3531, DOI 10.1073/pnas.78.6.3531; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WELCH WJ, 1989, STRESS INDUCED PROTE, P187; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; WILLIAMS KJ, 1989, CANCER RES, V49, P2735; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190; [No title captured]	62	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23189	23196						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429666				2022-12-27	WOS:A1992JY16300075
J	NATHANSON, MH; MOYER, MS; BURGSTAHLER, AD; OCARROLL, AM; BROWNSTEIN, MJ; LOLAIT, SJ				NATHANSON, MH; MOYER, MS; BURGSTAHLER, AD; OCARROLL, AM; BROWNSTEIN, MJ; LOLAIT, SJ			MECHANISMS OF SUBCELLULAR CYTOSOLIC CA2+ SIGNALING EVOKED BY STIMULATION OF THE VASOPRESSIN V(1A) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; INDUCED CALCIUM RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR CALCIUM; ACINAR-CELLS; OSCILLATIONS; CA-2+; HEPATOCYTES; TRISPHOSPHATE; CHANNELS	Receptor activation may result in distinct subcellular patterns of Ca2+ release. To define the subcellular distribution of Ca2+i signals induced by stimulation of the vasopressin V1a receptor, we expressed the cloned receptor in Xenopus oocytes. Oocytes were then loaded with fluo-3 and observed using confocal microscopy. Vasopressin induced a single concentric wave of increased Ca2+ that radiated inward from the plasma membrane. With submaximal stimulation, however, regions of the Ca2+ wave spontaneously reorganized into repetitive (oscillatory) waves. Focal stimulation of a small part of the plasma membrane resulted in a Ca2+ wave which began at the point of stimulation, radiated toward the center of the cell, then reorganized into multiple foci of repetitive, colliding waves and spirals of increased Ca2+i. The pattern of Ca2+ signaling induced by foeal or global stimulation was not altered in Ca2+-free medium, although signals did not propagate as fast. Finally, subcellular Ca2+ signaling patterns induced by vasopressin were inhibited by caffeine, while neither vasopressin nor microinjection of inositol trisphosphate blocked caffeine-induced increases in cytosolic Ca2+. Thus, stimulation of the V1a receptor in this cell system induces a complex pattern of Ca2+ signaling which is influenced by (1) the magnitude of the stimulus, (2) the distribution of the surface receptors that are stimulated, and (3) mobilization of Ca2+ from the extracellular space as well as from two distinct endogenous Ca2+ pools. The manner in which a single type of receptor is activated may represent an important potential mechanism for subcellular Ca2+i signaling.	NIMH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	NATHANSON, MH (corresponding author), YALE UNIV,SCH MED,CTR LIVER,LIVER STUDY UNIT,1080 LMP,NEW HAVEN,CT 06510, USA.		Lolait, Stephen/AAG-4483-2020; Brownstein, Michael/B-8609-2009		NIDDK NIH HHS [P30 DK34989] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKX PH, 1989, J GEN PHYSIOL, V93, P963, DOI 10.1085/jgp.93.5.963; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DELISLE S, 1990, J BIOL CHEM, V265, P11726; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HABARA Y, 1991, CELL CALCIUM, V12, P533, DOI 10.1016/0143-4160(91)90073-N; HUGHES BP, 1986, BIOCHEM PHARMACOL, V35, P3045, DOI 10.1016/0006-2952(86)90384-9; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEONG DA, 1991, J BIOL CHEM, V266, P9016; MANNING M, 1989, J LAB CLIN MED, V114, P617; MAUGER JP, 1988, J HEPATOL, V7, P278, DOI 10.1016/S0168-8278(88)80492-6; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; NATHANSON MH, 1992, AM J PHYSIOL, V262, pG1079, DOI 10.1152/ajpgi.1992.262.6.G1079; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1992, CELL CALCIUM, V13, P89, DOI 10.1016/0143-4160(92)90002-A; NATHANSON MH, 1992, HEPATOLOGY, V15, P107, DOI 10.1002/hep.1840150119; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SPEKSNIJDER JE, 1990, DEV BIOL, V142, P246, DOI 10.1016/0012-1606(90)90168-I; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WATANABE S, 1985, LAB INVEST, V53, P275; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	42	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23282	23289						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429675				2022-12-27	WOS:A1992JY16300088
J	RHODES, CJ; LINCOLN, B; SHOELSON, SE				RHODES, CJ; LINCOLN, B; SHOELSON, SE			PREFERENTIAL CLEAVAGE OF DES-31,32-PROINSULIN OVER INTACT PROINSULIN BY THE INSULIN SECRETORY GRANULE TYPE-II ENDOPEPTIDASE - IMPLICATIONS OF A FAVORED ROUTE FOR PROHORMONE PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATT20 CELLS; BETA-CELL; CONVERSION; SITE; KEX2; CDNA; RAT; PC2; IDENTIFICATION; SEQUENCE	Two Ca2+-dependent endopeptidase activities are involved in proinsulin to insulin conversion: type I cleaves COOH-terminal to proinsulin Arg31-Arg32 (B-chain/C-peptide junction); and type II preferentially cleaves at the Lys64-Arg65 site (C-peptide/A-chain junction). To further understand the mechanism of proinsulin processing, we have investigated types I and II endopeptidase processing of intact proinsulin in parallel to that of the conversion intermediates, des31,32-proinsulin and des-64,65-proinsulin. The type I processed des-64,65-proinsulin and proinsulin at the same rate. In contrast, the type II endopeptidase processed des-31,32-proinsulin at a much faster rate (> 19-fold; p < 0.001) than it did intact proinsulin. Furthermore, unlabeled proinsulin concentrations required for competitive inhibition of I-125-labeled des-64,65-proinsulin and I-125-proinsulin processing by a purified insulin secretory granule lysate were similar (ID50 = 14-16 muM), whereas inhibition of I-125-labeled des-31,32-proinsulin processing required a higher nonradiolabeled proinsulin concentration (ID50 = 197 muM). Synthetic peptides corresponding to the sequences surrounding Lys64-Arg65 (AC-peptide/substrate) and Arg31-Arg32 (BC-peptide/substrate) of human proinsulin were synthesized for use as specific substrates or competitive inhibitors. Cleavage of the BC-substrate by type I and AC-substrate by type II was COOH-terminal of the dibasic sequence, with similar Ca2+- and pH requirements previously observed for proinsulin cleavage. Apparent K(m) and V(max) for type I processing of the BC-substrate was K(m) = 20 muM; V(max) = 22.8 pmol/min, and for type II processing of the AC-substrate was K(m) = 68 muM; V(max) = 97 pmol/min. In competitive inhibition assays, the BC-peptide similarly blocked insulin secretory granule lysate processing of des-64,65-proinsulin and proinsulin (ID50 = 45-55 muM), but did not inhibit des-31,32-proinsulin processing. However, the AC-peptide preferentially inhibited insulin secretory granule lysate processing of des-31,32-proinsulin (ID50 = 83 muM) compared to proinsulin (ID50 = 330 muM), and not des-64,65-proinsulin. We conclude that the type I endopeptidase recognized des-64,65-proinsulin and proinsulin as similar substrates, whereas the type II endopeptidase has a stronger preference for des-31,32-proinsulin compared to intact proinsulin. Furthermore, we suggest that in intact proinsulin there exists a constraint to efficient processing that is relieved following type I processing. Structural flexibility, in addition to the presence of Lys64 -Arg65, therefore appears to be important for type II endopeptidase specificity and may provide a molecular basis for a preferential route of proinsulin conversion via des-31,32-proinsulin.			RHODES, CJ (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR,EP JOSLIN RES LAB,1 JOSLIN PL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NCRR NIH HHS [BRGS07RR05673] Funding Source: Medline; NIDDK NIH HHS [DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKCH N, 1989, J BIOL CHEM, V264, P15912; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DAVIDSON HW, 1987, BIOCHEM J, V246, P279, DOI 10.1042/bj2460279; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOCHERTY K, 1983, FEBS LETT, V162, P137, DOI 10.1016/0014-5793(83)81065-5; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; EDWARDS K, 1976, BIOCHEM BIOPH RES CO, V72, P310, DOI 10.1016/0006-291X(76)90995-5; GIVEN BD, 1985, J CLIN INVEST, V76, P1398, DOI 10.1172/JCI112116; GROSS DJ, 1989, J BIOL CHEM, V264, P21486; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; IKEHARA Y, 1976, BIOCHEM BIOPH RES CO, V72, P319, DOI 10.1016/0006-291X(76)90996-7; LINDBERG I, 1992, BIOCHEM BIOPH RES CO, V183, P1, DOI 10.1016/0006-291X(92)91599-L; LIOUBIN MN, 1984, PREP BIOCHEM, V14, P303, DOI 10.1080/10826068408070637; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; OLSON TS, 1988, J BIOL CHEM, V263, P7342; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; PORTE D, 1989, DIABETES, V38, P1333, DOI 10.2337/diabetes.38.11.1333; RHODES CJ, 1989, BIOCHEM J, V258, P305, DOI 10.1042/bj2580305; RHODES CJ, 1987, J BIOL CHEM, V262, P10712; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; Segel I.H., 1975, ENZYME KINETICS; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; STEINER DF, 1987, P NATL ACAD SCI USA, V84, P6184, DOI 10.1073/pnas.84.17.6184; STEINER DF, 1972, HDB PHYSL 7, P175; STORER AC, 1976, BIOCHEM J, V159, P1; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028	42	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22719	22727						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429623				2022-12-27	WOS:A1992JY16300007
J	ROGHANI, M; MOSCATELLI, D				ROGHANI, M; MOSCATELLI, D			BASIC FIBROBLAST GROWTH-FACTOR IS INTERNALIZED THROUGH BOTH RECEPTOR-MEDIATED AND HEPARAN SULFATE-MEDIATED MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; CAPILLARY ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROTEOLYTIC DEGRADATION; LIPOPROTEIN-LIPASE; PROTEOGLYCANS; METABOLISM; BINDING; FGF; GLYCOSAMINOGLYCAN	Basic fibroblast growth factor (bFGF) was internalized at a rapid rate by Chinese hamster ovary (CHO) cells that do not express significant numbers of high affinity receptors for bFGF as well as CHO cells that have been transfected with cDNA encoding FGF receptor-1 or FGF receptor-2. Internalization of bFGF was completely blocked by the addition of 10 mug/ml heparin in the parental CHO cells but only partially inhibited in cells expressing transfected FGF receptors. Bovine aortic endothelial cells also exhibit heparin-sensitive and heparin-resistant internalization of bFGF. The internalization of bFGF through the heparin-resistant pathway in CHO cells was efficiently competed by addition of unlabeled bFGF, was proportional to the number of receptors expressed, and approached saturation, suggesting that the heparin-resistant internalization was due to high affinity receptors. Internalization of bFGF through the heparin-sensitive pathway was not efficiently competed by unlabeled bFGF and did not approach saturation at concentrations of bFGF up to 50 ng/ml, properties similar to the interaction of bFGF with low affinity heparan sulfate binding sites on the cell surface. Internalization of bFGF in CHO cells not expressing FGF receptors was inhibited by heparin, heparan sulfate, and dermatan sulfate, the same glycosaminoglycans that block binding to cell-surface heparan sulfates. Internalization of bFGF in the parental CHO cells was inhibited at the same concentrations of heparin that block binding to cell-surface heparan sulfates. Finally, inhibition of the sulfation of CHO cell heparan sulfates by the addition of chlorate or digestion of CHO cell heparan sulfates with heparinase inhibited bFGF internalization in the parental CHO cells. These results demonstrate that bFGF can be internalized through a direct interaction with cell-surface heparan sulfates. Thus, there are two pathways for internalization of bFGF: high affinity receptor-mediated and heparan sulfate-mediated.	NYU MED CTR,DEPT CELL BIOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016	New York University; New York University				Moscatelli, David/0000-0002-4627-4213	NATIONAL CANCER INSTITUTE [R01CA042229] Funding Source: NIH RePORTER; NCI NIH HHS [CA34289, CA42229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; CISAR LA, 1989, J BIOL CHEM, V264, P1767; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GROSS JL, 1982, J CELL BIOL, V95, P947; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; Moenner M, 1989, GROWTH FACTORS, V1, P115, DOI 10.3109/08977198909029121; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Moscatelli D, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037499; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SQUIRES CH, 1988, J BIOL CHEM, V263, P16297; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	193	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22156	22162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429568				2022-12-27	WOS:A1992JW71900028
J	SOMLYO, AV; HORIUTI, K; TRENTHAM, DR; KITAZAWA, T; SOMLYO, AP				SOMLYO, AV; HORIUTI, K; TRENTHAM, DR; KITAZAWA, T; SOMLYO, AP			KINETICS OF CA2+ RELEASE AND CONTRACTION INDUCED BY PHOTOLYSIS OF CAGED D-MYO-INOSITOL 1,4,5-TRISPHOSPHATE IN SMOOTH-MUSCLE - THE EFFECTS OF HEPARIN, PROCAINE, AND ADENINE-NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM RELEASE; CA-2+ RELEASE; SARCOPLASMIC-RETICULUM; TRISPHOSPHATE RECEPTOR; FLASH-PHOTOLYSIS; SINGLE CELLS; PORTAL-VEIN; CHANNEL; ACTIVATION; DEPENDENCE	The kinetics of Ca2+ release and contraction induced by photolytic release of inositol 1,4,5-trisphosphate (InSP3) were determined in permeabilized smooth muscle. The rate of Ca2+ release was half-maximal at 1 muM InSP3. The concentration-dependent delay of Ca2+ release at saturating InsP3 concentration was approximately 10 ms and within the uncertainty of the measurements. The relationship between the delay and InSP3 concentration showed no evidence of a high level (n = 4 or higher) of cooperativity but could not distinguish between no cooperativity (n = 1) or a low level (n = 2) of cooperativity. Submaximal [InSP3] caused only partial Ca2+ release from the InSP3-sensitive stores. InsP3-induced Ca2+ release was markedly potentiated by ATP or by adenosine 5'-(beta,gamma-methylenetriphosphate), but neither the rate nor the amplitude of release was significantly affected by procaine (2-5 mM). Heparin increased the delay between photolysis and Ca2+ release, indicating that the off rate of inert ligand(s) bound to InsP3 receptors may contribute to the physiological delay in Ca2+ release. There was a much longer (370 ms +/- 45 S.E.) delay between the rise of Ca2+ and force development, presumably reflecting events preceding and associated with myosin light chain phosphorylation.	UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	University of Virginia; University of Virginia; MRC National Institute for Medical Research	SOMLYO, AV (corresponding author), UNIV VIRGINIA, SCH MED,DEPT PHYSIOL,BOX 449,JORDAN HALL, 1300 JEFFERSON PK AVE, CHARLOTTESVILLE, VA 22908 USA.				NHLBI NIH HHS [5P01HL19242-16] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOND M, 1984, J PHYSIOL-LONDON, V357, P185, DOI 10.1113/jphysiol.1984.sp015496; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHILVERS ER, 1990, BRIT J PHARMACOL, V99, P297, DOI 10.1111/j.1476-5381.1990.tb14698.x; CHILVERS ER, 1989, EUR J PHARMACOL, V164, P587, DOI 10.1016/0014-2999(89)90269-0; DUNCAN RA, 1987, BIOCHEM PHARMACOL, V36, P307, DOI 10.1016/0006-2952(87)90286-3; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GONG MC, 1992, J BIOL CHEM, V267, P14662; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; HENNE V, 1988, EUR J BIOCHEM, V174, P95, DOI 10.1111/j.1432-1033.1988.tb14067.x; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; HORIUTI K, 1989, J GEN PHYSIOL, V94, P769, DOI 10.1085/jgp.94.4.769; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KOMORI S, 1991, J PHYSIOL-LONDON, V433, P495, DOI 10.1113/jphysiol.1991.sp018440; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUALLEM S, 1989, J BIOL CHEM, V264, P205; PIETRI F, 1990, J BIOL CHEM, V265, P17478; SMITH JB, 1985, J BIOL CHEM, V260, P4413; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AP, 1984, NATURE, V309, P516, DOI 10.1038/309516b0; SOMLYO AP, 1990, ANNU REV PHYSIOL, V52, P857; SOMLYO AP, 1988, PHILOS T ROY SOC B, V320, P399, DOI 10.1098/rstb.1988.0084; SOMLYO AP, 1991, HEART CAREDIOVASCULA; SOMLYO AV, 1990, BIOPHYS J, V57, pA293; SOMLYO AV, 1990, J PHYSIOL-LONDON, V429, pP14; SOMLYO AV, 1985, P NATL ACAD SCI USA, V82, P5231, DOI 10.1073/pnas.82.15.5231; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; SUEMATSU E, 1984, BIOCHEM BIOPH RES CO, V120, P481, DOI 10.1016/0006-291X(84)91279-8; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WILLCOCKS AL, 1988, BIOCHEM J, V255, P1061, DOI 10.1042/bj2551061; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109; ZHAO H, 1990, J BIOL CHEM, V265, P14822	51	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22316	22322						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429583				2022-12-27	WOS:A1992JW71900052
J	CORONEL, CE; WINNICA, DE; NOVELLA, ML; LARDY, HA				CORONEL, CE; WINNICA, DE; NOVELLA, ML; LARDY, HA			PURIFICATION, STRUCTURE, AND CHARACTERIZATION OF CALTRIN PROTEINS FROM SEMINAL-VESICLE OF THE RAT AND MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-TRANSPORT INHIBITOR; BOVINE SPERMATOZOA; GUINEA-PIG; PLASMA; SEPARATION; MEMBRANE; SPERM; ACID	Caltrins, small basic proteins that inhibit calcium uptake by epididymal spermatozoa, have been purified from seminal vesicle content of the mouse and rat. Mouse caltrin (M(r) 8,476) contains 75 amino acid residues, 14 basic, 5 acidic, and 7 cysteines while rat caltrin (M(r) 6,217) has 56 residues, 10 basic, 5 acidic, and 6 cysteines; their pI values are 10.2 and 9.3, respectively. The proteins did not react with Ellman's reagent unless the cystine residues were previously reduced. The primary structures were determined by sequencing fragments generated by trypsin, clostripain, and endoproteinase Lys-C digestion. The sequences were ordered to give the total structural formula. The two molecules have no sequence similarity and are different from those of the bull and guinea pig previously reported. Only rat caltrin has a sequence of 13 residues nearly identical to that in guinea pig caltrin I. Both rat and mouse caltrin react with antibodies against bovine and guinea pig caltrins. Reduction and alkylation of cysteine residues suppressed the immunologic response of mouse caltrin; however, modified rat caltrin retained partially its immunoreactivity with the antiserum against guinea pig caltrin I. The same treatment abolished the calcium transport inhibitory activity of mouse caltrin and greatly reduced that of rat caltrin. It is likely that rat and mouse caltrins have the same physiological function as proposed for bovine caltrin; namely, to regulate the development of the Ca2+-dependent processes that "capacitate" sperm for fertilization.	UNIV WISCONSIN,INST ENZYME RES,1710 UNIV AVE,MADISON,WI 53705; NATL UNIV CORDOBA,FAC CIENCIAS MED,CATEDRA QUIM BIOL,RA-5000 CORDOBA,ARGENTINA	University of Wisconsin System; University of Wisconsin Madison; National University of Cordoba					NIADDK NIH HHS [AM 10334] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM010334] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN G, 1989, LAB TECHNIQUES BIOCH, V9, P55; BABCOCK DF, 1979, DEV BIOL, V69, P85, DOI 10.1016/0012-1606(79)90276-8; BABCOCK DF, 1975, J BIOL CHEM, V250, P6488; BABCOCK DF, 1976, J BIOL CHEM, V251, P3881; CORONEL CE, 1987, BIOL REPROD, V37, P1097, DOI 10.1095/biolreprod37.5.1097; CORONEL CE, 1990, J BIOL CHEM, V265, P6854; CORONEL CE, 1992, IN PRESS MOL REPROD; CORONEL CE, 1988, DEV REPROD, V38, P713; DIXON HBF, 1968, BIOCHEM J, V109, P312, DOI 10.1042/bj1090312; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Hayashi R, 1977, Methods Enzymol, V47, P84; HUANG TTF, 1981, J EXP ZOOL, V217, P287, DOI 10.1002/jez.1402170215; KIDO H, 1990, EUR J BIOCHEM, V188, P501, DOI 10.1111/j.1432-1033.1990.tb15428.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDY H, 1988, ROOTS OF MODERN BIOCHEMISTRY, P759; LEWIS RV, 1985, P NATL ACAD SCI USA, V82, P6490, DOI 10.1073/pnas.82.19.6490; Mitchell W M, 1977, Methods Enzymol, V47, P165; MITCHELL WM, 1968, J BIOL CHEM, V243, P4683; OLDS D, 1957, FERTIL STERIL, V8, P345; ROGERS BJ, 1975, BIOL REPROD, V13, P568, DOI 10.1095/biolreprod13.5.568; RUFO GA, 1984, J BIOL CHEM, V259, P2547; RUFO GA, 1982, J BIOL CHEM, V257, P4627; SANAGUSTIN JT, 1987, FASEB J, V1, P60, DOI 10.1096/fasebj.1.1.3301499; SANAGUSTIN JT, 1990, J BIOL CHEM, V265, P6860; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIH JWK, 1971, J BIOL CHEM, V246, P994; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUAREZ SS, 1991, BIOL REPROD, V44, P375, DOI 10.1095/biolreprod44.2.375; SUAREZ SS, 1992, BIOL REPROD, V46, P686, DOI 10.1095/biolreprod46.4.686; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDA K, 1988, BIOL CHEM H-S, V369, P55; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891	32	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20909	20915						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400406				2022-12-27	WOS:A1992JT97800063
J	WIELAND, T; RONZANI, M; JAKOBS, KH				WIELAND, T; RONZANI, M; JAKOBS, KH			STIMULATION AND INHIBITION OF HUMAN PLATELET ADENYLYLCYCLASE BY THIOPHOSPHORYLATED TRANSDUCIN BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY COMPONENT; ROD OUTER SEGMENTS; ADENYLATE-CYCLASE; G-PROTEINS; MEMBRANES; EPINEPHRINE; BOVINE; RECONSTITUTION; DISSOCIATION; NUCLEOTIDES	The effect of betagamma-dimers isolated from the retinal guanine nucleotide-binding protein (G protein) transducin eluted from illuminated bovine rod outer segment membranes with GTP, guanosine 5'-O-(beta,gamma-imino)triphosphate (Gpp(NH)p), or guanosine 5'-O-(gamma-thio)triphosphate (GTPgammaS) on basal and forskolin-stimulated adenylylcyclase activities in membranes of human platelets was studied. Betagamma-subunits isolated from transducin eluted with GTPgammaS (TDbetagamma(GTPgammaS)) had a concentration-dependent stimulatory effect on basal adenylylcyclase activity. The stimulatory agonist prostaglandin E1 increased the potency and the maximum extent of stimulation due to TDbetagamma(GTPgammaS). With a similar concentration dependence, TDbetagamma(GTPgammaS) exerted an inhibitory influence on forskolin-stimulated adenylylcyclase activity. At the same concentrations, betagamma-dimers isolated with either GTP or Gpp(NH)p did not alter enzyme activities. The observed effects of TDbetagamma(GTPgammaS) were similar to those of directly added GTPgammaS with regard to maximum levels, time dependence, and persistence; however, TDbetagamma(GTPgammaS) was approximately 10-fold more potent than GTPgammaS. Treatment of TDbetagamma(GTPgammaS), but not of free GTPgammaS, with hydroxylamine caused a loss of adenylylcyclase regulation by TDbetagamma(GTPgammaS). The data presented indicated that TDbetagamma(GTPgammaS) potently and efficiently activates the stimulatory and inhibitory G proteins of adenylylcyclase in human platelet membranes. Furthermore, evidence is provided suggesting that the observed effects of TDbetagamma(GTPgammaS) which can be thiophosphorylated by GTPgammaS at the beta-subunit (Wieland, T., Ulibarri, I., Gierschik, P., and Jakobs, K. H. (1991) Eur. J. Biochem. 196, 707-716), are due to formation of GTPgammaS at the G proteins.	UNIV HEIDELBERG,INST PHARMAKOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	WIELAND, T (corresponding author), UNIV ESSEN GESAMTHSCH KLINIKUM,INST PHARMAKOL,HUFELANDSTR 44,W-4300 ESSEN 1,GERMANY.		Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				AMIRZALTSMAN Y, 1989, MOL CELL ENDOCRINOL, V63, P175, DOI 10.1016/0303-7207(89)90094-4; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bitte L, 1974, Methods Enzymol, V30, P563; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; HOKIN LS, 1965, P NATL ACAD SCI USA, V54, P7177; JAKOBS KH, 1983, EUR J BIOCHEM, V132, P125, DOI 10.1111/j.1432-1033.1983.tb07336.x; JAKOBS KH, 1983, BIOCHIM BIOPHYS ACTA, V732, P352, DOI 10.1016/0005-2736(83)90051-2; JAKOBS KH, 1989, EUR J BIOCHEM, V183, P115, DOI 10.1111/j.1432-1033.1989.tb14903.x; JAKOBS KH, 1982, J BIOL CHEM, V257, P2829; JAKOBS KH, 1983, P NATL ACAD SCI-BIOL, V80, P3899, DOI 10.1073/pnas.80.13.3899; JAKOBS KH, 1976, J CYCLIC NUCL PROT, V2, P381; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATADA T, 1984, J BIOL CHEM, V259, P3568; KATADA T, 1984, J BIOL CHEM, V259, P3578; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WIELAND T, 1990, FEBS LETT, V274, P111, DOI 10.1016/0014-5793(90)81342-L; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316	31	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20791	20797						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400395				2022-12-27	WOS:A1992JT97800045
J	OCONNELL, BC; HAGEN, FK; TABAK, LA				OCONNELL, BC; HAGEN, FK; TABAK, LA			THE INFLUENCE OF FLANKING SEQUENCE ON THE O-GLYCOSYLATION OF THREONINE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; UDP-N-ACETYLGALACTOSAMINE; OVINE SUBMAXILLARY MUCIN; ERYTHROCYTE GLYCOPHORIN; ATTACHMENT SITES; PURIFICATION; TRANSFERASE; IDENTIFICATION; GLYCOPROTEINS; PROTEIN	To investigate the influence of flanking amino acid sequence on the O-glycosylation of a single threonine residue in vitro, we have examined a series of 52 related peptides. The substrates were based upon a sequence from human von Willebrand factor which is known to be glycosylated in vivo (-6PHMAQVTVGPGL+5). Each residue of the parent peptide was substituted, in turn, with isoleucine, alanine, proline, glutamic acid, or arginine. Peptides were glycosylated using a UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase purified 15,000-fold from bovine colostrum by chromatography on DEAE-Sephacel, SP-Sephadex, Sephacryl S-300, Affi-Gel Blue, and 5-mercuri-UDP-GalNAc thiopropyl-Sepharose. Single amino acid changes in the sequences flanking the threonine could profoundly alter the glycosylation of the substrate peptides. Substitution of any amino acid tested at positions +3, -3, and -2 markedly decreased O-glycosylation, as did the presence of a charged residue at position -1. The substitution of amino acids at the other positions of the peptide substrate had little effect on the incorporation of GalNAc. Statistical analysis of sequences flanking known glycosylated threonine and serine residues suggests that they should be glycosylated with equal efficiency in the same sequence context (O'Connell et al., 1991). However, the bovine colostrum transferase failed to glycosylate a peptide derived from human erythropoietin which contains a serine that is glycosylated in vivo (-5PPDAASAAPLR+5). When a threonine was substituted for the serine in this peptide (-5PPDAATAAPLR+5), the substrate proved to be an excellent acceptor of GalNAc. These observations indicate that although flanking amino acid sequence is important for the O-glycosylation of specific hydroxyamino acids, discrete threonine- and serine-specific transferases may exist.	UNIV ROCHESTER, SCH MED & DENT, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				O'Connell, Brian/0000-0003-4529-7664	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108, K16DE000159] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08108, DE-089511, K16 DE-00159] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; COTTRELL JM, 1992, BIOCHEM J, V283, P299, DOI 10.1042/bj2830299; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; HAGOPIAN A, 1971, J BIOL CHEM, V246, P2519; HAGOPIAN A, 1969, ARCH BIOCHEM BIOPHYS, V129, P515, DOI 10.1016/0003-9861(69)90209-4; HILL HD, 1977, J BIOL CHEM, V252, P3799; HONMA K, 1980, J BIOCHEM-TOKYO, V88, P1679, DOI 10.1093/oxfordjournals.jbchem.a133143; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; LAI PH, 1986, J BIOL CHEM, V261, P3116; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; MURAYAMA JI, 1982, J MEMBRANE BIOL, V64, P205, DOI 10.1007/BF01870887; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OPPENHEIM FG, 1985, J BIOL CHEM, V260, P671; PUTNAM FW, 1981, P NATL ACAD SCI-BIOL, V78, P6168, DOI 10.1073/pnas.78.10.6168; RALL SC, 1982, J BIOL CHEM, V257, P4171; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SMYTH DS, 1967, NATURE, V216, P332, DOI 10.1038/216332a0; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026	29	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25010	25018						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460004				2022-12-27	WOS:A1992KB60300018
J	PARR, JS; KHALIFAH, RG				PARR, JS; KHALIFAH, RG			INHIBITION OF CARBONIC ANHYDRASES-I AND ANHYDRASES-II BY N-UNSUBSTITUTED CARBAMATE ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; HYDROPHOBIC POCKET; REFINED STRUCTURE; BINDING-AFFINITY; ESSENTIAL TREMOR; VISIBLE SPECTRA; ISOENZYME-II; AMIDE GROUP; SULFONAMIDES; KINETICS	We previously showed that the zinc metalloenzyme carbonic anhydrases (CA I and II isozymes) bind "neutral" amides and related compounds as anions through coordination of their deprotonated amide nitrogen to the active site zinc (Rogers, J. I., Mukherjee, J., and Khalifah, R. G. (1987) Biochemistry 26, 5672-5679). Urethan, the ethyl carbamate ester, was among such compounds. The present study was designed to test whether other N-unsubstituted carbamate esters of pharmacological interest (as sedatives, hypnotics, anxiolytics, and skeletal muscle relaxants) were capable of binding to CA in the same manner. We studied the interaction of human CA I and II with urethan, phenyl carbamate, ethinamate, meprobamate, and methocarbamol. Phenyl carbamate studies were greatly complicated by its uncatalyzed hydrolysis via an elimination mechanism to form cyanate, a powerful CA inhibitor. In general, the compounds display: 1) slow on-off inhibition binding kinetics in the seconds range, 2) maximal inhibitor affinity at alkaline pH, and 3) characteristic three-band visible spectra of their complexes with cobalt-substituted CA I. These properties are shared with the previously studied amide inhibitors and are taken as evidence that the deprotonated carbamate nitrogen coordinates to the active site metal ion. CA I appeared to bind carbamate esters more tightly than CA II, an unusual 1000-fold selectivity being seen in the case of methocarbamol. The inhibition by these drugs is not sufficiently strong to implicate CA I and II in their mechanism of action. However, it does suggest the possible existence of previously unsuspected similarities between binding to CA and to their physiological receptors or targets, particularly the involvement of zinc.	VET ADM MED CTR,RES SERV 151,4801 LINWOOD BLVD,KANSAS CITY,MO 64128; UNIV KANSAS,MED CTR,SCH MED,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66103	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas Medical Center								ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; BEHRAVAN G, 1991, EUR J BIOCHEM, V198, P589, DOI 10.1111/j.1432-1033.1991.tb16054.x; BEHRAVAN G, 1990, EUR J BIOCHEM, V190, P351, DOI 10.1111/j.1432-1033.1990.tb15582.x; BEHRAVEN G, 1989, HIGHLIGHTS MODERN BI, V1, P291; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERTINI I, 1983, ACCOUNTS CHEM RES, V16, P272, DOI 10.1021/ar00092a002; BERTINI I, 1978, J AM CHEM SOC, V100, P4873, DOI 10.1021/ja00483a038; BLACKBURN GM, 1985, EUR J BIOCHEM, V153, P553, DOI 10.1111/j.1432-1033.1985.tb09336.x; BOTRE F, 1981, CARBONIC ANYDRASE BI; Budavari S., 1989, MERCK INDEX; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CARTER ND, 1984, FEBS LETT, V165, P197, DOI 10.1016/0014-5793(84)80168-4; CHAPMAN SK, 1978, BIOCHIM BIOPHYS ACTA, V527, P272, DOI 10.1016/0005-2744(78)90277-2; COLEMAN JE, 1975, ANNU REV PHARMACOL, V15, P221, DOI 10.1146/annurev.pa.15.040175.001253; CONROY CW, 1985, CLIN CHIM ACTA, V152, P347, DOI 10.1016/0009-8981(85)90110-X; CROSS PE, 1978, J MED CHEM, V21, P845, DOI 10.1021/jm00207a001; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; DITTERT LW, 1963, J PHARM SCI, V52, P852, DOI 10.1002/jps.2600520908; DODGSON SJ, 1991, CARBONIC ANHYDRASES; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; ERIKSSON AE, 1991, CARBONIC ANHYDRASES, P33; Eriksson E. A., 1986, ZINC ENZYMES, P317; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; Gilman AG, 1985, GOODMAN GILMANS PHAR, V7th; GOTHE PO, 1972, FEBS LETT, V21, P159, DOI 10.1016/0014-5793(72)80127-3; Hewett-Emmett D., 1991, CARBONIC ANHYDRASES, P15; HUNT JB, 1977, ANAL BIOCHEM, V79, P614, DOI 10.1016/0003-2697(77)90444-4; JILKA RL, 1985, BONE, V6, P445, DOI 10.1016/8756-3282(85)90222-4; KANAMORI K, 1983, BIOCHEMISTRY-US, V22, P2658, DOI 10.1021/bi00280a011; KANNAN KK, 1984, ANN NY ACAD SCI, V429, P49, DOI 10.1111/j.1749-6632.1984.tb12314.x; KARARLI T, 1985, J BIOL CHEM, V260, P3484; KATO K, 1990, FEBS LETT, V271, P137, DOI 10.1016/0014-5793(90)80390-5; Khalifah R. G., 1991, CARBONIC ANHYDRASES, P49, DOI DOI 10.1007/978-1-4899-0750-9_4; KHALIFAH RG, 1987, BIOCHEMISTRY-US, V26, P7057, DOI 10.1021/bi00396a030; KING RW, 1976, PROC R SOC SER B-BIO, V193, P107, DOI 10.1098/rspb.1976.0034; KOLLER WC, 1991, MAYO CLIN PROC, V66, P1085, DOI 10.1016/S0025-6196(12)61734-0; LIANG JY, 1989, BIOCHEMISTRY-US, V28, P9724, DOI 10.1021/bi00451a028; LINDAHL M, 1991, CARBONIC ANHYDRASE, P111; LINDSKOG S, 1982, ADV INORG BIOCHEM, V4, P115; LINDSKOG S, 1991, CARBONIC ANHYDRASE, P1; Lindskog S., 1983, ZINC ENZYMES, P78; Lindskog S, 1971, ENZYMES, P587; Lippa E. A., 1991, CARBONIC ANHYDRASES, P171; LOGRASSO PV, 1991, BIOCHEMISTRY-US, V30, P8463, DOI 10.1021/bi00098a025; MARCH J, 1977, ADV ORG CHEM, P353; MAREN TH, 1991, CARBONIC ANHYDRASE, P186; MAREN TH, 1992, MOL PHARMACOL, V41, P419; MAREN TH, 1983, ANNU REV PHARMACOL, V23, P439, DOI 10.1146/annurev.pa.23.040183.002255; MAREN TH, 1976, SCIENCE, V191, P469; MAREN TH, 1983, EXP EYE RES, V36, P457, DOI 10.1016/0014-4835(83)90041-6; MAREN TH, 1967, PHYSIOL REV, V47, P595, DOI 10.1152/physrev.1967.47.4.595; MUENTER MD, 1991, MAYO CLIN PROC, V66, P991, DOI 10.1016/S0025-6196(12)61721-2; MUKHERJEE J, 1987, J AM CHEM SOC, V109, P7232, DOI 10.1021/ja00257a077; NAIR SK, 1991, J BIOL CHEM, V266, P17320; POCKER Y, 1974, BIOCHEMISTRY-US, V13, P70, DOI 10.1021/bi00698a012; PRABHANANDA BS, 1987, BIOPHYS CHEM, V26, P217, DOI 10.1016/0301-4622(87)80024-8; ROGERS JI, 1987, BIOCHEMISTRY-US, V26, P5672, DOI 10.1021/bi00392a014; SANYAL G, 1983, BIOCHIM BIOPHYS ACTA, V744, P171, DOI 10.1016/0167-4838(83)90087-0; SANYAL G, 1982, MOL PHARMACOL, V22, P211; SAPERSTEIN VS, 1984, ANN NY ACAD SCI, V429, P481; Segel I.H., 1975, ENZYME KINETICS; SHEPARD KL, 1991, J MED CHEM, V34, P3098, DOI 10.1021/jm00114a020; SIGEL H, 1983, CHEM REV, V80, P2752; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SUGRUE MF, 1985, J PHARMACOL EXP THER, V232, P534; SUNDARAM V, 1986, AM J HUM GENET, V38, P125; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; TASHIAN RE, 1984, ANN NY ACAD SCI, V429; THORSLUND A, 1967, EUR J BIOCHEM, V3, P117, DOI 10.1111/j.1432-1033.1967.tb19504.x; VERPOORTE JA, 1967, J BIOL CHEM, V242, P4221; VIDGREN J, 1990, INT J BIOL MACROMOL, V12, P342, DOI 10.1016/0141-8130(90)90040-H; WHITNEY PL, 1970, EUR J BIOCHEM, V16, P126, DOI 10.1111/j.1432-1033.1970.tb01063.x; [No title captured]	75	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25044	25050						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460006				2022-12-27	WOS:A1992KB60300023
J	CLARK, BJ; WATERMAN, MR				CLARK, BJ; WATERMAN, MR			FUNCTIONAL EXPRESSION OF BOVINE 17-ALPHA-HYDROXYLASE IN COS-1 CELLS IS DEPENDENT UPON THE PRESENCE OF AN AMINO-TERMINAL SIGNAL ANCHOR SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHESIZING SECRETORY PROTEIN; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; INSERTION SIGNAL; CYTOCHROME-P-450; TRANSLOCATION; ORIENTATION; PEPTIDE; ENZYME; CDNA	Microsomal forms of eukaryotic cytochrome P450 proteins are integral membrane proteins of the endoplasmic reticulum (ER) membrane which are targeted to the ER via the signal recognition particle pathway. A hydrophobic amino terminus serves as a combined signal sequence and major membrane anchor (signal-anchor sequence) for the microsomal P450s. We have examined the insertion of bovine 17alpha-hydroxylase (P45017alpha) into the ER of COS 1 cells in order to evaluate the role of membrane insertion of the amino-terminal signal-anchor of microsomal P450s as a functional determinant for these enzymes. Previously, we have shown that deletion of the hydrophobic amino terminus from P45017alpha reduced membrane targeting and insertion by 5-fold compared with the wild-type protein, abolished enzymatic activity, and resulted in an aberrant CO difference spectrum. In the present study we have replaced the amino terminus of P45017alpha with two heterologous signal-anchor sequences, one that is similar and one that is very different from the P45017alpha sequence. The chimeric proteins were expressed in COS 1 cells. Immunoblot analysis of isolated microsomal membranes show that the heterologous signal-anchor sequences functioned to target the P45017alpha protein to the ER. Enzymatic assays in intact COS 1 cells indicate that both the chimeric proteins are efficient 17alpha-hydroxylase enzymes. The amino terminus of P45017alpha was also replaced with a sequence that is not a signal-anchor, and the expressed protein was neither targeted to the ER nor was functional in COS 1 cells. In conclusion, both the structure and catalytic activity of P45017alpha in COS 1 cells is dependent upon an amino-terminal sequence that functions as a signal-anchor sequence and not upon the precise sequence of the amino terminus.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT OBSTET & GYNECOL,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235	Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Clark, Barbara/0000-0003-1558-1904	NIGMS NIH HHS [GM 37429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM037429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; COATS WS, 1991, J BIOL CHEM, V266, P16113; ESTABROOK RW, 1988, OXIDASES RELATED RED, P525; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSON JR, 1991, P NATL ACAD SCI USA, V88, P9141, DOI 10.1073/pnas.88.20.9141; LI YC, 1991, J BIOL CHEM, V266, P19186; LORENCE MC, 1989, ARCH BIOCHEM BIOPHYS, V273, P79, DOI 10.1016/0003-9861(89)90164-1; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701	25	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24568	24574						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447202				2022-12-27	WOS:A1992KA26300064
J	JOHANSSON, C; BUTKOWSKI, R; WIESLANDER, J				JOHANSSON, C; BUTKOWSKI, R; WIESLANDER, J			THE STRUCTURAL ORGANIZATION OF TYPE-IV COLLAGEN - IDENTIFICATION OF 3 NC1 POPULATIONS IN THE GLOMERULAR-BASEMENT-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOODPASTURE ANTIGEN; GLOBULAR DOMAIN; NONCOLLAGENOUS DOMAIN; POLYACRYLAMIDE GELS; PROTEINS; CHAIN; LOCALIZATION; KIDNEY	Type IV collagen, which has long been assumed to contain two alpha1(IV) and one alpha2(IV) chains, also contains alpha3(IV), alpha4(IV), and alpha5(IV) chains. Stoichiometry of collagenous alpha(IV) chains differs among tissues, suggesting the existence of subclasses of type IV collagen, each with a unique chain composition. This study seeks to define, by characterization of subunit compositions of NC1 domain populations, the structural organization of type IV collagen from bovine glomerular basement membrane. NC1 hexamers from type IV collagen were separated on two affinity chromatography columns, one containing monoclonal antibodies to the alpha3 chain, and another, to the alpha1 chain. SDS-polyacrylamide gel electrophoresis, immunoblotting, reversed phase high-performance liquid chromatography, and enzyme-linked immunosorbent assay identified three NC1 hexamer populations: 1) a hexamer composed of (alpha1)2 and (alpha2)2 homodimers; 2) a hexamer composed of (alpha3)2 and (alpha4)2 homodimers; 3) a hexamer containing all four alpha chains connected in heterodimers, alpha1-alpha3 and alpha2-alpha4. Results suggest that there are two distinct type IV collagen molecules, one composed of alpha1(IV) and alpha2(IV) chains and another composed of alpha3(IV) and alpha4(IV) chains. Furthermore, polymerization occurs between molecules with the same chain composition and between molecules with different chain composition. Moreover, crosslinking between different alpha chains is restricted, thus limiting the number of possible macromolecular structures.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; STATE SERUM INST,DK-2300 COPENHAGEN,DENMARK	University of Minnesota System; University of Minnesota Twin Cities; Statens Serum Institut	JOHANSSON, C (corresponding author), UNIV LUND HOSP,DEPT NEPHROL,S-22185 LUND,SWEDEN.							BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; SAUS J, 1988, J BIOL CHEM, V263, P13374; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564	17	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24533	24537						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447198				2022-12-27	WOS:A1992KA26300059
J	DIXON, KH; MULLIGAN, T; CHUNG, KN; ELWOOD, PC; COWAN, KH				DIXON, KH; MULLIGAN, T; CHUNG, KN; ELWOOD, PC; COWAN, KH			EFFECTS OF FOLATE RECEPTOR EXPRESSION FOLLOWING STABLE TRANSFECTION INTO WILD-TYPE AND METHOTREXATE TRANSPORT-DEFICIENT ZR-75-1 HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KB-CELLS; PROBENECID-SENSITIVE CARRIER; AMINO-ACID-SEQUENCE; CCRF-CEM CELLS; BINDING-PROTEIN; L1210 CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; LEUKEMIA-CELLS; OVARIAN-CANCER; HUMAN-PLACENTA	Two biochemically distinct systems, the high affinity folate receptor and the lower affinity reduced-folate carrier, have each been implicated in mediating the transport of folates and antifolates into cells. Previous studies from our laboratory have shown that methotrexate accumulation into wild type (WT) ZR-75-1 human breast cancer cells involves a system with characteristics of the reduced-folate carrier, that this system is deficient in methotrexate resistant (MTX(R)) ZR-75-1 cells in which methotrexate transport is undetectable and that neither breast cancer cell line expresses folate receptors. In this report we examined the possible interaction of the reduced-folate carrier with folate receptors by stably transfecting both WT ZR-75-1 and MTX(R) ZR-75-1 cells with an expression vector containing a folate receptor cDNA. Clones of stably transfected MTX(R) ZR-75-1 and WT ZR-75-1 cells expressing comparable levels of folate receptors were studied and compared to the nontransfected cell lines. Although nontransfected WT and MTX(R) ZR-751 cell lines require concentrations greater-than-or-equal-to 100 nM folic acid for growth, the expression of folate receptors in transfected WT and MTX(R) ZR-75-1 cells permitted the growth of both cell lines in low concentrations (1 nM) of folic acid. While the defect in the reduced-folate carrier system in MTX(R) ZR-75-1 cells inhibits their growth in medium containing low concentrations of folinic acid (less-than-or-equal-to 1 muM), MTX(R) ZR-75-1 cells expressing folate receptors display uninhibited growth in 1 nM folinic acid. The accumulation of folic acid, folinic acid, and methotrexate is enhanced in folate receptor-transfected WT ZR-75-1 cells and MTX(R) ZR-75-1 cells. Furthermore, the accumulation of folates and antifolate was similar in both transfected WT and MTX(R) ZR751 cell lines that expressed folate receptors. This suggests that alterations in the reduced-folate carrier do not affect folate receptor function. We also examined the effect of folate receptor expression on the sensitivity of WT and MTX(R) ZR-75-1 cells to methotrexate and to the lipophillic antifolate trimetrexate. Increased folate receptor expression decreased the sensitivity of WT ZR-75-1 cells toward the antifolate trimetrexate, presumably through increased uptake of reduced folates. Although the expression of the folate receptor enhanced the growth of both cell lines in low folate concentrations, it did not affect the sensitivity of either WT or MTX(R) ZR-75-1 cells to methotrexate.			DIXON, KH (corresponding author), NCI, MED BRANCH, BLDG 10, RM 12N226, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ALBERTI S, 1990, BIOCHEM BIOPH RES CO, V171, P1051, DOI 10.1016/0006-291X(90)90790-T; ANTONY AC, 1985, J BIOL CHEM, V260, P4911; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHELLO PL, 1977, CANCER RES, V37, P4297; CONEY LR, 1991, CANCER RES, V51, P6125; COWAN KH, 1984, J BIOL CHEM, V259, P793; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; ELWOOD PC, 1991, J BIOL CHEM, V266, P2346; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FREISHEIM JH, 1989, ADV ENZYME REGUL, V29, P13, DOI 10.1016/0065-2571(89)90091-5; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HENDERSON GB, 1985, J MEMBRANE BIOL, V85, P263, DOI 10.1007/BF01871521; HOLM J, 1991, BIOCHEM J, V280, P267, DOI 10.1042/bj2800267; JANSEN G, 1989, CANCER RES, V49, P2455; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1975, J BIOL CHEM, V250, P2203; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KAMEN BA, 1986, BIOCHEM PHARMACOL, V35, P2323, DOI 10.1016/0006-2952(86)90458-2; KNIGHT CB, 1989, ADV ENZYME REGUL, V29, P3, DOI 10.1016/0065-2571(89)90090-3; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; REISENAUER AM, 1990, BIOCHEM J, V267, P249, DOI 10.1042/bj2670249; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; Sambrook J, 1989, MOL CLONING LABORATO; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1981, CANCER TREAT REP, V65, P19; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SVENDSEN IB, 1984, CARLSBERG RES COMMUN, V49, P123, DOI 10.1007/BF02913971; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDERVEER LJ, 1989, LEUKEMIA RES, V13, P981, DOI 10.1016/0145-2126(89)90005-2; VERMA RS, 1991, J BIOL CHEM, V266, P12522; VERMA RS, 1992, J BIOL CHEM, V267, P4119; WESTERHOF GR, 1991, CANCER RES, V51, P5507	57	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24140	24147						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429743				2022-12-27	WOS:A1992JZ23900106
J	SUNDARAM, KS; LEV, M				SUNDARAM, KS; LEV, M			PURIFICATION AND ACTIVATION OF BRAIN SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; GALACTOCEREBROSIDE SULFOTRANSFERASE; SULFATED GLYCOLIPIDS; ACTIVITY INVITRO; VITAMIN-K; ENZYME; BINDS; MODULATION; KINASE	Galactosylceramide sulfotransferase (EC 2.8.2.11) catalyzes the biosynthesis of sulfatide from galactocerebroside and adenosine 3'-phosphate 5'-phosphosulfate (PAPS). This enzyme is developmentally controlled, reaching a maximum activity in the brains of mice corresponding to that of maximum myelination. The product, sulfatide, is an important component of myelin. This transferase from mouse brain has been purified 2600-fold using a combination of pyridoxal 5'-phosphate- and ATP-ligated columns. The purified enzyme yielded a single band following SDS-polyacrylamide gel electrophoresis with an apparent M(r) of 31,000. The entire purification procedure can be completed in 1 day. The pH optimum for the enzyme is 7.0. The K(m) for PAPS is 1.2 x 10(-6) M, and the K(m) for cerebroside is 2.6 x 10(-5) M. Cerebroside concentrations >80 pmol/ml are inhibitory. Enzyme preparations were associated with several lipids. Vitamin K + P(i) activated purified preparations of the sulfotransferase and maintained enzyme activity during storage at -80-degrees-C.			SUNDARAM, KS (corresponding author), CUNY,SCH MED,SOPHIE DAVIS SCH BIOMED EDUC,DEPT MICROBIOL,NEW YORK,NY 10031, USA.				NCRR NIH HHS [RRO3060] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; CHURCHICH JE, 1984, EUR J BIOCHEM, V138, P327, DOI 10.1111/j.1432-1033.1984.tb07918.x; FARRELL DF, 1971, J BIOL CHEM, V246, P4694; FRESSINAUD C, 1990, CR ACAD SCI III-VIE, V310, P303; FUJIKI H, 1986, BIOCHEM BIOPH RES CO, V138, P153, DOI 10.1016/0006-291X(86)90259-7; HOLT GD, 1990, J BIOL CHEM, V265, P2852; KOLODNY EH, 1989, METABOLIC BASIS INHE; LEV M, 1991, FASEB J, V5, pA457; LINGWOOD CA, 1986, BIOCHIM BIOPHYS ACTA, V877, P246, DOI 10.1016/0005-2760(86)90301-2; LINGWOOD CA, 1981, CAN J BIOCHEM, V57, P556; OTTERNESS DM, 1991, MOL PHARMACOL, V39, P34; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; SAKAC D, 1992, J BIOL CHEM, V267, P1655; SAKAC D, 1989, BIOCHEM J, V261, P423, DOI 10.1042/bj2610423; SARLIEVE LL, 1976, J NEUROCHEM, V26, P211; SIEGRIST HP, 1977, BIOCHIM BIOPHYS ACTA, V489, P58, DOI 10.1016/0005-2760(77)90231-4; SUNDARAM KS, 1990, ARCH BIOCHEM BIOPHYS, V277, P109, DOI 10.1016/0003-9861(90)90557-F; SUNDARAM KS, 1990, BIOCHEM BIOPH RES CO, V169, P927, DOI 10.1016/0006-291X(90)91982-X; SUNDARAM KS, 1988, J LIPID RES, V29, P1475; TAYLOR T, 1987, BIOCHIM BIOPHYS ACTA, V913, P131, DOI 10.1016/0167-4838(87)90321-9; TENNEKOON G, 1978, J NEUROCHEM, V31, P329, DOI 10.1111/j.1471-4159.1978.tb12466.x; TENNEKOON G, 1985, ARCH BIOCHEM BIOPHYS, V240, P932, DOI 10.1016/0003-9861(85)90102-X; TENNEKOON GI, 1981, J CELL BIOL, V91, P332, DOI 10.1083/jcb.91.2.332	24	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24041	24044						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429739				2022-12-27	WOS:A1992JZ23900091
J	PERRINO, FW; MEKOSH, HL				PERRINO, FW; MEKOSH, HL			INCORPORATION OF CYTOSINE-ARABINOSIDE MONOPHOSPHATE INTO DNA AT INTERNUCLEOTIDE LINKAGES BY HUMAN DNA-POLYMERASE ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF THYMUS; ENZYMOLOGICAL CHARACTERIZATION; KINETIC MECHANISM; HIGH FIDELITY; I KLENOW; REVERSE-TRANSCRIPTASE; 3'->5' EXONUCLEASE; ARA-C; PRIMASE; REPLICATION	The incorporation of cytosine arabinoside monophosphate (araCMP) into DNA at internucleotide linkages by DNA polymerase alpha (DNA pol alpha) has been investigated by using oligonucleotide primed DNA templates. The products of reactions catalyzed by DNA pol alpha in vitro were analyzed on polyacrylamide gels to measure insertion of araCMP, extension from an araCMP 3' terminus, and binding of the enzyme to an araCMP 3' terminus. The results show that insertion of araCMP opposite dGMP in the DNA template is about 3-fold less efficient than insertion of dCMP. Extension from an araCMP 3' terminus by addition of the next complementary nucleotide is approximately 2000-fold less efficient than extension from a correctly base-paired 3' terminus. In the absence of the second substrate, dNTP, DNA pol alpha binds with approximately equal affinities to DNA templates that contain oligonucleotide primers with araCMP or dCMP positioned at the 3' terminus. In the presence of dNTP, the enzyme extends the araCMP 3' terminus or dissociates, but it is not trapped at the araCMP 3' terminus in a nonproductive ternary complex as is observed at the ddCMP 3' terminus. To determine if slow phosphodiester bond formation contributes to the observed extension rate from the araCMP 3' terminus by DNA pol alpha, oligonucleotide primers with araCMP positioned at the 3' terminus were elongated by addition of the alpha-phosphorothioate analogue of the next complementary nucleotide. The rate of extension from araCMP by addition of 2'-deoxyadenosine 5'-O-phosphorothioate (dAMPalphaS) was 6-fold slower than by addition of dAMP, indicating that bond formation is partially rate limiting in the extension reaction. Thus, inefficient extension from the araCMP 3' terminus is the major determinant contributing to the low incorporation frequency of araCMP into DNA by DNA pol alpha, and this inefficiency can be attributed, in part, to slower phosphodiester bond formation at the araCMP 3' terminus.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center	PERRINO, FW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157, USA.							BEARDSLEY GP, 1988, NUCLEIC ACIDS RES, V16, P9165, DOI 10.1093/nar/16.19.9165; Benkovic S. J, 1973, ENZYMES, P201; BIALEK G, 1989, EMBO J, V8, P1833, DOI 10.1002/j.1460-2075.1989.tb03578.x; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CATAPANO CV, 1991, CANCER RES, V51, P1829; CHANG LMS, 1984, J BIOL CHEM, V259, P4679; CHEN YC, 1979, J BIOL CHEM, V254, P1678; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; COZZARELLI NR, 1977, ANNU REV BIOCHEM, V46, P641, DOI 10.1146/annurev.bi.46.070177.003233; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9222; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; Kornberg A., 1992, DNA REPLICATION; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MYWT, 1980, BIOCHEMISTRY-US, V19, P215, DOI 10.1021/bi00542a032; LOEB LA, 1969, J BIOL CHEM, V244, P1672; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; Maniatis T., 1982, MOL CLONING; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NG L, 1989, J BIOL CHEM, V264, P13018; OTTIGER H, 1987, NUCLEIC ACIDS RES, V15, P4789, DOI 10.1093/nar/15.12.4789; PARKER WB, 1987, MOL PHARMACOL, V31, P146; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; REYLAND ME, 1987, J BIOL CHEM, V262, P10824; ROSS DD, 1990, CANCER RES, V50, P2658; SKARNES W, 1986, J BIOL CHEM, V261, P6629; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAHL AF, 1984, BIOCHEMISTRY-US, V23, P1895, DOI 10.1021/bi00304a001; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YOSHIDA S, 1985, J BIOCHEM-TOKYO, V98, P427, DOI 10.1093/oxfordjournals.jbchem.a135297	51	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23043	23051						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429652				2022-12-27	WOS:A1992JY16300053
J	FENG, ZH; ANGELETTI, RH; LEVIN, BE; SABBAN, EL				FENG, ZH; ANGELETTI, RH; LEVIN, BE; SABBAN, EL			GLYCOSYLATION AND MEMBRANE INSERTION OF NEWLY SYNTHESIZED RAT DOPAMINE BETA-HYDROXYLASE IN A CELL-FREE SYSTEM WITHOUT SIGNAL CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; ADRENAL CHROMAFFIN GRANULES; NERVE GROWTH-FACTOR; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; BOUND FORMS; BOVINE; SEQUENCE; PROTEIN	Dopamine beta-hydroxylase (DBH, EC 1.14.17.1) is present in both membrane-bound and soluble forms in neurosecretory vesicles. This study was designed to investigate the differences between membrane-bound and soluble DBH and how they may arise from translation of a single mRNA. Antisera to a peptide corresponding to the carboxyl terminus of rat DBH was found to specifically immunoprecipitate the 77- and 73-kDa subunits of newly synthesized DBH in rat brain. Thus, both soluble and membrane-bound forms contain the same carboxyl terminus. To investigate differences at the amino terminus, full-length rat DBH mRNA, translated in a cell-free system, produced a 66-kDa peptide. An additional higher molecular mass product was synthesized upon co-translational addition of microsomal membranes. This product was glycosylated since it bound to concanavalin A-Sepharose and reverted to the 66-kDa polypeptide after treatment with endoglycosidase H. This glycosylated product was resistant to protease digestion and fractionated with microsomal membranes on sucrose gradients, indicating that it is incorporated into the microsomal membranes. Amino-terminal sequencing of the glycosylated translation product indicated that the amino-terminal "signal" sequence was not cleaved. The results indicate that in the cell-free system newly synthesized DBH undergoes glycosylation and incorporation into microsomal membranes without cleavage of the NH2-terminal signal sequence.	NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,BRONX,NY 10461; VET ADM,NEUROL SERV,E ORANGE,NJ 07019; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103	New York Medical College; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869, K04NS001121] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01121, NS 28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALETTA JM, 1988, J NEUROCHEM, V51, P1317, DOI 10.1111/j.1471-4159.1988.tb03104.x; BJERRUM OJ, 1979, BIOCHEM J, V181, P231, DOI 10.1042/bj1810231; BON S, 1991, J NEUROCHEM, V57, P1100, DOI 10.1111/j.1471-4159.1991.tb08267.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CIOFFI JA, 1989, J BIOL CHEM, V264, P15052; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; Erickson B. W., 1976, PROTEINS, VII, P255; FOUCHIER F, 1988, BIOCHEM J, V256, P103, DOI 10.1042/bj2560103; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAVINE FS, 1984, J NEUROCHEM, V43, P1243, DOI 10.1111/j.1471-4159.1984.tb05379.x; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; KAUFMAN S, 1965, PHARMACOL REV, V17, P71; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHN LJ, 1986, J BIOL CHEM, V261, P3816; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; MANS RJ, 1961, ARCH BIOCHEM BIOPHYS, V94, P48, DOI 10.1016/0003-9861(61)90009-1; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MCMAHON A, 1992, IN PRESS J NEUROCHEM; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; RINDLER MJ, 1990, EUR J CELL BIOL, V53, P154; ROBERTSON JG, 1990, J BIOL CHEM, V265, P1029; SABBAN E, 1981, J CELL BIOL, V91, P637, DOI 10.1083/jcb.91.3.637; SABBAN EL, 1987, J NEUROSCI, V7, P192; SABBAN EL, 1983, J BIOL CHEM, V258, P7819; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SABBAN EL, 1989, BIOCHEM INT, V19, P769; SABBAN EL, 1987, ANN NY ACAD SCI, V493, P339; Sambrook J, 1989, MOL CLONING LABORATO; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1641; SKOTLAND T, 1977, BIOCHEM BIOPH RES CO, V74, P1483, DOI 10.1016/0006-291X(77)90609-X; SLATER EP, 1981, ARCH BIOCHEM BIOPHYS, V211, P288, DOI 10.1016/0003-9861(81)90456-2; SOKOLOFF RL, 1985, J NEUROCHEM, V44, P411, DOI 10.1111/j.1471-4159.1985.tb05431.x; STEWART LC, 1988, J BIOL CHEM, V263, P12183; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TAYLOR CS, 1989, J BIOL CHEM, V264, P14; TAYLOR CS, 1989, J BIOL CHEM, V264, P15242; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P304; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WANG NY, 1990, BIOCHEMISTRY-US, V29, P6466, DOI 10.1021/bi00479a019; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WU HJ, 1990, J NEUROCHEM, V55, P97, DOI 10.1111/j.1471-4159.1990.tb08826.x; ZAREMBA S, 1981, J BIOL CHEM, V256, P2310	56	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21808	21815						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400490				2022-12-27	WOS:A1992JV01100085
J	HOLTZMAN, MJ; TURK, J; SHORNICK, LP				HOLTZMAN, MJ; TURK, J; SHORNICK, LP			IDENTIFICATION OF A PHARMACOLOGICALLY DISTINCT PROSTAGLANDIN-H SYNTHASE IN CULTURED EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID CYCLOOXYGENASE; SHEEP VESICULAR GLAND; ARACHIDONIC-ACID; MESSENGER-RNA; ENDOPEROXIDE SYNTHASE; PORCINE LEUKOCYTES; COMPLEMENTARY-DNA; BIOSYNTHESIS; 12-LIPOXYGENASE; OXYGENATION	Nonsteroidal anti-inflammatory drugs inhibit the action of prostaglandin H synthase (PGH synthase), and this effect may constitute the basis for therapeutic and idiosyncratic responses to these agents. We found that aspirin treatment of cultured ovine tracheal epithelial cells blocked PGH synthase-catalyzed formation of PG as expected but also caused a dose-dependent increase in 15-hydroxyeicosatetraenoic acid (15-HETE) production from arachidonic acid. In contrast, aspirin caused only inhibition of PG production without enhancing 15-HETE formation in ovine seminal vesicle and other tissues. The 15-HETE formed by aspirin-treated ovine tracheal epithelial cells was generated by a PGH synthase-dependent mechanism because: (i) the 15-HETE forming activity was just as sensitive as PG forming activity to selective inhibition by indomethacin; (ii) both 15-HETE and PG forming activities were quantitatively immunoprecipitated (depleted from supernatants and recovered in immune complex pellets) by a specific anti-PGH synthase antiserum. Additional immunoprecipitation experiments indicated that anti-PGH synthase monoclonal antibodies (cyo-1 and cyo-5) raised against the aspirin-inhibited form of the enzyme (contained in seminal vesicle) did not recognize the aspirin-stimulated 15-HETE-forming PGH synthase (contained in cultured epithelial cells). Thus, sequential immunoprecipitation of cultured epithelial cell material first with excess cyo-1 followed by anti-PGH synthase antiserum indicated that two isoforms of PGH synthase were expressed in these cells. SDS-polyacrylamide gel electrophoresis of immunoprecipitated PGH synthase from cultured epithelial cells revealed distinct protein bands for each form of the enzyme (M(r) = 70,000 and 72,000). The identification of a distinct PGH synthase which may be modified by aspirin so that selective oxygenation of fatty acid substrate is enhanced (while PG formation is inhibited) indicates that isozymes of PGH synthase exist which are pharmacologically distinct.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)	HOLTZMAN, MJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID AVE,BOX 8052,ST LOUIS,MO 63110, USA.			Shornick, Laurie/0000-0001-6652-1878	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001553, P01DK038111] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40078] Funding Source: Medline; NIDDK NIH HHS [DK-38111, DK-01553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY JM, 1983, J LIPID RES, V24, P1419; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; DEWITT DL, 1982, METHOD ENZYMOL, V86, P229; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLOWER R, 1973, NATURE, V240, P410; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HOLTZMAN MJ, 1992, ANNU REV PHYSIOL, V54, P303; HOLTZMAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V963, P401, DOI 10.1016/0005-2760(88)90308-6; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAETHEM RM, 1992, J BIOL CHEM, V267, P552; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LIN AH, 1989, J BIOL CHEM, V264, P17379; LYSZ TW, 1988, BIOCHEM PHARMACOL, V37, P921, DOI 10.1016/0006-2952(88)90182-7; LYSZ TW, 1982, J NEUROCHEM, V38, P1111, DOI 10.1111/j.1471-4159.1982.tb05355.x; MAAS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2884, DOI 10.1073/pnas.80.10.2884; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OBANION MK, 1991, J BIOL CHEM, V266, P23261; PAGELS WR, 1983, J BIOL CHEM, V258, P6517; PENTLAND AP, 1990, J CLIN INVEST; ROME LH, 1976, PROSTAGLANDINS, V11, P23, DOI 10.1016/0090-6980(76)90169-6; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; ROTH GJ, 1978, J BIOL CHEM, V253, P3782; SETTY BNY, 1985, BIOCHIM BIOPHYS ACTA, V833, P484, DOI 10.1016/0005-2760(85)90106-7; SHANNON VR, 1991, AM J PHYSIOL, V261, pL399, DOI 10.1152/ajplung.1991.261.6.L399; SHANNON VR, 1992, IN PRESS AM REV RESP, V145; SHANNON VR, 1992, IN PRESS AM J PHYSL, V263; SHANNON VR, 1993, IN PRESS AM J PHYSL, V264; SIEGEL MI, 1980, BIOCHEM BIOPH RES CO, V92, P688, DOI 10.1016/0006-291X(80)90388-5; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; TURK J, 1989, BIOCHIM BIOPHYS ACTA, V1001, P16, DOI 10.1016/0005-2760(89)90301-9; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V524, P240; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	49	194	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21438	21445						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400457				2022-12-27	WOS:A1992JV01100030
J	KWONG, FYP; FINCHAM, HE; DAVIES, A; BEAUMONT, N; HENDERSON, PJF; YOUNG, JD; BALDWIN, SA				KWONG, FYP; FINCHAM, HE; DAVIES, A; BEAUMONT, N; HENDERSON, PJF; YOUNG, JD; BALDWIN, SA			MAMMALIAN NITROBENZYLTHIOINOSINE-SENSITIVE NUCLEOSIDE TRANSPORT PROTEINS - IMMUNOLOGICAL EVIDENCE THAT TRANSPORTERS DIFFERING IN SIZE AND INHIBITOR SPECIFICITY SHARE SEQUENCE HOMOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; GUINEA-PIG; ENERGY-METABOLISM; ANIMAL-CELLS; RAT LUNG; BINDING; PURIFICATION; MEMBRANE; PEPTIDE; SYSTEM	Polyclonal antibodies were raised against the nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter of human erythrocyte membranes. On Western blots of these membranes they labeled the broad "band 4.5" region (average apparent M(r) 55,000), which contains both the nucleoside and glucose transport proteins. However, they did not recognize the glucose transporter when this was prepared free of nucleoside transporter by expression from a cDNA clone. Their specificity for the nucleoside transporter was confirmed by the ability to immunoadsorb NBMPR- but not cytochalasin B-binding sites from a detergent-solubilized mixture of band 4.5 proteins. Although a large proportion of the antibodies recognized extracellular epitopes, these appeared to be located primarily on the polypeptide moiety of the glycoprotein, as demonstrated by the ability of the antibodies strongly to label the deglycosylated transporter (apparent M(r) 45,000) on Western blots. The antibodies were species-cross-reactive, recognizing nucleoside transporters from pig and rabbit erythrocytes and from rat liver. The pig protein is similar to the human transporter in its inhibitor sensitivity but is considerably larger (apparent M(r) 57,000 after deglycosylation). In contrast, the rat protein is similar in size to the human transporter (apparent M(r) 45,000 after deglycosylation) but much less sensitive to the inhibitors dilazep and dipyridamole. These findings indicate that despite their differences in size and inhibitor specificity, the NBMPR-sensitive nucleoside transporters of these mammalian species are related in amino acid sequence.	UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT BIOCHEM & CHEM,LONDON NW3 2PF,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PROT & MOLEC BIOL,LONDON NW3 2PF,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV ALBERTA,DEPT PHYSIOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Cambridge; University of Alberta			Henderson, Peter JF/Q-1907-2018	Henderson, Peter/0000-0002-9187-0938				BARROS L F, 1992, Biochemical Society Transactions, V20, p244S; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; DAVIES A, 1987, J BIOL CHEM, V262, P9347; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HASPEL HC, 1988, J BIOL CHEM, V263, P398; JARVIS SM, 1986, J MEMBRANE BIOL, V93, P1, DOI 10.1007/BF01871013; JARVIS SM, 1987, PHARMACOL THERAPEUT, V32, P339, DOI 10.1016/0163-7258(87)90080-5; JARVIS SM, 1986, J BIOL CHEM, V261, P1077; JARVIS SM, 1981, BIOCHEM J, V194, P331, DOI 10.1042/bj1940331; KIM HD, 1971, BIOCHIM BIOPHYS ACTA, V230, P1; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1987, BIOCHIM BIOPHYS ACTA, V904, P105, DOI 10.1016/0005-2736(87)90091-5; KWONG FYP, 1986, BIOCHEM J, V240, P349, DOI 10.1042/bj2400349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; SHI MM, 1986, BIOCHEM SOC T, V14, P647, DOI 10.1042/bst0140647; SHI MM, 1984, BIOCHEM BIOPH RES CO, V118, P594, DOI 10.1016/0006-291X(84)91344-5; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; WU JSR, 1983, J BIOL CHEM, V258, P3745; WU JSR, 1984, BIOCHEM J, V220, P499, DOI 10.1042/bj2200499; YI CK, 1992, BIOCHEM J, V283, P643, DOI 10.1042/bj2830643; YOUNG JD, 1986, AM J PHYSIOL, V251, pC90, DOI 10.1152/ajpcell.1986.251.1.C90; YOUNG JD, 1985, BIOCHIM BIOPHYS ACTA, V842, P214, DOI 10.1016/0304-4165(85)90205-3; YOUNG JD, 1983, BIOSCIENCE REP, V3, P309, DOI 10.1007/BF01122895; ZOCCOLI MA, 1978, J BIOL CHEM, V253, P6923	29	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21954	21960						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400505				2022-12-27	WOS:A1992JV01100106
J	MITTLER, R; ZILINSKAS, BA				MITTLER, R; ZILINSKAS, BA			MOLECULAR-CLONING AND CHARACTERIZATION OF A GENE ENCODING PEA CYTOSOLIC ASCORBATE PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; RESPONSIVE ELEMENT; STRESS; EXPRESSION; LEAVES; INTRON; MAIZE; BINDING	A gene encoding cytosolic ascorbate peroxidase (ApxI) from pea (Pisum sativum L.) was isolated and its nucleotide sequence determined. By homologous alignment between the ApxI cDNA (Mittler, R., and Zilinskas, B. (1991) FEBS Lett. 289, 257-259) and the genomic clone, positions of introns and exons were determined. The isolated ApxI gene was found to contain 9 introns, the first of which was located within the 5'-untranslated region of the mRNA. Southern blot analysis of pea genomic DNA suggests that in pea cytosolic ascorbate peroxidase is encoded by a single copy gene. Steady state ApxI transcript levels were found to increase in response to several stresses imposed by drought, heat, and application of ethephon, abscisic acid, and the superoxide-generating agent paraquat. Increases in ascorbate peroxidase activity in response to stresses were less marked than changes observed in transcript levels; cytosolic ascorbate peroxidase protein levels measured by immunoblot analysis remained unchanged.	RUTGERS STATE UNIV,COOK COLL,DEPT BIOCHEM & MOLEC BIOL,LIPMAN HALL,NEW BRUNSWICK,NJ 08903	Rutgers State University New Brunswick			Mittler, Ron/ABE-6496-2020					ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; Asada K., 1987, PHOTOINHIBITION, P227; BECKER J, 1990, EUR J BIOCHEM, V189, P553, DOI 10.1111/j.1432-1033.1990.tb15522.x; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOWLER C, 1989, EMBO J, V8, P31, DOI 10.1002/j.1460-2075.1989.tb03345.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAKMAK I, 1992, PLANT PHYSIOL, V98, P1222, DOI 10.1104/pp.98.4.1222; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; CHEN GX, 1992, PLANT CELL PHYSIOL, V33, P109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN AH, 1989, GENE, V85, P381, DOI 10.1016/0378-1119(89)90431-9; CHRISTENSEN AH, 1992, PLANT MOL BIOL, V18, P675, DOI 10.1007/BF00020010; DAVIS LG, 1986, BASIC METHODS MOL BI, P158; DEAN C, 1987, NUCLEIC ACIDS RES, V14, P9549; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; GILLHAM DJ, 1987, PLANT SCI, V50, P105, DOI 10.1016/0168-9452(87)90145-2; GURLEY WB, 1991, BIOCHEMISTRY-US, V30, P1, DOI 10.1021/bi00215a001; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KATAGIRI F, 1992, TRENDS GENET, V8, P22, DOI 10.1016/0168-9525(92)90020-5; KUBO A, 1992, PLANT MOL BIOL, V18, P691, DOI 10.1007/BF00020011; MASCARENHAS D, 1990, PLANT MOL BIOL, V15, P913, DOI 10.1007/BF00039430; MELHORN H, 1990, PLANT CELL ENVIRON, V13, P971; MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962; MITTLER R, 1991, FEBS LETT, V289, P257, DOI 10.1016/0014-5793(91)81083-K; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PEARSON L, 1990, PLANT MOL BIOL, V14, P513, DOI 10.1007/BF00027497; PERLTREVES R, 1991, PLANT MOL BIOL, V17, P745, DOI 10.1007/BF00037058; ROGERS SO, 1988, PLANT MOL BIOL MANUA, P1; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANAKA K, 1985, PLANT CELL PHYSIOL, V26, P1425; TANAKA K, 1990, AGR BIOL CHEM TOKYO, V54, P2629, DOI 10.1080/00021369.1990.10870355; THOMSEN B, 1992, PLANTA, V186, P600, DOI 10.1007/BF00198042; TSANG EWT, 1991, PLANT CELL, V3, P783, DOI 10.1105/tpc.3.8.783; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; WERR W, 1985, EMBO J, V4, P1373, DOI 10.1002/j.1460-2075.1985.tb03789.x	36	188	198	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21802	21807						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400489				2022-12-27	WOS:A1992JV01100084
J	NETTO, LES; RAMAKRISHNA, NVS; KOLAR, C; CAVALIERI, EL; ROGAN, EG; LAWSON, TA; AUGUSTO, O				NETTO, LES; RAMAKRISHNA, NVS; KOLAR, C; CAVALIERI, EL; ROGAN, EG; LAWSON, TA; AUGUSTO, O			IDENTIFICATION OF C(8)-METHYLGUANINE IN THE HYDROLYSATES OF DNA FROM RATS ADMINISTERED 1,2-DIMETHYLHYDRAZINE - EVIDENCE FOR INVIVO DNA ALKYLATION BY METHYL RADICALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDRAZINE DERIVATIVES; PURINE-BASES; CARCINOGEN 1,2-DIMETHYLHYDRAZINE; NUCLEIC-ACIDS; ASCORBIC-ACID; COLON CANCER; OXIDATION; DIMETHYLHYDRAZINE; NUCLEOSIDES; MECHANISM	C-8-Methylguanine was identified in the neutral hydrolysates of DNA isolated from the liver or colon tissue of rats administered 1,2-dimethylhydrazine. In all the samples examined, the biologically isolated adducts were characterized by co-elution with synthetic C-8-methylguanine under different high pressure liquid chromatography conditions. The sample isolated from liver DNA was also identified by UV spectroscopy at different pH values and by mass spectrometry. The estimated yields of C-8-methylguanine obtained in hydrolysates of DNA from the liver or colon tissue were comparable to those of O6-methylguanine. C-8-Methylguanine was not detected when the spin trap alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone was administered together with 1,2-dimethylhydrazine. The spin trap also inhibited N7-methylguanine and O6-methylguanine yields, although to a lesser extent. These results constitute the first evidence that DNA alkylation by carbon-centered radicals can occur in vivo.	UNIV SAO PAULO,INST QUIM,DEPT BIOCHEM,CXP 20780,BR-01498 SAO PAULO,BRAZIL; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198	Universidade de Sao Paulo; University of Nebraska System; University of Nebraska Medical Center			Netto, Luis/A-3783-2008; Augusto, Ohara/D-3839-2012	Netto, Luis/0000-0002-4250-9177; Augusto, Ohara/0000-0002-7220-4286	NCI NIH HHS [P30-CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANO E, 1989, FREE RADICAL BIO MED, V6, P3, DOI 10.1016/0891-5849(89)90152-4; ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; AUGUSTO O, 1982, J BIOL CHEM, V257, P1288; AUGUSTO O, 1990, J BIOL CHEM, V265, P22093; AUGUSTO O, 1985, BIOCHEM BIOPH RES CO, V126, P853, DOI 10.1016/0006-291X(85)90263-3; AUGUSTO O, 1989, HDB BIOMEDICINE FREE, V3, P193; BALSIGER RW, 1960, J ORG CHEM, V25, P1573, DOI 10.1021/jo01079a026; CHEESEMAN KH, 1985, LIFE CHEM REPORTS, V3, P259; COOK MG, 1980, CANCER RES, V40, P1329; DEVANESAN P, 1991, P AM ASSOC CANC RES, V31, P95; Druckrey H., 1970, CARCINOMA COLON ANTE, P267; FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447; FONG LYY, 1990, CARCINOGENESIS, V11, P411, DOI 10.1093/carcin/11.3.411; GANNETT PM, 1991, CHEM-BIOL INTERACT, V80, P57, DOI 10.1016/0009-2797(91)90031-2; GROSS ML, 1982, INT J MASS SPECTROM, V42, P243, DOI 10.1016/0020-7381(82)80069-7; HATT HH, 1943, ORG SYNTH, V2, P208; HAWKS A, 1974, BRIT J CANCER, V30, P440, DOI 10.1038/bjc.1974.218; HERRON DC, 1981, CANCER RES, V41, P3967; HERRON DC, 1979, ANAL BIOCHEM, V100, P58, DOI 10.1016/0003-2697(79)90109-X; JACOBS MM, 1981, CANCER RES, V41, P4458; KALYANARAMAN B, 1985, ENVIRON HEALTH PERSP, V64, P179, DOI 10.2307/3430008; KANG JO, 1988, BIOCHEM PHARMACOL, V37, P2967, DOI 10.1016/0006-2952(88)90283-3; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KAWANISHI S, 1991, BIOCHEMISTRY-US, V30, P3069, DOI 10.1021/bi00226a013; KIMBALL RF, 1977, MUTAT RES, V39, P111, DOI 10.1016/0165-1110(77)90018-5; KIRBY KS, 1967, BIOCHEM J, V104, P254, DOI 10.1042/bj1040254; KRIEK E, 1974, BIOCHIM BIOPHYS ACTA, V355, P177, DOI 10.1016/0304-419X(74)90003-1; LEITE LCC, 1989, ARCH BIOCHEM BIOPHYS, V270, P560, DOI 10.1016/0003-9861(89)90538-9; MAEDA M, 1974, TETRAHEDRON, V30, P2677, DOI 10.1016/S0040-4020(01)97428-9; NETTO LES, 1988, ARCH BIOCHEM BIOPHYS, V266, P562, DOI 10.1016/0003-9861(88)90289-5; NETTO LES, 1991, CHEM-BIOL INTERACT, V79, P1, DOI 10.1016/0009-2797(91)90048-C; OBRIEN PJ, 1985, ENVIRON HEALTH PERSP, V64, P219, DOI 10.2307/3430012; PARK JW, 1988, P NATL ACAD SCI USA, V85, P7467, DOI 10.1073/pnas.85.20.7467; PARODI S, 1981, CANCER RES, V41, P1469; PRYOR WA, 1988, FREE RADICAL BIO MED, V4, P219, DOI 10.1016/0891-5849(88)90043-3; RAMAKRISHNA NVS, 1992, J AM CHEM SOC, V114, P1863, DOI 10.1021/ja00031a047; REDDY BS, 1979, FED PROC, V38, P714; RICE JM, 1967, J AM CHEM SOC, V89, P2719, DOI 10.1021/ja00987a039; ROGAN EG, 1988, J AM CHEM SOC, V110, P4023, DOI 10.1021/ja00220a049; ROGERS KJ, 1977, CANCER RES, V37, P4082; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SHIGENAGA MK, 1991, FREE RADICAL BIO MED, V10, P211, DOI 10.1016/0891-5849(91)90078-H; SNYDER CA, 1986, CANCER LETT, V33, P175, DOI 10.1016/0304-3835(86)90022-4; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; STEINMAUS H, 1971, J ORG CHEM, V36, P3594; TACHIBEDFORD AM, 1988, TOXICOLOGY, V50, P181; TOTH B, 1980, J CANCER RES CLIN, V97, P97, DOI 10.1007/BF00409895; TSO POP, 1977, FREE RADICALS BIOL, V3, P251; WIESTLER OD, 1984, J CANCER RES CLIN, V108, P56, DOI 10.1007/BF00390973; ZADY MF, 1977, J AM CHEM SOC, V99, P5096, DOI 10.1021/ja00457a033	50	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21524	21527						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400464				2022-12-27	WOS:A1992JV01100042
J	RAPP, JC; BAUMGARTNER, BJ; MULLET, J				RAPP, JC; BAUMGARTNER, BJ; MULLET, J			QUANTITATIVE-ANALYSIS OF TRANSCRIPTION AND RNA LEVELS OF 15 BARLEY CHLOROPLAST GENES - TRANSCRIPTION RATES AND MESSENGER-RNA LEVELS VARY OVER 300-FOLD - PREDICTED MESSENGER-RNA STABILITIES VARY 30-FOLD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; PSBD-PSBC; ILLUMINATED BARLEY; LEAF DEVELOPMENT; PHOTOSYSTEM-II; ALPHA-SUBUNIT; RIBOSOMAL-RNA; PSAA-PSAB; RBCL GENE; ZEA-MAYS	Higher plant plastid genomes encode rRNAs, tRNAs, and protein subunits of the RNA polymerase, ribosomes, and the photosynthetic apparatus which vary over 1000-fold in abundance. Quantitative analysis of transcription and RNA levels was carried out on 15 plastid genes which are located in 14 different transcription units covering 50% of the barley plastid genome. Transcription of 16S rRNA, trnfM-trnG, and trnK was high relative to most other plastid genes. Transcription of trnfM-trnG was 5 times greater than trnK indicating that differences in tRNA levels in plastids could be due, in part, to differences in transcription. Among the protein coding genes, mRNA levels varied over 900-fold and transcription over 300-fold. The gene showing the lowest transcription rate and mRNA level, rpoB, is located in a gene cluster which encodes subunits of the plastid RNA polymerase (rpoB-rpoC1-rpoC2). RpoA, which encodes the alpha subunit of the RNA polymerase, was located in a gene cluster encoding ribosomal proteins (rpl23, rps19, rpl16) and infA. RNA from this gene cluster is 30-fold more abundant than rpoB mRNA, suggesting that expression of rpoA is regulated at the level of translation or protein stability. Polycistronic operons encoding subunits of the photosynthetic apparatus (psbB-psbH-petB-petD; psbK-psbI-psbD-psbC; atpB-atpE; psaA-psaB) had higher transcription rates and correspondingly higher mRNA levels than genes which encode ribosomal proteins or RNA polymerase subunits. RbcL and psbA, which are located in separate transcription units, exhibited the highest transcription rates and mRNA levels. Correspondence between transcription rate, mRNA level, and protein abundance indicates that transcription is a primary determinant of barley plastid gene expression. In addition, a 30-fold variation in predicted mRNA stability was observed which further increases the dynamic range of plastid mRNA abundance.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843	Texas A&M University System; Texas A&M University College Station								BALDAUF SL, 1990, NATURE, V344, P262, DOI 10.1038/344262a0; BAUMGARTNER BJ, 1989, PLANT PHYSIOL, V89, P1011, DOI 10.1104/pp.89.3.1011; BENDICH AJ, 1987, BIOESSAYS, V6, P279, DOI 10.1002/bies.950060608; BENNETT DC, 1990, PLANT MOL BIOL, V15, P111, DOI 10.1007/BF00017728; BERENDS T, 1987, NUCLEIC ACIDS RES, V15, P5217, DOI 10.1093/nar/15.13.5217; BOYER SK, 1988, NUCLEIC ACIDS RES, V16, P8184, DOI 10.1093/nar/16.16.8184; BURGESS RR, 1969, J BIOL CHEM, V244, P6168; CHAKHMAKHCHEVA OG, 1989, NUCLEIC ACIDS RES, V17, P2858, DOI 10.1093/nar/17.7.2858; CHOW WS, 1990, AUST J PLANT PHYSIOL, V17, P665; DEAN C, 1982, PLANT PHYSIOL, V70, P1605, DOI 10.1104/pp.70.6.1605; DENG XW, 1987, CELL, V49, P379, DOI 10.1016/0092-8674(87)90290-X; GANTT JS, 1991, EMBO J, V10, P3073, DOI 10.1002/j.1460-2075.1991.tb07859.x; GREENBERG BM, 1984, J BIOL CHEM, V259, P4880; GRUISSEM W, 1985, EMBO J, V4, P3375, DOI 10.1002/j.1460-2075.1985.tb04093.x; GRUISSEM W, 1985, MOL FORM FUNCTION PL, V83, P199; HANLEYBOWDOIN L, 1987, TRENDS BIOCHEM SCI, V12, P67, DOI 10.1016/0968-0004(87)90033-8; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; KEUS RJA, 1984, CURR GENET, V9, P91, DOI 10.1007/BF00396209; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1990, J BIOL CHEM, V265, P1895; KRUPINSKA K, 1989, MOL GEN GENET, V219, P467, DOI 10.1007/BF00259621; LINDAHL L, 1982, ADV GENET, V21, P53, DOI 10.1016/S0065-2660(08)60297-7; MATSUBAYASHI T, 1987, MOL GEN GENET, V210, P385, DOI 10.1007/BF00327187; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1985, PLANT MOL BIOL, V4, P39, DOI 10.1007/BF02498714; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; NEUMANN EM, 1988, CARLSBERG RES COMMUN, V53, P259, DOI 10.1007/BF02907182; NGERNPRASIRTSIRI J, 1990, CELL STRUCT FUNCT, V15, P273, DOI 10.1247/csf.15.273; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHYAMA K, 1988, TRENDS BIOCHEM SCI, V13, P19, DOI 10.1016/0968-0004(88)90013-8; OLIVER RP, 1984, CARLSBERG RES COMMUN, V49, P647, DOI 10.1007/BF02907497; OLIVER RP, 1984, CARLSBERG RES COMMUN, V49, P555, DOI 10.1007/BF02908683; OROZCO EM, 1985, NUCLEIC ACIDS RES, V13, P1283, DOI 10.1093/nar/13.4.1283; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; PALMER JD, 1985, ANNU REV GENET, V19, P325, DOI 10.1146/annurev.ge.19.120185.001545; PFITZINGER H, 1987, NUCLEIC ACIDS RES, V15, P1377, DOI 10.1093/nar/15.4.1377; POULSEN C, 1983, CARLSBERG RES COMMUN, V48, P57, DOI 10.1007/BF02906170; POULSEN C, 1984, CARLSBERG RES COMMUN, V49, P89, DOI 10.1007/BF02913968; RAJASEKHAR VK, 1991, EUR J BIOCHEM, V195, P215, DOI 10.1111/j.1432-1033.1991.tb15697.x; REVERDATTO SV, 1989, NUCLEIC ACIDS RES, V17, P2859, DOI 10.1093/nar/17.7.2859; RUF M, 1988, NUCLEIC ACIDS RES, V16, P5741, DOI 10.1093/nar/16.13.5741; Sambrook J, 1989, MOL CLONING LABORATO; SEXTON TB, 1990, EMBO J, V9, P4485, DOI 10.1002/j.1460-2075.1990.tb07899.x; SEXTON TB, 1990, CURR GENET, V17, P445, DOI 10.1007/BF00334526; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SOGAARD B, 1987, CARLSBERG RES COMMUN, V52, P123, DOI 10.1007/BF02907531; STERN DB, 1991, PLANT CELL, V3, P285; STRITTMATTER G, 1984, NUCLEIC ACIDS RES, V12, P7633, DOI 10.1093/nar/12.20.7633; TANAKA M, 1987, MOL GEN GENET, V209, P427, DOI 10.1007/BF00331145; THOMAS F, 1988, PLANT MOL BIOL, V10, P447, DOI 10.1007/BF00014950; TILLER K, 1991, EUR J BIOCHEM, V198, P93, DOI 10.1111/j.1432-1033.1991.tb15990.x; UMESONO K, 1987, TRENDS GENET, V3, P281, DOI 10.1016/0168-9525(87)90269-1; WESTHOFF P, 1988, EUR J BIOCHEM, V171, P551, DOI 10.1111/j.1432-1033.1988.tb13824.x; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; ZHOU DX, 1989, MOL GEN GENET, V101, P439; ZURAWSKI G, 1984, GENETICS, V106, P735; ZURAWSKI G, 1984, NUCLEIC ACIDS RES, V12, P2549, DOI 10.1093/nar/12.5.2549	60	91	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21404	21411						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400453				2022-12-27	WOS:A1992JV01100025
J	VALENTINRANC, C; CARLIER, MF				VALENTINRANC, C; CARLIER, MF			CHARACTERIZATION OF OLIGOMERS AS KINETIC INTERMEDIATES IN MYOSIN SUBFRAGMENT 1-INDUCED POLYMERIZATION OF G-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; F-ACTIN; BINDING-SITES; COMPLEX; GELSOLIN; MECHANISMS; FILAMENTS; PROTEINS; PROBE; CELLS	The nature of the kinetic intermediates involved in S1-induced polymerization of G-actin into F-acto-S1-decorated filaments has been investigated using as probes light scattering, the fluorescence of pyrenyl- or NBD-labeled actin, and the anisotropy of fluorescence of N-iodoacetyl-N'-(5-sulfo-1-napthyl)ethylene diamine (AEDANS)-labeled actin. With AEDANS-G-actin, the initial formation of a ternary G2S complex between two G-actin and one S1 molecules (Valentin-Ranc, C., Combeau, C., Carlier, M. F., and Pantaloni, D. (199 1) J. Biol. Chem. 266, 17871-17879) has been confirmed. Data obtained with all probes are consistent with the subsequent rapid formation of G-actin-S1 oligomers in which the actin/S1 molar ratio is 2:1. Oligomers form above 0.6 mum G-actin with S1(A1) and above 3.5 muM G-actin with S1(A2), at 20-degrees-C. Oligomerization is endothermic with a DELTAH of 14 kcal/mol. A tentative model is proposed to comprehensively account for the data and the structural features of the F-actin-S1 filament. Within this model, longitudinal actin-actin interactions take place in G2S, and lateral, hydrophobic actin-actin interactions appear upon formation of (G2S)n oligomers.			VALENTINRANC, C (corresponding author), CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE.							BRYAN J, 1984, J BIOL CHEM, V259, P7480; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P463; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CHAUSSEPIED P, 1989, J BIOL CHEM, V264, P20752; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; COMBEAU C, 1992, BIOCHEMISTRY-US, V31, P300, DOI 10.1021/bi00116a041; COMBEAU C, 1992, BIOPHYS J, V61; COOKE R, 1971, J MOL BIOL, V60, P249, DOI 10.1016/0022-2836(71)90291-9; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; COUE M, 1985, J BIOL CHEM, V260, P16033; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P8503, DOI 10.1021/bi00488a043; DETMERS P, 1981, J BIOL CHEM, V256, P99; DOI YK, 1991, BIOCHEMISTRY-US, V30, P5769, DOI 10.1021/bi00237a020; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GRAZI E, 1980, FEBS LETT, V112, P67, DOI 10.1016/0014-5793(80)80129-3; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN S, 1980, BIOCHEMISTRY-US, V19, P5358; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; OOSAWA F, 1975, THERMODYNAMICS POLYM, P28; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17871; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; WEEDS AG, 1986, EUR J BIOCHEM, V161, P77, DOI 10.1111/j.1432-1033.1986.tb10126.x; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; YAGI K, 1965, J BIOL CHEM, V240, P2448; YAZAWA Y, 1973, J BIOCHEM-TOKYO, V73, P567, DOI 10.1093/oxfordjournals.jbchem.a130115	43	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21543	21550						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400465				2022-12-27	WOS:A1992JV01100045
J	LANKER, S; MULLER, PP; ALTMANN, M; GOYER, C; SONENBERG, N; TRACHSEL, H				LANKER, S; MULLER, PP; ALTMANN, M; GOYER, C; SONENBERG, N; TRACHSEL, H			INTERACTIONS OF THE EIF-4F SUBUNITS IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; EUKARYOTIC TRANSLATION INITIATION; MESSENGER-RNA; INHIBITION; POLIOVIRUS; GENES	Recognition of the cap structure at the 5' end of mRNA is one of the first events in initiation of eukaryotic translation. This step is mediated by the translation initiation factor 4F (eIF-4F). In mammalian cells this factor is composed of the cap-binding protein eIF-4E, eIF-4A, and a 220-kDa polypeptide. In yeast Saccharomyces cerevisiae, eIF-4E is found associated with a 150-kDa protein (p150) and a 20-kDa protein (p20). The resulting protein complex is proposed to represent yeast eIF-4F. To study the functions of p150 and p20 and their interaction with eIF-4E, we disrupted the genes encoding p150 and p20 and analyzed the effects on protein complex formation and cell viability. Yeast cells with single and double disruptions of the genes encoding p 150 and p20 are viable, but p150 single and p150/p20 double disruptions show a slow growth phenotype. Gel chromatography and immunoadsorption experiments with a monoclonal anti-eIF-4E antibody coupled to protein G-Sepharose show that both p150 and p20 bind independently of each other to eIF-4E.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA	McGill University	LANKER, S (corresponding author), UNIV BERN, INST BIOCHEM & MOLEK BIOL, BUHLSTR 28, CH-3012 BERN, SWITZERLAND.			Mueller, Peter/0000-0002-1209-7546				ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P7520, DOI 10.1093/nar/17.18.7520; ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Davis R W, 1980, Methods Enzymol, V65, P404; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DUNCAN R, 1987, J BIOL CHEM, V262, P380; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GOYER C, 1989, J BIOL CHEM, V264, P7603; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HUEMBELIN M, 1991, TRANSLATION EUKARYOT, P231; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1990, BIOESSAYS, V12, P519, DOI 10.1002/bies.950121103; MULLER PP, 1990, EUR J BIOCHEM, V191, P257, DOI 10.1111/j.1432-1033.1990.tb19118.x; RAY BK, 1983, P NATL ACAD SCI-BIOL, V80, P663, DOI 10.1073/pnas.80.3.663; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sambrook J, 1989, MOL CLONING LABORATO; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Sherman F., 1986, METHODS YEAST GENETI; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P805, DOI 10.1093/nar/17.2.805; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	35	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21167	21171						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400427				2022-12-27	WOS:A1992JT97800101
J	MAHNKEZIZELMAN, DK; SABINA, RL				MAHNKEZIZELMAN, DK; SABINA, RL			CLONING OF HUMAN AMP DEAMINASE ISOFORM-E CDNAS - EVIDENCE FOR A 3RD AMPD GENE EXHIBITING ALTERNATIVELY SPLICED 5'-EXONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SKELETAL-MUSCLE; ALPHA-SPECTRIN; ISOZYMES; SEQUENCE; MYOSIN; YEAST; AMINOHYDROLASE; PURIFICATION; POLYPEPTIDES	Higher eukaryotes express multiple isoforms of AMP deaminase (EC 3.5.4.6). In humans, four AMP deaminase variants, termed M (muscle), L (liver), E1, and E2 (erythrocyte) can be distinguished by a variety of biochemical and immunological criteria. Previous molecular studies have reported two genes, AMPD1 and AMPD2, that produce isoform M and L transcripts, respectively. This study identifies a third human AMP deaminase gene, AMPD3. Nucleotide sequence alignments between AMPD3 cDNAs isolated from several human libraries indicate three different extreme 5'-ends. Alternate forms of the AMPD3 cDNAs contain a common 2301-bp open reading frame (ORF) and 3'-untranslated region of 1245 bp. Two of the three forms, however, exhibit additional 5'-end nucleotide sequences that would extend their respective ORFs by 21 and 27 nucleotides. RNase protection analyses and the partial characterization of human AMPD3 genomic clones demonstrate alternative splicing of three different 5'-terminal exons. Western blot analyses detect anti-E-specific immunoreactivity in affinity-purified extracts derived from the bacterial expression of a truncated AMPD3 cDNA. These results are discussed in relation to AMP deaminase isoform diversity.	MED COLL WISCONSIN,DEPT CELLULAR BIOL & ANAT,MILWAUKEE,WI 53226	Medical College of Wisconsin					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040766] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03326] Funding Source: Medline; NIAMS NIH HHS [AR40766] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHBY B, 1979, J CELL BIOL, V81, P361, DOI 10.1083/jcb.81.2.361; ASHBY B, 1977, J BIOL CHEM, V252, P1869; AVRAMEAS S, 1972, BIOCHIMIE, V54, P837, DOI 10.1016/S0300-9084(72)80004-X; BURNS NR, 1983, FEBS LETT, V153, P165, DOI 10.1016/0014-5793(83)80140-9; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; COOPER J, 1984, J MOL BIOL, V177, P137, DOI 10.1016/0022-2836(84)90061-5; KARN J, 1984, GENE, V32, P217, DOI 10.1016/0378-1119(84)90049-0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1987, CELL, V51, P345, DOI 10.1016/0092-8674(87)90631-3; MANIATIS T, 1982, MOL CLONING LABORATO, P196; MARQUETANT R, 1987, P NATL ACAD SCI USA, V84, P2345, DOI 10.1073/pnas.84.8.2345; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; MERKLER DJ, 1988, FASEB J, V2, pA552; MEYER SL, 1989, BIOCHEMISTRY-US, V28, P8734, DOI 10.1021/bi00448a009; MINEO I, 1991, MOL CELL BIOL, V11, P5356, DOI 10.1128/MCB.11.10.5356; MINEO I, 1990, MOL CELL BIOL, V10, P5271, DOI 10.1128/MCB.10.10.5271; MOON RT, 1990, J BIOL CHEM, V265, P4427; MORISAKI T, 1990, J BIOL CHEM, V265, P11482; MORISAKI T, 1992, P NATL ACAD SCI USA, V89, P6457, DOI 10.1073/pnas.89.14.6457; MOSELEY WS, 1990, GENOMICS, V6, P572, DOI 10.1016/0888-7543(90)90490-L; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OGASAWARA N, 1982, BIOCHIM BIOPHYS ACTA, V714, P298; OGASAWARA N, 1984, BIOCHEM BIOPH RES CO, V122, P1344, DOI 10.1016/0006-291X(84)91239-7; OGASAWARA N, 1984, INT J BIOCHEM, V16, P269, DOI 10.1016/0020-711X(84)90099-5; OGASAWARA N, 1978, BIOCHIM BIOPHYS ACTA, V524, P442, DOI 10.1016/0005-2744(78)90182-1; OGASAWARA N, 1978, EUR J BIOCHEM, V87, P297, DOI 10.1111/j.1432-1033.1978.tb12378.x; PIPOLY GM, 1979, J CLIN INVEST, V63, P1066, DOI 10.1172/JCI109376; RAO SN, 1968, BIOCHIM BIOPHYS ACTA, V151, P651, DOI 10.1016/0005-2744(68)90012-0; SABINA RL, 1992, NEUROLOGY, V42, P170, DOI 10.1212/WNL.42.1.170; SABINA RL, 1990, J BIOL CHEM, V265, P9423; SABINA RL, 1987, J BIOL CHEM, V262, P12397; SABINA RL, 1989, MOL CELL BIOL, V9, P2244, DOI 10.1128/MCB.9.5.2244; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SAMMONS DW, 1978, ARCH BIOCHEM BIOPHYS, V191, P561, DOI 10.1016/0003-9861(78)90394-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKI H, 1979, BIOCHIM BIOPHYS ACTA, V566, P335, DOI 10.1016/0005-2744(79)90037-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; ZIELKE CL, 1971, J BIOL CHEM, V246, P2179	43	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20866	20877						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400401				2022-12-27	WOS:A1992JT97800057
J	WILCOX, BD; RYDELEKFITZGERALD, L; JEFFREY, JJ				WILCOX, BD; RYDELEKFITZGERALD, L; JEFFREY, JJ			REGULATION OF COLLAGENASE GENE-EXPRESSION BY SEROTONIN AND PROGESTERONE IN RAT UTERINE SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HT2 BINDING CHARACTERISTICS; ENZYME PRODUCTION; TISSUE CULTURE; PURIFICATION; METABOLISM; RECEPTOR; ANALOGS	The regulation of collagenase gene expression by serotonin and progesterone was investigated in primary cultures of rat uterine smooth muscle cells. Northern blot analysis demonstrates that serotonin (5-hydroxytryptamine (5-HT)), when administered to cells in serotonin-depleted medium, causes 6-8-fold increases in levels of collagenase mRNA. Selective serotonin 5-HT2 receptor agonists were able to mimic the effect of the natural hormone, while the induction by serotonin could be blocked by 5-HT2 receptor antagonists. Addition of phorbol ester (PMA) to 5-HT-depleted cultures fully mimicked the effect of 5-HT on collagenase mRNA induction. Treatment with progesterone analogs caused a decrease in collagenase mRNA, even in the presence of saturating levels of serotonin or PMA. In all experiments, levels of secreted collagenase were observed to correspond to levels of collagenase mRNA. Experiments with cycloheximide demonstrate that serotonin- and PMA-induced increases in collagenase mRNA are dependent on protein synthesis. Furthermore, nuclear run-on analysis shows that mRNA increases are accompanied by increases in initiation of transcripts. These data indicate that transcription of collagenase mRNA in myometrial smooth muscle cells is stimulated by serotonin, possibly via activation of protein kinase C, but is in some way prevented by the negative influence of progesterone.	UNION UNIV, DEPT MED, ALBANY, NY 12208 USA; UNION UNIV, DEPT PHARMACOL & TOXICOL, ALBANY, NY 12208 USA; UNION UNIV, DEPT BIOCHEM & MOLEC BIOL, ALBANY, NY 12208 USA	Union College; Union College; Union College					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R37HD005291] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 05291] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHARYA S B, 1989, Indian Journal of Experimental Biology, V27, P505; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; BRINCKERHOFF CE, 1990, ANN NY ACAD SCI, V580, P355, DOI 10.1111/j.1749-6632.1990.tb17944.x; CHALLIS JRG, 1986, OXFORD REV REPROD B, V8, P61; CONN PJ, 1984, NEUROPHARMACOLOGY, V23, P993, DOI 10.1016/0028-3908(84)90017-0; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DOYLE VM, 1986, N-S ARCH PHARMACOL, V333, P98, DOI 10.1007/BF00506510; FAHIM I, 1966, BRIT J PHARM CHEMOTH, V26, P237, DOI 10.1111/j.1476-5381.1966.tb01826.x; GLENNON RA, 1986, J MED CHEM, V29, P2375, DOI 10.1021/jm00161a038; GLENNON RA, 1986, J MED CHEM, V29, P194, DOI 10.1021/jm00152a005; HALME J, 1980, ARCH BIOCHEM BIOPHYS, V199, P51, DOI 10.1016/0003-9861(80)90255-6; HARKNESS MLR, 1956, J PHYSIOL-LONDON, V132, P492, DOI 10.1113/jphysiol.1956.sp005542; HARKNESS RD, 1964, INT REV CONNECT TISS, V2, P155; HARKNESS RD, 1956, J PHYSIOL-LONDON, V132, P502, DOI 10.1113/jphysiol.1956.sp005543; JEFFREY JJ, 1971, BIOCHIM BIOPHYS ACTA, V252, P136, DOI 10.1016/0304-4165(71)90101-2; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; JEFFREY JJ, 1991, J CELL PHYSIOL, V146, P399, DOI 10.1002/jcp.1041460310; JEFFREY JJ, 1970, BIOCHEMISTRY-US, V9, P268, DOI 10.1021/bi00804a012; JEFFREY JJ, 1971, BIOCHIM BIOPHYS ACTA, V252, P143, DOI 10.1016/0304-4165(71)90102-4; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; LEYSEN JE, 1982, MOL PHARMACOL, V21, P301; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MORRIONE TG, 1962, J EXP MED, V115, P357, DOI 10.1084/jem.115.2.357; NAGAI Y, 1966, BIOCHEMISTRY-US, V5, P3123, DOI 10.1021/bi00874a007; PEPE GJ, 1974, ENDOCRINOLOGY, V95, P275, DOI 10.1210/endo-95-1-275; PEROUTKA SJ, 1979, MOL PHARMACOL, V16, P687; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSWIT WT, 1988, ARCH BIOCHEM BIOPHYS, V262, P67, DOI 10.1016/0003-9861(88)90169-5; RYAN JN, 1971, BIOCHEM BIOPH RES CO, V44, P144, DOI 10.1016/S0006-291X(71)80170-5; SCHATZ F, 1983, ENDOCRINOLOGY, V113, P1274, DOI 10.1210/endo-113-4-1274; SHERWOOD OD, 1983, ENDOCRINOLOGY, V113, P997, DOI 10.1210/endo-113-3-997; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; WOESSNER JF, 1963, BIOCHEM J, V89, P75, DOI 10.1042/bj0890075	34	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20752	20757						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400391				2022-12-27	WOS:A1992JT97800039
J	MCKNIGHT, GL; MUDRI, SL; MATHEWES, SL; TRAXINGER, RR; MARSHALL, S; SHEPPARD, PO; OHARA, PJ				MCKNIGHT, GL; MUDRI, SL; MATHEWES, SL; TRAXINGER, RR; MARSHALL, S; SHEPPARD, PO; OHARA, PJ			MOLECULAR-CLONING, CDNA SEQUENCE, AND BACTERIAL EXPRESSION OF HUMAN GLUTAMINE - FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-INDUCED DESENSITIZATION; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; HEXOSAMINE BIOSYNTHESIS; INSULIN RESISTANCE; TRANSPORT SYSTEM; ESCHERICHIA-COLI; MESSENGER-RNA; DNA; INHIBITORS; PROTEINS	Glutamine:fructose-6-phosphate amidotransferase (GFAT) has recently been shown to be an insulin-regulated enzyme that plays a key role in the induction of insulin resistance in cultured cells. As a first step in understanding the molecular regulation of this enzyme the human form of this enzyme has been cloned and the functional protein has been expressed in Escherichia coli. A 3.1-kilobase cDNA was isolated which contains the complete coding region of 681 amino acids. Expression of the cDNA in E. coli produced a protein of approximately 77 kDa and increased GFAT activity 4.5-fold over endogenous bacterial levels. Recombinant GFAT activity was inhibited 51% by UDP-GlcNAc whereas bacterial GFAT activity was insensitive to inhibition by UDP-GlcNAc. On the basis of these results we conclude that: 1) functional human GFAT protein was expressed, and 2) the cloned human cDNA encodes both the catalytic and regulatory domains of GFAT since the recombinant GFAT was sensitive to UDP-GlcNAc. Overall, the development of cloned GFAT molecular probes should provide new insights into the development of insulin resistance by allowing quantitation of GFAT mRNA levels in pathophysiological states such as non-insulin-dependent diabetes mellitus and obesity.	UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center	MCKNIGHT, GL (corresponding author), ZYMOGENET INC,4225 ROOSEVELT WAY NE,SEATTLE,WA 98105, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVVY GA, 1959, BIOCHEM J, V73, P127, DOI 10.1042/bj0730127; LIMA FB, 1991, ENDOCRINOLOGY, V128, P2415, DOI 10.1210/endo-128-5-2415; MARSHALL S, 1991, J BIOL CHEM, V266, P10155; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; MAYOR P, 1992, DIABETES, V41, P274, DOI 10.2337/diabetes.41.3.274; MCKNIGHT GL, 1992, DIABETES, V41, P82, DOI 10.2337/diabetes.41.1.82; OHARA PJ, 1991, COMPUT APPL BIOSCI, V7, P533; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICHARDS TC, 1973, BIOCHIM BIOPHYS ACTA, V304, P842, DOI 10.1016/0304-4165(73)90231-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SURIN BP, 1988, MOL MICROBIOL, V2, P173, DOI 10.1111/j.1365-2958.1988.tb00019.x; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRUJILLO JL, 1974, INT J BIOCHEM, V5, P515, DOI 10.1016/0020-711X(74)90109-8; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; YANISCHPERRON C, 1985, GENE AMST, V32, P481; 1985, EUR J BIOCHEM, V146, P237	29	120	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25208	25212						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460020				2022-12-27	WOS:A1992KB60300046
J	DEMPSEY, LA; BIRCH, P; KHAN, SA				DEMPSEY, LA; BIRCH, P; KHAN, SA			6 AMINO-ACIDS DETERMINE THE SEQUENCE-SPECIFIC DNA-BINDING AND REPLICATION SPECIFICITY OF THE INITIATOR PROTEINS OF THE PT181 FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROLLING-CIRCLE REPLICATION; STAPHYLOCOCCUS-AUREUS; PLASMID PT181; REPC PROTEIN; ORIGIN; INVITRO	The replication of pT181 and related plasmids of Staphylococcus aureus proceeds by a rolling circle mechanism. The initiator proteins encoded by the plasmids of the pT181 family have sequence-specific DNA binding and topoisomerase activities. These proteins nick one strand of the DNA at the origin of replication. The free 3'-hydroxyl end at the nick is then used as a primer for the replication of the leading strand of the DNA. Although these initiator proteins are highly homologous, they show specificity in DNA binding and replication for their cognate DNAs. In this study, we have generated hybrid initiator proteins and studied their various biochemical activities in vitro. Our results show that 6 amino acids are sufficient to determine the DNA binding and replication specificities of such initiator proteins.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Dempsey, Laurie/0000-0002-3304-796X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031685] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM005104] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31685] Funding Source: Medline; NLM NIH HHS [LM05104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		COMPAGNONEPOST P, 1991, J BACTERIOL, V173, P1827, DOI 10.1128/jb.173.5.1827-1830.1991; DEMPSEY LA, 1992, P NATL ACAD SCI USA, V89, P3083, DOI 10.1073/pnas.89.7.3083; DOTTO GP, 1984, P NATL ACAD SCI-BIOL, V81, P1336, DOI 10.1073/pnas.81.5.1336; GENNARO ML, 1989, J MOL BIOL, V205, P355, DOI 10.1016/0022-2836(89)90346-X; GROS MF, 1987, EMBO J, V6, P3863, DOI 10.1002/j.1460-2075.1987.tb02724.x; GRUSS A, 1989, MICROBIOL REV, V53, P231, DOI 10.1128/MMBR.53.2.231-241.1989; IORDANESCU S, 1989, MOL GEN GENET, V217, P481, DOI 10.1007/BF02464921; KHAN SA, 1983, PLASMID, V10, P251, DOI 10.1016/0147-619X(83)90039-2; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOEPSEL RR, 1985, J BIOL CHEM, V260, P8571; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KOEPSEL RR, 1986, P NATL ACAD SCI USA, V83, P5484, DOI 10.1073/pnas.83.15.5484; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRAY RW, 1989, J BIOL CHEM, V264, P1051; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NOVICK RP, 1972, J MOL BIOL, V68, P285, DOI 10.1016/0022-2836(72)90214-8; NOVICK RP, 1989, ANNU REV MICROBIOL, V43, P537, DOI 10.1146/annurev.micro.43.1.537; PROJAN SJ, 1988, PLASMID, V19, P203, DOI 10.1016/0147-619X(88)90039-X; PROJAN SJ, 1985, MOL GEN GENET, V199, P452, DOI 10.1007/BF00330758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; Varshavsky A, 1987, Methods Enzymol, V151, P551, DOI 10.1016/S0076-6879(87)51044-8; WANG PZ, 1992, J MOL BIOL, V223, P145, DOI 10.1016/0022-2836(92)90722-V; WANG PZ, 1990, MOL BIOL STAPHYLOCOC, P231; ZOCK JM, 1990, J BIOL CHEM, V265, P3484	27	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24538	24543						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447199				2022-12-27	WOS:A1992KA26300060
J	FOMINAYA, JM; HOFSTEENGE, J				FOMINAYA, JM; HOFSTEENGE, J			INACTIVATION OF RIBONUCLEASE INHIBITOR BY THIOL-DISULFIDE EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL RIBONUCLEASE; ANGIOGENIN; OXIDATION; PROTEINS; CLEAVAGE; BINDING	Porcine ribonuclease inhibitor (RI) contains 30 1/2-cystinyl residues, all of which occur in the reduced form. Reaction of the native protein with 5,5'-dithiobis(2-nitrobenzoic acid) resulted in the release of 30 mol of the product 5-mercapto-2-nitrobenzoate, and the loss of the RNase inhibitory activity. A linear relationship between the degree of modification and inactivation was observed. The rate of modification was greatly increased in the presence of 6 M guanidinium HCl. Reaction with substoichiometric amounts of 5,5'-dithiobis(2-nitrobenzoic acid) was found to yield a mixture of fully reduced active molecules, and fully oxidized inactive ones, but no partially oxidized forms were detected. This suggests that an "all-or-none" type of modification and inactivation took place. All 1/2-cystinyl residues in the inactive, monomeric inhibitor had formed disulfide bridges, judged by the absence of either free thiol groups or mixed disulfides with 5-mercapto-2-nitrobenzoate. This fully disulfide-cross-linked molecule had an open conformation compared to the native one, as shown by gel filtration and limited proteolysis. Reaction of phenylarsinoxide with vicinal dithiols yields products that are much more stable than those with monothiols. Titration of RI with this reagent yielded complete inactivation at a reagent/thiol ratio of 0.5. Taken together, these observations suggest that the thiol groups in RI have a diminished reactivity due to three-dimensional constraints. After the initial modification of a small number of thiol groups, a conformational change occurs which causes an increase in reactivity of the remaining thiols. The thiol groups are situated close enough together to permit the formation of 15 disulfide bridges in the inactive molecule.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								BATES DJ, 1985, NEUROCHEM RES, V10, P713, DOI 10.1007/BF00964409; BISHAY ES, 1973, ARCH BIOCHEM BIOPHYS, V158, P185, DOI 10.1016/0003-9861(73)90612-7; Blackburn P, 1982, ENZYMES, VXV, P317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON LE, 1982, INT J PEPT PROT RES, V19, P372; CAVALLI L, 1979, OPHTHALMIC RES, V11, P416, DOI 10.1159/000265044; FOMINAYA JM, 1988, BIOCHIM BIOPHYS ACTA, V954, P216, DOI 10.1016/0167-4838(88)90074-X; FRIEDMAN M, 1975, CHEM BIOCH SULFHYDRY, P311; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GIRIJA NS, 1966, BIOCHEM J, V98, P562, DOI 10.1042/bj0980562; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P219, DOI 10.1021/bi00427a030; MIRABELLI F, 1988, ARCH BIOCHEM BIOPHYS, V264, P261, DOI 10.1016/0003-9861(88)90593-0; ROTH JS, 1956, BIOCHIM BIOPHYS ACTA, V21, P34, DOI 10.1016/0006-3002(56)90091-9; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; SHORTMAN K, 1962, BIOCHIM BIOPHYS ACTA, V55, P88; SPECTOR A, 1978, P NATL ACAD SCI USA, V75, P3244, DOI 10.1073/pnas.75.7.3244; SRIVASTAVA SK, 1973, EXP EYE RES, V17, P33, DOI 10.1016/0014-4835(73)90165-6; Torchinskii Y. M., 1974, SULFHYDRYL DISULFIDE, P7; TORCHINSKII YM, 1974, SULFHYDRYL DISULFIDE, P125; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8	28	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24655	24660						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447207				2022-12-27	WOS:A1992KA26300076
J	JUVONEN, M; SANDBERG, M; PIHLAJANIEMI, T				JUVONEN, M; SANDBERG, M; PIHLAJANIEMI, T			PATTERNS OF EXPRESSION OF THE 6 ALTERNATIVELY SPLICED EXONS AFFECTING THE STRUCTURES OF THE COL1 AND NC2 DOMAINS OF THE ALPHA-1(XIII) COLLAGEN CHAIN IN HUMAN TISSUES AND CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XIII COLLAGEN; GENE; TRANSCRIPTS; ACID	Reverse transcription-polymerase chain reactions and RNA protection experiments were used to examine alternative splicing of the six exons 3B-5, 12, and 13 affecting the COL1 and NC2 domains of type XIII collagen in seven human tissues and four cell lines. Distinct differences in the proportions of the variant mRNAs were found. With respect to the COL1 domain, all studied samples contained mRNAs corresponding to the shortest COL1 variants of 57 and 66 residues, with the former variant being prominent in most samples. Most of the samples also contained notable amounts of mRNAs that corresponded to the longest COL1 variants, mainly those of 104 and 95 residues. Particularly the extent of inclusion of exon 12 and 13 sequences, encoding most of the NC2 domain, varied according to the type of tissue or cell analyzed. Bone, cartilage, and colon adenocarcinoma samples contained little or none of the mRNAs corresponding to the long NC2 variants, whereas in fibroblast, lung, muscle, and osteosarcoma cells, those mRNAs were the major variants. The relative proportions of the various combinations of exons 3B-5, 12, and 13 were evaluated in four of the RNA samples. Interestingly, each of these samples appeared to contain only one to three major combinations of the six exons, representing about 40% to nearly 100% of all variants.	UNIV OULU, DEPT MED BIOCHEM, KAJAANINTIE 52A, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND; UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU 52, FINLAND	University of Oulu; University of Oulu; University of Turku				Pihlajaniemi, Taina/0000-0002-1664-9045				CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HIRVONEN H, 1990, ONCOGENE, V5, P1787; JUVONEN M, 1992, J BIOL CHEM, V267, P24693; LATCHMAN D S, 1990, New Biologist, V2, P297; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG M, 1989, J CELL BIOL, V109, P1371, DOI 10.1083/jcb.109.3.1371; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TIKKA L, 1991, J BIOL CHEM, V266, P17713; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491	16	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24700	24707						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447210				2022-12-27	WOS:A1992KA26300083
J	PREVIATO, JO; MENDONCAPREVIATO, L; JONES, C; WAIT, R; FOURNET, B				PREVIATO, JO; MENDONCAPREVIATO, L; JONES, C; WAIT, R; FOURNET, B			STRUCTURAL CHARACTERIZATION OF A NOVEL CLASS OF GLYCOPHOSPHOSPHINGOLIPIDS FROM THE PROTOZOAN LEPTOMONAS-SAMUELI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI LIPOPHOSPHOGLYCAN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; NUCLEAR MAGNETIC-RESONANCE; GLYCOSYLATED-PHOSPHATIDYLINOSITOLS; KINETOPLASTID PARASITES; EVOLUTIONARY ASPECTS; GPI METABOLISM; C-13; MONOSACCHARIDES; SPHINGOLIPIDS	Aqueous phenol extraction of the lower trypanosomatid Leptomonas samueli released into the aqueous layer a chloroform/methanol/water-soluble glycophosphosphingolipid fraction. Alkaline degradation and purification by gel filtration chromatography resulted in a tetrasaccharide (phosphatidylinositol (PI)-oligosaccharide A), and a pentasaccharide (PI-oligosaccharide B), each containing 2 mol of 2-aminoethylphosphonate and 1 mol of phosphate. Nuclear magnetic resonance spectroscopy and fast atom bombardment-mass spectrometry suggested that the structure of PI-oligosaccharide A is [GRAPHICS] and that of PI-oligosaccharide B is as shown. [GRAPHICS] Both compounds contain an inositol unit linked to ceramide via a phosphodiester bridge. The major aliphatic components of the ceramide portion are stearic acid, lignoceric acid, and C20-phytosphingosine. These novel glycolipids fall within the glycosylated phosphatidylinositol (GPI) family, since they contain the core structure Manalpha(1-->4)GlcNH2alpha(1-->6)myo-inositol-1-PO4, which is also found in the glycoinositolphospholipids and lipophosphoglycan of Leishmania spp., the L. major promastigote surface protease, the glycosylphosphatidylinositol anchor of Trypanosoma brucei variant surface glycoprotein, and the lipopeptidophosphoglycan of Trypanosoma cruzi. The glycophosphosphingolipids of Leptomonas have features in common with the glycolipids of both Leishmania and T. cruzi, resembling the former by the alpha(1-->3) linkage of mannose to the GPI core, while the 2-aminoethylphosphonate substituent on O-6 of glucosamine and the presence of ceramide in place of glycerol lipids is more reminiscent of T. cruzi. Thus these data lend some support to the hypothesis that both T. cruzi and Leishmania evolved from a Leptomonas-like ancestor.	NATL INST BIOL STAND & CONTROLS,MOLEC STRUCT LAB,POTTERS BAR EN6 3QG,HERTS,ENGLAND; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,DIV PATHOL,SALISBURY SP4 0JG,WILTS,ENGLAND; UNIV LILLE 1,CHIM BIOL LAB,F-59655 VILLENEUVE DASCQ,FRANCE	National Institute for Biological Standards & Control; Universite de Lille - ISITE; Universite de Lille	PREVIATO, JO (corresponding author), UNIV FED RIO DE JANEIRO,INST MICROBIOL,DEPT MICROBIOL GERAL,RIO JANEIRO,BRAZIL.		Jones, Chris/AAF-4063-2021	Jones, Chris/0000-0001-7109-492X; Mendonca Previato, Lucia/0000-0003-3927-3244; Previato, Jose Osvaldo/0000-0002-9233-9954				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ARAKI S, 1987, J BIOL CHEM, V262, P14141; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAKER JR, 1963, EXP PARASITOL, V13, P219, DOI 10.1016/0014-4894(63)90074-2; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAX A, 1981, J MAGN RESON, V42, P501, DOI 10.1016/0022-2364(81)90272-9; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; CARTER HE, 1967, BIOCHEM BIOPH RES CO, V29, P886, DOI 10.1016/0006-291X(67)90304-X; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1991, SCIENCE, V15, P991; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HORIGUCHI M, 1984, BIOCH NATURAL C P CO, P8; LAINE RA, 1987, METHOD ENZYMOL, V138, P186; LAUTER CJ, 1962, J LIPID RES, V3, P136; LEDERKREMER RM, 1990, EUR J BIOCHEM, V192, P337; LEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCOCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; OCONNOR JV, 1979, BIOCHEMISTRY-US, V18, P500, DOI 10.1021/bi00570a020; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PALATNIK CB, 1987, COMP BIOCHEM PHYS B, V86, P593, DOI 10.1016/0305-0491(87)90454-8; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PUENTES SM, 1990, J IMMUNOL, V145, P4311; RITCHIE RGS, 1975, CAN J CHEM, V53, P1424, DOI 10.1139/v75-197; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SMITH SW, 1974, J BIOL CHEM, V249, P3395; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THORPE SR, 1967, BIOCHEMISTRY-US, V6, P887, DOI 10.1021/bi00855a033; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; WALLACE FG, 1966, EXP PARASITOL, V18, P124, DOI 10.1016/0014-4894(66)90015-4; WALLACE FG, 1979, BIOL KINETOPLASTIDA, V2, P213	45	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24279	24286						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447177				2022-12-27	WOS:A1992KA26300024
J	VANDERIJN, I; DRAKE, RR				VANDERIJN, I; DRAKE, RR			ANALYSIS OF THE STREPTOCOCCAL HYALURONIC-ACID SYNTHASE COMPLEX USING THE PHOTOAFFINITY PROBE 5-AZIDO-UDP-GLUCURONIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBILIZATION; BIOSYNTHESIS; SYNTHETASE; CELLS	The mucopolysaccharide, hyaluronic acid, is an important component of both mammals and pathogenic streptococci. This high molecular weight polymer is synthesized by a membrane-associated, multisubunit hyaluronate synthase which utilizes UDP-glucuronic acid and UDP-N-acetylglucosamine as substrates. Using the photoaffinity probe, [beta-P-32]5-azido-UDP-glucuronic acid, three streptococcal membrane proteins (42, 33, and 27 kDa) specifically photoincorporated this probe. Labeling of these proteins was enhanced in the presence of UDP-N-acetylglucosamine, whereas UDP-galactose or UDP-glucose had no effect on incorporation. UDP-glucuronic acid inhibited the labeling of the three proteins in a dose-dependent manner. Detergent-solubilized membrane proteins from transposon-inactivated hyaluronic acid capsule mutants no longer incorporated the probe. This was also the case when membranes from stationary phase organisms were tested. Finally, glucuronic acid no longer was incorporated into high molecular weight hyaluronic acid with either the mutant or stationary phase preparations. Further biochemical analysis will be required to demonstrate the exact role each of the proteins play in hyaluronic acid biosynthesis.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences	VANDERIJN, I (corresponding author), WAKE FOREST UNIV,MED CTR,WINSTON SALEM,NC 27157, USA.				NIAID NIH HHS [AI19756] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019756] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; DRAKE RR, 1991, J BIOL CHEM, V266, P23257; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; DRAKE RR, 1992, J BIOL CHEM, V267, P11300; KETCHAM K, 1992, J BIOL CHEM, V267, P11645; KLEINE TO, 1981, INT REV CONNECT TISS, V9, P27; KORO LA, 1982, CELL, V31, P739, DOI 10.1016/0092-8674(82)90328-2; Krause RM, 1972, STREPTOCOCCI STREPTO, P3; LIN FC, 1990, J BIOL CHEM, V265, P4782; MARCHASE RB, 1990, ARCH BIOCHEM BIOPHYS, V280, P122, DOI 10.1016/0003-9861(90)90526-5; MIAN N, 1986, BIOCHEM J, V237, P343, DOI 10.1042/bj2370343; NG KF, 1989, J BIOL CHEM, V264, P11776; PHILIPSON LH, 1985, BIOCHEMISTRY-US, V24, P7899, DOI 10.1021/bi00348a008; PREHM P, 1985, BIOCHEM J, V225, P699, DOI 10.1042/bj2250699; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1983, J BACTERIOL, V156, P1059, DOI 10.1128/JB.156.3.1059-1065.1983; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980	21	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24302	24306						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447180				2022-12-27	WOS:A1992KA26300027
J	BUTLER, JD; BLANCHETTEMACKIE, J; GOLDIN, E; ONEILL, RR; CARSTEA, G; ROFF, CF; PATTERSON, MC; PATEL, S; COMLY, ME; COONEY, A; VANIER, MT; BRADY, RO; PENTCHEV, PG				BUTLER, JD; BLANCHETTEMACKIE, J; GOLDIN, E; ONEILL, RR; CARSTEA, G; ROFF, CF; PATTERSON, MC; PATEL, S; COMLY, ME; COONEY, A; VANIER, MT; BRADY, RO; PENTCHEV, PG			PROGESTERONE BLOCKS CHOLESTEROL TRANSLOCATION FROM LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; ACYL-COENZYME-A; MACROPHAGE FOAM CELLS; HAMSTER OVARY CELLS; INTRACELLULAR-TRANSPORT; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; REDUCTASE-ACTIVITY	Fluorescent microscopic examination of fibroblasts cultured with low density lipoprotein (LDL) and progesterone (10 mug/ml) for 24 h revealed extensive filipin-cholesterol staining of perinuclear lysosomes. Levels of unesterified cholesterol were 2-fold greater than in fibroblasts cultured with LDL alone. Progesterone strongly blocked cholesteryl ester synthesis. When cellular uptake of LDL was monitored in the presence of 58035, a specific inhibitor of acyl-CoA:cholesterol acyltransferase, excess unesterified cholesterol was not stored in lysosomes. Discontinuation of LDL uptake in conjunction with progesterone washout markedly reversed the filipin-cholesterol staining of lysosomes. Reversal of the lysosomal cholesterol lipidosis was associated with a rapid burst of cholesteryl ester synthesis and a normalization of the cellular levels of free and esterified cholesterol. In contrast to normal cells, progesterone removal from Niemann-Pick C fibroblasts did not reverse the lysosomal cholesterol accumulation of these mutant cultures. The metabolic precursor of progesterone, pregnenolone, also induced extensive accumulation of cholesterol in lysosomes. Other steroids induced less vacuolar cholesterol accumulation in the following decreasing order: corticosterone and testosterone, promegestone, RU 486. The relative inhibition of cellular cholesterol esterification by the steroids paralleled their respective abilities to sequester cholesterol in lysosomes rather than their inhibition of acyl-CoA:cholesterol acyltransferase activity in cell-free extracts. The progesterone-related inhibition and restoration of lysosomal cholesterol trafficking is a useful experimental means of studying intracellular cholesterol transport. A particularly important feature of its utility is the facile reversibility of the steroid-induced block. The lysosomal cholesterol lipidosis established with a hydrophobic amine, U18666A, was not as readily reversed.	NINCDS,DEV & METAB NEUROL BRANCH,BETHESDA,MD 20892; NICHHD,HUMAN GENET BRANCH,BETHESDA,MD 20892; NIDDKD,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892; VET ADM MED CTR,NEUROL SERV,NEWINGTON,CT 06111; FAC MED LYON SUD,BIOCHIM LAB,INSERM,U189,F-69921 OULLINS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Institut National de la Sante et de la Recherche Medicale (Inserm)			Patterson, Marc/AAI-5056-2020; Patterson, Marc C./H-5331-2019	Patterson, Marc/0000-0002-1116-126X				AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; BILLHEIMER JT, 1990, SUBCELLULAR BIOCH, P301; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BYERS DM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P20, DOI 10.1016/0925-4439(92)90146-E; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DILORENZO D, 1991, CANCER RES, V51, P4470; DRANGOVA R, 1980, J STEROID BIOCHEM, V13, P629, DOI 10.1016/0022-4731(80)90029-1; DUVAL D, 1983, BIOCHIM BIOPHYS ACTA, V737, P409, DOI 10.1016/0304-4157(83)90008-4; FLINT APF, 1973, BIOCHEM J, V132, P313, DOI 10.1042/bj1320313; GAL D, 1981, J CLIN ENDOCR METAB, V53, P29, DOI 10.1210/jcem-53-1-29; GAMBLE W, 1978, J LIPID RES, V19, P1068; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GOLDSTEIN JL, 1978, P NATL ACAD SCI USA, V75, P1877, DOI 10.1073/pnas.75.4.1877; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KALIMI M, 1987, RECEPTOR MEDIATED AN, P121; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KODAVANTI UP, 1990, PHARMACOL REV, V42, P327; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; KUTE T, 1976, BIOCHIM BIOPHYS ACTA, V420, P195, DOI 10.1016/0005-2795(76)90358-5; LAN NC, 1990, EUR J PHARM-MOLEC PH, V188, P403, DOI 10.1016/0922-4106(90)90201-8; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHFOUDI A, 1991, MOL CELL ENDOCRINOL, V79, pR15, DOI 10.1016/0303-7207(91)90112-6; MARTYR R J, 1973, Biochemistry, V12, P2172, DOI 10.1021/bi00735a025; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; MIDDLETON B, 1987, BIOCHEM BIOPH RES CO, V145, P350, DOI 10.1016/0006-291X(87)91328-3; MOREAU M, 1980, DEV BIOL, V78, P201, DOI 10.1016/0012-1606(80)90329-2; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; PANINI SR, 1987, J BIOL CHEM, V262, P14435; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTCHEV PG, 1986, J BIOL CHEM, V261, P2772; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; QIAN XD, 1990, J BIOL CHEM, V265, P18753; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; ROFF CF, 1991, DEV NEUROSCI-BASEL, V13, P315, DOI 10.1159/000112179; ROSS AC, 1984, J BIOL CHEM, V259, P815; SEXTON R, 1986, J LIPID RES, V27, P567; SIMPSON ER, 1980, ARCH BIOCHEM BIOPHYS, V200, P79, DOI 10.1016/0003-9861(80)90333-1; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V1005, P303, DOI 10.1016/0005-2760(89)90053-2; SLOTTE JP, 1987, BIOCHEM J, V248, P237, DOI 10.1042/bj2480237; SOKOL J, 1988, J BIOL CHEM, V263, P3411; TABAS I, 1988, J BIOL CHEM, V263, P1266; URBANI L, 1990, J BIOL CHEM, V265, P1919; WALTERS MR, 1979, ENDOCRINOLOGY, V105, P382, DOI 10.1210/endo-105-2-382; WASSERMAN WJ, 1980, P NATL ACAD SCI-BIOL, V77, P1534, DOI 10.1073/pnas.77.3.1534; WESTPHAL U, 1966, H-S Z PHYSIOL CHEM, V346, P243, DOI 10.1515/bchm2.1966.346.1-2.243; WILKIN DJ, 1992, J BIOL CHEM, V267, P2831; XU XX, 1991, J BIOL CHEM, V266, P17040	58	152	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23797	23805						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429719				2022-12-27	WOS:A1992JZ23900057
J	LOLLAR, P; PARKER, ET; FAY, PJ				LOLLAR, P; PARKER, ET; FAY, PJ			COAGULANT PROPERTIES OF HYBRID HUMAN PORCINE FACTOR-VIII MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; HUMAN FACTOR-V; SUBUNIT STRUCTURE; MONOCLONAL-ANTIBODIES; PROCOAGULANT ACTIVITY; FACTOR XA; THROMBIN; INACTIVATION; CONCENTRATE; RECONSTITUTION	Human and porcine factor VIII (fVIII) are activated by thrombin to form a heterotrimer composed of subunits designated A1 and A2 derived from the fVIII heavy chain (HC) and a subunit designated A3-C1-C2 derived from the fVIII light chain (LC). Human and porcine fVIII were activated at the same rate to the same peak levels but dissociation of the A2 subunit and concomitant loss of fVIIIa activity at pH 7.4 and 22-degrees-C was 3-fold faster with human fVIIIa compared to porcine fVIIIa (0.35 min-1 versus 0.12 min-1, respectively). To determine structural requirements for the increased activity of porcine FVIII, plasma-derived hybrid human/porcine fVIII molecules were isolated. Porcine HC/human LC (pHC/hLC) fVIII had 44-fold higher coagulant activity than reconstituted human fVIII (hHC/hLC), 40-fold higher activity than hHC/pLC, and slightly (1.4-fold) higher activity than reconstituted porcine fVIII (pHC/pLC). Additionally, human and porcine A2 subunits and inactive A1/A3-C1-C2 human and porcine dimers were isolated and reconstitution experiments were done. Addition of the porcine A2 subunit to the human A1/A3-C1-C2 dimer produced coagulant activity similar to that found with porcine fVIIIa and superior to human fVIIIa. These results suggest that human fVIII has weaker coagulant activity than porcine fVIII due to faster dissociation of the A2 subunit and that the A2 subunit itself is responsible for the difference.	UNIV ROCHESTER, MED CTR, HEMATOL UNIT, ROCHESTER, NY 14642 USA	University of Rochester	LOLLAR, P (corresponding author), EMORY UNIV, DEPT MED, DIV HEMATOL ONCOL, ATLANTA, GA 30322 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215, R01HL038199, R01HL040921] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46215, HL-40921, HL-38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Bevington P. R, 1969, DATA REDUCTION ERROR; COOPER HA, 1975, J CLIN INVEST, V56, P751, DOI 10.1172/JCI108146; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESMON CT, 1979, J BIOL CHEM, V254, P964; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, BIOCHIM BIOPHYS ACTA, V952, P181, DOI 10.1016/0167-4838(88)90114-8; FULCHER CA, 1985, P NATL ACAD SCI USA, V82, P7728, DOI 10.1073/pnas.82.22.7728; FULCHER CA, 1983, BLOOD, V61, P807; GATTI L, 1984, THROMB HAEMOSTASIS, V51, P379; HEMKER HC, 1967, NATURE, V215, P1201, DOI 10.1038/2151201a0; HULTIN MB, 1981, BLOOD, V57, P476; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KERNOFF PBA, 1984, BLOOD, V63, P31; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LAMPHEAR BJ, 1992, IN PRESS BLOOD; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; Moore J.W., 1981, KINETICS MECH, V3rd, P284; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; PIETERS J, 1989, BLOOD, V74, P1021; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; SCANDELLA D, 1989, BLOOD, V74, P1618; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001	45	110	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23652	23657						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429706				2022-12-27	WOS:A1992JZ23900037
J	HAEBERLE, JR; TRYBUS, KM; HEMRIC, ME; WARSHAW, DM				HAEBERLE, JR; TRYBUS, KM; HEMRIC, ME; WARSHAW, DM			THE EFFECTS OF SMOOTH-MUSCLE CALDESMON ON ACTIN FILAMENT MOTILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD CALDESMON; ATPASE ACTIVITY; HEAVY-MEROMYOSIN; F-ACTIN; CROSS-LINKING; MYOSIN SUBFRAGMENTS; LIGHT CHAIN; BINDING; TROPOMYOSIN; PHOSPHORYLATION	The movement of reconstituted thin filaments over an immobilized surface of thiophosphorylated smooth muscle myosin was examined using an in vitro motility assay. Reconstituted thin filaments contained actin, tropomyosin, and either purified chicken gizzard caldesmon or the purified COOH-terminal actin-binding fragment of caldesmon. Control actin-tropomyosin filaments moved at a velocity of 2.3 +/- 0.5 mum/s. Neither intact caldesmon nor the COOH-terminal fragment, when maintained in the monomeric form by treatment with 10 mM dithiothreitol, had any effect on filament velocity; and yet both were potent inhibitors of actin-activated myosin ATPase activity, indicating that caldesmon primarily inhibits myosin binding as reported by Chalovich et al. (Chalovich, J. M., Hemric, M. E., and Velaz, L. (1990) Ann. N. Y. Acad. Sci. 599, 85-99). Inhibition of filament motion was, however, observed under conditions where cross-linking of caldesmon via disulfide bridges was present. To determine if monomeric caldesmon could "tether" actin filaments to the myosin surface by forming an actin-caldesmon-myosin complex as suggested by Chalovich et al., we looked for caldesmon-dependent filament binding and motility under conditions (80 mM KCl) where filament binding to myosin is weak and motility is not normally seen. At caldesmon concentrations greater-than-or-equal-to 0.26 muM, actin filament binding was increased and filament motion (2.6 +/- 0.6 mum/s) was observed. The enhanced motility seen with intact caldesmon was not observed with the addition of up to 26 muM COOH-terminal fragment. Moreover, a molar excess of the COOH-terminal fragment competitively reversed the enhanced binding seen with intact caldesmon. These results show that tethering of actin filaments to myosin by the formation of an actin-caldesmon-myosin complex enhanced productive actomyosin interaction without placing a significant mechanical load on the moving filaments.	BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA	Brandeis University	HAEBERLE, JR (corresponding author), UNIV VERMONT, DEPT PHYSIOL & BIOPHYS, GIVEN BLDG, BURLINGTON, VT 05405 USA.				NHLBI NIH HHS [HL45161, HL28001] Funding Source: Medline; NIAMS NIH HHS [AR40259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028001, R01HL045161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040259] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS S, 1990, J BIOL CHEM, V265, P19652; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BRENNER B, 1990, BIOPHYS J, V57, pA397; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; FREEDMAN M, 1992, Biophysical Journal, V61, pA154; FUJII T, 1987, J BIOL CHEM, V262, P2757; HAEBERLE JR, 1992, J MUSCLE RES CELL M, V13, P81, DOI 10.1007/BF01738431; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEMRIC M E, 1992, Biophysical Journal, V61, pA6; HEMRIC M E, 1991, Biophysical Journal, V59, p237A; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KATAYAMA E, 1989, BIOCHEM BIOPH RES CO, V160, P1316, DOI 10.1016/S0006-291X(89)80147-0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH W, 1986, METHOD ENZYMOL, V134, P37; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MARSTON S, 1988, FEBS LETT, V238, P147, DOI 10.1016/0014-5793(88)80245-X; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; SZPACENKO A, 1985, FEBS LETT, V192, P9, DOI 10.1016/0014-5793(85)80032-6; TAGGART MJ, 1988, FEBS LETT, V242, P171, DOI 10.1016/0014-5793(88)81009-3; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; Walsh M P, 1989, Adv Exp Med Biol, V255, P337; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	47	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23001	23006						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429647				2022-12-27	WOS:A1992JY16300047
J	LEADON, SA; LAWRENCE, DA				LEADON, SA; LAWRENCE, DA			STRAND-SELECTIVE REPAIR OF DNA DAMAGE IN THE YEAST GAL7-GENE REQUIRES RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENE; HAMSTER OVARY CELLS; DIFFERENTIAL REPAIR; NUCLEOTIDE-SEQUENCES; PARTIAL-PURIFICATION; TRANSCRIBED STRAND; THYMINE GLYCOLS; ACTIVE GENE; DHFR GENE; EFFICIENT	We examined the role of transcription in directing repair of DNA damage in active genes by comparing the repair of thymine glycols produced by H2O2 and of UV-induced pyrimidine dimers on each strand of the GAL7 gene of Saccharomyces cerevisiae. Repair of both thymine glycols and pyrimidine dimers on the transcribed strand of the gene occurs two to three times faster than on its nontranscribed strand or in the genome overall. When the gene is inactive, no preferential or strand-selective repair is observed. Using a yeast strain containing a temperature-sensitive mutation in one of the subunits of RNA polymerase II, we find that inactivating RNA polymerase II by shifting the cells to the nonpermissive temperature during repair eliminates the strand selectivity of repair under conditions where repair on the nontranscribed strand of the gene and in the genome overall are only slightly affected. Our observation of strand-selective repair of thymine glycols in the GAL7 gene is the first evidence that this repair process occurs for a nonbulky lesion. In addition, we demonstrate that the transcriptional complex plays a critical role in directing repair to the transcribed strand of active genes.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LEADON, SA (corresponding author), UNIV N CAROLINA,DEPT RADIAT ONCOL,CB 7512,CHAPEL HILL,NC 27599, USA.				NCI NIH HHS [CA40453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, DNA REPAIR; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BRENT TP, 1979, BIOCHEMISTRY-US, V18, P911, DOI 10.1021/bi00572a028; CATHCART R, 1981, BIOCHEMISTRY-US, V20, P273, DOI 10.1021/bi00505a007; GOSSETT J, 1988, BIOCHEMISTRY-US, V27, P2629, DOI 10.1021/bi00407a054; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; KANEKO M, 1988, MUTAT RES, V207, P17, DOI 10.1016/0165-7992(88)90005-X; LEADON SA, 1983, MUTAT RES, V112, P191, DOI 10.1016/0167-8817(83)90006-8; LEADON SA, 1986, NUCLEIC ACIDS RES, V14, P8979, DOI 10.1093/nar/14.22.8979; LEADON SA, 1988, MOL CELL BIOL, V8, P5331, DOI 10.1128/MCB.8.12.5331; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LEADON SA, 1988, DNA REPAIR LABORATOR, V3, P311; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHOLES G, 1960, J MOL BIOL, V2, P379, DOI 10.1016/S0022-2836(60)80049-6; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STJOHN TP, 1981, J MOL BIOL, V152, P317, DOI 10.1016/0022-2836(81)90245-X; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	128	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23175	23182						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429664				2022-12-27	WOS:A1992JY16300073
J	RHOADES, KL; GOLUB, SH; ECONOMOU, JS				RHOADES, KL; GOLUB, SH; ECONOMOU, JS			THE REGULATION OF THE HUMAN TUMOR-NECROSIS-FACTOR-ALPHA PROMOTER REGION IN MACROPHAGE, T-CELL, AND B-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR CACHECTIN; C-FOS; GENE-EXPRESSION; PROTO-ONCOGENE; LYMPHOCYTES-T; PHORBOL ESTER; KAPPA-B; TRANSCRIPTION; AP-1; ACTIVATION	The 1311-base pair human tumor necrosis factor (TNF) alpha promoter region was fused to the luciferase (Luc) reporter gene and studied in a transient transfection system in three TNF producing cell lines, the U937 macrophage cell line, the MLA 144 T cell line, and the 729-6 B cell line. This full length promoter construct can be induced by phorbol 13-myristate acetate (PMA) in each of these cell types. Analysis of a series of 5'-truncations showed several peaks of basal and PMA induced activity suggesting the presence of several positive and negative regulatory elements. A PMA responsive element was localized to a region between -95 and -36 bp relative to the transcription start site. Within this region, single AP-2- and AP-1-like consensus sequences were noted. These AP-2 and AP-1 sites were each modified with a double point mutation. A modest (20-50%) reduction in TNF promoter activity was observed with the AP-2 site mutation. However, mutation of the AP-1 site markedly diminished both the basal and PMA-activated promoter activity. Also co-transfections of the wild-type promoter construct with an AP-1/c-jun expression vector resulted in augmented basal and PMA-induced promoter activity.	UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,DIV SURG ONCOL,54-140 CHS,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA-09120, R29 CA 50780] Funding Source: Medline; PHS HHS [K08 01360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA050780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARZILAY J, 1987, LEUKEMIA, V1, P198; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CANN AJ, 1988, ONCOGENE, V3, P123; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DREXLER HG, 1989, BLOOD, V73, P1656; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; ECONOMOU JS, 1989, IMMUNOLOGY, V67, P514; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRINSTEIN S, 1988, J BIOL CHEM, V263, P8658; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HEINKOFF S, 1984, GENE, V28, P351; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NEDWIN GE, 1985, J IMMUNOL, V135, P2492; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; STEFFEN M, 1988, J IMMUNOL, V140, P2621; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937	33	205	209	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22102	22107						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429562				2022-12-27	WOS:A1992JW71900021
J	GILCHRIST, JSC; BELCASTRO, AN; KATZ, S				GILCHRIST, JSC; BELCASTRO, AN; KATZ, S			INTRALUMINAL CA2+ DEPENDENCE OF CA2+ AND RYANODINE-MEDIATED REGULATION OF SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED CA-2+ RELEASE; JUNCTIONAL TERMINAL CISTERNAE; CALCIUM RELEASE; CARDIAC-MUSCLE; SMOOTH-MUSCLE; GUINEA-PIG; CONTRACTION; CHANNEL; MEMBRANE; IDENTIFICATION	The action of ryanodine upon sarcoplasmic reticulum (SR) Ca2+ handling is controversial with evidence for both activation and inhibition of SR Ca2+ release. In this study, the role of the intraluminal SR Ca2+ load was probed as a potential regulator of ryanodine-mediated effects upon SR Ca2+ release. Through dual-wavelength spectroscopy of Ca2+:antipyrylazo III difference absorbance, the intraluminal Ca2+ dependence of ryanodine and Ca2+-induced Ca2+ release (CICR) from skeletal SR vesicles was examined. Ryanodine addition after initiation of Ca2+ uptake (a) increased the intraluminal Ca2+ sensitivity of CICR and (b) stimulated spontaneous Ca2+ release with a delayed onset. These ryanodine effects were inversely proportional to the intraluminal Ca2+ load. Ryanodine also inhibited subsequent CICR after reaccumulation of Ca2+ released from the initial CICR. These results provide evidence that ryanodine inhibits transitions between low and high affinity Ca2+ binding states of an intraluminal Ca2+ compartment, possibly calsequestrin. Conformational transitions of calsequestrin may be reciprocally coupled to transitions between open and closed states of the Ca2+ release channel.	UNIV BRITISH COLUMBIA,FAC GRAD STUDIES,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,FAC EDUC,DIV KINESIOL,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,VANCOUVER V6T 1Z1,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ASHIDA T, 1988, CIRC RES, V62, P854, DOI 10.1161/01.RES.62.4.854; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CANNELL MB, 1985, FED PROC, V44, P2964; CHU A, 1986, BIOCHEMISTRY-US, V25, P8315, DOI 10.1021/bi00373a028; COLLINS JH, 1990, BIOCHEM BIOPH RES CO, V167, P189, DOI 10.1016/0006-291X(90)91749-I; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1989, MOL CELL BIOCHEM, V89, P135; FABIATO A, 1985, RFED P, V41, P2238; FAIRHURST AS, 1970, EUR J BIOCHEM, V13, P504, DOI 10.1111/j.1432-1033.1970.tb00953.x; FEHER JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P171, DOI 10.1016/0003-9861(88)90382-7; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; GILCHRIST JSC, 1990, BIOCHEM BIOPH RES CO, V168, P364, DOI 10.1016/0006-291X(90)91717-7; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HUNTER DR, 1983, CIRC RES, V53, P703, DOI 10.1161/01.RES.53.5.703; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; IKEMOTO N, 1989, J BIOENERG BIOMEMBR, V21, P247, DOI 10.1007/BF00812071; IKEMOTO N, 1984, J BIOL CHEM, V259, P3151; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; ITO K, 1986, CIRC RES, V58, P730, DOI 10.1161/01.RES.58.5.730; KIM DH, 1983, J BIOL CHEM, V258, P9662; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1989, J BIOL CHEM, V264, P16676; LAKATTA EG, 1985, FED PROC, V44, P2977; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; MARBAN E, 1985, CIRC RES, V56, P133, DOI 10.1161/01.RES.56.1.133; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MORII H, 1985, J BIOL CHEM, V260, P1536; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; NESTEROV VP, 1988, FIZIOL ZH SSSR, V34, P60; OHNISHI ST, 1979, J BIOCHEM, V86, P1147, DOI 10.1093/oxfordjournals.jbchem.a132609; PALADE P, 1987, J BIOL CHEM, V262, P6149; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; RAESS BU, 1980, J PHARMACOL METHOD, V4, P273, DOI 10.1016/0160-5402(80)90019-4; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; RUEST L, 1985, CAN J CHEM, V63, P2840, DOI 10.1139/v85-474; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SUTKO JL, 1983, J GEN PHYSIOL, V82, P385, DOI 10.1085/jgp.82.3.385	40	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20850	20856						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400399				2022-12-27	WOS:A1992JT97800055
J	LAVERY, PE; KOWALCZYKOWSKI, SC				LAVERY, PE; KOWALCZYKOWSKI, SC			BIOCHEMICAL BASIS OF THE CONSTITUTIVE REPRESSOR CLEAVAGE ACTIVITY OF RECA730 PROTEIN - A COMPARISON TO RECA441 AND RECA803 PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LARGE-SCALE PURIFICATION; PHAGE LAMBDA-REPRESSOR; ESCHERICHIA-COLI K-12; GENETIC-RECOMBINATION; PROTEOLYTIC ACTIVITY; LEXA REPRESSOR; SOS FUNCTIONS; SSB PROTEIN; BINDING	The recA730 mutation results in constitutive SOS and prophage induction. We examined biochemical properties of recA730 protein in an effort to explain the constitutive activity observed in recA730 strains. We find that recA730 protein is more proficient than the wild-type recA protein in the competition with single-stranded DNA binding protein (SSB protein) for single-stranded DNA (ssDNA) binding sites. Because an increased aptitude in the competition with SSB protein has been previously reported for recA441 protein and recA803 protein, we directly compared their in vitro activities with those of recA730 protein. At low magnesium ion concentration, both ATP hydrolysis and lexA protein cleavage experiments demonstrate that these recA proteins displace SSB protein from ssDNA in a manner consistent with their in vivo repressor cleavage activity, i.e. recA730 protein > recA441 protein > recA803 protein > recAwt protein. Additionally, a correlation exists between the proficiency of the recA proteins in SSB protein displacement and their rate of association with ssDNA. We propose that an increased rate of association with ssDNA allows recA730 protein to displace SSB protein from the ssDNA that occurs naturally in Escherichia coli and thereby to become activated for the repressor cleavage that leads to SOS induction. RecA441 protein is similarly activated for repressor cleavage; however, in this case, significant SSB protein displacement occurs only at elevated temperature. At physiological magnesium ion concentration, we argue that recA803 protein and wild-type recA protein do not displace sufficient SSB protein from ssDNA to constitutively induce the SOS response.	UNIV CALIF DAVIS,DIV BIOL SCI,RADIOL SECT,HUTCHISON HALL 258,DAVIS,CA 95616; UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,DIV BIOL SCI,CELL BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,DIV BIOL SCI,BIOCHEM SECT,DAVIS,CA 95616; NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Northwestern University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; GARVEY N, 1985, J BACTERIOL, V163, P870, DOI 10.1128/JB.163.3.870-876.1985; GOLDTHWAIT DA, 1964, CR HEBD ACAD SCI, V258, P661; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; KIRBY EP, 1967, P NATL ACAD SCI USA, V58, P1903, DOI 10.1073/pnas.58.5.1903; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LU C, 1987, J MOL BIOL, V196, P497, DOI 10.1016/0022-2836(87)90027-1; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; Radding C.M., 1988, GENETIC RECOMBINATIO, P193; ROBERTS JW, 1978, P NATL ACAD SCI USA, V75, P4714, DOI 10.1073/pnas.75.10.4714; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TESSMAN ES, 1985, J BACTERIOL, V163, P677, DOI 10.1128/JB.163.2.677-687.1985; THOMAS A, 1983, J GEN MICROBIOL, V129, P681; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; VOLKERT MR, 1984, J BACTERIOL, V160, P702, DOI 10.1128/JB.160.2.702-705.1984; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WITKIN EM, 1982, MOL GEN GENET, V185, P43, DOI 10.1007/BF00333788; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976	40	80	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20648	20658						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400384				2022-12-27	WOS:A1992JT97800024
J	STURROCK, AB; FRANKLIN, KF; RAO, G; MARSHALL, BC; REBENTISCH, MB; LEMONS, RS; HOIDAL, JR				STURROCK, AB; FRANKLIN, KF; RAO, G; MARSHALL, BC; REBENTISCH, MB; LEMONS, RS; HOIDAL, JR			STRUCTURE, CHROMOSOMAL ASSIGNMENT, AND EXPRESSION OF THE GENE FOR PROTEINASE-3 - THE WEGENERS GRANULOMATOSIS AUTOANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL ELASTASE GENE; CATHEPSIN-G GENE; SERINE PROTEASE; GENOMIC ORGANIZATION; NUCLEOTIDE-SEQUENCE; POLYMORPHONUCLEAR LEUKOCYTE; TRANSCRIPTION FACTOR; TISSUE-INJURY; DNA-SEQUENCES; MESSENGER-RNA	Proteinase-3 (PR-3) is a neutral serine proteinase present in the azurophil granules of human polymorphonuclear leukocytes. It degrades a variety of extracellular matrix proteins including elastin in vitro and causes emphysema when administered by tracheal insufflation to hamsters. It is identical to the target autoantigen (c-ANCA) associated with Wegener's granulomatosis and to myeloblastin, a serine proteinase first identified in HL-60 leukemia cells. In this study, the gene encoding PR-3 was cloned and sequenced. The gene spans approximately 6.5 kilobase pairs and consists of five exons and four introns. The genomic organization of PR-3 is similar to that of the other serine proteinases expressed in hemopoietic cells. Each residue of the catalytic triad of PR-3 is located on a separate exon, and the positions of the residues within the exons are similar to those in human leukocyte elastase and cathepsin G. The phase and placement of the introns in the PR-3 gene are also similar to those in human leukocyte elastase and cathepsin G. The 400-base pair (bp) 5'-flanking sequence of the PR-3 gene contains a TATA box at position 379. There is no CAAT box promoter element. The 3'-untranslated region is 200 bp, extending from a TGA stop codon to the site of polyadenylation 10 bp after the canonical AATAAA signal. Amplification of PR-3 from a human/hamster hybrid cell line localizes the gene to human chromosome 19. Evidence from Northern analysis suggests that PR-3 expression is primarily confined to the promyelocytic/myelocytic stage of bone marrow development.	UNIV UTAH, DEPT MED,DIV PULM CRIT CARE & OCCUPAT PULM MED, 50 N MED DR,RM 4R240, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT PEDIAT, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [1K08 HL-02370, HL-37615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002370, R01HL037615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; CAMPANELLI D, 1990, J CLIN INVEST, V85, P904, DOI 10.1172/JCI114518; CAPUTO A, 1990, J IMMUNOL, V145, P737; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEININGER PL, 1986, TRENDS GENET, V2, P76, DOI 10.1016/0168-9525(86)90183-6; EWERT BH, 1991, AM J KIDNEY DIS, V18, P188, DOI 10.1016/S0272-6386(12)80879-1; FARLEY D, 1989, BIOL CHEM H-S, V370, P737, DOI 10.1515/bchm3.1989.370.2.737; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HADDAD P, 1991, INT IMMUNOL, V3, P57, DOI 10.1093/intimm/3.1.57; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HOHN PA, 1989, J BIOL CHEM, V264, P13412; IRWIN DM, 1988, J MOL BIOL, V200, P31, DOI 10.1016/0022-2836(88)90331-2; JANOFF A, 1985, ANNU REV MED, V36, P207; JENNE DE, 1991, J IMMUNOL, V147, P1045; JENNETTE JC, 1990, BLOOD, V75, P2263; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LABBAYE C, 1991, P NATL ACAD SCI USA, V88, P9253, DOI 10.1073/pnas.88.20.9253; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; MIN HY, 1986, NUCLEIC ACIDS RES, V14, P8879; MITANI K, 1989, AM J HEMATOL, V31, P253, DOI 10.1002/ajh.2830310407; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NILES JL, 1989, BLOOD, V74, P1888; OHLSSON K, 1990, BIOL CHEM H-S, V371, P549, DOI 10.1515/bchm3.1990.371.2.549; OHYASHIKI K, 1990, CANCER, V65, P940, DOI 10.1002/1097-0142(19900215)65:4<940::AID-CNCR2820650420>3.0.CO;2-W; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; RAO NV, 1991, J BIOL CHEM, V266, P9540; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; SEED B, 1982, GENE, V19, P201, DOI 10.1016/0378-1119(82)90007-5; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUN L, 1984, NUCLEIC ACIDS RES, V12, P2669, DOI 10.1093/nar/12.6.2669; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TUCKER KA, 1987, BLOOD, V70, P372; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X	56	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21193	21199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400430				2022-12-27	WOS:A1992JT97800105
J	WERNER, PK; SAIER, MH; MULLER, M				WERNER, PK; SAIER, MH; MULLER, M			MEMBRANE INSERTION OF THE MANNITOL PERMEASE OF ESCHERICHIA-COLI OCCURS UNDER CONDITIONS OF IMPAIRED SECA FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; BACTERIAL PHOSPHOTRANSFERASE SYSTEM; PROTEIN EXPORT; PLASMA-MEMBRANE; M13 PROCOAT; ENZYME-II; CYTOPLASMIC MEMBRANE; LEADER PEPTIDASE; LACTOSE PERMEASE; SECY24 DEFECT	The membrane insertion of the mannitol permease (MtlA protein) of Escherichia coli, a polytopic cytoplasmic membrane protein possessing an uncleaved amphiphilic signal sequence, was studied using a cell-free protein synthesis system. The MtlA protein synthesized in the presence of inside-out cytoplasmic membrane vesicles was shown to insert into the membranes based on the following criteria: (a) co-sedimentation of the majority of the MtlA protein with the vesicles; (b) selective extraction of the membrane-associated MtlA by deoxycholate but not by urea treatment; and (c) protease resistance of a defined MtlA fragment observed exclusively in the presence of membranes. Post-translational addition of membrane vesicles allowed membrane association of MtlA but did not allow efficient integration. In cell-free systems having reduced levels of the export factors SecA and SecB and exhibiting defective translocation of preOmpA and preLamB, insertion of the in vitro synthesized MtlA apparently occurred normally. In contrast, when membranes from the secY24ts mutant or trypsin-treated membranes were used, insertion of MtlA was reduced. In vivo experiments monitoring the permease activity of MtlA in the secA and secY mutants supported the conclusions of the in vitro results. Thus, the insertion of MtlA is essentially SecA- and SecB-independent but may be dependent on SecY and/or an as yet unidentified membrane protein. The requirements for the insertion of the mannitol permease are therefore clearly different from those for the translocation of most proteins having a cleavable hydrophobic signal sequence.	UNIV FREIBURG, INST BIOCHEM, W-7800 FREIBURG, GERMANY; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of Freiburg; University of California System; University of California San Diego					NIAID NIH HHS [5 RO1 AI 21702] Funding Source: Medline; PHS HHS [2 ROI 14176] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHREM B, 1989, J CELL BIOL, V108, P1637, DOI 10.1083/jcb.108.5.1637; AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALBEY RE, 1987, J BIOL CHEM, V262, P13241; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DECOCK H, 1989, BIOCHIM BIOPHYS ACTA, V985, P313, DOI 10.1016/0005-2736(89)90418-5; FANDL J, 1990, J BIOENERG BIOMEMBR, V22, P369, DOI 10.1007/BF00763173; FANDL JP, 1987, P NATL ACAD SCI USA, V84, P7448, DOI 10.1073/pnas.84.21.7448; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GELLER BL, 1985, J BIOL CHEM, V260, P3281; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; ITO K, 1990, J BIOENERG BIOMEMBR, V22, P353, DOI 10.1007/BF00763172; JACOBSON GR, 1983, J BIOL CHEM, V258, P2955; JACOBSON GR, 1983, J BIOL CHEM, V258, P748; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LEE CA, 1981, P NATL ACAD SCI-BIOL, V78, P7336, DOI 10.1073/pnas.78.12.7336; LEE CA, 1983, J BACTERIOL, V153, P685, DOI 10.1128/JB.153.2.685-692.1983; LEE CA, 1983, J BIOL CHEM, V258, P761; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MACINTYRE S, 1989, FEBS LETT, V247, P396, DOI 10.1016/0014-5793(89)81378-X; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7737, DOI 10.1073/pnas.81.24.7737; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1976, J BIOL CHEM, V251, P6584; SAIER MH, 1988, BIOCHIMIE, V70, P1743, DOI 10.1016/0300-9084(88)90033-8; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SAIER MH, 1988, FASEB J, V2, P199, DOI 10.1096/fasebj.2.3.2832233; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SINGER SJ, 1990, TRENDS BIOCHEM SCI, V15, P369, DOI 10.1016/0968-0004(90)90230-9; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; STOCHAJ U, 1988, J BACTERIOL, V170, P2639, DOI 10.1128/jb.170.6.2639-2645.1988; STOCHAJ U, 1987, EUR J BIOCHEM, V163, P653, DOI 10.1111/j.1432-1033.1987.tb10914.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STRAUCH KL, 1986, J BACTERIOL, V166, P505, DOI 10.1128/jb.166.2.505-512.1986; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; THOME BM, 1991, MOL MICROBIOL, V5, P2815, DOI 10.1111/j.1365-2958.1991.tb01990.x; TROSCHEL D, 1990, J CELL BIOL, V111, P87, DOI 10.1083/jcb.111.1.87; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YAMADA Y, 1991, J BIOL CHEM, V266, P17863; YAMATO I, 1992, J BIOCHEM-TOKYO, V111, P444, DOI 10.1093/oxfordjournals.jbchem.a123777; ZHU HY, 1989, J BIOL CHEM, V264, P11833	63	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24523	24532						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447197				2022-12-27	WOS:A1992KA26300058
J	NISHIZAKI, T; WALENT, JH; KOWALCHYK, JA; MARTIN, TFJ				NISHIZAKI, T; WALENT, JH; KOWALCHYK, JA; MARTIN, TFJ			A KEY ROLE FOR A 145-KDA CYTOSOLIC PROTEIN IN THE STIMULATION OF CA2+-DEPENDENT SECRETION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; THYROTROPIN-RELEASING-HORMONE; GH3 PITUITARY-CELLS; CALCIUM-DEPENDENT EXOCYTOSIS; PERMEABILIZED PC12 CELLS; PHORBOL ESTER TPA; RAT MAST-CELLS; GTP-GAMMA-S; CATECHOLAMINE RELEASE; TRANSMITTER RELEASE	Cytoplasmic Ca2+ is a major regulator of exocytosis in secretory cells; however, the Ca2+-dependent mechanisms that trigger secretion have not been elucidated. Protein kinase C (PKC) has been proposed to be an important Ca2+-dependent component of this regulation; however, the effects of this enzyme on the exocytotic apparatus have not been identified. We developed a PKC-deficient, semi-intact PC12 cell system in which direct stimulatory effects of purified PKC on Ca2+-dependent norepinephrine secretion were studied. The reconstitution of optimal Ca2+-activated norepinephrine secretion by semi-intact PC12 cells required the addition of MgATP and cytosolic proteins. PKC-deficient cytosol exhibited reduced reconstituting activity that was fully restored by the addition of purified PKC. The restoration of Ca2+-dependent norepinephrine secretion by PKC required the presence of other proteins in the cytosol, in particular, a high molecular weight protein. The high molecular weight protein was identified as p145, a recently characterized 145-kDa brain protein. The addition of PKC enhanced phosphorylation of p145 under conditions of fully reconstituted Ca2+-activated norepinephrine secretion. The results indicate that 1) PKC is neither necessary nor sufficient for Ca2+-activated secretion, whereas other cytosolic proteins are required; and 2) the stimulation of Ca2+-activated secretion by PKC is dependent upon cytosolic proteins such as p145 and may be largely mediated through the phosphorylation of p145.	UNIV WISCONSIN, DEPT ZOOL, ZOOL RES BLDG, 1117 W JOHNSON ST, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025861, R37DK025861, R01DK040428] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40428, DK 25861] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGNER PD, 1990, J BIOL CHEM, V265, P10352; AHNERTHILGER G, 1987, BIOCHEMISTRY-US, V26, P7842, DOI 10.1021/bi00398a046; ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ALI SM, 1990, CELL SIGNAL, V2, P265, DOI 10.1016/0898-6568(90)90054-E; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BENSHLOMO H, 1991, BIOCHEM J, V280, P65, DOI 10.1042/bj2800065; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; BROCKLEHURST KW, 1985, FEBS LETT, V183, P107, DOI 10.1016/0014-5793(85)80964-9; BURGOYNE RD, 1984, BIOCHIM BIOPHYS ACTA, V779, P201, DOI 10.1016/0304-4157(84)90009-1; BURGOYNE RD, 1988, FEBS LETT, V238, P151, DOI 10.1016/0014-5793(88)80246-1; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; CHURCHER Y, 1990, CELL REGUL, V1, P523, DOI 10.1091/mbc.1.7.523; CONN PM, 1985, BIOCHEM BIOPH RES CO, V126, P532, DOI 10.1016/0006-291X(85)90638-2; DELISLE RC, 1986, ANNU REV PHYSIOL, V48, P225; DERIEMER SA, 1985, NATURE, V313, P313, DOI 10.1038/313313a0; DEVIRGILIO F, 1984, NATURE, V310, P691; DRUST DS, 1984, J BIOL CHEM, V259, P4520; DUFY B, 1987, ENDOCRINOLOGY, V121, P793, DOI 10.1210/endo-121-2-793; HARLOW E, 1988, ANTIBODIES LABORATOR; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; HUTTON JC, 1986, CELL CALCIUM, V7, P339, DOI 10.1016/0143-4160(86)90037-0; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KNIGHT DE, 1988, J MEMBRANE BIOL, V104, P21, DOI 10.1007/BF01871899; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; KOFFER A, 1989, J CELL SCI, V94, P585; KOOPMANN WR, 1990, BIOCHEM J, V265, P365, DOI 10.1042/bj2650365; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MARTIN TFJ, 1984, ENDOCRINOLOGY, V115, P1517, DOI 10.1210/endo-115-4-1517; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MATTHIES HJG, 1988, FEBS LETT, V229, P238, DOI 10.1016/0014-5793(88)81132-3; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; RONNING SA, 1986, J BIOL CHEM, V261, P7840; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; VANDERMERWE PA, 1990, BIOCHEM J, V268, P493, DOI 10.1042/bj2680493; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WALKER JH, 1987, BIOCHEM J, V247, P249, DOI 10.1042/bj2470249; WILSON SP, 1990, J BIOL CHEM, V265, P648	50	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23972	23981						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429734				2022-12-27	WOS:A1992JZ23900081
J	SATOYOSHITAKE, R; YORIFUJI, H; INAGAKI, M; HIROKAWA, N				SATOYOSHITAKE, R; YORIFUJI, H; INAGAKI, M; HIROKAWA, N			THE PHOSPHORYLATION OF KINESIN REGULATES ITS BINDING TO SYNAPTIC VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MEMBRANOUS ORGANELLES INVIVO; FAST AXONAL-TRANSPORT; MICROTUBULES INVITRO; MONOCLONAL-ANTIBODY; SINGLE MICROTUBULES; PROTEIN-KINASES; SQUID AXOPLASM; HEAVY-CHAIN; IDENTIFICATION	Membrane organella are transported bidirectionally in cells, and the axonal transport system has provided an ideal model system for studying this bidirectional transport. Kinesin and cytoplasmic dynein were identified as candidates for the motor molecules of fast axonal transport, which transport organella along microtubules anterogradely and retrogradely. However, the mechanism that controls this bidirectional transport is unknown. Our previous work revealed that kinesin in axons was associated abundantly with anterogradely transported membranous organella, most of which are believed to be precursors of synaptic vesicles and axonal plasma membranes, while the fractions bound to retrogradely transported ones were very small (Hirokawa, N., Sato-Yoshitake, R., Kobayashi, N., Pfister, K. K., Bloom, G. S., and Brady, S. T. (1991) J. Cell Biol. 114, 295-302). Here we demonstrated in vitro that the binding of kinesin to synaptic vesicles was concentration-dependent and saturable and could be released by high salt concentration. When kinesin was phosphorylated by cAMP-dependent protein kinase, its binding to synaptic vesicles was significantly reduced. By motility assay and by statistical analysis using electron microscopy, we further revealed that synaptic vesicles preincubated with phosphorylated kinesin associated less frequently with microtubules than synaptic vesicles preincubated with unphosphorylated kinesin. The phosphorylation of kinesin should therefore play an essential role in regulating the direction of fast axonal transport by inhibiting its binding to membrane organella, thus releasing it from membrane organella at nerve terminals.	UNIV TOKYO, SCH MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, NEUROPHYSIOL LAB, ITABASHI KU, TOKYO 173, JAPAN	University of Tokyo			Inagaki, Masaki/B-9920-2016					ALLEN RD, 1981, CELL MOTIL CYTOSKEL, V1, P291, DOI 10.1002/cm.970010303; Beavo J A, 1974, Methods Enzymol, V38, P299; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BREUER AC, 1975, J CELL BIOL, V65, P562, DOI 10.1083/jcb.65.3.562; BUSTER D, 1990, J CELL BIOL, V111, P418; DUNKLEY PR, 1988, J NEUROCHEM, V51, P57, DOI 10.1111/j.1471-4159.1988.tb04835.x; EDSTROM A, 1977, J NEUROBIOL, V8, P371, DOI 10.1002/neu.480080408; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1986, J CELL BIOL, V103, P1539, DOI 10.1083/jcb.103.4.1539; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASEK RJ, 1984, J CELL BIOL, V99, pS212, DOI 10.1083/jcb.99.1.212s; LESLIE RJ, 1987, P NATL ACAD SCI USA, V84, P2771, DOI 10.1073/pnas.84.9.2771; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MUROFUSHI H, 1988, J BIOL CHEM, V263, P12744; MURPHY DB, 1989, J CELL BIOL, V109, P80; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NESTLER EJ, 1989, BASIC NEUROCHEMISTRY, P373; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHWARTZ JH, 1979, ANNU REV NEUROSCI, V2, P467, DOI 10.1146/annurev.ne.02.030179.002343; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SHELANSKI ML, 1973, P NATL ACAD SCI USA, V76, P4350; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; TSUKITA S, 1980, J CELL BIOL, V84, P513, DOI 10.1083/jcb.84.3.513; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WALTER U, 1978, J BIOL CHEM, V253, P6275; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	47	132	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23930	23936						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429730				2022-12-27	WOS:A1992JZ23900075
J	HEES, B; DANBOLT, NC; KANNER, BI; HAASE, W; HEITMANN, K; KOEPSELL, H				HEES, B; DANBOLT, NC; KANNER, BI; HAASE, W; HEITMANN, K; KOEPSELL, H			A MONOCLONAL-ANTIBODY AGAINST A NA+-L-GLUTAMATE COTRANSPORTER FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSMITTERS; D-GLUCOSE COTRANSPORTER; CENTRAL NERVOUS-SYSTEM; GRANULE CELL LOLL; TRANSPORT GLYCOPROTEIN; FUNCTIONAL EXPRESSION; PARTIAL-PURIFICATION; SELECTIVE DEPLETION; HAMSTER CEREBELLUM; CLONING	A monoclonal mouse IgM antibody (Z8E9) was raised against the Na+-L-glutamate cotransporter from rat brain. In a preparation of brain plasma membrane vesicles, Z8E9 binds specifically to a polypeptide with an apparent molecular weight of 70,000 and inhibits Na+ gradient-dependent L-glutamate cotransport (up to 50%) in brain membrane vesicles. In the membrane vesicles, the antibody does not alter the membrane permeability for Na+ and K+ nor the Na+ gradient-dependent uptake of gamma-aminobutyric acid. Kinetic experiments showed that Z8E9 does not alter the K0.5 values for L-glutamate and Na+ activation of L-glutamate transport. However, an apparent cooperativity observed for L-glutamate activation was increased, and the V(max) of L-glutamate transport was decreased. Immunostaining of rat cerebellum identified antigenic sites of Z8E9 in Golgi epithelial cells and astrocytes (by light and electron microscopy), whereas no labeling at nerve terminals was detected. The data suggest that a component of a Na+-L-glutamate cotransporter subtype has been identified that is specific for glia cells in brain.	MAX PLANCK INST BIOPHYS,KENNEDYALLEE 70,W-6000 FRANKFURT 70,GERMANY	Max Planck Society			Danbolt, Niels Christian/A-1907-2014	Danbolt, Niels Christian/0000-0003-4227-4520				BIRK HW, 1987, ANAL BIOCHEM, V164, P12, DOI 10.1016/0003-2697(87)90360-5; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DREJER J, 1982, EXP BRAIN RES, V47, P259; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; FLETCHER EJ, 1991, J NEUROCHEM, V57, P911, DOI 10.1111/j.1471-4159.1991.tb08237.x; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FONNUM F, 1981, NEUROSCIENCE, V6, P863, DOI 10.1016/0306-4522(81)90168-8; GARTHWAITE G, 1985, BRAIN RES, V343, P129, DOI 10.1016/0006-8993(85)91166-7; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAASE W, 1989, EUR J CELL BIOL, V48, P360; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HENN FA, 1976, BRAIN RES, V101, P341, DOI 10.1016/0006-8993(76)90274-2; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KOEPSELL H, 1988, J BIOL CHEM, V263, P18419; KOEPSELL H, 1990, J MEMBRANE BIOL, V114, P113, DOI 10.1007/BF01869093; KOEPSELL H, 1983, J BIOL CHEM, V258, P1888; KOEPSELL H, 1984, J BIOL CHEM, V259, P6548; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEVI G, 1982, BRAIN RES, V239, P425, DOI 10.1016/0006-8993(82)90520-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NEEB M, 1987, J BIOL CHEM, V262, P10718; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OTTERSEN OP, 1989, ANAT EMBRYOL, V180, P1, DOI 10.1007/BF00321895; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RAUEN T, 1992, NEUROCHEM INT, V21, pB26; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; SCHOUSBOE A, 1977, J NEUROCHEM, V29, P999, DOI 10.1111/j.1471-4159.1977.tb06503.x; Schousboe A, 1981, Adv Biochem Psychopharmacol, V27, P103; SOMOGYI P, 1986, NEUROSCIENCE, V19, P1045, DOI 10.1016/0306-4522(86)90121-1; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; STEFFGEN J, 1991, BIOCHIM BIOPHYS ACTA, V1066, P14, DOI 10.1016/0005-2736(91)90244-3; STORMMATHISEN J, 1979, NEUROSCIENCE, V4, P1237, DOI 10.1016/0306-4522(79)90154-4; TAXT T, 1984, NEUROSCIENCE, V11, P79, DOI 10.1016/0306-4522(84)90215-X; VEYHL M, 1992, FASEB J, V6, pA1459; WANIEWSKI RA, 1984, J NEUROSCI, V4, P2237; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WILKIN GP, 1982, BRAIN RES, V244, P69, DOI 10.1016/0006-8993(82)90905-2; YOUNG AB, 1974, BRAIN RES, V73, P1, DOI 10.1016/0006-8993(74)91002-6; ZACZEK R, 1987, J NEUROSCI RES, V18, P425, DOI 10.1002/jnr.490180307	56	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23275	23281						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429674				2022-12-27	WOS:A1992JY16300087
J	SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD				SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD			PURIFICATION AND PROPERTIES OF SACCHAROMYCES-CEREVISIAE RNA POLYMERASE-II GENERAL INITIATION FACTOR-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIE; PROMOTER INVITRO; PROTEINS; CLONING; SUBUNIT; MOTIFS; DNA	RNA polymerase II initiation factor a was purified to apparent homogeneity from yeast whole cell extract and consisted of two highly charged polypeptides with apparent masses of 66 and 43 kDa. Separation and renaturation of the subunits showed that both were required for transcription activity. The native mass of factor a was estimated to be 240-260 kDa by gel filtration, but its sedimentation rate in a glycerol gradient was similar to that of a much smaller globular protein, suggesting an extended conformation. Factor a was required for utilization of six different eukaryotic promoters in vitro, indicating a general role in promoter-directed transcription by yeast RNA polymerase II.			SAYRE, MH (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM-36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1989, J BIOL CHEM, V264, P8913; GERARD M, 1991, J BIOL CHEM, V266, P20940; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HENRY NL, 1992, J BIOL CHEM, V267, P23388; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0	27	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23383	23387						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429681				2022-12-27	WOS:A1992JY16300102
J	BAUSCHJURKEN, MT; MAHNKEZIZELMAN, DK; MORISAKI, T; SABINA, RL				BAUSCHJURKEN, MT; MAHNKEZIZELMAN, DK; MORISAKI, T; SABINA, RL			MOLECULAR-CLONING OF AMP DEAMINASE ISOFORM-L - SEQUENCE AND BACTERIAL EXPRESSION OF HUMAN AMPD2 CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ADENYLATE DEAMINASE; RAT MUSCLE; ESCHERICHIA-COLI; MYOSIN; BINDING; AMINOHYDROLASE; IDENTIFICATION; PURIFICATION; SUBFRAGMENTS	Human AMPD2 cDNA clones have been isolated from T-lymphoblast and placental lambdagt11 libraries utilizing a previously cloned rat partial AMPD2 cDNA as the probe. Alignment analysis of all cDNA clones indicates the presence of intervening sequences in several placental isolates. This has been confirmed by sequencing human AMPD2 genomic clones. Intervening sequences can be removed from the cDNA clones by restriction with endonucleases at unique sites within the proposed open reading frame. This results in a 3292-base pair cDNA proposed to contain the entire AMPD2 open reading frame, which would encode a 760-amino acid polypeptide with a predicted subunit molecular mass of 88.1 kDa. Nucleotide and predicted amino acid comparisons with the 264 base pairs of proposed coding sequences in the rat AMPD2 cDNA demonstrate 91% similarity and identity, respectively. A comparison of the predicted human AMPD1 and AMPD2 polypeptides demonstrates homology in their C-terminal domains. Included in this region is the conserved motif, SLSTDDP, proposed to be part of the catalytic site of all AMP deaminases. In contrast, the predicted N-terminal domains of the human AMPD1 and AMPD2 polypeptides are unique. When placed in a prokaryotic expression vector, the human AMPD2 cDNA expresses AMP deaminase activity which can be precipitated with polyclonal antisera specific for isoform L.	MED COLL WISCONSIN,DEPT CELLULAR BIOL & ANAT,MILWAUKEE,WI 53226; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	Medical College of Wisconsin; University of Pennsylvania					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040766] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40766] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHBY B, 1979, J CELL BIOL, V81, P361, DOI 10.1083/jcb.81.2.361; ASHBY B, 1977, J BIOL CHEM, V252, P1869; ASHBY B, 1981, J BIOL CHEM, V256, P519; ASHBY B, 1978, J BIOL CHEM, V253, P8728; BARSHOP BA, 1984, J BIOL CHEM, V259, P60; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; COOPER J, 1984, J MOL BIOL, V177, P137, DOI 10.1016/0022-2836(84)90061-5; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; GILLOTEAUX J, 1983, ACTA HISTOCHEM, V73, P47, DOI 10.1016/S0065-1281(83)80074-9; KORETZ JF, 1982, P NATL ACAD SCI-BIOL, V79, P6205, DOI 10.1073/pnas.79.20.6205; KORETZ JF, 1980, P NATL ACAD SCI-BIOL, V77, P7186, DOI 10.1073/pnas.77.12.7186; MAHNKEZIZELMAN DK, 1992, J BIOL CHEM, V267, P20866; MAKAREWICZ W, 1974, BIOCHEM MED METAB B, V10, P180, DOI 10.1016/0006-2944(74)90021-0; MARQUETANT R, 1989, BIOCHEMISTRY-US, V28, P8744, DOI 10.1021/bi00448a010; MARQUETANT R, 1987, P NATL ACAD SCI USA, V84, P2345, DOI 10.1073/pnas.84.8.2345; MEYER RA, 1980, EXPERIENTIA, V36, P676, DOI 10.1007/BF01970134; MEYER SL, 1989, BIOCHEMISTRY-US, V28, P8734, DOI 10.1021/bi00448a009; MINEO I, 1990, MOL CELL BIOL, V10, P5271, DOI 10.1128/MCB.10.10.5271; MORISAKI T, 1990, J BIOL CHEM, V265, P11482; MORISAKI T, 1992, P NATL ACAD SCI USA, V89, P6457, DOI 10.1073/pnas.89.14.6457; MORISAKI T, 1991, J CELL BIOCHEM     S, V15, P77; OGASAWARA N, 1975, BIOCHIM BIOPHYS ACTA, V403, P530, DOI 10.1016/0005-2744(75)90081-9; OGASAWARA N, 1982, BIOCHIM BIOPHYS ACTA, V714, P298; OGASAWARA N, 1984, INT J BIOCHEM, V16, P269, DOI 10.1016/0020-711X(84)90099-5; RAGGI A, 1979, BIOCHIM BIOPHYS ACTA, V566, P353, DOI 10.1016/0005-2744(79)90039-1; SABINA RL, 1992, NEUROLOGY, V42, P170, DOI 10.1212/WNL.42.1.170; SABINA RL, 1990, J BIOL CHEM, V265, P9423; SABINA RL, 1987, J BIOL CHEM, V262, P12397; SABINA RL, 1989, MOL CELL BIOL, V9, P2244, DOI 10.1128/MCB.9.5.2244; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKI H, 1981, BIOCHEM BIOPH RES CO, V100, P1099, DOI 10.1016/0006-291X(81)91936-7; SHIRAKI H, 1979, BIOCHIM BIOPHYS ACTA, V566, P345, DOI 10.1016/0005-2744(79)90038-X; SHIRAKI H, 1979, BIOCHIM BIOPHYS ACTA, V566, P335, DOI 10.1016/0005-2744(79)90037-8; SWAIN JL, 1982, AM J PHYSIOL, V242, pH818, DOI 10.1152/ajpheart.1982.242.5.H818; THOMPSON JL, 1992, J HISTOCHEM CYTOCHEM, V40, P931, DOI 10.1177/40.7.1607642; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YE RD, 1987, J BIOL CHEM, V262, P3718; YUN SL, 1978, J BIOL CHEM, V253, P404	38	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22407	22413						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429593				2022-12-27	WOS:A1992JW71900066
J	RICHARDSON, RM; HOSEY, MM				RICHARDSON, RM; HOSEY, MM			AGONIST-INDUCED PHOSPHORYLATION AND DESENSITIZATION OF HUMAN M2 MUSCARINIC CHOLINERGIC RECEPTORS IN SF9 INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ACETYLCHOLINE-RECEPTOR; CHICK HEART; REGULATORY PROTEINS; GUANINE-NUCLEOTIDES; ADENYLYL CYCLASE; HIGH-AFFINITY; KINASE-C; EXPRESSION; RECONSTITUTION	The human m1 (hm1) and m2 (hm2) muscarinic cholinergic receptors (mAChR) expressed in Sf9 insect cells using recombinant baculovirus were tested for their ability to undergo agonist-dependent phosphorylation and desensitization. The muscarinic agonist carbachol induced phosphorylation of the hm2 mAChR in the Sf9 cells incubated with P-32i, to an extent of 4-5 mol of phosphate/mol of receptor. In contrast, no phosphorylation of the hm1 mAChR was observed. The hm2 mAChR stimulated [S-35]GTPgammaS binding to, and GTPase activity of, the insect cell G-proteins. These receptor-mediated activities were reduced by 50% in membranes prepared from agonist-treated cells compared to control, suggesting that the agonist-induced phosphorylation of the hm2 mAChR resulted in desensitization of the receptors. No role for protein kinase C or cyclic nucleotide-dependent kinases in receptor phosphorylation and desensitization was suggested from studies using agents known to modulate the activity of these enzymes. However, pertussis toxin was found to completely eliminate the interaction of the hm2 receptors with the insect cell G-proteins, but did not perturb the ability of carbachol to induce agonist-dependent phosphorylation of the receptors. These results suggested that G-proteins and/or G-protein-activated signalling were not necessary for the agonist-induced phosphorylation of the receptors. Overall, the data indicated that the human m2 (but not the human m1) mAChR expressed in Sf9 insect cells undergo phosphorylation and desensitization in an agonist-dependent, G-protein-independent fashion by an endogenous insect cell kinase. The results demonstrated that a human G-protein-linked receptor is regulated in insect cells in a manner that is similar to that involving members of the G-protein receptor-kinase family.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007140] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31601] Funding Source: Medline; NINDS NIH HHS [5T32-NS07140-80] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1983, J BIOL CHEM, V258, P3575; HAGA K, 1991, FEBS LETT, V268, P443; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LIAO CF, 1989, J BIOL CHEM, V264, P7328; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RICHARDSON MR, 1991, MOL PHARMACOL, V40, P908; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WONG SKF, 1990, J BIOL CHEM, V265, P6219	37	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22249	22255						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429577				2022-12-27	WOS:A1992JW71900042
J	GUREVICH, VV; BENOVIC, JL				GUREVICH, VV; BENOVIC, JL			CELL-FREE EXPRESSION OF VISUAL ARRESTIN - TRUNCATION MUTAGENESIS IDENTIFIES MULTIPLE DOMAINS INVOLVED IN RHODOPSIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; BETA-ADRENERGIC-RECEPTOR; 48-KDA PROTEIN; BOVINE RETINA; ALPHA-SUBUNIT; MESSENGER-RNA; BINDING; INVITRO; KINASE; ACTIVATION	Visual arrestin plays an important role in regulating light responsiveness via its ability to specifically bind to the phosphorylated and light-activated form of rhodopsin. To further characterize rhodopsin/arrestin interactions we have utilized a rabbit reticulocyte lysate translation system to synthesize bovine visual arrestin. The translated arrestin (404 amino acids) was demonstrated to be fully functional in terms of its ability to specifically recognize and bind to phosphorylated light-activated rhodopsin (P-Rh*). Competitive binding studies revealed that the in vitro synthesized arrestin and purified bovine visual arrestin had comparable affinities for P-Rh*. In an effort to assess the functional role of different regions of the arrestin molecule, two truncated arrestin mutants were produced by cutting within the open reading frame of the bovine arrestin cDNA with selective restriction enzymes. In vitro translation of the transcribed truncated mRNAs resulted in the production of arrestins truncated from the carboxyl terminus. The ability of each of the mutant arrestins to bind to dark (Rh), light-activated (Rh*), dark phosphorylated (P-Rh), and light-activated phosphorylated rhodopsin were then compared. Arrestin lacking 39 carboxyl-terminal residues binds specifically not only to P-Rh* but also to Rh* and P-Rh. This suggests that the carboxyl-terminal domain of arrestin plays an important regulatory role in ensuring strict arrestin binding selectivity to P-Rh*. Arrestin that has only the first 191 amino-terminal residues predominately discriminates the phosphorylation state of the rhodopsin; however, it also retains some binding specificity for the activation state. These results suggest that the amino-terminal half of arrestin contains key rhodopsin recognition sites responsible for interaction with both the phosphorylated and light-activated forms of rhodopsin.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; GUREVICH VV, 1989, BIOL MEMBRANY, V6, P647; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HUPPERTZ B, 1990, J BIOL CHEM, V265, P9470; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; OLATE J, 1988, J BIOL CHEM, V263, P10394; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453; ZOZULYA SA, 1988, Patent No. 1547313	32	107	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21919	21923						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400502				2022-12-27	WOS:A1992JV01100101
J	BROSCH, G; GEORGIEVA, EI; LOPEZRODAS, G; LINDNER, H; LOIDL, P				BROSCH, G; GEORGIEVA, EI; LOPEZRODAS, G; LINDNER, H; LOIDL, P			SPECIFICITY OF ZEA-MAYS HISTONE DEACETYLASE IS REGULATED BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEAR MATRIX; CELL-CYCLE; PHYSARUM-POLYCEPHALUM; RNA-POLYMERASE; ACETYLATION; CHROMATIN; ASSOCIATION; CHICKEN; CORES	Mono Q ion exchange high performance liquid chromatography (HPLC) reveals that the main histone deacetylase activity (HD1) of germinating Zea mays embryos consists of multiple enzyme forms. Chromatography of HD1 after treatment with alkaline phosphatase yields two distinct histone deacetylase forms (HD1-A, HD1-B). The same is true for chromatography after phosphatase treatment of a total cell extract. One of these enzyme forms (HD1-A) is subject to phosphorylation, which causes a change in the substrate specificity of the enzyme, as shown with HPLC-purified individual core histone species; the substrate specificity for H2A increases more than 2-fold after phosphorylation, whereas the specificity for H3 decreases to about 60%. The total histone deacetylase activity is quantitatively released from isolated nuclei after extraction with moderate ionic strength buffers; no significant residual enzyme activity could be detected in the nuclear matrix.	UNIV INNSBRUCK,SCH MED,DEPT MICROBIOL,A-6020 INNSBRUCK,AUSTRIA; UNIV INNSBRUCK,SCH MED,DEPT MED CHEM & BIOCHEM,A-6020 INNSBRUCK,AUSTRIA; BULGARIAN ACAD SCI,INST GENET,DEPT MOLEC GENET,BU-1113 SOFIA,BULGARIA; UNIV VALENCIA,FAC SCI,DEPT BIOCHEM & MOLEC BIOL,VALENCIA,SPAIN	University of Innsbruck; University of Innsbruck; Bulgarian Academy of Sciences; University of Valencia			Georgieva, Elena/O-1674-2019; LOPEZ-RODAS, GERARDO/I-1349-2015	LOPEZ-RODAS, GERARDO/0000-0001-8367-653X				ALONSO WR, 1986, BIOCHIM BIOPHYS ACTA, V866, P161, DOI 10.1016/0167-4781(86)90113-2; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; DOENECKE D, 1982, MOL CELL BIOCHEM, V44, P113; FERENZ CR, 1985, NUCLEIC ACIDS RES, V13, P1977, DOI 10.1093/nar/13.6.1977; GEORGIEVA EI, 1991, J BIOL CHEM, V266, P18751; GONZALEZ PJ, 1987, J BIOL CHEM, V262, P11280; HAY CW, 1983, J BIOL CHEM, V258, P3726; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HELLIGER W, 1988, BIOCHEM J, V255, P23, DOI 10.1042/bj2550023; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HENDZEL MJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P307, DOI 10.1016/0167-4781(92)90443-4; LOIDL P, 1987, J BIOL CHEM, V262, P10195; LOIDL P, 1987, NUCLEIC ACIDS RES, V15, P8351, DOI 10.1093/nar/15.20.8351; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; LOPEZRODAS G, 1992, FEBS LETT, V296, P82, DOI 10.1016/0014-5793(92)80408-9; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; MOLD DE, 1987, BIOCHEMISTRY-US, V26, P8257, DOI 10.1021/bi00399a036; SENDRA R, 1988, PLANT MOL BIOL, V11, P857, DOI 10.1007/BF00019525; SENDRA R, 1991, PLANT SCI, V78, P43, DOI 10.1016/0168-9452(91)90160-A; TURNER BM, 1991, J CELL SCI, V99, P13; WAITZ W, 1991, ONCOGENE, V6, P29; WAITZ W, 1988, J CELL SCI, V90, P621	22	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20561	20564						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400375				2022-12-27	WOS:A1992JT97800011
J	PAN, YT; KAMITANI, T; BHUVANESWARAN, C; HALLAQ, Y; WARREN, CD; YEH, ETH; ELBEIN, AD				PAN, YT; KAMITANI, T; BHUVANESWARAN, C; HALLAQ, Y; WARREN, CD; YEH, ETH; ELBEIN, AD			INHIBITION OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR FORMATION BY MANNOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEIN; T-CELL RECEPTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; TAP TRANSCRIPTION; LINKAGE MUTANTS; BIOSYNTHESIS; THY-1; ACTIVATION	Many eucaryotic cell surface proteins are anchored to the plasma membrane via a glycosylphosphatidylinositol (GPI), of which the core region is highly conserved from protozoa to mammalian cells. Previous studies (Lisanti, M. P., Field, M. C., Caras, I. W., Menon, A. K., and Rodiguez-Boulan, E. (1991) EMBO J. 10, 1969-1977) showed that mannosamine blocked the expression of a recombinant GPI-anchored protein in Madin-Darby canine kidney cells and converted this protein to an unpolarized secretory product. In the present study, we examined the effect of mannosamine on the formation of the glycan portion of the GPI anchor precursors. This amino sugar inhibited the incorporation of mannose into the glycan portion, and the inhibition was dose-dependent. Mannosamine was shown to be incorporated into the glycan as mannosamine, probably mostly in the second mannose position and thereby to block the further addition of mannose and other anchor components. The products formed in the presence of this drug were characterized by gel filtration and high resolution TLC both before and after deamination with nitrous acid and dephosphorylation by HF. Galactosamine and trehalosamine were inactive in this system, whereas glucosamine also inhibited mannose incorporation into GPI intermediates.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114	University of Arkansas System; University of Arkansas Medical Sciences; Harvard University; Harvard Medical School; Massachusetts General Hospital				Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800, R01DK040930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIDDK NIH HHS [DK-40930, DK-21800] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Defaye J., 1970, ADV CARBOHYD CHEM BI, V25, P181; DEGESPARI R, 1990, SCIENCE, V250, P988; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HOLDER AA, 1981, MOL BIOCHEM PARASIT, V2, P135, DOI 10.1016/0166-6851(81)90095-5; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KANG MS, 1978, J BIOL CHEM, V253, P8860; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; PAN YT, 1979, J BACTERIOL, V139, P507, DOI 10.1128/JB.139.2.507-514.1979; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHWARZ RT, 1988, BIOCH SOC T LOND, V17, P746; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAMI N, 1992, J BIOL CHEM, V267, P1042; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	25	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21250	21255						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400435				2022-12-27	WOS:A1992JT97800114
J	SHIN, K; NAKAMOTO, RK; MAEDA, M; FUTAI, M				SHIN, K; NAKAMOTO, RK; MAEDA, M; FUTAI, M			F0F1-ATPASE GAMMA-SUBUNIT MUTATIONS PERTURB THE COUPLING BETWEEN CATALYSIS AND TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; COLI H+-ATPASE; CARBOXYL-TERMINAL REGION; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; CROSS-LINKING; ALPHA-SUBUNITS; CDNA SEQUENCE; SYNTHASE	We introduced mutations to test the function of the conserved amino-terminal region of the gamma subunit from the Escherichia coli ATP synthase (F0F1-ATPase). Plasmid-borne mutant genes were expressed in an uncG strain which is deficient for the gamma subunit (gammaGln-14 --> end). Most of the changes, which were between gammaIle-19 and gammaLys-33, gammaAsp-83 and gammaCys-87, or at gammaAsp-165, had little effect on growth by oxidative phosphorylation, membrane ATPase activity, or H+ pumping. Notable exceptions were gammaMet-23 --> Arg or Lys mutations. Strains carrying these mutations grew only very slowly by oxidative phosphorylation. Membranes prepared from the strains had substantial levels of ATPase activity, 100% compared with wild type for gammaArg-23 and 65% for gammaLys-23, but formed only 32 and 17%, respectively, of the electrochemical gradient of protons. In contrast, other mutant enzymes with similar ATPase activities (including gammaMet-23 --> Asp or Glu) formed H+ gradients like the wild type. Membranes from the gammaArg-23 and gammaLys-23 mutants were not passively leaky to protons and had functional F0 sectors. These results suggested that substitution by positively charged side chains at position 23 perturbed the energy coupling. The catalytic sites of the mutant enzymes were still regulated by the electrochemical H+ gradient but were inefficiently coupled to H+ translocation in both ATP-dependent H+ pumping and DELTAmu(H+) driven ATP synthesis.	OSAKA UNIV, INST SCI & IND RES, DEPT ORGAN CHEM & BIOCHEM, IBARAKI, OSAKA 567, JAPAN	Osaka University								ARIS JP, 1983, J BIOL CHEM, V258, P4599; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1020, P49, DOI 10.1016/0005-2728(90)90092-I; BRAGG PD, 1980, EUR J BIOCHEM, V106, P495, DOI 10.1111/j.1432-1033.1980.tb04596.x; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DUNN SD, 1980, J BIOL CHEM, V255, P113; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; FILLINGAME RH, 1984, J BACTERIOL, V158, P1078, DOI 10.1128/JB.158.3.1078-1083.1984; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V103, P604; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INOHARA N, 1991, J BIOL CHEM, V266, P7333; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KANAZAWA H, 1985, ARCH BIOCHEM BIOPHYS, V241, P364, DOI 10.1016/0003-9861(85)90558-2; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MIKI J, 1986, ARCH BIOCHEM BIOPHYS, V251, P458, DOI 10.1016/0003-9861(86)90352-8; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1980, J BIOL CHEM, V255, P6670; MORONEY JV, 1979, J BIOL CHEM, V254, P8951; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SLAYMAN CL, 1989, ANN NY ACAD SCI, V574, P233; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4250; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WEISS MA, 1977, J BIOL CHEM, V252, P8007; YU LM, 1988, J BIOL CHEM, V263, P19342	36	70	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20835	20839						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400398				2022-12-27	WOS:A1992JT97800052
J	SOKOLOVSKY, M; AMBAR, I; GALRON, R				SOKOLOVSKY, M; AMBAR, I; GALRON, R			A NOVEL SUBTYPE OF ENDOTHELIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT; BINDING; CLONING; CDNA; HETEROGENEITY; VASODILATOR; EXPRESSION; AGONIST	A new subtype of endothelin receptors with binding properties typical of "super-high" affinity sites, i.e. with affinities in the picomolar range, were identified and characterized in several rat brain regions and atrium. The pharmacological profile of these sites is indicative of the endothelin receptor type B (ET(B)-R). These sites differ from the "conventional" high affinity sites (nanomolar range) in several respects; they do not induce phosphoinositide hydrolysis (whereas the high affinity sites do), and they are affected differently by deglycosylation. Thus, there appear to be at least two subtypes of the ET(B)-R, namely ET(B1)-R (super-high affinity sites) and ET(B2)-R (high affinity sites). We suggest the possibility that the super-high affinity sites are related to the vasodilatation property of endothelins, whereas the high affinity sites participate in their vasoconstrictive action.			SOKOLOVSKY, M (corresponding author), TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,NEUROBIOCHEM LAB,IL-69978 TEL AVIV,ISRAEL.							AMBAR I, 1990, BIOCHEMISTRY-US, V29, P6415, DOI 10.1021/bi00479a012; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BOUSSO D, 1992, NEUROSCI LETT, V140, P247, DOI 10.1016/0304-3940(92)90113-L; BOUSSOMITTLER D, 1991, BIOCHEM BIOPH RES CO, V178, P921, DOI 10.1016/0006-291X(91)90979-H; COURAUD PO, 1991, EUR J PHARM-MOLEC PH, V206, P191, DOI 10.1016/S0922-4106(05)80018-5; DEGOUVILLE ACL, 1990, J PHARMACOL EXP THER, V254, P1024; DEVESLY P, 1990, BIOCHEM BIOPH RES CO, V172, P126, DOI 10.1016/S0006-291X(05)80182-2; FARACI FM, 1989, AM J PHYSIOL, V257, pH799, DOI 10.1152/ajpheart.1989.257.3.H799; GALRON R, 1990, BIOCHEM BIOPH RES CO, V171, P949, DOI 10.1016/0006-291X(90)90776-J; GALRON R, 1990, FEBS LETT, V238, P11; GURWITZ D, 1985, BIOCHEMISTRY-US, V24, P8086, DOI 10.1021/bi00348a038; HILEY CR, 1990, BRIT J PHARMACOL, V101, P319, DOI 10.1111/j.1476-5381.1990.tb12708.x; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V154, P868, DOI 10.1016/0006-291X(88)90220-3; JONES CR, 1991, J RECEPTOR RES, V11, P299, DOI 10.3109/10799899109066409; KLOOG Y, 1989, FEBS LETT, V253, P199, DOI 10.1016/0014-5793(89)80958-5; KLOOG Y, 1989, TRENDS PHARMACOL SCI, V10, P212, DOI 10.1016/0165-6147(89)90261-7; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MINKES RK, 1990, J PHARMACOL EXP THER, V253, P1118; NAKATA H, 1986, BIOCHEM PHARMACOL, V35, P4089; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SOKOLOVSKY M, 1992, J NEUROCHEM, V59, P809, DOI 10.1111/j.1471-4159.1992.tb08318.x; SOKOLOVSKY M, 1992, IN PRESS PHARM THER; WARNER TD, 1989, EUR J PHARMACOL, V159, P325, DOI 10.1016/0014-2999(89)90167-2; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374	28	126	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20551	20554						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400372				2022-12-27	WOS:A1992JT97800008
J	DESCHAMPS, BJ; LAWLESS, DE; CARR, FE; WONG, NCW				DESCHAMPS, BJ; LAWLESS, DE; CARR, FE; WONG, NCW			RAT HEPATONUCLEAR FACTOR PS-1 REGULATES TISSUE-SPECIFIC ACTIVITY OF THE S14 PROMOTER INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC GENE-EXPRESSION; HORMONE-RESPONSIVE GENE; THYROID-HORMONE; MESSENGER-RNA; ALBUMIN PROMOTER; BINDING PROTEINS; TRANSCRIPTION; LIVER; DNA; BOX	We have previously identified a rat hepatonuclear factor, PS-1 that binds to the thyroid hormone responsive gene, S14. To determine whether PS-1 is involved in regulating tissue-specific expression of the S14 gene, we have correlated the DNA binding activity of PS-1 with mRNA-S14 expression in a variety of tissues. Gel retardation analysis revealed a pattern of binding to the recognition site that was characteristic of tissues with high levels of mRNA-S14, a different pattern was found in tissues which do not express the gene. Competition studies using mutant oligonucleotides showed that the first 4 nucleotides and the CAAT motif contained within the PS-1 recognition sequence are essential for protein binding. C/EBP, a CCAAT-transcription factor binds to the PS-1 recognition site thus raising the possibility that both C/EBP and PS-1 may belong to the same family of proteins. Next we used a cell-free transcription assay to measure activity of a template, pS14-GFC(-72), that contained the PS-1 sequence. The pS14-GFC(-72) template was active in hepatonuclear extracts but deletion of or competition with the PS-1 binding sequence rendered the construct inactive. A template containing three PS-1 binding sequences increased S14 promoter activity by 12- to 13-fold. In nuclear extracts from spleen and testis, relative S14 promoter activity was only 2% of that in the liver, this observation mimicked closely in vivo expression of the gene. Mixing together extracts from liver and spleen in varying proportions, prior to incubation with S14 template, yielded a linear increase in S14 promoter activity that correlated with the amount of liver extract in the reaction. This finding is consistent with the absence of an essential factor or factors in spleen that is/are required for S14 promoter activity in vitro. In summary, PS-1 binds to a DNA sequence that contains a CAAT motif and appears to play a critical role in determining tissue-specific activity of the S14 promoter in vitro.	UNIV CALGARY,HLTH SCI CTR,FAC MED,DEPT MED,3330 HOSP DR NW,CALGARY T2N 4N1,ALBERTA,CANADA; WALTER REED ARMY MED CTR,KYLE METAB UNIT,WASHINGTON,DC 20307; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Calgary								CARR FE, 1983, J CLIN INVEST, V72, P154, DOI 10.1172/JCI110953; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JUMP DB, 1984, J BIOL CHEM, V259, P2789; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1987, J BIOL CHEM, V262, P778; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KINLAW WB, 1987, ENDOCRINOLOGY, V120, P1563, DOI 10.1210/endo-120-4-1563; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; LIAW CW, 1984, J BIOL CHEM, V259, P7253; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; Maniatis T., 1982, MOL CLONING; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; NARAYAN P, 1985, MOL CELL BIOL, V5, P2642, DOI 10.1128/MCB.5.10.2642; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PEREZCASTILLO A, 1987, AM J PHYSIOL, V253, pE530; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RYFFEL GU, 1989, NUCLEIC ACIDS RES, V17, P939, DOI 10.1093/nar/17.3.939; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SEELIG S, 1981, P NATL ACAD SCI-BIOL, V78, P4733, DOI 10.1073/pnas.78.8.4733; WANKE IE, 1991, J BIOL CHEM, V266, P6068; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WONG NCW, 1990, J BIOL CHEM, V265, P8775; WONG NCW, 1989, J BIOL CHEM, V264, P4466	35	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25167	25171						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460016				2022-12-27	WOS:A1992KB60300040
J	PASCALE, MC; ERRA, MC; MALAGOLINI, N; SERAFINICESSI, F; LEONE, A; BONATTI, S				PASCALE, MC; ERRA, MC; MALAGOLINI, N; SERAFINICESSI, F; LEONE, A; BONATTI, S			POSTTRANSLATIONAL PROCESSING OF AN O-GLYCOSYLATED PROTEIN, THE HUMAN CD8 GLYCOPROTEIN, DURING THE INTRACELLULAR-TRANSPORT TO THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; DENSITY-LIPOPROTEIN RECEPTOR; CELL-SURFACE SIALOMUCIN; LINKED OLIGOSACCHARIDES; TEMPORAL ASPECTS; GOLGI-APPARATUS; N-GLYCOSYLATION; BREFELDIN-A; BIOSYNTHESIS; OLIGOMERIZATION	The biosynthesis of human CD8 glycoprotein in transfected rat epithelial cells produces an unglycosylated precursor, an intermediate species only initially O-glycosylated, and a doublet mature form carrying neutral and sialylated O-linked oligosaccharides with the core-2 structure (Pascale, M. C., Malagolini, N., Serafini-Cessi, F., Migliaccio, G., Leone, A., and Bonatti, S. (1992) J. Biol. Chem. 267, 9940-9947). In this study the most relevant post-translational events: dimerization, addition of the first O-linked GalNAc, fulfillment of O-linked chains, as well as expression of involved glycosyltransferases, have been examined and correlated with the localization and transit rate of CD8 through the exocytic pathway. The glycosyltransferase activities measured in rat epithelial cells transfected with human CD8 DNA are entirely consistent with the primary structure assigned to CD8 oligosaccharides. The half-time of appearance of the initially O-glycosylated precursor and mature form was estimated to be 4 and 14 min, respectively, and the half-time for delivery of mature CD8 to the cell surface was found to be about 30 min, indicating a very fast routing. Pulse experiments with [S-35]cysteine at 37-degrees-C followed by chase-periods at low temperatures showed that folding/dimerization occurs before routing to the Golgi apparatus, whereas the addiction of O-linked GalNAc appears to take place later, very likely in cis-Golgi cisternae. Treatment of cells with monensin accumulated the intermediate CD8 form carrying non-elongated O-linked GalNAc, whereas brefeldin A treatment produced a sialylated glycoprotein species with a mobility faster than the mature CD8. These results indicate that the two drugs affect assembly of O-linked chains at different time of their processing.	NAPLES UNIV, DEPT BIOCHEM & MED BIOTECHNOL, I-80131 NAPLES, ITALY	University of Naples Federico II			Pascale, Maria/B-4273-2012					BONATTI S, 1989, J BIOL CHEM, V264, P12590; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DALLOLIO F, 1992, BIOCHEM BIOPH RES CO, V184, P1405, DOI 10.1016/S0006-291X(05)80039-7; DEKKER J, 1990, J BIOL CHEM, V265, P18116; ELHAMMER A, 1984, J CELL BIOL, V99, P327, DOI 10.1083/jcb.99.1.327; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANOVER JA, 1982, J BIOL CHEM, V257, P172; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; MORROW B, 1987, J BIOL CHEM, V262, P13812; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; NITSCH L, 1985, EUR J CELL BIOL, V38, P57; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PASCALE MC, 1992, J BIOL CHEM, V267, P9940; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1990, J BIOL CHEM, V265, P9264; PILLER V, 1989, EUR J BIOCHEM, V183, P123, DOI 10.1111/j.1432-1033.1989.tb14904.x; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINICESSI F, 1989, BIOCHEM J, V262, P479, DOI 10.1042/bj2620479; SERAFINICESSI F, 1985, ARCH BIOCHEM BIOPHYS, V240, P866, DOI 10.1016/0003-9861(85)90097-9; SERAFINICESSI F, 1977, BIOCHEM J, V166, P381, DOI 10.1042/bj1660381; SHITE S, 1990, J BIOL CHEM, V265, P17385; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SPIELMAN J, 1987, J BIOL CHEM, V262, P269; SPIELMAN J, 1988, J BIOL CHEM, V263, P9621; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	50	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25196	25201						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460019				2022-12-27	WOS:A1992KB60300044
J	SATOH, T; NAKAFUKU, M; KAZIRO, Y				SATOH, T; NAKAFUKU, M; KAZIRO, Y			FUNCTION OF RAS AS A MOLECULAR SWITCH IN SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; PC12 CELLS; TYROSINE KINASE; GROWTH-FACTOR; GENE-EXPRESSION; CYCLASE PATHWAY; DIFFERENTIATION; P21RAS; MICROINJECTION		DNAX RES INST MOLEC & CELLULAR BIOL INC,901 CALIF AVE,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Nakafuku, Masato/J-3068-2013; Satoh, Takaya/K-2628-2014	Nakafuku, Masato/0000-0001-7783-9005				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAVES JD, 1991, J IMMUNOL, V146, P3709; GRAVES JD, 1992, J IMMUNOL, V148, P2417; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HOSHINO M, 1988, MOL CELL BIOL, V8, P4159; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; IMAI Y, 1991, MOL CELL BIOL, V11, P3088, DOI 10.1128/MCB.11.6.3088; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORIGOE T, 1992, BLOOD, V80, P617; TORTI M, 1992, J BIOL CHEM, V267, P8293; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	77	440	446	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24149	24152						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447166				2022-12-27	WOS:A1992KA26300001
J	ANDERSON, L; DENNY, JB				ANDERSON, L; DENNY, JB			PROTEIN TRANSLOCATION IN THE ENDOPLASMIC-RETICULUM - ULTRAVIOLET-LIGHT INDUCES THE NONCOVALENT ASSOCIATION OF NASCENT PEPTIDES WITH TRANSLOCON PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SYNTHESIZING SECRETORY PROTEIN; RIBOSOME-MEMBRANE JUNCTION; GTP-BINDING PROTEIN; MICROSOMAL-MEMBRANES; SEQUENCE RECEPTOR; ESCHERICHIA-COLI; PREPROLACTIN; COMPLEX; PARTICIPATION	We have photolyzed cell-free translation systems synthesizing beta-lactamase with 254-nm ultraviolet light. In the presence of canine rough microsomes (RM), incomplete chains of beta-lactamase became enriched relative to the full-length molecule in pellet fractions obtained following photolysis and alkaline carbonate extraction. In addition, high molecular weight aggregates were present on SDS-polyacrylamide gels and occurred only when translocation-competent microsomal membranes were used in translation mixtures. The incomplete chains and high molecular weight aggregates were not obtained when RM were inactivated by reaction with N-ethylmaleimide. The incomplete chains did not bind to concanavalin A-Sepharose, indicating that they had not sedimented as a result of being covalently cross-linked to membrane glycoproteins. Both photolysis and alkaline carbonate extraction were required to produce the results. Nascent peptides that were not exposed to alkaline carbonate following photolysis did not appear as high molecular weight bands on SDS-polyacrylamide gels. The high molecular weight aggregates therefore represent denatured protein complexes that contain nascent peptides and microsomal translocon proteins. The results suggest that the translocon is a large proteinaceous complex and that at least a portion of it, when denatured, migrates at a molecular mass of approximately 205 kDa.	UNIV TEXAS, DIV LIFE SCI, 6900 LOOP 1604 NW, SAN ANTONIO, TX 78249 USA	University of Texas System								BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; IWANIJ V, 1985, P NATL ACAD SCI USA, V82, P325, DOI 10.1073/pnas.82.2.325; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; SVOBODA M, 1982, REGUL PEPTIDES, V4, P163, DOI 10.1016/0167-0115(82)90084-2; UMBREIT JN, 1973, J BIOL CHEM, V248, P6759; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617	49	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23916	23921						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429729				2022-12-27	WOS:A1992JZ23900073
J	KORNBERG, L; EARP, HS; PARSONS, JT; SCHALLER, M; JULIANO, RL				KORNBERG, L; EARP, HS; PARSONS, JT; SCHALLER, M; JULIANO, RL			CELL-ADHESION OR INTEGRIN CLUSTERING INCREASES PHOSPHORYLATION OF A FOCAL ADHESION-ASSOCIATED TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXTRACELLULAR-MATRIX COMPONENTS; GLYCOPROTEIN-IIB-IIIA; SIGNAL TRANSDUCTION; GENE-EXPRESSION; FIBRONECTIN; PROTEINS; VLA-5	We have recently shown that changes in tyrosine phosphorylation of a 130-kDa protein(s) (pp130) may be involved in integrin signaling (Kornberg, L., Earp, H. S., Turner, C., Prokop, and Juliano, R. L. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8392-8396). One component of the pp130 protein complex reacts with an antibody generated against p125fak, which is a focal contact-associated tyrosine kinase (Schaller, M.D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196). Both antibody-mediated integrin clustering and adhesion of KB cells to fibronectin leads to increased tyrosine phosphorylation of p125fak. The phosphorylation of p125fak is coincident with adhesion of cells to fibronectin and is maximal prior to cell spreading. Tyrosine phosphorylation of p125fak is induced when KB cells are allowed to adhere to fibronectin, collagen type IV, or laminin, but is not induced on polylysine. When KB cells are subjected to indirect immunofluorescence microscopy, p125fak co-localizes with talin in focal contacts. These data provide additional evidence that tyrosine kinases are involved in integrin signaling.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of North Carolina; University of North Carolina Chapel Hill; University of Virginia	KORNBERG, L (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HASKILL S, 1988, J IMMUNOL, V140, P1690; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHREINER C, 1991, CANCER RES, V51, P1738; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARZ MA, 1984, EXP CELL RES, V152, P302, DOI 10.1016/0014-4827(84)90632-3; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; STREULI CH, 1990, J CELL BIOL, V110, P1405; TURNER CE, 1989, J BIOL CHEM, V264, P11938; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	31	707	715	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23439	23442						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429685				2022-12-27	WOS:A1992JZ23900002
J	ROY, S; YU, S; BANERJEE, D; OVERTON, O; MUKHOPADHYAY, G; ODDOUX, C; GRIENINGER, G; REDMAN, C				ROY, S; YU, S; BANERJEE, D; OVERTON, O; MUKHOPADHYAY, G; ODDOUX, C; GRIENINGER, G; REDMAN, C			ASSEMBLY AND SECRETION OF FIBRINOGEN - DEGRADATION OF INDIVIDUAL CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; NEWLY SYNTHESIZED PROTEINS; CELL ANTIGEN RECEPTOR; PRE-GOLGI DEGRADATION; CULTURED LIVER-CELLS; HEP G2 CELLS; BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; B-BETA	Hep G2 cells produce surplus Aalpha and gamma fibrinogen chains. These excess chains, which are not secreted, exist primarily as free gamma chains and as an Aalpha-gamma complex. We have determined the intracellular location and the degradative fate of these polypeptides by treatment with endoglycosidase-H and by inhibiting lysosomal enzyme activity, using NH4Cl, chloroquine, and leupeptin. Free gamma chain and the gamma component of Aalpha-gamma are both cleaved by endoglycosidase-H, indicating that the gamma chains accumulate in a pre-Golgi compartment. Lysosomal enzyme inhibitors did not affect the disappearance of free gamma chains but inhibited Aalpha-gamma by 50%, suggesting that Aalpha-gamma is degraded in lysosomes. The degradative fate of individual chains was determined in transfected COS cells which express but do not secrete single chains. Leupeptin did not affect Bbeta chain degradation, had very little affect on gamma chain, but markedly inhibited Aalpha chain degradation. Antibody to immunoglobulin heavy chain-binding protein (GRP 78) co-immunoprecipitated Bbeta but not Aalpha or gamma chains. Preferential binding of heavy chain-binding protein to Bbeta was also noted in Hep G2 cells and in chicken hepatocytes. Taken together these studies indicate that Bbeta and gamma chains are degraded in the endoplasmic reticulum, but only Bbeta is bound to BiP. By contrast Aalpha chains and the Aalpha-gamma complex undergo lysosomal degradation.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVING BM, 1982, ARCH BIOCHEM BIOPHYS, V217, P1, DOI 10.1016/0003-9861(82)90472-6; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; AMRANI DL, 1983, BIOCHIM BIOPHYS ACTA, V743, P394, DOI 10.1016/0167-4838(83)90398-9; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLIKSTAD I, 1983, CELL, V32, P1081, DOI 10.1016/0092-8674(83)90292-1; BLOMBACK B, 1979, FIBRINOGEN FIBRIN FO, P223; BLUNT P, 1991, J CELL BIOL, V113, P1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; Chung D W, 1980, Ann N Y Acad Sci, V343, P210, DOI 10.1111/j.1749-6632.1980.tb47253.x; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GRIENINGER G, 1984, J BIOL CHEM, V259, P4973; GRIENINGER G, 1984, BIOCHEMISTRY-US, V23, P5888, DOI 10.1021/bi00319a031; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HIROSE S, 1988, BIOCHEM J, V251, P373, DOI 10.1042/bj2510373; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KANT JA, 1983, P NATL ACAD SCI-BIOL, V80, P3953, DOI 10.1073/pnas.80.13.3953; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; KUDRYK B, 1982, BIOCHIM BIOPHYS ACTA, V703, P77, DOI 10.1016/0167-4838(82)90013-9; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICKERSON JM, 1981, BIOCHEMISTRY-US, V20, P2818, DOI 10.1021/bi00513a017; PARKES JL, 1985, J BIOL CHEM, V260, P8090; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFEFFER SR, 1986, J CELL BIOL, V103, P103, DOI 10.1083/jcb.103.1.103; PLANT PW, 1986, J BIOL CHEM, V261, P2331; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; SASSA S, 1977, J BIOL CHEM, V252, P2428; STROUS GJ, 1985, J CELL BIOL, V101, P531, DOI 10.1083/jcb.101.2.531; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; YU S, 1980, BIOCHEM BIOPH RES CO, V96, P1032, DOI 10.1016/0006-291X(80)90056-X; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1987, THROMB RES, V46, P281, DOI 10.1016/0049-3848(87)90290-8; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, P665	55	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23151	23158						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429662				2022-12-27	WOS:A1992JY16300069
J	GARCIARUIZ, C; FERNANDEZCHECA, JC; KAPLOWITZ, N				GARCIARUIZ, C; FERNANDEZCHECA, JC; KAPLOWITZ, N			BIDIRECTIONAL MECHANISM OF PLASMA-MEMBRANE TRANSPORT OF REDUCED GLUTATHIONE IN INTACT RAT HEPATOCYTES AND MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOGENOUS GLUTATHIONE; OXIDATIVE INJURY; EFFLUX; LIVER; INHIBITION; METHIONINE; ETHANOL; CELLS; PROTECTION; KINETICS	We determined the trans effects of extracellular reduced glutathione (GSH) on the rate of efflux of endogenous labeled GSH from freshly isolated rat hepatocytes. The presence of GSH (10 mM) in the medium significantly stimulated the fractional rate of efflux of [S-35]GSH from 5.2 to 12.6%/15 min (p < 0.01). This effect was concentration-dependent, had sigmoid type of kinetics (D50 of 0.32 mM), and was reversible upon removal of external GSH. trans-Stimulation (counter-transport) was also observed with 5 mM oxidized glutathione (GSSG) and ophthalmic acid (fractional [S-35]GSH efflux: 13.4% +/- 4.1 and 8.8% +/- 2.3 in 15 min, respectively, compared with control: 4.7 +/- 2.5/15 min). Bromosulphthalein-glutathione (BSP-GSH, 5 mm) in Krebs buffer inhibited the fractional [S-35]GSH efflux (1.1%/15 min), whereas in Cl--free buffer, GSH efflux was stimulated (14.2%/15 min) compared with control. trans-Stimulation was independent of chloride. BSP-GSH cis-inhibited and trans-stimulated the initial rate of GSH transport in basolateral-enriched membrane vesicles (bLPM) but not in canalicular-enriched membrane vesicles (cLPM). Gamma-glutamyl compounds also cis-inhibited and trans-stimulated GSH transport in bLPM vesicles. GSH-depleted hepatocytes incubated with 10 mM [S-35]GSH accumulated more GSH than repleted cells, but the initial rate of uptake of radioactivity was faster in repleted cells. In contrast, repleted hepatocytes incubated with tracer or 50 muM [S-35]GSH did not take up GSH. Thus, the sinusoidal membrane GSH transporter exhibits low affinity kinetics with sigmoid features for both GSH uptake and trans-stimulation of efflux, explaining the lack of uptake of GSH at low physiologic extracellular concentrations. Therefore, our findings support and explain the widely held view that GSH transport is unidirectional under physiologic conditions. However, the efflux of GSH may also occur in exchange for the uptake of organic anions and gamma-glutamyl compounds.	UNIV SO CALIF,SCH MED,DEPT MED,DIV GASTROINTESTINAL & LIVER DIS,LOS ANGELES,CA 90033	University of Southern California			Fernández-Checa, José Carlos/L-8342-2014	Fernández-Checa, José Carlos/0000-0003-3422-2990	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030312, R01DK030312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1986, AM J PHYSIOL, V250, pG236, DOI 10.1152/ajpgi.1986.250.2.G236; AW TY, 1987, BIOCHEM BIOPH RES CO, V143, P377, DOI 10.1016/0006-291X(87)90676-0; AW TY, 1986, AM J PHYSIOL, V251, pG354, DOI 10.1152/ajpgi.1986.251.3.G354; AW TY, 1984, J BIOL CHEM, V259, P9355; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; FERNANDEZCHECA JC, 1987, J CLIN INVEST, V80, P57, DOI 10.1172/JCI113063; FERNANDEZCHECA JC, 1990, AM J PHYSIOL, V258, pG967, DOI 10.1152/ajpgi.1990.258.6.G967; FERNANDEZCHECA JC, 1989, J CLIN INVEST, V83, P1247, DOI 10.1172/JCI114008; FERNANDEZCHECA JC, 1988, AM J PHYSIOL, V255, pG403, DOI 10.1152/ajpgi.1988.255.4.G403; Fiske CH, 1925, J BIOL CHEM, V66, P375; HAGEN TM, 1988, KIDNEY INT, V34, P74, DOI 10.1038/ki.1988.147; HAHN R, 1978, BIOCHIM BIOPHYS ACTA, V539, P324, DOI 10.1016/0304-4165(78)90037-5; Hatefi Y, 1978, Methods Enzymol, V53, P21; HAUSSINGER D, 1990, EUR J BIOCHEM, V193, P891, DOI 10.1111/j.1432-1033.1990.tb19414.x; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KELTZIEN RF, 1975, ANAL BIOCHEM, V68, P537; LASH LH, 1986, P NATL ACAD SCI USA, V83, P4641, DOI 10.1073/pnas.83.13.4641; LU SC, 1990, J BIOL CHEM, V265, P16088; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Moldeus P, 1978, Methods Enzymol, V52, P60; OOKHTENS M, 1988, J CLIN INVEST, V82, P608, DOI 10.1172/JCI113639; OOKHTENS M, 1985, J CLIN INVEST, V75, P258, DOI 10.1172/JCI111682; OOKHTENS M, 1991, AM J PHYSIOL, V261, pG458; WHELAN G, 1970, J LAB CLIN MED, V75, P542; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946; YOUNES M, 1990, TOXICOL LETT, V50, P229, DOI 10.1016/0378-4274(90)90015-E	29	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22256	22264						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429578				2022-12-27	WOS:A1992JW71900043
J	HARRIS, HW; HOSSELET, C; GUAYWOODFORD, L; ZEIDEL, ML				HARRIS, HW; HOSSELET, C; GUAYWOODFORD, L; ZEIDEL, ML			PURIFICATION AND PARTIAL CHARACTERIZATION OF CANDIDATE ANTIDIURETIC-HORMONE WATER CHANNEL PROTEINS OF M(R) 55,000 AND 53,000 FROM TOAD URINARY-BLADDER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; PERMEABILITY RESPONSE; TRANSPORT; IDENTIFICATION; QUANTITATION; VESICLES; SPECTRIN; COMPLEX; CELLS; SKIN	Antidiuretic hormone (ADH) increases toad bladder granular cell apical membrane osmotic water permeability (P(f)) by insertion of cytoplasmic vesicles containing water channels into the apical membrane. Termination of ADH stimulation results in endocytosis of water channel-containing membrane. In previous work, we have purified water channel-containing vesicles and demonstrated that they contain 12 major protein bands when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). On the basis of vectorial labeling studies of granular cells and purified vesicles, we have proposed previously that vesicle proteins of 55, 53, and 17 kDa are ADH water channel components. In this report, we have purified and analyzed these three proteins using a combination of SDS-PAGE, peptide mapping, amino acid composition, and amino-terminal analyses. The 55- and 53-kDa proteins are distinct protein species possessing a high degree of structural similarity. Both possess a large content of cysteine. The 17-kDa protein appears to be a proteolytic fragment of the 53-kDa protein. None of these three proteins is phosphorylated or contains large amounts of covalently linked carbohydrate. ADH-elicited P(f) is inhibited by the organic mercurial reagent fluorescein mercuric acetate (FMA). Exposure of water channel-containing vesicles to FMA labels selectively four vesicle proteins of 92, 55, 53, and 29 kDa while reducing vesicle P(f) by 82%. The combination of FMA and 2-mercaptoethanol or exposure to another mercurial reagent, n-ethylmaleimide, does not inhibit vesicle P(f). Together, these data provide additional evidence for the role of the 55- and 53-kDa proteins as components of the ADH water channel. These candidate ADH water channel proteins are distinct from a 28-kDa candidate water channel protein (CHIP 28) isolated recently from human erythrocyte membranes and kidney proximal tubule by Agre and co-workers (Preston, G. M., Carroll, T. P., Guggino, W. B., and Agre, P. (1992) Science 256, 385-387).	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; W ROXBURY VET ADM MED CTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	HARRIS, HW (corresponding author), CHILDRENS HOSP,DIV NEPHROL,BOSTON,MA 02030, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038874, R01DK038690] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38874, DK 38690] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADRAGNA N, 1987, MEMBRANE BIOCHEM, V7, P23, DOI 10.3109/09687688709029427; ASTER JC, 1986, J CELL BIOL, V103, P115, DOI 10.1083/jcb.103.1.115; CALAMITA G, 1992, AM J PHYSIOL, V262, pF267, DOI 10.1152/ajprenal.1992.262.2.F267; CHEVALIER J, 1981, CELL TISSUE RES, V218, P595; COLEMAN RA, 1987, J HISTOCHEM CYTOCHEM, V35, P1405, DOI 10.1177/35.12.3119700; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FINKELSTEIN A, 1986, WATER MOVEMENT LIPID; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; GLUCK S, 1980, NATURE, V284, P631, DOI 10.1038/284631a0; GROSSMAN E, 1990, J AM SOC NEPHROL, V1, pA674; HARRIS HW, 1990, AM J PHYSIOL, V259, pF366, DOI 10.1152/ajprenal.1990.259.2.F366; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HARRIS HW, 1986, J CLIN INVEST, V78, P703, DOI 10.1172/JCI112630; HARRIS HW, 1990, AM J PHYSIOL, V258, pF237, DOI 10.1152/ajprenal.1990.258.2.F237; HARRIS HW, 1987, J MEMBRANE BIOL, V96, P175, DOI 10.1007/BF01869243; HARRIS HW, 1988, P NATL ACAD SCI USA, V85, P1942, DOI 10.1073/pnas.85.6.1942; HARRIS HW, 1988, J MEMBRANE BIOL, V103, P207, DOI 10.1007/BF01993980; HARRIS HW, 1991, AM J PHYSIOL, V261, pC143, DOI 10.1152/ajpcell.1991.261.1.C143; HARRIS HW, 1990, J AM SOC NEPHROL, V1, P1114; HARVEY B, 1991, J GEN PHYSIOL, V97, P749, DOI 10.1085/jgp.97.4.749; HOCH BS, 1989, AM J PHYSIOL, V256, pF948, DOI 10.1152/ajprenal.1989.256.5.F948; IBARRA C, 1989, J MEMBRANE BIOL, V110, P115, DOI 10.1007/BF01869467; KACHADORIAN WA, 1985, AM J PHYSIOL, V248, pF260, DOI 10.1152/ajprenal.1985.248.2.F260; KONIECZKOWSKI M, 1985, J PHARMACOL EXP THER, V234, P515; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; MULLER J, 1980, J CELL BIOL, V85, P83, DOI 10.1083/jcb.85.1.83; MULLER J, 1984, AM J PHYSIOL, V247, pC90, DOI 10.1152/ajpcell.1984.247.1.C90; OJCIUS DM, 1988, BIOCHIM BIOPHYS ACTA, V942, P73, DOI 10.1016/0005-2736(88)90276-3; OSHANNESSY DJ, 1987, ANAL BIOCHEM, V163, P204, DOI 10.1016/0003-2697(87)90114-X; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SMITH BL, 1991, J BIOL CHEM, V266, P6407; STRANGE K, 1987, J MEMBRANE BIOL, V96, P27, DOI 10.1007/BF01869332; TARR GE, 1991, TECHNIQUES PROTEIN C, V2, pCH13; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; VALENTI G, 1991, AM J PHYSIOL, V261, pF437, DOI 10.1152/ajprenal.1991.261.3.F437; VALENTI G, 1990, BIOL CELL, V67, P115; VERBAVATZ JM, 1991, VASOPRESSIN, P105; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x; WHITFIELD CF, 1985, AM J PHYSIOL, V248, pC70, DOI 10.1152/ajpcell.1985.248.1.C70; ZEIDEL M, 1992, IN PRESS AM J PHYSL	45	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22115	22121						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429563				2022-12-27	WOS:A1992JW71900023
J	OZAKI, M; FUJINAMI, K; TANAKA, K; AMEMIYA, Y; SATO, T; OGURA, N; NAKAGAWA, H				OZAKI, M; FUJINAMI, K; TANAKA, K; AMEMIYA, Y; SATO, T; OGURA, N; NAKAGAWA, H			PURIFICATION AND INITIAL CHARACTERIZATION OF THE PROTEASOME FROM THE HIGHER-PLANT SPINACIA-OLERACEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MOLECULAR-WEIGHT PROTEASES; SODIUM DODECYL-SULFATE; MAMMALIAN-CELLS; RAT-LIVER; EUKARYOTIC CELLS; UBIQUITIN; SUBUNITS; DEGRADATION; INVOLVEMENT	The proteasome (multicatalytic protease complex), a high molecular weight protein complex, has been purified from spinach leaves by successive chromatography on DEAE-cellulose, Bio-Gel A-1.5m, DEAE-TOYOPEARL 650C, and DEAE-5PW. The molecular mass was estimated to be 850 kDa by gel filtration. Polyacrylamide gel electrophoresis of the proteasome gave a single protein band under nondenaturing conditions and at least 10 bands in the range of 21-32 kDa in the presence of sodium dodecyl sulfate. By electron microscopy after negative staining with uranyl acetate, the proteasome from spinach appeared as symmetrical ring-shaped particles. The substrate specificity of proteasomes indicates that they contain at least three types of activity, namely, chymotrypsin-like, Staphylococcus aureus V8 protease-like, and trypsin-like activities. The former two activities were enhanced by poly-L-lysine or sodium dodecyl sulfate. Moreover, we examined the immunological reactivities of proteasomes from various eukaryotes. As a result, cross-immunoreactivities of some subunits were observed. These properties of the proteasome are similar to those of proteasomes isolated from various other eukaryotic sources.	CHIBA UNIV, FAC HORT, PLANT PATHOL LAB, MATSUDO, CHIBA 271, JAPAN; UNIV TOKUSHIMA, INST ENZYME RES, TOKUSHIMA 770, JAPAN	Chiba University; Tokushima University	OZAKI, M (corresponding author), CHIBA UNIV, DEPT AGR CHEM, MATSUDO, CHIBA 271, JAPAN.							ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLA DD, 1991, FEBS LETT, V280, P137; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; MATSUMURA K, 1991, MOL REPROD DEV, V29, P189, DOI 10.1002/mrd.1080290215; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NISHIMURA M, 1978, PLANT PHYSIOL, V62, P44, DOI 10.1104/pp.62.1.44; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; SAITOH Y, 1989, J BIOCHEM-TOKYO, V105, P254, DOI 10.1093/oxfordjournals.jbchem.a122649; SAITOH Y, 1991, COMP BIOCHEM PHYS B, V99, P71, DOI 10.1016/0305-0491(91)90009-3; SCHLIEPHACKE M, 1991, EUR J CELL BIOL, V55, P114; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V164, P1253, DOI 10.1016/0006-291X(89)91804-4; TANAKA K, 1988, FEBS LETT, V236, P159, DOI 10.1016/0014-5793(88)80306-5; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TANAKA K, 1989, J BIOCHEM-TOKYO, V106, P495, DOI 10.1093/oxfordjournals.jbchem.a122880; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIERSTRA RD, 1987, PHYSIOL PLANTARUM, V70, P103, DOI 10.1111/j.1399-3054.1987.tb08704.x; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	41	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21678	21684						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400479				2022-12-27	WOS:A1992JV01100066
J	SUKUMAR, M; HIGASHIJIMA, T				SUKUMAR, M; HIGASHIJIMA, T			G-PROTEIN-BOUND CONFORMATION OF MASTOPARAN-X, A RECEPTOR-MIMETIC PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; WASP VENOM; MOLECULAR-DYNAMICS; BINDING; MEMBRANE; CELLS; ALPHA	Mastoparans are a family of 14-residue peptide toxins from wasp venom which have been proposed to stimulate secretion from a variety of cells, by directly activating GTP-binding regulatory proteins (G proteins). In vitro studies have shown that mastoparans activate G proteins by a mechanism remarkably similar to that used by agonist-bound receptors (Higashijima, T., Uzu, S., Nakajima, T., and Ross, E. M. (1988) J. Biol. Chem. 263, 6491-6494). Here, we report the conformation of mastoparan-X (INWKGIAAMAKKLL-NH2) when it is bound to the alpha subunits of recombinant G(i) and G(o), derived from an analysis of transferred nuclear Overhauser effects in a two-dimensional H-1 NMR spectrum of mastoparan-X obtained in the presence of these G proteins. Restrained molecular dynamic simulations with NMR-derived distance constraints were used to determine conformations consistent with NMR data. The G(i)- and G(o)-bound conformations of mastoparan-X are very similar, and in both cases, a major part of the molecule adopts an amphiphilic alpha-helical conformation. The lysine residues are known to be crucial for activity, and it is thus likely that at least the polar face of the amphiphilic helix is in contact with the G proteins. These conclusions should be useful in the design of potent and selective analogs of mastoparan and in the development of models for receptor-G protein interaction.			SUKUMAR, M (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NIGMS NIH HHS [GM40676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1991, ACCOUNTS CHEM RES, V24, P54; CAMPBELL AP, 1991, J MAGN RESON, V93, P77, DOI 10.1016/0022-2364(91)90033-P; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1984, BIOCHIM BIOPHYS ACTA, V802, P157, DOI 10.1016/0304-4165(84)90156-9; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIGASHIJIMA T, 1987, PEPTIDE CHEM 1986, P75; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; ITOH H, 1991, J BIOL CHEM, V266, P16226; KOIDE S, 1989, J BIOL CHEM, V264, P8676; KURIHARA H, 1986, CELL TISSUE RES, V243, P311; KURODA Y, 1980, P JPN ACAD B-PHYS, V56, P660, DOI 10.2183/pjab.56.660; LINDER ME, 1991, METHOD ENZYMOL, V195, P202; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OIDA T, 1986, J BIOCHEM-TOKYO, V100, P99, DOI 10.1093/oxfordjournals.jbchem.a121710; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WAKAMATSU K, 1983, FEBS LETT, V162, P123, DOI 10.1016/0014-5793(83)81062-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21421	21424						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400455				2022-12-27	WOS:A1992JV01100027
J	BOHREN, KM; GRIMSHAW, CE; GABBAY, KH				BOHREN, KM; GRIMSHAW, CE; GABBAY, KH			CATALYTIC EFFECTIVENESS OF HUMAN ALDOSE REDUCTASE - CRITICAL ROLE OF C-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE; COMPLICATIONS; BRAIN	Human aldose reductase and aldehyde reductase are members of the aldo-keto reductase superfamily that share three domains of homology and a nonhomologous COOH-terminal region. The two enzymes catalyze the NADPH-dependent reduction of a wide variety of carbonyl compounds. To probe the function of the domains and investigate the basis for substrate specificity, we interchanged cDNA fragments encoding the NH2-terminal domains of aldose and aldehyde reductase. A chimeric enzyme (CH1, 317 residues) was constructed in which the first 71 residues of aldose reductase were replaced with first 73 residues of aldehyde reductase. Catalytic effectiveness (k(cat)/K(m)) of CH1 for the reduction of various substrates remained virtually identical to wild-type aldose reductase, changing a maximal 4-fold. Deletion of the 13-residue COOH-terminal end of aldose reductase, yielded a mutant enzyme (AR(solid black triangle 303-315) with markedly decreased catalytic effectiveness for uncharged substrates ranging from 80- to more than 600-fold (average 300-fold). The K(mNADPH) of CH1 and AR(solid black triangle 303-315 were nearly identical to that of the wild-type enzyme indicating that cofactor binding is unaffected. The truncated AR(solid black triangle 303-315) displayed a NADPH/D isotope effect in k(cat) and an increased (k(cat)/K(m) value for DL-glyceraldehyde, suggesting that hydride transfer has become partially rate-limiting for the overall reaction. We conclude that the COOH-terminal domain of aldose reductase is crucial to the proper orientation of substrates in the active site.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; WHITTIER INST DIABET & ENDOCRINOL,LUTCHER BROWN DEPT BIOCHEM,LA JOLLA,CA 92037	Baylor College of Medicine	BOHREN, KM (corresponding author), BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030, USA.			Bohren, Kurt/0000-0002-3183-4118	NIDDK NIH HHS [DK-43595, DK-39044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043595, R01DK039044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; Cleland W W, 1979, Methods Enzymol, V63, P103; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FRSHT A, 1985, ENZYME STRUCTURE FUN, P105; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1980, BIOCHEMISTRY-US, V19, P3153, DOI 10.1021/bi00555a006; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; MASSON EA, 1990, DRUGS, V39, P190, DOI 10.2165/00003495-199039020-00003; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; RYLE CM, 1985, BIOCHEM J, V227, P621, DOI 10.1042/bj2270621; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; Stribling D, 1989, J Diabet Complications, V3, P139, DOI 10.1016/0891-6632(89)90036-6; VIOLA RE, 1979, ANAL BIOCHEM, V96, P334, DOI 10.1016/0003-2697(79)90590-6; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; Wermuth B, 1985, Prog Clin Biol Res, V174, P209; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; SCI GRAPHING SOFTWAR	20	81	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20965	20970						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400412				2022-12-27	WOS:A1992JT97800072
J	KUSUBATA, M; TOKUI, T; MATSUOKA, Y; OKUMURA, E; TACHIBANA, K; HISANAGA, S; KISHIMOTO, T; YASUDA, H; KAMIJO, M; OHBA, Y; TSUJIMURA, K; YATANI, R; INAGAKI, M				KUSUBATA, M; TOKUI, T; MATSUOKA, Y; OKUMURA, E; TACHIBANA, K; HISANAGA, S; KISHIMOTO, T; YASUDA, H; KAMIJO, M; OHBA, Y; TSUJIMURA, K; YATANI, R; INAGAKI, M			P13SUC1 SUPPRESSES THE CATALYTIC FUNCTION OF P34CDC2 KINASE FOR INTERMEDIATE FILAMENT PROTEINS, INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; MATURATION-PROMOTING FACTOR; GERMINAL VESICLE BREAKDOWN; XENOPUS CDC2 PROTEIN; H-1 HISTONE KINASE; CONTROL GENE CDC2+; FISSION YEAST; M-PHASE; DIVISION CYCLE; TYROSINE DEPHOSPHORYLATION	The regulation of p34cdc2 kinase activity controls the entry into and exit from mitosis. Although genetic and biochemical evidence suggested close interactions between cyclins, p13suc1 and p34cdc2 kinase, the roles of p13suc1 on p34cdc2 kinase functions remain unclear. To examine the effects of p13suc1 on p34cdc2 kinase function we developed a simple purification procedure for p34cdc2 kinase, unassociated with p13suc1. The key to the purification procedures we used was buffer containing 0.5 m NaCl and 50% ethylene glycol, as a specific elutant of p34cdc2 kinase from p13suc1-Sepharose. This purified p34cdc2 kinase stoichiometrically phosphorylated vimentin and desmin. Exogenous p13suc1 suppressed the phosphorylation of these filament proteins by the kinase and prevented disassembly, although histone H1 phosphorylation was not affected. Peptide mapping analysis showed a similar extent of inhibition by p13suc1 for all five phosphorylation sites by p34cdc2 kinase of vimentin and desmin, hence these p13suc1-induced inhibitions are probably not site-specific. It thus appears that p13suc1 has a selective effect on the catalytic activity of p34cdc2 kinase for these filament proteins.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT NEUROPHYSIOL,ITABASHI KU,TOKYO 173,JAPAN; MIE UNIV,SCH MED,DEPT PATHOL,TSU,MIE 514,JAPAN; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,CELL & DEV BIOL LAB,YOKOHAMA,KANAGAWA 227,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,DIV BIOL,KANAZAWA,ISHIKAWA 920,JAPAN	Mie University; Aichi Cancer Center; Tokyo Institute of Technology; Kanazawa University			Inagaki, Masaki/B-9920-2016					BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRADBURY EM, 1974, NATURE, V249, P553, DOI 10.1038/249553a0; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVANS RM, 1988, EUR J CELL BIOL, V46, P152; EVANS RM, 1984, J BIOL CHEM, V259, P5372; EVANS RM, 1989, J CELL BIOL, V108, P67, DOI 10.1083/jcb.108.1.67; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; FEY SJ, 1983, FEBS LETT, V157, P251; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HOFSTEE BHJ, 1973, BIOCHEM BIOPH RES CO, V50, P751, DOI 10.1016/0006-291X(73)91308-9; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LAZARUS LH, 1976, ANAL BIOCHEM, V174, P138; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MAK AS, 1991, J BIOL CHEM, V266, P6678; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; TACHIBANA K, 1987, J CELL SCI, V88, P273; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WESTWOOD JT, 1985, J BIOL CHEM, V260, P308; YASUDA H, 1990, BIOCHEM BIOPH RES CO, V172, P371, DOI 10.1016/0006-291X(90)90682-D	68	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20937	20942						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400409				2022-12-27	WOS:A1992JT97800068
J	TENG, BB; DAVIDSON, NO				TENG, BB; DAVIDSON, NO			EVOLUTION OF INTESTINAL APOLIPOPROTEIN-B MESSENGER-RNA EDITING - CHICKEN APOLIPOPROTEIN-B MESSENGER-RNA IS NOT EDITED, BUT CHICKEN ENTEROCYTES CONTAIN INVITRO EDITING ENHANCEMENT FACTOR(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SEQUENCE REQUIREMENTS; SITE; BINDS	Mammalian intestinal apolipoprotein B (apoB) messenger RNA (mRNA) undergoes posttranscriptional editing, changing codon 2153 from CAA in apoB100 mRNA to an in-frame translational stop codon (UAA) in apoB48 mRNA. By contrast, chicken intestinal apoB cDNA contains a CAA codon at the corresponding site and apoB mRNA from chicken enterocytes, kidney, and liver is unedited. The cDNA sequence of chicken apoB spanning the edited base is divergent from mammalian apoB cDNA sequence, with 70% homology over the conserved 29-nucleotide sequence (6662-6690) flanking codon 2153. Efficient in vitro editing of both human and rat, but not chicken, synthetic apoB RNA was achieved using rat enterocyte S-100 extracts. By contrast, chicken enterocyte S-100 extracts failed to edit chicken, rat, or human synthetic apoB RNA. Mixing experiments, however, revealed that chicken enterocyte S-100 extracts enhance the in vitro editing activity of rat, pig, and human enterocyte S-100 extracts upon homologous RNAs. The editing enhancement activity of chicken enterocyte S-100 extracts is tissue-specific, heat-sensitive, substrate-saturable, and sensitive to proteinase K, but resistant to micrococcal nuclease. The activity was partially purified by Q-Sepharose chromatography and has an average molecular mass of 49 kDa when analyzed by gel filtration chromatography. We conclude that the evolutionary adaptation of intestinal apoB mRNA editing requires both a requisite RNA motif and tissue-specific factors which mediate the site-specific modification.	UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,5841 S MARYLAND AVE,CHICAGO,IL 60637	University of Chicago					NHLBI NIH HHS [KO-4 HL02166, R0-1 HL38180] Funding Source: Medline; NIDDK NIH HHS [DK-26676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, K04HL002166] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BAUM CL, 1990, J BIOL CHEM, V265, P19263; BLUE ML, 1980, J BIOL CHEM, V255, P48; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P362; DAVIDSON NO, 1990, MOL ENDOCRINOL, V4, P779, DOI 10.1210/mend-4-5-779; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; KIRCHGESSNER TG, 1987, GENE, V59, P241, DOI 10.1016/0378-1119(87)90332-5; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; LAW A, 1990, J LIPID RES, V31, P1109; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; NAVARATNAM N, 1991, NUCLEIC ACIDS RES, V19, P1741, DOI 10.1093/nar/19.8.1741; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SEISHIMA M, 1991, J LIPID RES, V32, P941; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; TARUGI P, 1990, J LIPID RES, V31, P417; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WU JH, 1990, J BIOL CHEM, V265, P12312; YAO ZM, 1992, J BIOL CHEM, V267, P1175; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	32	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21265	21272						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400437				2022-12-27	WOS:A1992JT97800116
